PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hock, C; Konietzko, U; Papassotiropoulos, A; Wollmer, A; Streffer, J; von Rotz, RC; Davey, G; Moritz, E; Nitsch, RM				Hock, C; Konietzko, U; Papassotiropoulos, A; Wollmer, A; Streffer, J; von Rotz, RC; Davey, G; Moritz, E; Nitsch, RM			Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease	NATURE MEDICINE			English	Article							TRANSGENIC MICE; PRECURSOR PROTEIN; MOUSE MODEL; PEPTIDE; PLAQUES; IMMUNIZATION; MUTANT; PATHOLOGY; PRESENILIN-1; CLEARANCE	To characterize antibodies produced in humans in response to Abeta(42) vaccination, we carried out immunohistochemical examinations of the brains of both transgenic mice and human patients with beta-amyloid pathology. We collected sera from patients with Alzheimer disease who received a primary injection of pre-aggregated Abeta(42) followed by one booster injection in a placebo-controlled study. Antibodies in immune sera recognized beta-amyloid plaques, diffuse AD deposits and vascular beta-amyloid in brain blood vessels. The antibodies did not cross-react with native full-length beta-amyloid precursor protein or its physiological derivatives, including soluble Abeta(42). These findings indicate that vaccination of AD patients with Abeta(42) induces antibodies that have a high degree of selectivity for the pathogenic target structures. Whether vaccination to produce antibodies against beta-amyloid will halt the cognitive decline in AD will depend upon clinical assessments over time.	Univ Zurich, Div Psychiat Res, Zurich, Switzerland	University of Zurich	Nitsch, RM (corresponding author), Univ Zurich, Div Psychiat Res, Zurich, Switzerland.		Wollmer, Marc A/B-5038-2009	Rolf Streffer, Johannes/0000-0002-9387-5951; Papassotiropoulos, Andreas/0000-0002-2210-9651				Backskai BJ, 2001, NAT MED, V7, P369, DOI 10.1038/85525; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bishop GM, 2002, NATURE, V416, P677, DOI 10.1038/416677d; Calhoun ME, 1999, P NATL ACAD SCI USA, V96, P14088, DOI 10.1073/pnas.96.24.14088; Check E, 2002, NATURE, V415, P462, DOI 10.1038/415462a; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; Hyman BT, 2001, ANN NEUROL, V49, P808, DOI 10.1002/ana.1061; Iglesias A, 2001, GLIA, V36, P220, DOI 10.1002/glia.1111; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Monsonego A, 2001, P NATL ACAD SCI USA, V98, P10273, DOI 10.1073/pnas.191118298; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Poduslo JF, 2001, NEUROREPORT, V12, P3197, DOI 10.1097/00001756-200110290-00011; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schenk D, 2001, J MOL NEUROSCI, V17, P259, DOI 10.1385/JMN:17:2:259; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sigurdsson EM, 2001, AM J PATHOL, V159, P439, DOI 10.1016/S0002-9440(10)61715-4; Solomon B, 1997, P NATL ACAD SCI USA, V94, P4109, DOI 10.1073/pnas.94.8.4109; Van Dorpe J, 2000, AM J PATHOL, V157, P1283, DOI 10.1016/S0002-9440(10)64644-5; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Younkin SG, 2001, NAT MED, V7, P18, DOI 10.1038/83292	30	220	272	1	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2002	8	11					1270	1275		10.1038/nm783	http://dx.doi.org/10.1038/nm783			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12379846				2022-12-27	WOS:000179221200033
J	Hoshijima, M; Ikeda, Y; Iwanaga, Y; Minamisawa, S; Date, MO; Gu, YS; Iwatate, M; Li, MX; Wang, LL; Wilson, JM; Wang, YB; Ross, J; Chien, KR				Hoshijima, M; Ikeda, Y; Iwanaga, Y; Minamisawa, S; Date, MO; Gu, YS; Iwatate, M; Li, MX; Wang, LL; Wilson, JM; Wang, YB; Ross, J; Chien, KR			Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery	NATURE MEDICINE			English	Article							ADENOASSOCIATED VIRUS VECTORS; LEFT-VENTRICULAR FUNCTION; DILATED CARDIOMYOPATHY; FACTOR-IX; MEMBRANE-PROTEINS; EXPRESSION; ADENOVIRUS; MUSCLE; DYSFUNCTION; EFFICIENT	The feasibility of gene therapy for cardiomyopathy, heart failure and other chronic cardiac muscle diseases is so far unproven. Here, we developed an in vivo recombinant adeno-associated virus (rAAV) transcoronary delivery system that allows stable, high efficiency and relatively cardiac-selective gene expression. We used rAAV to express a pseudophosphorylated mutant of human phospholamban (PLN), a key regulator of cardiac sarcoplasmic reticulum (SR) Ca2+ cycling in BIO14.6 cardiomyopathic hamsters. The rAAV/S16EPLN treatment enhanced myocardial SR Ca2+ uptake and suppressed progressive impairment of left ventricular (LV) systolic function and contractility for 28 - 30 weeks, thereby protecting cardiac myocytes from cytopathic plasma-membrane disruption. Low LV systolic pressure and deterioration in LV relaxation were also largely prevented by rAAV/S16EPLN treatment. Thus, transcoronary gene transfer of S16EPLN via rAAV vector is a potential therapy for progressive dilated cardiomyopathy and associated heart failure.	Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Maryland, Dept Physiol, Baltimore, MD 21201 USA; Univ Penn, Inst Human Gene Therapy, Philadelphia, PA 19104 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University System of Maryland; University of Maryland Baltimore; University of Pennsylvania	Chien, KR (corresponding author), Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA.		gu, yu/GSD-4507-2022; Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131; Ikeda, Yasuhiro/0000-0002-2970-7304; Wang, Lili/0000-0001-9347-3939; Minamisawa, Susumu/0000-0003-4728-2116; Wang, Yibin/0000-0003-0852-0767				Antos CL, 2001, CIRC RES, V89, P997, DOI 10.1161/hh2301.100003; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Asundi VK, 1997, EXP CELL RES, V230, P145, DOI 10.1006/excr.1996.3400; Auricchio A, 2001, HUM GENE THER, V12, P71, DOI 10.1089/104303401450988; Brauner R, 1997, J THORAC CARDIOV SUR, V114, P923, DOI 10.1016/S0022-5223(97)70006-0; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Christensen G, 2000, CIRCULATION, V101, P178, DOI 10.1161/01.CIR.101.2.178; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; del Monte F, 2001, CIRCULATION, V104, P1424, DOI 10.1161/hc3601.095574; Frank K, 2000, BIOCHEMISTRY-US, V39, P14176, DOI 10.1021/bi001049k; Freeman K, 2001, J CLIN INVEST, V107, P967, DOI 10.1172/JCI12083; Hoshijima M, 2002, J CLIN INVEST, V109, P849, DOI 10.1172/JCI15380; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Ikeda Y, 2000, AM J PHYSIOL-HEART C, V278, pH1362, DOI 10.1152/ajpheart.2000.278.4.H1362; Ikeda Y, 2002, CIRCULATION, V105, P502, DOI 10.1161/hc0402.102953; Jackson WA, 1996, BIOCHEM J, V316, P201, DOI 10.1042/bj3160201; Kawada T, 2002, P NATL ACAD SCI USA, V99, P901, DOI 10.1073/pnas.022641799; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; Lai NC, 2000, CIRCULATION, V102, P2396, DOI 10.1161/01.CIR.102.19.2396; Logeart D, 2000, HUM GENE THER, V11, P1015, DOI 10.1089/10430340050015329; Melo LG, 2002, CIRCULATION, V105, P602, DOI 10.1161/hc0502.103363; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; Nakai H, 1998, BLOOD, V91, P4600, DOI 10.1182/blood.V91.12.4600.412k22_4600_4607; Pruchnic R, 2000, HUM GENE THER, V11, P521, DOI 10.1089/10430340050015716; Ryoke T, 1999, CIRCULATION, V100, P1734, DOI 10.1161/01.CIR.100.16.1734; Sato Y, 2001, J BIOL CHEM, V276, P9392, DOI 10.1074/jbc.M006889200; Shah AS, 2001, CIRCULATION, V103, P1311; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Svensson EC, 1999, CIRCULATION, V99, P201, DOI 10.1161/01.CIR.99.2.201; TADA M, 2001, HDB PHYSL 2, V1, P301; White DC, 2000, P NATL ACAD SCI USA, V97, P5428, DOI 10.1073/pnas.090091197; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996	38	265	305	0	8	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2002	8	8					864	871		10.1038/nm739	http://dx.doi.org/10.1038/nm739			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12134142				2022-12-27	WOS:000177200900033
J	Belyakov, IM; Hel, Z; Kelsall, B; Kuznetsov, VA; Ahlers, JD; Nacsa, J; Watkins, DI; Allen, TM; Sette, A; Altman, J; Woodward, R; Markham, PD; Clements, JD; Franchini, G; Strober, W; Berzofsky, JA				Belyakov, IM; Hel, Z; Kelsall, B; Kuznetsov, VA; Ahlers, JD; Nacsa, J; Watkins, DI; Allen, TM; Sette, A; Altman, J; Woodward, R; Markham, PD; Clements, JD; Franchini, G; Strober, W; Berzofsky, JA			Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXIC T-LYMPHOCYTES; MAJOR HISTOCOMPATIBILITY COMPLEX; HIV-1 PEPTIDE VACCINE; RHESUS-MONKEYS; NEUTRALIZING ANTIBODY; ENVELOPE GLYCOPROTEIN; CELL RESPONSES; IN-VIVO; EPITOPE	Given the mucosal transmission of HIV-1, we compared whether a mucosal vaccine could Induce mucosal cytotoxic T lymphocytes (CTLs) and protect rhesus macaques against mucosal infection with simian/human immunodeficiency virus (SHIV) more effectively than the same vaccine given subcutaneously. Here we show that mucosal CTLs specific for simian immunodeficiency virus can be induced by intrarectal immunization of macaques with a synthetic-peptide vaccine incorporating the LT(R192G) adjuvant. This response correlated with the level of T-helper response. After intrarectal challenge with pathogenic SHIV-Ku2, viral titers were eliminated more completely (to undetectable levels) both in blood and intestine, a major reservoir for virus replication, in intrarectally immunized animals than in subcutaneously immunized or control macaques. Moreover, CD4(+) T cells were better preserved. Thus, induction of CTLs in the intestinal mucosa, a key site of virus replication, with a mucosal AIDS vaccine ameliorates infection by SHIV in non-human primates.	NCI, Mol Immunogenet & Vaccine Res Sect, Metab Branch, Bethesda, MD 20892 USA; NCI, Anim Model & Retroviral Vaccines Sect, Basic Res Lab, Bethesda, MD 20892 USA; NIAID, Mucosal Immun Sect, Clin Invest Lab, Bethesda, MD 20892 USA; NICHHD, Sect Med Biophys, Lab Integrat & Med Biophys, Bethesda, MD 20892 USA; Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI USA; Epimmune, San Diego, CA USA; Emory Univ, Vaccine Ctr Yerkes, Atlanta, GA 30322 USA; Adv Biosci Labs, Kensington, MD USA; Tulane Univ, Sch Med, Dept Microbiol & Immunol, Program Mol Pathogenesis & Immun, New Orleans, LA 70112 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Wisconsin System; University of Wisconsin Madison; Emory University; Tulane University	Belyakov, IM (corresponding author), NCI, Mol Immunogenet & Vaccine Res Sect, Metab Branch, Bethesda, MD 20892 USA.	belyakov@box-b.nih.gov; berzofsk@helix.nih.gov	Allen, Todd/F-5473-2011; Sette, Alessandro/AFO-8916-2022	Allen, Todd/0000-0002-6609-1318; Hel, Zdenek/0000-0002-4923-4794	NCRR NIH HHS [R24 RR 15731] Funding Source: Medline; NIAID NIH HHS [N01-AI-95362] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095362] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHLERS JD, 1993, J IMMUNOL, V150, P5647; Ahlers JD, 1997, P NATL ACAD SCI USA, V94, P10856, DOI 10.1073/pnas.94.20.10856; Ahlers JD, 1996, AIDS RES HUM RETROV, V12, P259, DOI 10.1089/aid.1996.12.259; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Allen TM, 2001, J VIROL, V75, P738, DOI 10.1128/JVI.75.2.738-749.2001; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Belyakov IM, 2000, J IMMUNOL, V165, P6454, DOI 10.4049/jimmunol.165.11.6454; Belyakov IM, 1998, J VIROL, V72, P8264, DOI 10.1128/JVI.72.10.8264-8272.1998; Belyakov IM, 1998, J CLIN INVEST, V102, P2072, DOI 10.1172/JCI5102; Belyakov IM, 1998, P NATL ACAD SCI USA, V95, P1709, DOI 10.1073/pnas.95.4.1709; BERZOFSKY JA, 1991, J CLIN INVEST, V88, P876, DOI 10.1172/JCI115389; Berzofsky JA, 1999, IMMUNOL REV, V170, P151, DOI 10.1111/j.1600-065X.1999.tb01336.x; Braun MC, 1999, J EXP MED, V189, P541, DOI 10.1084/jem.189.3.541; Brunner E, 1999, J MULTIVARIATE ANAL, V70, P286, DOI 10.1006/jmva.1999.1821; Brunner E, 2001, STAT PAP, V42, P1, DOI 10.1007/s003620000039; BULL DM, 1977, J CLIN INVEST, V59, P966, DOI 10.1172/JCI108719; CRANAGE MP, 1992, LANCET, V339, P273, DOI 10.1016/0140-6736(92)91335-6; Czerkinsky C, 1999, IMMUNOL REV, V170, P197, DOI 10.1111/j.1600-065X.1999.tb01339.x; DICKINSON BL, 1995, INFECT IMMUN, V63, P1617, DOI 10.1128/IAI.63.5.1617-1623.1995; Egan MA, 1999, J VIROL, V73, P5466, DOI 10.1128/JVI.73.7.5466-5472.1999; HART MK, 1991, P NATL ACAD SCI USA, V88, P9448, DOI 10.1073/pnas.88.21.9448; HOSMALIN A, 1991, J IMMUNOL, V146, P1667; Joag SV, 1998, J MED PRIMATOL, V27, P59, DOI 10.1111/j.1600-0684.1998.tb00227.x; Joag SV, 1996, J VIROL, V70, P3189, DOI 10.1128/JVI.70.5.3189-3197.1996; Kaul R, 2000, J IMMUNOL, V164, P1602, DOI 10.4049/jimmunol.164.3.1602; Knapp LA, 1997, TISSUE ANTIGENS, V50, P657, DOI 10.1111/j.1399-0039.1997.tb02927.x; Kuroda MJ, 1998, J EXP MED, V187, P1373, DOI 10.1084/jem.187.9.1373; Kuroda MJ, 1999, J IMMUNOL, V162, P5127; Lehner T, 1999, IMMUNOL REV, V170, P183, DOI 10.1111/j.1600-065X.1999.tb01338.x; MILLER MD, 1991, J IMMUNOL, V147, P320; Morris CB, 2000, VACCINE, V18, P1944, DOI 10.1016/S0264-410X(99)00447-8; Murphey-Corb M, 1999, J IMMUNOL, V162, P540; Ossendorp F, 1998, J EXP MED, V187, P693, DOI 10.1084/jem.187.5.693; PALKER TJ, 1989, J IMMUNOL, V142, P3612; Romano JW, 2000, J VIROL METHODS, V86, P61, DOI 10.1016/S0166-0934(99)00184-6; Rose JR, 1998, J VIROL, V72, P726; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; SHIRAI M, 1994, J IMMUNOL, V152, P549; TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; YASUTOMI Y, 1993, J IMMUNOL, V151, P5096	44	213	219	0	10	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2001	7	12					1320	1326		10.1038/nm1201-1320	http://dx.doi.org/10.1038/nm1201-1320			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726972				2022-12-27	WOS:000172610300037
J	Priller, J; Flugel, A; Wehner, T; Boentert, M; Haas, CA; Prinz, M; Fernandez-Klett, F; Prass, K; Bechmann, I; de Boer, BA; Frotscher, M; Kreutzberg, GW; Persons, DA; Dirnagl, U				Priller, J; Flugel, A; Wehner, T; Boentert, M; Haas, CA; Prinz, M; Fernandez-Klett, F; Prass, K; Bechmann, I; de Boer, BA; Frotscher, M; Kreutzberg, GW; Persons, DA; Dirnagl, U			Targeting gene-modified hematopoietic cells to the central nervous system: Use of green fluorescent protein uncovers microglial engraftment	NATURE MEDICINE			English	Article							MARROW; BRAIN; MICE; TRANSPLANTATION; DIFFERENTIATE; ACTIVATION	Gene therapy in the central nervous system (CNS) is hindered by the presence of the blood-brain barrier, which restricts access of serum constituents and peripheral cells to the brain parenchyma. Expression of exogenously administered genes in the CNS has been achieved in vivo using highly invasive routes, or ex vivo relying on the direct implantation of genetically modified cells into the brain. Here we provide evidence for a novel, noninvasive approach for targeting potential therapeutic factors to the CNS. Genetically-modified hematopoietic cells enter the CNS and differentiate into microglia after bone-marrow transplantation. Up to a quarter of the regional microglial population is donor-derived by four months after transplantation. Microglial engraftment is enhanced by neuropathology, and gene-modified myeloid cells are specifically attracted to the sites of neuronal damage. Thus, microglia may serve as vehicles for gene delivery to the nervous system.	Humboldt Univ, Charite, Dept Neurol, Berlin, Germany; Max Planck Inst Neurobiol, Munich, Germany; Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany; Univ Freiburg, Inst Anat, Freiburg, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Humboldt Univ, Charite, Dept Anat, Berlin, Germany; FRFZ, D-10117 Berlin, Germany; St Jude Childrens Res Hosp, Dept Hematol & Oncol, Memphis, TN 38105 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; University of Munich; University of Freiburg; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; St Jude Children's Research Hospital	Priller, J (corresponding author), Humboldt Univ, Charite, Dept Neurol, Berlin, Germany.	josef.priller@charite.de	Priller, Josef/ABW-3835-2022; Wehner, Tim/AAS-8045-2021; Wehner, Tim/AAE-1683-2021	Wehner, Tim/0000-0003-3319-2339; Priller, Josef/0000-0001-7596-0979; Dirnagl, Ulrich/0000-0003-0755-6119				Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Burt RK, 2000, J CLIN IMMUNOL, V20, P1, DOI 10.1023/A:1006673408343; Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Flugel A, 2001, J CEREBR BLOOD F MET, V21, P69; Goldman S, 2000, NAT MED, V6, P483, DOI 10.1038/74920; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002; Hollerbach EH, 1998, J COMP NEUROL, V390, P481; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Kennedy DW, 1997, BLOOD, V90, P986, DOI 10.1182/blood.V90.3.986.986_986_993; Kennedy DW, 1998, P NATL ACAD SCI USA, V95, P14944, DOI 10.1073/pnas.95.25.14944; KRALL WJ, 1994, BLOOD, V83, P2737; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; LAWSON LJ, 1992, NEUROSCIENCE, V48, P405, DOI 10.1016/0306-4522(92)90500-2; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Pawliuk R, 1997, HUM GENE THER, V8, P1595, DOI 10.1089/hum.1997.8.13-1595; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; Schluter D, 2001, BRAIN PATHOL, V11, P44, DOI 10.1111/j.1750-3639.2001.tb00380.x; Wada R, 2000, P NATL ACAD SCI USA, V97, P10954, DOI 10.1073/pnas.97.20.10954; Wu YP, 2000, AM J PATHOL, V156, P1849, DOI 10.1016/S0002-9440(10)65058-4	25	490	511	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2001	7	12					1356	1361		10.1038/nm1201-1356	http://dx.doi.org/10.1038/nm1201-1356			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726978				2022-12-27	WOS:000172610300043
J	Bell, MP; Huntoon, CJ; Graham, D; McKean, DJ				Bell, MP; Huntoon, CJ; Graham, D; McKean, DJ			The analysis of costimulatory receptor signaling cascades in normal T lymphocytes using in vitro gene transfer and reporter gene analysis	NATURE MEDICINE			English	Article							TRANSIENT TRANSFECTION; CELLS; TRANSDUCTION	Ligation of the antigen receptor and costimulatory receptors on the surface of T lymphocytes initiates intracellular signals that regulate cell-cycle progression and cell differentiation. To effectively manipulate the activation of T cells for immunotherapeutic applications, it will be important to understand how these signaling pathways are integrated to control specific gene transcription events. Here we describe a novel transient transfection procedure that efficiently introduces DNA into non-dividing normal human and murine T lymphocytes while maintaining high cell viability. Using this technique, reporter genes can be introduced to characterize intracellular signaling pathways that regulate specific gene transcription events in normal T-lymphocyte populations. We show that the CD28 receptor can be differentially coupled to downstream signaling pathways in different T-lymphocyte populations. In addition, we demonstrate that a gene encoding a tagged constitutively active mitogen-activated kinase kinase-1 protein can be transfected and rapidly expressed to regulate the expression of Bcl-2 in normal thymocytes.	Mayo Clin, Dept Immunol, Rochester, MN 55905 USA	Mayo Clinic	McKean, DJ (corresponding author), Mayo Clin, Dept Immunol, Rochester, MN 55905 USA.							CIBOTTI R, 1997, IMMUNITY, V6, P1; Costa GL, 2000, J IMMUNOL, V164, P3581, DOI 10.4049/jimmunol.164.7.3581; Cron RQ, 1997, J IMMUNOL METHODS, V205, P145, DOI 10.1016/S0022-1759(97)00065-3; Huang H, 1998, J IMMUNOL METHODS, V215, P173, DOI 10.1016/S0022-1759(98)00088-X; Hughes CCW, 1996, J BIOL CHEM, V271, P5369, DOI 10.1074/jbc.271.10.5369; Kalli K, 1998, MOL CELL BIOL, V18, P3140, DOI 10.1128/MCB.18.6.3140; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; McKean DJ, 2001, J IMMUNOL, V166, P3468, DOI 10.4049/jimmunol.166.5.3468; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x	11	26	26	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1155	1158		10.1038/nm1001-1155	http://dx.doi.org/10.1038/nm1001-1155			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590441				2022-12-27	WOS:000171524500039
J	Hong, S; Wilson, MT; Serizawa, I; Wu, L; Singh, N; Naidenko, OV; Miura, T; Haba, T; Scherer, DC; Wei, J; Kronenberg, M; Koezuka, Y; Van Kaer, L				Hong, S; Wilson, MT; Serizawa, I; Wu, L; Singh, N; Naidenko, OV; Miura, T; Haba, T; Scherer, DC; Wei, J; Kronenberg, M; Koezuka, Y; Van Kaer, L			The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice	NATURE MEDICINE			English	Article							NKT CELLS; CD1D TETRAMERS; ACTIVATION; RECOGNITION; THYMOCYTES; MELLITUS; MOUSE	Diabetes in non-obese diabetic (NOD) mice is mediated by pathogenic T-helper type 1 (Th1) cells that arise because of a deficiency in regulatory or suppressor T cells(1,2). V alpha 14-J alpha 15 natural killer T (NKT) cells recognize lipid antigens presented by the major histocompatibility complex class I-like protein CD1d (refs. 3,4). We have previously shown that in vivo activation of V alpha 14 NKT cells by alpha -galactosylceramide (alpha -GalCer) and CD1d potentiates Th2-mediated adaptive immune responses Here we show that alpha -GalCer prevents development of diabetes in wild-type but not CD1d-deficient NOD mice. Disease prevention correlated with the ability of alpha -GalCer to suppress interferon-gamma but not interleukin-4 production by NKT cells, to increase serum immunoglobulin E levels, and to promote the generation of islet autoantigen-specific Th2 cells. Because alpha -GalCer recognition by NKT cells is conserved among mice and humans(7,8), these findings indicate that alpha -GalCer might be useful for therapeutic intervention in human diseases characterized by Th1-mediated pathology such as Type 1 diabetes.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, Nashville, TN 37212 USA; Kirin Brewery Co Ltd, Pharmaceut Res Lab, Gunma, Japan; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; La Jolla Inst Allergy & Immunol, San Diego, CA USA	Howard Hughes Medical Institute; Vanderbilt University; Kirin Brewery Company Limited; Vanderbilt University; La Jolla Institute for Immunology	Van Kaer, L (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, Nashville, TN 37212 USA.		Van Kaer, Luc/H-1033-2015	Van Kaer, Luc/0000-0001-5275-2309				Bach JF, 2001, ANNU REV IMMUNOL, V19, P131, DOI 10.1146/annurev.immunol.19.1.131; Baxter AG, 1997, DIABETES, V46, P572, DOI 10.2337/diabetes.46.4.572; Benlagha K, 2000, J EXP MED, V191, P1895, DOI 10.1084/jem.191.11.1895; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Burdin N, 1999, EUR J IMMUNOL, V29, P2014, DOI 10.1002/(SICI)1521-4141(199906)29:06<2014::AID-IMMU2014>3.0.CO;2-G; Delovitch TL, 1997, IMMUNITY, V7, P727, DOI 10.1016/S1074-7613(00)80392-1; Falcone M, 1999, J EXP MED, V190, P963, DOI 10.1084/jem.190.7.963; Godfrey DI, 2000, IMMUNOL TODAY, V21, P573, DOI 10.1016/S0167-5699(00)01735-7; Gombert JM, 1996, EUR J IMMUNOL, V26, P2989, DOI 10.1002/eji.1830261226; Hammond KJL, 1998, J EXP MED, V187, P1047, DOI 10.1084/jem.187.7.1047; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Laloux V, 2001, J IMMUNOL, V166, P3749, DOI 10.4049/jimmunol.166.6.3749; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3; Moodycliffe AM, 2000, NAT IMMUNOL, V1, P521, DOI 10.1038/82782; MORITA M, 1995, J MED CHEM, V38, P2176, DOI 10.1021/jm00012a018; Osman Y, 2000, EUR J IMMUNOL, V30, P1919, DOI 10.1002/1521-4141(200007)30:7<1919::AID-IMMU1919>3.0.CO;2-3; Pearson CI, 1999, CURR TOP MICROBIOL, V238, P79; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Sharif S, 2001, NAT MED, V7, P1057, DOI 10.1038/nm0901-1057; Shi FD, 2001, P NATL ACAD SCI USA, V98, P6777, DOI 10.1073/pnas.121169698; Singh N, 1999, J IMMUNOL, V163, P2373; Sonoda KH, 1999, J EXP MED, V190, P1215, DOI 10.1084/jem.190.9.1215; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; Terabe M, 2000, NAT IMMUNOL, V1, P515, DOI 10.1038/82771	25	472	505	2	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2001	7	9					1052	1056		10.1038/nm0901-1052	http://dx.doi.org/10.1038/nm0901-1052			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533710				2022-12-27	WOS:000170853300032
J	Turcanu, V; Williams, NA				Turcanu, V; Williams, NA			Cell identification and isolation on the basis of cytokine secretion: A novel tool for investigating immune responses	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; T-CELLS; FLOW-CYTOMETRY; CD4(+); MICRODROPLETS; COLITIS; SURFACE		Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Bristol BS8 1TD, Avon, England	University of Bristol	Williams, NA (corresponding author), Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Univ Walk, Bristol BS8 1TD, Avon, England.							Beech JT, 1997, J IMMUNOL METHODS, V205, P163, DOI 10.1016/S0022-1759(97)00072-0; Brosterhus H, 1999, EUR J IMMUNOL, V29, P4053, DOI 10.1002/(SICI)1521-4141(199912)29:12<4053::AID-IMMU4053>3.3.CO;2-3; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Davies M, 1997, INT J CANCER, V73, P68, DOI 10.1002/(SICI)1097-0215(19970926)73:1<68::AID-IJC12>3.3.CO;2-D; Gift EA, 2000, CYTOMETRY, V39, P243; GRAY F, 1995, J IMMUNOL METHODS, V182, P155, DOI 10.1016/0022-1759(94)00319-R; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Groux H, 1999, IMMUNOL TODAY, V20, P442, DOI 10.1016/S0167-5699(99)01510-8; Hermanson G. T., 1996, BIOCONJUGATE TECHNIQ; JOHNSTON JB, 1995, AM J CLIN PATHOL, V103, P574; MANZ R, 1995, P NATL ACAD SCI USA, V92, P1921, DOI 10.1073/pnas.92.6.1921; Mossmann TR, 1987, IMMUNOL TODAY, V8, P223; Parikh I, 1974, Methods Enzymol, V34, P77; POWELL KT, 1990, BIO-TECHNOL, V8, P333, DOI 10.1038/nbt0490-333; Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669; Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X; Scheffold A, 2000, NAT MED, V6, P107, DOI 10.1038/71441; Weaver JC, 1997, NAT MED, V3, P583, DOI 10.1038/nm0597-583	18	23	39	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					373	376		10.1038/85533	http://dx.doi.org/10.1038/85533			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231640				2022-12-27	WOS:000167380400047
J	Elenitoba-Johnson, KSJ; Bohling, SD; Wittwer, CT; King, TC				Elenitoba-Johnson, KSJ; Bohling, SD; Wittwer, CT; King, TC			Multiplex PCR by multicolor fluorimetry and fluorescence melting curve analysis	NATURE MEDICINE			English	Article							POLYMERASE-CHAIN-REACTION; NEAREST-NEIGHBOR THERMODYNAMICS; RESONANCE ENERGY-TRANSFER; MOLECULAR BEACONS; HYBRIDIZATION PROBES; AMPLIFICATION; PARAMETERS; MUTATION; GENE		Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84112 USA; ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA; Brown Univ, Sch Med, Providence, RI 02912 USA; Brown Univ, Lifespan Med Ctr, Providence, RI 02912 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; ARUP Laboratories; Brown University; Brown University; Lifespan Health Rhode Island	Elenitoba-Johnson, KSJ (corresponding author), Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84112 USA.			Elenitoba-Johnson, Kojo/0000-0002-1082-1545	NATIONAL CANCER INSTITUTE [R21CA083984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R42GM058983, R41GM058983] Funding Source: NIH RePORTER; NCI NIH HHS [CA83984] Funding Source: Medline; NIGMS NIH HHS [GM58983] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGWELL CB, 1993, ANN NY ACAD SCI, V677, P167, DOI 10.1111/j.1749-6632.1993.tb38775.x; Bernard PS, 1999, ANAL BIOCHEM, V273, P221, DOI 10.1006/abio.1999.4217; Bernard PS, 1998, ANAL BIOCHEM, V255, P101, DOI 10.1006/abio.1997.2427; Bernard PS, 1998, AM J PATHOL, V153, P1055, DOI 10.1016/S0002-9440(10)65650-7; CARDULLO RA, 1988, P NATL ACAD SCI USA, V85, P8790, DOI 10.1073/pnas.85.23.8790; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HELLER MJ, 1985, RAPID DETECTION IDEN, P245; IKUTA S, 1987, NUCLEIC ACIDS RES, V15, P797, DOI 10.1093/nar/15.2.797; Kostrikis LG, 1998, SCIENCE, V279, P1228, DOI 10.1126/science.279.5354.1228; Kyger EM, 1998, ANAL BIOCHEM, V260, P142, DOI 10.1006/abio.1998.2687; Lay MJ, 1997, CLIN CHEM, V43, P2262; Lee LG, 1999, BIOTECHNIQUES, V27, P342, DOI 10.2144/99272rr01; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Peyret N, 1999, BIOCHEMISTRY-US, V38, P3468, DOI 10.1021/bi9825091; Ririe KM, 1997, ANAL BIOCHEM, V245, P154, DOI 10.1006/abio.1996.9916; SantaLucia J, 1996, BIOCHEMISTRY-US, V35, P3555, DOI 10.1021/bi951907q; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49; Vogelstein B, 1999, P NATL ACAD SCI USA, V96, P9236, DOI 10.1073/pnas.96.16.9236; WETMUR JG, 1995, MOL BIOL BIOTECHNOLO, P605; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01	22	61	71	2	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					249	253		10.1038/84708	http://dx.doi.org/10.1038/84708			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175859				2022-12-27	WOS:000166756300045
J	Chawla, A; Barak, Y; Nagy, L; Liao, D; Tontonoz, P; Evans, RM				Chawla, A; Barak, Y; Nagy, L; Liao, D; Tontonoz, P; Evans, RM			PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation	NATURE MEDICINE			English	Article							ACTIVATED RECEPTOR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); OXIDIZED LDL; DIFFERENTIATION; LIGAND; LIPOPROTEIN; REGULATOR; DISEASE; CULTURE	Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is highly expressed in lipid-accumulating macrophages of the coronary artery. In light of this, the wide-spread clinical use of thiazolidinediones (TZDs) in the treatment of type II diabetes raises concerns about the role of PPAR-gamma in macrophage function and disease progression. To define the role of PPAR-gamma in macrophage biology, we used homologous recombination to create embryonic stem cells that were homozygous for a null mutation in the PPAR-gamma gene. We demonstrate here that PPAR-gamma is neither essential for nor substantially affects the development of the macrophage lineage both in vitro and in vivo. In contrast, we show it is an important regulator of the scavenger receptor CD36, which has been genetically linked to lipid accumulation in macrophages. Both 15-deoxy-Delta (12,14)prostaglandin J(2) and thiazolidinediones have anti-inflammatory effects that are independent of PPAR-gamma. We show that PPAR-gamma is required for positive effects of its ligands in modulating macrophage lipid metabolism, but that inhibitory effects on cytokine production and inflammation may be receptor independent.	Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Debrecen, Med & Hlth Sci Ctr, Dept Biochem & Mol Biol, H-4012 Debrecen, Hungary	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of Debrecen	Chawla, A (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA.	evans@salk.edu	Nagy, Laszlo/A-3814-2008	Nagy, Laszlo/0000-0001-6653-2155; Evans, Ronald/0000-0002-9986-5965	NHLBI NIH HHS [T32 HL07770] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007770] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBONDANZO SJ, 1993, METHOD ENZYMOL, V225, P803; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; McKnight AJ, 1998, ADV IMMUNOL, V68, P271, DOI 10.1016/S0065-2776(08)60562-3; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Reginato MJ, 1999, TRENDS ENDOCRIN MET, V10, P9, DOI 10.1016/S1043-2760(98)00110-6; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rocchi S, 1999, ANN MED, V31, P342, DOI 10.3109/07853899908995901; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Tontonoz P, 1999, CURR OPIN LIPIDOL, V10, P485, DOI 10.1097/00041433-199912000-00002; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; TONTONOZ P, 1995, CELL, V80, P957; WILES MV, 1991, DEVELOPMENT, V111, P259	25	937	970	0	54	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					48	52		10.1038/83336	http://dx.doi.org/10.1038/83336			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135615				2022-12-27	WOS:000166243100034
J	Chitaley, K; Wingard, CJ; Webb, RC; Branam, H; Stopper, VS; Lewis, RW; Mills, TM				Chitaley, K; Wingard, CJ; Webb, RC; Branam, H; Stopper, VS; Lewis, RW; Mills, TM			Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE; ANDROGENIC MAINTENANCE; G-PROTEINS; MYOSIN; ENDOTHELIN-1; PHOSPHATASE; PHYSIOLOGY	Relaxation of the smooth muscle cells in the cavernosal arterioles and sinuses results in increased blood flow into the penis, raising corpus cavernosum pressure to culminate in penile erection(1). Nitric oxide, released from non-adrenergic/non-cholinergic nerves, is considered the principle stimulator of cavernosal smooth muscle relaxation(2-4), however, the inhibition of vasoconstrictors (that is, norepinephrine and endothelin-1, refs. 5-9) cannot be ignored as a potential regulator of penile erection. The calcium-sensitizing rho -A/Rho-kinase pathway may play a synergistic role in cavernosal vasoconstriction to maintain penile flaccidity. Rho-kinase is known to inhibit myosin light chain phosphatase(10-12), and to directly phosphorylate myosin light-chain (in solution), altogether resulting in a net increase in activated myosin and the promotion of cellular contraction(10,11,13-16) Although Rho-kinase protein and mRNA have been detected in cavernosal tissue(17), the role of Rho-kinase in the regulation of cavernosal tone is unknown. Using pharmacologic antagonism (Y-27632, ref. 13, 18), we examined the role of Rho-kinase in cavernosal tone, based on the hypothesis that antagonism of Rho-kinase results in increased corpus cavernosum pressure, initiating the erectile response independently of nitric oxide. Our finding, that Rho-kinase antagonism stimulates rat penile erection independently of nitric oxide, introduces a potential alternate avenue for the treatment of erectile dysfunction.	Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; Med Coll Georgia, Dept Physiol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Surg, Urol Sect, Augusta, GA 30912 USA	University of Michigan System; University of Michigan; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Chitaley, K (corresponding author), Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA.	kanchanc@umich.du	Wingard, Christopher/R-5042-2019	Wingard, Christopher/0000-0002-8251-5678	NHLBI NIH HHS [HL18575] Funding Source: Medline; NIGMS NIH HHS [2-T32-GM0832211] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008322] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Anderssen B, 1997, J SOIL CONTAM, V6, P15, DOI 10.1080/15320389709383543; Ari G, 1996, EUR J PHARMACOL, V307, P69, DOI 10.1016/0014-2999(96)00172-0; BURNETT AL, 1999, HDB SEXUAL DYSFUNCTI, P12; Cellek S, 1997, P NATL ACAD SCI USA, V94, P8226, DOI 10.1073/pnas.94.15.8226; Cellek S, 2000, DRUG TODAY, V36, P135, DOI 10.1358/dot.2000.36.2-3.568787; Chang H, 2000, BIOPHYS J, V78, p137A; Dai Y, 2000, AM J PHYSIOL-REG I, V279, pR25, DOI 10.1152/ajpregu.2000.279.1.R25; Escrig A, 1999, J PHYSIOL-LONDON, V516, P261, DOI 10.1111/j.1469-7793.1999.261aa.x; Feng JH, 1999, J BIOL CHEM, V274, P3744, DOI 10.1074/jbc.274.6.3744; Giraldi A, 1998, J UROLOGY, V160, P1856, DOI 10.1016/S0022-5347(01)62432-7; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Jarow JP, 1999, J UROLOGY, V162, P722, DOI 10.1097/00005392-199909010-00024; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mills TM, 1998, BIOL REPROD, V59, P1413, DOI 10.1095/biolreprod59.6.1413; Moody JA, 1997, J UROLOGY, V158, P942, DOI 10.1016/S0022-5347(01)64368-4; Reilly CM, 1997, J ANDROL, V18, P110; Reilly CM, 1997, J ANDROL, V18, P588; Rosselli M, 1998, HUM REPROD UPDATE, V4, P3, DOI 10.1093/humupd/4.1.3; Somlyo AP, 1998, ACTA PHYSIOL SCAND, V164, P437; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Virag R, 1999, UROLOGY, V54, P1073, DOI 10.1016/S0090-4295(99)00310-6; WEBER DS, IN PRESS PHARMACOLOG	26	258	306	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					119	122		10.1038/83258	http://dx.doi.org/10.1038/83258			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135626				2022-12-27	WOS:000166243100045
J	Limmer, A; Ohl, J; Kurts, C; Ljunggren, HG; Reiss, Y; Groettrup, M; Momburg, F; Arnold, B; Knolle, PA				Limmer, A; Ohl, J; Kurts, C; Ljunggren, HG; Reiss, Y; Groettrup, M; Momburg, F; Arnold, B; Knolle, PA			Efficient presentation of exogenous antigen by liver endothelial cells to CD8(+) T cells results in antigen-specific T-cell tolerance	NATURE MEDICINE			English	Article							CLASS-I PRESENTATION; RECEPTOR-TRANSGENIC MICE; DENDRITIC CELLS; PERIPHERAL TOLERANCE; CYTOKINE PRODUCTION; INDUCTION; LYMPHOCYTES; PATHWAY; LOCALIZATION; MACROPHAGES	Myeloid antigen-presenting cells (APC) are known to cross-present exogenous antigen on major histocompatibility class I molecules to CD8(+) T cells and thereby induce protective immunity against infecting microorganisms. Here we report that liver sinusoidal endothelial cells (LSEC) are organ-resident, non-myeloid APC capable of cross-presenting soluble exogenous antigen to CD8(+) T cells. Though LSEC employ similar molecular mechanisms for cross-presentation as dendritic cells, the outcome of cross-presentation by LSEC is CD8(+) T cell tolerance rather than immunity. As uptake of circulating antigens into LSEC occurs efficiently in vivo, it is likely that cross-presentation by LSEC contributes to CD8(+) T cell tolerance observed in situations where soluble antigen is present in the circulation.	ZMBH, D-69120 Heidelberg, Germany; Med Hsch Hannover, Dept Nephrol, Hannover, Germany; Karolinska Inst, Ctr Microbiol & Tumor Biol, Stockholm, Sweden; Tel Aviv Univ, Dept Biochem, IL-69978 Tel Aviv, Israel; Cantonal Hosp St Gall, Res Dept, St Gallen, Switzerland; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Hannover Medical School; Karolinska Institutet; Tel Aviv University; Kantonsspital St. Gallen; Helmholtz Association; German Cancer Research Center (DKFZ)	Knolle, PA (corresponding author), ZMBH, D-69120 Heidelberg, Germany.			Knolle, Percy A./0000-0003-2983-0414				ASHWELL G, 1981, JAMA-J AM MED ASSOC, V246, P2358, DOI 10.1001/jama.246.20.2358; Belz GT, 1998, P NATL ACAD SCI USA, V95, P13812, DOI 10.1073/pnas.95.23.13812; Bercovici N, 1999, EUR J IMMUNOL, V29, P345, DOI 10.1002/(SICI)1521-4141(199901)29:01<345::AID-IMMU345>3.0.CO;2-K; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; CALLERY MP, 1989, TRANSPLANTATION, V47, P1092; CALNE RY, 1969, NATURE, V223, P472, DOI 10.1038/223472a0; CANTOR HM, 1967, NATURE, V215, P744, DOI 10.1038/215744a0; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.iy.13.040195.000333; Falb D, 1996, EUR J IMMUNOL, V26, P130, DOI 10.1002/eji.1830260120; Gorczynski L, 1999, J IMMUNOL, V162, P774; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; HAMMERLING GJ, 1993, IMMUNOL REV, V133, P93, DOI 10.1111/j.1600-065X.1993.tb01511.x; HARDING CV, 1994, J IMMUNOL, V153, P4925; Heath WR, 1998, J EXP MED, V187, P1549, DOI 10.1084/jem.187.10.1549; HUANG L, 1994, IMMUNITY, V1, P741, DOI 10.1016/S1074-7613(94)80016-2; KAMADA N, 1984, TRANSPLANTATION, V38, P217, DOI 10.1097/00007890-198409000-00004; Ke Y, 1996, J EXP MED, V184, P1179, DOI 10.1084/jem.184.3.1179; KINDBERG GM, 1990, BIOCHEM J, V270, P197, DOI 10.1042/bj2700197; Knolle PA, 2000, IMMUNOL REV, V174, P21, DOI 10.1034/j.1600-0528.2002.017408.x; Knolle PA, 1999, GASTROENTEROLOGY, V116, P1428, DOI 10.1016/S0016-5085(99)70508-1; KOVACSOVICSBANKOWSKI M, 1993, P NATL ACAD SCI USA, V90, P4942, DOI 10.1073/pnas.90.11.4942; Kurts C, 1999, P NATL ACAD SCI USA, V96, P12703, DOI 10.1073/pnas.96.22.12703; Lanzavecchia A, 1996, CURR OPIN IMMUNOL, V8, P348, DOI 10.1016/S0952-7915(96)80124-5; Liblau RS, 1996, P NATL ACAD SCI USA, V93, P3031, DOI 10.1073/pnas.93.7.3031; Ljunggren HG, 1996, IMMUNOL REV, V151, P123, DOI 10.1111/j.1600-065X.1996.tb00706.x; MACPHEE PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG692, DOI 10.1152/ajpgi.1995.269.5.G692; Mitchell DA, 1998, EUR J IMMUNOL, V28, P1923, DOI 10.1002/(SICI)1521-4141(199806)28:06<1923::AID-IMMU1923>3.0.CO;2-9; Morelli AE, 2000, TRANSPLANTATION, V69, P2647, DOI 10.1097/00007890-200006270-00027; O'Connell PJ, 2000, J IMMUNOL, V165, P795, DOI 10.4049/jimmunol.165.2.795; Paglia P, 1996, J EXP MED, V183, P317, DOI 10.1084/jem.183.1.317; Rodriguez A, 1999, NAT CELL BIOL, V1, P362, DOI 10.1038/14058; RUBINSTEIN D, 1986, J IMMUNOL, V137, P1803; Schwarz K, 2000, J IMMUNOL METHODS, V237, P199, DOI 10.1016/S0022-1759(99)00236-7; SCOAZEC JY, 1994, J HEPATOL, V20, P296, DOI 10.1016/S0168-8278(05)80072-8; Sigal LJ, 1999, NATURE, V398, P77, DOI 10.1038/18038; SMEDSROD B, 1990, BIOCHEM J, V266, P313, DOI 10.1042/bj2660313; Sprent J, 1999, J IMMUNOL, V163, P4629; Starzl TE, 1998, NEW ENGL J MED, V339, P1905, DOI 10.1056/NEJM199812243392607; Sun JR, 1999, J IMMUNOL, V162, P5868; Thomson AW, 1999, IMMUNOL TODAY, V20, P27, DOI 10.1016/S0167-5699(98)01378-4; Vabulas RM, 2000, J IMMUNOL, V164, P2372, DOI 10.4049/jimmunol.164.5.2372; Wong J, 1997, J CLIN INVEST, V99, P2782, DOI 10.1172/JCI119468; WOO J, 1994, TRANSPLANTATION, V58, P484, DOI 10.1097/00007890-199408270-00015; WU JY, 1994, CELL IMMUNOL, V154, P393, DOI 10.1006/cimm.1994.1086; Zinkernagel RM, 1997, IMMUNOL REV, V156, P199, DOI 10.1111/j.1600-065X.1997.tb00969.x	45	548	571	1	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1348	1354		10.1038/82161	http://dx.doi.org/10.1038/82161			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100119	Green Submitted			2022-12-27	WOS:000165704100038
J	McKinney, JD				McKinney, JD			In vivo veritas: The search for TB drug targets goes live	NATURE MEDICINE			English	Review							MYCOBACTERIUM-TUBERCULOSIS; GENE-EXPRESSION; RESISTANCE; VIRULENCE; IDENTIFICATION; ATTENUATION; MUTATIONS; SYNTHASE; RNA	The term microbial persistence' describes a phenomenon whereby microorganisms which are drug-susceptible when tested outside the body are nevertheless capable of surviving within the body despite intensive therapy with the appropriate antimicrobial drug. In clinical practice this phenomenon obviously has to do with the post-treatment 'carrier state' and with post-treatment relapse. In short, it is this phenomenon which is responsible for our inability to eradicate an infection from a person or a community by the use of drugs.	Rockefeller Univ, Lab Infect Biol, New York, NY 10021 USA	Rockefeller University	McKinney, JD (corresponding author), Rockefeller Univ, Lab Infect Biol, 1230 York Ave, New York, NY 10021 USA.	mckinney@rockefeller.edu						Alland D, 1998, P NATL ACAD SCI USA, V95, P13227, DOI 10.1073/pnas.95.22.13227; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BARCLAY WR, 1953, JAMA-J AM MED ASSOC, V151, P1384; Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; Berthet FX, 1998, SCIENCE, V282, P759, DOI 10.1126/science.282.5389.759; Buchmeier N, 2000, MOL MICROBIOL, V35, P1375, DOI 10.1046/j.1365-2958.2000.01797.x; Caceres NE, 1997, J BACTERIOL, V179, P5046, DOI 10.1128/jb.179.16.5046-5055.1997; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; CANETTI G, 1965, AM REV RESPIR DIS, V92, P687; Chen P, 2000, INFECT IMMUN, V68, P5575, DOI 10.1128/IAI.68.10.5575-5580.2000; CLARK DWJ, 1985, DRUGS, V29, P342, DOI 10.2165/00003495-198529040-00003; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; DAVID HL, 1969, AM REV RESPIR DIS, V100, P579; De Voss JJ, 2000, P NATL ACAD SCI USA, V97, P1252, DOI 10.1073/pnas.97.3.1252; DRLICA K, 1996, TUBERCULOSIS, P817; Ehrlich P, 1913, LANCET, V2, P445; FINKEN M, 1993, MOL MICROBIOL, V9, P1239, DOI 10.1111/j.1365-2958.1993.tb01253.x; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; HANDWERGER S, 1985, REV INFECT DIS, V7, P368; Hondalus MK, 2000, INFECT IMMUN, V68, P2888, DOI 10.1128/IAI.68.5.2888-2898.2000; Jackson M, 1999, INFECT IMMUN, V67, P2867, DOI 10.1128/IAI.67.6.2867-2873.1999; JINDANI A, 1980, AM REV RESPIR DIS, V121, P939; MAHER D, 1999, TUBERCULOSIS NONTUBE, P104; Manabe YC, 1999, P NATL ACAD SCI USA, V96, P12844, DOI 10.1073/pnas.96.22.12844; MCCUNE R, 1957, AM REV TUBERC PULM, V76, P1106; MCCUNE RM, 1956, J EXP MED, V104, P763, DOI 10.1084/jem.104.5.763; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; MITCHISON DA, 1979, CHEST, V76, P771, DOI 10.1378/chest.76.6_Supplement.771; Nopponpunth V, 1999, J BACTERIOL, V181, P6814, DOI 10.1128/JB.181.21.6814-6821.1999; Primm TP, 2000, J BACTERIOL, V182, P4889, DOI 10.1128/JB.182.17.4889-4898.2000; Ramakrishnan L, 2000, SCIENCE, V288, P1436, DOI 10.1126/science.288.5470.1436; SEGAL W, 1956, J BACTERIOL, V72, P132, DOI 10.1128/JB.72.2.132-141.1956; Sharma V, 2000, NAT STRUCT BIOL, V7, P663, DOI 10.1038/77964; STEWART GR, 2000, ASM C TUB PAST PRES; Stover CK, 2000, NATURE, V405, P962, DOI 10.1038/35016103; TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F; VANDIVIERE H M, 1956, Am J Med Sci, V232, P30, DOI 10.1097/00000441-195607000-00006; Waksman, 1964, CONQUEST TUBERCULOSI; WHO, 2000, ANT DRUG RES WORLD; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833; Zimhony O, 2000, NAT MED, V6, P1043, DOI 10.1038/79558	43	65	66	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2000	6	12					1330	1333		10.1038/82142	http://dx.doi.org/10.1038/82142			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100116				2022-12-27	WOS:000165704100035
J	Nathan, DG; Varmus, HE				Nathan, DG; Varmus, HE			The National Institutes of Health and clinical research: a progress report	NATURE MEDICINE			English	Editorial Material							PHYSICIAN-SCIENTISTS		Dana Farber Canc Inst, Boston, MA 02115 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Harvard University; Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer Center	Nathan, DG (corresponding author), Dana Farber Canc Inst, 44 Binney St,Suite 1628, Boston, MA 02115 USA.							*ADV COMM NIH DIR, 1997, REP NIH DIR PAN CLIN; Funkenstein DH., 1978, MED STUDENTS MED SCH; Goldstein JL, 1997, J CLIN INVEST, V99, P2803, DOI 10.1172/JCI119470; Nathan DG, 1998, JAMA-J AM MED ASSOC, V280, P1427, DOI 10.1001/jama.280.16.1427; *PHYS SCI TRACK PR, 1999, HHMI AAMC COMP MATR; Rosenberg LE, 1999, SCIENCE, V283, P331, DOI 10.1126/science.283.5400.331; Schechter AN, 1998, JAMA-J AM MED ASSOC, V280, P1440, DOI 10.1001/jama.280.16.1440; Shine KI, 1998, JAMA-J AM MED ASSOC, V280, P1442, DOI 10.1001/jama.280.16.1442; Zemlo TR, 2000, FASEB J, V14, P221, DOI 10.1096/fasebj.14.2.221	9	40	40	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1201	1204		10.1038/81282	http://dx.doi.org/10.1038/81282			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062519				2022-12-27	WOS:000165114800013
J	Nair, SK; Heiser, A; Boczkowski, D; Majumdar, A; Naoe, M; Lebkowski, JS; Vieweg, J; Gilboa, E				Nair, SK; Heiser, A; Boczkowski, D; Majumdar, A; Naoe, M; Lebkowski, JS; Vieweg, J; Gilboa, E			Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.	NATURE MEDICINE			English	Article							CATALYTIC SUBUNIT GENE; IN-VITRO; LYMPHOCYTE RESPONSES; MOUSE TELOMERASE; ANTIGEN; EPITOPES; CANCER; LENGTH; IMMUNODOMINANCE; IMMUNOTHERAPY	The polypeptide component of telomerase (TERT) is an attractive candidate for a broadly expressed tumor rejection antigen because telomerase is silent in normal tissues but is reactivated in more than 85% of cancers. Here we show that immunization against TERT induces immunity against tumors of unrelated origin. Immunization of mice with TERT RNA-transfected dendritic cells (DC) stimulated cytotoxic T lymphocytes (CTL), which lysed melanoma and thymoma tumor cells and inhibited the growth of three unrelated tumors in mice of distinct genetic backgrounds. TERT RNA-transfected human DC stimulated TERT-specific CTL in vitro that lysed human tumor cells, including Epstein Barr virus (EBV)-transformed B cells as well as autologous tumor targets from patients with renal and prostate cancer. Tumor RNA-transfected DC were used as surrogate targets in the CTL assays, obviating the difficulties in obtaining tumor cells from cancer patients. In one instance, where a tumor cell line was successfully established in culture from a patient with renal cancer, the patient's tumor cells were efficiently lysed by the CTL. Immunization with tumor RNA was generally more effective than immunization with TERT RNA, suggesting that an optimal immunization protocol may have to include TERT as well as additional tumor antigens.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Div Urol, Durham, NC 27710 USA; Geron Corp, Menlo Park, CA 94025 USA	Duke University; Duke University; Geron Corporation	Gilboa, E (corresponding author), Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.		Heiser, Axel/W-4473-2019; Nair, Smita/GYR-2993-2022; Nair Jain, Smita/M-2765-2018	Heiser, Axel/0000-0003-0389-6132; Nair, Smita/0000-0001-5615-7056; Nair Jain, Smita/0000-0002-1542-9913				Ashley DM, 1997, J EXP MED, V186, P1177, DOI 10.1084/jem.186.7.1177; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Boczkowski D, 2000, CANCER RES, V60, P1028; Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; Chen YJ, 1998, J IMMUNOL, V160, P2425; Coveney E, 1996, SURGERY, V120, P265, DOI 10.1016/S0039-6060(96)80297-2; DeKernion J B, 1974, Urology, V4, P63, DOI 10.1016/0090-4295(74)90110-1; Fu TM, 1997, J VIROL, V71, P2715, DOI 10.1128/JVI.71.4.2715-2721.1997; Garrido F, 1997, IMMUNOL TODAY, V18, P89, DOI 10.1016/S0167-5699(96)10075-X; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Hicklin DJ, 1999, MOL MED TODAY, V5, P178, DOI 10.1016/S1357-4310(99)01451-3; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Hodes RJ, 1999, J EXP MED, V190, P153, DOI 10.1084/jem.190.2.153; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Johnston JV, 1996, J EXP MED, V183, P791, DOI 10.1084/jem.183.3.791; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MYLIN LM, 1995, J VIROL, V69, P6665, DOI 10.1128/JVI.69.11.6665-6677.1995; Nair SK, 1999, INT J CANCER, V82, P121, DOI 10.1002/(SICI)1097-0215(19990702)82:1<121::AID-IJC20>3.0.CO;2-X; Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364; Oukka M, 1996, J IMMUNOL, V157, P3039; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; PORGADOR A, 1989, J IMMUNOGENET, V16, P291; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Ramakrishnan S, 1998, CANCER RES, V58, P622; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SIMPSON E, 1977, IMMUNOL REV, V35, P59, DOI 10.1111/j.1600-065X.1977.tb00235.x; Srivastava P K, 1996, Semin Immunol, V8, P295, DOI 10.1006/smim.1996.0038; VanWaes C, 1996, TISSUE ANTIGENS, V47, P399; VOLGMANN T, 1989, J IMMUNOL METHODS, V119, P45, DOI 10.1016/0022-1759(89)90379-7; Vonderheide RH, 1999, IMMUNITY, V10, P673, DOI 10.1016/S1074-7613(00)80066-7; Weidt G, 1998, J IMMUNOL, V160, P2923; Weng NP, 1998, IMMUNITY, V9, P151, DOI 10.1016/S1074-7613(00)80597-X; Yewdell JTW, 1999, ANNU REV IMMUNOL, V17, P51, DOI 10.1146/annurev.immunol.17.1.51; Yewdell JW, 1999, ADV IMMUNOL, V73, P1, DOI 10.1016/S0065-2776(08)60785-3	42	304	368	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					1011	1017		10.1038/79519	http://dx.doi.org/10.1038/79519			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973321				2022-12-27	WOS:000089190500033
J	Burger, KNJ; Staffhorst, RWHM; de Vijlder, HC; Velinova, MJ; Bomans, PH; Frederik, PM; de Kruijff, B				Burger, KNJ; Staffhorst, RWHM; de Vijlder, HC; Velinova, MJ; Bomans, PH; Frederik, PM; de Kruijff, B			Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity	NATURE MEDICINE			English	Article							PHOSPHOLIPID-VESICLES; LIPOSOMES; PHOSPHATIDYLSERINE; COMPLEXES; CHEMISTRY	Cisplatin is one of the most widely used agents in the treatment of solid tumors, but its clinical utility is limited by toxicity. The development of less toxic, liposomal formulations of cisplatin has been hampered by the low water solubility and low lipophilicity of cisplatin, resulting in very low encapsulation efficiencies. We describe a novel method allowing the efficient encapsulation of cisplatin in a lipid formulation; it is based on repeated freezing and thawing of a concentrated solution of cisplatin in the presence of negatively charged phospholipids. The method is unique in that it generates nanocapsules, which area small aggregates of cisplatin covered by a single lipid bilayer. The nanocapsules have an unprecedented drug-to-lipid ratio and an in vitro cytotoxicity up to 1000-fold higher than the free drug. Analysis of the mechanism of nanocapsule formation suggests that the method may be generalized to other drugs showing low water solubility and lipophilicity.	Univ Utrecht, Dept Biochem Membranes, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, Utrecht, Netherlands; Univ Limburg, Dept Pathol, EM Unit, NL-6200 MD Maastricht, Netherlands	Utrecht University; Hasselt University; Maastricht University	Burger, KNJ (corresponding author), Univ Utrecht, Dept Biochem Membranes, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, Utrecht, Netherlands.							APPLETON TG, 1984, INORG CHEM, V23, P3514, DOI 10.1021/ic00190a016; Bandak S, 1999, ANTI-CANCER DRUG, V10, P911, DOI 10.1097/00001813-199911000-00007; Burger KNJ, 1999, BBA-BIOMEMBRANES, V1419, P43, DOI 10.1016/S0005-2736(99)00052-8; BURNELL EE, 1980, BIOCHIM BIOPHYS ACTA, V603, P63, DOI 10.1016/0005-2736(80)90391-0; CHAPMAN CJ, 1991, CHEM PHYS LIPIDS, V60, P201, DOI 10.1016/0009-3084(91)90042-A; FREDERIK PM, 1989, J MICROSC-OXFORD, V153, P81, DOI 10.1111/j.1365-2818.1989.tb01469.x; HOPE MJ, 1986, CHEM PHYS LIPIDS, V40, P89, DOI 10.1016/0009-3084(86)90065-4; HOWEGRANT ME, 1980, MET IONS BIOL SYST, V11, P63; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; Lippert B., 1999, CISPLATIN CHEM BIOCH; LONG DF, 1981, BIOPHARM DRUG DISPOS, V2, P1, DOI 10.1002/bdd.2510020102; Newman MS, 1999, CANCER CHEMOTH PHARM, V43, P1, DOI 10.1007/s002800050855; PerezSoler R, 1997, CLIN CANCER RES, V3, P373; Reedijk J, 1999, CHEM REV, V99, P2499, DOI 10.1021/cr980422f; RILEY CM, 1985, ANAL PROFILES DRUG S, V14, P78; Sharma A, 1997, INT J PHARM, V154, P123, DOI 10.1016/S0378-5173(97)00135-X; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Speelmans G, 1997, BIOCHEMISTRY-US, V36, P10545, DOI 10.1021/bi9703047; STEERENBERG PA, 1988, CANCER CHEMOTH PHARM, V21, P299, DOI 10.1007/BF00264195; SUR B, 1983, ONCOLOGY, V40, P372, DOI 10.1159/000225765	20	157	169	1	54	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2002	8	1					81	84		10.1038/nm0102-81	http://dx.doi.org/10.1038/nm0102-81			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	507XQ	11786911	Green Published			2022-12-27	WOS:000173056900035
J	Grand-Perret, T; Bouillot, A; Perrot, A; Commans, S; Walker, M; Issandou, M				Grand-Perret, T; Bouillot, A; Perrot, A; Commans, S; Walker, M; Issandou, M			SCAP ligands are potent new lipid-lowering drugs	NATURE MEDICINE			English	Article							STEROL REGULATORY ELEMENT; LOW-DENSITY-LIPOPROTEIN; TRIGLYCERIDE TRANSFER PROTEIN; BINDING PROTEINS; CHOLESTEROL; SREBP; RECEPTOR; CLEAVAGE; PROMOTER; STATINS	Upregulation of low-density lipoprotein receptor (LDLr) is a key mechanism to control elevated plasma LDL-cholesterol levels. Here we identify a new class of compounds that directly binds to the sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP). We show that a C-14-labeled, photo-activatable analog specifically labeled both SCAP and a truncated form of SCAP containing the sterol-sensing domain. When administered to hyperlipidemic hamsters, SCAP ligands reduced both LDL cholesterol and triglycerides levels by up to 80% with a three-fold increase in LDLr mRNA in the livers. Using human hepatoma cells, we show that these compounds act through the sterol-responsive element of the LDLr promoter and activate the SCAP/SREBP pathway, leading to increased LDLr expression and activity, even in presence of excess of sterols. These findings have led to the identification of a class of compounds that represent a promising new class of hypolipidemic drugs.	GlaxoSmithKline, F-91951 Les Ulis, France	GlaxoSmithKline	Grand-Perret, T (corresponding author), GlaxoSmithKline, F-91951 Les Ulis, France.	tgp288760@gsk.com	Eckhardt, Erik/G-1567-2010					Aguilar-Salinas CA, 1998, ATHEROSCLEROSIS, V141, P203, DOI 10.1016/S0021-9150(98)00198-1; Ansell BJ, 1999, JAMA-J AM MED ASSOC, V282, P2051, DOI 10.1001/jama.282.21.2051; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BILHEIMER DW, 1983, P NATL ACAD SCI-BIOL, V80, P4124, DOI 10.1073/pnas.80.13.4124; Blumenthal RS, 2000, AM HEART J, V139, P577, DOI 10.1016/S0002-8703(00)90033-4; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Brown WV, 2001, AM J CARDIOL, V87, p23B; Chen JY, 1999, ELECTROCHEM COMMUN, V1, P274, DOI 10.1016/S1388-2481(99)00056-9; Chong PH, 2000, DRUGS, V60, P55, DOI 10.2165/00003495-200060010-00005; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Duncan EA, 1998, J BIOL CHEM, V273, P17801, DOI 10.1074/jbc.273.28.17801; Edwards PA, 2000, BBA-MOL CELL BIOL L, V1529, P103, DOI 10.1016/S1388-1981(00)00140-2; HAM J, 1991, EMBO J, V10, P2931, DOI 10.1002/j.1460-2075.1991.tb07843.x; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; KOVANEN PT, 1999, ADV VASC BIOL, V5, P165; Liu JW, 2000, J BIOL CHEM, V275, P5214, DOI 10.1074/jbc.275.7.5214; Luong A, 2000, J BIOL CHEM, V275, P26458, DOI 10.1074/jbc.M004160200; MA PTS, 1986, P NATL ACAD SCI USA, V83, P8370, DOI 10.1073/pnas.83.21.8370; Makar RSJ, 2000, J LIPID RES, V41, P762; Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301; Natarajan R, 1998, BIOCHEM BIOPH RES CO, V243, P349, DOI 10.1006/bbrc.1997.8030; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Olsson AG, 2001, AM J CARDIOL, V87, p33B; Sakai J, 2001, CURR OPIN LIPIDOL, V12, P261, DOI 10.1097/00041433-200106000-00004; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimomura I, 1997, P NATL ACAD SCI USA, V94, P12354, DOI 10.1073/pnas.94.23.12354; Thompson GR, 2000, EXPERT OPIN INV DRUG, V9, P2619, DOI 10.1517/13543784.9.11.2619; Vaughan CJ, 2000, J AM COLL CARDIOL, V35, P1, DOI 10.1016/S0735-1097(99)00525-2; Yang T, 2000, J BIOL CHEM, V275, P29881, DOI 10.1074/jbc.M005439200	36	59	73	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2001	7	12					1332	1338		10.1038/nm1201-1332	http://dx.doi.org/10.1038/nm1201-1332			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726974				2022-12-27	WOS:000172610300039
J	Zou, WP; Machelon, V; Coulomb-L'Hermin, A; Borvak, J; Nome, F; Isaeva, T; Wei, S; Krzysiek, R; Durand-Gasselin, I; Gordon, A; Pustilnik, T; Curiel, DT; Galanaud, P; Capron, F; Emilie, D; Curiel, TJ				Zou, WP; Machelon, V; Coulomb-L'Hermin, A; Borvak, J; Nome, F; Isaeva, T; Wei, S; Krzysiek, R; Durand-Gasselin, I; Gordon, A; Pustilnik, T; Curiel, DT; Galanaud, P; Capron, F; Emilie, D; Curiel, TJ			Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells	NATURE MEDICINE			English	Article							T-CELLS; CHEMOKINE RECEPTORS; GENE-EXPRESSION; BREAST; DIFFERENTIATION; VACCINATION; MATURATION; IMMATURE; ACTIVATION; MONOCYTES	Dendritic-cell (DQ trafficking and function in tumors is poorly characterized, with studies confined to myeloid DCs (DC1s). Tumors inhibit DC1 migration and function, likely hindering specific immunity. The role of plasmacytoid DCs (DC2s) in tumor immunity is unknown. We show here that malignant human ovarian epithelial tumor cells express very: high levels of stromal-derived factor-1, which induces DC2 precursor (preDC2) chemotaxis and adhesion/transmigration, upregulates preDC2 very late antigen (VLA)-5, and protects preDC2s from tumor macrophage interleukin-10-induced apoptosis, all through CXC chemokine receptor-4. The VLA-5 ligand vascular-cell adhesion molecule-1 mediated preDC2 adhesion/transmig ration. Tumor preDC2s induced significant T-cell interleukin-10 unrelated to preDC2 differentiation or activation state, and this contributed to poor T-cell activation. Myeloid precursor DCs (preDC1s) were not detected. Tumors may weaken immunity by attracting preDC2s and protecting them from the harsh microenvironment, and by altering preDC1 distribution.	Tulane Univ, Sch Med, Sect Hematol & Med Oncol, New Orleans, LA 70112 USA; Baylor Inst Immunol Res, Dallas, TX USA; Inst Paris Sud Cytokines, INSERM, U355, Clamart, France; Hop Antoine Beclere, Serv Anat Pathol, Clamart, France; Inst Paris Sud Cytokines, INSERM, U131, Clamart, France; Baylor Univ, Med Ctr, Dallas, TX USA; Univ Alabama Birmingham, Wallace Tumor Inst, Birmingham, AL USA	Tulane University; Baylor Scott & White Health; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Baylor University; Baylor University Medical Center; University of Alabama System; University of Alabama Birmingham	Zou, WP (corresponding author), Tulane Univ, Sch Med, Sect Hematol & Med Oncol, 1430 Tulane Ave, New Orleans, LA 70112 USA.	wzou@tulane.edu; tcuriel@tulane.edu						Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Beatty P, 2001, CLIN CANCER RES, V7, p781S; Bell D, 1999, J EXP MED, V190, P1417, DOI 10.1084/jem.190.10.1417; Berard F, 2000, J EXP MED, V192, P1535, DOI 10.1084/jem.192.11.1535; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Cella M, 2000, NAT IMMUNOL, V1, P305, DOI 10.1038/79747; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; Chomarat P, 2000, NAT IMMUNOL, V1, P510, DOI 10.1038/82763; Coulomb-L'Hermine A, 1999, P NATL ACAD SCI USA, V96, P8585, DOI 10.1073/pnas.96.15.8585; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Enk AH, 1997, INT J CANCER, V73, P309, DOI 10.1002/(SICI)1097-0215(19971104)73:3<309::AID-IJC1>3.0.CO;2-3; Foti M, 1999, INT IMMUNOL, V11, P979, DOI 10.1093/intimm/11.6.979; Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166; Gabrilovich DI, 1997, CLIN CANCER RES, V3, P483; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101; Groux H, 1998, J IMMUNOL, V160, P3188; Holtl L, 1998, LANCET, V352, P1358, DOI 10.1016/S0140-6736(05)60748-9; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Ito T, 1999, J IMMUNOL, V163, P1409; Jahnsen FL, 2000, J IMMUNOL, V165, P4062, DOI 10.4049/jimmunol.165.7.4062; Kadowaki N, 2000, J EXP MED, V192, P219, DOI 10.1084/jem.192.2.219; Kellermann SA, 1999, J IMMUNOL, V162, P3859; Kiertscher SM, 2000, J IMMUNOL, V164, P1269, DOI 10.4049/jimmunol.164.3.1269; Kohrgruber N, 1999, J IMMUNOL, V163, P3250; Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; Menetrier-Caux C, 1998, BLOOD, V92, P4778, DOI 10.1182/blood.V92.12.4778; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nanki T, 2000, J IMMUNOL, V164, P5010, DOI 10.4049/jimmunol.164.10.5010; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; Pulendran B, 2000, J IMMUNOL, V165, P566, DOI 10.4049/jimmunol.165.1.566; Rabinowich H, 1996, INT J CANCER, V68, P276, DOI 10.1002/(SICI)1097-0215(19961104)68:3<276::AID-IJC2>3.3.CO;2-0; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; ROERS A, 1994, J INFECT DIS, V169, P807, DOI 10.1093/infdis/169.4.807; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rubbert A, 1998, J IMMUNOL, V160, P3933; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Tillman BW, 1999, J IMMUNOL, V162, P6378; Tilton B, 2000, J EXP MED, V192, P313, DOI 10.1084/jem.192.3.313; ZOU W, IN PRESS EUR J IMMUN; Zou W., 2001, DENDRITIC CELLS BIOL, P77; Zou WP, 2000, J IMMUNOL, V165, P4388, DOI 10.4049/jimmunol.165.8.4388; Zou WP, 1995, EUR CYTOKINE NETW, V6, P257	47	491	530	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2001	7	12					1339	1346		10.1038/nm1201-1339	http://dx.doi.org/10.1038/nm1201-1339			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726975				2022-12-27	WOS:000172610300040
J	Chen, K; Aradi, I; Thon, N; Eghbal-Ahmadi, M; Baram, TZ; Soltesz, I				Chen, K; Aradi, I; Thon, N; Eghbal-Ahmadi, M; Baram, TZ; Soltesz, I			Persistently modified h-channels after complex febrile seizures convert the seizure-induced enhancement of inhibition to hyperexcitability	NATURE MEDICINE			English	Article							TEMPORAL-LOBE EPILEPSY; HYPERPOLARIZATION-ACTIVATED CURRENT; CA1 PYRAMIDAL NEURONS; CURRENT I-H; PACEMAKER CHANNELS; GUINEA-PIG; HIPPOCAMPAL-NEURONS; GABA(A) RECEPTORS; DEVELOPING BRAIN; INCREASED NUMBER	Febrile seizures are the most common type of developmental seizures, affecting up to 5% of children. Experimental complex febrile seizures involving the immature rat hippocampus led to a persistent lowering of seizure threshold despite an upregulation of inhibition. Here we provide a mechanistic resolution to this paradox by showing that, in the hippocampus of rats that had febrile seizures, the long-lasting enhancement of the widely expressed intrinsic: membrane conductance I-h converts the potentiated synaptic inhibition to hyperexcitability in a frequency-dependent manner. The altered gain of this molecular inhibition-excitation converter reveals a new mechanism for controlling the balance of excitation-inhibition in the limbic system. In addition, here we show for the first time that h-channels are modified in a human neurological disease paradigm.	Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Pediat, Irvine, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Soltesz, I (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92717 USA.		Thon, Niklas/AAI-9069-2021; Baram, Tallie Z/J-6447-2014	Thon, Niklas/0000-0003-0011-5281; 	NINDS NIH HHS [R01 NS035439, NS35439, R37 NS035439, NS38580, R01 NS038580] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035439, R01NS038580, R37NS035439] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aradi I, 1999, J COMPUT NEUROSCI, V6, P215, DOI 10.1023/A:1008801821784; Baker K, 1997, P NATL ACAD SCI USA, V94, P4554, DOI 10.1073/pnas.94.9.4554; Baram TZ, 1997, DEV BRAIN RES, V98, P265, DOI 10.1016/S0165-3806(96)00190-3; Beaumont V, 2000, NAT NEUROSCI, V3, P133, DOI 10.1038/72072; BOSMITH RE, 1993, BRIT J PHARMACOL, V110, P343, DOI 10.1111/j.1476-5381.1993.tb13815.x; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; BROWN HF, 1979, NATURE, V280, P235, DOI 10.1038/280235a0; Buhl EH, 1996, SCIENCE, V271, P369, DOI 10.1126/science.271.5247.369; CENDES F, 1993, NEUROLOGY, V43, P1083, DOI 10.1212/WNL.43.6.1083; Chen K, 1999, NAT MED, V5, P888, DOI 10.1038/11330; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; Dube C, 2000, ANN NEUROL, V47, P336, DOI 10.1002/1531-8249(200003)47:3<336::AID-ANA9>3.0.CO;2-W; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Harris NC, 1995, J NEUROPHYSIOL, V74, P2366, DOI 10.1152/jn.1995.74.6.2366; Hines M, 1995, HDB BRAIN THEORY NEU, P226; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412, DOI 10.1152/jn.1996.76.4.2412; Holmes GL, 1998, NEURON, V21, P1231, DOI 10.1016/S0896-6273(00)80642-X; Krause M, 2000, NEUROPHARMACOLOGY, V39, P1274, DOI 10.1016/S0028-3908(99)00227-0; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Luthi A, 1999, NAT NEUROSCI, V2, P634, DOI 10.1038/10189; MACCAFERRI G, 1993, J NEUROPHYSIOL, V69, P2129, DOI 10.1152/jn.1993.69.6.2129; Maccaferri G, 1996, J PHYSIOL-LONDON, V497, P119, DOI 10.1113/jphysiol.1996.sp021754; MAGEE JC, 1995, J PHYSIOL-LONDON, V487, P67, DOI 10.1113/jphysiol.1995.sp020862; Magee JC, 1998, J NEUROSCI, V18, P7613; MAYER ML, 1983, J PHYSIOL-LONDON, V340, P19, DOI 10.1113/jphysiol.1983.sp014747; Moosmang S, 1999, BIOL CHEM, V380, P975, DOI 10.1515/BC.1999.121; NUMANN RE, 1987, J PHYSIOL-LONDON, V393, P331, DOI 10.1113/jphysiol.1987.sp016826; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; PAPE HC, 1989, NATURE, V340, P715, DOI 10.1038/340715a0; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; Shinnar S, 1998, ANN NEUROL, V43, P411, DOI 10.1002/ana.410430402; Siegelbaum SA, 2000, NAT NEUROSCI, V3, P101, DOI 10.1038/72038; SMITH RL, 1995, J NEUROSCI, V15, P4057; SOLTESZ I, 1991, J PHYSIOL-LONDON, V441, P175, DOI 10.1113/jphysiol.1991.sp018745; SOLTESZ I, 1993, J NEUROPHYSIOL, V70, P97, DOI 10.1152/jn.1993.70.1.97; SPRUSTON N, 1992, J NEUROPHYSIOL, V67, P508, DOI 10.1152/jn.1992.67.3.508; STALEY KJ, 1995, SCIENCE, V269, P977, DOI 10.1126/science.7638623; STORM JF, 1988, NATURE, V336, P379, DOI 10.1038/336379a0; VanLandingham KE, 1998, ANN NEUROL, V43, P413, DOI 10.1002/ana.410430403; Villeneuve N, 2000, ANN NEUROL, V47, P729, DOI 10.1002/1531-8249(200006)47:6<729::AID-ANA5>3.3.CO;2-3; Walker MC, 1999, NAT MED, V5, P871, DOI 10.1038/11308	45	366	374	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					331	337		10.1038/85480	http://dx.doi.org/10.1038/85480			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231632	Green Accepted, Green Published			2022-12-27	WOS:000167380400039
J	Wang, N; Chintala, SK; Fini, ME; Schuman, JS				Wang, N; Chintala, SK; Fini, ME; Schuman, JS			Activation of a tissue-specific stress response in the aqueous outflow pathway of the eye defines the glaucoma disease phenotype	NATURE MEDICINE			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; TRABECULAR MESHWORK; ADHESION MOLECULES; MATRIX-METALLOPROTEINASE; ENDOTHELIAL-CELLS; IN-VIVO; EXPRESSION; INTERLEUKIN-1; BIOLOGY	The glaucomas are a group of optic neuropathies comprising the leading cause of irreversible blindness worldwide. Elevated intraocular pressure due to a reduction in normal aqueous outflow is a major causal risk factor. We found that endothelial leukocyte adhesion molecule-1 (ELAM-1), the earliest marker for the atherosclerotic plaque in the vasculature, was consistently present on trabecular meshwork (TM) cells in the outflow pathways of eyes with glaucomas of diverse etiology. We determined expression of ELAM-1 to be controlled by activation of an interleukin-1 (IL-1) autocrine feedback loop through transcription factor NF-kappaB, and activity of this signaling pathway was shown to protect TM cells against oxidative stress. These findings characterize a protective stress response specific to the eye's aqueous outflow pathways and provide the first known diagnostic indicator of glaucomatous TM cells. They further indicate that common mechanisms contribute to the pathophysiology of the glaucomas and vascular diseases.	Tufts Univ, Sch Med, New England Med Ctr, Vis Res Labs, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Schuman, JS (corresponding author), Tufts Univ, Sch Med, New England Med Ctr, Vis Res Labs, Boston, MA 02111 USA.	jss@mediaone.net	Schuman, Joel S/K-7304-2012; Schuman, Joel S/M-2389-2019	Schuman, Joel S/0000-0002-8885-3766; Schuman, Joel S/0000-0002-8885-3766	NEI NIH HHS [EY09828, R01 EY009828-08, R01 EY009828] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009828] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alexander JP, 1998, CURR EYE RES, V17, P276, DOI 10.1076/ceyr.17.3.276.5219; Bacon AS, 1998, INVEST OPHTH VIS SCI, V39, P322; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BAUERLE PA, 1988, SCIENCE, V242, P540; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Cook JR, 1999, INVEST OPHTH VIS SCI, V40, P3122; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DUNN CJ, 1991, CYTOKINES INFLAMMATI, P1; EPSTEIN DL, 1996, CHANDLER GRANTS GLAU, P18; FINI ME, 1995, INVEST OPHTH VIS SCI, V36, P622; Flammer J, 1999, J GLAUCOMA, V8, P212; FOETS B, 1992, GRAEF ARCH CLIN EXP, V230, P269, DOI 10.1007/BF00176303; Gimbrone MA, 1997, J CLIN INVEST, V99, P1809, DOI 10.1172/JCI119346; GRANT WM, 1963, ARCH OPHTHALMOL-CHIC, V69, P783; GREEN K, 1995, OPHTHALMIC RES, V27, P143, DOI 10.1159/000267860; Itoh H, 1999, DIABETES RES CLIN PR, V45, P83, DOI 10.1016/S0168-8227(99)00035-2; KAWA JE, 1993, EXP EYE RES, V14, P560; Kee C, 1997, J GLAUCOMA, V6, P246; Krohn J, 1999, ACTA OPHTHALMOL SCAN, V77, P9, DOI 10.1034/j.1600-0420.1999.770102.x; KUMAR S, 1992, P NATL ACAD SCI USA, V89, P4683, DOI 10.1073/pnas.89.10.4683; LOPPNOW H, 1992, EXP CELL RES, V198, P283, DOI 10.1016/0014-4827(92)90381-H; LUTJENDRECOLL E, 1986, EXP EYE RES, V42, P443, DOI 10.1016/0014-4835(86)90004-7; LYNCH MG, 1987, OPHTHALMOLOGY, V94, P851; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Pappa A, 1997, CLIN EXP IMMUNOL, V108, P309, DOI 10.1046/j.1365-2249.1997.3621258.x; PAULSON JC, 1992, ADHESION ITS ROLE IN, P19; Petruzzelli L, 1999, AM J MED, V106, P467, DOI 10.1016/S0002-9343(99)00058-3; Polansky JR, 1997, OPHTHALMOLOGICA, V211, P126, DOI 10.1159/000310780; Price DT, 1999, AM J MED, V107, P85, DOI 10.1016/S0002-9343(99)00153-9; Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHUMAN JS, 1994, INT CONGR SER, V1068, P47; SCHUMAN JS, 1995, EXP EYE RES, V61, P609, DOI 10.1016/S0014-4835(05)80054-5; TRIPATHI RC, 1971, EXP EYE RES, V11, P116, DOI 10.1016/S0014-4835(71)80073-8; Underwood JL, 1999, AM J PHYSIOL-CELL PH, V277, pC330, DOI 10.1152/ajpcell.1999.277.2.C330; WESTMAYS JA, 1995, P NATL ACAD SCI USA, V92, P6768, DOI 10.1073/pnas.92.15.6768; WHITCUP SM, 1992, INVEST OPHTH VIS SCI, V33, P2626; Yeh LH, 1999, AM J PHYSIOL-CELL PH, V276, pC838, DOI 10.1152/ajpcell.1999.276.4.C838	42	198	207	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					304	309		10.1038/85446	http://dx.doi.org/10.1038/85446			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231628	Green Accepted			2022-12-27	WOS:000167380400035
J	Rothbard, JB; Garlington, S; Lin, Q; Kirschberg, T; Kreider, E; McGrane, PL; Wender, PA; Khavari, PA				Rothbard, JB; Garlington, S; Lin, Q; Kirschberg, T; Kreider, E; McGrane, PL; Wender, PA; Khavari, PA			Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation	NATURE MEDICINE			English	Article							EPIDERMAL PERMEABILITY BARRIER; ALLERGIC CONTACT-DERMATITIS; ATOPIC-DERMATITIS; DRUG-DELIVERY; ALOPECIA-AREATA; DOUBLE-BLIND; PSORIASIS; EFFICACY; SKIN; PROTEINS	Many systemically effective drugs such as cyclosporin A are ineffective topically because of their poor penetration into skin. To surmount this problem, we conjugated a heptamer of arginine to cyclosporin A through a pH-sensitive linker to produce R7-CsA. In contrast to unmodified cyclosporin A,which fails to penetrate skin, topically applied R7-CsA was efficiently transported into cells in mouse and human skin. R7-CsA reached dermal T lymphocytes and inhibited cutaneous inflammation. These data establish a general strategy for enhancing delivery of poorly absorbed drugs across tissue barriers and provide a new topical approach to the treatment of inflammatory skin disorders.	CellGate, Sunnyvale, CA 94086 USA; Vet Adm Palo Alto, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University; Stanford University	Khavari, PA (corresponding author), CellGate, Sunnyvale, CA 94086 USA.	Khavari@cmgm.stanford.edu	Chen, Yao/AAJ-2409-2020					Bach M, 1998, EUR J PHARM BIOPHARM, V46, P1, DOI 10.1016/S0939-6411(97)00149-5; BAUMANN L, 1999, TOPICAL GLUCOCORTICO, P2713; BerthJones J, 1996, BRIT J DERMATOL, V135, P775; BerthJones J, 1997, BRIT J DERMATOL, V136, P76, DOI 10.1046/j.1365-2133.1997.d01-1146.x; BERTI JJ, 1995, MAYO CLIN PROC, V70, P581, DOI 10.4065/70.6.581; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; DEPROST Y, 1986, LANCET, V2, P803; DERIE MA, 1991, ACTA DERM-VENEREOL, V71, P452; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Doering T, 1999, J BIOL CHEM, V274, P11038, DOI 10.1074/jbc.274.16.11038; DUNCAN JI, 1993, ACTA DERM-VENEREOL, V73, P84; Furlanut M, 1996, PHARMACOL RES, V33, P349, DOI 10.1006/phrs.1996.0048; GHADIALLY R, 1995, J CLIN INVEST, V95, P2281, DOI 10.1172/JCI117919; Gilbertson EO, 1998, J AM ACAD DERMATOL, V38, P318, DOI 10.1016/S0190-9622(98)70573-0; GILHAR A, 1989, ACTA DERM-VENEREOL, V69, P252; Hadgraft J, 1998, J Investig Dermatol Symp Proc, V3, P131; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; Ho VC, 1999, BRIT J DERMATOL, V141, P283; Kim DT, 1997, J IMMUNOL, V159, P1666; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; Koo J, 1998, BRIT J DERMATOL, V139, P88; MIYACHI Y, 1982, ARCH DERMATOL, V118, P451, DOI 10.1001/archderm.118.7.451; MROWIETZ U, 1992, ACTA DERM-VENEREOL, V72, P321; Naeyaert JM, 1999, DERMATOLOGY, V198, P145, DOI 10.1159/000018091; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Oikarinen A, 1998, BRIT J DERMATOL, V139, P1106; Powles AV, 1998, BRIT J DERMATOL, V138, P443; Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3; PROKSCH E, 1993, BRIT J DERMATOL, V128, P473, DOI 10.1111/j.1365-2133.1993.tb00222.x; RANADE VV, 1991, J CLIN PHARMACOL, V31, P401, DOI 10.1002/j.1552-4604.1991.tb01895.x; Roberts MS, 1997, CLIN EXP PHARMACOL P, V24, P874, DOI 10.1111/j.1440-1681.1997.tb02708.x; SCHMOOK FP, 1993, SKIN PHARMACOL, V6, P116; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; SIEG P, 1995, BRIT J DERMATOL, V132, P790; Simpson J, 1998, THER DRUG MONIT, V20, P294, DOI 10.1097/00007691-199806000-00009; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; SURBER C, 1992, CONTACT DERMATITIS, V26, P116, DOI 10.1111/j.1600-0536.1992.tb00895.x; WISKOCIL R, 1985, J IMMUNOL, V134, P1599	38	533	623	5	108	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2000	6	11					1253	1257		10.1038/81359	http://dx.doi.org/10.1038/81359			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062537				2022-12-27	WOS:000165114800033
J	Li, B; Nolte, LA; Ju, JS; Han, DH; Coleman, T; Holloszy, JO; Semenkovich, CF				Li, B; Nolte, LA; Ju, JS; Han, DH; Coleman, T; Holloszy, JO; Semenkovich, CF			Skeletal muscle respiratory uncoupling prevents diet-induced obesity and insulin resistance in mice	NATURE MEDICINE			English	Article							HIGH-FAT DIET; LIPOPROTEIN-LIPASE; GLUCOSE-TRANSPORT; GENE-EXPRESSION; PROTEIN-KINASE; MITOCHONDRIAL; HOMEOSTASIS; RESTRICTION; GLYCOGEN; EXERCISE	To determine whether uncoupling respiration from oxidative phosphorylation in skeletal muscle is a suitable treatment for obesity and type 2 diabetes, we generated transgenic mice expressing the mitochondrial uncoupling protein (Ucp) in skeletal muscle. Skeletal muscle oxygen consumption was 98% higher in Ucp-L mice (with low expression) and 246% higher in Ucp-H mice (with high expression) than in wild-type mice. Ucp mice fed a chow diet had the same food intake as wild-type mice, but weighed less and had lower levels of glucose and triglycerides and better glucose tolerance than did control mice. Ucp-L mice were resistant to obesity induced by two different high-fat diets. Ucp-L mice fed a high-fat diet had less adiposity, lower levels of glucose, insulin and cholesterol, and an increased metabolic rate at rest and with exercise. They were also more responsive to insulin, and had enhanced glucose transport in skeletal muscle in the setting of increased muscle triglyceride content. These data suggest that manipulating respiratory uncoupling in muscle is a viable treatment for obesity and its metabolic sequelae.	Washington Univ, Sch Med, Dept Med, Div Atherosclerosis Nutr & Lipid Res, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, Div Atherosclerosis Nutr & Lipid Res, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Div Geriatr & Gerontol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Semenkovich, CF (corresponding author), Washington Univ, Sch Med, Dept Med, Div Atherosclerosis Nutr & Lipid Res, Box 8046,660 S Euclid Ave, St Louis, MO 63110 USA.			Semenkovich, Clay/0000-0003-1163-1871; Ju, Jeong-sun/0000-0001-7276-9941	NHLBI NIH HHS [HL58427] Funding Source: Medline; NIA NIH HHS [AG00425] Funding Source: Medline; NIDDK NIH HHS [DK53198] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG000425, R56AG000425, R37AG000425] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Beckman KB, 1998, ANN NY ACAD SCI, V854, P118, DOI 10.1111/j.1749-6632.1998.tb09897.x; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Chung WK, 1999, DIABETES, V48, P1890, DOI 10.2337/diabetes.48.9.1890; Cline GW, 1999, NEW ENGL J MED, V341, P240, DOI 10.1056/NEJM199907223410404; COLEMAN T, 1995, J BIOL CHEM, V270, P12518, DOI 10.1074/jbc.270.21.12518; DOBUSH GR, CAN J ZOOL, V63; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820; Gerbitz KD, 1996, DIABETES, V45, P113, DOI 10.2337/diabetes.45.2.113; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Han DH, 1997, DIABETES, V46, P1761, DOI 10.2337/diabetes.46.11.1761; Hansen PA, 1998, J BIOL CHEM, V273, P26157, DOI 10.1074/jbc.273.40.26157; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; HOLLOSZY JO, 1976, ANNU REV PHYSIOL, V38, P273, DOI 10.1146/annurev.ph.38.030176.001421; Holmes BF, 1999, J APPL PHYSIOL, V87, P1990, DOI 10.1152/jappl.1999.87.5.1990; Hoppeler H, 2000, ACTA PHYSIOL SCAND, V168, P445, DOI 10.1046/j.1365-201x.2000.00696.x; Huang X, 1999, DIABETES, V48, P1508, DOI 10.2337/diabetes.48.8.1508; Klaus S, 1998, AM J PHYSIOL-REG I, V274, pR287, DOI 10.1152/ajpregu.1998.274.2.R287; KLINGENBERG M, 1985, EMBO J, V4, P3087, DOI 10.1002/j.1460-2075.1985.tb04049.x; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Kopecky J, 1996, AM J PHYSIOL-ENDOC M, V270, pE768, DOI 10.1152/ajpendo.1996.270.5.E768; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Li B, 1999, J BIOL CHEM, V274, P17534, DOI 10.1074/jbc.274.25.17534; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Marshall BA, 1999, J BIOL CHEM, V274, P27426, DOI 10.1074/jbc.274.39.27426; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Perseghin G, 1999, DIABETES, V48, P1600, DOI 10.2337/diabetes.48.8.1600; Portillo MP, 1999, REPROD NUTR DEV, V39, P189, DOI 10.1051/rnd:19990204; Poulton J, 1998, DIABETOLOGIA, V41, P54, DOI 10.1007/s001250050866; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; Rolfe DFS, 1999, AM J PHYSIOL-CELL PH, V276, pC692, DOI 10.1152/ajpcell.1999.276.3.C692; Ross R, 2000, ANN INTERN MED, V133, P92, DOI 10.7326/0003-4819-133-2-200007180-00008; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; SCOTT MD, 1992, J CHROMATOGR-BIOMED, V576, P149, DOI 10.1016/0378-4347(92)80186-T; Seip RL, 1998, EXERCISE SPORT SCI R, V26, P191; TATARANNI PA, 1995, INT J OBESITY, V19, pS102; Taylor BA, 1996, GENOMICS, V34, P389, DOI 10.1006/geno.1996.0302; Towler DA, 1998, J BIOL CHEM, V273, P30427, DOI 10.1074/jbc.273.46.30427; UYEDA K, 1965, J BIOL CHEM, V240, P4682; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199	44	254	275	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1115	1120		10.1038/80450	http://dx.doi.org/10.1038/80450			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017142				2022-12-27	WOS:000089674700035
J	Molldrem, JJ; Lee, PP; Wang, CQ; Felio, K; Kantarjian, HM; Champlin, RE; Davis, MM				Molldrem, JJ; Lee, PP; Wang, CQ; Felio, K; Kantarjian, HM; Champlin, RE; Davis, MM			Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia	NATURE MEDICINE			English	Article							CHRONIC MYELOID-LEUKEMIA; MINOR HISTOCOMPATIBILITY ANTIGEN; BONE-MARROW TRANSPLANTATION; TUMOR-ASSOCIATED ANTIGENS; VERSUS-HOST DISEASE; INTERFERON-ALPHA; CELL THERAPY; REMISSION; PEPTIDE; IDENTIFICATION	Although the immune system has long been implicated in the control of cancer, evidence for specific and efficacious immune responses in human cancer has been lacking. In the case of chronic myelogenous leukemia (CML), either allogeneic bone marrow transplant (BMT) or interferon-alpha 2b (IFN alpha 2b) therapy can result in complete remission, but the mechanism for prolonged disease control is unknown and may involve immune anti-leukemic responses. We previously demonstrated that PR1, a peptide derived from proteinase 3, is a potential target for CML-specific T cells. Here we studied 38 CML patients treated with allogeneic BMT, IFN-alpha 2b or chemotherapy to look for PR1-specific T cells using PR1/HLA-A*0201 tetrameric complexes. There was a strong correlation between the presence of PR1-specific T cells and clinical responses after IFN-alpha and allogeneic BMT. This provides for the first time direct evidence of a role for T-cell immunity in clearing malignant cells.	Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Sect Transplantat Immunol, Houston, TX 77030 USA; Stanford Univ, Dept Med, Stanford, CA 94305 USA; Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA	University of Texas System; UTMD Anderson Cancer Center; Stanford University; University of Texas System; UTMD Anderson Cancer Center; Howard Hughes Medical Institute; Stanford University; Stanford University	Molldrem, JJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Sect Transplantat Immunol, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Lee, Peter P./0000-0002-2660-4377; Davis, Mark/0000-0001-6868-657X	NATIONAL CANCER INSTITUTE [R01CA081247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022511, R01AI022511] Funding Source: NIH RePORTER; NCI NIH HHS [CA81247] Funding Source: Medline; NIAID NIH HHS [AI22511] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; Childs R, 1999, BRIT J HAEMATOL, V107, P396, DOI 10.1046/j.1365-2141.1999.01706.x; Collins RH, 1997, J CLIN ONCOL, V15, P433, DOI 10.1200/JCO.1997.15.2.433; den Haan JMM, 1998, SCIENCE, V279, P1054, DOI 10.1126/science.279.5353.1054; DENGLER R, 1995, BRIT J HAEMATOL, V89, P250, DOI 10.1111/j.1365-2141.1995.tb03297.x; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; Dermime S, 1997, BONE MARROW TRANSPL, V19, P989, DOI 10.1038/sj.bmt.1700778; DOWDING C, 1991, BRIT J HAEMATOL, V77, P165, DOI 10.1111/j.1365-2141.1991.tb07972.x; FABER LM, 1995, J CLIN INVEST, V96, P877, DOI 10.1172/JCI118134; Faderl S, 1999, ANN INTERN MED, V131, P207, DOI 10.7326/0003-4819-131-3-199908030-00008; Falkenburg JHF, 1999, BLOOD, V94, P1201, DOI 10.1182/blood.V94.4.1201.416k08_1201_1208; Gordon MY, 1998, J CLIN INVEST, V102, P710, DOI 10.1172/JCI3094; Goulmy E, 1996, NEW ENGL J MED, V334, P281, DOI 10.1056/NEJM199602013340501; GREINER JW, 1984, CANCER RES, V44, P3208; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; Konstantinidou P, 2000, BONE MARROW TRANSPL, V25, P143, DOI 10.1038/sj.bmt.1702133; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; MARIJT WA, 1995, BLOOD, V82, P3778; McGlave P, 1998, HEMATOL ONCOL CLIN N, V12, P93, DOI 10.1016/S0889-8588(05)70498-6; MCLAUGHLINTAYLOR E, 1994, J MED VIROL, V43, P103, DOI 10.1002/jmv.1890430119; Molldrem J, 1996, BLOOD, V88, P2450, DOI 10.1182/blood.V88.7.2450.bloodjournal8872450; Molldrem JJ, 1999, CANCER RES, V59, P2675; Molldrem JJ, 1997, BLOOD, V90, P2529, DOI 10.1182/blood.V90.7.2529.2529_2529_2534; Natali P G, 1988, Int J Biol Markers, V3, P211; RIDDELL SR, 1995, ANNU REV IMMUNOL, V13, P545; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; VANRHEE F, 1994, BLOOD, V83, P3377	29	541	570	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					1018	1023		10.1038/79526	http://dx.doi.org/10.1038/79526			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973322				2022-12-27	WOS:000089190500034
J	Mota, MM; Hafalla, JCR; Rodriguez, A				Mota, MM; Hafalla, JCR; Rodriguez, A			Migration through host cells activates Plasmodium sporozoites for infection	NATURE MEDICINE			English	Article							TOXOPLASMA-GONDII; GLIDING MOTILITY; INVASION; PROTEINS; ANTIBODIES; SECRETION; BERGHEI; HEPATOCYTES; MEROZOITES; MICROSCOPY	Plasmodium sporozoites, the infective stage of the malaria parasite transmitted by mosquitoes, migrate through several hepatocytes before infecting a final one. Migration through hepatocytes occurs by breaching their plasma membranes, and final infection takes place with the formation of a vacuole around the sporozoite(1). Once in the liver, sporozoites have already reached their target cells, making migration through hepatocytes prior to infection seem unnecessary. Here we show that this migration is required for infection of hepatocytes. Migration through host cells, but not passive contact with hepatocytes, induces the exocytosis of sporozoite apical organelles, a prerequisite for infection with formation of a vacuole. Sporozoite activation induced by migration through host cells is an essential step of Plasmodium life cycle.	NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10012 USA; NYU, Sch Med, Dept Pathol, New York, NY USA	New York University; New York University	Rodriguez, A (corresponding author), NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10012 USA.		Mota, Maria/AAF-2048-2019	Mota, Maria Manuel/0000-0002-2858-1041; Rodriguez, Ana/0000-0002-0060-3405	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049432] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 49432] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANNISTER LH, 1989, J PROTOZOOL, V36, P362, DOI 10.1111/j.1550-7408.1989.tb05527.x; Blanco ARA, 1999, MOL BIOCHEM PARASIT, V98, P163, DOI 10.1016/S0166-6851(98)00162-5; Briones MRS, 1996, MOL BIOCHEM PARASIT, V77, P7, DOI 10.1016/0166-6851(96)02574-1; Bruna-Romero O, 2001, INT J PARASITOL, V31, P1499, DOI 10.1016/S0020-7519(01)00265-X; Bumstead J, 2000, MOL BIOCHEM PARASIT, V110, P311, DOI 10.1016/S0166-6851(00)00280-2; Carruthers VB, 1999, CELL MICROBIOL, V1, P225, DOI 10.1046/j.1462-5822.1999.00023.x; CHOBOTAR B, 1993, PARASITOL RES, V79, P15, DOI 10.1007/BF00931212; Coppens I, 1999, EUR J CELL BIOL, V78, P463, DOI 10.1016/S0171-9335(99)80073-9; DANFORTH HD, 1992, PARASITOL RES, V78, P570, DOI 10.1007/BF00936454; Dobrowolski JM, 1997, MOL MICROBIOL, V26, P163, DOI 10.1046/j.1365-2958.1997.5671913.x; Gantt S, 2000, INFECT IMMUN, V68, P3667, DOI 10.1128/IAI.68.6.3667-3673.2000; Howard RF, 1998, MOL BIOCHEM PARASIT, V92, P111, DOI 10.1016/S0166-6851(97)00238-7; Karsten V, 1998, J CELL BIOL, V141, P1323, DOI 10.1083/jcb.141.6.1323; Matuschewski K, 2001, MOL BIOCHEM PARASIT, V112, P157, DOI 10.1016/S0166-6851(00)00360-1; MCNEIL PL, 1999, CURRENT PROTOCOLS S2, V2; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Mota MM, 2001, MICROBES INFECT, V3, P1123, DOI 10.1016/S1286-4579(01)01473-3; Mota MM, 2000, EXP PARASITOL, V96, P257, DOI 10.1006/expr.2000.4570; Mota MM, 2001, SCIENCE, V291, P141, DOI 10.1126/science.291.5501.141; Speer CA, 1997, J PARASITOL, V83, P565, DOI 10.2307/3284226; STEWART MJ, 1986, INFECT IMMUN, V51, P859, DOI 10.1128/IAI.51.3.859-864.1986; STEWART MJ, 1988, J PROTOZOOL, V35, P389, DOI 10.1111/j.1550-7408.1988.tb04115.x; TSUJI M, 1994, PARASITOL RES, V80, P16, DOI 10.1007/BF00932618; YOSHIDA N, 1980, SCIENCE, V207, P71, DOI 10.1126/science.6985745	24	139	146	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2002	8	11					1318	1322		10.1038/nm785	http://dx.doi.org/10.1038/nm785			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12379848				2022-12-27	WOS:000179221200040
J	Perretti, M; Chiang, N; La, M; Fierro, IM; Marullo, S; Getting, SJ; Solito, E; Serhan, CN				Perretti, M; Chiang, N; La, M; Fierro, IM; Marullo, S; Getting, SJ; Solito, E; Serhan, CN			Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A(4) receptor	NATURE MEDICINE			English	Article							PROTEIN-COUPLED RECEPTOR; NONPHLOGISTIC PHAGOCYTOSIS; HUMAN-LEUKOCYTES; LEUKOTRIENE B-4; ANNEXIN I; NEUTROPHILS; INHIBITION; DEXAMETHASONE; INFLAMMATION; MECHANISMS	Aspirin (ASA) and dexamethasone (DEX) are widely used anti-inflammatory agents yet their mechanism(s) for blocking polymorphonuclear neutrophil (PMN) accumulation at sites of inflammation remains unclear. Here, we report that inhibition of PMN infiltration by ASA and DEX is a property shared by aspirin-triggered lipoxins (ATL) and the glucocorticoid-induced annexin 1 (ANXA1)-derived peptides that are both generated in vivo and act at the lipoxin A(4) receptor (ALXR/FPRL1) to halt PMN diapedesis. These structurally diverse ligands specifically interact directly with recombinant human ALXR demonstrated by specific radioligand binding and function as well as immunoprecipitation of PMN receptors. In addition, the combination of both ATL and ANXA1-derived peptides limited PMN infiltration and reduced production of inflammatory mediators (that is, prostaglandins and chemokines) in vivo. Together, these results indicate functional redundancies in endogenous lipid and peptide anti-inflammatory circuits that are spatially and temporally separate, where both ATL and specific ANXA1-derived peptides act in concert at ALXR to downregulate PMN recruitment to inflammatory loci.	Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Queen Mary Univ London, Barts & London Sch Med, William Harvey Res Inst, Dept Biochem Pharmacol, London, England; Harvard Univ, Sch Med, Boston, MA USA; ICGM, Dept Cell Biol, Paris, France; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Neuroendocrinol, London, England	Harvard University; Brigham & Women's Hospital; University of London; Queen Mary University London; Harvard University; Harvard Medical School; Universite de Montpellier; Imperial College London	Serhan, CN (corresponding author), Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, 75 Francis St, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu	Marullo, Stefano/C-6142-2008; Fierro, Iolanda/AAJ-2705-2021; Chiang, Nan/ABA-4924-2021	Marullo, Stefano/0000-0001-9604-9973; Chiang, Nan/0000-0003-1963-1585; Solito, Egle/0000-0001-5279-0049	Arthritis Research UK [15755] Funding Source: Medline; NIDCR NIH HHS [P01 DE013499, P01-DE13499] Funding Source: Medline; NIGMS NIH HHS [R37 GM038765, R01 GM038765, GM38765] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038765, R29GM038765, R01GM038765] Funding Source: NIH RePORTER	Arthritis Research UK(Versus Arthritis); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ariel A, 1998, J IMMUNOL, V161, P2465; Barnes CJ, 1997, DIGEST DIS SCI, V42, P920, DOI 10.1023/A:1018812430512; BOUMPAS DT, 2001, ARTHRITIS ALLIED CON, P827; Chiang N, 2000, J EXP MED, V191, P1197, DOI 10.1084/jem.191.7.1197; Chiang N, 1998, J PHARMACOL EXP THER, V287, P779; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Cotran R.S., 1999, INFLAMMATION BASIC P, P5; Cotter MJ, 2001, AM J PATHOL, V159, P473, DOI 10.1016/S0002-9440(10)61719-1; CRONSTEIN BN, 1995, ANNU REV PHARMACOL, V35, P449, DOI 10.1146/annurev.pa.35.040195.002313; Derry S, 2000, BMJ-BRIT MED J, V321, P1183, DOI 10.1136/bmj.321.7270.1183; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; FLOWER RJ, 1994, TRENDS PHARMACOL SCI, V15, P71, DOI 10.1016/0165-6147(94)90281-X; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; HENCH PS, 1949, P STAFF M MAYO CLIN, V24, P181; JICK H, 1965, LANCET, V2, P1203; Kang Y, 2000, BIOCHEMISTRY-US, V39, P13551, DOI 10.1021/bi001196i; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; LINKE RP, 1991, BIOCHEM BIOPH RES CO, V176, P1100, DOI 10.1016/0006-291X(91)90397-P; Liu YQ, 1999, J IMMUNOL, V162, P3639; MARCUS AJ, 1995, NEW ENGL J MED, V333, P656, DOI 10.1056/NEJM199509073331011; MARIDONNEAUPARINI I, 1989, J CLIN INVEST, V83, P1936, DOI 10.1172/JCI114101; Oliani SM, 2001, AM J PATHOL, V158, P603, DOI 10.1016/S0002-9440(10)64002-3; Papayianni A, 1996, J IMMUNOL, V156, P2264; PATRONO C, 2001, AM J MED, V110, P625; Perretti M, 2001, AM J PATHOL, V158, P1969, DOI 10.1016/S0002-9440(10)64667-6; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; Perretti M, 1996, BRIT J PHARMACOL, V117, P1145, DOI 10.1111/j.1476-5381.1996.tb16709.x; Samuelsson B, 1982, PRIX NOBEL NOBEL PRI, P153; Serhan CN, 2000, AM J RESP CRIT CARE, V161, pS95, DOI 10.1164/ajrccm.161.supplement_1.ltta-19; SIN YM, 1986, ANN RHEUM DIS, V45, P873, DOI 10.1136/ard.45.10.873; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Tsao FHC, 1998, AM J RESP CELL MOL, V18, P120, DOI 10.1165/ajrcmb.18.1.2808; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Walther A, 2000, MOL CELL, V5, P831, DOI 10.1016/S1097-2765(00)80323-8; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; Yokomizo T, 2001, ARCH BIOCHEM BIOPHYS, V385, P231, DOI 10.1006/abbi.2000.2168; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	38	364	383	5	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2002	8	11					1296	1302		10.1038/nm786	http://dx.doi.org/10.1038/nm786			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12368905	Green Accepted			2022-12-27	WOS:000179221200037
J	Goldstein, JL				Goldstein, JL			Synergy and symbiosis a la Matisse-Picasso - Foreword	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2002	8	10					1053	1054		10.1038/nm768	http://dx.doi.org/10.1038/nm768			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12357230				2022-12-27	WOS:000178311000016
J	Luttun, A; Tjwa, M; Moons, L; Wu, Y; Angelillo-Scherrer, A; Liao, F; Nagy, JA; Hooper, A; Priller, J; De Klerck, B; Compernolle, V; Daci, E; Bohlen, P; Dewerchin, M; Herbert, JM; Fava, R; Matthys, P; Carmeliet, G; Collen, D; Dvorak, HF; Hicklin, DJ; Carmeliet, P				Luttun, A; Tjwa, M; Moons, L; Wu, Y; Angelillo-Scherrer, A; Liao, F; Nagy, JA; Hooper, A; Priller, J; De Klerck, B; Compernolle, V; Daci, E; Bohlen, P; Dewerchin, M; Herbert, JM; Fava, R; Matthys, P; Carmeliet, G; Collen, D; Dvorak, HF; Hicklin, DJ; Carmeliet, P			Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; COLLAGEN-INDUCED ARTHRITIS; TYROSINE KINASE; FACTOR RECEPTOR-1; FLT-1; VEGF; DISEASE; CELLS; ARTERIOGENESIS; MECHANISMS	The therapeutic potential of placental growth factor (PlGF) and its receptor Flt1 in angiogenesis is poorly understood. Here, we report that PlGF stimulated angiogenesis and collateral growth in ischemic heart and limb with at least a comparable efficiency to vascular endothelial growth factor ( VEGF). An antibody against Flt1 suppressed neovascularization in tumors and ischemic retina, and angiogenesis and inflammatory joint destruction in autoimmune arthritis. Anti-Flt1 also reduced atherosclerotic plaque growth and vulnerability, but the atheroprotective effect was not attributable to reduced plaque neovascularization. Inhibition of VEGF receptor Flk1 did not affect arthritis or atherosclerosis, indicating that inhibition of Flk1-driven angiogenesis alone was not sufficient to halt disease progression. The anti-inflammatory effects of anti-Flt1 were attributable to reduced mobilization of bone marrow - derived myeloid progenitors into the peripheral blood; impaired infiltration of Flt1-expressing leukocytes in inflamed tissues; and defective activation of myeloid cells. Thus, PlGF and Flt1 constitute potential candidates for therapeutic modulation of angiogenesis and inflammation.	Univ Louvain VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium; Univ Louvain, Rega Inst Med Res, Immunobiol Lab, Louvain, Belgium; Univ Louvain, Lab Expt Med & Endocrinol, Louvain, Belgium; ImClone Syst Inc, New York, NY USA; Ctr Med Univ Geneva, Div Angiol & Hemostasis, Geneva, Switzerland; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA USA; Humboldt Univ, Charite, Dept Neurol, Berlin, Germany; Sanofi Synthelabo, Cardiovasc Thrombosis Res Dept, Toulouse, France; Dept Vet Affairs Med Ctr, White River Jct, VT USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Hanover, NH 03756 USA	Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven; Eli Lilly; University of Geneva; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Sanofi-Aventis; Sanofi France; Dartmouth College	Carmeliet, P (corresponding author), Univ Louvain VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	Luttun, Aernout/AAZ-6540-2020; Matthys, Patrick/B-4813-2018; Carmeliet, Peter/AAQ-5140-2020; Priller, Josef/ABW-3835-2022	Luttun, Aernout/0000-0001-7902-9524; Matthys, Patrick/0000-0002-9685-6836; Carmeliet, Peter/0000-0001-7961-1821; Angelillo-Scherrer, Anne/0000-0003-2872-4863; Priller, Josef/0000-0001-7596-0979; Moons, Lieve (Godelieve)/0000-0003-0186-1411				Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Bottomley MJ, 2000, CLIN EXP IMMUNOL, V119, P182, DOI 10.1046/j.1365-2249.2000.01097.x; Brenchley PEC, 2000, CLIN EXP IMMUNOL, V121, P426, DOI 10.1046/j.1365-2249.2000.01299.x; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Clauss M, 1998, TRENDS CARDIOVAS MED, V8, P241, DOI 10.1016/S1050-1738(98)00015-2; Couffinhal T, 1998, AM J PATHOL, V152, P1667; COURTENAY JS, 1980, NATURE, V283, P666, DOI 10.1038/283666a0; DVORAK HF, 1979, JNCI-J NATL CANCER I, V62, P1459; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Folkman J, 2001, SEMIN ONCOL, V28, P536, DOI 10.1053/sonc.2001.29543; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hiratsuka S, 2001, CANCER RES, V61, P1207; Hoefer IE, 2001, CARDIOVASC RES, V49, P609, DOI 10.1016/S0008-6363(00)00243-1; Ishida A, 2001, J CELL PHYSIOL, V188, P359, DOI 10.1002/jcp.1121; Isner JM, 2002, NATURE, V415, P234, DOI 10.1038/415234a; Lazarous DF, 2000, J AM COLL CARDIOL, V36, P1239, DOI 10.1016/S0735-1097(00)00882-2; Lee DM, 2001, LANCET, V358, P903, DOI 10.1016/S0140-6736(01)06075-5; Libby P, 2001, AM J CARDIOL, V88, p3J; Lutgens E, 2000, P NATL ACAD SCI USA, V97, P7464, DOI 10.1073/pnas.97.13.7464; Luttun A, 2002, ARTERIOSCL THROM VAS, V22, P499, DOI 10.1161/hq0302.104529; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Matsumoto K, 1996, J APPL PHYSIOL, V81, P1843, DOI 10.1152/jappl.1996.81.4.1843; Matthys P, 1999, J IMMUNOL, V163, P3503; Matthys P, 1998, EUR J IMMUNOL, V28, P2143, DOI 10.1002/(SICI)1521-4141(199807)28:07<2143::AID-IMMU2143>3.0.CO;2-C; McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P474; Miotla J, 2000, LAB INVEST, V80, P1195, DOI 10.1038/labinvest.3780127; Moulton K S, 2001, Curr Atheroscler Rep, V3, P225, DOI 10.1007/s11883-001-0065-0; PARK JE, 1994, J BIOL CHEM, V269, P25646; Persico MG, 1999, CURR TOP MICROBIOL, V237, P31; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; Post MJ, 2001, CARDIOVASC RES, V49, P522, DOI 10.1016/S0008-6363(00)00216-9; Priller J, 2001, NAT MED, V7, P1356, DOI 10.1038/nm1201-1356; Riessen R, 1998, AM HEART J, V135, P357, DOI 10.1016/S0002-8703(98)70105-X; Sawano A, 2001, BLOOD, V97, P785, DOI 10.1182/blood.V97.3.785; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Simons M, 2000, CIRCULATION, V102, pE73, DOI 10.1161/01.CIR.102.11.e73; Sone H, 2001, BIOCHEM BIOPH RES CO, V281, P562, DOI 10.1006/bbrc.2001.4395; van Royen N, 2001, CARDIOVASC RES, V49, P543, DOI 10.1016/S0008-6363(00)00206-6; Veikkola T, 2000, CANCER RES, V60, P203; Weber AJ, 2000, JOINT BONE SPINE, V67, P366; Weng D E, 2001, Curr Oncol Rep, V3, P141, DOI 10.1007/s11912-001-0014-7; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427	49	838	904	1	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2002	8	8					831	840		10.1038/nm731	http://dx.doi.org/10.1038/nm731			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12091877	Green Published			2022-12-27	WOS:000177200900029
J	Xiong, DD; Lee, GH; Badorff, C; Dorner, A; Lee, S; Wolf, P; Knowlton, KU				Xiong, DD; Lee, GH; Badorff, C; Dorner, A; Lee, S; Wolf, P; Knowlton, KU			Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: A genetic predisposition to viral heart disease	NATURE MEDICINE			English	Article							LINKED DILATED CARDIOMYOPATHY; DUCHENNE MUSCULAR-DYSTROPHY; COXSACKIE-B VIRUSES; CLEAVES DYSTROPHIN; EXPRESSION; MUTATION; REGION; MYOCARDITIS; SARCOLEMMA; DISRUPTION	Both enteroviral infection of the heart and mutations in the dystrophin gene can cause cardiomyopathy. Little is known, however, about the interaction between genetic and acquired forms of cardiomyopathy. We previously demonstrated that the enteroviral protease 2A cleaves dystrophin; therefore, we hypothesized that dystrophin deficiency would predispose to enterovirus-induced cardiomyopathy. We observed more severe cardiomyopathy, worsening over time, and greater viral replication in dystrophin-deficient mice infected with enterovirus than in infected wild-type mice. This difference appears to be a result of more efficient release of the virus from dystrophin-deficient myocytes. In addition, we found that expression of wild-type dystrophin in cultured cells decreased the cytopathic effect of enteroviral infection and the release of virus from the cell. We also found that expression of a cleavage- resistant mutant dystrophin further inhibited the virally mediated cytopathic effect and viral release. These results indicate that viral infection can influence the severity and penetrance of the cardiomyopathy that occurs in the hearts of dystrophin-deficient individuals.	Univ Calif San Diego, Inst Mol Med, Dept Med, San Diego, CA 92103 USA; Univ Calif San Diego, Ctr Cardiovasc, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Knowlton, KU (corresponding author), Univ Calif San Diego, Inst Mol Med, Dept Med, San Diego, CA 92103 USA.				NHLBI NIH HHS [5 R01 HL57365-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057365] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baboonian C, 1997, CURR TOP MICROBIOL, V223, P31; Badorff C, 2000, J BIOL CHEM, V275, P11191, DOI 10.1074/jbc.275.15.11191; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; Bergelson JM, 1998, J VIROL, V72, P415, DOI 10.1128/JVI.72.1.415-419.1998; Clark W.H., 1993, CRC HDB MARICULTURE, VI, P133; CLEMENS PR, 1995, HUM GENE THER, V6, P1477, DOI 10.1089/hum.1995.6.11-1477; Cohn RD, 2001, J CLIN INVEST, V107, pR1, DOI 10.1172/JCI11642; DANILOWICZ D, 1980, MUSCLE NERVE, V3, P298, DOI 10.1002/mus.880030405; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Feldman AM, 2000, NEW ENGL J MED, V343, P1388, DOI 10.1056/NEJM200011093431908; GOLDBERG SJ, 1983, J AM COLL CARDIOL, V2, P136, DOI 10.1016/S0735-1097(83)80386-6; HENKE A, 1995, J VIROL, V69, P6720, DOI 10.1128/JVI.69.11.6720-6728.1995; JACKSON P, 1985, J VIROL, V55, P644, DOI 10.1128/JVI.55.3.644-650.1985; Knowlton KU, 1996, J VIROL, V70, P7811, DOI 10.1128/JVI.70.11.7811-7818.1996; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LEE CC, 1991, NATURE, V349, P334, DOI 10.1038/349334a0; Lee GH, 2000, CIRC RES, V87, P489; Luftig Ronald B., 1994, Trends in Microbiology, V2, P178, DOI 10.1016/0966-842X(94)90669-6; MARTINO TA, 1994, CIRC RES, V74, P182, DOI 10.1161/01.RES.74.2.182; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; NIGRO G, 1990, INT J CARDIOL, V26, P271, DOI 10.1016/0167-5273(90)90082-G; OrtizLopez R, 1997, CIRCULATION, V95, P2434, DOI 10.1161/01.CIR.95.10.2434; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Rafael JA, 1996, J CELL BIOL, V134, P93, DOI 10.1083/jcb.134.1.93; Rueckert Roland R., 1996, P477; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; SELPELT J, 2000, J BIOL CHEM, V275, P20084; SHOEMAN RL, 1990, P NATL ACAD SCI USA, V87, P6336, DOI 10.1073/pnas.87.16.6336; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Towbin JA, 1999, NAT MED, V5, P266, DOI 10.1038/6474; TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854; Vatta M, 2002, LANCET, V359, P936, DOI 10.1016/S0140-6736(02)08026-1; ZHANG Y, 1994, J VIROL, V68, P2544, DOI 10.1128/JVI.68.4.2544-2555.1994	33	83	83	0	5	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2002	8	8					872	877		10.1038/nm737	http://dx.doi.org/10.1038/nm737			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12118246				2022-12-27	WOS:000177200900034
J	Maeda, N; Shimomura, I; Kishida, K; Nishizawa, H; Matsuda, M; Nagaretani, H; Furuyama, N; Kondo, H; Takahashi, M; Arita, Y; Komuro, R; Ouchi, N; Kihara, S; Tochino, Y; Okutomi, K; Horie, M; Takeda, S; Aoyama, T; Funahashi, T; Matsuzawa, Y				Maeda, N; Shimomura, I; Kishida, K; Nishizawa, H; Matsuda, M; Nagaretani, H; Furuyama, N; Kondo, H; Takahashi, M; Arita, Y; Komuro, R; Ouchi, N; Kihara, S; Tochino, Y; Okutomi, K; Horie, M; Takeda, S; Aoyama, T; Funahashi, T; Matsuzawa, Y			Diet-induced insulin resistance in mice lacking adiponectin/ACRP30	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; ADIPOSE-SPECIFIC PROTEIN; FACTOR-ALPHA; PLASMA-PROTEIN; GENE-EXPRESSION; OBESITY; RECEPTOR; TISSUE; SENSITIVITY; METABOLISM	Here we investigated the biological functions of adiponectin/ACRP30, a fat-derived hormone, by disrupting the gene that encodes it in mice. Adiponectin/ACRP30-knockout (KO) mice showed delayed clearance of free fatty acid in plasma, low levels of fatty-acid transport protein 1 (FATP-1) mRNA in muscle, high levels of tumor necrosis factor-alpha (TNF-alpha) mRNA in adipose tissue and high plasma TNF-alpha concentrations. The KO mice exhibited severe diet-induced insulin resistance with reduced insulin-receptor substrate 1 (IRS-1)-associated phosphatidylinositol 3 kinase (PI3-kinase) activity in muscle. Viral mediated adiponectin/ACRP30 expression in KO mice reversed the reduction of FATP-1 mRNA, the increase of adipose TNF-alpha mRNA and the diet-induced insulin resistance. In cultured myocytes, TNF-alpha decreased FATP-1 mRNA, IRS-1-associated PI3-kinase activity and glucose uptake, whereas adiponectin increased these parameters. Our results indicate that adiponectin/ACRP30 deficiency and high TNF-alpha levels in KO mice reduced muscle FATP-1 mRNA and IRS-1-mediated insulin signaling, resulting in severe diet-induced insulin resistance.	Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Osaka, Japan; Otsuka Pharmaceut Co Ltd, Otsuga GEN Res Inst, Tokushima 77101, Japan; Shinshu Univ, Sch Med, Dept Aging Biochem, Nagano, Japan	Osaka University; Otsuka Pharmaceutical; Shinshu University	Shimomura, I (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, Dept Organismal Biosyst, Osaka, Japan.		Horie, Minoru/ABG-7128-2020; OUCHI, Noriyuki/I-7306-2014					Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Binnert C, 2000, AM J PHYSIOL-ENDOC M, V279, pE1072, DOI 10.1152/ajpendo.2000.279.5.E1072; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; DELQAUILA LF, 1999, AM J PHYSIOL, V276, pE849; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Halleux CM, 2001, BIOCHEM BIOPH RES CO, V288, P1102, DOI 10.1006/bbrc.2001.5904; Hara K, 2002, DIABETES, V51, P536, DOI 10.2337/diabetes.51.2.536; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; Hotta K, 2001, DIABETES, V50, P1126, DOI 10.2337/diabetes.50.5.1126; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kissebah AH, 2000, P NATL ACAD SCI USA, V97, P14478, DOI 10.1073/pnas.97.26.14478; KONDO H, IN PRESS DIABETES; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Vionnet N, 2000, AM J HUM GENET, V67, P1470, DOI 10.1086/316887; Watanabe K, 2000, J BIOL CHEM, V275, P22293, DOI 10.1074/jbc.M000248200; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Yamauchi T, 2002, NAT GENET, V30, P221, DOI 10.1038/ng829; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	43	1661	1790	3	117	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2002	8	7					731	737		10.1038/nm724	http://dx.doi.org/10.1038/nm724			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12068289				2022-12-27	WOS:000176495200035
J	Egan, ME; Glockner-Pagel, J; Ambrose, CA; Cahill, PA; Pappoe, L; Balamuth, N; Cho, E; Canny, S; Wagner, CA; Geibel, J; Caplan, MJ				Egan, ME; Glockner-Pagel, J; Ambrose, CA; Cahill, PA; Pappoe, L; Balamuth, N; Cho, E; Canny, S; Wagner, CA; Geibel, J; Caplan, MJ			Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells	NATURE MEDICINE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDOPLASMIC-RETICULUM; FLUORESCENT INDICATOR; CHLORIDE SECRETION; HELA-CELLS; CFTR; MUTATION; THAPSIGARGIN; 2,5-DI-(TERT-BUTYL)-1,4-HYDROQUINONE; PERTURBATION	The most common mutation in cystic fibrosis, DeltaF508, results in a cystic fibrosis transmembrane conductance regulator (CFTR) protein that is retained in the endoplasmic reticulum (ER). Retention is dependent upon chaperone proteins, many of which require Ca++ for optimal activity. Interfering with chaperone activity by depleting ER Ca++ stores might allow functional DeltaF508-CFTR to reach the cell surface. We exposed several cystic fibrosis cell lines to the ER Ca++ pump inhibitor thapsigargin and evaluated surface expression of DeltaF508-CFTR. Treatment released ER-retained DeltaF508-CFTR to the plasma membrane, where it functioned effectively as a Cl- channel. Treatment with aerosolized calcium-pump inhibitors reversed the nasal epithelial potential defect observed in a mouse model of DeltaF508-CFTR expression. Thus, ER calcium-pump inhibitors represent a potential target for correcting the cystic fibrosis defect.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA	Yale University; Yale University; Yale University	Caplan, MJ (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA.			Canny, Susan/0000-0002-1762-6718; Caplan, Michael/0000-0001-5768-4405	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD032573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK050203, P01DK017433, R01DK053428, R01DK050203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32573] Funding Source: Medline; NIDDK NIH HHS [R01 DK053428, DK50203, DK53428, DK17433] Funding Source: Medline; NIGMS NIH HHS [GM42136] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIEMESDERFER D, 1992, AM J PHYSIOL, V262, pF55, DOI 10.1152/ajprenal.1992.262.1.F55; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; CHAO AC, 1995, J CLIN INVEST, V96, P1794, DOI 10.1172/JCI118225; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Choudhury P, 1997, J BIOL CHEM, V272, P13446, DOI 10.1074/jbc.272.20.13446; CHRISTENSEN SB, 1993, FEBS LETT, V335, P345, DOI 10.1016/0014-5793(93)80416-R; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; EGAN ME, 1995, AM J PHYSIOL-CELL PH, V268, pC243, DOI 10.1152/ajpcell.1995.268.1.C243; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GRUBB B, 1993, AM J RESP CELL MOL, V8, P454, DOI 10.1165/ajrcmb/8.4.454; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; Haws CM, 1996, AM J PHYSIOL-CELL PH, V270, pC1544, DOI 10.1152/ajpcell.1996.270.5.C1544; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; Hwang TC, 1997, AM J PHYSIOL-CELL PH, V273, pC988, DOI 10.1152/ajpcell.1997.273.3.C988; KUNZELMANN K, 1993, AM J RESP CELL MOL, V8, P522, DOI 10.1165/ajrcmb/8.5.522; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Llewellyn DH, 1996, BIOCHEM J, V318, P555, DOI 10.1042/bj3180555; LODISH HF, 1990, J BIOL CHEM, V265, P10893; Maitra R, 2001, AM J PHYSIOL-CELL PH, V280, pC1031, DOI 10.1152/ajpcell.2001.280.5.C1031; MASON MJ, 1991, J BIOL CHEM, V266, P20856; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Montero M, 1997, J CELL BIOL, V139, P601, DOI 10.1083/jcb.139.3.601; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; PIND S, 1994, J BIOL CHEM, V269, P12784; Rosenfeld MA, 1996, CHEST, V109, P241, DOI 10.1378/chest.109.1.241; Rubenstein RC, 1997, J CLIN INVEST, V100, P2457, DOI 10.1172/JCI119788; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; Schultz BD, 1996, AM J PHYSIOL-LUNG C, V271, pL192, DOI 10.1152/ajplung.1996.271.2.L192; SHACHAR I, 1994, J BIOL CHEM, V269, P27344; Sheppard DN, 1999, PHYSIOL REV, V79, P23; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; VERKMAN AS, 1990, AM J PHYSIOL, V259, pC375, DOI 10.1152/ajpcell.1990.259.3.C375; WARD CL, 1995, CELL, V83, P122; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; ZEIHER BG, 1995, J CLIN INVEST, V96, P2051, DOI 10.1172/JCI118253; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313; Zeitlin PL, 1999, J CLIN INVEST, V103, P447, DOI 10.1172/JCI6346; Zhang ZR, 2000, J MEMBRANE BIOL, V175, P35, DOI 10.1007/s002320001053	45	176	188	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					485	492		10.1038/nm0502-485	http://dx.doi.org/10.1038/nm0502-485			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984593				2022-12-27	WOS:000175336800034
J	Grossman, Z; Meier-Schellersheim, M; Sousa, AE; Victorino, RMM; Paul, WE				Grossman, Z; Meier-Schellersheim, M; Sousa, AE; Victorino, RMM; Paul, WE			CD4(+) T-cell depletion in HIV infection: Are we closer to understanding the cause?	NATURE MEDICINE			English	Editorial Material							ACTIVE ANTIRETROVIRAL THERAPY; RAPID TURNOVER; ACTIVATION; LYMPHOCYTES; DYNAMICS; AIDS; HOMEOSTASIS; DYSFUNCTION; POPULATION; KINETICS	Is CD4(+) cell depletion due to rapid elimination by HIV and failure of the immune system to replace these cells at the required rate? Increasing evidence suggests that this is not the case, and that infection-induced immune activation drives both viral replication and CD4(+) cell depletion.	Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; Fac Med Lisbon, Inst Mol Med, Lisbon, Portugal	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Universidade de Lisboa	Grossman, Z (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.		Grossman, Zvi/A-9643-2008; Sousa, Ana E./L-2642-2014; Victorino, Rui/N-7948-2013	Sousa, Ana E./0000-0002-4618-9799; Victorino, Rui/0000-0001-7567-1704	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000493, ZIAAI000493, Z01AI000926, ZIAAI000926] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson RW, 1998, J ACQ IMMUN DEF SYND, V17, P245, DOI 10.1097/00042560-199803010-00010; ARRON ST, 2002, 9 C RETR OPP INF SEA; Broussard SR, 2001, J VIROL, V75, P2262, DOI 10.1128/JVI.75.5.2262-2275.2001; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; Deeks SG, 2002, J INFECT DIS, V185, P315, DOI 10.1086/338467; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Douek DC, 2001, J IMMUNOL, V167, P6663, DOI 10.4049/jimmunol.167.11.6663; FEINBERG M, 2002, 9 C RETR OPP INF SEA; Grossman Z, 1997, NAT MED, V3, P486, DOI 10.1038/nm0597-486; GROSSMAN Z, 1993, CLIN IMMUNOL IMMUNOP, V69, P123, DOI 10.1006/clin.1993.1160; Grossman Z, 2001, CURR OPIN IMMUNOL, V13, P687, DOI 10.1016/S0952-7915(01)00280-1; Grossman Z, 1998, P NATL ACAD SCI USA, V95, P6314, DOI 10.1073/pnas.95.11.6314; Grossman Z, 2000, NAT MED, V6, P976, DOI 10.1038/79667; Grossman Z, 1999, SCIENCE, V284, p555a, DOI [DOI 10.1126/SCIENCE.284.5414.555A, 10.1126/science.284.5414.555a]; Grossman Zvi, 2001, Journal of Human Virology, V4, P132; Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625; HAYASHI NLD, IN PRESS P NATL ACAD; Hazenberg MD, 2000, BLOOD, V95, P249, DOI 10.1182/blood.V95.1.249.001k40_249_255; Hazenberg MD, 2000, NAT MED, V6, P1036, DOI 10.1038/79549; Hazenberg MD, 2000, NAT IMMUNOL, V1, P285, DOI 10.1038/79724; HELLERSTEIN MK, 2002, 9 C RETR OPP INF SEA; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kalinkovich A, 1998, CLIN EXP IMMUNOL, V114, P414; Kaur A, 1998, J VIROL, V72, P9597, DOI 10.1128/JVI.72.12.9597-9611.1998; Kovacs JA, 2001, J EXP MED, V194, P1731, DOI 10.1084/jem.194.12.1731; Lempicki RA, 2000, P NATL ACAD SCI USA, V97, P13778, DOI 10.1073/pnas.250472097; Lyles RH, 2000, J INFECT DIS, V181, P872, DOI 10.1086/315339; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; Mohri H, 2001, J EXP MED, V194, P1277, DOI 10.1084/jem.194.9.1277; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; Pantaleo G, 1999, NAT MED, V5, P27, DOI 10.1038/4706; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Roederer M, 1997, Semin Immunol, V9, P389, DOI 10.1006/smim.1997.0097; Stuart JWTC, 2000, J ACQ IMMUN DEF SYND, V25, P203, DOI 10.1097/00126334-200011010-00001; Veazey RS, 2000, J VIROL, V74, P57, DOI 10.1128/JVI.74.1.57-64.2000; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	36	360	375	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2002	8	4					319	323		10.1038/nm0402-319	http://dx.doi.org/10.1038/nm0402-319			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927927				2022-12-27	WOS:000174704800016
J	Sata, M; Saiura, A; Kunisato, A; Tojo, A; Okada, S; Tokuhisa, T; Hirai, H; Makuuchi, M; Hirata, Y; Nagai, R				Sata, M; Saiura, A; Kunisato, A; Tojo, A; Okada, S; Tokuhisa, T; Hirai, H; Makuuchi, M; Hirata, Y; Nagai, R			Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis	NATURE MEDICINE			English	Article							TRANSPLANT ATHEROSCLEROSIS; NEOINTIMAL HYPERPLASIA; MOUSE MODEL; MICE; APOPTOSIS; RESTENOSIS; EXPRESSION; DISEASE; INJURY	Excessive accumulation of smooth-muscle cells ( SMCs) has a key role in the pathogenesis of vascular diseases. It has been assumed that SMCs derived from the outer medial layer migrate, proliferate and synthesize extracellular matrix components on the luminal side of the vessel. Although much effort has been devoted to targeting migration and proliferation of medial SMCs, there is no effective therapy that prevents occlusive vascular remodeling. We show here that in models of post-angioplasty restenosis, graft vasculopathy and hyperlipidemia-induced atherosclerosis, bone-marrow cells give rise to most of the SMCs that contribute to arterial remodeling. Notably, purified hematopoietic stem cells differentiate into SMCs in vitro and in vivo. Our findings indicate that somatic stem cells contribute to pathological remodeling of remote organs, and may provide the basis for the development of new therapeutic strategies for vascular diseases through targeting mobilization, homing, differentiation and proliferation of bone marrow-derived vascular progenitor cells.	Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan; Univ Tokyo, Grad Sch Med, Dept Surg, Tokyo, Japan; Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo, Japan; Univ Tokyo, Grad Sch Med, Dept Nephrol & Endocrinol, Tokyo, Japan; Chiba Univ, Grad Sch Med, Dept Dev Genet, Chiba, Japan; Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Kawaguchi, Saitama, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Chiba University; Japan Science & Technology Agency (JST)	Sata, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan.		幕内, 雅敏 m/A-2140-2012					Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; BILLINGHAM ME, 1987, TRANSPLANT P, V19, P19; CORRY RJ, 1973, TRANSPLANTATION, V16, P343, DOI 10.1097/00007890-197310000-00010; Farb A, 1999, CIRCULATION, V99, P44, DOI 10.1161/01.CIR.99.1.44; Feldman LJ, 2001, CIRCULATION, V103, P3117, DOI 10.1161/01.CIR.103.25.3117; Furukawa Y, 1999, CIRC RES, V84, P306, DOI 10.1161/01.RES.84.3.306; Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035; Kearney M, 1997, CIRCULATION, V95, P1998, DOI 10.1161/01.CIR.95.8.1998; Manka D, 2001, CIRCULATION, V103, P1000; McKay R, 2000, NATURE, V406, P361, DOI 10.1038/35019186; Miller AM, 2001, CARDIOVASC RES, V49, P838, DOI 10.1016/S0008-6363(00)00304-7; Miyamoto T, 1997, ATHEROSCLEROSIS, V129, P207, DOI 10.1016/S0021-9150(96)06043-1; *NIH, 1985, NIH PUBL, V8623; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Okada S, 2000, INT IMMUNOL, V12, P861, DOI 10.1093/intimm/12.6.861; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Perlman H, 1998, EMBO J, V17, P3576, DOI 10.1093/emboj/17.13.3576; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Roque M, 2000, ARTERIOSCL THROM VAS, V20, P335, DOI 10.1161/01.ATV.20.2.335; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Ross R, 1996, NAT MED, V2, P527, DOI 10.1038/nm0596-527; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Saiura A, 2001, NAT MED, V7, P382, DOI 10.1038/86394; Sata M, 2000, J MOL CELL CARDIOL, V32, P2097, DOI 10.1006/jmcc.2000.1238; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Schwartz RS, 1998, AM J CARDIOL, V81, p14E, DOI 10.1016/S0002-9149(98)00191-X; Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121; Tojo A, 1999, J AM SOC NEPHROL, V10, P464; Tricot O, 2000, CIRCULATION, V101, P2450, DOI 10.1161/01.CIR.101.21.2450; Walsh K, 1996, Semin Interv Cardiol, V1, P173; Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789; Zohlnhofer D, 2001, MOL CELL, V7, P1059, DOI 10.1016/S1097-2765(01)00239-8; Zohlnhofer D, 2001, CIRCULATION, V103, P1396, DOI 10.1161/01.CIR.103.10.1396	36	956	1041	1	47	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2002	8	4					403	409		10.1038/nm0402-403	http://dx.doi.org/10.1038/nm0402-403			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927948				2022-12-27	WOS:000174704800034
J	Harper, SQ; Hauser, MA; DelloRusso, C; Duan, DS; Crawford, RW; Phelps, SF; Harper, HA; Robinson, AS; Engelhardt, JF; Brooks, SV; Chamberlain, JS				Harper, SQ; Hauser, MA; DelloRusso, C; Duan, DS; Crawford, RW; Phelps, SF; Harper, HA; Robinson, AS; Engelhardt, JF; Brooks, SV; Chamberlain, JS			Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy	NATURE MEDICINE			English	Article							RECOMBINANT ADENOASSOCIATED VIRUS; TRANSGENIC MDX MICE; GLYCOPROTEIN COMPLEX; IMMUNOCOMPETENT MICE; TERMINAL DOMAIN; MUSCLE; VECTOR; EXPRESSION; SEQUENCE; SPECTRIN	Attempts to develop gene therapy for Duchenne muscular dystrophy (DMD) have been complicated by the enormous size of the dystrophin gene. We have performed a detailed functional analysis of dystrophin structural domains and show that multiple regions of the protein can be deleted in various combinations to generate highly functional mini- and micro-dystrophins. Studies in transgenic mdx mice, a model for DMD, reveal that a wide variety of functional characteristics of dystrophy are prevented by some of these truncated dystrophins. Muscles expressing the smallest dystrophins are fully protected against damage caused by muscle activity and are not morphologically different from normal muscle. Moreover, injection of adeno-associated viruses carrying micro-dystrophins into dystrophic muscles of immunocompetent mdx mice results in a striking reversal of histopathological features of this disease. These results demonstrate that the dystrophic pathology can be both prevented and reversed by gene therapy using micro-dystrophins.	Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA; Univ Michigan, Sch Med, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA; Univ Iowa, Sch Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA	University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Duke University; Duke University; University of Iowa	Chamberlain, JS (corresponding author), Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA.			Engelhardt, John/0000-0003-2389-9277; Brooks, Susan/0000-0003-1954-967X; Duan, Dongsheng/0000-0003-4109-1132; Chamberlain, Jeffrey/0000-0001-5299-0059				BYERS TJ, 1989, J CELL BIOL, V109, P1633, DOI 10.1083/jcb.109.4.1633; Corrado K, 1996, J CELL BIOL, V134, P873, DOI 10.1083/jcb.134.4.873; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; Crawford GE, 2000, J CELL BIOL, V150, P1399, DOI 10.1083/jcb.150.6.1399; CROSS RA, 1990, FEBS LETT, V262, P87, DOI 10.1016/0014-5793(90)80160-K; DELLORUSSO C, IN PRESS J MUS RES C; Duan DS, 2000, NAT MED, V6, P595, DOI 10.1038/75080; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; Greelish JP, 1999, NAT MED, V5, P439, DOI 10.1038/7439; Hartigan-O'Connor D, 2000, MICROSC RES TECHNIQ, V48, P223, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<223::AID-JEMT10>3.0.CO;2-L; Hartigan-O'Connor D, 2001, MOL THER, V4, P525, DOI 10.1006/mthe.2001.0496; Hauser MA, 2000, MOL THER, V2, P16, DOI 10.1006/mthe.2000.0089; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KAHANA E, 1994, J MOL BIOL, V235, P1271, DOI 10.1006/jmbi.1994.1080; KAHANA E, 1995, BIOCHEMISTRY-US, V34, P8110, DOI 10.1021/bi00025a017; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lynch GS, 1997, AM J PHYSIOL-CELL PH, V272, pC2063, DOI 10.1152/ajpcell.1997.272.6.C2063; Lynch GS, 2000, AM J PHYSIOL-CELL PH, V279, pC1290, DOI 10.1152/ajpcell.2000.279.4.C1290; Pascual J, 1997, BIOESSAYS, V19, P811, DOI 10.1002/bies.950190911; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PHELPS SF, 1995, HUM MOL GENET, V4, P1251, DOI 10.1093/hmg/4.8.1251; Rafael JA, 1996, J CELL BIOL, V134, P93, DOI 10.1083/jcb.134.1.93; Snyder RO, 1997, HUM GENE THER, V8, P1891, DOI 10.1089/hum.1997.8.16-1891; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Thomas GH, 1997, MOL BIOL EVOL, V14, P1285, DOI 10.1093/oxfordjournals.molbev.a025738; Wang B, 2000, P NATL ACAD SCI USA, V97, P13714, DOI 10.1073/pnas.240335297; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996; Yazaki M, 1999, EUR NEUROL, V42, P145, DOI 10.1159/000008089; Yuasa K, 1998, FEBS LETT, V425, P329, DOI 10.1016/S0014-5793(98)00251-8	37	419	444	0	37	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2002	8	3					253	261		10.1038/nm0302-253	http://dx.doi.org/10.1038/nm0302-253			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875496				2022-12-27	WOS:000174139500030
J	Kreisel, D; Krupnick, AS; Gelman, AE; Engels, FH; Popma, SH; Krasinskas, AM; Balsara, KR; Szeto, WY; Turka, LA; Rosengard, BR				Kreisel, D; Krupnick, AS; Gelman, AE; Engels, FH; Popma, SH; Krasinskas, AM; Balsara, KR; Szeto, WY; Turka, LA; Rosengard, BR			Non-hematopoietic allograft cells directly activate CD8(+) T cells and trigger acute rejection: An alternative mechanism of allorecognition	NATURE MEDICINE			English	Article							ANTIGEN-PRESENTING CELLS; VASCULAR ENDOTHELIAL-CELLS; CARDIAC ALLOGRAFTS; CLASS-I; IMMUNOGENICITY; COSTIMULATION; PREVENTION; RESPONSES; INVIVO; RAT	Despite evidence that human non-hematopoietic cells, such as vascular endothelium, can activate allogeneic T lymphocytes in vitro, the prevailing view has been that hematopoietic antigen-presenting cells are required to trigger alloimmune responses in vivo. Here we report that mouse non-hematopoietic cells activate alloreactive CD8(+) T lymphocytes in vitro and in vivo. We also show that vascularized cardiac allografts are acutely rejected via CD8(+) direct allorecognition even if the alloantigen is not presented by hematopoietic professional antigen-presenting cells. Because activation of alloreactive CD8(+) T cells by donor-type non-hematopoietic cells can continue for the life of the allograft, these findings present a new clinically relevant mechanism of allorecognition and should be taken into consideration when developing strategies to prevent allograft vasculopathy or to induce tolerance.	Univ Penn, Med Ctr, Dept Surg, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Rosengard, BR (corresponding author), Univ Penn, Med Ctr, Dept Surg, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043626, P01AI041521, R01AI047257, R21AI043626, R01AI037691] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-43626, AI-37691, AI-41521, AI47257-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUCHINCLOSS H, 1988, TRANSPLANTATION, V45, P1118, DOI 10.1097/00007890-198806000-00024; Benichou G, 1999, J IMMUNOL, V162, P352; BENNUN A, 1983, J EXP MED, V157, P2147, DOI 10.1084/jem.157.6.2147; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Chin R, 2001, NAT MED, V7, P1165, DOI 10.1038/nm1101-1165a; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; Dengler TJ, 2000, J IMMUNOL, V164, P5146, DOI 10.4049/jimmunol.164.10.5146; ENGERS HD, 1975, J IMMUNOL, V115, P356; EPPERSON DE, 1994, J IMMUNOL, V153, P5402; FERRY B, 1987, TRANSPLANTATION, V44, P499, DOI 10.1097/00007890-198710000-00008; GAO EK, 1991, J EXP MED, V174, P435, DOI 10.1084/jem.174.2.435; HADLEY GA, 1992, TRANSPLANTATION, V54, P537, DOI 10.1097/00007890-199209000-00028; Hornick PI, 1998, CIRCULATION, V97, P1257, DOI 10.1161/01.CIR.97.13.1257; Hornick PI, 2000, CIRCULATION, V101, P2405, DOI 10.1161/01.CIR.101.20.2405; Jones ND, 2001, J IMMUNOL, V166, P2824, DOI 10.4049/jimmunol.166.4.2824; Jones ND, 2000, J IMMUNOL, V165, P1111, DOI 10.4049/jimmunol.165.2.1111; Kaech SM, 2001, NAT IMMUNOL, V2, P415, DOI 10.1038/87720; KOSAKA H, 1992, J EXP MED, V176, P1291, DOI 10.1084/jem.176.5.1291; Krasinskas AM, 2000, TRANSPLANTATION, V70, P514, DOI 10.1097/00007890-200008150-00020; Kreisel D, 2001, J IMMUNOL METHODS, V254, P31, DOI 10.1016/S0022-1759(01)00371-4; LACY PE, 1979, TRANSPLANTATION, V27, P171, DOI 10.1097/00007890-197903000-00006; LAFFERTY KJ, 1975, SCIENCE, V188, P259, DOI 10.1126/science.1118726; Lakkis FG, 2000, NAT MED, V6, P686, DOI 10.1038/76267; LARSEN CP, 1990, J EXP MED, V171, P307, DOI 10.1084/jem.171.1.307; Latouche JB, 2000, NAT BIOTECHNOL, V18, P405, DOI 10.1038/74455; LODGE PA, 1993, TRANSPLANTATION, V56, P656, DOI 10.1097/00007890-199309000-00030; LOMBARDI G, 1990, INT IMMUNOL, V2, P9, DOI 10.1093/intimm/2.1.9; Marelli-Berg FM, 2000, J IMMUNOL, V165, P4182, DOI 10.4049/jimmunol.165.8.4182; MEDAWAR PB, 1957, P ROY SOC LOND B BIO, V149, P145; MILTON AD, 1985, J EXP MED, V161, P98, DOI 10.1084/jem.161.1.98; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Perez VL, 1998, CELL IMMUNOL, V189, P31, DOI 10.1006/cimm.1998.1362; ROSENBERG AS, 1987, J EXP MED, V165, P1296, DOI 10.1084/jem.165.5.1296; ROUABHIA M, 1993, TRANSPLANTATION, V56, P259, DOI 10.1097/00007890-199308000-00001; Sayegh MH, 1997, TRANSPLANTATION, V64, P1646, DOI 10.1097/00007890-199712270-00003; SAYEGH MH, 1991, TRANSPLANTATION, V51, P296, DOI 10.1097/00007890-199102000-00003; Sigal LJ, 1999, NATURE, V398, P77, DOI 10.1038/18038; SINGER A, 1984, J IMMUNOL, V132, P2199; STROBER S, 1965, J EXP MED, V122, P347, DOI 10.1084/jem.122.2.347; Suchin EJ, 2001, J IMMUNOL, V166, P973, DOI 10.4049/jimmunol.166.2.973; Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221; Trambley J, 1999, J CLIN INVEST, V104, P1715, DOI 10.1172/JCI8082; van Stipdonk MJB, 2001, NAT IMMUNOL, V2, P423, DOI 10.1038/87730; Wang B, 2000, J IMMUNOL, V164, P1216, DOI 10.4049/jimmunol.164.3.1216; Whitmire JK, 1999, J IMMUNOL, V163, P3194	45	174	181	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2002	8	3					233	239		10.1038/nm0302-233	http://dx.doi.org/10.1038/nm0302-233			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875493				2022-12-27	WOS:000174139500027
J	Robinson, WH; DiGennaro, C; Hueber, W; Haab, BB; Kamachi, M; Dean, EJ; Fournel, S; Fong, D; Genovese, MC; de Vegvar, HEN; Skriner, K; Hirschberg, DL; Morris, RI; Muller, S; Pruijn, GJ; van Venrooij, WJ; Smolen, JS; Brown, PO; Steinman, L; Utz, PJ				Robinson, WH; DiGennaro, C; Hueber, W; Haab, BB; Kamachi, M; Dean, EJ; Fournel, S; Fong, D; Genovese, MC; de Vegvar, HEN; Skriner, K; Hirschberg, DL; Morris, RI; Muller, S; Pruijn, GJ; van Venrooij, WJ; Smolen, JS; Brown, PO; Steinman, L; Utz, PJ			Autoantigen microarrays for multiplex characterization of autoantibody responses	NATURE MEDICINE			English	Article							AUTOIMMUNE; PROTEINS; CELLS	We constructed miniaturized autoantigen arrays to perform large-scale multiplex characterization of autoantibody responses directed against structurally diverse autoantigens, using submicroliter quantities of clinical samples. Autoantigen microarrays were produced by attaching hundreds of proteins, peptides and other biomolecules to the surface of derivatized glass slides using a robotic arrayer. Arrays were incubated with patient serum, and spectrally resolvable fluorescent labels were used to detect autoantibody binding to specific autoantigens on the array. We describe and characterize arrays containing the major autoantigens in eight distinct human autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. This represents the first report of application of such technology to multiple human disease sera, and will enable validated detection of antibodies recognizing autoantigens including proteins, peptides, enzyme complexes, ribonucleoprotein complexes, DNA and post-translationally modified antigens. Autoantigen microarrays represent a powerful tool to study the specificity and pathogenesis of autoantibody responses, and to identify and define relevant autoantigens in human autoimmune diseases.	Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Tolerion, Palo Alto, CA USA; Van Andel Res Inst, Grand Rapids, MI USA; CNRS, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France; Univ Vienna, Dept Internal Med 3, Div Rheumatol, Vienna, Austria; Rheumatol Diagnost Lab, Los Angeles, CA USA; Katholieke Univ Nijmegen, Dept Biochem, Nijmegen, Netherlands	Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; Van Andel Institute; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Vienna; Radboud University Nijmegen	Robinson, WH (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA.	wrobins@stanford.edu	Pruijn, Ger/D-6664-2012; Muller, Sylviane/J-5319-2014; Fournel, Sylvie/C-1195-2014	Fournel, Sylvie/0000-0003-3583-6548; Robinson, William/0000-0003-4385-704X; Skriner, Karl/0000-0002-5415-270X; Steinman, Lawrence/0000-0002-2437-2250	NIAID NIH HHS [K08 AI01521] Funding Source: Medline; NIAMS NIH HHS [K08 AR02133] Funding Source: Medline; NIDDK NIH HHS [U19 DK61934, U19DK61934] Funding Source: Medline; NINDS NIH HHS [5R01NS18235] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR002133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK061934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018235] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Brocke S, 1996, NATURE, V379, P343, DOI 10.1038/379343a0; CRITCHFIELD JM, 1994, SCIENCE, V263, P1139, DOI 10.1126/science.7509084; EKINS RP, 1989, J PHARMACEUT BIOMED, V7, P155, DOI 10.1016/0731-7085(89)80079-2; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Garren H, 2001, IMMUNITY, V15, P15, DOI 10.1016/S1074-7613(01)00171-6; Haab BB, 2001, GENOME BIOL, V2; Joos TO, 2000, ELECTROPHORESIS, V21, P2641, DOI 10.1002/1522-2683(20000701)21:13<2641::AID-ELPS2641>3.3.CO;2-X; Lu LJ, 1999, J CLIN INVEST, V104, P345, DOI 10.1172/JCI6801; MacBeath G, 2000, SCIENCE, V289, P1760; Monestier M, 2000, J BIOL CHEM, V275, P13558, DOI 10.1074/jbc.275.18.13558; Pruijn GJM, 1997, EUR J CELL BIOL, V74, P123; Robinson WH, 2002, ARTHRITIS RHEUM-US, V46, P885, DOI 10.1002/art.10129; STEINER G, 1992, J CLIN INVEST, V90, P1061, DOI 10.1172/JCI115921; Steinman L, 1996, P NATL ACAD SCI USA, V93, P2253, DOI 10.1073/pnas.93.6.2253; Utz PJ, 2000, ARTHRITIS RES, V2, P101, DOI 10.1186/ar75; Utz PJ, 1997, J EXP MED, V185, P843, DOI 10.1084/jem.185.5.843; VONMUHLEN CA, 1995, SEMIN ARTHRITIS RHEU, V24, P323, DOI 10.1016/S0049-0172(95)80004-2; WARREN KG, 1995, P NATL ACAD SCI USA, V92, P11061, DOI 10.1073/pnas.92.24.11061; Yeaman SJ, 2000, IMMUNOL REV, V174, P238, DOI 10.1034/j.1600-0528.2002.00021h.x	20	562	658	0	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2002	8	3					295	301		10.1038/nm0302-295	http://dx.doi.org/10.1038/nm0302-295			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875502				2022-12-27	WOS:000174139500036
J	Guba, M; von Breitenbuch, P; Steinbauer, M; Koehl, G; Flegel, S; Hornung, M; Bruns, CJ; Zuelke, C; Farkas, S; Anthuber, M; Jauch, KW; Geissler, EK				Guba, M; von Breitenbuch, P; Steinbauer, M; Koehl, G; Flegel, S; Hornung, M; Bruns, CJ; Zuelke, C; Farkas, S; Anthuber, M; Jauch, KW; Geissler, EK			Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor	NATURE MEDICINE			English	Article							IN-VIVO; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; ANGIOGENESIS; TRANSPLANTATION; MECHANISM; CARCINOMA; CANCER; CELLS; VEGF	Conventional immunosuppressive drugs have been used effectively to prevent immunologic rejection in organ transplantation. Individuals taking these drugs are at risk, however, for the development and recurrence of cancer. In the present study we show that the new immunosuppressive drug rapamycin (RAPA) may reduce the risk of cancer development while simultaneously providing effective immunosuppression. Experimentally, RAPA inhibited metastatic tumor growth and angiogenesis in in vivo mouse models. In addition, normal immunosuppressive doses of RAPA effectively controlled the growth of established tumors. In contrast, the most widely recognized immunosuppressive drug, cyclosporine, promoted tumor growth. From a mechanistic perspective, RAPA showed antiangiogenic activities linked to a decrease in production of vascular endothelial growth factor (VEGF) and to a markedly inhibited response of vascular endothelial cells to stimulation by VEGF. Thus, the use of RAPA, instead of cyclosporine, may reduce the chance of recurrent or de novo cancer in high-risk transplant patients.	Univ Regensburg, Dept Surg, D-8400 Regensburg, Germany	University of Regensburg	Guba, M (corresponding author), Univ Regensburg, Dept Surg, D-8400 Regensburg, Germany.	markus.guba@klinik.uni-regensburg.de; edward.geissler@klinik.uni-regensburg.de	Guba, Markus/M-4309-2019; Geissler, Edward/R-4131-2016; Farkas, Stefan/AAG-5843-2020	Hornung, Matthias/0000-0001-9759-8958				ASAISHI K, 1981, CANCER RES, V41, P1898; Benelli U, 1997, INVEST OPHTH VIS SCI, V38, P274; BRATTAIN MG, 1980, CANCER RES, V40, P2142; Browder T, 2000, CANCER RES, V60, P1878; Bruns CJ, 2000, CANCER, V89, P488, DOI 10.1002/1097-0142(20000801)89:3<488::AID-CNCR3>3.3.CO;2-O; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Drixler TA, 2000, CANCER RES, V60, P1761; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ENG CP, 1984, J ANTIBIOT, V37, P1231, DOI 10.7164/antibiotics.37.1231; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; Folkman J, 2001, THROMB HAEMOSTASIS, V86, P23; Fukumura D, 1997, AM J PATHOL, V151, P679; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Garver RI, 1999, NEW ENGL J MED, V340, P1071, DOI 10.1056/NEJM199904083401403; Gohongi T, 1999, NAT MED, V5, P1203, DOI 10.1038/13524; Guba M, 2000, SHOCK, V13, P190, DOI 10.1097/00024382-200003000-00004; Guba M, 2001, CANCER RES, V61, P5575; Hajitou A, 2001, CANCER RES, V61, P3450; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Ilan N, 1998, J CELL SCI, V111, P3621; Iurlaro M, 1998, EXP HEMATOL, V26, P1215; Kahan BD, 2000, LANCET, V356, P194, DOI 10.1016/S0140-6736(00)02480-6; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Meyer CG, 2000, TRANSPLANTATION, V69, P1633; Ondrus D., 1999, International Urology and Nephrology, V31, P417, DOI 10.1023/A:1007194607496; Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426; Penn I, 1998, Clin Transpl, P147; Salomon-Nguyen F, 2000, P NATL ACAD SCI USA, V97, P6757, DOI 10.1073/pnas.120162297; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Saunders RN, 2001, KIDNEY INT, V59, P3, DOI 10.1046/j.1523-1755.2001.00460.x; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Sehgal SN, 1998, CLIN BIOCHEM, V31, P335, DOI 10.1016/S0009-9120(98)00045-9; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; Wiederrecht G J, 1995, Prog Cell Cycle Res, V1, P53; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J; Zheng W, 2001, AM J PHYSIOL-HEART C, V280, pH909, DOI 10.1152/ajpheart.2001.280.2.H909; Zhong H, 2000, CANCER RES, V60, P1541	41	1395	1508	2	117	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2002	8	2					128	135		10.1038/nm0202-128	http://dx.doi.org/10.1038/nm0202-128			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821896				2022-12-27	WOS:000173600600021
J	Chung, KKK; Zhang, Y; Lim, KL; Tanaka, Y; Huang, H; Gao, J; Ross, CA; Dawson, VL; Dawson, TM				Chung, KKK; Zhang, Y; Lim, KL; Tanaka, Y; Huang, H; Gao, J; Ross, CA; Dawson, VL; Dawson, TM			Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease	NATURE MEDICINE			English	Article							RECESSIVE JUVENILE PARKINSONISM; OXIDATIVE STRESS; NEURODEGENERATIVE DISORDERS; NACP/ALPHA-SYNUCLEIN; 2 PARTS; BODIES; DEMENTIA; MUTATION; LIGASE; AGGREGATION	Parkinson disease is a common neurodegenerative disorder characterized by the loss of dopaminergic neurons and the presence of intracytoplasmic-ubiquitinated inclusions (Lewy bodies). Mutations in alpha -synuclein (A53T, A30P) and parkin cause familial Parkinson disease, Both these proteins are found in Lewy bodies. The absence of Lewy bodies in patients with parkin mutations suggests that parkin might be required for the formation of Lewy bodies. Here we show that parkin interacts with and ubiquitinates the alpha -synuclein-interacting protein, synphilin-1. Coexpression of alpha -synuclein, synphilin-1 and parkin result in the formation of Lewy-body-like ubiquitin-positive cytosolic inclusions. We further show that familial-linked mutations in parkin disrupt the ubiquitination of synphilin-1 and the formation of the ubiquitin-positive inclusions. These results provide a molecular basis for the ubiquitination of Lewy-body-associated proteins and link parkin and alpha -synuclein in a common pathogenic mechanism through their interaction with synphilin-1.	Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Dawson, TM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.	tdawson@jhmi.edu	Lim, Kah-Leong/AAY-3308-2020; Lim, Kah/L-5426-2019; Dawson, Valina/Y-9757-2019; Ross, Christopher A/H-8395-2013	Lim, Kah-Leong/0000-0002-5440-2588; Dawson, Valina/0000-0002-2915-3970	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038377] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38377] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Ancolio K, 2000, NEUROSCI LETT, V285, P79, DOI 10.1016/S0304-3940(00)01049-1; Bayer TA, 1999, NEUROSCI LETT, V266, P213, DOI 10.1016/S0304-3940(99)00311-0; CHUNG KKK, IN PRESS TRENDS NEUR; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Dawson TM, 2000, CELL, V101, P115, DOI 10.1016/S0092-8674(00)80629-7; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Galvin J E, 1999, Adv Neurol, V80, P313; Gomez-Tortosa E, 2000, ACTA NEUROPATHOL, V99, P352, DOI 10.1007/s004010051135; Hashimoto M, 1999, J BIOL CHEM, V274, P28849, DOI 10.1074/jbc.274.41.28849; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Ishikawa A, 1998, J NEUROL, V245, pP4, DOI 10.1007/PL00007745; Kanda S, 2000, NEUROSCIENCE, V97, P279, DOI 10.1016/S0306-4522(00)00077-4; Kawamata H, 2001, J NEUROCHEM, V77, P929, DOI 10.1046/j.1471-4159.2001.00301.x; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Mori H, 1998, NEUROLOGY, V51, P890, DOI 10.1212/WNL.51.3.890; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Sambrock J, 1989, MOL CLONING LAB MANU, V1; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; TAKAHASHI H, 1994, NEUROLOGY, V44, P437, DOI 10.1212/WNL.44.3_Part_1.437; Takeda A, 1998, AM J PATHOL, V152, P367; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhang Y, 2000, NEUROBIOL DIS, V7, P240, DOI 10.1006/nbdi.2000.0319	45	588	611	2	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2001	7	10					1144	1150		10.1038/nm1001-1144	http://dx.doi.org/10.1038/nm1001-1144			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590439				2022-12-27	WOS:000171524500037
J	Braciale, TJ				Braciale, TJ			Life after death: Controlling autoreactive CD8(+) T-cell responses	NATURE MEDICINE			English	Editorial Material							DENDRITIC CELLS; CLASS-I; LYMPHOCYTES; ANTIGEN	The uptake of apoptotic CD40L(+) cells by immature dendritic cells leads to dendritic-cell activation. This mechanism might account for the generation of autoreactive CD8(+) T cells in HIV infection and indicates a general mechanism for the regulation of autoimmune T-cell responses during infection.	Univ Virginia, Hlth Sci Ctr, Carter Immunol Ctr, Charlottesville, VA 22903 USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA USA; Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA USA	University of Virginia; University of Virginia; University of Virginia	Braciale, TJ (corresponding author), Univ Virginia, Hlth Sci Ctr, Carter Immunol Ctr, Charlottesville, VA 22903 USA.							Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; Kaech SM, 2001, NAT IMMUNOL, V2, P415, DOI 10.1038/87720; Propato A, 2001, NAT MED, V7, P807, DOI 10.1038/89930; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; Veronese FD, 1996, J EXP MED, V183, P2509, DOI 10.1084/jem.183.6.2509; Watts C, 1999, Rev Immunogenet, V1, P60	10	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					774	775		10.1038/89886	http://dx.doi.org/10.1038/89886			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433336				2022-12-27	WOS:000169808600019
J	Hughes, RE; Olson, JM				Hughes, RE; Olson, JM			Therapeutic opportunities in polyglutamine disease	NATURE MEDICINE			English	Review							TRANSGENIC MOUSE MODEL; CREB-BINDING PROTEIN; HUNTINGTONS-DISEASE; HEAT-SHOCK; NUCLEAR-LOCALIZATION; AGGREGATE FORMATION; CASPASE CLEAVAGE; SUPPRESSION; GENES; NEURODEGENERATION	Polyglutamine diseases comprise a class of familial neurodegenerative disorders caused by expression of proteins containing expanded polyglutamine tracts. Great progress has been made in elucidating the molecular mechanisms contributing to polyglutamine pathology, and in identifying potential drug targets. Although much remains to be learned, these advances provide an opportunity for rational approaches to target-based drug discovery.	Univ Washington, Dept Genet, Dept Med, Div Med Genet, Seattle, WA 98195 USA; Childrens Hosp & Med Ctr, Pediat Oncol Div, Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98105 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Seattle Children's Hospital	Hughes, RE (corresponding author), Univ Washington, Dept Genet, Dept Med, Div Med Genet, Seattle, WA 98195 USA.	rehughes@u.washington.edu; jimmyo@u.washington.edu						Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; Boutell JM, 1999, HUM MOL GENET, V8, P1647, DOI 10.1093/hmg/8.9.1647; Brouillet E, 1999, PROG NEUROBIOL, V59, P427, DOI 10.1016/S0301-0082(99)00005-2; Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; Chai YH, 1999, J NEUROSCI, V19, P10338; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; COYLE JT, 1976, NATURE, V263, P244, DOI 10.1038/263244a0; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; DRAGUNOW M, 1995, NEUROREPORT, V6, P1053, DOI 10.1097/00001756-199505090-00026; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Ferrante RJ, 2000, J NEUROSCI, V20, P4389, DOI 10.1523/JNEUROSCI.20-12-04389.2000; Freeman TB, 2000, P NATL ACAD SCI USA, V97, P13877, DOI 10.1073/pnas.97.25.13877; GREENSPAN AS, 1993, DEPAUL BUS LJ, V6, P1; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Kieburtz K, 1999, J NEURAL TRANSM-SUPP, P97; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; Kremer B, 1999, NEUROLOGY, V53, P1000, DOI 10.1212/WNL.53.5.1000; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Lin X, 2000, NAT NEUROSCI, V3, P157, DOI 10.1038/72101; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; Marsh JL, 2000, HUM MOL GENET, V9, P13, DOI 10.1093/hmg/9.1.13; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; MCGEER EG, 1976, NATURE, V263, P517, DOI 10.1038/263517a0; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Murman DL, 1997, NEUROLOGY, V49, P153, DOI 10.1212/WNL.49.1.153; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Paulson HL, 1999, AM J HUM GENET, V64, P339, DOI 10.1086/302269; Perez MK, 1998, J CELL BIOL, V143, P1457, DOI 10.1083/jcb.143.6.1457; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Satyal SH, 2000, P NATL ACAD SCI USA, V97, P5750, DOI 10.1073/pnas.100107297; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; SHOULSON I, 1989, ANN NEUROL, V25, P252, DOI 10.1002/ana.410250308; Singhrao SK, 1999, EXP NEUROL, V159, P362, DOI 10.1006/exnr.1999.7170; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Vigh L, 1997, NAT MED, V3, P1150, DOI 10.1038/nm1097-1150; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Wellington CL, 2000, CLIN GENET, V57, P1, DOI 10.1034/j.1399-0004.2000.570101.x; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898; Young ET, 2000, GENETICS, V154, P1053; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	56	55	57	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2001	7	4					419	423		10.1038/86486	http://dx.doi.org/10.1038/86486			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283667				2022-12-27	WOS:000167960500035
J	Wolfers, J; Lozier, A; Raposo, G; Regnault, A; Thery, C; Masurier, C; Flament, C; Pouzieux, S; Faure, F; Tursz, T; Angevin, E; Amigorena, S; Zitvogel, L				Wolfers, J; Lozier, A; Raposo, G; Regnault, A; Thery, C; Masurier, C; Flament, C; Pouzieux, S; Faure, F; Tursz, T; Angevin, E; Amigorena, S; Zitvogel, L			Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming	NATURE MEDICINE			English	Article							DENDRITIC CELLS ACQUIRE; CYTOLYTIC T-LYMPHOCYTES; CLASS-II MOLECULES; APOPTOTIC CELLS; IN-VITRO; B7 COSTIMULATION; MURINE TUMORS; MATURATION; COMPLEX; IMMUNOTHERAPY	The initiation of T-cell-mediated antitumor immune responses requires the uptake and processing of tumor antigens by dendritic cells and their presentation on MHC-I molecules. Here we show in a human in vitro model system that exosomes, a population of small membrane vesicles secreted by living tumor cells, contain and transfer tumor antigens to dendritic cells. After mouse tumor exosome uptake, dendritic cells induce potent CD8(+) T-cell-dependent antitumor effects on syngeneic and allogeneic established mouse tumors. Therefore, exosomes represent a novel source of tumor-rejection antigens for T-cell cross priming, relevant for immunointerventions.	Inst Curie, INSERM, U520, Paris, France; Inst Curie, CNRS, UMR 144, Paris, France; Inst Gustave Roussy, APCells SA, F-94805 Villejuif, France; Inst Gustave Roussy, Dept Biol Clin, Immunol Unit, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Amigorena, S (corresponding author), Inst Curie, INSERM, U520, Paris, France.		thery, clotilde/F-6373-2013; REGNAULT, Armelle/G-4142-2011; faure, florence/P-9064-2016	thery, clotilde/0000-0001-8294-6884; REGNAULT, Armelle/0000-0001-7286-9491; faure, florence/0000-0002-8359-4283; Amigorena, Sebastian/0000-0001-8583-8416; ZITVOGEL, laurence/0000-0003-1596-0998; ANGEVIN, Eric/0000-0001-6249-7209				Ahmed M, 1998, ONCOGENE, V16, P489, DOI 10.1038/sj.onc.1201556; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Angevin E, 1999, LAB INVEST, V79, P879; Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; Brandle D, 1998, EUR J IMMUNOL, V28, P4010, DOI 10.1002/(SICI)1521-4141(199812)28:12<4010::AID-IMMU4010>3.0.CO;2-5; Caignard A, 1996, INT J CANCER, V66, P564, DOI 10.1002/(SICI)1097-0215(19960516)66:4<564::AID-IJC23>3.0.CO;2-6; CHEN LP, 1994, J EXP MED, V179, P523, DOI 10.1084/jem.179.2.523; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; COGGIN JHJ, 1989, MOL BIOTHER, V4, P223; Dufour E, 1997, J IMMUNOL, V158, P3787; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; Fernandez NC, 1999, NAT MED, V5, P405, DOI 10.1038/7403; Fields RC, 1998, P NATL ACAD SCI USA, V95, P9482, DOI 10.1073/pnas.95.16.9482; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Gromme M, 1999, P NATL ACAD SCI USA, V96, P10326, DOI 10.1073/pnas.96.18.10326; Imro MA, 1999, CANCER RES, V59, P2287; Johnston JV, 1996, J EXP MED, V183, P791, DOI 10.1084/jem.183.3.791; JOHNSTONE RM, 1991, J CELL PHYSIOL, V147, P27, DOI 10.1002/jcp.1041470105; KLEIN G, 1960, CANCER RES, V20, P1561; Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364; OLD LJ, 1981, CANCER RES, V41, P361; OLD LJ, 1962, ANN NY ACAD SCI, V101, P80, DOI 10.1111/j.1749-6632.1962.tb26446.x; PAN BT, 1983, CELL, V33, P967, DOI 10.1016/0092-8674(83)90040-5; RAMARATHINAM L, 1995, J IMMUNOL, V155, P5323; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Raposo G, 1997, MOL BIOL CELL, V8, P2631, DOI 10.1091/mbc.8.12.2631; Rieu S, 2000, EUR J BIOCHEM, V267, P583, DOI 10.1046/j.1432-1327.2000.01036.x; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; Russo V, 2000, P NATL ACAD SCI USA, V97, P2185, DOI 10.1073/pnas.040540197; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; Stauss HJ, 1999, IMMUNOL TODAY, V20, P180, DOI 10.1016/S0167-5699(99)01443-7; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; Wubbolts R, 1996, J CELL BIOL, V135, P611, DOI 10.1083/jcb.135.3.611; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87; Zorn E, 1999, EUR J IMMUNOL, V29, P592, DOI 10.1002/(SICI)1521-4141(199902)29:02<592::AID-IMMU592>3.0.CO;2-2	41	1124	1218	5	150	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					297	303		10.1038/85438	http://dx.doi.org/10.1038/85438			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231627				2022-12-27	WOS:000167380400034
J	Owens, T; Wekerle, H; Antel, S				Owens, T; Wekerle, H; Antel, S			Genetic models for CNS inflammation	NATURE MEDICINE			English	Review							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; TNF-ALPHA EXPRESSION; COMPLEX CLASS-I; INTERFERON-GAMMA; MULTIPLE-SCLEROSIS; TRANSGENIC MICE; PRIMARY DEMYELINATION		McGill Univ, Montreal Neurol Inst, Neuroimmunol Unit, Montreal, PQ, Canada; Max Planck Inst Neurobiol, Planegg Martinsreid, Germany	McGill University; Max Planck Society	Owens, T (corresponding author), McGill Univ, Montreal Neurol Inst, Neuroimmunol Unit, Montreal, PQ, Canada.	trevor@med.mcgill.ca		antel, jack/0000-0002-5148-0636; Owens, Trevor/0000-0001-9315-6036				Akassoglou K, 1998, AM J PATHOL, V153, P801, DOI 10.1016/S0002-9440(10)65622-2; [Anonymous], 1999, Neurology, V53, P457; Arnason BGW, 1999, ANNU REV MED, V50, P291; Asensio VC, 1999, AM J PATHOL, V154, P1181, DOI 10.1016/S0002-9440(10)65370-9; Baerwald KD, 2000, J NEUROSCI RES, V59, P160, DOI 10.1002/(SICI)1097-4547(20000115)59:2<160::AID-JNR2>3.3.CO;2-B; Bettelli E, 1998, J IMMUNOL, V161, P3299; BEVER CT, 1991, NEUROLOGY, V41, P1124, DOI 10.1212/WNL.41.7.1124; BILLIAU A, 1988, J IMMUNOL, V140, P1506; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Calabresi PA, 1998, J NEUROIMMUNOL, V89, P198, DOI 10.1016/S0165-5728(98)00139-8; Campbell IL, 1998, NEUROIMMUNOMODULAT, V5, P126, DOI 10.1159/000026329; CASH E, 1994, J IMMUNOL, V153, P4258; Chu CQ, 2000, J EXP MED, V192, P123, DOI 10.1084/jem.192.1.123; Corbin JG, 1996, MOL CELL NEUROSCI, V7, P354, DOI 10.1006/mcne.1996.0026; Cua DJ, 1999, J EXP MED, V189, P1005, DOI 10.1084/jem.189.6.1005; DUONG TT, 1992, J NEUROIMMUNOL, V36, P105, DOI 10.1016/0165-5728(92)90042-J; Eugster HP, 1999, EUR J IMMUNOL, V29, P626, DOI 10.1002/(SICI)1521-4141(199902)29:02<626::AID-IMMU626>3.3.CO;2-1; Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D; Eynon EE, 1999, IMMUNOL REV, V169, P5, DOI 10.1111/j.1600-065X.1999.tb01301.x; Falcone M, 1998, J IMMUNOL, V160, P4822; Fife BT, 2000, J EXP MED, V192, P899, DOI 10.1084/jem.192.6.899; FUENTES ME, 1995, J IMMUNOL, V155, P5769; Furlan R, 1999, J IMMUNOL, V163, P2403; Genain CP, 2000, NAT MED, V6, P1098, DOI 10.1038/80424; Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054; Green EA, 2000, IMMUNITY, V12, P459, DOI 10.1016/S1074-7613(00)80198-3; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Hjelmstrom P, 1998, RES IMMUNOL, V149, P794, DOI 10.1016/S0923-2494(99)80007-8; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; HOFMAN FM, 1991, CLIN IMMUNOL IMMUNOP, V58, P331, DOI 10.1016/0090-1229(91)90124-S; Horwitz MS, 1999, LAB INVEST, V79, P235; Horwitz MS, 1997, NAT MED, V3, P1037, DOI 10.1038/nm0997-1037; ISSAZADEH S, 1995, J NEUROIMMUNOL, V61, P205, DOI 10.1016/0165-5728(95)00100-G; Jander S, 1998, J NEUROIMMUNOL, V91, P93, DOI 10.1016/S0165-5728(98)00162-3; Jensen MB, 2000, J NEUROSCI, V20, P3612, DOI 10.1523/JNEUROSCI.20-10-03612.2000; JOHNS LD, 1993, J NEUROIMMUNOL, V47, P1, DOI 10.1016/0165-5728(93)90278-7; KARPUS WJ, 1995, J IMMUNOL, V155, P5003; Krakowski M, 1996, EUR J IMMUNOL, V26, P1641, DOI 10.1002/eji.1830260735; LEONARD JP, 1995, J EXP MED, V181, P381, DOI 10.1084/jem.181.1.381; LING ZD, 1993, J CLIN IMMUNOL, V13, P302, DOI 10.1007/BF00920238; Litzenburger T, 1998, J EXP MED, V188, P169, DOI 10.1084/jem.188.1.169; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; MARTIN D, 1995, J NEUROIMMUNOL, V61, P241, DOI 10.1016/0165-5728(95)00108-E; OKUDA Y, 1995, J NEUROIMMUNOL, V62, P103, DOI 10.1016/0165-5728(95)00114-H; OWENS T, 1995, NEUROL CLIN, V13, P51, DOI 10.1016/S0733-8619(18)30061-6; OWENS T, 1994, IMMUNOL TODAY, V15, P566, DOI 10.1016/0167-5699(94)90218-6; PANITCH HS, 1987, NEUROLOGY, V37, P1097, DOI 10.1212/WNL.37.7.1097; Popko B, 1997, MOL NEUROBIOL, V14, P19, DOI 10.1007/BF02740619; Pouly S, 2000, J NEUROPATH EXP NEUR, V59, P280, DOI 10.1093/jnen/59.4.280; Power C, 1996, J NEUROSCI RES, V44, P165, DOI 10.1002/(SICI)1097-4547(19960415)44:2<165::AID-JNR9>3.0.CO;2-B; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; RACKE MK, 1991, J IMMUNOL, V146, P3012; Ransohoff RM, 1999, J NEUROIMMUNOL, V98, P57, DOI 10.1016/S0165-5728(99)00082-X; Renno T, 1998, MOL CELL NEUROSCI, V12, P376, DOI 10.1006/mcne.1998.0725; RENNO T, 1995, J IMMUNOL, V154, P944; Samoilova EB, 1998, CELL IMMUNOL, V188, P118, DOI 10.1006/cimm.1998.1365; Sedgwick JD, 2000, IMMUNOL TODAY, V21, P110, DOI 10.1016/S0167-5699(99)01573-X; Segal BM, 1998, J EXP MED, V187, P537, DOI 10.1084/jem.187.4.537; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; SELMAJ KW, 1995, NEUROLOGY, V45, pS44, DOI 10.1212/WNL.45.6_Suppl_6.S44; SETHNA MP, 1991, J NEUROIMMUNOL, V34, P121, DOI 10.1016/0165-5728(91)90121-M; SIMMONS RD, 1990, J NEUROL SCI, V100, P37, DOI 10.1016/0022-510X(90)90010-K; Stalder AK, 1998, AM J PATHOL, V153, P767, DOI 10.1016/S0002-9440(10)65620-9; Tani M, 1996, J CLIN INVEST, V98, P529, DOI 10.1172/JCI118821; Taupin VR, 1997, EUR J IMMUNOL, V27, P905, DOI 10.1002/eji.1830270416; Tran EH, 2000, J IMMUNOL, V164, P2759, DOI 10.4049/jimmunol.164.5.2759; Tran EH, 2000, EUR J IMMUNOL, V30, P1410, DOI 10.1002/(SICI)1521-4141(200005)30:5<1410::AID-IMMU1410>3.0.CO;2-L; TUMLEY AM, 1991, NATURE, V353, P566; VOORTHUIS JAC, 1990, CLIN EXP IMMUNOL, V81, P183; Wiendl H, 2000, NERVENARZT, V71, P597, DOI 10.1007/s001150050636; Wildbaum G, 1998, J IMMUNOL, V161, P6368; Willenborg DO, 1996, J IMMUNOL, V157, P3223; Wyss-Coray T, 2000, AM J PATHOL, V156, P139, DOI 10.1016/S0002-9440(10)64713-X; WyssCoray T, 1997, J NEUROIMMUNOL, V77, P45, DOI 10.1016/S0165-5728(97)00049-0; Youssef S, 1998, J IMMUNOL, V161, P3870	75	143	147	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2001	7	2					161	166		10.1038/84603	http://dx.doi.org/10.1038/84603			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175845				2022-12-27	WOS:000166756300031
J	Traynelis, SF; Lipton, SA				Traynelis, SF; Lipton, SA			Is tissue plasminogen activator a threat to neurons?	NATURE MEDICINE			English	Editorial Material							TPA	The clot-busting drug tissue plasminogen activator (tPA) is currently the only FDA-approved therapy for acute stroke. However, increasing evidence suggests that tPA can also contribute to excitotoxic neuronal damage in animal models of stroke.	Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA; Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA USA	Emory University; Sanford Burnham Prebys Medical Discovery Institute	Traynelis, SF (corresponding author), Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA.			Lipton, Stuart/0000-0002-3490-1259				Del Zoppo GJ, 1998, NAT MED, V4, P148, DOI 10.1038/nm0298-148; delZoppo GJ, 1997, DRUGS, V54, P9, DOI 10.2165/00003495-199754010-00002; Gingrich MB, 2000, J NEUROSCI, V20, P4582, DOI 10.1523/JNEUROSCI.20-12-04582.2000; Gingrich MB, 2000, TRENDS NEUROSCI, V23, P399, DOI 10.1016/S0166-2236(00)01617-9; Gualandris A, 1996, J NEUROSCI, V16, P2220; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Tsirka SE, 1997, J MOL MED, V75, P341, DOI 10.1007/s001090050119; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	11	26	28	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					17	18		10.1038/83289	http://dx.doi.org/10.1038/83289			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135603				2022-12-27	WOS:000166243100018
J	Buhman, KK; Accad, M; Novak, S; Choi, RS; Wong, JS; Hamilton, RL; Turley, S; Farese, RV				Buhman, KK; Accad, M; Novak, S; Choi, RS; Wong, JS; Hamilton, RL; Turley, S; Farese, RV			Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice	NATURE MEDICINE			English	Article							COA-CHOLESTEROL ACYLTRANSFERASE; HUMAN ACYL-COENZYME; APOLIPOPROTEIN-B; ESTERIFICATION ENZYMES; BILIARY CHOLESTEROL; MOLECULAR-CLONING; TRANSGENIC MICE; INBRED STRAINS; HUMAN LIVER; EXPRESSION	The importance of cholesterol ester synthesis by acyl CoA:cholesterol acyltransferase (ACAT) enzymes in intestinal and hepatic cholesterol metabolism has been unclear. We now demonstrate that ACAT2 is the major ACAT in mouse small intestine and liver, and suggest that ACAT2 deficiency has profound effects on cholesterol metabolism in mice fed a cholesterol-rich diet, including complete resistance to diet-induced hypercholesterolemia and cholesterol gallstone formation. The underlying mechanism involves the lack of cholesterol ester synthesis in the intestine and a resultant reduced capacity to absorb cholesterol. Our results indicate that ACAT2 has an important role in the response to dietary cholesterol, and suggest that ACAT2 inhibition may be a useful strategy for treating hypercholesterolemia or cholesterol gallstones.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Texas, SW Med Sch, Dept Med, Dallas, TX 75235 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Farese, RV (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.	bfarese@gladstone.ucsf.edu	Buhman, Kimberly/AAV-3111-2021	Buhman, Kimberly/0000-0002-3784-1028	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL009610, R01HL060844, R01HL057170, R37HL009610] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57170, HL09610, R01 HL057170, HL60844] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Accad M, 2000, J CLIN INVEST, V105, P711, DOI 10.1172/JCI9021; Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; BLOCH K, 1991, BIOCH LIPIDS LIPOPRO, P363; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Chang CCY, 2000, J BIOL CHEM, V275, P28083; Chang CCY, 1999, CIRCULATION, V100, P612; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; DAVIS RA, 1982, J BIOL CHEM, V257, P2634; DIXON JL, 1993, J LIPID RES, V34, P167; ERICKSON SK, 1980, J LIPID RES, V21, P930; Farese RV, 1996, J LIPID RES, V37, P347; GOODMAN DS, 1965, PHYSIOL REV, V45, P747, DOI 10.1152/physrev.1965.45.4.747; HAMILTON RL, 1980, J LIPID RES, V21, P981; HORIE Y, 1992, J BIOL CHEM, V267, P1962; Jensen DR, 1997, AM J PHYSIOL-REG I, V273, pR683, DOI 10.1152/ajpregu.1997.273.2.R683; KHANUJA B, 1995, P NATL ACAD SCI USA, V92, P7729, DOI 10.1073/pnas.92.17.7729; KLEIN RL, 1983, J LIPID RES, V24, P343; Krause B.R., 1995, INFLAMMATION MEDIATO, P173; Lammert F, 1999, FALK SYMP, V108, P224; Lee O, 1998, J LIPID RES, V39, P1722; Machleder D, 1997, J CLIN INVEST, V99, P1406, DOI 10.1172/JCI119300; McCormick SPA, 1996, J BIOL CHEM, V271, P11963, DOI 10.1074/jbc.271.20.11963; Meiner V, 1997, J LIPID RES, V38, P1928; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; MORTENSEN R, 1999, CURRENT PROTOCOLS MO, V2; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PURCELLHUYNH DA, 1995, J CLIN INVEST, V96, P1845, DOI 10.1172/JCI118230; Schwarz M, 1998, J LIPID RES, V39, P1833; Sehayek E, 1998, P NATL ACAD SCI USA, V95, P10194, DOI 10.1073/pnas.95.17.10194; SMITH JL, 1995, J LIPID RES, V36, P641; SMITH JL, 1990, J LIPID RES, V31, P1993; TURLEY SD, 1994, GASTROENTEROLOGY, V107, P444, DOI 10.1016/0016-5085(94)90170-8; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; Wang DQH, 1999, AM J PHYSIOL-GASTR L, V276, pG751, DOI 10.1152/ajpgi.1999.276.3.G751; WILSON MD, 1994, J LIPID RES, V35, P943; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365	38	258	268	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1341	1347		10.1038/82153	http://dx.doi.org/10.1038/82153			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100118				2022-12-27	WOS:000165704100037
J	Manabe, YC; Bishai, WR				Manabe, YC; Bishai, WR			Latent Mycobacterium tuberculosis - persistence, patience, and winning by waiting	NATURE MEDICINE			English	Review							EXOGENOUS REINFECTION; TUBERCLE-BACILLI; SIGMA-FACTOR; MODEL; METRONIDAZOLE; VIRULENCE	Mycobacterium tuberculosis is a globally successful pathogen due to its ability to persist for long periods of time unrecognized by the human immune system. The panoply of genes that allows the organism to enter latency and then re-emerge later during endogenous reinfection are now being elucidated. Novel antimicrobials and vaccines will need to target these mycobacterial pathogenic mechanisms to succeed against tuberculosis.	Johns Hopkins Univ, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Int Hlth, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Manabe, YC (corresponding author), Johns Hopkins Univ, Dept Med, Baltimore, MD 21205 USA.	ymanabe@jhmi.edu; wbishai@jhsph.edu						Chen P, 2000, INFECT IMMUN, V68, P5575, DOI 10.1128/IAI.68.10.5575-5580.2000; Chen P, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P149; Cole ST, 1998, NATURE, V396, P190, DOI 10.1038/24206; COMSTOCK GW, 1979, AM REV RESPIR DIS, V119, P827; DeMaio J, 1996, P NATL ACAD SCI USA, V93, P2790, DOI 10.1073/pnas.93.7.2790; Dhillon J, 1998, INT J TUBERC LUNG D, V2, P736; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; HOBBY GL, 1954, AM REV TUBERC PULM, V70, P191; MCCUNE RM, 1966, J EXP MED, V123, P445, DOI 10.1084/jem.123.3.445; MCCUNE RM, 1966, J EXP MED, V123, P469, DOI 10.1084/jem.123.3.469; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; MEDLAR EM, 1952, AM REV TUBERC PULM, V66, P36; Miyazaki E, 1999, ANTIMICROB AGENTS CH, V43, P2126, DOI 10.1128/AAC.43.9.2126; NARDELL E, 1996, NEW ENGL J MED, V315, P1570; Opie EL, 1927, ARCH PATHOL LAB MED, V4, P1; Ramakrishnan L, 2000, SCIENCE, V288, P1436, DOI 10.1126/science.288.5470.1436; Scanga CA, 1999, INFECT IMMUN, V67, P4531, DOI 10.1128/IAI.67.9.4531-4538.1999; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; STEAD WW, 1967, AM REV RESPIR DIS, V95, P729; Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602; WAYNE LG, 1994, ANTIMICROB AGENTS CH, V38, P2054, DOI 10.1128/AAC.38.9.2054; WAYNE LG, 1977, INFECT IMMUN, V17, P528, DOI 10.1128/IAI.17.3.528-530.1977; Wayne LG, 1996, INFECT IMMUN, V64, P2062, DOI 10.1128/IAI.64.6.2062-2069.1996; WAYNE LG, 1994, EUR J CLIN MICROBIOL, V13, P908, DOI 10.1007/BF02111491; WAYNE LG, 1982, INFECT IMMUN, V37, P1042, DOI 10.1128/IAI.37.3.1042-1049.1982	25	229	235	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2000	6	12					1327	1329		10.1038/82139	http://dx.doi.org/10.1038/82139			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100115				2022-12-27	WOS:000165704100034
J	Birmingham, K				Birmingham, K			Oxford scientists defect to Imperial	NATURE MEDICINE			English	News Item																		2000, NATURE, V404, P696; 2000, NATURE, V404, P802	2	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1070	1070		10.1038/80373	http://dx.doi.org/10.1038/80373			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017119	Bronze			2022-12-27	WOS:000089674700011
J	Tebbutt, NC; Giraud, AS; Inglese, M; Jenkins, B; Waring, P; Clay, FJ; Malki, S; Alderman, BM; Grail, D; Hollande, F; Heath, JK; Ernst, M				Tebbutt, NC; Giraud, AS; Inglese, M; Jenkins, B; Waring, P; Clay, FJ; Malki, S; Alderman, BM; Grail, D; Hollande, F; Heath, JK; Ernst, M			Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice	NATURE MEDICINE			English	Article							CYTOKINE RECEPTORS; TRANSGENIC MICE; IN-VIVO; INTESTINAL INFLAMMATION; INTERLEUKIN-6 FAMILY; SIGNAL TRANSDUCER; HEPATIC CELLS; RESPONSES; DISEASE; COLITIS	The intracellular signaling mechanisms that specify tissue-specific responses to the interleukin-6 (IL-6) family of cytokines are not well understood. Here, we evaluated the functions of the two major signaling pathways, the signal transducers and activators of transcription 1 and 3 (STAT1/3) and the Src-homology tyrosine phosphatase 2 (SHP2)-Ras-ERK, emanating from the common signal transducer, gp130, in the gastrointestinal tract. Gp130(757F) mice, with a `knock-in' mutation abrogating SHP2-Ras-ERK signaling, developed gastric adenomas by three months of age. In contrast, mice harboring the reciprocal mutation ablating STAT1/3 signaling (gp130Delta(STAT)), or deficient in IL-6-mediated gp130 signaling (IL- 6(-/-) mice), showed impaired colonic mucosal wound healing. These gastrointestinal phenotypes are highly similar to the phenotypes exhibited by mice deficient in trefoil factor 1 (pS2/TFF1) and intestinal trefoil factor (ITF)/TFF3, respectively, and corresponded closely with the capacity of the two pathways to stimulate transcription of the genes encoding pS2/TFF1 and ITF/TFF3. We propose a model whereby mucosal wound healing depends solely on activation of STAT1/3, whereas gastric hyperplasia ensues when the coordinated activation of the STAT1/3 and SHP2-Ras-ERK pathways is disrupted.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Parkville, Vic, Australia; Univ Melbourne, Western Hosp, Dept Med, Footscray, Vic, Australia; Peter MacCallum Canc Inst, Dept Pathol, Melbourne, Vic, Australia; Fac Pharm Montpellier, Lab Signalisat Cellulaire Normale & Tumorale, Montpellier, France	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; University of Melbourne; Western Hospital; Peter Maccallum Cancer Center; Universite de Montpellier	Ernst, M (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, Parkville, Vic, Australia.	matthias.ernst@ludwig.edu.au	Hollande, Frederic/E-3133-2013; Hollande, Frederic/GLS-4120-2022; Ernst, Matthias/D-5111-2012; jenkins, brendan/J-7854-2012; jenkins, brendan/A-2401-2009; Heath, Joan/D-3054-2012	Hollande, Frederic/0000-0002-7046-8392; Ernst, Matthias/0000-0002-6399-1177; Heath, Joan/0000-0001-6955-232X; Jenkins, Brendan/0000-0002-7552-4656				Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; BAUMANN H, 1994, J BIOL CHEM, V269, P16297; Betz UAK, 1998, J EXP MED, V188, P1955, DOI 10.1084/jem.188.10.1955; Boivin GP, 1996, LAB INVEST, V74, P513; Bossenmeyer-Pourie C, 2002, J CELL BIOL, V157, P761, DOI 10.1083/jcb200108056; COOPER HS, 1993, LAB INVEST, V69, P238; Du XX, 1997, BLOOD, V89, P3897, DOI 10.1182/blood.V89.11.3897; Egger B, 1999, DIGEST DIS SCI, V44, P836, DOI 10.1023/A:1026642715764; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Ernst M, 1999, J BIOL CHEM, V274, P9729, DOI 10.1074/jbc.274.14.9729; Ernst M, 2001, J EXP MED, V194, P189, DOI 10.1084/jem.194.2.189; Giraud AS, 2000, AM J PHYSIOL-GASTR L, V278, pG501, DOI 10.1152/ajpgi.2000.278.4.G501; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; Hollande F, 2001, AM J PHYSIOL-GASTR L, V280, pG910, DOI 10.1152/ajpgi.2001.280.5.G910; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kim H, 1999, MOL CELL BIOL, V19, P5326; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; NICOLA NA, 1994, STEM CELLS, V12, P3; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; Park WS, 2000, GASTROENTEROLOGY, V119, P691, DOI 10.1053/gast.2000.16483; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Peters M, 1997, J EXP MED, V185, P755, DOI 10.1084/jem.185.4.755; Podolsky Daniel K., 2000, Journal of Gastroenterology, V35, P69; RAMSAY AJ, 1994, SCIENCE, V264, P561, DOI 10.1126/science.8160012; Robb L, 1998, NAT MED, V4, P303, DOI 10.1038/nm0398-303; SANDS BE, 1995, J BIOL CHEM, V270, P9353, DOI 10.1074/jbc.270.16.9353; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Srivatsa G, 2002, HISTOPATHOLOGY, V40, P261, DOI 10.1046/j.1365-2559.2002.01347.x; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; Taupin D, 1999, J CLIN INVEST, V103, pR31, DOI 10.1172/JCI3304; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; TAUPIN DR, 1995, PEPTIDES, V16, P1001, DOI 10.1016/0196-9781(95)00070-Z; Terada T, 2001, BIOL PHARM BULL, V24, P135, DOI 10.1248/bpb.24.135; Ulaganathan M, 2001, J GASTROEN HEPATOL, V16, P506, DOI 10.1046/j.1440-1746.2001.02469.x; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	43	383	405	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1089	1097		10.1038/nm763	http://dx.doi.org/10.1038/nm763			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12219085				2022-12-27	WOS:000178311000035
J	Adams, JY; Johnson, M; Sato, M; Berger, F; Gambhir, SS; Carey, M; Iruela-Arispe, ML; Wu, L				Adams, JY; Johnson, M; Sato, M; Berger, F; Gambhir, SS; Carey, M; Iruela-Arispe, ML; Wu, L			Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging	NATURE MEDICINE			English	Article							ANDROGEN RECEPTOR; THERAPY; CELLS; AMPLIFICATION; MECHANISM	Non-invasive imaging and transcriptional targeting can improve the safety of therapeutic approaches in cancer. Here we demonstrate the ability to identify metastases in a human-prostate cancer model, employing a prostate-specific adenovirus vector (AdPSE-BC-luc) and a charge-coupled device-imaging system. AdPSE-BC-luc, which expresses firefly luciferase from an enhanced prostate-specific antigen promoter, restricted expression in the liver but produced robust signals in prostate tumors. In fact, expression was higher in advanced, androgen-independent tumors than in androgen-dependent lesions. Repetitive imaging over a three-week period after AdPSE-BC-luc injection into tumor-bearing mice revealed that the virus could locate and illuminate metastases in the lung and spine. Systemic injection of low doses of AdPSE-BC-luc illuminated lung metastasis. These results demonstrate the potential use of a non-invasive imaging modality in therapeutic and diagnostic strategies to manage prostate cancer.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Crump Inst Mol Imaging, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Coll Letters & Sci, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Wu, L (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA.		Iruela-Arispe, M. Luisa/AAJ-1297-2020	Iruela-Arispe, M. Luisa/0000-0002-3050-4168; Carey, Michael/0000-0003-3899-6280	NATIONAL CANCER INSTITUTE [R24CA092865, R01CA082214, P50CA086306] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA92865, R0-1 CA82214, P50 CA86306] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bloomfield DJ, 1998, J CLIN ONCOL, V16, P2272, DOI 10.1200/JCO.1998.16.6.2272; Craft N, 1999, CANCER RES, V59, P5030; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; FREIDMANN T, 1999, DEV HUMAN GENE THERA; Gregory CW, 2001, CANCER RES, V61, P4315; Harrington KJ, 2001, J UROLOGY, V166, P1220, DOI 10.1016/S0022-5347(05)65742-4; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Leav I, 2001, AM J PATHOL, V159, P79, DOI 10.1016/S0002-9440(10)61676-8; Linja MJ, 2001, CANCER RES, V61, P3550; Nash AF, 2000, ENDOCR-RELAT CANCER, V7, P37, DOI 10.1677/erc.0.0070037; Rehemtulla A, 2000, NEOPLASIA, V2, P491, DOI 10.1038/sj.neo.7900121; Rini BI, 2001, CURR OPIN ONCOL, V13, P204, DOI 10.1097/00001622-200105000-00013; Tao NJ, 2001, MOL THER, V3, P28, DOI 10.1006/mthe.2000.0227; Waller AS, 2000, J MOL ENDOCRINOL, V24, P339, DOI 10.1677/jme.0.0240339; Wu JC, 2001, MOL THER, V4, P297, DOI 10.1006/mthe.2001.0460; Wu L, 2001, GENE THER, V8, P1416, DOI 10.1038/sj.gt.3301549; Yaghoubi SS, 2001, GENE THER, V8, P1072, DOI 10.1038/sj.gt.3301490; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; Zhang LQ, 2002, MOL THER, V5, P223, DOI 10.1006/mthe.2002.0551; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287	20	130	136	0	6	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2002	8	8					891	896		10.1038/nm743	http://dx.doi.org/10.1038/nm743			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12134144				2022-12-27	WOS:000177200900037
J	Greene, WC; Peterlin, BM				Greene, WC; Peterlin, BM			Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy	NATURE MEDICINE			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; CD4 DOWN-MODULATION; RNA-POLYMERASE-II; T-CELLS; LIPID RAFTS; P-TEFB; VIRAL REPLICATION; EARLY STEPS; TRANSCRIPTIONAL ELONGATION; PREINTEGRATION COMPLEXES		Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Rosalind Russell Med Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Dept Microbiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Greene, WC (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA.	wgreene@gladstone.ucsf.edu; matija@itsa.ucsf.edu			NCI NIH HHS [R01 CA86814] Funding Source: Medline; NIAID NIH HHS [R01AI46967, R01AI38532, R01AI45234, R01AI49104] Funding Source: Medline; NICHD NIH HHS [P01 HD40543] Funding Source: Medline; NIMH NIH HHS [P30MH59037] Funding Source: Medline; PHS HHS [R01A151165-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD040543] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA086814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046967, R01AI038532, R01AI049104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH059037] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADAMS M, 1994, P NATL ACAD SCI USA, V91, P3862, DOI 10.1073/pnas.91.9.3862; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; Bell P, 2001, J VIROL, V75, P7683, DOI 10.1128/JVI.75.16.7683-7691.2001; Bieniasz PD, 2000, J VIROL, V74, P9868, DOI 10.1128/JVI.74.21.9868-9877.2000; Bukrinskaya A, 1998, J EXP MED, V188, P2113, DOI 10.1084/jem.188.11.2113; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; Campbell SM, 2001, J CLIN VIROL, V22, P217, DOI 10.1016/S1386-6532(01)00193-7; Cartier C, 1999, J BIOL CHEM, V274, P19434, DOI 10.1074/jbc.274.27.19434; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Chen BK, 1996, J VIROL, V70, P6044, DOI 10.1128/JVI.70.9.6044-6053.1996; Chen HM, 1998, P NATL ACAD SCI USA, V95, P15270, DOI 10.1073/pnas.95.26.15270; Cohen O J, 2001, Adv Intern Med, V46, P207; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; Cullen BR, 1998, VIROLOGY, V249, P203, DOI 10.1006/viro.1998.9331; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; Doms RW, 2000, GENE DEV, V14, P2677, DOI 10.1101/gad.833300; Dupont S, 1999, NATURE, V402, P681, DOI 10.1038/45272; Eckstein DA, 2001, J EXP MED, V194, P1407, DOI 10.1084/jem.194.10.1407; Fackler OT, 2000, CURR BIOL, V10, P1005, DOI 10.1016/S0960-9822(00)00654-0; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; Garber ME, 2000, MOL CELL BIOL, V20, P6958, DOI 10.1128/MCB.20.18.6958-6969.2000; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Garnier L, 1999, J VIROL, V73, P2309, DOI 10.1128/JVI.73.3.2309-2320.1999; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141; Glushakova S, 2001, J VIROL, V75, P10113, DOI 10.1128/JVI.75.21.10113-10117.2001; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; Greenway AL, 2002, J VIROL, V76, P2692, DOI 10.1128/JVI.76.6.2692-2702.2002; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jordan A, 2001, EMBO J, V20, P1726, DOI 10.1093/emboj/20.7.1726; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KARAGEORGOS L, 1993, AIDS RES HUM RETROV, V9, P817, DOI 10.1089/aid.1993.9.817; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Khan IH, 1998, J VIROL, V72, P5820, DOI 10.1128/JVI.72.7.5820-5830.1998; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; Kozak SL, 2002, J VIROL, V76, P1802, DOI 10.1128/JVI.76.4.1802-1815.2002; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lama J, 1999, CURR BIOL, V9, P622, DOI 10.1016/S0960-9822(99)80284-X; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; Li L, 2001, EMBO J, V20, P3272, DOI 10.1093/emboj/20.12.3272; Liao ZH, 2001, AIDS RES HUM RETROV, V17, P1009, DOI 10.1089/088922201300343690; Lind KE, 2002, CHEM BIOL, V9, P185, DOI 10.1016/S1074-5521(02)00106-0; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mariani R, 2000, J VIROL, V74, P3859, DOI 10.1128/JVI.74.8.3859-3870.2000; Martinson JJ, 1997, NAT GENET, V16, P100, DOI 10.1038/ng0597-100; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; Ohagen A, 2000, J VIROL, V74, P11055, DOI 10.1128/JVI.74.23.11055-11066.2000; Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Powell DM, 1997, P NATL ACAD SCI USA, V94, P973, DOI 10.1073/pnas.94.3.973; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; Schaeffer E, 2001, J VIROL, V75, P2993, DOI 10.1128/JVI.75.6.2993-3000.2001; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; Simmons A, 2001, IMMUNITY, V14, P763, DOI 10.1016/S1074-7613(01)00158-3; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; SOMASUNDARAN M, 1988, SCIENCE, V242, P1554, DOI 10.1126/science.3201245; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; Takeda M, 2002, J VIROL, V76, P1391, DOI 10.1128/JVI.76.3.1391-1399.2002; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wilk T, 2001, J VIROL, V75, P759, DOI 10.1128/JVI.75.2.759-771.2001; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Wu YT, 2001, SCIENCE, V293, P1503, DOI 10.1126/science.1061548; Xu XN, 1999, J EXP MED, V189, P1489, DOI 10.1084/jem.189.9.1489; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zheng YH, 2001, CURR BIOL, V11, P875, DOI 10.1016/S0960-9822(01)00237-8; Zimmerman C, 2002, NATURE, V415, P88, DOI 10.1038/415088a	100	185	193	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2002	8	7					673	680		10.1038/nm0702-673	http://dx.doi.org/10.1038/nm0702-673			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12091904				2022-12-27	WOS:000176495200027
J	Teshima, T; Ordemann, R; Reddy, P; Gagin, S; Liu, C; Cooke, KR; Ferrara, JLM				Teshima, T; Ordemann, R; Reddy, P; Gagin, S; Liu, C; Cooke, KR; Ferrara, JLM			Acute graft-versus-host disease does not require alloantigen expression on host epithelium	NATURE MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; ANTIGEN-PRESENTING CELLS; NECROSIS-FACTOR-ALPHA; RAT EPIDERMAL-CELLS; DONOR T-CELLS; IA-ANTIGEN; FAS LIGAND; GUT EPITHELIUM; LYMPHOCYTES; PATHOGENESIS	Alloantigen expression on host antigen-presenting cells (APCs) is essential to initiate graft-versus-host disease (GvHD); therefore, alloantigen expression on host target epithelium is also thought to be essential for tissue damage. We tested this hypothesis in mouse models of GvHD using bone-marrow chimeras in which either major histocompatibility complex class I or class II alloantigen was expressed only on APCs. We found that acute GvHD does not require alloantigen expression on host target epithelium and that neutralization of tumor necrosis factor-alpha and interleukin-1 prevents acute GvHD. These results pertain particularly to CD4-mediated GvHD but also apply, at least in part, to CD8-mediated GvHD. These results challenge current paradigms about the antigen specificity of GvHD effector mechanisms and confirm the central roles of both host APCs and inflammatory cytokines in acute GvHD.	Univ Michigan, Ctr Canc, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Canc, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Florida, Coll Med, Dept Pathol, Gainesville, FL USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; State University System of Florida; University of Florida	Ferrara, JLM (corresponding author), Univ Michigan, Ctr Canc, Dept Internal Med, Ann Arbor, MI 48109 USA.		teshima, takanori/G-1671-2012	Reddy, Pavan/0000-0001-7264-8429	NATIONAL CANCER INSTITUTE [P01CA039542] Funding Source: NIH RePORTER; NCI NIH HHS [CA39542] Funding Source: Medline; NHLBI NIH HHS [HL03565-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amrani A, 2000, J CLIN INVEST, V105, P459, DOI 10.1172/JCI8185; Baker MB, 1996, J EXP MED, V183, P2645, DOI 10.1084/jem.183.6.2645; BARCLAY AN, 1982, J EXP MED, V156, P1665, DOI 10.1084/jem.156.6.1665; Blazar BR, 1997, TRANSPLANTATION, V64, P571, DOI 10.1097/00007890-199708270-00004; Braun MY, 1996, J EXP MED, V183, P657, DOI 10.1084/jem.183.2.657; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; Cooke KR, 1998, BLOOD, V92, P2571, DOI 10.1182/blood.V92.7.2571.2571_2571_2580; Crawford JM., 1997, GRAFT VERSUS HOST DI, P315; FERRARA JLM, 1991, NEW ENGL J MED, V324, P667; Graubert TA, 1997, J CLIN INVEST, V100, P904, DOI 10.1172/JCI119606; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; Hattori K, 1998, BLOOD, V91, P4051, DOI 10.1182/blood.V91.11.4051.411k16_4051_4055; Hill GR, 1999, J CLIN INVEST, V104, P459, DOI 10.1172/JCI6896; Hill GR, 1998, J CLIN INVEST, V102, P115, DOI 10.1172/JCI3132; Hill GR, 1997, BLOOD, V90, P3204, DOI 10.1182/blood.V90.8.3204; Jiang Z, 2001, BLOOD, V98, P390, DOI 10.1182/blood.V98.2.390; KORNGOLD R, 1990, GRAFT VERSUS HOST DI, P31; Krasinskas AM, 2000, TRANSPLANTATION, V70, P514, DOI 10.1097/00007890-200008150-00020; LAMPERT IA, 1981, NATURE, V293, P149, DOI 10.1038/293149a0; Martin PJ, 1998, BLOOD, V92, P2177, DOI 10.1182/blood.V92.6.2177.418k02_2177_2181; MASON DW, 1981, NATURE, V293, P150, DOI 10.1038/293150a0; Mori T, 1998, BLOOD, V92, P101, DOI 10.1182/blood.V92.1.101.413k14_101_107; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Murai M, 1999, J CLIN INVEST, V104, P49, DOI 10.1172/JCI6642; NESTEL FP, 1992, J EXP MED, V175, P405, DOI 10.1084/jem.175.2.405; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; PIGUET PF, 1987, J EXP MED, V166, P1280, DOI 10.1084/jem.166.5.1280; Reddy P, 2001, J EXP MED, V194, P1433, DOI 10.1084/jem.194.10.1433; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; Santamaria P, 2001, CURR OPIN IMMUNOL, V13, P663, DOI 10.1016/S0952-7915(01)00276-X; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; SITKOVSKY MV, 1997, GRAFT VERSUS HOST DI, P219; SPRENT J, 1988, J EXP MED, V167, P556, DOI 10.1084/jem.167.2.556; Surh CD, 2000, J EXP MED, V192, pF9, DOI 10.1084/jem.192.4.F9; Teshima T, 2001, CANCER RES, V61, P162; TRUITT RL, 1997, GRAFT VERSUS HOST DI, P385; Via CS, 1996, J IMMUNOL, V157, P5387; WALL DA, 1988, J IMMUNOL, V140, P2970	38	412	420	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2002	8	6					575	581		10.1038/nm0602-575	http://dx.doi.org/10.1038/nm0602-575			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042807				2022-12-27	WOS:000175907300027
J	Foege, WH				Foege, WH			The wonder that is global health	NATURE MEDICINE			English	Editorial Material									Emory Univ, Rollins Sch Publ Hlth, Dept Int Hlth, Atlanta, GA 30322 USA	Emory University; Rollins School Public Health	Foege, WH (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Dept Int Hlth, Atlanta, GA 30322 USA.								0	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1095	1096		10.1038/nm1001-1095	http://dx.doi.org/10.1038/nm1001-1095			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590422	Bronze			2022-12-27	WOS:000171524500017
J	Goldstein, JL				Goldstein, JL			Laskers for 2001: Knockout mice and test-tube babies	NATURE MEDICINE			English	Editorial Material																			0	16	17	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1079	1080		10.1038/nm1001-1079	http://dx.doi.org/10.1038/nm1001-1079			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590416				2022-12-27	WOS:000171524500011
J	Anderson, DJ; Gage, FH; Weissman, IL				Anderson, DJ; Gage, FH; Weissman, IL			Can stem cells cross lineage boundaries?	NATURE MEDICINE			English	Editorial Material							IN-VIVO; BIOLOGY; FATE; CNS		CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA; Stanford Univ, Stanford, CA 94305 USA	California Institute of Technology; Howard Hughes Medical Institute; Salk Institute; Stanford University	Anderson, DJ (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.							Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; DONOVAN PJ, 1994, CURR TOP DEV BIOL, V29, P189, DOI 10.1016/S0070-2153(08)60551-7; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092-8674(00)81691-8; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Galli R, 2000, NAT NEUROSCI, V3, P986, DOI 10.1038/79924; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Morrison SJ, 2001, CURR BIOL, V11, pR7, DOI 10.1016/S0960-9822(00)00033-6; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Palmer TD, 1999, J NEUROSCI, V19, P8487; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Watt FM, 1998, PHILOS T R SOC B, V353, P831, DOI 10.1098/rstb.1998.0247; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442; WU AM, 1968, J EXP MED, V127, P455, DOI 10.1084/jem.127.3.455	20	384	439	1	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2001	7	4					393	395		10.1038/86439	http://dx.doi.org/10.1038/86439			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283651				2022-12-27	WOS:000167960500017
J	Han, BH; DeMattos, RB; Dugan, LL; Kim-Han, JS; Brendza, RP; Fryer, JD; Kierson, M; Cirrito, J; Quick, K; Harmony, JAK; Aronow, BJ; Holtzman, DM				Han, BH; DeMattos, RB; Dugan, LL; Kim-Han, JS; Brendza, RP; Fryer, JD; Kierson, M; Cirrito, J; Quick, K; Harmony, JAK; Aronow, BJ; Holtzman, DM			Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; SULFATED GLYCOPROTEIN-2; CELL-DEATH; IN-VITRO; APOLIPOPROTEIN-J/CLUSTERIN; RAT MODEL; NEURONS; APOPTOSIS; PROTECTS; RECEPTOR	Clusterin, also known as apolipoprotein J, is a ubiquitously expressed molecule thought to influence a variety of processes including cell death. In the brain, it accumulates in dying neurons following seizures and hypoxic-ischemic (H-I) Injury. Despite this, in vivo evidence that clusterin directly influences cell death is lacking. Following neonatal H-I brain injury in mice (a model of cerebral palsy), there was evidence of apoptotic changes (neuronal caspase-3 activation), as well as accumulation of clusterin in dying neurons. Clusterin-deficient mice had 50% less brain injury following neonatal H-I. Surprisingly, the absence of clusterin had no effect on caspase-3 activation, and clusterin accumulation and caspase-3 activation did not colocalize to the same cells. Studies with cultured cortical neurons demonstrated that exogenous purified astrocyte-secreted clusterin exacerbated oxygen/glucose-deprivation-induced necrotic death. These results indicate that clusterin may be a new therapeutic target to modulate non-caspase-dependent neuronal death following acute brain injury.	Washington Univ, Sch Med, Ctr Study Nervous System Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA; Childrens Hosp Res Fdn, Div Mol & Dev Biol, Cincinnati, OH 45229 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Holtzman, DM (corresponding author), Washington Univ, Sch Med, Ctr Study Nervous System Injury, St Louis, MO 63110 USA.		Aronow, Bruce J/F-8438-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS035902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG011355, P50AG005681] Funding Source: NIH RePORTER; NIA NIH HHS [AG05681, AG11355] Funding Source: Medline; NINDS NIH HHS [NS35902] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; Boggs LN, 1996, J NEUROCHEM, V67, P1324; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; DeMattos RB, 1998, J BIOL CHEM, V273, P4206, DOI 10.1074/jbc.273.7.4206; DRAGUNOW M, 1995, MOL BRAIN RES, V32, P279, DOI 10.1016/0169-328X(95)00088-A; DUGAN LL, 1995, J NEUROSCI, V15, P6377; During MJ, 2000, SCIENCE, V287, P1453, DOI 10.1126/science.287.5457.1453; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Han BH, 2000, NEUROBIOL DIS, V7, P38; Humphreys D, 1997, BIOCHEMISTRY-US, V36, P15233, DOI 10.1021/bi9703507; KISSINGER C, 1982, BIOL REPROD, V27, P233, DOI 10.1095/biolreprod27.1.233; Kounnas M Z, 1994, In Vivo, V8, P343; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Lakins J, 1998, J BIOL CHEM, V273, P27887, DOI 10.1074/jbc.273.43.27887; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lendon CL, 2000, EUR J NEUROSCI, V12, P2235, DOI 10.1046/j.1460-9568.2000.00113.x; MAY PC, 1992, TRENDS NEUROSCI, V15, P391, DOI 10.1016/0166-2236(92)90190-J; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MCDONALD JW, 1987, EUR J PHARMACOL, V140, P359, DOI 10.1016/0014-2999(87)90295-0; Mclaughlin L, 2000, J CLIN INVEST, V106, P1105, DOI 10.1172/JCI9037; Nakajima W, 2000, J NEUROSCI, V20, P7994; Parsadanian AS, 1998, J NEUROSCI, V18, P1009; PASINETTI GM, 1991, NEUROSCI LETT, V130, P1, DOI 10.1016/0304-3940(91)90213-D; PASINETTI GM, 1994, J COMP NEUROL, V339, P387, DOI 10.1002/cne.903390307; Plummer KL, 1999, J COMP NEUROL, V404, P408; Pulera MR, 1998, STROKE, V29, P2622, DOI 10.1161/01.STR.29.12.2622; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Schwochau GB, 1998, KIDNEY INT, V53, P1647, DOI 10.1046/j.1523-1755.1998.00902.x; SENSIBAR JA, 1995, CANCER RES, V55, P2431; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sintich SM, 1999, PROSTATE, V39, P87; VANUCCI RC, 1990, PEDIATR RES, V27, P317; Volpe J., 1995, NEUROLOGY NEWBORN; Walton M, 1996, MOL BRAIN RES, V39, P137, DOI 10.1016/0169-328X(96)00019-8; Wilson MR, 2000, TRENDS BIOCHEM SCI, V25, P95, DOI 10.1016/S0968-0004(99)01534-0; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907	38	173	183	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					338	343		10.1038/85487	http://dx.doi.org/10.1038/85487			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231633				2022-12-27	WOS:000167380400040
J	Brown, P				Brown, P			Finally, a plan to reduce measles deaths	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1305	1305		10.1038/82100	http://dx.doi.org/10.1038/82100			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100101				2022-12-27	WOS:000165704100018
J	Heise, C; Hermiston, T; Johnson, L; Brooks, G; Sampson-Johannes, A; Williams, A; Hawkins, L; Kirn, D				Heise, C; Hermiston, T; Johnson, L; Brooks, G; Sampson-Johannes, A; Williams, A; Hawkins, L; Kirn, D			An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy	NATURE MEDICINE			English	Article							CELL-TRANSFORMATION; PROTEINS; VIRUS; GENE; PHOSPHORYLATION; REPLICATION; INFECTION; CYTOLYSIS; ONYX-015; THERAPY	Replication-selective oncolytic viruses constitute a rapidly evolving and new treatment platform for cancer. Gene-deleted viruses have been engineered for tumor selectivity, but these gene deletions also reduce the anti-cancer potency of the viruses. We have identified an E1A mutant adenovirus, dl922-947, that replicates in and lyses a broad range of cancer cells with abnormalities in cell-cycle checkpoints. This mutant demonstrated reduced S-phase induction and replication in non-proliferating normal cells, and superior in vivo potency relative to other gene-deleted adenoviruses. In some cancers, its potency was superior to even wild-type adenovirus. Intravenous administration reduced the incidence of metastases in a breast tumor xenograft model. dl922-947 holds promise as a potent, replication-selective virus for the local and systemic treatment of cancer.	Hammersmith Hosp, Imperial Coll Sch Med, Imperial Canc Res Fund, Viral & Genet Therapy Programme, London W12 0HS, England; Onyx Pharmaceut, Richmond, CA USA; Berlex Biosci, Richmond, CA USA; Chiron Corp, Emeryville, CA 94608 USA	Cancer Research UK; Imperial College London; Novartis	Kirn, D (corresponding author), Hammersmith Hosp, Imperial Coll Sch Med, Imperial Canc Res Fund, Viral & Genet Therapy Programme, London W12 0HS, England.	d.kirn@icrf.icnet.uk						BARBEAU D, 1994, ONCOGENE, V9, P359; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Carew JF, 1999, HUM GENE THER, V10, P1599, DOI 10.1089/10430349950017608; DUMONT DJ, 1993, J GEN VIROL, V74, P583, DOI 10.1099/0022-1317-74-4-583; DUMONT DJ, 1992, VIROLOGY, V189, P111, DOI 10.1016/0042-6822(92)90686-J; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hay JG, 1999, HUM GENE THER, V10, P579, DOI 10.1089/10430349950018652; Heise C, 2000, J CLIN INVEST, V105, P847, DOI 10.1172/JCI9762; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kirn D, 1998, NAT MED, V4, P1341, DOI 10.1038/3902; KIRN D, 1998, P AN M AM SOC CLIN, V17, pA391; Kirn DH, 2000, J CLIN INVEST, V105, P837, DOI 10.1172/JCI9761; KIRN DH, 1999, P AN M AM SOC CLIN, V18, P1505; Kucharczuk JC, 1997, CANCER RES, V57, P466; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; Medina DJ, 1999, BLOOD, V94, P3499; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; RUDIN C, 1999, P AM SOC CLIN ONCOL, V18, P1715; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Whalen SG, 1996, J VIROL, V70, P5373, DOI 10.1128/JVI.70.8.5373-5383.1996; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YUAN F, 1995, CANCER RES, V55, P3752	32	487	537	0	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2000	6	10					1134	1139		10.1038/80474	http://dx.doi.org/10.1038/80474			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017145				2022-12-27	WOS:000089674700038
J	Jochum, W; David, JP; Elliott, C; Wutz, A; Plenk, H; Matsuo, K; Wagner, EF				Jochum, W; David, JP; Elliott, C; Wutz, A; Plenk, H; Matsuo, K; Wagner, EF			Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-l	NATURE MEDICINE			English	Article							C-FOS; AP-1 COMPLEX; GENE; TRANSFORMATION; MUTATION; PROTEINS; JUN; DIFFERENTIATION; EXPRESSION; CELLS	Bone formation by osteoblasts is essential for skeletal growth and remodeling. Fra-1 is a c-fos-related protein belonging to the AP-1 family of transcription factors. Here we show that transgenic mice overexpressing Fra-1 in various organs develop a progressive increase in bone mass leading to osteosclerosis of the entire skeleton, which is due to a cell-autonomous increase in the number of mature osteoblasts. Moreover, osteoblast differentiation, but not proliferation, was enhanced and osteoclastogenesis was also elevated in vitro. These data indicate that, unlike c-Fos, which causes osteosarcomas, Fra-1 specifically enhances bone formation, which may be exploited to stimulate bone formation in pathological conditions.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Univ Vienna, Inst Histol & Embryol Bone & Biomat Res, A-1090 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Vienna	Wagner, EF (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Elliott, Candace/F-1860-2011; Matsuo, Koichi/K-5695-2012	Elliott, Candace/0000-0002-9174-0244; Matsuo, Koichi/0000-0002-1490-8955; Wagner, Erwin F/0000-0001-7872-0196				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; CHAMBERS TJ, 2000, IN PRESS J PATHOL; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Filvaroff E, 1998, CURR BIOL, V8, pR679, DOI 10.1016/S0960-9822(98)70434-8; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Kajimoto Y, 1998, ENDOCR J, V45, P1, DOI 10.1507/endocrj.45.1; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KRATOCHWIL K, 1989, CELL, V57, P807, DOI 10.1016/0092-8674(89)90795-2; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; Owens JM, 1999, J CELL PHYSIOL, V179, P170, DOI 10.1002/(SICI)1097-4652(199905)179:2<170::AID-JCP7>3.0.CO;2-K; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Plenk HJ., 1986, TECHNIQUES BIOCOMPAT, P35; Recker RR., 1983, BONE HISTOMORPHOMETR; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schreiber M, 1997, ONCOGENE, V15, P1171, DOI 10.1038/sj.onc.1201460; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429	30	245	254	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					980	984		10.1038/79676	http://dx.doi.org/10.1038/79676			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973316				2022-12-27	WOS:000089190500028
J	Li, AC; Glass, CK				Li, AC; Glass, CK			The macrophage foam cell as a target for therapeutic intervention	NATURE MEDICINE			English	Review							LOW-DENSITY-LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN-1; ACTIVATED RECEPTOR-GAMMA; E KNOCKOUT MICE; SCAVENGER RECEPTOR; INCREASED ATHEROSCLEROSIS; CHOLESTEROL EFFLUX; SR-BI; REDUCES ATHEROSCLEROSIS; HYPERLIPIDEMIC MICE	Specialized functions of macrophages have evolved to protect the body from infection. However, the same mechanisms that enable phagocytosis of pathogens and activation of leukocytes also permit the uptake of lipoproteins and release of reactive oxygen species and immune mediators that collectively contribute to atherosclerosis. New approaches to inhibit lipid accumulation in macrophage foam cells and reduce inflammatory responses may be of therapeutic value in preventing coronary artery disease.	Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Glass, CK (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.	cglass@ucsd.edu	Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592				Accad M, 2000, J CLIN INVEST, V105, P711, DOI 10.1172/JCI9021; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P630, DOI 10.1161/01.ATV.0000014804.35824.DA; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Babaev VR, 1999, J CLIN INVEST, V103, P1697, DOI 10.1172/JCI6117; Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; Barbier O, 2002, ARTERIOSCL THROM VAS, V22, P717, DOI 10.1161/01.ATV.0000015598.86369.04; Bocan TMA, 1998, ATHEROSCLEROSIS, V136, P203, DOI 10.1016/S0021-9150(97)00204-9; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Boullier A, 2001, ANN NY ACAD SCI, V947, P214; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; Brewer HB, 2000, J CLIN INVEST, V105, P703, DOI 10.1172/JCI9664; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Burleigh ME, 2002, CIRCULATION, V105, P1816, DOI 10.1161/01.CIR.0000014927.74465.7F; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chen WG, 2000, J BIOL CHEM, V275, P30794, DOI 10.1074/jbc.M004552200; Claudel T, 2001, P NATL ACAD SCI USA, V98, P2610, DOI 10.1073/pnas.041609298; Clee SM, 2001, CIRCULATION, V103, P1198; Collins RG, 2000, J EXP MED, V191, P189, DOI 10.1084/jem.191.1.189; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; Dansky HM, 1997, P NATL ACAD SCI USA, V94, P4642, DOI 10.1073/pnas.94.9.4642; Dansky HM, 2001, ARTERIOSCL THROM VAS, V21, P1662, DOI 10.1161/hq1001.096625; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Daugherty A, 1997, J CLIN INVEST, V100, P1575, DOI 10.1172/JCI119681; DAVIES MJ, 1993, BRIT HEART J, V69, P377; de Villiers WJS, 1999, J LEUKOCYTE BIOL, V66, P740, DOI 10.1002/jlb.66.5.740; Detmers PA, 2000, J IMMUNOL, V165, P3430, DOI 10.4049/jimmunol.165.6.3430; Escary JL, 1999, J LIPID RES, V40, P397; Fazio S, 2001, J CLIN INVEST, V107, P163, DOI 10.1172/JCI10310; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Gaut JP, 2001, TRENDS CARDIOVAS MED, V11, P103, DOI 10.1016/S1050-1738(01)00101-3; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Goldschmidt HMJ, 2001, ACCREDIT QUAL ASSUR, V6, P388, DOI 10.1007/s007690100386; GORDON S, 1995, CURR OPIN IMMUNOL, V7, P24, DOI 10.1016/0952-7915(95)80025-5; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Gough PJ, 2000, MICROBES INFECT, V2, P305, DOI 10.1016/S1286-4579(00)00297-5; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; Haffner SM, 2002, CIRCULATION, V106, P679, DOI 10.1161/01.CIR.0000025403.20953.23; Han KH, 1999, J LIPID RES, V40, P1053; Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220; Harats D, 2000, ARTERIOSCL THROM VAS, V20, P2100, DOI 10.1161/01.ATV.20.9.2100; Hayek T, 1999, CARDIOVASC RES, V44, P579, DOI 10.1016/S0008-6363(99)00239-4; Horkko S, 2000, FREE RADICAL BIO MED, V28, P1771, DOI 10.1016/S0891-5849(00)00333-6; Huszar D, 2000, ARTERIOSCL THROM VAS, V20, P1068, DOI 10.1161/01.ATV.20.4.1068; Ihrig M, 2001, ATHEROSCLEROSIS, V156, P103, DOI 10.1016/S0021-9150(00)00636-5; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Klappacher GW, 2002, CURR OPIN LIPIDOL, V13, P305, DOI 10.1097/00041433-200206000-00011; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Kusunoki J, 2001, CIRCULATION, V103, P2604; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Linton MF, 2001, CURR OPIN LIPIDOL, V12, P489, DOI 10.1097/00041433-200110000-00003; Mallat Z, 1999, CIRC RES, V85, pE17, DOI 10.1161/01.RES.85.8.e17; Mead JR, 2002, CARDIOVASC RES, V55, P261, DOI 10.1016/S0008-6363(02)00405-4; Mehrabian M, 2002, CIRC RES, V91, P120, DOI 10.1161/01.RES.0000028008.99774.7F; Ni WH, 2001, CIRCULATION, V103, P2096; Niu XL, 2001, CIRCULATION, V103, P1115, DOI 10.1161/01.CIR.103.8.1115; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Palinski W, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000018400.39687.8C; Panousis CG, 2000, ARTERIOSCL THROM VAS, V20, P1565, DOI 10.1161/01.ATV.20.6.1565; Pinderski LJ, 2002, CIRC RES, V90, P1064, DOI 10.1161/01.RES.0000018941.10726.FA; Reardon CA, 2001, ARTERIOSCL THROM VAS, V21, P1011, DOI 10.1161/01.ATV.21.6.1011; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Scheidegger KJ, 1997, J BIOL CHEM, V272, P21609, DOI 10.1074/jbc.272.34.21609; Sendobry SM, 1997, BRIT J PHARMACOL, V120, P1199, DOI 10.1038/sj.bjp.0701007; Shaw PX, 2000, J CLIN INVEST, V105, P1731, DOI 10.1172/JCI8472; Shen JH, 1996, J CLIN INVEST, V98, P2201, DOI 10.1172/JCI119029; Shi WB, 2002, CIRCULATION, V105, P2078, DOI 10.1161/01.CIR.0000015853.59427.32; Singaraja RR, 2002, J CLIN INVEST, V110, P35, DOI 10.1172/JCI200215748; Skalen K, 2002, NATURE, V417, P750, DOI 10.1038/nature00804; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; Song L, 2001, J CLIN INVEST, V108, P251, DOI 10.1172/JCI11380; Steinberg D, 2002, CIRCULATION, V105, P2107, DOI 10.1161/01.CIR.0000014762.06201.06; Steinberg D., 1999, MOL BASIS CARDIOVASC, P458; Subbanagounder G, 2002, J BIOL CHEM, V277, P7271, DOI 10.1074/jbc.M107602200; Tall AR, 2000, J CLIN INVEST, V106, P1205, DOI 10.1172/JCI11538; Van Eck M, 2002, P NATL ACAD SCI USA, V99, P6298, DOI 10.1073/pnas.092327399; Wang YT, 2002, J BIOL CHEM, V277, P5692, DOI 10.1074/jbc.M109977200; Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341; Wilson K, 2001, ARTERIOSCL THROM VAS, V21, P1809, DOI 10.1161/hq1101.097805; Yagyu H, 1999, J LIPID RES, V40, P1677; Yasojima K, 2001, AM J PATHOL, V158, P1039, DOI 10.1016/S0002-9440(10)64051-5	93	559	586	2	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2002	8	11					1235	1242		10.1038/nm1102-1235	http://dx.doi.org/10.1038/nm1102-1235			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12411950				2022-12-27	WOS:000179221200028
J	Linggi, B; Muller-Tidow, C; van de Locht, L; Hu, M; Nip, J; Serve, H; Berdel, WE; van der Reijden, B; Quelle, DE; Rowley, JD; Cleveland, J; Jansen, JH; Pandolfi, PP; Hiebert, SW				Linggi, B; Muller-Tidow, C; van de Locht, L; Hu, M; Nip, J; Serve, H; Berdel, WE; van der Reijden, B; Quelle, DE; Rowley, JD; Cleveland, J; Jansen, JH; Pandolfi, PP; Hiebert, SW			The t(8;21) fusion protein, AML1-ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia	NATURE MEDICINE			English	Article							WILD-TYPE P53; HEMATOLOGICAL MALIGNANCIES; INK4A LOCUS; GENE; P19(ARF); P16(INK4A); CELLS; MDM2; SENESCENCE; EXPRESSION	The t( 8; 21) is one of the most frequent chromosomal translocations associated with acute leukemia. This translocation creates a fusion protein consisting of the acute myeloid leukemia-1 transcription factor and the eight-twenty-one corepressor (AML1-ETO), which represses transcription through AML1 (RUNX1) DNA binding sites and immortalizes hematopoietic progenitor cells. We have identified the p14(ARF) tumor suppressor, a mediator of the p53 oncogene checkpoint, as a direct transcriptional target of AML1-ETO. AML1-ETO repressed the p14(ARF) promoter and reduced endogenous levels of p14(ARF) expression in multiple cell types. In contrast, AML1 stimulated p14(ARF) expression and induced phenotypes consistent with cellular senescence. Chromatin immunoprecipitation assays demonstrated that AML1-ETO was specifically bound to the p14(ARF) promoter. In acute myeloid leukemia samples containing the t( 8; 21), levels of p14(ARF) mRNA were markedly lower when compared with other acute myeloid leukemias lacking this translocation. Repression of p14(ARF) may explain why p53 is not mutated in t( 8; 21)-containing leukemias and suggests that p14(ARF) is an important tumor suppressor in a large number of human leukemias.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37212 USA; Univ Munster, Dept Med Hematol & Oncol, D-4400 Munster, Germany; Radboud Univ Nijmegen Med Ctr, Dept Hematol, Nijmegen, Netherlands; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Cornell Univ, New York, NY USA; Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA; Univ Chicago, Dept Hematol & Oncol, Chicago, IL 60637 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Dept Mol Sci, Memphis, TN USA	Vanderbilt University; University of Munster; Radboud University Nijmegen; Memorial Sloan Kettering Cancer Center; Cornell University; University of Iowa; University of Chicago; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Hiebert, SW (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37212 USA.	scott.hiebert@mcmail.vanderbilt.edu	Müller-Tidow, Carsten CMT/B-5257-2014; Hiebert, Scott W/C-9979-2010; Jansen, J.H./H-8054-2014; van der Reijden, Bert A/A-3543-2014; Müller-Tidow, Carsten/O-7207-2018	Jansen, J.H./0000-0001-9459-568X; Müller-Tidow, Carsten/0000-0002-7166-5232; Quelle, Dawn/0000-0001-8776-0122	NATIONAL CANCER INSTITUTE [R01CA064140, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013726] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, R01-CA64140] Funding Source: Medline; NIA NIH HHS [R01-AG13726] Funding Source: Medline; PHS HHS [R01-87549] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Banker DE, 1998, CLIN CANCER RES, V4, P3051; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; LENNY N, 1995, ONCOGENE, V11, P1761; Licht JD, 2001, ONCOGENE, V20, P5660, DOI 10.1038/sj.onc.1204593; MELNIKOVA IN, 1993, J VIROL, V67, P2408, DOI 10.1128/JVI.67.4.2408-2411.1993; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Quesnel B, 1996, LEUKEMIA LYMPHOMA, V22, P11, DOI 10.3109/10428199609051724; Rhoades KL, 2000, BLOOD, V96, P2108; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIMMONS D, 1988, J IMMUNOL, V141, P2797; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Taniguchi T, 1999, LEUKEMIA, V13, P1760, DOI 10.1038/sj.leu.2401557; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	44	202	209	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2002	8	7					743	750		10.1038/nm726	http://dx.doi.org/10.1038/nm726			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12091906				2022-12-27	WOS:000176495200037
J	Appay, V; Dunbar, PR; Callan, M; Klenerman, P; Gillespie, GMA; Papagno, L; Ogg, GS; King, A; Lechner, F; Spina, CA; Little, S; Havlir, DV; Richman, DD; Gruener, N; Pape, G; Waters, A; Easterbrook, P; Salio, M; Cerundolo, V; McMichael, AJ; Rowland-Jones, SL				Appay, V; Dunbar, PR; Callan, M; Klenerman, P; Gillespie, GMA; Papagno, L; Ogg, GS; King, A; Lechner, F; Spina, CA; Little, S; Havlir, DV; Richman, DD; Gruener, N; Pape, G; Waters, A; Easterbrook, P; Salio, M; Cerundolo, V; McMichael, AJ; Rowland-Jones, SL			Memory CD8(+) T cells vary in differentiation phenotype in different persistent virus infections	NATURE MEDICINE			English	Article							HEPATITIS-C VIRUS; LYMPHOCYTE RESPONSES; IMMUNE-RESPONSES; HIV-INFECTION; IN-VIVO; EXPRESSION; CYTOMEGALOVIRUS; CYTOKINES; APOPTOSIS; ANTIGEN	The viruses HIV-1, Epstein Barr virus (EBV), cytomegalovirus ( CMV) and hepatitis C virus ( HCV) are characterized by the establishment of lifelong infection in the human host, where their replication is thought to be tightly controlled by virus-specific CD8(+) T cells. Here we present detailed studies of the differentiation phenotype of these cells, which can be separated into three distinct subsets based on expression of the costimulatory receptors CD28 and CD27. Whereas CD8(+) T cells specific for HIV, EBV and HCV exhibit similar characteristics during primary infection, there are significant enrichments at different stages of cellular differentiation in the chronic phase of persistent infection according to the viral specificity, which suggests that distinct memory T-cell populations are established in different virus infections. These findings challenge the current definitions of memory and effector subsets in humans, and suggest that ascribing effector and memory functions to subsets with different differentiation phenotypes is no longer appropriate.	John Radcliffe Hosp, Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DU, England; Peter Medawar Bldg Pathogen Res, Nuffield Dept Med, Oxford, England; Univ Calif San Diego, La Jolla, CA 92093 USA; San Diego VA Res Ctr AIDS & HIV Infect, San Diego, CA USA; Inst Immunol, D-8000 Munich, Germany; Guys Kings & St Thomas Sch Med, Dept HIV GUM, London, England; Weston Educ Ctr, London, England	University of Oxford; University of Oxford; University of California System; University of California San Diego; University of London; King's College London	Appay, V (corresponding author), John Radcliffe Hosp, Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DU, England.		Little, Susan/AAA-6116-2019; Easterbrook, Philippa J/A-3937-2009; Appay, Victor/M-4830-2017; Dunbar, Rod/C-2570-2012; Appay, Victor/AAM-7701-2021	Dunbar, Rod/0000-0001-9626-2600; Cerundolo, Vincenzo/0000-0003-0040-3793; Ogg, Graham/0000-0002-3097-045X; Easterbrook, Philippa/0000-0002-2603-5418; Appay, Victor/0000-0001-5434-3963; klenerman, paul/0000-0003-4307-9161; Salio, Mariolina/0000-0002-4821-3801	Medical Research Council [G116/121] Funding Source: Medline; MRC [G116/121] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Altman JD, 1998, SCIENCE, V280, P1821; ANDREWS DM, 2001, NATURE IMMUNOL, V22, P22; Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63; Baars PA, 2000, J IMMUNOL, V165, P1910, DOI 10.4049/jimmunol.165.4.1910; Bevan MJ, 2001, NAT IMMUNOL, V2, P381, DOI 10.1038/87676; Borthwick NJ, 2000, INT IMMUNOL, V12, P1005, DOI 10.1093/intimm/12.7.1005; Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x; Callan MFC, 2000, J CLIN INVEST, V106, P1251, DOI 10.1172/JCI10590; Callan MFC, 1996, NAT MED, V2, P906, DOI 10.1038/nm0896-906; Campbell JJ, 1998, J CELL BIOL, V141, P1053, DOI 10.1083/jcb.141.4.1053; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Chen G, 2001, BLOOD, V98, P156, DOI 10.1182/blood.V98.1.156; De Rosa SC, 2001, NAT MED, V7, P245, DOI 10.1038/84701; Doherty PC, 2000, ANNU REV IMMUNOL, V18, P561, DOI 10.1146/annurev.immunol.18.1.561; Easterbrook PJ, 1999, J INFECTION, V38, P71, DOI 10.1016/S0163-4453(99)90071-3; EFFROS RB, 1996, AIDS, V10, P17; FERBAS J, 1995, J INFECT DIS, V172, P329, DOI 10.1093/infdis/172.2.329; Gillespie GMA, 2000, J VIROL, V74, P8140, DOI 10.1128/JVI.74.17.8140-8150.2000; Globerson A, 2000, IMMUNOL TODAY, V21, P515, DOI 10.1016/S0167-5699(00)01714-X; Grayson JM, 2000, J IMMUNOL, V164, P3950, DOI 10.4049/jimmunol.164.8.3950; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; Hamann D, 1999, INT IMMUNOL, V11, P1027, DOI 10.1093/intimm/11.7.1027; Hendriks J, 2000, NAT IMMUNOL, V1, P433, DOI 10.1038/80877; Hislop AD, 2001, J IMMUNOL, V167, P2019, DOI 10.4049/jimmunol.167.4.2019; Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950; Hu H, 2001, NAT IMMUNOL, V2, P705, DOI 10.1038/90643; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; Kostense S, 2001, EUR J IMMUNOL, V31, P677, DOI 10.1002/1521-4141(200103)31:3<677::AID-IMMU677>3.0.CO;2-M; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lechner F, 2000, EUR J IMMUNOL, V30, P2479, DOI 10.1002/1521-4141(200009)30:9<2479::AID-IMMU2479>3.0.CO;2-B; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Medley QG, 1996, P NATL ACAD SCI USA, V93, P685, DOI 10.1073/pnas.93.2.685; Mueller YM, 2001, IMMUNITY, V15, P871, DOI 10.1016/S1074-7613(01)00246-1; Posnett DN, 1999, INT IMMUNOL, V11, P229, DOI 10.1093/intimm/11.2.229; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Roos MTL, 2000, J INFECT DIS, V182, P451, DOI 10.1086/315737; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Wills MR, 1996, J VIROL, V70, P7569, DOI 10.1128/JVI.70.11.7569-7579.1996	42	1246	1297	1	61	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2002	8	4					379	385		10.1038/nm0402-379	http://dx.doi.org/10.1038/nm0402-379			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927944				2022-12-27	WOS:000174704800030
J	Lawrence, T; Gilroy, DW; Colville-Nash, PR; Willoughby, DA				Lawrence, T; Gilroy, DW; Colville-Nash, PR; Willoughby, DA			Possible new role for NF-kappa B in the resolution of inflammation	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); CYCLOPENTENONE PROSTAGLANDINS; TRANSCRIPTIONAL ACTIVATION; CYCLOOXYGENASE-2 GENE; P53 PROMOTER; MICE LACKING; APOPTOSIS; PHOSPHORYLATION; EXPRESSION	Inflammation involves the sequential activation of signaling pathways leading to the production of both pro- and anti-inflammatory mediators. Although much attention has focused on pro-inflammatory pathways that initiate inflammation, relatively little is known about the mechanisms that switch off inflammation and resolve the inflammatory response. The transcription factor NF-kappaB is thought to have a central role in the induction of pro-inflammatory gene expression and has attracted interest as a new target for the treatment of inflammatory disease. We, show here that NF-kappaB activation in leukocytes recruited during the onset of inflammation is associated with pro-inflammatory gene expression, whereas such activation during the resolution of inflammation is associated with the expression of anti-inflammatory genes and the induction of apoptosis. Inhibition of NF-kappaB during the resolution of inflammation protracts the inflammatory response and prevents apoptosis. This:suggests that NF-kappaB has an anti-inflammatory role in vivo involving the regulation of inflammatory resolution.	William Harvey Res Inst, Dept Expt Pathol, London EC1M 6BQ, England	University of London; Queen Mary University London	Lawrence, T (corresponding author), William Harvey Res Inst, Dept Expt Pathol, Charterhouse Sq, London EC1M 6BQ, England.	t.lawrence@mds.qmw.ac.uk	Gilroy, Derek/AAP-7227-2020; Gilroy, Derek W/C-2588-2009; Lawrence, Toby/GLU-3895-2022	Gilroy, Derek/0000-0003-3476-0844; Lawrence, Toby/0000-0003-0967-6122				Alcamo E, 2001, J IMMUNOL, V167, P1592, DOI 10.4049/jimmunol.167.3.1592; Bohuslav J, 1998, J CLIN INVEST, V102, P1645, DOI 10.1172/JCI3877; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Carrasco D, 1998, J EXP MED, V187, P973, DOI 10.1084/jem.187.7.973; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Grigoriadis G, 1996, EMBO J, V15, P7099, DOI 10.1002/j.1460-2075.1996.tb01101.x; Grossmann M, 1999, P NATL ACAD SCI USA, V96, P11848, DOI 10.1073/pnas.96.21.11848; Haslett C, 1997, BRIT MED BULL, V53, P669; HOBBS AJ, 1999, PROG INFLAM RES, P31; Hortelano S, 2000, J IMMUNOL, V165, P6525, DOI 10.4049/jimmunol.165.11.6525; Igata E, 1999, GENE, V238, P407, DOI 10.1016/S0378-1119(99)00348-0; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin BH, 1999, CELL DEATH DIFFER, V6, P570, DOI 10.1038/sj.cdd.4400528; Liu L, 1999, CIRCULATION, V100, P1; Lotem J, 1997, P NATL ACAD SCI USA, V94, P9349, DOI 10.1073/pnas.94.17.9349; MCDONALD DG, 1964, PSYCHOPHYSIOLOGY, V1, P163, DOI 10.1111/j.1469-8986.1964.tb03231.x; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; SUN XG, 1995, MOL CELL BIOL, V15, P4489; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Thomas B, 2000, EUR J BIOCHEM, V267, P6798, DOI 10.1046/j.1432-1327.2000.01778.x; TOMLINSON A, 1994, BRIT J PHARMACOL, V113, P693, DOI 10.1111/j.1476-5381.1994.tb17048.x; TOMLINSON A, 1999, PROG INFLAM RES, P187; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; WU HY, 1994, J BIOL CHEM, V269, P20067; Xaus J, 2000, BLOOD, V95, P3823; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	45	623	653	2	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2001	7	12					1291	1297		10.1038/nm1201-1291	http://dx.doi.org/10.1038/nm1201-1291			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726968				2022-12-27	WOS:000172610300033
J	Novak, K				Novak, K			Creutzfeldt-Jakob gene	NATURE MEDICINE			English	News Item														Novak, Kristine/0000-0001-9314-1803					0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2001	7	12					1290	1290		10.1038/nm1201-1290	http://dx.doi.org/10.1038/nm1201-1290			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726967	Bronze			2022-12-27	WOS:000172610300029
J	O'Rahilly, S				O'Rahilly, S			Uncoupling protein 2: Adiposity angel and diabetes devil?	NATURE MEDICINE			English	Editorial Material							SKELETAL-MUSCLE; BROWN FAT; GENE; MICE; OVEREXPRESSION; ISLETS	The discovery of a family of proteins with strong homology to the uncoupling protein of brown fat has generated great interest as these molecules might represent therapeutic targets for human obesity. Two recent studies have used genetics to explore the role of one of these proteins, UCP2, in the control of mammalian metabolism and come to rather different conclusions.	Univ Cambridge, Addenbrookes Hosp, Cambridge CB2 2QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	O'Rahilly, S (corresponding author), Univ Cambridge, Addenbrookes Hosp, Cambridge CB2 2QQ, England.		O'Rahilly, Stephen/ABF-6509-2020	O'Rahilly, Stephen/0000-0003-2199-4449				Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Chan CB, 1999, DIABETES, V48, P1482, DOI 10.2337/diabetes.48.7.1482; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Esterbauer H, 2001, NAT GENET, V28, P178, DOI 10.1038/88911; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Stuart JA, 2001, BBA-BIOENERGETICS, V1504, P144, DOI 10.1016/S0005-2728(00)00243-7; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Wang MY, 1999, DIABETES, V48, P1020, DOI 10.2337/diabetes.48.5.1020; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	12	15	15	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					770	772		10.1038/89877	http://dx.doi.org/10.1038/89877			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433333				2022-12-27	WOS:000169808600016
J	Duckers, HJ; Boehm, M; True, AL; Yet, SF; San, H; Park, JL; Webb, RC; Lee, ME; Nabel, GJ; Nabel, EG				Duckers, HJ; Boehm, M; True, AL; Yet, SF; San, H; Park, JL; Webb, RC; Lee, ME; Nabel, GJ; Nabel, EG			Heme oxygenase-1 protects against vascular constriction and proliferation	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE-CELLS; CARBON-MONOXIDE; NITRIC-OXIDE; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; GENE-EXPRESSION; P21; ACTIVATION; INHIBITORS; INDUCTION	Heme oxygenase (HO-1, encoded by Hmox1) is an inducible protein activated in systemic inflammatory conditions by oxidant stress. Vascular injury is characterized by a local reparative process with inflammatory components, indicating a potential protective role for HO-1 in arterial wound repair. Here we report that HO-1 directly reduces vasoconstriction and inhibits cell proliferation during vascular injury. Expression of HO-1 in arteries stimulated vascular relaxation, mediated by guanylate cyclase and cGMP, independent of nitric oxide. The unexpected effects of HO-1 on vascular smooth muscle cell growth were mediated by cell-cycle arrest involving p21(Cip1). HO-1 reduced the proliferative response to vascular injury in vivo; expression of HO-1 in pig arteries inhibited lesion formation and Hmox1(-/-) mice produced hyperplastic arteries compared with controls. Induction of the HO-1 pathway moderates the severity of vascular injury by at least two adaptive mechanisms independent of nitric oxide, and is a potential therapeutic target for diseases of the vasculature.	NHLBI, Vasc Biol Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; Med Coll Georgia, Dept Physiol, Augusta, GA 30912 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University System of Georgia; Augusta University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Nabel, EG (corresponding author), NHLBI, Vasc Biol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.	enabel@nih.gov	Yet, Shaw-Fang/O-8583-2019; Yet, Shaw-Fang/B-1067-2010	Yet, Shaw-Fang/0000-0001-9097-3962	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005601] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Durante W, 1997, CIRC RES, V80, P557, DOI 10.1161/01.RES.80.4.557; Foresti R, 1997, J BIOL CHEM, V272, P18411, DOI 10.1074/jbc.272.29.18411; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; Hancock WW, 1998, NAT MED, V4, P1392, DOI 10.1038/3982; Hartsfield CL, 1997, AM J PHYSIOL-LUNG C, V273, pL980; Layne MD, 1998, J BIOL CHEM, V273, P15654, DOI 10.1074/jbc.273.25.15654; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MARKS GS, 1991, TRENDS PHARMACOL SCI, V12, P185, DOI 10.1016/0165-6147(91)90544-3; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Morita T, 1995, J CLIN INVEST, V96, P2676, DOI 10.1172/JCI118334; Morita T, 1997, J BIOL CHEM, V272, P32804, DOI 10.1074/jbc.272.52.32804; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; Motterlini R, 1996, AM J PHYSIOL-HEART C, V270, pH107, DOI 10.1152/ajpheart.1996.270.1.H107; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; OTTERBEIN LE, 1999, AM J PHYSIOL, V276, P688; Sammut IA, 1998, BRIT J PHARMACOL, V125, P1437, DOI 10.1038/sj.bjp.0702212; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; SUEMATSU M, 1995, J CLIN INVEST, V96, P2431, DOI 10.1172/JCI118300; Tanner FC, 2000, CIRCULATION, V101, P1982, DOI 10.1161/01.CIR.101.16.1982; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Wagner CT, 1997, J CLIN INVEST, V100, P589, DOI 10.1172/JCI119569; Wang LJ, 1998, AM J PATHOL, V152, P711; WOLIN MS, 1982, J BIOL CHEM, V257, P13312; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163; Yet SF, 1997, J BIOL CHEM, V272, P4295, DOI 10.1074/jbc.272.7.4295; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7778; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795	36	454	485	1	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2001	7	6					693	698		10.1038/89068	http://dx.doi.org/10.1038/89068			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385506				2022-12-27	WOS:000169081500037
J	Fujita, T; Toda, K; Karimova, A; Yan, SF; Naka, Y; Yet, SF; Pinsky, DJ				Fujita, T; Toda, K; Karimova, A; Yan, SF; Naka, Y; Yet, SF; Pinsky, DJ			Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by derepression of fibrinolysis	NATURE MEDICINE			English	Article							HUMAN SKIN FIBROBLASTS; SMOOTH-MUSCLE CELLS; HEME OXYGENASE-1; NITRIC-OXIDE; OXIDATIVE STRESS; ISCHEMIA/REPERFUSION INJURY; PROVIDES PROTECTION; UP-REGULATION; NULL MICE; GENE	Carbon monoxide (CO) can arrest cellular respiration, but paradoxically, it is synthesized endogenously by heme oxygenase type 1 (Ho-1) in response to ischemic stress. Ho-1-deficient (Hmox1(-/-)) mice exhibited lethal ischemic lung injury, but were rescued from death by inhaled CO. CO drove ischemic protection by activating soluble guanylate cyclase and thereby suppressed hypoxic induction of the gene encoding plasminogen activator inhibitor-1 (PAI-1) in mononuclear phagocytes, which reduced accrual of microvascular fibrin. GO-mediated ischemic protection observed in wild-type mice was lost in mice null for the gene encoding PAI-1 (Serpine1). These data establish a fundamental link between CO and prevention of ischemic injury based on the ability of CO to derepress the fibrinolytic axis. These data also point to a potential therapeutic use for inhaled CO.	Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Columbia University; Harvard University; Brigham & Women's Hospital	Pinsky, DJ (corresponding author), Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA.		Yet, Shaw-Fang/B-1067-2010; Tomoyuki, Fujita/AAC-7464-2020; Yet, Shaw-Fang/O-8583-2019	Yet, Shaw-Fang/0000-0001-9097-3962	NHLBI NIH HHS [R01 HL60900, R01 HL55397, R01 HL59488] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059488, R01HL060900, R01HL055397] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amersi F, 1999, J CLIN INVEST, V104, P1631, DOI 10.1172/JCI7903; Bouchie JL, 1998, ARTERIOSCL THROM VAS, V18, P1771, DOI 10.1161/01.ATV.18.11.1771; BOWRY VW, 1995, J BIOL CHEM, V270, P5756, DOI 10.1074/jbc.270.11.5756; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CHRISTODOULIDES N, 1995, CIRCULATION, V91, P2306, DOI 10.1161/01.CIR.91.9.2306; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; GETTLER AO, 1940, AM J CLIN PATHOL, V11, P603; Goda N, 1998, J CLIN INVEST, V101, P604, DOI 10.1172/JCI1324; GOLDBAUM LR, 1975, AVIAT SPACE ENVIR MD, V46, P1289; Hancock WW, 1998, NAT MED, V4, P1392, DOI 10.1038/3982; Hayashi S, 1999, CIRC RES, V85, P663, DOI 10.1161/01.RES.85.8.663; Ischiropoulos H, 1996, J CLIN INVEST, V97, P2260, DOI 10.1172/JCI118667; Lawson CA, 1997, J CLIN INVEST, V99, P1729, DOI 10.1172/JCI119337; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Maines MD, 1999, J PHARMACOL EXP THER, V291, P911; Morita T, 1995, J CLIN INVEST, V96, P2676, DOI 10.1172/JCI118334; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; Naka Y, 1997, P NATL ACAD SCI USA, V94, P757, DOI 10.1073/pnas.94.2.757; Naka Y, 1997, TRANSPLANTATION, V64, P1248, DOI 10.1097/00007890-199711150-00004; Okada K, 2000, J BIOL CHEM, V275, P21468, DOI 10.1074/jbc.M002682200; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595, DOI 10.1165/ajrcmb.13.5.7576696; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Panahian N, 1999, J NEUROCHEM, V72, P1187; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; PINSKY DJ, 1994, P NATL ACAD SCI USA, V91, P12086, DOI 10.1073/pnas.91.25.12086; Polte T, 2000, ARTERIOSCL THROM VAS, V20, P1209, DOI 10.1161/01.ATV.20.5.1209; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; SOKAL JA, 1975, ARCH TOXICOL, V34, P331, DOI 10.1007/BF00353853; Taylor JL, 1998, AM J PHYSIOL-LUNG C, V274, pL582, DOI 10.1152/ajplung.1998.274.4.L582; Thom SR, 2000, P NATL ACAD SCI USA, V97, P1305, DOI 10.1073/pnas.97.3.1305; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; VILE GF, 1993, J BIOL CHEM, V268, P14678; Weng YH, 2000, AM J PHYSIOL-LUNG C, V278, pL1273, DOI 10.1152/ajplung.2000.278.6.L1273; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368; Zingarelli B, 1999, CRIT CARE MED, V27, P1701, DOI 10.1097/00003246-199909000-00001	45	357	391	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					598	604		10.1038/87929	http://dx.doi.org/10.1038/87929			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329062				2022-12-27	WOS:000169961100040
J	Manji, HK; Drevets, WC; Charney, DS				Manji, HK; Drevets, WC; Charney, DS			The cellular neurobiology of depression	NATURE MEDICINE			English	Review							MOOD-DISORDERS; SYNAPTIC PLASTICITY; NEUROPSYCHIATRIC DISORDERS; HIPPOCAMPAL NEUROGENESIS; N-ACETYLASPARTATE; BIPOLAR DISORDER; CUSHINGS-DISEASE; HUMAN BRAIN; IN-VIVO; LITHIUM	Major depressive disorders, long considered to be of neurochemical origin, have recently been associated with impairments in signaling pathways that regulate neuroplasticity and cell survival. Agents designed to directly target molecules in these pathways may hold promise as new therapeutics for depression.	NIMH, Mol Pathophysiol Lab, Bethesda, MD 20892 USA; NIMH, Sect Neuroimaging, Bethesda, MD 20892 USA; NIMH, Mood & Anxiety Disorders Res Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Manji, HK (corresponding author), NIMH, Mol Pathophysiol Lab, Bethesda, MD 20892 USA.	manjih@intra.nimh.nih.gov			NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002790, ZIAMH002790] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Black IB, 1999, J NEUROBIOL, V41, P108, DOI 10.1002/(SICI)1097-4695(199910)41:1<108::AID-NEU14>3.0.CO;2-U; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; Brown ES, 1999, NEUROPSYCHOPHARMACOL, V21, P474, DOI 10.1016/S0893-133X(99)00054-8; Calabrese JR, 1999, AM J PSYCHIAT, V156, P1019; Charney DS, 1998, J CLIN PSYCHIAT, V59, P11; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chen G, 2000, J NEUROCHEM, V75, P1729, DOI 10.1046/j.1471-4159.2000.0751729.x; Chen G, 1999, J NEUROCHEM, V72, P879, DOI 10.1046/j.1471-4159.1999.720879.x; Chen RW, 1999, J BIOL CHEM, V274, P6039, DOI 10.1074/jbc.274.10.6039; Ciechanowski PS, 2000, ARCH INTERN MED, V160, P3278, DOI 10.1001/archinte.160.21.3278; Coyle JT, 2000, ARCH GEN PSYCHIAT, V57, P90, DOI 10.1001/archpsyc.57.1.90; Drevets WC, 2000, BIOL PSYCHIAT, V48, P813, DOI 10.1016/S0006-3223(00)01020-9; Drevets WC, 2001, CURR OPIN NEUROBIOL, V11, P240, DOI 10.1016/S0959-4388(00)00203-8; DREVETS WC, 1999, NEUROBIOLOGY MENTAL, P394; Duman RS, 2000, BIOL PSYCHIAT, V48, P732, DOI 10.1016/S0006-3223(00)00935-5; Duman RS, 1997, ARCH GEN PSYCHIAT, V54, P597; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; FOLSTEIN SE, 1991, AM PSYCHOP, P65; Francis D, 1999, SCIENCE, V286, P1155, DOI 10.1126/science.286.5442.1155; GARLOW SJ, 1999, NEUROBIOLOGY MENTAL, P348; Gould E, 2000, BIOL PSYCHIAT, V48, P715, DOI 10.1016/S0006-3223(00)01021-0; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Graham YP, 1999, DEV PSYCHOPATHOL, V11, P545, DOI 10.1017/S0954579499002205; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; Guo ZH, 2000, SCIENCE, V288, P2042, DOI 10.1126/science.288.5473.2042; Heim C, 1999, BIOL PSYCHIAT, V46, P1509, DOI 10.1016/S0006-3223(99)00224-3; Holsboer F, 2000, NEUROPSYCHOPHARMACOL, V23, P477, DOI 10.1016/S0893-133X(00)00159-7; Jacobs BL, 2000, MOL PSYCHIATR, V5, P262, DOI 10.1038/sj.mp.4000712; Janowsky David S., 1995, P945; Kessler RC, 1997, ANNU REV PSYCHOL, V48, P191, DOI 10.1146/annurev.psych.48.1.191; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lambert G, 2000, ARCH GEN PSYCHIAT, V57, P787, DOI 10.1001/archpsyc.57.8.787; LEDOUX JE, 1987, HDB PHYSL NERVOUS SY, V5, P373; Maes M., 1995, PSYCHOPHARMACOLOGY 4, P921; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Manji HK, 2000, MOL PSYCHIATR, V5, P578, DOI 10.1038/sj.mp.4000811; Manji HK, 2000, BIOL PSYCHIAT, V48, P518, DOI 10.1016/S0006-3223(00)00929-X; MANJI HK, 2000, BIPOLAR MED MECH ACT, P129; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Mesulam NM, 1999, NEURON, V24, P521, DOI 10.1016/S0896-6273(00)81109-5; Michelson D, 1996, NEW ENGL J MED, V335, P1176, DOI 10.1056/NEJM199610173351602; Moore GJ, 2000, LANCET, V356, P1241, DOI 10.1016/S0140-6736(00)02793-8; Moore GJ, 2000, BIOL PSYCHIAT, V48, P1, DOI 10.1016/S0006-3223(00)00252-3; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Musselman DL, 1998, ARCH GEN PSYCHIAT, V55, P580, DOI 10.1001/archpsyc.55.7.580; Nestler EJ, 1998, BIOL PSYCHIAT, V44, P526, DOI 10.1016/S0006-3223(98)00095-X; Ongur D, 1998, P NATL ACAD SCI USA, V95, P13290, DOI 10.1073/pnas.95.22.13290; Owens, 1999, Expert Opin Investig Drugs, V8, P1849, DOI 10.1517/13543784.8.11.1849; Petrie RXA, 2000, PHARMACOL THERAPEUT, V87, P11, DOI 10.1016/S0163-7258(00)00063-2; Rajkowska G, 2000, BIOL PSYCHIAT, V48, P766, DOI 10.1016/S0006-3223(00)00950-1; Rajkowska G, 1999, BIOL PSYCHIAT, V45, P1085, DOI 10.1016/S0006-3223(99)00041-4; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Sanacora G, 1999, ARCH GEN PSYCHIAT, V56, P1043, DOI 10.1001/archpsyc.56.11.1043; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; Schatzberg Alan F., 1995, P911; Schulz R, 2000, ARCH INTERN MED, V160, P1761, DOI 10.1001/archinte.160.12.1761; Sonino N, 1998, PSYCHOTHER PSYCHOSOM, V67, P140, DOI 10.1159/000012274; Starkman MN, 1999, BIOL PSYCHIAT, V46, P1595, DOI 10.1016/S0006-3223(99)00203-6; Starkstein, 1996, Semin Clin Neuropsychiatry, V1, P272; STARKSTEIN SE, 1989, BRIT J PSYCHIAT, V154, P170, DOI 10.1192/bjp.154.2.170; Steffens DC, 1998, PSYCHIAT RES-NEUROIM, V83, P95, DOI 10.1016/S0925-4927(98)00032-8; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; TSAI GC, 1995, PROG NEUROBIOL, V46, P531, DOI 10.1016/0301-0082(95)00014-M; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Willner Paul, 1995, P921; Wolkowitz OM, 1999, PSYCHOSOM MED, V61, P698, DOI 10.1097/00006842-199909000-00011	72	871	913	2	135	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					541	547		10.1038/87865	http://dx.doi.org/10.1038/87865			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329053				2022-12-27	WOS:000169961100031
J	Nathanson, KN; Wooster, R; Weber, BL				Nathanson, KN; Wooster, R; Weber, BL			Breast cancer genetics: What we know and what we need	NATURE MEDICINE			English	Review							DNA-DAMAGE RESPONSE; OVARIAN-CANCER; FAMILIAL BREAST; EARLY-ONSET; BRCA2 GENE; ATAXIA-TELANGIECTASIA; GERMLINE MUTATIONS; ATM MUTATIONS; RISK; WOMEN	Breast cancer results from genetic and environmental factors leading to the accumulation of mutations in essential genes. Genetic predisposition may have a strong, almost singular effect, as with BRCA1 and BRCA2, or may represent the cumulative effects of multiple low-penetrance susceptibility alleles. Here we review high- and low-penetrance breast-cancer-susceptibility alleles and discuss ongoing efforts to identify additional susceptibility genes. Ultimately these discoveries will lead to individualized breast cancer risk assessment and a reduction in breast cancer incidence.	Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Sanger Ctr, Hinxton, England	University of Pennsylvania; Pennsylvania Medicine; Wellcome Trust Sanger Institute	Nathanson, KN (corresponding author), Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.		anand, amit/A-7222-2009	Nathanson, Katherine/0000-0002-6740-0901				Boardman LA, 1998, ANN INTERN MED, V128, P896, DOI 10.7326/0003-4819-128-11-199806010-00004; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Broeks A, 2000, AM J HUM GENET, V66, P494, DOI 10.1086/302746; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JD, 1998, CANCER RES, V58, P1376; Chen JJ, 1999, CANCER RES, V59, p1752S; Claus EB, 1998, J NATL CANCER I, V90, P1824, DOI 10.1093/jnci/90.23.1824; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; EASTON DF, 1995, AM J HUM GENET, V56, P265; EASTON DF, 1994, LANCET, V344, P761, DOI 10.1016/S0140-6736(94)92256-X; EASTON DF, 1993, AM J HUM GENET, V52, P678; Eisen A, 2000, J CLIN ONCOL, V18, P1980, DOI 10.1200/JCO.2000.18.9.1980; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Fodor FH, 1998, AM J HUM GENET, V63, P45, DOI 10.1086/301903; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Friedman LS, 1998, CANCER RES, V58, P1338; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Inskip HM, 1999, BRIT J CANCER, V79, P1304, DOI 10.1038/sj.bjc.6690209; Izatt L, 1999, GENE CHROMOSOME CANC, V26, P286, DOI 10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.0.CO;2-X; Janin N, 1999, BRIT J CANCER, V80, P1042, DOI 10.1038/sj.bjc.6690460; Kainu T, 2000, P NATL ACAD SCI USA, V97, P9603, DOI 10.1073/pnas.97.17.9603; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Laake K, 2000, BRIT J CANCER, V83, P1650, DOI 10.1054/bjoc.2000.1519; Lakhani SR, 2000, CLIN CANCER RES, V6, P782; Larson JS, 1997, CANCER RES, V57, P3351; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LOBACCARO JM, 1993, HUM MOL GENET, V2, P1799, DOI 10.1093/hmg/2.11.1799; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MORRELL D, 1986, J NATL CANCER I, V77, P89; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Park JJ, 2000, CANCER RES, V60, P5946; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Peto J, 2000, NAT GENET, V26, P411, DOI 10.1038/82533; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; Phelan CM, 1996, NAT GENET, V12, P309, DOI 10.1038/ng0396-309; Ponder BAJ, 2000, BRIT J CANCER, V83, P1301; Rebbeck TR, 1999, AM J HUM GENET, V64, P1371, DOI 10.1086/302366; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shih HA, 2000, CLIN CANCER RES, V6, P4259; Struewing JP, 1996, LANCET, V347, P1493, DOI 10.1016/S0140-6736(96)91732-8; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; THOMPSON D, 2001, P AM ASS CANC RES; Tirkkonen M, 1997, CANCER RES, V57, P1222; Vorechovsky I, 1996, CANCER RES, V56, P4130; Warner E, 1999, J NATL CANCER I, V91, P1241, DOI 10.1093/jnci/91.14.1241; WOOSTER R, 1992, NAT GENET, V2, P132, DOI 10.1038/ng1092-132; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	61	331	356	0	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2001	7	5					552	556		10.1038/87876	http://dx.doi.org/10.1038/87876			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329055				2022-12-27	WOS:000169961100033
J	Fulda, S; Wick, W; Weller, M; Debatin, KM				Fulda, S; Wick, W; Weller, M; Debatin, KM			Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo	NATURE MEDICINE			English	Article							TRAIL-INDUCED APOPTOSIS; DEATH RECEPTOR; TUMORICIDAL ACTIVITY; CD95 APO-1/FAS; SMAC/DIABLO; INHIBITION; PROTEIN; INACTIVATION; ACTIVATION; CASPASES	A major concern in cancer therapy is resistance of tumors such as glioblastoma to current treatment protocols. Here, we report that transfer of the gene encoding second mitochondria-derived activator of caspase ( Smac) or Smac peptides sensitized various tumor cells in vitro and malignant glioma cells in vivo for apoptosis induced by death-receptor ligation or cytotoxic drugs. Expression of a cytosolic active form of Smac or cell-permeable Smac peptides bypassed the Bcl-2 block, which prevented the release of Smac from mitochondria, and also sensitized resistant neuroblastoma or melanoma cells and patient-derived primary neuroblastoma cells ex vivo. Most importantly, Smac peptides strongly enhanced the antitumor activity of Apo2L/tumor necrosis factor - related apoptosis-inducing ligand ( TRAIL) in an intracranial malignant glioma xenograft model in vivo. Complete eradication of established tumors and survival of mice was only achieved upon combined treatment with Smac peptides and Apo2L/TRAIL without detectable toxicity to normal brain tissue. Thus, Smac agonists are promising candidates for cancer therapy by potentiating cytotoxic therapies.	Univ Childrens Hosp, Ulm, Germany; Univ Tubingen, Dept Neurol, D-7400 Tubingen, Germany; German Canc Res Ctr, Div Mol Oncol Pediat, D-6900 Heidelberg, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ)	Debatin, KM (corresponding author), Univ Childrens Hosp, Ulm, Germany.	klaus-michael.debatin@medizin.uni-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011; Wick, Wolfgang/AAA-2545-2020	Debatin, Klaus-Michael/0000-0002-8397-1886; Wick, Wolfgang/0000-0002-6171-634X; Fulda, Simone/0000-0002-0459-6417; Weller, Michael/0000-0002-1748-174X				Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hanemann CO, 1998, GLIA, V23, P89, DOI 10.1002/(SICI)1098-1136(199806)23:2<89::AID-GLIA1>3.0.CO;2-Z; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Mow BMF, 2001, CURR OPIN ONCOL, V13, P453, DOI 10.1097/00001622-200111000-00007; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Roy S, 2000, J EXP MED, V192, pF21, DOI 10.1084/jem.192.8.F21; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Weissert R, 1998, J CLIN INVEST, V102, P1265, DOI 10.1172/JCI3022; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang XD, 2001, CANCER RES, V61, P7339	45	644	740	0	58	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2002	8	8					808	815		10.1038/nm735	http://dx.doi.org/10.1038/nm735			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12118245				2022-12-27	WOS:000177200900026
J	Neurath, MF; Finotto, S; Glimcher, LH				Neurath, MF; Finotto, S; Glimcher, LH			The role of Th1/Th2 polarization in mucosal immunity	NATURE MEDICINE			English	Review							CHRONIC INTESTINAL INFLAMMATION; TH2 CYTOKINE EXPRESSION; IFN-GAMMA PRODUCTION; REGULATORY T-CELLS; SIGNAL TRANSDUCER; EXPERIMENTAL COLITIS; TRANSCRIPTION FACTOR; INTERFERON-GAMMA; DENDRITIC CELLS; MURINE MODEL	Mucosal immunity relies on the delicate balance between antigen responsiveness and tolerance. The polarization of T helper cells plays a key role in maintaining or disrupting this equilibrium.	Johannes Gutenberg Univ Mainz, Dept Med 1, Immunol Lab, D-6500 Mainz, Germany; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Johannes Gutenberg University of Mainz; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Neurath, MF (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med 1, Immunol Lab, D-6500 Mainz, Germany.	neurath@1-med.klinik.uni-mainz.de	Finotto, Susetta/H-2753-2019					Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; Akira S, 2000, CURR OPIN IMMUNOL, V12, P59, DOI 10.1016/S0952-7915(99)00051-5; Asnagli H, 2001, CURR OPIN IMMUNOL, V13, P242, DOI 10.1016/S0952-7915(00)00210-7; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; Barbulescu K, 1998, J IMMUNOL, V160, P3642; Barnes PJ, 2001, J ALLERGY CLIN IMMUN, V108, pS72, DOI 10.1067/mai.2001.116435; Blumberg RS, 1999, CURR OPIN IMMUNOL, V11, P648, DOI 10.1016/S0952-7915(99)00032-1; Boirivant M, 1998, J EXP MED, V188, P1929, DOI 10.1084/jem.188.10.1929; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Carter LL, 1999, J EXP MED, V189, P1355, DOI 10.1084/jem.189.8.1355; Christodoulopoulos P, 2001, J ALLERGY CLIN IMMUN, V107, P586, DOI 10.1067/mai.2001.114883; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Davidson NJ, 1998, J IMMUNOL, V161, P3143; de Jong YP, 2001, NAT IMMUNOL, V2, P1061, DOI 10.1038/ni720; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; Fuss IJ, 1999, GASTROENTEROLOGY, V117, P1078, DOI 10.1016/S0016-5085(99)70392-6; Fuss IJ, 1996, J IMMUNOL, V157, P1261; Gao PS, 2000, J MED GENET, V37, P380; Gelfand EW, 1998, ALLERGY ASTHMA PROC, V19, P365, DOI 10.2500/108854198778612744; Glimcher LH, 2000, GENE DEV, V14, P1693; Grogan JL, 2001, IMMUNITY, V14, P205, DOI 10.1016/S1074-7613(01)00103-0; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Higgins LM, 1999, J IMMUNOL, V162, P486; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; IQBAL N, IN PRESS J EXP MED; Iwasaki A, 1999, J EXP MED, V190, P229, DOI 10.1084/jem.190.2.229; Jember AGH, 2001, J EXP MED, V193, P387, DOI 10.1084/jem.193.3.387; Kanai T, 2001, GASTROENTEROLOGY, V121, P875, DOI 10.1053/gast.2001.28021; Kelsall B, 1999, MUCOSAL IMMUNOLOGY, P293; Kurata H, 1999, IMMUNITY, V11, P677, DOI 10.1016/S1074-7613(00)80142-9; Lee GR, 2001, IMMUNITY, V14, P447, DOI 10.1016/S1074-7613(01)00125-X; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Lee NA, 2001, J ALLERGY CLIN IMMUN, V107, P945, DOI 10.1067/mai.2001.116002; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Lighvani AA, 2001, P NATL ACAD SCI USA, V98, P15137, DOI 10.1073/pnas.261570598; Liu ZJ, 2001, J IMMUNOL, V167, P1830, DOI 10.4049/jimmunol.167.3.1830; Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Mathew A, 2001, J EXP MED, V193, P1087, DOI 10.1084/jem.193.9.1087; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; Miaw SC, 2000, IMMUNITY, V12, P323, DOI 10.1016/S1074-7613(00)80185-5; Mizoguchi A, 1999, GASTROENTEROLOGY, V116, P320, DOI 10.1016/S0016-5085(99)70128-9; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; Monteleone G, 1997, GASTROENTEROLOGY, V112, P1169, DOI 10.1016/S0016-5085(97)70128-8; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Mullen AC, 2001, SCIENCE, V292, P1907, DOI 10.1126/science.1059835; NEURATH MF, 1995, J EXP MED, V182, P1281, DOI 10.1084/jem.182.5.1281; NEURATH MF, IN PRESS J EXP MED; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; Pizarro TT, 1999, J IMMUNOL, V162, P6829; PODOLSKY DK, 1999, AM J PHYSIOL, V277, pG495; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669; Pulendran B, 2001, TRENDS IMMUNOL, V22, P41, DOI 10.1016/S1471-4906(00)01794-4; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; Rengarajan J, 2002, NAT IMMUNOL, V3, P48, DOI 10.1038/ni744; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; Shanahan F, 2002, LANCET, V359, P62, DOI 10.1016/S0140-6736(02)07284-7; Siegmund B, 2001, AM J PHYSIOL-REG I, V281, pR1264, DOI 10.1152/ajpregu.2001.281.4.R1264; Simpson SJ, 1998, J EXP MED, V187, P1225, DOI 10.1084/jem.187.8.1225; Strober W, 1997, IMMUNOL TODAY, V18, P61, DOI 10.1016/S0167-5699(97)01000-1; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Temann UA, 2002, J CLIN INVEST, V109, P29, DOI 10.1172/JCI13696; Ten Hove T, 2001, GASTROENTEROLOGY, V121, P1372, DOI 10.1053/gast.2001.29579; Tesciuba AG, 2001, J IMMUNOL, V167, P1996, DOI 10.4049/jimmunol.167.4.1996; Tomkinson A, 2001, J IMMUNOL, V166, P5792, DOI 10.4049/jimmunol.166.9.5792; Weiner HL, 2001, MICROBES INFECT, V3, P947, DOI 10.1016/S1286-4579(01)01456-3; Wiekowski MT, 2001, J IMMUNOL, V166, P7563, DOI 10.4049/jimmunol.166.12.7563; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wills-Karp M, 2001, NAT IMMUNOL, V2, P1095, DOI 10.1038/ni1201-1095; Wirtz S, 2002, J IMMUNOL, V168, P411, DOI 10.4049/jimmunol.168.1.411; Wirtz S, 1999, J IMMUNOL, V162, P1884; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhu Z, 2001, AM J RESP CRIT CARE, V164, pS67, DOI 10.1164/ajrccm.164.supplement_2.2106070	100	482	538	0	53	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2002	8	6					567	573		10.1038/nm0602-567	http://dx.doi.org/10.1038/nm0602-567			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042806				2022-12-27	WOS:000175907300026
J	De Vries, TJ; Shaham, Y; Homberg, JR; Crombag, H; Schuurman, K; Dieben, J; Vanderschuren, LJMJ; Schoffelmeer, ANM				De Vries, TJ; Shaham, Y; Homberg, JR; Crombag, H; Schuurman, K; Dieben, J; Vanderschuren, LJMJ; Schoffelmeer, ANM			A cannabinoid mechanism in relapse to cocaine seeking	NATURE MEDICINE			English	Article							EXTRACELLULAR DOPAMINE LEVELS; STRESS-INDUCED RELAPSE; NUCLEUS-ACCUMBENS; CB1 RECEPTOR; BEHAVIOR; RATS; AMYGDALA; HEROIN; WITHDRAWAL; ACTIVATION	Treatment of cocaine addiction is hampered by high rates of relapse even after prolonged drug abstinence. This relapse to compulsive cocaine use can be triggered by re-exposure to cocaine(1), by re-exposure to stimuli previously associated with cocaine(2) or by exposure to stress(3). In laboratory rats, similar events reinstate cocaine seeking after prolonged withdrawal periods', thus providing a model to study neuronal mechanisms underlying the relapse to cocaine. The endocannabinoid system has been implicated in a number of neuropsychiatric conditions, including drug addiction(7,8). The active ingredient of marijuana, Delta9-tetrahydrocannabinol, activates the mesolimbic dopamine (DA) reward system(9,10) and has rewarding effects in preclinical models of drug abuse(8,11,12). We report here that the synthetic cannabinoid agonist, HU210 (ref. 13), provokes relapse to cocaine seeking after prolonged withdrawal periods. Furthermore, the selective CB1 receptor antagonist, SR141716A (ref. 14), attenuates relapse induced by re-exposure to cocaine-associated cues or cocaine itself, but not relapse induced by exposure to stress. These data reveal an important role of the cannabinoid system in the neuronal processes underlying relapse to cocaine seeking, and provide a rationale for the use of cannabinoid receptor antagonists for the prevention of relapse to cocaine use.	Vrije Univ Amsterdam, Neurosci Res Inst, Dept Med Pharmacol, Med Ctr, Amsterdam, Netherlands; NIDA, Behav Neurosci Branch, Intramural Res Program, NIH, Baltimore, MD USA	Vrije Universiteit Amsterdam; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	De Vries, TJ (corresponding author), Vrije Univ Amsterdam, Neurosci Res Inst, Dept Med Pharmacol, Med Ctr, Amsterdam, Netherlands.		Homberg, J.R./N-4172-2019; De Vries, Taco J/B-2831-2014; Homberg, Judith R/D-2473-2010; Vanderschuren, Louk/AAS-4391-2020; shaham, yavin/G-1306-2014	Vanderschuren, Louk/0000-0002-5379-0363; De Vries, Taco/0000-0002-0340-4946				Ameri A, 1999, PROG NEUROBIOL, V58, P315, DOI 10.1016/S0301-0082(98)00087-2; Chaperon F, 1999, CRIT REV NEUROBIOL, V13, P243, DOI 10.1615/CritRevNeurobiol.v13.i3.20; CHEN JP, 1991, NEUROSCI LETT, V129, P136, DOI 10.1016/0304-3940(91)90739-G; Childress AR, 1992, SUBSTANCE ABUSE COMP, P56; COMER SD, 1993, J PHARMACOL EXP THER, V267, P1470; Cossu G, 2001, BEHAV BRAIN RES, V118, P61, DOI 10.1016/S0166-4328(00)00311-9; De Vries TJ, 1999, PSYCHOPHARMACOLOGY, V143, P254, DOI 10.1007/s002130050944; deWit H, 1996, EXP CLIN PSYCHOPHARM, V4, P5, DOI 10.1037/1064-1297.4.1.5; Di Marzo V, 2000, J NEUROCHEM, V74, P1627, DOI 10.1046/j.1471-4159.2000.0741627.x; Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x; Giuffrida A, 1999, NAT NEUROSCI, V2, P358, DOI 10.1038/7268; Grimm JW, 2000, NEUROPSYCHOPHARMACOL, V22, P473, DOI 10.1016/S0893-133X(99)00157-8; Huestis MA, 2001, ARCH GEN PSYCHIAT, V58, P322, DOI 10.1001/archpsyc.58.4.322; Khroyan TV, 2000, J PHARMACOL EXP THER, V294, P680; Landsman RS, 1997, EUR J PHARMACOL, V334, pR1, DOI 10.1016/S0014-2999(97)01160-6; Mascia MS, 1999, EUR J PHARMACOL, V383, pR1, DOI 10.1016/S0014-2999(99)00656-1; Mechoulam R, 1998, EUR J PHARMACOL, V359, P1, DOI 10.1016/S0014-2999(98)00649-9; Pilla M, 1999, NATURE, V400, P371, DOI 10.1038/43944; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586; Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2; Sinha R, 1999, PSYCHOPHARMACOLOGY, V142, P343, DOI 10.1007/s002130050898; Stewart J, 2000, J PSYCHIATR NEUROSCI, V25, P125; Tanda G, 2000, NAT NEUROSCI, V3, P1073, DOI 10.1038/80577; Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048; Tran-Nguyen LTL, 1998, NEUROPSYCHOPHARMACOL, V19, P48; Weiss F, 2000, P NATL ACAD SCI USA, V97, P4321, DOI 10.1073/pnas.97.8.4321	28	348	359	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1151	1154		10.1038/nm1001-1151	http://dx.doi.org/10.1038/nm1001-1151			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590440	Bronze			2022-12-27	WOS:000171524500038
J	Heeschen, C; Jang, JJ; Weis, M; Pathak, A; Kaji, S; Hu, RS; Tsao, PS; Johnson, FL; Cooke, JP				Heeschen, C; Jang, JJ; Weis, M; Pathak, A; Kaji, S; Hu, RS; Tsao, PS; Johnson, FL; Cooke, JP			Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis	NATURE MEDICINE			English	Article							HUMAN-ENDOTHELIAL-CELLS; ARTERIAL SMOOTH-MUSCLE; DNA-SYNTHESIS; NITRIC-OXIDE; MATRIX METALLOPROTEINASES; TRANSDERMAL NICOTINE; CIGARETTE-SMOKING; ACETYLCHOLINE; PROSTACYCLIN; MODULATION	We provide anatomic and functional evidence that nicotine induces angiogenesis. We also show that nicotine accelerates the growth of tumor and atheroma in association with increased neovascularization. Nicotine increased endothelial-cell growth and tube formation in vitro, and accelerated fibrovascular growth in vivo. In a mouse model of hind-limb ischemia, nicotine increased capillary and collateral growth, and enhanced tissue perfusion. In mouse models of lung cancer and atherosclerosis, we found that nicotine enhanced lesion growth in association with an increase in lesion vascularity. These effects of nicotine were mediated through nicotinic acetylcholine receptors at nicotine concentrations that are pathophysiologically relevant. The endothelial production of nitric oxide, prostacyclin and vascular endothelial growth factor might have a role in these effects.	Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA	Stanford University	Cooke, JP (corresponding author), Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA.		Guba, Markus/M-4309-2019	Cooke, John/0000-0003-0033-9138; Heeschen, Christopher/0000-0002-1158-8554	NHLBI NIH HHS [R01 HL-58638] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BADIO B, 1994, MOL PHARMACOL, V45, P563; BARGER AC, 1984, NEW ENGL J MED, V310, P175, DOI 10.1056/NEJM198401193100307; BOUTHERINFALSON O, 1990, NOUV REV FR HEMATOL, V32, P253; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carty CS, 1996, J VASC SURG, V24, P927, DOI 10.1016/S0741-5214(96)70038-1; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Clouse WD, 2000, J APPL PHYSIOL, V89, P1213, DOI 10.1152/jappl.2000.89.3.1213; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Cucina A, 1999, BIOCHEM BIOPH RES CO, V257, P306, DOI 10.1006/bbrc.1999.0478; Cucina A, 2000, SURGERY, V127, P316, DOI 10.1067/msy.2000.104249; FOLTS JD, 1990, ADV EXP MED BIOL, V273, P339; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GULLINO PM, 1978, JNCI-J NATL CANCER I, V61, P639; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Hecht SS, 2000, P NATL ACAD SCI USA, V97, P12493, DOI 10.1073/pnas.220207697; HILL P, 1983, J CHRON DIS, V36, P439, DOI 10.1016/0021-9681(83)90136-4; Jang JJ, 2000, CIRCULATION, V102, P1414, DOI 10.1161/01.CIR.102.12.1414; Jones MK, 1999, NAT MED, V5, P1418; Joseph AM, 1996, NEW ENGL J MED, V335, P1792, DOI 10.1056/NEJM199612123352402; KAWASHIMA K, 1990, NEUROSCI LETT, V119, P156, DOI 10.1016/0304-3940(90)90822-Q; KAWASHIMA K, 1989, NEUROSCI LETT, V104, P336, DOI 10.1016/0304-3940(89)90599-5; Krupski W C, 1991, Ann Vasc Surg, V5, P291, DOI 10.1007/BF02329389; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Lee WO, 1999, METABOLISM, V48, P845, DOI 10.1016/S0026-0495(99)90216-0; LI Z, 1994, J PHARMACOL EXP THER, V271, P1135; Macklin KD, 1998, J PHARMACOL EXP THER, V287, P435; MAGERS T, 1995, REPROD TOXICOL, V9, P513, DOI 10.1016/0890-6238(95)02002-0; Melkonian G, 2000, TOXICOL APPL PHARM, V163, P26, DOI 10.1006/taap.1999.8789; Moulton KS, 1999, CIRCULATION, V99, P1726, DOI 10.1161/01.CIR.99.13.1726; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; Payne JB, 1996, J PERIODONTAL RES, V31, P99, DOI 10.1111/j.1600-0765.1996.tb00470.x; PITTILO RM, 1990, INT J EXP PATHOL, V71, P573; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; Powell J T, 1998, Vasc Med, V3, P21, DOI 10.1191/135886398670269973; Pratico D, 2001, P NATL ACAD SCI USA, V98, P3358, DOI 10.1073/pnas.061607398; Schaper W, 1999, CARDIOVASC RES, V43, P835, DOI 10.1016/S0008-6363(99)00191-1; Sopori ML, 1998, ADV EXP MED BIOL, V437, P279; St Croix B, 2000, SCIENCE, V289, P1197; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; THYBERG J, 1986, VIRCHOWS ARCH B, V52, P25, DOI 10.1007/BF02889947; Tonnessen BH, 2000, J PHARMACOL EXP THER, V295, P601; Villablanca AC, 1998, J APPL PHYSIOL, V84, P2089, DOI 10.1152/jappl.1998.84.6.2089; Waldum HL, 1996, LIFE SCI, V58, P1339, DOI 10.1016/0024-3205(96)00100-2; Wilke N, 1997, RADIOLOGY, V204, P373, DOI 10.1148/radiology.204.2.9240523; Zhang SL, 2001, ATHEROSCLEROSIS, V154, P277, DOI 10.1016/S0021-9150(00)00475-5	46	596	680	1	44	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					833	839		10.1038/89961	http://dx.doi.org/10.1038/89961			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433349				2022-12-27	WOS:000169808600036
J	Jain, RK				Jain, RK			Clearing the smoke on nicotine and angiogenesis	NATURE MEDICINE			English	Editorial Material							PROLIFERATION	Nicotine is widely used as an aid to smoking cessation and is being evaluated to treat non-smoking related disorders. Stimulation of angiogenesis by nicotine raises many questions about its mechanism of action and use in therapy.	Harvard Univ, Massachusetts Gen Hosp, Dept Radiat Oncol, Steele Lab Tumor Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Jain, RK (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Dept Radiat Oncol, Steele Lab Tumor Biol, Boston, MA 02114 USA.		Jain, Rakesh K/I-1384-2017	Jain, Rakesh K/0000-0001-7571-3548				Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cucina A, 2000, SURGERY, V127, P316, DOI 10.1067/msy.2000.104249; GULLINO PM, 1978, JNCI-J NATL CANCER I, V61, P639; Hecht SS, 2000, P NATL ACAD SCI USA, V97, P12493, DOI 10.1073/pnas.220207697; Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961; Joseph AM, 1996, NEW ENGL J MED, V335, P1792, DOI 10.1056/NEJM199612123352402; Melkonian G, 2000, TOXICOL APPL PHARM, V163, P26, DOI 10.1006/taap.1999.8789; Powell J T, 1998, Vasc Med, V3, P21, DOI 10.1191/135886398670269973; Pratico D, 2001, P NATL ACAD SCI USA, V98, P3358, DOI 10.1073/pnas.061607398; Villablanca AC, 1998, J APPL PHYSIOL, V84, P2089, DOI 10.1152/jappl.1998.84.6.2089; Waldum HL, 1996, LIFE SCI, V58, P1339, DOI 10.1016/0024-3205(96)00100-2	11	20	21	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					775	777		10.1038/89889	http://dx.doi.org/10.1038/89889			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433337				2022-12-27	WOS:000169808600020
J	Stubbs, AC; Martin, KS; Coeshott, C; Skaates, SV; Kuritzkes, DR; Bellgrau, D; Franzusoff, A; Duke, RC; Wilson, CC				Stubbs, AC; Martin, KS; Coeshott, C; Skaates, SV; Kuritzkes, DR; Bellgrau, D; Franzusoff, A; Duke, RC; Wilson, CC			Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity	NATURE MEDICINE			English	Article							CLASS-II; IN-VIVO; MANNOSE RECEPTOR; IL-12 PRODUCTION; DOWN-REGULATION; T-HELPER; ANTIGEN; RESPONSES; LIPOPOLYSACCHARIDE; MOLECULES	There is currently a need for vaccines that stimulate cell-mediated immunity-particularly that mediated by CD8(+) cytotoxic T lymphocytes (CTLs)-against viral and tumor antigens. The optimal induction of cell-mediated immunity requires the presentation of antigens by specialized cells of the immune system called dendritic cells(1) (DCs). DCs are unique in their ability to process exogenous antigens via the major histocompatibility complex (MHC) class I pathway(2) as well as in their ability to activate naive, antigen-specific CD8(+) and CD4(+) T cells(1,3). Vaccine strategies that target or activate DCs in order to elicit potent CTL-mediated immunity are the subject of intense research. We report here that whole recombinant Saccharomyces cerevisiae yeast expressing tumor or HIV-1 antigens potently induced antigen-specific, CTL responses, including those mediating tumor protection, in vaccinated animals. Interactions between yeast and DCs led to DC maturation, IL-12 production and the efficient priming of MHC class I- and class II-restricted, antigen-specific T-cell responses. Yeast exerted a strong adjuvant effect, augmenting DC presentation of exogenous whole-protein antigen to MHC class I- and class II-restricted T cells. Recombinant yeast represent a novel vaccine strategy for the induction of broad-based cellular immune responses.	Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Cellular & Struct Biol, Denver, CO 80262 USA; CERES Pharmaceut, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Duke, RC (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Immunol, 4200 E 9th Ave, Denver, CO 80206 USA.				NCI NIH HHS [CA-46934] Funding Source: Medline; NIAID NIH HHS [AI-42704, AI-01459, AI-33299, AI-34747, AI-42688] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI042688, R01AI034747, R21AI034747, R29AI033299, R21AI042704] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Brossart P, 1997, J IMMUNOL, V158, P3270; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Cho HJ, 2000, NAT BIOTECHNOL, V18, P509, DOI 10.1038/75365; DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413; FALO LD, 1995, NAT MED, V1, P649, DOI 10.1038/nm0795-649; FRANZUSOFF A, 1995, J BIOL CHEM, V270, P3154, DOI 10.1074/jbc.270.7.3154; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Inaba K, 1998, J EXP MED, V188, P2163, DOI 10.1084/jem.188.11.2163; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; Mayordomo JI, 1996, J EXP MED, V183, P1357, DOI 10.1084/jem.183.4.1357; MCCABE BJ, 1995, CANCER RES, V55, P1741; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; O'Hagan DT, 1998, J PHARM PHARMACOL, V50, P1, DOI 10.1111/j.2042-7158.1998.tb03298.x; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Rios-Hernandez M, 1994, Arch Med Res, V25, P179; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; Rodriguez A, 1999, NAT CELL BIOL, V1, P362, DOI 10.1038/14058; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Schreuder MP, 1996, VACCINE, V14, P383, DOI 10.1016/0264-410X(95)00206-G; Shibata Y, 1997, J IMMUNOL, V159, P2462; Toda S, 1997, IMMUNOLOGY, V92, P111, DOI 10.1046/j.1365-2567.1997.00307.x; WILLIAMS DL, 1992, CARBOHYD RES, V235, P247, DOI 10.1016/0008-6215(92)80093-G; Yewdell JW, 1999, ADV IMMUNOL, V73, P1, DOI 10.1016/S0065-2776(08)60785-3	24	177	220	2	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					625	629		10.1038/87974	http://dx.doi.org/10.1038/87974			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329066				2022-12-27	WOS:000169961100044
J	Zhang, ZJ; Butler, JD; Levin, SW; Wisniewski, KE; Brooks, SS; Mukherjee, AB				Zhang, ZJ; Butler, JD; Levin, SW; Wisniewski, KE; Brooks, SS; Mukherjee, AB			Lysosomal ceroid depletion by drugs: Therapeutic implications for a hereditary neurodegenerative disease of childhood	NATURE MEDICINE			English	Article							PALMITOYL-PROTEIN THIOESTERASE; NEUROBLASTOMA-CELLS; LIPID MODIFICATIONS; MOLECULAR-GENETICS; FATTY ACYLATION; RAT-BRAIN; LIPOFUSCINOSIS; EXPRESSION; IDENTIFICATION; ENZYME	Neuronal ceroid lipofuscinoses (NCLs) are the most common hereditary neurodegenerative diseases of childhood. The infantile form, INCL, is caused by lysosomal palmitoyl-protein thioesterase (PPT) deficiency, which impairs the cleavage of thioester linkages in palmitoylated proteins, preventing their hydrolysis by lysosomal proteinases. Consequent accumulation of these lipid-modified proteins (constituents of ceroid) in lysosomes leads to INCL. Because thioester linkages are susceptible to nucleophilic attack, drugs with this property may have therapeutic potential for INCL. We report here that two such drugs, phosphocysteamine and N-acetylcystelne, disrupt thioester linkages in a model thioester compound, [C-14]palmitoyl-CoA. Most importantly, in lymphoblasts derived from INCL patients, phosphocysteamine, a known lysosomotrophic drug, mediates the depletion of lysosomal ceroids, prevents their re-accumulation and inhibits apoptosis. Our results define a novel pharmacological approach to lysosomal ceroid depletion and raise the possibility that nucleophilic drugs such as phosphocysteamine hold therapeutic potential for INCL.	NICHHD, Sect Dev Genet, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA; Inst Basic Res Dev Disabilities, Staten Isl, NY USA; New York State Inst Basic Res Dev Disabil, Dept Pathol Neurobiol, Staten Isl, NY 10314 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Institute for Basic Research in Developmental Disabilities	Mukherjee, AB (corresponding author), NICHHD, Sect Dev Genet, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA.	mukherja@exchange.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000910] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038988] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS389 88-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Armstrong D, 1982, CEROID LIPOFUSCINOSI; Assadi FK, 1998, TERATOLOGY, V58, P88, DOI 10.1002/(SICI)1096-9926(199809/10)58:3/4<88::AID-TERA4>3.0.CO;2-5; Bellizzi JJ, 2000, P NATL ACAD SCI USA, V97, P4573, DOI 10.1073/pnas.080508097; BENSASSON SA, 1995, METHOD CELL BIOL, V46, P29; Bizzozero OA, 1997, NEUROPEDIATRICS, V28, P23, DOI 10.1055/s-2007-973660; BOLANOWSKI MA, 1984, J BIOL CHEM, V259, P4934; Broyer M, 1996, J INHERIT METAB DIS, V19, P65, DOI 10.1007/BF01799350; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; Cho SG, 2000, J NEUROCHEM, V74, P1478, DOI 10.1046/j.1471-4159.2000.0741478.x; Cho SG, 2000, J NEUROSCI RES, V62, P234, DOI 10.1002/1097-4547(20001015)62:2<234::AID-JNR8>3.0.CO;2-8; Das AK, 1998, J CLIN INVEST, V102, P361, DOI 10.1172/JCI3112; GAHL WA, 1995, METABOLIC MOL BASES, V3, P3763; GOEBEL HH, 1999, BIOMEDICAL HLTH RES, P211; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hellsten E, 1996, EMBO J, V15, P5240, DOI 10.1002/j.1460-2075.1996.tb00909.x; HOEG JM, 1986, J BIOL CHEM, V261, P3911; Hofmann SL, 1997, NEUROPEDIATRICS, V28, P27, DOI 10.1055/s-2007-973661; HUANG G, 1988, BIOCHEMISTRY-US, V27, P1395, DOI 10.1021/bi00405a001; Isosomppi J, 1999, DEV BRAIN RES, V118, P1, DOI 10.1016/S0165-3806(99)00115-7; JARVELA I, 1991, GENOMICS, V9, P170, DOI 10.1016/0888-7543(91)90235-7; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; JOCELYN PC, 1972, BIOCH SH GROUP, P63; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; Lu JY, 1996, P NATL ACAD SCI USA, V93, P10046, DOI 10.1073/pnas.93.19.10046; RANDALL WR, 1994, J BIOL CHEM, V269, P12367; RAPOLA J, 1973, BRAIN, V96, P833, DOI 10.1093/brain/96.4.833; Riikonen R, 2000, NEUROLOGY, V54, P1828, DOI 10.1212/WNL.54.9.1828; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; SANTAVUORI P, 1988, BRAIN DEV-JPN, V10, P80, DOI 10.1016/S0387-7604(88)80075-5; SCHLESINGER MJ, 1972, PALMITOYLATION CELLU, P1; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; Sleat DE, 1996, J BIOL CHEM, V271, P19191, DOI 10.1074/jbc.271.32.19191; STULTS JT, 1991, AM J PHYSIOL, V261, pL118, DOI 10.1152/ajplung.1991.261.2.L118; Suopanki J, 1999, NEUROSCI LETT, V265, P53, DOI 10.1016/S0304-3940(99)00207-4; TYYNELA J, 1993, FEBS LETT, V330, P8, DOI 10.1016/0014-5793(93)80908-D; Verkruyse LA, 1996, J BIOL CHEM, V271, P15831, DOI 10.1074/jbc.271.26.15831; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; Waliany S, 2000, Hum Mutat, V15, P206, DOI 10.1002/(SICI)1098-1004(200002)15:2<206::AID-HUMU14>3.0.CO;2-L; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WISNIEWSKI KE, 1992, AM J MED GENET, V42, P525, DOI 10.1002/ajmg.1320420420; Wisniewski KE, 1998, PEDIATR NEUROL, V18, P119, DOI 10.1016/S0887-8994(97)00173-2; Yalovsky S, 1999, TRENDS PLANT SCI, V4, P439, DOI 10.1016/S1360-1385(99)01492-2; Zhang ZJ, 1997, SCIENCE, V276, P1408, DOI 10.1126/science.276.5317.1408; Zhang ZJ, 1999, GENE, V231, P203, DOI 10.1016/S0378-1119(99)00050-5; Zheng F, 1999, NAT MED, V5, P1018, DOI 10.1038/12458	47	70	71	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2001	7	4					478	484		10.1038/86554	http://dx.doi.org/10.1038/86554			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283676				2022-12-27	WOS:000167960500044
J	Cullen, BR				Cullen, BR			A new entry route for HIV	NATURE MEDICINE			English	Editorial Material							T-LYMPHOCYTES; INFECTION; HARBOR; AIDS	Identification of HIV-1 variants capable of entering T cells via the CD8 receptor suggests a new mode of viral pathogenesis. But are these variants rare, aberrant viruses or a real problem?	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Genet, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Cullen, BR (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.							Doms RW, 2000, VIROLOGY, V276, P229, DOI 10.1006/viro.2000.0612; Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026; Livingstone WJ, 1996, LANCET, V348, P649, DOI 10.1016/S0140-6736(96)02091-0; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; ROEDERER M, 1995, J CLIN INVEST, V95, P2061, DOI 10.1172/JCI117892; Saha K, 2001, NAT MED, V7, P65, DOI 10.1038/83365; SEMENSATO G, 1995, BLOOD, V85, P2308, DOI 10.1182/blood.V85.9.2308.bloodjournal8592308; TSUBOTA H, 1989, J IMMUNOL, V143, P858	8	5	5	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					20	21		10.1038/83295	http://dx.doi.org/10.1038/83295			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135605				2022-12-27	WOS:000166243100020
J	Kirk, AD				Kirk, AD			Hitting the reset button for immune tolerance	NATURE MEDICINE			English	Editorial Material							ALLOGRAFT RECIPIENTS; TRANSPLANTATION; MICROCHIMERISM; CHIMERISM	Migratory cells can lead both to rejection and tolerance following organ transplantation, suggesting a direction for protolerant immunomodulatory therapies.	NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Kirk, AD (corresponding author), NIH, Room 11S-219,Bldg 10 Ctr Dr, Bethesda, MD 20892 USA.		Kirk, Allan D./B-6905-2012	Kirk, Allan/0000-0003-2004-5962	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK062007] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson CC, 2001, NAT MED, V7, P80, DOI 10.1038/83393; Calne R, 1998, LANCET, V351, P1701, DOI 10.1016/S0140-6736(05)77739-4; Elwood ET, 1997, LANCET, V349, P1358, DOI 10.1016/S0140-6736(96)09105-2; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; Lakkis FG, 2000, NAT MED, V6, P686, DOI 10.1038/76267; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; Nikolic B, 1997, CURR OPIN IMMUNOL, V9, P634, DOI 10.1016/S0952-7915(97)80042-8; SCHLITT HJ, 1994, LANCET, V343, P1469, DOI 10.1016/S0140-6736(94)92584-4; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; SUBERBIELLE C, 1994, LANCET, V343, P1468, DOI 10.1016/S0140-6736(94)92583-6	10	1	1	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					24	25		10.1038/83304	http://dx.doi.org/10.1038/83304			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135608				2022-12-27	WOS:000166243100023
J	Lazar, MA				Lazar, MA			Progress in cardiovascular biology: PPAR for the course	NATURE MEDICINE			English	Editorial Material							OXIDIZED LDL; GAMMA; ACTIVATION	Studies on mice lacking the peroxisome proliferator-activated receptor (PPAR) suggest that PPAR ligands reduce lipid accumulation in foamy macrophages, and may target other receptors. These findings warrant an in-depth investigation into the gene regulatory mechanisms of PPAR ligands, which are currently being developed as drugs to treat atherosclerosis and diabetes.	Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lazar, MA (corresponding author), Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.		Lazar, Mitchell A/AAF-3738-2019					Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rosen ED, 2000, J CLIN INVEST, V106, P629, DOI 10.1172/JCI10909; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Seed B, 1998, NAT MED, V4, P1004, DOI 10.1038/1990; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5	12	48	49	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					23	24		10.1038/83301	http://dx.doi.org/10.1038/83301			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135607				2022-12-27	WOS:000166243100022
J	Birmingham, K				Birmingham, K			Gates Foundation hires preeminent scientist	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1303	1303		10.1038/82088	http://dx.doi.org/10.1038/82088			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100096	Bronze			2022-12-27	WOS:000165704100013
J	Brenner, S				Brenner, S			From cell physiology to cell physiology	NATURE MEDICINE			English	Editorial Material									Inst Mol Sci, Berkeley, CA 94704 USA	The Molecular Sciences Institute	Brenner, S (corresponding author), Inst Mol Sci, 2168 Shattuck Ave,2nd Floor, Berkeley, CA 94704 USA.							BRENNER S, 1974, NATURE, V248, P785, DOI 10.1038/248785a0; BRENNER S, 1958, NATURE, V182, P983, DOI 10.1038/182983a0; BRENNER S, 1953, BIOCHIM BIOPHYS ACTA, V11, P480, DOI 10.1016/0006-3002(53)90085-7; BRENNER S, 1950, STAIN TECHNOL, V25, P163, DOI 10.3109/10520295009110982; BRENNER S, 1973, CIBA FDN S EXCERPTA, V66, P1; BRENNER S, 1947, S AFRICAN J MED SC, V12, P53; BRENNER SYDNEY, 1949, S AFRICAN JOUR MED SCI, V14, P13; CRICK FH, 1961, NATURE, V192, P1227, DOI 10.1038/1921227a0; von Neumann J., 1951, GEN LOGICAL THEORY A	9	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1087	1088		10.1038/80400	http://dx.doi.org/10.1038/80400			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017127				2022-12-27	WOS:000089674700018
J	Shin, I; Yakes, FM; Rojo, F; Shin, NY; Bakin, AV; Baselga, J; Arteaga, CL				Shin, I; Yakes, FM; Rojo, F; Shin, NY; Bakin, AV; Baselga, J; Arteaga, CL			PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization	NATURE MEDICINE			English	Article							KINASE INHIBITOR P27; AKT PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SUBCELLULAR-LOCALIZATION; GENE-TRANSCRIPTION; COMPLEX-FORMATION; CDK-INHIBITORS; TUMOR-CELLS; DEGRADATION; EXPRESSION	We have shown a novel mechanism of Akt-mediated regulation of the CDK inhibitor p27(kip1). Blockade of HER2/neu in tumor cells inhibits Akt kinase activity and upregulates nuclear levels of the CDK inhibitor p27(Kip1). Recombinant Akt and Akt precipitated from tumor cells phosphorylated wild-type p27 in vitro. p27 contains an Akt consensus RXRXXT157 D within its nuclear localization motif. Active (myristoylated) Akt phosphorylated wild-type p27 in vivo but was unable to phosphorylate a T157A-p27 mutant. Wild-type p27 localized in the cytosol and nucleus, whereas T157A-p27 localized exclusively in the nucleus and was resistant to nuclear exclusion by Akt. T157A-p27 was more effective than wild-type p27 in inhibiting cyclin E/CDK2 activity and cell proliferation; these effects were not rescued by active Akt. Expression of Ser(473) phospho Akt in primary human breast cancers statistically correlated with expression of p27 in tumor cytosol. These data indicate that Akt may contribute to tumor-cell proliferation by phosphorylation and cytosolic retention of p27, thus relieving CDK2 from p27-induced inhibition.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA; Vall Hebron Univ Hosp, Oncol Serv, Barcelona, Spain	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Hospital Universitari Vall d'Hebron	Arteaga, CL (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA.		Rojo, Federico/S-6551-2016	Bakin, Andrei/0000-0002-7728-1969	NCI NIH HHS [CA68485, R01 CA80195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, R01CA080195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Albanell J, 2001, CANCER RES, V61, P6500; Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Ciaparrone M, 1998, CANCER RES, V58, P114; DEL PL, 1997, SCIENCE, V278, P687; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lenferink AEG, 2001, CANCER RES, V61, P6583; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sanchez-Beato M, 1999, BLOOD, V94, P765, DOI 10.1182/blood.V94.2.765.414a29_765_772; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Singh SP, 1998, CANCER RES, V58, P1730; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; UREN A, 1997, J BIOL CHEM, V272, P21699; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	44	652	680	3	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2002	8	10					1145	1152		10.1038/nm759	http://dx.doi.org/10.1038/nm759			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12244301				2022-12-27	WOS:000178311000042
J	Monje, ML; Mizumatsu, S; Fike, JR; Palmer, TD				Monje, ML; Mizumatsu, S; Fike, JR; Palmer, TD			Irradiation induces neural precursor-cell dysfunction	NATURE MEDICINE			English	Article							DENTATE GYRUS; ADULT NEUROGENESIS; BRAIN IRRADIATION; STEM-CELLS; RADIATION; MICE; DIFFERENTIATION; PROLIFERATION; NEURONS; NICHE	In both pediatric and adult patients, cranial radiation therapy causes a debilitating cognitive decline that is poorly understood and currently untreatable. This decline is characterized by hippocampal dysfunction, and seems to involve a radiation-induced decrease in postnatal hippocampal neurogenesis. Here we show that the deficit in neurogenesis reflects alterations in the microenvironment that regulates progenitor-cell fate, as well as a defect in the proliferative capacity of the neural progenitor-cell population. Not only is hippocampal neurogenesis ablated, but the remaining neural precursors adopt glial fates and transplants of non-irradiated neural precursor cells fail to differentiate into neurons in the irradiated hippocampus. The inhibition of neurogenesis is accompanied by marked alterations in the neurogenic microenvironment, including disruption of the microvascular angiogenesis associated with adult neurogenesis and a marked increase in the number and activation status of microglia within the neurogenic zone. These findings provide clear targets for future therapeutic interventions.	Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	Stanford University; University of California System; University of California San Francisco	Palmer, TD (corresponding author), Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA.	tpalmer@stanford.edu	Palmer, Theo/GSI-6635-2022	Palmer, Theo/0000-0002-6266-1862	NCI NIH HHS [R01CA76141] Funding Source: Medline; NIMH NIH HHS [MH20016-05] Funding Source: Medline; NINDS NIH HHS [R01NS40088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS040088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abayomi OK, 1996, ACTA ONCOL, V35, P659, DOI 10.3109/02841869609083995; CALVO W, 1988, BRIT J RADIOL, V61, P1043, DOI 10.1259/0007-1285-61-731-1043; CROSSEN JR, 1994, J CLIN ONCOL, V12, P627, DOI 10.1200/JCO.1994.12.3.627; Dawirs RR, 1998, J NEURAL TRANSM, V105, P317, DOI 10.1007/s007020050061; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; Hodges H, 1998, BEHAV BRAIN RES, V91, P99, DOI 10.1016/S0166-4328(97)00108-3; HONG JH, 1995, INT J RADIAT ONCOL, V33, P619, DOI 10.1016/0360-3016(95)00279-8; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kuhn HG, 1996, J NEUROSCI, V16, P2027; LEE PWH, 1989, J NEUROL NEUROSUR PS, V52, P488, DOI 10.1136/jnnp.52.4.488; Leventhal C, 1999, MOL CELL NEUROSCI, V13, P450, DOI 10.1006/mcne.1999.0762; Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896-6273(00)00148-3; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; MARKS JE, 1981, INT J RADIAT ONCOL, V7, P243, DOI 10.1016/0360-3016(81)90443-0; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Parent JM, 1999, J NEUROSCI, V19, P4508; Peissner W, 1999, MOL BRAIN RES, V71, P61, DOI 10.1016/S0169-328X(99)00170-9; PEZNER RD, 1981, INT J RADIAT ONCOL, V7, P397, DOI 10.1016/0360-3016(81)90115-2; ROMAN DD, 1995, INT J RADIAT ONCOL, V31, P983, DOI 10.1016/0360-3016(94)00550-8; Seaberg RM, 2002, J NEUROSCI, V22, P1784, DOI 10.1523/JNEUROSCI.22-05-01784.2002; SHELINE GE, 1980, INT J RADIAT ONCOL, V6, P1215, DOI 10.1016/0360-3016(80)90175-3; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; SIENKIEWICZ ZJ, 1994, INT J RADIAT BIOL, V65, P611, DOI 10.1080/09553009414550701; Snyder JS, 2001, J NEUROPHYSIOL, V85, P2423, DOI 10.1152/jn.2001.85.6.2423; STROTHER DR, 2002, PRINCIPLES PRACTICE, P751; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; Surma-aho O, 2001, NEUROLOGY, V56, P1285, DOI 10.1212/WNL.56.10.1285; Tada E, 2000, NEUROSCIENCE, V99, P33, DOI 10.1016/S0306-4522(00)00151-2; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002	32	900	983	1	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2002	8	9					955	962		10.1038/nm749	http://dx.doi.org/10.1038/nm749			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12161748				2022-12-27	WOS:000177757900030
J	Levin, MC; Lee, SM; Kalume, F; Morcos, Y; Dohan, FC; Hasty, KA; Callaway, JC; Zunt, J; Desiderio, DM; Stuart, JM				Levin, MC; Lee, SM; Kalume, F; Morcos, Y; Dohan, FC; Hasty, KA; Callaway, JC; Zunt, J; Desiderio, DM; Stuart, JM			Autoimmunity due to molecular mimicry as a cause of neurological disease	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; I-ASSOCIATED MYELOPATHY; MYELIN BASIC-PROTEIN; MULTIPLE-SCLEROSIS; VIRUS; LYMPHOCYTES; MECHANISMS; EXPRESSION; HAM/TSP; CELLS	One hypothesis that couples infection with autoimmune disease is molecular mimicry. Molecular mimicry is characterized by an immune response to an environmental agent that cross-reacts with a host antigen, resulting in disease(1,2). This hypothesis has been implicated in the pathogenesis of diabetes, lupus and multiple sclerosis (MS)(1-4). There is limited direct evidence linking causative agents with pathogenic immune reactions in these diseases. Our study establishes a clear link between viral infection, autoimmunity and neurological disease in humans. As a model for molecular mimicry, we studied patients with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a disease that can be indistinguishable from MS (refs. 5-7). HAM/TSP patients develop antibodies to neurons(8). We hypothesized these antibodies would identify a central nervous system (CNS) autoantigen. Immunoglobulin G isolated from HAM/TSP patients identified heterogeneous nuclear ribonuclear protein-A1 (hnRNP-A1) as the autoantigen. Antibodies to hnRNP-A1 cross-reacted with HTLV-1-tax, the immune response to which is associated with HAM/TSP (refs. 5,9). Immunoglobulin G specifically stained human Betz cells, whose axons are preferentially damaged(7). Infusion of autoantibodies in brain sections inhibited neuronal firing, indicative of their pathogenic nature. These data demonstrate the importance of molecular mimicry between an infecting agent and hnRNP-A1 in autoimmune disease of the CNS.	Vet Affairs Med Ctr, Res Serv, Memphis, TN 38104 USA; Univ Tennessee, Hlth Sci Ctr, Ctr Neurobiol Brain Dis, Memphis, TN USA; Univ Tennessee, Hlth Sci Ctr, Dept Neurol, Memphis, TN USA; Univ Tennessee, Hlth Sci Ctr, Dept Anat, Memphis, TN USA; Univ Tennessee, Hlth Sci Ctr, Dept Pathol, Memphis, TN USA; Univ Tennessee, Hlth Sci Ctr, Orthoped Campbell Clin, Memphis, TN USA; Univ Tennessee, Hlth Sci Ctr, Dept Mol Sci, Memphis, TN USA; Univ Tennessee, Hlth Sci Ctr, Dept Med, Charles B Stout Neurosci Mass Spect Lab, Memphis, TN USA; Univ Tennessee, Hlth Sci Ctr, Ctr Excellence Connect Tissue Dis, Memphis, TN USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Washington; University of Washington Seattle	Levin, MC (corresponding author), Vet Affairs Med Ctr, Res Serv, Memphis, TN 38104 USA.		Zunt, Joseph/ABD-2886-2021	Levin, Michael/0000-0002-3880-9193	NCRR NIH HHS [RR 10522] Funding Source: Medline; NIAID NIH HHS [K23 AI001600, K23 AI001600-04] Funding Source: Medline; NINDS NIH HHS [R01-NS-38876] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI001600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038876] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albert LJ, 1999, NEW ENGL J MED, V341, P2068, DOI 10.1056/NEJM199912303412707; Beranova-Giorgianni S, 2000, RAPID COMMUN MASS SP, V14, P161, DOI 10.1002/(SICI)1097-0231(20000215)14:3<161::AID-RCM859>3.0.CO;2-7; Biamonti G, 1998, CLIN EXP RHEUMATOL, V16, P317; CALLAWAY JC, 1993, J NEUROSCI, V13, P1157; Chen WH, 1999, J NEUROSCI RES, V57, P706, DOI 10.1002/(SICI)1097-4547(19990901)57:5<706::AID-JNR12>3.3.CO;2-7; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; Giraudon P, 2000, J IMMUNOL, V164, P2718, DOI 10.4049/jimmunol.164.5.2718; Gran B, 1999, ANN NEUROL, V45, P559, DOI 10.1002/1531-8249(199905)45:5<559::AID-ANA3>3.0.CO;2-Q; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; KAHN R, 2001, NEUROLOGIST, V7, P271; KAMMA H, 1995, EXP CELL RES, V221, P187, DOI 10.1006/excr.1995.1366; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; LAL RB, 1994, J INFECT DIS, V169, P496, DOI 10.1093/infdis/169.3.496; Lassek AM, 1942, J COMP NEUROL, V76, P217, DOI 10.1002/cne.900760203; Levin MC, 1998, ANN NEUROL, V44, P87, DOI 10.1002/ana.410440115; Levin MC, 1997, J NEUROVIROL, V3, P126, DOI 10.3109/13550289709015802; Levin MC, 1997, NEW ENGL J MED, V336, P839, DOI 10.1056/NEJM199703203361205; MULLER S, 1995, CLIN IMMUNOL IMMUNOP, V77, P282, DOI 10.1006/clin.1995.1154; Munro TP, 1999, J BIOL CHEM, V274, P34389, DOI 10.1074/jbc.274.48.34389; Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; Oldstone MBA, 1998, FASEB J, V12, P1255, DOI 10.1096/fasebj.12.13.1255; Romero IA, 2000, J VIROL, V74, P6021, DOI 10.1128/JVI.74.13.6021-6030.2000; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; WARREN KG, 1995, P NATL ACAD SCI USA, V92, P11061, DOI 10.1073/pnas.92.24.11061	25	184	192	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					509	513		10.1038/nm0502-509	http://dx.doi.org/10.1038/nm0502-509			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984596	Green Accepted			2022-12-27	WOS:000175336800037
J	Varki, A; Rosenberg, LE				Varki, A; Rosenberg, LE			Emerging opportunities and career paths for the young physician-scientist	NATURE MEDICINE			English	Editorial Material									Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Princeton University; Princeton University	Varki, A (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.							Andrews NC, 2002, NAT MED, V8, P439, DOI 10.1038/nm0502-439; Goldstein JL, 1997, J CLIN INVEST, V99, P2803, DOI 10.1172/JCI119470; Ley TJ, 2002, NEW ENGL J MED, V346, P368, DOI 10.1056/NEJM200201313460515; Rosenberg LE, 1999, J CLIN INVEST, V103, P1621, DOI 10.1172/JCI7304; ROSENBERG LE, IN PRESS ENDANGERED; VARKI A, 1999, J CLIN INVEST S, V104, pS1; WYNGAARDEN JB, 1979, NEW ENGL J MED, V301, P1254, DOI 10.1056/NEJM197912063012303; Zemlo TR, 2000, FASEB J, V14, P221, DOI 10.1096/fasebj.14.2.221	8	53	53	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					437	439		10.1038/nm0502-437	http://dx.doi.org/10.1038/nm0502-437			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984577				2022-12-27	WOS:000175336800015
J	Greeley, SAW; Katsumata, M; Yu, LP; Eisenbarth, GS; Moore, DJ; Goodarzi, H; Barker, CF; Naji, A; Noorchashm, H				Greeley, SAW; Katsumata, M; Yu, LP; Eisenbarth, GS; Moore, DJ; Goodarzi, H; Barker, CF; Naji, A; Noorchashm, H			Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice	NATURE MEDICINE			English	Article							ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTES; NOD MICE; TRANSGENIC MICE; VIRUS-INFECTION; EXPRESSION; INITIATION; APPEARANCE; BABYDIAB	The influence of maternally transmitted immunoglobulins on the development of autoimmune diabetes mellitus in genetically susceptible human progeny remains unknown. Given the presence of islet beta cell reactive autoantibodies in prediabetic nonobese diabetic (NOD) mice(1,2), we abrogated the maternal transmission of such antibodies in order to assess their influence on the susceptibility of progeny to diabetes. First, we used B cell deficient NOD mothers to eliminate the transmission of maternal immunoglobulins. In a complementary approach, we used immunoglobulin transgenic NOD mothers to exclude autoreactive specificities from the maternal B- cell repertoire. Finally, we implanted NOD embryos in pseudopregnant mothers of a non-autoimmune strain. The NOD progeny in all three groups were protected from spontaneous diabetes. These findings demonstrate that the maternal transmission of antibodies is a critical environmental parameter influencing the ontogeny of T cell-mediated destruction of islet beta cells in NOD mice(3). It will be important to definitively determine whether the transmission of maternal autoantibodies in humans(4-8) affects diabetes progression in susceptible offspring.	Univ Penn, Sch Med, Harrison Dept Surg Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA	University of Pennsylvania; University of Pennsylvania; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Naji, A (corresponding author), Univ Penn, Sch Med, Harrison Dept Surg Res, Philadelphia, PA 19104 USA.		Moore, Daniel/V-6145-2019; Greeley, Siri Atma W./N-1294-2014; Moore, Daniel J/A-4924-2008	Moore, Daniel/0000-0002-6889-9345; Greeley, Siri Atma W./0000-0002-0741-3567; Moore, Daniel J/0000-0002-6889-9345	NICHD NIH HHS [HD37754] Funding Source: Medline; NIDDK NIH HHS [DK54215] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054215] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abiru N, 2001, J AUTOIMMUN, V17, P1, DOI 10.1006/jaut.2001.0530; Bach JF, 2001, ANNU REV IMMUNOL, V19, P131, DOI 10.1146/annurev.immunol.19.1.131; Bras A, 1996, IMMUNOLOGY, V89, P20, DOI 10.1046/j.1365-2567.1996.d01-717.x; Cooke A, 1999, PARASITE IMMUNOL, V21, P169, DOI 10.1046/j.1365-3024.1999.00213.x; Falcone M, 1998, J IMMUNOL, V161, P1163; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; Greeley SAW, 2001, J IMMUNOL, V167, P4351, DOI 10.4049/jimmunol.167.8.4351; Hamalainen AM, 2000, J CLIN ENDOCR METAB, V85, P4249, DOI 10.1210/jc.85.11.4249; HERMITTE L, 1990, EUR J IMMUNOL, V20, P1297, DOI 10.1002/eji.1830200615; Hulbert C, 2001, J IMMUNOL, V167, P5535, DOI 10.4049/jimmunol.167.10.5535; Naserke HE, 1999, J CLIN ENDOCR METAB, V84, P1239, DOI 10.1210/jc.84.4.1239; Naserke HE, 2001, J CLIN ENDOCR METAB, V86, P4826; Noorchashm H, 2000, J IMMUNOL, V165, P4685, DOI 10.4049/jimmunol.165.8.4685; Noorchashm H, 1999, J IMMUNOL, V163, P743; OLDSTONE MBA, 1988, SCIENCE, V239, P500, DOI 10.1126/science.3277269; REILLY MP, 1994, METHOD ENZYMOL, V231, P403; Serreze DV, 1998, J IMMUNOL, V161, P3912; Serreze DV, 1996, J EXP MED, V184, P2049, DOI 10.1084/jem.184.5.2049; TAKEI I, 1992, J AUTOIMMUN, V5, P665, DOI 10.1016/0896-8411(92)90184-R; Yu LP, 2000, P NATL ACAD SCI USA, V97, P1701, DOI 10.1073/pnas.040556697; ZIEGLER AG, 1993, DIABETOLOGIA, V36, P402, DOI 10.1007/BF00402275; Ziegler AG, 1999, DIABETES, V48, P460, DOI 10.2337/diabetes.48.3.460	22	157	163	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2002	8	4					399	402		10.1038/nm0402-399	http://dx.doi.org/10.1038/nm0402-399			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927947				2022-12-27	WOS:000174704800033
J	Feinberg, MB; Moore, JP				Feinberg, MB; Moore, JP			AIDS vaccine models: Challenging challenge viruses	NATURE MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; RHESUS-MONKEYS; VIRAL LOAD; INFECTION; MACAQUES; TYPE-1; DISEASE; SIV; PROGRESSION; VIREMIA		Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY USA	Emory University; Emory University; Emory University; Cornell University	Feinberg, MB (corresponding author), Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA.							Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Barouch DH, 2001, J VIROL, V75, P5151, DOI 10.1128/JVI.75.11.5151-5158.2001; Blancou P, 2001, P NATL ACAD SCI USA, V98, P13237, DOI 10.1073/pnas.231348598; Chen XN, 2001, NAT MED, V7, P1225, DOI 10.1038/nm1101-1225; Etemad-Moghadam B, 2001, J VIROL, V75, P5646, DOI 10.1128/JVI.75.12.5646-5655.2001; Harouse JM, 1999, SCIENCE, V284, P816, DOI 10.1126/science.284.5415.816; Hirsch V M, 2000, Adv Pharmacol, V49, P437; Joag SV, 1996, J VIROL, V70, P3189, DOI 10.1128/JVI.70.5.3189-3197.1996; KUWATA T, 1995, J GEN VIROL, V76, P2181, DOI 10.1099/0022-1317-76-9-2181; LI JT, 1995, J VIROL, V69, P7061, DOI 10.1128/JVI.69.11.7061-7067.1995; Lifson JD, 2000, J VIROL, V74, P2584, DOI 10.1128/JVI.74.6.2584-2593.2000; Lori F, 2000, SCIENCE, V290, P1591, DOI 10.1126/science.290.5496.1591; Mascola JR, 2001, CURR OPIN IMMUNOL, V13, P489, DOI 10.1016/S0952-7915(00)00246-6; Matano T, 2001, J VIROL, V75, P11891, DOI 10.1128/JVI.75.23.11891-11896.2001; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Michael NL, 1997, J INFECT DIS, V175, P1352, DOI 10.1086/516467; Montagnier L, 1997, J INFECT DIS, V175, P955, DOI 10.1086/513999; Montefiori DC, 1998, J VIROL, V72, P3427, DOI 10.1128/JVI.72.4.3427-3431.1998; Nathanson N, 1999, AIDS, V13, pS113; Ourmanov I, 2000, J VIROL, V74, P2740, DOI 10.1128/JVI.74.6.2740-2751.2000; Oxenius A, 2001, EUR J IMMUNOL, V31, P3782, DOI 10.1002/1521-4141(200112)31:12<3782::AID-IMMU3782>3.0.CO;2-#; Parker RA, 2001, J VIROL, V75, P11234, DOI 10.1128/JVI.75.22.11234-11238.2001; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Reimann KA, 1996, J VIROL, V70, P6922, DOI 10.1128/JVI.70.10.6922-6928.1996; Rose NF, 2001, CELL, V106, P539, DOI 10.1016/S0092-8674(01)00482-2; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHULTZ AM, 2001, AIDS S, V15, pS127; Seth A, 2000, J VIROL, V74, P2502, DOI 10.1128/JVI.74.6.2502-2509.2000; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; Veazey RS, 2001, TRENDS IMMUNOL, V22, P626, DOI 10.1016/S1471-4906(01)02039-7; Zhang YJ, 2000, J VIROL, V74, P6893, DOI 10.1128/JVI.74.15.6893-6910.2000	35	155	181	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2002	8	3					207	210		10.1038/nm0302-207	http://dx.doi.org/10.1038/nm0302-207			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875482	Bronze			2022-12-27	WOS:000174139500018
J	Chang, J; Braciale, TJ				Chang, J; Braciale, TJ			Respiratory syncytial virus infection suppresses lung CD8(+) T-cell effector activity and peripheral CD8(+) T-cell memory in the respiratory tract	NATURE MEDICINE			English	Article							EPITHELIAL-CELLS; VACCINIA VIRUS; LYMPHOCYTES-T; CLEAR VIRUS; M2 PROTEIN; MICE; DISEASE; ANERGY; DNA; IMMUNIZATION	Respiratory syncytial virus (RSV) is a major cause of morbidity from respiratory infection in infants, young children and the elderly. No effective vaccine against RSV is currently available and studies of the natural history of RSV infection suggest repeated infections with antigenically related virus strains are common throughout an individual's lifetime. We have studied the CD8(+) T-cell response during experimental murine RSV infection and found that RSV inhibits the expression of effector activity by activated RSV-specific CD8(+) T cells infiltrating the lung parenchyma and the development of pulmonary CD8(+) T-cell memory by interfering with TCR-mediated signaling. These data suggest a possible mechanism to explain the limited duration of protective immunity in RSV infection.	Univ Virginia, Hlth Sci Ctr, Beirne B Carter Ctr Immunol Res, Charlottesville, VA 22903 USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol & Microbiol, Charlottesville, VA USA	University of Virginia; University of Virginia	Braciale, TJ (corresponding author), Univ Virginia, Hlth Sci Ctr, Beirne B Carter Ctr Immunol Res, Charlottesville, VA 22903 USA.			CHANG, JUN/0000-0002-8423-5987				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; ALWAN WH, 1994, J EXP MED, V179, P81, DOI 10.1084/jem.179.1.81; ALWAN WH, 1992, CLIN EXP IMMUNOL, V88, P527; BECKER S, 1991, J IMMUNOL, V147, P4307; BEEM M, 1967, J IMMUNOL, V98, P1115; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; CANNON MJ, 1988, J EXP MED, V168, P1163, DOI 10.1084/jem.168.3.1163; Chang J, 2001, J IMMUNOL, V167, P4254, DOI 10.4049/jimmunol.167.8.4254; CHANOCK RM, 1992, PEDIATRICS, V90, P137; Falsey AR, 1998, J INFECT DIS, V177, P463, DOI 10.1086/517376; Flynn KJ, 1998, IMMUNITY, V8, P683, DOI 10.1016/S1074-7613(00)80573-7; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; GLEZEN WP, 1973, NEW ENGL J MED, V288, P498, DOI 10.1056/NEJM197303082881005; HALL CB, 1981, INFECT IMMUN, V33, P779, DOI 10.1128/IAI.33.3.779-783.1981; HALL CB, 1991, J INFECT DIS, V163, P693, DOI 10.1093/infdis/163.4.693; HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004; KULKARNI AB, 1995, J VIROL, V69, P1261, DOI 10.1128/JVI.69.2.1261-1264.1995; KULKARNI AB, 1993, J VIROL, V67, P1044, DOI 10.1128/JVI.67.2.1044-1049.1993; Madrenas J, 1996, P NATL ACAD SCI USA, V93, P9736, DOI 10.1073/pnas.93.18.9736; McCluskie MJ, 1999, MOL MED, V5, P287, DOI 10.1007/BF03402065; McCluskie MJ, 1998, ANTISENSE NUCLEIC A, V8, P401, DOI 10.1089/oli.1.1998.8.401; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Olszewska-Pazdrak B, 1998, J VIROL, V72, P4756, DOI 10.1128/JVI.72.6.4756-4764.1998; OPENSHAW PJM, 1990, J VIROL, V64, P1683, DOI 10.1128/JVI.64.4.1683-1689.1990; PRESTON FM, 1995, J INFECT DIS, V172, P919, DOI 10.1093/infdis/172.4.919; SAD S, 1995, IMMUNITY, V2, P271, DOI 10.1016/1074-7613(95)90051-9; Schwartz DA, 1997, J CLIN INVEST, V100, P68, DOI 10.1172/JCI119523; Slifka MK, 1999, NATURE, V401, P76, DOI 10.1038/43454; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; Srikiatkhachorn A, 1997, J EXP MED, V186, P421, DOI 10.1084/jem.186.3.421; SWEETSER MT, 1989, J EXP MED, V170, P1357, DOI 10.1084/jem.170.4.1357; Thomas LH, 2000, J VIROL, V74, P8425, DOI 10.1128/JVI.74.18.8425-8433.2000; Tripp RA, 1999, J VIROL, V73, P7099, DOI 10.1128/JVI.73.9.7099-7107.1999; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	35	176	178	1	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2002	8	1					54	60		10.1038/nm0102-54	http://dx.doi.org/10.1038/nm0102-54			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	507XQ	11786907				2022-12-27	WOS:000173056900031
J	Dazzi, F; Simpson, E; Goldman, JM				Dazzi, F; Simpson, E; Goldman, JM			Minor antigen solves major problem	NATURE MEDICINE			English	Editorial Material							BONE-MARROW TRANSPLANTATION; CHRONIC MYELOID-LEUKEMIA; VERSUS-HOST DISEASE; HISTOCOMPATIBILITY ANTIGENS; RELAPSE	A mouse model for donor lymphocyte infusion reveals that a single immunodominant minor H antigen is responsible for the beneficial effects of donor T lymphocytes against host leukemia. Separating the good from the bad could mean the end of graft-versus-host disease in bone marrow transplants.	Univ London Imperial Coll Sci Technol & Med, Dept Haematol, Sch Med, Hammersmith Hosp, London, England	Imperial College London	Dazzi, F (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Haematol, Sch Med, Hammersmith Hosp, London, England.		Dazzi, Francesco/ABD-6171-2021	Dazzi, Francesco/0000-0003-2407-236X; Simpson, Elizabeth/0000-0002-2118-3139				APPERLEY JF, 1986, BONE MARROW TRANSPL, V1, P53; Barrett AJ, 1998, BONE MARROW TRANSPL, V21, P543, DOI 10.1038/sj.bmt.1701131; Dazzi F, 2000, BLOOD, V95, P67, DOI 10.1182/blood.V95.1.67.001k07_67_71; Dazzi F, 1999, EXP HEMATOL, V27, P1477, DOI 10.1016/S0301-472X(99)00096-X; Fontaine P, 2001, NAT MED, V7, P789, DOI 10.1038/89907; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; Goulmy E, 1996, NEW ENGL J MED, V334, P281, DOI 10.1056/NEJM199602013340501; Krenger W, 1997, TRANSPLANTATION, V64, P553, DOI 10.1097/00007890-199708270-00001; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; Mutis T, 1999, BLOOD, V93, P2336, DOI 10.1182/blood.V93.7.2336.407k26_2336_2341; Simpson E, 1997, CURR OPIN IMMUNOL, V9, P655, DOI 10.1016/S0952-7915(97)80045-3	11	3	3	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					769	770		10.1038/89874	http://dx.doi.org/10.1038/89874			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433332				2022-12-27	WOS:000169808600015
J	Jiang, XC; Qin, SC; Qiao, CP; Kawano, K; Lin, M; Skold, A; Xiao, X; Tall, AR				Jiang, XC; Qin, SC; Qiao, CP; Kawano, K; Lin, M; Skold, A; Xiao, X; Tall, AR			Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency	NATURE MEDICINE			English	Article							CONTAINING LIPOPROTEINS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; RECEPTOR; SITE; RNA	Increased secretion and levels of ApoB-containing lipoproteins (BLp) commonly occur in familiar hyperlipidemia, obesity and diabetes. The plasma phospholipid-transfer protein (PLTP) is known to mediate transfer of phospholipids between BLp and HDL during their intravascular metabolism. To address a possible role of PLTP in dyslipidemia and atherogenesis, we bred mice deficient in the gene encoding PLTP (PLTP-deficient mice) using different hyperlipidemic mouse strains. In ApoB-transgenic and ApoE-deficient backgrounds, PLTP deficiency resulted in reduced production and levels of BLp and markedly decreased atherosclerosis. BLp secretion was diminished in hepatocytes from ApoB-transgenic PLTP-deficient mice, a defect that was corrected when PLTP was reintroduced in adenovirus. The studies reveal a major, unexpected role of PLTP in regulating the secretion of BLp and identify PLTP as a therapeutic target.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10027 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Columbia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Tall, AR (corresponding author), Columbia Univ, Dept Med, Div Mol Med, New York, NY 10027 USA.	art1@columbia.edu	Tall, Alan/AAT-8528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; Bruce C, 1998, CURR OPIN STRUC BIOL, V8, P426, DOI 10.1016/S0959-440X(98)80118-8; BRUNZELL JD, 1983, J LIPID RES, V24, P147; CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Duvillard L, 2000, EUR J CLIN INVEST, V30, P685, DOI 10.1046/j.1365-2362.2000.00702.x; Fang M, 1998, BBA-MOL CELL RES, V1404, P85, DOI 10.1016/S0167-4889(98)00049-4; Ginsberg HN, 1997, CLIN EXP PHARMACOL P, V24, pA29, DOI 10.1111/j.1440-1681.1997.tb03051.x; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; Hamilton RL, 1998, J LIPID RES, V39, P1543; HAVEL RJ, 1973, J CLIN INVEST, V52, P32, DOI 10.1172/JCI107171; HAVEL RJ, 1989, METABOLIC BASIS INHE, P1129; Honkakoski P, 1998, BIOCHEM J, V330, P889, DOI 10.1042/bj3300889; Huuskonen J, 1999, J LIPID RES, V40, P1123; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; Li J, 1999, GENE THER, V6, P74, DOI 10.1038/sj.gt.3300830; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MATTHEWS CME, 1957, PHYS MED BIOL, V2, P36, DOI 10.1088/0031-9155/2/1/305; Okamoto H, 2000, NATURE, V406, P203, DOI 10.1038/35018119; PLUMP AS, 1995, ANNU REV NUTR, V15, P495, DOI 10.1146/annurev.nu.15.070195.002431; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Riches FM, 1998, INT J OBESITY, V22, P414, DOI 10.1038/sj.ijo.0800602; Rinninger F, 1999, ARTERIOSCL THROM VAS, V19, P1325, DOI 10.1161/01.ATV.19.5.1325; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TALL AR, 1983, J BIOL CHEM, V258, P2174; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; Veniant MM, 1999, J NUTR, V129, p451S, DOI 10.1093/jn/129.2.451S; Veniant MM, 1997, J CLIN INVEST, V100, P180, DOI 10.1172/JCI119511; WETTERAU JR, 1992, SCIENCE, V258, P999; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P16741; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	40	223	234	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2001	7	7					847	852		10.1038/89977	http://dx.doi.org/10.1038/89977			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433351				2022-12-27	WOS:000169808600038
J	Hsu, SY; Hsueh, AJW				Hsu, SY; Hsueh, AJW			Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor	NATURE MEDICINE			English	Article							MICE LACKING; RAT-BRAIN; UROCORTIN; CLONING; EXPRESSION; ANXIETY; BEHAVIOR; INJURY; FAMILY; CELLS	Adaptive stress responses mediated by the endocrine, autonomic, cardiovascular and immune systems are essential for the survival of the individual. Initial stress-induced responses provide a vital short-term metabolic lift, but prolonged or inappropriate exposure to stress can compromise homeostasis thereby leading to disease. This 'fight-or-flight' response is characterized by the activation of the corticotropin-releasing hormone (CRH)-adrenocorticotropin-glucocorticoid axis, mediated by the type 1 CRH receptor. In contrast, the type 2 CRH receptor mediates the stress-coping responses during the recovery phase of stress. We identified human stresscopin (SCP) and stresscopin-related peptide (SRP) as specific ligands for the type 2 CRH receptor. The genes encoding these peptides were expressed in diverse peripheral tissues as well as in the central nervous system. Treatment with SCP or SRP suppressed food intake, delayed gastric emptying and decreased heat-induced edema. Thus SCP and SRP might represent endogenous ligands for maintaining homeostasis after stress, and could allow the design of drugs to ameliorate stress-related diseases.	Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA	Stanford University	Hsueh, AJW (corresponding author), Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA.							Asakawa A, 1999, GASTROENTEROLOGY, V116, P1287, DOI 10.1016/S0016-5085(99)70491-9; Bale TL, 2000, NAT GENET, V24, P410, DOI 10.1038/74263; Bittencourt JC, 1999, J COMP NEUROL, V415, P285; Brar BK, 2000, J BIOL CHEM, V275, P8508, DOI 10.1074/jbc.275.12.8508; Brunner B, 2000, CHROMOSOME RES, V8, P465, DOI 10.1023/A:1009263504671; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; Chrousos GP, 1998, ANN NY ACAD SCI, V851, P311, DOI 10.1111/j.1749-6632.1998.tb09006.x; Coste SC, 2000, NAT GENET, V24, P403, DOI 10.1038/74255; Hauger RL, 1997, J NEUROCHEM, V68, P2308; Heinrichs SC, 1999, NEUROPEPTIDES, V33, P350, DOI 10.1054/npep.1999.0047; Hsu SY, 1999, MOL ENDOCRINOL, V13, P2163, DOI 10.1210/me.13.12.2163; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830; HSUEH AJW, 1978, NATURE, V273, P57, DOI 10.1038/273057a0; Kageyama K, 2000, ENDOCRINOLOGY, V141, P2285, DOI 10.1210/en.141.7.2285; Kishimoto T, 2000, NAT GENET, V24, P415, DOI 10.1038/74271; LAU SH, 1983, P NATL ACAD SCI-BIOL, V80, P7070, DOI 10.1073/pnas.80.23.7070; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; Nozu T, 1999, AM J PHYSIOL-GASTR L, V276, pG867, DOI 10.1152/ajpgi.1999.276.4.G867; PERRIN M, 1995, P NATL ACAD SCI USA, V92, P2969, DOI 10.1073/pnas.92.7.2969; Perrin MH, 1999, ANN NY ACAD SCI, V885, P312, DOI 10.1111/j.1749-6632.1999.tb08687.x; Reyes TM, 2001, P NATL ACAD SCI USA, V98, P2843, DOI 10.1073/pnas.051626398; SELYE H, 1946, J CLIN ENDOCR METAB, V6, P117, DOI 10.1210/jcem-6-2-117; SEYLE H, 1955, SCIENCE, V122, P625; Smith GW, 1998, NEURON, V20, P1093, DOI 10.1016/S0896-6273(00)80491-2; SPIESS J, 1981, P NATL ACAD SCI-BIOL, V78, P6517, DOI 10.1073/pnas.78.10.6517; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; Turnbull AV, 1996, EUR J PHARMACOL, V303, P213, DOI 10.1016/0014-2999(96)00141-0; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; Weninger SC, 1999, P NATL ACAD SCI USA, V96, P8283, DOI 10.1073/pnas.96.14.8283	29	566	587	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					605	611		10.1038/87936	http://dx.doi.org/10.1038/87936			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329063				2022-12-27	WOS:000169961100041
J	Pashmforoush, M; Pomies, P; Peterson, KL; Kubalak, S; Ross, JR; Hefti, A; Aebi, U; Beckerle, MC; Chien, KR				Pashmforoush, M; Pomies, P; Peterson, KL; Kubalak, S; Ross, JR; Hefti, A; Aebi, U; Beckerle, MC; Chien, KR			Adult mice deficient in actinin-associated LIM-domain protein reveal a developmental pathway for right ventricular cardiomyopathy	NATURE MEDICINE			English	Article							ALPHA-ACTININ; HEART-FAILURE; DILATED CARDIOMYOPATHY; MUSCLE DIFFERENTIATION; CARDIAC-HYPERTROPHY; PLAKOGLOBIN; DISEASE; PDZ; IDENTIFICATION; DISRUPTION	Although cytoskeletal mutations are known causes of genetically based forms of dilated cardiomyopathy, the pathways that link these defects with cardiomyopathy are unclear. Here we report that the alpha -actinin-associated LIM protein (ALP; Alp in mice) has an essential role in the embryonic development of the right ventricular (RV) chamber during its exposure to high biomechanical workloads in utero. Disruption of the gene encoding Alp (Alp) is associated with RV chamber dilation and dysfunction, directly implicating alpha -actinin-associated proteins in the onset of cardiomyopathy. In vitro assays showed that Alp directly enhances the capacity of a-actinin to cross-link actin filaments, indicating that the loss of Alp function contributes to destabilization of actin anchorage sites in cardiac muscle. Alp also colocalizes at the intercalated disc with alpha -actinin and gamma -catenin, the latter being a known disease gene for human RV dysplasia. Taken together, these studies point to a novel developmental pathway for RV dilated cardiomyopathy via instability of alpha -actinin complexes.	Univ Calif San Diego, Salk Program Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; Univ Basel, Biozentrum, Basel, Switzerland; Med Univ S Carolina, Dept Cell Biol, Charleston, SC 29425 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of Basel; Medical University of South Carolina	Chien, KR (corresponding author), Univ Calif San Diego, Salk Program Mol Med, La Jolla, CA 92093 USA.		Pomiès, Pascal/AAC-8037-2020	Pomiès, Pascal/0000-0002-5301-6087				Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Basso C, 1996, CIRCULATION, V94, P983, DOI 10.1161/01.CIR.94.5.983; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Chien KR, 2000, NATURE, V407, P227, DOI 10.1038/35025196; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Corrado D, 2000, CIRCULATION, V101, pE101, DOI 10.1161/01.CIR.101.11.e101; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Fontaine G, 1999, ANNU REV MED, V50, P17, DOI 10.1146/annurev.med.50.1.17; Fontaine G, 1998, CIRCULATION, V97, P1532, DOI 10.1161/01.CIR.97.16.1532; Fontaine G, 1999, ACTA CARDIOL, V54, P189; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; KIESS M, 1995, ONCOGENE, V10, P61; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; McKoy G, 2000, LANCET, V355, P2119, DOI 10.1016/S0140-6736(00)02379-5; MEYER RK, 1990, J CELL BIOL, V110, P2013, DOI 10.1083/jcb.110.6.2013; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; Murata K, 1997, CARDIOVASC RES, V33, P359, DOI 10.1016/S0008-6363(96)00218-0; Nieset JE, 1997, J CELL SCI, V110, P1013; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Pomies P, 1999, J BIOL CHEM, V274, P29242, DOI 10.1074/jbc.274.41.29242; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Ruiz P, 1996, J CELL BIOL, V135, P215, DOI 10.1083/jcb.135.1.215; SUTTON MS, 1991, BRIT HEART J, V66, P285; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; Towbin J A, 2000, Curr Cardiol Rep, V2, P475, DOI 10.1007/s11886-000-0063-9; Vallenius T, 2000, J BIOL CHEM, V275, P11100, DOI 10.1074/jbc.275.15.11100; WANG HC, 1995, GENE, V165, P267, DOI 10.1016/0378-1119(95)00542-E; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507	34	149	151	1	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					591	597		10.1038/87920	http://dx.doi.org/10.1038/87920			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329061				2022-12-27	WOS:000169961100039
J	Gribkoff, VK; Starrett, JE; Dworetzky, SI; Hewawasam, P; Boissard, CG; Cook, DA; Frantz, SW; Heman, K; Hibbard, JR; Huston, K; Johnson, G; Krishnan, BS; Kinney, GG; Lombardo, LA; Meanwell, NA; Molinoff, PB; Myers, RA; Moon, SL; Ortiz, A; Pajor, L; Pieschl, RL; Post-Munson, DJ; Signor, LJ; Srinivas, N; Taber, MT; Thalody, G; Trojnacki, JT; Wiener, H; Yeleswaram, K; Yeola, SW				Gribkoff, VK; Starrett, JE; Dworetzky, SI; Hewawasam, P; Boissard, CG; Cook, DA; Frantz, SW; Heman, K; Hibbard, JR; Huston, K; Johnson, G; Krishnan, BS; Kinney, GG; Lombardo, LA; Meanwell, NA; Molinoff, PB; Myers, RA; Moon, SL; Ortiz, A; Pajor, L; Pieschl, RL; Post-Munson, DJ; Signor, LJ; Srinivas, N; Taber, MT; Thalody, G; Trojnacki, JT; Wiener, H; Yeleswaram, K; Yeola, SW			Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels	NATURE MEDICINE			English	Article							LARGE-CONDUCTANCE; CEREBRAL-ISCHEMIA; BK CHANNELS; CELL-DEATH; RAT; CLONING; BRAIN; EXPRESSION; MODULATION; OCCLUSION	During ischemic stroke, neurons at risk are exposed to pathologically high levels of intracellular calcium (Ca++), initiating a fatal biochemical cascade. To protect these neurons, we have developed openers of large-conductance, Ca++-activated (maxi-K or BK) potassium channels, thereby augmenting an endogenous mechanism for regulating Ca++ entry and membrane potential. The novel fluoro-oxindoles BMS-204352 and racemic compound 1 are potent, effective and uniquely Ca++-sensitive openers of maxi-K channels. In rat models of permanent large-vessel stroke, BMS-204352 provided significant levels of cortical neuroprotection when administered two hours after the onset of occlusion, but had no effects on blood pressure or cerebral blood flow. This novel approach may restrict Ca++ entry in neurons at risk while having minimal side effects.	Bristol Myers Squibb Pharmaceut Res Inst, Neurosci Drug Discovery Div, Wallingford, CT 06492 USA; Bristol Myers Squibb Pharmaceut Res Inst, Neurosci Chem Div, Wallingford, CT USA; Bristol Myers Squibb Pharmaceut Res Inst, Drug Safety Evaluat Div, Wallingford, CT USA; Bristol Myers Squibb Pharmaceut Res Inst, Metab & Pharmacokinet Div, Wallingford, CT USA; Bristol Myers Squibb Pharmaceut Res Inst, Analyt Sci Div, Wallingford, CT USA	Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb	Gribkoff, VK (corresponding author), Bristol Myers Squibb Pharmaceut Res Inst, Neurosci Drug Discovery Div, Wallingford, CT 06492 USA.			Meanwell, Nicholas/0000-0002-8857-1515				Bowler JV, 1998, J NEUROL NEUROSUR PS, V64, P90, DOI 10.1136/jnnp.64.1.90; Brenner R, 2000, J BIOL CHEM, V275, P6453, DOI 10.1074/jbc.275.9.6453; BRINT S, 1988, J CEREBR BLOOD F MET, V8, P474, DOI 10.1038/jcbfm.1988.88; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dworetzky SI, 1996, J NEUROSCI, V16, P4543; DWORETZKY SI, 1994, MOL BRAIN RES, V27, P189, DOI 10.1016/0169-328X(94)90203-8; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Fisher M, 1999, J THROMB THROMBOLYS, V7, P165, DOI 10.1023/A:1008889605137; Gillard JH, 1997, AM J NEURORADIOL, V18, P343; Gribkoff V K, 1997, Adv Pharmacol, V37, P319; Gribkoff V K, 1999, Expert Opin Pharmacother, V1, P61, DOI 10.1517/14656566.1.1.61; Gribkoff V.K., 1997, 3-substituted oxindole derivatives as potassium channel modulators,, Patent No. [US5602169A, 5602169, US5602169]; Gribkoff VK, 1996, MOL PHARMACOL, V50, P206; HEWAWASAM P, 1996, Patent No. 5565483; Jain KK, 2000, EXPERT OPIN INV DRUG, V9, P695, DOI 10.1517/13543784.9.4.695; Joiner WJ, 1998, NAT NEUROSCI, V1, P462, DOI 10.1038/2176; Juhng KN, 1999, EPILEPSY RES, V34, P177, DOI 10.1016/S0920-1211(98)00111-9; Knaus HG, 1996, J NEUROSCI, V16, P955; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Li FH, 2000, NEUROLOGY, V54, P689, DOI 10.1212/WNL.54.3.689; MCCOBB DP, 1995, AM J PHYSIOL-HEART C, V269, pH767, DOI 10.1152/ajpheart.1995.269.3.H767; MCKAY MC, 1994, J NEUROPHYSIOL, V71, P1873, DOI 10.1152/jn.1994.71.5.1873; MCMANUS OB, 1991, J BIOENERG BIOMEMBR, V23, P537, DOI 10.1007/BF00785810; Meera P, 1997, P NATL ACAD SCI USA, V94, P14066, DOI 10.1073/pnas.94.25.14066; Penner Reinhold, 1995, P3; Schlaug G, 1999, NEUROLOGY, V53, P1528, DOI 10.1212/WNL.53.7.1528; Schreiber M, 1999, NAT NEUROSCI, V2, P416, DOI 10.1038/8077; Starrett JE, 1996, CURR PHARM DESIGN, V2, P413; Strobaek D, 1996, NEUROPHARMACOLOGY, V35, P903, DOI 10.1016/0028-3908(96)00096-2; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Vang C, 1999, STROKE, V30, P2119, DOI 10.1161/01.STR.30.10.2119; WANN KT, 1994, EUR J NEUROSCI, V6, P607, DOI 10.1111/j.1460-9568.1994.tb00305.x; WILLETTE RN, 1990, STROKE, V21, P451, DOI 10.1161/01.STR.21.3.451; Williams GR, 1999, STROKE, V30, P2523, DOI 10.1161/01.STR.30.12.2523	39	253	262	1	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2001	7	4					471	477		10.1038/86546	http://dx.doi.org/10.1038/86546			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283675				2022-12-27	WOS:000167960500043
J	O'Connell, J; Houston, A; Bennett, MW; O'Sullivan, G; Shanahan, F				O'Connell, J; Houston, A; Bennett, MW; O'Sullivan, G; Shanahan, F			Immune privilege or inflammation? Insights into the Fas ligand enigma	NATURE MEDICINE			English	Editorial Material							SMOOTH-MUSCLE CELLS; COLON-CANCER; PROGNOSTIC-SIGNIFICANCE; COLORECTAL-CANCER; LIVER METASTASES; BREAST-CANCER; TUMOR-CELLS; IN-VIVO; EXPRESSION; COUNTERATTACK		Natl Univ Ireland, Univ Hosp, Dept Med, Cork, Ireland; Natl Univ Ireland, Mercy Hosp, Dept Surg, Cork, Ireland	University College Cork; University College Cork	O'Connell, J (corresponding author), Natl Univ Ireland, Univ Hosp, Dept Med, Cork, Ireland.		Houston, Aileen/ABF-2473-2020; Shanahan, Fergus/ABF-2390-2020	Houston, Aileen/0000-0003-1362-5256; Shanahan, Fergus/0000-0003-0467-0936				Arbuckle E, 2000, ONCOL REP, V7, P45; Bennett MW, 1998, J IMMUNOL, V160, P5669; Chen JJ, 1998, SCIENCE, V282, P1714, DOI 10.1126/science.282.5394.1714; Eberl LP, 1999, INT J CANCER, V81, P772, DOI 10.1002/(SICI)1097-0215(19990531)81:5<772::AID-IJC18>3.0.CO;2-S; Griffith TS, 1997, IMMUNOL TODAY, V18, P240, DOI 10.1016/S0167-5699(97)81663-5; Hohlbaum AM, 2000, J EXP MED, V191, P1209, DOI 10.1084/jem.191.7.1209; Ito Y, 2000, BRIT J CANCER, V82, P1211; Jarry A, 1999, GUT, V45, P246, DOI 10.1136/gut.45.2.246; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Kelly L, 1999, INT J EXP PATHOL, V80, P217, DOI 10.1046/j.1365-2613.1999.00117.x; Khar A, 1998, CELL IMMUNOL, V189, P85, DOI 10.1006/cimm.1998.1367; Kim YS, 2000, ARCH PATHOL LAB MED, V124, P687; Lepple-Wienhues A, 1999, P NATL ACAD SCI USA, V96, P13795, DOI 10.1073/pnas.96.24.13795; Li XK, 1998, TRANSPLANTATION, V66, P1416, DOI 10.1097/00007890-199812150-00003; Mann B, 1999, BRIT J CANCER, V79, P1262, DOI 10.1038/sj.bjc.6690202; Matsue H, 1999, NAT MED, V5, P930, DOI 10.1038/11375; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; Mor G, 2000, J STEROID BIOCHEM, V73, P185, DOI 10.1016/S0960-0760(00)00081-9; Mottolese M, 2000, INT J CANCER, V89, P127, DOI 10.1002/(SICI)1097-0215(20000320)89:2<127::AID-IJC5>3.0.CO;2-4; Munakata S, 2000, BRIT J CANCER, V82, P1446, DOI 10.1054/bjoc.1999.1073; Nagarkatti N, 2000, CANCER IMMUNOL IMMUN, V49, P46, DOI 10.1007/s002620050025; O'Connell J, 1998, J PATHOL, V186, P240; O'Connell J, 1999, IMMUNOL TODAY, V20, P46, DOI 10.1016/S0167-5699(98)01382-6; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Okada K, 2000, CLIN CANCER RES, V6, P3560; PAPOFF G, 1998, SCIENCE, V279, pA2015; Reimer T, 2000, CANCER RES, V60, P822; Restifo NP, 2000, NAT MED, V6, P493, DOI 10.1038/74955; Sampalo A, 2000, BLOOD, V96, P3168; Schaub FJ, 2000, NAT MED, V6, P790, DOI 10.1038/77521; Shibakita M, 1999, CLIN CANCER RES, V5, P2464; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; Sikora J, 1998, NAT IMMUN, V16, P244, DOI 10.1159/000069450; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; Swenson KM, 1998, TRANSPLANTATION, V65, P155; Volm M, 2000, BRIT J CANCER, V82, P1747; Waku T, 2000, J IMMUNOL, V165, P5884, DOI 10.4049/jimmunol.165.10.5884; Yakes FM, 2000, CANCER RES, V60, P5740; Yoong KF, 1999, AM J PATHOL, V154, P693, DOI 10.1016/S0002-9440(10)65316-3; Zaks TZ, 1999, J IMMUNOL, V162, P3273	40	132	135	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					271	274		10.1038/85395	http://dx.doi.org/10.1038/85395			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231613				2022-12-27	WOS:000167380400018
J	Crosbie, RH				Crosbie, RH			NO vascular control in Duchenne muscular dystrophy	NATURE MEDICINE			English	Editorial Material							SKELETAL-MUSCLE; SMOOTH-MUSCLE; NITRIC-OXIDE; GLYCOPROTEIN; COMPLEX; VASOCONSTRICTION	A new investigation into Duchenne muscular dystrophy (DMD) pathogenesis suggests that at least part of the muscle degeneration observed in DMD patients may result from the reduced production of muscle membrane-associated neuronal nitric oxide synthase. This reduction may lead to impaired regulation of the vasoconstrictor response and eventual muscle damage.	Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Crosbie, RH (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048179] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR048179] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRENNAN JE, 1995, CELL, V85, P743; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; Chang WJ, 1996, P NATL ACAD SCI USA, V93, P9142, DOI 10.1073/pnas.93.17.9142; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Crosbie RH, 1998, HUM MOL GENET, V7, P823, DOI 10.1093/hmg/7.5.823; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Durbeej M, 2000, MOL CELL, V5, P141, DOI 10.1016/S1097-2765(00)80410-4; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; Lau KS, 1998, FEBS LETT, V431, P71, DOI 10.1016/S0014-5793(98)00728-5; Lau KS, 2000, PHYSIOL GENOMICS, V2, P21, DOI 10.1152/physiolgenomics.2000.2.1.21; MENKE A, 1995, J CELL SCI, V108, P727; PASTERNAK C, 1995, J CELL BIOL, V128, P355, DOI 10.1083/jcb.128.3.355; Sander M, 2000, P NATL ACAD SCI USA, V97, P13818, DOI 10.1073/pnas.250379497; Thomas GD, 1997, J CLIN INVEST, V99, P2602, DOI 10.1172/JCI119448; Thomas GD, 1998, P NATL ACAD SCI USA, V95, P15090, DOI 10.1073/pnas.95.25.15090; Tidball JG, 1998, AM J PHYSIOL-CELL PH, V275, pC260, DOI 10.1152/ajpcell.1998.275.1.C260; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	18	28	28	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					27	29		10.1038/83309	http://dx.doi.org/10.1038/83309			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135610				2022-12-27	WOS:000166243100025
J	Raw, M				Raw, M			Fighting tobacco dependence in Europe	NATURE MEDICINE			English	Editorial Material								The World Health Organization estimates that tobacco will become the largest single health problem by 2020, causing an estimated 8.4 million deaths annually. But the smoking burden will not be distributed evenly across the globe; deaths in developed nations are set to rise 50% to 2.4 million while those in Asia will soar fourfold to an estimated 4.2 million in 2020. In the face of such discrepancy, Martin Raw, Honorary Lecturer in evidence-based treatment at Guys, Kings and St Thomas' School of Medicine, London, explains why attention can not be focused solely on Asia and why efforts are still needed to stop smoking in Europe.	Univ London, Guys Kings & St Thomas Sch Med, London WC1E 7HU, England	University of London; King's College London	Raw, M (corresponding author), Univ London, Guys Kings & St Thomas Sch Med, London WC1E 7HU, England.							CALLUM C, 2000, UK SMOKING EPIDEMIC; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; Peto R., 2001, CRITICAL ISSUES GLOB, P154, DOI DOI 10.4314/NMP.V55I6.45441; *ROYAL COLL PHYS, 2000, NIC ADD BRIT REP TOB; *WHO EUR PARTN PRO, 2000, 1 EUR REC TREATM TOB; World Bank, 1999, CURB EP GOV EC TOB C	6	2	3	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					13	14		10.1038/83281	http://dx.doi.org/10.1038/83281			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135600				2022-12-27	WOS:000166243100017
J	Zheng, TS; Hunot, S; Kuida, K; Momoi, T; Srinivasan, A; Nicholson, DW; Lazebnik, Y; Flavell, RA				Zheng, TS; Hunot, S; Kuida, K; Momoi, T; Srinivasan, A; Nicholson, DW; Lazebnik, Y; Flavell, RA			Deficiency in caspase-9 or caspase-3 induces compensatory caspase activation	NATURE MEDICINE			English	Article							ANTI-FAS ANTIBODY; CYTOCHROME-C; IN-VIVO; APOPTOSIS; MICE; PATHWAYS; RELEASE; BCL-2; MITOCHONDRIA; CLEAVAGE	Dysregulation of apoptosis contributes to the pathogenesis of many human diseases. As effecters of the apoptotic machinery, caspases are considered potential therapeutic targets. Using an established in vivo model of Fas-mediated apoptosis, we demonstrate here that elimination of certain caspases was compensated in vivo by the activation of other caspases. Hepatocyte apoptosis and mouse death induced by the Fas agonistic antibody Jo2 required proapoptotic Bcl-2 family member Bid and used a Bid-mediated mitochondrial pathway of caspase activation; deficiency in caspases essential for this pathway, caspase-9 or caspase-3, unexpectedly resulted in rapid activation of alternate caspases after injection of Jo2, and therefore failed to protect mice against Jo2 toxicity. Moreover, both ultraviolet and gamma irradiation, two established inducers of the mitochondrial caspase-activation pathway, also elicited compensatory activation of caspases in cultured caspase-3(-/-) hepatocytes, indicating that the compensatory caspase activation was mediated through the mitochondria. Our findings provide direct experimental evidence for compensatory pathways of caspase activation. This issue should therefore be considered in developing caspase inhibitors for therapeutic applications.	Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Vertex Pharmaceut, Cambridge, MA 02139 USA; NCNP, Natl Inst Neurosci, Div Dev & Differentiat, Tokyo 187, Japan; IDUN Pharmaceut, La Jolla, CA 92037 USA; Merck Frosst Canada Inc, Pointe Claire, PQ H9R 4P8, Canada; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Yale University; Howard Hughes Medical Institute; Yale University; Vertex Pharmaceuticals; National Center for Neurology & Psychiatry - Japan; Merck & Company; Cold Spring Harbor Laboratory	Flavell, RA (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA.	richard.flavell@yale.edu	Hunot, Stephane/ABE-4204-2021	Hunot, Stephane/0000-0002-8266-5211	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13106-25] Funding Source: Medline; NIDDK NIH HHS [1 P30 DK34989] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kouroku Y, 1998, BIOCHEM BIOPH RES CO, V247, P780, DOI 10.1006/bbrc.1998.8815; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Woo M, 1999, J IMMUNOL, V163, P4909; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zheng TS, 2000, EXP CELL RES, V256, P67, DOI 10.1006/excr.2000.4841; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618	31	262	263	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2000	6	11					1241	1247		10.1038/81343	http://dx.doi.org/10.1038/81343			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062535				2022-12-27	WOS:000165114800031
J	Ruggeri, ZM				Ruggeri, ZM			Platelets in atherothrombosis	NATURE MEDICINE			English	Review							VON-WILLEBRAND-FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; CAROTID-ARTERY STENOSIS; GLYCOPROTEIN IB; VONWILLEBRAND-FACTOR; RECEPTOR INTERACTIONS; COLLAGEN RECEPTORS; VESSEL WALL; SHEAR RATE; ADHESION	The participation of platelets in atherogenesis and the subsequent formation of occlusive thrombi depend on platelets' adhesive properties and the inability to respond to stimuli with rapid activation. By understanding the multifaceted mechanisms involved in platelet interaction with vascular surfaces and aggregation, new approaches can be tailored to selectively inhibit the pathways most relevant to the pathological aspects of atherothrombosis.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Ruggeri, ZM (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.	ruggeri@scripps.edu						Abumiya T, 2000, STROKE, V31, P1402, DOI 10.1161/01.STR.31.6.1402; Andre P, 2002, NAT MED, V8, P247, DOI 10.1038/nm0302-247; Balasubramanian V, 2002, BLOOD, V100, P2787, DOI 10.1182/blood-2002-03-0902; BALBONA K, 1992, J BIOL CHEM, V267, P20120; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; BEUMER S, 1994, BLOOD, V84, P3724, DOI 10.1182/blood.V84.11.3724.bloodjournal84113724; BEUMER S, 1995, BLOOD, V86, P3452, DOI 10.1182/blood.V86.9.3452.bloodjournal8693452; Bornstein NM, 2001, CEREBROVASC DIS, V11, P96, DOI 10.1159/000049131; Celi A, 1997, SEMIN HEMATOL, V34, P327; Clemetson KJ, 2001, THROMB HAEMOSTASIS, V86, P189; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; De Meyer GRY, 2002, CIRC RES, V90, P1197, DOI 10.1161/01.RES.0000020017.84398.61; DENT JA, 1990, P NATL ACAD SCI USA, V87, P6306, DOI 10.1073/pnas.87.16.6306; Furlan M, 1997, BLOOD, V89, P3097, DOI 10.1182/blood.V89.9.3097; Gachet C, 2000, ANN MED, V32, P15; Garlichs CD, 2001, CIRCULATION, V104, P2395, DOI 10.1161/hc4501.099312; Godyna S, 1996, BLOOD, V88, P2569, DOI 10.1182/blood.V88.7.2569.bloodjournal8872569; Goto S, 1999, CIRCULATION, V99, P608, DOI 10.1161/01.CIR.99.5.608; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; Gross PL, 2000, SEMIN THROMB HEMOST, V26, P463, DOI 10.1055/s-2000-13202; Holtkotter O, 2002, J BIOL CHEM, V277, P10789, DOI 10.1074/jbc.M112307200; Hynes R. O., 1989, FIBRONECTINS; Inzitari D, 2000, NEW ENGL J MED, V342, P1693, DOI 10.1056/NEJM200006083422302; Inzitari D, 2000, NEUROLOGY, V54, P660, DOI 10.1212/WNL.54.3.660; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; Kunicki TJ, 2001, CIRCULATION, V104, P1451, DOI 10.1161/circ.104.13.1451; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; MAILHAC A, 1994, CIRCULATION, V90, P988, DOI 10.1161/01.CIR.90.2.988; Matsagas MI, 2002, ANN VASC SURG, V16, P246, DOI 10.1007/s10016-001-0159-8; Mazzucato M, 1998, J BIOL CHEM, V273, P1880, DOI 10.1074/jbc.273.4.1880; Mazzucato M, 2002, BLOOD, V100, P2793, DOI 10.1182/blood-2002-02-0514; Methia N, 2001, BLOOD, V98, P1424, DOI 10.1182/blood.V98.5.1424; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; Ni HY, 2000, J CLIN INVEST, V106, P385, DOI 10.1172/JCI9896; NIEUWENHUIS HK, 1986, BLOOD, V68, P692; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Olsen Bjorn Reino, 1993, P35; Patil S, 2001, BLOOD, V97, P1727, DOI 10.1182/blood.V97.6.1727; Pratico D, 2001, P NATL ACAD SCI USA, V98, P3358, DOI 10.1073/pnas.061607398; Quinn MJ, 2002, CIRCULATION, V106, P379, DOI 10.1161/01.CIR.0000019581.22812.B2; Ramakrishnan V, 2001, P NATL ACAD SCI USA, V98, P1823, DOI 10.1073/pnas.98.4.1823; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ruberg FL, 2002, PROG CARDIOVASC DIS, V44, P381, DOI 10.1053/pcad.2002.123469; Ruggeri ZM, 1999, BLOOD, V94, P172, DOI 10.1182/blood.V94.1.172.413k17_172_178; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; Sachais B S, 2001, Curr Atheroscler Rep, V3, P412, DOI 10.1007/s11883-001-0080-1; Sachais BS, 2002, BLOOD, V99, P3613, DOI 10.1182/blood.V99.10.3613; SAELMAN EUM, 1994, BLOOD, V83, P1244; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Savage B, 2002, P NATL ACAD SCI USA, V99, P425, DOI 10.1073/pnas.012459599; Savage B, 2001, CURR OPIN HEMATOL, V8, P270, DOI 10.1097/00062752-200109000-00002; Savage B, 1999, BLOOD, V94, P2704, DOI 10.1182/blood.V94.8.2704.420k41_2704_2715; Shpilberg O, 2002, CIRCULATION, V105, P1044, DOI 10.1161/hc0902.104676; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; SJOBRING U, 2002, BLOOD           0801, DOI DOI 10.1182/BLOOD-2002-01-0069; Soslau G, 2001, J BIOL CHEM, V276, P21173, DOI 10.1074/jbc.M008249200; STRONY J, 1993, AM J PHYSIOL, V265, pH1787; Talley J D, 2001, J Interv Cardiol, V14, P129; TANGELDER GJ, 1988, AM J PHYSIOL, V254, pH1059, DOI 10.1152/ajpheart.1988.254.6.H1059; Taylor DW, 1999, LANCET, V353, P2179, DOI 10.1016/S0140-6736(99)05388-X; Theilmeier G, 2002, BLOOD, V99, P4486, DOI 10.1182/blood.V99.12.4486; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; TRAN H, 1995, J BIOL CHEM, V270, P19458, DOI 10.1074/jbc.270.33.19458; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; Vivekananthan Deepak P, 2002, J Interv Cardiol, V15, P131, DOI 10.1111/j.1540-8183.2002.tb01045.x; WARE JA, 1993, NEW ENGL J MED, V328, P628; Watson S, 2000, PLATELETS, V11, P252; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703; Willerson JT, 2002, PROG CARDIOVASC DIS, V44, P469, DOI 10.1053/pcad.2002.123782; Woodside DG, 2001, THROMB HAEMOSTASIS, V86, P316, DOI 10.1055/s-0037-1616229; Xie LJ, 2001, J EXP MED, V193, P1341, DOI 10.1084/jem.193.12.1341; ZIMMERMAN TS, 1986, J CLIN INVEST, V77, P947, DOI 10.1172/JCI112394	78	1236	1308	0	119	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2002	8	11					1227	1234		10.1038/nm1102-1227	http://dx.doi.org/10.1038/nm1102-1227			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12411949				2022-12-27	WOS:000179221200027
J	Blanc-Brude, OP; Yu, J; Simosa, H; Conte, MS; Sessa, WC; Altieri, DC				Blanc-Brude, OP; Yu, J; Simosa, H; Conte, MS; Sessa, WC; Altieri, DC			Inhibitor of apoptosis protein survivin regulates vascular injury	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE-CELLS; EXPRESSION INDUCES APOPTOSIS; INTIMAL HYPERPLASIA; NEOINTIMAL HYPERPLASIA; GROWTH; ANGIOPLASTY; ACTIVATION; RIBOZYME; SPINDLE	Survivin (also termed Birc5) belongs to the family of genes known as inhibitors of apoptosis, and it has been implicated in both prevention of cell death and control of mitosis. The survivin pathway is exploited in cancer, but its potential role in vascular injury is unknown. Here, we show that balloon-mediated arterial injury in rabbits resulted in expression of survivin in vascular cells. Serum or PDGF-AB stimulated survivin expression in cultured smooth-muscle cells (SMCs), which suppressed apoptosis and prevented caspase activation. Adenoviral delivery of a phosphorylation-defective survivin mutant reversed the cytoprotective effect of PDGF in SMCs without affecting mitotic progression, suppressed neointimal formation in wire-injured mouse femoral arteries, and induced vascular cell apoptosis in vivo. These data identify survivin as a critical regulator of SMC apoptosis after acute vascular injury. Disrupting the survivin pathway may provide a novel therapy to limit pathological vessel-wall remodeling.	Yale Univ, Sch Med, Boyer Ctr Mol Med, New Haven, CT 06510 USA; Harvard Univ, Sch Med, Harvard Inst Med, Brigham & Womens Hosp,Div Vasc Surg, Boston, MA USA	Yale University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Altieri, DC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, 333 Cedar St, New Haven, CT 06510 USA.	dario.altieri@umassmed.edu	Sessa, William C/B-6844-2011; BLANC-BRUDE, Olivier/O-8629-2017	Sessa, William C/0000-0001-5759-1938; BLANC-BRUDE, Olivier/0000-0002-4015-0615	NCI NIH HHS [CA90917, CA78810] Funding Source: Medline; NHLBI NIH HHS [HL54131, HL57665, HL64793] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078810, R01CA090917] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054131, R37HL054131, R01HL057665, R01HL064793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Bennett MR, 1999, CARDIOVASC RES, V41, P361, DOI 10.1016/S0008-6363(98)00212-0; Carter BZ, 2001, BLOOD, V97, P2784, DOI 10.1182/blood.V97.9.2784; Charles R, 2000, CIRC RES, V87, P282, DOI 10.1161/01.RES.87.4.282; Choy JC, 2001, J MOL CELL CARDIOL, V33, P1673, DOI 10.1006/jmcc.2001.1419; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Ekhterae D, 2001, AM J PHYSIOL-CELL PH, V281, pC157, DOI 10.1152/ajpcell.2001.281.1.C157; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; FORTUGNO P, IN PRESS J CELL SCI; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; Hart CE, 1999, CIRCULATION, V99, P564, DOI 10.1161/01.CIR.99.4.564; Hayakawa Y, 1999, ARTERIOSCL THROM VAS, V19, P2066, DOI 10.1161/01.ATV.19.9.2066; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Kanwar JR, 2001, J NATL CANCER I, V93, P1541, DOI 10.1093/jnci/93.20.1541; Leppanen O, 2000, ARTERIOSCL THROM VAS, V20, pE89, DOI 10.1161/01.ATV.20.11.e89; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Mahboubi K, 2001, LAB INVEST, V81, P327, DOI 10.1038/labinvest.3780241; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Mesri M, 2001, AM J PATHOL, V158, P1757, DOI 10.1016/S0002-9440(10)64131-4; Miyamoto T, 1998, J CELL PHYSIOL, V177, P58, DOI 10.1002/(SICI)1097-4652(199810)177:1<58::AID-JCP6>3.0.CO;2-D; Niemann-Jonsson A, 2001, ARTERIOSCL THROM VAS, V21, P1909, DOI 10.1161/hq1201.100222; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; Okura Y, 2000, CIRCULATION, V102, P2680, DOI 10.1161/01.CIR.102.22.2680; Olie RA, 2000, CANCER RES, V60, P2805; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Pennati M, 2002, J CLIN INVEST, V109, P285; Perlman H, 2000, CARDIOVASC RES, V45, P570, DOI 10.1016/S0008-6363(99)00346-6; Perlman H, 1997, CIRCULATION, V95, P981; Plescia J, 1998, J BIOL CHEM, V273, P20372, DOI 10.1074/jbc.273.32.20372; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schaub FJ, 2000, NAT MED, V6, P790, DOI 10.1038/77521; Signore PE, 2001, J VASC INTERV RADIOL, V12, P79, DOI 10.1016/S1051-0443(07)61408-0; SOLLOTT SJ, 1995, J CLIN INVEST, V95, P1869, DOI 10.1172/JCI117867; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Walsh K, 2000, CIRC RES, V87, P184, DOI 10.1161/01.RES.87.3.184; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X	42	114	130	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2002	8	9					987	994		10.1038/nm750	http://dx.doi.org/10.1038/nm750			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12172543				2022-12-27	WOS:000177757900034
J	Novina, CD; Murray, MF; Dykxhoorn, DM; Beresford, PJ; Riess, J; Lee, SK; Collman, RG; Lieberman, J; Shankar, P; Sharp, PA				Novina, CD; Murray, MF; Dykxhoorn, DM; Beresford, PJ; Riess, J; Lee, SK; Collman, RG; Lieberman, J; Shankar, P; Sharp, PA			siRNA-directed inhibition of HIV-1 infection	NATURE MEDICINE			English	Article							SHORT-INTERFERING RNAS; SMALL TEMPORAL RNAS; CAENORHABDITIS-ELEGANS; GENE-EXPRESSION; HAIRPIN RNAS; C-ELEGANS; DROSOPHILA; RECEPTOR; PROTEIN; INDIVIDUALS	RNA interference silences gene expression through short interfering 21-23-mer double-strand RNA segments that guide mRNA degradation in a sequence-specific fashion. Here we report that siRNAs inhibit virus production by targeting the mRNAs for either the HIV-1 cellular receptor CD4, the viral structural Gag protein or green fluorescence protein substituted for the Nef regulatory protein. siRNAs effectively inhibit pre- and/or post-integration infection events in the HIV-1 life cycle. Thus, siRNAs may have potential for therapeutic intervention in HIV-1 and other viral infections.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA USA; MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; University of Pennsylvania	Novina, CD (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA.	shankar@cbr.harvard.med.edu; sharppa@mit.edu	Lieberman, Judy/A-2717-2015; Dykxhoorn, Derek M/D-1357-2015	Collman, Ronald/0000-0002-0508-3701	NATIONAL CANCER INSTITUTE [P01CA042063, P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010523, R21AI045306, R01AI035502, R29AI035502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034277, T32GM007748] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA42063, P30-CA14051] Funding Source: Medline; NIAID NIH HHS [F32AI10523, AI 35502, AI45306] Funding Source: Medline; NIGMS NIH HHS [T32-GM07748, R37-GM34277] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banerjee D, 2002, BIOESSAYS, V24, P119, DOI 10.1002/bies.10046; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; BITKO V, 2001, BMC MICROBIOL, V34, P1; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chackerian B, 1997, J VIROL, V71, P3932, DOI 10.1128/JVI.71.5.3932-3939.1997; COCHRANE AW, 1990, P NATL ACAD SCI USA, V87, P1198, DOI 10.1073/pnas.87.3.1198; Dorman N, 2001, HIV Med, V2, P114, DOI 10.1046/j.1468-1293.2001.00052.x; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Gaudet J, 1996, MOL BIOL CELL, V7, P1107, DOI 10.1091/mbc.7.7.1107; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; James HA, 1998, BLOOD, V91, P371, DOI 10.1182/blood.V91.2.371.371_371_382; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Kumar M, 1998, MICROBIOL MOL BIOL R, V62, P1415, DOI 10.1128/MMBR.62.4.1415-1434.1998; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; McManus MT, 2002, RNA, V8, P842, DOI 10.1017/S1355838202024032; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Page KA, 1997, AIDS RES HUM RETROV, V13, P1077, DOI 10.1089/aid.1997.13.1077; Pal-Bhadra M, 1999, CELL, V99, P35, DOI 10.1016/S0092-8674(00)80060-4; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; PAVLAKIS GN, 1991, ANN REV AIDS RES, P41; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; Rougvie AE, 2001, NAT REV GENET, V2, P690, DOI 10.1038/35088566; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Shankar P, 1999, BLOOD, V94, P3084, DOI 10.1182/blood.V94.9.3084.421k02_3084_3093; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168; Wu YT, 2001, SCIENCE, V293, P1503, DOI 10.1126/science.1061548; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	45	648	811	1	55	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2002	8	7					681	686		10.1038/nm725	http://dx.doi.org/10.1038/nm725			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12042777				2022-12-27	WOS:000176495200028
J	Butzkueven, H; Zhang, JG; Hanninen, MS; Hochrein, H; Chionh, F; Shipham, KA; Emery, B; Turnley, AM; Petratos, S; Ernst, M; Bartlett, PF; Kilpatrick, TJ				Butzkueven, H; Zhang, JG; Hanninen, MS; Hochrein, H; Chionh, F; Shipham, KA; Emery, B; Turnley, AM; Petratos, S; Ernst, M; Bartlett, PF; Kilpatrick, TJ			LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival	NATURE MEDICINE			English	Article							LEUKEMIA INHIBITORY FACTOR; CILIARY NEUROTROPHIC FACTOR; MULTIPLE-SCLEROSIS LESIONS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CELL-DEATH; KAPPA-B; ACTIVATION; GAMMA; MICE; GENE	Multiple sclerosis (MS) is a disabling inflammatory demyelinating disease of the central nervous system (CNS) that primarily affects young adults. Available therapies can inhibit the inflammatory component of MS but do not suppress progressive clinical disability. An alternative approach would be to inhibit mechanisms that drive the neuropathology of MS, which often includes the death of oligodendrocytes, the cells responsible for myelinating the CNS. Identification of molecular mechanisms that mediate the stress response of oligodendrocytes to optimize their survival would serve this need. This study shows that the neurotrophic cytokine leukemia inhibitory factor (LIF) directly prevents oligodendrocyte death in animal models of MS. We also demonstrate that this therapeutic effect complements endogenous LIF receptor signaling, which already serves to limit oligodendrocyte loss during immune attack. Our results provide a novel approach for the treatment of MS.	Univ Melbourne, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic, Australia	University of Melbourne; Walter & Eliza Hall Institute; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Kilpatrick, TJ (corresponding author), Univ Melbourne, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia.	kilpatrick@wehi.edu.au	Emery, Ben/I-6223-2013; Bartlett, Perry/F-3813-2012; Ernst, Matthias/D-5111-2012; Turnley, Ann/A-8125-2010; Hochrein, Hubertus/L-3697-2013	Ernst, Matthias/0000-0002-6399-1177; Hochrein, Hubertus/0000-0001-9904-1934; Butzkueven, Helmut/0000-0003-3940-8727; Turnley, Ann/0000-0002-8442-127X; Emery, Ben/0000-0002-9132-3045; Kilpatrick, Trevor/0000-0003-3999-085X				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; *AIHW, 2000, 7 AIHW; ALOISI F, 1994, J IMMUNOL, V152, P5022; Banner LR, 1997, EXP NEUROL, V147, P1, DOI 10.1006/exnr.1997.6536; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1993, CURR BIOL, V3, P489, DOI 10.1016/0960-9822(93)90039-Q; BARRES BA, 1993, DEVELOPMENT, V118, P283; Bonetti B, 1999, AM J PATHOL, V155, P1433, DOI 10.1016/S0002-9440(10)65456-9; Bonetti B, 1997, J IMMUNOL, V159, P5733; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; Bugga L, 1998, J NEUROBIOL, V36, P509, DOI 10.1002/(SICI)1097-4695(19980915)36:4<509::AID-NEU5>3.0.CO;2-#; COMPSTON DAS, 1998, MCALPINES MULTIPLE S, P437; DSouza SD, 1996, J NEUROSCI RES, V43, P289, DOI 10.1002/(SICI)1097-4547(19960201)43:3<289::AID-JNR4>3.0.CO;2-F; Ernst M, 2001, J EXP MED, V194, P189, DOI 10.1084/jem.194.2.189; Fukunaga K, 1998, MOL NEUROBIOL, V16, P79, DOI 10.1007/BF02740604; GARD AL, 1995, DEV BIOL, V167, P596, DOI 10.1006/dbio.1995.1051; Giess R, 2002, ARCH NEUROL-CHICAGO, V59, P407, DOI 10.1001/archneur.59.3.407; GOW A, 1992, J CELL BIOL, V119, P605, DOI 10.1083/jcb.119.3.605; Hisahara S, 2000, EMBO J, V19, P341, DOI 10.1093/emboj/19.3.341; Hochrein H, 2001, J IMMUNOL, V166, P5448, DOI 10.4049/jimmunol.166.9.5448; Kappos L, 1998, LANCET, V352, P1491, DOI 10.1016/S0140-6736(98)10039-9; Kuchroo VK, 1998, RES IMMUNOL, V149, P759, DOI 10.1016/S0923-2494(99)80003-0; Lucchinetti C, 1999, BRAIN, V122, P2279, DOI 10.1093/brain/122.12.2279; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Marmur R, 1998, J NEUROSCI, V18, P9800; Massaro AR, 1997, EUR NEUROL, V37, P243, DOI 10.1159/000117451; Mathisen PM, 1997, J EXP MED, V186, P159, DOI 10.1084/jem.186.1.159; MATTOLI S, 1990, AM J RESP CELL MOL, V3, P145, DOI 10.1165/ajrcmb/3.2.145; MAYER M, 1994, DEVELOPMENT, V120, P143; Middleton G, 2000, J CELL BIOL, V148, P325, DOI 10.1083/jcb.148.2.325; Miller SD, 1998, RES IMMUNOL, V149, P753, DOI 10.1016/S0923-2494(99)80002-9; Morita Y, 2000, P NATL ACAD SCI USA, V97, P5405, DOI 10.1073/pnas.090084797; POZZILLI C, 1988, J NEUROL NEUROSUR PS, V51, P1058, DOI 10.1136/jnnp.51.8.1058; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Skaper SD, 1998, MOL CELL NEUROSCI, V12, P179, DOI 10.1006/mcne.1998.0714; Slavin A, 1998, AUTOIMMUNITY, V28, P109, DOI 10.3109/08916939809003872; Soilu-Hanninen M, 2000, J NEUROSCI RES, V59, P712, DOI 10.1002/(SICI)1097-4547(20000315)59:6<712::AID-JNR3>3.3.CO;2-C; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; TUOHY VK, 1992, J NEUROIMMUNOL, V39, P67, DOI 10.1016/0165-5728(92)90175-K; Turnley AM, 2000, J NEUROCHEM, V74, P889, DOI 10.1046/j.1471-4159.2000.0740889.x; VANDERVEEN RC, 1989, J NEUROIMMUNOL, V21, P183, DOI 10.1016/0165-5728(89)90174-4; VARTANIAN T, 1995, MOL MED, V1, P732, DOI 10.1007/BF03401888; WARE CB, 1995, DEVELOPMENT, V121, P1283	45	220	224	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2002	8	6					613	619		10.1038/nm0602-613	http://dx.doi.org/10.1038/nm0602-613			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042813				2022-12-27	WOS:000175907300033
J	Hafezi-Moghadam, A; Simoncini, T; Yang, ZQ; Limbourg, FP; Plumier, JC; Rebsamen, MC; Hsieh, CM; Chui, DS; Thomas, KL; Prorock, AJ; Laubach, VE; Moskowitz, MA; French, BA; Ley, K; Liao, JK				Hafezi-Moghadam, A; Simoncini, T; Yang, ZQ; Limbourg, FP; Plumier, JC; Rebsamen, MC; Hsieh, CM; Chui, DS; Thomas, KL; Prorock, AJ; Laubach, VE; Moskowitz, MA; French, BA; Ley, K; Liao, JK			Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase	NATURE MEDICINE			English	Article							PROTEIN-KINASE-B; GLUCOCORTICOID RECEPTOR; LEUKOCYTE ADHESION; DNA-BINDING; CELLS; AKT; DEFICIENCY; INHIBITION; INDUCTION; HORMONE	Corticosteroids have been shown to exert beneficial effects in the treatment of acute myocardial infarction, but the precise mechanisms underlying their protective effects are unknown. Here we show that high-dose corticosteroids exert cardiovascular protection through a novel mechanism involving the rapid, non-transcriptional activation of endothelial nitric oxide synthase (eNOS). Binding of corticosteroids to the glucocorticoid receptor (GR) stimulated phosphatidylinositol 3-kinase and protein kinase Akt, leading to eNOS activation and nitric oxide-dependent vasorelaxation. Acute administration of pharmacological concentrations of corticosteroids in mice led to decreased vascular inflammation and reduced myocardial infarct size following ischemia and reperfusion injury. These beneficial effects of corticosteroids were abolished by GR antagonists or eNOS inhibitors in wild-type mice and were completely absent in eNOS-deficient (Nos3(-/-)) mice. The rapid activation of eNOS by the non-nuclear actions of GR, therefore, represents an important cardiovascular protective effect of acute high-dose corticosteroid therapy.	Brigham & Womens Hosp, Dept Med, Vasc Med Res Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Stroke & Neurovasc Regulat Lab, Charlestown, MA USA; Harvard Univ, Sch Med, Charlestown, MA USA; Univ Virginia, Dept Biomed Engn, Charlottesville, VA USA; Univ Virginia, Dept Surg, Charlottesville, VA USA; Univ Pisa, Dept Reprod Med & Child Dev, Pisa, Italy	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; University of Virginia; University of Virginia; University of Pisa	Liao, JK (corresponding author), Brigham & Womens Hosp, Dept Med, Vasc Med Res Unit, 75 Francis St, Boston, MA 02115 USA.		Simoncini, Tommaso/AAC-1879-2019; Limbourg, Florian/AAF-5010-2019; Moskowitz, Michael A/D-9916-2011; Laubach, Victor E./E-8818-2015	Simoncini, Tommaso/0000-0002-2971-0079; Limbourg, Florian/0000-0002-8313-7226; Laubach, Victor E./0000-0001-9673-5383; Hafezi-Moghadam, Ali/0000-0002-5336-0697	NHLBI NIH HHS [HL48743, HL58582, R01 HL052233, P01 HL048743-080008, R01 HL052233-07, P01 HL048743-100008, F32 HL067574, R01 HL070274, R01 HL052233-06, R01 HL058582, R01 HL052233-05, HL65754, HL54136, HL62602, P01 HL048743-090008, P01 HL048743, HL70274] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065754, R01HL058582, R01HL054136, P01HL048743, R01HL062602, F32HL067574, R01HL070274, R01HL052233] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BARZILAI D, 1972, CHEST, V61, P488, DOI 10.1378/chest.61.5.488; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Charmandari E, 2001, J ENDOCRINOL, V169, P65, DOI 10.1677/joe.0.1690065; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; CRONSTEIN BN, 1992, P NATL ACAD SCI USA, V89, P9991, DOI 10.1073/pnas.89.21.9991; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Damiano ER, 1996, CIRC RES, V79, P1122, DOI 10.1161/01.RES.79.6.1122; DE CR, 1995, J CLIN INVEST, V96, P60; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; FLOWER RJ, 1979, NATURE, V278, P456, DOI 10.1038/278456a0; Frangogiannis NG, 1998, J MOL CELL CARDIOL, V30, P2567, DOI 10.1006/jmcc.1998.0829; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; HAMMERMAN H, 1984, CIRCULATION, V69, P611, DOI 10.1161/01.CIR.69.3.611; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; Ishida A, 1997, J BIOL CHEM, V272, P10050; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kawashima S, 2001, ARTERIOSCL THROM VAS, V21, P201, DOI 10.1161/01.ATV.21.2.201; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; Laufs U, 2000, J CLIN INVEST, V106, P15, DOI 10.1172/JCI9639; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; LEWIS GP, 1975, NATURE, V254, P308, DOI 10.1038/254308a0; LIBBY P, 1973, J CLIN INVEST, V52, P599, DOI 10.1172/JCI107221; LOSCALZO J, 1995, NEW ENGL J MED, V333, P251, DOI 10.1056/NEJM199507273330410; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCGREGOR AM, 1990, NEW ENGL J MED, V322, P1739, DOI 10.1056/NEJM199006143222409; Moroi M, 1998, J CLIN INVEST, V101, P1225, DOI 10.1172/JCI1293; MULVANY MJ, 1977, CIRC RES, V41, P19, DOI 10.1161/01.RES.41.1.19; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Sholter DE, 2000, CAN J CARDIOL, V16, P505; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; SPATH JA, 1974, CIRC RES, V35, P44, DOI 10.1161/01.RES.35.1.44; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; VYDEN JK, 1974, AM J CARDIOL, V34, P677, DOI 10.1016/0002-9149(74)90157-X; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; Wenting-Van Wijk MJG, 1999, CLIN EXP RHEUMATOL, V17, P305; Yang ZQ, 2000, CIRCULATION, V101, P1019, DOI 10.1161/01.CIR.101.9.1019	44	423	441	1	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					473	479		10.1038/nm0502-473	http://dx.doi.org/10.1038/nm0502-473			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984591	Green Accepted			2022-12-27	WOS:000175336800032
J	O'Connor, DH; Allen, TM; Vogel, TU; Jing, PC; DeSouza, IP; Dodds, E; Dunphy, EJ; Melsaether, C; Mothe, B; Yamamoto, H; Horton, H; Wilson, N; Hughes, AL; Watkins, DI				O'Connor, DH; Allen, TM; Vogel, TU; Jing, PC; DeSouza, IP; Dodds, E; Dunphy, EJ; Melsaether, C; Mothe, B; Yamamoto, H; Horton, H; Wilson, N; Hughes, AL; Watkins, DI			Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection	NATURE MEDICINE			English	Article							I MOLECULE MAMU-A-ASTERISK-01; CELLULAR IMMUNE-RESPONSES; MHC CLASS-I; RHESUS MACAQUES; CD8(+) LYMPHOCYTES; HIGH-AVIDITY; NUCLEOTIDE SUBSTITUTIONS; PERIPHERAL-BLOOD; RAPID SELECTION; HIV-1 INFECTION	Cytotoxic T-lymphocyte (CTL) responses peak coincident with the decline in acute HIV viremia. Despite two reports of CTL-resistant HIV variants emerging during acute infection, the contribution of acute CTL escape to HIV pathogenesis remains unclear. Difficulties inherent in studying acute HIV infection can be overcome by modeling virus-host interactions in SIV-infected rhesus macaques. We sequenced 21 complete simian immunodeficiency virus (SIV) mac239 genomes at four weeks post-infection to determine the extent of acute CTL escape. Here we show that viruses from 19 of 21 macaques escaped from CTLs during acute infection and that these escape-selecting CTLs were responsive to lower concentrations of peptide than other SIV-specific CTLs. Interestingly, CTLs that require low peptide concentrations for stimulation (high 'functional avidity') are particularly effective at controlling other viral infections. Our results suggest that acute viral escape from CTLs is a hallmark of SIV infection and that CTLs with high functional avidity can rapidly select for escape variants.	Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53706 USA; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA; Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Watkins, DI (corresponding author), Univ Wisconsin, Wisconsin Reg Primate Res Ctr, 1223 Capitol Court, Madison, WI 53706 USA.		Allen, Todd/F-5473-2011	Allen, Todd/0000-0002-6609-1318; o'connor, david/0000-0003-2139-470X	NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR015371, P51RR000167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI049120, R01AI049120, R01AI046366] Funding Source: NIH RePORTER; NCRR NIH HHS [RR0167, RR15371] Funding Source: Medline; NIAID NIH HHS [AI49120, AI 46366] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexander L, 2001, J VIROL, V75, P4019, DOI 10.1128/JVI.75.8.4019-4022.2001; AlexanderMiller MA, 1996, P NATL ACAD SCI USA, V93, P4102, DOI 10.1073/pnas.93.9.4102; Allen TM, 2002, J VIROL, V76, P4108, DOI 10.1128/JVI.76.8.4108-4112.2002; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Allen TM, 2000, J IMMUNOL, V164, P4968, DOI 10.4049/jimmunol.164.9.4968; Allen TM, 1998, J IMMUNOL, V160, P6062; Allen TM, 2001, J VIROL, V75, P738, DOI 10.1128/JVI.75.2.738-749.2001; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Chen ZW, 2000, J IMMUNOL, V164, P6474, DOI 10.4049/jimmunol.164.12.6474; Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8; Day CL, 2001, J VIROL, V75, P6279, DOI 10.1128/JVI.75.14.6279-6291.2001; Derby MA, 2001, J IMMUNOL, V166, P1690, DOI 10.4049/jimmunol.166.3.1690; Evans DT, 1999, NAT MED, V5, P1270, DOI 10.1038/15224; Gallimore A, 1998, J EXP MED, V187, P1647; Goulder PJR, 2001, J EXP MED, V193, P181, DOI 10.1084/jem.193.2.181; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Gray PM, 2001, J VIROL, V75, P10065, DOI 10.1128/JVI.75.21.10065-10072.2001; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Kaul R, 2001, IMMUNOL LETT, V79, P3, DOI 10.1016/S0165-2478(01)00260-7; Kaul R, 2001, J CLIN INVEST, V107, P1303, DOI 10.1172/JCI12433; Kaul R, 2001, J CLIN INVEST, V107, P341, DOI 10.1172/JCI10714; Knapp LA, 1997, TISSUE ANTIGENS, V50, P657, DOI 10.1111/j.1399-0039.1997.tb02927.x; KOUP RA, 1994, NATURE, V370, P416, DOI 10.1038/370416a0; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Kuroda MJ, 1999, J VIROL, V73, P1573, DOI 10.1128/JVI.73.2.1573-1579.1999; Matano T, 1998, J VIROL, V72, P164, DOI 10.1128/JVI.72.1.164-169.1998; McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Mortara L, 1998, J VIROL, V72, P1403, DOI 10.1128/JVI.72.2.1403-1410.1998; NEI M, 1986, MOL BIOL EVOL, V3, P418; NEI M, 1989, MOL BIOL EVOL, V6, P290; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; REGIER DA, 1990, AIDS RES HUM RETROV, V6, P1221, DOI 10.1089/aid.1990.6.1221; REIMANN KA, 1994, J VIROL, V68, P2362, DOI 10.1128/JVI.68.4.2362-2370.1994; Robinson S, 2001, J VIROL, V75, P10179, DOI 10.1128/JVI.75.21.10179-10186.2001; Rowland-Jones SL, 2001, IMMUNOL LETT, V79, P15, DOI 10.1016/S0165-2478(01)00261-9; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Slifka MK, 2001, NAT IMMUNOL, V2, P711, DOI 10.1038/90650; Soudeyns H, 1999, EUR J IMMUNOL, V29, P3629, DOI 10.1002/(SICI)1521-4141(199911)29:11<3629::AID-IMMU3629>3.0.CO;2-O; Trivedi P, 1996, J VIROL, V70, P6876, DOI 10.1128/JVI.70.10.6876-6883.1996; Van Baalen CA, 1998, J VIROL, V72, P6851, DOI 10.1128/JVI.72.8.6851-6857.1998; Vidal C, 1998, AIDS, V12, P1285, DOI 10.1097/00002030-199811000-00009; Wilson CC, 1999, J VIROL, V73, P3975, DOI 10.1128/JVI.73.5.3975-3985.1999; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; YASUTOMI Y, 1993, J VIROL, V67, P1707, DOI 10.1128/JVI.67.3.1707-1711.1993	47	318	324	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					493	499		10.1038/nm0502-493	http://dx.doi.org/10.1038/nm0502-493			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984594				2022-12-27	WOS:000175336800035
J	Peng, KW; Facteau, S; Wegman, T; O'Kane, D; Russell, SJ				Peng, KW; Facteau, S; Wegman, T; O'Kane, D; Russell, SJ			Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides	NATURE MEDICINE			English	Article							ATTENUATED MEASLES-VIRUS; CARCINOEMBRYONIC ANTIGEN; LIVING ANIMALS; MICE; XENOGRAFTS; THERAPY; REGRESSION; KINETICS; DISEASE; SPREAD	Noninvasive methods are needed to study the kinetic properties of viruses in living organisms. Oncolytic viruses are used increasingly for cancer therapy but there is currently no satisfactory way to measure efficiency of tumor transduction, changing levels of viral gene expression or the timing of virus elimination. We therefore generated trackable oncolytic measles viruses expressing inert (nonimmunogenic, nonfunctional and accurately measurable) soluble marker peptides. The marker peptides did not compromise virus replication. Ex vivo and in vivo kinetics of the trackable viruses could be easily followed by measuring the concentrations of virally encoded marker peptides in culture supernatant or in serum. When mice bearing human tumor xenografts were challenged with the trackable viruses, distinct kinetic profiles of marker-gene expression could be correlated with distinct therapeutic outcomes. Oncolytic viruses expressing inert soluble marker polypeptides should greatly facilitate the rational development of effective, individually tailored cancer virotherapy.	Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA; Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN USA	Mayo Clinic; Mayo Clinic	Russell, SJ (corresponding author), Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA.				NHLBI NIH HHS [HL 66958-1 A1] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bennett JJ, 2001, NAT MED, V7, P859, DOI 10.1038/89991; Bidart JM, 1999, CLIN CHEM, V45, P1695; Duprex WP, 1999, J VIROL, V73, P9568, DOI 10.1128/JVI.73.11.9568-9575.1999; GO VLW, 1976, CANCER, V37, P562, DOI 10.1002/1097-0142(197601)37:1+<562::AID-CNCR2820370721>3.0.CO;2-0; Grote D, 2001, BLOOD, V97, P3746, DOI 10.1182/blood.V97.12.3746; Heise C, 2000, J CLIN INVEST, V105, P847, DOI 10.1172/JCI9762; KIM D, 2001, NAT MED, V7, P781; LORENCE RM, 1994, JNCI-J NATL CANCER I, V86, P1228, DOI 10.1093/jnci/86.16.1228; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; MARTIN KW, 1984, CANCER RES, V44, P5475; Martuza RL, 2000, J CLIN INVEST, V105, P841, DOI 10.1172/JCI9744; Mrkic B, 1998, J VIROL, V72, P7420, DOI 10.1128/JVI.72.9.7420-7427.1998; Nemunaitis J, 2001, J CLIN ONCOL, V19, P289, DOI 10.1200/JCO.2001.19.2.289; Norman KL, 2000, J CLIN INVEST, V105, P1035, DOI 10.1172/JCI9871; Oldstone MBA, 1999, CELL, V98, P629, DOI 10.1016/S0092-8674(00)80050-1; Peng KW, 2001, BLOOD, V98, P2002, DOI 10.1182/blood.V98.7.2002; RADECKE F, 1995, EMBO J, V14, P5773, DOI 10.1002/j.1460-2075.1995.tb00266.x; Shih IM, 2000, NAT MED, V6, P711, DOI 10.1038/76299; Sun X, 2001, GENE THER, V8, P1572, DOI 10.1038/sj.gt.3301554; Yoshimasu T, 1999, INT J BIOL MARKER, V14, P99, DOI 10.1177/172460089901400207	20	146	155	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					527	531		10.1038/nm0502-527	http://dx.doi.org/10.1038/nm0502-527			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984600				2022-12-27	WOS:000175336800041
J	Homey, B; Alenius, H; Muller, A; Soto, H; Bowman, EP; Yuan, W; McEvoy, L; Lauerma, AI; Assmann, T; Bunemann, E; Lehto, M; Wolff, H; Yen, D; Marxhausen, H; To, W; Sedgwick, J; Ruzicka, T; Lehmann, P; Zlotnik, A				Homey, B; Alenius, H; Muller, A; Soto, H; Bowman, EP; Yuan, W; McEvoy, L; Lauerma, AI; Assmann, T; Bunemann, E; Lehto, M; Wolff, H; Yen, D; Marxhausen, H; To, W; Sedgwick, J; Ruzicka, T; Lehmann, P; Zlotnik, A			CCL27-CCR10 interactions regulate T cell-mediated skin inflammation	NATURE MEDICINE			English	Article							PROTEIN-COUPLED RECEPTOR-2; ALLERGIC DERMATITIS; ENDOTHELIAL-CELLS; ATOPIC-DERMATITIS; CUTTING EDGE; CHEMOKINE; PSORIASIS; EXPRESSION; ANTIGEN; BINDING	The skin-associated chemokine CCL27 (also called CTACK, ALP and ESkine) and its receptor CCR10 (GPR-2) mediate chemotactic responses of skin-homing T cells in vitro. Here we report that most skin-infiltrating lymphocytes in patients suffering from psoriasis, atopic or allergic-contact dermatitis express CCR10. Epidermal basal keratinocytes produced CCL27 protein that bound to extracellular matrix, mediated adhesion and was displayed on the surface of dermal endothelial cells. Tumor necrosis factor-alpha and interleukin-1beta induced CCL27 production whereas the glucocorticosteroid clobetasol propionate suppressed it. Circulating skin-homing CLA(+) T cells, dermal microvascular endothelial cells and fibroblasts expressed CCR10 on their cell surface. In vivo, intracutaneous CCL27 injection attracted lymphocytes and, conversely, neutralization of CCL27-CCR10 interactions impaired lymphocyte recruitment to the skin leading to the suppression of allergen-induced skin inflammation. Together, these findings indicate that CCL27-CCR10 interactions have a pivotal role in T cell-mediated skin inflammation.	DNAX Res Inst Molec & Cellular Biol Inc, Palo Alto, CA USA; Finnish Inst Occupat Hlth, Dept Ind Hyg & Toxicol, Helsinki, Finland; Univ Dusseldorf, Dept Dermatol, D-4000 Dusseldorf, Germany; Univ Dusseldorf, Dept Radiat Oncol, D-4000 Dusseldorf, Germany; Univ Helsinki, Cent Hosp, Dept Dermatol, FIN-00170 Helsinki, Finland; Finnish Inst Occupat Hlth, Dept Pathol, Helsinki, Finland; Kymenlaakso Cent Hosp, Kotka, Finland; R&D Syst, Minneapolis, MN USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Finnish Institute of Occupational Health; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; University of Helsinki; Helsinki University Central Hospital; Finnish Institute of Occupational Health	Homey, B (corresponding author), DNAX Res Inst Molec & Cellular Biol Inc, Palo Alto, CA USA.		Lauerma, Antti/J-8180-2016; Zlotnik, Albert/C-3791-2011	Alenius, Harri/0000-0003-0106-8923				ANCDREW DP, 2001, J IMMUNOL, V166, P103; Baekkevold ES, 2001, J EXP MED, V193, P1105, DOI 10.1084/jem.193.9.1105; Bondeson J, 2001, INT J CLIN PRACT, V55, P211; BOS JD, 1993, ARCH DERMATOL RES, V285, P179, DOI 10.1007/BF00372006; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Cinamon G, 2001, NAT IMMUNOL, V2, P515, DOI 10.1038/88710; Goebeler M, 1998, J PATHOL, V184, P89, DOI 10.1002/(SICI)1096-9896(199801)184:1<89::AID-PATH975>3.0.CO;2-Z; GOTTLIEB AB, 1988, J EXP MED, V168, P941, DOI 10.1084/jem.168.3.941; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Homey B, 1999, CURR OPIN IMMUNOL, V11, P626, DOI 10.1016/S0952-7915(99)00028-X; Homey B, 2000, J IMMUNOL, V164, P3465, DOI 10.4049/jimmunol.164.7.3465; Homey B, 2000, J IMMUNOL, V164, P6621, DOI 10.4049/jimmunol.164.12.6621; Hong K, 1999, J IMMUNOL, V162, P7480; Jarmin DI, 2000, J IMMUNOL, V164, P3460, DOI 10.4049/jimmunol.164.7.3460; Kirby B, 2001, CLIN EXP DERMATOL, V26, P27, DOI 10.1046/j.1365-2230.2001.00753.x; Leung DYM, 2001, J AM ACAD DERMATOL, V44, pS1, DOI 10.1067/mjd.2001.109815; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nickoloff BJ, 2000, EXP DERMATOL, V9, P359, DOI 10.1034/j.1600-0625.2000.009005359.x; PICKER LJ, 1990, J IMMUNOL, V145, P3247; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PIGUET PF, 1993, RES IMMUNOL, V144, P320, DOI 10.1016/S0923-2494(93)80074-9; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; Reiss Y, 2001, J EXP MED, V194, P1541, DOI 10.1084/jem.194.10.1541; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; Rot A, 1996, J LEUKOCYTE BIOL, V59, P39, DOI 10.1002/jlb.59.1.39; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; Ruzicka T, 1999, ARCH DERMATOL, V135, P574, DOI 10.1001/archderm.135.5.574; SANTAMARIA LF, 1995, INT ARCH ALLERGY IMM, V107, P359, DOI 10.1159/000237032; Schon MP, 1999, J INVEST DERMATOL, V112, P405, DOI 10.1046/j.1523-1747.1999.00538.x; Schon MP, 1997, NAT MED, V3, P183, DOI 10.1038/nm0297-183; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; SPRECHER E, 1992, ARCH VIROL, V126, P253, DOI 10.1007/BF01309699; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TSAI JC, 1994, ARCH DERMATOL RES, V286, P242, DOI 10.1007/BF00387595; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; WOOD LC, 1992, J CLIN INVEST, V90, P482, DOI 10.1172/JCI115884; Woodward AL, 2001, J ALLERGY CLIN IMMUN, V107, P359, DOI 10.1067/mai.2001.112695; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	45	578	607	1	31	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2002	8	2					157	165		10.1038/nm0202-157	http://dx.doi.org/10.1038/nm0202-157			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821900				2022-12-27	WOS:000173600600025
J	Mantyh, PW; Yaksh, TL				Mantyh, PW; Yaksh, TL			Sensory neurons are PARtial to pain	NATURE MEDICINE			English	Editorial Material							SPINAL-CORD INJURY; CALPAIN ACTIVITY; RAT-BRAIN; EXPRESSION; LIPOPOLYSACCHARIDE; CYCLOOXYGENASE-2; INHIBITION; CELLS	Recent insights into the receptors expressed by sensory neurons are providing the beginnings of a biological basis for designing therapies to block nociceptive information before it reaches the spinal cord. This approach could potentially avoid some of the side effects in the central nervous system caused by currently available analgesics.	Univ Minnesota, Dept Prevent Sci Neurosci & Psychiat, Minneapolis, MN 55455 USA; Univ Calif San Diego, Med Ctr, Dept Anesthesiol, San Diego, CA 92103 USA	University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California San Diego	Mantyh, PW (corresponding author), Univ Minnesota, Dept Prevent Sci Neurosci & Psychiat, Minneapolis, MN 55455 USA.		Yaksh, Tony/D-4119-2009					Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; DeLeo JA, 2001, PAIN, V90, P1, DOI 10.1016/S0304-3959(00)00490-5; Fu KY, 2000, NEUROSCIENCE, V101, P1127, DOI 10.1016/S0306-4522(00)00376-6; Honore P, 2000, NEUROSCIENCE, V98, P585, DOI 10.1016/S0306-4522(00)00110-X; Hunt SP, 2001, NAT REV NEUROSCI, V2, P83, DOI 10.1038/35053509; Lacroix S, 1998, J NEUROCHEM, V70, P452, DOI 10.1046/j.1471-4159.1998.70020452.x; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; Matsumura K, 1998, J NEUROSCI, V18, P6279; O'Brien PJ, 2001, ONCOGENE, V20, P1570, DOI 10.1038/sj.onc.1204194; Quan N, 1998, BRAIN RES, V802, P189, DOI 10.1016/S0006-8993(98)00402-8; Ray SK, 1999, BRAIN RES, V816, P375, DOI 10.1016/S0006-8993(98)01128-7; Shields DC, 2000, J NEUROSCI RES, V61, P146; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Vergnolle N, 2001, NAT MED, V7, P821, DOI 10.1038/89945; Watkins LR, 1999, P NATL ACAD SCI USA, V96, P7710, DOI 10.1073/pnas.96.14.7710	15	5	5	1	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					772	773		10.1038/89880	http://dx.doi.org/10.1038/89880			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433334				2022-12-27	WOS:000169808600017
J	Telling, G				Telling, G			Protein-based PCR for prion diseases?	NATURE MEDICINE			English	Editorial Material							SCRAPIE INFECTIVITY; PROPAGATION	The development of a sensitive in vitro method to amplify the pathological form of the prion protein might provide a tool for the pre-clinical diagnosis of prion diseases.	Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA; Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	Telling, G (corresponding author), Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA.		Telling, Glenn C/G-1217-2019	Telling, Glenn C/0000-0002-6294-1805				BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riesner D, 1996, J VIROL, V70, P1714, DOI 10.1128/JVI.70.3.1714-1722.1996; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8	8	1	1	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					778	779		10.1038/89895	http://dx.doi.org/10.1038/89895			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433339				2022-12-27	WOS:000169808600022
J	Vergnolle, N; Bunnett, NW; Sharkey, KA; Brussee, V; Compton, SJ; Grady, EF; Cirino, G; Gerard, N; Basbaum, AI; Andrade-Gordon, P; Hollenberg, MD; Wallace, JL				Vergnolle, N; Bunnett, NW; Sharkey, KA; Brussee, V; Compton, SJ; Grady, EF; Cirino, G; Gerard, N; Basbaum, AI; Andrade-Gordon, P; Hollenberg, MD; Wallace, JL			Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway	NATURE MEDICINE			English	Article							GENE-RELATED PEPTIDE; MUCOSAL MAST-CELLS; SUBSTANCE-P; (PAR(2))-ACTIVATING PEPTIDES; MICE LACKING; DORSAL-HORN; SPINAL-CORD; INFLAMMATION; ANTAGONISTS; EXPRESSION	Using a combined pharmacological and gene-deletion approach, we have delineated a novel mechanism of neurokinin-1 (NK-1) receptor-dependent hyperalgesia induced by proteinase-activated receptor-2 (PAR2), a G-protein-coupled receptor expressed on nociceptive primary afferent neurons. Injections into the paw of sub-inflammatory doses of PAR2 agonists in rats and mice induced a prolonged thermal and mechanical hyperalgesia and elevated spinal Fos protein expression. This hyperalgesia was markedly diminished or absent in mice lacking the NK-1 receptor, preprotachykinin-A or PAR2 genes, or in rats treated with a centrally acting cyclooxygenase inhibitor or treated by spinal cord injection of NK-1 antagonists. Here we identify a previously unrecognized nociceptive pathway with important therapeutic implications, and our results point to a direct role for proteinases and their receptors in pain transmission.	Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB, Canada; Univ Calgary, Dept Physiol & Biophys, Calgary, AB, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy; Beth Israel Deaconess Med Ctr, Dept Med, Div Pulm, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; RW Johnson Pharmaceut Res Inst, Spring House, PA 19477 USA	University of Calgary; University of Calgary; University of Calgary; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Naples Federico II; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Johnson & Johnson; Johnson & Johnson USA	Wallace, JL (corresponding author), Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB, Canada.	wallacej@ucalgary.ca	Hollenberg, Morley/AFV-6966-2022; Vergnolle, Nathalie/C-7677-2018; Wallace, John/AAL-3763-2021	Vergnolle, Nathalie/0000-0003-1825-6015; Bunnett, Nigel W./0000-0003-3367-0644; Cirino, Giuseppe/0000-0003-3954-4083; Sharkey, Keith/0000-0001-9560-1711	NHLBI NIH HHS [HL 41587] Funding Source: Medline; NIDDK NIH HHS [DK 43207, DK 39957, DK 57840, DK 52388] Funding Source: Medline; NINDS NIH HHS [NS 14627] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK043207, R01DK039957, R01DK057840, R01DK043207, R01DK052388, R37DK039957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014627, R37NS014627] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMANN R, 1995, N-S ARCH PHARMACOL, V352, P201; Bohm SK, 1996, J BIOL CHEM, V271, P22003; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Cao T, 1999, AM J PHYSIOL-REG I, V277, pR476, DOI 10.1152/ajpregu.1999.277.2.R476; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Compton SJ, 1998, J IMMUNOL, V161, P1939; Coudore-Civiale MA, 1998, EUR J PHARMACOL, V361, P175, DOI 10.1016/S0014-2999(98)00722-5; Couture R, 1999, LIFE SCI, V66, P51; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Dickinson T, 1998, Trends Pharmacol Sci, V19, P346, DOI 10.1016/S0165-6147(98)01237-1; FERRAZ JGP, 1995, GASTROENTEROLOGY, V108, P1183, DOI 10.1016/0016-5085(95)90218-X; FERREIRA SH, 1972, NATURE-NEW BIOL, V240, P200, DOI 10.1038/newbio240200a0; FERREIRA SH, 1978, EUR J PHARMACOL, V53, P39, DOI 10.1016/0014-2999(78)90265-0; He SH, 1997, EUR J PHARMACOL, V328, P89, DOI 10.1016/S0014-2999(97)83033-6; Hill R, 2000, TRENDS PHARMACOL SCI, V21, P244, DOI 10.1016/S0165-6147(00)01502-9; Hollenberg MD, 1999, TRENDS PHARMACOL SCI, V20, P271, DOI 10.1016/S0165-6147(99)01333-4; Hua XY, 1998, J NEUROCHEM, V70, P688; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; Kawabata A, 1999, J PHARMACOL EXP THER, V288, P358; Koshikawa N, 1997, FEBS LETT, V409, P442, DOI 10.1016/S0014-5793(97)00565-6; LEGREVES P, 1985, EUR J PHARMACOL, V115, P309, DOI 10.1016/0014-2999(85)90706-X; Liu HT, 1999, P NATL ACAD SCI USA, V96, P12096, DOI 10.1073/pnas.96.21.12096; MCCARSON KE, 1991, BRAIN RES, V568, P109, DOI 10.1016/0006-8993(91)91385-E; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Miampamba M, 1999, J AUTONOM NERV SYST, V77, P140, DOI 10.1016/S0165-1838(99)00048-X; Miller HRP, 1996, VET IMMUNOL IMMUNOP, V54, P331, DOI 10.1016/S0165-2427(96)05696-6; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; NAKAMURACRAIG M, 1991, NEUROSCI LETT, V124, P49, DOI 10.1016/0304-3940(91)90819-F; OHKUBO T, 1990, J PHARMACOL EXP THER, V252, P1261; OKU R, 1987, BRAIN RES, V403, P350, DOI 10.1016/0006-8993(87)90074-6; Saifeddine M, 1996, BRIT J PHARMACOL, V118, P521, DOI 10.1111/j.1476-5381.1996.tb15433.x; SHANAHAN F, 1985, J IMMUNOL, V135, P1331; STEAD RH, 1987, P NATL ACAD SCI USA, V84, P2975, DOI 10.1073/pnas.84.9.2975; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Takasaki I, 2001, J PHARMACOL EXP THER, V296, P270; TAM EK, 1990, AM J RESP CELL MOL, V3, P27, DOI 10.1165/ajrcmb/3.1.27; Vergnolle N, 2001, TRENDS PHARMACOL SCI, V22, P146, DOI 10.1016/S0165-6147(00)01634-5; Vergnolle N, 1999, BRIT J PHARMACOL, V127, P1083, DOI 10.1038/sj.bjp.0702634; Vergnolle N, 1998, P NATL ACAD SCI USA, V95, P7766, DOI 10.1073/pnas.95.13.7766; Wallace JL, 1998, GASTROENTEROLOGY, V115, P101, DOI 10.1016/S0016-5085(98)70370-1; Xu GY, 2000, J PHYSIOL-LONDON, V528, P339, DOI 10.1111/j.1469-7793.2000.00339.x	43	372	386	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2001	7	7					821	826		10.1038/89945	http://dx.doi.org/10.1038/89945			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433347				2022-12-27	WOS:000169808600034
J	Ochoa, MT; Stenger, S; Sieling, PA; Thoma-Uszynski, S; Sabet, S; Cho, SG; Krensky, AM; Rollinghoff, M; Sarno, EN; Burdick, AE; Rea, TH; Modlin, RL				Ochoa, MT; Stenger, S; Sieling, PA; Thoma-Uszynski, S; Sabet, S; Cho, SG; Krensky, AM; Rollinghoff, M; Sarno, EN; Burdick, AE; Rea, TH; Modlin, RL			T-cell release of granulysin contributes to host defense in leprosy	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; MYCOBACTERIUM-TUBERCULOSIS; CYTOTOXICITY; INFECTION; PATHWAYS; PERFORIN; IDENTIFICATION; INTERLEUKIN-2; MECHANISMS; ACTIVATION	A novel mechanism by which T cells contribute to host defense against microbial pathogens is release of the antimicrobial protein granulysin. We investigated the role of granulysin in human infectious disease using leprosy as a model. Granulysin-expressing T cells were detected in cutaneous leprosy lesions at a six-fold greater frequency in patients with the localized tuberculoid as compared with the disseminated lepromatous form of the disease. In contrast, perforin, a cytolytic molecule that colocalizes with granulysin in cytotoxic granules, was expressed at similar levels across the spectrum of disease. Within leprosy lesions, granulysin colocalized in CD4(+) T cells and was expressed in CD4(+) T-cell lines derived from skin lesions. These CD4(+) T-cell lines lysed targets by the granule exocytosis pathway and reduced the viability of mycobacteria in infected targets. Given the broad antimicrobial spectrum of granulysin, these data provide evidence that T-cell release of granulysin contributes to host defense in human infectious disease.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Div Dermatol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90024 USA; Univ Erlangen Nurnberg, Inst Clin Microbiol Immunol & Hyg, Erlangen, Germany; Stanford Univ, Dept Pediat, Div Immunol & Transplantat Biol, Stanford, CA 94305 USA; Inst Oswaldo Cruz, Leprosy Lab, BR-20001 Rio De Janeiro, Brazil; Univ Miami, Dept Dermatol & Cutaneous Surg, Miami, FL 33152 USA; Univ So Calif, Sch Med, Los Angeles, CA USA; Univ So Calif, Dermatol Sect, Los Angeles, CA USA; Int Ctr Med Res & Training CIDEIM, Cali, Colombia	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Erlangen Nuremberg; Stanford University; Fundacao Oswaldo Cruz; University of Miami; University of Southern California; University of Southern California	Modlin, RL (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Div Dermatol, Los Angeles, CA 90024 USA.		Modlin, Robert L/M-7941-2014; Sabet, Shereen/K-8575-2019; Krensky, Alan/F-7956-2011	Modlin, Robert L/0000-0003-4720-031X; Nunes Sarno, Euzenir/0000-0003-0129-2159; Ochoa, Maria T/0000-0001-6550-5008	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI022553, R01AI022553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040312] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 22553, AI 07118] Funding Source: Medline; NIAMS NIH HHS [AR 40312] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ab B K, 1990, Eur J Immunol, V20, P369, DOI 10.1002/eji.1830200221; ANDERSSON M, 1995, EMBO J, V14, P1615; ANG Z, 2000, J IMMUNOL, V165, P1486; Bloom BR, 1999, NAT MED, V5, P872, DOI 10.1038/11309; Bloom BR, 1999, NATURE, V402, pC63, DOI [10.1038/35011557, 10.1038/44959]; CHAN J, 1995, INFECT IMMUN, V63, P736, DOI 10.1128/IAI.63.2.736-740.1995; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; DELIBERO G, 1988, EUR J IMMUNOL, V18, P59, DOI 10.1002/eji.1830180110; Froelich CJ, 1998, IMMUNOL TODAY, V19, P30, DOI 10.1016/S0167-5699(97)01184-5; Gamen S, 1998, J IMMUNOL, V161, P1758; Hansen GHA., 1874, NORSK MAG LAEGEVIDEN, V4, P1; Hanson DA, 1999, MOL IMMUNOL, V36, P413, DOI 10.1016/S0161-5890(99)00063-2; JONGSTRA J, 1987, J EXP MED, V165, P601, DOI 10.1084/jem.165.3.601; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Kim J, 1997, J IMMUNOL, V159, P335; LEIPPE M, 1994, MOL MICROBIOL, V14, P895, DOI 10.1111/j.1365-2958.1994.tb01325.x; Lewinsohn DM, 1998, J IMMUNOL, V160, P2374; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; MANNING WC, 1992, J IMMUNOL, V148, P4036; MODLIN RL, 1984, J IMMUNOL, V132, P3085; MODLIN RL, 1983, J AM ACAD DERMATOL, V8, P182, DOI 10.1016/S0190-9622(83)70021-6; MUTIS T, 1993, EUR J IMMUNOL, V23, P2189, DOI 10.1002/eji.1830230921; NEIGHBOUR PA, 1982, EUR J IMMUNOL, V12, P588, DOI 10.1002/eji.1830120711; Pena SV, 1997, J IMMUNOL, V158, P2680; QUAN PC, 1982, J IMMUNOL, V128, P1786; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; Sieling PA, 2000, J IMMUNOL, V164, P4790, DOI 10.4049/jimmunol.164.9.4790; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Spada FM, 2000, J EXP MED, V191, P937, DOI 10.1084/jem.191.6.937; Stenger S, 1998, J IMMUNOL, V161, P3582; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Stenger S, 1997, SCIENCE, V276, P1684, DOI 10.1126/science.276.5319.1684; WEMAMBU SNC, 1969, LANCET, V2, P933	35	136	142	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					174	179		10.1038/84620	http://dx.doi.org/10.1038/84620			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175847				2022-12-27	WOS:000166756300033
J	Kappos, L; Comi, G; Panitch, H; Oger, J; Antel, J; Conlon, P; Steinman, L				Kappos, L; Comi, G; Panitch, H; Oger, J; Antel, J; Conlon, P; Steinman, L		Atlered Peptide Ligand Relapsing	Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial	NATURE MEDICINE			English	Article							MYELIN BASIC-PROTEIN; NECROSIS-FACTOR-ALPHA; RECEPTOR ANTAGONISM; CYTOKINE PROFILE; ENCEPHALOMYELITIS; DISEASE; GAMMA; RECOGNITION; INTERFERON; LESIONS	In this 'double-blind', randomized, placebo-controlled phase II trial, we compared an altered peptide ligand of myelin basic protein with placebo, evaluating their safety and influence on magnetic resonance imaging in relapsing-remitting multiple sclerosis. A safety board suspended the trial because of hypersensitivity reactions in 9% of the patients. There were no increases in either clinical relapses or in new enhancing lesions in any patient, even those with hypersensitivity reactions. Secondary analysis of those patients completing the study showed that the volume and number of enhancing lesions were reduced at a dose of 5 mg. There was also a regulatory type 2 T helper-cell response to altered peptide ligand that cross-reacted with the native peptide.	Stanford Univ, Sch Med, Beckman Ctr B002, Dept Neurol Neurosci, Stanford, CA 94305 USA; Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland; San Raffaele Sci Inst, Dept Neurol, I-20132 Milan, Italy; Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; Univ British Columbia, Div Neurol, Vancouver, BC V6T 2B5, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Neuroimmunol Unit, Montreal, PQ H3A 2B4, Canada; Neurocrine Biosci, San Diego, CA 92121 USA	Stanford University; University of Basel; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University System of Maryland; University of Maryland Baltimore; University of British Columbia; McGill University; McGill University; Neurocrine Biosciences	Steinman, L (corresponding author), Stanford Univ, Sch Med, Beckman Ctr B002, Dept Neurol Neurosci, Stanford, CA 94305 USA.		Filippi, Massimo/K-1755-2018	Filippi, Massimo/0000-0002-5485-0479; Bastianello, Stefano/0000-0002-8414-9077; antel, jack/0000-0002-5148-0636; BERRY, Isabelle/0000-0002-0886-3252; Steinman, Lawrence/0000-0002-2437-2250				Aharoni R, 1999, P NATL ACAD SCI USA, V96, P634, DOI 10.1073/pnas.96.2.634; Arnason BGW, 1999, ANNU REV MED, V50, P291; BIELEKOVA B, 1999, BRAIN PATHOL, V9, P69; Brocke S, 1996, NATURE, V379, P343, DOI 10.1038/379343a0; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Comi G, 1999, NEUROLOGY, V52, pA289; CROWE PD, IN PRESS ANN NEURO; Duda PW, 2000, J CLIN INVEST, V105, P967, DOI 10.1172/JCI8970; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; EVAVOLD BD, 1993, J IMMUNOL, V150, P3131; Gaur A, 1997, J NEUROIMMUNOL, V74, P149, DOI 10.1016/S0165-5728(96)00220-2; Goris A, 1999, J INTERF CYTOK RES, V19, P1037, DOI 10.1089/107999099313262; Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469; Hemmer B, 1998, J IMMUNOL, V160, P5807; Hermans G, 1997, ANN NEUROL, V42, P18, DOI 10.1002/ana.410420106; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; KARIN N, 1994, J EXP MED, V180, P2227, DOI 10.1084/jem.180.6.2227; KOTZIN BL, 1991, P NATL ACAD SCI USA, V88, P9161, DOI 10.1073/pnas.88.20.9161; Krogsgaard M, 2000, J EXP MED, V191, P1395, DOI 10.1084/jem.191.8.1395; KUCHROO VK, 1994, J IMMUNOL, V153, P3326; LUCHINETTI CF, 1996, BRAIN PATHOL, V6, P259; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MARTIN R, 1991, J EXP MED, V173, P19, DOI 10.1084/jem.173.1.19; Navikas V, 1996, BRAIN, V119, P213, DOI 10.1093/brain/119.1.213; Noseworthy JH, 1999, NATURE, V399, pA40, DOI 10.1038/399a040; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; PANITCH HS, 1987, NEUROLOGY, V37, P1097, DOI 10.1212/WNL.37.7.1097; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; STARK SR, 1999, MULTIPLES SCLEROSIS, P596; STEINMAN L, 1995, CELL, V80, P7, DOI 10.1016/0092-8674(95)90443-3; Steinman L, 1997, NAT MED, V3, P1085, DOI 10.1038/nm1097-1085; STEINMAN L, 1995, MOL MED TODAY, V1, P79, DOI 10.1016/S1357-4310(95)92366-7; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; TRAUGOTT U, 1988, ANN NEUROL, V24, P245; VALLI A, 1993, J CLIN INVEST, V91, P616, DOI 10.1172/JCI116242; Vandenbark AA, 1996, NAT MED, V2, P1109, DOI 10.1038/nm1096-1109; WINDHAGEN A, 1995, IMMUNITY, V2, P373, DOI 10.1016/1074-7613(95)90145-0; YU M, 1996, J EXP MED, V183, P1771; ZIJDENBOS A, 1909, P 1 INT C MED IM COM, P439	41	432	462	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1176	1182		10.1038/80525	http://dx.doi.org/10.1038/80525			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017151				2022-12-27	WOS:000089674700044
J	McKenna, N; O'Malley, BW				McKenna, N; O'Malley, BW			An issue of tissues: divining the split personalities of selective estrogen receptor modulators	NATURE MEDICINE			English	News Item							COACTIVATOR GENE; BREAST-CANCER; AMPLIFICATION; SRC-1; AIB1; RNA; RECRUITMENT; EXPRESSION		Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	McKenna, N (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.			McKenna, Neil/0000-0001-6689-0104				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; *ATL HILT TOW, 2000, ER HOP DEP DEF BREAS; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; GRAHAM JD, 1998, KEYST S NUCL REC GEN; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Leygue E, 1999, CANCER RES, V59, P4190; Leygue E, 1999, CANCER RES, V59, P1175; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Peto R, 2000, LANCET, V355, P1822, DOI 10.1016/S0140-6736(00)02277-7; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	17	55	57	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					960	962		10.1038/79637	http://dx.doi.org/10.1038/79637			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973303				2022-12-27	WOS:000089190500017
J	Liang, J; Zubovitz, J; Petrocelli, T; Kotchetkov, R; Connor, MK; Han, K; Lee, JH; Ciarallo, S; Catzavelos, C; Beniston, R; Franssen, E; Slingerland, JM				Liang, J; Zubovitz, J; Petrocelli, T; Kotchetkov, R; Connor, MK; Han, K; Lee, JH; Ciarallo, S; Catzavelos, C; Beniston, R; Franssen, E; Slingerland, JM			PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; PROTEIN-KINASE B; CELL-CYCLE ARREST; DEPENDENT KINASE; CDK INHIBITORS; BREAST-CANCER; SUBCELLULAR-LOCALIZATION; P27(KIP1); AKT; P15(INK4B)	Mechanisms linking mitogenic and growth inhibitory cytokine signaling and the cell cycle have not been fully elucidated in either cancer or in normal cells. Here we show that activation of protein kinase B (PKB)/Akt contributes to resistance to antiproliferative signals and breast cancer progression in part by impairing the nuclear import and action of p27. Akt transfection caused cytoplasmic p27 accumulation and resistance to cytokine-mediated G1 arrest. The nuclear localization signal of p27 contains an Akt consensus site at threonine 157, and p27 phosphorylation by Akt impaired its nuclear import in vitro. Akt phosphorylated wild-type p27 but not p27T157A. In cells transfected with constitutively active Akt(T308DS473D) (PKBDD), p27WT mislocalized to the cytoplasm, but p27T157A was nuclear. In cells with activated Akt, p27WT failed to cause G1 arrest, while the antiproliferative effect of p27T157A was not impaired. Cytoplasmic p27 was seen in 41% (52 of 128) of primary human breast cancers in conjunction with Akt activation and was correlated with a poor patient prognosis. Thus, we show a novel mechanism whereby Akt impairs p27 function that is associated with an aggressive phenotype in human breast cancer.	McGill Univ, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Pathol, Montreal, PQ, Canada; McGill Univ, St Marys Hosp, Dept Pathol, Montreal, PQ, Canada; Toronto Sunnybrook Reg Canc Ctr, Div Clin Epidemiol & Biostat, Toronto, ON, Canada	McGill University; University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center; McGill University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Slingerland, JM (corresponding author), McGill Univ, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Pathol, Montreal, PQ, Canada.	jslingerland@med.miami.edu		Han, Kathy/0000-0001-8439-3929				ADAM SA, 1992, METHOD ENZYMOL, V219, P97; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BOS JL, 1989, CANCER RES, V49, P4682; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Coffer PJ, 1998, BIOCHEM J, V335, P1; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Donovan J, 2000, BREAST CANCER RES, V2, P116, DOI 10.1186/bcr43; Donovan JCH, 2001, J BIOL CHEM, V276, P40888, DOI 10.1074/jbc.M106448200; Florenes VA, 1999, ONCOGENE, V18, P1023, DOI 10.1038/sj.onc.1202382; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HERLYN M, 1990, CANCER METAST REV, V9, P101, DOI 10.1007/BF00046337; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Kretzschmar M, 2000, BREAST CANCER RES, V2, P107, DOI 10.1186/bcr42; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Singh SP, 1998, CANCER RES, V58, P1730; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tsihlias J, 1999, ANNU REV MED, V50, P401; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Zeng Y, 2000, BIOCHEM BIOPH RES CO, V274, P37, DOI 10.1006/bbrc.2000.3098; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	45	765	791	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1153	1160		10.1038/nm761	http://dx.doi.org/10.1038/nm761			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12244302				2022-12-27	WOS:000178311000043
J	Compernolle, V; Brusselmans, K; Acker, T; Hoet, P; Tjwa, M; Beck, H; Plaisance, S; Dor, Y; Keshet, E; Lupu, F; Nemery, B; Dewerchin, M; Van Veldhoven, P; Plate, K; Moons, L; Collen, D; Carmeliet, P				Compernolle, V; Brusselmans, K; Acker, T; Hoet, P; Tjwa, M; Beck, H; Plaisance, S; Dor, Y; Keshet, E; Lupu, F; Nemery, B; Dewerchin, M; Van Veldhoven, P; Plate, K; Moons, L; Collen, D; Carmeliet, P			Loss of HIF-2 and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTION FACTOR; HYPOXIA; EXPRESSION; GLYCOGEN; ANGIOGENESIS; DECREASES; HOMEOSTASIS; MECHANISMS; ISOFORMS	Respiratory distress syndrome (RDS) due to insufficient production of surfactant is a common and severe complication of preterm delivery. Here, we report that loss of the hypoxia-inducible transcription factor-2alpha (HIF-2alpha) caused fatal RDS in neonatal mice due to insufficient surfactant production by alveolar type 2 cells. VEGF, a target of HIF-2alpha, regulates fetal lung maturation: because VEGF levels in alveolar cells were reduced in HIF-2alpha-deficient fetuses; mice with a deficiency of the VEGF(164) and VEGF(188) isoforms or of the HIF-binding site in the VEGF promotor died of RDS; intrauterine delivery of anti-VEGF-receptor-2 antibodies caused RDS and VEGF stimulated production of surfactant proteins by cultured type 2 pneumocytes. Intrauterine delivery or postnatal intratracheal instillation of VEGF stimulated conversion of glycogen to surfactant and protected preterm mice against RDS. The pneumotrophic effect of VEGF may have therapeutic potential for lung maturation in preterm infants.	Flanders Interuniv, Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium; Goethe Univ Frankfurt, Inst Neurol, D-6000 Frankfurt, Germany; Katholieke Univ Leuven, Unit Lung Toxicol, Lab Pneumol, Louvain, Belgium; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91010 Jerusalem, Israel; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Katholieke Univ Leuven, Dept Pharmacol, Louvain, Belgium	Goethe University Frankfurt; KU Leuven; Hebrew University of Jerusalem; Oklahoma Medical Research Foundation; KU Leuven	Carmeliet, P (corresponding author), Flanders Interuniv, Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	Lupu, Florea/C-3162-2009; Carmeliet, Peter/AAQ-5140-2020; Plaisance, Stephane/ABI-6307-2020; Lupu, Florea/AAV-3257-2021; , Van Veldhoven Paul/U-6359-2019; Hoet, Peter/H-9987-2013; Nemery, Benoit/N-3155-2019; Plaisance, Stephane/B-3488-2009; Keshet, Eli/GQR-0445-2022; Dor, Yuval/C-2405-2011; Nemery, Benoit/D-1224-2013	Lupu, Florea/0000-0003-1249-9278; Carmeliet, Peter/0000-0001-7961-1821; Plaisance, Stephane/0000-0002-1651-241X; Lupu, Florea/0000-0003-1249-9278; , Van Veldhoven Paul/0000-0002-4478-2564; Hoet, Peter/0000-0002-0292-6603; Nemery, Benoit/0000-0003-0571-4689; Plaisance, Stephane/0000-0002-1651-241X; Acker, Till/0000-0001-6357-7227; Moons, Lieve (Godelieve)/0000-0003-0186-1411				Bernatchez PN, 2001, BRIT J PHARMACOL, V134, P197, DOI 10.1038/sj.bjp.0704215; Bhakoo O. N., 2000, Indian Journal of Pediatrics, V67, P803, DOI 10.1007/BF02726222; Bhatt AJ, 2001, AM J RESP CRIT CARE, V164, P1971, DOI 10.1164/ajrccm.164.10.2101140; Bhatt AJ, 2000, PEDIATR RES, V47, P606, DOI 10.1203/00006450-200005000-00009; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BOURBON JR, 1991, EXP LUNG RES, V17, P789, DOI 10.3109/01902149109062878; BOURBON JR, 1982, BIOCHIM BIOPHYS ACTA, V712, P382, DOI 10.1016/0005-2760(82)90356-3; Brown KRS, 2001, AM J PHYSIOL-LUNG C, V281, pL1001, DOI 10.1152/ajplung.2001.281.4.L1001; Brusselmans K, 2001, J BIOL CHEM, V276, P39192, DOI 10.1074/jbc.C100428200; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Corne J, 2000, J CLIN INVEST, V106, P783, DOI 10.1172/JCI9674; D'Angio CT, 1999, BIOL NEONATE, V76, P266, DOI 10.1159/000014168; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; GILDEN C, 1977, PEDIATR RES, V11, P845, DOI 10.1203/00006450-197707000-00014; Goldenberg RL, 2000, NEW ENGL J MED, V342, P1500, DOI 10.1056/NEJM200005183422007; Healy AM, 2000, DEV DYNAM, V219, P341, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1061>3.0.CO;2-M; Hoet PHM, 2001, TOXICOL APPL PHARM, V175, P184, DOI 10.1006/taap.2001.9247; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Jakkula M, 2000, AM J PHYSIOL-LUNG C, V279, pL600, DOI 10.1152/ajplung.2000.279.3.L600; Kaner RJ, 2001, MOL MED, V7, P240, DOI 10.1007/BF03401843; Kennedy JD, 1999, J PAEDIATR CHILD H, V35, P516, DOI 10.1046/j.1440-1754.1999.00422.x; Klekamp JG, 1999, AM J PATHOL, V154, P823, DOI 10.1016/S0002-9440(10)65329-1; Lassus P, 1999, AM J RESP CRIT CARE, V159, P1429, DOI 10.1164/ajrccm.159.5.9806073; Lassus P, 2001, AM J RESP CRIT CARE, V164, P1981, DOI 10.1164/ajrccm.164.10.2012036; LIANG Y, 2002, J BIOL CHEM     0323; Ng YS, 2001, DEV DYNAM, V220, P112, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; PUGAZHENTHI S, 1995, MOL CELL BIOCHEM, V149, P95, DOI 10.1007/BF01076568; Rannels SR, 1996, EXP LUNG RES, V22, P213, DOI 10.3109/01902149609050848; Rayani HH, 1999, EXP LUNG RES, V25, P69, DOI 10.1080/019021499270439; REN JM, 1992, AM J PHYSIOL, V263, pE1086; Rooney SA, 2001, COMP BIOCHEM PHYS A, V129, P233, DOI 10.1016/S1095-6433(01)00320-8; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; Walfisch A, 2001, OBSTET GYNECOL, V98, P491, DOI 10.1016/S0029-7844(01)01368-0; Yu AY, 1998, AM J PHYSIOL-LUNG C, V275, pL818, DOI 10.1152/ajplung.1998.275.4.L818	43	566	586	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2002	8	7					702	710		10.1038/nm721	http://dx.doi.org/10.1038/nm721			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12053176				2022-12-27	WOS:000176495200031
J	Gray, ML; Bonventre, JV				Gray, ML; Bonventre, JV			Training PhD researchers to translate science to clinical medicine: Closing the gap from the other side	NATURE MEDICINE			English	Editorial Material							PHYSICIAN-SCIENTISTS; TECHNOLOGY		MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Div Hlth Sci & Technol, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Gray, ML (corresponding author), MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.							Abelmann WH, 1997, J INVEST MED, V45, P272; ARIAS I, IN PRESS P NATL ACAD; ARIAS IM, 1989, NEW ENGL J MED, V321, P972, DOI 10.1056/NEJM198910053211412; BUNN HF, 1995, FASEB J, V9, P1392, DOI 10.1096/fasebj.9.14.7589979; Rosenberg LE, 1999, SCIENCE, V283, P331, DOI 10.1126/science.283.5400.331; Varki A, 2002, NAT MED, V8, P437, DOI 10.1038/nm0502-437; WILKERSON L, 1993, ACAD MED, V68, P214, DOI 10.1097/00001888-199303000-00014; WYNGAARDEN JB, 1979, NEW ENGL J MED, V301, P1254, DOI 10.1056/NEJM197912063012303; Zemlo TR, 2000, FASEB J, V14, P221, DOI 10.1096/fasebj.14.2.221	9	26	27	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					433	436		10.1038/nm0502-433	http://dx.doi.org/10.1038/nm0502-433			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984576				2022-12-27	WOS:000175336800014
J	Lee, TS; Chau, LY				Lee, TS; Chau, LY			Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice	NATURE MEDICINE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; NECROSIS-FACTOR-ALPHA; CARBON-MONOXIDE; MONONUCLEAR PHAGOCYTES; PROVIDES PROTECTION; NITRIC-OXIDE; KINASE; CELLS; P38; TRANSCRIPTION	The mechanisms underlying the action of the potent anti-inflammatory interleukin-10 (IL-10) are poorly understood. Here we show that, in murine macrophages, IL-10 induces expression of heme oxygenase-1 (HO-1), a stress-inducible protein with potential anti-inflammatory effect, via a p38 mitogen-activated protein kinase-dependent pathway. Inhibition of HO-1 protein synthesis or activity significantly reversed the inhibitory effect of IL-10 on production of tumor necrosis factor-alpha induced by lipopolysaccharide (LPS). Additional experiments revealed the involvement of carbon monoxide, one of the products of HO-1-mediated heme degradation, in the anti-inflammatory effect of IL-10 in vitro. Induction of HO-1 by IL-10 was also evident in vivo. IL-10-mediated protection against LPS-induced septic shock in mice was significantly attenuated by cotreatment with the HO inhibitor, zinc protoporphyrin. The identification of HO-1 as a downstream effector of IL-10 provides new possibilities for improved therapeutic approaches for treating inflammatory diseases.	Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei, Taiwan	National Defense Medical Center; Academia Sinica - Taiwan	Chau, LY (corresponding author), Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan.	lyc@mail.ibms.sinica.edu.tw	Chau, Lee-Young/N-7659-2018; Lee, Tzong-Shyuan/AAE-5803-2020	Chau, Lee-Young/0000-0002-6316-2328; Lee, Tzong-Shyuan/0000-0002-9593-4062				Alam J, 2000, J BIOL CHEM, V275, P27694; Aste-Amezaga M, 1998, J IMMUNOL, V160, P5936; BONKOVSKY HL, 1990, EUR J BIOCHEM, V189, P155, DOI 10.1111/j.1432-1033.1990.tb15472.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen K, 2000, CELL MOL BIOL, V46, P609; Crawley JB, 1996, J BIOL CHEM, V271, P16357, DOI 10.1074/jbc.271.27.16357; Deramaudt TB, 1999, P SOC EXP BIOL MED, V222, P185, DOI 10.1046/j.1525-1373.1999.d01-130.x; DING AH, 1988, J IMMUNOL, V141, P2407; Donnelly RP, 1999, J INTERF CYTOK RES, V19, P563, DOI 10.1089/107999099313695; Geiss G, 2001, J BIOL CHEM, V276, P30178, DOI 10.1074/jbc.C100137200; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; HOWARD M, 1992, IMMUNOL TODAY, V13, P198, DOI 10.1016/0167-5699(92)90153-X; Kacimi R, 2000, CARDIOVASC RES, V46, P139, DOI 10.1016/S0008-6363(00)00007-9; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; LACRAZ S, 1995, J CLIN INVEST, V96, P2304, DOI 10.1172/JCI118286; Lai CF, 1996, J BIOL CHEM, V271, P13968, DOI 10.1074/jbc.271.24.13968; Lee PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL175, DOI 10.1152/ajplung.2000.279.1.L175; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; Mtairag E, 2001, CARDIOVASC RES, V49, P882; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595, DOI 10.1165/ajrcmb.13.5.7576696; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Ponka P, 1999, AM J MED SCI, V318, P241, DOI 10.1097/00000441-199910000-00004; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; PRABHAKAR NR, 1995, P NATL ACAD SCI USA, V92, P1994, DOI 10.1073/pnas.92.6.1994; PRICHETT W, 1995, J INFLAMM, V45, P97; Riley JK, 1999, J BIOL CHEM, V274, P16513, DOI 10.1074/jbc.274.23.16513; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Terry CM, 1998, AM J PHYSIOL-HEART C, V274, pH883, DOI 10.1152/ajpheart.1998.274.3.H883; van den Blink B, 2001, J IMMUNOL, V166, P582, DOI 10.4049/jimmunol.166.1.582; Wang LJ, 1998, AM J PATHOL, V152, P711; WANG P, 1994, J IMMUNOL, V153, P811; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Xu K, 2001, J IMMUNOL, V166, P6358, DOI 10.4049/jimmunol.166.10.6358; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397	45	872	920	0	47	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2002	8	3					240	246		10.1038/nm0302-240	http://dx.doi.org/10.1038/nm0302-240			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875494				2022-12-27	WOS:000174139500028
J	Liang, JS; Distler, O; Cooper, DA; Jamil, H; Deckelbaum, RJ; Ginsberg, HN; Sturley, SL				Liang, JS; Distler, O; Cooper, DA; Jamil, H; Deckelbaum, RJ; Ginsberg, HN; Sturley, SL			HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia	NATURE MEDICINE			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; INSULIN-RESISTANCE; PERIPHERAL LIPODYSTROPHY; CONTAINING LIPOPROTEINS; SECRETION; CELLS; B100; ATHEROSCLEROSIS; TRANSLOCATION; PATHOGENESIS	Highly active anti-retroviral therapies, which incorporate HIV protease inhibitors, resolve many AIDS-defining illnesses. However, patients receiving protease inhibitors develop a marked lipodystrophy and hyperlipidemia. Using cultured human and rat hepatoma cells and primary hepatocytes from transgenic mice we demonstrate that protease inhibitor treatment inhibits proteasomal degradation of nascent apolipoprotein B, the principal protein component of triglyceride and cholesterol-rich plasma lipoproteins. Unexpectedly, protease inhibitors also inhibited the secretion of apolipoprotein B. This was associated with inhibition of cholesteryl-ester synthesis and microsomal triglyceride transfer-protein activity. However, in the presence of oleic acid, which stimulates neutral-lipid biosynthesis, protease-inhibitor treatment increased secretion of apolipoprotein B-lipoproteins above controls. These findings suggest a molecular basis for protease-inhibitor-associated hyperlipidemia, a serious adverse effect of an otherwise efficacious treatment for HIV infection.	Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; Bristol Myers Squibb Co, Princeton, NJ USA	Columbia University; Columbia University; Columbia University; University of New South Wales Sydney; Kirby Institute; Bristol-Myers Squibb	Sturley, SL (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pediat, 630 W 168th St, New York, NY 10032 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055638, R01HL040404, R01HL065954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI042848] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55638, HL65954, HL40404] Funding Source: Medline; NIAID NIH HHS [P30 AI42848] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andre P, 1998, P NATL ACAD SCI USA, V95, P13120, DOI 10.1073/pnas.95.22.13120; BILLHEIMER JT, 1981, ANAL BIOCHEM, V111, P331, DOI 10.1016/0003-2697(81)90570-4; BILLHEIMER JT, 1991, 9TH INT S ATH ROS, V184, pA94; Breslow JL, 1996, SCIENCE, V272, P685, DOI 10.1126/science.272.5262.685; CALLOW MJ, 1995, J CLIN INVEST, V96, P1639, DOI 10.1172/JCI118203; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; CARR TP, 1995, J LIPID RES, V36, P25; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Flynn TE, 1999, ANN INTERN MED, V131, P548, DOI 10.7326/0003-4819-131-7-199910050-00032; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Henry K, 1998, LANCET, V351, P1328, DOI 10.1016/S0140-6736(05)79053-X; Honkakoski P, 1998, BIOCHEM J, V330, P889, DOI 10.1042/bj3300889; HUFF MW, 1994, ARTERIOSCLER THROMB, V14, P1498, DOI 10.1161/01.ATV.14.9.1498; Lenhard JM, 2000, ARTERIOSCL THROM VAS, V20, P2625, DOI 10.1161/01.ATV.20.12.2625; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Moyle GJ, 1999, DRUG SAFETY, V20, P299, DOI 10.2165/00002018-199920040-00002; Olofsson SO, 2000, TRENDS CARDIOVAS MED, V10, P338, DOI 10.1016/S1050-1738(01)00071-8; Purnell JQ, 2000, AIDS, V14, P51, DOI 10.1097/00002030-200001070-00006; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; STEINBERG D, 1989, CIRCULATION, V80, P719, DOI 10.1161/01.CIR.80.3.719; WETTERAU JR, 1992, SCIENCE, V258, P999; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; WU XJ, 1994, J BIOL CHEM, V269, P12375; Yao ZM, 1997, J LIPID RES, V38, P1937; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	34	177	185	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2001	7	12					1327	1331		10.1038/nm1201-1327	http://dx.doi.org/10.1038/nm1201-1327			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726973				2022-12-27	WOS:000172610300038
J	Martin-Serrano, J; Zang, T; Bieniasz, PD				Martin-Serrano, J; Zang, T; Bieniasz, PD			HIV-I and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress	NATURE MEDICINE			English	Article							ROUS-SARCOMA VIRUS; VESICULAR STOMATITIS-VIRUS; PROLINE-RICH MOTIF; GAG POLYPROTEIN; MATRIX PROTEIN; UBIQUITIN LIGASE; TYPE-1; DOMAIN; RELEASE; REPLICATION	Retroviral Gag proteins encode sequences, termed late domains, which facilitate the final stages of particle budding from the plasma membrane. We report here that interactions between Tsg101, a factor involved in endosomal protein sorting, and short peptide motifs in the HIV-1 Gag late domain and Ebola virus matrix (EbVp40) proteins are essential for efficient egress of HIV-1 virions and Ebola virus-like particles. EbVp40 recruits Tsg101 to sites of particle assembly and a short, EbVp40-derived Tsg101-binding peptide sequence can functionally substitute for the HIV-1 Gag late domain. Notably, recruitment of Tsg101 to assembling virions restores budding competence to a late-domain-defective HIV-1 in the complete absence of viral late domain. These studies define an essential virus-host interaction that is conserved in two unrelated viruses. Because the Tsg101 is recruited by small, conserved viral sequence motifs, agents that mimic these structures are potential inhibitors of the replication of these lethal human pathogens.	Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Bieniasz, PD (corresponding author), Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA.			Martin-Serrano, Juan/0000-0002-8183-3914	NIAID NIH HHS [AI50111] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050111] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Bieniasz PD, 2000, J VIROL, V74, P9868, DOI 10.1128/JVI.74.21.9868-9877.2000; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; BOGERD HP, 1993, J VIROL, V67, P5030, DOI 10.1128/JVI.67.8.5030-5034.1993; Craven RC, 1999, J VIROL, V73, P3359, DOI 10.1128/JVI.73.4.3359-3365.1999; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; Harty RN, 2000, P NATL ACAD SCI USA, V97, P13871, DOI 10.1073/pnas.250277297; Harty RN, 1999, J VIROL, V73, P2921, DOI 10.1128/JVI.73.4.2921-2929.1999; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; Jasenosky LD, 2001, J VIROL, V75, P5205, DOI 10.1128/JVI.75.11.5205-5214.2001; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Kikonyogo A, 2001, P NATL ACAD SCI USA, V98, P11199, DOI 10.1073/pnas.201268998; LEE PP, 1994, J VIROL, V68, P6644, DOI 10.1128/JVI.68.10.6644-6654.1994; LUBAN J, 1992, J VIROL, V66, P5157, DOI 10.1128/JVI.66.8.5157-5160.1992; PARENT LJ, 1995, J VIROL, V69, P5455, DOI 10.1128/JVI.69.9.5455-5460.1995; Patnaik A, 2000, P NATL ACAD SCI USA, V97, P13069, DOI 10.1073/pnas.97.24.13069; Puffer BA, 1998, J VIROL, V72, P10218, DOI 10.1128/JVI.72.12.10218-10221.1998; Puffer BA, 1997, J VIROL, V71, P6541, DOI 10.1128/JVI.71.9.6541-6546.1997; Reil H, 1998, EMBO J, V17, P2699, DOI 10.1093/emboj/17.9.2699; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; Timmins J, 2001, VIROLOGY, V283, P1, DOI 10.1006/viro.2001.0860; Tritel M, 2000, J VIROL, V74, P5845, DOI 10.1128/JVI.74.13.5845-5855.2000; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; WILLS JW, 1994, J VIROL, V68, P6605, DOI 10.1128/JVI.68.10.6605-6618.1994; Xiang Y, 1996, J VIROL, V70, P5695, DOI 10.1128/JVI.70.8.5695-5700.1996; Yasuda J, 1998, J VIROL, V72, P4095, DOI 10.1128/JVI.72.5.4095-4103.1998; Yuan B, 2000, J VIROL, V74, P7250, DOI 10.1128/JVI.74.16.7250-7260.2000; YUAN X, 1993, J VIROL, V67, P6387, DOI 10.1128/JVI.67.11.6387-6394.1993	31	593	616	1	275	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2001	7	12					1313	1319		10.1038/nm1201-1313	http://dx.doi.org/10.1038/nm1201-1313			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726971				2022-12-27	WOS:000172610300036
J	Chen, XN; Scala, G; Quinto, I; Liu, WM; Chun, TW; Justement, JS; Cohen, OJ; vanCott, TC; Iwanicki, M; Lewis, MG; Greenhouse, J; Barry, T; Venzon, D; Fauci, AS				Chen, XN; Scala, G; Quinto, I; Liu, WM; Chun, TW; Justement, JS; Cohen, OJ; vanCott, TC; Iwanicki, M; Lewis, MG; Greenhouse, J; Barry, T; Venzon, D; Fauci, AS			Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; GP120 ENVELOPE GLYCOPROTEIN; RANDOM PEPTIDE LIBRARIES; FILAMENTOUS BACTERIOPHAGE; NEUTRALIZING ANTIBODIES; MONOCLONAL-ANTIBODY; CHIMERIC VIRUS; VIRAL LOAD; IN-VIVO; TYPE-1	The antigenic polymorphism of HIV-1 is a major obstacle in developing an effective vaccine. Accordingly, we screened random peptide libraries (RPLs) displayed on phage with antibodies from HIV-infected individuals and identified an array of HIV-specific epitopes that behave as antigenic mimics of conformational epitopes of gp120 and gp41 proteins. We report that the selected epitopes are shared by a collection of HIV-1 isolates of clades A-F. The phage-borne epitopes are immunogenic in rhesus macaques, where they elicit envelope-specific antibody responses. Upon intravenous challenge with 60 MID50 of pathogenic SHIV-89.6PD, all monkeys became infected; however, in contrast to the naive and mock-immunized monkeys, four of five mimotope-immunized monkeys experienced lower levels of peak viremia, followed by viral set points of undetectable or transient levels of viremia and a mild decline of CD4(+) T cells, and were protected from progression to AIDS-like illness. These results provide a new approach to the design of broadly protective HIV-1 vaccines.	NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; Univ Catanzaro, Sch Med, Dept Clin & Expt Med, Catanzaro, Italy; Univ Naples Federico II, Sch Med, Dept Biochem & Biomed Technol, Naples, Italy; HM Jackson Fdn, Rockville, MD USA; So Res Inst, Frederick, MD USA; NCI, Hematopathol Sect, NIH, Bethesda, MD 20892 USA; NCI, Biostat & Data Management Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Magna Graecia University of Catanzaro; University of Naples Federico II; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Scala, G (corresponding author), NIAID, Immunoregulat Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.		SCALA, GIUSEPPE/A-3280-2009; Chun, Tae-Wook/W-9187-2019; Chun, Tae-Wook/AAC-3101-2020; Venzon, David J/B-3078-2008	Chun, Tae-Wook/0000-0001-5153-7340; QUINTO, Ileana/0000-0001-8212-8515	Telethon [A.045] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000778, Z01AI000886, ZIAAI000886] Funding Source: NIH RePORTER	Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Beyrer C, 1998, AIDS RES HUM RETROV, V14, P1687, DOI 10.1089/aid.1998.14.1687; Bures R, 2000, AIDS RES HUM RETROV, V16, P2019, DOI 10.1089/088922200750054756; Cho MW, 2001, J VIROL, V75, P2224, DOI 10.1128/JVI.75.5.2224-2234.2001; Chun TW, 2001, P NATL ACAD SCI USA, V98, P253, DOI 10.1073/pnas.98.1.253; Connor RI, 1998, J VIROL, V72, P1552, DOI 10.1128/JVI.72.2.1552-1576.1998; Cortese R, 1996, CURR OPIN BIOTECH, V7, P616, DOI 10.1016/S0958-1669(96)80072-3; Cotropia J, 1996, J ACQ IMMUN DEF SYND, V12, P221, DOI 10.1097/00042560-199607000-00002; De Berardinis P, 2000, NAT BIOTECHNOL, V18, P873, DOI 10.1038/78490; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; Fogelman I, 2000, J INFECT DIS, V182, P435, DOI 10.1086/315739; Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602; GREENWOOD J, 1991, J MOL BIOL, V220, P821, DOI 10.1016/0022-2836(91)90354-9; Karlsson GB, 1997, J VIROL, V71, P4218, DOI 10.1128/JVI.71.6.4218-4225.1997; KUIKEN C, 1999, THEORETICAL BIOL BIO, P1; Kumar A, 2000, VIROLOGY, V274, P149, DOI 10.1006/viro.2000.0444; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LETWIN NL, 2001, J VIROL, V75, P4165; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; Nabel GJ, 2000, NEW ENGL J MED, V343, P1263, DOI 10.1056/NEJM200010263431711; Parren PWHI, 1999, AIDS, V13, pS137; Phalipon A, 1997, EUR J IMMUNOL, V27, P2620, DOI 10.1002/eji.1830271022; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Reimann KA, 1996, J VIROL, V70, P3198, DOI 10.1128/JVI.70.5.3198-3206.1996; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; Scala G, 1999, J IMMUNOL, V162, P6155; SHAPSHAK P, 1995, ADV EXP MED BIOL, V373, P225; Shibata R, 1999, NAT MED, V5, P204, DOI 10.1038/5568; Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017; Stamatos NM, 1998, J VIROL, V72, P9656, DOI 10.1128/JVI.72.12.9656-9667.1998; Suryanarayana K, 1998, AIDS RES HUM RETROV, V14, P183, DOI 10.1089/aid.1998.14.183; VANDENHAESEVELDE M, 1994, J VIROL, V68, P1586, DOI 10.1128/JVI.68.3.1586-1596.1994; VERONESE FDM, 1994, J MOL BIOL, V243, P167, DOI 10.1006/jmbi.1994.1643; Wasserstein AG, 1997, J AM SOC NEPHROL, V8, P664; Weng YK, 1998, J VIROL, V72, P9676, DOI 10.1128/JVI.72.12.9676-9682.1998; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; ZHU TF, 1995, J VIROL, V69, P1324, DOI 10.1128/JVI.69.2.1324-1327.1995; Zolla-Pazner S, 1999, J VIROL, V73, P4042, DOI 10.1128/JVI.73.5.4042-4051.1999	44	69	84	2	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2001	7	11					1225	1231		10.1038/nm1101-1225	http://dx.doi.org/10.1038/nm1101-1225			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689887				2022-12-27	WOS:000172054100030
J	Ready, T				Ready, T			Pfizer in "unethical" trial suit	NATURE MEDICINE			English	News Item																			0	4	4	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1077	1077		10.1038/nm1001-1077c	http://dx.doi.org/10.1038/nm1001-1077c			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590414	Bronze			2022-12-27	WOS:000171524500009
J	Yuhanna, IS; Zhu, Y; Cox, BE; Hahner, LD; Osborne-Lawrence, S; Marcel, YL; Anderson, RGW; Mendelsohn, ME; Hobbs, HH; Shaul, PW				Yuhanna, IS; Zhu, Y; Cox, BE; Hahner, LD; Osborne-Lawrence, S; Marcel, YL; Anderson, RGW; Mendelsohn, ME; Hobbs, HH; Shaul, PW			High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase	NATURE MEDICINE			English	Article							A-I; ARTERY ENDOTHELIUM; SR-BI; ATHEROSCLEROSIS; CHOLESTEROL; EXPRESSION; CAVEOLAE; HDL; IDENTIFICATION; INHIBITION	Atherosclerosis is the primary cause of cardiovascular disease, and the risk for atherosclerosis is inversely proportional to circulating levels of high-density lipoprotein (HDL) cholesterol. However, the mechanisms by which HDL is atheroprotective are complex and not well understood(1,2), Here we show that HDL stimulates endothelial nitric oxide synthase (eNOS) in cultured endothelial cells. In contrast, eNOS is not activated by purified forms of the major HDL apolipoproteins ApoA-I and ApoA-II or by low-density lipoprotein. Heterologous expression experiments in Chinese hamster ovary cells reveal that scavenger receptor-BI (SR-BI) mediates the effects of HDL on the enzyme. HDL activation of eNOS is demonstrable in isolated endothelial-cell caveolae where SR-BI and eNOS are colocalized, and the response in isolated plasma membranes is blocked by antibodies to ApoA-I and SR-BI, but not by antibody to ApoA-II. HDL also enhances endothelium- and nitric-oxide-dependent relaxation in aortae from wild-type mice, but not in aortae from homozygous null SR-BI knockout mice. Thus, HDL activates eNOS via SR-BI through a process that requires ApoA-I binding. The resulting increase in nitric-oxide production might be critical to the atheroprotective properties of HDL and ApoA-I.	Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA; Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Ottawa, ON, Canada	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tufts Medical Center; Tufts University; University of Ottawa; University of Ottawa Heart Institute	Shaul, PW (corresponding author), Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA.		Eckhardt, Erik/G-1567-2010		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030276] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058888, R01HL053546, R01HL059953, R01HL056069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052016] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53546, HL58888, HL59953, HL56069] Funding Source: Medline; NICHD NIH HHS [HD30276] Funding Source: Medline; NIGMS NIH HHS [GM52016] Funding Source: Medline; PHS HHS [NL20948] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BABBITT J, 1997, J BIOL CHEM, V272, P13242; Bergeron J, 1997, BBA-LIPID LIPID MET, V1344, P139, DOI 10.1016/S0005-2760(96)00136-1; CAYATTE AJ, 1994, ARTERIOSCLER THROMB, V14, P753, DOI 10.1161/01.ATV.14.5.753; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; COHEN RA, 1995, PROG CARDIOVASC DIS, V38, P105, DOI 10.1016/S0033-0620(05)80002-7; Fidge NH, 1999, J LIPID RES, V40, P187; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; HARRISON DG, 1994, BASIC RES CARDIOL, V89, P87; HAYASHI T, 1992, P NATL ACAD SCI USA, V89, P11259, DOI 10.1073/pnas.89.23.11259; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Jolley CD, 1998, J LIPID RES, V39, P2143; Jun SS, 1998, J CLIN INVEST, V102, P176, DOI 10.1172/JCI2034; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; Krieger M, 1998, P NATL ACAD SCI USA, V95, P4077, DOI 10.1073/pnas.95.8.4077; LEFER AM, 1993, ARTERIOSCLER THROMB, V13, P771, DOI 10.1161/01.ATV.13.6.771; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; Pace MC, 1999, AM J PHYSIOL-LUNG C, V277, pL106, DOI 10.1152/ajplung.1999.277.1.L106; Reaven E, 2001, P NATL ACAD SCI USA, V98, P1613, DOI 10.1073/pnas.98.4.1613; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SHAUL PW, 1992, AM J PHYSIOL, V262, pH355, DOI 10.1152/ajpheart.1992.262.2.H355; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; Xia P, 1999, J BIOL CHEM, V274, P33143, DOI 10.1074/jbc.274.46.33143; ZANNIS VI, 1993, ADV HUM GENET, V21, P145; ZHU Y, 1999, CIRCULATION, V100, P1	35	588	609	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					853	857		10.1038/89986	http://dx.doi.org/10.1038/89986			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433352				2022-12-27	WOS:000169808600039
J	Weitz-Schmidt, G; Welzenbach, K; Brinkmann, V; Kamata, T; Kallen, J; Bruns, C; Cottens, S; Takada, Y; Hommel, U				Weitz-Schmidt, G; Welzenbach, K; Brinkmann, V; Kamata, T; Kallen, J; Bruns, C; Cottens, S; Takada, Y; Hommel, U			Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site	NATURE MEDICINE			English	Article							HMG-COA-REDUCTASE; INTERCELLULAR-ADHESION MOLECULE-1; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; TRANSPLANTATION; RECEPTOR; DOMAIN; ICAM-1; CD11A; LFA-1	The beta2 integrin leukocyte function antigen-1 (LFA-1) has an important role in the pathophysiology of inflammatory and autoimmune diseases. Here we report that statin compounds commonly used for the treatment of hypercholesterolemia selectively blocked LFA-1-mediated adhesion and costimulation of lymphocytes. This effect was unrelated to the statins' inhibition of 3-hydroxy-3-methylglutaryl coenzyme-A reductase; instead it occurred via binding to a novel allosteric site within LFA-1. Subsequent optimization of the statins for LFA-1 binding resulted in potent, selective and orally active LFA-1 inhibitors that suppress the inflammatory response in a murine model of peritonitis. Targeting of the statin-binding site of LFA-1 could be used to treat diseases such as psoriasis, rheumatoid arthritis, ischemia/reperfusion injury and transplant rejection.	Novartis Pharma AG, Preclin Res, Basel, Switzerland; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA USA	Novartis; Scripps Research Institute	Weitz-Schmidt, G (corresponding author), Novartis Pharma AG, Preclin Res, Basel, Switzerland.	gabriele.weitz@pharma.novartis.com		takada, yoshikazu/0000-0001-5481-9589				Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CARLOS TM, 1994, BLOOD, V84, P2068; CORSINI A, 1995, PHARMACOL RES, V31, P9, DOI 10.1016/1043-6618(95)80042-5; de Fougerolles AR, 2000, J CLIN INVEST, V105, P721, DOI 10.1172/JCI7911; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DUGGAN DE, 1990, DRUG METAB REV, V22, P333, DOI 10.3109/03602539009041088; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; FISCHER A, 1991, BLOOD, V77, P249; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hourmant M, 1996, TRANSPLANTATION, V62, P1565, DOI 10.1097/00007890-199612150-00006; HUTCH JR, 2000, P NATL ACAD SCI USA, V97, P5231; Issekutz AC, 1998, INFLAMM RES, V47, pS123; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; KATZNELSON S, 1995, KIDNEY INT, V48, pS112; Kelly TA, 1999, J IMMUNOL, V163, P5173; KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003; Krueger J, 2000, J INVEST DERMATOL, V115, P333, DOI 10.1046/j.1523-1747.2000.00abs-8.x; Kurakata S, 1996, IMMUNOPHARMACOLOGY, V34, P51, DOI 10.1016/0162-3109(96)00108-7; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Legge GB, 2000, J MOL BIOL, V295, P1251, DOI 10.1006/jmbi.1999.3409; Leitinger B, 2000, NAT STRUCT BIOL, V7, P614, DOI 10.1038/77895; Liu G, 2000, J MED CHEM, V43, P4025, DOI 10.1021/jm0002782; Maron DJ, 2000, CIRCULATION, V101, P207, DOI 10.1161/01.CIR.101.2.207; Martin X, 2000, TRANSPLANT P, V32, P481, DOI 10.1016/S0041-1345(00)00849-6; Mousa SA, 1997, DRUG DISCOV TODAY, V2, P187, DOI 10.1016/S1359-6446(97)01027-1; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Nakakura EK, 1996, TRANSPLANTATION, V62, P547, DOI 10.1097/00007890-199609150-00001; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; Poston RS, 2000, TRANSPLANTATION, V69, P2005, DOI 10.1097/00007890-200005270-00006; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Romano M, 2000, LAB INVEST, V80, P1095, DOI 10.1038/labinvest.3780115; Scheynius A, 1996, J IMMUNOL, V156, P1804; Shum YY, 1998, THER DRUG MONIT, V20, P41, DOI 10.1097/00007691-199802000-00008; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; Wenke K, 1997, CIRCULATION, V96, P1398, DOI 10.1161/01.CIR.96.5.1398	40	845	906	2	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2001	7	6					687	692		10.1038/89058	http://dx.doi.org/10.1038/89058			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385505				2022-12-27	WOS:000169081500036
J	Birmingham, K				Birmingham, K			Klaus Rajewsky	NATURE MEDICINE			English	Biographical-Item																		RAJEWSKY K, PUBLICATION LIST	1	0	0	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2001	7	4					392	392		10.1038/86436	http://dx.doi.org/10.1038/86436			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283650				2022-12-27	WOS:000167960500016
J	Brown, J; Saracoglu, K; Uhrig, S; Speicher, MR; Eils, R; Kearney, L				Brown, J; Saracoglu, K; Uhrig, S; Speicher, MR; Eils, R; Kearney, L			Subtelomeric chromosome rearrangements are detected using an innovative 12-color FISH assay (M-TEL)	NATURE MEDICINE			English	Article							RECURRENT TRANSLOCATION; MULTIPLEX-FISH; HYBRIDIZATION; DELETIONS; GENOME		John Radcliffe Hosp, Inst Mol Med, MRC, Mol Haematol Unit, Oxford OX3 9DU, England; Heidelberg Univ, Interdisciplinary Ctr Sci Comp, Heidelberg, Germany; Univ Munich, Inst Anthropol & Human Genet, D-8000 Munich, Germany; German Canc Res Ctr, D-6900 Heidelberg, Germany	University of Oxford; Ruprecht Karls University Heidelberg; University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ)	Kearney, L (corresponding author), John Radcliffe Hosp, Inst Mol Med, MRC, Mol Haematol Unit, Oxford OX3 9DU, England.	lkearney@hammer.imm.ox.ac.uk	Speicher, Michael R/B-5362-2013; Eils, Roland/B-6121-2009	Speicher, Michael R/0000-0003-0105-955X; Eils, Roland/0000-0002-0034-4036				Bentz M, 1998, GENE CHROMOSOME CANC, V21, P172, DOI 10.1002/(SICI)1098-2264(199802)21:2<172::AID-GCC14>3.0.CO;2-T; Brown J, 2000, EUR J HUM GENET, V8, P903, DOI 10.1038/sj.ejhg.5200545; BUCKLE VJ, 1994, CURR OPIN GENET DEV, V4, P374, DOI 10.1016/0959-437X(94)90024-8; CRAIG JM, 1994, NAT GENET, V7, P376, DOI 10.1038/ng0794-376; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; FLINT J, 1995, NAT GENET, V9, P132, DOI 10.1038/ng0295-132; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Holinski-Feder E, 2000, AM J HUM GENET, V66, P16, DOI 10.1086/302703; Horsley SW, 1998, J MED GENET, V35, P722, DOI 10.1136/jmg.35.9.722; Jaju RJ, 1999, BLOOD, V94, P773; Karhu R, 1997, CYTOMETRY, V28, P198, DOI 10.1002/(SICI)1097-0320(19970701)28:3<198::AID-CYTO3>3.0.CO;2-A; Knight SJL, 2000, AM J HUM GENET, V67, P320, DOI 10.1086/302998; Knight SJL, 1999, LANCET, V354, P1676, DOI 10.1016/S0140-6736(99)03070-6; Knight SJL, 1997, EUR J HUM GENET, V5, P1; MACINA RA, 1994, HUM MOL GENET, V3, P1847, DOI 10.1093/hmg/3.10.1847; NEDERLOF PM, 1990, CYTOMETRY, V11, P126, DOI 10.1002/cyto.990110115; NESSLINGER NJ, 1994, AM J HUM GENET, V54, P464; *NIH I MOL MED COL, 1996, NAT GENET, V13, P86; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Raynham H, 1996, QJM-MON J ASSOC PHYS, V89, P169; ROMANA SP, 1994, GENE CHROMOSOME CANC, V9, P186, DOI 10.1002/gcc.2870090307; SACCONE S, 1992, P NATL ACAD SCI USA, V89, P4913, DOI 10.1073/pnas.89.11.4913; SARACOGLU K, IN PRESS CYTOMETRY; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; TOSI S, 2000, CANCER, V29, P325; Uhrig S, 1999, AM J HUM GENET, V65, P448, DOI 10.1086/302508; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	29	54	58	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2001	7	4					497	501		10.1038/86581	http://dx.doi.org/10.1038/86581			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283680				2022-12-27	WOS:000167960500048
J	Kocher, AA; Schuster, MD; Szabolcs, MJ; Takuma, S; Burkhoff, D; Wang, J; Homma, S; Edwards, NM; Itescu, S				Kocher, AA; Schuster, MD; Szabolcs, MJ; Takuma, S; Burkhoff, D; Wang, J; Homma, S; Edwards, NM; Itescu, S			Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function	NATURE MEDICINE			English	Article							ENDOTHELIAL PROGENITOR CELLS; ANGIOTENSIN-II; PLASMINOGEN-ACTIVATOR; THERAPEUTIC ANGIOGENESIS; HEMATOPOIETIC-CELLS; COMMON PRECURSOR; CORONARY-ARTERY; INFARCTION; HEART; TRANSPLANTATION	Left ventricular remodeling is a major cause of progressive heart failure and death after myocardial infarction. Although neoangiogenesis within the infarcted tissue is an integral component of the remodeling process, the capillary network is unable to support the greater demands of the hypertrophied myocardium, resulting in progressive loss of viable tissue, infarct extension and fibrous replacement. Here we show that bone marrow from adult humans contains endothelial precursors with phenotypic and functional characteristics of embryonic hemangioblasts, and that these can be used to directly induce new blood vessel formation in the infarct-bed (vasculogenesis) and proliferation of preexisting vasculature (angiogenesis) after experimental myocardial infarction. The neoangiogenesis resulted in decreased apoptosis of hypertrophied myocytes in the peri-infarct region, long-term salvage and survival of viable myocardium, reduction in collagen deposition and sustained improvement in cardiac function. The use of cytokine-mobilized autologous human bone-marrow-derived angioblasts for revascularization of infarcted myocardium (alone or in conjunction with currently used therapies) has the potential to significantly reduce morbidity and mortality associated with left ventricular remodeling.	Columbia Univ, Dept Surg, New York, NY 10027 USA; Columbia Univ, Dept Med, New York, NY USA; Columbia Univ, Dept Pathol, New York, NY USA	Columbia University; Columbia University; Columbia University	Itescu, S (corresponding author), Columbia Univ, Dept Surg, New York, NY 10027 USA.	si5@columbia.edu	Burkhoff, Daniel/D-7674-2011					Agocha A, 1997, J MOL CELL CARDIOL, V29, P2233, DOI 10.1006/jmcc.1997.0462; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; BRAUNWALD E, 1991, AM J CARDIOL, V68, pD1; Cheng W, 1996, EXP CELL RES, V226, P316, DOI 10.1006/excr.1996.0232; Choi K, 1998, DEVELOPMENT, V125, P725; Colucci WS, 1997, AM J CARDIOL, V80, pL15, DOI 10.1016/S0002-9149(97)00845-X; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; Elefanty AG, 1997, BLOOD, V90, P1435, DOI 10.1182/blood.V90.4.1435.1435_1435_1447; Folkman J, 1998, CIRCULATION, V97, P1108, DOI 10.1161/01.CIR.97.12.1108; HART PH, 1991, BLOOD, V77, P841; Heymans S, 1999, NAT MED, V5, P1135, DOI 10.1038/13459; HOCHMAN JS, 1987, CIRCULATION, V75, P299, DOI 10.1161/01.CIR.75.1.299; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; Jaffredo T, 1998, DEVELOPMENT, V125, P4575; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kalkman EAJ, 1997, J MOL CELL CARDIOL, V29, P1487, DOI 10.1006/jmcc.1997.0388; Kalkman EAJ, 1996, CARDIOVASC RES, V32, P1088, DOI 10.1016/S0008-6363(96)00166-6; Kawano H, 2000, CIRCULATION, V101, P1130, DOI 10.1161/01.CIR.101.10.1130; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; Labastie MC, 1998, BLOOD, V92, P3624, DOI 10.1182/blood.V92.10.3624.422k17_3624_3635; Liechty KW, 2000, NAT MED, V6, P1282, DOI 10.1038/81395; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Mahon NG, 1999, HEART, V81, P478, DOI 10.1136/hrt.81.5.478; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; McEwan PE, 1998, CIRCULATION, V98, P2765, DOI 10.1161/01.CIR.98.24.2765; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; NelissenVrancken HJMG, 1996, CIRCULATION, V93, P349; NIDORF SM, 1992, J AM COLL CARDIOL, V20, P307; Ogawa M, 1999, BLOOD, V93, P1168, DOI 10.1182/blood.V93.4.1168.404k12_1168_1177; OLIVETTI G, 1991, CIRC RES, V68, P856, DOI 10.1161/01.RES.68.3.856; Pei XH, 1998, CLIN EXP METASTAS, V16, P551, DOI 10.1023/A:1006546402703; Pelchev M., 2000, BLOOD, V95, P952; PFEFFER JM, 1991, AM J PHYSIOL, V260, pH1406, DOI 10.1152/ajpheart.1991.260.5.H1406; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; RAFII S, 1994, BLOOD, V84, P10; RAVICHANDRAN LV, 1991, BIOCHEM INT, V24, P405; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Tavian M, 1996, BLOOD, V87, P67, DOI 10.1182/blood.V87.1.67.bloodjournal87167; Tomita S, 1999, CIRCULATION, V100, P247, DOI 10.1161/01.cir.100.suppl_2.ii-247; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; WHITE HD, 1994, CIRCULATION, V89, P61, DOI 10.1161/01.CIR.89.1.61; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	48	1985	2351	5	144	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2001	7	4					430	436		10.1038/86498	http://dx.doi.org/10.1038/86498			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283669				2022-12-27	WOS:000167960500037
J	Bosch, X				Bosch, X			BSE panic spreads to Spain	NATURE MEDICINE			English	News Item																		2000, NATURE MED, V6, P1301	1	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					138	138		10.1038/84553	http://dx.doi.org/10.1038/84553			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175828				2022-12-27	WOS:000166756300012
J	De Rosa, SC; Herzenberg, LA; Herzenberg, LA; Roederer, M				De Rosa, SC; Herzenberg, LA; Herzenberg, LA; Roederer, M			11-color, 13-parameter flow cytometry: Identification of human naive T cells by phenotype, function, and T-cell receptor diversity	NATURE MEDICINE			English	Article							ANTIRETROVIRAL THERAPY; HIV-INFECTION; L-SELECTIN; SUBSETS; CD4(+); AGE		NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA	National Institutes of Health (NIH) - USA; Stanford University	Roederer, M (corresponding author), NIH, Vaccine Res Ctr, 40 Convent Dr, Bethesda, MD 20892 USA.		Roederer, Mario/G-1887-2011		NATIONAL CANCER INSTITUTE [R35CA042509, R21CA081543] Funding Source: NIH RePORTER; NCI NIH HHS [CA-81543-02, CA-42509-14] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKBAR AN, 1991, IMMUNOL TODAY, V12, P184, DOI 10.1016/0167-5699(91)90050-4; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Baumgarth N, 2000, J IMMUNOL METHODS, V243, P77, DOI 10.1016/S0022-1759(00)00229-5; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904; Gray CM, 1998, AIDS RES HUM RETROV, V14, P561, DOI 10.1089/aid.1998.14.561; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Mitra DK, 1999, INT IMMUNOL, V11, P1801, DOI 10.1093/intimm/11.11.1801; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; MORIMOTO C, 1993, CLIN EXP RHEUMATOL, V11, P241; OKUMURA M, 1993, EUR J IMMUNOL, V23, P1057, DOI 10.1002/eji.1830230512; PICKER LJ, 1993, J IMMUNOL, V150, P1105; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; RABIN RL, 1995, J CLIN INVEST, V95, P2054, DOI 10.1172/JCI117891; Roederer M, 1997, J CLIN INVEST, V99, P1555, DOI 10.1172/JCI119318; ROEDERER M, 1995, J CLIN INVEST, V95, P2061, DOI 10.1172/JCI117892; ROEDERER M, 1995, CYTOMETRY, V21, P187, DOI 10.1002/cyto.990210211	18	338	358	1	25	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					245	248		10.1038/84701	http://dx.doi.org/10.1038/84701			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175858				2022-12-27	WOS:000166756300044
J	King, C; Hoenger, RM; Cleary, MM; Murali-Krishna, K; Ahmed, R; King, E; Sarvetnick, N				King, C; Hoenger, RM; Cleary, MM; Murali-Krishna, K; Ahmed, R; King, E; Sarvetnick, N			Interleukin-4 acts at the locus of the antigen-presenting dendritic cell to counter-regulate cytotoxic CD8+T-cell responses	NATURE MEDICINE			English	Article							T-CELLS; LYMPHOCYTIC CHORIOMENINGITIS; STIMULATORY FACTOR; IN-VITRO; ACTIVATION; CD8+; COSTIMULATION; IL-2; MICE; APOPTOSIS	The mechanism underlying suppression of immune responses by interleukin-4 (IL-4) has remained unexplained. Here we show that the antigen-presenting dendritic cell Is central to counter-regulation of autoimmune disease by IL-4. IL-4 acts at the locus of the dendritic cell to decrease the cytolytic T-cell response, preventing autoimmunity. Stimulation of cytotoxic precursors by antigen pulsed dendritic cells induces their differentiation but the process is blocked by IL-4. IL-40-influenced DC produce distinct effects on CD8(+) T cells depending on their state of activation. The molecular basis for this regulation is the alteration of the expression ratio of the costimulatory ligands B7.1/B7.2 on dendritic cells. Our findings demonstrate that B7.2 induces expansion of CD8(+) T cells and B7.1 governs their acquisition of cytolytic activity. IL-4 influences the dendritic cell to elicit qualitative differences in T-cell responses, providing the basis for counter-regulation mediated by IL-4.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Emory Univ, Emory Vaccine Ctr, Atlanta, GA USA; Emory Univ, Dept Microbiol & Immunol, Atlanta, GA USA	Scripps Research Institute; Emory University; Emory University	Sarvetnick, N (corresponding author), Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA.	noras@scripps.edu	King, Cecile/Q-9794-2019	King, Cecile/0000-0003-2193-2563				ACRES RB, 1988, ANN NY ACAD SCI, V532, P1, DOI 10.1111/j.1749-6632.1988.tb36319.x; AICHELE P, 1994, P NATL ACAD SCI USA, V91, P444, DOI 10.1073/pnas.91.2.444; AlexanderMiller MA, 1996, J EXP MED, V184, P485, DOI 10.1084/jem.184.2.485; Aung S, 1999, J VIROL, V73, P8944, DOI 10.1128/JVI.73.11.8944-8949.1999; Bembridge GP, 1998, J VIROL, V72, P4080, DOI 10.1128/JVI.72.5.4080-4087.1998; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; BLUESTONE JA, 1995, IMMUNITY, V2, P555, DOI 10.1016/1074-7613(95)90000-4; Borrow P, 1996, J EXP MED, V183, P2129, DOI 10.1084/jem.183.5.2129; Chai JG, 1999, J IMMUNOL, V163, P1298; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; CHEN LP, 1993, IMMUNOL TODAY, V14, P483, DOI 10.1016/0167-5699(93)90262-J; CRONIN DC, 1994, IMMUNOL RES, V13, P215, DOI 10.1007/BF02935614; DUTKO FJ, 1983, J GEN VIROL, V64, P1689, DOI 10.1099/0022-1317-64-8-1689; Garza KM, 2000, J EXP MED, V191, P2021, DOI 10.1084/jem.191.11.2021; HARDING FA, 1993, J EXP MED, V177, P1791, DOI 10.1084/jem.177.6.1791; HENGST JCD, 1985, CELL IMMUNOL, V90, P281, DOI 10.1016/0008-8749(85)90193-5; Homann D, 1999, IMMUNITY, V11, P463, DOI 10.1016/S1074-7613(00)80121-1; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LEONARD WJ, 1994, ADV EXP MED BIOL, V365, P225; Ludewig B, 1999, J IMMUNOL, V163, P1839; McAdam AJ, 2000, J VIROL, V74, P203, DOI 10.1128/JVI.74.1.203-208.2000; MCLELLAN AD, 1995, EUR J IMMUNOL, V25, P2064, DOI 10.1002/eji.1830250739; MERROW MW, 1991, INT IMMUNOL, V3, P551, DOI 10.1093/intimm/3.6.551; Mueller R, 1996, J EXP MED, V184, P1093, DOI 10.1084/jem.184.3.1093; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; PALIARD X, 1988, J IMMUNOL, V141, P849; RABINOVITCH A, 1994, DIABETES, V43, P613, DOI 10.2337/diabetes.43.5.613; RAPOPORT MJ, 1993, J EXP MED, V178, P87, DOI 10.1084/jem.178.1.87; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Schofield M, 1998, CLASSICAL REV, V48, P483, DOI 10.1017/S0009840X98420031; Selin LK, 1999, IMMUNITY, V11, P733, DOI 10.1016/S1074-7613(00)80147-8; SPRENT J, 1990, IMMUNOL REV, V117, P213, DOI 10.1111/j.1600-065X.1990.tb00574.x; STARLING GC, 1995, EUR J IMMUNOL, V25, P2528, DOI 10.1002/eji.1830250918; Stremmel C, 1999, J EXP MED, V189, P919, DOI 10.1084/jem.189.6.919; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; VanParijs L, 1997, J IMMUNOL, V158, P3738; Villacres MC, 1999, J IMMUNOL, V162, P2663; vonHerrath MG, 1995, IMMUNITY, V3, P727, DOI 10.1016/1074-7613(95)90062-4; WAGNER H, 1988, ANN NY ACAD SCI, V532, P128, DOI 10.1111/j.1749-6632.1988.tb36332.x; Whitmire JK, 1997, J VIROL, V71, P1736; WHITTON JL, 1989, J VIROL, V63, P4303, DOI 10.1128/JVI.63.10.4303-4310.1989; WIDMER MB, 1987, NATURE, V326, P795, DOI 10.1038/326795a0; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	47	77	79	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2001	7	2					206	214		10.1038/84659	http://dx.doi.org/10.1038/84659			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175852				2022-12-27	WOS:000166756300038
J	Li, XC; Demirci, G; Ferrari-Lacraz, S; Groves, C; Coyle, A; Malek, TR; Strom, TB				Li, XC; Demirci, G; Ferrari-Lacraz, S; Groves, C; Coyle, A; Malek, TR; Strom, TB			IL-15 and IL-2: a matter of life and death for T cells in vivo	NATURE MEDICINE			English	Article							GAMMA-CHAIN; ALPHA-CHAIN; RECEPTOR; CYTOKINE; INDUCTION; APOPTOSIS; IDENTIFICATION; LYMPHOCYTES; HOMEOSTASIS; ENDOCYTOSIS	Interleukin (IL)-2 and IL-15 are redundant in stimulating T-cell proliferation in vitro. Their precise role in vivo in governing T-cell expansion and T-cell homeostasis is less clear. Each may have distinct functions and regulate distinct aspects of T-cell activation(1-6). The functional receptors for IL-2 and IL-15 consist of a private ex-chain, which defines the binding specificity for IL-2 or IL-15, and shared IL-2 receptor beta- and gamma -chains. The gamma -chain is also a critical signaling component of IL-4, IL-7 and IL-9 receptors(7). Thus, the gamma -chain is called the common gamma or gamma -c. As these receptor subunits can be expressed individually or in various combinations resulting in the formation of receptors with different affinities, distinct signaling capabilities or both(7,8), We hypothesized that differential expression of IL-2 and IL-15 receptor subunits on cycling T cells in vivo may direct activated T cells to respond to IL-2 or IL-15, thereby regulating the homeostasis of T-cell response in vivo. By observing in vivo T-cell divisions and expression of IL-2 and IL-15 receptor subunits, we demonstrate that IL-15 is a critical growth factor in initiating T cell divisions in vivo, whereas IL-2 limits continued T-cell expansion via downregulation of the gamma -c expression. Decreased gamma -c expression on cycling T cells reduced sustained Bcl-2 expression and rendered cells susceptible to apoptotic cell death. Our study provides data that IL-2 and IL-15 regulate distinct aspects of primary T-cell expansion in vivo.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Immunol, Boston, MA 02215 USA; Millennium Pharmaceut Inc, Cambridge, MA USA; Univ Miami, Dept Microbiol & Immunol, Miami, FL 33152 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; University of Miami	Li, XC (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Immunol, Boston, MA 02215 USA.	xli@caregroup.harvard.edu	Strom, Terry B./E-9268-2010	Strom, Terry B./0000-0002-7570-0736; Li, Xian Chang/0000-0002-5981-2762				BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; Chae DW, 1996, J IMMUNOL, V157, P2813; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; HEMAR A, 1995, J CELL BIOL, V129, P55, DOI 10.1083/jcb.129.1.55; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Kim YS, 1998, J IMMUNOL, V160, P5742; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Li XC, 1999, J IMMUNOL, V163, P2500; Li XC, 2000, J IMMUNOL, V164, P1193, DOI 10.4049/jimmunol.164.3.1193; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Morelon E, 1998, J BIOL CHEM, V273, P22044, DOI 10.1074/jbc.273.34.22044; Nakajima H, 1997, J EXP MED, V185, P189, DOI 10.1084/jem.185.2.189; Noguchi M, 1997, P NATL ACAD SCI USA, V94, P11534, DOI 10.1073/pnas.94.21.11534; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sugamura K, 1996, ANNU REV IMMUNOL, V14, P179, DOI 10.1146/annurev.immunol.14.1.179; Suzuki K, 2000, INT IMMUNOL, V12, P123, DOI 10.1093/intimm/12.2.123; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873	20	242	259	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					114	118		10.1038/83253	http://dx.doi.org/10.1038/83253			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135625				2022-12-27	WOS:000166243100044
J	Bosch, X				Bosch, X			Brazilian studies supported long-term	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1198	1198		10.1038/81271	http://dx.doi.org/10.1038/81271			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062515	Bronze			2022-12-27	WOS:000165114800009
J	Pouvelle, B; Buffet, PA; Lepolard, C; Scherf, A; Gysin, J				Pouvelle, B; Buffet, PA; Lepolard, C; Scherf, A; Gysin, J			Cytoadhesion of Plasmodium falciparum ring-stage-infected erythrocytes	NATURE MEDICINE			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; CHONDROITIN-SULFATE-A; IN-VITRO MODEL; HUMAN BRAIN; PREGNANT-WOMEN; HUMAN PLACENTA; MALARIA; THROMBOMODULIN; RECEPTOR; SEQUESTRATION	A common pathological characteristic of Plasmodium folciparum infection is the cytoadhesion of mature-stage-infected erythrocytes (IE) to host endothelium and syncytiotrophoblasts. Massive accumulation of IE in the brain microvasculature or placenta is strongly correlated with severe forms of malaria(1). Extensive binding of IE to placental chondroitin sulfate A (CSA) is associated with physiopathology during pregnancy(2,3). The adhesive phenotype of IE correlates with the appearance of Plasmodium:falciparum erythrocyte membrane protein 1 (PfEMP1) at the erythrocyte surface (approximately 16 h after merozoite invasion), so that only early blood-stage (ring-stage) IE appear in the peripheral blood. Here, we describe results that challenge the existing view of blood-stage IE biology by demonstrating the specific adhesion of IE, during the early ring-stage, to endothelial cell lines from the brain and lung and to placental syncytiotrophoblasts. Later, during blood-stage development of these IE; trophozoites switch to an exclusively CSA cytoadhesion phenotype. Therefore, adhesion to an individual endothelial cell or syncytiotrophoblast may occur throughout the blood-stage cycle, indicating the presence in malaria patients of noncirculating (cryptic) parasite subpopulations. We detected two previously unknown parasite proteins on the surface of ring-stage IE. These proteins disappear shortly after the start of PfEMP1-mediated adhesion.	Univ Aix Marseille 2, Fac Med, Lab Parasitol Expt, F-13385 Marseille 5, France; Inst Pasteur, Unite Biol Interact Hote Parasite, CNRS, URA 1960, F-75724 Paris, France	UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Gysin, J (corresponding author), Univ Aix Marseille 2, Fac Med, Lab Parasitol Expt, F-13385 Marseille 5, France.		Scherf, Artur/A-9674-2014; Buffet, Pierre A/O-6189-2017; catherine, lepolard/P-5653-2016; Pouvelle, Bruno/AAA-3968-2022	Buffet, Pierre A/0000-0003-4010-929X; Scherf, Artur/0000-0003-2411-3328				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Beeson JG, 1999, J INFECT DIS, V180, P464, DOI 10.1086/314899; BOFFA MC, 1991, NOUV REV FR HEMATOL, V33, P423; Buffet PA, 1999, P NATL ACAD SCI USA, V96, P12743, DOI 10.1073/pnas.96.22.12743; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; Fernandez V, 1999, J EXP MED, V190, P1393, DOI 10.1084/jem.190.10.1393; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Fusai T, 2000, MOL BIOCHEM PARASIT, V108, P25, DOI 10.1016/S0166-6851(00)00199-7; GAY F, 1995, J IMMUNOL METHODS, V184, P15, DOI 10.1016/0022-1759(95)00070-Q; Gysin J, 1999, INFECT IMMUN, V67, P6596; GYSIN J, 1983, AM J TROP MED HYG, V32, P461, DOI 10.4269/ajtmh.1983.32.461; Gysin J, 1997, MOL BIOCHEM PARASIT, V88, P267, DOI 10.1016/S0166-6851(97)00082-0; Lou J, 1997, J NEUROIMMUNOL, V77, P107, DOI 10.1016/S0165-5728(97)00067-2; MATTEELLI A, 1994, ANN TROP MED PARASIT, V88, P475, DOI 10.1080/00034983.1994.11812894; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; Muanza K, 1996, RES IMMUNOL, V147, P149, DOI 10.1016/0923-2494(96)83167-1; Pouvelle B, 1998, INFECT IMMUN, V66, P4950, DOI 10.1128/IAI.66.10.4950-4956.1998; Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; Silamut K, 1999, AM J PATHOL, V155, P395, DOI 10.1016/S0002-9440(10)65136-X; WATKINSON M, 1983, BMJ-BRIT MED J, V287, P251, DOI 10.1136/bmj.287.6387.251; WONG VLY, 1991, BRAIN RES, V556, P1, DOI 10.1016/0006-8993(91)90540-C	22	92	96	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1264	1268		10.1038/81374	http://dx.doi.org/10.1038/81374			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062539				2022-12-27	WOS:000165114800035
J	Hel, Z; Venzon, D; Poudyal, M; Tsai, WP; Giuliani, L; Woodward, R; Chougnet, C; Shearer, G; Altman, JD; Watkins, D; Bischofberger, N; Abimiku, A; Markham, P; Tartaglia, J; Franchini, G				Hel, Z; Venzon, D; Poudyal, M; Tsai, WP; Giuliani, L; Woodward, R; Chougnet, C; Shearer, G; Altman, JD; Watkins, D; Bischofberger, N; Abimiku, A; Markham, P; Tartaglia, J; Franchini, G			Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXIC T-LYMPHOCYTES; VACCINIA VIRUS; IMMUNE-RESPONSES; CELL RESPONSES; HIV-1 TAT; INDIVIDUALS; APOPTOSIS; MAMU-A-ASTERISK-01; DISCONTINUATION	Prolonged antiretroviral therapy (ART) is not likely to eradicate human immunodeficiency virus type I (HIV-I) infection. Here we explore the effect of therapeutic immunization in the context of ART during primary infection using the simian immunodeficiency virus (SIV251) macaque model. Vaccination of rhesus macaques with the highly attenuated poxvirus-based NYVAC-SIV vaccine expressing structural genes elicited vigorous virus-specific CD4(+) and CD8(+) T cell responses in macaques that responded effectively to ART. Following discontinuation of a six-month ART regimen, viral rebound occurred in most animals, but was transient in six of eight vaccinated animals. Viral rebound was also transient in four of seven mock-vaccinated control animals. These data establish the importance of antiretroviral treatment during primary infection and demonstrate that virus-specific immune responses in the infected host can be expanded by therapeutic immunization.	NCI, Basic Res Lab, Bethesda, MD 20892 USA; NCI, Biostat & Data Management Sect, Bethesda, MD 20892 USA; Adv BioSci Labs Inc, Kensington, MD 20895 USA; NCI, Expt Immunol Branch, Bethesda, MD 20892 USA; Emory Univ, Vaccine Ctr Yerkes, Atlanta, GA 30329 USA; Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53715 USA; Gilead Sci Inc, Foster City, CA 94404 USA; Inst Human Virol, Baltimore, MD 21201 USA; Virogenet Corp, Troy, NY 12180 USA; Ave Pasteur Ltd, N York, ON M2R 3T4, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Emory University; University of Wisconsin System; University of Wisconsin Madison; Gilead Sciences; University System of Maryland; University of Maryland Baltimore	Franchini, G (corresponding author), NCI, Basic Res Lab, 41-D804, Bethesda, MD 20892 USA.	veffa@helix.nih.gov	Venzon, David J/B-3078-2008	Hel, Zdenek/0000-0002-4923-4794	DIVISION OF BASIC SCIENCES - NCI [Z01BC010422] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01BC005688, ZIABC005688] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen TM, 1998, J IMMUNOL, V160, P6062; ALLEN TM, IN PRESS NATURE; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Barouch DH, 2000, P NATL ACAD SCI USA, V97, P4192, DOI 10.1073/pnas.050417697; Benson J, 1998, J VIROL, V72, P4170, DOI 10.1128/JVI.72.5.4170-4182.1998; Binley JM, 2000, J INFECT DIS, V181, P1249, DOI 10.1086/315379; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; Evans TG, 1999, J INFECT DIS, V180, P290, DOI 10.1086/314895; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FRANCHINI G, 1995, AIDS RES HUM RETROV, V11, P909, DOI 10.1089/aid.1995.11.909; FRANCHINI G, 1987, NATURE, V328, P539, DOI 10.1038/328539a0; Gray CM, 1999, J IMMUNOL, V162, P1780; Hanke T, 1999, J VIROL, V73, P7524, DOI 10.1128/JVI.73.9.7524-7532.1999; Haslett PAJ, 2000, J INFECT DIS, V181, P1264, DOI 10.1086/315381; Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026; Jacobson EL, 1996, P NATL ACAD SCI USA, V93, P10405, DOI 10.1073/pnas.93.19.10405; KLEIN J, 1990, IMMUNOGENETICS, V31, P217, DOI 10.1007/BF00204890; Knapp LA, 1997, TISSUE ANTIGENS, V50, P657, DOI 10.1111/j.1399-0039.1997.tb02927.x; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; Letvin NL, 1998, ADV EXP MED BIOL, V452, P177; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114; Millington G., 1991, IEEE Microwave and Guided Wave Letters, V1, P320, DOI 10.1109/75.93898; Morris L, 1998, J EXP MED, V188, P233, DOI 10.1084/jem.188.2.233; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; Ogg GS, 1999, J VIROL, V73, P797, DOI 10.1128/JVI.73.1.797-800.1999; Ortiz GM, 1999, J CLIN INVEST, V104, pR13, DOI 10.1172/JCI7371; Oxenius A, 2000, P NATL ACAD SCI USA, V97, P3382, DOI 10.1073/pnas.97.7.3382; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; Romano JW, 1997, IMMUNOL INVEST, V26, P15, DOI 10.3109/08820139709048912; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Seth A, 2000, J VIROL, V74, P2502, DOI 10.1128/JVI.74.6.2502-2509.2000; TARTAGLIA J, 1992, VIROLOGY, V188, P217, DOI 10.1016/0042-6822(92)90752-B; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; YASUTOMI Y, 1995, J VIROL, V69, P2279, DOI 10.1128/JVI.69.4.2279-2284.1995	42	166	171	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2000	6	10					1140	1146		10.1038/80481	http://dx.doi.org/10.1038/80481			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017146				2022-12-27	WOS:000089674700039
J	Kaufmann, SHE				Kaufmann, SHE			Is the development of a new tuberculosis vaccine possible?	NATURE MEDICINE			English	News Item							MYCOBACTERIUM-TUBERCULOSIS; PROTECTIVE EFFICACY; DNA VACCINE; GENOMICS; BCG; IMMUNOGENICITY; STRAINS; MALARIA; MODEL		Max Planck Inst Infect Biol, Dept Immunol, D-10117 Berlin, Germany	Max Planck Society	Kaufmann, SHE (corresponding author), Max Planck Inst Infect Biol, Dept Immunol, Schumannstr 21-22, D-10117 Berlin, Germany.	kaufmann@mpiib-berlin.mpg.de	Kaufmann, Stefan HE/I-5454-2014	Kaufmann, Stefan HE/0000-0001-9866-8268				[Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 1999, WORLD HLTH REPORT 19; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Berthet FX, 1998, SCIENCE, V282, P759, DOI 10.1126/science.282.5389.759; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; Hess J, 2000, ADV IMMUNOL, V75, P1, DOI 10.1016/S0065-2776(00)75001-2; Hess J, 1998, P NATL ACAD SCI USA, V95, P5299, DOI 10.1073/pnas.95.9.5299; Hill AVS, 1998, ANNU REV IMMUNOL, V16, P593, DOI 10.1146/annurev.immunol.16.1.593; Hoffman SL, 1998, NAT MED, V4, P1351, DOI 10.1038/3934; Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893; Jungblut PR, 1999, MOL MICROBIOL, V33, P1103, DOI 10.1046/j.1365-2958.1999.01549.x; Lowrie DB, 1999, NATURE, V400, P269, DOI 10.1038/22326; Sedegah M, 1998, P NATL ACAD SCI USA, V95, P7648, DOI 10.1073/pnas.95.13.7648; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602; Walsh GP, 1996, NAT MED, V2, P430, DOI 10.1038/nm0496-430; *WHO, 2000, GLOB TUB CONTR	18	190	206	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2000	6	9					955	960		10.1038/79631	http://dx.doi.org/10.1038/79631			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973302	Bronze			2022-12-27	WOS:000089190500016
J	Viglietto, G; Motti, ML; Bruni, P; Melillo, RM; D'Alessio, A; Califano, D; Vinci, F; Chiappetta, G; Tsichlis, P; Bellacosa, A; Fusco, A; Santoro, M				Viglietto, G; Motti, ML; Bruni, P; Melillo, RM; D'Alessio, A; Califano, D; Vinci, F; Chiappetta, G; Tsichlis, P; Bellacosa, A; Fusco, A; Santoro, M			Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer	NATURE MEDICINE			English	Article							PROTEIN-KINASE; CDK-INHIBITORS; AKT ACTIVATION; CELL-SURVIVAL; EXPRESSION; GROWTH; P27; LOCALIZATION; D1; DEGRADATION	The cyclin-dependent kinase inhibitor p27(kip1) is a putative tumor suppressor for human cancer. The mechanism underlying p27(kip1) deregulation in human cancer is, however, poorly understood. We demonstrate that the serine/threonine kinase Akt regulates cell proliferation in breast cancer cells by preventing p27(kip1)-mediated growth arrest. Threonine 157 (T157), which maps within the nuclear localization signal of p27(kip1), is a predicted Akt-phosphorylation site. Akt-induced T157 phosphorylation causes retention of p27(kip1) in the cytoplasm, precluding p27(kip1)-induced G1 arrest. Conversely, the p27(kip1)-T157A mutant accumulates in cell nuclei and Akt does not affect p27(kip1)-T157A-mediated cell cycle arrest. Lastly, T157-phosphorylated p27(kip1) accumulates in the cytoplasm of primary human breast cancer cells coincident with Akt activation. Thus, cytoplasmic relocalization of p27(kip1), secondary to Akt-mediated phosphorylation, is a novel mechanism whereby the growth inhibitory properties of p27(kip1) are functionally inactivated and the proliferation of breast cancer cells is sustained.	Dipartimento Biol & Patol Cellulare & Mol, CNR, Ist Endocrinol & Oncol Sperimentale, Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg 2, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Ist Nazl Tumori, Fdn Pascale, Naples, Italy; Complesso Univ Monte S Angelo, Dipartimento Chim Organ & Biochim, Naples, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Univ Cattolica Sacro Cuore, Sch Med, Dept Med Genet, I-00168 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; IRCCS Fondazione Pascale; Jefferson University; Fox Chase Cancer Center; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Viglietto, G (corresponding author), Dipartimento Biol & Patol Cellulare & Mol, CNR, Ist Endocrinol & Oncol Sperimentale, Naples, Italy.	viglietto@sun.ceos.na.cnr.it	Viglietto, Giuseppe/AAC-2852-2019; melillo, rosa marina/O-5255-2015; Califano, Daniela/Y-6313-2018	Viglietto, Giuseppe/0000-0003-2327-7515; Califano, Daniela/0000-0001-6945-3209; Fusco, Alfredo/0000-0003-3332-5197; MELILLO, Rosa Marina/0000-0002-9233-5275				Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Ciaparrone M, 1998, CANCER RES, V58, P114; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang YH, 2000, P NATL ACAD SCI USA, V97, P10538, DOI 10.1073/pnas.190104497; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lenferink AEG, 2001, CANCER RES, V61, P6583; Liu XD, 2000, ONCOGENE, V19, P5926, DOI 10.1038/sj.onc.1203991; Lloyd RV, 1997, AM J PATHOL, V150, P401; Lobenhofer EK, 2000, CELL GROWTH DIFFER, V11, P99; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; OTSUKI T, 1995, CANCER RES, V55, P1436; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Singh SP, 1998, CANCER RES, V58, P1730; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsai EM, 2001, CANCER RES, V61, P8390; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Yang HY, 2001, ONCOGENE, V20, P3695, DOI 10.1038/sj.onc.1204472; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	44	572	601	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1136	1144		10.1038/nm762	http://dx.doi.org/10.1038/nm762			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12244303				2022-12-27	WOS:000178311000041
J	Arvidsson, A; Collin, T; Kirik, D; Kokaia, Z; Lindvall, O				Arvidsson, A; Collin, T; Kirik, D; Kokaia, Z; Lindvall, O			Neuronal replacement from endogenous precursors in the adult brain after stroke	NATURE MEDICINE			English	Article							CEREBRAL-ARTERY OCCLUSION; CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; DENTATE GYRUS; NEUROTROPHIC FACTOR; SUBVENTRICULAR ZONE; PROGENITOR CELLS; RAT; NEUROGENESIS; DIFFERENTIATION	In the adult brain, new neurons are continuously generated in the subventricular zone and dentate gyrus, but it is unknown whether these neurons can replace those lost following damage or disease. Here we show that stroke, caused by transient middle cerebral artery occlusion in adult rats, leads to a marked increase of cell proliferation in the subventricular zone. Stroke-generated new neurons, as well as neuroblasts probably already formed before the insult, migrate into the severely damaged area of the striatum, where they express markers of developing and mature, striatal medium-sized spiny neurons. Thus, stroke induces differentiation of new neurons into the phenotype of most of the neurons destroyed by the ischemic lesion. Here we show that the adult brain has the capacity for self-repair after insults causing extensive neuronal death. If the new neurons are functional and their formation can be stimulated, a novel therapeutic strategy might be developed for stroke in humans.	Univ Lund Hosp, Sect Restorat Neurol, Wallenberg Neurosci Ctr, S-22185 Lund, Sweden; Univ Lund Hosp, Neurobiol Sect, Wallenberg Neurosci Ctr, S-22185 Lund, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital	Arvidsson, A (corresponding author), Univ Lund Hosp, Sect Restorat Neurol, Wallenberg Neurosci Ctr, S-22185 Lund, Sweden.		Kirik, Deniz/E-5156-2011; Kokaia, Zaal/AAL-6009-2020	Kokaia, Zaal/0000-0003-2296-2449				Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Arvidsson A, 2001, EUR J NEUROSCI, V14, P10, DOI 10.1046/j.0953-816x.2001.01611.x; BARAMI K, 1995, J NEUROBIOL, V28, P82, DOI 10.1002/neu.480280108; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; Benraiss A, 2001, J NEUROSCI, V21, P6718, DOI 10.1523/JNEUROSCI.21-17-06718.2001; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Davies CA, 1998, EXP NEUROL, V154, P199, DOI 10.1006/exnr.1998.6891; Doetsch F, 1999, P NATL ACAD SCI USA, V96, P11619, DOI 10.1073/pnas.96.20.11619; Ekdahl CT, 2001, EUR J NEUROSCI, V14, P937, DOI 10.1046/j.0953-816x.2001.01713.x; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gu WG, 2000, J CEREBR BLOOD F MET, V20, P1166, DOI 10.1097/00004647-200008000-00002; Heimer L., 1995, P579; Herrera DG, 1999, ANN NEUROL, V46, P867, DOI 10.1002/1531-8249(199912)46:6<867::AID-ANA9>3.0.CO;2-Z; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Koizumi J., 1986, JPN J STROKE, V8, P1, DOI DOI 10.3995/JSTROKE.8.1; KOKAIA Z, 1995, EXP NEUROL, V136, P73, DOI 10.1006/exnr.1995.1085; Liu JL, 1998, J NEUROSCI, V18, P7768; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; Mason HA, 2001, J NEUROSCI, V21, P7654, DOI 10.1523/JNEUROSCI.21-19-07654.2001; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; Ouimet CC, 1998, BRAIN RES, V808, P8, DOI 10.1016/S0006-8993(98)00724-0; OUIMET CC, 1984, J NEUROSCI, V4, P111; Parent JM, 1997, J NEUROSCI, V17, P3727; Pencea V, 2001, J NEUROSCI, V21, P6706, DOI 10.1523/JNEUROSCI.21-17-06706.2001; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Toresson H, 2000, MECH DEVELOP, V94, P183, DOI 10.1016/S0925-4773(00)00324-5; Toresson H, 1999, DEVELOPMENT, V126, P1317; Veizovic T, 2001, STROKE, V32, P1012, DOI 10.1161/01.STR.32.4.1012; Wichterle H, 1997, NEURON, V18, P779, DOI 10.1016/S0896-6273(00)80317-7; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; ZHAO Q, 1994, BRAIN RES, V649, P253, DOI 10.1016/0006-8993(94)91071-5	34	2204	2360	2	181	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2002	8	9					963	970		10.1038/nm747	http://dx.doi.org/10.1038/nm747			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12161747	Green Published			2022-12-27	WOS:000177757900031
J	Otani, A; Kinder, K; Ewalt, K; Otero, FJ; Schimmel, P; Friedlander, M				Otani, A; Kinder, K; Ewalt, K; Otero, FJ; Schimmel, P; Friedlander, M			Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis	NATURE MEDICINE			English	Article							PROLIFERATIVE DIABETIC-RETINOPATHY; ADULT MAMMALIAN EYE; GROWTH; NEOVASCULARIZATION; INVOLVEMENT; VESSELS; INJURY; MICE; VIVO	Adult bone marrow (BM) contains cells capable of differentiating along hematopoietic (Lin(+)) or non-hematopoietic (Lin(-)) lineages. Lin(-) hematopoietic stem cells (HSCs) have recently been shown to contain a population of endothelial precursor cells (EPCs) capable of forming blood vessels. Here we show that intravitreally injected Lin(-) BM cells selectively target retinal astrocytes, cells that serve as a template for both developmental and injury-associated retinal angiogenesis. When Lin(-) BM cells were injected into neonatal mouse eyes, they extensively and stably incorporated into forming retinal vasculature. When EPC-enriched HSCs were injected into the eyes of neonatal rd/rd mice, whose vasculature ordinarily degenerates with age, they rescued and maintained a normal vasculature. In contrast, normal retinal angiogenesis was inhibited when EPCs expressing a potent angiostatic protein were injected. We have demonstrated that Lin(-) BM cells and astrocytes specifically interact with one another during normal angiogenesis and pathological vascular degeneration in the retina. Selective targeting with Lin(-) HSC may be a useful therapeutic approach for the treatment of many ocular diseases.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Biol Mol, La Jolla, CA USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Friedlander, M (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.				NCI NIH HHS [CA92577] Funding Source: Medline; NEI NIH HHS [EY12598, EY11254, EY12599] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092577] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY012598, R01EY012599, R01EY011254] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahmad I, 2000, BIOCHEM BIOPH RES CO, V270, P517, DOI 10.1006/bbrc.2000.2473; Amin RH, 1997, INVEST OPHTH VIS SCI, V38, P36; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; Davidoff AM, 2001, CLIN CANCER RES, V7, P2870; Dyer MA, 2000, NAT NEUROSCI, V3, P873, DOI 10.1038/78774; Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; MacLaren RE, 1996, BRIT J OPHTHALMOL, V80, P458, DOI 10.1136/bjo.80.5.458; MADIGAN MC, 1994, RETINA-J RET VIT DIS, V14, P65, DOI 10.1097/00006982-199401000-00014; MATTHES MT, 1984, INVEST OPHTH VIS SCI, V25, P364; McLeod DS, 1998, INVEST OPHTH VIS SCI, V39, P1918; Mizutani M, 1998, DIABETES, V47, P445, DOI 10.2337/diabetes.47.3.445; NORK TM, 1987, ARCH OPHTHALMOL-CHIC, V105, P1424; OHIRA A, 1990, OPHTHALMOLOGICA, V201, P187, DOI 10.1159/000310150; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Otani A, 2002, P NATL ACAD SCI USA, V99, P178, DOI 10.1073/pnas.012601899; Priller J, 2001, NAT MED, V7, P1356, DOI 10.1038/nm1201-1356; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rungger-Brandle E, 2000, INVEST OPHTH VIS SCI, V41, P1971; SCHNITZER J, 1988, GLIA, V1, P74, DOI 10.1002/glia.440010109; Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032; Wakasugi K, 2002, P NATL ACAD SCI USA, V99, P173, DOI 10.1073/pnas.012602099; Wang SM, 2000, INVEST OPHTH VIS SCI, V41, P537; Zhang YF, 1997, INVEST OPHTH VIS SCI, V38, P1653	28	263	303	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2002	8	9					1004	1010		10.1038/nm744	http://dx.doi.org/10.1038/nm744			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12145646	Green Submitted			2022-12-27	WOS:000177757900036
J	Takeshita, S; Namba, N; Zhao, JJ; Jiang, YB; Genant, HK; Silva, MJ; Brodt, MD; Helgason, CD; Kalesnikoff, J; Rauh, MJ; Humphries, RK; Krystal, G; Teitelbaum, SL; Ross, FP				Takeshita, S; Namba, N; Zhao, JJ; Jiang, YB; Genant, HK; Silva, MJ; Brodt, MD; Helgason, CD; Kalesnikoff, J; Rauh, MJ; Humphries, RK; Krystal, G; Teitelbaum, SL; Ross, FP			SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts	NATURE MEDICINE			English	Article							BONE MECHANICAL-PROPERTIES; INOSITOL PHOSPHATASE SHIP; COLONY-STIMULATING FACTOR; PAGETS-DISEASE; MULTIPLE CYTOKINES; SHC; DIFFERENTIATION; RECEPTOR; PROTEIN; LIGAND	The hematopoietic-restricted protein Src homology 2-containing inositol-5-phosphatase (SHIP) blunts phosphatidylinositol-3-kinase-initiated signaling by dephosphorylating its major substrate, phosphatidylinositol-3,4,5-trisphosphate. As SHIP-/- mice contain increased numbers of osteoclast precursors, that is, macrophages, we examined bones from these animals and found that osteoclast number is increased two-fold. This increased number is due to the prolonged life span of these cells and to hypersensitivity of precursors to macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-B ligand (RANKL). Similar to pagetic osteoclasts, SHIP-/- osteoclasts are enlarged, containing upwards of 100 nuclei, and exhibit enhanced resorptive activity. Moreover, as in Paget disease, serum levels of interleukin-6 are markedly increased in SHIP-/- mice. Consistent with accelerated resorptive activity, 3D trabecular volume fraction, trabecular thickness, number and connectivity density of SHIP-/- long bones are reduced, resulting in a 22% loss of bone-mineral density and a 49% decrease in fracture energy. Thus, SHIP negatively regulates osteoclast formation and function and the absence of this enzyme results in severe osteoporosis.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63108 USA; Okayama Univ, Grad Sch Med & Dent, Dept Pediat, Okayama, Japan; Univ Calif San Francisco, Dept Radiol, Osteoporosis & Arthritis Res Grp, San Francisco, CA 94143 USA; Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO 63108 USA; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada	Washington University (WUSTL); Okayama University; University of California System; University of California San Francisco; Washington University (WUSTL); British Columbia Cancer Agency	Ross, FP (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63108 USA.	rossf@medicine.wustl.edu		Humphries, Richard/0000-0003-0540-7005; Silva, Matthew/0000-0001-7375-4522; Teitelbaum, Steven/0000-0002-4054-6679; Rauh, Michael/0000-0002-8346-5537; Krystal, Gerald/0000-0002-1961-6281				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Brodt MD, 1999, J BONE MINER RES, V14, P2159, DOI 10.1359/jbmr.1999.14.12.2159; Cantley LC, 2001, SCIENCE, V292, P2019, DOI 10.1126/science.1062796; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hocking LJ, 2001, AM J HUM GENET, V69, P1055, DOI 10.1086/323798; HOSKING DJ, 1981, BRIT MED J, V283, P686, DOI 10.1136/bmj.283.6293.686; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; IBBOTSON KJ, 1984, J CELL BIOL, V99, P471, DOI 10.1083/jcb.99.2.471; JIANG Y, 2002, PRINCIPLES BONE BIOL, P1599; Jiang YB, 1998, J BONE MINER RES, V13, P1783, DOI 10.1359/jbmr.1998.13.11.1783; Jiang YB, 1999, J CLIN DENSITOM, V2, P423, DOI 10.1016/S1094-6950(06)60408-3; Kalesnikoff J, 2002, J IMMUNOL, V168, P4737, DOI 10.4049/jimmunol.168.9.4737; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Lorenzo J.A., 2002, PRINCIPLES BONE BIOL, VSecond, P961; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014-5793(95)00153-Z; Nandurkar HH, 2001, P NATL ACAD SCI USA, V98, P9499, DOI 10.1073/pnas.171306098; Neale SD, 2000, BONE, V27, P409, DOI 10.1016/S8756-3282(00)00345-8; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Rohrschneider LR, 2000, GENE DEV, V14, P505; Roodman GD, 1996, BONE, V19, P209, DOI 10.1016/8756-3282(96)00211-6; SAXTON TM, 1994, J IMMUNOL, V153, P623; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; TEITELBAUM SL, 1977, PATHOLOGY, P1905; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; VIGNERY A, 1980, ANAT REC, V196, P191, DOI 10.1002/ar.1091960210; Ware MD, 1996, BLOOD, V88, P2833, DOI 10.1182/blood.V88.8.2833.bloodjournal8882833; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	45	198	210	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2002	8	9					943	949		10.1038/nm752	http://dx.doi.org/10.1038/nm752			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12161749				2022-12-27	WOS:000177757900028
J	Weijzen, S; Rizzo, P; Braid, M; Vaishnav, R; Jonkheer, SM; Zlobin, A; Osborne, BA; Gottipati, S; Aster, JC; Hahn, WC; Rudolf, M; Siziopikou, K; Kast, WM; Miele, L				Weijzen, S; Rizzo, P; Braid, M; Vaishnav, R; Jonkheer, SM; Zlobin, A; Osborne, BA; Gottipati, S; Aster, JC; Hahn, WC; Rudolf, M; Siziopikou, K; Kast, WM; Miele, L			Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells	NATURE MEDICINE			English	Article							INTRACELLULAR DOMAIN; NUCLEAR ACCESS; EXPRESSION; DROSOPHILA; PATHWAY; DIFFERENTIATION; TRANSCRIPTION; INDUCTION; ALLELES; GENE	Truncated Notch receptors have transforming activity in vitro and in vivo. However, the role of wild-type Notch signaling in neoplastic transformation remains unclear. Ras signaling is deregulated in a large fraction of human malignancies and is a major target for the development of novel cancer treatments. We show that oncogenic Ras activates Notch signaling and that wildtype Notch-1 is necessary to maintain the neoplastic phenotype in Ras-transformed human cells in vitro and in vivo. Oncogenic Ras increases levels and activity of the intracellular form of wildtype Notch-1, and upregulates Notch ligand Delta-1 and also presenilin-1, a protein involved in Notch processing, through a p38-mediated pathway. These observations place Notch signaling among key downstream effectors of oncogenic Ras and suggest that it might be a novel therapeutic target.	Univ Illinois, Dept Biopharmaceut Sci & Canc Ctr, Chicago, IL 60607 USA; Loyola Univ, Canc Immunol Program, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA; Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA USA; Loyola Univ, Dept Pathol, Maywood, IL 60153 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Loyola University Chicago; University of Massachusetts System; University of Massachusetts Amherst; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Loyola University Chicago	Miele, L (corresponding author), Univ Illinois, Dept Biopharmaceut Sci & Canc Ctr, Chicago, IL 60607 USA.			Miele, Lucio/0000-0002-5853-7287; Kast, W Martin/0000-0003-2321-3159; rizzo, paola/0000-0001-7174-9674	NATIONAL CANCER INSTITUTE [R01CA078399, R01CA084065] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA/AI 78399, R01 CA 84065/01] Funding Source: Medline; PHS HHS [R01 A47922] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BOS JL, 1989, CANCER RES, V49, P4682; Callahan R, 2001, J MAMMARY GLAND BIOL, V6, P23, DOI 10.1023/A:1009512414430; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Carlesso N, 1999, BLOOD, V93, P838, DOI 10.1182/blood.V93.3.838.403k29_838_848; Carmena A, 2002, DEV BIOL, V244, P226, DOI 10.1006/dbio.2002.0606; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fitzgerald K, 2000, ONCOGENE, V19, P4191, DOI 10.1038/sj.onc.1203766; Garces C, 1997, J BIOL CHEM, V272, P29729, DOI 10.1074/jbc.272.47.29729; Gohring UJ, 1999, TUMOR BIOL, V20, P173, DOI 10.1159/000030061; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hoemann CD, 2000, MOL CELL BIOL, V20, P3831, DOI 10.1128/MCB.20.11.3831-3842.2000; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Jehn BM, 1999, J IMMUNOL, V162, P635; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Li LH, 1998, GENOMICS, V51, P45, DOI 10.1006/geno.1998.5330; Malaney S, 2001, J MAMMARY GLAND BIOL, V6, P101, DOI 10.1023/A:1009572700317; McLendon C, 2000, FASEB J, V14, P2383; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074-7613(00)80140-5; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Price JV, 1997, GENETICS, V147, P1139; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Tohda S, 2001, LEUKEMIA LYMPHOMA, V42, P467, DOI 10.3109/10428190109064603; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Yasutomo K, 2000, NATURE, V404, P506, DOI 10.1038/35006664; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zecchini V, 1999, CURR BIOL, V9, P460, DOI 10.1016/S0960-9822(99)80211-5; Zentrich E, 2002, J BIOL CHEM, V277, P4110, DOI 10.1074/jbc.M107824200	45	445	499	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2002	8	9					979	986		10.1038/nm754	http://dx.doi.org/10.1038/nm754			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12185362				2022-12-27	WOS:000177757900033
J	Kuperman, DA; Huang, XZ; Koth, LL; Chang, GH; Dolganov, GM; Zhu, Z; Elias, JA; Sheppard, D; Erle, DJ				Kuperman, DA; Huang, XZ; Koth, LL; Chang, GH; Dolganov, GM; Zhu, Z; Elias, JA; Sheppard, D; Erle, DJ			Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma	NATURE MEDICINE			English	Article							SIGNAL TRANSDUCER; MURINE MODEL; INFLAMMATION; EXPRESSION; MICE; LUNG; HYPERRESPONSIVENESS; RESPONSIVENESS; IL-13; GENE	Asthma is an increasingly common disease that remains poorly understood and difficult to manage. This disease is characterized by airway hyperreactivity (AHR, defined by exaggerated airflow obstruction in response to bronchoconstrictors), mucus overproduction and chronic eosinophilic inflammation(1). AHR and mucus overproduction are consistently linked to asthma symptoms and morbidity(2,3). Asthma is mediated by Th2 lymphocytes(4-7), which produce a limited repertoire of cytokines, including interleukin-4 (IL-4), IL-5, IL-9 and IL-13. Although each of these cytokines has been implicated in asthma(4,5,7-11), IL-13 is now thought to be especially critical. In animal models of allergic asthma, blockade of IL-13 markedly inhibits allergen-induced AHR, mucus production and eosinophilia(10,11). Furthermore, IL-13 delivery to the airway causes all of these effects(10,11). IL-13 is thus both necessary and sufficient for experimental models of asthma. However, the IL-13-responsive cells causing these effects have not been identified. Here we show that mice lacking signal transducer and activator of transcription 6 (STAT6) were protected from all pulmonary effects of IL-13. Reconstitution of STAT6 only in epithelial cells was sufficient for IL-13-induced AHR and mucus production in the absence of inflammation, fibrosis or other lung pathology. These results demonstrate the importance of direct effects of IL-13 on epithelial cells in causing two central features of asthma.	Univ Calif San Francisco, Sch Med, Dept Med, Lung Biol Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Program Immunol, San Francisco, CA USA; Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, New Haven, CT 06510 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Yale University	Erle, DJ (corresponding author), Univ Calif San Francisco, Sch Med, Dept Med, Lung Biol Ctr, San Francisco, CA 94143 USA.	erle@itsa.ucsf.edu		Erle, David/0000-0002-2171-0648				Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254, DOI 10.1165/ajrcmb.12.3.7873190; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Dolganov GM, 2001, GENOME RES, V11, P1473, DOI 10.1101/gr.191301; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haley KJ, 1998, AM J RESP CRIT CARE, V157, P1; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; LUKACS NW, 1994, AM J RESP CELL MOL, V10, P526, DOI 10.1165/ajrcmb.10.5.8179915; McLane MP, 1998, AM J RESP CELL MOL, V19, P713, DOI 10.1165/ajrcmb.19.5.3457; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; Mullings RE, 2001, J ALLERGY CLIN IMMUN, V108, P832, DOI 10.1067/mai.2001.119554; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517, DOI 10.1164/ajrccm.163.2.2004039; Richter A, 2001, AM J RESP CELL MOL, V25, P385, DOI 10.1165/ajrcmb.25.3.4437; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhu Z, 2002, J IMMUNOL, V168, P2953, DOI 10.4049/jimmunol.168.6.2953	26	706	758	0	57	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2002	8	8					885	889		10.1038/nm734	http://dx.doi.org/10.1038/nm734			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12091879				2022-12-27	WOS:000177200900036
J	Giordano, RJ; Cardo-Vila, M; Lahdenranta, J; Pasqualini, R; Arap, W				Giordano, RJ; Cardo-Vila, M; Lahdenranta, J; Pasqualini, R; Arap, W			Biopanning and rapid analysis of selective interactive ligands	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; HEMATOPOIETIC-CELLS; TRYPANOSOMA-CRUZI; PEPTIDES; BINDING; NEUROPILIN-1; RECEPTORS; LIBRARIES	Here we introduce a new approach for the screening, selection and sorting of cell-surface-binding peptides from phage libraries. Biopanning and rapid analysis of selective interactive ligands (termed BRASIL) is based on differential centrifugation in which a cell suspension incubated with phage in an aqueous upper phase is centrifuged through a non-miscible organic lower phase. This single-step organic phase separation is faster, more sensitive and more specific than current methods that rely on washing steps or limiting dilution. As a proof-of-principle, we screened human endothelial cells stimulated with vascular endothelial growth factor (VEGF) and constructed a peptide-based ligand-receptor map of the VEGF family. Next, we validated the motif PQPRPL as a novel chimeric ligand mimic that binds specifically to VEGF receptor-1 and to neuropilin-1. BRASIL may prove itself a superior method for probing target cell surfaces with a broad range of potential applications.	Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Pasqualini, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rpasqual@notes.mdacc.tmc.edu; warap@notes.mdacc.tmc.edu	Giordano, Ricardo/A-2074-2010	Giordano, Ricardo/0000-0001-8116-6771	NCI NIH HHS [CA9081001, CA90270, CA8297601] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA090810, P50CA090270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Brown KC, 2000, CURR OPIN CHEM BIOL, V4, P16, DOI 10.1016/S1367-5931(99)00045-9; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; GIORDANO R, 1994, MOL BIOCHEM PARASIT, V65, P85, DOI 10.1016/0166-6851(94)90117-1; HATZFELD JA, 1982, P NATL ACAD SCI-BIOL, V79, P6280, DOI 10.1073/pnas.79.20.6280; Koivunen E, 1999, METH MOL B, V129, P3; Koivunen E, 2001, J CELL BIOL, V153, P905, DOI 10.1083/jcb.153.5.905; Kolonin M, 2001, CURR OPIN CHEM BIOL, V5, P308, DOI 10.1016/S1367-5931(00)00207-6; LEVESQUE JP, 1985, EXP CELL RES, V156, P558, DOI 10.1016/0014-4827(85)90563-4; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Olofsson B, 1999, CURR OPIN BIOTECH, V10, P528, DOI 10.1016/S0958-1669(99)00024-5; OUAISSI MA, 1984, NATURE, V308, P380, DOI 10.1038/308380a0; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; PASQUALINI R, 2000, PHAGE DISPLAY LAB MA, P1; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6	16	215	244	0	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2001	7	11					1249	1253		10.1038/nm1101-1249	http://dx.doi.org/10.1038/nm1101-1249			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689892				2022-12-27	WOS:000172054100035
J	Partida-Sanchez, S; Cockayne, DA; Monard, S; Jacobson, EL; Oppenheimer, N; Garvy, B; Kusser, K; Goodrich, S; Howard, M; Harmsen, A; Randall, TD; Lund, FE				Partida-Sanchez, S; Cockayne, DA; Monard, S; Jacobson, EL; Oppenheimer, N; Garvy, B; Kusser, K; Goodrich, S; Howard, M; Harmsen, A; Randall, TD; Lund, FE			Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo	NATURE MEDICINE			English	Article							CA2+ INFLUX; RECEPTOR; MICE; CYCLASE; 2ND-MESSENGER; LYMPHOCYTES; METABOLITE; ACTIVATION; TISSUES; ENZYMES	Cyclic ADP-ribose is believed to be an important calcium-mobilizing second messenger in invertebrate, mammalian and plant cells. CD38, the best-characterized mammalian ADP-ribosyl cyclase, is postulated to be an important source of cyclic ADP-ribose in vivo. Using CD38-deficient mice, we demonstrate that the loss of CD38 renders mice susceptible to bacterial infections due to an inability of CD38-deficient neutrophils to directionally migrate to the site of infection. Furthermore, we show that cyclic ADP-ribose can directly induce intracellular Cal release in neutrophils and is required for sustained extracellular Ca++ influx in neutrophils that have been stimulated by the bacterial chemoattractant, formyl-methionyl-leucyl-phenylalanine (fMLP). Finally, we demonstrate that neutrophil chemotaxis to fMLP is dependent on Cal mobilization mediated by cyclic ADP-ribose. Thus, CD38 controls neutrophil chemotaxis to bacterial chemoattractants through its production of cyclic ADP-ribose, and acts as a critical regulator of inflammation and innate immune responses.	Trudeau Inst Inc, Saranac Lake, NY 12983 USA; Roche Biosci, Neurobiol Unit, Palo Alto, CA USA; Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85721 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Kentucky, Dept Internal Med, Lexington, KY USA; Chemocentryx, San Carlos, CA USA; Montana State Univ, Dept Vet Mol Biol, Bozeman, MT 59717 USA	Trudeau Institute; Roche Holding; University of Arizona; Arizona Center Cancer Care; University of Arizona; University of California System; University of California San Francisco; University of Kentucky; Montana State University System; Montana State University Bozeman	Lund, FE (corresponding author), Trudeau Inst Inc, POB 59, Saranac Lake, NY 12983 USA.		Partida-Sanchez, Santiago/B-7523-2008	Partida-Sanchez, Santiago/0000-0003-2996-9440				ABDALLAH MA, 1975, EUR J BIOCHEM, V50, P475, DOI 10.1111/j.1432-1033.1975.tb09885.x; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Cockayne DA, 1998, BLOOD, V92, P1324, DOI 10.1182/blood.V92.4.1324.416k26_1324_1333; DEMAUREX N, 1994, BIOCHEM J, V297, P595, DOI 10.1042/bj2970595; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; Favre CJ, 1996, J LAB CLIN MED, V128, P19, DOI 10.1016/S0022-2143(96)90110-9; Fernandez JE, 1998, J BIOL REG HOMEOS AG, V12, P81; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Gao JL, 1999, J EXP MED, V189, P657, DOI 10.1084/jem.189.4.657; Garvy BA, 1996, INFLAMMATION, V20, P499, DOI 10.1007/BF01487042; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; Guse AH, 1999, CELL SIGNAL, V11, P309, DOI 10.1016/S0898-6568(99)00004-2; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HANSEN PR, 1995, CIRCULATION, V91, P1872, DOI 10.1161/01.CIR.91.6.1872; Higashida H, 2001, J NEUROCHEM, V76, P321, DOI 10.1046/j.1471-4159.2001.00082.x; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; HUB E, 1996, CHEMOATTRACTANT LIGA, P301; KRAUSE KH, 1989, CELL CALCIUM, V10, P351, DOI 10.1016/0143-4160(89)90061-4; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 1997, ADV EXP MED BIOL, V419, P411; Lentsch AB, 2000, J PATHOL, V190, P343; LEW DP, 1989, EUR J CLIN INVEST, V19, P338, DOI 10.1111/j.1365-2362.1989.tb00240.x; Lund FE, 1998, IMMUNOL REV, V161, P79, DOI 10.1111/j.1600-065X.1998.tb01573.x; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; MERRITT JE, 1991, CELL SIGNAL, V3, P73, DOI 10.1016/0898-6568(91)90010-R; MESZAROS L, 1993, NATURE, V354, P76; Murphy P.M., 1996, CHEMOATTRACTANT LIGA, P269; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; PILLINGER MH, 1995, RHEUM DIS CLIN N AM, V21, P691; PRENTKI M, 1984, J BIOL CHEM, V259, P3777; ROTNES JS, 1992, CELL CALCIUM, V13, P487, DOI 10.1016/0143-4160(92)90017-M; Schorr W, 1999, EUR J IMMUNOL, V29, P897, DOI 10.1002/(SICI)1521-4141(199903)29:03<897::AID-IMMU897>3.3.CO;2-X; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; Vu CQ, 1997, BIOCHEM BIOPH RES CO, V236, P723, DOI 10.1006/bbrc.1997.7038; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596	41	358	371	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2001	7	11					1209	1216		10.1038/nm1101-1209	http://dx.doi.org/10.1038/nm1101-1209			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689885				2022-12-27	WOS:000172054100028
J	Homann, D; Teyton, L; Oldstone, MBA				Homann, D; Teyton, L; Oldstone, MBA			Differential regulation of antiviral T-cell immunity results in stable CD8(+) but declining CD4(+) T-cell memory	NATURE MEDICINE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; QUANTITATIVE-ANALYSIS; VIRAL-INFECTION; DEFICIENT MICE; B-CELLS; RESPONSES; IMMUNOTHERAPY; PERSISTENCE; ACTIVATION; EXPRESSION	Emerging evidence indicates that CD8(+) and CD4(+) T-cell immunity is differentially regulated. Here we have delineated differences and commonalities among antiviral T-cell responses by enumeration and functional profiling of eight specific CD8(+) and CD4(+) T-cell populations during primary, memory and recall responses. A high degree of coordinate regulation among all specific T-cell populations stood out against an approximately 20-fold lower peak expansion and prolonged contraction phase of specific CD4(+) T-cell populations. Surprisingly, although CD8(+) T-cell memory was stably maintained for life, levels of specific CD4(+) memory T cells gradually declined. However, this decay, which seemed to result from less efficient rescue from apoptosis, did not affect functionality of surviving virus-specific CD4(+) T cells. Our results indicate that CD4(+) T-cell memory might become limiting under physiological conditions and that conditions precipitating CD4(+) T-cell loss might compromise protective immunity even in the presence of unimpaired CD8+ T-cell responses.	Scripps Res Inst, Dept Neuropharmacol, Div Virol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA USA	Scripps Research Institute; Scripps Research Institute	Homann, D (corresponding author), Scripps Res Inst, Dept Neuropharmacol, Div Virol, La Jolla, CA 92037 USA.	dhomann@scripps.edu		Homann, Dirk/0000-0002-7622-5754	NIAID NIH HHS [AI-09484] Funding Source: Medline; NIA NIH HHS [AG-00080, AG-04342] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009484, R37AI009484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004342] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Belz GT, 1998, P NATL ACAD SCI USA, V95, P13812, DOI 10.1073/pnas.95.23.13812; Berger DP, 2000, VIROLOGY, V266, P257, DOI 10.1006/viro.1999.0074; Beverley PCL, 2000, PHILOS T R SOC B, V355, P401, DOI 10.1098/rstb.2000.0580; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Christensen JP, 1999, J VIROL, V73, P4279, DOI 10.1128/JVI.73.5.4279-4283.1999; Ciurea A, 1999, P NATL ACAD SCI USA, V96, P11964, DOI 10.1073/pnas.96.21.11964; Doherty PC, 2000, ANNU REV IMMUNOL, V18, P561, DOI 10.1146/annurev.immunol.18.1.561; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Ferlin W, 2000, CURR OPIN IMMUNOL, V12, P670, DOI 10.1016/S0952-7915(00)00161-8; Garcia S, 1999, IMMUNITY, V11, P163, DOI 10.1016/S1074-7613(00)80091-6; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; Grayson JM, 2000, J IMMUNOL, V164, P3950, DOI 10.4049/jimmunol.164.8.3950; Guidotti LG, 1999, CURR OPIN MICROBIOL, V2, P388; HOBBS MV, 1993, J IMMUNOL, V150, P3602; Homann D, 1998, J VIROL, V72, P9208, DOI 10.1128/JVI.72.11.9208-9216.1998; HOMANN D, IN PRESS CURR TOP MI; HOU S, 1994, NATURE, V369, P652, DOI 10.1038/369652a0; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; Kamperschroer C, 1999, CELL IMMUNOL, V193, P134, DOI 10.1006/cimm.1999.1458; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; Maini MK, 1999, IMMUNOL TODAY, V20, P262, DOI 10.1016/S0167-5699(99)01472-3; Marrack P, 2000, NAT IMMUNOL, V1, P107, DOI 10.1038/77778; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; Mehal WZ, 1999, J IMMUNOL, V163, P3202; Murali-Krishna K, 1999, SCIENCE, V286, P1377, DOI 10.1126/science.286.5443.1377; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; OLDSTONE MBA, 1987, CURR TOP MICROBIOL, V134, P211; Opferman JT, 1999, SCIENCE, V283, P1745, DOI 10.1126/science.283.5408.1745; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; Rentenaar RJ, 2000, J CLIN INVEST, V105, P541, DOI 10.1172/JCI8229; Slifka MK, 2000, J IMMUNOL, V164, P208, DOI 10.4049/jimmunol.164.1.208; Stratmann T, 2000, J IMMUNOL, V165, P3214, DOI 10.4049/jimmunol.165.6.3214; Swain SL, 1999, SCIENCE, V286, P1381, DOI 10.1126/science.286.5443.1381; Topham DJ, 1996, J IMMUNOL, V157, P2947; Topham DJ, 1998, J IMMUNOL, V161, P4530; van Essen D, 2000, PHILOS T ROY SOC B, V355, P351, DOI 10.1098/rstb.2000.0572; Varga SM, 2000, J VIROL, V74, P4429, DOI 10.1128/JVI.74.9.4429-4432.2000; Varga SM, 1998, J IMMUNOL, V161, P367; Welsh RM, 2001, J EXP MED, V193, pF19, DOI 10.1084/jem.193.5.F19; Whitmire JK, 2000, CURR OPIN IMMUNOL, V12, P448, DOI 10.1016/S0952-7915(00)00119-9; Whitmire JK, 1998, J VIROL, V72, P8281, DOI 10.1128/JVI.72.10.8281-8288.1998; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	45	464	470	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2001	7	8					913	919		10.1038/90950	http://dx.doi.org/10.1038/90950			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479623				2022-12-27	WOS:000171740400028
J	Batkai, S; Jarat, Z; Wagner, JA; Goparaju, SK; Varga, K; Liu, J; Wang, L; Mirshahi, F; Khanolkar, AD; Makriyannis, A; Urbaschek, R; Garcia, N; Sanyal, AJ; Kunos, G				Batkai, S; Jarat, Z; Wagner, JA; Goparaju, SK; Varga, K; Liu, J; Wang, L; Mirshahi, F; Khanolkar, AD; Makriyannis, A; Urbaschek, R; Garcia, N; Sanyal, AJ; Kunos, G			Endocannabinoids acting at vascular CB, receptors mediate the vasodilated state in advanced liver cirrhosis	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; HYPERDYNAMIC CIRCULATION; CANNABINOID RECEPTORS; PORTAL-HYPERTENSION; ENDOTOXIN LEVELS; WATER-RETENTION; RATS; ANTAGONIST; RESISTANCE; SODIUM	Advanced cirrhosis is associated with generalized vasodilation of unknown origin, which contributes to mortality. Cirrhotic patients are endotoxemic, and activation of Vascular cannabinoid CB1 receptors has been implicated in endotoxin-induced hypotension. Here we show that rats with biliary cirrhosis have low blood pressure, which is elevated by the CB1 receptor antagonist SR141716A. The low blood pressure of rats with CCl4-induced cirrhosis was similarly reversed by SR141716A, which also reduced the elevated mesenteric blood flow and portal pressure. Monocytes from cirrhotic but not control patients or rats elicited SR141716A-sensitive hypotension in normal recipient rats and showed significantly elevated levels of anandamide. Compared with non-cirrhotic controls, in cirrhotic human livers there was a three-fold increase in CB1 receptors on isolated vascular endothelial cells. These results implicate anandamide and vascular CB1 receptors in the vasodilated state in advanced cirrhosis and indicate a novel approach for its management.	NIAAA, NIH, Bethesda, MD USA; Virginia Commonwealth Univ, Dept Med, Richmond, VA 23298 USA; Univ Connecticut, Sch Pharm, Dept Pharmaceut Sci, Storrs, CT USA; Heidelberg Univ, Klinikum Mannheim, Inst Med Microbiol & Hyg, Mannheim, Germany	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Virginia Commonwealth University; University of Connecticut; Ruprecht Karls University Heidelberg	Kunos, G (corresponding author), NIAAA, NIH, Bethesda, MD USA.	gkunos@mail.nih.gov	Goparaju, Sravan/H-3422-2011; Batkai, Sandor/H-7983-2014; Batkai, Sandor/G-3889-2010		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000065] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000351] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR-00065-38] Funding Source: Medline; NHLBI NIH HHS [HL-59257] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARROYO V, 1993, J HEPATOL, V17, pS24, DOI 10.1016/S0168-8278(05)80451-9; BILLINGER TV, 1998, INT J CARDIOL S1, V64, pS15; Bosch Jaume, 1994, P1343; CAHILL PA, 1995, HEPATOLOGY, V22, P598, DOI 10.1016/0270-9139(95)90585-5; Chan CC, 1997, SCAND J GASTROENTERO, V32, P942, DOI 10.3109/00365529709011206; Chu CJ, 1997, CLIN SCI, V93, P219, DOI 10.1042/cs0930219; Deutsch DG, 1997, J CLIN INVEST, V100, P1538, DOI 10.1172/JCI119677; FERNANDEZ M, 1995, GASTROENTEROLOGY, V108, P1487, DOI 10.1016/0016-5085(95)90698-3; Garcia N, 2001, AM J PHYSIOL-GASTR L, V280, pG14, DOI 10.1152/ajpgi.2001.280.1.G14; Gatley SJ, 1997, LIFE SCI, V61, pPL191, DOI 10.1016/S0024-3205(97)00690-5; Gebremedhin D, 1999, AM J PHYSIOL-HEART C, V276, pH2085, DOI 10.1152/ajpheart.1999.276.6.H2085; Genecin Paul, 1994, P1327; GINES P, 1987, HEPATOLOGY, V7, P122, DOI 10.1002/hep.1840070124; Heller S, 1999, CRIT CARE MED, V27, P756, DOI 10.1097/00003246-199904000-00031; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KROEGER RJ, 1985, HEPATOLOGY, V5, P97, DOI 10.1002/hep.1840050120; Lake KD, 1997, J PHARMACOL EXP THER, V281, P1030; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; LIN RS, 1995, J HEPATOL, V22, P165, DOI 10.1016/0168-8278(95)80424-2; Liu J, 2000, BIOCHEM J, V346, P835, DOI 10.1042/0264-6021:3460835; LUMSDEN AB, 1988, HEPATOLOGY, V8, P232, DOI 10.1002/hep.1840080207; Martin PY, 1998, NEW ENGL J MED, V339, P533, DOI 10.1056/NEJM199808203390807; Martin PY, 1996, AM J PHYSIOL-RENAL, V270, pF494, DOI 10.1152/ajprenal.1996.270.3.F494; Mathie RT, 1996, HEPATOLOGY, V23, P130; McCuskey RS, 1996, CARDIOVASC RES, V32, P752, DOI 10.1016/S0008-6363(96)00113-7; Pilette C, 1996, J GASTROEN HEPATOL, V11, P1, DOI 10.1111/j.1440-1746.1996.tb00002.x; Piscaglia F, 1997, EUR J GASTROEN HEPAT, V9, P799, DOI 10.1097/00042737-199708000-00012; PROCTOR E, 1982, GASTROENTEROLOGY, V83, P1183; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; ROEY G, 1997, CLIN SCI, V93, P549; Ryan J, 1996, CLIN SCI, V91, P23, DOI 10.1042/cs0910023; Sanyal AJ, 1998, LAB INVEST, V78, P1469; Sarela AI, 1999, GUT, V44, P749, DOI 10.1136/gut.44.5.749; SCHRIER RW, 1988, HEPATOLOGY, V8, P1151, DOI 10.1002/hep.1840080532; SIEBER CC, 1993, GASTROENTEROLOGY, V104, P1750, DOI 10.1016/0016-5085(93)90655-V; SIKULER E, 1986, AM J PHYSIOL, V250, pG205, DOI 10.1152/ajpgi.1986.250.2.G205; Sugiura T, 1998, BIOCHEM BIOPH RES CO, V243, P838, DOI 10.1006/bbrc.1998.8187; VALLANCE P, 1991, LANCET, V337, P776, DOI 10.1016/0140-6736(91)91384-7; Varga K, 1998, FASEB J, V12, P1035, DOI 10.1096/fasebj.12.11.1035; VARGA K, 1995, EUR J PHARMACOL, V278, P279, DOI 10.1016/0014-2999(95)00181-J; Wagner JA, 1997, NATURE, V390, P518, DOI 10.1038/37371; Wiest R, 1999, J CLIN INVEST, V104, P1223, DOI 10.1172/JCI7458	43	277	289	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2001	7	7					827	832		10.1038/89953	http://dx.doi.org/10.1038/89953			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433348				2022-12-27	WOS:000169808600035
J	Griffin, E; Re, A; Hamel, N; Fu, CZ; Bush, H; McCaffrey, T; Asch, AS				Griffin, E; Re, A; Hamel, N; Fu, CZ; Bush, H; McCaffrey, T; Asch, AS			A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation	NATURE MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; SCAVENGER RECEPTOR CD36; GLYCATION END-PRODUCTS; OPEN READING FRAMES; PPAR-GAMMA; MESSENGER-RNA; FATTY-ACID; SECONDARY STRUCTURE; INSULIN-RESISTANCE; OXIDIZED LDL	Both the risk and the rate of development of atherosclerosis are increased in diabetics, but the mechanisms involved are unknown. Here we report a glucose-mediated increase in CD36 mRNA translation efficiency that results in increased expression of the macrophage scavenger receptor CD36. Expression of CD36 was increased in endarterectomy lesions from patients with a history of hyperglycemia. Macrophages that were differentiated from human peripheral blood monocytes in the presence of high glucose concentrations showed increased expression of cell-surface CD36 secondary to an increase in translational efficiency of CD36 mRNA. We obtained similar data from primary cells isolated from human vascular lesions, and we found that glucose sensitivity is a function of ribosomal reinitiation following translation of an upstream open reading frame (uORF). Increased translation of macrophage CD36 transcript under high glucose conditions provides a mechanism for accelerated atherosclerosis in diabetics.	Cornell Univ, Weill Med Coll, New York, NY 10021 USA	Cornell University	Asch, AS (corresponding author), Cornell Univ, Weill Med Coll, New York, NY 10021 USA.	asasch@med.cornell.edu		Re, Alessandro/0000-0003-1156-6395	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048698] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48698] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Ashe MP, 2000, MOL BIOL CELL, V11, P833, DOI 10.1091/mbc.11.3.833; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; BEAUMONT C, 1995, NAT GENET, V11, P444, DOI 10.1038/ng1295-444; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Davuluri RV, 2000, GENOME RES, V10, P1807, DOI 10.1101/gr.GR-1460R; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; GREENWALT DE, 1995, J CLIN INVEST, V96, P1382, DOI 10.1172/JCI118173; GUEST PC, 1991, BIOCHEM J, V274, P73, DOI 10.1042/bj2740073; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huh HY, 1996, BLOOD, V87, P2020; HUNT JV, 1994, BIOCHEM J, V300, P243, DOI 10.1042/bj3000243; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Laakso M, 1996, ANN MED, V28, P415, DOI 10.3109/07853899608999101; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; MACH M, 1986, J BIOL CHEM, V261, P1697; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; McCaffrey TA, 1995, J CLIN INVEST, V96, P2667, DOI 10.1172/JCI118333; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Schmidt AM, 1999, CIRC RES, V84, P489, DOI 10.1161/01.RES.84.5.489; SCHMIDT AM, 1996, DIABETES, V45, P77; SEMENKOVICH CF, 1995, J LIPID RES, V36, P1507; Semenkovich CF, 1997, DIABETES, V46, P327, DOI 10.2337/diabetes.46.3.327; Skelly RH, 1996, DIABETES, V45, P37, DOI 10.2337/diabetes.45.1.37; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; VLASSARA H, 1997, DIABETES S2, V46, P19; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	44	201	221	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					840	846		10.1038/89969	http://dx.doi.org/10.1038/89969			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433350				2022-12-27	WOS:000169808600037
J	Springall, T; Sheerin, NS; Abe, K; Holers, VM; Wan, H; Sacks, SH				Springall, T; Sheerin, NS; Abe, K; Holers, VM; Wan, H; Sacks, SH			Epithelial secretion of C3 promotes colonization of the upper urinary tract by Escherichia coli	NATURE MEDICINE			English	Article							COMPLEMENT COMPONENT C3; EXPERIMENTAL PYELONEPHRITIS; MEDIATES STIMULATION; HUMAN-KIDNEY; CELLS; EXPRESSION; MICE; INFECTION; GLOMERULONEPHRITIS; BIOSYNTHESIS	To assess the role of complement in renal infection, we studied a model of Escherichia coli-induced pyelonephritis in mice deficient in complement components C3 and C4. Renal infection occurred less frequently in C3- and C4-deficient mice compared with wild-type mice. In vitro, renal epithelial cells internalized fewer bacteria in the absence of C3 or in the presence of blockade of C3 bound to the bacteria. Moreover, upregulation of epithelial C3 production by stimulation with lipopolysaccharide enhanced bacterial internalization. Here we provide evidence that uropathogenic E, coli might use host C3 to invade the renal epithelium and that local complement production is sufficient for the bacteria to achieve this effect.	Kings Coll London, Dept Nephrol & Transplantat, Guys Hosp, GKT, London WC2R 2LS, England; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA; Kings Coll London, Dept Cell & Mol Pathol, St Thomas Hosp, GKT,St Johns Inst Dermatol, London, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Sheerin, NS (corresponding author), Kings Coll London, Dept Nephrol & Transplantat, Guys Hosp, GKT, London WC2R 2LS, England.	neil.sheerin@kcl.ac.uk		Sacks, Steven/0000-0001-6361-9095				ANDREWS PA, 1995, EUR J IMMUNOL, V25, P1087, DOI 10.1002/eji.1830250434; AULT BH, 1994, IMMUNOLOGY, V81, P655; BIANCONE L, 1994, KIDNEY INT, V45, P451, DOI 10.1038/ki.1994.59; BOTTO M, 1992, J IMMUNOL, V149, P1348; BROOIMANS RA, 1991, J CLIN INVEST, V88, P379, DOI 10.1172/JCI115314; Connell H, 1997, Adv Dent Res, V11, P50; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; DASILVA RP, 1989, J IMMUNOL, V143, P617; DETRISAC CJ, 1984, KIDNEY INT, V25, P383, DOI 10.1038/ki.1984.28; Ernst JD, 1998, INFECT IMMUN, V66, P1277, DOI 10.1128/IAI.66.4.1277-1281.1998; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; FALKOW S, 1987, REV INFECT DIS, V9, pS450; Fischer MB, 1996, J IMMUNOL, V157, P549; GLAUSER MP, 1978, J CLIN INVEST, V61, P403, DOI 10.1172/JCI108951; HAGBERG L, 1983, INFECT IMMUN, V40, P273, DOI 10.1128/IAI.40.1.273-283.1983; Hori Y, 1999, KIDNEY INT, V56, P2096, DOI 10.1046/j.1523-1755.1999.00765.x; Ichinose H, 1996, CLIN EXP IMMUNOL, V103, P125; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; IVANYI B, 1985, VIRCHOWS ARCH B, V50, P59; KUNIN CM, 1968, NEW ENGL J MED, V278, P635, DOI 10.1056/NEJM196803212781201; Kunin CM, 1994, CLIN INFECT DIS, V18, P11; Li WX, 1999, MICROBIOL IMMUNOL, V43, P585, DOI 10.1111/j.1348-0421.1999.tb02445.x; MCDOUGAL JS, 1986, J IMMUNOL, V137, P2937; MILLER TE, 1978, CLIN EXP IMMUNOL, V33, P115; Morita Y, 1997, J AM SOC NEPHROL, V8, P1363; OHANLEY P, 1985, J CLIN INVEST, V75, P347, DOI 10.1172/JCI111707; Palmer LM, 1997, INFECT IMMUN, V65, P2570, DOI 10.1128/IAI.65.7.2570-2575.1997; Quigg RJ, 1998, J IMMUNOL, V160, P4553; QUIGG RJ, 1997, KIDNEY INT, V53, P1124; Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3; ROBERTS JA, 1983, J UROLOGY, V129, P193, DOI 10.1016/S0022-5347(17)51981-3; SEELEN MAJ, 1993, KIDNEY INT, V44, P50, DOI 10.1038/ki.1993.212; Sheerin NS, 1997, CLIN EXP IMMUNOL, V110, P403, DOI 10.1046/j.1365-2249.1997.4261438.x; SHIMAMURA T, 1981, EXP MOL PATHOL, V34, P34, DOI 10.1016/0014-4800(81)90033-2; STAMM WE, 1993, NEW ENGL J MED, V329, P1328, DOI 10.1056/NEJM199310283291808; Tang S, 1999, J IMMUNOL, V162, P4336; TAUB M, 1980, J CELL PHYSIOL, V105, P369, DOI 10.1002/jcp.1041050220; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; VANDERBIEST I, 1994, KIDNEY INT, V45, P85, DOI 10.1038/ki.1994.10; WALKER DG, 1995, J NEUROSCI RES, V40, P478, DOI 10.1002/jnr.490400407; WELCH TR, 1993, J CLIN INVEST, V92, P1451, DOI 10.1172/JCI116722; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490	42	68	70	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2001	7	7					801	806		10.1038/89923	http://dx.doi.org/10.1038/89923			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433344				2022-12-27	WOS:000169808600031
J	Wyss-Coray, T; Lin, C; Yan, FR; Yu, GQ; Rohde, M; McConlogue, L; Masliah, E; Mucke, L				Wyss-Coray, T; Lin, C; Yan, FR; Yu, GQ; Rohde, M; McConlogue, L; Masliah, E; Mucke, L			TGF-beta 1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; DISEASE-LIKE PATHOLOGY; E EPSILON-4 ALLELE; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; APOLIPOPROTEIN-E; MOUSE MODEL; TRANSFORMING GROWTH-FACTOR-BETA-1; CELL BIOLOGY; HEAD-INJURY	Abnormal accumulation of the amyloid-beta peptide (A beta) in the brain appears crucial to pathogenesis in all forms of Alzheimer disease (AD), but the underlying mechanisms in the sporadic forms of AD remain unknown. Transforming growth factor beta1 (TGF-beta1), a key regulator of the brain's responses to injury and inflammation, has been implicated in A beta Delta deposition in vivo. Here we demonstrate that a modest increase in astroglial TGF-beta1 production in aged transgenic mice expressing the human beta -amyloid precursor protein (hAPP) results in a three-fold reduction in the number of parenchymal amyloid plaques, a 50% reduction in the overall A beta load in the hippocampus and neocortex, and a decrease in the number of dystrophic neurites. In mice expressing hAPP and TGF-beta1, A beta accumulated substantially in cerebral blood vessels, but not in parenchymal plaques. In human cases of AD, A beta immunoreactivity associated with parenchymal plaques was inversely correlated with A beta in blood vessels and cortical TGF-beta1 mRNA levels. The reduction of parenchymal plaques in hAPP/TGF-beta1 mice was associated with a strong activation of microglia and an increase in inflammatory mediators. Recombinant TGF-beta1 stimulated A beta clearance in microglial cell cultures. These results demonstrate that TGF-beta1 is an important modifier of amyloid deposition in vivo and indicate that TGF-beta1 might promote microglial processes that inhibit the accumulation of A beta in the brain parenchyma.	Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA; Elan Pharmaceut, S San Francisco, CA USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Diego; University of California System; University of California San Diego	Wyss-Coray, T (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94143 USA.		Wyss-Coray, Tony/AAF-3380-2019	Wyss-Coray, Tony/0000-0001-5893-0831	NIA NIH HHS [AG-11385, AG-51131, AG-15871, AG-10689] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG011385, R01AG015871, R01AG010689, R01AG011385] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Border WA, 1997, KIDNEY INT, V51, P1388, DOI 10.1038/ki.1997.190; Calhoun ME, 1999, P NATL ACAD SCI USA, V96, P14088, DOI 10.1073/pnas.96.24.14088; FINCH CE, 1993, J CELL BIOCHEM, V53, P314, DOI 10.1002/jcb.240530408; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; Frautschy SA, 1996, NEUROBIOL AGING, V17, P311, DOI 10.1016/0197-4580(95)02073-X; FRAUTSCHY SA, 1992, AM J PATHOL, V140, P1389; GALBREATH E, 1995, J NEUROPATH EXP NEUR, V54, P339, DOI 10.1097/00005072-199505000-00007; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Giulian D, 1999, AM J HUM GENET, V65, P13, DOI 10.1086/302477; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Holtzman DM, 1999, J CLIN INVEST, V103, pR15, DOI 10.1172/JCI6179; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; KISILEVSKY R, 1994, MOL NEUROBIOL, V9, P23, DOI 10.1007/BF02816101; KUO YM, IN PRESS J BIOL CHEM; Mann DMA, 1996, AM J PATHOL, V148, P1257; Masliah E, 1996, J NEUROSCI, V16, P5795; McGeer PL, 1999, J LEUKOCYTE BIOL, V65, P409, DOI 10.1002/jlb.65.4.409; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Olichney JM, 1996, NEUROLOGY, V47, P190, DOI 10.1212/WNL.47.1.190; Paxinos G, 1995, RAT NERVOUS SYSTEM, V2nd; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; TERRY R, 1999, ALZHEIMER DIS; Verbeek MM, 1998, ACTA NEUROPATHOL, V96, P628, DOI 10.1007/s004010050944; WAHL SM, 1992, J CLIN IMMUNOL, V12, P61, DOI 10.1007/BF00918135; Weller RO, 1998, AM J PATHOL, V153, P725, DOI 10.1016/S0002-9440(10)65616-7; Wyss-Coray T, 2000, AM J PATHOL, V156, P139, DOI 10.1016/S0002-9440(10)64713-X; WyssCoray T, 1997, NATURE, V389, P603, DOI 10.1038/39321; WYSSCORAY T, 1995, AM J PATHOL, V147, P53; WyssCoray T, 1997, J NEUROIMMUNOL, V77, P45, DOI 10.1016/S0165-5728(97)00049-0; Yan SD, 1999, AM J PATHOL, V155, P1403, DOI 10.1016/S0002-9440(10)65452-1; YAO J, 1990, J NEUROSCI RES, V27, P36, DOI 10.1002/jnr.490270106; Zlokovic BV, 1996, LIFE SCI, V59, P1483, DOI 10.1016/0024-3205(96)00310-4	44	478	500	0	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					612	618		10.1038/87945	http://dx.doi.org/10.1038/87945			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329064				2022-12-27	WOS:000169961100042
J	Sun, YH; Bakshi, S; Chalmers, R; Tang, CM				Sun, YH; Bakshi, S; Chalmers, R; Tang, CM			Functional genomics of Neisseria meningitidis pathogenesis	NATURE MEDICINE			English	Article							SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; ANTIBODIES; STRAINS	The pathogenic bacterium Neisseria meningitidis is an important cause of septicemia and meningitis, especially in childhood(1). The establishment and maintenance of bacteremic infection is a prerequisite for all the pathological sequelae of meningococcal infection. To further understand the genetic basis of this essential step in pathogenesis, we analyzed a library of 2,850 insertional mutants of N. meningitidis for their capacity to cause systemic infection in an infant rat model. The library was constructed by in vitro modification of Neisseria genomic DNA with the purified components of Tn10 transposition(2). We identified 73 genes in the N. meningitidis genome that are essential for bacteremic disease. Eight insertions were in genes encoding known pathogenicity factors. Involvement of the remaining 65 genes in meningocoocal pathogenesis has not been demonstrated previously, and the identification of these genes provides insights into the pathogenic mechanisms that underlie meningococcal infection. Our results provide a genome-wide analysis of the attributes of N, meningitidis required for disseminated infection, and may lead to new interventions to prevent and treat meningococcal infection.	Univ Oxford, John Radcliffe Hosp, Univ Dept Paediat, Oxford OX3 9DU, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford; University of Oxford	Tang, CM (corresponding author), Univ Oxford, John Radcliffe Hosp, Univ Dept Paediat, Oxford OX3 9DU, England.			chalmers, ronald/0000-0002-1395-7173				AlaAldeen DAA, 1996, VACCINE, V14, P49, DOI 10.1016/0264-410X(95)00136-O; CATLIN BW, 1960, J BACTERIOL, V79, P579, DOI 10.1128/JB.79.4.579-590.1960; CHALMERS RM, 1994, J BIOL CHEM, V269, P8029; Feavers IM, 2000, NATURE, V404, P451, DOI 10.1038/35006546; Granoff DM, 1998, J IMMUNOL, V160, P5028; Hajnsdorf E, 2000, P NATL ACAD SCI USA, V97, P1501, DOI 10.1073/pnas.040549897; Hammerschmidt S, 1996, MOL MICROBIOL, V20, P1211, DOI 10.1111/j.1365-2958.1996.tb02641.x; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; Hinton JCD, 1997, MOL MICROBIOL, V26, P417, DOI 10.1046/j.1365-2958.1997.6371988.x; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; LAVITOLA A, 1992, RES MICROBIOL, V143, P295, DOI 10.1016/0923-2508(92)90021-F; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; Parkhill J, 2000, NATURE, V404, P502, DOI 10.1038/35006655; PAWLOWSKI K, 1991, MOL GEN GENET, V231, P124, DOI 10.1007/BF00293830; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; Plested JS, 1999, INFECT IMMUN, V67, P5417, DOI 10.1128/IAI.67.10.5417-5426.1999; Ramsay M, 1997, COMMUN DIS REP CDR R, V7, pR49; Tacket CO, 1997, INFECT IMMUN, V65, P452, DOI 10.1128/IAI.65.2.452-456.1997; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; VIRJI M, 1991, MOL MICROBIOL, V5, P1831, DOI 10.1111/j.1365-2958.1991.tb00807.x	20	170	179	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1269	1273		10.1038/81380	http://dx.doi.org/10.1038/81380			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062540	Bronze			2022-12-27	WOS:000165114800036
J	Sano, M; Abdellatif, M; Oh, H; Xie, M; Bagella, L; Giordano, A; Michael, LH; DeMayo, FJ; Schneider, MD				Sano, M; Abdellatif, M; Oh, H; Xie, M; Bagella, L; Giordano, A; Michael, LH; DeMayo, FJ; Schneider, MD			Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy	NATURE MEDICINE			English	Article							RNA-POLYMERASE-II; P-TEFB; TRANSGENIC MICE; TERMINAL DOMAIN; HEART-FAILURE; IN-VIVO; PATHWAY; TAT; PHOSPHORYLATION; INHIBITION	Hypertrophic growth is a risk factor for mortality in heart diseases. Mechanisms are lacking for this global increase in RNA and protein per cell, which underlies hypertrophy. Hypertrophic signals cause phosphorylation of the RNA polymerase II C-terminal domain, required for transcript elongation. RNA polymerase II kinases include cyclin-dependent kinases-7 (Cdk7) and Cdk9, components of two basal transcription factors. We report activation of Cdk7 and -9 in hypertrophy triggered by signaling proteins (Galphaq, calcineurin) or chronic mechanical stress. Only Cdk9 was activated by acute load or, in culture, by endothelin. A preferential role for Cdk9 was shown in RNA polymerase II phosphorylation and growth induced by endothelin, using pharmacological and dominant-negative inhibitors. All four hypertrophic signals dissociated 7SK small nuclear RNA, an endogenous inhibitor, from cyclin T-Cdk9. Cdk9 was limiting for cardiac growth, shown by suppressing its inhibitor (7SK) in culture and preventing downregulation of its activator (cyclin T1) in mouse myocardium.	Baylor Coll Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Baylor Coll Med, DeBakey Heart Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Univ Med & Dent New Jersey, Cardiovasc Res Inst, Dept Cell Biol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, Cardiovasc Res Inst, Dept Mol Med, Newark, NJ 07103 USA; Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA	Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Methodist DeBakey Heart & Vascular Center; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Schneider, MD (corresponding author), Baylor Coll Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA.		Sano, Motoaki/L-3405-2013; Xie, Min/AAY-3426-2020; Giordano, Antonio/F-1927-2010; DeMayo, Francesco/C-6255-2019	Xie, Min/0000-0002-2967-3490; Giordano, Antonio/0000-0002-5959-016X; DeMayo, Francesco/0000-0002-9480-7336; BAGELLA, Luigi/0000-0003-2815-037X; Schneider, Michael/0000-0001-9645-1938	NATIONAL CANCER INSTITUTE [R01CA060999] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 60999-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdellatif M, 1998, MOL CELL BIOL, V18, P6729, DOI 10.1128/MCB.18.11.6729; Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Akhtar A, 1996, EMBO J, V15, P4654, DOI 10.1002/j.1460-2075.1996.tb00842.x; Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; De Luca A, 2001, J HISTOCHEM CYTOCHEM, V49, P693, DOI 10.1177/002215540104900603; Doi T, 1999, BIOCHEMISTRY-US, V38, P3090, DOI 10.1021/bi981919m; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Esposito G, 2002, CIRCULATION, V105, P85, DOI 10.1161/hc0102.101365; Gaussin V, 2002, P NATL ACAD SCI USA, V99, P2878, DOI 10.1073/pnas.042390499; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herrmann CH, 2001, J CELL SCI, V114, P1491; Kwak YT, 1999, J MOL BIOL, V288, P57, DOI 10.1006/jmbi.1999.2664; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; Majello B, 2001, FRONT BIOSCI-LANDMRK, V6, pD1358, DOI 10.2741/Majello; Mathew J, 2001, CIRCULATION, V104, P1615, DOI 10.1161/hc3901.096700; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; McKinsey TA, 1999, CURR OPIN GENET DEV, V9, P267, DOI 10.1016/S0959-437X(99)80040-9; Minamino T, 2002, P NATL ACAD SCI USA, V99, P3866, DOI 10.1073/pnas.062453699; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Oh H, 2001, P NATL ACAD SCI USA, V98, P10308, DOI 10.1073/pnas.191169098; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Sano M, 2002, CIRCULATION, V105, P8, DOI 10.1161/circ.105.1.8; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; Verdecchia P, 2001, J AM COLL CARDIOL, V38, P1829, DOI 10.1016/S0735-1097(01)01663-1; Wada T, 2000, MOL CELL, V5, P1067, DOI 10.1016/S1097-2765(00)80272-5; Wimmer J, 1999, VIROLOGY, V255, P182, DOI 10.1006/viro.1998.9589; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Zhang D, 2000, NAT MED, V6, P556, DOI 10.1038/75037; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	45	201	215	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2002	8	11					1310	1317		10.1038/nm778	http://dx.doi.org/10.1038/nm778			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12368904				2022-12-27	WOS:000179221200039
J	Schekman, R				Schekman, R			SEC mutants and the secretory apparatus	NATURE MEDICINE			English	Editorial Material							ENDOPLASMIC-RETICULUM; PROTEIN-TRANSPORT; VESICLE FORMATION; GENE-PRODUCT; ALPHA-FACTOR; YEAST; TRANSLOCATION; COMPLEX; RECONSTITUTION; PATHWAY		Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Schekman, R (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.			Schekman, Randy/0000-0001-8615-6409				BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; LETOURNEUR F, 1994, CELL, V79, P2299; LINNEMANS WAM, 1977, J BACTERIOL, V131, P638, DOI 10.1128/JB.131.2.638-644.1977; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1856; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PAYNE GS, 1985, SCIENCE, V230, P1009, DOI 10.1126/science.2865811; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	30	44	44	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2002	8	10					1055	1058		10.1038/nm769	http://dx.doi.org/10.1038/nm769			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12357231				2022-12-27	WOS:000178311000017
J	Camenisch, TD; Schroeder, JA; Bradley, J; Klewer, SE; McDonald, JA				Camenisch, TD; Schroeder, JA; Bradley, J; Klewer, SE; McDonald, JA			Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors	NATURE MEDICINE			English	Article							NEU DIFFERENTIATION FACTOR; ERBB SIGNALING NETWORK; CARDIAC DEVELOPMENT; NEUREGULIN RECEPTOR; PROTEIN-KINASE; MICE; CD44; MORPHOGENESIS; GROWTH; RAS	Heart septation and valve malformations constitute the most common anatomical birth defects. These structures arise from the endocardial cushions within the atrioventricular canal (AVC) through dynamic interactions between cushion cells and the extracellular matrix ( termed cardiac jelly). Transformation of endothelial cells to mesenchymal cells is essential for the proper development of the AVC and subsequent septation and valve formation. Atrioventricular septal defects can result from incomplete endocardial cushion morphogenesis. We show that hyaluronan-deficient AVC explants from Has2(-/-) embryos, which normally lack mesenchyme formation, are rescued by heregulin treatment, which restores phosphorylation of ErbB2 and ErbB3. These events were blocked using a soluble ErbB3 molecule, as well as with an inhibitor of ErbB2, herstatin. We show further that ErbB3 is activated during hyaluronan treatment of Has2(-/-) explants. These data provide a link between extracellular matrix-hyaluronan and ErbB receptor activation during development of early heart-valve and septal mesenchyme.	Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA; Univ Arizona, Sch Med, Steele Mem Childrens Res Ctr, Tucson, AZ USA; Mayo Clin, Dept Biochem & Mol Biol, Scottsdale, AZ USA; Univ Arizona, Sch Med, Dept Pediat, Tucson, AZ USA; Salt Lake City Vet Adm Hlth Care Syst, Salt Lake City, UT USA; Univ Utah, Salt Lake City, UT USA	University of Arizona; University of Arizona; Mayo Clinic; Mayo Clinic Phoenix; University of Arizona; Utah System of Higher Education; University of Utah	Camenisch, TD (corresponding author), Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA.			Camenisch, Todd/0000-0002-7797-9822; schroeder, joyce/0000-0003-1277-5172				Anderson RH, 1998, CARDIOVASC RES, V39, P155, DOI 10.1016/S0008-6363(98)00037-6; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BALDWIN HS, 1996, CARDIOVASC RES, V31, P34; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Camenisch T D, 2001, Exp Clin Cardiol, V6, P4; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; EISENBERG LM, 1995, CIRC RES, V77, P1, DOI 10.1161/01.RES.77.1.1; Erickson SL, 1997, DEVELOPMENT, V124, P4999; Ferencz Charlotte, 1993, Cardiology Clinics, V11, P557; Fitzgerald KA, 2000, J IMMUNOL, V164, P2053, DOI 10.4049/jimmunol.164.4.2053; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Hertig CM, 1999, J BIOL CHEM, V274, P37362, DOI 10.1074/jbc.274.52.37362; Lakkis MM, 1998, DEVELOPMENT, V125, P4359; Lee H, 2001, CANCER RES, V61, P4467; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Markwald R, 1996, ACTA ANAT, V156, P173; MEYER D, 1995, NATURE, V378, P753, DOI 10.1038/378753a0; O'Shea S, 2001, AM J PATHOL, V158, P1871, DOI 10.1016/S0002-9440(10)64144-2; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; RUBIN JD, 1985, MARYLAND MED J, V34, P1079; RUNYAN RB, 1983, DEV BIOL, V95, P108, DOI 10.1016/0012-1606(83)90010-6; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; Serbulea M, 1999, INT J ONCOL, V14, P733; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; Srivastava D, 2001, ANNU REV PHYSIOL, V63, P451, DOI 10.1146/annurev.physiol.63.1.451; Walsh EC, 2001, SCIENCE, V293, P1670, DOI 10.1126/science.293.5535.1670; Webb S, 1998, CIRC RES, V82, P645, DOI 10.1161/01.RES.82.6.645; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	34	248	255	0	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2002	8	8					850	855		10.1038/nm742	http://dx.doi.org/10.1038/nm742			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12134143				2022-12-27	WOS:000177200900031
J	Morshead, CM; Benveniste, P; Iscove, NN; van der Kooy, D				Morshead, CM; Benveniste, P; Iscove, NN; van der Kooy, D			Hematopoietic competence is a rare property of neural stem cells that may depend on genetic and epigenetic alterations	NATURE MEDICINE			English	Article							IN-VIVO; BONE-MARROW; BRAIN; EXPRESSION; FOREBRAIN; MUSCLE; BLOOD; EGF; CNS	The concept of stem-cell plasticity received strong support from a recent observation that extensively passaged, clonally derived neural stem cells could contribute to hematopoiesis. We investigated whether hematopoietic potential was a consistent or unusual feature of neural stem cells, and whether it depended on the extent of in vitro passaging before transplantation. Here we transplanted over 128 x 10(6) neurosphere cells into 128 host animals; however, we never observed contribution to hematopoiesis, irrespective of the number of passages and despite the use of an assay that could detect the contribution of a single blood stem cell to hematopoietic repopulation. Although extensively cultured neurosphere cells continued to generate neural progeny, marked changes in their growth properties occurred, including changes in growth-factor dependence, cell-cycle kinetics, cell adhesion and gene expression. Our results exclude hematopoietic competence as a consistent property of intravenously infused neural stem cells. However, the consistent changes that occurred during extended passaging are compatible with genetic or epigenetic alterations and suggest that rare transformation events may account for the neural-to-blood fate switch originally reported.	Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Anat & Cell Biol, Toronto, ON, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Morshead, CM (corresponding author), Univ Toronto, Dept Surg, Toronto, ON, Canada.			Benveniste, Patricia/0000-0002-5673-0542				Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; CABOT B, 1988, NATURE, V335, P88; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Gage FH, 1998, NATURE, V392, P18; Galli R, 2000, NAT NEUROSCI, V3, P986, DOI 10.1038/79924; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; LANGFORD LA, 1988, J NEUROCYTOL, V17, P521, DOI 10.1007/BF01189807; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Morshead CM, 1998, DEVELOPMENT, V125, P2251; Namba M, 1996, CRIT REV ONCOGENESIS, V7, P19, DOI 10.1615/CritRevOncog.v7.i1-2.20; PORTER S, 1987, P NATL ACAD SCI USA, V84, P7768, DOI 10.1073/pnas.84.21.7768; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Shih CC, 2001, BLOOD, V98, P2412, DOI 10.1182/blood.V98.8.2412; Trevisan M, 1996, BLOOD, V88, P4149, DOI 10.1182/blood.V88.11.4149.bloodjournal88114149; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998	22	307	343	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2002	8	3					268	273		10.1038/nm0302-268	http://dx.doi.org/10.1038/nm0302-268			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875498				2022-12-27	WOS:000174139500032
J	Liu, LZ; Chahroudi, A; Silvestri, G; Wernett, ME; Kaiser, WJ; Safrit, JT; Komoriya, A; Altman, JD; Packard, BZ; Feinberg, MB				Liu, LZ; Chahroudi, A; Silvestri, G; Wernett, ME; Kaiser, WJ; Safrit, JT; Komoriya, A; Altman, JD; Packard, BZ; Feinberg, MB			Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates	NATURE MEDICINE			English	Article							IMMUNE EVASION; GRANZYME-B; INFECTION; ACTIVATION	We have developed a non-radioactive flow-cytometry assay to monitor and quantify the target-cell killing activities mediated by cytotoxic T lymphocytes (CTLs). This flow-cytometry CTL (FCC) assay is predicated on measurement of CTL-induced caspase activation in target cells through detection of the specific cleavage of fluorogenic caspase substrates. Here we show that this assay reliably detects antigen-specific CTL killing of target cells, and demonstrate that it provides a more sensitive, more informative and safer alternative to the standard Cr-51-release assay most often used to quantify CTL responses. The FCC assay can be used to study CTL-mediated killing of primary host target cells of different cell lineages, and enables the study of antigen-specific cellular immune responses in real time at the single-cell level. As such, the FCC assay can provide a valuable tool for studies of infectious disease pathogenesis and development of new vaccines and immunotherapies.	Emory Vaccine Ctr, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Atlanta, GA USA; Oncolmmunin, Gaithersburg, MD USA	Emory University; Emory University	Feinberg, MB (corresponding author), Emory Vaccine Ctr, Atlanta, GA 30322 USA.		Kaiser, William/A-3079-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI049089, P01AI046007] Funding Source: NIH RePORTER; NIAID NIH HHS [R2AI49089, P01AI46007] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman JD, 1998, SCIENCE, V280, P1821; Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63; Atkinson EA, 1998, J BIOL CHEM, V273, P21261, DOI 10.1074/jbc.273.33.21261; BRUNNER KT, 1968, IMMUNOLOGY, V14, P181; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Doherty PC, 2000, ANNU REV IMMUNOL, V18, P561, DOI 10.1146/annurev.immunol.18.1.561; Komoriya A, 2000, J EXP MED, V191, P1819, DOI 10.1084/jem.191.11.1819; Lecoeur H, 2001, J IMMUNOL METHODS, V253, P177, DOI 10.1016/S0022-1759(01)00359-3; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Liu LZ, 1999, J VIROL, V73, P9849, DOI 10.1128/JVI.73.12.9849-9857.1999; Maino VC, 1998, CYTOMETRY, V34, P207, DOI 10.1002/(SICI)1097-0320(19981015)34:5<207::AID-CYTO1>3.0.CO;2-J; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Nociari MM, 1998, J IMMUNOL METHODS, V213, P157, DOI 10.1016/S0022-1759(98)00028-3; Packard BZ, 1996, P NATL ACAD SCI USA, V93, P11640, DOI 10.1073/pnas.93.21.11640; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; Sheehy ME, 2001, J IMMUNOL METHODS, V249, P99, DOI 10.1016/S0022-1759(00)00329-X; Sheehy ME, 2001, J IMMUNOL METHODS, V252, P219, DOI 10.1016/S0022-1759(01)00383-0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	21	121	127	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2002	8	2					185	189		10.1038/nm0202-185	http://dx.doi.org/10.1038/nm0202-185			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821904				2022-12-27	WOS:000173600600029
J	Edwards, RG				Edwards, RG			The bumpy road to human in vitro fertilization	NATURE MEDICINE			English	Editorial Material							EMBRYOS GROWN-INVITRO; PREGNANCIES		Reprod Biomed Online, Cambridge, England		Edwards, RG (corresponding author), Reprod Biomed Online, Duck End Farm, Cambridge, England.							COLES MGH, 1987, J PSYCHOPHYSIOL, V1, P13; CSAPO AI, 1974, AM J OBSTET GYNECOL, V118, P985, DOI 10.1016/0002-9378(74)90671-1; DONINI P, 1964, ACTA ENDOCRINOL-COP, V45, P329, DOI 10.1530/acta.0.0450329; Dunstan G., 1974, ARTIFICE ETHICS; EDWARDS RG, 1980, BRIT J OBSTET GYNAEC, V87, P737, DOI 10.1111/j.1471-0528.1980.tb04610.x; EDWARDS RG, 1964, J REPROD FERTIL, V7, P413, DOI 10.1530/jrf.0.0070413; EDWARDS RG, 1965, NATURE, V208, P349, DOI 10.1038/208349a0; EDWARDS RG, 1957, PROC R SOC SER B-BIO, V146, P488, DOI 10.1098/rspb.1957.0026; EDWARDS RG, 1969, NATURE, V221, P632, DOI 10.1038/221632a0; EDWARDS RG, 1971, NATURE, V231, P87, DOI 10.1038/231087a0; EDWARDS RG, 2001, REPROD BIOMED ONLINE, V3; EDWARDS RG, 1972, NATURE, V196, P446; EDWARDS RG, 1965, LANCET, V208, P39; EDWARDS RG, 1982, HUMAN CONCEPTION IN, P371; EDWARDS RG, 1995, PRINCIPLES PRACTICE; FISHEL SB, 1984, SCIENCE, V223, P816, DOI 10.1126/science.6546453; FOWLER RE, 1957, J ENDOCRINOL, V15, P374, DOI 10.1677/joe.0.0150374; GARDNER RL, 1968, NATURE, V220, P596, DOI 10.1038/220596a0; GEMZELL C, 1971, NOBEL S, V15; HOLLANDS P, 1991, HUM REPROD, V6, P79, DOI 10.1093/oxfordjournals.humrep.a137262; JONES KW, 1987, HUM REPROD, V2, P439, DOI 10.1093/oxfordjournals.humrep.a136565; LUNENFELD B, IN PRESS REPROD BIOM, V2; Pincus G, 1939, ANAT REC, V75, P537, DOI 10.1002/ar.1090750410; ROBERT EDWARDS AND PATRICK STEPTOE, 1980, MATTER LIFE; SIRLIN JL, 1958, J EXP ZOOL, V137, P363, DOI 10.1002/jez.1401370302; STEPTOE P C, 1967, LAPAROSCOPY GYNAECOL; STEPTOE PC, 1976, LANCET, V1, P880; STEPTOE PC, 1980, BRIT J OBSTET GYNAEC, V87, P757, DOI 10.1111/j.1471-0528.1980.tb04611.x; STEPTOE PC, 1986, HUM REPROD, V1, P89, DOI 10.1093/oxfordjournals.humrep.a136366; STEPTOE PC, 1971, NATURE, V229, P132, DOI 10.1038/229132a0; YANAGIMACHI R, 1964, J EXP ZOOL, V156, P361, DOI 10.1002/jez.1401560312	31	23	24	1	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1091	1094		10.1038/nm1001-1091	http://dx.doi.org/10.1038/nm1001-1091			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590421				2022-12-27	WOS:000171524500016
J	Altucci, L; Rossin, A; Raffelsberger, W; Reitmair, A; Chomienne, C; Gronemeyer, H				Altucci, L; Rossin, A; Raffelsberger, W; Reitmair, A; Chomienne, C; Gronemeyer, H			Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL	NATURE MEDICINE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; NF-KAPPA-B; 13-CIS-RETINOIC ACID; INTERFERON ALPHA-2A; RECEPTOR; CASPASE-8; DIFFERENTIATION; MATURATION; ACTIVATION; INDUCTION	The therapeutic and preventive activities of retinoids in cancer are due to their ability to modulate the growth, differentiation, and survival or apoptosis of cancer cells. Here we show that in NB4 acute promyelocyeic leukemia cells, retinoids selective for retinoic-acid receptor-alpha induced an autoregulatory circuitry of survival programs followed by expression of the membrane-bound tumor-selective death ligand, TRAIL (tumor necrosis factor-related apoptosis-inducing ligand, also called Apo-2L). In a paracrine mode of action, TRAIL killed NB4 as well as heterologous and retinoic-acid-resistant cells. In the leukemic blasts of freshly diagnosed acute promyelocytic leukemia patients, retinoic-acid-induced expression of TRAIL most likely caused blast apoptosis. Thus, induction of TRAIL-mediated death signaling appears to contribute to the therapeutic value of retinoids.	Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, CU de Strasbourg, France; Hop St Louis, LBCH, Inst Hematol, Paris, France; Univ Naples 2, Ist Patol Gen & Oncol, Naples, Italy	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Universita della Campania Vanvitelli	Gronemeyer, H (corresponding author), Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, CU de Strasbourg, France.		Gronemeyer, Hinrich/H-7002-2016; Gronemeyer, Hinrich/G-6240-2011; Altucci, Lucia/S-8031-2019; Gronemeyer, Hinrich/AAH-5575-2019	Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; altucci, lucia/0000-0002-7312-5387; CHOMIENNE, Christine/0000-0001-5513-5752; Rossin, Aurelie/0000-0002-6110-1249				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BONHOMME L, 1991, ANN ONCOL, V2, P234, DOI 10.1093/oxfordjournals.annonc.a057916; BRUEL A, 1995, LEUKEMIA, V9, P1173; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; CHOMIENNE C, 1990, BLOOD, V76, P1710; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Fenaux P, 1997, NEW ENGL J MED, V337, P1076, DOI 10.1056/NEJM199710093371509; Gehin M, 1999, CHEM BIOL, V6, P519, DOI 10.1016/S1074-5521(99)80084-2; Gianni M, 2000, CELL DEATH DIFFER, V7, P447, DOI 10.1038/sj.cdd.4400673; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; *INT AG RES CANC, 1999, IARC HDB CANC PREV, V4; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; LANOTTE M, 1991, BLOOD, V77, P1080; LIPPMAN SM, 1992, J NATL CANCER I, V84, P235, DOI 10.1093/jnci/84.4.235; LIPPMAN SM, 1992, JNCI-J NATL CANCER I, V84, P241, DOI 10.1093/jnci/84.4.241; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Moreb JS, 1997, LEUKEMIA, V11, P998, DOI 10.1038/sj.leu.2400719; NAGY L, 1995, MOL CELL BIOL, V15, P3540; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pomerantz JL, 2000, NATURE, V406, P26, DOI 10.1038/35017673; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Slack JL, 1999, CANC TREAT, V99, P75; Sporn M.B., 1994, RETINOIDS BIOL CHEM; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sun SY, 2000, MOL PHARMACOL, V58, P508, DOI 10.1124/mol.58.3.508; Sun SY, 2000, CANCER RES, V60, P7149; TUCKER KA, 1987, BLOOD, V70, P372; VERMA AK, 1987, CANCER RES, V47, P5097; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zamai L, 2000, BLOOD, V95, P3716; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	44	294	307	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2001	7	6					680	686		10.1038/89050	http://dx.doi.org/10.1038/89050			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385504				2022-12-27	WOS:000169081500035
J	Makowski, L; Boord, JB; Maeda, K; Babaev, VR; Uysal, KT; Morgan, MA; Parker, RA; Suttles, J; Fazio, S; Hotamisligil, GS; Linton, MF				Makowski, L; Boord, JB; Maeda, K; Babaev, VR; Uysal, KT; Morgan, MA; Parker, RA; Suttles, J; Fazio, S; Hotamisligil, GS; Linton, MF			Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis	NATURE MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; BONE-MARROW TRANSPLANTATION; ACTIVATED RECEPTOR-GAMMA; FOAM CELL-FORMATION; PPAR-GAMMA; INSULIN-RESISTANCE; GENE-EXPRESSION; CHOLESTEROL ACYLTRANSFERASE; HUMAN MONOCYTES; OXIDIZED LDL	The adipocyte fatty-acid-binding protein, aP2, has an important role in regulating systemic insulin resistance and lipid metabolism. Here we demonstrate that aP2 is also expressed in macrophages, has a significant role in their biological responses and contributes to the development of atherosclerosis. Apolipoprotein E (ApoE)-deficient mice also deficient for aP2 showed protection from atherosclerosis in the absence of significant differences in serum lipids or insulin sensitivity. aP2-deficient macrophages showed alterations in inflammatory cytokine production and a reduced ability to accumulate cholesterol esters when exposed to modified lipoproteins. Apoe(-/-) mice with Ap2(+/+) adipocytes and Ap2(-/-) macrophages generated by bone-marrow transplantation showed a comparable reduction in atherosclerotic lesions to those with total aP2 deficiency, indicating an independent role for macrophage aP2 in atherogenesis. Through its distinct actions in adipocytes and macrophages, aP2 provides a link between features of the metabolic syndrome and could be a new therapeutic target for the prevention of atherosclerosis.	Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37240 USA; Harvard Univ, Sch Publ Hlth, Div Biol Sci, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Bristol Myers Squibb PRI, Dept Metab Res, Princeton, NJ USA; Univ Louisville, Sch Med, Dept Microbiol & Immunol, Louisville, KY 40292 USA	Vanderbilt University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Vanderbilt University; Vanderbilt University; Bristol-Myers Squibb; University of Louisville	Linton, MF (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37240 USA.			Makowski, Liza/0000-0002-5337-8037	NHLBI NIH HHS [R01 HL065405, F32 HL075970, HL65405-01] Funding Source: Medline; NIDDK NIH HHS [T32 DK7061, T32 DK007061] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL075970, R01HL065405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007061] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMRI EZ, 1991, J LIPID RES, V32, P1449; Babaev VR, 1999, J CLIN INVEST, V103, P1697, DOI 10.1172/JCI6117; Babaev VR, 2000, J BIOL CHEM, V275, P26293, DOI 10.1074/jbc.M002423200; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BROWN WJ, 1988, ARCH PATHOL LAB MED, V112, P295; Coe NR, 1999, J LIPID RES, V40, P967; Coe NR, 1998, BBA-LIPID LIPID MET, V1391, P287, DOI 10.1016/S0005-2760(97)00205-1; Cousin B, 1999, FASEB J, V13, P305, DOI 10.1096/fasebj.13.2.305; DAVIS PJ, 1992, BIOCHEM CELL BIOL, V70, P1313, DOI 10.1139/o92-178; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; Fazio S, 1997, J LIPID RES, V38, P391; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Fazio S, 2001, J CLIN INVEST, V107, P163, DOI 10.1172/JCI10310; Fu YC, 2000, J LIPID RES, V41, P2017; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KIENER PA, 1995, J IMMUNOL, V155, P4917; KRAAL G, 1987, SCAND J IMMUNOL, V26, P653, DOI 10.1111/j.1365-3083.1987.tb02301.x; Kunjathoor VV, 1996, J CLIN INVEST, V97, P1767, DOI 10.1172/JCI118604; Linton MF, 1999, J BIOL CHEM, V274, P19204, DOI 10.1074/jbc.274.27.19204; Linton MF, 1998, J CLIN INVEST, V101, P1726, DOI 10.1172/JCI2181; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; Pelton PD, 1999, BIOCHEM BIOPH RES CO, V261, P456, DOI 10.1006/bbrc.1999.1071; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; RUMSEY SC, 1995, J BIOL CHEM, V270, P10008, DOI 10.1074/jbc.270.17.10008; Scheja L, 1999, DIABETES, V48, P1987, DOI 10.2337/diabetes.48.10.1987; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SURWIT RS, 1988, DIABETES, V37, P1163, DOI 10.2337/diabetes.37.9.1163; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Uysal KT, 2000, ENDOCRINOLOGY, V141, P3388, DOI 10.1210/en.141.9.3388; Uysal KT, 1998, ENDOCRINOLOGY, V139, P4832, DOI 10.1210/en.139.12.4832; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	40	539	571	0	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2001	7	6					699	705		10.1038/89076	http://dx.doi.org/10.1038/89076			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385507	Green Accepted			2022-12-27	WOS:000169081500038
J	Pola, R; Ling, LE; Silver, M; Corbley, MJ; Kearney, M; Pepinsky, RB; Shapiro, R; Taylor, FR; Baker, DP; Asahara, T; Isner, JM				Pola, R; Ling, LE; Silver, M; Corbley, MJ; Kearney, M; Pepinsky, RB; Shapiro, R; Taylor, FR; Baker, DP; Asahara, T; Isner, JM			The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors	NATURE MEDICINE			English	Article							KINESIN-RELATED PROTEIN; SIGNALING PATHWAY; REGULATES PROLIFERATION; NEGATIVE REGULATOR; LIMB DEVELOPMENT; HAIR DEVELOPMENT; GENE-EXPRESSION; COUP-TFII; SUPPRESSOR; VEGF	Sonic hedgehog (Shh) is a prototypical morphogen known to regulate epithelial/mesenchymal interactions during embryonic development. We found that the hedgehog-signaling pathway is present in adult cardiovascular tissues and can be activated in vivo. Shh was able to induce robust angiogenesis, characterized by distinct large-diameter vessels. Shh also augmented blood-flow recovery and limb salvage following operatively induced hind-limb ischemia in aged mice. In vitro, Shh had no effect on endothelial-cell migration or proliferation; instead, it induced expression of two families of angiogenic cytokines, including all three vascular endothelial growth factor-1 isoforms and angiopoietins-1 and -2 from interstitial mesenchymal cells. These findings reveal a novel role for Shh as an indirect angiogenic factor regulating expression of multiple angiogenic cytokines and indicate that Shh might have potential therapeutic use for ischemic disorders.	Tufts Univ, Sch Med, Dept Med, St Elizabeths Med Ctr, Boston, MA 02111 USA; Biogen Inc, Cambridge, MA 02142 USA	St. Elizabeth's Medical Center; Tufts University; Biogen	Isner, JM (corresponding author), Tufts Univ, Sch Med, Dept Med, St Elizabeths Med Ctr, Boston, MA 02111 USA.			Pola, Roberto/0000-0001-5224-2931				Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; Brown LA, 2000, MECH DEVELOP, V90, P237, DOI 10.1016/S0925-4773(99)00256-7; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Cho CS, 2000, J IMMUNOL, V164, P5055, DOI 10.4049/jimmunol.164.10.5055; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Detmar M, 1997, J INVEST DERMATOL, V108, P263, DOI 10.1111/1523-1747.ep12286453; Ding Q, 1999, CURR BIOL, V9, P1119, DOI 10.1016/S0960-9822(99)80482-5; Fuse N, 1999, P NATL ACAD SCI USA, V96, P10992, DOI 10.1073/pnas.96.20.10992; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; KALDERON D, 1997, CURR BIOL, V7, P759; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Krishnan V, 1997, SCIENCE, V278, P1947, DOI 10.1126/science.278.5345.1947; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Mecklenburg L, 2000, J INVEST DERMATOL, V114, P909, DOI 10.1046/j.1523-1747.2000.00954.x; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; Parmantier E, 1999, NEURON, V23, P713, DOI 10.1016/S0896-6273(01)80030-1; Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4; Pepinsky RB, 2000, J BIOL CHEM, V275, P10995, DOI 10.1074/jbc.275.15.10995; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Pereira FA, 1999, GENE DEV, V13, P1037, DOI 10.1101/gad.13.8.1037; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; Scheid A, 2000, PEDIATR SURG INT, V16, P232, DOI 10.1007/s003830050735; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Stone DM, 1999, J CELL SCI, V112, P4437; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Tokunaga T, 1998, BRIT J CANCER, V77, P998, DOI 10.1038/bjc.1998.164; VOLPERT OV, 1997, ONCOGENE, V14, P1492; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang LC, 2000, J INVEST DERMATOL, V114, P901, DOI 10.1046/j.1523-1747.2000.00951.x; Williams KP, 1999, J CELL SCI, V112, P4405; Zardoya R, 1996, TRENDS GENET, V12, P496, DOI 10.1016/S0168-9525(96)20014-9; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	45	494	532	1	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2001	7	6					706	711		10.1038/89083	http://dx.doi.org/10.1038/89083			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385508				2022-12-27	WOS:000169081500039
J	Sanger, F				Sanger, F			The early days of DNA sequences	NATURE MEDICINE			English	Editorial Material									MRC, Mol Biol Lab, Cambridge, England	MRC Laboratory Molecular Biology	Sanger, F (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge, England.							GRONENBORN B, 1978, NATURE, V272, P375, DOI 10.1038/272375a0; WU R, 1968, J MOL BIOL, V35, P523, DOI 10.1016/S0022-2836(68)80012-9	2	13	15	0	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					267	268		10.1038/85389	http://dx.doi.org/10.1038/85389			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231611				2022-12-27	WOS:000167380400016
J	Kung, AL; Wang, S; Klco, JM; Kaelin, WG; Livingston, DM				Kung, AL; Wang, S; Klco, JM; Kaelin, WG; Livingston, DM			Suppression of tumor growth through disruption of hypoxia-inducible transcription	NATURE MEDICINE			English	Article							BINDING-PROTEIN; FACTOR 1-ALPHA; SOLID TUMORS; TRANSACTIVATION; ANGIOGENESIS; HIF-1-ALPHA; ACTIVATION; P300/CBP; CELLS; STABILIZATION	Chronic hypoxia, a hallmark of many tumors, is associated with angiogenesis and tumor progression. Strategies to treat tumors have been developed in which tumor cells are targeted with drugs or gene-therapy vectors specifically activated under hypoxic conditions. Here we report a different approach, in which the normal transcriptional response to hypoxia is selectively disrupted. Our data indicate that specific blockade of the interaction of hypoxia-inducible factor with the CH1 domain of its p300 and CREB binding protein transcriptional coactivators leads to attenuation of hypoxia-inducible gene expression and diminution of tumor growth. Thus, disrupting the normal co-activational response to hypoxia may be a new and useful therapeutic strategy.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Livingston, DM (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.		Klco, Jeffery/M-9717-2018; Kung, Andrew/AAL-2384-2020; Kung, Andrew L/AEU-0826-2022	Klco, Jeffery/0000-0003-2961-6960; Kung, Andrew L/0000-0002-9091-488X				Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Ausubel FM., 1988, CURRENT PROTOCOLS MO; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Binley K, 1999, GENE THER, V6, P1721, DOI 10.1038/sj.gt.3301001; Brizel DM, 1996, CANCER RES, V56, P941; Brown JM, 2000, MOL MED TODAY, V6, P157, DOI 10.1016/S1357-4310(00)01677-4; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Hockel M, 1996, CANCER RES, V56, P4509; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; NORDSMARK M, 1994, ACTA ONCOL, V33, P383, DOI 10.3109/02841869409098433; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Olumi AF, 1999, CANCER RES, V59, P5002; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shibata T, 2000, GENE THER, V7, P493, DOI 10.1038/sj.gt.3301124; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WILSON IA, 1985, P NATL ACAD SCI USA, V82, P5255, DOI 10.1073/pnas.82.16.5255; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; ZEMAN EM, 1986, INT J RADIAT ONCOL, V12, P1239, DOI 10.1016/0360-3016(86)90267-1; Zhong H, 1999, CANCER RES, V59, P5830; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	44	450	484	0	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1335	1340		10.1038/82146	http://dx.doi.org/10.1038/82146			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100117				2022-12-27	WOS:000165704100036
J	Yan, SF; Fujita, T; Lu, JS; Okada, K; Zou, YS; Mackman, N; Pinsky, DJ; Stern, DM				Yan, SF; Fujita, T; Lu, JS; Okada, K; Zou, YS; Mackman, N; Pinsky, DJ; Stern, DM			Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; VASCULAR-PERMEABILITY FACTOR; MIDDLE CEREBRAL-ARTERY; NGFI-A EGR-1; NF-KAPPA-B; IN-VIVO; RENAL ISCHEMIA; MESSENGER-RNA; TISSUE FACTOR	Activation of the zinc-finger transcription factor early growth response (Egr)-1, initially linked to developmental processes, is shown here to function as a master switch activated by ischemia to trigger expression of pivotal regulators of inflammation, coagulation and vascular hyperpermeability. Chemokine, adhesion receptor, procoagulant and permeability-related genes are coordinately upregulated by rapid ischemia-mediated activation of Egr-1. Deletion of the gene encoding Egr-1 strikingly diminished expression of these mediators of vascular injury in a murine model of lung ischemia/reperfusion, and enhanced animal survival and organ function. Rapid activation of Egr-1 in response to oxygen deprivation primes the vasculature for dysfunction manifest during reperfusion. These studies define a central and unifying role for Egr-1 activation in the pathogenesis of ischemic tissue damage.	Columbia Univ, Dept Surg, New York, NY 10032 USA; Columbia Univ, Dept Physiol, New York, NY 10032 USA; Columbia Univ, Dept Cellular Biophys & Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Scripps Res Inst, Dept Immunol & Vasc Biol, La Jolla, CA 92037 USA	Columbia University; Columbia University; Columbia University; Columbia University; Scripps Research Institute	Yan, SF (corresponding author), Columbia Univ, Dept Surg, 630 W 168th St, New York, NY 10032 USA.		Tomoyuki, Fujita/AAC-7464-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059488, R01HL055397, R37HL063967, R01HL063967] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59488, HL55397, HL63967] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bless NM, 1999, AM J PHYSIOL-LUNG C, V276, pL57, DOI 10.1152/ajplung.1999.276.1.L57; BRAND T, 1992, CIRC RES, V71, P1351, DOI 10.1161/01.RES.71.6.1351; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Cenci S, 2000, J CLIN INVEST, V105, P1279, DOI 10.1172/JCI8672; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; COLLEN D, 1992, ANN NY ACAD SCI, V667, P259, DOI 10.1111/j.1749-6632.1992.tb51623.x; Colletti LM, 2000, HEPATOLOGY, V31, P435, DOI 10.1002/hep.510310225; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GOLDBLUM SE, 1985, J APPL PHYSIOL, V59, P1978, DOI 10.1152/jappl.1985.59.6.1978; Gourmala NG, 1997, J NEUROIMMUNOL, V74, P35, DOI 10.1016/S0165-5728(96)00203-2; Hayashi T, 1997, STROKE, V28, P2039, DOI 10.1161/01.STR.28.10.2039; IKOMMINOTH P, 1996, NONRADIOACTIVE IN SI, P126; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kunkel SL, 1999, J CLIN INVEST, V104, P1333, DOI 10.1172/JCI8511; Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Lefer AM, 1999, ANN THORAC SURG, V68, P1920, DOI 10.1016/S0003-4975(99)01017-6; Lemay S, 2000, TRANSPLANTATION, V69, P959; Lentsch AB, 1998, HEPATOLOGY, V27, P1172; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Liu PT, 2000, SHOCK, V13, P217, DOI 10.1097/00024382-200003000-00008; LOSKUTOFF DJ, 1993, THROMB HAEMOSTASIS, V70, P135; Maltzman JS, 1996, J EXP MED, V183, P1747, DOI 10.1084/jem.183.4.1747; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Millet I, 2000, J BIOL CHEM, V275, P15114, DOI 10.1074/jbc.275.20.15114; Mitsui Y, 1999, BRAIN RES, V844, P192, DOI 10.1016/S0006-8993(99)01830-2; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Okada K, 2000, J BIOL CHEM, V275, P21468, DOI 10.1074/jbc.M002682200; OUELLETTE AJ, 1990, J CLIN INVEST, V85, P766, DOI 10.1172/JCI114502; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Saadane N, 2000, AM J PHYSIOL-HEART C, V278, pH796, DOI 10.1152/ajpheart.2000.278.3.H796; SAFIRSTEIN R, 1990, KIDNEY INT, V37, P1515, DOI 10.1038/ki.1990.143; Schecter AD, 1997, J BIOL CHEM, V272, P28568, DOI 10.1074/jbc.272.45.28568; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Wang CY, 1998, CIRC RES, V82, P762, DOI 10.1161/01.RES.82.7.762; Wang XK, 1998, J NEUROCHEM, V71, P1194; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; Yoshidome H, 1999, AM J PHYSIOL-LUNG C, V277, pL919, DOI 10.1152/ajplung.1999.277.5.L919; Zhu H, 1999, RESP PHYSIOL, V115, P239, DOI 10.1016/S0034-5687(99)00024-9	50	381	413	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1355	1361		10.1038/82168	http://dx.doi.org/10.1038/82168			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100120				2022-12-27	WOS:000165704100039
J	Amagai, M; Matsuyoshi, N; Wang, ZH; Andl, C; Stanley, JR				Amagai, M; Matsuyoshi, N; Wang, ZH; Andl, C; Stanley, JR			Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1	NATURE MEDICINE			English	Article							VULGARIS; CADHERIN; ANTIGEN	Exfoliative toxin A, produced by Staphylococcus aureus, causes blisters in bullous impetigo and its more generalized form, staphylococcal scalded-skin syndrome(1-3). The toxin shows exquisite specificity in causing loss of cell adhesion only in the superficial epidermis. Although exfoliative toxin A has the structure of a serine protease, a target protein has not been identified(4,5). Desmoglein (Dsg) 1, a desmosomal cadherin that mediates cell-cell adhesion, may be the target of exfoliative toxin A, because it is the target of autoantibodies in pemphigus foliaceus, in which blisters form with identical tissue specificity and histology. We show here that exfoliative toxin A cleaved mouse and human Dsg1, but not closely related cadherins such as Dsg3. We demonstrate this specific cleavage in cell culture, in neonatal mouse skin and with recombinant Dsg1, and conclude that Dsg1 is the specific receptor for exfoliative toxin A cleavage. This unique proteolytic attack on the desmosome causes a blister just below the stratum corneum, which forms the epidermal barrier, presumably allowing the bacteria in bullous impetigo to proliferate and spread beneath this barrier.	Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA; Keio Univ, Sch Med, Dept Dermatol, Shinjuku Ku, Tokyo 1608582, Japan	University of Pennsylvania; Keio University	Stanley, JR (corresponding author), Univ Penn, Sch Med, Dept Dermatol, 211 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	jrstan@mail.med.upenn.edu	Amagai, Masayuki/K-5325-2013	Amagai, Masayuki/0000-0003-3314-7052				Amagai M, 2000, J CLIN INVEST, V105, P625, DOI 10.1172/JCI8748; DANCER SJ, 1990, FEBS LETT, V268, P129, DOI 10.1016/0014-5793(90)80990-Z; ELIAS PM, 1977, ARCH DERMATOL, V113, P207, DOI 10.1001/archderm.113.2.207; Farrell AM, 1999, LANCET, V354, P880, DOI 10.1016/S0140-6736(99)90120-4; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Ishii K, 1997, J IMMUNOL, V159, P2010; Ishikawa H, 2000, EXP DERMATOL, V9, P229, DOI 10.1034/j.1600-0625.2000.009004229.x; ISHIKAWA H, 1994, MAMM GENOME, V5, P803, DOI 10.1007/BF00292018; Koch PJ, 1998, J CELL SCI, V111, P2529; LYELL A, 1983, J AM ACAD DERMATOL, V9, P285, DOI 10.1016/S0190-9622(83)80161-3; Mahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252; MELISH ME, 1971, J PEDIATR-US, V78, P958, DOI 10.1016/S0022-3476(71)80425-0; MELISH ME, 1970, NEW ENGL J MED, V282, P1114, DOI 10.1056/NEJM197005142822002; NILLES LA, 1991, J CELL SCI, V99, P809; Rago JV, 2000, J IMMUNOL, V164, P2207, DOI 10.4049/jimmunol.164.4.2207; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; Vath GM, 1997, BIOCHEMISTRY-US, V36, P1559, DOI 10.1021/bi962614f; Wu H, 2000, NEW ENGL J MED, V343, P31, DOI 10.1056/NEJM200007063430105	18	305	316	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2000	6	11					1275	1277		10.1038/81385	http://dx.doi.org/10.1038/81385			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062541				2022-12-27	WOS:000165114800037
J	Matkowskyj, KA; Danilkovich, A; Marrero, J; Savkovic, SD; Hecht, G; Benya, RV				Matkowskyj, KA; Danilkovich, A; Marrero, J; Savkovic, SD; Hecht, G; Benya, RV			Galanin-l receptor up-regulation mediates the excess colonic fluid production caused by infection with enteric pathogens	NATURE MEDICINE			English	Article							NF-KAPPA-B; ESCHERICHIA-COLI; SALMONELLA; EXPRESSION; GLUCOCORTICOIDS; DEXAMETHASONE; MECHANISM; MODEL	Galanin is widely distributed in enteric nerve terminals lining the gastrointestinal tract(1,2). We previously showed that pathogenic Escherichia coli, but not normal commensal organisms, increase galanin-1 receptor expression by epithelial cells lining the colon(3) (i.e., colonocytes), When present, galanin-l receptor activation by ligand causes colonocyte Cl secretion(4). We herein demonstrate that disparate pathogens including Salmonella typhimurium and Shigella flexerii also increase colonocyte galanin-1 receptor expression, whose activation is responsible for a principal component of the increased colonic fluid secretion observed. Although eliminating the GAL1R gene by homologous recombination does not alter basal colonic fluid secretion, removal of one or both alleles completely attenuates the increase in fluid secretion due to infection with enteric pathogens. Galanin-1 receptor up-regulation therefore represents a novel mechanism accounting for the increased colonic fluid secretion observed in infectious diarrhea due to several different pathogens.	Univ Illinois, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Dept Pathol, Chicago, IL 60612 USA; Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; W Side Vet Adm Med Ctr, W Side Div, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Benya, RV (corresponding author), Univ Illinois, Dept Med, Chicago, IL 60612 USA.		Danilkovich, Alexey/E-4014-2010	Danilkovich, Alexey/0000-0002-4650-9860	NIDDK NIH HHS [DK-50694, DK-54777] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054777, R01DK050694] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUER FE, 1986, GASTROENTEROLOGY, V91, P877, DOI 10.1016/0016-5085(86)90689-X; BNYA RV, 1999, AM J PHYSIOL, V276, pG64; Castagliuolo I, 1998, J CLIN INVEST, V101, P1547, DOI 10.1172/JCI2039; Davis LG, 1994, BASIC METHODS MOL BI; DYER RB, 1993, INFECT IMMUN, V61, P4427, DOI 10.1128/IAI.61.10.4427-4433.1993; Everest P, 1999, INFECT IMMUN, V67, P2815, DOI 10.1128/IAI.67.6.2815-2821.1999; GALLIN JI, 1982, BLOOD, V59, P1317; Hecht G, 1999, J CLIN INVEST, V104, P253, DOI 10.1172/JCI6373; HOYLE CHV, 1989, J ANAT, V166, P23; Jasani B, 1993, IMMUNOCYTOCHEMISTRY; Lorimer DD, 1996, BIOCHEM BIOPH RES CO, V222, P379, DOI 10.1006/bbrc.1996.0752; Marrero JA, 2000, AM J PHYSIOL-GASTR L, V278, pG797, DOI 10.1152/ajpgi.2000.278.5.G797; Matkowskyj KA, 2000, J HISTOCHEM CYTOCHEM, V48, P303, DOI 10.1177/002215540004800216; PARKOS CA, 1991, J CLIN INVEST, V88, P1605, DOI 10.1172/JCI115473; Peterson JW, 1998, LAB INVEST, V78, P523; Rosen T, 1998, J CLIN ENDOCR METAB, V83, P3647, DOI 10.1210/jc.83.10.3647; Sacks M, 1998, BIOCHEM BIOPH RES CO, V253, P181, DOI 10.1006/bbrc.1998.9763; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Waynforth HB, 1992, EXPT SURG TECHNIQUE, P1; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; Zunjic M, 1997, GASTROENTEROLOGY, V112, pA1128	21	59	59	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					1048	1051		10.1038/79563	http://dx.doi.org/10.1038/79563			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973327	Bronze			2022-12-27	WOS:000089190500039
J	Covic, L; Misra, M; Badar, J; Singh, C; Kuliopulos, A				Covic, L; Misra, M; Badar, J; Singh, C; Kuliopulos, A			Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation	NATURE MEDICINE			English	Article							CRYSTAL-STRUCTURE; ANTAGONIST; AGGREGATION; REVEALS; PATIENT; CLONING	Transmembrane signaling through G protein-coupled receptors (GPCRs) controls a diverse array of cellular processes including metabolism, growth, motility, adhesion, neuronal signaling and blood coagulation. The numerous GPCRs and their key roles in both normal physiology and disease have made them the target for more than 50% of all prescribed drugs. GPCR agonists and antagonists act on the extracellular side of the receptors, whereas the intracellular surface has not yet been exploited for development of new therapeutic agents. Here, we demonstrate the utility of novel cell-penetrating peptides, termed 'pepducins', that act as intracellular inhibitors of signal transference from receptors to G proteins(1). Attachment of a palmitate lipid to peptides based on the third intracellular loop of protease-activated receptor 1 (PAR1)(2) or PAR4 (refs. 3-5) yielded potent inhibitors of thrombin-mediated aggregation of human platelets. Infusion of the anti-PAR4 pepducin into mice extended bleeding time and protected against systemic platelet activation, consistent with the phenotype of PAR4-deficient mice. We show that pepducins might be used to ascertain the physiological roles of GPCRs and rapidly determine the potential therapeutic value of blockade of a particular signaling pathway.	Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, Div Hematol Oncol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts University	Kuliopulos, A (corresponding author), Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, Div Hematol Oncol, 750 Washington St, Boston, MA 02111 USA.	athan.kuliopulos@tufts.edu			NHLBI NIH HHS [R01HL57905, R01HL64701] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057905, R01HL064701] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrade-Gordon P, 2001, J PHARMACOL EXP THER, V298, P34; Andrade-Gordon P, 1999, P NATL ACAD SCI USA, V96, P12257, DOI 10.1073/pnas.96.22.12257; Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; Bernatowicz MS, 1996, J MED CHEM, V39, P4879, DOI 10.1021/jm960455s; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899; Covic L, 2002, THROMB HAEMOSTASIS, V87, P722, DOI 10.1055/s-0037-1613071; Fabre JE, 1999, NAT MED, V5, P1199, DOI 10.1038/13522; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Ma L, 2001, BRIT J PHARMACOL, V134, P701, DOI 10.1038/sj.bjp.0704312; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MURRAY R, 1989, P NATL ACAD SCI USA, V86, P124, DOI 10.1073/pnas.86.1.124; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Seiler SM, 1996, MOL PHARMACOL, V49, P190; Smyth SS, 2001, BLOOD, V98, P1055, DOI 10.1182/blood.V98.4.1055; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Woulfe D, 2001, J CLIN INVEST, V107, P1503, DOI 10.1172/JCI13361; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	24	215	240	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1161	1165		10.1038/nm760	http://dx.doi.org/10.1038/nm760			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12357249				2022-12-27	WOS:000178311000044
J	Falati, S; Gross, P; Merrill-Skoloff, G; Furie, BC; Furie, B				Falati, S; Gross, P; Merrill-Skoloff, G; Furie, BC; Furie, B			Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse	NATURE MEDICINE			English	Article							FACTOR ANTIGEN; RECEPTOR; CDNA	We have used confocal and widefield microscopy to image thrombus formation in real time in the microcirculation of a living mouse. This system provides high-speed, near-simultaneous acquisition of images of multiple fluorescent probes and of a brightfield channel. Vascular injury is induced with a laser focused through the microscope optics. We observed platelet deposition, tissue factor accumulation and fibrin generation after laser-induced endothelial injury in a single developing thrombus. The initiation of blood coagulation in vivo entailed the initial accumulation of tissue factor on the upstream and thrombus-vessel wall interface of the developing thrombus. Subsequently tissue factor was associated with the interior of the thrombus. Tissue factor was biologically active, and was associated with fibrin generation within the thrombus.	Beth Israel Deaconess Med Ctr, Ctr Hemostasis & Thrombosis Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Furie, B (corresponding author), Beth Israel Deaconess Med Ctr, Ctr Hemostasis & Thrombosis Res, Boston, MA 02215 USA.			Merrill-Skoloff, Glenn/0000-0003-2337-5107	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015680] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069435, R01HL051926] Funding Source: NIH RePORTER; NCRR NIH HHS [S10RR15680] Funding Source: Medline; NHLBI NIH HHS [HL51926, HL69435] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		FAREED J, 1995, BLOOD COAGUL FIBRIN, V6, pS32, DOI 10.1097/00001721-199506001-00006; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; INOUE S, 2000, DIRECT VIEW HIGH SPE; KOYAMA T, 1994, BRIT J HAEMATOL, V87, P343, DOI 10.1111/j.1365-2141.1994.tb04919.x; Ley Klaus, 1995, Microcirculation (New York), V2, P141, DOI 10.3109/10739689509146762; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; Morrissey JH, 2001, THROMB HAEMOSTASIS, V86, P66; Rosen ED, 2001, AM J PATHOL, V158, P1613, DOI 10.1016/S0002-9440(10)64117-X; SPICER EK, 1987, P NATL ACAD SCI USA, V84, P5148, DOI 10.1073/pnas.84.15.5148; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769; Zumbach M, 1997, EXP CLIN ENDOCR DIAB, V105, P206, DOI 10.1055/s-0029-1211753	12	517	539	4	73	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2002	8	10					1175	1180		10.1038/nm782	http://dx.doi.org/10.1038/nm782			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12244306	Green Published			2022-12-27	WOS:000178311000047
J	Rothman, JE				Rothman, JE			The machinery and principles of vesicle transport in the cell	NATURE MEDICINE			English	Editorial Material							ADP-RIBOSYLATION FACTOR; MEMBRANE-FUSION; SUCCESSIVE COMPARTMENTS; PROTEIN-TRANSPORT; COATED VESICLES; GOLGI; GLYCOPROTEIN; CLATHRIN; BINDING; PURIFICATION		Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biophys & Biochem Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Rothman, JE (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biophys & Biochem Program, 1275 York Ave, New York, NY 10021 USA.							BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BRAELL WA, 1984, CELL, V39, P511, DOI 10.1016/0092-8674(84)90458-6; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; FRIES E, 1980, P NATL ACAD SCI-BIOL, V77, P3870, DOI 10.1073/pnas.77.7.3870; FRIES E, 1981, J CELL BIOL, V90, P697, DOI 10.1083/jcb.90.3.697; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; Parlati F, 2002, P NATL ACAD SCI USA, V99, P5424, DOI 10.1073/pnas.082100899; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	23	114	118	2	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1059	1062		10.1038/nm770	http://dx.doi.org/10.1038/nm770			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12357232	Bronze			2022-12-27	WOS:000178311000018
J	Nagase, T; Uozumi, N; Ishii, S; Kita, Y; Yamamoto, H; Ohga, E; Ouchi, Y; Shimizu, T				Nagase, T; Uozumi, N; Ishii, S; Kita, Y; Yamamoto, H; Ohga, E; Ouchi, Y; Shimizu, T			A pivotal role of cytosolic phospholipase A(2) in bleomycin-induced pulmonary fibrosis	NATURE MEDICINE			English	Article							PLATELET-ACTIVATING-FACTOR; FACTOR-RECEPTOR; TRANSGENIC MICE; MOLECULAR-CLONING; AIRWAY HYPERRESPONSIVENESS; ARACHIDONIC-ACID; LEUKOTRIENE B-4; LUNG INJURY; EXPRESSION; ENDOTOXIN	Pulmonary fibrosis is an interstitial disorder of the lung parenchyma whose mechanism is poorly understood. Potential mechanisms include the infiltration of inflammatory cells to the lungs and the generation of pro-inflammatory mediators. In particular, idiopathic pulmonary fibrosis is a progressive and fatal form of the disorder characterized by alveolar inflammation, fibroblast proliferation and collagen deposition. Here, we investigated the role of cytosolic phospholipase A(2) (cPLA(2)) in pulmonary fibrosis using cPLA(2)-null mutant mice, as cPLA(2) is a key enzyme in the generation of pro-inflammatory eicosanoids. Disruption of the gene encoding cPLA(2) (Pla2g4a) attenuated IPF and inflammation induced by bleomycin administration. Bleomycin-induced overproduction of thromboxanes and leukotrienes in lung was significantly reduced in cPLA(2)-null mice. Our data suggest that cPLA(2) has an important role in the pathogenesis of pulmonary fibrosis. The inhibition of cPLA(2)-initiated pathways might provide a novel therapeutic approach to pulmonary fibrosis, for which no pharmaceutical agents are currently available.	Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Tokyo, Japan; Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Tokyo, Japan; Japan Sci & Technol Corp, CREST, Tokyo, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Nagase, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Tokyo, Japan.	takahide-tky@umin.ac.jp	Uozumi, Nobuyuki/AAG-3252-2019	Yamamoto, Hiroshi/0000-0001-8907-3166				*AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00; BITO H, 1994, EUR J BIOCHEM, V221, P211, DOI 10.1111/j.1432-1033.1994.tb18731.x; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; Chiang N, 1999, J CLIN INVEST, V104, P309, DOI 10.1172/JCI7016; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; Eitzman DT, 1996, J CLIN INVEST, V97, P232, DOI 10.1172/JCI118396; Hattori N, 2000, J CLIN INVEST, V106, P1341, DOI 10.1172/JCI10531; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Ishii S, 1996, BIOCHEM J, V314, P671, DOI 10.1042/bj3140671; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KUNZ D, 1992, J BIOL CHEM, V267, P9101; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOEHRER PJ, 1995, J CLIN ONCOL, V13, P470, DOI 10.1200/JCO.1995.13.2.470; Lynch KR, 1999, NATURE, V399, P789; MOSELEY PL, 1986, J CLIN INVEST, V78, P1150, DOI 10.1172/JCI112695; Nagase T, 1999, J CLIN INVEST, V104, P1071, DOI 10.1172/JCI7727; Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897; Nagase T, 1997, AM J RESP CRIT CARE, V156, P1621, DOI 10.1164/ajrccm.156.5.9703016; Nagase T, 2002, AM J RESP CRIT CARE, V165, P200, DOI 10.1164/ajrccm.165.2.2106131; Nagase T, 1997, J APPL PHYSIOL, V83, P46, DOI 10.1152/jappl.1997.83.1.46; Nagase T, 1998, AM J RESP CRIT CARE, V157, P560, DOI 10.1164/ajrccm.157.2.9706009; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; SCHEULE RK, 1992, AM J PHYSIOL, V262, pL386, DOI 10.1152/ajplung.1992.262.4.L386; SHARP JD, 1991, J BIOL CHEM, V266, P14850; Shindou H, 2000, BIOCHEM BIOPH RES CO, V271, P812, DOI 10.1006/bbrc.2000.2723; SUGIMOTO T, 1992, BIOCHEM BIOPH RES CO, V189, P617, DOI 10.1016/0006-291X(92)92245-S; Tran PL, 1997, J CLIN INVEST, V99, P608, DOI 10.1172/JCI119203; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Wilborn J, 1996, J CLIN INVEST, V97, P1827, DOI 10.1172/JCI118612; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	39	128	131	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2002	8	5					480	484		10.1038/nm0502-480	http://dx.doi.org/10.1038/nm0502-480			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984592				2022-12-27	WOS:000175336800033
J	Reynolds, LE; Wyder, L; Lively, JC; Taverna, D; Robinson, SD; Huang, XZ; Sheppard, D; Hynes, O; Hodivala-Dilke, KM				Reynolds, LE; Wyder, L; Lively, JC; Taverna, D; Robinson, SD; Huang, XZ; Sheppard, D; Hynes, O; Hodivala-Dilke, KM			Enhanced pathological angiogenesis in mice lacking beta(3) integrin or beta(3) and beta(5) integrins	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; RECONSTITUTED BASEMENT-MEMBRANE; ALPHA-V INTEGRINS; TUMOR-GROWTH; PROGENITOR CELLS; POSTNATAL NEOVASCULARIZATION; BLOOD-VESSELS; ALPHA(V)BETA(3); INHIBITION; CANCER	Inhibition of a alpha (v)beta (3) or alpha (v)beta (5) integrin function has been reported to suppress neovascularization and tumor growth, suggesting that these integrins are critical modulators of angiogenesis. Here we report that mice lacking beta (3) integrins or both beta (3) and beta (5) integrins not only support tumorigenesis, but have enhanced tumor growth as well: Moreover, the tumors in these integrin-deficient mice display enhanced angiogenesis, strongly suggesting that neither beta (3) nor beta (5) integrins are essential for neovascularization. We, also observed that angiogenic responses to hypoxia and vascular endothelial growth factor (VEGF) are augmented significantly in the absence of beta (3) integrins. We found no evidence that the expression or functions of other integrins were altered as a consequence of the beta (3) deficiency, but we did observe elevated levels of VEGF receptor-2 (also called Flk-1) in beta (3)-null endothelial cells. These data indicate that a alpha (v)beta (3) and alpha (v)beta (5) integrins are not essential for vascular development or pathological angiogenesis and highlight the need for further evaluation of the mechanisms of action of alpha (v)-integrin antagonists in anti-angiogenic therapeutics.	St Thomas Hosp, Cell Adhes & Dis Lab, Richard Dimbleby Dept, Imperial Canc Res Fund, London, England; MIT, Ctr Canc Res, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University of California System; University of California San Francisco	Hodivala-Dilke, KM (corresponding author), St Thomas Hosp, Cell Adhes & Dis Lab, Richard Dimbleby Dept, Imperial Canc Res Fund, London, England.	k.hodivala-dilke@icrf.icnet.uk	taverna, daniela/J-8358-2016	taverna, daniela/0000-0002-6365-527X; Robinson, Stephen/0000-0002-6606-7588; Hodivala-Dilke, Kairbaan/0000-0002-2859-749X	NCI NIH HHS [R01CA17007] Funding Source: Medline; NHLBI NIH HHS [P01HL66105, R01 HL53949, R01 HL64353, P01HL41484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA017007] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053949, P01HL041484, R01HL064353, P01HL066105] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; Brekken RA, 2000, CANCER RES, V60, P5117; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHEN YP, 1994, J BIOL CHEM, V269, P18307; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DRAKE CJ, 1995, J CELL SCI, V108, P2655; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Hammes HP, 1996, NAT MED, V2, P820; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; Huang XZ, 2000, MOL CELL BIOL, V20, P755, DOI 10.1128/MCB.20.3.755-759.2000; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; Hynes RO, 1999, BRAZ J MED BIOL RES, V32, P501, DOI 10.1590/S0100-879X1999000500002; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Kroon ME, 2000, BLOOD, V96, P2775; Kumar CC, 2001, CANCER RES, V61, P2232; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; NICOSIA RF, 1990, IN VITRO CELL DEV B, V26, P119; PASSANITI A, 1992, LAB INVEST, V67, P519; Pierce EA, 1997, ARCH OPHTHALMOL-CHIC, V115, P427; Saaristo A, 2000, ONCOGENE, V19, P6122, DOI 10.1038/sj.onc.1203969; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Stone EM, 1996, INVEST OPHTH VIS SCI, V37, P3100; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Taverna D, 2001, CANCER RES, V61, P5255; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3	45	511	538	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2002	8	1					27	34		10.1038/nm0102-27	http://dx.doi.org/10.1038/nm0102-27			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	507XQ	11786903				2022-12-27	WOS:000173056900027
J	Evans, MJ				Evans, MJ			The cultural mouse	NATURE MEDICINE			English	Editorial Material									Cardiff Univ, Cardiff, S Glam, Wales	Cardiff University	Evans, MJ (corresponding author), Cardiff Univ, Biomed Sci Bldg,Museum Ave, Cardiff, S Glam, Wales.								0	32	41	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1081	1083		10.1038/nm1001-1081	http://dx.doi.org/10.1038/nm1001-1081			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590418				2022-12-27	WOS:000171524500013
J	Zhou, S; Schuetz, JD; Bunting, KD; Colapietro, AM; Sampath, J; Morris, JJ; Lagutina, I; Grosveld, GC; Osawa, M; Nakauchi, H; Sorrentino, BP				Zhou, S; Schuetz, JD; Bunting, KD; Colapietro, AM; Sampath, J; Morris, JJ; Lagutina, I; Grosveld, GC; Osawa, M; Nakauchi, H; Sorrentino, BP			The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype	NATURE MEDICINE			English	Article							BONE-MARROW-CELLS; HEMATOPOIETIC STEM; P-GLYCOPROTEIN; IN-VITRO; GENE-TRANSFER; EFFLUX PUMP; DYE EFFLUX; VIVO; RESISTANCE; PROGENITOR	Stem cells from bone marrow, skeletal muscle and possibly other tissues can be identified by the 'side-population' (SP) phenotype. Although it has been assumed that expression of ABC transporters is responsible for this phenotype, the specific molecules involved have not been defined. Here we show that expression of the Bcrp1 (also known as Abcg2 murine/ABCG2 human) gene is a conserved feature of stem cells from a wide variety of sources. Bcrp1 mRNA was expressed at high levels in primitive murine hematopoietic stem cells, and was sharply downregulated with differentiation. Enforced expression of the ABCG2 cDNA directly conferred the SP phenotype to bone-marrow cells and caused a reduction in maturing progeny both in vitro and in transplantation-based assays. These results show that expression of the Bcrp1/ABCG2 gene is an important determinant of the SP phenotype, and that it might serve as a marker for stem cells from various sources.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Div Expt Hematol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA; Univ Tsukuba, Inst Basic Med Sci, Dept Immunol, Tsukuba, Ibaraki, Japan	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; University of Tsukuba	Sorrentino, BP (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, Div Expt Hematol, 332 N Lauderdale St, Memphis, TN 38105 USA.	brian.sorrentino@stjude.org	Schuetz, John D/N-2692-2018	Zhou, Sheng/0000-0001-5902-5868	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749, R01HL067366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005851, R29ES005851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM060904, R01GM060904] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL 53749, R01 HL67366-01] Funding Source: Medline; NIEHS NIH HHS [ES05851] Funding Source: Medline; NIGMS NIH HHS [GM60904] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allay JA, 1997, BLOOD, V90, P3546, DOI 10.1182/blood.V90.9.3546; Allay JA, 1998, NAT MED, V4, P1136, DOI 10.1038/2632; Bodine DM, 1996, BLOOD, V88, P89; Bunting KD, 2000, BLOOD, V96, P902, DOI 10.1182/blood.V96.3.902.015k40_902_909; Bunting KD, 1998, BLOOD, V92, P2269, DOI 10.1182/blood.V92.7.2269.2269_2269_2279; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; DHondt V, 1997, HUM GENE THER, V8, P1745, DOI 10.1089/hum.1997.8.15-1745; Doyle LA, 1999, P NATL ACAD SCI USA, V96, P2569; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Geschwind DH, 2001, NEURON, V29, P325, DOI 10.1016/S0896-6273(01)00209-4; Good JR, 2000, DEV BIOL, V220, P53, DOI 10.1006/dbio.2000.9611; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hulspas R, 2000, CYTOMETRY, V40, P245, DOI 10.1002/1097-0320(20000701)40:3<245::AID-CYTO10>3.3.CO;2-X; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Johnstone RW, 1999, BLOOD, V93, P1075, DOI 10.1182/blood.V93.3.1075.403k35_1075_1085; KLIMECKI WT, 1995, J CLIN IMMUNOL, V15, P152, DOI 10.1007/BF01543107; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Maliepaard M, 1999, CANCER RES, V59, P4559; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Miyake K, 1999, CANCER RES, V59, P8; Nakamura Y, 1999, BLOOD, V94, P4053, DOI 10.1182/blood.V94.12.4053.424k41_4053_4059; Orkin SH, 2000, NAT MED, V6, P1212, DOI 10.1038/81303; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Pallis M, 2000, BLOOD, V95, P2897, DOI 10.1182/blood.V95.9.2897.009k14_2897_2904; Persons DA, 1998, BLOOD CELL MOL DIS, V24, P167, DOI 10.1006/bcmd.1998.0184; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Sato T, 1999, BLOOD, V94, P2548, DOI 10.1182/blood.V94.8.2548.420k38_2548_2554; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; SORRENTINO BP, 1995, BLOOD, V86, P491, DOI 10.1182/blood.V86.2.491.bloodjournal862491; SPANGRUDE GJ, 1990, P NATL ACAD SCI USA, V87, P7433, DOI 10.1073/pnas.87.19.7433; Storms RW, 2000, BLOOD, V96, P2125; WOLF NS, 1993, EXP HEMATOL, V21, P614; Zeng H, 2000, CANCER RES, V60, P4779	37	1714	1891	3	108	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2001	7	9					1028	1034		10.1038/nm0901-1028	http://dx.doi.org/10.1038/nm0901-1028			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533706				2022-12-27	WOS:000170853300028
J	Yung, E; Sorin, M; Pal, A; Craig, E; Morozov, A; Delattre, O; Kappes, J; Oti, D; Kalpana, GV				Yung, E; Sorin, M; Pal, A; Craig, E; Morozov, A; Delattre, O; Kappes, J; Oti, D; Kalpana, GV			Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FINGER-LIKE DOMAIN; TYPE-1 INTEGRASE; VIRAL REPLICATION; MUTATIONS; DNA; COMPLEX; BINDING; PROTEIN; CELLS	Integase Interactor 1(INI), also known as hSNF5, is a protein that interacts with HIV-1 integrase. We report here that a cytoplasmically localized fragment of INI (S6; aa183-294) containing the minimal integrase-interaction domain potently inhibits HIV-1 particle production and replication. Mutations in 56 or integrase that disrupt integrase-INI1 interaction abrogated the inhibitory effect. An integrase-deficient HIV-1 transcomplemented with integrase fused to Vpr was not affected by S6. INI1 was specifically incorporated into virions and was required for efficient HIV-1 particle production. These results indicate that INI1 is required for late events in the viral life cycle, and that ectopic expression of S6 inhibits HIV-1 replication in a transdominant manner via its specific interaction with integrase within the context of Gag-Pol, providing a novel strategy to control HIV-1 replication.	Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10467 USA; NCI, AIDS Vaccine Program, SAIC Frederick, Frederick, MD 21701 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Inst Curie, Lab Pathol Mol Canc, Paris, France	Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Alabama System; University of Alabama Birmingham; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Kalpana, GV (corresponding author), Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10467 USA.	kalpana@aecom.yu.edu		delattre, olivier/0000-0002-8730-2276; Kalpana, Ganjam/0000-0003-4111-0604; Yung, Eric/0000-0002-7328-7204	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007501] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline; NIAID NIH HHS [AI/GM 399951, T32-AI07501] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1991, ARCH VIROL, V117, P45, DOI 10.1007/BF01310491; ANSARILARI MA, 1995, VIROLOGY, V211, P332, DOI 10.1006/viro.1995.1412; Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; Biegel JA, 1999, CANCER RES, V59, P74; Brown P. O., 1997, P161; BROWN PO, 1990, CURR TOP MICROBIOL, V157, P19; Bukovsky A, 1996, J VIROL, V70, P6820, DOI 10.1128/JVI.70.10.6820-6825.1996; CANNON PM, 1994, J VIROL, V68, P4768, DOI 10.1128/JVI.68.8.4768-4775.1994; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Desrosiers RC, 1999, NAT MED, V5, P723, DOI 10.1038/10439; ENGELMAN A, 1995, J VIROL, V69, P2729, DOI 10.1128/JVI.69.5.2729-2736.1995; Fletcher TM, 1997, EMBO J, V16, P5123, DOI 10.1093/emboj/16.16.5123; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Leavitt AD, 1996, J VIROL, V70, P721, DOI 10.1128/JVI.70.2.721-728.1996; Leung DW, 1989, TECHNIQUE, V1, P11; MASUDA T, 1995, J VIROL, V69, P6687, DOI 10.1128/JVI.69.11.6687-6696.1995; Mathe' C, 1999, NUCLEOS NUCLEOT, V18, P681, DOI 10.1080/15257779908041539; Morozov A, 1998, P NATL ACAD SCI USA, V95, P1120, DOI 10.1073/pnas.95.3.1120; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Nakamura T, 1997, BIOCHEM BIOPH RES CO, V239, P715, DOI 10.1006/bbrc.1997.7541; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Ott DE, 1996, J VIROL, V70, P7734, DOI 10.1128/JVI.70.11.7734-7743.1996; Pani A, 2000, CURR PHARM DESIGN, V6, P569, DOI 10.2174/1381612003400759; Pommier Y, 1999, ADV VIRUS RES, V52, P427, DOI 10.1016/S0065-3527(08)60310-3; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; Swanstrom R., 1997, P263; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; WISKERCHEN M, 1995, J VIROL, V69, P376, DOI 10.1128/JVI.69.1.376-386.1995; Wu XY, 1997, EMBO J, V16, P5113, DOI 10.1093/emboj/16.16.5113; Wu XY, 1999, J VIROL, V73, P2126, DOI 10.1128/JVI.73.3.2126-2135.1999	33	110	120	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2001	7	8					920	926		10.1038/90959	http://dx.doi.org/10.1038/90959			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479624				2022-12-27	WOS:000171740400029
J	Fabre, JW				Fabre, JW			The allogeneic response and tumor immunity	NATURE MEDICINE			English	Editorial Material							CYTOTOXIC T-LYMPHOCYTES; DENDRITIC CELLS; ALLOGRAFT-REJECTION; CANCER-CELLS; IFN-GAMMA; IN-VIVO; ANTIGENS; HYBRIDS; ALLOREACTIVITY; VACCINATION	The strong allogeneic response to donor MHC molecules in transplantation and the weak response to tumor antigens represent two important and divergent but potentially interactive immune responses. A patient's response to allogeneic MHC molecules might promote an effective T-cell response to self MHC-restricted tumor peptides and the possibilities for this are discussed here. These allogeneic responses might successfully be harnessed to promote the immune eradication of metastatic cancer.	Guys Kings & St Thomas Sch Med, Inst Liver Studies, Dept Clin Sci, London, England	University of London; King's College London	Fabre, JW (corresponding author), Guys Kings & St Thomas Sch Med, Inst Liver Studies, Dept Clin Sci, London, England.							BACH FH, 1966, SCIENCE, V153, P545, DOI 10.1126/science.153.3735.545; BENHAM AM, 1995, TRANSPLANTATION, V59, P1028, DOI 10.1097/00007890-199504150-00019; BEVAN MJ, 1984, IMMUNOL TODAY, V5, P128, DOI 10.1016/0167-5699(84)90233-0; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BURROWS SR, 1994, J EXP MED, V179, P1155, DOI 10.1084/jem.179.4.1155; DAAR AS, 1983, EUR J CANCER CLIN ON, V19, P209, DOI 10.1016/0277-5379(83)90419-4; FANGMANN J, 1992, J EXP MED, V175, P1521, DOI 10.1084/jem.175.6.1521; FLEMING KA, 1981, J CLIN PATHOL, V34, P779, DOI 10.1136/jcp.34.7.779; FREY AB, 1995, J IMMUNOL, V154, P4613; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Gjertsen H A, 1993, Transpl Immunol, V1, P126, DOI 10.1016/0966-3274(93)90005-S; Gong JL, 2000, J IMMUNOL, V165, P1705, DOI 10.4049/jimmunol.165.3.1705; Grene E, 2000, AIDS, V14, P1497, DOI 10.1097/00002030-200007280-00005; HALL BM, 1991, TRANSPLANTATION, V51, P1141, DOI 10.1097/00007890-199106000-00001; HART DNJ, 1980, TRANSPLANTATION, V30, P73, DOI 10.1097/00007890-198007000-00016; HART DNJ, 1981, J EXP MED, V154, P347, DOI 10.1084/jem.154.2.347; HELLSTRO.I, 1967, SCIENCE, V156, P981, DOI 10.1126/science.156.3777.981; HELLSTROM I, 1968, NATURE, V220, P1352, DOI 10.1038/2201352a0; Kelly CM, 1996, TRANSPLANTATION, V61, P1094, DOI 10.1097/00007890-199604150-00018; KIM BS, 1979, J IMMUNOL, V123, P739; Koopman LA, 2000, J EXP MED, V191, P961, DOI 10.1084/jem.191.6.961; Kugler A, 2000, NAT MED, V6, P332, DOI 10.1038/73193; Lahn M, 1997, EUR SURG RES, V29, P292, DOI 10.1159/000129536; LECHLER RI, 1990, IMMUNOL TODAY, V11, P83, DOI 10.1016/0167-5699(90)90033-6; MASON DW, 1984, IMMUNOL REV, V77, P167, DOI 10.1111/j.1600-065X.1984.tb00721.x; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; MILLAR JW, 1980, THORAX, V35, P856, DOI 10.1136/thx.35.11.856; MITCHISON NA, 1987, EUR J IMMUNOL, V17, P1579, DOI 10.1002/eji.1830171109; MORALES A, 1976, J UROLOGY, V116, P180, DOI 10.1016/S0022-5347(17)58737-6; Mumberg D, 1999, P NATL ACAD SCI USA, V96, P8633, DOI 10.1073/pnas.96.15.8633; Newton DA, 2000, J IMMUNOTHER, V23, P246, DOI 10.1097/00002371-200003000-00009; Newton DA, 2001, J IMMUNOTHER, V24, P19, DOI 10.1097/00002371-200101000-00003; NISBET NW, 1969, J EXP MED, V129, P459, DOI 10.1084/jem.129.3.459; PAYELLE B, 1981, INT J CANCER, V27, P783, DOI 10.1002/ijc.2910270609; REISERJB, 2000, NATURE IMMUNOL, V1, P291; SANTOSAGUADO J, 1989, P NATL ACAD SCI USA, V86, P8936, DOI 10.1073/pnas.86.22.8936; Shearer GM, 1999, IMMUNOL TODAY, V20, P66, DOI 10.1016/S0167-5699(98)01392-9; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; Suchin EJ, 2001, J IMMUNOL, V166, P973, DOI 10.4049/jimmunol.166.2.973; THATCHER N, 1984, BRIT J DIS CHEST, V78, P89, DOI 10.1016/0007-0971(84)90101-3; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; TOFFALETTI DL, 1983, J IMMUNOL, V130, P2982; Vaughan JW, 1914, J AMER MED ASSOC, V63, P1258	45	82	86	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2001	7	6					649	652		10.1038/89008	http://dx.doi.org/10.1038/89008			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385492				2022-12-27	WOS:000169081500020
J	Steinwaerder, DS; Carlson, CA; Otto, DL; Li, ZY; Ni, SH; Lieber, A				Steinwaerder, DS; Carlson, CA; Otto, DL; Li, ZY; Ni, SH; Lieber, A			Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector	NATURE MEDICINE			English	Article							IN-VIVO; THERAPY; GENERATION; CANCER; LIVER	Clinical applications of tumor gene therapy require tumor-specific delivery or expression of therapeutic genes in order to maximize the oncolytic index and minimize side effects(1,2). This study demonstrates activation of transgene expression exclusively in hepatic metastases after systemic application of a modified first-generation (E1A/E1B-deleted) adenovirus vector (AdE1(-)) in mouse tumor models. The discrimination between tumors and normal liver tissue is based on selective DNA replication of AdE1(-) vectors in tumor cells. This new AdE1(-) based vector system uses homologous recombination between inverted repeats to mediate precise rearrangements within the viral genome. As a result of these rearrangements, a promoter is brought into conjunction with a reporter gene creating a functional expression cassette. Genomic rearrangements are dependent upon viral DNA replication, which in turn occurs specifically in tumor cells. In a mouse tumor model with liver metastases derived from human tumor cells, a single systemic administration of replication activated AdE1(-) vectors achieved transgene expression in every metastasis, whereas no extra-tumoral transgene induction was observed. Here we provide a new concept for tumor-specific gene expression that is also applicable for other conditionally replicating adenovirus vectors.	Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lieber, A (corresponding author), Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA.			Lieber, Andre/0000-0001-6742-6266	NCI NIH HHS [R01 CA80192] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080192] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alemany R, 2000, NAT BIOTECHNOL, V18, P723, DOI 10.1038/77283; BABISS LE, 1986, MOL CELL BIOL, V6, P3798, DOI 10.1128/MCB.6.11.3798; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Dachs GU, 1997, ONCOL RES, V9, P313; Doronin K, 2000, J VIROL, V74, P6147, DOI 10.1128/JVI.74.13.6147-6155.2000; Haag A, 2000, HUM GENE THER, V11, P597, DOI 10.1089/10430340050015789; Hallenbeck PL, 1999, HUM GENE THER, V10, P1721, DOI 10.1089/10430349950017725; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Lieber A, 1996, J VIROL, V70, P8944, DOI 10.1128/JVI.70.12.8944-8960.1996; LIU ML, 1994, HEPATOLOGY, V19, P1521; Nelson JE, 1997, J VIROL, V71, P8902, DOI 10.1128/JVI.71.11.8902-8907.1997; Peeters MJTFDV, 1996, BIOTECHNIQUES, V20, P278; RUSSELL DW, 1995, P NATL ACAD SCI USA, V92, P5719, DOI 10.1073/pnas.92.12.5719; SATOH J, 1995, J NEUROPATH EXP NEUR, V54, P504, DOI 10.1097/00005072-199507000-00004; Shayakhmetov DM, 2000, J VIROL, V74, P2567, DOI 10.1128/JVI.74.6.2567-2583.2000; Steinwaerder DS, 1999, J VIROL, V73, P9303, DOI 10.1128/JVI.73.11.9303-9313.1999; Steinwaerder DS, 2000, HUM GENE THER, V11, P1933, DOI 10.1089/10430340050129549; Steinwaerder DS, 2000, GENE THER, V7, P556, DOI 10.1038/sj.gt.3301139; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Sullivan DE, 1997, HUM GENE THER, V8, P1195, DOI 10.1089/hum.1997.8.10-1195; SUSSENBACH JS, 1973, VIROLOGY, V54, P299, DOI 10.1016/0042-6822(73)90142-6; Yoon SS, 2000, FASEB J, V14, P301, DOI 10.1096/fasebj.14.2.301; Zhang WW, 1999, CANCER GENE THER, V6, P113, DOI 10.1038/sj.cgt.7700024	25	47	52	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					240	243		10.1038/84696	http://dx.doi.org/10.1038/84696			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175857				2022-12-27	WOS:000166756300043
J	Surolia, N; Surolia, A				Surolia, N; Surolia, A			Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum	NATURE MEDICINE			English	Article							CARRIER PROTEIN REDUCTASE; FATTY-ACID BIOSYNTHESIS; ESCHERICHIA-COLI; BRASSICA-NAPUS; TARGET; FABI; NADH; PURIFICATION; MYCOPLASMAS; EXPRESSION	The antimicrobial biocide triclosan [5-chloro-2-(2,4-dichlorophenoxy)phenol] potently inhibits the growth of Plasmodium falciparum in vitro and, in a mouse model, Plasmodium berghei in vivo. Inhibition of [C-14]acetate and [C-14]malonyl-CoA incorporation into fatty acids in vivo and in vitro, respectively, by triclosan implicate FabI as its target. Here we demonstrate that the enoyl-ACP reductase purified from P. falciparum is triclosan sensitive. Also, we present the evidence for the existence of FabI gene in P, falciparum. We establish the existence of the de novo fatty acid biosynthetic pathway in this parasite, and identify a key enzyme of this pathway for the development of new antimalarials.	Indian Inst Sci, Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bangalore 560012, Karnataka, India; Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India	Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore	Surolia, N (corresponding author), Indian Inst Sci, Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bangalore 560012, Karnataka, India.		SUROLIA, AVADESHA/C-5442-2009					AGARWAL AK, 1987, BIOCHEM BIOPH RES CO, V148, P357; Ancelin ML, 1998, BLOOD, V91, P1426, DOI 10.1182/blood.V91.4.1426; Bergler H, 1996, EUR J BIOCHEM, V242, P689, DOI 10.1111/j.1432-1033.1996.0689r.x; BERGLER H, 1994, J BIOL CHEM, V269, P5493; Bhargava HN, 1996, AM J INFECT CONTROL, V24, P209, DOI 10.1016/S0196-6553(96)90017-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHORNCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; DUSSURGET O, 1994, APPL ENVIRON MICROB, V60, P953, DOI 10.1128/AEM.60.3.953-959.1994; FITCH CD, 1982, ANTIMICROB AGENTS CH, V21, P819, DOI 10.1128/AAC.21.5.819; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; HALDAR K, 1985, J BIOL CHEM, V260, P4969; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; Heath RJ, 1999, J BIOL CHEM, V274, P11110, DOI 10.1074/jbc.274.16.11110; HEUSSER D, 1968, J CHROMATOGR, V33, P62, DOI 10.1016/S0021-9673(00)98620-5; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HOLZ GG, 1977, B WORLD HEALTH ORGAN, V55, P237; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; KATER MM, 1991, PLANT MOL BIOL, V17, P895, DOI 10.1007/BF00037070; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Levy CW, 1999, NATURE, V398, P383, DOI 10.1038/18803; Matesanz F, 1999, J MOL BIOL, V291, P59, DOI 10.1006/jmbi.1999.2964; McConkey GA, 1997, J BIOL CHEM, V272, P2046, DOI 10.1074/jbc.272.4.2046; MCKEON TA, 1982, J BIOL CHEM, V257, P2141; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; MITRUKA M, 1977, CLIN BIOCH HEMATOLOG; PETERS W, 1980, MALARIA; Razin S, 1998, MICROBIOL MOL BIOL R, V62, P1094, DOI 10.1128/MMBR.62.4.1094-1156.1998; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Rowe JA, 1998, MOL BIOCHEM PARASIT, V92, P177, DOI 10.1016/S0166-6851(97)00237-5; Sambrook J., 2002, MOL CLONING LAB MANU; SLABAS AR, 1986, BIOCHIM BIOPHYS ACTA, V877, P271, DOI 10.1016/0005-2760(86)90304-8; SUROLIA N, 1992, BIOCHEM BIOPH RES CO, V187, P744, DOI 10.1016/0006-291X(92)91258-R; SUROLIA N, 1991, P NATL ACAD SCI USA, V88, P4786, DOI 10.1073/pnas.88.11.4786; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TURNOWSKY F, 1989, J BACTERIOL, V171, P6555, DOI 10.1128/jb.171.12.6555-6565.1989; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; WEEKS G, 1968, J BIOL CHEM, V243, P1180	40	367	378	0	51	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					167	173		10.1038/84612	http://dx.doi.org/10.1038/84612			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175846				2022-12-27	WOS:000166756300032
J	Younkin, SG				Younkin, SG			Amyloid beta vaccination: reduced plaques and improved cognition	NATURE MEDICINE			English	Editorial Material							TRANSGENIC MICE	Studies in three different transgenic mouse models suggest that the amyloid beta -protein contributes to memory loss in Alzheimer disease. Immunization with an amyloid beta -peptide fragment reduces learning and memory impairments in mice, and this approach may eventually be used to prevent and/or treat this disease in people.	Mayo Clin Jacksonville, Ctr Neurosci, Jacksonville, FL 32224 USA	Mayo Clinic	Younkin, SG (corresponding author), Mayo Clin Jacksonville, Ctr Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.							Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; CHEN GZ, IN PRESS NATURE; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JANUS C, IN PRESS NATURE; MORGAN D, IN PRESS NATURE; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; SCHENK, 1999, NATURE, V40, P173	9	40	63	1	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					18	19		10.1038/83292	http://dx.doi.org/10.1038/83292			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135604				2022-12-27	WOS:000166243100019
J	Cheng, T; Rodrigues, N; Dombkowski, D; Stier, S; Scadden, DT				Cheng, T; Rodrigues, N; Dombkowski, D; Stier, S; Scadden, DT			Stem cell repopulation efficiency but not pool size is governed by p27(kip1)	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; HEMATOPOIETIC PROGENITORS; COMPETITIVE REPOPULATION; MICE LACKING; CYCLE; EXPRESSION; DIFFERENTIATION; MOUSE; INHIBITOR; ASSAY	Sustained blood cell production requires preservation of a quiescent, multipotential stem cell pool that intermittently gives rise to progenitors with robust proliferative potential. The ability of cells to shift from a highly constrained to a vigorously active proliferative state is critical for maintaining stem cells while providing the responsiveness necessary for host defense. The cy clin-dependent kinase inhibitor (CDKI), p21(cip1/waf1) (p21) dominates stem cell kinetics. Here we report that another CDKI, p27(kip1) (p27), does not affect stem cell number, cell cycling, or self-renewal, but markedly alters progenitor proliferation and pool size. Therefore, distinct CDKIs govern the highly divergent stem and progenitor cell populations. When competitively transplanted, p27-deficient stem cells generate progenitors that eventually dominate blood cell production. Modulating p27 expression in a small number of stem cells may translate into effects on the majority of mature cells, thereby providing a strategy for potentiating the impact of transduced cells in stem cell gene therapy.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, AIDS Res Ctr, Boston, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02129 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Scadden, DT (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, AIDS Res Ctr, 149 13th St,Room 5212, Boston, MA 02129 USA.	cheng-tao@mgh.harvard.edu; scadden.david@mgh.harvard.edu		Rodrigues, Neil/0000-0002-1925-7733; Cheng, Tao/0000-0002-5925-2769	NHLBI NIH HHS [HL 44851, HL 55718] Funding Source: Medline; NIAID NIH HHS [AI07387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044851, R01HL055718] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asiedu C, 1997, BLOOD, V90, P3430, DOI 10.1182/blood.V90.9.3430; Becker PS, 1999, EXP HEMATOL, V27, P533, DOI 10.1016/S0301-472X(98)00037-X; BERARDI AC, 1995, SCIENCE, V267, P104, DOI 10.1126/science.7528940; CarverMoore K, 1996, BLOOD, V88, P803; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Dao MA, 1998, P NATL ACAD SCI USA, V95, P13006, DOI 10.1073/pnas.95.22.13006; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gardner RV, 1997, EXP HEMATOL, V25, P495; Gothot A, 1997, BLOOD, V90, P4384, DOI 10.1182/blood.V90.11.4384.4384_4384_4393; GRZEGORZEWSKI K, 1994, J EXP MED, V180, P1047, DOI 10.1084/jem.180.3.1047; HARRISON DE, 1980, BLOOD, V55, P77; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LERNER C, 1990, EXP HEMATOL, V18, P114; Levine EM, 2000, DEV BIOL, V219, P299, DOI 10.1006/dbio.2000.9622; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; MAUCH P, 1989, BONE MARROW TRANSPL, V4, P601; MAUCH P, 1995, INT J RADIAT ONCOL, V31, P1319, DOI 10.1016/0360-3016(94)00430-S; MULLER AM, 1993, DEVELOPMENT, V118, P1343; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PLOEMACHER RE, 1989, BLOOD, V74, P2755; PLOEMACHER RE, 1991, BLOOD, V78, P2527; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Roy V, 1999, EXP HEMATOL, V27, P302, DOI 10.1016/S0301-472X(98)00031-9; Shen HM, 1999, J VIROL, V73, P728, DOI 10.1128/JVI.73.1.728-737.1999; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SPANGRUDE GJ, 1989, SCIENCE, V244, P1030; SZILVASSY SJ, 1990, P NATL ACAD SCI USA, V87, P8736, DOI 10.1073/pnas.87.22.8736; Taniguchi T, 1999, BLOOD, V93, P4167, DOI 10.1182/blood.V93.12.4167.412k05_4167_4178; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Testa U, 1996, BLOOD, V88, P3391, DOI 10.1182/blood.V88.9.3391.bloodjournal8893391; Tong X, 1998, EXP HEMATOL, V26, P684; WESTON SA, 1990, J IMMUNOL METHODS, V133, P87, DOI 10.1016/0022-1759(90)90322-M; Yaroslavskiy B, 1999, BLOOD, V93, P2907	45	270	285	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2000	6	11					1235	1240		10.1038/81335	http://dx.doi.org/10.1038/81335			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062534				2022-12-27	WOS:000165114800030
J	John, GR; Shankar, SL; Shafit-Zagardo, B; Massimi, A; Lee, SC; Raine, CS; Brosnan, CF				John, GR; Shankar, SL; Shafit-Zagardo, B; Massimi, A; Lee, SC; Raine, CS; Brosnan, CF			Multiple sclerosis: Re-expression of a developmental pathway that restricts oligodendrocyte maturation	NATURE MEDICINE			English	Article							NOTCH RECEPTOR; LESIONS; DIFFERENTIATION; ASTROCYTES; MECHANISMS; DISEASE	During mammalian central nervous system (CNS) development, contact-mediated activation of Notch1 receptors on oligodendrocyte precursors by the ligand Jagged1 induces Hes5, which inhibits maturation of these cells. Here we tested whether the Notch pathway is re-expressed in the adult CNS in multiple sclerosis (MS), an inflammatory demyelinating disease in which remyelination is typically limited. We found that transforming growth factor-beta1 (TGF-beta1), a cytokine upregulated in MS, specifically re-induced Jagged1 in primary cultures of human astrocytes. Within and around active MS plaques lacking remyelination, Jagged1 was expressed at high levels by hypertrophic astrocytes, whereas Notch1 and Hes5 localized to cells with an immature oligodendrocyte phenotype, and TGF-beta1 was associated with perivascular extracellular matrix in the same areas. In contrast, there was negligible Jagged1 expression in remyelinated lesions. Experiments in vitro showed that Jagged1 signaling inhibited process outgrowth from primary human oligodendrocytes. These data are the first to implicate the Notch pathway in the limited remyelination in MS. Thus, Notch may represent a potential target for therapeutic intervention in this disease.	Albert Einstein Coll Med, Dept Pathol Neuropathol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	John, GR (corresponding author), Albert Einstein Coll Med, Dept Pathol Neuropathol, Bronx, NY 10467 USA.		Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Massimi, Aldo/0000-0002-1549-386X	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH055477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038102, R01NS040137, P50NS011920, P01NS011920, R01NS008952] Funding Source: NIH RePORTER; NIMH NIH HHS [MH55477] Funding Source: Medline; NINDS NIH HHS [NS11920, NS38102, NS40137, NS08952] Funding Source: Medline; CSR NIH HHS [RG3020] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); CSR NIH HHS		Baranzini SE, 2000, J IMMUNOL, V165, P6576, DOI 10.4049/jimmunol.165.11.6576; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bottinger EP, 1996, P NATL ACAD SCI USA, V93, P5877, DOI 10.1073/pnas.93.12.5877; Brosnan CF, 1996, BRAIN PATHOL, V6, P243, DOI 10.1111/j.1750-3639.1996.tb00853.x; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; Chang A, 2002, NEW ENGL J MED, V346, P165, DOI 10.1056/NEJMoa010994; Givogri MI, 2002, J NEUROSCI RES, V67, P309, DOI 10.1002/jnr.10128; Gray GE, 1999, AM J PATHOL, V154, P785, DOI 10.1016/S0002-9440(10)65325-4; Kondo T, 2000, DEVELOPMENT, V127, P2989; Lassmann H, 1998, J NEUROIMMUNOL, V86, P213, DOI 10.1016/S0165-5728(98)00031-9; LEE SC, 1997, MOL BIOL MULTIPLE SC, P71; Liu J, 1996, J IMMUNOL, V157, P3569; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084; McCartney-Francis N L, 1998, Int Rev Immunol, V16, P553, DOI 10.3109/08830189809043009; MCDONALD WI, 1969, NATURE, V221, P182, DOI 10.1038/221182a0; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Prineas J. W., 1997, GREENFIELDS NEUROPAT, P813; PRINEAS JW, 1990, LAB INVEST, V63, P624; RAINE CS, 1997, TXB NEUROPATHOLOGY, P243; Raine CS, 1997, MULTIPLE SCLEROSIS C, P151; Redmond L, 2000, NAT NEUROSCI, V3, P30, DOI 10.1038/71104; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SMITH KJ, 1979, NATURE, V280, P395, DOI 10.1038/280395a0; Stears RL, 2000, PHYSIOL GENOMICS, V3, P93, DOI 10.1152/physiolgenomics.2000.3.2.93; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; Wolswijk G, 1998, J NEUROSCI, V18, P601; WU E, 1992, LAB INVEST, V67, P88	31	382	397	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2002	8	10					1115	1121		10.1038/nm781	http://dx.doi.org/10.1038/nm781			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12357247				2022-12-27	WOS:000178311000038
J	Chavakis, T; Hussain, M; Kanse, SM; Peters, G; Bretzel, RG; Flock, JI; Herrmann, M; Preissner, KT				Chavakis, T; Hussain, M; Kanse, SM; Peters, G; Bretzel, RG; Flock, JI; Herrmann, M; Preissner, KT			Staphylococcus aureus extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes	NATURE MEDICINE			English	Article							FIBRINOGEN-BINDING PROTEIN; UROKINASE RECEPTOR; CLUMPING FACTOR; MOLECULAR CHARACTERIZATION; VITRONECTIN-BINDING; P-SELECTIN; INTEGRIN; ADHESION; EXPRESSION; COAGULASE	Staphylococcus aureus is a human pathogen that secretes proteins that contribute to bacterial colonization. Here we describe the extracellular adherence protein (Eap) as a novel anti-inflammatory factor that inhibits host leukocyte recruitment. Due to its direct interactions with the host adhesive proteins intercellular adhesion molecule 1 (ICAM-1), fibrinogen or vitronectin, Eap disrupted beta(2)-integrin and urokinase receptor-mediated leukocyte adhesion in vitro. Whereas Eap-expressing S. aureus induced a 2-3-fold lower neutrophil recruitment in bacterial peritonitis in mice as compared with an Eap-negative strain, isolated Eap prevented beta(2)-integrin-dependent neutrophil recruitment in a mouse model of acute thioglycollate-induced peritonitis. Thus, the specific interactions with ICAM-1 and extracellular matrix proteins render Eap a potent anti-inflammatory factor, which may serve as a new therapeutic substance to block leukocyte extravasation in patients with hyperinflammatory pathologies.	Univ Giessen, Inst Biochem, Giessen, Germany; Univ Giessen, Dept Internal Med 3, Giessen, Germany; Univ Hosp, Inst Med Microbiol, Munster, Germany; Huddinge Univ Hosp, Karolinska Inst, Dept Microbiol Pathol & Immunol, S-14186 Huddinge, Sweden; Saarland Univ Hosp, Inst Med Microbiol & Hyg, Dept Bacteriol & Hyg, Homburg, Germany	Justus Liebig University Giessen; Justus Liebig University Giessen; University of Munster; Karolinska Institutet; Universitatsklinikum des Saarlandes	Chavakis, T (corresponding author), Univ Giessen, Inst Biochem, Giessen, Germany.	triantafyllos.chavakis@innere.med.uni-giessen.de	Herrmann, Mathias/B-6475-2013; Bruckner, Peter/F-4817-2019; Chavakis, Triantafyllos/ABE-8845-2020	Herrmann, Mathias/0000-0003-2638-2257; Bruckner, Peter/0000-0002-5566-5611; Kanse, Sandip/0000-0003-0782-9957				BODEN MK, 1989, INFECT IMMUN, V57, P2358; Borges E, 1997, BLOOD, V90, P1934, DOI 10.1182/blood.V90.5.1934; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; BRUMFITT W, 1989, NEW ENGL J MED, V320, P1188, DOI 10.1056/NEJM198905043201806; CARLOS TM, 1994, BLOOD, V84, P2068; Chapman HA, 1999, THROMB HAEMOSTASIS, V82, P291; Chavakis T, 2000, BLOOD, V96, P514; Chavakis T, 1999, BLOOD, V93, P2976; Chavakis T, 2001, FASEB J, V15, P2365, DOI 10.1096/fj.01-0201com; Flock JI, 1999, MOL MED TODAY, V5, P532, DOI 10.1016/S1357-4310(99)01597-X; FLOCK JI, 1987, EMBO J, V6, P2351, DOI 10.1002/j.1460-2075.1987.tb02511.x; Hartleib J, 2000, BLOOD, V96, P2149; HENDRIX H, 1983, J BIOL CHEM, V258, P3637; Hoyer-Hansen G, 1997, FEBS LETT, V420, P79, DOI 10.1016/S0014-5793(97)01491-9; HUSSAIN M, 1991, J MED MICROBIOL, V34, P143, DOI 10.1099/00222615-34-3-143; Hussain M, 2001, CLIN DIAGN LAB IMMUN, V8, P1271, DOI 10.1128/CDLI.8.6.1271-1276.2001; HUSSAIN M, 2002, IN PRESS INFECT IMMU; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONSSON K, 1995, J BIOL CHEM, V270, P21457, DOI 10.1074/jbc.270.37.21457; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; May AE, 1998, J EXP MED, V188, P1029, DOI 10.1084/jem.188.6.1029; MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x; MCGAVIN MH, 1993, INFECT IMMUN, V61, P2479, DOI 10.1128/IAI.61.6.2479-2485.1993; Mizgerd JP, 1998, J LEUKOCYTE BIOL, V64, P291, DOI 10.1002/jlb.64.3.291; MOREILLON P, 1995, INFECT IMMUN, V63, P4738, DOI 10.1128/IAI.63.12.4738-4743.1995; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; Palma M, 1996, INFECT IMMUN, V64, P5284, DOI 10.1128/IAI.64.12.5284-5289.1996; Palma M, 1999, J BACTERIOL, V181, P2840, DOI 10.1128/JB.181.9.2840-2845.1999; Palma M, 1998, J BIOL CHEM, V273, P13177, DOI 10.1074/jbc.273.21.13177; Park PW, 1996, J BIOL CHEM, V271, P15803, DOI 10.1074/jbc.271.26.15803; PATTI JM, 1992, J BIOL CHEM, V267, P4766; PAULSSON M, 1992, ZBL BAKT-INT J MED M, V277, P54; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; Sawai T, 1997, INFECT IMMUN, V65, P466, DOI 10.1128/IAI.65.2.466-471.1997; SCHLIEVERT PM, 1993, J INFECT DIS, V167, P997, DOI 10.1093/infdis/167.5.997; Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462-5822.1999.00011.x; Sinha B, 2000, INFECT IMMUN, V68, P6871, DOI 10.1128/IAI.68.12.6871-6878.2000; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; Waldvogel FA, 1999, NEW ENGL J MED, V340, P556, DOI 10.1056/NEJM199902183400709	42	180	184	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2002	8	7					687	693		10.1038/nm728	http://dx.doi.org/10.1038/nm728			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12091905				2022-12-27	WOS:000176495200029
J	Ntziachristos, V; Tung, CH; Bremer, C; Weissleder, R				Ntziachristos, Vasilis; Tung, Ching-Hsuan; Bremer, Christoph; Weissleder, Ralph			Fluorescence molecular tomography resolves protease activity in vivo	NATURE MEDICINE			English	Article							TUMORS	Systematic efforts are under way to develop novel technologies that would allow molecular sensing in intact organisms in vivo. Using near-infrared fluorescent molecular beacons and inversion techniques that take into account the diffuse nature of photon propagation in tissue, we were able to obtain three-dimensional in vivo images of a protease in orthopic gliomas. We demonstrate that enzyme-activatable fluorochromes can be detected with high positional accuracy in deep tissues, that molecular specificities of different beacons towards enzymes can be resolved and that tomography of beacon activation is linearly related to enzyme concentration. The tomographic imaging method offers a range of new capabilities for studying biological function; for example, identifying molecular-expression patterns by multispectral imaging or continuously monitoring the efficacy of therapeutic drugs.	[Ntziachristos, Vasilis] Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA; Harvard Med Sch, Charlestown, MA USA	Harvard University; Massachusetts General Hospital	Ntziachristos, V (corresponding author), Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA.	vasilis@helix.mgh.harvard.edu	Tung, Ching-Hsuan/AHC-5070-2022; Tung, Ching-Hsuan/AIE-6009-2022	Tung, Ching-Hsuan/0000-0001-6648-6195; Tung, Ching-Hsuan/0000-0001-6648-6195; /0000-0003-0828-4143				Arridge SR, 1999, INVERSE PROBL, V15, pR41, DOI 10.1088/0266-5611/15/2/022; Bremer C, 2001, NAT MED, V7, P743, DOI 10.1038/89126; Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; Demchik LL, 1999, INT J DEV NEUROSCI, V17, P483, DOI 10.1016/S0736-5748(99)00011-8; Gross LA, 2000, P NATL ACAD SCI USA, V97, P11990, DOI 10.1073/pnas.97.22.11990; Han MY, 2001, NAT BIOTECHNOL, V19, P631, DOI 10.1038/90228; MacBeath G, 2000, SCIENCE, V289, P1760; Ntziachristos V, 2000, P NATL ACAD SCI USA, V97, P2767, DOI 10.1073/pnas.040570597; Ntziachristos V, 2002, OPT LETT, V27, P333, DOI 10.1364/OL.27.000333; Ntziachristos V, 2001, OPT LETT, V26, P893, DOI 10.1364/OL.26.000893; Ntziachristos V, 2002, MED PHYS, V29, P803, DOI 10.1118/1.1470209; Paithankar DY, 1997, APPL OPTICS, V36, P2260, DOI 10.1364/AO.36.002260; Pepperkok R, 1999, CURR BIOL, V9, P269, DOI 10.1016/S0960-9822(99)80117-1; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Tung CH, 2000, CANCER RES, V60, P4953; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933; Weissleder R, 2002, NAT REV CANCER, V2, P11, DOI 10.1038/nrc701; Wouters FS, 2001, TRENDS CELL BIOL, V11, P203, DOI 10.1016/S0962-8924(01)01982-1	19	651	676	2	57	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2002	8	7					757	760		10.1038/nm729	http://dx.doi.org/10.1038/nm729			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VL1EJ	12091907				2022-12-27	WOS:000792138400001
J	Knabel, M; Franz, TJ; Schiemann, M; Wulf, A; Villmow, B; Schmidt, B; Bernhard, H; Wagner, H; Busch, DH				Knabel, M; Franz, TJ; Schiemann, M; Wulf, A; Villmow, B; Schmidt, B; Bernhard, H; Wagner, H; Busch, DH			Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer	NATURE MEDICINE			English	Article								Recently developed major histocompatibility complex (MHC) multimer technologies allow visualization and isolation of antigen-specific T cells. However, functional analysis and in vivo transfer of MHC multimer-stained cells is hampered by the persistence of T-cell receptor (TCR)-MHC interactions and subsequently induced signaling events. As MHC monomers do not stably bind to TCRs, we postulated that targeted disassembly of multimers into MHC monomers would result in dissociation of surface-bound TCR ligands. We generated a new type of MHC multimers, which can be monomerized in the presence of a competitor, resulting in rapid loss of the staining reagent. Following dissociation, the T cells are phenotypically and functionally indistinguishable from untreated cells. This 'reversible' T-cell staining procedure, which maintains the specificity and sensitivity of MHC multimer staining while preserving the functional status of T lymphocytes, may be of broad benefit for ex vivo investigation of T-cell functions and clinical applications.	Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-8000 Munich, Germany; Tech Univ Munich, Dept Hematol Oncol, D-8000 Munich, Germany	Technical University of Munich; Technical University of Munich	Busch, DH (corresponding author), Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-8000 Munich, Germany.								0	172	200	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2002	8	6					631	636		10.1038/nm0602-631	http://dx.doi.org/10.1038/nm0602-631			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042816				2022-12-27	WOS:000175907300036
J	Chen, WS; Calvo, PA; Malide, D; Gibbs, J; Schubert, U; Bacik, I; Basta, S; O'Neill, R; Schickli, J; Palese, P; Henklein, P; Bennink, JR; Yewdell, JW				Chen, WS; Calvo, PA; Malide, D; Gibbs, J; Schubert, U; Bacik, I; Basta, S; O'Neill, R; Schickli, J; Palese, P; Henklein, P; Bennink, JR; Yewdell, JW			A novel influenza A virus mitochondrial protein that induces cell death	NATURE MEDICINE			English	Article							A VIRUS; MESSENGER-RNA; EPITOPES; GENE	While searching for alternative reading-frame peptides encoded by influenza A virus that are recognized by CD8(+)T cells, we found an abundant immunogenic peptide encoded by the +1 reading frame of PB1. This peptide derives from a novel conserved 87-residue protein, PB1-F2, which has several unusual features compared with other influenza gene products in addition to its mode of translation. These include its absence from some animal (particularly swine) influenza virus Isolates, variable expression in individual infected cells, rapid proteasome-dependent degradation and mitochondrial localization. Exposure of cells to a synthetic version of PB1-F2 induces apoptosis, and influenza viruses with targeted mutations that interfere with PB1-F2 expression Induce less extensive apoptosis in human monocytic cells than those with intact PB1-F2. We propose that PB1-F2 functions to kill host immune cells responding to influenza virus infection.	NIAID, Viral Dis Lab, Bethesda, MD 20892 USA; Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-2000 Hamburg, Germany; Humboldt Univ, Inst Biochem, Berlin, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Icahn School of Medicine at Mount Sinai; Heinrich Pette Institute; University of Hamburg; Humboldt University of Berlin	Yewdell, JW (corresponding author), NIAID, Viral Dis Lab, Bethesda, MD 20892 USA.	jyewdell@nih.gov	Chen, Weisan/E-7828-2012; yewdell, jyewdell@nih.gov jonathan/A-1702-2012	Chen, Weisan/0000-0002-5221-9771; Palese, Peter/0000-0002-0337-5823	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000658, ZIAAI000658] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECERRA SP, 1988, J VIROL, V62, P2745, DOI 10.1128/JVI.62.8.2745-2754.1988; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; Chen WS, 1999, J EXP MED, V189, P1757, DOI 10.1084/jem.189.11.1757; Chen WS, 2000, IMMUNITY, V12, P83, DOI 10.1016/S1074-7613(00)80161-2; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Ferri KF, 2000, ANN NY ACAD SCI, V926, P149; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; KAWAOKA Y, 1989, J VIROL, V63, P4603, DOI 10.1128/JVI.63.11.4603-4608.1989; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb R. A, 1983, GENETICS INFLUENZA V, P26; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Mandelboim O, 2001, NATURE, V409, P1055, DOI 10.1038/35059110; Mayrand SM, 1998, IMMUNOL TODAY, V19, P551, DOI 10.1016/S0167-5699(98)01342-5; Pleschka S, 1996, J VIROL, V70, P4188, DOI 10.1128/JVI.70.6.4188-4192.1996; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; Schultz-Cherry S, 2001, J VIROL, V75, P7875, DOI 10.1128/JVI.75.17.7875-7881.2001; Schultz-Cherry S, 1998, SEMIN VIROL, V8, P491, DOI 10.1006/smvy.1998.0153; Taubenberger JK, 2000, VIROLOGY, V274, P241, DOI 10.1006/viro.2000.0495; VANCAMPEN H, 1989, J GEN VIROL, V70, P467, DOI 10.1099/0022-1317-70-2-467; Vitiello A, 1996, J IMMUNOL, V157, P5555; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Webster RG, 1997, ARCH VIROL, P105; WILLIAMS MA, 1989, J VIROL, V63, P28, DOI 10.1128/JVI.63.1.28-35.1989	25	752	820	4	113	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2001	7	12					1306	1312		10.1038/nm1201-1306	http://dx.doi.org/10.1038/nm1201-1306			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726970				2022-12-27	WOS:000172610300035
J	Gurjar, RS; Backman, V; Perelman, LT; Georgakoudi, I; Badizadegan, K; Itzkan, I; Dasari, RR; Feld, MS				Gurjar, RS; Backman, V; Perelman, LT; Georgakoudi, I; Badizadegan, K; Itzkan, I; Dasari, RR; Feld, MS			Imaging human epithelial properties with polarized light-scattering spectroscopy	NATURE MEDICINE			English	Article							TISSUES; CANCER; MEDIA	Biomedical imaging with light-scattering spectroscopy (LSS) is a novel optical technology developed to probe the structure of living epithelial cells in situ without need for tissue removal. LSS makes it possible to distinguish between single backscattering from epithelial-cell nuclei and multiply scattered light. The spectrum of the single backscattering component is further analyzed to provide quantitative information about the epithelial-cell nuclei such as nuclear size, degree of pleomorphism, degree of hyperchromasia and amount of chromatin. LSS imaging allows mapping these histological properties over wide areas of epithelial lining. Because nuclear enlargement, pleomorphism and hyperchromasia are principal features of nuclear atypia associated with precancerous and cancerous changes in virtually all epithelia, LSS imaging can be used to detect precancerous lesions in optically accessible organs.	Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA; MIT, GR Harrison Spect Lab, Cambridge, MA 02139 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Northwestern University; Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital; Harvard Medical School	Backman, V (corresponding author), Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.	v-backman@northwestern.edu	Backman, Vadim/B-6689-2009		NATIONAL CANCER INSTITUTE [R01CA053717] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002594] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA53717] Funding Source: Medline; NCRR NIH HHS [P41 RR02594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSON RR, 1991, ARCH DERMATOL, V127, P1000, DOI 10.1001/archderm.127.7.1000; Backman V, 1999, IEEE J SEL TOP QUANT, V5, P1019, DOI 10.1109/2944.796325; Backman V, 2000, NATURE, V406, P35, DOI 10.1038/35017638; Bartel S, 2000, APPL OPTICS, V39, P1580, DOI 10.1364/AO.39.001580; Boone CW, 2000, CANCER EPIDEM BIOMAR, V9, P495; BROWN GL, 1955, NATURE, V176, P161, DOI 10.1038/176161a0; Crawford J.M., 1994, ROBBINS PATHOLOGIC B, V5th, P910; DAVIES H. G., 1957, EXPTL CELL RES SUPPL, V4, P136; DAVIES HG, 1958, GEN CYTOCHEMICAL MET, V1; Demos SG, 1997, APPL OPTICS, V36, P150, DOI 10.1364/AO.36.000150; Jacques SL, 2000, LASER SURG MED, V26, P119, DOI 10.1002/(SICI)1096-9101(2000)26:2<119::AID-LSM3>3.0.CO;2-Y; LEE LH, 1973, ACTA CYTOL, V17, P214; Mourant JR, 1995, LASER SURG MED, V17, P350, DOI 10.1002/lsm.1900170403; Perelman LT, 1999, PROC SPIE, V3597, P474, DOI 10.1117/12.356844; Perelman LT, 1998, PHYS REV LETT, V80, P627, DOI 10.1103/PhysRevLett.80.627; Russ J.C, 1992, IMAGE PROCESSING HDB; Sankaran V, 1999, APPL OPTICS, V38, P4252, DOI 10.1364/AO.38.004252; Sokolov K, 1999, OPT EXPRESS, V5, P302, DOI 10.1364/OE.5.000302; van de Hulst H.C., 1981, LIGHT SCATTERING SMA; Wallace MB, 2000, GASTROENTEROLOGY, V119, P677, DOI 10.1053/gast.2000.16511	20	332	351	1	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2001	7	11					1245	1248		10.1038/nm1101-1245	http://dx.doi.org/10.1038/nm1101-1245			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689891				2022-12-27	WOS:000172054100034
J	Avota, E; Avots, A; Niewiesk, S; Kane, LP; Bommhardt, U; ter Meulen, V; Schneider-Schaulies, S				Avota, E; Avots, A; Niewiesk, S; Kane, LP; Bommhardt, U; ter Meulen, V; Schneider-Schaulies, S			Disruption of Akt kinase activation is important for immunosuppression induced by measles virus	NATURE MEDICINE			English	Article							CELL-CYCLE ARREST; INTEGRIN-LINKED KINASE; RECEPTOR-BETA-CHAIN; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; IN-VITRO; INTERLEUKIN-2 RECEPTOR; VIRAL GLYCOPROTEINS; B ACTIVATION; KAPPA-B	Surface-contact-mediated signaling induced by the measles virus (MV) fusion and hemagglutinin glycoproteins is necessary and sufficient to induce T-cell unresponsiveness in vitro and in vivo. To define the intracellular pathways involved, we analyzed interleukin (IL)-2R signaling in primary human T cells and in Kit-225 cells. Unlike IL-2-dependent activation of JAK/STAT pathways, activation of Akt kinase was impaired after MV contact both in vitro and in vivo. MV interference with Akt activation was important for immunosuppression, as expression of a catalytically active Akt prevented negative signaling by the MV glycoproteins. Thus, we show here that MV exploits a novel strategy to interfere with T-cell activation during immunosuppression.	Univ Wurzburg, Inst Virol & Immunobiol, D-8700 Wurzburg, Germany; Univ Wurzburg, Inst Med Radiat & Cell Res, D-8700 Wurzburg, Germany; Univ Calif San Francisco, Dept Med, San Francisco, CA USA	University of Wurzburg; University of Wurzburg; University of California System; University of California San Francisco	Schneider-Schaulies, S (corresponding author), Univ Wurzburg, Inst Virol & Immunobiol, Versbacher Str 7, D-8700 Wurzburg, Germany.	s-s-s@vim.uni-wuerzburg.de		Kane, Lawrence/0000-0001-5198-516X				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Avots A, 1997, MOL CELL BIOL, V17, P4381, DOI 10.1128/MCB.17.8.4381; Bell AF, 1997, VIROLOGY, V232, P241, DOI 10.1006/viro.1997.8577; Borgatti P, 1997, EUR J IMMUNOL, V27, P2805, DOI 10.1002/eji.1830271110; BORROW P, 1995, CURR TOP MICROBIOL, V191, P85; Brennan P, 1999, MOL CELL BIOL, V19, P4729; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Bright JJ, 1997, J IMMUNOL, V159, P175; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Engelking O, 1999, J GEN VIROL, V80, P1599, DOI 10.1099/0022-1317-80-7-1599; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRIFFIN DE, 1995, CURR TOP MICROBIOL, V191, P117; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Lord JD, 1998, J IMMUNOL, V161, P4627; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; Migone TS, 1998, MOL CELL BIOL, V18, P6416, DOI 10.1128/MCB.18.11.6416; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; Naniche D, 1999, J VIROL, V73, P1894, DOI 10.1128/JVI.73.3.1894-1901.1999; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; Niewiesk S, 1999, J GEN VIROL, V80, P2023, DOI 10.1099/0022-1317-80-8-2023; Niewiesk S, 1997, J VIROL, V71, P7214, DOI 10.1128/JVI.71.10.7214-7219.1997; Niewiesk S, 2000, P NATL ACAD SCI USA, V97, P4251, DOI 10.1073/pnas.060012097; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Rusterholz C, 1999, MOL CELL BIOL, V19, P2681; Schlender J, 1996, P NATL ACAD SCI USA, V93, P13194, DOI 10.1073/pnas.93.23.13194; Schneider-Schaulies S, 1999, ARCH VIROL, P139; Schnorr JJ, 1997, J GEN VIROL, V78, P3217, DOI 10.1099/0022-1317-78-12-3217; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; Spielhofer P, 1998, J VIROL, V72, P2150, DOI 10.1128/JVI.72.3.2150-2159.1998; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Van Dooren S, 1998, J GEN VIROL, V79, P2695, DOI 10.1099/0022-1317-79-11-2695; Weidmann A, 2000, J VIROL, V74, P1985, DOI 10.1128/JVI.74.4.1985-1993.2000; Weidmann A, 2000, J VIROL, V74, P7548, DOI 10.1128/JVI.74.16.7548-7553.2000; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	45	93	94	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2001	7	6					725	731		10.1038/89106	http://dx.doi.org/10.1038/89106			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385511				2022-12-27	WOS:000169081500042
J	Thaker, GK; Carpenter, WT				Thaker, GK; Carpenter, WT			Advances in schizophrenia	NATURE MEDICINE			English	Review							POSITRON-EMISSION-TOMOGRAPHY; SUSCEPTIBILITY LOCUS; DEFICIT SYNDROME; DOPAMINE-RECEPTORS; PREFRONTAL CORTEX; NEGATIVE SYMPTOMS; BIPOLAR-DISORDER; DENSITY; LOCALIZATION; GENETICS	Recent studies into the etiology of schizophrenia have yielded both promising leads and disappointing dead ends, indicating the multifactored and complex nature of the disorder. The focus has subsequently shifted back to refining the phenotype and identifying clinical and biological subtypes. Recent technological breakthroughs in genomics and proteomics hold promise for advancing our understanding of the molecular pathophysiology of schizophrenia.	Univ Maryland, Maryland Psychiat Res Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Thaker, GK (corresponding author), Univ Maryland, Maryland Psychiat Res Ctr, Baltimore, MD 21201 USA.	wcarpent@mprc.umaryland.edu			NIMH NIH HHS [MH49826] Funding Source: Medline; PHS HHS [40279] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH049826] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abi-Dargham A, 1998, AM J PSYCHIAT, V155, P761; Arolt V, 1996, AM J MED GENET, V67, P564, DOI 10.1002/(SICI)1096-8628(19961122)67:6<564::AID-AJMG10>3.0.CO;2-R; Baron M, 2001, AM J HUM GENET, V68, P299, DOI 10.1086/318212; Benes FM, 2000, BRAIN RES REV, V31, P251, DOI 10.1016/S0165-0173(99)00041-7; Bergson C, 1995, J NEUROSCI, V15, P7821; Berrettini WH, 2000, BIOL PSYCHIAT, V48, P531, DOI 10.1016/S0006-3223(00)00883-0; BLUELER M, 1950, DEMENTIAL PRAECOX GR; Bogerts B, 1999, EUR ARCH PSY CLIN N, V249, P2; Breier A, 1997, P NATL ACAD SCI USA, V94, P2569, DOI 10.1073/pnas.94.6.2569; Brzustowicz LM, 2000, SCIENCE, V288, P678, DOI 10.1126/science.288.5466.678; Callicott JH, 1998, BIOL PSYCHIAT, V44, P941, DOI 10.1016/S0006-3223(98)00264-9; Cannon TD, 1998, ARCH GEN PSYCHIAT, V55, P67, DOI 10.1001/archpsyc.55.1.67; CANNON TD, 1994, ARCH GEN PSYCHIAT, V51, P651; CARLSSON A, 1963, ACTA PHARMACOL TOX, V20, P140; CARPENTER WT, 1993, ARCH GEN PSYCHIAT, V50, P825; CARPENTER WT, 1988, AM J PSYCHIAT, V145, P578; Detera-Wadleigh SD, 1999, P NATL ACAD SCI USA, V96, P5604, DOI 10.1073/pnas.96.10.5604; EGAN MF, IN PRESS P NATL ACAD; FENTON WS, 1994, AM J PSYCHIAT, V151, P351; Freedman R, 1999, BIOL PSYCHIAT, V45, P551, DOI 10.1016/S0006-3223(98)00321-7; Freedman R, 1997, P NATL ACAD SCI USA, V94, P587, DOI 10.1073/pnas.94.2.587; FREEDMAN R, IN PRESS AM J MED GE; Gao WJ, 2001, P NATL ACAD SCI USA, V98, P295, DOI 10.1073/pnas.011524298; Glantz LA, 2000, ARCH GEN PSYCHIAT, V57, P65, DOI 10.1001/archpsyc.57.1.65; GOFF DC, 1995, AM J PSYCHIAT, V152, P1213; Heresco-Levy U, 1999, ARCH GEN PSYCHIAT, V56, P29, DOI 10.1001/archpsyc.56.1.29; HOLZMAN PS, 1973, SCIENCE, V181, P179, DOI 10.1126/science.181.4095.179; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; Karlsson H, 2001, P NATL ACAD SCI USA, V98, P4634, DOI 10.1073/pnas.061021998; Kelsoe JR, 2001, P NATL ACAD SCI USA, V98, P585, DOI 10.1073/pnas.011358498; KENDLER KS, 1995, COMPREHENSIVE TXB PS, V6, P942; Kirkpatrick B, 2001, ARCH GEN PSYCHIAT, V58, P165, DOI 10.1001/archpsyc.58.2.165; Kraepelin E., 1919, CUTTING SHEPHERD; Lidow MS, 2001, BIOL PSYCHIAT, V49, P1, DOI 10.1016/S0006-3223(00)01058-1; MEDNICK SA, 1988, ARCH GEN PSYCHIAT, V45, P189, DOI 10.1001/archpsyc.1988.01800260109013; Mirnics K, 2000, NEURON, V28, P53, DOI 10.1016/S0896-6273(00)00085-4; Mirnics K, 2001, MOL PSYCHIATR, V6, P293, DOI 10.1038/sj.mp.4000866; Myles-Worsley M, 1999, AM J MED GENET, V88, P544, DOI 10.1002/(SICI)1096-8628(19991015)88:5<544::AID-AJMG20>3.0.CO;2-V; Otani S, 1999, J NEUROSCI, V19, P9788; Pulver AE, 2000, MOL PSYCHIATR, V5, P650, DOI 10.1038/sj.mp.4000814; Pulver AE, 2000, BIOL PSYCHIAT, V47, P221; Ross DE, 2000, AM J PSYCHIAT, V157, P1071, DOI 10.1176/appi.ajp.157.7.1071; Sanfilipo M, 2000, ARCH GEN PSYCHIAT, V57, P471, DOI 10.1001/archpsyc.57.5.471; SCAMBLER PJ, 1992, LANCET, V339, P1138, DOI 10.1016/0140-6736(92)90734-K; Seamans JK, 2001, P NATL ACAD SCI USA, V98, P301, DOI 10.1073/pnas.011518798; Selemon LD, 1999, BIOL PSYCHIAT, V45, P17, DOI 10.1016/S0006-3223(98)00281-9; SHERRINGTON R, 1988, NATURE, V336, P164, DOI 10.1038/336164a0; SMILEY JF, 1994, P NATL ACAD SCI USA, V91, P5720, DOI 10.1073/pnas.91.12.5720; TAMMINGA CA, 1992, ARCH GEN PSYCHIAT, V49, P522; Tamminga CA, 1998, CRIT REV NEUROBIOL, V12, P21, DOI 10.1615/CritRevNeurobiol.v12.i1-2.20; Thaker G K, 2000, Curr Psychiatry Rep, V2, P398, DOI 10.1007/s11920-000-0022-6; Tsuang MT, 1999, HARVARD REV PSYCHIAT, V7, P185, DOI 10.1093/hrp/7.4.185; Waltrip RW, 1997, SCHIZOPHR RES, V23, P253, DOI 10.1016/S0920-9964(96)00114-4	53	161	175	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2001	7	6					667	671		10.1038/89040	http://dx.doi.org/10.1038/89040			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385502				2022-12-27	WOS:000169081500033
J	van den Hoogen, BG; de Jong, J; Groen, J; Kuiken, T; de Groot, R; Fouchier, RAM; Osterhaus, ADME				van den Hoogen, BG; de Jong, J; Groen, J; Kuiken, T; de Groot, R; Fouchier, RAM; Osterhaus, ADME			A newly discovered human pneumovirus isolated from young children with respiratory tract disease	NATURE MEDICINE			English	Article							TURKEY RHINOTRACHEITIS VIRUS; GENE ORDER DIFFERENT; AVIAN PNEUMOVIRUS; SYNCYTIAL VIRUS; INFECTION; REVEAL; PCR	From 28 young children in the Netherlands, we isolated a paramyxovirus that was identified as a tentative new member of the Metapneumovirus genus based on virological data, sequence homology and gene constellation. Previously, avian pneumovirus was the sole member of this recently assigned genus, hence the provisional name for the newly discovered virus: human metapneumovirus. The clinical symptoms of the children from whom the virus was isolated were similar to those caused by human respiratory syncytial virus infection, ranging from upper respiratory tract disease to severe bronchiolitis and pneumonia. Serological studies showed that by the age of five years, virtually all children in the Netherlands have been exposed to human metapneumovirus and that the virus has been circulating in humans for at least 50 years.	Erasmus Sch Ctr, Dept Virol, Rotterdam, Netherlands; Erasmus Sch Ctr, Dept Pediat, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam	Osterhaus, ADME (corresponding author), Erasmus Sch Ctr, Dept Virol, Rotterdam, Netherlands.	osterhaus@viro.fgg.eur.nl	Fouchier, Ron A/A-1911-2014; van den Hoogen, Bernadette/J-5461-2013	Fouchier, Ron A/0000-0001-8095-2869; 				Bayon-Auboyer MH, 2000, J GEN VIROL, V81, P2723, DOI 10.1099/0022-1317-81-11-2723; Brandenburg AH, 1997, J MED VIROL, V52, P97, DOI 10.1002/(SICI)1096-9071(199705)52:1&lt;97::AID-JMV16&gt;3.0.CO;2-Y; Cook JKA, 1999, AVIAN PATHOL, V28, P607, DOI 10.1080/03079459994407; Cool JKA, 2000, REV SCI TECH OIE, V19, P602, DOI 10.20506/rst.19.2.1233; DORNACHOWSKE JB, 1999, CLIN MICROBIOL REV, V12, P298; EVANS AS, 1989, VIRAL INFECT HUMANS, P22; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fields B. N, 1996, FIELDS VIROLOGY, V1, P1177; GIRAUD P, 1986, VET REC, V119, P606; LENNETTE DA, 1995, DIAGNOSTIC PROCEDURE; LING R, 1992, J GEN VIROL, V73, P1709, DOI 10.1099/0022-1317-73-7-1709; Madeley C.R., 1988, VIRUS MORPHOLOGY; MASUREL N, 1969, LANCET, V1, P907; MULDER J, 1958, LANCET, V1, P810; OSTERHAUS ADME, 1985, ARCH VIROL, V86, P239, DOI 10.1007/BF01309828; PRINGLE CR, 1986, J GEN VIROL, V67, P975, DOI 10.1099/0022-1317-67-6-975; PRINGLE CR, 1991, PARAMYXOVIRUSES, P1; RALPH D, 1993, P NATL ACAD SCI USA, V90, P10710, DOI 10.1073/pnas.90.22.10710; Randhawa JS, 1997, J VIROL, V71, P9849, DOI 10.1128/JVI.71.12.9849-9854.1997; REGENMORTEL MH, 2000, VIRUS TAXONOMY, P551; Rothbarth PH, 1999, J VIROL METHODS, V78, P163, DOI 10.1016/S0166-0934(98)00174-8; SELWYN BJ, 1990, REV INFECT DIS, V12, pS870; WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213; YU Q, 1992, VIROLOGY, V186, P426, DOI 10.1016/0042-6822(92)90007-C	24	1472	1573	1	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2001	7	6					719	724		10.1038/89098	http://dx.doi.org/10.1038/89098			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385510	Green Published, Bronze			2022-12-27	WOS:000169081500041
J	Antoniou, M				Antoniou, M			The case against ...	NATURE MEDICINE			English	Editorial Material							EMBRYONIC STEM-CELLS; HUMAN BLASTOCYSTS; BONE-MARROW; DIFFERENTIATION; TRANSPLANTS; LINES; MICE		Guys Hosp, GKT Sch Med, Div Med & Mol Genet, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Antoniou, M (corresponding author), Guys Hosp, GKT Sch Med, Div Med & Mol Genet, London SE1 9RT, England.							ABULJADAYEL IMS, 1995, Patent No. 2297558; Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Benninger Y, 2000, BRAIN PATHOL, V10, P330; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Dickson D, 2000, NATURE, V408, P277, DOI 10.1038/35042708; *EUR ETH COMM, 2000, NATURE, V408, P275; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; 2001, DAILY TELEGRAPH 0124; 2001, TIMES LONDON    0115; 2001, SUNDAY TIMES LO 0128; 2000, INDEPENDENT LON 0830	19	16	16	1	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2001	7	4					397	399		10.1038/86444	http://dx.doi.org/10.1038/86444			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283653				2022-12-27	WOS:000167960500019
J	Ibbotson, GC; Doig, C; Kaur, J; Gill, V; Ostrovsky, L; Fairhead, T; Kubes, P				Ibbotson, GC; Doig, C; Kaur, J; Gill, V; Ostrovsky, L; Fairhead, T; Kubes, P			Functional alpha(4)-integrin: A newly identified pathway of neutrophil recruitment in critically ill septic patients	NATURE MEDICINE			English	Article							P-SELECTIN; LEUKOCYTE EMIGRATION; ADHESION; MECHANISM; FLOW; PERITONEUM; ACTIVATION; EXPRESSION; PLATELETS; ADHERENCE	Using a novel flow chamber assay system and whole blood, we show that leukocytes from septic individuals have a four-fold elevation of adhesion, but not rolling, on a P-seIectin/beta (2)-integrin substrate. Most leukocytes from septic patients (but not healthy controls) that bound vascular cell adhesion molecule 1 (VCAM-1) were neutrophils. All adhesion was inhibited with an antibody specific for the VCAM-1 ligand alpha (4)-integrin. The alpha (4)-integrin was present on neutrophils from septic patients but not on neutrophils from patients with localized bacterial infections. The plasma milieu of septic patients was sufficient to induce neutrophils from healthy subjects to bind VCAM-1 under flow conditions. This is the first description of alpha (4)-integrin/VCAM-1 pathway of neutrophil recruitment in human disease. This pathway may provide a new therapeutic target to reduce inappropriate neutrophil adhesion without altering the normal yet critical beta (2)-integrin-mediated adhesive function of neutrophils.	Univ Calgary, Med Ctr, Dept Physiol & Biophys, Calgary, AB, Canada; Univ Calgary, Med Ctr, Dept Surg, Calgary, AB, Canada; Univ Calgary, Med Ctr, Dept Med, Calgary, AB, Canada; Univ Calgary, Med Ctr, Immunol Res Grp, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary	Kubes, P (corresponding author), Univ Calgary, Med Ctr, Dept Physiol & Biophys, Calgary, AB, Canada.	pkubes@ucalgary.ca	Doig, Christopher/AAC-7949-2020	Doig, Christopher/0000-0002-8576-9139				ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; [Anonymous], 1989, AM REV RESPIR DIS, V139, P1058; ASTIZ ME, 1995, CRIT CARE MED, V23, P265, DOI 10.1097/00003246-199502000-00011; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BONE RC, 1991, ANN INTERN MED, V114, P332, DOI 10.7326/0003-4819-114-4-332; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTTRUM SM, 1993, BLOOD, V82, P1165; Center of Disease Control and Prevention, 1993, MONTHLY VITAL STAT R, V41, P5; Connolly ES, 1997, CIRC RES, V81, P304, DOI 10.1161/01.RES.81.3.304; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; Diacovo TG, 1996, BLOOD, V88, P146; DOERSCHUK CM, 1990, J IMMUNOL, V144, P2327; FEIN AM, 1991, CHEST, V99, P1456, DOI 10.1378/chest.99.6.1456; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Horan TC, 1997, AM J INFECT CONTROL, V25, P112, DOI 10.1016/S0196-6553(97)90037-7; Jaeschke H, 1996, SHOCK, V6, P345; Kanwar S, 1999, J IMMUNOL, V162, P2709; Kirveskari J, 2000, J LEUKOCYTE BIOL, V68, P243; KUBES P, 1995, FASEB J, V9, P1103; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Maekawa K, 1998, J TRAUMA, V44, P460, DOI 10.1097/00005373-199803000-00007; Mazo IB, 1998, J EXP MED, V188, P465, DOI 10.1084/jem.188.3.465; McGill SN, 1996, ARCH SURG-CHICAGO, V131, P1141; MercerJones MA, 1997, SHOCK, V8, P193, DOI 10.1097/00024382-199709000-00007; Mizgerd JP, 1997, J EXP MED, V186, P1357, DOI 10.1084/jem.186.8.1357; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; Ostrovsky L, 1998, BLOOD, V91, P3028, DOI 10.1182/blood.V91.8.3028.3028_3028_3036; Patel KD, 1998, BLOOD, V92, P3904, DOI 10.1182/blood.V92.10.3904.422k41_3904_3911; Reinhardt PH, 1997, BLOOD, V89, P3837, DOI 10.1182/blood.V89.10.3837.3837_3837_3846; Reinhardt PH, 1998, BLOOD, V92, P4691, DOI 10.1182/blood.V92.12.4691.424k18_4691_4699; Robinson SD, 1999, P NATL ACAD SCI USA, V96, P11452, DOI 10.1073/pnas.96.20.11452; Rosenbloom AJ, 1999, J LEUKOCYTE BIOL, V66, P83, DOI 10.1002/jlb.66.1.83; SCHLEIFFENBAUM B, 1989, J IMMUNOL, V142, P3537; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Terregino CA, 1997, ANN EMERG MED, V29, P400, DOI 10.1016/S0196-0644(97)70353-6; VENEZIO FR, 1982, J INFECT DIS, V145, P351, DOI 10.1093/infdis/145.3.351; WINN RK, 1993, J CLIN INVEST, V92, P1168, DOI 10.1172/JCI116686; Yodice PC, 1997, AM J RESP CRIT CARE, V155, P38, DOI 10.1164/ajrccm.155.1.9001286	38	113	115	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2001	7	4					465	470		10.1038/86539	http://dx.doi.org/10.1038/86539			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283674	Bronze			2022-12-27	WOS:000167960500042
J	Skobe, M; Hawighorst, T; Jackson, DG; Prevo, R; Janes, L; Velasco, P; Riccardi, L; Alitalo, K; Claffey, K; Detmar, M				Skobe, M; Hawighorst, T; Jackson, DG; Prevo, R; Janes, L; Velasco, P; Riccardi, L; Alitalo, K; Claffey, K; Detmar, M			Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis	NATURE MEDICINE			English	Article							LYMPH-NODE METASTASIS; GROWTH-FACTOR VEGF; EXPRESSION; ANGIOGENESIS; CARCINOMA; ENDOTHELIUM; RECEPTOR-3; TRANSPORT; CELLS; GENE	Metastasis of breast cancer occurs primarily through the lymphatic system, and the extent of lymph node involvement is a key prognostic factor for the disease. Whereas the significance of angiogenesis for tumor progression has been well documented, the ability of tumor cells to induce the growth of lymphatic vessels (lymphangiogenesis) and the presence of intratumoral lymphatic vessels have been controversial. Using a novel marker for lymphatic endothelium, LYVE-1, we demonstrate here the occurrence of intratumoral lymphangiogenesis within human breast cancers after orthotopic transplantation onto nude mice. Vascular endothelial growth factor (VEGF)-C overexpression in breast cancer cells potently increased intratumoral lymphangiogenesis, resulting in significantly enhanced metastasis to regional lymph nodes and to lungs. The degree of tumor lymphangiogenesis was highly correlated with the extent of lymph node and lung metastases. These results establish the occurrence and biological significance of intratumoral lymphangiogenesis in breast cancer and identify VEGF-C as a molecular link between tumor lymphangiogenesis and metastasis.	Massachusetts Gen Hosp, Dept Dermatol, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA USA; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England; Univ Helsinki, Haartman Inst, Helsinki, Finland; Univ Connecticut, Ctr Hlth, Farmington, CT 06030 USA	Harvard University; Massachusetts General Hospital; Harvard University; University of Oxford; University of Helsinki; University of Connecticut	Detmar, M (corresponding author), Massachusetts Gen Hosp, Dept Dermatol, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.		Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; , david/0000-0002-4133-9364	NCI NIH HHS [CA69184, CA86410] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069184, R01CA086410] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Akagi K, 2000, BRIT J CANCER, V83, P887, DOI 10.1054/bjoc.2000.1396; Andre T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.3.CO;2-5; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BAXTER LT, 1990, MICROVASC RES, V40, P246, DOI 10.1016/0026-2862(90)90023-K; Bunone G, 1999, AM J PATHOL, V155, P1967, DOI 10.1016/S0002-9440(10)65515-0; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Detmar M, 2000, AM J PATHOL, V156, P159, DOI 10.1016/S0002-9440(10)64715-3; Eggert A, 2000, CLIN CANCER RES, V6, P1900; EVANS HM, 1908, J HOPKINS MED J, V19, P232; Fellmer PT, 1999, SURGERY, V126, P1056, DOI 10.1067/msy.2099.101432; Fisher B, 1968, LYMPH LYMPHATIC SYST, P324; Folkman J, 1996, NEW ENGL J MED, V334, P921; GILCHRIST RK, 1950, AMA ARCH SURG, V61, P913, DOI 10.1001/archsurg.1950.01250020921013; Hoffman RM, 1998, CANCER METAST REV, V17, P271, DOI 10.1023/A:1006188412324; JAIN RK, 1990, CANCER METAST REV, V9, P253, DOI 10.1007/BF00046364; JAIN RK, 1987, CANCER RES, V47, P3039; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P1751; Jussila L, 1998, CANCER RES, V58, P1599; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kurebayashi J, 1999, JPN J CANCER RES, V90, P977, DOI 10.1111/j.1349-7006.1999.tb00844.x; LEAK L V, 1970, Microvascular Research, V2, P361, DOI 10.1016/0026-2862(70)90031-2; Lee FC, 1933, ARCH SURG-CHICAGO, V26, P602, DOI 10.1001/archsurg.1933.01170040065004; Leu AJ, 2000, CANCER RES, V60, P4324; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Niki T, 2000, CLIN CANCER RES, V6, P2431; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Ohta Y, 1999, BRIT J CANCER, V81, P54, DOI 10.1038/sj.bjc.6690650; Ohta Y, 2000, J THORAC CARDIOV SUR, V119, P804, DOI 10.1016/S0022-5223(00)70017-1; PRICE JE, 1990, CANCER RES, V50, P717; Pullinger BD, 1935, BRIT J EXP PATHOL, V16, P49; Reichert FL, 1926, ARCH SURG-CHICAGO, V13, P871, DOI 10.1001/archsurg.1926.01130120095004; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; Shushanov S, 2000, INT J CANCER, V86, P47, DOI 10.1002/(SICI)1097-0215(20000401)86:1<47::AID-IJC7>3.0.CO;2-R; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; Skobe M, 2000, J INVEST DERM SYMP P, V5, P14, DOI 10.1046/j.1087-0024.2000.00001.x; St Croix B, 2000, SCIENCE, V289, P1197; TANIGAWA N, 1981, LYMPHOLOGY, V14, P149; Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356; Witte M H, 1997, EXS, V79, P65; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823; ZEIDMAN I, 1955, CANCER, V8, P123, DOI 10.1002/1097-0142(1955)8:1<123::AID-CNCR2820080116>3.0.CO;2-A	44	1378	1536	2	93	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					192	198		10.1038/84643	http://dx.doi.org/10.1038/84643			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175850				2022-12-27	WOS:000166756300036
J	Aronson, JK				Aronson, JK			Forbidden fruit	NATURE MEDICINE			English	Editorial Material							GRAPEFRUIT JUICE; ASCORBIC-ACID; FURANOCOUMARIN DERIVATIVES; QUALITY EVALUATION; CITRUS-FRUITS; ANTIOXIDANT; TECHNOLOGY; INHIBITION; CHEMISTRY; SAFETY	Although citrus fruits prevent and cure scurvy, they may not always be as good for you as you thought.	Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Aronson, JK (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Woodstock Rd, Oxford OX2 6HE, England.							Auer BL, 1998, CLIN CHEM LAB MED, V36, P143, DOI 10.1515/CCLM.1998.027; BAILEY DG, 1989, CLIN INVEST MED, V12, P357; Bailey DG, 1998, BRIT J CLIN PHARMACO, V46, P101, DOI 10.1046/j.1365-2125.1998.00764.x; BARNESS LA, 1975, ANN NY ACAD SCI, V258, P523, DOI 10.1111/j.1749-6632.1975.tb29311.x; Basu TK, 1982, VITAMIN C HLTH DIS, P61; Blanchard J, 1997, AM J CLIN NUTR, V66, P1165, DOI 10.1093/ajcn/66.5.1165; Carr AC, 1999, AM J CLIN NUTR, V69, P1086; DOUGLAS RM, 2000, COCHRANE LIB; Dresser GK, 2000, CLIN PHARMACOKINET, V38, P41, DOI 10.2165/00003088-200038010-00003; Dresser GK, 2000, CLIN PHARMACOL THER, V68, P28, DOI 10.1067/mcp.2000.107524; Eagling VA, 1999, BRIT J CLIN PHARMACO, V48, P543, DOI 10.1046/j.1365-2125.1999.00052.x; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; GERSHOFF SN, 1993, NUTR REV, V51, P313, DOI 10.1111/j.1753-4887.1993.tb03757.x; Guo LQ, 2000, DRUG METAB DISPOS, V28, P766; KAUR B, 2000, COCHRANE LIB; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; *MED CONTR AG COMM, 1999, CURR PROBL PHARMACOV, V25, P2; Meyers DG, 1996, ARCH INTERN MED, V156, P925, DOI 10.1001/archinte.156.9.925; Ohnishi A, 2000, BRIT J PHARMACOL, V130, P1369, DOI 10.1038/sj.bjp.0703433; RANGANNA S, 1983, CRC CR REV FOOD SCI, V18, P313, DOI 10.1080/10408398309527366; RANGANNA S, 1983, CRC CR REV FOOD SCI, V19, P1; Shaw PE, 2000, J AGR FOOD CHEM, V48, P2425, DOI 10.1021/jf0001076; STEWART ML, 1985, J AM DIET ASSOC, V85, P1585; TROHLER U, 2000, IMPROVE EVIDENCE MED, P68; 1998, DRUGS THER PERSPECT, V12, P12; 1997, CURR PROBL PHARMACOV, V23, P9	26	8	9	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					29	30		10.1038/83312	http://dx.doi.org/10.1038/83312			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135611				2022-12-27	WOS:000166243100026
J	Millstone, E; van Zwanenberg, P				Millstone, E; van Zwanenberg, P			A crisis of trust: for science, scientists or for institutions?	NATURE MEDICINE			English	Editorial Material								Stem cell research, xenotransplantation and somatic and germ line gene therapy are examples of emerging technologies that, if successful will forever change the way we live. But how well does the pubic understand the benefits and risks of these technologies, and whose responsibility is it to communicate them? Here, Erik Millstone and Patrick van Zwanenberg of the University of Sussex, UK, discuss whether science is suffering because of a lack of transparence in presenting scientific information to its main consumer group-the general public.	Univ Sussex, SPRU Sci & Technol Policy, Brighton BN1 9RF, E Sussex, England	University of Sussex	Millstone, E (corresponding author), Univ Sussex, SPRU Sci & Technol Policy, Mantell Bldg, Brighton BN1 9RF, E Sussex, England.							DERBY B, 2000, JOINT C SOC SOC STUD; FREWER L, 1998, RISK MODERN SOC, P193; GREENBERG S, 1998, BRIT TEST       1005; Irwin A, 1996, MISUNDERSTANDING SCI, DOI DOI 10.1017/CBO9780511563737; MAY R, 2000, C SCI GOV KNOWL SOC; Millstone E, 1999, NATURE, V401, P525, DOI 10.1038/44006; PHILLIPS, 2000, BSE INQUIRY, V1, P233; WHITE RG, 1997, UNCERTAIN WORLD GENE	8	45	47	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1307	1308		10.1038/82102	http://dx.doi.org/10.1038/82102			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100103				2022-12-27	WOS:000165704100019
J	Noble, S				Noble, S			UK tries to increase physician scientist numbers	NATURE MEDICINE			English	News Item																			0	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1303	1303		10.1038/82086	http://dx.doi.org/10.1038/82086			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100095	Bronze			2022-12-27	WOS:000165704100012
J	Hayashi, T; Kodama, S; Faustman, DL				Hayashi, T; Kodama, S; Faustman, DL			LMP2 expression and proteasome activity in NOD mice	NATURE MEDICINE			English	Letter							NF-KAPPA-B; PEPTIDASE		Massachusetts Gen Hosp E, Immunobiol Lab, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University	Faustman, DL (corresponding author), Massachusetts Gen Hosp E, Immunobiol Lab, Bldg 149,13th St, Charlestown, MA 02129 USA.	enise.Faustman@cbrc2.mgh.harvard.edu						Gueckel R, 1998, J BIOL CHEM, V273, P19443, DOI 10.1074/jbc.273.31.19443; Hayashi T, 1999, MOL CELL BIOL, V19, P8646; MAKINO S, 1980, Experimental Animals (Tokyo), V29, P1; Sears C, 1998, J BIOL CHEM, V273, P1409, DOI 10.1074/jbc.273.3.1409; Stephens LA, 1997, J AUTOIMMUN, V10, P293, DOI 10.1006/jaut.1997.0133; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4	6	28	29	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2000	6	10					1065	1066		10.1038/80353	http://dx.doi.org/10.1038/80353			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017113				2022-12-27	WOS:000089674700004
J	Hazenberg, MD; Otto, SA; Stuart, JWTC; Verschuren, MCM; Borleffs, JCC; Boucher, CAB; Coutinho, RA; Lange, JMA; De Wit, TFR; Tsegaye, A; Van Dongen, JJM; Hamann, D; De Boer, RJ; Miedema, F				Hazenberg, MD; Otto, SA; Stuart, JWTC; Verschuren, MCM; Borleffs, JCC; Boucher, CAB; Coutinho, RA; Lange, JMA; De Wit, TFR; Tsegaye, A; Van Dongen, JJM; Hamann, D; De Boer, RJ; Miedema, F			Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection	NATURE MEDICINE			English	Article							DELETING ELEMENTS; TYPE-1 INFECTION; GENE DELETION; DELTA-GENE; MEMORY; LYMPHOCYTES; TURNOVER; CD4(+); REARRANGEMENTS; PHENOTYPE	Recent thymic emigrants can be identified by T cell receptor excision circles (TRECs) formed during T-cell receptor rearrangement. Decreasing numbers of TRECs have been observed with aging and in human immunodeficiency virus (HIV)-1 infected individuals, suggesting for thymic impairment. Here, we show that in healthy individuals, declining thymic output will affect the TREC content only when accompanied by naive T-cell division. The rapid decline in TRECs observed during HIV-1 infection and the increase following HAART are better explained not by thymic impairment, but by changes in peripheral T-cell division rates. Our data indicate that TREC content in healthy individuals is only indirectly related to thymic output, and in HIV-1 infection is mainly affected by immune activation.	Univ Amsterdam, Acad Med Ctr, CLB, Dept Clin Viroimmunol, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Expt & Clin Immunol Lab, NL-1066 CX Amsterdam, Netherlands; Univ Utrecht, Med Ctr, Dept Internal Med, NL-3584 CX Utrecht, Netherlands; Erasmus Univ, Dept Immunol, NL-3000 DR Rotterdam, Netherlands; Univ Utrecht, Med Ctr, Dept Virol, Eijkman Winkler Inst, NL-3584 CX Utrecht, Netherlands; Municipal Hlth Serv, Dept Publ Hlth & Environm, NL-1000 CE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Natl AIDS Therapy Evaluat Ctr, NL-1105 AZ Amsterdam, Netherlands; ENARP, Addis Ababa, Ethiopia; EHNRI, Addis Ababa, Ethiopia; Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Erasmus University Rotterdam; Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Ethiopian Health & Nutrition Research Institute; University of Amsterdam; Academic Medical Center Amsterdam	Miedema, F (corresponding author), Univ Amsterdam, Acad Med Ctr, CLB, Dept Clin Viroimmunol, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.	F_Miedema@CLB.nl	de Boer, Rob/B-6050-2011; de Wit, Tobias TF Rinke/A-1224-2013; van Dongen, Jacques J.M./F-8537-2015; Tsegaye, Aster/AAH-7028-2020	de Boer, Rob/0000-0002-2130-691X; van Dongen, Jacques J.M./0000-0001-7686-0021; Tsegaye, Aster/0000-0002-9026-4629; van Dongen, Jacques J.M./0000-0002-3650-7087				BAARS PA, 1995, J IMMUNOL, V154, P17; BREIT TM, 1994, IMMUNOGENETICS, V40, P70, DOI 10.1007/BF00163967; Breit TM, 1997, J IMMUNOL, V159, P4341; Clark DR, 1999, ADV IMMUNOL, V73, P301, DOI 10.1016/S0065-2776(08)60789-0; DEVILLARTAY JP, 1988, NATURE, V335, P170, DOI 10.1038/335170a0; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Gaulton GN, 1997, AIDS, V11, P403, DOI 10.1097/00002030-199704000-00002; George AJT, 1996, IMMUNOL TODAY, V17, P267, DOI 10.1016/0167-5699(96)80543-3; GERDES J, 1984, J IMMUNOL, V133, P1710; Grossman Z, 1999, SCIENCE, V284, p555a, DOI [DOI 10.1126/SCIENCE.284.5414.555A, 10.1126/science.284.5414.555a]; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; Hatzakis A, 2000, LANCET, V355, P599, DOI 10.1016/S0140-6736(99)10311-8; Hazenberg MD, 2000, BLOOD, V95, P249, DOI 10.1182/blood.V95.1.249.001k40_249_255; HAZENBERG MD, 1999, AIDS REV, V1, P67; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; Hellerstein MK, 1997, IMMUNITY, V7, P583, DOI 10.1016/S1074-7613(00)80379-9; HINTZEN RQ, 1993, J IMMUNOL, V151, P2426; Jamieson BD, 1999, IMMUNITY, V10, P569, DOI 10.1016/S1074-7613(00)80056-4; Kong FK, 1999, P NATL ACAD SCI USA, V96, P1536, DOI 10.1073/pnas.96.4.1536; Livak F, 1996, MOL CELL BIOL, V16, P609; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; Messele T, 1999, CLIN EXP IMMUNOL, V115, P443; MEYAARD L, 1994, J CLIN INVEST, V93, P982, DOI 10.1172/JCI117105; NAKAJIMA PB, 1995, IMMUNITY, V3, P609, DOI 10.1016/1074-7613(95)90132-9; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Pongers-Willemse MJ, 1998, LEUKEMIA, V12, P2006, DOI 10.1038/sj.leu.2401246; Poulin JF, 1999, J EXP MED, V190, P479, DOI 10.1084/jem.190.4.479; ROOS MTL, 1994, AIDS, V8, P1533, DOI 10.1097/00002030-199411000-00003; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; Sachsenberg N, 1998, J EXP MED, V187, P1295, DOI 10.1084/jem.187.8.1295; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; UNUTMAZ D, 1994, J EXP MED, V180, P1159, DOI 10.1084/jem.180.3.1159; UNUTMAZ D, 1995, INT IMMUNOL, V7, P1417, DOI 10.1093/intimm/7.9.1417; VANNOORLOOS AAB, 1980, CANCER RES, V40, P2890; Verschuren MCM, 1997, J IMMUNOL, V158, P1208; Walker RE, 1998, NAT MED, V4, P852, DOI 10.1038/nm0798-852; Wolthers KC, 1999, AIDS RES HUM RETROV, V15, P1053, DOI 10.1089/088922299310340; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543; Zhang LQ, 1999, J EXP MED, V190, P725, DOI 10.1084/jem.190.5.725	40	334	343	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2000	6	9					1036	1042		10.1038/79549	http://dx.doi.org/10.1038/79549			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973325	Green Published			2022-12-27	WOS:000089190500037
J	Sharp, R; Recio, JA; Jhappan, C; Otsuka, T; Liu, SQ; Yu, YL; Liu, WJ; Anver, M; Navid, F; Helman, LJ; DePinho, RA; Merlino, G				Sharp, R; Recio, JA; Jhappan, C; Otsuka, T; Liu, SQ; Yu, YL; Liu, WJ; Anver, M; Navid, F; Helman, LJ; DePinho, RA; Merlino, G			Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis	NATURE MEDICINE			English	Article							SKELETAL-MUSCLE CELLS; GROWTH-FACTOR; TUMOR-SUPPRESSOR; SCATTER-FACTOR; GENE-EXPRESSION; MET RECEPTOR; PROTEIN; DIFFERENTIATION; INHIBITION; ACTIVATION	Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in children, yet molecular events associated with the genesis and progression of this potentially fatal disease are largely unknown. For the molecules and pathways that have been implicated, genetic validation has been impeded by lack of a mouse model of RMS. Here we show that simultaneous loss of Ink4a/Arf function and disruption of c-Met signaling in Ink4a/Arf(-/-) mice transgenic for hepatocyte growth factor/scatter factor (HGF/SF) induces RMS with extremely high penetrance and short latency. In cultured myoblasts, c-Met activation and Ink4a/Arf loss suppress myogenesis in an additive fashion. Our data indicate that human c-MET and INK4a/ARF, situated at the nexus of pathways regulating myogenic growth and differentiation, represent critical targets in RMS pathogenesis. The marked synergism in mice between aberrant c-Met signaling and Ink4a/Arf inactivation, lesions individually implicated in human RMS, suggests a therapeutic combination to combat this devastating childhood cancer.	NCI, Mol Biol Lab, Bethesda, MD 20892 USA; Frederick Canc Res & Dev Ctr, SAIC, Pathol Histotechnol Lab, Frederick, MD USA; NCI, Pediat Branch, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol Med & Genet, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Merlino, G (corresponding author), NCI, Mol Biol Lab, Bldg 37, Bethesda, MD 20892 USA.	gmerlino@helix.nih.gov		DePinho, Ronald/0000-0002-5625-577X; Recio, Juan Angel/0000-0002-7320-3832	NATIONAL CANCER INSTITUTE [U01CA084313, Z01BC008756] Funding Source: NIH RePORTER; NCI NIH HHS [U01CA84313-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN RE, 1995, J CELL PHYSIOL, V165, P307, DOI 10.1002/jcp.1041650211; Allen RE, 1997, METHOD CELL BIOL, V52, P155, DOI 10.1016/S0091-679X(08)60378-7; Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Chakravarthy MV, 2000, J APPL PHYSIOL, V89, P1365, DOI 10.1152/jappl.2000.89.4.1365; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; Ferracini R, 1996, ONCOGENE, V12, P1697; FILMUS J, 1994, ONCOGENE, V9, P3627; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; Gal-Levi R, 1998, BBA-MOL CELL RES, V1402, P39, DOI 10.1016/S0167-4889(97)00124-9; Ginsberg JP, 1998, CANCER RES, V58, P3542; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Leshem Y, 2000, J CELL PHYSIOL, V184, P101, DOI 10.1002/(SICI)1097-4652(200007)184:1<101::AID-JCP11>3.0.CO;2-D; MAELANDSMO GM, 1995, BRIT J CANCER, V72, P393, DOI 10.1038/bjc.1995.344; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Otsuka T, 1998, CANCER RES, V58, P5157; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051	39	127	129	0	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2002	8	11					1276	1280		10.1038/nm787	http://dx.doi.org/10.1038/nm787			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12368906				2022-12-27	WOS:000179221200034
J	Guan, HP; Li, Y; Jensen, MV; Newgard, CB; Steppan, CM; Lazar, MA				Guan, HP; Li, Y; Jensen, MV; Newgard, CB; Steppan, CM; Lazar, MA			A futile metabolic cycle activated in adipocytes by antidiabetic agents	NATURE MEDICINE			English	Article							OB GENE-EXPRESSION; PPAR-GAMMA; ADIPOSE-TISSUE; RECEPTOR-GAMMA; FATTY-ACIDS; BODY-WEIGHT; ALPHA; GLUCOSE; THIAZOLIDINEDIONE; DIFFERENTIATION	Thiazolidinediones (TZDs) are effective therapies for type 2 diabetes, which has reached epidemic proportions in industrialized societies. TZD treatment reduces circulating free fatty acids (FFAs), which oppose insulin actions in skeletal muscle and other insulin target tissues. Here we report that TZDs, acting as ligands for the nuclear receptor peroxisome proliferator-activated receptor (PPAR)-gamma, markedly induce adipocyte glycerol kinase (GyK) gene expression. This is surprising, as standard textbooks indicate that adipocytes lack GyK and thereby avoid futile cycles of triglyceride breakdown and resynthesis from glycerol and FFAs. By inducing GyK, TZDs markedly stimulate glycerol incorporation into triglyceride and reduce FFA secretion from adipocytes. The 'futile' fuel cycle resulting from expression of GyK in adipocytes is thus a novel mechanism contributing to reduced FFA levels and perhaps insulin sensitization by antidiabetic therapies.	Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA; Duke Univ, Med Ctr, Sarah Stedman Ctr Nutr Studies, Durham, NC USA; Duke Univ, Med Ctr, Dept Pharmacol, Duke Program Diabet Res, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Canc Biol, Duke Program Diabet Res, Durham, NC USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Duke University; Duke University; Duke University	Lazar, MA (corresponding author), Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.	lazar@mail.med.upenn.edu	Lazar, Mitchell A/AAF-3738-2019	Guan, Hong-Ping/0000-0002-2282-3193	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049780] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49780] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Air EL, 2002, NAT MED, V8, P179, DOI 10.1038/nm0202-179; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Boden G, 2001, ENDOCRIN METAB CLIN, V30, P801, DOI 10.1016/S0889-8529(05)70216-4; Camp HS, 2001, ENDOCRINOLOGY, V142, P3207, DOI 10.1210/en.142.7.3207; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; Felig P, 1995, ENDOCRINOL METAB, P1107; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gaudet D, 2000, AM J HUM GENET, V66, P1558, DOI 10.1086/302903; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Huq AHMM, 1997, HUM MOL GENET, V6, P1803, DOI 10.1093/hmg/6.11.1803; IBRAHIMI A, 1994, MOL PHARMACOL, V46, P1070; Jequier E, 1999, PHYSIOL REV, V79, P451, DOI 10.1152/physrev.1999.79.2.451; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; KAPLAN ML, 1981, AM J PHYSIOL, V240, pE101, DOI 10.1152/ajpendo.1981.240.2.E101; Kishida K, 2001, J BIOL CHEM, V276, P48572, DOI 10.1074/jbc.M108213200; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; KRUSYNSKA YT, 1997, TXB DIABETES; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li Y, 2002, MOL ENDOCRINOL, V16, P1040, DOI 10.1210/me.16.5.1040; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Matthews CK, 1996, BIOCHEMISTRY-US, P819; Mauvais-Jarvis F, 2001, DIABETES METAB, V27, P415; Mukherjee R, 2000, MOL ENDOCRINOL, V14, P1425, DOI 10.1210/me.14.9.1425; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Noel RJ, 1997, J BIOL CHEM, V272, P18621, DOI 10.1074/jbc.272.30.18621; Roden M, 2000, DIABETES, V49, P701, DOI 10.2337/diabetes.49.5.701; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; ROSEN ED, IN PRESS GENES DEV; Ruan H, 2001, DIABETES, V50, P233, DOI 10.2337/diabetes.50.2.233; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Souza SC, 1998, DIABETES, V47, P691, DOI 10.2337/diabetes.47.4.691; STEINBERG D, 1961, J BIOL CHEM, V236, P1631; Steppan CM, 2002, TRENDS ENDOCRIN MET, V13, P18, DOI 10.1016/S1043-2760(01)00522-7; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Stumvoll M, 2002, ANN MED, V34, P217, DOI 10.1080/713782132; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Zhang B, 1996, J BIOL CHEM, V271, P9455, DOI 10.1074/jbc.271.16.9455	46	303	317	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1122	1128		10.1038/nm780	http://dx.doi.org/10.1038/nm780			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12357248				2022-12-27	WOS:000178311000039
J	Okamoto, R; Yajima, T; Yamazaki, M; Kanai, T; Mukai, M; Okamoto, S; Ikeda, Y; Hibi, T; Inazawa, J; Watanabe, M				Okamoto, R; Yajima, T; Yamazaki, M; Kanai, T; Mukai, M; Okamoto, S; Ikeda, Y; Hibi, T; Inazawa, J; Watanabe, M			Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract	NATURE MEDICINE			English	Article							STEM-CELLS; HEPATOCYTES; DIFFERENTIATION; ORIGIN	Studies have shown that bone marrow cells have the potential to differentiate into a variety of cell types. Here we show that bone marrow cells can repopulate the epithelia of the human gastrointestinal tract. Epithelial cells of male donor origin were distributed in every part of the gastrointestinal tract of female bone marrow transplant recipients. Donor-derived epithelial cells substantially repopulated the gastrointestinal tract during epithelial regeneration after graft-versus-host disease or ulcer formation. Regeneration of gastrointestinal epithelia with donor-derived cells in humans shows a potential clinical application of bone marrow-derived cells for repairing severely damaged epithelia, not only in the gastrointestinal tract but also in other tissues.	Tokyo Med & Dent Univ, Grad Sch, Dept Gastroenterol & Hepatol, Bunkyo Ku, Tokyo, Japan; Keio Univ, Sch Med, Dept Internal Med, Tokyo, Japan; Keio Univ, Sch Med, Div Diagnost Pathol, Tokyo, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Keio University; Keio University; Tokyo Medical & Dental University (TMDU)	Watanabe, M (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Dept Gastroenterol & Hepatol, Bunkyo Ku, Tokyo, Japan.	mamoru.gast@tmd.ac.jp	Okamoto, Ryuichi/I-1130-2019; Watanabe, Mamoru/AHE-0489-2022	Okamoto, Ryuichi/0000-0002-7047-571X; 				Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Bach SP, 2000, CARCINOGENESIS, V21, P469, DOI 10.1093/carcin/21.3.469; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Booth C, 2000, J CLIN INVEST, V105, P1493, DOI 10.1172/JCI10229; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Ishino S, 1998, CANCER, V83, P360, DOI 10.1002/(SICI)1097-0142(19980715)83:2<360::AID-CNCR21>3.0.CO;2-Q; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Korbling M, 2002, NEW ENGL J MED, V346, P738, DOI 10.1056/NEJMoa3461002; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; McKay R, 2002, NAT BIOTECHNOL, V20, P426, DOI 10.1038/nbt0502-426; NAKAHORI Y, 1986, NUCLEIC ACIDS RES, V14, P7569, DOI 10.1093/nar/14.19.7569; NEGRIN RS, 2001, WILLIAMS HEMATOLOGY, P209; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; Wright Nicholas A., 1997, P315, DOI 10.1016/B978-012563455-7/50011-8; WUMSER AE, 2002, NATURE, V416, P485; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	22	311	345	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2002	8	9					1011	1017		10.1038/nm755	http://dx.doi.org/10.1038/nm755			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12195435				2022-12-27	WOS:000177757900037
J	Dong, HD; Strome, SE; Salomao, DR; Tamura, H; Hirano, F; Flies, DB; Roche, PC; Lu, J; Zhu, GF; Tamada, K; Lennon, VA; Celis, E; Chen, LP				Dong, HD; Strome, SE; Salomao, DR; Tamura, H; Hirano, F; Flies, DB; Roche, PC; Lu, J; Zhu, GF; Tamada, K; Lennon, VA; Celis, E; Chen, LP			Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion	NATURE MEDICINE			English	Article; Proceedings Paper	Symposium on Tumor Escape from Immune Recognition: Molecular Mechanism and Functional Significance	AUG 22-23, 1999	BALTIMORE, MARYLAND				FAS LIGAND; COSTIMULATORY MOLECULES; MELANOMA-CELLS; B7 FAMILY; EXPRESSION; ACTIVATION; DEATH; PD-1; ANTIGEN; CD28	B7-H1, a recently described member of the B7 family of costimulatory molecules, is thought to be involved in the regulation of cellular and humoral immune responses through the PD-1 receptor on activated T and B cells. We report here that, except for cells of the macrophage lineage, normal human tissues do not express B7-H1. In contrast, B7-H1 is abundant in human carcinomas of lung, ovary and colon and in melanomas. The pro-inflammatory cytokine interferon. upregulates B7-H1 on the surface of tumor cell lines. Cancer cell - associated B7-H1 increases apoptosis of antigen-specific human T-cell clones in vitro, and the apoptotic effect of B7-H1 is mediated largely by one or more receptors other than PD-1. In addition, expression of B7-H1 on mouse P815 tumor increases apoptosis of activated tumor-reactive T cells and promotes the growth of highly immunogenic B7-1(+) tumors in vivo. These findings have implications for the design of T cell - based cancer immunotherapy.	Mayo Clin, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin, Dept Otorhinolaryngol, Rochester, MN USA; Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; Mayo Clin, Dept Neurol, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Chen, LP (corresponding author), Mayo Clin, Dept Immunol, Rochester, MN 55905 USA.		Tamura, Hideto/AAV-3532-2020	Chen, Lieping/0000-0002-6825-3069; Dong, Haidong/0000-0002-5782-2983	NCI NIH HHS [CA37343, CA85721, CA79915, CA80782, CA15083, CA82677] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037343, R01CA080782, R01CA082677, R01CA079915, R01CA085721, P30CA015083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agata Y, 1996, INT IMMUNOL, V8, P765, DOI 10.1093/intimm/8.5.765; Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; BOISE LH, 1995, CURR OPIN IMMUNOL, V7, P620, DOI 10.1016/0952-7915(95)80067-0; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; Chapoval AI, 2000, METH MOLEC MED, V45, P247, DOI 10.1385/1-59259-079-9:247; Chappell DB, 1999, CANCER RES, V59, P59; CHEN LP, 1994, J EXP MED, V179, P523, DOI 10.1084/jem.179.2.523; CHEN LP, 1993, IMMUNOL TODAY, V14, P483, DOI 10.1016/0167-5699(93)90262-J; Dong HD, 1999, NAT MED, V5, P1365; Finger LR, 1997, GENE, V197, P177, DOI 10.1016/S0378-1119(97)00260-6; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Georgescu L, 1997, J CLIN INVEST, V100, P2622, DOI 10.1172/JCI119806; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hurtado JC, 1997, J IMMUNOL, V158, P2600; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Kobayashi H, 2000, CANCER RES, V60, P5228; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; Lu J, 2000, CANCER RES, V60, P5223; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nakashima M, 1999, NAT MED, V5, P938, DOI 10.1038/11383; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Noel PJ, 1996, J IMMUNOL, V157, P636; O'Connell J, 1999, NAT MED, V5, P267, DOI 10.1038/6477; RIVOLTINI L, 1995, CANCER RES, V55, P3149; Rogers PR, 2001, IMMUNITY, V15, P445, DOI 10.1016/S1074-7613(01)00191-1; Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297; Strand S, 1998, MOL MED TODAY, V4, P63, DOI 10.1016/S1357-4310(97)01191-X; SYKULEV Y, 1994, P NATL ACAD SCI USA, V91, P11487, DOI 10.1073/pnas.91.24.11487; Takahashi C, 1999, J IMMUNOL, V162, P5037; Tamada K, 2002, J CLIN INVEST, V109, P549, DOI 10.1172/JCI200213604; Tamura H, 2001, BLOOD, V97, P1809, DOI 10.1182/blood.V97.6.1809; Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541; Watts TH, 1999, CURR OPIN IMMUNOL, V11, P286, DOI 10.1016/S0952-7915(99)80046-6; Yu ZY, 2001, ANN NEUROL, V49, P146; Zhao SR, 1999, BRIT J HAEMATOL, V106, P827, DOI 10.1046/j.1365-2141.1999.01630.x	39	3327	3803	18	426	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2002	8	8					793	800		10.1038/nm730	http://dx.doi.org/10.1038/nm730			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12091876				2022-12-27	WOS:000177200900024
J	Crone, SA; Zhao, YY; Fan, L; Gu, YS; Minamisawa, S; Liu, Y; Peterson, KL; Chen, J; Kahn, R; Condorelli, G; Ross, J; Chien, KR; Lee, KF				Crone, SA; Zhao, YY; Fan, L; Gu, YS; Minamisawa, S; Liu, Y; Peterson, KL; Chen, J; Kahn, R; Condorelli, G; Ross, J; Chien, KR; Lee, KF			ErbB2 is essential in the prevention of dilated cardiomyopathy	NATURE MEDICINE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; DEFICIENT MICE; HEART-FAILURE; TRASTUZUMAB HERCEPTIN; CARDIAC DEVELOPMENT; SIGNALING NETWORK; REQUIREMENT; EXPRESSION; RECEPTORS; CANCER	Amplification of the gene encoding the ErbB2 (Her2/neu) receptor tyrosine kinase is critical for the progression of several forms of breast cancer. In a large-scale clinical trial, treatment with Herceptin (trastuzumab), a humanized blocking antibody against ErbB2, led to marked improvement in survival. However, cardiomyopathy was uncovered as a mitigating side effect, thereby suggesting an important role for ErbB2 signaling as a modifier of human heart failure. To investigate the physiological role of ErbB2 signaling in the adult heart, we generated mice with a ventricular-restricted deletion of Erbb2. These ErbB2-deficient conditional mutant mice were viable and displayed no overt phenotype. However, physiological analysis revealed the onset of multiple independent parameters of dilated cardiomyopathy, including chamber dilation, wall thinning and decreased contractility. Additionally, cardiomyocytes isolated from these conditional mutants were more susceptible to anthracycline toxicity. ErbB2 signaling in cardiomyocytes is therefore essential for the prevention of dilated cardiomyopathy.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; Univ Calif San Diego, UCSD Salk Program Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Salk Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Lee, KF (corresponding author), Salk Inst Biol Studies, La Jolla, CA 92037 USA.	klee@salk.edu	Chen, Ju/E-5579-2011; gu, yu/GSD-4507-2022; Condorelli, Gianluigi/Q-6736-2017	Condorelli, Gianluigi/0000-0003-0481-6843; Crone, Steven/0000-0001-9644-2767; ZHAO, YOU-YANG/0000-0002-0041-0339; Minamisawa, Susumu/0000-0003-4728-2116				Agus DB, 2000, SEMIN ONCOL, V27, P53; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Baselga J, 2000, SEMIN ONCOL, V27, P27; BENJAMIN RS, 1978, CANCER TREAT REP, V62, P935; BILLINGHAM ME, 1978, CANCER TREAT REP, V62, P865; Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825; Chen J, 1998, J BIOL CHEM, V273, P1252, DOI 10.1074/jbc.273.2.1252; Chen J, 1998, DEVELOPMENT, V125, P1943; Cho MC, 1999, J BIOL CHEM, V274, P22251, DOI 10.1074/jbc.274.32.22251; Christensen G, 2000, CIRCULATION, V101, P178, DOI 10.1161/01.CIR.101.2.178; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Erickson SL, 1997, DEVELOPMENT, V124, P4999; FERRANS VJ, 1978, CANCER TREAT REP, V62, P955; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; GROVE D, 1969, CIRC RES, V25, P473, DOI 10.1161/01.RES.25.4.473; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; HUNTER JJ, 1999, MOL BASIS CARDIOVASC, P211; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Ikeda S, 1999, CLIN SCI, V97, P239, DOI 10.1042/CS19980374; Klapper LN, 2000, ADV CANCER RES, V77, P25; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Rohrbach S, 1999, CIRCULATION, V100, P407, DOI 10.1161/01.CIR.100.4.407; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sparano JA, 2001, SEMIN ONCOL, V28, P20, DOI 10.1053/sonc.2001.22813; Sun XH, 2001, EUR J ORAL SCI, V109, P103, DOI 10.1034/j.1600-0722.2001.00982.x; Suzuki T, 2001, AM J PHYSIOL-REG I, V280, pR1399, DOI 10.1152/ajpregu.2001.280.5.R1399; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; Wang X, 1999, CLIN HEMORHEOL MICRO, V21, P137; YOUNG RC, 1981, NEW ENGL J MED, V305, P139, DOI 10.1056/NEJM198107163050305; Zhao YY, 1998, J BIOL CHEM, V273, P10261, DOI 10.1074/jbc.273.17.10261	37	623	652	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2002	8	5					459	465		10.1038/nm0502-459	http://dx.doi.org/10.1038/nm0502-459			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984589				2022-12-27	WOS:000175336800030
J	Schon, MP; Krahn, T; Schon, M; Rodriguez, ML; Antonicek, H; Schultz, JE; Ludwig, RJ; Zollner, TM; Bischoff, E; Bremm, KD; Schramm, M; Henninger, K; Kaufmann, R; Gollnick, HPM; Parker, CM; Boehncke, WH				Schon, MP; Krahn, T; Schon, M; Rodriguez, ML; Antonicek, H; Schultz, JE; Ludwig, RJ; Zollner, TM; Bischoff, E; Bremm, KD; Schramm, M; Henninger, K; Kaufmann, R; Gollnick, HPM; Parker, CM; Boehncke, WH			Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation	NATURE MEDICINE			English	Article							HOMING T-CELLS; CYCLOSPORINE-A; SCID MICE; LYMPHOCYTE RECIRCULATION; ENDOTHELIAL-CELLS; HUMAN SKIN; PSORIASIS; NEUTROPHILS; EXPRESSION; RAPAMYCIN	Specific interference with molecular mechanisms guiding tissue localization of leukocytes may be of great utility for selective immunosuppressive therapies. We have discovered and characterized efomycines, a new family of selective small-molecule inhibitors of selectin functions. Members of this family significantly inhibited leukocyte adhesion in vitro. Efomycine M, which was nontoxic and showed the most selective inhibitory effects on selectin-mediated leukocyte-endothelial adhesion in vitro, significantly diminished rolling in mouse ear venules in vivo as seen by intravital microscopy. In addition, efomycine M alleviated cutaneous inflammation in two complementary mouse models of psoriasis, one of the most common chronic inflammatory skin disorders. Molecular modeling demonstrated a spatial conformation of efomycines mimicking naturally occurring selectin ligands. Efomycine M might be efficacious in the treatment of human inflammatory disorders through a similar mechanism.	Otto Von Guericke Univ, Dept Dermatol, Magdeburg, Germany; Bayer AG, Pharmaceut Res, D-5600 Wuppertal, Germany; Bayer AG, Cent Res, D-5090 Leverkusen, Germany; Univ Frankfurt, Dept Dermatol, D-6000 Frankfurt, Germany; Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA	Otto von Guericke University; Bayer AG; Bayer AG; Goethe University Frankfurt; Harvard University; Brigham & Women's Hospital	Schon, MP (corresponding author), Otto Von Guericke Univ, Dept Dermatol, Magdeburg, Germany.		Ludwig, Ralf/F-3996-2018; Ludwig, Ralf J/A-2629-2008	Ludwig, Ralf/0000-0002-1394-1737; Ludwig, Ralf J/0000-0002-1394-1737; Schon, Michael/0000-0002-0698-4130				Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Barros LFM, 2000, SHOCK, V13, P67, DOI 10.1097/00024382-200013010-00012; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; Boehncke WH, 1996, NATURE, V379, P777, DOI 10.1038/379777a0; BOEHNCKE WH, 1994, ARCH DERMATOL RES, V286, P325, DOI 10.1007/BF00402223; Boehncke WH, 1999, ARCH DERMATOL RES, V291, P104, DOI 10.1007/s004030050391; BONFANTI R, 1989, BLOOD, V73, P1109; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Christophers E, 1996, INT ARCH ALLERGY IMM, V110, P199, DOI 10.1159/000237288; Dam TN, 1999, J INVEST DERMATOL, V113, P1082, DOI 10.1046/j.1523-1747.1999.00811.x; DETMAR M, 1992, J INVEST DERMATOL, V98, P147, DOI 10.1111/1523-1747.ep12555746; Falke P, 2000, CEREBROVASC DIS, V10, P97, DOI 10.1159/000016037; Goodarzi MT, 1998, GLYCOCONJUGATE J, V15, P1149, DOI 10.1023/A:1006920007227; GOTTLIEB SL, 1995, NAT MED, V1, P442, DOI 10.1038/nm0595-442; HAMANN P, 1990, J ANTIBIOT, V43, P1431; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MILLER KE, 1992, BIOCHEMISTRY-US, V31, P6703, DOI 10.1021/bi00144a009; MORRISSEY PJ, 1993, J EXP MED, V178, P237, DOI 10.1084/jem.178.1.237; NICKOLOFF BJ, 1991, ARCH DERMATOL, V127, P871, DOI 10.1001/archderm.127.6.871; Nickoloff BJ, 1999, ARCH DERMATOL, V135, P1104, DOI 10.1001/archderm.135.9.1104; NICKOLOFF BJ, 1995, AM J PATHOL, V146, P580; PETERS DH, 1993, DRUGS, V46, P746, DOI 10.2165/00003495-199346040-00009; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1993, J IMMUNOL, V150, P1122; POWRIE F, 1993, INT IMMUNOL, V5, P1461, DOI 10.1093/intimm/5.11.1461; Robert C, 1999, J EXP MED, V189, P627, DOI 10.1084/jem.189.4.627; Salmi M, 1998, INFLAMM BOWEL DIS, V4, P149; Schon M, 2000, J INVEST DERMATOL, V114, P976, DOI 10.1046/j.1523-1747.2000.00953.x; Schon MP, 1999, J INVEST DERMATOL, V112, P405, DOI 10.1046/j.1523-1747.1999.00538.x; Schon MP, 1997, NAT MED, V3, P183, DOI 10.1038/nm0297-183; Schon MP, 2001, NAT IMMUNOL, V2, P91, DOI 10.1038/84293; SCHON MP, 2000, DERMATOPHARMACOLOGY, P179; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHRODER JM, 1992, J INVEST DERMATOL, V98, P241, DOI 10.1111/1523-1747.ep12556058; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SMITH CH, 1993, J IMMUNOL, V151, P3274; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SRIVASTAVA D, 1990, ENDOCRINOLOGY, V127, P1770, DOI 10.1210/endo-127-4-1770; Todderud G, 1997, J PHARMACOL EXP THER, V282, P1298; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; Weninger W, 2000, IMMUNITY, V12, P665, DOI 10.1016/S1074-7613(00)80217-4; WroneSmith T, 1996, J CLIN INVEST, V98, P1878, DOI 10.1172/JCI118989	45	113	118	1	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2002	8	4					366	372		10.1038/nm0402-366	http://dx.doi.org/10.1038/nm0402-366			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927942				2022-12-27	WOS:000174704800028
J	Arap, W; Kolonin, MG; Trepel, M; Lahdenranta, J; Cardo-Vila, M; Giordano, RJ; Mintz, PJ; Ardelt, PU; Yao, VJ; Vidal, CI; Chen, L; Flamm, A; Valtanen, H; Weavind, LM; Hicks, ME; Pollock, RE; Botz, GH; Bucana, CD; Koivunen, E; Cahill, D; Troncoso, P; Baggerly, KA; Pentz, RD; Do, KA; Logothetis, CJ; Pasqualini, R				Arap, W; Kolonin, MG; Trepel, M; Lahdenranta, J; Cardo-Vila, M; Giordano, RJ; Mintz, PJ; Ardelt, PU; Yao, VJ; Vidal, CI; Chen, L; Flamm, A; Valtanen, H; Weavind, LM; Hicks, ME; Pollock, RE; Botz, GH; Bucana, CD; Koivunen, E; Cahill, D; Troncoso, P; Baggerly, KA; Pentz, RD; Do, KA; Logothetis, CJ; Pasqualini, R			Steps toward mapping the human vasculature by phage display	NATURE MEDICINE			English	Article							TARGETED DRUG-DELIVERY; AMINOPEPTIDASE N; PEPTIDES; EXPRESSION; RECEPTOR; NEOVASCULATURE; ENDOTHELIUM; INHIBITION; INTEGRINS; SEQUENCE	The molecular diversity of receptors in human blood vessels remains largely unexplored. We developed a selection method in which peptides that home to specific vascular beds are identified after administration of a peptide library. Here we report the first in vivo screening of a peptide library in a patient. We surveyed 47,160 motifs that localized to different organs. This large-scale screening indicates that the tissue distribution of circulating peptides is nonrandom. High-throughput analysis of the motifs revealed similarities to ligands for differentially expressed cell-surface proteins, and a candidate ligand-receptor pair was validated. These data represent a step toward the construction of a molecular map of human vasculature and may have broad implications for the development of targeted therapies.	Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Eth, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Crit Care, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Helsinki, Dept Biochem, Div Biosci, Helsinki, Finland; Max Planck Inst Mol Genet, Berlin, Germany	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Finland National Institute for Health & Welfare; University of Helsinki; Max Planck Society	Arap, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	warap@notes.mdacc.tmc.edu; rpasqual@notes/mdacc.tmc.edu	Giordano, Ricardo/A-2074-2010	Giordano, Ricardo/0000-0001-8116-6771; Kolonin, Mikhail/0000-0002-3743-7869; Koivunen, Erkki/0000-0002-6443-9595	NATIONAL CANCER INSTITUTE [U54CA090810, P50CA090270, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA9081001, CA90270, CA8297601, P30 CA016672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Bacich DJ, 2001, MAMM GENOME, V12, P117, DOI 10.1007/s003350010240; Barrow PA, 1997, TRENDS MICROBIOL, V5, P268, DOI 10.1016/S0966-842X(97)01054-8; Bhagwat SV, 2001, BLOOD, V97, P652, DOI 10.1182/blood.V97.3.652; Burg MA, 1999, CANCER RES, V59, P2869; Campbell CL, 2001, AM J PATHOL, V158, P25, DOI 10.1016/S0002-9440(10)63940-5; Carson-Walter EB, 2001, CANCER RES, V61, P6649; Chang SS, 1999, CANCER RES, V59, P3192; Curnis F, 2000, NAT BIOTECHNOL, V18, P1185, DOI 10.1038/81183; Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Hong FD, 2000, CANCER RES, V60, P6551; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Koivunen E, 2001, J CELL BIOL, V153, P905, DOI 10.1083/jcb.153.5.905; Kolonin M, 2001, CURR OPIN CHEM BIOL, V5, P308, DOI 10.1016/S1367-5931(00)00207-6; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Latham PW, 1999, NAT BIOTECHNOL, V17, P755, DOI 10.1038/11686; Lin BZ, 1997, J BIOL CHEM, V272, P24145, DOI 10.1074/jbc.272.39.24145; Mahboubi K, 2000, J IMMUNOL, V164, P3837, DOI 10.4049/jimmunol.164.7.3837; Nugent MA, 2000, P NATL ACAD SCI USA, V97, P6722, DOI 10.1073/pnas.97.12.6722; Pasqualini R, 2000, CANCER RES, V60, P722; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; PASQUALINI R, 2000, PHAGE DISPLAY LAB MA, P1; *PC, 1983, PRES COMM STUD ETH P; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; Rajotte D, 1999, J BIOL CHEM, V274, P11593, DOI 10.1074/jbc.274.17.11593; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; St Croix B, 2000, SCIENCE, V289, P1197; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trepel M, 2000, HUM GENE THER, V11, P1971, DOI 10.1089/10430340050143408; Vendruscolo M, 2001, NATURE, V409, P641, DOI 10.1038/35054591; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; Wu KK, 2001, CIRCULATION, V103, P1386, DOI 10.1161/01.CIR.103.10.1386	35	472	525	0	60	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2002	8	2					121	127		10.1038/nm0202-121	http://dx.doi.org/10.1038/nm0202-121			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821895				2022-12-27	WOS:000173600600020
J	Tsukiyama-Kohara, K; Poulin, F; Kohara, M; DeMaria, CT; Cheng, A; Wu, ZD; Gingras, AC; Katsume, A; Elchebly, M; Spiegelman, BM; Harper, ME; Tremblay, ML; Sonenberg, N				Tsukiyama-Kohara, K; Poulin, F; Kohara, M; DeMaria, CT; Cheng, A; Wu, ZD; Gingras, AC; Katsume, A; Elchebly, M; Spiegelman, BM; Harper, ME; Tremblay, ML; Sonenberg, N			Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1	NATURE MEDICINE			English	Article							MITOCHONDRIAL UNCOUPLING PROTEIN; WHITE FAT; PHAS-I; GENE; EXPRESSION; OBESITY; PHOSPHORYLATION; COACTIVATOR; SELECTION; INSULIN	All nuclear-encoded mRNAs contain a 5' cap structure (m(7)GpppN, where N is any nucleotide), which is recognized by the eukaryotic translation initiation factor 4E (eIF4E) subunit of the eIF4F complex. The elF4E-binding proteins constitute a family of three polypeptides that reversibly repress cap-dependent translation by binding to eIF4E, thus preventing the formation of the eIF4F complex. We investigated the biological function of 4E-BP1 by disrupting its gene (Eif4ebp1) in the mouse. Eif4ebp1(-/-) mice manifest markedly smaller white fat pads than wild-type animals, and knockout males display an increase in metabolic rate. The males' white adipose tissue contains cells that exhibit the distinctive multilocular appearance of brown adipocytes, and expresses the uncoupling protein 1 (UCP1), a specific marker of brown fat. Consistent with these observations, translation of the peroxisome proliferator-activated receptor-gamma co-activator 1 (PGC1), a transcriptional co-activator implicated in mitochondrial biogenesis and adaptive thermogenesis, is increased in white adipose tissue of Eif4ebp1(-/-) mice. These findings demonstrate that 4E-BP1 is a novel regulator of adipogenesis and metabolism in mammals.	McGill Univ, Dept Biochem, Montreal, PQ, Canada; McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada; Tokyo Metropolitan Inst Med Sci, Dept Microbiol & Cell Biol, Tokyo 113, Japan; Dana Farber Canc Inst, Boston, MA 02115 USA; Chugai Pharmaceut Co Ltd, Fuji Gotemba Res Labs, Shizuoka, Japan; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; Univ Tokyo, Inst Med Sci, Tokyo, Japan	McGill University; McGill University; Tokyo Metropolitan Institute of Medical Science; Harvard University; Dana-Farber Cancer Institute; Chugai Pharmaceutical Co., Ltd.; Roche Holding; University of Ottawa; University of Tokyo	Sonenberg, N (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ, Canada.	nsonen@med.mcgill.ca	Gingras, Anne-Claude/ABA-8341-2020; Gingras, Anne-Claude/E-9982-2010; Cheng, Alan/M-9319-2013	Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437; Cheng, Alan/0000-0001-7897-4751; Wu, Zhidan/0000-0001-7289-9420; Harper, Mary-Ellen/0000-0003-3864-5886				BELSHAM G J, 1980, Biochemical Society Transactions, V8, P382; Blackshear PJ, 1997, J BIOL CHEM, V272, P31510, DOI 10.1074/jbc.272.50.31510; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Ewart-Toland A, 1999, ENDOCRINOLOGY, V140, P732, DOI 10.1210/en.140.2.732; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Koza RA, 2000, J BIOL CHEM, V275, P34486, DOI 10.1074/jbc.M002136200; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; SHIBATA H, 1987, J APPL PHYSIOL, V63, P465, DOI 10.1152/jappl.1987.63.2.465; Soukas A, 2000, GENE DEV, V14, P963; SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X; TsukiyamaKohara K, 1996, GENOMICS, V38, P353, DOI 10.1006/geno.1996.0638; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X	29	296	309	0	19	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2001	7	10					1128	1132		10.1038/nm1001-1128	http://dx.doi.org/10.1038/nm1001-1128			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590436				2022-12-27	WOS:000171524500034
J	Dormond, O; Foletti, A; Paroz, C; Ruegg, C				Dormond, O; Foletti, A; Paroz, C; Ruegg, C			NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis	NATURE MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FAMILIAL ADENOMATOUS POLYPOSIS; GROWTH-FACTOR; CYCLOOXYGENASE-2 INHIBITORS; THROMBOXANE A(2); IN-VITRO; ACTIVATION; CANCER; ALPHA(V)BETA(3); SULINDAC	Cyclooxygenase-2 (COX-2), a key enzyme in arachidonic acid metabolism, is overexpressed in many cancers. Inhibition of COX-2 by nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of cancer development in humans and suppresses tumor growth in animal models. The anticancer effect of NSAIDs seems to involve suppression of tumor angiogenesis, but the underlying mechanism is not completely understood. Integrin alphaV beta3 is an adhesion receptor critically involved in mediating tumor angiogenesis. Here we show that inhibition of endothelial-cell COX-2 by NSAIDs suppresses alphaV beta3-dependent activation of the small GTPases Cdc42 and Rac, resulting in inhibition of endothelial-cell spreading and migration in vitro and suppression of fibroblast growth factor-2-induced angiogenesis in vivo. These results establish a novel functional link between COX-2, integrin alphaV beta3 and Cdc42-/Rac-dependent endothelial-cell migration. Moreover, they provide a rationale to the understanding of the anti-angiogenic activity of NSAIDs.	Univ Lausanne, Sch Med, Ctr Pluridisciplinaire Oncol, Lausanne, Switzerland	University of Lausanne	Ruegg, C (corresponding author), Univ Lausanne, Sch Med, Ctr Pluridisciplinaire Oncol, Lausanne, Switzerland.		Dormond, Olivier/B-5347-2017	Dormond, Olivier/0000-0002-6418-1782				BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Byzova TV, 1998, J CELL BIOL, V143, P2081, DOI 10.1083/jcb.143.7.2081; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; COYNE DW, 1992, AM J PHYSIOL, V263, pF97, DOI 10.1152/ajprenal.1992.263.1.F97; Daniel TO, 1999, CANCER RES, V59, P4574; Dominguez-Jimenez C, 1999, FEBS LETT, V446, P318, DOI 10.1016/S0014-5793(99)00236-7; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GarciaVicuna R, 1997, ARTHRITIS RHEUM-US, V40, P143, DOI 10.1002/art.1780400119; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Honda S, 2001, BLOOD, V97, P175, DOI 10.1182/blood.V97.1.175; Hoper MM, 1997, AM J RESP CELL MOL, V17, P748; Hull MA, 1999, BRIT J CANCER, V79, P1399, DOI 10.1038/sj.bjc.6690224; Jones MK, 1999, NAT MED, V5, P1418; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Masferrer JL, 2000, CANCER RES, V60, P1306; Nie DT, 2000, BIOCHEM BIOPH RES CO, V267, P245, DOI 10.1006/bbrc.1999.1840; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; SANO H, 1995, CANCER RES, V55, P3785; Shiff SJ, 1999, J EXP MED, V190, P445, DOI 10.1084/jem.190.4.445; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Skopinska-Rozewska E, 1998, INT J TISSUE REACT, V20, P85; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Taketo MM, 1998, J NATL CANCER I, V90, P1529, DOI 10.1093/jnci/90.20.1529; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	44	244	255	1	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2001	7	9					1041	1047		10.1038/nm0901-1041	http://dx.doi.org/10.1038/nm0901-1041			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533708				2022-12-27	WOS:000170853300030
J	Celletti, FL; Waugh, JM; Amabile, PG; Brendolan, A; Hilfiker, PR; Dake, MD				Celletti, FL; Waugh, JM; Amabile, PG; Brendolan, A; Hilfiker, PR; Dake, MD			Vascular endothelial growth factor enhances atherosclerotic plaque progression	NATURE MEDICINE			English	Article							PERMEABILITY FACTOR; INTIMAL NEOVASCULARIZATION; GENE-TRANSFER; VEGF; MACROPHAGES; EXPRESSION; CELLS; MICROVESSELS; PATHOGENESIS; RECEPTORS	Vascular endothelial growth factor (VEGF) can promote angiogenesis but may also exert certain effects to alter the rate of atherosclerotic plaque development. To evaluate this potential impact on plaque progression, we treated cholesterol-fed mice doubly deficient in apolipoprotein E/apolipoprotein B100 with low doses of VEGF (2 mug/kg) or albumin. VEGF significantly increased macrophage levels in bone marrow and peripheral blood and increased plaque area 5-, 14- and 4-fold compared with controls at weeks 1, 2 and 3, respectively. Plaque macrophage and endothelial cell content also increased disproportionately over controls. In order to confirm that the VEGF-mediated plaque progression was not species-specific, the experiment was repeated in cholesterol-fed rabbits at the three-week timepoint, which showed comparable increases in plaque progression.	Stanford Univ, Med Ctr, Stanford, CA 94305 USA; WHO, CH-1211 Geneva, Switzerland	Stanford University; World Health Organization	Dake, MD (corresponding author), Stanford Univ, Med Ctr, Stanford, CA 94305 USA.	mddake@stanford.edu		Brendolan, Andrea/0000-0003-0109-6879				Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BHARDWAY R, 1994, J LEUKOCYTE BIOL, V57, P747; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; GOWN AM, 1986, AM J PATHOL, V125, P191; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; Kaartinen M, 1996, ATHEROSCLEROSIS, V123, P123, DOI 10.1016/0021-9150(95)05794-3; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kolodgie FD, 1996, ARTERIOSCL THROM VAS, V16, P1454, DOI 10.1161/01.ATV.16.12.1454; KRATKY RG, 1993, ATHEROSCLEROSIS, V99, P121, DOI 10.1016/0021-9150(93)90057-2; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; Lazarous DF, 1996, CIRCULATION, V94, P1074, DOI 10.1161/01.CIR.94.5.1074; Leek RD, 2000, J PATHOL, V190, P430, DOI 10.1002/(SICI)1096-9896(200003)190:4<430::AID-PATH538>3.0.CO;2-6; LIBBY P, 1986, AM J PATHOL, V124, P179; Lopez JJ, 1998, CARDIOVASC RES, V40, P272, DOI 10.1016/S0008-6363(98)00136-9; Moulton KS, 1999, CIRCULATION, V99, P1726, DOI 10.1161/01.CIR.99.13.1726; Paterson JC, 1938, ARCH PATHOL, V25, P474; POLVERINI PJ, 1977, NATURE, V269, P804, DOI 10.1038/269804a0; Pujol BF, 2000, DIFFERENTIATION, V65, P287, DOI 10.1046/j.1432-0436.2000.6550287.x; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHEN H, 1993, BLOOD, V81, P2767; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Sueishi K, 1997, ANN NY ACAD SCI, V811, P311, DOI 10.1111/j.1749-6632.1997.tb52011.x; Tenaglia AN, 1998, AM HEART J, V135, P10, DOI 10.1016/S0002-8703(98)70336-9; Veniant MM, 1997, J CLIN INVEST, V100, P180, DOI 10.1172/JCI119511; Yonemitsu Y, 1996, LAB INVEST, V75, P313	31	574	616	2	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2001	7	4					425	429		10.1038/86490	http://dx.doi.org/10.1038/86490			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283668				2022-12-27	WOS:000167960500036
J	Kirveskari, J; Vesaluoma, MH; Moilanen, JAO; Tervo, TMT; Petroll, MW; Linnolahti, E; Renkonen, R				Kirveskari, J; Vesaluoma, MH; Moilanen, JAO; Tervo, TMT; Petroll, MW; Linnolahti, E; Renkonen, R			A novel non-invasive, in vivo technique for the quantification of leukocyte rolling and extravasation at sites of inflammation in human patients	NATURE MEDICINE			English	Article							P-SELECTIN; IN-VIVO; CONFOCAL MICROSCOPY; ADHESION; LIGANDS; MICROVESSELS; TRAFFICKING; ENDOTHELIUM; REPERFUSION; REJECTION		Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, Helsinki, Finland; Hlth Care Reg Helsinki & Uusimaa, HUCH, Diagnost Lab, Helsinki, Finland; Univ Helsinki, Dept Ophthalmol, Helsinki, Finland; Univ Texas, SW Med Ctr, Dept Ophthalmol, Dallas, TX USA	University of Helsinki; University of Helsinki; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Renkonen, R (corresponding author), Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, Helsinki, Finland.			Petroll, W. Matthew/0000-0003-0795-4539				Berlin-Rufenach C, 1999, J EXP MED, V189, P1467, DOI 10.1084/jem.189.9.1467; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; CAVANAGH HD, 1993, OPHTHALMOLOGY, V100, P1444; Chee SP, 1999, J CATARACT REFR SURG, V25, P1280, DOI 10.1016/S0886-3350(99)00161-3; Jung U, 1999, J IMMUNOL, V162, P6755; JUNG U, 1998, AM J PHYSIOL, V274, P1785; Li HF, 1997, CURR EYE RES, V16, P214, DOI 10.1076/ceyr.16.3.214.15412; Liu XW, 1999, J SURG RES, V87, P77, DOI 10.1006/jsre.1999.5725; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Mazo IB, 1999, J LEUKOCYTE BIOL, V66, P25, DOI 10.1002/jlb.66.1.25; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; Petroll WM, 1996, SCANNING, V18, P45, DOI 10.1002/sca.1996.4950180107; Robinson SD, 1999, P NATL ACAD SCI USA, V96, P11452, DOI 10.1073/pnas.96.20.11452; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; Sanz MJ, 1999, AM J PHYSIOL-HEART C, V277, pH1823, DOI 10.1152/ajpheart.1999.277.5.H1823; Toppila S, 1999, AM J PATHOL, V155, P1303, DOI 10.1016/S0002-9440(10)65232-7; Tsujikawa A, 1999, INVEST OPHTH VIS SCI, V40, P1183; TURUNEN JP, 1995, J EXP MED, V182, P1133, DOI 10.1084/jem.182.4.1133; Veihelmann A, 1999, MICROCIRCULATION, V6, P281, DOI 10.1080/713773963; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Von Andrian Ulrich H., 1996, Microcirculation (Philadelphia), V3, P287, DOI 10.3109/10739689609148303	21	28	28	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					376	379		10.1038/85538	http://dx.doi.org/10.1038/85538			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231641				2022-12-27	WOS:000167380400048
J	Sakai, T; Johnson, KJ; Murozono, M; Sakai, K; Magnuson, MA; Wieloch, T; Cronberg, T; Isshiki, A; Erickson, HP; Fassler, R				Sakai, T; Johnson, KJ; Murozono, M; Sakai, K; Magnuson, MA; Wieloch, T; Cronberg, T; Isshiki, A; Erickson, HP; Fassler, R			Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis.	NATURE MEDICINE			English	Article							PLATELET-AGGREGATION; MICE LACKING; FIBRINOGEN; GENE; ADHESION; CELLS; BCL-2; LOCALIZATION; EXPRESSION; MIGRATION	Fibronectin performs essential roles in embryonic development and is prominently expressed during tissue repair. Two forms of fibronectin have been Identified: plasma fibronectin (pFn), which Is expressed by hepatocytes and secreted In soluble form into plasma; and cellular fibronectin (cFn), an insoluble form expressed locally by fibroblasts and other cell types and deposited and assembled into the extracellular matrix. To investigate the role of pFn in vivo, we generated pfn-deficient adult mice using Cre-loxP conditional gene-knockout technology. Here we show that pfn-deficient mice show increased neuronal apoptosis and larger Infarction areas following transient focal cerebral ischemia. However, pFn is dispensable for skin-wound healing and hemostasis.	Lund Univ, Dept Expt Pathol, Lund, Sweden; Lund Univ, Wallenberg Neurosci Ctr, Lund, Sweden; Brown Univ, Dept Pathol & Lab Med, Providence, RI 02912 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Tokyo Med Univ, Dept Anesthesiol, Tokyo, Japan; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN USA	Lund University; Lund University; Brown University; Duke University; Tokyo Medical University; Vanderbilt University	Fassler, R (corresponding author), Lund Univ, Dept Expt Pathol, Lund, Sweden.	reinhard.fassler@pat.lu.se	Magnuson, Mark/AAY-7172-2021	Magnuson, Mark/0000-0002-8824-6499; Johnson, Kamin/0000-0003-4550-5566; Wieloch, Tadeusz/0000-0002-7669-2520	NCI NIH HHS [CA47056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA047056, R01CA047056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Aoshiba K, 1997, AM J PHYSIOL-LUNG C, V272, pL28, DOI 10.1152/ajplung.1997.272.1.L28; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; BROWN LF, 1993, AM J PATHOL, V142, P793; Clark R. A. F, 1996, MOL CELLULAR BIOL WO; CLARK RAF, 1990, J INVEST DERMATOL, V94, pS128, DOI 10.1111/1523-1747.ep12876104; Corbett SA, 1996, BLOOD, V88, P158; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; de la Fuente MT, 1999, LEUKEMIA, V13, P266, DOI 10.1038/sj.leu.2401275; DENO DC, 1983, AM J PHYSIOL, V245, pR564, DOI 10.1152/ajpregu.1983.245.4.R564; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; Forsberg E, 1996, P NATL ACAD SCI USA, V93, P6594, DOI 10.1073/pnas.93.13.6594; GARCIA JH, 1994, AM J PATHOL, V144, P188; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Globus RK, 1998, J CELL SCI, V111, P1385; HAMANN GF, 1995, STROKE, V26, P2120, DOI 10.1161/01.STR.26.11.2120; HANDAGAMA PJ, 1989, J CLIN INVEST, V84, P73, DOI 10.1172/JCI114173; HARRISON P, 1989, J CLIN INVEST, V84, P1320, DOI 10.1172/JCI114300; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; Kitagawa K, 1998, J CEREBR BLOOD F MET, V18, P570, DOI 10.1097/00004647-199805000-00012; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Mosher DF, 1989, FIBRONECTIN; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Ni HY, 2000, J CLIN INVEST, V106, P385, DOI 10.1172/JCI9896; NIWA K, 1993, BLOOD, V82, P3658; OWENS MR, 1982, BLOOD, V59, P1305; PESCIOTTAPETERS DM, 1990, J CELL BIOL, V111, P249; Potocnik AJ, 2000, IMMUNITY, V12, P653, DOI 10.1016/S1074-7613(00)80216-2; Rooney MM, 1996, J BIOL CHEM, V271, P8553, DOI 10.1074/jbc.271.15.8553; Schick PK, 1996, BLOOD, V87, P1817; Schmid-Elsaesser R, 1998, STROKE, V29, P2162, DOI 10.1161/01.STR.29.10.2162; Schwarzbauer JE, 1991, CURR OPIN CELL BIOL, V3, P786, DOI 10.1016/0955-0674(91)90051-Y; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; TALTS JF, 1995, J CELL SCI, V108, P2153; WENCELDRAKE JD, 1985, BLOOD, V65, P929; WILSON CL, 1992, J CELL BIOL, V119, P923, DOI 10.1083/jcb.119.4.923; Yamada KM, 2000, J CLIN INVEST, V105, P1507, DOI 10.1172/JCI10119; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	45	264	273	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2001	7	3					324	330		10.1038/85471	http://dx.doi.org/10.1038/85471			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231631				2022-12-27	WOS:000167380400038
J	D'Cruz, CM; Gunther, EJ; Boxer, RB; Hartman, JL; Sintasath, L; Moody, SE; Cox, JD; Ha, SI; Belka, GK; Golant, A; Cardiff, RD; Chodosh, LA				D'Cruz, CM; Gunther, EJ; Boxer, RB; Hartman, JL; Sintasath, L; Moody, SE; Cox, JD; Ha, SI; Belka, GK; Golant, A; Cardiff, RD; Chodosh, LA			c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations	NATURE MEDICINE			English	Article							TRANSGENIC MICE; ORNITHINE DECARBOXYLASE; BREAST CARCINOMAS; HA-RAS; EXPRESSION; ONCOGENE; GENE; CELLS; DIFFERENTIATION; ACTIVATION	Although the process of mammary tumorigenesis requires multiple genetic events, it is unclear to what extent carcinogenesis proceeds through preferred secondary pathways following a specific initiating oncogenic event. Similarly, the extent to which established mammary tumors remain dependent on individual mutations for maintenance of the transformed state is unknown. Here we use the tetracycline regulatory system to conditionally express the human c-MYC oncogene in the mammary epithelium of transgenic mice. MYC encodes a transcription factor implicated in multiple human cancers. In particular, amplification and overexpression of c-MYC in human breast cancers is associated with poor prognosis, although the genetic mechanisms by which c-MYC promotes tumor progression are poorly understood(1,2). We show that deregulated c-MYC expression in this inducible system results in the formation of invasive mammary adenocarcinomas, many of which fully regress following c-MYC deinduction. Approximately half of these tumors harbor spontaneous activating point mutations in the ros family of proto-oncogenes with a strong preference for Kras2 compared with Hras1. Nearly all tumors lacking activating ras mutations fully regressed following c-MYC deinduction, whereas tumors bearing ras mutations did not, suggesting that secondary mutations in ras contribute to tumor progression. These findings demonstrate that c-MYC-induced mammary tumorigenesis proceeds through a preferred secondary oncogenic pathway involving Kras2.	Univ Penn, Sch Med, Dept Mol & Cellular Engn, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of California System; University of California Davis	Chodosh, LA (corresponding author), Univ Penn, Sch Med, Dept Mol & Cellular Engn, Philadelphia, PA 19104 USA.							ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BOS JL, 1990, CANCER RES, V50, P1352; CARDIFF RD, 1991, AM J PATHOL, V139, P495; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GUERIN M, 1988, ONCOGENE RES, V3, P21; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Miyakis S, 1998, BIOCHEM BIOPH RES CO, V251, P609, DOI 10.1006/bbrc.1998.9527; MURPHY W, 1986, P NATL ACAD SCI USA, V83, P2939, DOI 10.1073/pnas.83.9.2939; NISHIKURA K, 1988, ONCOGENE, V2, P493; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PENA A, 1993, J BIOL CHEM, V268, P27277; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; VARLEY JM, 1987, ONCOGENE, V1, P423; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	24	326	334	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					235	239		10.1038/84691	http://dx.doi.org/10.1038/84691			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175856				2022-12-27	WOS:000166756300042
J	Wei, YQ; Wang, QR; Zhao, X; Yang, L; Tian, L; Lu, Y; Kang, B; Lu, CJ; Huang, MJ; Lou, YY; Xiao, F; He, QM; Shu, JM; Xie, XJ; Mao, YQ; Lei, S; Luo, F; Zhou, LQ; Liu, CE; Zhou, H; Jiang, Y; Peng, F; Yuan, LP; Li, Q; Wu, Y; Liu, JY				Wei, YQ; Wang, QR; Zhao, X; Yang, L; Tian, L; Lu, Y; Kang, B; Lu, CJ; Huang, MJ; Lou, YY; Xiao, F; He, QM; Shu, JM; Xie, XJ; Mao, YQ; Lei, S; Luo, F; Zhou, LQ; Liu, CE; Zhou, H; Jiang, Y; Peng, F; Yuan, LP; Li, Q; Wu, Y; Liu, JY			Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine	NATURE MEDICINE			English	Article							GROWTH-FACTOR; T-CELLS; GENE-THERAPY; BINDING-SITE; IN-VIVO; ANGIOGENESIS; RECEPTOR; IDENTIFICATION; ANTIGENS; VEGF	The breaking of immune tolerance against autologous angiogenic endothelial cells should be a useful approach for cancer therapy. Here we show that immunotherapy of tumors using fixed xenogeneic whole endothelial cells as a vaccine was effective in affording protection from tumor growth, inducing regression of established tumors and prolonging survival of tumor-bearing mice. Furthermore, autoreactive immunity targeting to microvessels in solid tumors was induced and was probably responsible for the anti-tumor activity. These observations may provide a new vaccine strategy for cancer therapy through the induction of an autoimmune response against the tumor endothelium in a cross-reaction.	W China Univ Med Sci, Sichuan Univ, HuaXi Sch Med, Univ Hosp 1,Ctr Biotherapy Canc, Chengdu 610041, Sichuan, Peoples R China; W China Univ Med Sci, Sichuan Univ, Sch Med, Univ Hosp 1,Ctr Canc, Chengdu 610041, Sichuan, Peoples R China; W China Univ Med Sci, Sichuan Univ, HuaXi Med Sch, Univ Hosp 2,Dept Gynecol & Obstet, Chengdu 610041, Peoples R China	Sichuan University; Sichuan University; Sichuan University	Wei, YQ (corresponding author), W China Univ Med Sci, Sichuan Univ, HuaXi Sch Med, Univ Hosp 1,Ctr Biotherapy Canc, Guo Xue Xiang 37, Chengdu 610041, Sichuan, Peoples R China.			Wei, Yu-quan/0000-0002-6211-3217				Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; BARTH RJ, 1990, J IMMUNOL, V144, P1531; Beekhuizen H, 1997, J IMMUNOL, V158, P774; Bicknell R, 1997, TUMOUR ANGIOGENESIS, P19; Boon T, 1997, IMMUNOL TODAY, V18, P267, DOI 10.1016/S0167-5699(97)80020-5; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; De Silva HD, 1998, IMMUNOLOGY, V93, P405; DJAFFAR I, 1994, BIOCHEM J, V300, P69, DOI 10.1042/bj3000069; Eichmann A, 1996, GENE, V174, P3, DOI 10.1016/0378-1119(96)00159-X; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; FAN TPD, 1995, TRENDS PHARMACOL SCI, V16, P57, DOI 10.1016/S0165-6147(00)88979-8; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; HANAHAN D, 1996, J NATL CANCER I, V88, P1091; Horton HM, 1999, P NATL ACAD SCI USA, V96, P1553, DOI 10.1073/pnas.96.4.1553; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Kerbel RS, 1997, NATURE, V390, P335, DOI 10.1038/36978; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kumar V, 1996, J EXP MED, V184, P1609, DOI 10.1084/jem.184.5.1609; Lin ECK, 1998, CELL ADHES COMMUN, V6, P451, DOI 10.3109/15419069809010794; Mandriota SJ, 1996, J BIOL CHEM, V271, P11500, DOI 10.1074/jbc.271.19.11500; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; Murray JS, 1998, IMMUNOL TODAY, V19, P157, DOI 10.1016/S0167-5699(97)01237-1; Ohashi PS, 1996, CURR OPIN IMMUNOL, V8, P808, DOI 10.1016/S0952-7915(96)80009-4; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; PAN ZK, 1995, NAT MED, V1, P471, DOI 10.1038/nm0595-471; Piossek C, 1999, J BIOL CHEM, V274, P5612, DOI 10.1074/jbc.274.9.5612; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; Pummerer CL, 1996, J CLIN INVEST, V97, P2057, DOI 10.1172/JCI118642; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; Rosenberg SA, 1997, IMMUNOL TODAY, V18, P175, DOI 10.1016/S0167-5699(97)84664-6; Schellekens GA, 1998, J CLIN INVEST, V101, P273, DOI 10.1172/JCI1316; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SMITH JW, 1990, J BIOL CHEM, V265, P2168; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; WEI YQ, 1994, CANCER RES, V54, P4952; Wei YQ, 1996, CANCER RES, V56, P1104; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Yeh CH, 1999, EXP CELL RES, V251, P57, DOI 10.1006/excr.1999.4560; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	46	211	255	0	34	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1160	1166		10.1038/80506	http://dx.doi.org/10.1038/80506			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017149				2022-12-27	WOS:000089674700042
J	Hanke, T; McMichael, AJ				Hanke, T; McMichael, AJ			Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya.	NATURE MEDICINE			English	News Item							CYTOTOXIC T-LYMPHOCYTES; IMMUNODEFICIENCY-VIRUS TYPE-1; CELL RESPONSES; EFFECTIVE INDUCTION; BETA-CHEMOKINES; EPITOPES; ANKARA; CTL; WORKERS; IMMUNOGENICITY		John Radcliffe Hosp, Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England	University of Oxford	Hanke, T (corresponding author), John Radcliffe Hosp, Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England.							Allen TM, 2000, J IMMUNOL, V164, P4968, DOI 10.4049/jimmunol.164.9.4968; Betts MR, 1997, J VIROL, V71, P8908, DOI 10.1128/JVI.71.11.8908-8911.1997; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; Blank RR, 1998, INT J WILDLAND FIRE, V8, P79, DOI 10.1071/WF9980079; Cafaro A, 1999, NAT MED, V5, P643, DOI 10.1038/9488; CALLAHAN LF, 1995, ARTHRIT CARE RES, V8, P1; CLERICI M, 1994, JAMA-J AM MED ASSOC, V271, P42, DOI 10.1001/jama.271.1.42; Dorrell L, 1999, J VIROL, V73, P1708, DOI 10.1128/JVI.73.2.1708-1714.1999; Ferrari G, 1997, P NATL ACAD SCI USA, V94, P1396, DOI 10.1073/pnas.94.4.1396; Gahery-Segard H, 2000, J VIROL, V74, P1694, DOI 10.1128/JVI.74.4.1694-1703.2000; Hanke T, 1999, J VIROL, V73, P7524, DOI 10.1128/JVI.73.9.7524-7532.1999; Hanke T, 1998, VACCINE, V16, P426, DOI 10.1016/S0264-410X(97)00296-X; Hanke T, 1999, IMMUNOL LETT, V66, P177, DOI 10.1016/S0165-2478(98)00164-3; Hanke T, 1999, VACCINE, V17, P589, DOI 10.1016/S0264-410X(98)00238-2; Hanke T, 1998, J GEN VIROL, V79, P83, DOI 10.1099/0022-1317-79-1-83; Hanke T, 1998, VACCINE, V16, P439, DOI 10.1016/S0264-410X(97)00226-0; KALAMS SA, 1999, J VIROL, V73, P6175; Kaul R, 1999, AIDS, V13, P23, DOI 10.1097/00002030-199901140-00004; Kolchinsky P, 1999, J VIROL, V73, P8120, DOI 10.1128/JVI.73.10.8120-8126.1999; MAYR A, 1974, INFECTION, V2, P64, DOI 10.1007/BF01642023; McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2; McMichael AJ, 1999, NAT MED, V5, P612, DOI 10.1038/9455; Moss B, 1996, Adv Exp Med Biol, V397, P7; Neilson JR, 1999, J VIROL, V73, P4393, DOI 10.1128/JVI.73.5.4393-4403.1999; Ogg GS, 1998, AIDS, V12, P1561, DOI 10.1097/00002030-199812000-00026; PINTO LA, 1995, J CLIN INVEST, V96, P867, DOI 10.1172/JCI118133; Price DA, 1998, CURR BIOL, V8, P355, DOI 10.1016/S0960-9822(98)70138-1; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rowland-Jones SL, 1998, J CLIN INVEST, V102, P1758, DOI 10.1172/JCI4314; Rowland-Jones SL, 1999, IMMUNOL LETT, V66, P9, DOI 10.1016/S0165-2478(98)00179-5; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397; Seth A, 1998, P NATL ACAD SCI USA, V95, P10112, DOI 10.1073/pnas.95.17.10112; TAKAHASHI H, 1993, INT IMMUNOL, V5, P849, DOI 10.1093/intimm/5.8.849; Thompson JL, 1998, INT J SPORT NUTR, V8, P160, DOI 10.1123/ijsn.8.2.160; THOMSON SA, 1995, P NATL ACAD SCI USA, V92, P5845, DOI 10.1073/pnas.92.13.5845; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; WHITTLE N, 1987, PROTEIN ENG, V1, P499, DOI 10.1093/protein/1.6.499; WHITTON JL, 1993, J VIROL, V67, P348, DOI 10.1128/JVI.67.1.348-352.1993; Williams SG, 1998, NUCLEIC ACIDS RES, V26, P2120, DOI 10.1093/nar/26.9.2120; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Yang OO, 1997, J VIROL, V71, P3120, DOI 10.1128/JVI.71.4.3120-3128.1997	45	162	171	0	3	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2000	6	9					951	955		10.1038/79626	http://dx.doi.org/10.1038/79626			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973301				2022-12-27	WOS:000089190500015
J	Heaney, AP; Fernando, M; Yong, WH; Melmed, S				Heaney, AP; Fernando, M; Yong, WH; Melmed, S			Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; CUSHINGS-SYNDROME; IN-VITRO; DIFFERENTIAL-DIAGNOSIS; SERUM CORTISOL; RETINOIC ACID; PEROXISOME; DISEASE; ACTIVATION; LIGANDS	Adrenocorticotrophic hormone (ACTH)-secreting pituitary tumors are associated with high morbidity due to excess glucocorticoid production. No suitable drug therapies are currently available, and surgical excision is not invariably curative. Here we demonstrate immunoreactive expression of the nuclear hormone receptor peroxisome proliferator-activated receptor-gamma (PPAR-gamma) exclusively in normal ACTH-secreting human anterior pituitary cells: PPAR-gamma was abundantly expressed in all of six human ACTH-secreting pituitary tumors studied. PPAR-gamma activators induced G(0)/G(1) cell-cycle arrest and apoptosis and suppressed ACTH secretion in human and murine corticotroph tumor cells. Development of murine corticotroph tumors, generated by subcutaneous injection of ACTH-secreting AtT20 cells, was prevented in four of five mice treated with the thiazolidinedione compound rosiglitazone, and ACTH and corticosterone secretion was suppressed in all treated mice. Based on these findings, thiazolidinediones may be an effective therapy for Cushing disease.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Pathol, Los Angeles, CA USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Heaney, AP (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med, Los Angeles, CA 90024 USA.				NATIONAL CANCER INSTITUTE [R01CA075979] Funding Source: NIH RePORTER; NCI NIH HHS [CA75979] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bousquet C, 2000, J CLIN INVEST, V106, P1417, DOI 10.1172/JCI11182; BRADA M, 1993, CLIN ENDOCRINOL, V38, P571, DOI 10.1111/j.1365-2265.1993.tb02137.x; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Findling JW, 2001, ENDOCRIN METAB CLIN, V30, P729, DOI 10.1016/S0889-8529(05)70209-7; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Goke R, 2000, CELL IMMUNOL, V201, P77, DOI 10.1006/cimm.2000.1650; Goldstein BJ, 2000, INT J CLIN PRACT, V54, P333; HAMMER GD, 1990, MOL ENDOCRINOL, V4, P1689, DOI 10.1210/mend-4-11-1689; Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275; Heaney AP, 2002, OXFORD TXB ENDOCRINO, P109; Hoybye C, 2001, NEUROSURGERY, V49, P284; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KRIEGER DT, 1975, NEW ENGL J MED, V293, P893, DOI 10.1056/NEJM197510302931802; Kubota T, 1998, CANCER RES, V58, P3344; MAMPALAM TJ, 1988, ANN INTERN MED, V109, P487, DOI 10.7326/0003-4819-109-6-487; Melmed S, 2002, J CLIN ENDOCR METAB, V87, P4054, DOI 10.1210/jc.2002-011841; Motomura W, 2000, CANCER RES, V60, P5558; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; ORTH DN, 1995, NEW ENGL J MED, V332, P791, DOI 10.1056/NEJM199503233321207; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROSS EJ, 1982, LANCET, V2, P646; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Shimon I, 1998, ANN INTERN MED, V129, P472, DOI 10.7326/0003-4819-129-6-199809150-00009; Simmons NE, 2001, J NEUROSURG, V95, P1, DOI 10.3171/jns.2001.95.1.0001; SONINO N, 1987, NEW ENGL J MED, V317, P812, DOI 10.1056/NEJM198709243171307; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Sugimura A, 1999, BIOCHEM BIOPH RES CO, V261, P833, DOI 10.1006/bbrc.1999.1049; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TRAINER PJ, 1994, ENDOCRIN METAB CLIN, V23, P571, DOI 10.1016/S0889-8529(18)30085-9; TRAINER PJ, 1993, CLIN ENDOCRINOL, V38, P73, DOI 10.1111/j.1365-2265.1993.tb00975.x; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; Wakino S, 2000, J BIOL CHEM, V275, P22435, DOI 10.1074/jbc.M910452199; White A, 1998, CLIN ENDOCRINOL, V48, P251, DOI 10.1046/j.1365-2265.1998.00451.x; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116	41	183	191	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2002	8	11					1281	1287		10.1038/nm784	http://dx.doi.org/10.1038/nm784			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12379847				2022-12-27	WOS:000179221200035
J	Sambandamurthy, VK; Wang, XJ; Chen, B; Russell, RG; Derrick, S; Collins, FM; Morris, SL; Jacobs, WR				Sambandamurthy, VK; Wang, XJ; Chen, B; Russell, RG; Derrick, S; Collins, FM; Morris, SL; Jacobs, WR			A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis	NATURE MEDICINE			English	Article							BCG VACCINES; VIRULENCE; PERSISTENCE; GENE	With the advent of HIV and the widespread emergence of drug-resistant strains of Mycobacterium tuberculosis, newer control strategies in the form of a better vaccine could decrease the global incidence of tuberculosis. A desirable trait in an effective live attenuated vaccine strain is an ability to persist within the host in a limited fashion in order to produce important protective antigens in vivo(1,2). Attenuated M. tuberculosis vaccine candidates have been constructed by deleting genes required for growth in mice(3-5). These candidate vaccines did not elicit adequate protective immunity in animal models, due to their inability to persist sufficiently long within the host tissues. Here we report that an auxotrophic mutant of M. tuberculosis defective in the de novo biosynthesis of pantothenic acid (vitamin B5) is highly attenuated in immunocompromised SCID mice and in immunocompetent BALB/c mice. SCID mice infected with the pantothenate auxotroph survived significantly longer (250 days) than mice infected with either bacille Calmette-Guerin (BCG) vaccine or virulent M. tuberculosis (77 and 35 days, respectively). Subcutaneous immunization with this auxotroph conferred protection in C57BL/6J mice against an aerosol challenge with virulent M. tuberculosis, which was comparable with that afforded by BCG vaccination. Our findings highlight the importance of de novo pantothenate biosynthesis in limiting the intracellular survival and pathogenesis of M. tuberculosis without reducing its immunogenicity in vaccinated mice.	Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD USA	Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; US Food & Drug Administration (FDA)	Jacobs, WR (corresponding author), Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10467 USA.	jacobsw@hhmi.org		Jacobs, William/0000-0003-3321-3080				Afshar K, 2001, GENETICS, V157, P1267; BARDAROV S, 1999, ONE STEP ALLELIC EXC, V6034; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; COLLINS FM, 1985, TUBERCLE, V66, P267, DOI 10.1016/0041-3879(85)90064-9; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; De Voss JJ, 2000, P NATL ACAD SCI USA, V97, P1252, DOI 10.1073/pnas.97.3.1252; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; Hondalus MK, 2000, INFECT IMMUN, V68, P2888, DOI 10.1128/IAI.68.5.2888-2898.2000; JACKOWSKI S, 1990, J BACTERIOL, V172, P3842, DOI 10.1128/jb.172.7.3842-3848.1990; Jackowski S., 1996, ESCHERICHIA COLI SAL, P687; Jackson M, 1999, INFECT IMMUN, V67, P2867, DOI 10.1128/IAI.67.6.2867-2873.1999; KANAI K, 1955, Jpn J Med Sci Biol, V8, P115; Kaushal D, 2002, P NATL ACAD SCI USA, V99, P8330, DOI 10.1073/pnas.102055799; Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998; McKenney D, 1999, SCIENCE, V284, P1523, DOI 10.1126/science.284.5419.1523; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; Raman S, 2001, J BACTERIOL, V183, P6119, DOI 10.1128/JB.183.20.6119-6125.2001; Saliba KJ, 2001, J BIOL CHEM, V276, P18115, DOI 10.1074/jbc.M010942200; Slyshenkov VS, 1996, FREE RADICAL BIO MED, V20, P793, DOI 10.1016/0891-5849(95)02210-4; Smith DA, 2001, INFECT IMMUN, V69, P1142, DOI 10.1128/IAI.69.2.1442-1150.2001; Steyn AJC, 2002, P NATL ACAD SCI USA, V99, P3147, DOI 10.1073/pnas.052705399; Weber I, 2000, MOL MICROBIOL, V35, P1017, DOI 10.1046/j.1365-2958.2000.01794.x	23	269	290	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1171	1174		10.1038/nm765	http://dx.doi.org/10.1038/nm765			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12219086				2022-12-27	WOS:000178311000046
J	Cummings, DE; Clement, K; Purnell, JQ; Vaisse, C; Foster, KE; Frayo, RS; Schwartz, MW; Basdevant, A; Weigle, DS				Cummings, DE; Clement, K; Purnell, JQ; Vaisse, C; Foster, KE; Frayo, RS; Schwartz, MW; Basdevant, A; Weigle, DS			Elevated plasma ghrelin levels in Prader-Willi syndrome	NATURE MEDICINE			English	Letter							MELANOCORTIN-4 RECEPTOR; STOMACH; OBESITY; SIGNAL		VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA; Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA; Univ Paris 06, Hotel Dieu EA 3502, Serv Med & Nutr, F-75252 Paris, France; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Harborview Medical Center; University of Washington; University of Washington Seattle; UDICE-French Research Universities; Sorbonne Universite; Oregon Health & Science University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Cummings, DE (corresponding author), VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA.		Purnell, Jonathan Q/GVS-8854-2022; Vaisse, Christian/F-1067-2011; Clément, karine/R-1120-2017; Schwartz, Michael W/H-9950-2012	Purnell, Jonathan Q/0000-0001-5505-6333; 	NIDDK NIH HHS [R01 DK060540] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060540] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asakawa A, 2001, GASTROENTEROLOGY, V120, P337, DOI 10.1053/gast.2001.22158; Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35007519; Burman P, 2001, ENDOCR REV, V22, P787, DOI 10.1210/er.22.6.787; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cummings DE, 2001, DIABETES, V50, P1714, DOI 10.2337/diabetes.50.8.1714; Cummings DE, 2002, NEW ENGL J MED, V346, P1623, DOI 10.1056/NEJMoa012908; Dubern B, 2001, J PEDIATR-US, V139, P204, DOI 10.1067/mpd.2001.116284; Inui A, 2001, NAT REV NEUROSCI, V2, P551, DOI 10.1038/35086018; Janssen JAMJL, 2001, EUR J ENDOCRINOL, V145, P711, DOI 10.1530/eje.0.1450711; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Nicholls RD, 2001, ANNU REV GENOM HUM G, V2, P153, DOI 10.1146/annurev.genom.2.1.153; RITTMASTER RS, 1987, NEUROENDOCRINOLOGY, V45, P118, DOI 10.1159/000124713; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Weigle DS, 1997, J CLIN ENDOCR METAB, V82, P566, DOI 10.1210/jc.82.2.566; Wren AM, 2001, J CLIN ENDOCR METAB, V86, P5992, DOI 10.1210/jc.86.12.5992; Wren AM, 2001, DIABETES, V50, P2540, DOI 10.2337/diabetes.50.11.2540	18	443	461	0	31	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2002	8	7					643	644		10.1038/nm0702-643	http://dx.doi.org/10.1038/nm0702-643			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12091883	Green Published			2022-12-27	WOS:000176495200003
J	Miyawaki, K; Yamada, Y; Ban, N; Ihara, Y; Tsukiyama, K; Zhou, HY; Fujimoto, S; Oku, A; Tsuda, K; Toyokuni, S; Hiai, H; Mizunoya, W; Fushiki, T; Holst, JJ; Makino, M; Tashita, A; Kobara, Y; Tsubamoto, Y; Jinnouchi, T; Jomori, T; Seino, Y				Miyawaki, K; Yamada, Y; Ban, N; Ihara, Y; Tsukiyama, K; Zhou, HY; Fujimoto, S; Oku, A; Tsuda, K; Toyokuni, S; Hiai, H; Mizunoya, W; Fushiki, T; Holst, JJ; Makino, M; Tashita, A; Kobara, Y; Tsubamoto, Y; Jinnouchi, T; Jomori, T; Seino, Y			Inhibition of gastric inhibitory polypeptide signaling prevents obesity	NATURE MEDICINE			English	Article							RESISTANCE; MICE; FAT; METABOLISM; RECEPTOR; GENE; MEAL	Secretion of gastric inhibitory polypeptide (GIP), a duodenal hormone, is primarily induced by absorption of ingested fat. Here we describe a novel pathway of obesity promotion via GIP. Wild-type mice fed a high-fat diet exhibited both hypersecretion of GIP and extreme visceral and subcutaneous fat deposition with insulin resistance. In contrast, mice lacking the GIP receptor (Gipr(-/-)) fed a high-fat diet were clearly protected from both the obesity and the insulin resistance. Moreover, double-homozygous mice (Gipr(-/-), Lep(ob)/Lep(ob)) generated by crossbreeding Gipr(-/-) and obese ob/ob (Lep(ob)/Lep(ob)) mice gained less weight and had lower adiposity than Lep(ob)/Lep(ob) mice. The Gipr(-/-) mice had a lower respiratory quotient and used fat as the preferred energy substrate, and were thus resistant to obesity. Therefore, GIP directly links overnutrition to obesity and it is a potential target for anti-obesity drugs.	Kyoto Univ, Dept Diabet & Clin Nutr, Kyoto, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Kyoto, Japan; Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Kyoto, Japan; Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark; Sanwa Kagaku Kenkyusho Co Ltd, Inabe, Mie, Japan	Kyoto University; Kyoto University; Kyoto University; University of Copenhagen; Sanwa Kagaku Kenkyusho Co., Ltd.	Seino, Y (corresponding author), Kyoto Univ, Dept Diabet & Clin Nutr, Kyoto, Japan.		Yamada, Yuichiro/G-4766-2011; Toyokuni, Shinya/ABE-7714-2021; Holst, Jens/AAA-8022-2022; Mizunoya, Wataru/W-1674-2019; Toyokuni, Shinya/C-1358-2010	Toyokuni, Shinya/0000-0002-5757-1109; Mizunoya, Wataru/0000-0002-2258-1964; Toyokuni, Shinya/0000-0002-5757-1109; Holst, Jens Juul/0000-0001-6853-3805				Bray GA, 1998, AM J CLIN NUTR, V68, P1157, DOI 10.1093/ajcn/68.6.1157; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; EBERT R, 1980, CLIN GASTROENTEROL, V9, P679; FALKO JM, 1975, J CLIN ENDOCR METAB, V41, P260, DOI 10.1210/jcem-41-2-260; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Golay A, 1997, INT J OBESITY, V21, pS2; Goldberg IJ, 1996, J LIPID RES, V37, P693; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Guggenbuhl P, 1995, METHOD FIND EXP CLIN, V17, P621; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; KRARUP T, 1983, J CLIN ENDOCR METAB, V56, P1306, DOI 10.1210/jcem-56-6-1306; Miyawaki K, 1999, P NATL ACAD SCI USA, V96, P14843, DOI 10.1073/pnas.96.26.14843; Neel JV, 1999, NUTR REV, V57, pS2, DOI 10.1111/j.1753-4887.1999.tb01782.x; NEEL JV, 1962, AM J HUM GENET, V14, P353; Ohnuki K, 2001, LIPIDS, V36, P583, DOI 10.1007/s11745-001-0760-2; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Steinberg GR, 2000, AM J PHYSIOL-ENDOC M, V279, pE1374, DOI 10.1152/ajpendo.2000.279.6.E1374; STENGER J, 1995, PHYSIOL BEHAV, V57, P319, DOI 10.1016/0031-9384(94)00216-R; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; WOODS SC, 1981, DIABETOLOGIA, V20, P305, DOI 10.1007/BF00254497; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	24	653	729	1	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2002	8	7					738	742		10.1038/nm727	http://dx.doi.org/10.1038/nm727			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12068290				2022-12-27	WOS:000176495200036
J	Redegeld, FA; van der Heijden, MW; Kool, M; Heijdra, BM; Garssen, J; Kraneveld, AD; Van Loveren, H; Roholl, P; Saito, T; Verbeek, JS; Claassens, J; Koster, AS; Nijkamp, FP				Redegeld, FA; van der Heijden, MW; Kool, M; Heijdra, BM; Garssen, J; Kraneveld, AD; Van Loveren, H; Roholl, P; Saito, T; Verbeek, JS; Claassens, J; Koster, AS; Nijkamp, FP			Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses	NATURE MEDICINE			English	Article							DELAYED-TYPE HYPERSENSITIVITY; MAST-CELL ACTIVATION; FC-EPSILON-RI; CONTACT SENSITIVITY; MULTIPLE-SCLEROSIS; CEREBROSPINAL-FLUID; CYTOKINE PRODUCTION; DEFICIENT MICE; IGE ANTIBODY; GAMMA-CHAIN	Immunoglobulin (Ig)-free light chains IgLC are present in serum and their production is augmented under pathological conditions such as multiple sclerosis, rheumatoid arthritis and neurological disorders. Until now, no (patho)physiological function has been ascribed to circulating Ig light chains. Here we show that IgLCs can confer mast cell-dependent hypersensitivity in mice. Antigenic stimulation results in plasma extravasation, cutaneous swelling and mast-cell degranulation. We show that IgLCs have a crucial role in development of contact sensitivity, which could be completely prevented by a novel IgLC antagonist. Although IgE and IgG(1) are central to the induction of immediate hypersensitivity reactions, our results show that IgLCs have similar activity. IgLCs may therefore be a novel factor in the humoral immune response to antigen exposure. Our findings open new avenues in investigating the pathogenesis of autoimmune diseases and their treatments.	Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmacol & Pathophysiol, Utrecht, Netherlands; Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands; Chiba Univ, Dept Mol Genet, Chuo Ku, Chiba, Japan; Leiden Univ, Med Ctr, Dept Human Genet, Leiden, Netherlands	Utrecht University; Netherlands National Institute for Public Health & the Environment; Chiba University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Redegeld, FA (corresponding author), Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmacol & Pathophysiol, Utrecht, Netherlands.		garssen, johan/I-7159-2016; Kraneveld, Aletta D/J-3351-2016; Redegeld, Frank A/O-6534-2016; Saito, Takashi/C-9684-2009; Koster, Andries/T-8807-2019	Kraneveld, Aletta D/0000-0001-9819-383X; Redegeld, Frank A/0000-0001-8830-7960; Saito, Takashi/0000-0001-9495-3547; Koster, Andries/0000-0001-7772-4654				Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Askenase PW, 2000, CURR TOP MICROBIOL, V252, P171; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; Corry DB, 1999, NATURE, V402, pB18; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; FAGNART OC, 1988, J NEUROIMMUNOL, V19, P119, DOI 10.1016/0165-5728(88)90041-0; Geba GP, 1996, J IMMUNOL, V157, P557; HANNAMHARRIS AC, 1981, IMMUNOLOGY, V43, P417; HOPPER JE, 1986, CELL IMMUNOL, V101, P122, DOI 10.1016/0008-8749(86)90191-7; Hsu C, 1996, IMMUNOL LETT, V52, P129, DOI 10.1016/0165-2478(96)02599-0; Huang ZQ, 1997, J CLIN INVEST, V99, P732, DOI 10.1172/JCI119218; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Karimi K, 1999, EXP HEMATOL, V27, P654, DOI 10.1016/S0301-472X(98)00083-6; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; LEDBETTER JA, 1987, MOL IMMUNOL, V24, P1255, DOI 10.1016/0161-5890(87)90119-2; Lee KH, 2000, J IMMUNOL, V165, P4970, DOI 10.4049/jimmunol.165.9.4970; Lukacs NW, 1996, BLOOD, V87, P2262, DOI 10.1182/blood.V87.6.2262.bloodjournal8762262; Maeda A, 1998, J EXP MED, V188, P991, DOI 10.1084/jem.188.5.991; Marone G, 1998, CLIN EXP RHEUMATOL, V16, P245; MASAT L, 1994, P NATL ACAD SCI USA, V91, P893, DOI 10.1073/pnas.91.3.893; MEADE R, 1988, J IMMUNOL, V141, P2704; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; MOUTSOPOULOS HM, 1983, J IMMUNOL, V130, P2663; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; PAINTER RG, 1972, BIOCHEMISTRY-US, V11, P1327, DOI 10.1021/bi00758a001; PIROZZI G, 1995, J IMMUNOL, V155, P5811; ROZNIECKI JJ, 1995, ANN NEUROL, V37, P63, DOI 10.1002/ana.410370112; SCHECHTER I, 1976, BIOCHEMISTRY-US, V15, P2785, DOI 10.1021/bi00658a013; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; SHAPIRO AL, 1966, NATURE, V211, P243, DOI 10.1038/211243a0; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; SKVORTSOV VT, 1968, NATURE, V218, P377, DOI 10.1038/218377a0; Smith DA, 1995, MOL IMMUNOL, V32, P1339, DOI 10.1016/0161-5890(95)00113-1; SOLLING K, 1981, ACTA MED SCAND, V209, P473; SUN M, 1994, J BIOL CHEM, V269, P734; SUN M, 1994, J IMMUNOL, V153, P5121; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Thiagarajan P, 2000, BIOCHEMISTRY-US, V39, P6459, DOI 10.1021/bi992588w; TRIBBICK G, 1989, MOL IMMUNOL, V26, P625, DOI 10.1016/0161-5890(89)90044-8; Tsuji RF, 1997, J EXP MED, V186, P1015, DOI 10.1084/jem.186.7.1015; VANLOVEREN H, 1986, EUR J IMMUNOL, V16, P1203, DOI 10.1002/eji.1830161004; WALDMANN TA, 1972, J CLIN INVEST, V51, P2162, DOI 10.1172/JCI107023; Woolley DE, 2000, ARTHRITIS RES, V2, P65, DOI 10.1186/ar70; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; YOO TJ, 1967, SCIENCE, V157, P707, DOI 10.1126/science.157.3789.707	45	142	150	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2002	8	7					694	701		10.1038/nm722	http://dx.doi.org/10.1038/nm722			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12068287				2022-12-27	WOS:000176495200030
J	Fandrich, F; Lin, XB; Chai, GX; Schulze, M; Ganten, D; Bader, M; Holle, J; Huang, DS; Parwaresch, R; Zavazava, N; Binas, B				Fandrich, F; Lin, XB; Chai, GX; Schulze, M; Ganten, D; Bader, M; Holle, J; Huang, DS; Parwaresch, R; Zavazava, N; Binas, B			Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning	NATURE MEDICINE			English	Article							CONFER IMMUNE PRIVILEGE; DONOR BONE-MARROW; TRANSPLANTATION TOLERANCE; FAS LIGAND; CLASS-I; MIXED CHIMERISM; ALLOGRAFTS; MECHANISMS; PREGNANCY; THYMUS	Hematopoietic stem cells have been successfully employed for tolerance induction in a variety of rodent and large animal studies. However, clinical transplantation of fully allogeneic bone marrow or blood-borne stem cells is still associated with major obstacles, such as graft-versus-host disease or cytoreductive conditioning-related toxicity. Here we show that when rat embryonic stem cell-like cells of WKY origin are injected intraportally into fully MHC-mismatched DA rats, they engraft permanently (>150 days) without supplementary host conditioning. This deviation of a potentially alloreactive immune response sets the basis for long-term graft acceptance of second-set transplanted WKY cardiac allografts. Graft survival was strictly correlated with a state of mixed chimerism, which required functional thymic host competence. Our results provide a rationale for using preimplantation-stage stem cells as vehicles in gene therapy and for the induction of long-term graft acceptance.	Univ Kiel, Dept Gen Surg & Thorac Surg, D-24105 Kiel, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Univ Kiel, Inst Hematopathol, D-24105 Kiel, Germany; Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA; VA Med Ctr, Iowa City, IA USA; Texas A&M Univ, Coll Vet Med, Dept Vet Pathobiol, College Stn, TX 77843 USA	University of Kiel; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Yale University; University of Kiel; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; Texas A&M University System; Texas A&M University College Station	Fandrich, F (corresponding author), Univ Kiel, Dept Gen Surg & Thorac Surg, D-24105 Kiel, Germany.	ffaendrich@surgery.uni-kiel.de	Faendrich, Fred/B-1705-2010; Bader, Michael/K-2124-2013; Holle, Julia/G-6138-2012	Bader, Michael/0000-0003-4780-4164; Schulze, Maren/0000-0002-4577-6473				Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; Bianchi DW, 1998, J PERINAT MED, V26, P175; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; Fandrich F, 1999, J LEUKOCYTE BIOL, V65, P16, DOI 10.1002/jlb.65.1.16; FERRARA JL, 1989, BIOL BLOOD MARROW TR, V5, P347; FINK PJ, 1978, J EXP MED, V148, P766, DOI 10.1084/jem.148.3.766; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; George JF, 1999, INT J MOL MED, V4, P475; George JF, 1998, NAT MED, V4, P333, DOI 10.1038/nm0398-333; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; GRUSBY MJ, 1993, P NATL ACAD SCI USA, V90, P3913, DOI 10.1073/pnas.90.9.3913; HESS AD, 1990, J IMMUNOL, V145, P526; IANNACCONE PM, 1994, DEV BIOL, V163, P288, DOI 10.1006/dbio.1994.1146; Iannaccone PM, 1997, DEV BIOL, V185, P124, DOI 10.1006/dbio.1997.8558; ILDSTAD ST, 1984, NATURE, V307, P168, DOI 10.1038/307168a0; KAMPINGA J, 1990, TRANSPLANTATION, V50, P669, DOI 10.1097/00007890-199010000-00028; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Li XK, 1998, TRANSPLANTATION, V66, P1416, DOI 10.1097/00007890-199812150-00003; Liechty KW, 2000, NAT MED, V6, P1282, DOI 10.1038/81395; MEDAWAR PB, 1953, SYM SOC EXP BIOL, V7, P320; O'Connell J, 2001, NAT MED, V7, P271, DOI 10.1038/85395; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; Reisner Y, 2000, CURR OPIN IMMUNOL, V12, P536, DOI 10.1016/S0952-7915(00)00135-7; Reisner Y, 2000, EXP HEMATOL, V28, P119, DOI 10.1016/S0301-472X(99)00132-0; Restifo NP, 2000, NAT MED, V6, P493, DOI 10.1038/74955; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; Shizuru JA, 2000, P NATL ACAD SCI USA, V97, P9555, DOI 10.1073/pnas.170279297; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Swenson KM, 1998, TRANSPLANTATION, V65, P155; Sykes M, 1997, NAT MED, V3, P783, DOI 10.1038/nm0797-783; TAFURI A, 1995, SCIENCE, V270, P630, DOI 10.1126/science.270.5236.630; Vacchio MS, 1999, CRIT REV IMMUNOL, V19, P461; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442; Wekerle T, 1999, TRANSPLANTATION, V68, P459, DOI 10.1097/00007890-199908270-00001; Wekerle T, 1999, TRANSPLANTATION, V68, P1348, DOI 10.1097/00007890-199911150-00022; Werkele T, 2000, NAT MED, V6, P464, DOI 10.1038/74731; Zhou M, 1998, J REPROD IMMUNOL, V40, P47, DOI 10.1016/S0165-0378(98)00030-8; ZINKERNAGEL RM, 1978, NATURE, V271, P251, DOI 10.1038/271251a0	39	230	271	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2002	8	2					171	178		10.1038/nm0202-171	http://dx.doi.org/10.1038/nm0202-171			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821902				2022-12-27	WOS:000173600600027
J	Hwang, PM; Bunz, F; Yu, J; Rago, C; Chan, TA; Murphy, MP; Kelso, GF; Smith, RAJ; Kinzler, KW; Vogelstein, B				Hwang, PM; Bunz, F; Yu, J; Rago, C; Chan, TA; Murphy, MP; Kelso, GF; Smith, RAJ; Kinzler, KW; Vogelstein, B			Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells	NATURE MEDICINE			English	Article							REACTIVE OXYGEN; ADRENODOXIN REDUCTASE; ANTICANCER AGENTS; ELECTRON LEAKAGE; GENE-EXPRESSION; DNA-DAMAGE; P53; MITOCHONDRIA; P21; PROTEIN	Loss of p53 gene function, which occurs in most colon cancer cells, has been shown to abolish the apoptotic response to 5-fluorouracil (54U). To identify genes downstream of p53 that might mediate these effects, we assessed global patterns of gene expression following 5-FU treatment of isogenic cells differing only in their p53 status. The gene encoding mitochondrial ferredoxin reductase (protein, FR; gene, FDXR) was one of the few genes significantly induced by p53 after 5-FU treatment. The FR protein was localized to mitochondria and suppressed the growth of colon cancer cells when over-expressed. Targeted disruption of the FDXR gene in human colon cancer cells showed that it was essential for viability, and partial disruption of the gene resulted in decreased sensitivity to 5-FU-induced apoptosis. These data, coupled with the effects of pharmacologic inhibitors of reactive oxygen species, indicate that FIR contributes to p53-mediated apoptosis through the generation of oxidative stress in mitochondria.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA; NHLBI, Cardiovasc Branch, NIH, Bethesda, MD 20892 USA; Wellcome Trust Res Labs, Cambridge, England; Univ Otago, Dept Chem, Dunedin, New Zealand	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Wellcome Trust Sanger Institute; University of Otago	Vogelstein, B (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA.		Murphy, Michael P/C-2120-2009; Chan, Timothy A/ABD-5850-2021; Yu, Jian/A-8301-2009	Murphy, Michael P/0000-0003-1115-9618; Yu, Jian/0000-0002-4021-1000	NATIONAL CANCER INSTITUTE [R37CA043460, R01CA043460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007184] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA043460, CA 43460] Funding Source: Medline; NIGMS NIH HHS [GM 07184, T32 GM007184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HANUKOGLU I, 1993, ARCH BIOCHEM BIOPHYS, V305, P489, DOI 10.1006/abbi.1993.1452; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAMBETH JD, 1982, MOL CELL BIOCHEM, V45, P13, DOI 10.1007/BF01283159; Lee JM, 1998, ONCOGENE, V17, P1653, DOI 10.1038/sj.onc.1202102; Li J, 2001, J BIOL CHEM, V276, P1503, DOI 10.1074/jbc.M007198200; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; LIN D, 1990, P NATL ACAD SCI USA, V87, P8516, DOI 10.1073/pnas.87.21.8516; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Manzella L, 1998, YEAST, V14, P839, DOI 10.1002/(SICI)1097-0061(19980630)14:9<839::AID-YEA283>3.0.CO;2-A; Masramon L, 2000, CANCER GENET CYTOGEN, V121, P17, DOI 10.1016/S0165-4608(00)00219-3; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; OConnor PM, 1997, CANCER RES, V57, P4285; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pham NA, 2000, CYTOMETRY, V41, P245, DOI 10.1002/1097-0320(20001201)41:4<245::AID-CYTO2>3.0.CO;2-#; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1999, J PATHOL, V187, P112; RAPOPORT R, 1995, ARCH BIOCHEM BIOPHYS, V317, P412, DOI 10.1006/abbi.1995.1182; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Ziegler GA, 1999, J MOL BIOL, V289, P981, DOI 10.1006/jmbi.1999.2807	39	346	357	2	35	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1111	1117		10.1038/nm1001-1111	http://dx.doi.org/10.1038/nm1001-1111			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590433	Green Accepted			2022-12-27	WOS:000171524500031
J	Takano, T; Lin, JHC; Arcuino, G; Gao, Q; Yang, J; Nedergaard, M				Takano, T; Lin, JHC; Arcuino, G; Gao, Q; Yang, J; Nedergaard, M			Glutamate release promotes growth of malignant gliomas	NATURE MEDICINE			English	Article							NMDA RECEPTOR ANTAGONIST; EXTRACELLULAR GLUTAMATE; CELLS; TRANSPORT; C6; NEUROTOXICITY; LOCALIZATION; MODULATION; EXPRESSION; ASPARTATE	Glutamate neurotoxicity has been implicated in stroke, head trauma, multiple sclerosis and neurodegenerative diseases. Although recent data show that cultured glioma cells secrete glutamate, the growth potential of brain tumors has not yet been linked to an excitotoxic mechanism. Using bioluminescence detection of glutamate release from freshly prepared brain slices, we show that implanted glioma cells continue to secrete glutamate. Moreover, gliomas with high glutamate release have a distinct growth advantage in host brain that is not present in vitro. Treatment with the NMDA receptor antagonists MK801 or memantine slowed the growth of glutamate-secreting tumors in situ, suggesting that activation of NMDA receptors facilitates tumor expansion. These findings support a new approach for therapy of brain tumors, based upon antagonizing glutamate secretion or its target receptors.	New York Med Coll, Dept Cell Biol Anat & Pathol, Valhalla, NY 10595 USA; Univ Rochester, Med Ctr, Dept Anesthesiol, Rochester, NY 14642 USA	New York Medical College; University of Rochester	Nedergaard, M (corresponding author), New York Med Coll, Dept Cell Biol Anat & Pathol, Valhalla, NY 10595 USA.	maiken_nedergaard@nymc.edu		Takano, Takahiro/0000-0002-6235-6673	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS030007, R01NS030007, R01NS038073] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38073, NS30007] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abramovitch R, 1998, BRIT J CANCER, V77, P440, DOI 10.1038/bjc.1998.70; Anderson CM, 2000, GLIA, V32, P1; Barth RF, 1998, J NEURO-ONCOL, V36, P91, DOI 10.1023/A:1005805203044; Behrens PF, 2000, J NEURO-ONCOL, V47, P11, DOI 10.1023/A:1006426917654; Benedetti S, 2000, NAT MED, V6, P447, DOI 10.1038/74710; Bolton SJ, 1998, EXP NEUROL, V154, P231, DOI 10.1006/exnr.1998.6927; CASCINO GD, 1990, EPILEPSIA, V31, pS37, DOI 10.1111/j.1528-1157.1990.tb05858.x; Cotrina ML, 1998, J NEUROSCI, V18, P2520; Danysz W, 1997, NEUROSCI BIOBEHAV R, V21, P455, DOI 10.1016/S0149-7634(96)00037-1; Davis KE, 1998, J NEUROSCI, V18, P2475; FISHER B, 1967, CANCER, V20, P23, DOI 10.1002/1097-0142(1967)20:1<23::AID-CNCR2820200103>3.0.CO;2-P; FOSSE VM, 1986, J NEUROCHEM, V47, P340; Graf MR, 1999, J IMMUNOL, V163, P5544; Harkany T, 2000, EUR J NEUROSCI, V12, P2735, DOI 10.1046/j.1460-9568.2000.00164.x; Innocenti B, 2000, J NEUROSCI, V20, P1800; Jabaudon D, 1999, P NATL ACAD SCI USA, V96, P8733, DOI 10.1073/pnas.96.15.8733; Jain KK, 2000, EXPERT OPIN INV DRUG, V9, P1397, DOI 10.1517/13543784.9.6.1397; Kanda T, 1996, LIFE SCI, V59, P1607, DOI 10.1016/0024-3205(96)00492-4; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; MOOTS PL, 1995, ARCH NEUROL-CHICAGO, V52, P717, DOI 10.1001/archneur.1995.00540310091021; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; Pace A, 1998, J EXP CLIN CANC RES, V17, P479; PAILLAS JE, 1991, J NEURORADIOLOGY, V18, P79; Palmer GC, 1999, ANN NY ACAD SCI, V890, P406, DOI 10.1111/j.1749-6632.1999.tb08020.x; Palos TP, 1996, MOL BRAIN RES, V37, P297, DOI 10.1016/0169-328X(95)00331-L; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Russell D., 1989, PATHOLOGY TUMORS NER; Scali C, 2000, EUR J NEUROSCI, V12, P1900, DOI 10.1046/j.1460-9568.2000.00075.x; Schiffer D., 1997, BRAIN TUMORS BIOL PA; Smith T, 2000, NAT MED, V6, P62, DOI 10.1038/71548; Swanson RA, 1997, J NEUROSCI, V17, P932; Warr O, 1999, J PHYSIOL-LONDON, V514, P783, DOI 10.1111/j.1469-7793.1999.783ad.x; Ye ZC, 1999, CANCER RES, V59, P4383; Ye ZC, 1999, J NEUROSCI, V19, P10767, DOI 10.1523/JNEUROSCI.19-24-10767.1999; Zhang W, 2000, CANCER RES, V60, P5395; Zhang W, 1999, CANCER RES, V59, P1994	44	408	428	1	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2001	7	9					1010	1015		10.1038/nm0901-1010	http://dx.doi.org/10.1038/nm0901-1010			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533703				2022-12-27	WOS:000170853300025
J	Bansal-Pakala, P; Jember, AGH; Croft, M				Bansal-Pakala, P; Jember, AGH; Croft, M			Signaling through OX40 (CD134) breaks peripheral T-cell tolerance	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; IN-VIVO; CTLA-4 BLOCKADE; CLONAL ANERGY; B-CELLS; KAPPA-B; ANTITUMOR IMMUNITY; OX-40 LIGAND; INDUCTION; RECEPTOR	Peripheral T-cell tolerance is a mechanism to limit autoimmunity, but represents a major obstacle in diseases such as cancer. Tolerance is due to limited accumulation of antigen-specific T cells accompanied by functional hypo-responsiveness, and is induced by antigen encounter in a non-inflammatory environment. In contrast to advances in preventing induction of T-cell tolerance, there has been little progress in defining targets to reverse established tolerance. Here we show that signals from a single dose of an agonistic antibody against OX40 (CD134, a member of the tumor necrosis-factor family of receptors) can break an existing state of tolerance in the CD4(+) T-cell compartment. OX40 signals promote T-cell expansion after the hypo-responsive phenotype is induced and restore normal functionality. These data highlight the potent costimulatory capacity of OX40, and indicate OX40 as a target for therapeutic intervention in a variety of related diseases.	La Jolla Inst Allergy & Immunol, Div Immunochem, San Diego, CA USA	La Jolla Institute for Immunology	Croft, M (corresponding author), La Jolla Inst Allergy & Immunol, Div Immunochem, San Diego, CA USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042944] Funding Source: NIH RePORTER; NIAID NIH HHS [AI42944] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AICHELE P, 1995, J EXP MED, V182, P261, DOI 10.1084/jem.182.1.261; Akiba H, 1999, J IMMUNOL, V162, P7058; AlShamkhani A, 1996, EUR J IMMUNOL, V26, P1695, DOI 10.1002/eji.1830260805; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Boussiotis VA, 2000, NAT MED, V6, P290, DOI 10.1038/73144; BOUSSIOTIS VA, 1993, J EXP MED, V178, P1753, DOI 10.1084/jem.178.5.1753; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; CALDERHEAD DM, 1993, J IMMUNOL, V151, P5261; Chambers CA, 1997, IMMUNITY, V7, P885, DOI 10.1016/S1074-7613(00)80406-9; Chen AI, 1999, IMMUNITY, V11, P689, DOI 10.1016/S1074-7613(00)80143-0; Croft M, 1997, J IMMUNOL, V159, P3257; DESILVA DR, 1991, J IMMUNOL, V147, P3261; Dresser D W, 1968, Adv Immunol, V8, P129, DOI 10.1016/S0065-2776(08)60466-6; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; Garza KM, 2000, J EXP MED, V191, P2021, DOI 10.1084/jem.191.11.2021; GODFREY WR, 1994, J EXP MED, V180, P757, DOI 10.1084/jem.180.2.757; Gramaglia I, 1998, J IMMUNOL, V161, P6510; Gramaglia I, 2000, J IMMUNOL, V165, P3043, DOI 10.4049/jimmunol.165.6.3043; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Hurwitz AA, 1998, P NATL ACAD SCI USA, V95, P10067, DOI 10.1073/pnas.95.17.10067; JENKINS MK, 1990, J IMMUNOL, V144, P16; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; Kawamata S, 1998, J BIOL CHEM, V273, P5808, DOI 10.1074/jbc.273.10.5808; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Kopf M, 1999, IMMUNITY, V11, P699, DOI 10.1016/S1074-7613(00)80144-2; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; Maxwell JR, 2000, J IMMUNOL, V164, P107, DOI 10.4049/jimmunol.164.1.107; Murata K, 2000, J EXP MED, V191, P365, DOI 10.1084/jem.191.2.365; Pape KA, 1998, J IMMUNOL, V160, P4719; Perez VL, 1997, IMMUNITY, V6, P411, DOI 10.1016/S1074-7613(00)80284-8; RIA F, 1990, NATURE, V343, P381, DOI 10.1038/343381a0; ROMBALL CG, 1993, J EXP MED, V178, P1637, DOI 10.1084/jem.178.5.1637; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Shrikant P, 1999, IMMUNITY, V11, P483, DOI 10.1016/S1074-7613(00)80123-5; Sotomayor EM, 1999, NAT MED, V5, P780, DOI 10.1038/10503; STUBER E, 1995, IMMUNITY, V2, P507, DOI 10.1016/1074-7613(95)90031-4; Sundstedt A, 1996, P NATL ACAD SCI USA, V93, P979, DOI 10.1073/pnas.93.3.979; Weinberg AD, 2000, J IMMUNOL, V164, P2160, DOI 10.4049/jimmunol.164.4.2160	44	192	210	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2001	7	8					907	912		10.1038/90942	http://dx.doi.org/10.1038/90942			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479622				2022-12-27	WOS:000171740400027
J	Tamatani, M; Matsuyama, T; Yamaguchi, A; Mitsuda, N; Tsukamoto, Y; Taniguchi, M; Che, YH; Ozawa, K; Hori, O; Nishimura, H; Yamashita, A; Okabe, M; Yanagi, H; Stern, DM; Ogawa, S; Tohyama, M				Tamatani, M; Matsuyama, T; Yamaguchi, A; Mitsuda, N; Tsukamoto, Y; Taniguchi, M; Che, YH; Ozawa, K; Hori, O; Nishimura, H; Yamashita, A; Okabe, M; Yanagi, H; Stern, DM; Ogawa, S; Tohyama, M			ORP150 protects against hypoxia/ischemia-induced neuronal death	NATURE MEDICINE			English	Article							FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; APOPTOTIC CELL-DEATH; NF-KAPPA-B; ENDOPLASMIC-RETICULUM; NEUROTROPHIC FACTOR; CYTOCHROME-C; RAT-BRAIN; EXPRESSION; INDUCTION	Oxygen-regulated protein 150 kD (ORP150) is a novel endoplasmic-reticulum-associated chaperone induced by hypoxia/ischemia. Although ORP150 was sparingly upregulated in neurons from human brain undergoing ischemic stress, there was robust induction in astrocytes. Cultured neurons overexpressing ORP150 were resistant to hypoxemic stress, whereas astrocytes with inhibited ORP150 expression were more vulnerable. Mice with targeted neuronal overexpression of ORP150 had smaller strokes compared with controls. Neurons with increased ORP150 demonstrated suppressed caspase-3-like activity and enhanced brain-derived neurotrophic factor (BDNF) under hypoxia signaling. These data indicate that ORP150 is an integral participant in ischemic cytoprotective pathways.	Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Osaka, Japan; Hyogo Coll Med, Dept Internal Med 5, Hyogo, Japan; Natl Ctr Cardiac Dis & Circulat Res, Dept Pathol, Osaka, Japan; Kanazawa Univ, Sch Med, Dept Neuroanat, Kanazawa, Ishikawa 920, Japan; HSP Res Inst, Kyoto, Japan; Osaka Univ, Genome Informat Res Ctr, Osaka, Japan; Columbia Univ, Coll Phys & Surg, CREST, JST, New York, NY USA; Columbia Univ, Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY USA	Osaka University; Hyogo College of Medicine; National Cerebral & Cardiovascular Center - Japan; Kanazawa University; Osaka University; Columbia University; Columbia University	Tamatani, M (corresponding author), Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Osaka, Japan.		Taniguchi, Masateru/G-3185-2017; Okabe, Masaru/B-6917-2015	Okabe, Masaru/0000-0002-0803-9044				Abe K, 1997, BRAIN RES, V776, P230, DOI 10.1016/S0006-8993(97)01041-X; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Chen J, 1998, J NEUROSCI, V18, P4914; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Despres P, 1996, J VIROL, V70, P4090; Du C, 1996, BRAIN RES, V718, P233, DOI 10.1016/0006-8993(96)00162-X; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; Fujimura M, 1999, J NEUROSCI, V19, P3414; Gillardon F, 1996, NEUROSCI LETT, V207, P113, DOI 10.1016/0304-3940(96)12508-8; Hori O, 1996, J NEUROCHEM, V66, P973; IHARA K, 1997, J CEREB BLOOD FLOW M, V17, P1097; KOISTINAHO J, 1997, NEUROREPORT, V8, P1; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; Larsson E, 1999, J CEREBR BLOOD F MET, V19, P1220, DOI 10.1097/00004647-199911000-00006; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Namura S, 1998, J NEUROSCI, V18, P3659; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; Ozawa K, 1999, J BIOL CHEM, V274, P6397, DOI 10.1074/jbc.274.10.6397; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; Perez-Pinzon MA, 1999, J CEREBR BLOOD F MET, V19, P39, DOI 10.1097/00004647-199901000-00004; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SZAFLARSKI J, 1995, STROKE, V26, P1093, DOI 10.1161/01.STR.26.6.1093; Tamatani M, 1998, MOL BRAIN RES, V58, P27, DOI 10.1016/S0169-328X(98)00095-3; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531	31	171	177	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					317	323		10.1038/85463	http://dx.doi.org/10.1038/85463			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231630				2022-12-27	WOS:000167380400037
J	Moore, KJ; Rosen, ED; Fitzgerald, ML; Randow, F; Andersson, LP; Altshuler, D; Milstone, DS; Mortensen, RM; Spiegelman, BM; Freeman, MW				Moore, KJ; Rosen, ED; Fitzgerald, ML; Randow, F; Andersson, LP; Altshuler, D; Milstone, DS; Mortensen, RM; Spiegelman, BM; Freeman, MW			The role of PPAR-gamma in macrophage differentiation and cholesterol uptake	NATURE MEDICINE			English	Article							ACTIVATED RECEPTOR-GAMMA; LOW-DENSITY-LIPOPROTEIN; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); SCAVENGER RECEPTORS; AFFINITY LIGAND; GENE-EXPRESSION; RETINOIC ACID; OXIDIZED LDL; HUMAN CD36; IN-VITRO	Peroxisome proliferator-activated receptor-gamma (PPAR-gamma), the transcription factor target of the anti-diabetic thiazolidinedione (TZD) drugs, is reported to mediate macrophage differentiation and inflammatory responses. Using PPAR-gamma -deficient stem cells, we demonstrate that PPAR-gamma is neither essential for myeloid development, nor for such mature macrophage functions as phagocytosis and inflammatory cytokine production. PPAR-gamma is required for basal expression of CD36, but not for expression of the other major scavenger receptor responsible for uptake of modified lipoproteins, SR-A. In wild-type macrophages, TZD treatment divergently regulated CD36 and class A macrophage-scavenger receptor expression and failed to induce significant cellular cholesterol accumulation, indicating that TZDs may not exacerbate macrophage foam-cell formation.	Massachusetts Gen Hosp, Dept Med, Lipid Metab Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Cell Biol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; MIT, Whitehead Inst Biomed Res, Ctr Genome Res, Cambridge, MA 02139 USA; Brigham & Womens Hosp, Dept Pathol, Div Vasc Res, Boston, MA 02115 USA; Univ Michigan, Dept Physiol, Div Endocrine, Ann Arbor, MI 48109 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Brigham & Women's Hospital; University of Michigan System; University of Michigan	Freeman, MW (corresponding author), Massachusetts Gen Hosp, Dept Med, Lipid Metab Unit, Boston, MA 02114 USA.		Moore, Kathryn/ABE-6416-2020; Altshuler, David M/A-4476-2009	Moore, Kathryn/0000-0003-2505-2547; Altshuler, David M/0000-0002-7250-4107	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045098, P50HL056985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL5409, HL56985, HL45098] Funding Source: Medline; NIDDK NIH HHS [DK50305] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Armesilla AL, 1996, J BIOL CHEM, V271, P7781, DOI 10.1074/jbc.271.13.7781; ASHKENAS J, 1993, J LIPID RES, V34, P983; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Calvo D, 1998, J LIPID RES, V39, P777; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364; DEVILLIERS WJS, 1994, J EXP MED, V180, P705, DOI 10.1084/jem.180.2.705; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Feng JW, 2000, J LIPID RES, V41, P688; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; Ghazzi MN, 1997, DIABETES, V46, P433, DOI 10.2337/diabetes.46.3.433; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Huh HY, 1996, BLOOD, V87, P2020; Jacobs NL, 1997, J LIPID RES, V38, P1973; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Lindblad-Toh K, 2000, NAT GENET, V24, P381, DOI 10.1038/74215; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; MILSTONE DS, 1999, NUCLEIC ACIDS RES, V27, P10; Minamikawa J, 1998, J CLIN ENDOCR METAB, V83, P1041, DOI 10.1210/jc.83.3.1041; Moore KJ, 1998, ARTERIOSCL THROM VAS, V18, P1647, DOI 10.1161/01.ATV.18.10.1647; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Noguchi N, 1996, ATHEROSCLEROSIS, V123, P227, DOI 10.1016/0021-9150(96)05811-X; Pasceri V, 2000, CIRCULATION, V101, P235, DOI 10.1161/01.CIR.101.3.235; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rosenzweig ML, 1999, EVOL ECOL RES, V1, P1; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Shinohara E, 1998, ATHEROSCLEROSIS, V136, P275, DOI 10.1016/S0021-9150(97)00220-7; Spiegelman B M, 1997, Eur J Med Res, V2, P457; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Thieringer R, 2000, J IMMUNOL, V164, P1046, DOI 10.4049/jimmunol.164.2.1046; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Vaidya S, 1999, J IMMUNOL, V163, P6187; Willoughby DA, 2000, NAT MED, V6, P137, DOI 10.1038/72224	47	424	443	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					41	47		10.1038/83328	http://dx.doi.org/10.1038/83328			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135614				2022-12-27	WOS:000166243100033
J	Soriano, FG; Virag, L; Jagtap, P; Szabo, E; Mabley, JG; Liaudet, L; Marton, A; Hoyt, DG; Murthy, KGK; Salzman, AL; Southan, GJ; Szabo, C				Soriano, FG; Virag, L; Jagtap, P; Szabo, E; Mabley, JG; Liaudet, L; Marton, A; Hoyt, DG; Murthy, KGK; Salzman, AL; Southan, GJ; Szabo, C			Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; DNA STRAND BREAKS; RIBOSE SYNTHETASE; ENDOTOXIC-SHOCK; DEFICIENT MICE; PEROXYNITRITE; CELLS; GLUCOSE; EXPRESSION	Diabetic patients frequently suffer from retinopathy, nephropathy, neuropathy and accelerated atherosclerosis. The loss of endothelial function precedes these vascular alterations. Here we report that activation of poly(ADP-ribose) polymerase (PARP) is an important factor in the pathogenesis of endothelial dysfunction in diabetes. Destruction of islet cells with streptozotocin in mice induced hyperglycemia, intravascular oxidant production, DNA strand breakage, PARP activation and a selective loss of endothelium-dependent vasodilation. Treatment with a novel potent PARP inhibitor, starting after the time of islet destruction, maintained normal vascular responsiveness, despite the persistence of severe hyperglycemia. Endothelial cells incubated in high glucose exhibited production of reactive nitrogen and oxygen species, consequent single-strand DNA breakage, PARP activation and associated metabolic and functional Impairment. Basal and high-glucose-induced nuclear factor-kappaB activation were suppressed in the PARP-deficient cells. Our results indicate that PARP may be a novel drug target for the therapy of diabetic endothelial dysfunction.	Inotek Corp, Beverly, MA 01915 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Newark, NJ USA; Ohio State Univ, Coll Pharm, Div Pharmacol, Columbus, OH 43210 USA; Univ Sao Paulo, Hosp Clin, Dept Crit Care Med, Sao Paulo, Brazil; Univ Lausanne Hosp, Dept Internal Med, Div Crit Care, Lausanne, Switzerland	Inotek Pharmaceuticals; Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Ohio; Ohio State University; Universidade de Sao Paulo; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Szabo, C (corresponding author), Inotek Corp, Suite 419E,100 Cummings Ctr, Beverly, MA 01915 USA.	szabocsaba@aol.com	Szabo, Csaba/D-1882-2013; Soriano, Francisco/C-3382-2012; Szabo, Csaba/ABG-2644-2021; Liaudet, Lucas/E-1322-2017; Mabley, Jon G/D-2296-2010; Szabo, Eva/B-8574-2011; Virag, Laszlo/E-6124-2010	Soriano, Francisco/0000-0003-4898-0135; Liaudet, Lucas/0000-0003-2670-4930; Mabley, Jon/0000-0001-9423-6230; Virag, Laszlo/0000-0002-7099-6718	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL065145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060915] Funding Source: NIH RePORTER; NHLBI NIH HHS [R21 HL65145] Funding Source: Medline; NIGMS NIH HHS [R01 GM60915] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANASIK M, 1992, J BIOL CHEM, V267, P1569; Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Cosentino F, 1997, CIRCULATION, V96, P25; Didier M, 1996, J NEUROSCI, V16, P2238; Du XL, 1999, FREE RADICAL BIO MED, V27, P752, DOI 10.1016/S0891-5849(99)00079-9; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; FURCHGOTT RF, 1990, ACTA PHYSIOL SCAND, V139, P257, DOI 10.1111/j.1748-1716.1990.tb08923.x; Gerritsen Mary E., 1995, Microcirculation (New York), V2, P151, DOI 10.3109/10739689509146763; Gilad E, 1998, FASEB J, V12, P685, DOI 10.1096/fasebj.12.9.685; Graier WF, 1999, DIABETES RES CLIN PR, V45, P153, DOI 10.1016/S0168-8227(99)00045-5; Halliwell B, 1997, FEBS LETT, V411, P157, DOI 10.1016/S0014-5793(97)00469-9; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Karasu C, 2000, EUR J PHARMACOL, V392, P163, DOI 10.1016/S0014-2999(00)00140-0; Kaufmann SH, 2000, METHOD ENZYMOL, V322, P3; Keen H, 1999, DIABETES-METAB RES, V15, P186, DOI 10.1002/(SICI)1520-7560(199905/06)15:3<186::AID-DMRR30>3.0.CO;2-5; KLAIDMAN LK, 1995, ANAL BIOCHEM, V228, P312, DOI 10.1006/abio.1995.1356; Kobayashi T, 1999, BRIT J PHARMACOL, V127, P835, DOI 10.1038/sj.bjp.0702554; LAMAS S, 1991, AM J PHYSIOL, V261, P634; LantinHermoso RL, 1997, AM J PHYSIOL-LUNG C, V273, pL119, DOI 10.1152/ajplung.1997.273.1.L119; Morigi M, 1998, J CLIN INVEST, V101, P1905, DOI 10.1172/JCI656; Nishigaki R, 1999, Nihon Ika Daigaku Zasshi, V66, P166, DOI 10.1272/jnms.66.166; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pieper GM, 1997, J CARDIOVASC PHARM, V30, P528, DOI 10.1097/00005344-199710000-00019; Pieper GM, 1997, CARDIOVASC RES, V34, P145, DOI 10.1016/S0008-6363(96)00237-4; PIEPER GM, 1995, DIABETES, V44, P1106, DOI 10.2337/diabetes.44.9.1106; PIEPER GM, 1996, LIFE SCI, V58, P147; Rodriguez-Manas L, 1998, BRIT J PHARMACOL, V123, P1495, DOI 10.1038/sj.bjp.0701749; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Shen HM, 2000, FREE RADICAL BIO MED, V28, P529, DOI 10.1016/S0891-5849(99)00234-8; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; Szabo C., 2000, CELL DEATH ROLE PARP; Tooke JE, 1999, DIABETIC MED, V16, P710, DOI 10.1046/j.1464-5491.1999.00099.x; Virag L, 1999, MOL PHARMACOL, V56, P824; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Zhang J, 1997, METHOD ENZYMOL, V280, P255; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85	45	506	529	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					108	113		10.1038/83241	http://dx.doi.org/10.1038/83241			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135624				2022-12-27	WOS:000166243100043
J	Zuscik, MJ; Sands, S; Ross, SA; Waugh, DJJ; Gaivin, RJ; Morilak, D; Perez, DM				Zuscik, MJ; Sands, S; Ross, SA; Waugh, DJJ; Gaivin, RJ; Morilak, D; Perez, DM			Overexpression of the alpha(1B)-adrenergic receptor causes apoptotic neurodegeneration: Multiple system atrophy	NATURE MEDICINE			English	Article							PARKINSONS-DISEASE; TRANSGENIC MICE; MESSENGER-RNA; EXPRESSION; MODULATION; ACTIVATION; BRAIN; ACETYLCHOLINE; SEIZURES; CLONING	Progress toward elucidating the function of alpha (1B)-adrenergic receptors (alpha (1B)ARs) in the central nervous system has been constrained by a lack of agonists and antagonists with adequate alpha (1B)-specificity. We have obviated this constraint by generating transgenic mice engineered to overexpress either wild-type or constitutively active alpha (1B)ARs in tissues that normally express the receptor, including the brain. All transgenic lines showed granulovacular neurodegeneration, beginning in alpha (1B)-expressing domains of the brain and progressing with age to encompass all areas. The degeneration was apoptotic and did not occur in non-transgenic mice. Correspondingly, transgenic mice showed an age-progressive hindlimb disorder that was parkinsonian-like, as demonstrated by rescue of the dysfunction by 3, 4-dihydroxyphenylalanine and considerable dopaminergic-neuronal degeneration in the substantia nigra. Transgenic mice also had a grand mal seizure disorder accompanied by a corresponding dysplasia and neurodegeneration of the cerebral cortex. Both behavioral phenotypes (locomotor impairment and seizure) could be partially rescued with the alpha (1)AR antagonist terazosin, indicating that alpha (1)AR signaling participated directly in the pathology. Our results indicate that overstimulation of alpha (1B)AR leads to apoptotic neurodegeneration with a corresponding multiple system atrophy indicative of Shy-Drager syndrome, a disease whose etiology is unknown.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol NB50, Cleveland, OH 44195 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA	Cleveland Clinic Foundation; University of Texas System; University of Texas Health San Antonio	Perez, DM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol NB50, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Morilak, David/Q-4986-2019	Morilak, David/0000-0001-6689-6258; WAUGH, DAVID/0000-0002-4022-3765; Zuscik, Michael/0000-0003-0461-8708	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010004, R01HL061438] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL61438, F32HL1000402] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1997, J BIOL CHEM, V272, P21253, DOI 10.1074/jbc.272.34.21253; AMABEOKU G, 1994, PROG NEURO-PSYCHOPH, V18, P753, DOI 10.1016/0278-5846(94)90082-5; BALK JH, 1995, NATURE, V377, P424; BEANI L, 1986, J PHARMACOL EXP THER, V236, P230; BRIERE R, 1986, ANN NEUROL, V19, P26, DOI 10.1002/ana.410190106; BURT AM, 1993, TXB NEUROANATOMY, P367; CASH R, 1984, BRAIN RES, V322, P269, DOI 10.1016/0006-8993(84)90117-3; Cavalli A, 1997, P NATL ACAD SCI USA, V94, P11589, DOI 10.1073/pnas.94.21.11589; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; Day HEW, 1999, J NEUROSCI, V19, P10098; Domyancic AV, 1997, J COMP NEUROL, V386, P358, DOI 10.1002/(SICI)1096-9861(19970929)386:3<358::AID-CNE3>3.0.CO;2-0; DUTEIL J, 1990, EUR J PHARMACOL, V180, P49, DOI 10.1016/0014-2999(90)90591-S; FAHN S, 1998, HDB MOVEMENT DISORDE, P13; FRANDSEN A, 1993, J NEUROCHEM, V60, P1202, DOI 10.1111/j.1471-4159.1993.tb03278.x; Gioanni Y, 1998, SYNAPSE, V30, P362, DOI 10.1002/(SICI)1098-2396(199812)30:4<362::AID-SYN3>3.3.CO;2-N; Haavik J, 1998, MOL NEUROBIOL, V16, P285, DOI 10.1007/BF02741387; Hein L, 1999, ANN NY ACAD SCI, V881, P265, DOI 10.1111/j.1749-6632.1999.tb09368.x; Hwa J, 1997, BIOCHEMISTRY-US, V36, P633, DOI 10.1021/bi962141c; Ivanov A, 1995, J NEUROPHYSIOL, V74, P2427, DOI 10.1152/jn.1995.74.6.2427; JAZRAWI SP, 1986, J NEUROCHEM, V47, P173; Kirkwood A, 1999, J NEUROSCI, V19, P1599; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; PALACIOS JM, 1987, BRAIN RES, V419, P65, DOI 10.1016/0006-8993(87)90569-5; Perez DM, 1996, MOL PHARMACOL, V49, P112; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; Sallinen J, 1997, MOL PHARMACOL, V51, P36, DOI 10.1124/mol.51.1.36; Sirvio J, 1999, PHARMACOL THERAPEUT, V83, P49, DOI 10.1016/S0163-7258(99)00017-0; TUMER PR, 2000, MOL ENDOCRINOL, V14, P241; Vince DG, 1997, ANAL CELL PATHOL, V15, P119, DOI 10.1155/1997/607965; Zuscik MJ, 1999, MOL PHARMACOL, V56, P1288, DOI 10.1124/mol.56.6.1288	30	101	106	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1388	1394		10.1038/82207	http://dx.doi.org/10.1038/82207			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100125				2022-12-27	WOS:000165704100044
J	Ballmaier, M				Ballmaier, M			Can Italy catch up in genomics research?	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1071	1071		10.1038/80378	http://dx.doi.org/10.1038/80378			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017122				2022-12-27	WOS:000089674700013
J	Kolff, WJ				Kolff, WJ			The artificial kidney and its effect on the development of other artificial organs	NATURE MEDICINE			English	Editorial Material									Univ Utah, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Kolff, WJ (corresponding author), Univ Utah, Salt Lake City, UT 84112 USA.							Alexander S., 1962, LIFE, P102; Darrah J B, 1987, ASAIO Trans, V33, P791; KHASTAGI.B, 1969, ARCH INTERN MED, V123, P9; KOLFF WJ, 1956, J LAB CLIN MED, V47, P969; KOLFF WJ, 1965, ANN INTERN MED, V62, P608, DOI 10.7326/0003-4819-62-3-608; Kolff WJ, 2002, ASAIO J, V48, P335, DOI 10.1097/00002480-200207000-00001; KOLFF WJ, 1947, NEW WAYS TREATING UR, P112; KRALIOS AC, 1973, LETT APPLIED ENGR SC, V1, P179; NAKAMOTO S, 1967, TRANSPLANTATION, V5, P854; Stephens R L, 1976, Proc Eur Dial Transplant Assoc, V12, P511; STEPHENS RL, 1978, KIDNEY INT S, V8, P125; WATERFALL WK, 1980, BRIT MED J, V281, P726, DOI 10.1136/bmj.281.6242.726	12	23	27	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1063	1065		10.1038/nm771	http://dx.doi.org/10.1038/nm771			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12357233				2022-12-27	WOS:000178311000019
J	Hattori, K; Heissig, B; Wu, Y; Dias, S; Tejada, R; Ferris, B; Hicklin, DJ; Zhu, ZP; Bohlen, P; Witte, L; Hendrikx, J; Hackett, NR; Crystal, RG; Moore, MAS; Werb, Z; Lyden, D; Rafii, S				Hattori, K; Heissig, B; Wu, Y; Dias, S; Tejada, R; Ferris, B; Hicklin, DJ; Zhu, ZP; Bohlen, P; Witte, L; Hendrikx, J; Hackett, NR; Crystal, RG; Moore, MAS; Werb, Z; Lyden, D; Rafii, S			Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment	NATURE MEDICINE			English	Article							TUMOR ANGIOGENESIS; FACTOR RECEPTOR-1; PROGENITOR CELLS; TYROSINE KINASE; FACTOR VEGF; FLT-1; INHIBITION; LINEAGE; MOBILIZATION; ENGRAFTMENT	The mechanism by which angiogenic factors recruit bone marrow ( BM)-derived quiescent endothelial and hematopoietic stem cells ( HSCs) is not known. Here, we report that functional vascular endothelial growth factor receptor-1 (VEGFR1) is expressed on human CD34(+) and mouse Lin(-)Sca-1(+)c-Kit(+) BM-repopulating stem cells, conveying signals for recruitment of HSCs and reconstitution of hematopoiesis. Inhibition of VEGFR1, but not VEGFR2, blocked HSC cell cycling, differentiation and hematopoietic recovery after BM suppression, resulting in the demise of the treated mice. Placental growth factor ( PlGF), which signals through VEGFR1, restored early and late phases of hematopoiesis following BM suppression. PlGF enhanced early phases of BM recovery directly through rapid chemotaxis of VEGFR1(+) BM-repopulating and progenitor cells. The late phase of hematopoietic recovery was driven by PlGF-induced upregulation of matrix metalloproteinase-9, mediating the release of soluble Kit ligand. Thus, PlGF promotes recruitment of VEGFR1(+) HSCs from a quiescent to a proliferative BM microenvironment, favoring differentiation, mobilization and reconstitution of hematopoiesis.	Cornell Univ, Coll Med, Dept Med, New York, NY 10021 USA; Sloan Kettering Inst, New York, NY USA; ImClone Syst Inc, New York, NY USA; New York Blood Ctr, New York, NY 10021 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Eli Lilly; New York Blood Center; University of California System; University of California San Francisco	Rafii, S (corresponding author), Cornell Univ, Coll Med, Dept Med, New York, NY 10021 USA.	srafii@med.cornell.edu	Mordwinkin, Nicholas M/A-4347-2010; Dias, Sergio/L-1250-2014; Heissig, Beate/AAF-6771-2021	Dias, Sergio/0000-0002-7603-4616; Heissig, Beate/0000-0002-0348-5934	NATIONAL CANCER INSTITUTE [R01CA075072, P01CA072006] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061849, R01HL061401, R01HL058707, P01HL067839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039278] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA072006, R01 CA075072-03, CA 72006, P01 CA072006-07, CA 75072] Funding Source: Medline; NHLBI NIH HHS [P01 HL067839, R01 HL61401, R01 HL061849, R01 HL61849, R01 HL-58707, R01 HL-66592, R01 HL-67839] Funding Source: Medline; NIAMS NIH HHS [R01 AR046238-03, AR46238, R01 AR046238] Funding Source: Medline; NINDS NIH HHS [NS39278, R01 NS039278-05A1, R01 NS039278] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BERARDI AC, 1995, SCIENCE, V267, P104, DOI 10.1126/science.7528940; BRIDDELL RA, 1993, BLOOD, V82, P1720; Broxmeyer HE, 1995, INT J HEMATOL, V62, P203; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cho NK, 2002, CELL, V108, P865, DOI 10.1016/S0092-8674(02)00676-1; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Haruta H, 2001, FEBS LETT, V507, P45, DOI 10.1016/S0014-5793(01)02921-0; Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Hiratsuka S, 2001, CANCER RES, V61, P1207; Huang XL, 1999, BIOCHEM BIOPH RES CO, V264, P133, DOI 10.1006/bbrc.1999.1472; Kabrun N, 1997, DEVELOPMENT, V124, P2039; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; LATERVEER L, 1995, BLOOD, V85, P2269, DOI 10.1182/blood.V85.8.2269.bloodjournal8582269; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Morrison SJ, 1997, P NATL ACAD SCI USA, V94, P1908, DOI 10.1073/pnas.94.5.1908; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Prewett M, 1999, CANCER RES, V59, P5209; Randall TD, 1997, BLOOD, V89, P3596, DOI 10.1182/blood.V89.10.3596.3596_3596_3606; Ratajczak MZ, 1998, BRIT J HAEMATOL, V103, P969, DOI 10.1046/j.1365-2141.1998.01076.x; Sawano A, 2001, BLOOD, V97, P785, DOI 10.1182/blood.V97.3.785; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; VANZANT G, 1984, J EXP MED, V159, P679, DOI 10.1084/jem.159.3.679; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427; Zhu ZP, 1999, CANCER LETT, V136, P203, DOI 10.1016/S0304-3835(98)00324-3; Zhu ZP, 1998, CANCER RES, V58, P3209; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	42	489	543	2	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2002	8	8					841	849		10.1038/nm740	http://dx.doi.org/10.1038/nm740			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12091880	Green Accepted			2022-12-27	WOS:000177200900030
J	Marras, D; Bruggeman, LA; Gao, F; Tanji, N; Mansukhani, MM; Cara, A; Ross, MD; Gusella, GL; Benson, G; D'Agati, VD; Hahn, BH; Klotman, ME; Klotman, PE				Marras, D; Bruggeman, LA; Gao, F; Tanji, N; Mansukhani, MM; Cara, A; Ross, MD; Gusella, GL; Benson, G; D'Agati, VD; Hahn, BH; Klotman, ME; Klotman, PE			Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CHEMOKINE RECEPTOR CCR5; TRANSGENIC MICE; RENAL-DISEASE; INFECTION; EXPRESSION; RESERVOIR; TYPE-1; CELLS; CORECEPTORS	HIV-associated nephropathy is a clinicopathologic entity that includes proteinuria, focal segmental glomerulosclerosis often of the collapsing variant, and microcystic tubulointerstitial disease(1-4). Increasing evidence supports a role for HIV-1 infection of renal epithelium in the pathogenesis of HIV-associated nephropathy(5-8). Using in situ hybridization, we previously demonstrated HIV-1 gag and nef mRNA in renal epithelial cells of patients with HIV-associated nephropathy(9). Here, to investigate whether renal epithelial cells were productively infected by HIV-1, we examined renal tissue for the presence of HIV-1 DNA and mRNA by in situ hybridization and PCR, and we molecularly characterized the HIV-1 quasispecies in the renal compartment. Infected renal epithelial cells were removed by laser-capture microdissection from biopsies of two patients, DNA was extracted, and HIV-1 V3-loop or gp120-envelope sequences were amplified from individually dissected cells by nested PCR. Phylogenetic analysis of kidney-derived sequences as well as corresponding sequences from peripheral blood mononuclear cells of the same patients revealed evidence of tissue-specific viral evolution. In phylogenetic trees constructed from V3 and gp120 sequences, kidney-derived sequences formed tissue-specific subclusters within the radiation of blood mononuclear cell-derived viral sequences from both patients. These data, along with the detection of HIV-1-specific proviral DNA and mRNA in tubular epithelium cells, argue strongly for localized replication of HIV-1 in the kidney and the existence of a renal viral reservoir.	Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med, Div Infect Dis, New York, NY USA; Mt Sinai Sch Med, Dept Biomath Sci, New York, NY USA; Columbia Presbyterian Med Ctr, Dept Pathol, New York, NY 10032 USA; Univ Alabama, Dept Med & Microbiol, Birmingham, AL USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Ist Super Sanita, I-00161 Rome, Italy	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Columbia University; NewYork-Presbyterian Hospital; University of Alabama System; University of Alabama Birmingham; Duke University; Istituto Superiore di Sanita (ISS)	Marras, D (corresponding author), Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA.		Cara, Andrea/M-4865-2015; klotman, mary e/A-1921-2016; Cara, Andrea/AAA-4238-2021	Cara, Andrea/0000-0003-4967-1895; Cara, Andrea/0000-0003-4967-1895; Hahn, Beatrice/0000-0002-9400-9887	NIAID NIH HHS [P20AI27767, N01 AI85338] Funding Source: Medline; NIDDK NIH HHS [P01 DK50795, P01 DK56492] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI085338, P30AI027767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK056492, P01DK050795] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOTTARO M, 1994, BLOOD, V83, P3271, DOI 10.1182/blood.V83.11.3271.bloodjournal83113271; BOURGOIGNIE JJ, 1989, TRANSPLANT P, V21, P3899; Bruggeman LA, 1997, J CLIN INVEST, V100, P84, DOI 10.1172/JCI119525; BRUGGEMAN LA, 2000, J AM SOC NEPHROL; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; CANTOR ES, 1991, ARCH INTERN MED, V151, P125, DOI 10.1001/archinte.151.1.125; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; COHEN AH, 1989, MODERN PATHOL, V2, P125; Conaldi PG, 1998, J CLIN INVEST, V102, P2041, DOI 10.1172/JCI3480; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DICKIE P, 1991, VIROLOGY, V185, P109, DOI 10.1016/0042-6822(91)90759-5; Eitner F, 2000, J AM SOC NEPHROL, V11, P856, DOI 10.1681/ASN.V115856; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; FAULKNER DV, 1988, TRENDS BIOCHEM SCI, V13, P321, DOI 10.1016/0968-0004(88)90129-6; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hoffman TL, 1998, P NATL ACAD SCI USA, V95, P11360, DOI 10.1073/pnas.95.19.11360; HUMPHREYS MH, 1995, KIDNEY INT, V48, P311, DOI 10.1038/ki.1995.299; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Lagaye S, 2001, J VIROL, V75, P4780, DOI 10.1128/JVI.75.10.4780-4791.2001; Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498; Meng G, 2002, NAT MED, V8, P150, DOI 10.1038/nm0202-150; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; *NIH NIDDK, 1997, US REN DAT SYST; Owman C, 1998, P NATL ACAD SCI USA, V95, P9530, DOI 10.1073/pnas.95.16.9530; RAO TKS, 1987, NEW ENGL J MED, V316, P1062, DOI 10.1056/NEJM198704233161705; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; STRAUSS J, 1989, NEW ENGL J MED, V321, P625, DOI 10.1056/NEJM198909073211001; TANJI N, 2000, EXP NEPHROL; Winston JA, 2000, SEMIN NEPHROL, V20, P293; Winston JA, 2001, NEW ENGL J MED, V344, P1979, DOI 10.1056/NEJM200106283442604	31	233	241	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					522	526		10.1038/nm0502-522	http://dx.doi.org/10.1038/nm0502-522			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984599				2022-12-27	WOS:000175336800040
J	Zhao, M; Beauregard, DA; Loizou, L; Davletov, B; Brindle, KM				Zhao, M; Beauregard, DA; Loizou, L; Davletov, B; Brindle, KM			Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent	NATURE MEDICINE			English	Article							IN-VIVO DETECTION; MURINE TUMORS; IRON-OXIDE; CELL-DEATH; PHOSPHATIDYLSERINE; EXPRESSION; GLIOMA	The C-2 domain of synaptotagmin I, which binds to anionic phospholipids in cell membranes, was shown to bind to the plasma membrane of apoptotic cells by both flow cytometry and confocal microscopy. Conjugation of the protein to superparamagnetic iron oxide nanoparticles allowed detection of this binding using magnetic resonance imaging. Detection of apoptotic cells, using this novel contrast agent, was demonstrated both in vitro, with isolated apoptotic tumor cells, and in vivo, in a tumor treated with chemotherapeutic drugs.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Cambridge; MRC Laboratory Molecular Biology	Brindle, KM (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	kmb@mole.bio.cam.ac.uk	Davletov, Bazbek/ABA-8569-2021	Davletov, Bazbek/0000-0003-4658-3275				Blankenberg FG, 1998, P NATL ACAD SCI USA, V95, P6349, DOI 10.1073/pnas.95.11.6349; Blankenberg FG, 1997, BLOOD, V89, P3778, DOI 10.1182/blood.V89.10.3778.3778_3778_3786; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; DAVIETOV BA, 1993, J BIOL CHEM, V268, P26386; DUTTON AH, 1979, P NATL ACAD SCI USA, V76, P3392, DOI 10.1073/pnas.76.7.3392; Emoto K, 1997, EXP CELL RES, V232, P430, DOI 10.1006/excr.1997.3521; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Hakumaki JM, 1999, NAT MED, V5, P1323, DOI 10.1038/15279; HASEGAWA M, 1993, Patent No. 0656368; Kabelitz D, 1998, TRANSPLANTATION, V65, P869, DOI 10.1097/00007890-199804150-00003; Kavantzas NG, 2000, PATHOLOGY, V32, P176; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Louie AY, 2000, NAT BIOTECHNOL, V18, P321, DOI 10.1038/73780; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; MEYN RE, 1995, ANTI-CANCER DRUG, V6, P443, DOI 10.1097/00001813-199506000-00013; MEYN RE, 1993, INT J RADIAT BIOL, V64, P583, DOI 10.1080/09553009314551801; MOLDAY RS, 1982, J IMMUNOL METHODS, V52, P353, DOI 10.1016/0022-1759(82)90007-2; Nunn AVW, 1996, FEBS LETT, V392, P295, DOI 10.1016/0014-5793(96)00839-3; Poptani H, 1998, CANCER GENE THER, V5, P101; Sakurai H, 1998, INT J RADIAT ONCOL, V41, P1157, DOI 10.1016/S0360-3016(98)00158-8; SHEN T, 1993, MAGN RESON MED, V29, P599, DOI 10.1002/mrm.1910290504; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Taylor AM, 1999, JMRI-J MAGN RESON IM, V9, P220, DOI 10.1002/(SICI)1522-2586(199902)9:2<220::AID-JMRI11>3.0.CO;2-A; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Weber DA, 1999, J NUCL CARDIOL, V6, P332, DOI 10.1016/S1071-3581(99)90046-6; WEISSLEDER R, 1990, RADIOLOGY, V175, P489, DOI 10.1148/radiology.175.2.2326474; Weissleder Ralph, 2000, Nature Medicine, V6, P351, DOI 10.1038/73219; Williamson MS, 1998, GRADIVA, V6, P40	29	425	454	3	66	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2001	7	11					1241	1244		10.1038/nm1101-1241	http://dx.doi.org/10.1038/nm1101-1241			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689890				2022-12-27	WOS:000172054100033
J	Gautam, N; Olofsson, AM; Herwald, H; Iversen, LF; Lundgren-Akerlund, E; Hedqvist, P; Arfors, KE; Flodgaard, H; Lindbom, L				Gautam, N; Olofsson, AM; Herwald, H; Iversen, LF; Lundgren-Akerlund, E; Hedqvist, P; Arfors, KE; Flodgaard, H; Lindbom, L			Heparin-binding protein (HBP/CAP37): A missing link in neutrophil-evoked alteration of vascular permeability	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODY; TISSUE-INJURY; CAP37; INFLAMMATION; AZUROCIDIN; MONOCYTE; LEAKAGE; CDNA	Polymorphonuclear leukocyte infiltration into tissues in host defense and inflammatory disease causes increased vascular permeability and edema formation through unknown mechanisms. Here, we report the involvement of a paracrine mechanism in neutrophil-evoked alteration in endothelial barrier function. We show that upon neutrophil adhesion to the endothelial lining, leukocytic beta (2) integrin signaling triggers the release of neutrophil-borne heparin-binding protein (HBP), also known as CAP37/azurocidin, a member of the serprocidin family of neutrophil cationic proteins. HBP induced Ca++-dependent cytoskeletal rearrangement and intercellular gap formation in endothelial-cell monolayers in vitro, and increased macromolecular efflux in microvessels in vivo. Moreover, selective inactivation of HBP prevented the neutrophils from inducing endothelial hyperpermeability. Our data suggest a fundamental role of neutrophil-derived HBP in the vascular response to neutrophil trafficking in inflammation. Targeting this molecule in inflammatory disease conditions offers a new strategy for prevention of endothelial barrier dysfunction caused by misdirected leukocyte activation.	Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden; Lund Univ, Dept Cell & Mol Biol, Lund, Sweden; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark; Sidney Kimmel Canc Ctr, San Diego, CA USA	Karolinska Institutet; Lund University; Novo Nordisk	Lindbom, L (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden.	lennart.lindbom@fyfa.ki.se	Olofsson, Maria/E-8335-2012; Herwald, Heiko/AAN-3708-2021; Olofsson, Maria/F-6695-2011	Herwald, Heiko/0000-0002-8111-2842; Olofsson, Maria/0000-0002-7077-7072; Lindbom, Lennart/0000-0001-9243-257X				ALMEIDA RP, 1991, BIOCHEM BIOPH RES CO, V177, P688, DOI 10.1016/0006-291X(91)91843-2; ARFORS KE, 1987, BLOOD, V69, P338; Aveskogh M, 1997, IMMUNOGENETICS, V46, P181, DOI 10.1007/s002510050260; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; Dallegri F, 1997, INFLAMM RES, V46, P382, DOI 10.1007/s000110050208; Edens HA, 2000, ADV DRUG DELIVER REV, V41, P315, DOI 10.1016/S0169-409X(00)00049-1; FLODGAARD H, 1991, EUR J BIOCHEM, V197, P535, DOI 10.1111/j.1432-1033.1991.tb15942.x; GABAY JE, 1989, P NATL ACAD SCI USA, V86, P5610, DOI 10.1073/pnas.86.14.5610; Gautam N, 1998, BRIT J PHARMACOL, V125, P1109, DOI 10.1038/sj.bjp.0702186; Gautam N, 2000, J EXP MED, V191, P1829, DOI 10.1084/jem.191.11.1829; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; Iversen LF, 1997, NAT STRUCT BIOL, V4, P265, DOI 10.1038/nsb0497-265; KASLOVSKY RA, 1990, CIRC RES, V67, P795, DOI 10.1161/01.RES.67.4.795; Kastrup JS, 2001, PROTEINS, V42, P442, DOI 10.1002/1097-0134(20010301)42:4<442::AID-PROT30>3.0.CO;2-S; Lindmark A, 1999, J LEUKOCYTE BIOL, V66, P634, DOI 10.1002/jlb.66.4.634; Michel CC, 1999, PHYSIOL REV, V79, P703, DOI 10.1152/physrev.1999.79.3.703; MORGAN JG, 1991, J IMMUNOL, V147, P3210; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Olofsson AM, 1999, J CLIN INVEST, V104, P885, DOI 10.1172/JCI6671; PEREIRA HA, 1990, J CLIN INVEST, V85, P1468, DOI 10.1172/JCI114593; PEREIRA HA, 1995, J LEUKOCYTE BIOL, V57, P805, DOI 10.1002/jlb.57.6.805; PEREIRA HA, 1993, P NATL ACAD SCI USA, V90, P4733, DOI 10.1073/pnas.90.10.4733; Peters DC, 1999, DRUGS, V57, P233, DOI 10.2165/00003495-199957020-00015; PETERSEN LC, 1993, EUR J BIOCHEM, V214, P271, DOI 10.1111/j.1432-1033.1993.tb17921.x; PETERSON MW, 1987, J APPL PHYSIOL, V62, P1521, DOI 10.1152/jappl.1987.62.4.1521; Rasmussen PB, 1996, FEBS LETT, V390, P109, DOI 10.1016/0014-5793(96)00639-4; RAUD J, 1994, HDB IMMUNOPHARMACOLO, P127; ROSENGREN S, 1991, INFLAMMATION, V15, P159, DOI 10.1007/BF00918643; WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0	30	260	283	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2001	7	10					1123	1127		10.1038/nm1001-1123	http://dx.doi.org/10.1038/nm1001-1123			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590435				2022-12-27	WOS:000171524500033
J	Altfeld, M; Walker, BD				Altfeld, M; Walker, BD			Less is more? STI in acute and chronic HIV-1 infection	NATURE MEDICINE			English	Editorial Material							STRUCTURED TREATMENT INTERRUPTIONS; CYTOTOXIC T-LYMPHOCYTE; ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS-INFECTION; CELLULAR IMMUNE-RESPONSES; HIV-1-INFECTED PATIENTS; IMMUNOLOGICAL CONSEQUENCES; VIREMIA; CD8(+); CELLS	Emerging data has indicated that supervised treatment interruption (STI) of highly active antiretroviral therapy might significantly augment immune responses in HIV-1-infected patients and slow disease progression. Here the authors discuss the rationale behind STI and future directions for study.	Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Altfeld, M (corresponding author), Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA.	maltfeld@partners.org; bwalker@helix.mgh.harvard.edu	Altfeld, Marcus/AAE-7306-2019	Altfeld, Marcus/0000-0001-5972-2997				Altfeld M, 2000, CURR OPIN IMMUNOL, V12, P375, DOI 10.1016/S0952-7915(00)00103-5; Altfeld M, 2001, J EXP MED, V193, P169, DOI 10.1084/jem.193.2.169; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; BHARDWAJ N, 1994, J CLIN INVEST, V94, P797, DOI 10.1172/JCI117399; Blankson JN, 2001, J INFECT DIS, V183, P657, DOI 10.1086/318545; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; Colven R, 2000, ANN INTERN MED, V133, P430, DOI 10.7326/0003-4819-133-6-200009190-00010; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; Day CL, 2001, J VIROL, V75, P6279, DOI 10.1128/JVI.75.14.6279-6291.2001; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; DYBUL M, 2001, 8 C RETR OPP INF CHI; Flores-Villanueva PO, 2001, P NATL ACAD SCI USA, V98, P5140, DOI 10.1073/pnas.071548198; Garcia F, 1999, AIDS, V13, pF79, DOI 10.1097/00002030-199907300-00002; Garcia F, 2001, AIDS, V15, pF29, DOI 10.1097/00002030-200106150-00002; Goulder PJR, 1999, AIDS, V13, pS121; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; GOULDER PJR, IN PRESS NATURE; Harrer T, 1996, AIDS RES HUM RETROV, V12, P585, DOI 10.1089/aid.1996.12.585; Harrer T, 1996, J IMMUNOL, V156, P2616; Hatano H, 2000, AIDS, V14, P1357, DOI 10.1097/00002030-200007070-00008; Hel Z, 2000, NAT MED, V6, P1140, DOI 10.1038/80481; HERMANS P, 2001, 8 C RETR OPP INF CHI; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Kalams SA, 1999, J VIROL, V73, P6715, DOI 10.1128/JVI.73.8.6715-6720.1999; Kilby JM, 2000, ANN INTERN MED, V133, P435, DOI 10.7326/0003-4819-133-6-200009190-00011; Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114; Lori F, 2000, SCIENCE, V290, P1591, DOI 10.1126/science.290.5496.1591; Lori F, 1999, AIDS RES HUM RETROV, V15, P1333, DOI 10.1089/088922299310034; Lyles RH, 2000, J INFECT DIS, V181, P872, DOI 10.1086/315339; Malhotra U, 2000, J INFECT DIS, V181, P121, DOI 10.1086/315202; MARKOWITZ M, 2001, 8 C RETR OPP INF CHI; McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658; Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397; Miller V, 2001, CURR OPIN INFECT DIS, V14, P29, DOI 10.1097/00001432-200102000-00006; Miller V, 2000, AIDS, V14, P2857, DOI 10.1097/00002030-200012220-00007; Montaner LJ, 2001, TRENDS IMMUNOL, V22, P92, DOI 10.1016/S1471-4906(00)01809-3; Neumann AU, 1999, AIDS, V13, P677, DOI 10.1097/00002030-199904160-00008; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Ortiz GM, 1999, J CLIN INVEST, V104, pR13, DOI 10.1172/JCI7371; Ostrowski MA, 2000, J IMMUNOL, V165, P6133, DOI 10.4049/jimmunol.165.11.6133; Oxenius A, 2000, P NATL ACAD SCI USA, V97, P3382, DOI 10.1073/pnas.97.7.3382; Papasavvas E, 2000, J INFECT DIS, V182, P766, DOI 10.1086/315748; Poignard P, 1999, IMMUNITY, V10, P431, DOI 10.1016/S1074-7613(00)80043-6; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Ruiz L, 2000, AIDS, V14, P397, DOI 10.1097/00002030-200003100-00013; Ruiz L, 2001, AIDS, V15, pF19, DOI 10.1097/00002030-200106150-00001; Sarawar SR, 2001, P NATL ACAD SCI USA, V98, P6325, DOI 10.1073/pnas.101136898; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; Walker BD, 2001, NAT IMMUNOL, V2, P473, DOI 10.1038/88656; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	54	41	41	0	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2001	7	8					881	884		10.1038/90901	http://dx.doi.org/10.1038/90901			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479610				2022-12-27	WOS:000171740400013
J	Fontaine, P; Roy-Proulx, G; Knafo, L; Baron, C; Roy, DC; Perreault, C				Fontaine, P; Roy-Proulx, G; Knafo, L; Baron, C; Roy, DC; Perreault, C			Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease	NATURE MEDICINE			English	Article							DONOR LEUKOCYTE INFUSIONS; BONE-MARROW TRANSPLANTS; IMMUNOTHERAPY; IMMUNODOMINANCE; INDUCTION; RESPONSES	Adoptive transfer of T cells reactive to minor histocompatibility antigens has the unmatched ability to eradicate malignant hematopoietic cells. Unfortunately, its use is hampered by the associated graft-versus-host disease. The critical issue of a possible dissociation of the antileukemic effect and graft-versus-host disease by targeting specific minor histocompatibility antigens remains unresolved because of the unknown nature and number of minor histocompatibility antigens necessary or sufficient to elicit anti-leukemic activity and graft-versus-host disease. We found that injection of T lymphocytes primed against a single major histocompatibility complex class I-restricted immunodominant minor histocompatibility antigen (B6(dom1)) caused no graft-versus-host disease but produced a curative anti-leukemic response. Avoidance of graft-versus-host disease required that no other host-reactive T cells be co-injected with T cells primed with B6(dom1). Here we show that effective and non-toxic immunotherapy of hematologic malignancies can be achieved by targeting a single immunodominant minor histocompatibility antigen.	Maisonneuve Rosemont Hosp, Guy Bernier Res Ctr, Montreal, PQ, Canada	Universite de Montreal	Perreault, C (corresponding author), Maisonneuve Rosemont Hosp, Guy Bernier Res Ctr, Montreal, PQ, Canada.	c.perreault@videotron.ca	Perreault, Claude/A-7220-2008	Perreault, Claude/0000-0001-9453-7383; Roy, Denis-Claude/0000-0002-5921-1692				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Barrett AJ, 2000, BLOOD, V95, P3323; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; Brochu S, 1999, BLOOD, V94, P390, DOI 10.1182/blood.V94.2.390.414k27_390_400; Cheever MA, 1997, IMMUNOL REV, V157, P177, DOI 10.1111/j.1600-065X.1997.tb00982.x; Ciubotariu R, 1998, J CLIN INVEST, V101, P398, DOI 10.1172/JCI1117; Collins RH, 1997, J CLIN ONCOL, V15, P433, DOI 10.1200/JCO.1997.15.2.433; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; DAAR AS, 1984, TRANSPLANTATION, V38, P287, DOI 10.1097/00007890-198409000-00018; Drobyski WR, 1999, BLOOD, V94, P434, DOI 10.1182/blood.V94.2.434.414k42_434_441; Dulude G, 1999, J EXP MED, V189, P1329, DOI 10.1084/jem.189.8.1329; Eden PA, 1999, J IMMUNOL, V162, P4502; FONTAINE P, 1991, IMMUNOGENETICS, V34, P222, DOI 10.1007/BF00215256; Franco A, 2000, NAT IMMUNOL, V1, P145, DOI 10.1038/77827; GALE RP, 1994, ANN INTERN MED, V120, P646, DOI 10.7326/0003-4819-120-8-199404150-00004; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Goulmy E, 1996, NEW ENGL J MED, V334, P281, DOI 10.1056/NEJM199602013340501; Goulmy E, 1996, CURR OPIN IMMUNOL, V8, P75, DOI 10.1016/S0952-7915(96)80108-7; Goulmy E, 1997, IMMUNOL REV, V157, P125, DOI 10.1111/j.1600-065X.1997.tb00978.x; GRIEM P, 1991, CELL, V65, P633, DOI 10.1016/0092-8674(91)90095-G; HOROWITZ MM, 1990, BLOOD, V75, P555; Johnston JV, 1996, J EXP MED, V183, P791, DOI 10.1084/jem.183.3.791; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; Korngold R, 1997, Biol Blood Marrow Transplant, V3, P57; KORNGOLD R, 1983, IMMUNOL REV, V71, P5, DOI 10.1111/j.1600-065X.1983.tb01066.x; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; LOVELAND B, 1986, IMMUNOL TODAY, V7, P223, DOI 10.1016/0167-5699(86)90109-X; Mutis T, 1999, BLOOD, V93, P2336, DOI 10.1182/blood.V93.7.2336.407k26_2336_2341; Perreault C, 1998, IMMUNOL TODAY, V19, P69, DOI 10.1016/S0167-5699(97)01185-7; Perreault C, 1996, J CLIN INVEST, V98, P622, DOI 10.1172/JCI118832; PION S, 1995, J CLIN INVEST, V95, P1561, DOI 10.1172/JCI117829; Pion S, 1999, BLOOD, V93, P952, DOI 10.1182/blood.V93.3.952.403k33_952_962; Pion S, 1997, EUR J IMMUNOL, V27, P421, DOI 10.1002/eji.1830270212; RODERICK TH, 1989, GENETIC VARIANTS STR, P663; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; Staveley-O'Carroll K, 1998, P NATL ACAD SCI USA, V95, P1178, DOI 10.1073/pnas.95.3.1178; VandenEynde BJ, 1997, CURR OPIN IMMUNOL, V9, P684, DOI 10.1016/S0952-7915(97)80050-7	38	141	146	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2001	7	7					789	794		10.1038/89907	http://dx.doi.org/10.1038/89907			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433342				2022-12-27	WOS:000169808600029
J	Kirn, D; Martuza, RL; Zwiebel, J				Kirn, D; Martuza, RL; Zwiebel, J			Replication-selective virotherapy for cancer: Biological principles, risk management and future directions	NATURE MEDICINE			English	Review							HERPES-SIMPLEX-VIRUS; NEWCASTLE-DISEASE VIRUS; PROSTATE-SPECIFIC ANTIGEN; PHASE-I TRIAL; GENE-THERAPY; COMPETENT ADENOVIRUS; ATTENUATED ADENOVIRUS; ONCOLYTIC ADENOVIRUS; MALIGNANT-MELANOMA; FIBER PROTEINS	In the search for novel cancer therapies that can be used in conjunction with existing treatments, one promising area of research is the use of viral vectors and whole viruses. This review describes the underlying biological principles and current status of the field, outlines approaches for improving clinical effectiveness and discusses the unique safety and regulatory issues surrounding viral therapies.	Univ London Imperial Coll Sci Technol & Med, Viral & Genet Therapy Programme, Sch Med, London, England; Hammersmith Hosp, Imperial Canc Res Fund, London, England; Harvard Univ, Sch Med, Boston, MA USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; NCI, Div Canc Treatment, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA	Imperial College London; Cancer Research UK; Imperial College London; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kirn, D (corresponding author), Univ London Imperial Coll Sci Technol & Med, Viral & Genet Therapy Programme, Sch Med, London, England.	d.kirn@icrf.icnet.uk			NINDS NIH HHS [NS32677] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032677] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEMANY N, 2000, CLIN CANCER RES, V6, P3395; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Batliwalla FM, 1998, MOL MED, V4, P783, DOI 10.1007/BF03401771; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BRYSON JS, 1988, CANCER IMMUNOL IMMUN, V26, P132; CASSEL WA, 1983, CANCER, V52, P856, DOI 10.1002/1097-0142(19830901)52:5<856::AID-CNCR2820520519>3.0.CO;2-4; Chalavi A, 1999, NEOPLASIA, V1, P162; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Conry RM, 1999, CLIN CANCER RES, V5, P2330; Doronin K, 2000, J VIROL, V74, P6147, DOI 10.1128/JVI.74.13.6147-6155.2000; Douglas JT, 2001, CANCER RES, V61, P813; Eder JP, 2000, CLIN CANCER RES, V6, P1632; Freytag SO, 1998, HUM GENE THER, V9, P1323, DOI 10.1089/hum.1998.9.9-1323; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Ganly I, 2000, CLIN CANCER RES, V6, P798; Goodrum FD, 1997, J VIROL, V71, P548, DOI 10.1128/JVI.71.1.548-561.1997; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; Haag A, 2000, HUM GENE THER, V11, P597, DOI 10.1089/10430340050015789; Hallenbeck PL, 1999, HUM GENE THER, V10, P1721, DOI 10.1089/10430349950017725; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; HECHT R, 2000, P AN M AM SOC CLIN, V19, P1039; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Heise C, 2000, CLIN CANCER RES, V6, P4908; Heise CC, 1999, CANCER GENE THER, V6, P499, DOI 10.1038/sj.cgt.7700071; Heise CC, 1999, CANCER RES, V59, P2623; Hermiston T, 2000, J CLIN INVEST, V105, P1169, DOI 10.1172/JCI9973; Herrlinger U, 1998, GENE THER, V5, P809, DOI 10.1038/sj.gt.3300643; Ikeda K, 1999, NAT MED, V5, P881, DOI 10.1038/11320; Jakubczak JL, 2001, J VIROL, V75, P2972, DOI 10.1128/JVI.75.6.2972-2981.2001; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kirn D, 2000, ONCOGENE, V19, P6660, DOI 10.1038/sj.onc.1204094; Kirn D, 2001, GENE THER, V8, P89, DOI 10.1038/sj.gt.3301377; KIRN D, 1998, P CANC GEN THER M SA; Kirn DH, 2000, J CLIN INVEST, V105, P837, DOI 10.1172/JCI9761; Kurihara T, 2000, J CLIN INVEST, V106, P763, DOI 10.1172/JCI9180; LEHNER B, 1990, CANCER IMMUNOL IMMUN, V32, P173, DOI 10.1007/BF01771453; LIEBRICH W, 1991, EUR J CANCER, V27, P703, DOI 10.1016/0277-5379(91)90170-I; LORENCE RM, 1988, J NATL CANCER I, V80, P1305, DOI 10.1093/jnci/80.16.1305; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Martuza RL, 2000, J CLIN INVEST, V105, P841, DOI 10.1172/JCI9744; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; Mastrangelo MJ, 1999, CANCER GENE THER, V6, P409, DOI 10.1038/sj.cgt.7700066; Mastrangelo MJ, 2000, J CLIN INVEST, V105, P1031, DOI 10.1172/JCI9819; McCart JA, 2000, GENE THER, V7, P1217, DOI 10.1038/sj.gt.3301237; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; MINETA T, 1994, CANCER RES, V54, P3963; Miyatake S, 1997, J VIROL, V71, P5124, DOI 10.1128/JVI.71.7.5124-5132.1997; MOSS B, 1996, VIROLOGY; Mukherjee S, 2000, CANCER GENE THER, V7, P663, DOI 10.1038/sj.cgt.7700133; Nemunaitis J, 2000, CANCER RES, V60, P6359; NEUMUNAITIS J, IN PRESS GENE THER; Norman KL, 2000, J CLIN INVEST, V105, P1035, DOI 10.1172/JCI9871; Puhlmann M, 2000, CANCER GENE THER, V7, P66, DOI 10.1038/sj.cgt.7700075; Rampling R, 2000, GENE THER, V7, P859, DOI 10.1038/sj.gt.3301184; Reid T, 2000, P AN M AM SOC CLIN, V19, P953; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; Rodriguez R, 1997, CANCER RES, V57, P2559; Roelvink PW, 1999, SCIENCE, V286, P1568, DOI 10.1126/science.286.5444.1568; Rogulski KR, 2000, CANCER RES, V60, P1193; ROMMELAERE J, 1991, J VIROL METHODS, V33, P233, DOI 10.1016/0166-0934(91)90024-T; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; RUSSELL SJ, 1992, LANCET, V339, P1109, DOI 10.1016/0140-6736(92)90698-3; Sauthoff H, 2000, HUM GENE THER, V11, P379, DOI 10.1089/10430340050015851; SOUTHAM CM, 1960, NY ACAD SCI, V22, P656; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Sznol M, 2000, J CLIN INVEST, V105, P1027, DOI 10.1172/JCI9818; TELERMAN A, 1993, P NATL ACAD SCI USA, V90, P8702, DOI 10.1073/pnas.90.18.8702; Toda M, 1998, J IMMUNOL, V160, P4457; Todo T, 1999, HUM GENE THER, V10, P2741, DOI 10.1089/10430349950016483; VASEY P, 2000, P AN M AM SOC CLIN, V19, P1512; WHITLEY RJ, 1993, J CLIN INVEST, V91, P2837, DOI 10.1172/JCI116527; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; Wickham TJ, 1997, J VIROL, V71, P8221, DOI 10.1128/JVI.71.11.8221-8229.1997; Wildner O, 1999, CANCER RES, V59, P410; Yu DC, 1999, CANCER RES, V59, P4200; Yu DC, 2001, CANCER RES, V61, P517	78	344	391	1	65	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2001	7	7					781	787		10.1038/89901	http://dx.doi.org/10.1038/89901			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433341				2022-12-27	WOS:000169808600028
J	Propato, A; Cutrona, G; Francavilla, V; Ulivi, M; Schiaffella, E; Landt, O; Dunbar, R; Cerundolo, V; Ferrarini, M; Barnaba, V				Propato, A; Cutrona, G; Francavilla, V; Ulivi, M; Schiaffella, E; Landt, O; Dunbar, R; Cerundolo, V; Ferrarini, M; Barnaba, V			Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming	NATURE MEDICINE			English	Article							DENDRITIC CELLS; IN-VIVO; EFFICIENT PRESENTATION; ANTIGEN PRESENTATION; EXOGENOUS ANTIGEN; ENDOTHELIAL-CELLS; B-CELLS; LYMPHOCYTES; TOLERANCE; ACTIVATION	Here we show that apoptotic cells overexpress vinculin and are ingested by dendritic cells, which subsequently cross-prime vinculin-specific cytotoxic T lymphocytes (CTLs). Successful cross-priming requires that the apoptotic cells provide maturation signals to dendritic cells through CD40-CD40 ligand (CD40L) interactions. If apoptotic cells are CD40L; the help of a third T cell is needed for priming, indicating a regulatory role for apoptotic cells in determining priming or tolerance. Vinculin-specific CTL priming is also related to apoptosis in vivo, given that in HIV-seropositive individuals, the frequency of specific CTLs depends on the proportion of peripheral CD40L(+) apoptotic cells.	Univ Roma La Sapienza, Fdn Andrea Cesalpino, Dipartimento Med Interna, Rome, Italy; Ist Nazl Ric Canc, Serv Immunol Clin, I-16132 Genoa, Italy; TIB Mol Biol, Berlin, Germany; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Nuffield Dept Med, Oxford OX3 9DU, England; Univ Genoa, Dipartimento Oncol Biol & Genet, Genoa, Italy; Ist Pasteur Cenci Bolognetti, Rome, Italy	Sapienza University Rome; University of Genoa; IRCCS AOU San Martino IST; University of Oxford; University of Genoa; Fondazione Cenci Bolognetti	Barnaba, V (corresponding author), Univ Roma La Sapienza, Fdn Andrea Cesalpino, Dipartimento Med Interna, Rome, Italy.		Dunbar, Rod/C-2570-2012; Barnaba, Vincenzo/AAB-1945-2019; Cutrona, Giovanna/I-7868-2018	Dunbar, Rod/0000-0001-9626-2600; Cutrona, Giovanna/0000-0002-3335-1101; Ferrarini, Manlio/0000-0002-6154-2570; Cerundolo, Vincenzo/0000-0003-0040-3793				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Badley AD, 1998, J CLIN INVEST, V102, P79, DOI 10.1172/JCI2691; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barnaba V, 1996, IMMUNOL REV, V152, P47, DOI 10.1111/j.1600-065X.1996.tb00910.x; BARNABA V, 1990, NATURE, V345, P258, DOI 10.1038/345258a0; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; CACHO CAM, 1995, J IMMUNOL, V154, P5555; Carbone E, 1997, J EXP MED, V185, P2053, DOI 10.1084/jem.185.12.2053; Carbone FR, 1998, IMMUNOL TODAY, V19, P368, DOI 10.1016/S0167-5699(98)01301-2; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Cerundolo V, 1997, EUR J IMMUNOL, V27, P336, DOI 10.1002/eji.1830270148; Cutrona G, 1999, BLOOD, V94, P3067, DOI 10.1182/blood.V94.9.3067.421a32_3067_3076; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Dunbar PR, 1998, CURR BIOL, V8, P413, DOI 10.1016/S0960-9822(98)70161-7; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; Heath WR, 1999, CURR OPIN IMMUNOL, V11, P314, DOI 10.1016/S0952-7915(99)80050-8; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; Inaba K, 1998, J EXP MED, V188, P2163, DOI 10.1084/jem.188.11.2163; LANE P, 1992, EUR J IMMUNOL, V22, P2573, DOI 10.1002/eji.1830221016; Limmer A, 2000, NAT MED, V6, P1348, DOI 10.1038/82161; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Mevorach D, 1998, J EXP MED, V188, P387, DOI 10.1084/jem.188.2.387; PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.immunol.13.1.487; Prezzi C, 2001, EUR J IMMUNOL, V31, P894, DOI 10.1002/1521-4141(200103)31:3<894::AID-IMMU894>3.0.CO;2-I; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Reid SD, 2000, CURR OPIN IMMUNOL, V12, P114, DOI 10.1016/S0952-7915(99)00059-X; Restifo NP, 2000, CURR OPIN IMMUNOL, V12, P597, DOI 10.1016/S0952-7915(00)00148-5; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Rock KL, 1996, IMMUNOL TODAY, V17, P131, DOI 10.1016/0167-5699(96)80605-0; Ronchetti A, 1999, J IMMUNOL, V163, P130; ROSEN A, 1995, J EXP MED, V181, P1557, DOI 10.1084/jem.181.4.1557; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sallusto F, 1999, J EXP MED, V189, P611, DOI 10.1084/jem.189.4.611; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Scognamiglio P, 1999, J IMMUNOL, V162, P6681; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; Veronese FD, 1996, J EXP MED, V183, P2509, DOI 10.1084/jem.183.6.2509; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; Yewdell JW, 1999, ADV IMMUNOL, V73, P1, DOI 10.1016/S0065-2776(08)60785-3	45	76	80	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					807	813		10.1038/89930	http://dx.doi.org/10.1038/89930			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433345				2022-12-27	WOS:000169808600032
J	Stoddart, CA; Liegler, TJ; Mammano, F; Linquist-Stepps, VD; Hayden, MS; Deeks, SG; Grant, RM; Clavel, F; McCune, JM				Stoddart, CA; Liegler, TJ; Mammano, F; Linquist-Stepps, VD; Hayden, MS; Deeks, SG; Grant, RM; Clavel, F; McCune, JM			Impaired replication of protease inhibitor-resistant HIV-1 in human thymus	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; T-CELL FUNCTION; IN-VIVO; HIV-1-INFECTED INDIVIDUALS; VIROLOGICAL FAILURE; CONTROLLED TRIAL; VIRAL FITNESS; INFECTION; INDINAVIR	Many HIV-1-infected patients treated with protease inhibitors (PI) develop PI-resistant HIV-1 variants and rebounds in viremia, but their CD4(+) T-cell counts often do not fall. We hypothesized that in these patients, T-cell counts remain elevated because PI-resistant virus spares intrathymic T-cell production. To test this, we studied recombinant HIV-1 clones containing wild-type or PI-resistant protease domains, as well as uncloned isolates from patients, in activated peripheral blood mononuclear cells, human thymic organ cultures and human thymus implants in SCID-hu Thy/Liv mice. In most cases, wild-type and PI-resistant HIV-1 isolates replicated to similar degrees in peripheral blood mononuclear cells. However, the replication of PI-resistant but not wild-type HIV-1 isolates was highly impaired in thymocytes. In addition, patients who had PI-resistant HIV-1 had abundant thymus tissue as assessed by computed tomography. We propose that the inability of PI-resistant HIV-1 to replicate efficiently in thymus contributes to the preservation of CD4(+) T-cell counts in patients showing virologic rebound on PI therapy.	San Francisco Gen Hosp, Gladstone Inst Virol & Immunol, San Francisco, CA 94110 USA; San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Hop Bichat Claude Bernard, IMEA, Rech Antivirale, INSERM,U552, F-75877 Paris 18, France	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; The J David Gladstone Institutes; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Stoddart, CA (corresponding author), San Francisco Gen Hosp, Gladstone Inst Virol & Immunol, San Francisco, CA 94110 USA.		Mammano, Fabrizio/H-9423-2019; Hayden, Matthew/C-1263-2008	Mammano, Fabrizio/0000-0002-9193-7696; Grant, Robert/0000-0002-0851-7085; Hayden, Matthew/0000-0003-1670-6430	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI043864, N01AI005418, R01AI043864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH059037] Funding Source: NIH RePORTER; NCRR NIH HHS [5-MO1-RR00083] Funding Source: Medline; NIAID NIH HHS [AI05418, AI43864, AI65309] Funding Source: Medline; NIMH NIH HHS [P30 MH59037] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Borman AM, 1996, J GEN VIROL, V77, P419, DOI 10.1099/0022-1317-77-3-419; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Croteau G, 1997, J VIROL, V71, P1089, DOI 10.1128/JVI.71.2.1089-1096.1997; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Deeks SG, 2000, J INFECT DIS, V181, P946, DOI 10.1086/315334; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Emini EA, 1996, ADV EXP MED BIOL, V394, P327; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gulick RM, 1998, JAMA-J AM MED ASSOC, V280, P35, DOI 10.1001/jama.280.1.35; GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hatzakis A, 2000, LANCET, V355, P599, DOI 10.1016/S0140-6736(99)10311-8; Hirsch M, 1999, J INFECT DIS, V180, P659, DOI 10.1086/314948; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; Lecossier D, 2001, J INFECT DIS, V183, P1009, DOI 10.1086/319285; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Liegler TJ, 2001, AIDS, V15, P179, DOI 10.1097/00002030-200101260-00006; Mammano F, 1998, J VIROL, V72, P7632, DOI 10.1128/JVI.72.9.7632-7637.1998; Martinez-Picado J, 1999, J VIROL, V73, P3744, DOI 10.1128/JVI.73.5.3744-3752.1999; McCune JM, 2000, J CLIN INVEST, V105, pR1, DOI 10.1172/JCI8647; McCune JM, 1998, J CLIN INVEST, V101, P2301, DOI 10.1172/JCI2834; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Mezzaroma I, 1999, AIDS, V13, P1187, DOI 10.1097/00002030-199907090-00006; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; NAMIKAWA R, 1990, J EXP MED, V172, P1055, DOI 10.1084/jem.172.4.1055; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PENN ML, IN PRESS AIDS RES HU; Rabin L, 1996, ANTIMICROB AGENTS CH, V40, P755, DOI 10.1128/AAC.40.3.755; Renaud M, 1999, AIDS, V13, P669, DOI 10.1097/00002030-199904160-00007; Rey-Cuille MA, 1998, J VIROL, V72, P3872; Rose RE, 1996, P NATL ACAD SCI USA, V93, P1648, DOI 10.1073/pnas.93.4.1648; Smith KY, 2000, J INFECT DIS, V181, P141, DOI 10.1086/315169; Stoddart CA, 2000, ANTIMICROB AGENTS CH, V44, P783, DOI 10.1128/AAC.44.3.783-786.2000; STODDART CA, 1999, HDB ANIMAL MODELS IN, P1069; Winters MA, 1998, J VIROL, V72, P5303, DOI 10.1128/JVI.72.6.5303-5306.1998; Zennou V, 1998, J VIROL, V72, P3300, DOI 10.1128/JVI.72.4.3300-3306.1998; Zhang LQ, 1999, J EXP MED, V190, P725, DOI 10.1084/jem.190.5.725; Zhang YM, 1997, J VIROL, V71, P6662, DOI 10.1128/JVI.71.9.6662-6670.1997	41	115	115	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2001	7	6					712	718		10.1038/89090	http://dx.doi.org/10.1038/89090			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385509				2022-12-27	WOS:000169081500040
J	Consiglio, A; Quattrini, A; Martino, S; Bensadoun, JC; Dolcetta, D; Trojani, A; Benaglia, G; Marchesini, S; Cestari, V; Oliverio, A; Bordignon, C; Naldini, L				Consiglio, A; Quattrini, A; Martino, S; Bensadoun, JC; Dolcetta, D; Trojani, A; Benaglia, G; Marchesini, S; Cestari, V; Oliverio, A; Bordignon, C; Naldini, L			In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice	NATURE MEDICINE			English	Article							MUCOPOLYSACCHARIDOSIS TYPE-VII; HUMAN ARYLSULFATASE-A; ENZYME REPLACEMENT THERAPY; CENTRAL-NERVOUS-SYSTEM; LONG-TERM; LYSOSOMAL STORAGE; IN-VIVO; CEREBROSIDE SULFATE; BETA-GLUCURONIDASE; DEFICIENT MICE	Metachromatic leukodystrophy (MLD) is a lipidosis caused by deficiency of arylsulfatase A (ARSA). Although the genetics of MLD are known, its pathophysiology is not understood. The disease leads to progressive demyelination and early death and no effective treatment is available. We used lentiviral vectors to deliver a functional ARSA gene (human ARSA) into the brain of adult mice with germ-line inactivation of the mouse gene encoding ARSA, As2. We report sustained expression of active enzyme throughout a large portion of the brain, with long-term protection from development of neuropathology and hippocampal-related learning Impairments. We show that selective degeneration of hippocampal neurons Is a central step in disease pathogenesis, and provide evidence that in vivo transfer of ARSA by lentiviral vectors reverts the disease phenotype in all investigated areas. Therefore, in vivo gene therapy offers a unique option for MLD and other storage diseases affecting the central nervous system.	Sci Inst HS Raffaele HSR TIGET, Telethon Inst Gene Therapy, Milan, Italy; Sci Inst HS Raffaele HSR TIGET, Dept Neurol, Milan, Italy; Div Surg Res, Lausanne, Switzerland; Gene Therapy Ctr, Lausanne, Switzerland; Univ Brescia, Dept Biomed Sci & Biotechnol, Brescia, Italy; CNR, Inst Psychobiol & Psychopharmacol, Rome, Italy; Univ Turin, Lab Gene Transfer & Therapy, Inst Canc Res & Treatment, Turin, Italy	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); University of Brescia; Consiglio Nazionale delle Ricerche (CNR); University of Turin	Bordignon, C (corresponding author), Sci Inst HS Raffaele HSR TIGET, Telethon Inst Gene Therapy, Milan, Italy.	claudio.bordignon@hsr.it	Oliverio, Alberto/ABG-7454-2021; consiglio, antonella/AAA-5864-2019; Dolcetta, Diego/AAD-2079-2019; Naldini, Luigi/E-9083-2012; consiglio, antonella/G-1815-2016; Martino, Sabata/F-2309-2014; Dunnett, Stephen B/A-5869-2010; Quattrini, Angelo/J-8373-2018	consiglio, antonella/0000-0002-3988-6254; consiglio, antonella/0000-0002-3988-6254; Martino, Sabata/0000-0002-3942-237X; Dunnett, Stephen B/0000-0003-1826-1578; NALDINI, Luigi/0000-0002-7835-527X; Cestari, Vincenzo/0000-0002-9623-157X; Quattrini, Angelo/0000-0002-8226-8320; Dolcetta, Diego/0000-0002-2864-9667	Telethon [TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		BAUM H, 1959, CLIN CHIM ACTA, V4, P453, DOI 10.1016/0009-8981(59)90119-6; Bosch A, 2000, MOL THER, V1, P63, DOI 10.1006/mthe.1999.0005; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Cestari V, 1996, BRAIN RES, V713, P286, DOI 10.1016/0006-8993(95)01556-6; D'Hooge R, 1999, BRAIN RES, V847, P352, DOI 10.1016/S0006-8993(99)02085-5; D'Hooge R, 1999, NEUROSCI LETT, V273, P93, DOI 10.1016/S0304-3940(99)00647-3; Deglon N, 2000, HUM GENE THER, V11, P179, DOI 10.1089/10430340050016256; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Ferraresi S, 1997, MULT SCLER, V3, P80, DOI 10.1177/135245859700300204; Gieselmann V, 1998, J INHERIT METAB DIS, V21, P564, DOI 10.1023/A:1005471106088; Gould E, 1999, P NATL ACAD SCI USA, V96, P5263, DOI 10.1073/pnas.96.9.5263; Hess B, 1996, P NATL ACAD SCI USA, V93, P14821, DOI 10.1073/pnas.93.25.14821; Kapaun P, 1999, J CHILD NEUROL, V14, P222, DOI 10.1177/088307389901400402; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kolodny E.H., 1995, METABOLIC MOL BASES, V7th, P2693; KREYSING J, 1994, GENOMICS, V19, P249, DOI 10.1006/geno.1994.1055; Krivit W, 1999, Curr Opin Neurol, V12, P167, DOI 10.1097/00019052-199904000-00007; Learish R, 1996, GENE THER, V3, P343; LEINEKUGEL P, 1992, HUM GENET, V88, P513, DOI 10.1007/BF00219337; MARCHESINI S, 1990, CHEM PHYS LIPIDS, V53, P165, DOI 10.1016/0009-3084(90)90042-P; MCGAUGH JL, 1970, PHYSIOL BEHAV, V5, P1109, DOI 10.1016/0031-9384(70)90197-6; Minichiello L, 1999, NEURON, V24, P401, DOI 10.1016/S0896-6273(00)80853-3; MONTI E, 1992, BIOCHIM BIOPHYS ACTA, V1124, P80, DOI 10.1016/0005-2760(92)90129-J; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; NEMNI R, 1992, BRAIN RES, V591, P248, DOI 10.1016/0006-8993(92)91704-I; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; O'Connor LH, 1998, J CLIN INVEST, V101, P1394, DOI 10.1172/JCI1773; OHASHI T, 1993, J INHERIT METAB DIS, V16, P881, DOI 10.1007/BF00714283; Ohashi T, 1997, P NATL ACAD SCI USA, V94, P1287, DOI 10.1073/pnas.94.4.1287; OLTON DS, 1978, BRAIN RES, V139, P295, DOI 10.1016/0006-8993(78)90930-7; PAPAIOANNOU VE, 1993, LAB ANIM SCI, V43, P189; PENZIEN JM, 1993, AM J HUM GENET, V52, P557; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; SANDS MS, 1994, J CLIN INVEST, V93, P2324, DOI 10.1172/JCI117237; Sangalli A, 1998, HUM GENE THER, V9, P2111, DOI 10.1089/hum.1998.9.14-2111; STEIN C, 1989, J BIOL CHEM, V264, P1252; Taylor RM, 1997, NAT MED, V3, P771, DOI 10.1038/nm0797-771; Venters HD, 1999, P NATL ACAD SCI USA, V96, P9879, DOI 10.1073/pnas.96.17.9879; VIANI P, 1989, BIOCHIM BIOPHYS ACTA, V1002, P20, DOI 10.1016/0005-2760(89)90059-3; VOS JP, 1992, BIOCHIM BIOPHYS ACTA, V1126, P269, DOI 10.1016/0005-2760(92)90240-V; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999	45	171	180	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2001	7	3					310	316		10.1038/85454	http://dx.doi.org/10.1038/85454			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231629				2022-12-27	WOS:000167380400036
J	White, R; Leonardsson, G; Rosewell, I; Jacobs, MA; Milligan, S; Parker, M				White, R; Leonardsson, G; Rosewell, I; Jacobs, MA; Milligan, S; Parker, M			The nuclear receptor co-repressor Nrip1 (RIP140) is essential for female fertility	NATURE MEDICINE			English	Article							UNRUPTURED FOLLICLE SYNDROME; ESTROGEN-RECEPTOR; MICE LACKING; C/EBP-BETA; GENE; EXPRESSION; MOUSE; DISRUPTION; ANTAGONISM; OVULATION	Ovulatory dysfunction is the commonest cause of female infertility. Here we shaw that the co-repressor nuclear-receptor-interacting protein 1 (Nrip1; encoded by the gene Nrip1) is essential for ovulation. Mice null for this protein are viable, but female mice are infertile because of complete failure of mature follicles to release the oocyte at ovulation. In contrast, luteinization proceeds normally, resulting in a phenotype closely resembling that of luteinized unruptured follicle syndrome, often associated with infertility in women. Therefore, whereas the pre-ovulatory surge of luteinizing hormone induces both ovulation and luteinization, the ability to suppress the action of nuclear receptors is essential for the coordinated control of ovarian function with the essential process of oocyte release dependent on the activity of the transcriptional co-repressor Nrip1 (RIP40).	Imperial Canc Res Fund, Mol Endocrinol Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Clare Hall Labs, Potters Bar EN6 3LD, Herts, England; Kings Coll London, Sch Biomed Sci, London SE1 1UL, England	Cancer Research UK; University of London; Queen Mary University London; University of London; King's College London	Parker, M (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, Inst Reprod & Dev Biol, London W12 0NN, England.	M.Parker@ic.ac.uk						Abel MH, 2000, ENDOCRINOLOGY, V141, P1795, DOI 10.1210/en.141.5.1795; Brosens I A, 1980, Fertil Steril, V34, P179; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Byers M, 1997, MOL ENDOCRINOL, V11, P172, DOI 10.1210/me.11.2.172; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Coetsier T, 1996, HUM REPROD, V11, P583, DOI 10.1093/HUMREP/11.3.583; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Dierich A, 1998, P NATL ACAD SCI USA, V95, P13612, DOI 10.1073/pnas.95.23.13612; Dong LW, 1996, J MOL RECOGNIT, V9, P383, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<383::AID-JMR269>3.0.CO;2-Z; DONNEZ J, 1982, EUR J OBSTET GYN R B, V14, P187, DOI 10.1016/0028-2243(82)90095-8; Elvin JA, 1998, REV REPROD, V3, P183, DOI 10.1530/ror.0.0030183; Glass CK, 2000, GENE DEV, V14, P121; Groet J, 1998, GENOME RES, V8, P385, DOI 10.1101/gr.8.4.385; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hogan B, 1994, MANIPULATING MOUSE E; KONINCKX PR, 1980, BRIT J OBSTET GYNAEC, V87, P929, DOI 10.1111/j.1471-0528.1980.tb04454.x; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Lee CH, 1999, J BIOL CHEM, V274, P31320, DOI 10.1074/jbc.274.44.31320; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Nokelainen P, 2000, ENDOCRINOLOGY, V141, P772, DOI 10.1210/en.141.2.772; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; Pall M, 1997, EMBO J, V16, P5273, DOI 10.1093/emboj/16.17.5273; PENG XR, 1991, ENDOCRINOLOGY, V129, P3200, DOI 10.1210/endo-129-6-3200; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Poulsom R, 1998, EUR J HISTOCHEM, V42, P121; RAJENDRAKUMAR T, 1997, NAT GENET, V15, P201; Risma KA, 1997, ENDOCRINOLOGY, V138, P3540, DOI 10.1210/en.138.8.3540; Robker RL, 2000, P NATL ACAD SCI USA, V97, P4689, DOI 10.1073/pnas.080073497; Sharma SC, 1999, ENDOCRINOLOGY, V140, P4320, DOI 10.1210/en.140.9.4320; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; Thenot S, 1999, MOL CELL ENDOCRINOL, V156, P85, DOI 10.1016/S0303-7207(99)00139-2; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Wiersma A, 1998, J CLIN INVEST, V102, P532, DOI 10.1172/JCI2566; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922	45	151	160	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2000	6	12					1368	1374		10.1038/82183	http://dx.doi.org/10.1038/82183			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100122				2022-12-27	WOS:000165704100041
J	Cimons, M				Cimons, M			Abortion drug approval opens up research	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1196	1196		10.1038/81261	http://dx.doi.org/10.1038/81261			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062511				2022-12-27	WOS:000165114800005
J	De Edeleny, FS; Rubin, C; Esteve, F; Grand, S; Decorps, M; Lefournier, V; Le Bas, JF; Remy, C				De Edeleny, FS; Rubin, C; Esteve, F; Grand, S; Decorps, M; Lefournier, V; Le Bas, JF; Remy, C			A new approach for analyzing proton magnetic resonance spectroscopic images of brain tumors: nosologic images	NATURE MEDICINE			English	Article							H-1 MR SPECTROSCOPY; IN-VIVO; AUTOMATED CLASSIFICATION; METABOLIC HETEROGENEITY; INTRACRANIAL TUMORS; IMAGING METHOD; MULTICENTER; DIAGNOSIS; GLIOMAS; INVIVO		CHU Grenoble, LRC CEA, Unite Mixte INSERM Univ Joseph Fourier, U438, F-38043 Grenoble 9, France; CHU Grenoble, Unite IRM, F-38043 Grenoble 9, France; CHU Grenoble, Serv Neuroradiol, F-38043 Grenoble 9, France	CEA; CHU Grenoble Alpes; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Esteve, F (corresponding author), CHU Grenoble, LRC CEA, Unite Mixte INSERM Univ Joseph Fourier, U438, BP 217, F-38043 Grenoble 9, France.	FEsteve@chu-grenoble.fr	Remy, Chantal/L-9459-2014; Szabo de Edelenyi, Fabien/F-2715-2017; Grand, Sylvie/L-7958-2014	Szabo de Edelenyi, Fabien/0000-0002-8487-6557; 				BLUM A, 1995, J RADIOL, V76, P441; BURGER PC, 1989, CANCER-AM CANCER SOC, V63, P2014, DOI 10.1002/1097-0142(19890515)63:10<2014::AID-CNCR2820631025>3.0.CO;2-L; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; DEMAEREL P, 1991, J COMPUT ASSIST TOMO, V15, P67, DOI 10.1097/00004728-199101000-00009; ElDeredy W, 1997, NMR BIOMED, V10, P99, DOI 10.1002/(SICI)1099-1492(199705)10:3<99::AID-NBM461>3.0.CO;2-#; FULHAM MJ, 1992, RADIOLOGY, V185, P675, DOI 10.1148/radiology.185.3.1438744; Furuya S, 1997, NMR BIOMED, V10, P25, DOI 10.1002/(SICI)1099-1492(199701)10:1<25::AID-NBM445>3.0.CO;2-M; Hagberg G, 1998, NMR BIOMED, V11, P148, DOI 10.1002/(SICI)1099-1492(199806/08)11:4/5<148::AID-NBM511>3.0.CO;2-4; HAGBERG G, 1995, MAGN RESON MED, V34, P242, DOI 10.1002/mrm.1910340216; Hand D. J, 1981, WILEY SERIES PROBABI; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; KUGEL H, 1992, RADIOLOGY, V183, P701, DOI 10.1148/radiology.183.3.1584924; Negendank WG, 1996, J NEUROSURG, V84, P449, DOI 10.3171/jns.1996.84.3.0449; OTT D, 1993, RADIOLOGY, V186, P745, DOI 10.1148/radiology.186.3.8430183; PAULUS W, 1989, CANCER, V64, P442, DOI 10.1002/1097-0142(19890715)64:2<442::AID-CNCR2820640217>3.0.CO;2-S; Preul MC, 1998, NMR BIOMED, V11, P192, DOI 10.1002/(SICI)1099-1492(199806/08)11:4/5<192::AID-NBM535>3.0.CO;2-3; Preul MC, 1996, NAT MED, V2, P323, DOI 10.1038/nm0396-323; REMY C, 1995, MAGNET RESON MED, V34, P508, DOI 10.1002/mrm.1910340404; Roser W, 1997, MAGN RESON MATER PHY, V5, P179, DOI 10.1007/BF02594580; SEGEBARTH CM, 1990, MAGN RESON MED, V13, P62, DOI 10.1002/mrm.1910130108; SIJENS PE, 1995, MAGNET RESON MED, V33, P818, DOI 10.1002/mrm.1910330612; Tate AR, 1998, NMR BIOMED, V11, P177, DOI 10.1002/(SICI)1099-1492(199806/08)11:4/5<177::AID-NBM534>3.0.CO;2-U; Usenius JP, 1996, NEUROREPORT, V7, P1597, DOI 10.1097/00001756-199607080-00013	23	116	118	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2000	6	11					1287	1289		10.1038/81401	http://dx.doi.org/10.1038/81401			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062544				2022-12-27	WOS:000165114800040
J	Radkov, SA; Kellam, P; Boshoff, C				Radkov, SA; Kellam, P; Boshoff, C			The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells	NATURE MEDICINE			English	Article							MULTICENTRIC CASTLEMANS-DISEASE; MICROVASCULAR ENDOTHELIAL-CELLS; PRIMARY EFFUSION LYMPHOMA; LARGE-TUMOR-ANTIGEN; DNA-SEQUENCES; GENE-PRODUCT; CYCLIN-E; EXPRESSION; PROTEIN; HUMAN-HERPESVIRUS-8	Kaposi sarcoma-associated herpesvirus (KSHV) is involved in the etiopathogenesis of Kaposi sarcoma and certain lymphoproliferative disorders. Open reading frame (ORF) 73 encodes the main immunogenic latent nuclear antigen (LNA-1) of KSHV. LNA-1 maintains the KSHV episome and tethers the viral genome to chromatin during mitosis. In addition, LNA-1 interacts with p53 and represses its transcriptional activity. Here we show that LNA-1 also interacts with the retinoblastoma protein. LNA-1 transactivated an artificial promoter carrying the cell cycle transcription factor E2F DNA-binding sequences and also upregulated the cyclin E (CCNE1) promoter, but not the B-myb (MYBL2) promoter. LNA-1 overcame the flat-cell phenotype induced by retinoblastoma protein in Saos2 cells. In cooperation with the cellular oncogene Harvey rat sarcoma viral oncogene homolog (Hras), LNA-I transformed primary rat embryo fibroblasts and rendered them tumorigenic. These findings indicate that LNA-I acts as a transcription co-factor and may contribute to KSHV-induced oncogenesis by targeting the retinoblastoma protein-E2F transcriptional regulatory pathway.	UCL, Wolfson Inst Biomed Res, CRC, Viral Oncol Grp, London WC1E 6AE, England; UCL, Wohl Vir Ctr, Dept Oncol, London WC1E 6AE, England; UCL, Wohl Vir Ctr, Dept Mol Pathol, London WC1E 6AE, England	University of London; University College London; University of London; University College London; University of London; University College London	Boshoff, C (corresponding author), UCL, Wolfson Inst Biomed Res, CRC, Viral Oncol Grp, Cruciform Bldg, London WC1E 6AE, England.	c.boshoff@ucl.ac.uk		Kellam, Paul/0000-0003-3166-4734				Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; Bennett JD, 1996, ONCOGENE, V13, P1073; Boshoff C, 1998, BLOOD, V91, P1671, DOI 10.1182/blood.V91.5.1671.1671_1671_1679; Boshoff C, 1998, NATURE, V391, P24, DOI 10.1038/34054; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Cotter MA, 1999, VIROLOGY, V264, P254, DOI 10.1006/viro.1999.9999; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Dupin N, 2000, BLOOD, V95, P1406, DOI 10.1182/blood.V95.4.1406.004k26_1406_1412; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Hamburger A W, 1980, Prog Clin Biol Res, V48, P23; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kellam P, 1997, J Hum Virol, V1, P19; Kellam P, 1999, J VIROL, V73, P5149, DOI 10.1128/JVI.73.6.5149-5155.1999; KEYOMARSI K, 1995, ONCOGENE, V11, P941; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Lee H, 1998, NAT MED, V4, P435, DOI 10.1038/nm0498-435; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; Panyutich EA, 1998, AIDS, V12, P467, DOI 10.1097/00002030-199805000-00007; Parravicini C, 2000, AM J PATHOL, V156, P743, DOI 10.1016/S0002-9440(10)64940-1; Radkov SA, 1997, J VIROL, V71, P8552, DOI 10.1128/JVI.71.11.8552-8562.1997; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staskus KA, 1999, J VIROL, V73, P4181, DOI 10.1128/JVI.73.5.4181-4187.1999; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Sturzl M, 1999, J NATL CANCER I, V91, P1725, DOI 10.1093/jnci/91.20.1725; Thomas JT, 1999, P NATL ACAD SCI USA, V96, P8449, DOI 10.1073/pnas.96.15.8449; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	45	387	404	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1121	1127		10.1038/80459	http://dx.doi.org/10.1038/80459			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017143				2022-12-27	WOS:000089674700036
J	Sabatakos, G; Sims, NA; Chen, J; Aoki, K; Kelz, MB; Amling, M; Bouali, Y; Mukhopadhyay, K; Ford, K; Nestler, EJ; Baron, R				Sabatakos, G; Sims, NA; Chen, J; Aoki, K; Kelz, MB; Amling, M; Bouali, Y; Mukhopadhyay, K; Ford, K; Nestler, EJ; Baron, R			Overexpression of Delta FosB transcription factor(s) increases bone formation and inhibits adipogenesis	NATURE MEDICINE			English	Article							C-FOS; GENE-EXPRESSION; ADIPOCYTE DIFFERENTIATION; OSTEOCALCIN GENE; TRANSGENIC MICE; CELLS; MOUSE; OSTEOPETROSIS; OSTEOCLAST; JUN	Members of the AP-1 family of transcription factors participate in the regulation of bone cell proliferation and differentiation. We report here a potent AP-1-related regulator of osteoblast function: Delta FosB, a naturally occurring truncated form of FosB that arises from alternative splicing of the fosB transcript and is expressed in osteoblasts. Overexpression of Delta FosB in transgenic mice leads to increased bone formation throughout the skeleton and a continuous post-developmental increase in bone mass, leading to osteosclerosis. In contrast, Delta FosB inhibits adipogenesis both in vivo and in vitro, and downregulates the expression of early markers of adipocyte differentiation. Because osteoblasts and adipocytes are thought to share a common precursor, it is concluded that Delta FosB transcriptionally regulates osteoblastogenesis, possibly at the expense of adipogenesis.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Orthopaed, New Haven, CT 06520 USA; Yale Univ, Sch Med, Lab Mol Psychiat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ctr Genes & Behav, New Haven, CT 06520 USA; Univ Hamburg, Sch Med, Dept Trauma Surg, D-22529 Hamburg, Germany; Hoechst Marion Roussel France, F-93235 Romainville, France	Yale University; Yale University; Yale University; Yale University; University of Hamburg	Baron, R (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, SHM IE-55,333 Cedar St, New Haven, CT 06520 USA.	roland.baron@yale.edu	Kelz, Max/E-4054-2010; Sims, Natalie Ann/A-7192-2012; AOKI, Kazuhiro/GRO-6475-2022	Kelz, Max/0000-0002-2803-6078; Sims, Natalie Ann/0000-0003-1421-8468; AOKI, Kazuhiro/0000-0001-6643-6315				ANDERSON RE, 1986, CALCIFIED TISSUE INT, V39, P252, DOI 10.1007/BF02555214; Aoki K, 1999, BONE, V25, P261, DOI 10.1016/S8756-3282(99)00174-X; ARNETT TR, 1986, ENDOCRINOLOGY, V119, P119, DOI 10.1210/endo-119-1-119; Banerjee C, 1996, ENDOCRINOLOGY, V137, P1991, DOI 10.1210/en.137.5.1991; Baron R.A., 1983, BONE HISTOMORPHOMETR, P13; BELLOWS CG, 1994, ENDOCRINOLOGY, V134, P2221, DOI 10.1210/en.134.5.2221; BELLOWS CG, 1990, DEV BIOL, V140, P132, DOI 10.1016/0012-1606(90)90060-V; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen JS, 1998, MOL PHARMACOL, V54, P495, DOI 10.1124/mol.54.3.495; Chen JS, 1997, J NEUROSCI, V17, P4933; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DORHEIM MA, 1993, J CELL PHYSIOL, V154, P317, DOI 10.1002/jcp.1041540215; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Gruda MC, 1996, ONCOGENE, V12, P2177; Hayman AR, 1996, DEVELOPMENT, V122, P3151; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Kelz MB, 1999, NATURE, V401, P272, DOI 10.1038/45790; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; QUARLES LD, 1992, J BONE MINER RES, V7, P683; Sabatakos G, 1998, BIOCHEM J, V334, P205, DOI 10.1042/bj3340205; Sambrock J, 1989, MOL CLONING LAB MANU, V1; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEIFERT MF, 1985, AM J ANAT, V172, P141, DOI 10.1002/aja.1001720204; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEPHENS JM, 1992, J MOL ENDOCRINOL, V9, P61, DOI 10.1677/jme.0.0090061; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; WANG ZQ, 1995, CANCER RES, V55, P6244; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0	37	270	282	0	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2000	6	9					985	990		10.1038/79683	http://dx.doi.org/10.1038/79683			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973317				2022-12-27	WOS:000089190500029
J	Repa, JJ; Mangelsdorf, DJ				Repa, JJ; Mangelsdorf, DJ			The liver X receptor gene team: Potential new players in atherosclerosis	NATURE MEDICINE			English	Review							HIGH-DENSITY-LIPOPROTEIN; PHOSPHOLIPID-TRANSFER PROTEIN; ABCA1 MESSENGER-RNA; E-DEFICIENT MICE; E KNOCKOUT MICE; APOLIPOPROTEIN-E; TANGIER-DISEASE; CHOLESTEROL EFFLUX; OXYSTEROL RECEPTORS; ARTERIAL-WALL	Liver X receptors (LXRs) are sterol-responsive transcription factors that regulate expression of genes involved in cholesterol metabolism and homeostasis. Maintenance of normal cholesterol levels has implicated the involvement of LXR-induced genes in the pathophysiology of atherosclerosis. The modulation of LXRs of their downstream targets may provide alternative therapeutic strategies for the management of this disease.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dept Physiol, Dallas, TX USA; Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dept Internal Med, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mangelsdorf, DJ (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA.	davo.mango@utsouthwestern.edu		Mangelsdorf, David/0000-0002-4355-0796; Repa, Joyce/0000-0001-5740-1954				Agellon LB, 2002, J BIOL CHEM, V277, P20131, DOI 10.1074/jbc.C200105200; Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P630, DOI 10.1161/01.ATV.0000014804.35824.DA; Assmann G, 2001, METABOLIC MOL BASES, P2937; Attie AD, 2001, J LIPID RES, V42, P1717; Babaev VR, 2000, J BIOL CHEM, V275, P26293, DOI 10.1074/jbc.M002423200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Cao GQ, 2002, J BIOL CHEM, V277, P39561, DOI 10.1074/jbc.M207187200; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Claudel T, 2001, P NATL ACAD SCI USA, V98, P2610, DOI 10.1073/pnas.041609298; Collins JL, 2002, J MED CHEM, V45, P1963, DOI 10.1021/jm0255116; Costet P, 2000, J BIOL CHEM, V275, P28240; Curtiss LK, 2000, CURR OPIN LIPIDOL, V11, P243, DOI 10.1097/00041433-200006000-00004; Dietschy JM, 2002, J BIOL CHEM, V277, P3801, DOI 10.1074/jbc.R100057200; Drobnik W, 2001, GASTROENTEROLOGY, V120, P1203, DOI 10.1053/gast.2001.23250; Evans M, 2002, CURR OPIN LIPIDOL, V13, P415, DOI 10.1097/00041433-200208000-00009; Fan JL, 2001, J BIOL CHEM, V276, P40071, DOI 10.1074/jbc.M105456200; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Foger B, 1997, J BIOL CHEM, V272, P27393, DOI 10.1074/jbc.272.43.27393; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Goldberg IJ, 1996, J LIPID RES, V37, P693; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; Groen AK, 2001, J CLIN INVEST, V108, P843, DOI 10.1172/JCI12473; Jaari S, 2001, COMP BIOCHEM PHYS B, V128, P781, DOI 10.1016/S1096-4959(01)00297-4; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Joyce CW, 2002, P NATL ACAD SCI USA, V99, P407, DOI 10.1073/pnas.012587699; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; Lee MH, 2001, CURR OPIN LIPIDOL, V12, P141, DOI 10.1097/00041433-200104000-00007; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Mak PA, 2002, J BIOL CHEM, V277, P31900, DOI 10.1074/jbc.M202993200; McDonnell DP, 1999, TRENDS ENDOCRIN MET, V10, P301, DOI 10.1016/S1043-2760(99)00177-0; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Merkel M, 2002, J BIOL CHEM, V277, P7405, DOI 10.1074/jbc.M107914200; Murthy S, 2002, J LIPID RES, V43, P1054, DOI 10.1194/jlr.M100358-JLR200; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Pentikainen MO, 2002, ARTERIOSCL THROM VAS, V22, P211, DOI 10.1161/hq0102.101551; Plosch T, 2002, J BIOL CHEM, V277, P33870, DOI 10.1074/jbc.M206522200; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; PLUMP AS, 1909, ARTERIOSCLER THROMB, V19, P1105; Reardon CA, 2001, CURR OPIN LIPIDOL, V12, P167, DOI 10.1097/00041433-200104000-00010; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rinninger F, 1998, J LIPID RES, V39, P1335; Rong JX, 2000, ANN MED, V32, P642, DOI 10.3109/07853890009002035; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9; Shimada M, 1996, P NATL ACAD SCI USA, V93, P7242, DOI 10.1073/pnas.93.14.7242; Singaraja RR, 2002, J CLIN INVEST, V110, P35, DOI 10.1172/JCI200215748; Sparrow CP, 2002, J BIOL CHEM, V277, P10021, DOI 10.1074/jbc.M108225200; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; van Dam MJ, 2002, LANCET, V359, P37, DOI 10.1016/S0140-6736(02)07277-X; Van Eck M, 2002, P NATL ACAD SCI USA, V99, P6298, DOI 10.1073/pnas.092327399; van Haperen R, 2000, ARTERIOSCL THROM VAS, V20, P1082, DOI 10.1161/01.ATV.20.4.1082; van Tol A, 2002, CURR OPIN LIPIDOL, V13, P135, DOI 10.1097/00041433-200204000-00004; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Whitney KD, 2001, J BIOL CHEM, V276, P43509, DOI 10.1074/jbc.M106155200; Wilson K, 2001, ARTERIOSCL THROM VAS, V21, P1809, DOI 10.1161/hq1101.097805; Yagyu H, 1999, J LIPID RES, V40, P1677; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]; Zhang Y, 2001, J BIOL CHEM, V276, P43018, DOI 10.1074/jbc.M107823200; Zhang Yuan, 2002, Mol Interv, V2, P78, DOI 10.1124/mi.2.2.78; Zhang Z, 2001, J LIPID RES, V42, P649; Zsigmond E, 1997, HUM GENE THER, V8, P1921, DOI 10.1089/hum.1997.8.16-1921	76	332	337	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2002	8	11					1243	1248		10.1038/nm1102-1243	http://dx.doi.org/10.1038/nm1102-1243			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12411951				2022-12-27	WOS:000179221200029
J	Kelly, G; Bell, A; Rickinson, A				Kelly, G; Bell, A; Rickinson, A			Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2	NATURE MEDICINE			English	Article							C-MYC; INITIAL-STAGES; GENE PROMOTER; STRAIN P3HR-1; LATENT GENES; EXPRESSION; CELLS; TRANSCRIPTION; PHENOTYPE; DELETION	Epstein-Barr virus (EBV) is etiologically linked to endemic Burkitt lymphoma (BL), but its contribution to lymphomagenesis, versus that of the chromosomal translocation leading to c-myc gene deregulation, remains unclear. The virus's growth-transforming (Latency III) program of gene expression is extinguished in tumor cells, and only a single viral protein, the EBV nuclear antigen (EBNA) 1, is expressed via the alternative Latency I program. It is not known if BL arises from a B-cell subset in which EBV naturally adopts a Latency I infection or if a clone with limited antigen expression has been selected from an EBV-transformed Latency III progenitor pool. Here we identify a subset of BL tumors in which the Latency III-associated EBNA promoter Wp is active and most EBNAs are expressed, but where a gene deletion has specifically abrogated the expression of EBNA2. This implies that BL can be selected from a Latency III progenitor and that the principal selection pressure is for downregulation of the c-Myc antagonist EBNA2.	Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England	Cancer Research UK; University of Birmingham	Rickinson, A (corresponding author), Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England.	a.b.rickinson@bham.ac.uk	Kelly, Gemma/AAG-6352-2020	Bell, Andrew/0000-0001-9520-4417				AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; ABBOT SD, 1990, J VIROL, V64, P2126, DOI 10.1128/JVI.64.5.2126-2134.1990; Babcock GJ, 2000, IMMUNITY, V13, P497, DOI 10.1016/S1074-7613(00)00049-2; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BORNKAMM GW, 1982, J VIROL, V43, P952, DOI 10.1128/JVI.43.3.952-968.1982; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; FAHRAEUS R, 1990, P NATL ACAD SCI USA, V87, P7390, DOI 10.1073/pnas.87.19.7390; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; Gavioli R, 2001, NAT CELL BIOL, V3, P283, DOI 10.1038/35060076; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; GREGORY CD, 1987, J IMMUNOL, V139, P313; Habeshaw G, 1999, J VIROL, V73, P965, DOI 10.1128/JVI.73.2.965-975.1999; Hinuma Y, 1967, J Virol, V1, P1045; JONES MD, 1984, EMBO J, V3, P813, DOI 10.1002/j.1460-2075.1984.tb01890.x; Kaiser C, 1999, J VIROL, V73, P4481, DOI 10.1128/JVI.73.5.4481-4484.1999; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; KHANNA R, 1994, INT IMMUNOL, V6, P639, DOI 10.1093/intimm/6.4.639; Khanna R, 2000, ANNU REV MICROBIOL, V54, P19, DOI 10.1146/annurev.micro.54.1.19; KIEFF E, 2001, FIELDS VIROLOGY, P2511; Komano J, 1998, J VIROL, V72, P9150, DOI 10.1128/JVI.72.11.9150-9156.1998; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; Nonkwelo C, 1996, J VIROL, V70, P623, DOI 10.1128/JVI.70.1.623-627.1996; Pajic A, 2001, INT J CANCER, V93, P810, DOI 10.1002/ijc.1404; PARKER BD, 1990, VIROLOGY, V179, P339, DOI 10.1016/0042-6822(90)90302-8; Polack A, 1996, P NATL ACAD SCI USA, V93, P10411, DOI 10.1073/pnas.93.19.10411; RABSON M, 1982, J VIROL, V44, P834, DOI 10.1128/JVI.44.3.834-844.1982; ROONEY CM, 1986, J NATL CANCER I, V77, P681, DOI 10.1093/jnci/77.3.681; ROWE M, 1995, EUR J IMMUNOL, V25, P1374, DOI 10.1002/eji.1830250536; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Ruf IK, 1999, MOL CELL BIOL, V19, P1651; SAMPLE J, 1991, P NATL ACAD SCI USA, V88, P6343, DOI 10.1073/pnas.88.14.6343; SCHAEFER BC, 1991, P NATL ACAD SCI USA, V88, P6550, DOI 10.1073/pnas.88.15.6550; SCHAEFER BC, 1995, P NATL ACAD SCI USA, V92, P10565, DOI 10.1073/pnas.92.23.10565; Staege MS, 2002, P NATL ACAD SCI USA, V99, P4550, DOI 10.1073/pnas.072495599; SUNG NS, 1991, J VIROL, V65, P2164, DOI 10.1128/JVI.65.5.2164-2169.1991; TIERNEY RJ, 1994, J VIROL, V68, P7374, DOI 10.1128/JVI.68.11.7374-7385.1994; WANG F, 1990, J VIROL, V64, P3407, DOI 10.1128/JVI.64.7.3407-3416.1990; WOISETSCHLAEGER M, 1990, P NATL ACAD SCI USA, V87, P1725, DOI 10.1073/pnas.87.5.1725; WOISETSCHLAEGER M, 1991, P NATL ACAD SCI USA, V88, P3942, DOI 10.1073/pnas.88.9.3942; Yoo L, 2000, J VIROL, V74, P11115, DOI 10.1128/JVI.74.23.11115-11120.2000; Yoo LI, 1997, J VIROL, V71, P9134, DOI 10.1128/JVI.71.12.9134-9142.1997; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; ZIMBERSTROBL U, 1991, J VIROL, V65, P415, DOI 10.1128/JVI.65.1.415-423.1991	45	162	165	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1098	1104		10.1038/nm758	http://dx.doi.org/10.1038/nm758			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12219084				2022-12-27	WOS:000178311000036
J	Gonsalves, G				Gonsalves, G			Next steps on ART	NATURE MEDICINE			English	Letter									Gay Mens Hlth Crisis Inc, New York, NY 10011 USA		Gonsalves, G (corresponding author), Gay Mens Hlth Crisis Inc, New York, NY 10011 USA.							2002, NAT MED, V8, P429	1	2	2	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2002	8	7					644	644		10.1038/nm0702-644	http://dx.doi.org/10.1038/nm0702-644			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12091884	Bronze			2022-12-27	WOS:000176495200004
J	Blower, SM; Aschenbach, AN; Gershengorn, HB; Kahn, JO				Blower, SM; Aschenbach, AN; Gershengorn, HB; Kahn, JO			Predicting the unpredictable: Transmission of drug-resistant HIV	NATURE MEDICINE			English	Article							POTENT ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE; TUBERCULOSIS; SUSCEPTIBILITY; CONSEQUENCES; STRATEGIES; INFECTION; INDINAVIR; REGIMENS; FAILURE	We use a mathematical model to understand (from 1996 to 2001) and to predict (from 2001 to 2005) the evolution of the epidemic of drug-resistant HIV in San Francisco. We predict the evolutionary trajectories for 1,000 different drug-resistant strains with each strain having a different fitness relative to a drug-sensitive strain. We calculate that the current prevalence of resistance is high, and predict it will continue to rise. In contrast, we calculate that transmission of resistance is currently low, and predict it will remain low. We show that the epidemic of resistance is being generated mainly by the conversion of drug-sensitive cases to drug-resistant cases, and not by the transmission of resistant strains. We also show that transmission of resistant strains has not increased the overall number of new HIV infections. Our results indicate that transmission of resistant strains is, and will remain, a relatively minor public health problem.	Univ Calif Los Angeles, Sch Med, Dept Biomath, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, AIDS Inst, Los Angeles, CA 90024 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; San Francisco Gen Hosp, San Francisco, CA 94110 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center	Blower, SM (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biomath, Los Angeles, CA 90024 USA.	sblower@biomath.ucla.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH059037] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41935] Funding Source: Medline; NIMH NIH HHS [P30MH59037] Funding Source: Medline; PHS HHS [U01A41531] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Blower S, 2001, AIDS, V15, P1309, DOI 10.1097/00002030-200107060-00014; Blower S, 1999, NAT MED, V5, P358, DOI 10.1038/7328; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; Blower SM, 1998, J MOL MED, V76, P624, DOI 10.1007/s001090050260; BLOWER SM, 1994, INT STAT REV, V62, P229, DOI 10.2307/1403510; Blower SM, 2000, SCIENCE, V287, P650, DOI 10.1126/science.287.5453.650; Blower SM, 1998, NAT MED, V4, P673, DOI 10.1038/nm0698-673; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; Blower SM, 2001, P NATL ACAD SCI USA, V98, P3618, DOI 10.1073/pnas.061029998; Catania JA, 2000, SCIENCE, V290, P717, DOI 10.1126/science.290.5492.717; *CDC, 1998, MMWR-MORBID MORTAL W, V48, P45; *CDC, 2001, MMWR-MORBID MORTAL W, V50, P117; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P773; Conway B, 2001, AIDS, V15, P1269, DOI 10.1097/00002030-200107060-00008; Descamps D, 2000, JAMA-J AM MED ASSOC, V283, P205, DOI 10.1001/jama.283.2.205; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706; Gallant JE, 2000, JAMA-J AM MED ASSOC, V283, P1329, DOI 10.1001/jama.283.10.1329; Gazzard B, 1998, LANCET, V352, P314, DOI 10.1016/S0140-6736(98)04084-7; Ghani AC, 2001, AIDS, V15, P1133, DOI 10.1097/00002030-200106150-00008; HANSEL A, 2001, AIDS, V26, P191; Havlir DV, 2000, JAMA-J AM MED ASSOC, V283, P229, DOI 10.1001/jama.283.2.229; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; HOGG RS, 1998, JAMA-J AM MED ASSOC, V279, P50; Huang W, 2001, J INFECT DIS, V183, P1455, DOI 10.1086/320192; IMAN RL, 1988, RISK ANAL, V8, P71, DOI 10.1111/j.1539-6924.1988.tb01155.x; Kleijnen JPC, 1999, RELIAB ENG SYST SAFE, V65, P147, DOI 10.1016/S0951-8320(98)00091-X; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Little SJ, 2001, BRIT MED J, V322, P1074, DOI 10.1136/bmj.322.7294.1074; Little SJ, 1999, JAMA-J AM MED ASSOC, V282, P1142, DOI 10.1001/jama.282.12.1142; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paredes R, 2000, ARCH INTERN MED, V160, P1123, DOI 10.1001/archinte.160.8.1123; Pialoux G, 1998, NEW ENGL J MED, V339, P1269, DOI 10.1056/NEJM199810293391802; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Salomon H, 2000, AIDS, V14, pF17, DOI 10.1097/00002030-200001280-00003; *SAN FRANC DEP PUB, 2000, ANN SURV REP; Stoddart CA, 2001, NAT MED, V7, P712, DOI 10.1038/89090; Tchetgen E, 2001, J ACQ IMMUN DEF SYND, V26, P118, DOI 10.1097/00126334-200102010-00003; Yerly S, 1999, LANCET, V354, P729, DOI 10.1016/S0140-6736(98)12262-6	39	185	187	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2001	7	9					1016	1020		10.1038/nm0901-1016	http://dx.doi.org/10.1038/nm0901-1016			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533704				2022-12-27	WOS:000170853300026
J	Jain, RK				Jain, RK			Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy	NATURE MEDICINE			English	Editorial Material							ENDOTHELIAL GROWTH-FACTOR; BLOOD-VESSELS; SOLID TUMORS; CANCER; CHEMOTHERAPY; ABLATION; DELIVERY		Massachusetts Gen Hosp, Dept Radiat Oncol, Steele Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Jain, RK (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Steele Lab, Boston, MA 02114 USA.		Jain, Rakesh K/I-1384-2017	Jain, Rakesh K/0000-0001-7571-3548				Baish JW, 2000, CANCER RES, V60, P3683; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Browder T, 2000, CANCER RES, V60, P1878; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Fidler IJ, 2001, JNCI-J NATL CANCER I, V93, P1040, DOI 10.1093/jnci/93.14.1040; Gasparini G, 1998, CLIN CANCER RES, V4, P2625; Griffon-Etienne G, 1999, CANCER RES, V59, P3776; GULLINO PM, 1978, JNCI-J NATL CANCER I, V61, P639; Hansen-Algenstaedt N, 2000, CANCER RES, V60, P4556; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Jain RK, 1998, NAT MED, V4, P655, DOI 10.1038/nm0698-655; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; Kadambi A, 2001, CANCER RES, V61, P2404; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Kozin SV, 2001, CANCER RES, V61, P39; Lee CG, 2000, CANCER RES, V60, P5565; Ma JG, 2001, CANCER RES, V61, P5491; Milosevic M, 2001, CANCER RES, V61, P6400; Murata R, 1997, INT J RADIAT ONCOL, V37, P1107, DOI 10.1016/S0360-3016(96)00628-1; Ruoslahti E, 2000, SEMIN CANCER BIOL, V10, P435, DOI 10.1006/scbi.2000.0334; St Croix B, 2000, SCIENCE, V289, P1197; Teicher BA, 1996, CANCER METAST REV, V15, P247, DOI 10.1007/BF00437479; Thorpe PE, 2000, CANCER J, V6, pS237; Tsuzuki Y, 2000, CANCER RES, V60, P6248; UEHARA H, 2001, AM ASS CANC RES 92 A; Viloria-Petit A, 2001, CANCER RES, V61, P5090; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765	28	1607	1725	9	140	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2001	7	9					987	989		10.1038/nm0901-987	http://dx.doi.org/10.1038/nm0901-987			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533692				2022-12-27	WOS:000170853300012
J	Saha, K; Zhang, JC; Gupta, A; Dave, R; Yimen, M; Zerhouni, B				Saha, K; Zhang, JC; Gupta, A; Dave, R; Yimen, M; Zerhouni, B			Isolation of primary HIV-1 that target CD8(+) T Lymphocytes using CD8 as a receptor	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; GP120 ENVELOPE GLYCOPROTEIN; HERPESVIRUS-SAIMIRI; CELL CLONES; V3 LOOP; SOLUBLE FACTOR(S); TYPE-1 INFECTION; BETA-CHEMOKINES; AIDS PATIENTS; IN-VIVO	HIV-1 use CD4 receptors to infect their primary targets, CD4(+) cells, whereas CD8(+) cells have a protective role against HIV-1. We recently isolated HIV-1-producing CD8(+) clones from two AIDS patients. Here we show that although HIV-1 produced by CD8(+) cells maintained the ability to infect CD4(+) cells, these viruses were able to infect CD8(+) cells independent of CD4. Evidence indicates that these viruses used CD8 as a receptor to infect CD8(+) cells. First, expression of CD8 was downmodulated after infection. Second, anti-CD8 antibodies blocked viral entry and replication in CD8(+) cells. Finally, resistant cells became susceptible after expression of CD8. Although these viruses used CXCR4 to enter CD4(+) cells, it seems that infection of CD8(+) cells was independent of CXCR4 or CCR5 co-receptors. Novel changes were observed in envelope sequences of CD8-tropic viruses. These results provide initial evidence that HIV-1 can mutate to infect CD8(+) cells using CD8 as a receptor.	Childrens Res Inst, Dept Pediat, Div Mol Med, Columbus, OH 43205 USA; Childrens Res Inst, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43205 USA; Ohio State Univ, Med Ctr, Columbus, OH 43205 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University	Saha, K (corresponding author), Childrens Res Inst, Dept Pediat, Div Mol Med, Columbus, OH 43205 USA.				NIAID NIH HHS [AI-42715, AI-44974] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI042715, R29AI044974] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cao J, 1997, J VIROL, V71, P9808, DOI 10.1128/JVI.71.12.9808-9812.1997; Douglas NW, 1996, AIDS, V10, P39, DOI 10.1097/00002030-199601000-00006; Dumonceaux J, 1998, J VIROL, V72, P512, DOI 10.1128/JVI.72.1.512-519.1998; Flamand L, 1998, P NATL ACAD SCI USA, V95, P3111, DOI 10.1073/pnas.95.6.3111; Hoffman TL, 1998, P NATL ACAD SCI USA, V95, P11360, DOI 10.1073/pnas.95.19.11360; Hung CS, 1999, J VIROL, V73, P8216, DOI 10.1128/JVI.73.10.8216-8226.1999; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; Kaneko H, 1997, J VIROL, V71, P8918, DOI 10.1128/JVI.71.11.8918-8922.1997; Kitchen SG, 1998, J VIROL, V72, P9054, DOI 10.1128/JVI.72.11.9054-9060.1998; KOITO A, 1994, J VIROL, V68, P2253, DOI 10.1128/JVI.68.4.2253-2259.1994; Kolchinsky P, 1999, J VIROL, V73, P8120, DOI 10.1128/JVI.73.10.8120-8126.1999; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LaBranche CC, 1999, J VIROL, V73, P10310, DOI 10.1128/JVI.73.12.10310-10319.1999; McMichael AJ, 1997, ANNU REV IMMUNOL, V15, P271, DOI 10.1146/annurev.immunol.15.1.271; MEINL E, 1995, IMMUNOL TODAY, V16, P55, DOI 10.1016/0167-5699(95)80087-5; Moriuchi H, 1996, P NATL ACAD SCI USA, V93, P15341, DOI 10.1073/pnas.93.26.15341; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Reeves JD, 1999, J VIROL, V73, P7795, DOI 10.1128/JVI.73.9.7795-7804.1999; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; ROBEY WG, 1985, SCIENCE, V228, P593, DOI 10.1126/science.2984774; Ross TM, 1998, P NATL ACAD SCI USA, V95, P7682, DOI 10.1073/pnas.95.13.7682; Saha K, 1998, J VIROL, V72, P876, DOI 10.1128/JVI.72.1.876-881.1998; Saha K, 1996, J IMMUNOL, V157, P3876; Saha K, 1996, NAT MED, V2, P1272, DOI 10.1038/nm1196-1272; Saha K, 1999, J VIROL, V73, P7891, DOI 10.1128/JVI.73.9.7891-7898.1999; Saha K, 1997, J IMMUNOL METHODS, V206, P21, DOI 10.1016/S0022-1759(97)00080-X; SAHA K, UNPUB EVIDENCE PRODU; Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992	30	81	89	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					65	72		10.1038/83365	http://dx.doi.org/10.1038/83365			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135618				2022-12-27	WOS:000166243100037
J	Torrance, CJ; Jackson, PE; Montgomery, E; Kinzler, KW; Vogelstein, B; Wissner, A; Nunes, M; Frost, P; Discafani, CM				Torrance, CJ; Jackson, PE; Montgomery, E; Kinzler, KW; Vogelstein, B; Wissner, A; Nunes, M; Frost, P; Discafani, CM			Combinatorial chemoprevention of intestinal neoplasia	NATURE MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FAMILIAL ADENOMATOUS POLYPOSIS; HEREDITARY COLORECTAL-CANCER; HUMAN COLON-CARCINOMA; ALPHA-DIFLUOROMETHYLORNITHINE; TYROSINE KINASE; EXPRESSION; INHIBITION; CYCLOOXYGENASE-2	A combination of two drugs afforded remarkable protection from intestinal neoplasia in APC(Min/+) mice, a murine model of human familial adenomatous polyposis (FAP). One of the drugs was sulindac, a prototypical non-steroidal anti-inflammatory drug with established chemopreventative activity. The second drug was EKI-569, a newly developed, irreversible inhibitor of the epidermal growth factor receptor kinase. Although 100% of the untreated APC(Min/+) mice developed -20 polyps, nearly half the mice treated with these two agents developed no polyps at all. These results suggest a powerful strategy for the chemoprevention of human colonic neoplasia.	Wyeth Ayerst Res, Oncol & Immunoinflammatory Res, Pearl River, NY 10965 USA; Howard Hughes Med Inst, Baltimore, MD 21231 USA; Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21205 USA	Pfizer; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University	Frost, P (corresponding author), Wyeth Ayerst Res, Oncol & Immunoinflammatory Res, Pearl River, NY 10965 USA.	frostp@war.wyeth.com			NATIONAL CANCER INSTITUTE [R01CA057345, R37CA057345, P50CA062924] Funding Source: NIH RePORTER; NCI NIH HHS [CA 57345, CA 62924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADTIAN I, 1999, DRUGS, V58, P663; BeazerBarclay Y, 1996, CARCINOGENESIS, V17, P1757, DOI 10.1093/carcin/17.8.1757; Bjorkman David J., 1998, American Journal of Medicine, V105, p8S, DOI 10.1016/S0002-9343(98)00069-2; Boolbol SK, 1996, CANCER RES, V56, P2556; Brenner DE, 2000, J CELL BIOCHEM, P121; Carbone PP, 1998, CANCER EPIDEM BIOMAR, V7, P907; Casamassimi A, 2000, ANN ONCOL, V11, P319, DOI 10.1023/A:1008350811639; Ciardiello F, 1999, CLIN CANCER RES, V5, P909; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; De Angelis E, 1999, INT J ONCOL, V14, P437; Discafani CM, 1999, BIOCHEM PHARMACOL, V57, P917, DOI 10.1016/S0006-2952(98)00356-6; DuBois RN, 1996, J GASTROENTEROL, V31, P898, DOI 10.1007/BF02358623; Giardiello FM, 1996, GASTROENTEROL CLIN N, V25, P349, DOI 10.1016/S0889-8553(05)70251-X; Grann VR, 2000, CANCER J SCI AM, V6, P13; HAERI R, 2000, CANCER RES, V60, P560; Hawk E, 1999, CANCER-AM CANCER SOC, V86, P2551, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2551::AID-CNCR12>3.3.CO;2-T; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Jacoby RF, 2000, CANCER RES, V60, P1864; Johnson S C, 2000, Adv Intern Med, V45, P1; Kapitanovic S, 1997, GASTROENTEROLOGY, V112, P1103, DOI 10.1016/S0016-5085(97)70120-3; Karnes WE, 1998, GASTROENTEROLOGY, V114, P930, DOI 10.1016/S0016-5085(98)70312-9; Kinoshita T, 1999, BBA-MOL CELL BIOL L, V1438, P120, DOI 10.1016/S1388-1981(99)00034-7; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kirschbaum MH, 2000, J CELL BIOCHEM, P52; Kokoska ER, 1999, J SURG RES, V84, P186, DOI 10.1006/jsre.1999.5640; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Laken SJ, 1998, NAT BIOTECHNOL, V16, P1352, DOI 10.1038/4333; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; Li H, 1999, CARCINOGENESIS, V20, P425, DOI 10.1093/carcin/20.3.425; Maurer CA, 1998, HUM PATHOL, V29, P771, DOI 10.1016/S0046-8177(98)90444-0; Normanno N, 1998, CANCER DETECT PREV, V22, P62; Osborne MP, 1999, SURG CLIN N AM, V79, P1207, DOI 10.1016/S0039-6109(05)70069-4; Ozgul C, 1997, Acta Physiol Hung, V85, P121; Papadimitrakopoulou VA, 1999, ARCH OTOLARYNGOL, V125, P1083, DOI 10.1001/archotol.125.10.1083; RAO CV, 1991, CANCER RES, V51, P4528; Reddy BS, 1999, CARCINOGENESIS, V20, P1645, DOI 10.1093/carcin/20.8.1645; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; ROY SN, 1985, CANCER RES, V45, P3856; Rudbeck L, 1998, BIOTECHNIQUES, V25, P588, DOI 10.2144/98254bm09; SAEKI T, 1992, CANCER RES, V52, P3467; Shirai H, 1995, ANTICANCER RES, V15, P2889; Slack James L., 1999, Current Opinion in Oncology, V11, P9, DOI 10.1097/00001622-199901000-00003; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Toma S, 1999, ANN ONCOL, V10, P95; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Winde G, 1998, CANCER LETT, V134, P201, DOI 10.1016/S0304-3835(98)00254-7; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407; Woodburn JR, 1999, PHARMACOL THERAPEUT, V82, P241, DOI 10.1016/S0163-7258(98)00045-X	50	429	469	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2000	6	9					1024	1028		10.1038/79534	http://dx.doi.org/10.1038/79534			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973323				2022-12-27	WOS:000089190500035
J	Ortiz-Urda, S; Thyagarajan, B; Keene, DR; Lin, Q; Fang, M; Calos, MP; Khavari, PA				Ortiz-Urda, S; Thyagarajan, B; Keene, DR; Lin, Q; Fang, M; Calos, MP; Khavari, PA			Stable nonviral genetic correction of inherited human skin disease	NATURE MEDICINE			English	Article							DYSTROPHIC EPIDERMOLYSIS-BULLOSA; ANCHORING FIBRILS; STEM-CELLS; KERATINOCYTES; INTEGRATION; EXPRESSION; COL7A1; MICE	Current gene-transfer technologies display limitations in achieving effective gene delivery. Among these limitations are difficulties in stably integrating large corrective sequences into the genomes of long-lived progenitor-cell populations. Current larger-capacity viral vectors suffer from biosafety concerns, whereas plasmid-based approaches have poor efficiency of stable gene transfer(1,2). These barriers hinder genetic correction of many severe inherited human diseases, such as the blistering skin disorder recessive dystrophic epidermolysis bullosa (RDEB)(3), caused by mutations in the large COL7A1 gene. To circumvent these barriers, we used the phiC31 bacteriophage integrase(4-6), which stably integrates large DNA sequences containing a specific 285-base-pair attB sequence into genomic 'pseudo-attP sites'. phiC31 integrase-based gene transfer stably integrated the COL7A1 cDNA into genomes of primary epidermal progenitor cells from four unrelated RDEB patients. Skin regenerated using these cells displayed stable correction of hallmark RDEB disease features, including Type VII collagen protein expression, anchoring fibril formation and dermal-epidermal cohesion. These findings establish a practical approach to nonviral genetic correction of severe human genetic disorders requiring stable genomic integration of large DNA sequences.	VA Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Shriners Hosp Children, Portland, OR 97201 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Stanford University	Khavari, PA (corresponding author), VA Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA.				NHLBI NIH HHS [HL68112] Funding Source: Medline; NIAMS NIH HHS [AR44012] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068112, R56HL068112] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR044012] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Bruckner-Tuderman L, 1999, MATRIX BIOL, V18, P43, DOI 10.1016/S0945-053X(98)00007-9; Burton EA, 2002, CELL, V108, P5, DOI 10.1016/S0092-8674(01)00626-2; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; CHOATE KA, 1997, HUM GENE THER, V8, P1671; CHRISTIANO AM, 1994, GENOMICS, V21, P169, DOI 10.1006/geno.1994.1239; Evans JT, 2000, HUM GENE THER, V11, P2331, DOI 10.1089/104303400750038444; Freiberg RA, 1997, J CLIN INVEST, V99, P2610, DOI 10.1172/JCI119449; FREIBERG RA, 1997, HUM MOL GENET, V6, P937; Groth AC, 2000, P NATL ACAD SCI USA, V97, P5995, DOI 10.1073/pnas.090527097; Heinonen S, 1999, J CELL SCI, V112, P3641; Hengge UR, 1996, J CLIN INVEST, V97, P2911, DOI 10.1172/JCI118750; KEENE DR, 1987, J CELL BIOL, V104, P611, DOI 10.1083/jcb.104.3.611; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kochanek S, 1999, HUM GENE THER, V10, P2451, DOI 10.1089/10430349950016807; Kolodka TM, 1998, P NATL ACAD SCI USA, V95, P4356, DOI 10.1073/pnas.95.8.4356; KUHSTOSS S, 1991, J MOL BIOL, V222, P897, DOI 10.1016/0022-2836(91)90584-S; MARINKOVICH MP, 1999, DERMATOLOGY GEN MED, V1, P690; Mathor MB, 1996, P NATL ACAD SCI USA, V93, P10371, DOI 10.1073/pnas.93.19.10371; Medalie DA, 1996, J INVEST DERMATOL, V107, P121, DOI 10.1111/1523-1747.ep12298363; Pfutzner W, 1999, J INVEST DERMATOL, V112, P552; Robbins PB, 2001, P NATL ACAD SCI USA, V98, P5193, DOI 10.1073/pnas.091484998; Sclimenti CR, 2001, NUCLEIC ACIDS RES, V29, P5044, DOI 10.1093/nar/29.24.5044; Seitz CS, 1999, GENE THER, V6, P42, DOI 10.1038/sj.gt.3300809; STOCKSCHLADER MAR, 1994, GENE THER, V1, P317; Thyagarajan B, 2001, MOL CELL BIOL, V21, P3926, DOI 10.1128/MCB.21.12.3926-3934.2001	26	179	200	1	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2002	8	10					1166	1170		10.1038/nm766	http://dx.doi.org/10.1038/nm766			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12244305				2022-12-27	WOS:000178311000045
J	Alexopoulou, L; Thomas, V; Schnare, M; Lobet, Y; Anguita, J; Schoen, RT; Medzhitov, R; Fikrig, E; Flavell, RA				Alexopoulou, L; Thomas, V; Schnare, M; Lobet, Y; Anguita, J; Schoen, RT; Medzhitov, R; Fikrig, E; Flavell, RA			Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice	NATURE MEDICINE			English	Article							TOLL-LIKE RECEPTORS; SURFACE PROTEIN-A; LYME-DISEASE VACCINE; INNATE IMMUNITY; CUTTING EDGE; MICROBIAL LIPOPROTEINS; HOST-DEFENSE; RECOGNITION; ACTIVATION; TLR4	The Lyme disease vaccine is based on the outer-surface lipoprotein ( OspA) of the pathogen Borrelia burgdorferi, and 95% of vaccine recipients develop substantial titers of antibodies against OspA. Here, we identified seven individuals with very low antibody titers after vaccination ( low responders). The macrophages of low responders produced less tumor necrosis factor-alpha and interleukin-6 after OspA stimulation and had lower cell-surface expression of Toll-like receptor (TLR) 1 as compared to normal cells, but normal expression of TLR2. TLRs activate innate responses to pathogens, and TLR2 recognizes lipoproteins and peptidoglycan (PGN). After OspA immunization, mice genetically deficient in either TLR2 (TLR2(-/-)) or TLR1 (TLR1(-/-)) produced low titers of antibodies against OspA. Notably, macrophages from TLR2(-/-) mice were unresponsive to OspA and PGN, whereas those from TLR1(-/-) mice responded normally to PGN but not to OspA. These data indicate that TLR1 and TLR2 are required for lipoprotein recognition and that defects in the TLR1/2 signaling pathway may account for human hyporesponsiveness to OspA vaccination.	Yale Univ, Sch Med, Dept Internal Med, Rheumatol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; GlaxoSmithKline Biol, Rixensart, Belgium; Univ N Carolina, Dept Biol, Charlotte, NC 28223 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; GlaxoSmithKline; University of North Carolina; University of North Carolina Charlotte	Fikrig, E (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Rheumatol Sect, New Haven, CT 06510 USA.		Alexopoulou, Lena/A-5041-2017; Anguita, Juan/D-5432-2011	Alexopoulou, Lena/0000-0003-4619-697X; Anguita, Juan/0000-0003-2061-7182				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; ARMSTRONG AL, 1992, AM J TROP MED HYG, V47, P249, DOI 10.4269/ajtmh.1992.47.249; BARTHOLD SW, 1991, AM J PATHOL, V139, P263; BARTHOLD SW, 1993, AM J PATHOL, V143, P959; BARTHOLD SW, 1995, LAB INVEST, V72, P127; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; de Silva AM, 1999, INFECT IMMUN, V67, P30, DOI 10.1128/IAI.67.1.30-35.1999; Erdile LF, 1997, VACCINE, V15, P988, DOI 10.1016/S0264-410X(96)00295-2; ERDILE LF, 1993, INFECT IMMUN, V61, P81, DOI 10.1128/IAI.61.1.81-90.1993; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FIKRIG E, 1994, J INFECT DIS, V169, P568, DOI 10.1093/infdis/169.3.568; FIKRIG E, 1990, SCIENCE, V250, P553, DOI 10.1126/science.2237407; Hajjar AM, 2001, J IMMUNOL, V166, P15, DOI 10.4049/jimmunol.166.1.15; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hoshino K, 1999, J IMMUNOL, V162, P3749; Imler JL, 2001, TRENDS CELL BIOL, V11, P304, DOI 10.1016/S0962-8924(01)02004-9; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; MA Y, 1994, INFECT IMMUN, V62, P3663, DOI 10.1128/IAI.62.9.3663-3671.1994; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Modlin RL, 2001, J ALLERGY CLIN IMMUN, V108, pS104, DOI 10.1067/mai.2001.118299; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; PASPARAKIS M, 1995, CYTOKINES PRACTICAL, P297; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; SCHAIBLE UE, 1990, P NATL ACAD SCI USA, V87, P3768, DOI 10.1073/pnas.87.10.3768; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Seiler KP, 1996, CURR OPIN IMMUNOL, V8, P503, DOI 10.1016/S0952-7915(96)80038-0; Shapiro ED, 2000, CLIN INFECT DIS, V31, P533, DOI 10.1086/313982; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; Steere AC, 2001, NEW ENGL J MED, V345, P115, DOI 10.1056/NEJM200107123450207; Takeda K, 2001, GENES CELLS, V6, P733, DOI 10.1046/j.1365-2443.2001.00458.x; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; TELFORD SR, 1995, J INFECT DIS, V171, P1368, DOI 10.1093/infdis/171.5.1368; Thanassi WT, 2000, ANN INTERN MED, V132, P661, DOI 10.7326/0003-4819-132-8-200004180-00009; Thomas V, 2001, INFECT IMMUN, V69, P3359, DOI 10.1128/IAI.69.5.3359-3371.2001; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; WEIS JJ, 1994, INFECT IMMUN, V62, P4632, DOI 10.1128/IAI.62.10.4632-4636.1994; Wooten RM, 2002, J IMMUNOL, V168, P348, DOI 10.4049/jimmunol.168.1.348	42	334	350	0	18	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2002	8	8					878	884		10.1038/nm732	http://dx.doi.org/10.1038/nm732			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12091878				2022-12-27	WOS:000177200900035
J	Zuany-Amorim, C; Sawicka, E; Manlius, C; Le Moine, AL; Brunet, LR; Kemeny, DM; Bowen, G; Rook, G; Walker, C				Zuany-Amorim, C; Sawicka, E; Manlius, C; Le Moine, AL; Brunet, LR; Kemeny, DM; Bowen, G; Rook, G; Walker, C			Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells	NATURE MEDICINE			English	Article							IN-VITRO; INFECTION; MICE; PROLIFERATION; LYMPHOCYTE; RESPONSES; INHIBIT; GAMMA	Allergic asthma is a chronic inflammatory disease and despite the introduction of potent and effective drugs, the prevalence has increased substantially over the past few decades(1). The explanation that has attracted the most attention is the 'hygiene hypothesis', which suggests that the increase in allergic diseases is caused by a cleaner environment and fewer childhood infections(2-4). Indeed, certain mycobacterial strains can cause a shift from T-helper cell 2 (Th2) to Th1 immune responses, which may subsequently prevent the development of allergy in mice(5-7). Although the reconstitution of the balance between Th1 and Th2 is an attractive theory, it is unlikely to explain the whole story, as autoimmune diseases characterized by Th1 responses can also benefit from treatment with mycobacteria and their prevalence has also increased in parallel to allergies(8). Here we show that treatment of mice with SRP299, a killed Mycobacterium vaccae-suspension, gives rise to allergen-specific CD4(+)CD45RB(Lo) regulatory T cells, which confer protection against airway inflammation. This specific inhibition was mediated through interleukin-10 (IL-10) and transforming growth factor-beta (TGF-beta), as antibodies against IL-10 and TGF-beta completely reversed the inhibitory effect of CD4(+)CD45RB(Lo) T cells. Thus, regulatory T cells generated by mycobacteria treatment may have an essential role in restoring the balance of the immune system to prevent and treat allergic diseases.	Novartis Pharmaceut Ltd, Novartis Horsham Res Ctr, Horsham, W Sussex, England; Kings Coll London, Rayne Inst, London WC2R 2LS, England; Free Univ Brussels, Expt Immunol Lab, B-1050 Brussels, Belgium; UCL Royal Free & Univ Coll Med Sch, Windeyer Inst Med Sci, Dept Med Microbiol, London, England; SR Pharma, Ctr Point, London, England	Novartis; University of London; King's College London; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of London; University College London; UCL Medical School	Zuany-Amorim, C (corresponding author), Novartis Pharmaceut Ltd, Novartis Horsham Res Ctr, Wimblehurst Rd, Horsham, W Sussex, England.	claudia.zuany-amorim_fromond@pharma.novartis.com		Rook, Graham/0000-0002-8041-8110				Arkwright PD, 2001, J ALLERGY CLIN IMMUN, V107, P531, DOI 10.1067/mai.2001.113081; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; CAMPOROTA L, 2000, AM J RESP CRIT CARE, V161, pA477; Cottrez F, 2000, J IMMUNOL, V165, P4848, DOI 10.4049/jimmunol.165.9.4848; Davies JD, 1999, J IMMUNOL, V163, P5353; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Herz U, 1998, J ALLERGY CLIN IMMUN, V102, P867, DOI 10.1016/S0091-6749(98)70030-2; Hopkin JM, 2001, PROG R RES, V31, P226; Levings MK, 2001, J EXP MED, V193, P1295, DOI 10.1084/jem.193.11.1295; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; Roncarolo MG, 2001, J EXP MED, V193, pF5, DOI 10.1084/jem.193.2.F5; Roncarolo MG, 2000, CURR OPIN IMMUNOL, V12, P676, DOI 10.1016/S0952-7915(00)00162-X; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Shirtcliffe PM, 2001, AM J RESP CRIT CARE, V163, P1410, DOI 10.1164/ajrccm.163.6.2003050; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Wang CC, 1998, IMMUNOLOGY, V93, P307; Zuany-Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265; ZuanyAmorim C, 1996, J IMMUNOL, V157, P377	24	427	462	0	22	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2002	8	6					625	629		10.1038/nm0602-625	http://dx.doi.org/10.1038/nm0602-625			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042815				2022-12-27	WOS:000175907300035
J	Volpert, OV; Zaichuk, T; Zhou, W; Reiher, F; Ferguson, TA; Stuart, PM; Amin, M; Bouck, NP				Volpert, OV; Zaichuk, T; Zhou, W; Reiher, F; Ferguson, TA; Stuart, PM; Amin, M; Bouck, NP			Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium derived factor	NATURE MEDICINE			English	Article							CELL-SURFACE TRAFFICKING; GROWTH-FACTOR; DYNAMIC BALANCE; APOPTOSIS; EXPRESSION; LIGAND; INDUCTION; SURVIVAL; MECHANISMS; INHIBITOR	Natural inhibitors of angiogenesis are able to block pathological neovascularization without harming the preexisting vasculature. Here we show that two such inhibitors, thrombospondin-1 and pigment epithelium derived factor, derive specificity for remodeling vessels from their dependence on Fas/Fas ligand ( FasL)-mediated apoptosis to block angiogenesis. Both inhibitors upregulated FasL on endothelial cells. Expression of the essential partner of FasL, Fas/CD95 receptor, was low on quiescent endothelial cells and vessels but greatly enhanced by inducers of angiogenesis, thereby specifically sensitizing the stimulated cells to apoptosis by inhibitor-generated FasL. The anti-angiogenic activity of thrombospondin-1 and pigment epithelium derived factor both in vitro and in vivo was dependent on this dual induction of Fas and FasL and the resulting apoptosis. This example of cooperation between pro- and anti-angiogenic factors in the inhibition of angiogenesis provides one explanation for the ability of inhibitors to select remodeling capillaries for destruction.	Northwestern Univ, Sch Med, Dept Urol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Med, Chicago, IL USA; Northwestern Univ, Sch Med, Dept Microbiol & Immunol, Chicago, IL USA; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA; Washington Univ, Dept Ophthalmol & Visual Sci, St Louis, MO 63130 USA	Northwestern University; Northwestern University; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Washington University (WUSTL)	Volpert, OV (corresponding author), Northwestern Univ, Sch Med, Dept Urol, Chicago, IL 60611 USA.	olgavolp@northwestern.edu		Volpert, Olga/0000-0003-1381-5543	NCI NIH HHS [CA64239, R01 CA52750] Funding Source: Medline; NEI NIH HHS [EY12707, EY12826] Funding Source: Medline; PHS HHS [R01 68003-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052750, R01CA064239] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012707, R01EY012826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alberdi E, 1999, J BIOL CHEM, V274, P31605, DOI 10.1074/jbc.274.44.31605; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Becerra SP, 1997, ADV EXP MED BIOL, V425, P223; Benjamin LE, 2000, CANCER METAST REV, V19, P75, DOI 10.1023/A:1026552415576; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bossi G, 2000, EUR J CELL BIOL, V79, P539, DOI 10.1078/0171-9335-00077; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Carmeliet, 1999, Curr Interv Cardiol Rep, V1, P322; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Dejana E, 1999, EXP CELL RES, V252, P13, DOI 10.1006/excr.1999.4601; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Filleur S, 2001, GENE DEV, V15, P1373, DOI 10.1101/gad.193501; Freyberg MA, 2001, BIOCHEM BIOPH RES CO, V286, P141, DOI 10.1006/bbrc.2001.5314; Fukuo K, 1997, HEART VESSELS, P81; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Golstein P, 2000, SCIENCE, V288, P2328, DOI 10.1126/science.288.5475.2328; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jimenez B, 2001, ONCOGENE, V20, P3443, DOI 10.1038/sj.onc.1204464; Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Larsson H, 2000, CANCER RES, V60, P6723; Lucas R, 1998, BLOOD, V92, P4730; Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Okada Y, 2001, CYTOKINE, V15, P66, DOI 10.1006/cyto.2001.0916; PASSANITI A, 1992, LAB INVEST, V67, P519; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Sata M, 1998, NAT MED, V4, P415, DOI 10.1038/nm0498-415; Sata M, 2000, ARTERIOSCL THROM VAS, V20, P309, DOI 10.1161/01.ATV.20.2.309; Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com; Sodeman T, 2000, AM J PHYSIOL-GASTR L, V278, pG992, DOI 10.1152/ajpgi.2000.278.6.G992; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Volpert OV, 2000, CANCER METAST REV, V19, P87, DOI 10.1023/A:1026560618302; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951	46	338	371	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2002	8	4					349	357		10.1038/nm0402-349	http://dx.doi.org/10.1038/nm0402-349			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927940				2022-12-27	WOS:000174704800026
J	Bykov, VJN; Issaeva, N; Shilov, A; Hultcrantz, M; Pugacheva, E; Chumakov, P; Bergman, J; Wiman, KG; Selivanova, G				Bykov, VJN; Issaeva, N; Shilov, A; Hultcrantz, M; Pugacheva, E; Chumakov, P; Bergman, J; Wiman, KG; Selivanova, G			Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound	NATURE MEDICINE			English	Article							DNA-BINDING FUNCTION; C-TERMINAL PEPTIDE; HUMAN CANCER-CELLS; REGULATORY REGION; CORE DOMAIN; RESCUE; ACTIVATION; MUTATIONS; THERAPY; REACTIVATION	The tumor suppressor p53 inhibits tumor growth primarily through its ability to induce apoptosis. Mutations in p53 occur in at least 50% of human tumors. We hypothesized that reactivation of mutant p53 in such tumors should trigger massive apoptosis and eliminate the tumor cells. To test this, we screened a library of low-molecular-weight compounds in order to identify compounds that can restore wild-type function to mutant p53. We found one compound capable of inducing apoptosis in human tumor cells through restoration of the transcriptional transactivation function to mutant p53. This molecule, named PRIMA-1, restored sequence-specific DNA binding and the active conformation to mutant p53 proteins in vitro and in living cells. PRIMA-1 rescued both DNA contact and structural p53 mutants. In vivo studies in mice revealed an antitumor effect with no apparent toxicity. This molecule may serve as a lead compound for the development of anticancer drugs targeting mutant p53.	Karolinska Hosp, Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, S-10401 Stockholm, Sweden; RAN, Inst Cytol & Genet, Novosibirsk, Russia; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow, Russia; Karolinska Inst, Novum, Dept Biosci, Huddinge, Sweden	Karolinska Institutet; Karolinska University Hospital; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Hosp, Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, S-10401 Stockholm, Sweden.		Wiman, Klas/AAB-8399-2021; Issaeva, Natalia/K-4577-2019; Chumakov, Peter M/E-7731-2014	Wiman, Klas/0000-0002-7113-524X; Chumakov, Peter/0000-0002-8078-2908; Issaeva, Natalia/0000-0001-5483-6610; Selivanova, Galina/0000-0002-8698-4332; Pugacheva, Elena/0000-0001-9814-7446; Nakade Bykov, Vladimir/0000-0002-7199-8942				ABARZUA P, 1995, CANCER RES, V55, P3490; Asker C, 1999, BIOCHEM BIOPH RES CO, V265, P1, DOI 10.1006/bbrc.1999.1446; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cohen PA, 1999, FEBS LETT, V463, P179, DOI 10.1016/S0014-5793(99)01603-8; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hansen S, 1996, J BIOL CHEM, V271, P3917; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; Selivanova G, 1998, SEMIN CANCER BIOL, V8, P369, DOI 10.1006/scbi.1998.0099; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SELIVANOVA G, 2001, TUMOR SUPPRESSING VI, P397; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; WIMAN KG, 1991, ONCOGENE, V6, P1633	31	805	836	0	95	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2002	8	3					282	288		10.1038/nm0302-282	http://dx.doi.org/10.1038/nm0302-282			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875500				2022-12-27	WOS:000174139500034
J	Bolay, H; Reuter, U; Dunn, AK; Huang, ZH; Boas, DA; Moskowitz, MA				Bolay, H; Reuter, U; Dunn, AK; Huang, ZH; Boas, DA; Moskowitz, MA			Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model	NATURE MEDICINE			English	Article							GENE-RELATED PEPTIDE; CEREBRAL BLOOD-FLOW; VASCULAR HEAD PAIN; SPREADING DEPRESSION; SUBSTANCE-P; DURA-MATER; POSSIBLE PATHWAY; RAT; STIMULATION; NEURONS	Although the trigeminal nerve innervates the meninges and participates in the genesis of migraine headaches, triggering mechanisms remain controversial and poorly understood. Here we establish a link between migraine aura and headache by demonstrating that cortical spreading depression, implicated in migraine visual aura, activates trigeminovascular afferents and evokes a series of cortical meningeal and brainstem events consistent with the development of headache. Cortical spreading depression caused long-lasting blood-flow enhancement selectively within the middle meningeal artery dependent upon trigeminal and parasympathetic activation, and plasma protein leakage within the dura mater in part by a neurokinin-1-receptor mechanism. Our findings provide a neural mechanism by which extracerebral cephalic blood flow couples to brain events; this mechanism explains vasodilation during headache and links intense neurometabolic brain activity with the transmission of headache pain by the trigeminal nerve.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Stroke & Neurovasc Regulat Lab, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,NMR Ctr, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Moskowitz, MA (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Stroke & Neurovasc Regulat Lab, Boston, MA 02114 USA.		Moskowitz, Michael A/D-9916-2011; Bolay, Hayrunnisa/ABG-8829-2020; Dunn, Andrew/I-9527-2014	Bolay, Hayrunnisa/0000-0002-3357-7733; Reuter, Uwe/0000-0002-8527-0725	NINDS NIH HHS [K25 NS41291, 2P01 NS10828, 1R29NS38842] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K25NS041291, P01NS010828, R29NS038842] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen GV, 1996, BRAIN RES, V715, P125, DOI 10.1016/0006-8993(95)01580-9; Burstein R, 2000, ANN NEUROL, V47, P614, DOI 10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.3.CO;2-E; BUZZI MG, 1990, BRIT J PHARMACOL, V99, P202, DOI 10.1111/j.1476-5381.1990.tb14679.x; Cao Y, 1999, ARCH NEUROL-CHICAGO, V56, P548, DOI 10.1001/archneur.56.5.548; Cumberbatch MJ, 1999, BRIT J PHARMACOL, V126, P1478, DOI 10.1038/sj.bjp.0702444; DRUMMOND PD, 1983, J NEUROL NEUROSUR PS, V46, P611, DOI 10.1136/jnnp.46.7.611; DRUMMOND PD, 1993, BRAIN, V116, P233, DOI 10.1093/brain/116.1.233; Dunn AK, 2001, J CEREBR BLOOD F MET, V21, P195, DOI 10.1097/00004647-200103000-00002; Ebersberger A, 2001, ANN NEUROL, V49, P7, DOI 10.1002/1531-8249(200101)49:1<7::AID-ANA4>3.3.CO;2-B; EDVINSSON L, 1981, J PHYSIOL-LONDON, V318, P251; FEINDEL W, 1960, NEUROLOGY, V10, P555, DOI 10.1212/WNL.10.6.555; FERRARI MD, 1993, TRENDS PHARMACOL SCI, V14, P129, DOI 10.1016/0165-6147(93)90084-W; GOADSBY PJ, 1987, AM J PHYSIOL, V253, pR270, DOI 10.1152/ajpregu.1987.253.2.R270; GOBEL N, 2000, CEPHALALGIA, V20, P287; Grafstein B, 2000, ANN NEUROL, V47, P18, DOI 10.1002/1531-8249(200001)47:1<18::AID-ANA6>3.3.CO;2-E; Graham JR, 1938, ARCH NEURO PSYCHIATR, V39, P737, DOI 10.1001/archneurpsyc.1938.02270040093005; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; KRAIG RP, 1978, NEUROSCIENCE, V3, P1045, DOI 10.1016/0306-4522(78)90122-7; KUSCHINSKY W, 1978, PHYSIOL REV, V58, P656, DOI 10.1152/physrev.1978.58.3.656; LAMBERT GA, 1984, J NEUROSURG, V61, P307, DOI 10.3171/jns.1984.61.2.0307; LAURITZEN M, 1984, BRAIN, V107, P447, DOI 10.1093/brain/107.2.447; LAURITZEN M, 1990, J CEREBR BLOOD F MET, V10, P115, DOI 10.1038/jcbfm.1990.14; Leao AA, 1944, J NEUROPHYSIOL, V7; LEE WS, 1994, BRIT J PHARMACOL, V112, P920, DOI 10.1111/j.1476-5381.1994.tb13168.x; LIUCHEN LY, 1983, NEUROSCIENCE, V9, P803, DOI 10.1016/0306-4522(83)90268-3; MARKOWITZ S, 1987, J NEUROSCI, V7, P4129, DOI 10.1523/jneurosci.07-12-04129.1987; MAYBERG M, 1981, SCIENCE, V213, P228, DOI 10.1126/science.6166046; MOSKOWITZ MA, 1988, HEADACHE, V28, P584, DOI 10.1111/j.1526-4610.1988.hed2809584.x; MOSKOWITZ MA, 1991, NEUROLOGY, V41, P182, DOI 10.1212/WNL.41.2_Part_1.182; MOSKOWITZ MA, 1984, ANN NEUROL, V16, P157, DOI 10.1002/ana.410160202; MOSKOWITZ MA, 1993, J NEUROSCI, V13, P1167, DOI 10.1523/jneurosci.13-03-01167.1993; OCONNOR TP, 1986, J NEUROSCI, V6, P2200; Penfield W, 1940, ARCH NEURO PSYCHIATR, V44, P43, DOI 10.1001/archneurpsyc.1940.02280070051003; Ray BS, 1940, ARCH SURG-CHICAGO, V41, P813, DOI 10.1001/archsurg.1940.01210040002001; Richter F, 1998, EUR J NEUROSCI, V10, P135; SPENCER SE, 1990, BRAIN RES, V534, P149, DOI 10.1016/0006-8993(90)90125-U; Strassman AM, 1996, NATURE, V384, P560, DOI 10.1038/384560a0; SUZUKI N, 1988, J CEREBR BLOOD F MET, V8, P697, DOI 10.1038/jcbfm.1988.117; SUZUKI N, 1989, NEUROSCIENCE, V31, P427, DOI 10.1016/0306-4522(89)90385-0; SUZUKI N, 1990, J CEREBR BLOOD F MET, V10, P383, DOI 10.1038/jcbfm.1990.68; SUZUKI N, 1990, ACTA PHYSIOL SCAND, V138, P307, DOI 10.1111/j.1748-1716.1990.tb08851.x; UDDMAN R, 1989, J AUTONOM NERV SYST, V26, P69, DOI 10.1016/0165-1838(89)90109-4; Williamson DJ, 1997, CEPHALALGIA, V17, P518, DOI 10.1046/j.1468-2982.1997.1704518.x; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765	45	830	884	0	80	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2002	8	2					136	142		10.1038/nm0202-136	http://dx.doi.org/10.1038/nm0202-136			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821897				2022-12-27	WOS:000173600600022
J	Lemjabbar, H; Basbaum, C				Lemjabbar, H; Basbaum, C			Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells	NATURE MEDICINE			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN-COUPLED RECEPTORS; PSEUDOMONAS-AERUGINOSA; CYSTIC-FIBROSIS; STREPTOCOCCUS-PNEUMONIAE; INTESTINAL MUCIN; EGF RECEPTOR; LUNG; TRANSACTIVATION; SEQUESTRATION	In the lungs of cystic fibrosis patients, overproduction of mucus leads to morbidity and mortality by obstructing airflow and shielding bacteria from antibiotics. Here we demonstrate that overproduction of mucus is a direct result of the activation of mucin gene expression by Grampositive bacteria. Bacterial lipoteichoic acid activates the platelet-activating factor receptor, which is G protein-coupled. This results in activation of a disintegrin and metalloproteinase (ADAM10), kuzbanian, cleavage of pro heparin-binding epidermal growth factor and activation of the epidermal growth factor receptor. Unlike responses in macrophages, the epithelial-cell response to lipoteichoic acid does not require Toll-like receptor 2 or 4.	Univ Calif San Francisco, Program Biomed Sci, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Basbaum, C (corresponding author), Univ Calif San Francisco, Program Biomed Sci, Cardiovasc Res Inst, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43726, HL24136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Albert DH, 1996, SHOCK, V6, P112, DOI 10.1097/00024382-199608000-00006; BOAT TF, 1994, TXB RESP MED, P1418; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; Cundell DR, 1996, ADV EXP MED BIOL, V416, P89; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dohrman A, 1998, BBA-MOL BASIS DIS, V1406, P251, DOI 10.1016/S0925-4439(98)00010-6; FINKBEINER WE, 1988, AM J PATHOL, V131, P290; Gum JR, 1997, BIOCHEM J, V325, P259, DOI 10.1042/bj3250259; GUM JR, 1992, J BIOL CHEM, V267, P21375; Guzman K, 1995, BIOCHEM BIOPH RES CO, V217, P412, DOI 10.1006/bbrc.1995.2792; Hardie WD, 1999, PEDIATR DEVEL PATHOL, V2, P415, DOI 10.1007/s100249900144; Ishii I, 1998, J BIOL CHEM, V273, P9878, DOI 10.1074/jbc.273.16.9878; KUAN SF, 1987, CANCER RES, V47, P5715; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200; Mograbi B, 1997, EUR CYTOKINE NETW, V8, P73; Oliver A, 2000, SCIENCE, V288, P1251, DOI 10.1126/science.288.5469.1251; Opitz B, 2001, J BIOL CHEM, V276, P22041, DOI 10.1074/jbc.M010481200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; STAHLMAN MT, 1988, LAB INVEST, V59, P25; STGEORGE JA, 1991, AM J RESP CELL MOL, V4, P95, DOI 10.1165/ajrcmb/4.2.95; Taddei F, 1997, NATURE, V387, P700, DOI 10.1038/42696; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279	30	269	283	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2002	8	1					41	46		10.1038/nm0102-41	http://dx.doi.org/10.1038/nm0102-41			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	507XQ	11786905				2022-12-27	WOS:000173056900029
J	Shipp, MA; Ross, KN; Tamayo, P; Weng, AP; Kutok, JL; Aguiar, RCT; Gaasenbeek, M; Angelo, M; Reich, M; Pinkus, GS; Ray, TS; Koval, MA; Last, KW; Norton, A; Lister, TA; Mesirov, J; Neuberg, DS; Lander, ES; Aster, JC; Golub, TR				Shipp, MA; Ross, KN; Tamayo, P; Weng, AP; Kutok, JL; Aguiar, RCT; Gaasenbeek, M; Angelo, M; Reich, M; Pinkus, GS; Ray, TS; Koval, MA; Last, KW; Norton, A; Lister, TA; Mesirov, J; Neuberg, DS; Lander, ES; Aster, JC; Golub, TR			Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning	NATURE MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; NF-KAPPA-B; PROGNOSTIC-SIGNIFICANCE; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; THERAPEUTIC TARGET; APOPTOSIS; RECEPTOR; PROTEIN; DIFFERENTIATION	Diffuse large B-cell lymphoma (DLBCL), the most common lymphoid malignancy in adults, is curable in less than 50% of patients. Prognostic models based on pre-treatment characteristics, such as the International Prognostic Index (IPI), are currently used to predict outcome in DLBCL. However, clinical outcome models identify neither the molecular basis of clinical heterogeneity, nor specific therapeutic targets. We analyzed the expression of 6,817 genes in diagnostic tumor specimens from DLBCL patients who received cyclophosphamide, adriamycin, vincristine and prednisone (CHOP)-based chemotherapy, and applied a supervised learning prediction method to identify cured versus fatal or refractory disease. The algorithm classified two categories of patients with very different five-year overall survival rates (70% versus 12%). The model also effectively delineated patients within specific IPI risk categories who were likely to be cured or to die of their disease. Genes implicated in DLBCL outcome included some that regulate responses to B-cell-receptor signaling, critical serine/threonine phosphorylation pathways and apoptosis. Our data indicate that supervised learning classification techniques can predict outcome in DLBCL and identify rational targets for intervention.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; MIT, Whitehead Inst Biomed Res, Ctr Genome Res, Cambridge, MA 02139 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA USA; St Bartholomews Hosp, Imperial Canc Res Fund, Med Oncol Unit, London, England; St Bartholomews Hosp, Pathol Unit, London, England; Univ W Indies, Dept Comp Sci Math & Phys, Bridgetown, Barbados; MIT, Dept Biol, Cambridge, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Cancer Research UK; University of London; Queen Mary University London; University of London; Queen Mary University London; University West Indies Mona Jamaica; University of the West Indies Open Campus; Massachusetts Institute of Technology (MIT)	Shipp, MA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.		Mesirov, Jill/AGF-7626-2022; Aster, Jon C/B-6857-2009; Weng, Andrew P/I-5015-2014	Reich, Michael/0000-0003-4735-5514; Weng, Andrew/0000-0001-7394-5425				Aguiar RCT, 2000, BLOOD, V96, P4328, DOI 10.1182/blood.V96.13.4328.h8004328_4328_4334; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Chan WC, 1997, BLOOD, V89, P3909; CLEARY ML, 1986, CELL, V44, P97, DOI 10.1016/0092-8674(86)90488-5; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Finger LR, 1997, GENE, V197, P177, DOI 10.1016/S0378-1119(97)00260-6; Gascoyne RD, 1997, BLOOD, V90, P244; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HUBERTY CJ, 1994, APPL DISCRIMINANT AN; Ilangumaran S, 1999, LEUKEMIA LYMPHOMA, V35, P455, DOI 10.1080/10428199909169610; Kim DH, 1998, BLOOD, V92, P2484, DOI 10.1182/blood.V92.7.2484.2484_2484_2494; King LB, 1999, J IMMUNOL, V162, P2655; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Kramer MHH, 1998, BLOOD, V92, P3152, DOI 10.1182/blood.V92.9.3152.421a07_3152_3162; Kuang AA, 1999, EUR J IMMUNOL, V29, P3722, DOI 10.1002/(SICI)1521-4141(199911)29:11<3722::AID-IMMU3722>3.0.CO;2-N; Kuppers R, 1999, NEW ENGL J MED, V341, P1520; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Lerner A, 2000, LEUKEMIA LYMPHOMA, V37, P39, DOI 10.3109/10428190009057627; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Manning CD, 1999, BRIT J PHARMACOL, V128, P1393, DOI 10.1038/sj.bjp.0702911; Matarrese P, 2000, INT J CANCER, V85, P545, DOI 10.1002/(SICI)1097-0215(20000215)85:4<545::AID-IJC17>3.0.CO;2-N; MISCHAK H, 1991, J IMMUNOL, V147, P3981; Moller MB, 2000, LEUKEMIA, V14, P898, DOI 10.1038/sj.leu.2401761; RUEGG CL, 1995, J IMMUNOL, V154, P4434; Saeki H, 1999, J IMMUNOL, V162, P2472; Salven P, 1997, BLOOD, V90, P3167, DOI 10.1182/blood.V90.8.3167; Shipp MA, 1999, J CLIN ONCOL, V17, P423, DOI 10.1200/JCO.1999.17.1.423; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; Shipp Margaret A., 1997, P2165; Sommers CL, 1999, J EXP MED, V190, P1427, DOI 10.1084/jem.190.10.1427; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Teicher BA, 1999, ADV ENZYME REGUL, V39, P313, DOI 10.1016/S0065-2571(98)00026-0; Terol MJ, 1998, J CLIN ONCOL, V16, P35, DOI 10.1200/JCO.1998.16.1.35; TESTI R, 1994, IMMUNOL TODAY, V15, P479, DOI 10.1016/0167-5699(94)90193-7; Wang JX, 1999, CANCER RES, V59, P2766; Wellmann A, 2000, BLOOD, V96, P398; Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000; Xue YT, 1997, EUR J IMMUNOL, V27, P2048, DOI 10.1002/eji.1830270832; Yakushijin Y, 1998, BLOOD, V91, P4282, DOI 10.1182/blood.V91.11.4282.411k34_4282_4291; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Zhang H, 2000, J BIOL CHEM, V275, P11092, DOI 10.1074/jbc.275.15.11092; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	45	1758	1863	4	196	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2002	8	1					68	74		10.1038/nm0102-68	http://dx.doi.org/10.1038/nm0102-68			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	507XQ	11786909				2022-12-27	WOS:000173056900033
J	Narula, J; Acio, ER; Narula, N; Samuels, LE; Fyfe, B; Wood, D; Fitzpatrick, JM; Raghunath, PN; Tomaszewski, JE; Kelly, C; Steinmetz, N; Green, A; Tait, JF; Leppo, J; Blankenberg, FG; Jain, D; Strauss, HW				Narula, J; Acio, ER; Narula, N; Samuels, LE; Fyfe, B; Wood, D; Fitzpatrick, JM; Raghunath, PN; Tomaszewski, JE; Kelly, C; Steinmetz, N; Green, A; Tait, JF; Leppo, J; Blankenberg, FG; Jain, D; Strauss, HW			Annexin-V imaging for noninvasive detection of cardiac allograft rejection	NATURE MEDICINE			English	Article							MEMBRANE PHOSPHOLIPID ASYMMETRY; CELL-DEATH; IN-SITU; PHOSPHATIDYLSERINE EXPRESSION; APOPTOSIS; IDENTIFICATION; MYOCYTES; INJURY; HEARTS; VIVO	Heart transplant rejection is characterized pathologically by myocyte necrosis and apoptosis associated with interstitial! mononuclear cell infiltration. Any one of these components: can be targeted for noninvasive detection of transplant rejection. During apoptotic cell death, phosphatidylserine, a phospholipid that is normally confined to the inner leaflet of cell membrane bilayer, gets exteriorized. Technetium-99m-labeled annexin-V, an endogenous protein that has high affinity for binding to phosphatidylserine, has been administered intravenously for noninvasive identification of apoptotic cell death. In the present study of 18 cardiac allograft recipients, 13 patients had negative and five had positive myocardial uptake of annexin. These latter five demonstrated at least moderate transplant rejection and caspase-3 staining, suggesting apoptosis in their biopsy specimens. This study reveals the clinical feasibility and safety of annexin-V imaging for noninvasive detection of transplant rejection by targeting cell membrane phospholipid alterations that are commonly associated with the process of apoptosis.	Med Coll Penn & Hahnemann Univ, Philadelphia, PA 19102 USA; Hosp Univ Penn, Philadelphia, PA 19104 USA; Thesius Imaging Corp, Cambridge, MA USA; Univ Washington, Seattle, WA 98195 USA; Univ Massachusetts, Worcester, MA 01605 USA; Stanford Univ, Med Ctr, Stanford, CA 94305 USA	Drexel University; University of Pennsylvania; Pennsylvania Medicine; University of Washington; University of Washington Seattle; University of Massachusetts System; University of Massachusetts Worcester; Stanford University	Narula, J (corresponding author), Med Coll Penn & Hahnemann Univ, Philadelphia, PA 19102 USA.	jagat.narula@drexel.edu						Billingham M E, 1990, J Heart Transplant, V9, P587; Blankenberg FG, 1998, P NATL ACAD SCI USA, V95, P6349, DOI 10.1073/pnas.95.11.6349; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; HAMMOND EH, 1989, J HEART TRANSPLANT, V8, P430; Hofstra L, 2000, LANCET, V356, P209, DOI 10.1016/S0140-6736(00)02482-X; Johnson LL, 2000, CIRCULATION, V102, P404; Kanoh M, 1999, CIRCULATION, V99, P2757, DOI 10.1161/01.CIR.99.21.2757; KASINA S, 1991, J NUCL MED, V32, P1445; Laguens RP, 1996, J HEART LUNG TRANSPL, V15, P911; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; NARULA N, 2000, MODERN PATHOL, V13, pA52; Ohno M, 1998, CIRCULATION, V98, P1422, DOI 10.1161/01.CIR.98.14.1422; Petrov A, 2000, CIRCULATION, V102, P544; Puig M, 2000, J NUCL CARDIOL, V7, P132, DOI 10.1016/S1071-3581(00)90033-3; Strauss HW, 2000, LANCET, V356, P180, DOI 10.1016/S0140-6736(00)02474-0; Szabolcs MJ, 1998, TRANSPLANTATION, V65, P804, DOI 10.1097/00007890-199803270-00007; TAIT JF, 1994, J LAB CLIN MED, V123, P741; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	22	271	282	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2001	7	12					1347	1352		10.1038/nm1201-1347	http://dx.doi.org/10.1038/nm1201-1347			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726976				2022-12-27	WOS:000172610300041
J	DeGiorgio, LA; Konstantinov, KN; Lee, SC; Hardin, JA; Volpe, BT; Diamond, B				DeGiorgio, LA; Konstantinov, KN; Lee, SC; Hardin, JA; Volpe, BT; Diamond, B			A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus	NATURE MEDICINE			English	Article							SUBUNIT MESSENGER-RNAS; CEREBROSPINAL-FLUID; DISEASE-ACTIVITY; GENE-EXPRESSION; NIGRAL NEURONS; HUMAN BRAIN; BINDING; AUTOANTIBODIES; PHENCYCLIDINE; DEGENERATION	In systemic lupus erythematosus, antibodies against double-stranded DNA are a major contributor to renal disease. We have previously demonstrated that the pentapeptide Asp/Glu-TrpAsp/Glu-Tyr-Ser/Gly is a molecular mimic of double-stranded DNA. This sequence is also present in the extracellular domain of murine and human NMDA (N-methyl-D-aspartate) receptor subunits NR2a and NR2b. Here we show that the NR2 receptor is recognized by both murine and human anti-DNA antibodies. Moreover, anti-DNA antibodies with this cross-reactivity mediate apoptotic death of neurons in vivo and in vitro. Finally, we show that the cerebrospinal fluid of a patient with systemic lupus erythematosus contains these antibodies and also mediates neuronal death via an apoptotic pathway. These observations indicate that lupus antibodies cross-react with DNA and NMDA receptors, gain access to cerebrospinal fluid and may mediate non-thrombotic and non-vasculitic abnormalities of the central nervous system.	Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA; Cornell Univ, Weill Med Coll, Burke Med Res Inst, Dept Neurol & Neurosci, White Plains, NY USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Cornell University	Diamond, B (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.	diamond@aecom.yu.edu	volpe, b/U-8409-2019	Volpe, Bruce/0000-0002-1098-1848	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049126] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR049126] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akbarian S, 1996, J NEUROSCI, V16, P19; BELL CL, 1991, ARTHRITIS RHEUM, V34, P432, DOI 10.1002/art.1780340408; BLUESTEIN HG, 1983, HUM PATHOL, V14, P424, DOI 10.1016/S0046-8177(83)80287-1; Budhai L, 1996, J CLIN INVEST, V98, P1585, DOI 10.1172/JCI118952; CARR RI, 1975, J RHEUMATOL, V2, P184; Cavalheiro EA, 2001, P NATL ACAD SCI USA, V98, P5947, DOI 10.1073/pnas.121179198; CHAN TM, 1995, CLIN EXP IMMUNOL, V100, P506; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; DeGiorgio LA, 1999, NEUROSCIENCE, V90, P79, DOI 10.1016/S0306-4522(98)00428-X; DeGiorgio LA, 2000, BRAIN RES, V874, P137, DOI 10.1016/S0006-8993(00)02545-2; Downen M, 1999, GLIA, V28, P114, DOI 10.1002/(SICI)1098-1136(199911)28:2<114::AID-GLIA3>3.0.CO;2-O; Gahring LC, 2001, J IMMUNOL, V166, P1433, DOI 10.4049/jimmunol.166.3.1433; Gaynor B, 1997, P NATL ACAD SCI USA, V94, P1955, DOI 10.1073/pnas.94.5.1955; Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532; GOLOMBEK SJ, 1986, ARTHRITIS RHEUM, V29, P1090, DOI 10.1002/art.1780290906; GonzalezCrespo MR, 1995, BRIT J RHEUMATOL, V34, P1055; Hansen C, 1996, CLIN EXP RHEUMATOL, V14, pS59; HANSON VG, 1992, J EXP MED, V176, P565, DOI 10.1084/jem.176.2.565; HE XP, 2000, NEURON, V20, P7307; JACOB L, 1987, P NATL ACAD SCI USA, V84, P2956, DOI 10.1073/pnas.84.9.2956; JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301; Jentsch JD, 1999, NEUROPSYCHOPHARMACOL, V20, P201, DOI 10.1016/S0893-133X(98)00060-8; KATZ JB, 1994, J EXP MED, V180, P925, DOI 10.1084/jem.180.3.925; Kosinski CM, 1998, J COMP NEUROL, V390, P63; Kowal C, 1999, EUR J IMMUNOL, V29, P1901, DOI 10.1002/(SICI)1521-4141(199906)29:06<1901::AID-IMMU1901>3.0.CO;2-L; Kozora E, 1996, ARTHRITIS RHEUM, V39, P2035, DOI 10.1002/art.1780391213; Kuppenbender KD, 2000, J COMP NEUROL, V419, P407, DOI 10.1002/(SICI)1096-9861(20000417)419:4<407::AID-CNE1>3.0.CO;2-I; Lefkowith JB, 1996, J CLIN INVEST, V98, P1373, DOI 10.1172/JCI118924; LIMPANASITHIKUL W, 1995, J IMMUNOL, V155, P967; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; Monaghan DT, 1997, J PHARMACOL EXP THER, V280, P614; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Olney JW, 1999, J PSYCHIAT RES, V33, P523, DOI 10.1016/S0022-3956(99)00029-1; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; Putterman C, 1998, J EXP MED, V188, P29, DOI 10.1084/jem.188.1.29; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; Scherzer CR, 1998, J COMP NEUROL, V390, P75, DOI 10.1002/(SICI)1096-9861(19980105)390:1<75::AID-CNE7>3.0.CO;2-N; Sharma TA, 1999, J PHARMACOL EXP THER, V289, P1041; Skerry TM, 2001, TRENDS PHARMACOL SCI, V22, P174, DOI 10.1016/S0165-6147(00)01642-4; Spatz L, 1997, METHODS, V11, P70, DOI 10.1006/meth.1996.0389; STANDAERT DG, 1994, J COMP NEUROL, V343, P1, DOI 10.1002/cne.903430102; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; VIARD JP, 1992, AUTOIMMUNITY, V12, P61, DOI 10.3109/08916939209146131; Volpe BT, 1998, NEUROSCIENCE, V83, P741, DOI 10.1016/S0306-4522(97)00424-7; Volpe BT, 1997, ANN NY ACAD SCI, V823, P185, DOI 10.1111/j.1749-6632.1997.tb48390.x; Whitney KD, 1999, ANNU REV NEUROSCI, V22, P175, DOI 10.1146/annurev.neuro.22.1.175; Whitney KD, 2000, J NEUROSCI, V20, P7307; Williamson RA, 2001, P NATL ACAD SCI USA, V98, P1793, DOI 10.1073/pnas.031567598; Yang YYL, 1998, P NATL ACAD SCI USA, V95, P13254, DOI 10.1073/pnas.95.22.13254	49	552	575	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2001	7	11					1189	1193		10.1038/nm1101-1189	http://dx.doi.org/10.1038/nm1101-1189			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689882				2022-12-27	WOS:000172054100025
J	Nuyens, D; Stengl, M; Dugarmaa, S; Rossenbacker, T; Compernolle, V; Rudy, Y; Smits, JF; Flameng, W; Clancy, CE; Moons, L; Vos, MA; Dewerchin, M; Benndorf, K; Collen, D; Carmeliet, E; Carmeliet, P				Nuyens, D; Stengl, M; Dugarmaa, S; Rossenbacker, T; Compernolle, V; Rudy, Y; Smits, JF; Flameng, W; Clancy, CE; Moons, L; Vos, MA; Dewerchin, M; Benndorf, K; Collen, D; Carmeliet, E; Carmeliet, P			Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome	NATURE MEDICINE			English	Article							INHERITED CARDIAC-ARRHYTHMIA; BETA-ADRENERGIC AGONISTS; INFANT-DEATH-SYNDROME; NA+ CHANNEL BLOCKADE; TORSADE-DE-POINTES; QT SYNDROME; HEART-RATE; EARLY AFTERDEPOLARIZATIONS; TRANSMURAL DISPERSION; MOLECULAR MECHANISM	Deletion of amino-acid residues 1505-1507 (KPQ) in the cardiac SCN5A Na+ channel causes autosomal dominant prolongation of the electrocardiographic QT interval (long-QT syndrome type 3 or LQT3). Excessive prolongation of the action potential at low heart rates predisposes individuals with LQT3 to fatal arrhythmias, typically at rest or during sleep. Here we report that mice heterozygous for a knock-in KPQ-deletion (SCN5A(Delta/+)) show the essential LQT3 features and spontaneously develop life-threatening polymorphous ventricular arrhythmias. Unexpectedly, sudden accelerations in heart rate or premature beats caused lengthening of the action potential with early afterdepolarization and triggered arrhythmias in Scn5a(Delta/+) mice. Adrenergic agonists normalized the response to rate acceleration in vitro and suppressed arrhythmias upon premature stimulation in vivo. These results show the possible risk of sudden heart-rate accelerations. The Scn5a(Delta/+) mouse with its predisposition for pacing-induced arrhythmia might be useful for the development of new treatments for the LQT3 syndrome.	Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium; Univ Maastricht, Cardiovasc Res Inst Maastricht, Maastricht, Netherlands; Klinikum Friederich Schiller Univ Jena, Inst Physiol, Jena, Germany; Case Western Reserve Univ, Cardiac Bioelect Res & Training Ctr, Cleveland, OH USA; Katholieke Univ Leuven, Lab Expt Cardiac Surg, Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; Maastricht University; Friedrich Schiller University of Jena; Case Western Reserve University; KU Leuven	Carmeliet, P (corresponding author), Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	Stengl, Milan/CAA-2936-2022; Carmeliet, Peter/AAQ-5140-2020; Stengl, Milan/J-5918-2017; Clancy, Colleen/B-2528-2010; Stengl, Milan/AAH-1429-2022	Stengl, Milan/0000-0002-1135-0159; Carmeliet, Peter/0000-0001-7961-1821; Stengl, Milan/0000-0002-1135-0159; Stengl, Milan/0000-0002-1135-0159; Moons, Lieve (Godelieve)/0000-0003-0186-1411; Benndorf, Klaus/0000-0002-0707-4083; Nuyens, Dieter/0000-0001-9390-3273				An RH, 1996, CIRC RES, V79, P103, DOI 10.1161/01.RES.79.1.103; Antzelevitch C, 1999, J ELECTROCARDIOL, V32, P158, DOI 10.1016/S0022-0736(99)90074-2; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; Bezzina CR, 2001, CARDIOVASC RES, V49, P257, DOI 10.1016/S0008-6363(00)00272-8; BOYETT MR, 1980, PROG BIOPHYS MOL BIO, V36, P1; Burashnikov A, 1998, J CARDIOVASC ELECTR, V9, P934, DOI 10.1111/j.1540-8167.1998.tb00134.x; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Casimiro MC, 2001, P NATL ACAD SCI USA, V98, P2526, DOI 10.1073/pnas.041398998; Chandra R, 1998, AM J PHYSIOL-HEART C, V274, pH1643, DOI 10.1152/ajpheart.1998.274.5.H1643; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; Clancy CE, 1999, NATURE, V400, P566, DOI 10.1038/23034; Davies MP, 1996, CIRC RES, V78, P15, DOI 10.1161/01.RES.78.1.15; Drici MD, 1998, CIRC RES, V83, P95, DOI 10.1161/01.RES.83.1.95; Dumaine R, 1996, CIRC RES, V78, P916, DOI 10.1161/01.RES.78.5.916; Dzhura I, 2000, NAT CELL BIOL, V2, P173, DOI 10.1038/35004052; JIANG CA, 1994, NAT GENET, V8, P141, DOI 10.1038/ng1094-141; KANNEL WB, 1987, AM HEART J, V113, P799, DOI 10.1016/0002-8703(87)90722-8; MOSS AJ, 1995, CIRCULATION, V92, P2929, DOI 10.1161/01.CIR.92.10.2929; Nagatomo T, 1998, AM J PHYSIOL-HEART C, V275, pH2016, DOI 10.1152/ajpheart.1998.275.6.H2016; Napolitano C, 2000, J CARDIOVASC ELECTR, V11, P691, DOI 10.1111/j.1540-8167.2000.tb00033.x; Nerbonne JM, 2000, J PHYSIOL-LONDON, V525, P285, DOI 10.1111/j.1469-7793.2000.t01-1-00285.x; Priori SG, 1996, CIRC RES, V78, P1009, DOI 10.1161/01.RES.78.6.1009; SAGIE A, 1992, AM J CARDIOL, V70, P797, DOI 10.1016/0002-9149(92)90562-D; Schwartz PJ, 2000, NEW ENGL J MED, V343, P262, DOI 10.1056/NEJM200007273430405; SCHWARTZ PJ, 1995, CIRCULATION, V92, P3381, DOI 10.1161/01.CIR.92.12.3381; Schwartz PJ, 2001, CIRCULATION, V103, P89; Schwartz PJ, 1998, NEW ENGL J MED, V338, P1709, DOI 10.1056/NEJM199806113382401; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Shimizu W, 2000, J AM COLL CARDIOL, V35, P778, DOI 10.1016/S0735-1097(99)00582-3; Shimizu W, 1998, CIRCULATION, V98, P2314, DOI 10.1161/01.CIR.98.21.2314; Shimizu W, 1999, CIRCULATION, V99, P1499, DOI 10.1161/01.CIR.99.11.1499; Viskin S, 1999, LANCET, V354, P1625, DOI 10.1016/S0140-6736(99)02107-8; Viskin S, 2000, J CARDIOVASC ELECTR, V11, P593, DOI 10.1111/j.1540-8167.2000.tb00015.x; Viswanathan PC, 1999, CARDIOVASC RES, V42, P530, DOI 10.1016/S0008-6363(99)00035-8; Wang DW, 1996, P NATL ACAD SCI USA, V93, P13200, DOI 10.1073/pnas.93.23.13200; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7; Zareba W, 1998, NEW ENGL J MED, V339, P960, DOI 10.1056/NEJM199810013391404; Zhou J, 1998, CIRC RES, V83, P806, DOI 10.1161/01.RES.83.8.806	40	201	206	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2001	7	9					1021	1027		10.1038/nm0901-1021	http://dx.doi.org/10.1038/nm0901-1021			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533705				2022-12-27	WOS:000170853300027
J	Takebayashi, Y; Pourquier, P; Zimonjic, DB; Nakayama, K; Emmert, S; Ueda, T; Urasaki, Y; Kanzaki, A; Akiyama, S; Popescu, N; Kraemer, KH; Pommier, Y				Takebayashi, Y; Pourquier, P; Zimonjic, DB; Nakayama, K; Emmert, S; Ueda, T; Urasaki, Y; Kanzaki, A; Akiyama, S; Popescu, N; Kraemer, KH; Pommier, Y			Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair	NATURE MEDICINE			English	Article							DNA TOPOISOMERASE-I; MINOR-GROOVE; CARIBBEAN TUNICATE; MECHANISM; ACTIVATION; DAMAGE; CANCER; DRUG	While investigating the novel anticancer drug ecteinascidin 743 (Et743), a natural marine product isolated from the Caribbean sea squirt, we discovered a new cell-killing mechanism mediated by DNA nucleotide excision repair (NER). A cancer cell line selected for resistance to Et743 had chromosome alterations in a region that included the gene implicated in the hereditary disease xeroderma pigmentosum (XPG, also known as Ercc5). Complementation with wild-type XPG restored the drug sensitivity. Xeroderma pigmentosum cells deficient in the NER genes XPG, XPA, XPD or XPF were resistant to Et743, and sensitivity was restored by complementation with wildtype genes. Moreover, studies of cells deficient in XPC or in the genes implicated in Cockayne syndrome (CSA and CSS) indicated that the drug sensitivity is specifically dependent on the transcription-coupled pathway of NER. We found that Et743 interacts with the transcription-coupled NER machinery to induce lethal DNA strand breaks.	NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Basic Res Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Tohoku Univ, Inst Dev Aging & Canc, Dept Pathol, Sendai, Miyagi 980, Japan; Kagoshima Univ, Fac Med, Canc Res Inst, Dept Canc Chemotherapy, Kagoshima 890, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tohoku University; Kagoshima University	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	pommier@nih.gov	Zimonjic, Drazen/AAX-7513-2020; Pourquier, Philippe/O-8030-2018	Pourquier, Philippe/0000-0001-5326-3005; Kraemer, Kenneth/0000-0002-2689-3316	Intramural NIH HHS [Z01 BC004517-31] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC004517] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batty DP, 2000, GENE, V241, P193, DOI 10.1016/S0378-1119(99)00489-8; Bergmann E, 2001, TRENDS GENET, V17, P279, DOI 10.1016/S0168-9525(01)02280-6; CHEN AY, 1994, ANN REV PHARM TOXICO, V94, P194; Damia G, 2001, INT J CANCER, V92, P583, DOI 10.1002/ijc.1221; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Delaloge S, 2001, J CLIN ONCOL, V19, P1248, DOI 10.1200/JCO.2001.19.5.1248; Emmert S, 2000, P NATL ACAD SCI USA, V97, P2151, DOI 10.1073/pnas.040559697; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Hoeijmakers JHJ, 2001, MUTAT RES-DNA REPAIR, V485, P43, DOI 10.1016/S0921-8777(00)00079-3; Jin S, 2000, P NATL ACAD SCI USA, V97, P6775, DOI 10.1073/pnas.97.12.6775; Khan SG, 1999, J INVEST DERMATOL, V112, P402; Kohn KW, 1996, BIOESSAYS, V18, P505, DOI 10.1002/bies.950180613; LAMBERT B, 1988, NUCLEIC ACIDS RES, V16, P1063, DOI 10.1093/nar/16.3.1063; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Martinez EJ, 1999, P NATL ACAD SCI USA, V96, P3496, DOI 10.1073/pnas.96.7.3496; Minuzzo M, 2000, P NATL ACAD SCI USA, V97, P6780, DOI 10.1073/pnas.97.12.6780; Mu D, 1997, J BIOL CHEM, V272, P28971, DOI 10.1074/jbc.272.46.28971; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pommier Y, 1996, BIOCHEMISTRY-US, V35, P13303, DOI 10.1021/bi960306b; Rinehart KL, 2000, MED RES REV, V20, P1; RINEHART KL, 1990, J NAT PROD, V53, P771, DOI 10.1021/np50070a001; Ryan DP, 2001, CLIN CANCER RES, V7, P231; SAKAI R, 1992, P NATL ACAD SCI USA, V89, P11456, DOI 10.1073/pnas.89.23.11456; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Seaman FC, 1998, J AM CHEM SOC, V120, P13028, DOI 10.1021/ja983091x; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Taamma A, 2001, J CLIN ONCOL, V19, P1256, DOI 10.1200/JCO.2001.19.5.1256; Takebayashi Y, 1999, P NATL ACAD SCI USA, V96, P7196, DOI 10.1073/pnas.96.13.7196; Takebayashi Y, 2001, CLIN CANCER RES, V7, P185; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Zewail-Foote M, 1999, J MED CHEM, V42, P2493, DOI 10.1021/jm990241l; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306	36	289	304	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2001	7	8					961	966		10.1038/91008	http://dx.doi.org/10.1038/91008			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479630				2022-12-27	WOS:000171740400035
J	Yamauchi, T; Kamon, J; Waki, H; Terauchi, Y; Kubota, N; Hara, K; Mori, Y; Ide, T; Murakami, K; Tsuboyama-Kasaoka, N; Ezaki, O; Akanuma, Y; Gavrilova, O; Vinson, C; Reitman, ML; Kagechika, H; Shudo, K; Yoda, M; Nakano, Y; Tobe, K; Nagai, R; Kimura, S; Tomita, M; Froguel, P; Kadowaki, T				Yamauchi, T; Kamon, J; Waki, H; Terauchi, Y; Kubota, N; Hara, K; Mori, Y; Ide, T; Murakami, K; Tsuboyama-Kasaoka, N; Ezaki, O; Akanuma, Y; Gavrilova, O; Vinson, C; Reitman, ML; Kagechika, H; Shudo, K; Yoda, M; Nakano, Y; Tobe, K; Nagai, R; Kimura, S; Tomita, M; Froguel, P; Kadowaki, T			The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity	NATURE MEDICINE			English	Article							ACTIVATED RECEPTOR-ALPHA; PPAR-GAMMA; DIABETES-MELLITUS; ADIPOSE-TISSUE; PROTEIN; MICE; EXPRESSION; GENE; SENSITIVITY; METABOLISM	Adiponectin is an adipocyte-derived hormone. Recent genome-wide scans have mapped a susceptibility locus for type 2 diabetes and metabolic syndrome to chromosome 3q27, where the gene encoding adiponectin is located. Here we show that decreased expression of adiponectin correlates with insulin resistance in mouse models of altered insulin sensitivity. Adiponectin decreases insulin resistance by decreasing triglyceride content in muscle and liver in obese mice. This effect results from increased expression of molecules involved in both fatty-acid combustion and energy dissipation in muscle. Moreover, insulin resistance in lipoatrophic mice was completely reversed by the combination of physiological doses of adiponectin and leptin, but only partially by either adiponectin or leptin alone. We conclude that decreased adiponectin is implicated in the development of insulin resistance in mouse models of both obesity and lipoatrophy. These data also indicate that the replenishment of adiponectin might provide a novel treatment modality for insulin resistance and type 2 diabetes.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo, Japan; Pasteur Inst Lille, CNRS, Inst Biol, Lille, France; Natl Inst Hlth & Nutr, Div Clin Nutr, Tokyo 162, Japan; Asahi Life Fdn, Inst Diabet Care & Res, Tokyo, Japan; NIDDKD, Diabet Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Tokyo, Japan	University of Tokyo; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; National Institute of Health & Nutrition - Japan; Asahi Life Foundation; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Tokyo	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo, Japan.	kadowaki-3im@h.u-tokyo.ac.jp	Kubota, Naoto/N-7892-2015; sheng, jian/E-9474-2012; Waki, Hironori/AAE-3942-2020; Reitman, Marc/B-4448-2013; FROGUEL, Philippe/O-6799-2017; Terauchi, Yasuo/AAO-4347-2020	Waki, Hironori/0000-0002-5302-9793; Reitman, Marc/0000-0002-0426-9475; FROGUEL, Philippe/0000-0003-2972-0784; Kagechika, Hiroyuki/0000-0002-6747-1013	MRC [G0000477] Funding Source: UKRI; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK047031] Funding Source: NIH RePORTER; Medical Research Council [G0000477] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Ebisawa M, 1999, CHEM PHARM BULL, V47, P1778; Eggleton P, 1998, TRENDS CELL BIOL, V8, P428, DOI 10.1016/S0962-8924(98)01373-7; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kahn CR, 1996, ANNU REV MED, V47, P509; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kissebah AH, 2000, P NATL ACAD SCI USA, V97, P14478, DOI 10.1073/pnas.97.26.14478; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Masuzaki H, 1999, DIABETES, V48, P1615, DOI 10.2337/diabetes.48.8.1615; Matsuzawa Y, 1999, ANN NY ACAD SCI, V892, P146, DOI 10.1111/j.1749-6632.1999.tb07793.x; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; MONDON CE, 1981, AM J PHYSIOL, V240, pE482, DOI 10.1152/ajpendo.1981.240.5.E482; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Murakami K, 1998, DIABETES, V47, P1841, DOI 10.2337/diabetes.47.12.1841; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P802; Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Seip M, 1996, ACTA PAEDIATR, V85, P2, DOI 10.1111/j.1651-2227.1996.tb14262.x; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Vionnet N, 2000, AM J HUM GENET, V67, P1470, DOI 10.1086/316887; WHITE RT, 1992, J BIOL CHEM, V267, P9210; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	37	3755	4059	6	444	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2001	7	8					941	946		10.1038/90984	http://dx.doi.org/10.1038/90984			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479627				2022-12-27	WOS:000171740400032
J	Maier, S; Tertilt, C; Chambron, N; Gerauer, K; Huser, N; Heidecke, CD; Pfeffer, K				Maier, S; Tertilt, C; Chambron, N; Gerauer, K; Huser, N; Heidecke, CD; Pfeffer, K			Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28(-/-) mice	NATURE MEDICINE			English	Article							CLASS-I MOLECULES; CD8(+) T-CELLS; CD28-DEFICIENT MICE; GRAFT-REJECTION; BLOCKADE; EXPRESSION; ANTIGEN; CD28; TRANSPLANTATION; COSTIMULATION	Successful transplantation of allogeneic organs is an important objective in modern medicine. However, sophisticated immune defense mechanisms, primarily evolved to combat infections, often work against medical transplantation. To investigate the roles of natural and adaptive immune responses in transplant rejection, we functionally inactivated key effector systems of the innate (NK cells) and the adaptive immune system (CD28-mediated costimulation of T cells) in mice. Neither of these interventions alone led to acceptance of allogeneic vascularized cardiac grafts. In contrast, inhibition of NK-receptor-bearing cells combined with CD28-costimulation blockade established long-term graft acceptance. These results indicate a concerted interplay between innate and adaptive immune surveillance for graft rejection. Thus we suggest that inactivation of NK-receptor-bearing cells could be a new strategy for successful survival of solid-organ transplants.	Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-8000 Munich, Germany; Tech Univ Munich, Dept Surg, D-8000 Munich, Germany	Technical University of Munich; Technical University of Munich	Pfeffer, K (corresponding author), Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-8000 Munich, Germany.			Pfeffer, Klaus/0000-0002-5652-6330				Abbas AK, 2000, CELL, V100, P129, DOI 10.1016/S0092-8674(00)81689-X; BIRON CA, 1982, J IMMUNOL, V129, P2788; Boussiotis VA, 1996, IMMUNOL REV, V153, P5, DOI 10.1111/j.1600-065X.1996.tb00918.x; Colonna M, 1997, IMMUNOL REV, V155, P127, DOI 10.1111/j.1600-065X.1997.tb00945.x; CORREA I, 1995, IMMUNITY, V2, P61, DOI 10.1016/1074-7613(95)90079-9; CORRY RJ, 1973, TRANSPLANTATION, V16, P343, DOI 10.1097/00007890-197310000-00010; DELVAL M, 1992, J EXP MED, V176, P729, DOI 10.1084/jem.176.3.729; DHAMIDHARKA VR, 2000, NAT MED, V6, P115; Endres R, 1997, IMMUNITY, V7, P419, DOI 10.1016/S1074-7613(00)80363-5; Gould DS, 1999, IMMUNOL TODAY, V20, P77, DOI 10.1016/S0167-5699(98)01394-2; Hale DA, 1997, TRANSPLANTATION, V64, P897, DOI 10.1097/00007890-199709270-00018; HEIDECKE CD, 1985, TRANSPLANTATION, V40, P441; Honey K, 1999, J IMMUNOL, V163, P4805; JOHNSON JG, 1993, IMMUNOL RES, V12, P48, DOI 10.1007/BF02918368; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; Karre K, 1997, NATURE, V386, P446, DOI 10.1038/386446a0; KARRE K, 1998, SPECIFICITY FUNCTION; Kawai K, 1996, TRANSPLANTATION, V61, P352, DOI 10.1097/00007890-199602150-00003; Kimachi K, 1997, EUR J IMMUNOL, V27, P3310, DOI 10.1002/eji.1830271230; KLEIN J, 1982, IMMUNOLOGY SCI SELFN, P476; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LANIER LL, 1995, CURR OPIN IMMUNOL, V7, P626, DOI 10.1016/0952-7915(95)80068-9; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Li YS, 1998, TRANSPLANTATION, V66, P1387, DOI 10.1097/00007890-199811270-00021; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; Lin H, 1998, J EXP MED, V188, P199, DOI 10.1084/jem.188.1.199; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Manning TC, 1997, J IMMUNOL, V159, P4665; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; Newell KA, 1999, J IMMUNOL, V163, P2358; Ortaldo JR, 1998, J IMMUNOL, V160, P1158; PEARSON TC, 1994, TRANSPLANTATION, V57, P1701, DOI 10.1097/00007890-199457120-00002; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; Reay PA, 2000, J IMMUNOL, V164, P5626, DOI 10.4049/jimmunol.164.11.5626; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; SHELTON MW, 1992, TRANSPLANTATION, V54, P278, DOI 10.1097/00007890-199208000-00017; Shi FD, 2000, NAT IMMUNOL, V1, P245, DOI 10.1038/79792; Skold M, 2000, EUR J IMMUNOL, V30, P2488, DOI 10.1002/1521-4141(200009)30:9<2488::AID-IMMU2488>3.0.CO;2-F; Szot GL, 2000, TRANSPLANTATION, V69, P904; Trambley J, 1999, J CLIN INVEST, V104, P1715, DOI 10.1172/JCI8082; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; Warrens A N, 1994, Transpl Immunol, V2, P103, DOI 10.1016/0966-3274(94)90036-1; YU YYL, 1992, ANNU REV IMMUNOL, V10, P189, DOI 10.1146/annurev.iy.10.040192.001201; Zinkernagel RM, 1997, IMMUNOL TODAY, V18, P14, DOI 10.1016/S0167-5699(97)80008-4	45	174	182	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					557	562		10.1038/87880	http://dx.doi.org/10.1038/87880			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329056				2022-12-27	WOS:000169961100034
J	Krause, PR; Klinman, DM				Krause, PR; Klinman, DM			Varicella vaccine revisited - Reply	NATURE MEDICINE			English	Letter							HEALTHY-CHILDREN; ZOSTER VIRUS; EFFICACY; CHICKENPOX; LEUKEMIA		US FDA, Ctr Biol Evaluat & Res, Div Viral Prod, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Krause, PR (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Viral Prod, Bldg 29A,Rm 1 C 18, Bethesda, MD 20892 USA.			Krause, Philip/0000-0002-1045-7536				ARVIN AM, 1978, J INFECT DIS, V137, P531, DOI 10.1093/infdis/137.5.531; BRUNELL PA, 1975, J INFECT DIS, V132, P49, DOI 10.1093/infdis/132.1.49; Brunell PA, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.2.e28; FINGER R, 1994, PUBLIC HEALTH REP, V109, P750; GERSHON A, 1998, J INFECT DIS, V158, P132; GERSHON AA, 1984, JAMA-J AM MED ASSOC, V252, P355, DOI 10.1001/jama.252.3.355; HARDY I, 1991, NEW ENGL J MED, V325, P1545, DOI 10.1056/NEJM199111283252204; Johnson CE, 1997, PEDIATRICS, V100, P761, DOI 10.1542/peds.100.5.761; Krause PR, 2000, NAT MED, V6, P451, DOI 10.1038/74715; KUTER BJ, 1991, VACCINE, V9, P643, DOI 10.1016/0264-410X(91)90189-D; LARUSSA P, 1990, 15 INT HERP VIR WORK; LARUSSA P, IN PRESS PED INFECT; Moffat JF, 1998, J VIROL, V72, P965, DOI 10.1128/JVI.72.2.965-974.1998; SHAPIRO E, 1999, 24 INT HERP VIS WORK; SHARRAR R, IN PRESS VACCINE; WATSON B, 1993, PEDIATRICS, V81, P17; WEIBEL RE, 1984, NEW ENGL J MED, V310, P1409, DOI 10.1056/NEJM198405313102201; WHITE CJ, 1992, PEDIATR INFECT DIS J, V11, P19, DOI 10.1097/00006454-199201000-00006; WILLIAMS V, 1974, J INFECT DIS, V130, P669, DOI 10.1093/infdis/130.6.669	19	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1300	1300		10.1038/82072	http://dx.doi.org/10.1038/82072			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100090				2022-12-27	WOS:000165704100006
J	Bechert, T; Steinrucke, P; Guggenbichler, JP				Bechert, T; Steinrucke, P; Guggenbichler, JP			A new method for screening anti-infective biomaterials	NATURE MEDICINE			English	Article							CENTRAL VENOUS CATHETER; STAPHYLOCOCCUS-EPIDERMIDIS; ANTIMICROBIAL ACTIVITY; ADHERENCE; SILVER; BIOCOMPATIBILITY; POLYMERS		Univ Erlangen Nurnberg, Clin Children & Adolescents, D-91054 Erlangen, Germany; Inst Mol Biotechnol, D-07745 Jena, Germany	University of Erlangen Nuremberg	Bechert, T (corresponding author), Univ Erlangen Nurnberg, Clin Children & Adolescents, Loschgestr 15, D-91054 Erlangen, Germany.	tbechert@bio-gate.de						Bechert T, 1999, INFECTION, V27, pS24, DOI 10.1007/BF02561613; Behr A, 1998, INTENSIVMED, V35, P475; Bisno AL, 1994, INFECT ASS INDWELLIN; Boswald M, 1995, ZBL BAKT-INT J MED M, V283, P187; CHRISTENSEN GD, 1985, J CLIN MICROBIOL, V22, P996, DOI 10.1128/JCM.22.6.996-1006.1985; CHRISTENSEN GD, 1994, INDWELLING MED DEVIC; DUNNE WM, 1991, APPL ENVIRON MICROB, V57, P863, DOI 10.1128/AEM.57.3.863-866.1991; Guggenbichler JP, 1999, INFECTION, V27, pS16, DOI 10.1007/BF02561612; Heilmann C, 1996, INFECT IMMUN, V64, P277, DOI 10.1128/IAI.64.1.277-282.1996; Jansen B, 1994, J Biomater Appl, V9, P55, DOI 10.1177/088532829400900103; Joyce-Wohrmann RM, 1999, INFECTION, V27, pS46, DOI 10.1007/BF02561618; MACK D, 1992, INFECT IMMUN, V60, P2048, DOI 10.1128/IAI.60.5.2048-2057.1992; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MERMEL LA, 1993, J INFECT DIS, V167, P920, DOI 10.1093/infdis/167.4.920; Merritt K, 1998, J BIOMED MATER RES, V39, P415, DOI 10.1002/(SICI)1097-4636(19980305)39:3<415::AID-JBM10>3.0.CO;2-9; TEBBS SE, 1994, EUR J CLIN MICROBIOL, V13, P111, DOI 10.1007/BF01982182; Thomas VL, 1997, CURR MICROBIOL, V35, P249, DOI 10.1007/s002849900248; Zhao GJ, 1998, BIOMETALS, V11, P27, DOI 10.1023/A:1009253223055	18	79	89	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2000	6	9					1053	1056		10.1038/79568	http://dx.doi.org/10.1038/79568			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973328				2022-12-27	WOS:000089190500040
J	Haanen, JBAG; Van Oijen, MGCT; Tirion, F; Oomen, LCJM; Kruisbeek, AM; Vyth-Dreese, FA; Schumacher, TNM				Haanen, JBAG; Van Oijen, MGCT; Tirion, F; Oomen, LCJM; Kruisbeek, AM; Vyth-Dreese, FA; Schumacher, TNM			In situ detection of virus- and tumor-specific T-cell immunity	NATURE MEDICINE			English	Article							VIRAL-INFECTION; LYMPHOCYTES; ACTIVATION; SELECTION; MELANOMA; COMPLEX; GROWTH; VIVO		Netherlands Canc Inst, Dept Immunol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Dept Cell Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Schumacher, TNM (corresponding author), Netherlands Canc Inst, Dept Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Haanen, John/AAD-8578-2022; Haanen, John/AAD-8534-2022; Schumacher, Ton/Y-2432-2019	Haanen, John/0000-0001-5884-7704; Schumacher, Ton/0000-0003-0517-8804				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.3.CO;2-0; Flynn KJ, 1998, IMMUNITY, V8, P683, DOI 10.1016/S1074-7613(00)80573-7; Gonzalez M, 1998, J EXP MED, V187, P997, DOI 10.1084/jem.187.7.997; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Haanen JBAG, 1999, EUR J IMMUNOL, V29, P1168, DOI 10.1002/(SICI)1521-4141(199904)29:04<1168::AID-IMMU1168>3.0.CO;2-J; Hanke T, 1999, IMMUNITY, V11, P67, DOI 10.1016/S1074-7613(00)80082-5; Kuroda MJ, 1998, J EXP MED, V187, P1373, DOI 10.1084/jem.187.9.1373; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; LIPPONEN PK, 1993, EUR J CANCER, V29A, P69, DOI 10.1016/0959-8049(93)90579-5; MAMALAKI C, 1993, DEV IMMUNOL, V3, P159, DOI 10.1155/1993/98015; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Naito Y, 1998, CANCER RES, V58, P3491; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Ogg GS, 1998, J EXP MED, V188, P1203, DOI 10.1084/jem.188.6.1203; Reich Z, 1997, NATURE, V387, P617, DOI 10.1038/42500; Romero P, 1998, J EXP MED, V188, P1641, DOI 10.1084/jem.188.9.1641; Savage PA, 1999, IMMUNITY, V10, P485, DOI 10.1016/S1074-7613(00)80048-5; Toes REM, 1996, P NATL ACAD SCI USA, V93, P7855, DOI 10.1073/pnas.93.15.7855; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680	21	64	73	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					1056	1060		10.1038/79573	http://dx.doi.org/10.1038/79573			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973329				2022-12-27	WOS:000089190500041
J	Darnell, JE				Darnell, JE			The surprises of mammalian molecular cell biology	NATURE MEDICINE			English	Editorial Material							POLYADENYLIC ACID SEQUENCES; LABELED POLYRIBOSOMAL RNA; MESSENGER-RNA; HELA-CELLS; TRANSCRIPTIONAL CONTROL; ADENYLIC ACID; NUCLEAR RNA; INTERFERON; STAT3; ACTIVATION		Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA	Rockefeller University	Darnell, JE (corresponding author), Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA.							BERGET SM, 1977, P NATL ACAD SCI USA, V74, P3171, DOI 10.1073/pnas.74.8.3171; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; CHOW LT, 1977, CELL, V12, P1, DOI 10.1016/0092-8674(77)90180-5; CLAYTON DF, 1985, MOL CELL BIOL, V5, P2623, DOI 10.1128/MCB.5.10.2623; DARNELL JE, 1971, P NATL ACAD SCI USA, V68, P1321, DOI 10.1073/pnas.68.6.1321; DARNELL JE, 1958, J EXP MED, V107, P633, DOI 10.1084/jem.107.5.633; DARNELL JE, 1968, BACTERIOL REV, V32, P262, DOI 10.1128/MMBR.32.3.262-290.1968; DARNELL JE, 1971, SCIENCE, V174, P507, DOI 10.1126/science.174.4008.507; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DARNELL JE, 1960, J BIOL CHEM, V235, P70; DARNELL JE, 1960, VIROLOGY, V13, P271; DARNELL JE, IN PRESS NATURE REV; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; EDMONDS M, 1971, P NATL ACAD SCI USA, V68, P1336, DOI 10.1073/pnas.68.6.1336; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; GLASER RJ, 1956, J EXP MED, V103, P173, DOI 10.1084/jem.103.1.173; GOLDBERG S, 1977, CELL, V10, P617, DOI 10.1016/0092-8674(77)90094-0; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; KATES J, 1970, COLD SPRING HARB SYM, V35, P743, DOI 10.1101/SQB.1970.035.01.090; KNIGHT E, 1979, P NATL ACAD SCI USA, V76, P1824, DOI 10.1073/pnas.76.4.1824; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LEE SY, 1971, P NATL ACAD SCI USA, V68, P1331, DOI 10.1073/pnas.68.6.1331; LEVY D, 1990, New Biologist, V2, P923; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LINDBERG U, 1970, P NATL ACAD SCI USA, V65, P1089, DOI 10.1073/pnas.65.4.1089; PENMAN S, 1963, P NATL ACAD SCI USA, V49, P654, DOI 10.1073/pnas.49.5.654; PERRY RP, 1974, CELL, V1, P37, DOI 10.1016/0092-8674(74)90153-6; PHILIPSON L, 1971, P NATL ACAD SCI USA, V68, P2806, DOI 10.1073/pnas.68.11.2806; POWELL DJ, 1984, J MOL BIOL, V179, P21, DOI 10.1016/0022-2836(84)90304-8; SALDITTGEORGIEFF M, 1976, CELL, V7, P227, DOI 10.1016/0092-8674(76)90022-2; SCHERRER K, 1963, P NATL ACAD SCI USA, V49, P240, DOI 10.1073/pnas.49.2.240; SCHERRER K, 1962, BIOCHEM BIOPH RES CO, V7, P486, DOI 10.1016/0006-291X(62)90341-8; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SOEIRO R, 1966, J MOL BIOL, V19, P362; WARNER JR, 1966, J MOL BIOL, V19, P349, DOI 10.1016/S0022-2836(66)80009-8; WEBER J, 1977, CELL, V10, P611, DOI 10.1016/0092-8674(77)90093-9; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	42	2	2	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2002	8	10					1068	1071		10.1038/nm773	http://dx.doi.org/10.1038/nm773			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12357235				2022-12-27	WOS:000178311000021
J	Lazarov, M; Kubo, Y; Cai, T; Dajee, M; Tarutani, M; Lin, Q; Fang, M; Tao, SY; Green, CL; Khavari, PA				Lazarov, M; Kubo, Y; Cai, T; Dajee, M; Tarutani, M; Lin, Q; Fang, M; Tao, SY; Green, CL; Khavari, PA			CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis	NATURE MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; DEPENDENT KINASE-4 CDK4; HUMAN BREAST-CANCER; CYCLIN D1; ONCOGENIC TRANSFORMATION; BINDING DOMAIN; IN-VIVO; GENE; EXPRESSION; ACTIVATION	Ras acts with other proteins to induce neoplasia. By itself, however, strong Ras signaling can suppress proliferation of normal cells. In primary epidermal cells, we found that oncogenic Ras transiently decreases cyclin-dependent kinase (CDK) 4 expression in association with cell cycle arrest in G1 phase. CDK4 co-expression circumvents Ras growth suppression and induces invasive human neoplasia resembling squamous cell carcinoma. Tumorigenesis is dependent on CDK4 kinase function, with cyclin D1 required but not sufficient for this process. In facilitating escape from G1 growth restraints, Ras and CDK4 alter the composition of cyclin D and cyclin E complexes and promote resistance to growth inhibition by INK4 cyclin-dependent kinase inhibitors. These data identify a new role for oncogenic Ras in CDK4 regulation and highlight the functional importance of CDK4 suppression in preventing uncontrolled growth.	VA Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Khavari, PA (corresponding author), VA Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043799, R29AR043799, R01AR045192] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45192, AR43799] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; BENJAMIN T, 1990, VIROLOGY, P317; Berking C, 2002, CARCINOGENESIS, V23, P181, DOI 10.1093/carcin/23.1.181; Cheung TH, 2001, CANCER LETT, V166, P199, DOI 10.1016/S0304-3835(01)00457-8; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Dajee M, 2002, ONCOGENE, V21, P1527, DOI 10.1038/sj.onc.1205287; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Eisma RJ, 1997, AM J SURG, V174, P513; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Ewen M E, 2000, Prog Cell Cycle Res, V4, P1; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Inouye K, 2000, J BIOL CHEM, V275, P3737, DOI 10.1074/jbc.275.6.3737; KHATIB ZA, 1993, CANCER RES, V53, P5535; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Koontongkaew S, 2000, ORAL ONCOL, V36, P334, DOI 10.1016/S1368-8375(99)00093-7; Koseki Shin, 1999, Journal of Dermatology (Tokyo), V26, P416; LADANYI M, 1995, J PATHOL, V175, P211, DOI 10.1002/path.1711750209; Li A, 1998, P NATL ACAD SCI USA, V95, P3902, DOI 10.1073/pnas.95.7.3902; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Matsumoto M, 1999, BRIT J CANCER, V80, P256, DOI 10.1038/sj.bjc.6690348; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; Proby CM, 2000, EXP DERMATOL, V9, P104, DOI 10.1034/j.1600-0625.2000.009002104.x; Robbins PB, 2001, P NATL ACAD SCI USA, V98, P5193, DOI 10.1073/pnas.091484998; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SKOTZKO M, 1995, CANCER RES, V55, P5493; Sui L, 2000, GYNECOL ONCOL, V79, P230, DOI 10.1006/gyno.2000.5961; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; Tsukifuji R, 1999, BRIT J CANCER, V80, P1087, DOI 10.1038/sj.bjc.6690468; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; YUSPA SH, 1994, CANCER RES, V54, P1178; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	45	154	156	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2002	8	10					1105	1114		10.1038/nm779	http://dx.doi.org/10.1038/nm779			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12357246				2022-12-27	WOS:000178311000037
J	Bakre, MM; Zhu, YH; Yin, H; Burton, DW; Terkeltaub, R; Deftos, LJ; Varner, JA				Bakre, MM; Zhu, YH; Yin, H; Burton, DW; Terkeltaub, R; Deftos, LJ; Varner, JA			Parathyroid hormone-related peptide is a naturally occurring, protein kinase A-dependent angiogenesis inhibitor	NATURE MEDICINE			English	Article							VASCULAR SMOOTH-MUSCLE; ENDOCHONDRAL BONE-FORMATION; SIGNAL-TRANSDUCTION; CELL-MIGRATION; BREAST-CANCER; RECEPTOR; GROWTH; CARTILAGE; APOPTOSIS; MICE	Angiogenesis is a highly regulated process that results from the sequential actions of naturally occurring stimulators and inhibitors. Here, we show that parathyroid hormone-related peptide, a peptide hormone derived from normal and tumor cells that regulates bone metabolism and vascular tone, is a naturally occurring angiogenesis inhibitor. Parathyroid hormone-related peptide or a ten-amino-acid peptide from its N terminus inhibits endothelial cell migration in vitro and angiogenesis in vivo by activating endothelial cell protein kinase A. Activation of protein kinase A inhibits cell migration and angiogenesis by inhibiting the small GTPase Rac. In contrast, inhibition of protein kinase A reverses the anti-migratory and anti-angiogenic properties of parathyroid hormone-related peptide. These studies show that parathyroid hormone-related peptide is a naturally occurring angiogenesis inhibitor that functions by activation of protein kinase A.	Univ Calif San Diego, Ctr Comprehens Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Vet Affairs Med Ctr, La Jolla, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Varner, JA (corresponding author), Univ Calif San Diego, Ctr Comprehens Canc, La Jolla, CA 92093 USA.			Varner, Judith/0000-0002-9251-0600	NATIONAL CANCER INSTITUTE [R01CA083133, R01CA071619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060588] Funding Source: NIH RePORTER; NCI NIH HHS [CA71619, CA83133] Funding Source: Medline; NIAMS NIH HHS [AR47347] Funding Source: Medline; NIDDK NIH HHS [DK60588] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDEEN O, 1995, AM J GASTROENTEROL, V90, P1864; ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Akino K, 2000, ENDOCRINOLOGY, V141, P4313, DOI 10.1210/en.141.11.4313; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; BRINGHURST FR, 1998, WILLIAMS TXB ENDOCRI, P1155; BUKOSKI RD, 1995, SEMIN NEPHROL, V15, P536; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gasparini G, 1998, CLIN CANCER RES, V4, P2625; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Guijal A., 2001, CANCER RES, V61, P2282; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; HANSON AS, 1994, HYPERTENSION, V23, P468, DOI 10.1161/01.HYP.23.4.468; Hoare SRJ, 2001, J BIOL CHEM, V276, P7741, DOI 10.1074/jbc.M009395200; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; Ishikawa M, 1998, ATHEROSCLEROSIS, V136, P59, DOI 10.1016/S0021-9150(97)00187-1; IWAMOTO M, 1994, J BIOL CHEM, V269, P17245; Jiang BB, 1998, J CARDIOVASC PHARM, V31, pS142, DOI 10.1097/00005344-199800001-00042; Jin L, 2000, J BIOL CHEM, V275, P27238; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Lanske B, 1999, J CLIN INVEST, V104, P399, DOI 10.1172/JCI6629; Maeda S, 1999, ENDOCRINOLOGY, V140, P1815, DOI 10.1210/en.140.4.1815; Maeshima Y, 2001, J BIOL CHEM, V276, P15240, DOI 10.1074/jbc.M007764200; Morikawa S, 2002, AM J PATHOL, V160, P985, DOI 10.1016/S0002-9440(10)64920-6; Moseley J. M., 1996, P363; NICKOLS GA, 1989, ENDOCRINOLOGY, V125, P834, DOI 10.1210/endo-125-2-834; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Padmanabhan J, 1999, J NEUROBIOL, V39, P407, DOI 10.1002/(SICI)1097-4695(19990605)39:3<407::AID-NEU7>3.0.CO;2-S; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Shimizu M, 2000, J BIOL CHEM, V275, P21836, DOI 10.1074/jbc.M909861199; Terkeltaub R, 1998, ARTHRITIS RHEUM-US, V41, P2152, DOI 10.1002/1529-0131(199812)41:12<2152::AID-ART10>3.3.CO;2-O; Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451; Varner J A, 1997, EXS, V79, P361; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Yoneda T, 1998, EUR J CANCER, V34, P240, DOI 10.1016/S0959-8049(97)10132-0	45	81	87	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2002	8	9					995	1003		10.1038/nm753	http://dx.doi.org/10.1038/nm753			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12185361				2022-12-27	WOS:000177757900035
J	Grant, MB; May, WS; Caballero, S; Brown, GAJ; Guthrie, SM; Mames, RN; Byrne, BJ; Vaught, T; Spoerri, PE; Peck, AB; Scott, EW				Grant, MB; May, WS; Caballero, S; Brown, GAJ; Guthrie, SM; Mames, RN; Byrne, BJ; Vaught, T; Spoerri, PE; Peck, AB; Scott, EW			Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization	NATURE MEDICINE			English	Article							ENDOTHELIAL PROGENITOR CELLS; BONE-MARROW CELLS; POSTNATAL NEOVASCULARIZATION; DIABETIC-RETINOPATHY; BLOOD; TRANSPLANTATION; ANGIOGENESIS; ENGRAFTMENT; MYOCARDIUM; PHENOTYPE	Adults maintain a reservoir of hematopoietic stem cells that can enter the circulation to reach organs in need of regeneration. We developed a novel model of retinal neovascularization in adult mice to examine the role of hematopoietic stem cells in revascularizing ischemic retinas. Adult mice were durably engrafted with hematopoietic stem cells isolated from transgenic mice expressing green fluorescent protein. We performed serial long-term transplants, to ensure activity arose from self-renewing stem cells, and single hematopoietic stem-cell transplants to show clonality. After durable hematopoietic engraftment was established, retinal ischemia was induced to promote neovascularization. Our results indicate that self-renewing adult hematopoietic stem cells have functional hemangioblast activity, that is, they can clonally differentiate into all hematopoietic cell lineages as well as endothelial cells that revascularize adult retina. We also show that recruitment of endothelial precursors to sites of ischemic injury has a significant role in neovascularization.	Univ Florida, Program Stem Cell Biol, Gainesville, FL 32611 USA; Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL USA; Univ Florida, Shands Canc Ctr, Gainesville, FL USA; Univ Florida, McKnight Brain Inst, Gainesville, FL USA; Univ Florida, Dept Pathol, Gainesville, FL 32611 USA; Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL USA; Retina Ctr, Gainesville, FL USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Grant, MB (corresponding author), Univ Florida, Program Stem Cell Biol, Gainesville, FL 32611 USA.				NCI NIH HHS [CA72769] Funding Source: Medline; NEI NIH HHS [EY012601, EY007739] Funding Source: Medline; NIDDK NIH HHS [DK52558] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072769] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007739, R01EY012601, R29EY007739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK052558] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Bhattacharya V, 2000, BLOOD, V95, P581, DOI 10.1182/blood.V95.2.581; Choi K, 1998, BIOCHEM CELL BIOL, V76, P947, DOI 10.1139/bcb-76-6-947; Cilloni D, 2000, BLOOD, V96, P3637; Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728; Devine SM, 2001, EXP HEMATOL, V29, P244, DOI 10.1016/S0301-472X(00)00635-4; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRANK RN, 1991, OPHTHALMOLOGY, V98, P586; Gehling UM, 2000, BLOOD, V95, P3106; Goodell MA, 2001, ANN NY ACAD SCI, V938, P208; GRANT M, 1986, DIABETES, V35, P416, DOI 10.2337/diabetes.35.4.416; HARRISON DE, 1993, EXP HEMATOL, V21, P206; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198; Kawamoto A, 2001, CIRCULATION, V103, P634; Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307; Koc ON, 1999, EXP HEMATOL, V27, P1675, DOI 10.1016/S0301-472X(99)00101-0; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Limb GA, 1996, BRIT J OPHTHALMOL, V80, P168, DOI 10.1136/bjo.80.2.168; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Mosca JD, 2000, CLIN ORTHOP RELAT R, pS71; MULLERSIEBURG C, 1992, HEMATOPOIETIC STEM C; Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Sharkis SJ, 2001, ANN NY ACAD SCI, V938, P191; SIMMONS PJ, 1987, NATURE, V328, P429, DOI 10.1038/328429a0; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; VONBEKKUM DW, 1967, RAD CHIMERAS	37	537	592	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2002	8	6					607	612		10.1038/nm0602-607	http://dx.doi.org/10.1038/nm0602-607			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042812				2022-12-27	WOS:000175907300032
J	Meng, G; Wei, XP; Wu, XY; Sellers, MT; Decker, JM; Moldoveanu, Z; Orenstein, JM; Graham, MF; Kappes, JC; Mestecky, J; Shaw, GM; Smith, PD				Meng, G; Wei, XP; Wu, XY; Sellers, MT; Decker, JM; Moldoveanu, Z; Orenstein, JM; Graham, MF; Kappes, JC; Mestecky, J; Shaw, GM; Smith, PD			Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5(+) cells	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LAMINA PROPRIA LYMPHOCYTES; T-CELLS; TYPE-1 INFECTION; SEXUAL-BEHAVIOR; TRANSMISSION; CHEMOKINE; REPLICATION; EXPRESSION; MACROPHAGES	The upper gastrointestinal tract is a principal route of HIV-1 entry in vertical transmission and after oral-genital contact. The phenotype of the newly acquired virus is predominantly R5 (CCR5-tropic) and not X4 (CXCR4-tropic), although both R5 and X4 viruses are frequently inoculated onto the mucosa. Here we show that primary intestinal (jejunal) epithelial cells express galactosylceramide, an alternative primary receptor for HIV-1, and CCR5 but not CXCR4. Moreover, we show that intestinal epithelial cells transfer R5, but not X4, viruses to CCR5(+) indicator cells, which can efficiently replicate and amplify virus expression. Transfer was remarkably efficient and was not inhibited by the fusion blocker T-20, but was substantially reduced by colchicine and low (4 degreesC) temperature, suggesting endocytotic uptake and microtubule-dependent transcytosis of HIV-1. Our finding that CCR5(+) intestinal epithelial cells select and transfer exclusively R5 viruses indicates a mechanism for the selective transmission of R5 HIV-1 in primary infection acquired through the upper gastrointestinal tract.	Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; Vet Adm Med Ctr, Birmingham, AL USA; Howard Hughes Med Inst, Birmingham, AL 35294 USA; George Washington Univ, Med Ctr, Dept Pathol, Washington, DC 20037 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pediat, Richmond, VA 23298 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Howard Hughes Medical Institute; George Washington University; Virginia Commonwealth University	Smith, PD (corresponding author), Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.	pdsmith@uab.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041361] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA073470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027767, U01AI041530, U01AI028147, R01AI035467, U19AI028147, R37AI035467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [N01DE072621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047322] Funding Source: NIH RePORTER; NCI NIH HHS [CA-73470] Funding Source: Medline; NIAID NIH HHS [AI-28147, P30-AI-27767, AI-35467, AI-41530] Funding Source: Medline; NICHD NIH HHS [HD-41361] Funding Source: Medline; NIDCR NIH HHS [DE-72621] Funding Source: Medline; NIDDK NIH HHS [DK-47322] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agace WW, 2000, CURR BIOL, V10, P325, DOI 10.1016/S0960-9822(00)00380-8; Alfsen A, 2001, J IMMUNOL, V166, P6257, DOI 10.4049/jimmunol.166.10.6257; Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Baba TW, 1996, SCIENCE, V272, P1486, DOI 10.1126/science.272.5267.1486; Bomsel M, 1997, NAT MED, V3, P42, DOI 10.1038/nm0197-42; Bomsel M, 1998, IMMUNITY, V9, P277, DOI 10.1016/S1074-7613(00)80610-X; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; Cecilia D, 1998, J VIROL, V72, P6988, DOI 10.1128/JVI.72.9.6988-6996.1998; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; Dezzutti CS, 2001, J INFECT DIS, V183, P1204, DOI 10.1086/319676; Dwinell MB, 1999, GASTROENTEROLOGY, V117, P359, DOI 10.1053/gast.1999.0029900359; FANTINI J, 1993, P NATL ACAD SCI USA, V90, P2700, DOI 10.1073/pnas.90.7.2700; FANTINI J, 1992, J VIROL, V66, P580, DOI 10.1128/JVI.66.1.580-585.1992; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; GHOSH K, 1993, VIROLOGY, V194, P858, DOI 10.1006/viro.1993.1331; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; Jordan NJ, 1999, J CLIN INVEST, V104, P1061, DOI 10.1172/JCI6685; Kewenig S, 1999, GASTROENTEROLOGY, V116, P1115, DOI 10.1016/S0016-5085(99)70014-4; Lapenta C, 1999, EUR J IMMUNOL, V29, P1202, DOI 10.1002/(SICI)1521-4141(199904)29:04<1202::AID-IMMU1202>3.0.CO;2-O; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Li L, 1999, GASTROENTEROLOGY, V116, P1043, DOI 10.1016/S0016-5085(99)70007-7; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; MAAYAN S, 1993, ISRAEL J PSYCHIAT, V30, P150; MCNEARNEY T, 1992, P NATL ACAD SCI USA, V89, P10247, DOI 10.1073/pnas.89.21.10247; MCNEELY TB, 1995, J CLIN INVEST, V96, P456, DOI 10.1172/JCI118056; Meng G, 2000, J INFECT DIS, V182, P785, DOI 10.1086/315790; PHILLIPS DM, 1994, AIDS, V8, P719, DOI 10.1097/00002030-199406000-00001; Poles MA, 2001, J VIROL, V75, P8390, DOI 10.1128/JVI.75.18.8390-8399.2001; PRATT RD, 1995, J INFECT DIS, V172, P851, DOI 10.1093/infdis/172.3.851; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SCHNEIDER T, 1995, GUT, V37, P524, DOI 10.1136/gut.37.4.524; SCHWARCZ SK, 1995, AM J EPIDEMIOL, V142, P314, DOI 10.1093/oxfordjournals.aje.a117637; Smith PD, 1997, J IMMUNOL METHODS, V202, P1, DOI 10.1016/S0022-1759(96)00204-9; SMITH PD, 1994, J EXP MED, V180, P1541, DOI 10.1084/jem.180.4.1541; Smith PD, 2001, J IMMUNOL, V167, P2651, DOI 10.4049/jimmunol.167.5.2651; SMITH PD, 1999, MUCOSAL IMMUNOLOGY, P977; Stahl-Hennig C, 1999, SCIENCE, V285, P1261, DOI 10.1126/science.285.5431.1261; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; WAHL LM, 1991, CURRENT PROTOCOLS IM; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	46	200	208	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2002	8	2					150	156		10.1038/nm0202-150	http://dx.doi.org/10.1038/nm0202-150			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821899				2022-12-27	WOS:000173600600024
J	Becker, C; Pohla, H; Frankenberger, B; Schuler, T; Assenmacher, M; Schendel, DJ; Blankenstein, T				Becker, C; Pohla, H; Frankenberger, B; Schuler, T; Assenmacher, M; Schendel, DJ; Blankenstein, T			Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay	NATURE MEDICINE			English	Article							RENAL-CELL CARCINOMAS; ANTIGEN; EXPRESSION	Successful adoptive T-cell therapy has been demonstrated in viral disease(1,2) and selected forms of cancer(3). However, it is limited by the difficulty to efficiently isolate and amplify autologous tumor-reactive T-cell clones. Tetramers of major histocompatibility complex (MHC) class I and peptide have facilitated the characterization of CD8(+) T cells specific for tumor-associated antigens(4,5). However, for adoptive T-cell therapy, MHC-tetramers have limitations: they require knowledge of tumor antigens, which is often not available; they select T cells with a single specificity, thereby posing risk for selection of tumor escape variants; they do not select for function, so that T cells may be anergic when isolated from cancer patients; and they do not allow the isolation of CD4(+) T cells that can be essential for tumor rejection(6). Because interferon (IFN)-gamma is essential for tumor rejection(7,8), we isolated live T cells based on their IFN-gamma production(9). IFN-gamma secreted by previously activated T cells is retained on the cell surface, allowing their specific isolation and expansion(10). We show here that IFN-gamma (+) but not IFN-gamma (-) T cells from tumor-immunized mice are cytolytic and mediate tumor rejection upon adoptive transfer. Importantly, tumor-specific T cells can be enriched from lymphocytes infiltrating human renal cell carcinoma by the IFN-gamma capture assay.	Max Delbruck Ctr Mol Med, Berlin, Germany; Univ Munich, Dept Urol, Lab Tumor Immunol, Munich, Germany; GSF Munich, Natl Res Ctr Environm & Hlth, Inst Mol Immunol, Munich, Germany; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany; Free Univ Berlin, Inst Immunol, D-1000 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Miltenyi Biotec; Free University of Berlin	Blankenstein, T (corresponding author), Max Delbruck Ctr Mol Med, Berlin, Germany.	klahn@mdc-berlin.de	Becker, Christian/AAD-4549-2020; Becker, Christian/GLS-0862-2022; Pohla, Heike/GRS-3277-2022; Becker, Christian/F-5384-2010	Becker, Christian/0000-0002-1716-7208; Becker, Christian/0000-0002-1716-7208; Becker, Christian/0000-0002-1716-7208				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; BARTH RJ, 1991, J EXP MED, V173, P647, DOI 10.1084/jem.173.3.647; BERNHARD H, 1994, INT J CANCER, V59, P837, DOI 10.1002/ijc.2910590621; Brosterhus H, 1999, EUR J IMMUNOL, V29, P4053, DOI 10.1002/(SICI)1521-4141(199912)29:12<4053::AID-IMMU4053>3.3.CO;2-3; Chiodoni C, 1999, J EXP MED, V190, P125, DOI 10.1084/jem.190.1.125; Hoffman DMJ, 2000, SEMIN ONCOL, V27, P221; Huang AYC, 1996, P NATL ACAD SCI USA, V93, P9730, DOI 10.1073/pnas.93.18.9730; Jantzer P, 1998, CANCER RES, V58, P3078; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; Pardoll DM, 1998, CURR OPIN IMMUNOL, V10, P588, DOI 10.1016/S0952-7915(98)80228-8; Pohla H, 2000, BONE MARROW TRANSPL, V25, pS83, DOI 10.1038/sj.bmt.1702362; Qin ZH, 2000, IMMUNITY, V12, P677, DOI 10.1016/S1074-7613(00)80218-6; RIDDELL SR, 1990, J IMMUNOL METHODS, V128, P189, DOI 10.1016/0022-1759(90)90210-M; RIDDELL SR, 1995, ANNU REV IMMUNOL, V13, P545; Romero P, 1998, J EXP MED, V188, P1641, DOI 10.1084/jem.188.9.1641; Schendel DJ, 2000, GENE THER, V7, P2007, DOI 10.1038/sj.gt.3301349; Schendel DJ, 1997, J MOL MED-JMM, V75, P400, DOI 10.1007/s001090050125; Schepers E J, 1993, Implant Dent, V2, P151, DOI 10.1097/00008505-199309000-00002; Slifka MK, 1999, NATURE, V401, P76, DOI 10.1038/43454; Yee C, 1997, CURR OPIN IMMUNOL, V9, P702, DOI 10.1016/S0952-7915(97)80052-0	20	140	152	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2001	7	10					1159	1162		10.1038/nm1001-1159	http://dx.doi.org/10.1038/nm1001-1159			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590442				2022-12-27	WOS:000171524500040
J	Smithies, O				Smithies, O			Forty years with homologous recombination	NATURE MEDICINE			English	Editorial Material									Univ N Carolina, Dept Pathol, Chapel Hill, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill	Smithies, O (corresponding author), Univ N Carolina, Dept Pathol, Brinkhous Bullitt Bldg, Chapel Hill, NC 27514 USA.								0	39	53	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1083	1086		10.1038/nm1001-1083	http://dx.doi.org/10.1038/nm1001-1083			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590419				2022-12-27	WOS:000171524500014
J	Bange, J; Zwick, E; Ullrich, A				Bange, J; Zwick, E; Ullrich, A			Molecular targets for breast cancer therapy and prevention	NATURE MEDICINE			English	Review							PREDICTIVE-VALUE; PROGNOSTIC-FACTORS; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; HER-2 NEU; EXPRESSION; C-ERBB-2; GROWTH; TAMOXIFEN; OVEREXPRESSION	The recent completion of the human genome sequence has raised great hopes in the discovery of new breast cancer therapies based on newly-discovered genes linked to breast cancer development and progression. Here we describe breast cancer therapies that have emerged from gene-base scientific efforts over the past 20 years and that are now approved for clinical testing or treatment.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Max Planck Society	Bange, J (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany.	ullrich@biochem.mpg.de						Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; ARCHER SG, 1995, BRIT J CANCER, V72, P1259, DOI 10.1038/bjc.1995.497; Baselga J, 2001, EUR J CANCER, V37, pS18, DOI 10.1016/S0959-8049(00)00404-4; BERNS EMJJ, 1995, GENE, V159, P11, DOI 10.1016/0378-1119(94)00534-Y; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; CARTER SK, 1972, CANCER-AM CANCER SOC, V30, P1543, DOI 10.1002/1097-0142(197212)30:6<1543::AID-CNCR2820300621>3.0.CO;2-V; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fong TAT, 1999, CANCER RES, V59, P99; Fossati R, 1998, J CLIN ONCOL, V16, P3439, DOI 10.1200/JCO.1998.16.10.3439; Gail MH, 1999, J NATL CANCER I, V91, P1829, DOI 10.1093/jnci/91.21.1829; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Harris RE, 2000, CANCER RES, V60, P2101; Heffelfinger SC, 1999, CLIN CANCER RES, V5, P2867; HONG WK, 2000, ONCOL BIOTHERAPEUTIC, V1, P1; Hortobagyi G, 2000, ANNU REV MED, V51, P377, DOI 10.1146/annurev.med.51.1.377; Hortobagyi Gabriel N., 2000, Cancer, V88, P3073, DOI 10.1002/1097-0142(20000615)88:12+<3073::AID-CNCR26>3.3.CO;2-I; Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196; Huang LL, 2000, MOL MED, V6, P849, DOI 10.1007/BF03401823; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JACQUEMIER J, 1994, ANTICANCER RES, V14, P2773; Jarvinen TAH, 1998, BRIT J CANCER, V77, P2267, DOI 10.1038/bjc.1998.377; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Kurokawa H, 2000, CANCER RES, V60, P5887; Lanni JS, 1997, P NATL ACAD SCI USA, V94, P9679, DOI 10.1073/pnas.94.18.9679; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; LEITZEL K, 1995, J CLIN ONCOL, V13, P1129, DOI 10.1200/JCO.1995.13.5.1129; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NICHOLSON RI, 1994, BREAST CANCER RES TR, V29, P117, DOI 10.1007/BF00666187; Paik SM, 1998, JNCI-J NATL CANCER I, V90, P1361, DOI 10.1093/jnci/90.18.1361; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; Peto J, 2000, NAT GENET, V26, P411, DOI 10.1038/82533; Pietras RJ, 1999, CANCER RES, V59, P1347; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rozan S, 1998, INT J CANCER, V79, P27, DOI 10.1002/(SICI)1097-0215(19980220)79:1<27::AID-IJC6>3.3.CO;2-8; Saaristo A, 2000, ONCOGENE, V19, P6122, DOI 10.1038/sj.onc.1203969; Saphner T, 1996, J CLIN ONCOL, V14, P2738, DOI 10.1200/JCO.1996.14.10.2738; Sausville EA, 2000, ANN NY ACAD SCI, V910, P207; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Sjogren S, 1998, J CLIN ONCOL, V16, P462; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Smith SMR, 2000, AM J SURG, V180, P249, DOI 10.1016/S0002-9610(00)00453-0; Tazebay UH, 2000, NAT MED, V6, P871, DOI 10.1038/78630; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; Torrisi R, 2000, Curr Oncol Rep, V2, P263, DOI 10.1007/s11912-000-0077-x; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; WRIGHT C, 1992, BRIT J CANCER, V65, P118, DOI 10.1038/bjc.1992.22; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Yang LM, 1999, J MAMMARY GLAND BIOL, V4, P377, DOI 10.1023/A:1018718401126; Yang XW, 2000, CANCER RES, V60, P6890	63	226	241	3	24	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2001	7	5					548	552		10.1038/87872	http://dx.doi.org/10.1038/87872			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329054				2022-12-27	WOS:000169961100032
J	Makinen, T; Jussila, L; Veikkola, T; Karpanen, T; Kettunen, MI; Pulkkanen, KJ; Kauppinen, R; Jackson, DG; Kubo, H; Nishikawa, SI; Yla-Herttuala, S; Alitalo, K				Makinen, T; Jussila, L; Veikkola, T; Karpanen, T; Kettunen, MI; Pulkkanen, KJ; Kauppinen, R; Jackson, DG; Kubo, H; Nishikawa, SI; Yla-Herttuala, S; Alitalo, K			Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; FACTOR-C EXPRESSION; IN-VIVO; LYMPHATIC ENDOTHELIUM; TUMOR-GROWTH; GENE-EXPRESSION; ANGIOGENESIS; SUPPRESSION; METASTASIS; ANTIBODIES	The lymphatic vasculature transports extravasated tissue fluid, macromolecules and cells back into the blood circulation. Recent reports have focused on the molecular mechanisms regulating the lymphatic vessels. Vascular endothelial growth factor (VEGF)-C and VEGF-D have been shown to stimulate lymphangiogenesis and their receptor, VEGFR-3, has been linked to human hereditary lymphedema. Here we show that a soluble form of VEGFR-3 is a potent inhibitor of VEGF-C/VEGF-D signaling, and when expressed in the skin of transgenic mice, it inhibits fetal lymphangiogenesis and induces a regression of already formed lymphatic vessels, though the blood vasculature remains normal. Transgenic mice develop a lymphedema-like phenotype characterized by swelling of feet, edema and dermal fibrosis. They survive the neonatal period in spite of a virtually complete lack of lymphatic Vessels in several tissues, and later show regeneration of the lymphatic vasculature, indicating that induction of lymphatic regeneration may also be possible in humans.	Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, Helsinki, Finland; Univ Helsinki, Ludwig Inst Canc Res, Haartman Inst, Helsinki, Finland; Univ Kuopio, AI Virtanen Inst, Dept Mol Med, Kuopio, Finland; Univ Kuopio, Natl BioNMR Facil, Kuopio, Finland; Kuopio Univ Hosp, Dept Oncol, SF-70210 Kuopio, Finland; Univ Oxford, Mol Immunol Grp, Nuffield Dept Med, Oxford, England; Kyoto Univ, Dept Mol Genet, Kyoto, Japan	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; Finland National Institute for Health & Welfare; University of Eastern Finland; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; University of Oxford; Kyoto University	Alitalo, K (corresponding author), Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, Helsinki, Finland.	kari.alitalo@helsinki.fi	Kettunen, Mikko I/K-2299-2012; Kauppinen, Risto A/F-3274-2011; Makinen, Taija/CAI-2233-2022; Makinen, Taija/C-5765-2014; Alitalo, Kari K/J-5013-2014	Kettunen, Mikko I/0000-0002-2004-660X; Makinen, Taija/0000-0002-9338-1257; Makinen, Taija/0000-0002-9338-1257; Alitalo, Kari K/0000-0002-7331-0902; Yla-Herttuala, Seppo/0000-0001-7593-2708; Karpanen, Terhi/0000-0002-2803-083X; , david/0000-0002-4133-9364				Achen MG, 2000, EUR J BIOCHEM, V267, P2505, DOI 10.1046/j.1432-1327.2000.01257.x; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Fong GH, 1999, DEVELOPMENT, V126, P3015; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; Hakumaki JM, 1999, NAT MED, V5, P1323, DOI 10.1038/15279; Irrthum A, 2000, AM J HUM GENET, V67, P295, DOI 10.1086/303019; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; Jussila L, 1998, CANCER RES, V58, P1599; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Karkkainen MJ, 2001, TRENDS MOL MED, V7, P18, DOI 10.1016/S1471-4914(00)01864-5; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Kong HL, 1998, HUM GENE THER, V9, P823, DOI 10.1089/hum.1998.9.6-823; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; Kubo H, 2000, BLOOD, V96, P546; Lin PN, 1998, CELL GROWTH DIFFER, V9, P49; Lymboussaki A, 1998, AM J PATHOL, V153, P395, DOI 10.1016/S0002-9440(10)65583-6; MANDRIOTA SJ, 2001, IN PRESS EMBO J; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; Morishita M, 1998, MITSUBISHI ELECTR AD, V83, P1; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Takayama K, 2000, CANCER RES, V60, P2169; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Veikkola T, 2000, CANCER RES, V60, P203; Witte M H, 1997, EXS, V79, P65; Witzenbichler B, 1998, AM J PATHOL, V153, P381, DOI 10.1016/S0002-9440(10)65582-4; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823	45	594	652	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2001	7	2					199	205		10.1038/84651	http://dx.doi.org/10.1038/84651			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175851				2022-12-27	WOS:000166756300037
J	Kay, MA; Glorioso, JC; Naldini, L				Kay, MA; Glorioso, JC; Naldini, L			Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics	NATURE MEDICINE			English	Review							RECOMBINANT ADENOASSOCIATED VIRUS; SITE-SPECIFIC INTEGRATION; MEDIATED TRANSGENE EXPRESSION; DEPENDENT ADENOVIRAL VECTORS; HEPATOCYTES IN-VIVO; HUMAN-FACTOR VIII; LENTIVIRUS VECTOR; EFFICIENT TRANSDUCTION; STABLE TRANSDUCTION; IMMUNE-RESPONSES	Considered by some to be among the simpler forms of life, viruses represent highly evolved natural vectors for the transfer of foreign genetic information into cells. This attribute has led to extensive attempts to engineer recombinant viral vectors for the delivery of therapeutic genes into diseased tissues. While substantial progress has been made, and some clinical successes are over the horizon, further vector refinement and/or development is required before gene therapy will become standard care for any individual disorder.	Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA; Univ Pittsburgh, Dept Mol Genet & Biochem, Pittsburgh, PA USA; Univ Turin, Sch Med, Inst Canc Res & Treatment, Turin, Italy	Stanford University; Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Turin	Kay, MA (corresponding author), Stanford Univ, Dept Pediat, Stanford, CA 94305 USA.	markay@stanford.edu	Naldini, Luigi/E-9083-2012	NALDINI, Luigi/0000-0002-7835-527X; Kay, Mark/0000-0002-2799-2615	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034534] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64274] Funding Source: Medline; NIAMS NIH HHS [AR44526] Funding Source: Medline; NIDDK NIH HHS [DK49022] Funding Source: Medline; NIGMS NIH HHS [GM34534] Funding Source: Medline; Telethon [B.58] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Telethon(Fondazione Telethon)		Aghi M, 2000, J GENE MED, V2, P148, DOI 10.1002/(SICI)1521-2254(200005/06)2:3<148::AID-JGM105>3.0.CO;2-Q; An DS, 2000, J VIROL, V74, P1286, DOI 10.1128/JVI.74.3.1286-1295.2000; [Anonymous], 2000, HUM GENE THER, V11, P919; Armentano D, 1999, J VIROL, V73, P7031, DOI 10.1128/JVI.73.8.7031-7034.1999; Balague C, 2000, BLOOD, V95, P820, DOI 10.1182/blood.V95.3.820.003k32_820_828; BARR D, 1995, GENE THER, V2, P151; Benihoud K, 1999, CURR OPIN BIOTECH, V10, P440, DOI 10.1016/S0958-1669(99)00007-5; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; Bosch A, 2000, HUM GENE THER, V11, P1139, DOI 10.1089/10430340050015194; BRAMSON JL, 1995, CURR OPIN BIOTECH, V6, P590, DOI 10.1016/0958-1669(95)80097-2; BRODY SL, 1994, ANN NY ACAD SCI, V716, P90, DOI 10.1111/j.1749-6632.1994.tb21705.x; Bukovsky AA, 1999, J VIROL, V73, P7087, DOI 10.1128/JVI.73.8.7087-7092.1999; BUKRINSKY MI, 1999, FRONT BIOSCI, V4, P772; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; BURTON EA, 2000, GENE THER MOL BIOL, V5, P1; CAO L, 1998, STEM CELLS S, V16, P1251; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Chaisomchit S, 1997, GENE THER, V4, P1330, DOI 10.1038/sj.gt.3300544; CHANCELLOR M, 2000, MOL THER, V1, pS111; Chong H, 1998, J VIROL, V72, P2663, DOI 10.1128/JVI.72.4.2663-2670.1998; Christ M, 2000, HUM GENE THER, V11, P415, DOI 10.1089/10430340050015888; Clackson T, 2000, GENE THER, V7, P120, DOI 10.1038/sj.gt.3301120; Clark KR, 1999, HUM GENE THER, V10, P1031, DOI 10.1089/10430349950018427; COFFIN J, 2000, RETROVIRUSES; CONSIGLIO, IN PRESS NATURE MED; CORNETTA K, 1991, HUM GENE THER, V2, P215, DOI 10.1089/hum.1991.2.3-215; Curiel DT, 1999, ANN NY ACAD SCI, V886, P158, DOI 10.1111/j.1749-6632.1999.tb09409.x; Duan DS, 1998, J VIROL, V72, P8568, DOI 10.1128/JVI.72.11.8568-8577.1998; Duan DS, 1999, VIROLOGY, V261, P8, DOI 10.1006/viro.1999.9821; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Dutheil N, 2000, P NATL ACAD SCI USA, V97, P4862, DOI 10.1073/pnas.080079397; Feldman AL, 2000, CANCER-AM CANCER SOC, V89, P1181; Ferrari FK, 1996, J VIROL, V70, P3227, DOI 10.1128/JVI.70.5.3227-3234.1996; Fisher KJ, 1996, J VIROL, V70, P520, DOI 10.1128/JVI.70.1.520-532.1996; Goins WF, 1999, J VIROL, V73, P519, DOI 10.1128/JVI.73.1.519-532.1999; Gorziglia MI, 1999, J VIROL, V73, P6048, DOI 10.1128/JVI.73.7.6048-6055.1999; GOSS J, 2000, MOL THER, V1, pS110; GOSS J, 1999, ANN M SOC NEUR ABSTS, V29, P2280; Groth AC, 2000, P NATL ACAD SCI USA, V97, P5995, DOI 10.1073/pnas.090527097; Guenechea G, 2000, MOL THER, V1, P566, DOI 10.1006/mthe.2000.0077; Halene S, 2000, HUM GENE THER, V11, P1259, DOI 10.1089/10430340050032366; Hauswirth WW, 2000, METHOD ENZYMOL, V316, P743; Heise C, 2000, J CLIN INVEST, V105, P847, DOI 10.1172/JCI9762; Hermiston T, 2000, J CLIN INVEST, V105, P1169, DOI 10.1172/JCI9973; Hewson R, 2000, MOL MED TODAY, V6, P28, DOI 10.1016/S1357-4310(99)01622-6; Hitt M M, 1997, Adv Pharmacol, V40, P137, DOI 10.1016/S1054-3589(08)60140-4; HORWITZ MS, 1996, FIELDS VIROLOGY, P2149; Ilan Y, 1997, P NATL ACAD SCI USA, V94, P2587, DOI 10.1073/pnas.94.6.2587; Johnson LG, 2000, GENE THER, V7, P568, DOI 10.1038/sj.gt.3301138; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; KAY MA, 1995, NAT GENET, V11, P191, DOI 10.1038/ng1095-191; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; Kitson C, 2000, EXPERT OPIN INV DRUG, V9, P1523, DOI 10.1517/13543784.9.7.1523; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; Kordower JH, 1999, EXP NEUROL, V160, P1, DOI 10.1006/exnr.1999.7178; Kovesdi I, 1997, CURR OPIN BIOTECH, V8, P583, DOI 10.1016/S0958-1669(97)80033-X; Krisky DM, 1998, GENE THER, V5, P1517, DOI 10.1038/sj.gt.3300755; Lieber A, 1999, J VIROL, V73, P9314, DOI 10.1128/JVI.73.11.9314-9324.1999; Linden RM, 1996, P NATL ACAD SCI USA, V93, P11288, DOI 10.1073/pnas.93.21.11288; Loser P, 2000, GENE THER, V7, P1491, DOI 10.1038/sj.gt.3301260; Lusky M, 1998, J VIROL, V72, P2022, DOI 10.1128/JVI.72.3.2022-2032.1998; Martino G, 2000, GENE THER, V7, P1087, DOI 10.1038/sj.gt.3301215; Matsushita T, 1998, GENE THER, V5, P938, DOI 10.1038/sj.gt.3300680; May C, 2000, NATURE, V406, P82, DOI 10.1038/35017565; Miao CH, 1998, NAT GENET, V19, P13, DOI 10.1038/ng0598-13; Miao CH, 2000, J VIROL, V74, P3793, DOI 10.1128/JVI.74.8.3793-3803.2000; MILLER AD, 2000, RETROVIRUSES; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; Mitrophanous KA, 1999, GENE THER, V6, P1808, DOI 10.1038/sj.gt.3301023; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Monahan PE, 2000, MOL MED TODAY, V6, P433, DOI 10.1016/S1357-4310(00)01810-4; Monahan PE, 2000, GENE THER, V7, P24, DOI 10.1038/sj.gt.3301109; Morral N, 1998, HUM GENE THER, V9, P2709, DOI 10.1089/hum.1998.9.18-2709; Morral N, 1999, P NATL ACAD SCI USA, V96, P12816, DOI 10.1073/pnas.96.22.12816; Morsy MA, 1999, MOL MED TODAY, V5, P18, DOI 10.1016/S1357-4310(98)01376-8; MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97; Nakai H, 2000, J VIROL, V74, P9451, DOI 10.1128/JVI.74.20.9451-9463.2000; Nakai H, 2000, NAT BIOTECHNOL, V18, P527, DOI 10.1038/75390; Nakai H, 1999, J VIROL, V73, P5438, DOI 10.1128/JVI.73.7.5438-5447.1999; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; O'Neal WK, 1998, HUM GENE THER, V9, P1587, DOI 10.1089/hum.1998.9.11-1587; Olsen JC, 1998, GENE THER, V5, P1481, DOI 10.1038/sj.gt.3300768; OTTO E, 1994, HUM GENE THER, V5, P567, DOI 10.1089/hum.1994.5.5-567; Palese P, 1996, P NATL ACAD SCI USA, V93, P11354, DOI 10.1073/pnas.93.21.11354; Park F, 2000, BLOOD, V96, P1173, DOI 10.1182/blood.V96.3.1173.015k34_1173_1176; Park F, 2000, NAT GENET, V24, P49, DOI 10.1038/71673; Parks RJ, 1999, GENE THER, V6, P1565, DOI 10.1038/sj.gt.3300995; Peeters MJTFDV, 1996, BIOTECHNIQUES, V20, P278; Poeschla EM, 1998, NAT MED, V4, P354, DOI 10.1038/nm0398-354; Recchia A, 1999, P NATL ACAD SCI USA, V96, P2615, DOI 10.1073/pnas.96.6.2615; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Russell DW, 1999, BLOOD, V94, P864, DOI 10.1182/blood.V94.3.864.415k34_864_874; Saeki Y, 1998, HUM GENE THER, V9, P2787, DOI 10.1089/hum.1998.9.18-2787; Samaniego LA, 1998, J VIROL, V72, P3307, DOI 10.1128/JVI.72.4.3307-3320.1998; Schowalter DB, 1999, J VIROL, V73, P4755, DOI 10.1128/JVI.73.6.4755-4766.1999; Sclimenti CR, 1998, CURR OPIN BIOTECH, V9, P476, DOI 10.1016/S0958-1669(98)80032-3; SHENK T, 1996, FIELDS VIROLOGY, P2111; SPAETE RR, 1982, CELL, V30, P295, DOI 10.1016/0092-8674(82)90035-6; Stedman Hansell, 2000, Human Gene Therapy, V11, P777; Strayer DA, 1999, J CELL PHYSIOL, V181, P375, DOI 10.1002/(SICI)1097-4652(199912)181:3<375::AID-JCP1>3.0.CO;2-8; Sun LW, 2000, NAT MED, V6, P599, DOI 10.1038/75087; Takahashi M, 1999, J VIROL, V73, P7812, DOI 10.1128/JVI.73.9.7812-7816.1999; Tal J, 2000, J BIOMED SCI, V7, P279, DOI 10.1007/BF02253246; Thyagarajan B, 2000, GENE, V244, P47, DOI 10.1016/S0378-1119(00)00008-1; Trobridge GD, 1998, HUM GENE THER, V9, P2517, DOI 10.1089/10430349850019355; VANIN EF, 1994, J VIROL, V68, P4241, DOI 10.1128/JVI.68.7.4241-4250.1994; Vigna E, 2000, J GENE MED, V2, P308; Vincent-Lacaze N, 1999, J VIROL, V73, P1949, DOI 10.1128/JVI.73.3.1949-1955.1999; Wagner JA, 1999, LARYNGOSCOPE, V109, P266, DOI 10.1097/00005537-199902000-00017; Wahlfors JJ, 2000, GENE THER, V7, P472, DOI 10.1038/sj.gt.3301122; Wickham TJ, 2000, GENE THER, V7, P110, DOI 10.1038/sj.gt.3301115; WOLD WSM, 1991, VIROLOGY, V184, P1, DOI 10.1016/0042-6822(91)90815-S; WOLFE D, IN PRESS MOL THER; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; Yamada M, 1999, P NATL ACAD SCI USA, V96, P4078, DOI 10.1073/pnas.96.7.4078; Yan ZY, 2000, P NATL ACAD SCI USA, V97, P6716, DOI 10.1073/pnas.97.12.6716; Yang JS, 1999, J VIROL, V73, P9468, DOI 10.1128/JVI.73.11.9468-9477.1999; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1995, J IMMUNOL, V155, P2564; Yenari MA, 1998, ANN NEUROL, V44, P584, DOI 10.1002/ana.410440403; Zheng CY, 2000, NAT BIOTECHNOL, V18, P176, DOI 10.1038/72628; Zhu J, 2000, MOL THER, V2, P82, DOI 10.1006/mthe.2000.0093; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	127	958	1082	4	270	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					33	40		10.1038/83324	http://dx.doi.org/10.1038/83324			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135613				2022-12-27	WOS:000166243100032
J	Glenn, GM; Taylor, DN; Li, XR; Frankel, S; Montemarano, A; Alving, CR				Glenn, GM; Taylor, DN; Li, XR; Frankel, S; Montemarano, A; Alving, CR			Transcutaneous immunization: A human vaccine delivery strategy using a patch	NATURE MEDICINE			English	Article							ESCHERICHIA-COLI; CHOLERA-TOXIN; LANGERHANS CELLS; B-SUBUNIT; ENTEROTOXIN; RESPONSES	Transcutaneous immunization, a topical Vaccine application, combines the advantages of needle-free delivery while targeting the immunologically rich milieu of the skin. In animal studies, this simple technique induces robust systemic and mucosal antibodies against vaccine antigens. Here, we demonstrate safe application of a patch containing heat-labile enterotoxin (LT, derived from Escherichia coli) to humans, resulting in robust LT-antibody responses. These findings indicate that TCL is feasible for human immunization, and suggest that TCL may enhance efficacy as well as improve vaccine delivery.	Walter Reed Army Inst Res, Dept Membrane Biochem, Silver Spring, MD 20910 USA; IOMAI Corp, Washington, DC 20037 USA; Walter Reed Army Inst Res, Dept Enter Infect, Silver Spring, MD 20910 USA; Armed Forces Inst Pathol, Washington, DC 20307 USA; Walter Reed Army Med Ctr, Dept Dermatol, Washington, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); United States Department of Defense; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Glenn, GM (corresponding author), Walter Reed Army Inst Res, Dept Membrane Biochem, 503 Robert Grant Rd,Rm 2W-124, Silver Spring, MD 20910 USA.	gglenn@iomai.com						AIBA S, 1990, J IMMUNOL, V145, P2791; BARRY BW, 1985, PERCUTANEOUS ABSORPT, P33; Bouloc A, 1999, EUR J IMMUNOL, V29, P446, DOI 10.1002/(SICI)1521-4141(199902)29:02<446::AID-IMMU446>3.0.CO;2-A; Bouvet JP, 1999, INFECT IMMUN, V67, P2687, DOI 10.1128/IAI.67.6.2687-2691.1999; CLEMENS JD, 1988, J INFECT DIS, V158, P372, DOI 10.1093/infdis/158.2.372; Cope RB, 2000, AUST VET J, V78, P121, DOI 10.1111/j.1751-0813.2000.tb10540.x; Glenn G M, 1999, Expert Opin Investig Drugs, V8, P797, DOI 10.1517/13543784.8.6.797; Glenn GM, 1999, INFECT IMMUN, V67, P1100, DOI 10.1128/IAI.67.3.1100-1106.1999; Glenn GM, 1998, J IMMUNOL, V161, P3211; Glenn GM, 1998, NATURE, V391, P851, DOI 10.1038/36014; Gluck R, 2000, J INFECT DIS, V181, P1129, DOI 10.1086/315337; HOLMGREN J, 1975, INFECT IMMUN, V12, P1331, DOI 10.1128/IAI.12.6.1331-1340.1975; KRIPKE ML, 1990, J IMMUNOL, V145, P2833; Michetti P, 1999, GASTROENTEROLOGY, V116, P804, DOI 10.1016/S0016-5085(99)70063-6; NOBLE B, 1996, ACTA OTOLARYNGOL S S, V523, pS94; ROBERTSON GL, 1993, PACK CONV T, V6, P1; Rudin A, 1999, INFECT IMMUN, V67, P2884, DOI 10.1128/IAI.67.6.2884-2890.1999; Scharton-Kersten T, 2000, INFECT IMMUN, V68, P5306, DOI 10.1128/IAI.68.9.5306-5313.2000; Seo N, 2000, P NATL ACAD SCI USA, V97, P371, DOI 10.1073/pnas.97.1.371; Snider DP, 1995, CRIT REV IMMUNOL, V15, P317, DOI 10.1615/CritRevImmunol.v15.i3-4.70; SVENNERHOLM AM, 1983, J INFECT DIS, V147, P514, DOI 10.1093/infdis/147.3.514; Udey MC, 1997, CLIN EXP IMMUNOL, V107, P6; Wang LF, 1996, J IMMUNOL, V156, P4079; *WHO, 1996, RED RISK UNS INJ IMM; YU RC, 1994, BRIT J DERMATOL, V131, P843, DOI 10.1111/j.1365-2133.1994.tb08587.x	25	259	276	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2000	6	12					1403	1406		10.1038/82225	http://dx.doi.org/10.1038/82225			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100128				2022-12-27	WOS:000165704100047
J	Shafer, RW; Jung, DR; Betts, BJ				Shafer, RW; Jung, DR; Betts, BJ			Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries	NATURE MEDICINE			English	Article							SEQUENCE DATABASE		Stanford Univ, Sch Med, Div Infect Dis, Stanford, CA 94305 USA; Stanford Univ, Sch Engn, Stanford, CA 94305 USA	Stanford University; Stanford University	Shafer, RW (corresponding author), Stanford Univ, Sch Med, Div Infect Dis, Stanford, CA 94305 USA.			Betts, Bradley/0000-0002-1618-8285	NIAID NIH HHS [R01 AI046148, R01 AI046148-08] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046148] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashburner M, 1997, CURR OPIN GENET DEV, V7, P750, DOI 10.1016/S0959-437X(97)80036-6; Benson DA, 1999, NUCLEIC ACIDS RES, V27, P12, DOI 10.1093/nar/27.1.12; Frishman D, 1998, BIOINFORMATICS, V14, P551, DOI 10.1093/bioinformatics/14.7.551; HAMMOND J, 1998, HUMAN RETROVIRUSES A; HARDT D, 1998, PERL RESOURCE KIT WI; Hirsch MS, 2000, JAMA-J AM MED ASSOC, V283, P2417, DOI 10.1001/jama.283.18.2417; Imamichi T, 2000, J VIROL, V74, P1023, DOI 10.1128/JVI.74.2.1023-1028.2000; KORBER BT, 1998, HUMAN RETROVIRUSES A; LARDER B, 1999, ANTIVIR THER S, V4, P41; Learn GH, 1996, J VIROL, V70, P5720, DOI 10.1128/JVI.70.8.5720-5730.1996; *NAT CTR BIOT INF, 1998, HIV 1 SUBT TOOL; *PN CLIN PRACT TRE, 2000, GUID US ANT AG HIV I; Shafer RW, 1999, NUCLEIC ACIDS RES, V27, P348, DOI 10.1093/nar/27.1.348; STEUBAL J, 1997, INTRO COMPUTATIONAL, P61; Stoesser G, 1999, NUCLEIC ACIDS RES, V27, P18, DOI 10.1093/nar/27.1.18; Sugawara H, 1999, NUCLEIC ACIDS RES, V27, P25, DOI 10.1093/nar/27.1.25; Winters MA, 1998, J CLIN INVEST, V102, P1769, DOI 10.1172/JCI4948	17	63	65	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1290	1292		10.1038/81407	http://dx.doi.org/10.1038/81407			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062545	Green Accepted			2022-12-27	WOS:000165114800041
J	Kureishi, Y; Luo, ZY; Shiojima, I; Bialik, A; Fulton, D; Lefer, DJ; Sessa, WC; Walsh, K				Kureishi, Y; Luo, ZY; Shiojima, I; Bialik, A; Fulton, D; Lefer, DJ; Sessa, WC; Walsh, K			The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; ENDOTHELIAL GROWTH-FACTOR; CHOLESTEROL REDUCTION; SURVIVAL; ISCHEMIA; THERAPY; GENE; PRAVASTATIN; VESSELS; PATHWAY	Recent studies suggest that statins can function to protect the vasculature in a manner that is independent of their lipid-lowering activity. We show here that statins rapidly activate the protein kinase Akt/PKB in endothelial cells. Accordingly, simvastatin enhanced phosphorylation of the endogenous Akt substrate endothelial nitric oxide synthase (eNOS), inhibited apoptosis and accelerated vascular structure formation in vitro in an Akt-dependent manner. Similar to vascular endothelial growth factor (VEGF) treatment,both simvastatin administration and enhanced Akt signaling in the endothelium promoted angiogenesis in ischemic limbs of normocholesterolemic rabbits. Therefore, activation of Akt represents a mechanism that can account for some of the beneficial side effects of statins, including the promotion of new blood vessel growth.	Tufts Univ, Sch Med, St Elizabeths Med Ctr Boston, Div Cardiovasc Res, Boston, MA 02135 USA; Tufts Univ, Sch Med, Sackler Sch Biomed Sci, Program Cell Mol & Dev Biol, Boston, MA 02135 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Mol Cardiobiol Program, New Haven, CT 06536 USA; Louisiana State Univ, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA	St. Elizabeth's Medical Center; Tufts University; Tufts University; Yale University; Yale University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Walsh, K (corresponding author), Tufts Univ, Sch Med, St Elizabeths Med Ctr Boston, Div Cardiovasc Res, Boston, MA 02135 USA.	kwalsh@opal.tufts.edu	Lefer, David/A-6372-2012; Bando, Yasuko K./M-4831-2014; Sessa, William C/B-6844-2011	Bando, Yasuko K./0000-0003-4166-6784; Sessa, William C/0000-0001-5759-1938; Walsh, Kenneth/0000-0001-7580-2276; Lefer, David/0000-0003-2293-7278	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015052] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL50692, R01 HL050692-10] Funding Source: Medline; NIAMS NIH HHS [R01 AR040197, R01 AR040197-11, R01-AR40197] Funding Source: Medline; NIA NIH HHS [R01 AG015052, R01-AG15052, R01 AG015052-03] Funding Source: Medline; NICHD NIH HHS [P01 HD023681] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Baller D, 1999, CIRCULATION, V99, P2871, DOI 10.1161/01.CIR.99.22.2871; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dupuis J, 1999, CIRCULATION, V99, P3227, DOI 10.1161/01.CIR.99.25.3227; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Guo K, 1998, CIRCULATION, V97, P2066, DOI 10.1161/01.CIR.97.20.2066; Kaesemeyer WH, 1999, J AM COLL CARDIOL, V33, P234, DOI 10.1016/S0735-1097(98)00514-2; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Lefer AM, 1996, CARDIOVASC RES, V32, P743, DOI 10.1016/0008-6363(96)00073-9; Lefer AM, 1999, CIRCULATION, V100, P178, DOI 10.1161/01.CIR.100.2.178; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; LUO Z, 2000, IN PRESS J CLIN INVE; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; OSBORNE JA, 1989, AM J PHYSIOL, V256, pC591, DOI 10.1152/ajpcell.1989.256.3.C591; Packard CJ, 1998, CIRCULATION, V97, P1440; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; PEDERSEN TR, 1994, LANCET, V344, P1383; Pruefer D, 1999, ARTERIOSCL THROM VAS, V19, P2894, DOI 10.1161/01.ATV.19.12.2894; PU LQ, 1993, J SURG RES, V54, P575, DOI 10.1006/jsre.1993.1088; Qian HS, 1999, CIRCULATION, V99, P2979, DOI 10.1161/01.CIR.99.23.2979; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SIMON DI, 1993, ARTERIOSCLER THROMB, V13, P791, DOI 10.1161/01.ATV.13.6.791; *TASCWORK GROUP, 2000, J VASC SURG S, V31, pS62; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	36	1194	1283	7	60	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2000	6	9					1004	1010		10.1038/79510	http://dx.doi.org/10.1038/79510			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973320	Green Accepted			2022-12-27	WOS:000089190500032
J	Wallenius, V; Wallenius, K; Ahren, B; Rudling, M; Carlsten, H; Dickson, SL; Ohlsson, C; Jansson, JO				Wallenius, V; Wallenius, K; Ahren, B; Rudling, M; Carlsten, H; Dickson, SL; Ohlsson, C; Jansson, JO			Interleukin-6-deficient mice develop mature-onset obesity	NATURE MEDICINE			English	Article							SUBCUTANEOUS ADIPOSE-TISSUE; CILIARY NEUROTROPHIC FACTOR; INSULIN-RESISTANCE; VISCERAL OBESITY; BODY-WEIGHT; RAT; LEPTIN; HYPOTHALAMUS; INFLAMMATION; ACTIVATION	The immune-modulating cytokine interleukin-6 (IL-6) its expressed both in adipose tissue and centrally in hypothalamic nuclei that regulate body composition. We investigated the impact of loss of IL-6 on body composition in mice lacking the gene encoding IL-6 (116(-/-) mice) and found that they developed mature-onset obesity that was partly reversed by IL-6 replacement: The obese 116(-/-) mice had disturbed carbohydrate and lipid metabolism, increased leptin levels and decreased responsiveness to leptin treatment. To investigate the possible mechanism and site of action of the anti-obesity effect of IL-6, we injected rats centrally and peripherally with IL-6 at low doses. Intracerebroventricular, but not intraperitoneal IL-6 treatment increased energy expenditure. In conclusion, centrally acting IL-6 exerts anti-obesity effects in rodents.	Univ Gothenburg, Res Ctr Endocrinol & Metab, Sahlgrenska Acad, Gothenburg, Sweden; Univ Gothenburg, Dept Rheumatol & Clin Immunol, Sahlgrenska Acad, Gothenburg, Sweden; Lund Univ, Malmo Univ Hosp, Dept Med, Lund, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Gastroenterol, Stockholm, Sweden; Univ Cambridge, Dept Physiol, Cambridge, England	University of Gothenburg; University of Gothenburg; Lund University; Skane University Hospital; Karolinska Institutet; University of Cambridge	Jansson, JO (corresponding author), Univ Gothenburg, Res Ctr Endocrinol & Metab, Sahlgrenska Acad, Gothenburg, Sweden.	john-olov.jansson@medic.gu.se	Dickson, Suzanne L/U-4628-2019; Wallenius, Ville Raymond/C-5486-2014; Ohlsson, Claes/AGP-3544-2022	Wallenius, Ville Raymond/0000-0001-8668-3196; Ohlsson, Claes/0000-0002-9633-2805; Dickson, Suzanne/0000-0002-3822-5294; Wallenius, Kristina/0000-0002-3231-2733				Ahren B, 1997, AM J PHYSIOL-REG I, V273, pR113, DOI 10.1152/ajpregu.1997.273.1.R113; Aschner M, 1998, TOXICOL LETT, V103, P283, DOI 10.1016/S0378-4274(98)00324-5; Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35007519; Bastard JP, 2000, J CLIN ENDOCR METAB, V85, P3338, DOI 10.1210/jc.85.9.3338; Bjorbaek C, 1999, ENDOCRINOLOGY, V140, P2035, DOI 10.1210/en.140.5.2035; Bjorntorp P, 1997, NUTRITION, V13, P795, DOI 10.1016/S0899-9007(97)00191-3; Bray GA, 2000, NATURE, V404, P672, DOI 10.1038/35007544; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; DICKSON SL, 1995, NEUROENDOCRINOLOGY, V61, P36, DOI 10.1159/000126825; Ershler WB, 2000, ANNU REV MED, V51, P245, DOI 10.1146/annurev.med.51.1.245; Espat NJ, 1996, AM J PHYSIOL-REG I, V271, pR185, DOI 10.1152/ajpregu.1996.271.1.R185; FLIER JS, 1998, WILLIAMS TXB ENDOCRI, P1061; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gloaguen I, 1997, P NATL ACAD SCI USA, V94, P6456, DOI 10.1073/pnas.94.12.6456; GREENBERG AS, 1992, CANCER RES, V52, P4113; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Lambert PD, 2001, P NATL ACAD SCI USA, V98, P4652, DOI 10.1073/pnas.061034298; Liao W, 1996, BIOCHEM J, V313, P873, DOI 10.1042/bj3130873; Luheshi GN, 1999, P NATL ACAD SCI USA, V96, P7047, DOI 10.1073/pnas.96.12.7047; McCarty MF, 1999, MED HYPOTHESES, V52, P465, DOI 10.1054/mehy.1997.0684; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; NONOGAKI K, 1995, ENDOCRINOLOGY, V136, P2143, DOI 10.1210/en.136.5.2143; Pedersen BK, 2001, J PHYSIOL-LONDON, V536, P329, DOI 10.1111/j.1469-7793.2001.0329c.xd; Robinson SW, 2000, ANNU REV GENET, V34, P687, DOI 10.1146/annurev.genet.34.1.687; ROTHWELL NJ, 1991, CAN J PHYSIOL PHARM, V69, P1465, DOI 10.1139/y91-219; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; Shizuya K, 1998, LIFE SCI, V62, P2315, DOI 10.1016/S0024-3205(98)00212-4; Sjogren K, 2001, DIABETES, V50, P1539, DOI 10.2337/diabetes.50.7.1539; Sleeman M W, 2000, Pharm Acta Helv, V74, P265, DOI 10.1016/S0031-6865(99)00050-3; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Tsigos C, 1997, J CLIN ENDOCR METAB, V82, P4167, DOI 10.1210/jc.82.12.4167; Verdrengh M, 2000, ARTHRITIS RHEUM, V43, P2276, DOI 10.1002/1529-0131(200010)43:10<2276::AID-ANR15>3.0.CO;2-C; Vgontzas AN, 2000, J CLIN ENDOCR METAB, V85, P1151, DOI 10.1210/jc.85.3.1151; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3	36	917	958	1	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2002	8	1					75	79		10.1038/nm0102-75	http://dx.doi.org/10.1038/nm0102-75			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	507XQ	11786910				2022-12-27	WOS:000173056900034
J	Lane, HC; La Montagne, J; Fauci, AS				Lane, HC; La Montagne, J; Fauci, AS			Bioterrorism: A clear and present danger	NATURE MEDICINE			English	Editorial Material							ANTHRAX; VACCINE	The anthrax attacks in the United States, juxtaposed against the September 11 terrorist attacks on New York and Washington, DC, have transformed a theoretical threat to stark reality. The biomedical research community will be an Integral part of the preparation for, defense against and response to bioterrorism.	NIAID, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lane, HC (corresponding author), NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	clane@nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000636, ZIAAI000636] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alibek K., 1999, BIOHAZARD CHILLING S; ANDZHAPARIDZE OG, 1980, VOP VIRUSOL+, P443; Bray M, 2000, J INFECT DIS, V181, P10, DOI 10.1086/315190; De Clercq E, 2001, CLIN MICROBIOL REV, V14, P382, DOI 10.1128/CMR.14.2.382-397.2001; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Friedlander AM, 1999, JAMA-J AM MED ASSOC, V282, P2104, DOI 10.1001/jama.282.22.2104; FRIEDLANDER AM, 1993, J INFECT DIS, V167, P1239, DOI 10.1093/infdis/167.5.1239; HENDERSON DA, 1987, B WORLD HEALTH ORGAN, V65, P535; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; JERNIGAN JA, EMERG INFECT DIS; KLIMPEL KR, 1994, MOL MICROBIOL, V13, P1093, DOI 10.1111/j.1365-2958.1994.tb00500.x; LeDuc JW, 1999, EMERG INFECT DIS, V5, P593, DOI 10.3201/eid0504.990429; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; Reuveny S, 2001, INFECT IMMUN, V69, P2888, DOI 10.1128/IAI.69.5.2888-2893.2001; SINGH Y, 1989, J BIOL CHEM, V264, P19103; Singh Y, 2001, J BIOL CHEM, V276, P22090, DOI 10.1074/jbc.M010222200; Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108; THOMAS LJ, 2001, 4 INT C ANTHR; Turnbull PCB, 2000, CURR OPIN INFECT DIS, V13, P113, DOI 10.1097/00001432-200004000-00004; 2001, ANTHRAX CASE CONFIRM; 1994, B WHO, V72, P813; 2001, MMWR MORB MORTAL WKL, V50, P973; 2001, MMWR MORB MORTAL WKL, V50, P877; 2000, MMWR MORB MORTAL WKL, V49, pRR15; 1994, B WHO, V72, P817	25	134	143	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2001	7	12					1271	1273		10.1038/nm1201-1271	http://dx.doi.org/10.1038/nm1201-1271			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726956				2022-12-27	WOS:000172610300019
J	Lei, BF; DeLeo, FR; Hoe, NP; Graham, MR; Mackie, SM; Cole, RL; Liu, MY; Hill, HR; Low, DE; Federle, MJ; Scott, JR; Musser, JM				Lei, BF; DeLeo, FR; Hoe, NP; Graham, MR; Mackie, SM; Cole, RL; Liu, MY; Hill, HR; Low, DE; Federle, MJ; Scott, JR; Musser, JM			Evasion of human innate and acquired immunity by a bacterial homolog of CD11b that inhibits opsonophagocytosis	NATURE MEDICINE			English	Article							COMPLEMENT RECEPTOR TYPE-3; HYALURONIC-ACID CAPSULE; FC-GAMMA-RIII; BINDING-SITE; M-PROTEIN; MAC-1; IDENTIFICATION; ACTIVATION; VIRULENCE; CR3	Microbial pathogens must evade the human immune system to survive, disseminate and cause disease. By proteome analysis of the bacterium Group A Streptococcus (GAS), we identified a secreted protein with homology to the alpha -subunit of Mac-1, a leukocyte beta (2) integrin required for innate immunity to invading microbes. The GAS Mac-1-like protein (Mac) was secreted by most pathogenic strains, produced in log-phase and controlled by the covR-covS two-component gene regulatory system, which also regulates transcription of other GAS virulence factors. Patients with GAS infection had titers of antibody specific to Mac that correlated with the course of disease, demonstrating that Mac was produced in vivo. Mac bound to CD16 (Fc gamma RIIIB) on the surface of human polymorphonuclear leukocytes and inhibited opsonophagocytosis and production of reactive oxygen species, which resulted in significantly decreased pathogen killing. Thus, by mimicking a host-cell receptor required for an innate immune response, the GAS Mac protein inhibits professional phagocyte function by a novel strategy that enhances pathogen survival, establishment of infection and dissemination.	NIAID, Rocky Mt Labs, Lab Human Bacterial Pathogenesis, Hamilton, MT 59840 USA; Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA; Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA; Univ Utah, Sch Med, Dept Med, Salt Lake City, UT USA; Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Toronto, ON, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Emory University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Lei, BF (corresponding author), NIAID, Rocky Mt Labs, Lab Human Bacterial Pathogenesis, Hamilton, MT 59840 USA.		Federle, Michael J./E-5522-2017; Low, Donald/B-1726-2012	Lei, Benfang Lei/0000-0001-8133-6021; DeLeo, Frank/0000-0003-3150-2516	NIAID NIH HHS [T32AI07470, AI20823] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000900, ZIAAI000900, T32AI007470, Z01AI000921] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beall B, 1997, J CLIN MICROBIOL, V35, P1231, DOI 10.1128/JCM.35.5.1231-1235.1997; Belcher CE, 2000, P NATL ACAD SCI USA, V97, P13847, DOI 10.1073/pnas.230262797; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROWN G, 1988, ANTIBODIES, V1, P81; Chaussee MS, 2001, INFECT IMMUN, V69, P822, DOI 10.1128/IAI.69.2.822-831.2001; CORBI AL, 1988, J BIOL CHEM, V263, P12403; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Dale JB, 1999, J CLIN INVEST, V103, P1261, DOI 10.1172/JCI5118; DeLeo FR, 1999, J IMMUNOL, V163, P6732; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; Ernst JD, 2000, CELL MICROBIOL, V2, P379, DOI 10.1046/j.1462-5822.2000.00075.x; Federle MJ, 1999, J BACTERIOL, V181, P3649, DOI 10.1128/JB.181.12.3649-3657.1999; Ferrari G, 1999, CELL, V97, P435, DOI 10.1016/S0092-8674(00)80754-0; Galon J, 1996, J IMMUNOL, V157, P1184; Heath A, 1999, INFECT IMMUN, V67, P5298, DOI 10.1128/IAI.67.10.5298-5305.1999; Hoe NP, 2000, J INFECT DIS, V182, P1425, DOI 10.1086/315882; HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657; HORSTMANN RD, 1992, INFECT IMMUN, V60, P5036, DOI 10.1128/IAI.60.12.5036-5041.1992; Ingalls RR, 1997, J IMMUNOL, V159, P433; Ji YD, 1996, INFECT IMMUN, V64, P503, DOI 10.1128/IAI.64.2.503-510.1996; Lei BF, 2000, INFECT IMMUN, V68, P6807, DOI 10.1128/IAI.68.12.6807-6818.2000; Levin JC, 1998, MOL MICROBIOL, V30, P209, DOI 10.1046/j.1365-2958.1998.01057.x; Meresse S, 1999, NAT CELL BIOL, V1, pE183, DOI 10.1038/15620; Musser JM, 1998, BIOMED RES REP, P185; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; ROSS GD, 1987, COMPLEMENT INFLAMMAT, V4, P61, DOI 10.1159/000463010; Schnitzler N, 1999, NAT MED, V5, P231, DOI 10.1038/5597; SEHGAL G, 1993, J IMMUNOL, V150, P4571; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Stockbauer KE, 1999, P NATL ACAD SCI USA, V96, P242, DOI 10.1073/pnas.96.1.242; STOCKL J, 1995, J IMMUNOL, V154, P5452; TANIGUCHISIDLE A, 1992, J BIOL CHEM, V267, P635; Thakker M, 1998, INFECT IMMUN, V66, P5183, DOI 10.1128/IAI.66.11.5183-5189.1998; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; WEXLER DE, 1985, P NATL ACAD SCI USA, V82, P8144, DOI 10.1073/pnas.82.23.8144; WHITNACK E, 1982, J CLIN INVEST, V69, P1042, DOI 10.1172/JCI110508; Yang ZY, 1998, SCIENCE, V279, P1034, DOI 10.1126/science.279.5353.1034; ZHOU MJ, 1994, J CELL BIOL, V125, P1407, DOI 10.1083/jcb.125.6.1407	38	132	138	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2001	7	12					1298	1305		10.1038/nm1201-1298	http://dx.doi.org/10.1038/nm1201-1298			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726969				2022-12-27	WOS:000172610300034
J	Grivel, JC; Ito, Y; Faga, G; Santoro, F; Shaheen, F; Malnati, MS; Fitzgerald, W; Lusso, P; Margolis, L				Grivel, JC; Ito, Y; Faga, G; Santoro, F; Shaheen, F; Malnati, MS; Fitzgerald, W; Lusso, P; Margolis, L			Suppression of CCR5-but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6	NATURE MEDICINE			English	Article							CD4(+) T-CELLS; SYNCYTIUM-INDUCING PHENOTYPE; VIRUS TYPE-1 INFECTION; BETA-CHEMOKINES; BIOLOGICAL PHENOTYPE; CORECEPTOR USAGE; PROGNOSTIC VALUE; CC-CHEMOKINES; IN-VIVO; REPLICATION	HIV-1 infects target cells via a receptor complex formed by CD4 and a chemokine receptor, primarily CCR5 or CXCR4 (ref. 1). Commonly, HIV-1 transmission is mediated by CCR5-tropic variants, also designated slow/low, non-syncytia-inducer or macrophage-tropic, which dominate the early stages of HIV-1 infection and frequently persist during the entire course of the disease(2-9). In contrast, HIV-1 variants that use CXCR4 are typically detected at the later stages, and are associated with a rapid decline in CD4(+) T cells and progression to AIDS (refs. 2,7-11). Disease progression is also associated with the emergence of concurrent infections that may affect the course of HIV disease by unknown mechanisms. A lymphotropic agent frequently reactivated in HIV-Infected patients is human herpesvirus 6 (HHV-6), which has been proposed as a cofactor in AIDS progression(12). Here we show that in human lymphoid tissue ex vivo(13-15) HHV-6 affects HIV-1 infection in a coreceptor-dependent manner, suppressing CCR5-tropic but not CXCR4-tropic HIV-1 replication, as shown with both uncloned viral isolates and isogenic molecular chimeras. Furthermore, we demonstrate that HHV-6 increases the production of the CCR5 ligand RANTES ('regulated upon activation, normal T-cell expressed and secreted'), the most potent HIV-inhibitory CC chemokine(16), and that exogenous RANTES mimics the effects of HHV-6 on HIV-1, providing a mechanism for the selective blockade of CCR5-tropic HIV-1. Our data suggest that HHV-6 may profoundly influence the course of HIV-1 infection.	NICHHD, Lab Cellular & Mol Biophys, Bethesda, MD 20892 USA; DIBIT San Raffaele Sci Inst, Unit Human Virol, Milan, Italy; Univ Bologna, Dept Clin & Expt Med, Bologna, Italy; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Bologna; University of Pennsylvania	Margolis, L (corresponding author), NICHHD, Lab Cellular & Mol Biophys, Bethesda, MD 20892 USA.		Malnati, Mauro/AAN-4207-2020; Ito, Yoshinori/A-7591-2016; Faga, Giovanni/AAB-5540-2021	Malnati, mauro/0000-0001-5355-1680; Grivel, Jean-Charles/0000-0003-0365-3181	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001416] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001416] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bjorndal A, 1997, J VIROL, V71, P7478; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Dolei A, 1998, AIDS, V12, P183, DOI 10.1097/00002030-199802000-00008; FENYO EM, 1988, J VIROL, V62, P4414; FENYO EM, 1993, AIDS, V7, P1673, DOI 10.1097/00002030-199312000-00020; Fouchier RAM, 1996, VIROLOGY, V219, P87, DOI 10.1006/viro.1996.0225; Glushakova S, 1997, AIDS RES HUM RETROV, V13, P461, DOI 10.1089/aid.1997.13.461; GLUSHAKOVA S, 1995, NAT MED, V1, P1320, DOI 10.1038/nm1295-1320; Glushakova S, 1999, J CLIN INVEST, V104, pR7, DOI 10.1172/JCI7403; Gordon CJ, 1999, J VIROL, V73, P684, DOI 10.1128/JVI.73.1.684-694.1999; Grivel JC, 1999, NAT MED, V5, P344, DOI 10.1038/6565; Kelly MD, 1998, J IMMUNOL, V160, P3091; Kinter A, 1998, P NATL ACAD SCI USA, V95, P11880, DOI 10.1073/pnas.95.20.11880; Kinter AL, 1996, P NATL ACAD SCI USA, V93, P14076, DOI 10.1073/pnas.93.24.14076; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; Koot M, 1999, J INFECT DIS, V179, P254, DOI 10.1086/314539; Locatelli G, 2000, J CLIN MICROBIOL, V38, P4042, DOI 10.1128/JCM.38.11.4042-4048.2000; LUSSO P, 1995, IMMUNOL TODAY, V16, P67, DOI 10.1016/0167-5699(95)80090-5; Margolis LB, 1998, J CLIN INVEST, V101, P1876, DOI 10.1172/JCI2015; Milne RSB, 2000, J IMMUNOL, V164, P2396, DOI 10.4049/jimmunol.164.5.2396; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; Smyth RJ, 1998, J VIROL, V72, P4478, DOI 10.1128/JVI.72.5.4478-4484.1998; TERSMETTE M, 1989, LANCET, V1, P983; Watt G, 2000, LANCET, V356, P475, DOI 10.1016/S0140-6736(00)02557-5; Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364	31	90	93	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2001	7	11					1232	1235		10.1038/nm1101-1232	http://dx.doi.org/10.1038/nm1101-1232			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689888				2022-12-27	WOS:000172054100031
J	Wielockx, B; Lannoy, K; Shapiro, SD; Itoh, T; Itohara, S; Vandekerckhove, J; Libert, C				Wielockx, B; Lannoy, K; Shapiro, SD; Itoh, T; Itohara, S; Vandekerckhove, J; Libert, C			Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy	NATURE MEDICINE			English	Article							TNF-ALPHA; ALPHA(1)-ACID GLYCOPROTEIN; PROINFLAMMATORY MEDIATORS; EXTRACELLULAR-MATRIX; LIVER-FAILURE; MICE; GELATINASE; ACTIVATION; ARTHRITIS; ANGIOGENESIS	Acute and fulminant liver failure induced by viral hepatitis, alcohol or other hepatotoxic drugs, are associated with tumor necrosis factor (TNF) production. In a mouse model of lethal hepatitis induced by TNF, apoptosis and necrosis of hepatocytes, but also lethality, hypothermia and influx of leukocytes into the liver, are prevented by a broad-spectrum matrix metalloproteinase (MMP) inhibitor, BB-94. Mice deficient in MMP-2, MMP-3 or MMP-9 had lower levels of apoptosis and necrosis of hepatocytes, and better survival. We found induction of MMP-9 activity and fibronectin degradation. Our findings suggest that several MMPs play a critical role in acute, fulminant hepatitis by degrading the extracellular matrix and allowing massive leukocyte influx in the liver. BB-94 also prevented lethality in TNF/interferon-gamma therapy in tumor-bearing mice. A broad-spectrum MMP inhibitor may be potentially useful for the treatment of patients with acute and perhaps chronic liver failure, and in cancer therapies using inflammatory cytokines.	Flanders Interuniv Inst Biotechnol, Dept Mol Biol, Ghent, Belgium; Univ Ghent, B-9000 Ghent, Belgium; Washington Univ, Med Ctr, Jewish Hosp, Dept Med, St Louis, MO USA; Shionogi & Co Ltd, Shionogi Inst Med Sci, Osaka, Japan; RIKEN Brain Sci Inst, Lab Behav Genet, Wako, Saitama, Japan; Flanders Interuniv Inst Biotechnol, Dept Biochem, Ghent, Belgium	Ghent University; Barnes-Jewish Hospital; Washington University (WUSTL); Shionogi & Company Limited; RIKEN	Libert, C (corresponding author), Flanders Interuniv Inst Biotechnol, Dept Mol Biol, Ghent, Belgium.	claude.libert@dmb.rug.ac.be	Itohara, Shigeyoshi/I-8769-2012; Wielockx, Ben/AAC-6854-2020; Libert, Claude/A-6504-2010	Itohara, Shigeyoshi/0000-0002-2410-9989; Wielockx, Ben/0000-0002-4923-2596; 				ALEXANDER RB, 1991, BIOL THERAPY CANCER, P378; Amour A, 1999, ANN NY ACAD SCI, V878, P728, DOI 10.1111/j.1749-6632.1999.tb07774.x; Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245; Bernal W, 1999, EUR J GASTROEN HEPAT, V11, P977, DOI 10.1097/00042737-199909000-00005; Beyaert R, 1998, CYTOKINES, P335, DOI 10.1016/B978-012498340-3/50025-7; BIRD GLA, 1990, ANN INTERN MED, V112, P917, DOI 10.7326/0003-4819-112-12-917; Brennan FM, 1997, BRIT J RHEUMATOL, V36, P643; BROUCKAERT PGG, 1986, INT J CANCER, V38, P763, DOI 10.1002/ijc.2910380521; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; DECKER K, 1974, REV PHYSIOL BIOCH P, V71, P77, DOI 10.1007/BFb0027661; EVERAERDT B, 1994, J IMMUNOL, V152, P5041; FRANSEN L, 1986, CELL IMMUNOL, V100, P260, DOI 10.1016/0008-8749(86)90025-0; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Giavazzi R, 1998, CLIN CANCER RES, V4, P985; GONZALEZAMARO R, 1994, J EXP MED, V179, P841, DOI 10.1084/jem.179.3.841; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; HOOFNAGLE JH, 1995, HEPATOLOGY, V21, P240, DOI 10.1002/hep.1840210137; Iimuro Y, 1997, HEPATOLOGY, V26, P1530; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; JAESCHKE H, 1991, AM J PHYSIOL, V261, pG1051, DOI 10.1152/ajpgi.1991.261.6.G1051; Knittel T, 1999, J HEPATOL, V30, P48, DOI 10.1016/S0168-8278(99)80007-5; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Kowdley KV, 1999, AM J GASTROENTEROL, V94, P1132, DOI 10.1111/j.1572-0241.1999.01132.x; LEIST M, 1995, J IMMUNOL, V154, P1307; LIBERT C, 1994, J EXP MED, V180, P1571, DOI 10.1084/jem.180.4.1571; LIBERT C, 1994, EUR J IMMUNOL, V24, P2237, DOI 10.1002/eji.1830240945; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lochter A, 1998, ANN NY ACAD SCI, V857, P180, DOI 10.1111/j.1749-6632.1998.tb10116.x; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; Marcellin P, 1999, J HEPATOL, V31, P9, DOI 10.1016/S0168-8278(99)80368-7; MARTINEZHERNANDEZ A, 1993, VIRCHOWS ARCH A, V423, P1, DOI 10.1007/BF01606425; Mudgett JS, 1998, ARTHRITIS RHEUM-US, V41, P110, DOI 10.1002/1529-0131(199801)41:1<110::AID-ART14>3.0.CO;2-G; Murdoch WJ, 1999, J REPROD FERTIL, P353; MUTO Y, 1988, LANCET, V2, P72; Pugin J, 1999, AM J RESP CELL MOL, V20, P458, DOI 10.1165/ajrcmb.20.3.3311; Rajavashisth TB, 1999, CIRCULATION, V99, P3103, DOI 10.1161/01.CIR.99.24.3103; Schonbeck U, 1998, J IMMUNOL, V161, P3340; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; SHIRATORI Y, 1990, HEPATOLOGY, V11, P183, DOI 10.1002/hep.1840110205; Skotnicki JS, 1999, ANN NY ACAD SCI, V878, P61, DOI 10.1111/j.1749-6632.1999.tb07674.x; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Takenaka K, 1998, DIGEST DIS SCI, V43, P887, DOI 10.1023/A:1018898905478; Van Molle W, 1999, J IMMUNOL, V163, P5235; VanMolle W, 1997, J IMMUNOL, V159, P3555; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Yamamoto M, 1998, J MED CHEM, V41, P1209, DOI 10.1021/jm970404a; Yu Q, 2000, GENE DEV, V14, P163	49	158	164	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2001	7	11					1202	1208		10.1038/nm1101-1202	http://dx.doi.org/10.1038/nm1101-1202			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689884				2022-12-27	WOS:000172054100027
J	Sharif, S; Arreaza, GA; Zucker, P; Mi, QS; Sharif, S; Arreaza, GA; Zucker, P; Mi, QS; Sondhi, J; Naidenko, OV; Kronenberg, M; Koezuka, Y; Delovitch, TL; Gombert, JM; Leite-De-Moraes, M; Gouarin, C; Zhu, R; Hameg, A; Nakayama, T; Taniguchi, M; Lepault, F; Lehuen, A; Bach, JF; Herbelin, A				Sharif, S; Arreaza, GA; Zucker, P; Mi, QS; Sharif, S; Arreaza, GA; Zucker, P; Mi, QS; Sondhi, J; Naidenko, OV; Kronenberg, M; Koezuka, Y; Delovitch, TL; Gombert, JM; Leite-De-Moraes, M; Gouarin, C; Zhu, R; Hameg, A; Nakayama, T; Taniguchi, M; Lepault, F; Lehuen, A; Bach, JF; Herbelin, A			Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes	NATURE MEDICINE			English	Article							NKT CELLS; MICE; THYMOCYTES; CD1D; INTERLEUKIN-4; DEFICIENCY; TOLERANCE; GRAFTS; MOUSE; BETA	Type 1 diabetes (T1D) in non-obese diabetic (NOD) mice may be favored by immune dysregulation leading to the hyporesponsiveness of regulatory T cells and activation of effector T-helper type 1 (Th1) cells'. The immunoregulatory activity of natural killer T (NKT) cells is well documented(2,3) and both interleukin (IL)-4 and IL-10 secreted by NKT cells have important roles in mediating this activity(4,5). NKT cells are less frequent and display deficient IL-4 responses in both NOD mice(6,7) and individuals at risk for T1D (ref. 8), and this deficiency may lead to T1D (refs. 1,6-9). Thus, given that NKT cells respond to the alpha -galactosylceramide (alpha -GalCer) glycolipid in a CD1d-restricted manner by secretion of Th2 cytokines(10-12), we reasoned that activation of NKT cells by alpha -GalCer might prevent the onset and/or recurrence of T1D. Here we show that alpha -GalCer treatment, even when initiated after the onset of insulitis, protects female NOD mice from T1D and prolongs the survival of pancreatic islets transplanted into newly diabetic NOD mice. In addition, when administered after the onset of insulitis, alpha -GalCer and IL-7 displayed synergistic effects, possibly via the ability of IL-7 to render NKT cells fully responsive to alpha -GalCer. Protection from T1D by alpha -GalCer was associated with the suppression of both T- and B-cell autoimmunity to islet beta cells and with a polarized Th2-like response in spleen and pancreas of these mice. These findings raise the possibility that alpha -GalCer treatment might be used therapeutically to prevent the onset and recurrence of human T1D.	John P Robarts Res Inst, Autoimmun Diabet Grp, London, ON, Canada; La Jolla Inst Allergy & Immunol, San Diego, CA USA; Kirin Brewery Co Ltd, Pharmaceut Res Lab, Gunma, Japan; Univ Western Ontario, Dept Microbiol & Immunol, London, ON, Canada; Univ Western Ontario, Dept Med, London, ON, Canada	Western University (University of Western Ontario); La Jolla Institute for Immunology; Kirin Brewery Company Limited; Western University (University of Western Ontario); Western University (University of Western Ontario)	Delovitch, TL (corresponding author), John P Robarts Res Inst, Autoimmun Diabet Grp, London, ON, Canada.	del@rri.on.ca; bach@necker.fr	Nakayama, Toshinori/E-1067-2017; de Moraes, Maria Leite/AAV-9159-2020; Herbelin, Andre/D-3096-2017	Nakayama, Toshinori/0000-0002-1434-2007; de Moraes, Maria Leite/0000-0002-2891-2269; Herbelin, Andre/0000-0003-0193-7084; Lehuen, Agnes/0000-0002-0450-3321				Baxter AG, 1997, DIABETES, V46, P572, DOI 10.2337/diabetes.46.4.572; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Burdin N, 1999, EUR J IMMUNOL, V29, P2014, DOI 10.1002/(SICI)1521-4141(199906)29:06<2014::AID-IMMU2014>3.0.CO;2-G; Delovitch TL, 1997, IMMUNITY, V7, P727, DOI 10.1016/S1074-7613(00)80392-1; Godfrey DI, 2000, IMMUNOL TODAY, V21, P573, DOI 10.1016/S0167-5699(00)01735-7; Gombert JM, 1996, EUR J IMMUNOL, V26, P2989, DOI 10.1002/eji.1830261226; Gombert JM, 1996, INT IMMUNOL, V8, P1751, DOI 10.1093/intimm/8.11.1751; Hameg A, 2000, J IMMUNOL, V165, P4917, DOI 10.4049/jimmunol.165.9.4917; Hammond KJL, 1998, J EXP MED, V187, P1047, DOI 10.1084/jem.187.7.1047; Herbelin A, 1998, J IMMUNOL, V161, P2620; Hong S, 2001, NAT MED, V7, P1052, DOI 10.1038/nm0901-1052; Ikehara Y, 2000, J CLIN INVEST, V105, P1761, DOI 10.1172/JCI8922; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; KI SN, 2001, P NATL ACAD SCI USA, V98, P2577; Laloux V, 2001, J IMMUNOL, V166, P3749, DOI 10.4049/jimmunol.166.6.3749; Lehuen A, 1998, J EXP MED, V188, P1831, DOI 10.1084/jem.188.10.1831; LEPAULT F, 1995, EUR J IMMUNOL, V25, P1502, DOI 10.1002/eji.1830250605; Lepault F, 2000, J IMMUNOL, V164, P240, DOI 10.4049/jimmunol.164.1.240; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; Osman Y, 2000, EUR J IMMUNOL, V30, P1919, DOI 10.1002/1521-4141(200007)30:7<1919::AID-IMMU1919>3.0.CO;2-3; Rabinovitch A, 1997, TRANSPLANTATION, V64, P1525, DOI 10.1097/00007890-199712150-00004; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Singh N, 1999, J IMMUNOL, V163, P2373; Sonoda KH, 2001, J IMMUNOL, V166, P42, DOI 10.4049/jimmunol.166.1.42; Sonoda KH, 1999, J EXP MED, V190, P1215, DOI 10.1084/jem.190.9.1215; Tori M, 1999, TRANSPLANT P, V31, P2741, DOI 10.1016/S0041-1345(99)00548-5; Van der Vliet HJJ, 1999, IMMUNOLOGY, V98, P557, DOI 10.1046/j.1365-2567.1999.00920.x; Vicari AP, 1996, INT IMMUNOL, V8, P1759, DOI 10.1093/intimm/8.11.1759; Wilson SB, 1998, NATURE, V391, P177, DOI 10.1038/34419; YASUNAMI R, 1988, EUR J IMMUNOL, V18, P481, DOI 10.1002/eji.1830180325; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285	33	518	550	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2001	7	9					1057	1062		10.1038/nm0901-1057	http://dx.doi.org/10.1038/nm0901-1057			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533711				2022-12-27	WOS:000170853300033
J	Butler, SL; Hansen, MST; Bushman, FD				Butler, SL; Hansen, MST; Bushman, FD			A quantitative assay for HIV DNA integration in vivo	NATURE MEDICINE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; BLOOD MONONUCLEAR-CELLS; TRANSCRIPTION; REPLICATION; PERSISTENCE; VECTORS; PCR	Early steps of infection by HIV-1 involve entry of the viral core into cells, reverse transcription to form the linear viral DNA, and integration of that DNA into a chromosome of the host. The unintegrated DNA can also follow non-productive pathways, in which it is circularized by recombination between DNA long-terminal repeats (LTRs), circularized by ligation of the DNA ends or degraded. Here we report quantitative methods that monitor formation of reverse transcription products, two-LTR circles and integrated proviruses. The integration assay employs a novel quantitative form of Alu-PCR that should be generally applicable to studies of integrating viruses and gene transfer vectors.	Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA	Salk Institute	Bushman, FD (corresponding author), Salk Inst Biol Studies, Infect Dis Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NIAID NIH HHS [AI34786] Funding Source: Medline; NIGMS NIH HHS [GM56553] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056553] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENKIRANE M, 1993, EMBO J, V12, P4909, DOI 10.1002/j.1460-2075.1993.tb06185.x; Carteau S, 1998, J VIROL, V72, P4005, DOI 10.1128/JVI.72.5.4005-4014.1998; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; COURCOUL M, 1995, J VIROL, V69, P2068, DOI 10.1128/JVI.69.4.2068-2074.1995; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Kafri T, 1999, J VIROL, V73, P576, DOI 10.1128/JVI.73.1.576-584.1999; Lewin SR, 1999, J VIROL, V73, P6099, DOI 10.1128/JVI.73.7.6099-6103.1999; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Sharkey ME, 2000, NAT MED, V6, P76, DOI 10.1038/71569; Sonza S, 1996, J VIROL, V70, P3863, DOI 10.1128/JVI.70.6.3863-3869.1996; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	14	558	592	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					631	634		10.1038/87979	http://dx.doi.org/10.1038/87979			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329067				2022-12-27	WOS:000169961100045
J	Mabbott, NA; Bruce, ME; Botto, M; Walport, MJ; Pepys, MB				Mabbott, NA; Bruce, ME; Botto, M; Walport, MJ; Pepys, MB			Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie	NATURE MEDICINE			English	Article							FOLLICULAR DENDRITIC CELLS; LYMPHOID-TISSUES; PRION PROTEIN; MICE LACKING; AGENT; PRP; REPLICATION; INFECTION; SPLEENS; SYSTEM	Following peripheral exposure to transmissible spongiform encephalopathies (TSEs), infectivity usually accumulates in lymphoid tissues before neuroinvasion. The host prion protein (PrPc) is critical for TSE agent replication and accumulates as an abnormal, detergent insoluble, relatively proteinase-resistant isoform (PrPSc) in diseased tissues(1,2). Early PrPSc accumulation takes place on follicular dendritic cells (FDCs) within germinal centers in lymphoid tissues of patients with variant Creutzfeldt-Jakob disease(3) (vCJD), sheep with natural scrapie(4) or rodents following experimental peripheral infection with scrapie(5-7). In mouse scrapie models, the absence of FDCs blocks scrapie replication and PrPSc accumulation in the spleen, and neuroinvasion is significantly impaired(6-9). The mechanisms by which the TSE agent initially localizes to lymphoid follicles and interacts with FDCs are unknown. Antigens are trapped and retained on the surface of FDCs through interactions between complement and cellular complement receptors(10,11). Here we show that in mice, both temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays the onset of disease following peripheral infection, and reduces the early accumulation of PrPSc in the spleen. Thus, in the early stages of infection, C3 and perhaps C1q contribute to the localization of TSE infectivity in lymphoid tissue and may be therapeutic targets.	Inst Anim Hlth, Neuropathogenesis Unit, Edinburgh, Midlothian, Scotland; Imperial Coll Sch Med, Div Med, London, England; UCL Royal Free & Univ Coll Med Sch, Dept Med, Ctr Amyloidosis & Acute Phase Prot, London, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; University of Edinburgh; Imperial College London; University of London; University College London; UCL Medical School	Mabbott, NA (corresponding author), Inst Anim Hlth, Neuropathogenesis Unit, Edinburgh, Midlothian, Scotland.	neil.mabbott@bbsrc.ac.uk	Mabbott, Neil/AAF-8777-2020	Mabbott, Neil/0000-0001-7395-1796; Walport, Mark/0000-0001-7220-5273				Beringue V, 2000, J PATHOL, V190, P495, DOI 10.1002/(SICI)1096-9896(200003)190:4&lt;495::AID-PATH535&gt;3.0.CO;2-T; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Brown KL, 1999, NAT MED, V5, P1308, DOI 10.1038/15264; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Cutler AJ, 1998, J EXP MED, V187, P1789, DOI 10.1084/jem.187.11.1789; DICKINSON AG, 1969, J COMP PATHOL, V79, P15, DOI 10.1016/0021-9975(69)90021-8; Farquhar C, 1999, LANCET, V353, P117, DOI 10.1016/S0140-6736(98)05395-1; FARQUHAR CF, 1994, J GEN VIROL, V75, P495, DOI 10.1099/0022-1317-75-3-495; FARQUHAR CF, 1989, J VIROL METHODS, V24, P215, DOI 10.1016/0166-0934(89)90023-2; Fearon DT, 1998, SEMIN IMMUNOL, V10, P355, DOI 10.1006/smim.1998.0137; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Mabbott NA, 2000, NAT MED, V6, P719, DOI 10.1038/77401; Mabbott NA, 2000, J VIROL, V74, P3338, DOI 10.1128/JVI.74.7.3338-3344.2000; MCBRIDE PA, 1992, J PATHOL, V168, P413, DOI 10.1002/path.1711680412; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; Nielsen CH, 2000, IMMUNOLOGY, V100, P4, DOI 10.1046/j.1365-2567.2000.00009.x; Norsworthy PJ, 1999, MAMM GENOME, V10, P789, DOI 10.1007/s003359901093; PAPAMICHAIL M, 1975, SCAND J IMMUNOL, V4, P343, DOI 10.1111/j.1365-3083.1975.tb02635.x; PEPYS MB, 1977, IMMUNOLOGY, V33, P491; PEPYS MB, 1976, TRANSPLANT REV-DENMA, V32, P93; PEPYS MB, 1979, J IMMUNOL METHODS, V30, P105, DOI 10.1016/0022-1759(79)90085-1; Qin DH, 1998, J IMMUNOL, V161, P4549; Tas SW, 1999, J IMMUNOL, V163, P5056; Taylor PR, 1998, J BIOL CHEM, V273, P1699, DOI 10.1074/jbc.273.3.1699; VANDENBERG TK, 1992, EUR J IMMUNOL, V22, P957, DOI 10.1002/eji.1830220412; vanKeulen LJM, 1996, J CLIN MICROBIOL, V34, P1228, DOI 10.1128/JCM.34.5.1228-1231.1996; Wuillemin WA, 1997, J IMMUNOL, V159, P1953	28	193	196	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2001	7	4					485	487		10.1038/86562	http://dx.doi.org/10.1038/86562			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283677				2022-12-27	WOS:000167960500045
J	Reilly, PR				Reilly, PR			Legal issues in genomic medicine	NATURE MEDICINE			English	Editorial Material									Interleukin Genet, Waltham, MA 02154 USA		Reilly, PR (corresponding author), Interleukin Genet, Waltham, MA 02154 USA.	preilly@ilgenetics.com						Caulfield T, 2000, NAT REV GENET, V1, P227, DOI 10.1038/35042087; Myers A, 2000, SCIENCE, V290, P2304, DOI 10.1126/science.290.5500.2304; National Bioethics Advisory Commission, 1999, ETH ISS HUM STEM CEL; POLLITT R, 1997, NEWBORN SCREENING IN; Reilly PR, 1998, AM J HUM GENET, V63, P682, DOI 10.1086/302028; Reilly PR, 2000, ANNU REV GENOM HUM G, V1, P485, DOI 10.1146/annurev.genom.1.1.485; REILLY PR, 1997, MICROBIOL COMP GENOM, V2, P7; ROTHSTEIN M, 1997, GENETIC SECRETS PROT, P511; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145	9	6	6	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2001	7	3					268	271		10.1038/85392	http://dx.doi.org/10.1038/85392			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231612				2022-12-27	WOS:000167380400017
J	Islam, D; Bandholtz, L; Nilsson, J; Wigzell, H; Christensson, B; Agerberth, B; Gudmundsson, GH				Islam, D; Bandholtz, L; Nilsson, J; Wigzell, H; Christensson, B; Agerberth, B; Gudmundsson, GH			Downregulation of bactericidal peptides in enteric infections: A novel immune escape mechanism with bacterial DNA as a potential regulator	NATURE MEDICINE			English	Article							EPITHELIAL-CELLS; ANTIBACTERIAL PEPTIDES; ANTIMICROBIAL PEPTIDES; BETA-DEFENSIN; HOST-DEFENSE; PANETH CELLS; SHIGELLA; GENE; EXPRESSION; PARADIGM	Antibacterial peptides are active defense components of innate Immunity. Several studies confirm their importance at epithelial surfaces as immediate barrier effecters in preventing Infection. Here we report that early in Shigella spp. infections, expression of the antibacterial peptides LL-37 and human beta -defensin-1. is reduced or turned off. The downregulation is detected in biopsies from patients with bacillary dysenteries and in Shigella- infected cell cultures of epithelial and monocyte origin. This downregulation of immediate defense effecters might promote bacterial adherence and invasion into host epithelium and could be an important virulence parameter. Analyses of bacterial molecules causing the downregulation indicate Shigella plasmid DNA as one mediator.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Int Ctr Diarrhoeal Dis Res, Div Sci Lab, Dhaka 1000, Bangladesh; Huddinge Hosp, Dept Med, S-14186 Huddinge, Sweden; Huddinge Hosp, Dept Immunol Microbiol & Pathol, S-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet; International Centre for Diarrhoeal Disease Research (ICDDR)	Gudmundsson, GH (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.		Gudmundsson, Gudmundur H/K-9178-2015	Gudmundsson, Gudmundur H/0000-0001-5793-0565; Nilsson, Jakob/0000-0001-5091-8133				AGER, 2000, INFECT IMMUN, V68, P5412; Agerberth B, 1999, AM J RESP CRIT CARE, V160, P283, DOI 10.1164/ajrccm.160.1.9807041; Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Albert MJ, 1999, J CLIN MICROBIOL, V37, P3458, DOI 10.1128/JCM.37.11.3458-3464.1999; Bals R, 1998, P NATL ACAD SCI USA, V95, P9541, DOI 10.1073/pnas.95.16.9541; Bevins CL, 1999, GUT, V45, P911, DOI 10.1136/gut.45.6.911; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; Chu RS, 1999, J IMMUNOL, V163, P1188; COWLAND JB, 1995, FEBS LETT, V368, P173, DOI 10.1016/0014-5793(95)00634-L; Dorman CJ, 1998, MOL MICROBIOL, V29, P677, DOI 10.1046/j.1365-2958.1998.00902.x; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; ISLAM D, 1995, INFECT IMMUN, V63, P2054, DOI 10.1128/IAI.63.5.2054-2061.1995; Islam D, 1997, INFECT IMMUN, V65, P739, DOI 10.1128/IAI.65.2.739-749.1997; Islam D, 1997, J CLIN PATHOL, V50, P513, DOI 10.1136/jcp.50.6.513; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; Kagnoff MF, 1997, J CLIN INVEST, V100, P6, DOI 10.1172/JCI119522; Krieg AM, 2000, CURR OPIN IMMUNOL, V12, P35, DOI 10.1016/S0952-7915(99)00048-5; LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291-1297.1995; MandicMulec I, 1997, INFECT IMMUN, V65, P110, DOI 10.1128/IAI.65.1.110-115.1997; Menard R, 1996, TRENDS MICROBIOL, V4, P220, DOI 10.1016/0966-842X(96)10039-1; O'Neil DA, 1999, J IMMUNOL, V163, P6718; RAQIB R, 1995, INFECT IMMUN, V63, P289, DOI 10.1128/IAI.63.1.289-296.1995; Sansonetti PJ, 1998, FOLIA MICROBIOL, V43, P239, DOI 10.1007/BF02818608; Shafer WM, 1998, P NATL ACAD SCI USA, V95, P1829, DOI 10.1073/pnas.95.4.1829; SIEBERS A, 1995, TRENDS MICROBIOL, V3, P207, DOI 10.1016/S0966-842X(00)88923-4; Sorensen O, 1997, J IMMUNOL METHODS, V206, P53, DOI 10.1016/S0022-1759(97)00084-7; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686; Tarver AP, 1998, INFECT IMMUN, V66, P1045, DOI 10.1128/IAI.66.3.1045-1056.1998; Wagner H, 1999, ADV IMMUNOL, V73, P329, DOI 10.1016/S0065-2776(08)60790-7; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4; Zychlinsky A, 1997, TRENDS MICROBIOL, V5, P201, DOI 10.1016/S0966-842X(97)01044-5	36	341	349	2	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					180	185		10.1038/84627	http://dx.doi.org/10.1038/84627			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175848				2022-12-27	WOS:000166756300034
J	Abdulkadir, SA; Qu, ZC; Garabedian, E; Song, SK; Peters, TJ; Svaren, J; Carbone, JM; Naughton, CK; Catalona, WJ; Ackerman, JJH; Gordon, JI; Humphrey, PA; Milbrandt, J				Abdulkadir, SA; Qu, ZC; Garabedian, E; Song, SK; Peters, TJ; Svaren, J; Carbone, JM; Naughton, CK; Catalona, WJ; Ackerman, JJH; Gordon, JI; Humphrey, PA; Milbrandt, J			Impaired prostate tumorigenesis in Egr1-deficient mice	NATURE MEDICINE			English	Article							PROTEIN NGFI-A; TRANSGENIC MOUSE; GENE-EXPRESSION; PC12 CELLS; CANCER; GROWTH; TRANSCRIPTION; PROGRESSION; NAB2; DIFFERENTIATION	The transcription factor, early growth response protein 1 (ECR1), is overexpressed in a majority of human prostate cancers and is implicated in the regulation of several genes important for prostate tumor progression. Here we have assessed the effect of Egr1 deficiency on tumor development in two transgenic mouse models of prostate cancer (CR2-T-Ag and TRAMP). Using a combination of high-resolution magnetic resonance imaging and histopathological and survival analyses, we show that tumor progression was significantly impaired in Egr1(-/-) mice. Tumor initiation and tumor growth rate were not affected by the lack of Egr1; however, Egr1 deficiency significantly delayed the progression from prostatic intra-epithelial neoplasia to invasive carcinoma. These results indicate a unique role for Egr1 in regulating the transition from localized, carcinoma in situ to invasive carcinoma.	Washington Univ, Dept Pathol, St Louis, MO 63119 USA; Washington Univ, Dept Mol Biol, St Louis, MO 63119 USA; Washington Univ, Dept Pharmacol, St Louis, MO 63119 USA; Washington Univ, Dept Chem, St Louis, MO 63119 USA; Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA; Washington Univ, Div Urol Surg, St Louis, MO 63119 USA; Washington Univ, Dept Med, St Louis, MO 63119 USA; Washington Univ, Dept Radiol, St Louis, MO 63119 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Milbrandt, J (corresponding author), Washington Univ, Dept Pathol, Box 8118,660 S Euclid Ave, St Louis, MO 63119 USA.		Svaren, John/A-1605-2010	Svaren, John/0000-0003-2963-7921; Milbrandt, Jeffrey/0000-0002-5477-7689	NCI NIH HHS [5 T32CA09547-13, 5P01 CA49712-08, 1KO8CA8790101, R24 CA83060] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA083060, K08CA087901, T32CA009547, P01CA049712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrack ER, 1997, PROSTATE, V31, P61; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DAY ML, 1990, J BIOL CHEM, V265, P15253; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Eid MA, 1998, CANCER RES, V58, P2461; FUDGE K, 1994, MODERN PATHOL, V7, P549; Garabedian EM, 1997, J BIOL CHEM, V272, P23729, DOI 10.1074/jbc.272.38.23729; Garabedian EM, 1998, P NATL ACAD SCI USA, V95, P15382, DOI 10.1073/pnas.95.26.15382; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; IVANOVIC V, 1995, NAT MED, V1, P282, DOI 10.1038/nm0495-282; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kirsch KH, 1996, ONCOGENE, V12, P963; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Lee SL, 1996, MOL CELL BIOL, V16, P4566; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MCNEAL JE, 1986, HUM PATHOL, V17, P64, DOI 10.1016/S0046-8177(86)80156-3; Miano JM, 1999, AM J PATHOL, V155, P1009, DOI 10.1016/S0002-9440(10)65200-5; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; NAGLE RB, 1992, J CELL BIOCHEM, P26; PEDERSEN PH, 1994, INT J CANCER, V56, P255, DOI 10.1002/ijc.2910560219; Qu ZC, 1998, J CELL BIOL, V142, P1075, DOI 10.1083/jcb.142.4.1075; Riggs PK, 2000, MOL CARCINOGEN, V27, P247, DOI 10.1002/(SICI)1098-2744(200004)27:4<247::AID-MC1>3.0.CO;2-4; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Santiago FS, 1999, NAT MED, V5, P1438, DOI 10.1038/71020; Scharnhorst V, 2000, ONCOGENE, V19, P791, DOI 10.1038/sj.onc.1203390; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; STEINER MS, 1992, MOL ENDOCRINOL, V6, P15, DOI 10.1210/me.6.1.15; Svaren J, 1996, MOL CELL BIOL, V16, P3545; SVAREN J, IN PRESS J BIOL CHEM; Thigpen AE, 1996, J UROLOGY, V155, P975, DOI 10.1016/S0022-5347(01)66361-4; Tourtellotte WG, 2000, MOL CELL BIOL, V20, P5261, DOI 10.1128/MCB.20.14.5261-5268.2000	36	153	159	1	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					101	107		10.1038/83231	http://dx.doi.org/10.1038/83231			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135623				2022-12-27	WOS:000166243100042
J	Anderson, CC; Matzinger, P				Anderson, CC; Matzinger, P			Immunity or tolerance: Opposite outcomes of microchimerism from skin grafts	NATURE MEDICINE			English	Article							T-CELLS; BONE-MARROW; TRANSPLANTATION TOLERANCE; ORGAN-TRANSPLANTATION; ALLOGRAFT TOLERANCE; INDUCE TOLERANCE; DENDRITIC CELL; CHIMERISM; LIVER; REJECTION	Solid organ transplants contain small numbers of leukocytes that can migrate into the host and establish long-lasting microchimerism. Although such microchimerism is often associated with graft acceptance and tolerance, it has been difficult to demonstrate a true causal link. Using skin from mutant mice deficient for leukocyte subsets, we found that donor T-cell chimerism Is a 'double-edged sword' that can result in very different outcomes depending on the host's immunological maturity and the antigenic disparities involved. In immunologically mature hosts, chimerism resulted in immunity and stronger graft rejection. In immature hosts, it resulted in tolerance to the chimeric T cells, but not to graft antigens not expressed by the chimeric cells. Clinical efforts aimed at augmenting chimerism to induce tolerance must take into account the maturation state of host T cells, the type of chimerism produced by each organ and the antigenic disparities involved, lest the result be increased rejection rather than tolerance.	NIAID, Ghost Lab, Sect T Cell Tolerance & Memory, Lab Cellular & Mol Immunol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Anderson, CC (corresponding author), NIAID, Ghost Lab, Sect T Cell Tolerance & Memory, Lab Cellular & Mol Immunol, NIH Bldg 4 Room 111,9000 Rockville Pike, Bethesda, MD 20892 USA.	canderson@niaid.nih.gov		/0000-0003-1733-4237	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000581, ZIAAI000581] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALARD P, 1995, TRANSPLANTATION, V60, P1125, DOI 10.1097/00007890-199511270-00012; BONOMO A, 1993, J EXP MED, V177, P1153, DOI 10.1084/jem.177.4.1153; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; DEMETRIS AJ, 1993, TRANSPL P, V25, P3337; DONOHOE JA, 1983, TRANSPLANTATION, V35, P62, DOI 10.1097/00007890-198301000-00012; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; INTRONA M, 1981, TRANSPLANTATION, V31, P113, DOI 10.1097/00007890-198102000-00004; Jhaver KG, 1999, J IMMUNOL, V163, P4851; Ko S, 1999, NAT MED, V5, P1292, DOI 10.1038/15248; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MATZINGER P, 1989, NATURE, V338, P74, DOI 10.1038/338074a0; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MCCULLAGH P, 1989, IMMUNOLOGY, V67, P489; MICHIE SA, 1988, J EXP MED, V168, P1929, DOI 10.1084/jem.168.5.1929; Morita H, 1998, P NATL ACAD SCI USA, V95, P6947, DOI 10.1073/pnas.95.12.6947; MURASE N, 1995, TRANSPLANTATION, V60, P158, DOI 10.1097/00007890-199507270-00009; Pearson TC, 1996, TRANSPLANTATION, V61, P997, DOI 10.1097/00007890-199604150-00002; QIAN SW, 1994, HEPATOLOGY, V19, P916, DOI 10.1002/hep.1840190418; RAMMENSEE HG, 1989, EUR J IMMUNOL, V19, P643, DOI 10.1002/eji.1830190411; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; ROSENBERG AS, 1987, J EXP MED, V165, P1296, DOI 10.1084/jem.165.5.1296; SCHLITT HJ, 1994, NEW ENGL J MED, V330, P646, DOI 10.1056/NEJM199403033300919; SHIMONKEVITZ RP, 1988, J EXP MED, V168, P143, DOI 10.1084/jem.168.1.143; SNELL GD, 1957, ANNU REV MICROBIOL, V11, P439, DOI 10.1146/annurev.mi.11.100157.002255; SRIWATANAWONGSA V, 1995, NAT MED, V1, P428, DOI 10.1038/nm0595-428; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1993, IMMUNOL TODAY, V14, P326, DOI 10.1016/0167-5699(93)90054-O; SUN JH, 1995, TRANSPLANTATION, V60, P233, DOI 10.1097/00007890-199508000-00004; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; Thomas JM, 1997, TRANSPLANTATION, V64, P124, DOI 10.1097/00007890-199707150-00022; THOMSON AW, 1995, STEM CELLS, V13, P622, DOI 10.1002/stem.5530130607; Waldmann H, 1998, ANNU REV IMMUNOL, V16, P619, DOI 10.1146/annurev.immunol.16.1.619; Werkele T, 2000, NAT MED, V6, P464, DOI 10.1038/74731; Wise M, 1999, EUR J IMMUNOL, V29, P156, DOI 10.1002/(SICI)1521-4141(199901)29:01<156::AID-IMMU156>3.0.CO;2-K; Wise MP, 1998, J IMMUNOL, V161, P5813; WOOD KJ, 1991, IMMUNOL LETT, V29, P133, DOI 10.1016/0165-2478(91)90214-U; ZAMOYSKA R, 1989, EUR J IMMUNOL, V19, P111, DOI 10.1002/eji.1830190118; ZHANG L, 1994, J IMMUNOL, V152, P2222; ZHANG L, 1993, TRANSPLANTATION, V56, P918, DOI 10.1097/00007890-199310000-00027; Zijenah L, 1998, J INFECT DIS, V178, P109, DOI 10.1086/514264; ZWAN AD, BLOOD; 章梅荣, 1992, Acta Mathematica Sinica. New Series, V8, P148	45	91	94	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					80	87		10.1038/83393	http://dx.doi.org/10.1038/83393			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135620				2022-12-27	WOS:000166243100039
J	Keiser, N; Venkataraman, G; Shriver, Z; Sasisekharan, R				Keiser, N; Venkataraman, G; Shriver, Z; Sasisekharan, R			Direct isolation and sequencing of specific protein-binding glycosaminoglycans	NATURE MEDICINE			English	Article							FIBROBLAST GROWTH-FACTOR; MAMMALIAN HEPARANASE; HEPARIN; ANTITHROMBIN; METASTASIS; DROSOPHILA; COMPLEX; CLONING		MIT, Harvard Mit Div Hlth Sci & Technol, Ctr Biomed Engn, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA	Harvard University; Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), MIT, Harvard Mit Div Hlth Sci & Technol, Ctr Biomed Engn, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA.				NHLBI NIH HHS [R01HL59966] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059966] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; Brickman YG, 1998, GLYCOBIOLOGY, V8, P463, DOI 10.1093/glycob/8.5.463; Conrad H. E., 1998, HEPARIN BINDING PROT; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Faham S, 1998, CURR OPIN STRUC BIOL, V8, P578, DOI 10.1016/S0959-440X(98)80147-4; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fry EE, 1999, EMBO J, V18, P543, DOI 10.1093/emboj/18.3.543; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Padera R, 1999, FASEB J, V13, P1677, DOI 10.1096/fasebj.13.13.1677; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; Petitou M, 1999, NATURE, V398, P417, DOI 10.1038/18877; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P4176, DOI 10.1073/pnas.95.8.4176; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; Sperinde GV, 1998, BIOCHEMISTRY-US, V37, P13153, DOI 10.1021/bi980600z; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Wang H, 1999, ANAL CHEM, V71, P2014, DOI 10.1021/ac981347b	23	49	59	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					123	128		10.1038/83263	http://dx.doi.org/10.1038/83263			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135627				2022-12-27	WOS:000166243100046
J	Donahue, JK; Heldman, AW; Fraser, H; McDonald, AD; Miller, JM; Rade, JJ; Eschenhagen, T; Marban, E				Donahue, JK; Heldman, AW; Fraser, H; McDonald, AD; Miller, JM; Rade, JJ; Eschenhagen, T; Marban, E			Focal modification of electrical conduction in the heart by viral gene transfer	NATURE MEDICINE			English	Article							LEFT-VENTRICULAR DYSFUNCTION; IN-VIVO; REPLICATION-DEFICIENT; MYOCARDIAL-INFARCTION; G-PROTEINS; ADENOVIRUS; EXPRESSION; MORTALITY; MYOCYTES; ARTERIES	Modern treatment of cardiac arrhythmias is limited to pharmacotherapy, radiofrequency ablation, or implantable devices. Antiarrhythmic medications suppress arrhythmias, but their systemic effects are often poorly tolerated and their proarrhythmic tendencies increase mortality(1-3). Radiofrequency ablation can cure only a limited number of arrhythmias. Implantable devices can be curative for bradyarrhythmias and lifesaving for tachyarrhythmias, but require a lifetime commitment to repeated procedures, are a significant expense, and may lead to severe complications. One possibility is the use of gene therapy as an antia(r)rhythmic strategy. As an initial attempt to explore this option, we focused on genetic modification of the atrioventricular node. First, we developed an intracoronary perfusion model for gene delivery, building on our previous work in isolated cardiac myocytes and hearts perfused ex vivo(4,5). Using this method, we infected porcine hearts with Ad beta gal (recombinant adenovirus expressing Escherichia coli beta -galactosidase) or with AdG(i) (adenovirus encoding the G alpha (i2) subunit). We hypothesized that excess G alpha (i2)would mimic the effects of beta -adreneric antagonists, in effect creating a localized beta -blockade. G alpha (i2), overexpression suppressed baseline atrioventricular conduction and slowed the heart rate during atrial fibrillation without producing complete heart block. In contrast, expression of the reporter gene beta -galactosidase had no electrophysiological effects. Our results demonstrate the feasibility of using myocardial gene transfer strategies to treat common arrhythmias.	Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Cardiol, Baltimore, MD 21205 USA; Univ Erlangen Nurnberg, Inst Expt & Clin Pharmacol & Toxicol, D-91054 Erlangen, Germany	Johns Hopkins University; Johns Hopkins University; University of Erlangen Nuremberg	Donahue, JK (corresponding author), Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Ross 844,720 N Rutland Ave, Baltimore, MD 21205 USA.	kdonahue@jhmi.edu	Heldman, Alan W./K-8784-2012; Miller, Julie/B-6492-2009; Marban, Eduardo/GWC-8514-2022	Heldman, Alan W./0000-0002-1615-3883; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052307] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50HL52307] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1997, P NATL ACAD SCI USA, V94, P12100, DOI 10.1073/pnas.94.22.12100; Channon KM, 1998, CIRC RES, V82, P1253, DOI 10.1161/01.RES.82.12.1253; Cichon G, 1999, J GENE MED, V1, P360, DOI 10.1002/(SICI)1521-2254(199909/10)1:5<360::AID-JGM54>3.0.CO;2-Q; Dessauer CW, 1996, CLIN SCI, V91, P527, DOI 10.1042/cs0910527; Donahue JK, 1997, P NATL ACAD SCI USA, V94, P4664, DOI 10.1073/pnas.94.9.4664; Donahue JK, 1998, GENE THER, V5, P630, DOI 10.1038/sj.gt.3300649; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; ESCHENHAGEN T, 1993, CELL BIOL INT, V17, P723, DOI 10.1006/cbir.1993.1135; FRENCH BA, 1994, CIRCULATION, V90, P2414, DOI 10.1161/01.CIR.90.5.2414; KASSEISLER A, 1993, P NATL ACAD SCI USA, V90, P11498, DOI 10.1073/pnas.90.24.11498; KASSEISLER A, 1994, GENE THER, V1, P395; Lafont A, 1998, HUM GENE THER, V9, P2795, DOI 10.1089/hum.1998.9.18-2795; MACMAHON S, 1988, JAMA-J AM MED ASSOC, V260, P1910, DOI 10.1001/jama.260.13.1910; Marshall E, 1999, SCIENCE, V286, P2244, DOI 10.1126/science.286.5448.2244; Muhlhauser J, 1996, GENE THER, V3, P145; Pauschinger M, 1999, CIRCULATION, V99, P1348, DOI 10.1161/01.CIR.99.10.1348; Quinones MJ, 1996, CIRCULATION, V94, P1394, DOI 10.1161/01.CIR.94.6.1394; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; Wu HM, 1996, AM J PHYSIOL-HEART C, V271, pH2735, DOI 10.1152/ajpheart.1996.271.6.H2735	19	148	194	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2000	6	12					1395	1398						4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100126				2022-12-27	WOS:000165704100045
J	Lunardi, C; Bason, C; Navone, R; Millo, E; Damonte, G; Corrocher, R; Puccetti, A				Lunardi, C; Bason, C; Navone, R; Millo, E; Damonte, G; Corrocher, R; Puccetti, A			Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells	NATURE MEDICINE			English	Article							AUTOIMMUNE-DISEASE; PEPTIDE LIBRARIES; MOLECULAR MIMICRY; IN-VITRO; ANTIBODIES; INFECTION; SCLERODERMA; EXPRESSION	Systemic sclerosis is an autoimmune disease characterized by immunological and vascular abnormalities. Autoantibodies against intracellular antigens are associated with particular clinical features of the disease(1), whereas autoantibodies against cell surface antigens may be pathogenic by inducing endothelial cell damage(2,3), considered the primary event in the pathogenesis of the disease. Latent human cytomegalovirus infection may contribute to progression of systemic sclerosis through its ability to infect endothelial cells(4); however, direct links between human cytomegalovirus infection and systemic sclerosis are still lacking(5). Molecular mimicry is one of the mechanisms that account for the link between infection and autoimmunity(6-8). Here we have identified an immunodominant peptide using systemic sclerosis serum screening of a random peptide library; such peptide shares homology with autoantigens and with the human cytomegalovirus late protein UL94 (ref. 9). Immunoglobulin C antibodies against the peptide affinity-purified from the sera of patients with systemic sclerosis specifically recognized the viral product and autoantigens; moreover, such antibodies induced endothelial cell apoptosis through specific interaction with the cell surface integrin-NAG-2 protein complex(10). Our results provide evidence that antibodies against human cytomegalovirus cause apoptosis of endothelial cells(11), considered the initial pathogenic event of systemic sclerosis, and indicate a previously unknown mechanism for the etiological link between human cytomegalovirus infection and autoimmunity.	Univ Verona, Dept Clin & Expt Med, Policlin GB Rossi, I-37134 Verona, Italy; Univ Genoa, Dept Expt Med, I-16132 Genoa, Italy; Natl Canc Inst IST, I-16132 Genoa, Italy	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Genoa	Lunardi, C (corresponding author), Univ Verona, Dept Clin & Expt Med, Policlin GB Rossi, I-37134 Verona, Italy.		Millo, Enrico/K-3218-2018	Millo, Enrico/0000-0002-4019-0051				Bordron A, 1998, J CLIN INVEST, V101, P2029, DOI 10.1172/JCI2261; Bowditch RD, 1996, BLOOD, V88, P4579, DOI 10.1182/blood.V88.12.4579.bloodjournal88124579; Carvalho D, 1996, J CLIN INVEST, V97, P111, DOI 10.1172/JCI118377; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; Di Rosa F, 1998, IMMUNOL REV, V164, P17; Harvey Georgina R., 1999, Current Opinion in Rheumatology, V11, P495, DOI 10.1097/00002281-199911000-00010; Lunardi C, 1998, EUR J IMMUNOL, V28, P936, DOI 10.1002/(SICI)1521-4141(199803)28:03<936::AID-IMMU936>3.3.CO;2-O; Madaio MP, 1996, EUR J IMMUNOL, V26, P3035, DOI 10.1002/eji.1830261232; Neidhart M, 1999, ARTHRITIS RHEUM-US, V42, P389, DOI 10.1002/1529-0131(199902)42:2<389::AID-ANR23>3.0.CO;2-P; Pandey JP, 1998, ARTHRITIS RHEUM, V41, P10, DOI 10.1002/1529-0131(199801)41:1<10::AID-ART2>3.0.CO;2-P; Rose NR, 1998, SEMIN IMMUNOL, V10, P5, DOI 10.1006/smim.1997.0100; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Sgonc R, 1996, J CLIN INVEST, V98, P785, DOI 10.1172/JCI118851; Shahgasempour S, 1997, ARCH VIROL, V142, P125, DOI 10.1007/s007050050063; Sibille P, 1997, EUR J IMMUNOL, V27, P1221, DOI 10.1002/eji.1830270525; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; Wellings DA, 1997, METHOD ENZYMOL, V289, P44; Wing BA, 1996, J VIROL, V70, P3339, DOI 10.1128/JVI.70.6.3339-3345.1996; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; Zhao ZS, 1998, SCIENCE, V279, P1344, DOI 10.1126/science.279.5355.1344	20	219	226	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1183	1186		10.1038/80533	http://dx.doi.org/10.1038/80533			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017152				2022-12-27	WOS:000089674700045
J	LeCouter, J; Lin, R; Ferrara, N				LeCouter, J; Lin, R; Ferrara, N			Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis	NATURE MEDICINE			English	Editorial Material							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; SMOOTH-MUSCLE; CELLS; EXPRESSION; MITOGEN; GENE; MICROENVIRONMENT; IDENTIFICATION; PROLIFERATION		Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech	LeCouter, J (corresponding author), Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA.	nf@gene.com						Aird WC, 1997, J CELL BIOL, V138, P1117, DOI 10.1083/jcb.138.5.1117; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Basset DL, 1943, AM J ANAT, V73, P251, DOI 10.1002/aja.1000730206; Boisbouvier J, 1998, J MOL BIOL, V283, P205, DOI 10.1006/jmbi.1998.2057; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Cheng MY, 2002, NATURE, V417, P405, DOI 10.1038/417405a; Collin O, 1996, INT J ANDROL, V19, P221, DOI 10.1111/j.1365-2605.1996.tb00466.x; Dellian M, 1996, AM J PATHOL, V149, P59; Donovan MJ, 2000, DEVELOPMENT, V127, P4531; Dunaif A, 2001, ANNU REV MED, V52, P401, DOI 10.1146/annurev.med.52.1.401; Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garner Alec, 1994, P1625; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; GOLDZIEHER JW, 1962, J CLIN ENDOCR METAB, V22, P325, DOI 10.1210/jcem-22-3-325; GOSPODAROWICZ D, 1978, P NATL ACAD SCI USA, V75, P847, DOI 10.1073/pnas.75.2.847; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GREENBLATT M, 1968, JNCI-J NATL CANCER I, V41, P111; Hamilton W.J., 1962, HUMAN EMBRYOLOGY; HOLLENBERG MD, 1994, TRENDS PHARMACOL SCI, V15, P108, DOI 10.1016/0165-6147(94)90046-9; JOUBERT FJ, 1980, H-S Z PHYSIOL CHEM, V361, P1787, DOI 10.1515/bchm2.1980.361.2.1787; Karkkainen MJ, 2002, NAT CELL BIOL, V4, pE2, DOI 10.1038/ncb0102-e2; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li M, 2001, MOL PHARMACOL, V59, P692, DOI 10.1124/mol.59.4.692; Lin R, 2002, J BIOL CHEM, V277, P8724, DOI 10.1074/jbc.M110594200; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Masuda Y, 2002, BIOCHEM BIOPH RES CO, V293, P396, DOI 10.1016/S0006-291X(02)00239-5; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Mollay C, 1999, EUR J PHARMACOL, V374, P189, DOI 10.1016/S0014-2999(99)00229-0; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; NEULEN J, 1995, J CLIN ENDOCR METAB, V80, P1967, DOI 10.1210/jc.80.6.1967; PALADE GE, 1979, ACTA PHYSIOL SCAND, P11; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Roberts WG, 1997, CANCER RES, V57, P765; Roberts WG, 1998, AM J PATHOL, V153, P1239, DOI 10.1016/S0002-9440(10)65668-4; Ruoslahti E, 2000, ANNU REV IMMUNOL, V18, P813, DOI 10.1146/annurev.immunol.18.1.813; Schweitz H, 1999, FEBS LETT, V461, P183, DOI 10.1016/S0014-5793(99)01459-3; Shifren JL, 1998, J CLIN ENDOCR METAB, V83, P1342, DOI 10.1210/jc.83.4.1342; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Simionescu N., 1988, CELL TISSUE BIOL, P355; STEWART PA, 1981, DEV BIOL, V84, P183, DOI 10.1016/0012-1606(81)90382-1; Wechselberger C, 1999, FEBS LETT, V462, P177, DOI 10.1016/S0014-5793(99)01473-8; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; YANG JC, 2002, P ANN ASCO M; Yang RH, 1998, J PHARMACOL EXP THER, V284, P103	53	84	90	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2002	8	9					913	917		10.1038/nm0902-913	http://dx.doi.org/10.1038/nm0902-913			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12205443				2022-12-27	WOS:000177757900013
J	Hammer, SM; Turmen, T; Vareldzis, B; Perriens, J				Hammer, SM; Turmen, T; Vareldzis, B; Perriens, J			Antiretroviral guidelines for resource-limited settings: The WHO's public health approach	NATURE MEDICINE			English	Editorial Material									Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; WHO, CH-1211 Geneva, Switzerland	Columbia University; World Health Organization	Hammer, SM (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.								0	9	10	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2002	8	7					649	650		10.1038/nm0702-649	http://dx.doi.org/10.1038/nm0702-649			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12091891				2022-12-27	WOS:000176495200011
J	Bifulco, M; Di Marzo, V				Bifulco, M; Di Marzo, V			Targeting the endocannabinoid system in cancer therapy: A call for further research	NATURE MEDICINE			English	Editorial Material							HUMAN BREAST-CANCER; DELTA(9)-TETRAHYDROCANNABINOL INDUCES APOPTOSIS; CELL-PROLIFERATION; ENDOGENOUS CANNABINOIDS; VANILLOID RECEPTORS; ANANDAMIDE; INVOLVEMENT; INHIBITION; EXPRESSION; ACTIVATION		Univ Salerno, Dipartimento Sci Farmaceut, I-84100 Salerno, Italy; Univ Naples Federico II, Dipartimento Biol Patol Cell Mol, CNR, IEOS, Naples, Italy; CNR, Ist Chim Biomol, I-80125 Naples, Italy	University of Salerno; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR)	Bifulco, M (corresponding author), Univ Salerno, Dipartimento Sci Farmaceut, I-84100 Salerno, Italy.		Di Marzo, Vincenzo/AAD-7742-2019	Di Marzo, Vincenzo/0000-0002-1490-3070; Bifulco, Maurizio/0000-0002-1771-4531				Adams R., 1941, HARVEY LECT, V37, P168; Barsky SH, 1998, JNCI-J NATL CANCER I, V90, P1198, DOI 10.1093/jnci/90.16.1198; Berrendero F, 1999, SYNAPSE, V33, P181, DOI 10.1002/(SICI)1098-2396(19990901)33:3<181::AID-SYN3>3.0.CO;2-R; Bifulco M, 2001, FASEB J, V15, P2745, DOI 10.1096/fj.01-0320fje; Bisogno T, 1998, EUR J BIOCHEM, V254, P634, DOI 10.1046/j.1432-1327.1998.2540634.x; De Petrocellis L, 1998, P NATL ACAD SCI USA, V95, P8375, DOI 10.1073/pnas.95.14.8375; Di Marzo V, 2001, BIOCHEM J, V358, P249, DOI 10.1042/0264-6021:3580249; Di Marzo V, 1998, BBA-LIPID LIPID MET, V1392, P153, DOI 10.1016/S0005-2760(98)00042-3; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; Guzman M, 2001, J MOL MED-JMM, V78, P613, DOI 10.1007/s001090000177; Hollister LE, 1998, INT J NEUROPSYCHOP, V1, P71, DOI 10.1017/S1461145798001060; Jacobsson SOP, 2001, J PHARMACOL EXP THER, V299, P951; Kinzbrunner Barry M, 2002, ACP J Club, V136, P19; Maccarrone M, 2000, J BIOL CHEM, V275, P31938, DOI 10.1074/jbc.M005722200; Maccarrone M, 2001, J NEUROCHEM, V76, P594, DOI 10.1046/j.1471-4159.2001.00092.x; Melck D, 2000, ENDOCRINOLOGY, V141, P118, DOI 10.1210/en.141.1.118; Melck D, 1999, FEBS LETT, V463, P235, DOI 10.1016/S0014-5793(99)01639-7; Melck D, 1999, BIOCHEM BIOPH RES CO, V262, P275, DOI 10.1006/bbrc.1999.1105; MUNSON AE, 1975, J NATL CANCER I, V55, P597, DOI 10.1093/jnci/55.3.597; *NIH, 1996, NIH PUBL; Pagotto U, 2001, J CLIN ENDOCR METAB, V86, P2687, DOI 10.1210/jc.86.6.2687; PARIA BC, 1995, P NATL ACAD SCI USA, V92, P9460, DOI 10.1073/pnas.92.21.9460; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Ruiz L, 1999, FEBS LETT, V458, P400, DOI 10.1016/S0014-5793(99)01073-X; Sanchez C, 2001, CANCER RES, V61, P5784; Sanchez C, 1998, FEBS LETT, V436, P6, DOI 10.1016/S0014-5793(98)01085-0; Tramer MR, 2001, BMJ-BRIT MED J, V323, P16, DOI 10.1136/bmj.323.7303.16; WATSON ES, 1989, IMMUNOPHARM IMMUNOT, V11, P211, DOI 10.3109/08923978909005366; Zhu LX, 2000, J IMMUNOL, V165, P373, DOI 10.4049/jimmunol.165.1.373	30	143	150	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2002	8	6					547	550		10.1038/nm0602-547	http://dx.doi.org/10.1038/nm0602-547			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042794				2022-12-27	WOS:000175907300017
J	Kopf, M; Abel, B; Gallimore, A; Carroll, M; Bachmann, MF				Kopf, M; Abel, B; Gallimore, A; Carroll, M; Bachmann, MF			Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection	NATURE MEDICINE			English	Article							B-CELL; ACQUIRED-IMMUNITY; DEFICIENT MICE; ANTIBODY-RESPONSES; DEPENDENT ANTIGEN; HUMORAL RESPONSE; LYMPHOCYTES-B; IN-VITRO; RECEPTOR; INNATE	The complement cascade defines an important link between the innate and the specific immune system. Here we show that mice deficient for the third component of complement (C3(-/-) mice) are highly susceptible to primary infection with influenza virus. C3(-/-) mice showed delayed viral clearance and increased viral titers in lung, whereas mice deficient for complement receptors CR1 and CR2 (Cr2(-/-) mice) cleared the infection normally. Priming of T-helper cells and cytotoxic T cells ( CTLs) in lung-draining lymph nodes was reduced, and the recruitment into the lung of virus-specific CD4(+) and CD8(+) effector T cells producing interferon-gamma was severely impaired in C3(-/-) but not in Cr2(-/-) mice. Consequently, T-helper cell dependent IgG responses were reduced in C3(-/-) mice but remained intact in Cr2(-/-) mice. These results demonstrate that complement induces specific immunity by promoting T-cell responses.	Swiss Fed Inst Technol, Dept Environm Sci, Zurich, Switzerland; Basel Inst Immunol, Basel, Switzerland; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Cytos Biotechnol AG, Schlieren, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Oxford; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Kopf, M (corresponding author), Swiss Fed Inst Technol, Dept Environm Sci, Zurich, Switzerland.		Kopf, Manfred/B-6907-2009	Kopf, Manfred/0000-0002-0628-7140; Gallimore, Awen/0000-0001-6675-7004				Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; BACHMANN MF, 1994, EUR J IMMUNOL, V24, P2567, DOI 10.1002/eji.1830241046; Bachmann MF, 1999, J IMMUNOL METHODS, V225, P105, DOI 10.1016/S0022-1759(99)00034-4; BACHMANN MF, 1994, CURR OPIN IMMUNOL, V6, P320, DOI 10.1016/0952-7915(94)90108-2; BROWN EJ, 1992, INFECT AGENT DIS, V1, P63; Carroll MC, 1998, CURR OPIN IMMUNOL, V10, P36; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CARTER RH, 1988, J IMMUNOL, V141, P457; Croix DA, 1996, J EXP MED, V183, P1857, DOI 10.1084/jem.183.4.1857; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; Da Costa XJ, 1999, P NATL ACAD SCI USA, V96, P12708, DOI 10.1073/pnas.96.22.12708; DANIELS CA, 1969, SCIENCE, V165, P508, DOI 10.1126/science.165.3892.508; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Doherty PC, 1997, IMMUNOL REV, V159, P105, DOI 10.1111/j.1600-065X.1997.tb01010.x; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; Fischer MB, 1996, J IMMUNOL, V157, P549; Gerhard W, 1997, IMMUNOL REV, V159, P95, DOI 10.1111/j.1600-065X.1997.tb01009.x; Graham MB, 1997, J EXP MED, V186, P2063, DOI 10.1084/jem.186.12.2063; Guinamard R, 2000, NAT IMMUNOL, V1, P31, DOI 10.1038/76882; Hopken UE, 1996, NATURE, V383, P86, DOI 10.1038/383086a0; Huber VC, 2001, J IMMUNOL, V166, P7381, DOI 10.4049/jimmunol.166.12.7381; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; Karp CL, 2000, NAT IMMUNOL, V1, P221, DOI 10.1038/79759; Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567; Kopf M, 1999, IMMUNITY, V11, P699, DOI 10.1016/S1074-7613(00)80144-2; LINSCOTT WD, 1969, P NATL ACAD SCI USA, V64, P520, DOI 10.1073/pnas.64.2.520; Mabbott NA, 2001, NAT MED, V7, P485, DOI 10.1038/86562; MORGAN BP, 1991, IMMUNOL TODAY, V12, P301, DOI 10.1016/0167-5699(91)90003-C; MULLEREBERHARD HJ, 1986, ANNU REV IMMUNOL, V4, P503, DOI 10.1146/annurev.iy.04.040186.002443; Nataf S, 2000, J IMMUNOL, V165, P5867, DOI 10.4049/jimmunol.165.10.5867; Nataf S, 1999, J IMMUNOL, V162, P4018; Ochsenbein AF, 1999, J EXP MED, V190, P1165, DOI 10.1084/jem.190.8.1165; PAPAMICHAIL M, 1975, SCAND J IMMUNOL, V4, P343, DOI 10.1111/j.1365-3083.1975.tb02635.x; PEPYS MB, 1974, J EXP MED, V140, P126, DOI 10.1084/jem.140.1.126; Reid RR, 1997, J IMMUNOL, V159, P970; Ruedl C, 2000, EUR J IMMUNOL, V30, P2056, DOI 10.1002/1521-4141(200007)30:7<2056::AID-IMMU2056>3.0.CO;2-S; TEW JG, 1990, IMMUNOL REV, V117, P185, DOI 10.1111/j.1600-065X.1990.tb00573.x; THIEBLEMONT N, 1995, J IMMUNOL, V155, P4861; VANNOESEL CJM, 1993, IMMUNOL TODAY, V14, P8, DOI 10.1016/0167-5699(93)90316-D; WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955; WELSH RM, 1976, VIROLOGY, V73, P59, DOI 10.1016/0042-6822(76)90060-X; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490	43	245	254	3	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2002	8	4					373	378		10.1038/nm0402-373	http://dx.doi.org/10.1038/nm0402-373			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927943				2022-12-27	WOS:000174704800029
J	Mizumoto, N; Kumamoto, T; Robson, SC; Sevigny, J; Matsue, H; Enjyoji, K; Takashima, A				Mizumoto, N; Kumamoto, T; Robson, SC; Sevigny, J; Matsue, H; Enjyoji, K; Takashima, A			CD39 is the dominant Langerhans cell associated ecto-NTPDase: Modulatory roles in inflammation and immune responsiveness	NATURE MEDICINE			English	Article							MURINE DENDRITIC CELLS; EPIDERMAL T-CELLS; EXTRACELLULAR ATP; CONTACT SENSITIVITY; CYTOKINE PRODUCTION; PLATELET-FUNCTION; P2Y RECEPTORS; ANTIGEN; ACTIVATION; DIPHOSPHOHYDROLASE	CD39, the endothelial ecto-nucleoside triphosphate diphosphohydrolase ( NTPDase), regulates vascular inflammation and thrombosis by hydrolyzing ATP and ADP. Although ecto-NTPDase activities have been used as a marker of epidermal dendritic cells ( DCs) known as Langerhans cells, the identity and function of these activities remain unknown. Here we report that Langerhans cells in CD39(-/-) mice express no detectable ecto-NTPDase activity. Irritant chemicals triggered rapid ATP and ADP release from keratinocytes and caused exacerbated skin inflammation in CD39(-/-) mice. Paradoxically, T cell mediated allergic contact hypersensitivity was severely attenuated in CD39(-/-) mice. As to mechanisms, T cells increased pericellular ATP concentrations upon activation, and CD39(-/-) DCs showed ATP unresponsiveness ( secondary to P2-receptor desensitization) and impaired antigen-presenting capacity. Our results show opposing outcomes of CD39 deficiency in irritant versus allergic contact dermatitis, reflecting its diverse roles in regulating extracellular nucleotide-mediated signaling in inflammatory responses to environmental insults and DC T cell communication in antigen presentation.	Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75235 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Takashima, A (corresponding author), Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75235 USA.	akira.takashima@utsouthwestern.edu	Sevigny, Jean/E-8039-2012; Sévigny, Jean/AGH-9323-2022; Robson, Simon C./AAA-8537-2021	Sevigny, Jean/0000-0003-2922-1600; Sévigny, Jean/0000-0003-2922-1600; 				Abeyama K, 2000, J CLIN INVEST, V105, P1751, DOI 10.1172/JCI9745; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Berchtold S, 1999, FEBS LETT, V458, P424, DOI 10.1016/S0014-5793(99)01197-7; Burnett CA, 1998, AM J IND MED, V34, P568, DOI 10.1002/(SICI)1097-0274(199812)34:6&lt;568::AID-AJIM4&gt;3.0.CO;2-Z; CHAKER MB, 1984, J INVEST DERMATOL, V82, P496, DOI 10.1111/1523-1747.ep12261031; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; Ferrari D, 2000, FASEB J, V14, P2466, DOI 10.1096/fj.00-0031com; FILIPPINI A, 1990, P NATL ACAD SCI USA, V87, P8267, DOI 10.1073/pnas.87.21.8267; Gayle RB, 1998, J CLIN INVEST, V101, P1851, DOI 10.1172/JCI1753; GIROLOMONI G, 1993, J INVEST DERMATOL, V100, P282, DOI 10.1111/1523-1747.ep12469769; GOCINSKI BL, 1990, J IMMUNOL, V144, P4121; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; KANSAS GS, 1991, J IMMUNOL, V146, P2235; Khakh BS, 2001, NAT REV NEUROSCI, V2, P165, DOI 10.1038/35058521; Kumamoto T, 2002, NAT BIOTECHNOL, V20, P64, DOI 10.1038/nbt0102-64; Liu QH, 1999, FEBS LETT, V445, P402, DOI 10.1016/S0014-5793(99)00161-1; LOVESCHIMENTI CD, 1994, J IMMUNOL, V153, P3450; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; Marriott I, 1999, CELL IMMUNOL, V195, P147, DOI 10.1006/cimm.1999.1531; Matsue H, 1999, NAT MED, V5, P930, DOI 10.1038/11375; MATSUE H, 1993, J IMMUNOL, V151, P6012; Mummert ME, 2000, J EXP MED, V192, P769, DOI 10.1084/jem.192.6.769; Mutini C, 1999, J IMMUNOL, V163, P1958; Nihei OK, 2000, BLOOD, V96, P996, DOI 10.1182/blood.V96.3.996.015k02_996_1005; PILLAI S, 1992, J CLIN INVEST, V90, P42, DOI 10.1172/JCI115854; PLESNER L, 1995, INT REV CYTOL, V158, P141; Ralevic V, 1998, PHARMACOL REV, V50, P413; Sellers LK, 2001, J BIOL CHEM, V276, P16379, DOI 10.1074/jbc.M006617200; SREEKUMAR P, 1995, J CLIN INVEST, V96, P602, DOI 10.1172/JCI118075; SUTER MM, 1991, J INVEST DERMATOL, V97, P223, DOI 10.1111/1523-1747.ep12480162; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; WOLFF K, 1967, J INVEST DERMATOL, V48, P50, DOI 10.1038/jid.1967.8; Xu H, 1996, J EXP MED, V183, P1001, DOI 10.1084/jem.183.3.1001; XU S, 1995, J IMMUNOL, V154, P2697; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	41	256	272	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2002	8	4					358	365		10.1038/nm0402-358	http://dx.doi.org/10.1038/nm0402-358			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927941				2022-12-27	WOS:000174704800027
J	Andre, P; Prasad, KSS; Denis, CV; He, M; Papalia, JM; Hynes, RO; Phillips, DR; Wagner, DD				Andre, P; Prasad, KSS; Denis, CV; He, M; Papalia, JM; Hynes, RO; Phillips, DR; Wagner, DD			CD40L stabilizes arterial thrombi by a beta(3) integrin-dependent mechanism	NATURE MEDICINE			English	Article							VON-WILLEBRAND-FACTOR; TISSUE FACTOR; P-SELECTIN; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; LIGAND; PLATELETS; EXPRESSION; ADHESION; DEFECTS	CD40L, a member of the tumor necrosis factor family of ligands, plays a major role in immune responses via its receptor, CD40. Recently, CD40L has been detected on the surfaces of activated platelets and shown to activate endothelium. Here we further addressed the function of platelet CD40L. We show that absence of CD40L affects the stability of arterial thrombi and delays arterial occlusion in vivo. Infusion of recombinant soluble (rs) CD40L restored normal thrombosis, whereas rsCD40L lacking the KGD integrin-recognition sequence did not. CD40-deficient mice exhibited normal thrombogenesis. rsCD40L specifically bound to purified integrin alpha(IIb)beta(3) and to activated platelets in a beta(3)-dependent manner and induced platelet spreading. In addition, rsCD40L promoted the aggregation of either human or mouse platelets under high shear rates. Thus, CD40L appears to be an alpha(IIb)beta(3) ligand, a platelet agonist, and necessary for stability of arterial thrombi.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; COR Therapeut, San Francisco, CA USA; MIT, Ctr Canc Res, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Wagner, DD (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA.	wagner@cbr.med.harvard.edu	Denis, Cecile/A-7649-2011	Denis, Cecile/0000-0001-5152-9156	NHLBI NIH HHS [R37 HL41002, P01 HL056949, R01 HL041002, P01 HL56949] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056949, R01HL041002, R37HL041002] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andre P, 2000, BLOOD, V96, P3322, DOI 10.1182/blood.V96.10.3322.h8003322_3322_3328; Andre P, 1996, ARTERIOSCL THROM VAS, V16, P56, DOI 10.1161/01.ATV.16.1.56; Andre P, 2000, P NATL ACAD SCI USA, V97, P13835, DOI 10.1073/pnas.250475997; Aukrust P, 1999, CIRCULATION, V100, P614, DOI 10.1161/01.CIR.100.6.614; CELI A, 1994, P NATL ACAD SCI USA, V91, P8767, DOI 10.1073/pnas.91.19.8767; CHARO IF, 1991, J BIOL CHEM, V266, P1415; Denis C, 1998, P NATL ACAD SCI USA, V95, P9524, DOI 10.1073/pnas.95.16.9524; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; GRAF D, 1995, EUR J IMMUNOL, V25, P1749, DOI 10.1002/eji.1830250639; Henn V, 2001, BLOOD, V98, P1047, DOI 10.1182/blood.V98.4.1047; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Kawai T, 2000, NAT MED, V6, P114, DOI 10.1038/72162; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; Kotowicz K, 2000, IMMUNOLOGY, V100, P441, DOI 10.1046/j.1365-2567.2000.00061.x; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; LAWLER J, 1989, BLOOD, V74, P2022; Lindmark E, 2000, ARTERIOSCL THROM VAS, V20, P2322, DOI 10.1161/01.ATV.20.10.2322; Lutgens E, 2000, P NATL ACAD SCI USA, V97, P7464, DOI 10.1073/pnas.97.13.7464; Lutgens E, 1999, NAT MED, V5, P1313, DOI 10.1038/15271; Mach F, 1997, CIRCULATION, V96, P396; Melter M, 2000, BLOOD, V96, P3801, DOI 10.1182/blood.V96.12.3801.h8003801_3801_3808; Miller DL, 1998, J LEUKOCYTE BIOL, V63, P373, DOI 10.1002/jlb.63.3.373; Ni HY, 2000, J CLIN INVEST, V106, P385, DOI 10.1172/JCI9896; PHILLIPS DR, 1977, J CLIN INVEST, V60, P535, DOI 10.1172/JCI108805; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; Ramesh N, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P233; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAKARIASSEN KS, 1988, THROMB HAEMOSTASIS, V60, P392; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; Schonbeck U, 2000, P NATL ACAD SCI USA, V97, P7458, DOI 10.1073/pnas.97.13.7458; Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2	36	595	631	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2002	8	3					247	252		10.1038/nm0302-247	http://dx.doi.org/10.1038/nm0302-247			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875495				2022-12-27	WOS:000174139500029
J	Carvalho, LH; Sano, GI; Hafalla, JCR; Morrot, A; de Lafaille, MAC; Zavala, F				Carvalho, LH; Sano, GI; Hafalla, JCR; Morrot, A; de Lafaille, MAC; Zavala, F			IL-4-secreting CD4(+) T cells are crucial to the development of CD8(+) T-cell responses against malaria liver stages	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODY; CIRCUMSPOROZOITE PROTEIN; HELPER; MICE; LYMPHOCYTES; INDUCTION; IMMUNITY; INFLUENZA; MEMORY; REQUIREMENT	CD4(+) T cells are crucial to the development of CD8(+) T cell responses against hepatocytes infected with malaria parasites. In the absence of CD4(+) T cells, CD8(+) T cells initiate a seemingly normal differentiation and proliferation during the first few days after immunization. However, this response fails to develop further and is reduced by more than 90%, compared to that observed in the presence of CD4(+) T cells. We report here that interleukin-4 (IL-4) secreted by CD4(+) T cells is essential to the full development of this CD8(+) T cell response. This is the first demonstration that IL-4 is a mediator of CD4/CD8 cross-talk leading to the development of immunity against an infectious pathogen.	NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10003 USA; NYU, Sch Med, Skirball Inst Biomol Med, Mol Pathogenesis Program, New York, NY USA	New York University; New York University	Zavala, F (corresponding author), NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10003 USA.		carvalho, luzia H/C-4087-2013; Carvalho, Luzia H/AAW-3461-2021; Morrot, Alexandre/J-8727-2012	Curotto de Lafaille, Maria Alicia/0000-0002-3510-3777; Morrot, Alexandre/0000-0001-9432-9701				ALLAN W, 1990, J IMMUNOL, V144, P3980; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Andreasen SO, 2000, J IMMUNOL, V164, P3689, DOI 10.4049/jimmunol.164.7.3689; ARMITAGE RJ, 1990, INT IMMUNOL, V2, P1039, DOI 10.1093/intimm/2.11.1039; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; BODMER H, 1993, EUR J IMMUNOL, V23, P1649, DOI 10.1002/eji.1830230738; Borrow P, 1996, J EXP MED, V183, P2129, DOI 10.1084/jem.183.5.2129; Bucy RP, 2001, AIDS, V15, pS36, DOI 10.1097/00002030-200102002-00007; BULLER RML, 1987, NATURE, V328, P77, DOI 10.1038/328077a0; Cardin RD, 1996, J EXP MED, V184, P863, DOI 10.1084/jem.184.3.863; Carvalho LH, 2001, J IMMUNOL METHODS, V252, P207, DOI 10.1016/S0022-1759(01)00331-3; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; Franco A, 2000, NAT IMMUNOL, V1, P145, DOI 10.1038/77827; Huang LR, 2000, P NATL ACAD SCI USA, V97, P3406, DOI 10.1073/pnas.060026497; Kaplan MH, 1998, J LEUKOCYTE BIOL, V64, P2, DOI 10.1002/jlb.64.1.2; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; Kurts C, 1997, J EXP MED, V186, P2057, DOI 10.1084/jem.186.12.2057; Lu ZB, 2000, J EXP MED, V191, P541, DOI 10.1084/jem.191.3.541; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; MIYAHIRA Y, 1995, J IMMUNOL METHODS, V181, P45, DOI 10.1016/0022-1759(94)00327-S; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OHTEKI T, 1994, J EXP MED, V180, P699, DOI 10.1084/jem.180.2.699; Ossendorp F, 1998, J EXP MED, V187, P693, DOI 10.1084/jem.187.5.693; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PedrasVasconcelos JA, 1996, J IMMUNOL, V157, P3046; Peng LM, 2000, J IMMUNOL, V165, P5738, DOI 10.4049/jimmunol.165.10.5738; Riberdy JM, 2000, J VIROL, V74, P9762, DOI 10.1128/JVI.74.20.9762-9765.2000; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; RODRIGUES MM, 1991, INT IMMUNOL, V3, P579, DOI 10.1093/intimm/3.6.579; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; Sano G, 2001, J EXP MED, V194, P173, DOI 10.1084/jem.194.2.173; Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Schuler T, 1999, J EXP MED, V189, P803, DOI 10.1084/jem.189.5.803; SEAMAN WE, 1987, J IMMUNOL, V138, P4539; TRIPP RA, 1995, J IMMUNOL, V155, P2955; WEISS WR, 1993, J IMMUNOL, V151, P2690; Zavala F, 2001, VIROLOGY, V280, P155, DOI 10.1006/viro.2000.0792	39	174	179	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2002	8	2					166	170		10.1038/nm0202-166	http://dx.doi.org/10.1038/nm0202-166			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821901				2022-12-27	WOS:000173600600026
J	George, AJT; Gale, R; Winston, R; Korn, D				George, AJT; Gale, R; Winston, R; Korn, D			Research governance at the crossroads	NATURE MEDICINE			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, London, England; Assoc Amer Med Coll, Biomed & Hlth Sci Res, Washington, DC USA	Imperial College London; Association of American Medical Colleges	George, AJT (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, London, England.			George, Andrew/0000-0002-2866-0241				[Anonymous], 2001, NATURE, V414, P379	1	3	3	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2002	8	2					99	101		10.1038/nm0202-99	http://dx.doi.org/10.1038/nm0202-99			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821883				2022-12-27	WOS:000173600600011
J	Levine, BL; Bernstein, WB; Aronson, NE; Schlienger, K; Cotte, J; Perfetto, S; Humphries, MJ; Ratto-Kim, S; Birx, DL; Steffens, C; Landay, A; Carroll, RG; June, CH				Levine, BL; Bernstein, WB; Aronson, NE; Schlienger, K; Cotte, J; Perfetto, S; Humphries, MJ; Ratto-Kim, S; Birx, DL; Steffens, C; Landay, A; Carroll, RG; June, CH			Adoptive transfer of costimulated CD4(+) T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; ACTIVE ANTIRETROVIRAL THERAPY; CD28 COSTIMULATION; LYMPH-NODES; BONE-MARROW; LYMPHOCYTES; CD8(+); INTERLEUKIN-2; DYSFUNCTION; RECONSTITUTION	To study the safety and feasibility of T-cell reconstitution in HIV-infected individuals, we adoptively transferred activated autologous CD4(+) T cells. Polyclonal peripheral blood CD4(+) cells were costimulated ex vivo and subjects were given infusions of up to 3 x 10(10) activated CD4(+) Cells. Dose-dependent increases in CD4(+) cell counts and in the CD4:CD8 ratio were observed. Sustained increases in the fraction of cytokine-secreting T cells and decreases in the percentage of CD4(+)CCR5(+) cells were noted in vivo, suggesting enhanced function and resistance to HIV infection. The frequency of CD4(+)Ki-67(+) cells increased whereas CD4(+) T cells containing T cell-receptor rearrangement excision circles (TRECs) decreased. These findings indicate that expansion of the peripheral T-cell pool mediated the increase in CD4 counts and suggest that approaches to reconstitute CD4 helper cell activity and decrease CCR5 expression may augment natural immunity to HIV infection.	Univ Penn, Ctr Canc, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Walter Reed Army Inst Res, Div Retrovirol, Rockville, MD USA; Henry M Jackson Fdn, Rockville, MD USA; Natl Naval Med Ctr, Bethesda, MD USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; Walter Reed Army Med Ctr, Washington, DC 20307 USA; Rush Univ, Sch Med, Chicago, IL 60612 USA	University of Pennsylvania; Pennsylvania Medicine; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Rush University	Levine, BL (corresponding author), Univ Penn, Ctr Canc, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	levinebl@mail.med.upenn.edu; cjune@mail.med.upenn.edu	Levine, Bruce L/D-1688-2009	June, Carl/0000-0003-0241-3557; Ratto-Kim, Silvia/0000-0003-2025-6399				Al-Harthi L, 2000, J IMMUNOL METHODS, V237, P187, DOI 10.1016/S0022-1759(00)00136-8; BEX F, 1994, BLOOD, V84, P3317; Brites C, 2000, J INFECT DIS, V182, P1531, DOI 10.1086/315901; Brodie SJ, 2000, J CLIN INVEST, V105, P1407, DOI 10.1172/JCI8707; Brodie SJ, 1999, NAT MED, V5, P34, DOI 10.1038/4716; Carcelain G, 2001, CURR OPIN IMMUNOL, V13, P483, DOI 10.1016/S0952-7915(00)00245-4; Carroll RG, 1997, SCIENCE, V276, P273, DOI 10.1126/science.276.5310.273; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; Combadiere B, 2000, EUR J IMMUNOL, V30, P3598, DOI 10.1002/1521-4141(200012)30:12<3598::AID-IMMU3598>3.0.CO;2-E; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; Hazenberg MD, 2000, BLOOD, V95, P249, DOI 10.1182/blood.V95.1.249.001k40_249_255; Hazenberg MD, 2000, NAT MED, V6, P1036, DOI 10.1038/79549; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; KOVACS JA, 1995, NEW ENGL J MED, V332, P567, DOI 10.1056/NEJM199503023320904; Kovacs JA, 2001, EUR J IMMUNOL, V31, P1351, DOI 10.1002/1521-4141(200105)31:5<1351::AID-IMMU1351>3.0.CO;2-9; LANE HC, 1990, ANN INTERN MED, V113, P512, DOI 10.7326/0003-4819-113-7-512; Levine BL, 1997, J IMMUNOL, V159, P5921; Levine BL, 1998, J HEMATOTHER, V7, P437, DOI 10.1089/scd.1.1998.7.437; Levine BL, 1996, SCIENCE, V272, P1939, DOI 10.1126/science.272.5270.1939; Lori F, 2000, SCIENCE, V290, P1591, DOI 10.1126/science.290.5496.1591; Mitsuyasu RT, 2000, BLOOD, V96, P785, DOI 10.1182/blood.V96.3.785.015k10_785_793; Musey LK, 1999, J INFECT DIS, V180, P278, DOI 10.1086/314868; NIJHUIS EWP, 1990, CANCER IMMUNOL IMMUN, V32, P245, DOI 10.1007/BF01741708; Oxenius A, 2000, P NATL ACAD SCI USA, V97, P3382, DOI 10.1073/pnas.97.7.3382; RIDDELL SR, 1990, J IMMUNOL METHODS, V128, P189, DOI 10.1016/0022-1759(90)90210-M; Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296-216; Riley JL, 1997, J IMMUNOL, V158, P5545; ROEDERER M, 1995, NAT MED, V1, P621, DOI 10.1038/nm0795-621; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Tan RS, 1999, BLOOD, V93, P1506, DOI 10.1182/blood.V93.5.1506.405a38_1506_1510; Walker RE, 2000, BLOOD, V96, P467; Walker RE, 1998, NAT MED, V4, P852, DOI 10.1038/nm0798-852; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	42	142	153	0	5	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2002	8	1					47	53		10.1038/nm0102-47	http://dx.doi.org/10.1038/nm0102-47			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	507XQ	11786906				2022-12-27	WOS:000173056900030
J	Schwartz, TH; Bonhoeffer, T				Schwartz, TH; Bonhoeffer, T			In vivo optical mapping of epileptic foci and surround inhibition in ferret cerebral cortex	NATURE MEDICINE			English	Article							VISUAL-CORTEX; EPILEPTOGENESIS; MECHANISMS; SEIZURES; PATTERNS	The population of neurons participating in an epileptiform event varies from moment to moment. Most techniques currently used to localize epileptiform events in vivo have spatial and/or temporal sampling limitations. Here we show in an animal model that optical imaging based on intrinsic signals is an excellent method for in vivo mapping of clinically relevant epileptiform events, such as interictal spikes, ictal onsets, ictal spread and secondary homotopic foci. In addition, a decrease in the optical signal correlates spatially with a decrease in neuronal activity recorded from cortex surrounding an epileptic focus. Optical mapping of epilepsy might be a useful adjunct in the surgical treatment of neocortical epilepsy, which critically depends on the precise localization of intrinsically epileptogenic neurons.	Max Planck Inst Neurobiol, Munich, Germany	Max Planck Society	Schwartz, TH (corresponding author), Max Planck Inst Neurobiol, Munich, Germany.	tschwartz1@nyc.rr.com	Bonhoeffer, Tobias/B-9481-2009; Schwartz, Theodore/AAK-3320-2020	Bonhoeffer, Tobias/0000-0001-7897-6634; 				ANDREW RD, 1994, NEUROSCIENCE, V62, P371, DOI 10.1016/0306-4522(94)90372-7; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Bonhoeffer Tobias, 1996, P55; Buzaki G, 1997, EPILEPSY COMPREHENSI, P819; Duncan JS, 1997, BRAIN, V120, P339, DOI 10.1093/brain/120.2.339; ENGEL J, 1997, EPILEPSY COMPREHENSI, P499; FEDERICO P, 1994, NEUROSCIENCE, V58, P461, DOI 10.1016/0306-4522(94)90073-6; Goldensohn E S, 1986, Adv Neurol, V44, P559; GUMNIT RJ, 1965, ELECTROEN CLIN NEURO, V19, P63, DOI 10.1016/0013-4694(65)90007-6; HAGLUND MM, 1992, NATURE, V358, P668, DOI 10.1038/358668a0; HAUSER WEA, 1990, EPILLEPSY FREQUENCY; HOCHMAN DW, 1995, SCIENCE, V270, P99, DOI 10.1126/science.270.5233.99; Kiper DC, 1999, J NEUROPHYSIOL, V82, P3082, DOI 10.1152/jn.1999.82.6.3082; OLIVIER A, 1991, CONT ISSUES NEUROLOG, P150; ORBACH HS, 1985, J NEUROSCI, V5, P1886; Prince DA, 1997, CAN J PHYSIOL PHARM, V75, P500, DOI 10.1139/cjpp-75-5-500; PRINCE DA, 1967, ARCH NEUROL-CHICAGO, V16, P194, DOI 10.1001/archneur.1967.00470200082007; QUESNEY LF, 1995, ADV NEUROL, V66, P243; RATZLAFF EH, 1991, J NEUROSCI METH, V36, P127, DOI 10.1016/0165-0270(91)90038-2; Rubin BD, 1999, NEURON, V23, P499, DOI 10.1016/S0896-6273(00)80803-X; SCHWARTZKROIN PA, 1975, BRAIN RES, V99, P59, DOI 10.1016/0006-8993(75)90608-3; STANSFELD CE, 1986, NEUROSCI LETT, V64, P299, DOI 10.1016/0304-3940(86)90345-9; SZENTE M, 1979, ELECTROEN CLIN NEURO, V46, P605, DOI 10.1016/0013-4694(79)90014-2; SZENTE MB, 1994, BRAIN RES, V648, P203, DOI 10.1016/0006-8993(94)91119-3; WIESER HG, 1979, EPILEPSIA, V20, P47, DOI 10.1111/j.1528-1157.1979.tb04775.x; WYLER AR, 1980, EPILEPSY WINDOW BRAI, P51	26	136	142	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2001	7	9					1063	1067		10.1038/nm0901-1063	http://dx.doi.org/10.1038/nm0901-1063			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533712				2022-12-27	WOS:000170853300034
J	Berg, AH; Combs, TP; Du, XL; Brownlee, M; Scherer, PE				Berg, AH; Combs, TP; Du, XL; Brownlee, M; Scherer, PE			The adipocyte-secreted protein Acrp30 enhances hepatic insulin action	NATURE MEDICINE			English	Article							ADIPOSE-SPECIFIC GENE; TISSUE; THIAZOLIDINEDIONES; RESISTANCE; LIPODYSTROPHY; ADIPONECTIN; MECHANISMS; ENDOCRINE; OBESITY; PLASMA	Acrp30 is a circulating protein synthesized in adipose tissue. A single injection in mice of purified recombinant Acrp30 leads to a 2-3-fold elevation in circulating Acrp30 levels, which triggers a transient decrease in basal glucose levels. Similar treatment in ob/ob, NOD (non-obese diabetic) or streptozotocin-treated mice transiently abolishes hyperglycemia. This effect on glucose is not associated with an increase in insulin levels. Moreover, in isolated hepatocytes, Acrp30 increases the ability of sub-physiological levels of insulin to suppress glucose production. We thus propose that Acrp30 is a potent insulin enhancer linking adipose tissue and whole-body glucose metabolism.	Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Scherer, PE (corresponding author), Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA.	scherer@aecom.yu.edu	sheng, jian/E-9474-2012; Scherer, Philipp E/K-7819-2012	Scherer, Philipp E/0000-0003-0680-3392	NIDDK NIH HHS [T32-DK 07513-15, 1R01-DK55758] Funding Source: Medline; NIGMS NIH HHS [T32-GM07491] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007513, R01DK055758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Cherrington AD, 1999, DIABETES, V48, P1198, DOI 10.2337/diabetes.48.5.1198; Das K, 2001, BIOCHEM BIOPH RES CO, V280, P1120, DOI 10.1006/bbrc.2001.4217; Day C, 1999, DIABETIC MED, V16, P179, DOI 10.1046/j.1464-5491.1999.00023.x; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Ganda OP, 2000, ANN INTERN MED, V133, P304, DOI 10.7326/0003-4819-133-4-200008150-00017; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; Gupta G, 2000, AM J PHYSIOL-ENDOC M, V278, pE985, DOI 10.1152/ajpendo.2000.278.6.E985; Harlow E., 1988, ANTIBODIES LAB MANUA; Havel PJ, 2000, P NUTR SOC, V59, P359, DOI 10.1017/S0029665100000410; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kissebah AH, 2000, P NATL ACAD SCI USA, V97, P14478, DOI 10.1073/pnas.97.26.14478; KONDO N, 1992, J BIOL CHEM, V267, P473; LANG CH, 1987, METABOLISM, V36, P180, DOI 10.1016/0026-0495(87)90015-1; Leffert H L, 1979, Methods Enzymol, V58, P536; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Meng YG, 2000, GENE, V242, P201, DOI 10.1016/S0378-1119(99)00524-7; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P803; Reginato MJ, 1999, TRENDS ENDOCRIN MET, V10, P9, DOI 10.1016/S1043-2760(98)00110-6; REICHENBERGER E, 1992, FEBS LETT, V311, P305, DOI 10.1016/0014-5793(92)81126-7; REID KBM, 1982, BIOCHEM J, V203, P559, DOI 10.1042/bj2030559; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Seoane J, 1997, J BIOL CHEM, V272, P26972, DOI 10.1074/jbc.272.43.26972; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Takahashi M, 2000, INT J OBESITY, V24, P861, DOI 10.1038/sj.ijo.0801244	33	2025	2147	1	89	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2001	7	8					947	953		10.1038/90992	http://dx.doi.org/10.1038/90992			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479628				2022-12-27	WOS:000171740400033
J	Smith, ES; Mandokhot, A; Evans, EE; Mueller, L; Borrello, MA; Sahasrabudhe, DM; Zauderer, M				Smith, ES; Mandokhot, A; Evans, EE; Mueller, L; Borrello, MA; Sahasrabudhe, DM; Zauderer, M			Lethality-based selection of recombinant genes in mammalian cells: Application to identifying tumor antigens	NATURE MEDICINE			English	Article							CYTOLYTIC T-LYMPHOCYTES; MYELIN BASIC-PROTEIN; HUMAN-MELANOMA; REJECTION ANTIGEN; VACCINIA VIRUS; IDENTIFICATION; EXPRESSION; VECTORS; MICE	Many biological processes result in either cell death or cessation of cell growth. However, plasmid- and retrovirus-based mammalian expression vectors in which it has been possible to construct representative cDNA libraries cannot be readily recovered from cells that are not actively dividing. This has limited the efficiency of selection of recombinant genes that mediate either lytic events or growth arrest. Examples include genes that encode the target antigens of cytotoxic T cells, genes that promote stem-cell differentiation and pro-apoptotic genes. We have successfully constructed representative cDNA libraries in a poxvirus-based vector that can be recovered from cells that have undergone lethality-based selection. This strategy has been applied to selection of a gene that encodes a cytotoxic T-cell target antigen common to several independently derived tumors.	Vaccinex Inc, Rochester, NY USA; Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Ctr Canc, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Zauderer, M (corresponding author), Vaccinex Inc, Rochester, NY USA.			Evans, Elizabeth/0000-0002-9287-9221				Bloom MB, 1997, J EXP MED, V185, P453, DOI 10.1084/jem.185.3.453; BOEL P, 1995, IMMUNITY, V2, P167, DOI 10.1016/S1074-7613(95)80053-0; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; COLLINS JL, 1982, NATURE, V299, P169, DOI 10.1038/299169a0; Harrington CJ, 1998, IMMUNITY, V8, P571, DOI 10.1016/S1074-7613(00)80562-2; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P3515, DOI 10.1073/pnas.91.9.3515; KUWANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P58, DOI 10.1016/S0006-291X(05)81458-5; LIN Y, 1985, J NATL CANCER I, V74, P1025; Merchlinsky M, 1997, VIROLOGY, V238, P444, DOI 10.1006/viro.1997.8828; MOSS B, 1992, CURR TOP MICROBIOL, V158, P25; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982; PARK SB, 1994, PAC ASSOC KOREAN ST, V1, P163; PECKHAM I, 1989, GENE DEV, V3, P2062, DOI 10.1101/gad.3.12b.2062; SAHASRABUDHE DM, 1993, J IMMUNOL, V151, P6302; SIMONIC T, 1994, BBA-GENE STRUCT EXPR, V1219, P706, DOI 10.1016/0167-4781(94)90232-1; SOMOGYI P, 1993, VIROLOGY, V197, P439, DOI 10.1006/viro.1993.1608; Targoni OS, 1998, J EXP MED, V187, P2055, DOI 10.1084/jem.187.12.2055; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703	22	11	22	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2001	7	8					967	972		10.1038/91017	http://dx.doi.org/10.1038/91017			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479631				2022-12-27	WOS:000171740400036
J	Subramanian, C; Cotter, MA; Robertson, ES				Subramanian, C; Cotter, MA; Robertson, ES			Epstein-Barr virus nuclear protein EBNA-3C interacts with the human metastatic suppressor Nm23-H1: A molecular link to cancer metastasis	NATURE MEDICINE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; LYMPHOCYTE GROWTH TRANSFORMATION; INVASIVE BREAST CANCERS; ANTIGEN 3C; LATENT MEMBRANE-PROTEIN-1; CELL-LINES; IN-VITRO; EXPRESSION; TRANSFECTION; INHIBITION	Epstein-Barr virus (EBV) is an oncogenic virus associated with a number of human malignancies including Burkitt lymphoma, nasopharyngeal carcinoma, lymphoproliferative disease and, though still debated, breast carcinoma. A subset of latent EBV antigens is required for mediating immortalization of primary B-lymphocytes. Here we demonstrate that the carboxy-terminal region of the essential latent antigen, EBNA-3C, interacts specifically with the human metastatic suppressor protein Nm23-H1. Moreover, EBNA-3C reverses the ability of Nm23-H1 to suppress the migration of Burkitt lymphoma cells and breast carcinoma cells. We propose that EBNA-3C contributes to EBV-associated human cancers by targeting and altering the role of the metastasis suppressor Nm23-H1.	Univ Michigan, Sch Med, Dept Microbiol & Immunol, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Comprehens Canc & Geriatr Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Robertson, ES (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA.	esrobert@umich.edu			NATIONAL CANCER INSTITUTE [R29CA072150, R01CA072150] Funding Source: NIH RePORTER; NCI NIH HHS [CA072150-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, CANCER RES, V50, P6757; ALLDAY MJ, 1994, J VIROL, V68, P3491, DOI 10.1128/JVI.68.6.3491-3498.1994; Bonnet M, 1999, J NATL CANCER I, V91, P1376, DOI 10.1093/jnci/91.16.1376; Brink AATP, 2000, J NATL CANCER I, V92, P655, DOI 10.1093/jnci/92.8.655; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; Cotter MA, 2000, MOL CELL BIOL, V20, P5722, DOI 10.1128/MCB.20.15.5722-5735.2000; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Freije JMP, 1998, BIOCHEM SOC SYMP, P261; Glaser SL, 1998, INT J CANCER, V75, P555; GULLEY ML, 1992, CANCER, V70, P185, DOI 10.1002/1097-0142(19920701)70:1<185::AID-CNCR2820700129>3.0.CO;2-J; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; HARPER JW, 1993, CELL, V75, P805; Hartsough MT, 2000, J BIOENERG BIOMEMBR, V32, P301, DOI 10.1023/A:1005597231776; Huang S, 2000, ONCOGENE, V19, P1915, DOI 10.1038/sj.onc.1203509; KANTOR JD, 1993, CANCER RES, V53, P1971; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieff E., 1996, EPSTEINBARR VIRUS IT, P2343; LABRECQUE LG, 1995, CANCER RES, V55, P39; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; LEONE A, 1993, ONCOGENE, V8, P855; Lim SH, 1998, CANCER LETT, V133, P143, DOI 10.1016/S0304-3835(98)00219-5; Liu F, 2000, J CANCER RES CLIN, V126, P85; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MACDONALD NJ, 1995, EUR J CANCER, V31A, P1096, DOI 10.1016/0959-8049(95)00152-9; MARSHALL D, 1995, J VIROL, V69, P3624, DOI 10.1128/JVI.69.6.3624-3630.1995; Martin KK, 1998, ANTICANCER RES, V18, P919; MILLER WE, 1995, J VIROL, V69, P4390, DOI 10.1128/JVI.69.7.4390-4398.1995; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; RICKINSON AB, 1996, EPSTEIN BARR VIRUS F, P2397; Robertson E.S, 1997, EPSTEINBARR VIRUS RE, V4, P143; Robertson ES, 1996, J VIROL, V70, P3068, DOI 10.1128/JVI.70.5.3068-3074.1996; ROBERTSON ES, 1995, J VIROL, V69, P3108, DOI 10.1128/JVI.69.5.3108-3116.1995; Russell RL, 1998, BRIT J CANCER, V78, P710, DOI 10.1038/bjc.1998.566; SAMPLE J, 1990, J VIROL, V64, P4084, DOI 10.1128/JVI.64.9.4084-4092.1990; Speck P, 2000, J NATL CANCER I, V92, P1849, DOI 10.1093/jnci/92.22.1849; STEEG PS, 1988, CANCER RES, V48, P6550; SWAMINATHAN S, 1991, P NATL ACAD SCI USA, V88, P1546, DOI 10.1073/pnas.88.4.1546; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; WANG LM, 1993, CANCER RES, V53, P3652; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; Zhao B, 2000, J VIROL, V74, P5151, DOI 10.1128/JVI.74.11.5151-5160.2000	48	116	123	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2001	7	3					350	355		10.1038/85499	http://dx.doi.org/10.1038/85499			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231635				2022-12-27	WOS:000167380400042
J	Vigneri, P; Wang, JYJ				Vigneri, P; Wang, JYJ			Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase	NATURE MEDICINE			English	Article							CHRONIC MYELOID-LEUKEMIA; C-ABL; MYELOPROLIFERATIVE DISEASE; PHILADELPHIA-CHROMOSOME; POSITIVE CELLS; IN-VIVO; INHIBITOR; PROTEIN; MICE; TRANSFORMATION	The chimeric BCR-ABL oncoprotein is the molecular hallmark of chronic myelogenous leukemia (CML). BCR-ABL contains nuclear import and export signals but it is localized only In the cytoplasm where it activates mitogenic and anti-apoptotic pathways. We have found that inhibition of the BCR-ABL tyrosine kinase, either by mutation or by the drug STI571, can stimulate its nuclear entry. By combining STI571 with leptomycin B (LMB) to block nuclear export, we trapped BCR-ABL in the nucleus and the nuclear BCR-ABL tyrosine kinase activates apoptosis. As a result, the combined treatment with STI571 and LMB causes the irreversible and complete killing of BCR-ABL transformed cells, whereas the effect of either drug alone is fully reversible. The combined treatment with STI571 and LMB also preferentially eliminates mouse bone marrow cells that express BCR-ABL. These results indicate that nuclear entrapment of BCR-ABL can be used as a therapeutic strategy to selectively kill chronic myelogenous leukemia cells.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Studi Catanzaro, Catanzaro, Italy	University of California System; University of California San Diego; University of California System; University of California San Diego	Wang, JYJ (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	jywang@ucsd.edu	Vigneri, Paolo G/K-8504-2016	Vigneri, Paolo G/0000-0002-5943-6066	NCI NIH HHS [R01 CA043054, CA 43054, R37 CA043054] Funding Source: Medline; NHLBI NIH HHS [HL57900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beran M, 1998, CLIN CANCER RES, V4, P1661; Buchdunger E, 1996, CANCER RES, V56, P100; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Faderl S, 1999, ANN INTERN MED, V131, P207, DOI 10.7326/0003-4819-131-3-199908030-00008; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gambacorti-Passerini C, 2000, JNCI-J NATL CANCER I, V92, P1641, DOI 10.1093/jnci/92.20.1641; Goldman JM, 2000, LANCET, V355, P1031, DOI 10.1016/S0140-6736(00)02029-8; Gong JG, 1999, NATURE, V399, P806; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Jost CA, 1999, NATURE, V399, P817, DOI 10.1038/21710; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; KLEIN E, 1976, INT J CANCER, V18, P421, DOI 10.1002/ijc.2910180405; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Newlands ES, 1996, BRIT J CANCER, V74, P648, DOI 10.1038/bjc.1996.415; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Vastag B, 2000, J NATL CANCER I, V92, P6, DOI 10.1093/jnci/92.1.6; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WANG JYJ, 2000, INTEGRATIVE SIGNALIN, P303; Warmuth M, 1999, ANN HEMATOL, V78, P49, DOI 10.1007/s002770050473; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	45	256	268	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2001	7	2					228	234		10.1038/84683	http://dx.doi.org/10.1038/84683			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175855				2022-12-27	WOS:000166756300041
J	Crotty, S; Maag, D; Arnold, JJ; Zhong, WD; Lau, JYN; Hong, Z; Andino, R; Cameron, CE				Crotty, S; Maag, D; Arnold, JJ; Zhong, WD; Lau, JYN; Hong, Z; Andino, R; Cameron, CE			The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen	NATURE MEDICINE			English	Article							VESICULAR STOMATITIS-VIRUS; POLYMERASE 3D(POL); POLIOVIRUS; MECHANISM; INHIBITION; NUCLEOSIDE; MUTATIONS; MUTANTS; 1-BETA-D-RIBOFURANOSYL-1,2,4-TRIAZOLE-3-CARBOXAMIDE; INTERFERON-ALPHA-2B	The ribonucleoside analog ribavirin (1-beta -D-ribofuranosyl-1,2,4-triazole-3-carboxamide) shows antiviral activity against a variety of RNA viruses and is used in combination with interferon-alpha to treat hepatitis C virus infection. Here we show in vitro use of ribavirin triphosphate by a model viral RNA polymerase, poliovirus 3D(pol). Ribavirin incorporation is mutagenic, as it templates incorporation of cytidine and uridine with equal efficiency. Ribavirin reduces infectious poliovirus production to as little as 0.00001% in cell culture. The antiviral activity of ribavirin correlates directly with its mutagenic activity. These data indicate that ribavirin forces the virus into 'error catastrophe'. Thus, mutagenic ribonucleosides may represent an important class of anti-RNA virus agents.	Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 201, University Pk, PA 16802 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Schering Plough Corp, Res Inst, Antiviral Therapy, Kenilworth, NJ 07033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of California System; University of California San Francisco; Merck & Company; Schering Plough Corporation	Cameron, CE (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 201, University Pk, PA 16802 USA.	cec9@psu.edu	Crotty, Shane/AAC-6703-2019; Yang, Chen/G-1379-2010	Crotty, Shane/0000-0002-6484-6262; 	NCI NIH HHS [CA75118] Funding Source: Medline; NIAID NIH HHS [AI45818, AI40085] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045818, R21AI040085, R01AI040085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		*AFHS, 2000, AFHS DRUG INF; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; Arnold JJ, 2000, J BIOL CHEM, V275, P5329, DOI 10.1074/jbc.275.8.5329; BALTERA RF, 1989, J VIROL, V63, P4441, DOI 10.1128/JVI.63.10.4441-4444.1989; CASSIDY LF, 1989, ANTIMICROB AGENTS CH, V33, P2009, DOI 10.1128/AAC.33.11.2009; Davis GL, 1998, NEW ENGL J MED, V339, P1493, DOI 10.1056/NEJM199811193392102; DEA P, 1974, BIOCHEMISTRY-US, V13, P1862, DOI 10.1021/bi00706a014; DECLERCQ E, 1993, ADV VIRUS RES, V42, P1, DOI 10.1016/S0065-3527(08)60082-2; Domingo E, 2000, VIROLOGY, V270, P251, DOI 10.1006/viro.2000.0320; Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151; DOMINGO E, 1994, EVOLUTIONARY BIOL VI, V11, P353; ERIKSSON B, 1977, ANTIMICROB AGENTS CH, V11, P946, DOI 10.1128/AAC.11.6.946; GILBERT BE, 1986, ANTIMICROB AGENTS CH, V30, P201, DOI 10.1128/AAC.30.2.201; Gohara DW, 2000, J BIOL CHEM, V275, P25523, DOI 10.1074/jbc.M002671200; Gohara DW, 1999, PROTEIN EXPRES PURIF, V17, P128, DOI 10.1006/prep.1999.1100; GOSWAMI BB, 1979, BIOCHEM BIOPH RES CO, V89, P830, DOI 10.1016/0006-291X(79)91853-9; Herold J, 2000, J VIROL, V74, P6394, DOI 10.1128/JVI.74.14.6394-6400.2000; HOLLAND JJ, 1990, J VIROL, V64, P3960, DOI 10.1128/JVI.64.8.3960-3962.1990; IRURZUN A, 1992, VIROLOGY, V191, P166, DOI 10.1016/0042-6822(92)90178-R; Lee CH, 1997, J VIROL, V71, P3636, DOI 10.1128/JVI.71.5.3636-3640.1997; Loeb LA, 1999, P NATL ACAD SCI USA, V96, P1492, DOI 10.1073/pnas.96.4.1492; MAYNELL LA, 1992, J VIROL, V66, P1985, DOI 10.1128/JVI.66.4.1985-1994.1992; MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; MILLER JP, 1977, ANN NY ACAD SCI, V284, P211, DOI 10.1111/j.1749-6632.1977.tb21953.x; PATHAK VK, 1992, J VIROL, V66, P3093, DOI 10.1128/JVI.66.5.3093-3100.1992; Pfister T, 1999, J BIOL CHEM, V274, P6992, DOI 10.1074/jbc.274.11.6992; PINCUS SE, 1986, J VIROL, V57, P638, DOI 10.1128/JVI.57.2.638-646.1986; PRINGLE CR, 1970, J VIROL, V5, P559, DOI 10.1128/JVI.5.5.559-567.1970; RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391; SIDWELL RW, 1972, SCIENCE, V177, P705, DOI 10.1126/science.177.4050.705; SMITH RA, 1980, RIBAVIRIN BROAD SPEC, V13, P237; SMITH RA, 1984, CLIN APPL RIBAVIRIN, V19, P222; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; Wyde PR, 1998, ANTIVIR RES, V39, P63, DOI 10.1016/S0166-3542(98)00029-1	35	621	658	1	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2000	6	12					1375	1379		10.1038/82191	http://dx.doi.org/10.1038/82191			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100123				2022-12-27	WOS:000165704100042
J	Prakken, B; Wauben, M; Genini, D; Samodal, R; Barnett, J; Mendivil, A; Leoni, L; Albani, S				Prakken, B; Wauben, M; Genini, D; Samodal, R; Barnett, J; Mendivil, A; Leoni, L; Albani, S			Artificial antigen-presenting cells as a tool to exploit the immune 'synapse'	NATURE MEDICINE			English	Article							T-CELLS; POSITIVE SELECTION; PEPTIDE COMPLEXES; RESPONSES; COSTIMULATION	Recent progress in molecular medicine has provided important tools to identify antigen-specific T cells. In most cases, the approach is based on oligomeric combinations of recombinant major histocompatibility complex-peptide complexes fixed to various rigid supports available for binding by the T-cell receptor(1-8). These tools have greatly increased our insight into mechanisms of immune responses mediated by CD8(+) T cells(1,2). Examples of the diverse fields of application for this technology include immunization, viral infections and oral tolerance induction(1-6).	Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Univ Utrecht, Fac Vet Med, Dept Immunol & Infect Dis, NL-3508 TD Utrecht, Netherlands; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Androcius Therapeut, I-95030 Catania, Italy	University of California System; University of California San Diego; Utrecht University; University of California System; University of California San Diego	Albani, S (corresponding author), Univ Calif San Diego, Dept Pediat, 9500 Gilman Dr, La Jolla, CA 92093 USA.	salbani@ucsd.edu		Wauben, Marca/0000-0003-0360-0311				ALBANI S, 1995, NAT MED, V1, P448, DOI 10.1038/nm0595-448; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Anderson DE, 1997, J IMMUNOL, V159, P1669; Barton GM, 1999, SCIENCE, V283, P67, DOI 10.1126/science.283.5398.67; Bonnin D, 1999, EUR J IMMUNOL, V29, P3826, DOI 10.1002/(SICI)1521-4141(199912)29:12<3826::AID-IMMU3826>3.0.CO;2-S; BRIAN L, 2000, P NATL ACAD SCI USA, V97, P291; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Greten TF, 1998, P NATL ACAD SCI USA, V95, P7568, DOI 10.1073/pnas.95.13.7568; Janssen EM, 2000, J IMMUNOL, V164, P580, DOI 10.4049/jimmunol.164.2.580; KIRSTEN J, 1998, IMMUNITY, V8, P683; LaCava A, 1997, J CLIN INVEST, V100, P658, DOI 10.1172/JCI119577; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Luxembourg AT, 1998, NAT BIOTECHNOL, V16, P281, DOI 10.1038/nbt0398-281; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Mutis T, 1999, NAT MED, V5, P839, DOI 10.1038/10563; NANDA NK, 1998, IMMUNOL TODAY, V19, P495; Rees W, 1999, P NATL ACAD SCI USA, V96, P9781, DOI 10.1073/pnas.96.17.9781; SETTE A, 1992, J IMMUNOL, V148, P844; van Rensen AJML, 1999, PHARMACEUT RES, V16, P198, DOI 10.1023/A:1018864005620; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680	22	100	109	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2000	6	12					1406	1410		10.1038/82231	http://dx.doi.org/10.1038/82231			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100129				2022-12-27	WOS:000165704100048
J	Novak, K				Novak, K			Seeing is believing	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1211	1211		10.1038/81300	http://dx.doi.org/10.1038/81300			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062525	Bronze			2022-12-27	WOS:000165114800017
J	Bielekova, B; Goodwin, B; Richert, N; Cortese, I; Kondo, T; Afshar, G; Gran, B; Eaton, J; Antel, J; Frank, JA; McFarland, HF; Martin, R				Bielekova, B; Goodwin, B; Richert, N; Cortese, I; Kondo, T; Afshar, G; Gran, B; Eaton, J; Antel, J; Frank, JA; McFarland, HF; Martin, R			Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand	NATURE MEDICINE			English	Article							T-CELL RECEPTOR; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNE INTERVENTION; PROTEOLIPID PROTEIN; LYMPHOCYTES-T; RECOGNITION; DISEASE; NEUROPATHOLOGY; HETEROGENEITY	Myelin-specific T lymphocytes are considered essential in the pathogenesis of multiple sclerosis. The myelin basic protein peptide (a.a. 83-99) represents one candidate antigen; therefore, it was chosen to design an altered peptide ligand, CGP77116, for specific immunotherapy of multiple sclerosis. A magnetic resonance imaging-controlled phase II clinical trial with this altered peptide ligand documented that it was poorly tolerated at the dose tested, and the trial had therefore to be halted. Improvement or worsening of clinical or magnetic resonance imaging parameters could not be demonstrated in this small group of individuals because of the short treatment duration. Three patients developed exacerbations of multiple sclerosis, and in two this could be linked to altered peptide ligand treatment by immunological studies demonstrating the encephalitogenic potential of the myelin basic protein peptide (a.a. 83-99) in a subgroup of patients. These data raise important considerations for the use of specific immunotherapies in general.	NINDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA; NINDS, Lab Diagnost Radiol Res, Ctr Clin, NIH, Bethesda, MD 20892 USA; McGill Univ, Montreal Neurol Inst, Dept Neurol, Montreal, PQ H3A 2B4, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Institute of Neurological Disorders & Stroke (NINDS); McGill University	Martin, R (corresponding author), NINDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA.		Bielekova, Bibiana/V-1452-2017; Bielekova, Bibiana/AAA-8115-2020; Frank, Joseph/W-2021-2019	Bielekova, Bibiana/0000-0002-0959-9430; Bielekova, Bibiana/0000-0002-0959-9430; antel, jack/0000-0002-5148-0636; Gran, Bruno/0000-0001-6384-2342; Martin, Roland/0000-0002-0982-1329	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002853, Z01NS002205, ZIANS002853] Funding Source: NIH RePORTER; CLINICAL CENTER [Z01CL090001, ZIACL090001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); CLINICAL CENTER		ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; Bielekova B, 1999, J NEUROIMMUNOL, V100, P115, DOI 10.1016/S0165-5728(99)00200-3; Brocke S, 1996, NATURE, V379, P343, DOI 10.1038/379343a0; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; DECARLI C, 1992, J COMPUT ASSIST TOMO, V16, P274, DOI 10.1097/00004728-199203000-00018; DEIBLER GE, 1972, PREP BIOCHEM, V2, P139, DOI 10.1080/00327487208061467; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; FRITZ RB, 1989, CHEM IMMUNOL, V46, P101; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; Germain RN, 1999, ANNU REV IMMUNOL, V17, P467, DOI 10.1146/annurev.immunol.17.1.467; HAFLER DA, 1989, IMMUNOL TODAY, V10, P104, DOI 10.1016/0167-5699(89)90236-3; Hemmer B, 1998, J IMMUNOL, V160, P5807; Hemmer B, 1997, NEUROLOGY, V49, P1116, DOI 10.1212/WNL.49.4.1116; Hohlfeld R, 1997, BRAIN, V120, P865, DOI 10.1093/brain/120.5.865; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; KARIN N, 1994, J EXP MED, V180, P2227, DOI 10.1084/jem.180.6.2227; Krogsgaard M, 2000, J EXP MED, V191, P1395, DOI 10.1084/jem.191.8.1395; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lassmann H, 1998, J NEUROIMMUNOL, V86, P213, DOI 10.1016/S0165-5728(98)00031-9; Lassmann H, 1998, MULT SCLER J, V4, P93, DOI 10.1191/135245898678909367; LEFKOVITS I, 1984, IMMUNOL TODAY, V5, P265, DOI 10.1016/0167-5699(84)90137-3; LING N, 1984, P NATL ACAD SCI-BIOL, V81, P4302, DOI 10.1073/pnas.81.14.4302; Lucas B, 1999, IMMUNITY, V10, P367, DOI 10.1016/S1074-7613(00)80036-9; Lucchinetti CF, 1998, SEMIN NEUROL, V18, P337, DOI 10.1055/s-2008-1040885; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; Madsen LS, 1999, NAT GENET, V23, P343, DOI 10.1038/15525; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MARTIN R, 1991, J EXP MED, V173, P19, DOI 10.1084/jem.173.1.19; MARTIN R, 1990, J IMMUNOL, V145, P540; Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7; Muraro PA, 2000, J IMMUNOL, V164, P5474, DOI 10.4049/jimmunol.164.10.5474; Nicholson LB, 2000, INT IMMUNOL, V12, P205, DOI 10.1093/intimm/12.2.205; NICHOLSON LB, 1995, IMMUNITY, V3, P397, DOI 10.1016/1074-7613(95)90169-8; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; PATERSON PY, 1960, J EXP MED, V111, P119, DOI 10.1084/jem.111.1.119; PETTE M, 1990, P NATL ACAD SCI USA, V87, P7968, DOI 10.1073/pnas.87.20.7968; PETTINELLI CB, 1981, J IMMUNOL, V127, P1420; Raine C. S., 1983, MULTIPLE SCLEROSIS P, P413; REMLINGER J, 1905, ANN I PASTEUR, V19, P625; Rivers TM, 1933, J EXP MED, V58, P39, DOI 10.1084/jem.58.1.39; SCHUMACHER GA, 1965, ANN NY ACAD SCI, V122, P552; Sharrack B, 1996, J NEUROL SCI, V135, P1, DOI 10.1016/0022-510X(95)00261-Y; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; Stone LA, 1997, NEUROLOGY, V49, P862, DOI 10.1212/WNL.49.3.862; Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555, DOI 10.1038/9858; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; TUOHY VK, 1988, J IMMUNOL, V140, P1868; VALLI A, 1993, J CLIN INVEST, V91, P616, DOI 10.1172/JCI116242; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; Vergelli M, 1996, EUR J IMMUNOL, V26, P2624, DOI 10.1002/eji.1830261113; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; WINDHAGEN A, 1995, IMMUNITY, V2, P373, DOI 10.1016/1074-7613(95)90145-0; WRAITH DC, 1989, CELL, V57, P709, DOI 10.1016/0092-8674(89)90786-1; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZHANG JW, 1994, J EXP MED, V179, P973, DOI 10.1084/jem.179.3.973	57	651	701	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2000	6	10					1167	1175		10.1038/80516	http://dx.doi.org/10.1038/80516			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017150				2022-12-27	WOS:000089674700043
J	Hershko, A; Ciechanover, A; Varshavsky, A				Hershko, A; Ciechanover, A; Varshavsky, A			The ubiquitin system	NATURE MEDICINE			English	Editorial Material							N-END RULE; DEPENDENT PROTEOLYTIC SYSTEM; PROTEIN LIGASE SYSTEM; CYCLE MUTANT TS85; AFFINITY PURIFICATION; CONJUGATING ENZYME; ACTIVATING ENZYME; ABNORMAL PROTEINS; TRANSFER-RNA; DEGRADATION		Technion Israel Inst Technol, Fac Med, Biochem Unit, IL-31096 Haifa, Israel; CALTECH, Div Biol, Pasadena, CA 91125 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; California Institute of Technology	Hershko, A (corresponding author), Technion Israel Inst Technol, Fac Med, Biochem Unit, POB 9649, IL-31096 Haifa, Israel.		Ciechanover, Aaron J/C-9166-2017					BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Byrd C, 1998, EMBO J, V17, P269, DOI 10.1093/emboj/17.1.269; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; CIECHANOYER A, 1980, J BIOL CHEM, V255, P7525; Davydov IV, 2000, J BIOL CHEM, V275, P22931, DOI 10.1074/jbc.M001605200; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; FERBER S, 1987, NATURE, V326, P808, DOI 10.1038/326808a0; FERBER S, 1986, J BIOL CHEM, V261, P3128; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOLDKNOPF IL, 1977, P NATL ACAD SCI USA, V74, P864, DOI 10.1073/pnas.74.3.864; GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11; HAIDER M, 1972, ARCH BIOCHEM BIOPHYS, V148, P228, DOI 10.1016/0003-9861(72)90136-1; HERSHKO A, 1982, J BIOL CHEM, V257, P3964; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; Hershko A, 1996, TRENDS BIOCHEM SCI, V21, P445, DOI 10.1016/S0968-0004(96)10054-2; HERSHKO A, 1971, J BIOL CHEM, V246, P710; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P7021, DOI 10.1073/pnas.81.22.7021; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERSHKO A, 1982, ANNU REV BIOCHEM, V51, P335, DOI 10.1146/annurev.bi.51.070182.002003; Hershko A., 1978, PROTEIN TURNOVER LYS, P149; HOUGH R, 1986, J BIOL CHEM, V261, P2400; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kwon YT, 2000, MOL CELL BIOL, V20, P4135, DOI 10.1128/MCB.20.11.4135-4148.2000; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; LIPMANN F, 1971, ADV ENZYMOL RAMB, V35, P1; MAYER A, 1989, SCIENCE, V244, P1480, DOI 10.1126/science.2544030; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHIMKE RT, 1970, ANNU REV BIOCHEM, V39, P929, DOI 10.1146/annurev.bi.39.070170.004433; Schoenheimer R., 1942, DYNAMIC STATE BODY C; SIMPSON MV, 1953, J BIOL CHEM, V201, P143; Suzuki T, 1999, EMBO J, V18, P6017, DOI 10.1093/emboj/18.21.6017; Turner GC, 2000, NATURE, V405, P579, DOI 10.1038/35014629; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Varshavsky A, 1997, GENES CELLS, V2, P13, DOI 10.1046/j.1365-2443.1997.1020301.x; Varshavsky A, 2000, METHOD ENZYMOL, V327, P578, DOI 10.1016/S0076-6879(00)27303-5; WILKINSON KD, 1980, J BIOL CHEM, V255, P7529; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486	56	537	571	2	65	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1073	1081		10.1038/80384	http://dx.doi.org/10.1038/80384			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017125				2022-12-27	WOS:000089674700016
J	Naya, FJ; Black, BL; Wu, H; Bassel-Duby, R; Richardson, JA; Hill, JA; Olson, EN				Naya, FJ; Black, BL; Wu, H; Bassel-Duby, R; Richardson, JA; Hill, JA; Olson, EN			Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor	NATURE MEDICINE			English	Article							DILATED CARDIOMYOPATHY; MUSCLE DEVELOPMENT; HEART; GENE; DISORDERS; DISEASES; ENHANCER	The four MEF2 transcription factors (MEF2A, -B, -C, and -D) regulate differentiation and calcium-dependent gene expression in muscle cells. We generated mice deficient in MEF2A, the predominant Mef2 gene product expressed in post-natal cardiac muscle. Most mice lacking Mef2a died suddenly within the first week of life and exhibited pronounced dilation of the right ventricle, myofibrillar fragmentation, mitochondrial disorganization and activation of a fetal cardiac gene program. The few Mef2a(-/-) mice that survived to adulthood also showed a deficiency of cardiac mitochondria and susceptibility to sudden death. Paradoxically, MEF2 transcriptional activity, revealed by the expression of a MEF2-dependent transgene, was enhanced in the hearts of Mef2a-mutant mice, reflecting the transcriptional activation of residual MEF2D. These findings reveal specific roles for MEF2A in maintaining appropriate mitochondrial content and cyto-architectural integrity in the post-natal heart and show that other MEF2 isoforms cannot support these activities.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Iowa; University of Iowa	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA.	eolson@hamon.swmed.edu		Black, Brian/0000-0002-6664-8913				Antozzi C, 1997, CARDIOVASC RES, V35, P184, DOI 10.1016/S0008-6363(97)00141-7; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Bonnet D, 1999, CIRCULATION, V100, P2248, DOI 10.1161/01.CIR.100.22.2248; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Ibdah JA, 2001, J CLIN INVEST, V107, P1403, DOI 10.1172/JCI12590; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Kuo HC, 2001, CELL, V107, P801, DOI 10.1016/S0092-8674(01)00588-8; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P1065, DOI 10.1006/jmcc.2001.1378; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lin Q, 1998, DEVELOPMENT, V125, P4565; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Marin-Garcia J, 2001, CARDIOVASC RES, V49, P17, DOI 10.1016/S0008-6363(00)00241-8; MarinGarcia J, 1997, PEDIATR CARDIOL, V18, P251, DOI 10.1007/s002469900169; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Muscat George E. O., 1992, Gene Expression, V2, P111; Naya FJ, 1999, DEVELOPMENT, V126, P2045; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Ruiz-Lozano P, 1998, DEVELOPMENT, V125, P533; Spooner PM, 2001, CIRCULATION, V103, P2361; Towbin JA, 1999, CURR OPIN CARDIOL, V14, P250, DOI 10.1097/00001573-199905000-00010; Wallace DC, 2000, AM HEART J, V139, pS70, DOI 10.1067/mhj.2000.103934; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089; WILLIAMS RS, 1995, CIRCULATION, V91, P1266, DOI 10.1161/01.CIR.91.4.1266; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zipes DP, 1998, CIRCULATION, V98, P2334, DOI 10.1161/01.CIR.98.21.2334	32	245	261	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2002	8	11					1303	1309		10.1038/nm789	http://dx.doi.org/10.1038/nm789			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12379849				2022-12-27	WOS:000179221200038
J	Launay, JM; Herve, P; Peoc'h, K; Tournois, C; Callebert, J; Nebigil, CG; Etienne, N; Drouet, L; Humbert, M; Simonneau, G; Maroteaux, L				Launay, JM; Herve, P; Peoc'h, K; Tournois, C; Callebert, J; Nebigil, CG; Etienne, N; Drouet, L; Humbert, M; Simonneau, G; Maroteaux, L			Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension	NATURE MEDICINE			English	Article							VASCULAR SMOOTH-MUSCLE; 5-HT2B RECEPTORS; DEXFENFLURAMINE TREATMENT; PLASMA SEROTONIN; CHRONIC HYPOXIA; ARTERY SMOOTH; FENFLURAMINE; MICE; CELLS; RATS	Primary pulmonary hypertension is a progressive and often fatal disorder in humans that results from an increase in pulmonary blood pressure associated with abnormal vascular proliferation. Dexfenfluramine increases the risk of pulmonary hypertension in humans, and its active metabolite is a selective serotonin 5-hydroxytryptamine 2B (5-HT2B) receptor agonist. Thus, we investigated the contribution of the 5-HT2B receptor to the pathogenesis of pulmonary hypertension. Using the chronic-hypoxic-mouse model of pulmonary hypertension, we found that the hypoxia-dependent increase in pulmonary blood pressure and lung remodeling are associated with an increase in vascular proliferation, elastase activity and transforming growth factor-beta levels, and that these parameters are potentiated by dexfenfluramine treatment. In contrast, hypoxic mice with genetically or pharmacologically inactive 5-HT2B receptors manifested no change in any of these parameters. In both humans and mice, pulmonary hypertension is associated with a substantial increase in 5-HT2B receptor expression in pulmonary arteries. These data show that activation of 5-HT2B receptors is a limiting step in the development of pulmonary hypertension.	Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France; Hop Lariboisiere AP HP, Serv Biochim, CRC Bernard Pathol Expt & Commun Cellulaires, Paris, France; Hop Lariboisiere AP HP, Serv Angiohematol, CRC Bernard Pathol Expt & Commun Cellulaires, Paris, France; Ctr Chirurg Marie Lannelongue, Le Plessis Robinson, France; Hop Antoine Beclere AP HP, UPRES Malad Vasc & Pulm, Clamart, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Hopital Marie Lannelongue; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP	Maroteaux, L (corresponding author), Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France.	lucm@igbmc.u-strasbg.fr	Simonneau, Gerald/ABE-6614-2020; Nebigil, Canan/AAK-7162-2021; Maroteaux, Luc/H-4585-2019; Peoc'h, Katell/V-1604-2017; callebert, jacques/L-4569-2017	Nebigil, Canan/0000-0002-2035-5795; Maroteaux, Luc/0000-0002-9499-8603; Peoc'h, Katell/0000-0002-8203-1243; Humbert, Marc/0000-0003-0703-2892				Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; Belknap JK, 1997, AM J RESP CELL MOL, V16, P366, DOI 10.1165/ajrcmb.16.4.9115746; Bonhaus DW, 1999, BRIT J PHARMACOL, V127, P1075, DOI 10.1038/sj.bjp.0702632; BUCZKO W, 1975, BRIT J PHARMACOL, V53, P563, DOI 10.1111/j.1476-5381.1975.tb07395.x; Cowan KN, 2000, NAT MED, V6, P698, DOI 10.1038/76282; Cowan KN, 1999, CIRC RES, V84, P1223, DOI 10.1161/01.RES.84.10.1223; Eddahibi S, 1998, AM J RESP CRIT CARE, V157, P1111, DOI 10.1164/ajrccm.157.4.9704095; Eddahibi S, 2000, J CLIN INVEST, V105, P1555, DOI 10.1172/JCI8678; Eddahibi S, 2001, J CLIN INVEST, V108, P1141, DOI 10.1172/JCI12805; Eddahibi S, 2001, J PHARMACOL EXP THER, V297, P148; Egermayer P, 1999, THORAX, V54, P161, DOI 10.1136/thx.54.2.161; Fanburg BL, 1997, AM J PHYSIOL-LUNG C, V272, pL795, DOI 10.1152/ajplung.1997.272.5.L795; Fitzgerald LW, 2000, MOL PHARMACOL, V57, P75; Glusa E, 2000, BRIT J PHARMACOL, V130, P692, DOI 10.1038/sj.bjp.0703341; HERVE P, 1995, AM J MED, V99, P249, DOI 10.1016/S0002-9343(99)80156-9; Hoshikawa Y, 2001, AM J RESP CRIT CARE, V164, P314, DOI 10.1164/ajrccm.164.2.2010150; HUMBERT M, 1932, EUR RESPIR J, V20, P59; Keegan A, 2001, CIRC RES, V89, P1231, DOI 10.1161/hh2401.100426; Kereveur A, 2000, ARTERIOSCL THROM VAS, V20, P2233, DOI 10.1161/01.ATV.20.10.2233; Launay JM, 1996, J BIOL CHEM, V271, P3141, DOI 10.1074/jbc.271.6.3141; Lee SL, 1999, AM J PHYSIOL-LUNG C, V277, pL282, DOI 10.1152/ajplung.1999.277.2.L282; Loscalzo J, 2001, NEW ENGL J MED, V345, P367, DOI 10.1056/NEJM200108023450511; MacLean MR, 2000, BRIT J PHARMACOL, V131, P161, DOI 10.1038/sj.bjp.0703570; MacLean MR, 1999, TRENDS PHARMACOL SCI, V20, P490, DOI 10.1016/S0165-6147(99)01389-9; Mchelakis ED, 2001, AM J MED SCI, V321, P292, DOI 10.1097/00000441-200104000-00009; MIDHA KK, 1983, XENOBIOTICA, V13, P31, DOI 10.3109/00498258309052212; Morrell NW, 2001, CIRCULATION, V104, P790, DOI 10.1161/hc3201.094152; Naeije R, 1996, AM J RESP CRIT CARE, V154, P1347, DOI 10.1164/ajrccm.154.5.8912746; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P9508, DOI 10.1073/pnas.97.17.9508; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P2591, DOI 10.1073/pnas.050282397; Nebigil CG, 2001, CIRCULATION, V103, P2973, DOI 10.1161/01.CIR.103.24.2973; PITT BR, 1994, AM J PHYSIOL, V266, pL178, DOI 10.1152/ajplung.1994.266.2.L178; Rabinovitch M, 1999, AM J PHYSIOL-LUNG C, V277, pL5, DOI 10.1152/ajplung.1999.277.1.L5; Rabinovitch M, 1997, CARDIOVASC RES, V34, P268; Rabinovitch M, 2001, J CLIN INVEST, V108, P1109; RABINOVITCH M, 1988, Chest, V93, p119S; Rich S, 2000, CHEST, V117, P870, DOI 10.1378/chest.117.3.870; Rothman RB, 2000, CIRCULATION, V102, P2836; Rubin LJ, 1999, PEDIATR PULM, P194; Sanchez C, 1999, CELL MOL NEUROBIOL, V19, P467, DOI 10.1023/A:1006986824213; Steudel W, 1998, J CLIN INVEST, V101, P2468, DOI 10.1172/JCI2356; Tucker A, 2001, HIGH ALT MED BIOL, V2, P173, DOI 10.1089/152702901750265288; Ullmer C, 1996, BRIT J PHARMACOL, V117, P1081, DOI 10.1111/j.1476-5381.1996.tb16700.x; ULLMER C, 1995, FEBS LETT, V370, P215, DOI 10.1016/0014-5793(95)00828-W; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Zhao L, 1999, CIRCULATION, V99, P605, DOI 10.1161/01.CIR.99.5.605	46	301	322	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1129	1135		10.1038/nm764	http://dx.doi.org/10.1038/nm764			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12244304	Green Submitted			2022-12-27	WOS:000178311000040
J	Cho, JJ; Malhi, H; Wang, R; Joseph, B; Ludlow, JW; Susick, R; Gupta, S				Cho, JJ; Malhi, H; Wang, R; Joseph, B; Ludlow, JW; Susick, R; Gupta, S			Enzymatically labeled chromosomal probes for in situ identification of human cells in xenogeneic transplant models	NATURE MEDICINE			English	Article							IN-VIVO INFECTION; HEPATITIS-B VIRUS; HUMAN HEPATOCYTES; BONE-MARROW; LIVER; MICE; POLYPLOIDY; EXPRESSION; RATS	Analysis of the viability, differentiation, clonogenicity and function of human stem/progenitor cells requires suitable xenograft models. However, the identification of transplanted cells has been generally difficult. Fluorescence in situ hybridization is a tedious method for analyzing tissues, and localization of transplanted cells with X or Y chromosome probes is limited by the sparse signals produced. Therefore, we examined the possibility of generating either pan-nuclear signals with a total human DNA probe or multiple nuclear signals with a pan-centromeric human DNA probe. The probes were labeled with digoxigenin to make reaction products visible by light microscopy and to allow the use of immunohistochemistry methods incorporating various color schemes to demonstrate specific properties of transplanted cells. The ability to localize all types of nucleated human cells with such probes will facilitate studies of stem cell biology and cell and gene therapy, as well as the development of new animal models.	Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Pathol, Bronx, NY 10461 USA; Incara Cell Technol, Res Triangle Pk, NC 27709 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Gupta, S (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NIDDK NIH HHS [P30-DK-41296, R01 DK46952] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046952, P30DK041296] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brown JJ, 2000, HEPATOLOGY, V31, P173, DOI 10.1002/hep.510310126; Dandri M, 2001, HEPATOLOGY, V33, P981, DOI 10.1053/jhep.2001.23314; Gorla GR, 2001, J CELL SCI, V114, P2943; Gupta S, 1999, AM J PHYSIOL-GASTR L, V276, pG629, DOI 10.1152/ajpgi.1999.276.3.G629; GUPTA S, 1995, P NATL ACAD SCI USA, V92, P5860, DOI 10.1073/pnas.92.13.5860; Gupta S, 2000, SEMIN CANCER BIOL, V10, P161; Korbling M, 2002, NEW ENGL J MED, V346, P738, DOI 10.1056/NEJMoa3461002; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Malhi H, 2002, J CELL SCI, V115, P2679; Malhi H, 2001, J Hepatobiliary Pancreat Surg, V8, P40, DOI 10.1007/s005340170049; Mercer DF, 2001, NAT MED, V7, P927, DOI 10.1038/90968; Ohashi K, 2000, NAT MED, V6, P327; Ott M, 1999, GENE EXPRESSION, V8, P175; Ott M, 1999, J PATHOL, V187, P365, DOI 10.1002/(SICI)1096-9896(199902)187:3<365::AID-PATH237>3.0.CO;2-Z; Ouyang EC, 2001, WORLD J GASTROENTERO, V7, P324; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; PONDER KP, 1991, P NATL ACAD SCI USA, V88, P1217, DOI 10.1073/pnas.88.4.1217; Rajvanshi P, 1998, CELL TRANSPLANT, V7, P275, DOI 10.1016/S0963-6897(98)00002-5; Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135; Zahler MH, 2000, J GENE MED, V2, P186	20	11	11	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2002	8	9					1033	1036		10.1038/nm756	http://dx.doi.org/10.1038/nm756			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12185363				2022-12-27	WOS:000177757900040
J	Laakkonen, P; Porkka, K; Hoffman, JA; Ruoslahti, E				Laakkonen, P; Porkka, K; Hoffman, JA; Ruoslahti, E			A tumor-homing peptide with a targeting specificity related to lymphatic vessels	NATURE MEDICINE			English	Article							BLOOD-VESSELS; BREAST-CANCER; VEGF-C; LYMPHANGIOGENESIS; PROMOTES; GROWTH; CELLS; ENDOTHELIUM; LYVE-1; ANGIOGENESIS	Blood vessels of tumors carry specific markers that are usually angiogenesis-related(1,2). We previously used phage-displayed peptide libraries in vivo to identify peptides that home to tumors through the circulation and that specifically bind to the endothelia of tumor blood vessels(3,4). Here we devised a phage screening procedure that would favor tumor-homing to targets that are accessible to circulating phage, but are not blood vessels. Screening on MDA-MB-435 breast carcinoma xenografts yielded multiple copies of a phage that displays a cyclic 9-amino-acid peptide, LyP-1. Homing and binding to tumor-derived cell suspensions indicated that LyP-1 also recognizes an osteosarcoma xenograft, and spontaneous prostate and breast cancers in transgenic mice, but not two other tumor xenografts. Fluorescein-labeled LyP-1 peptide was detected in tumor structures that were positive for three lymphatic endothelial markers and negative for three blood vessel markers. LyP-1 accumulated in the nuclei of the putative lymphatic cells, and in the nuclei of tumor cells. These results suggest that tumor lymphatics carry specific markers and that it may be possible to specifically target therapies into tumor lymphatics.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; Univ Calif San Diego, Sch Med, Burnham Inst, Program Mol Pathol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Ruoslahti, E (corresponding author), Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA.		; Porkka, Kimmo/O-2323-2016	Laakkonen, Pirjo/0000-0002-9620-095X; Porkka, Kimmo/0000-0003-4112-5902	NATIONAL CANCER INSTITUTE [K23CA082715, P30CA030199, R01CA074238] Funding Source: NIH RePORTER; NCI NIH HHS [CA30199, CA82715, CA74238] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Beasley NJP, 2002, CANCER RES, V62, P1315; Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Carreira CM, 2001, CANCER RES, V61, P8079; Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOFFMAN JA, IN PRESS PHAGE DISPL; Jackson DG, 2001, TRENDS IMMUNOL, V22, P317, DOI 10.1016/S1471-4906(01)01936-6; Karpanen T, 2001, CANCER RES, V61, P1786; Kubo H, 2000, BLOOD, V96, P546; Leu AJ, 2000, CANCER RES, V60, P4324; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Oliver G, 2002, GENE DEV, V16, P773, DOI 10.1101/gad.975002; PORKKA K, IN PRESS P NATL ACAD; Prevo R, 2001, J BIOL CHEM, V276, P19420, DOI 10.1074/jbc.M011004200; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; St Croix B, 2000, SCIENCE, V289, P1197; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003	25	377	428	6	128	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2002	8	7					751	755		10.1038/nm720	http://dx.doi.org/10.1038/nm720			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12053175				2022-12-27	WOS:000176495200038
J	Borza, CM; Hutt-Fletcher, LM				Borza, CM; Hutt-Fletcher, LM			Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus	NATURE MEDICINE			English	Article							GENE-PRODUCT; CLASS-II; HLA-DQ; RECEPTOR; INFECTION; LYMPHOCYTES; ATTACHMENT; EXPRESSION; GH; IDENTIFICATION	Epstein-Barr virus is ubiquitous and is causally implicated in lymphoid and epithelial malignancies. Virus invades oropharyngeal mucosa and establishes latency in B lymphocytes. Reactivating lymphocytes shed virus into saliva for spread to new hosts. A complex of three virus glycoproteins, gH, gL and gp42, is essential for entry. B-cell entry requires binding of gp42 to human leukocyte antigen (HLA) class II whereas entry into epithelial cells lacking HLA class II requires complexes without gp42. To accommodate infection of each, the virus carries both three-part and two-part complexes. We show here that HLA class II in the virus-producing cell alters the ratio of three-part to two-part complexes. As a consequence, virus originating in epithelial cells efficiently infects B cells whereas B-cell-derived virus better infects epithelial cells. This molecular switch is a novel strategy that could alter tropism of virus from epithelium to B cells and then back to epithelium in a new host.	Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Borza, CM (corresponding author), Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA.	borzac@umkc.edu; huttfletcher@umkc.edu	Borza, Corina/A-1603-2013; Borza, Corina/AAF-5292-2020	Borza, Corina/0000-0001-9113-110X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020662] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI20662] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; Borza CM, 1998, J VIROL, V72, P7577, DOI 10.1128/JVI.72.9.7577-7582.1998; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; Geraghty RJ, 2000, VIROLOGY, V268, P147, DOI 10.1006/viro.1999.0157; Goff S, 2001, FIELDS VIROLOGY, P1871; Haan KM, 2000, P NATL ACAD SCI USA, V97, P9252, DOI 10.1073/pnas.160171697; Haan KM, 2000, J VIROL, V74, P2451, DOI 10.1128/JVI.74.5.2451-2454.2000; HADDAD RS, 1989, J VIROL, V63, P4998, DOI 10.1128/JVI.63.12.4998-5005.1989; LI QX, 1995, J VIROL, V69, P3987, DOI 10.1128/JVI.69.7.3987-3994.1995; Li QX, 1997, J VIROL, V71, P4657, DOI 10.1128/JVI.71.6.4657-4662.1997; LI QX, 1992, NATURE, V356, P347, DOI 10.1038/356347a0; MELLMAN I, 1995, CURR OPIN CELL BIOL, V7, P564, DOI 10.1016/0955-0674(95)80014-X; MILLER N, 1988, J VIROL, V62, P2366, DOI 10.1128/JVI.62.7.2366-2372.1988; Moghaddam A, 1997, SCIENCE, V276, P2030, DOI 10.1126/science.276.5321.2030; Molesworth SJ, 2000, J VIROL, V74, P6324, DOI 10.1128/JVI.74.14.6324-6332.2000; NEMEROW GR, 1987, J VIROL, V61, P1416, DOI 10.1128/JVI.61.5.1416-1420.1987; NEMEROW GR, 1985, J VIROL, V55, P347, DOI 10.1128/JVI.55.2.347-351.1985; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; SVEDMYR E, 1984, CLIN IMMUNOL IMMUNOP, V30, P437, DOI 10.1016/0090-1229(84)90029-1; TAKADA K, 1984, INT J CANCER, V33, P27, DOI 10.1002/ijc.2910330106; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; VANVOORHIS WC, 1983, J EXP MED, V158, P126, DOI 10.1084/jem.158.1.126; Wang X, 1998, J VIROL, V72, P5552, DOI 10.1128/JVI.72.7.5552-5558.1998; Wang X, 1998, J VIROL, V72, P158, DOI 10.1128/JVI.72.1.158-163.1998; YASWEN LR, 1993, VIROLOGY, V195, P387, DOI 10.1006/viro.1993.1388	27	327	349	1	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2002	8	6					594	599		10.1038/nm0602-594	http://dx.doi.org/10.1038/nm0602-594			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042810				2022-12-27	WOS:000175907300030
J	Pratt, JR; Basheer, SA; Sacks, SH				Pratt, JR; Basheer, SA; Sacks, SH			Local synthesis of complement component C3 regulates acute renal transplant rejection	NATURE MEDICINE			English	Article							ALLOGRAFT-REJECTION; ANTIGEN RECEPTOR; EXPRESSION; ACTIVATION; LOCALIZATION; PATHWAY; INNATE; GAMMA; B7-1; MHC	Accumulating evidence suggests that innate immunity interacts with the adaptive immune system to identify potentially harmful antigens and eliminate them from the host. A central facet of innate immunity is complement, which for some time has been recognized as a contributor to inflammation in transplant rejection but without detailed analysis of its role in what is principally a T cell-mediated process. Moreover, epithelial and vascular tissues at local sites of inflammation secrete complement components; however, the role of such local synthesis remains unclear. Here we show that the absence of locally synthesized complement component C3 is capable of modulating the rejection of renal allografts in vivo and regulating T-cell responses in vivo and in vitro. The results indicate that improved success in kidney transplantation could come from therapeutic manipulation of innate immunity in concert with T cell-directed immunosuppression.	Kings Coll London, Guys Hosp, Dept Nephrol & Transplantat, London WC2R 2LS, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Sacks, SH (corresponding author), Kings Coll London, Guys Hosp, Dept Nephrol & Transplantat, London WC2R 2LS, England.	steven.sacks@kcl.ac.uk		Sacks, Steven/0000-0001-6361-9095				Abe K, 1998, KIDNEY INT, V54, P120, DOI 10.1046/j.1523-1755.1998.00961.x; ANDREWS PA, 1995, EUR J IMMUNOL, V25, P1087, DOI 10.1002/eji.1830250434; ANDREWS PA, 1994, TRANSPLANTATION, V58, P637, DOI 10.1097/00007890-199409150-00023; ARVIEUX J, 1988, IMMUNOLOGY, V65, P229; Banu N, 1999, KIDNEY INT, V55, P2250, DOI 10.1046/j.1523-1755.1999.00495.x; BIANCONE L, 1994, KIDNEY INT, V45, P451, DOI 10.1038/ki.1994.59; BREITNER S, 1995, ARTHRITIS RHEUM, V38, P492, DOI 10.1002/art.1780380406; BROOIMANS RA, 1991, J CLIN INVEST, V88, P379, DOI 10.1172/JCI115314; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; GASQUE P, 1995, J IMMUNOL, V154, P4726; HAGERTY DT, 1992, J IMMUNOL, V148, P2324; JACQUIERSARLIN MR, 1995, IMMUNOLOGY, V84, P164; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; KALINA SL, 1993, AUST NZ J SURG, V63, P213, DOI 10.1111/j.1445-2197.1993.tb00521.x; KELLEY VR, 1993, EXP NEPHROL, V1, P102; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; Kozono Y, 1998, J IMMUNOL, V160, P1565; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; Meri S, 1998, VOX SANG, V74, P291, DOI 10.1111/j.1423-0410.1998.tb05434.x; Mongini PKA, 1997, J IMMUNOL, V159, P3782; Morgan BP, 1997, CLIN EXP IMMUNOL, V107, P1, DOI 10.1046/j.1365-2249.1997.d01-890.x; PASSWELL J, 1988, J CLIN INVEST, V82, P1676, DOI 10.1172/JCI113780; PASSWELL JH, 1990, IMMUNOLOGY, V71, P290; Pratt JR, 1996, AM J PATHOL, V149, P2055; Pratt JR, 2000, AM J PATHOL, V157, P825, DOI 10.1016/S0002-9440(10)64596-8; Prechl J, 2000, IMMUNOPHARMACOLOGY, V49, P117, DOI 10.1016/S0162-3109(00)80297-0; Sasaki O, 1997, AM J PATHOL, V151, P1249; Sheerin NS, 2001, EUR J IMMUNOL, V31, P1255, DOI 10.1002/1521-4141(200104)31:4<1255::AID-IMMU1255>3.0.CO;2-W; Takei Y, 2000, J AM SOC NEPHROL, V11, P250, DOI 10.1681/ASN.V112250; Tang S, 1999, J IMMUNOL, V162, P4336; TANG S, 1976, J COMPOS MATER, V10, P69, DOI 10.1177/002199837601000106; Tosello AC, 1998, J INFLAMM, V48, P13; Zhou WD, 2000, J CLIN INVEST, V105, P1363, DOI 10.1172/JCI8621	34	385	408	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2002	8	6					582	587		10.1038/nm0602-582	http://dx.doi.org/10.1038/nm0602-582			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042808				2022-12-27	WOS:000175907300028
J	Sotiriou, S; Gispert, S; Cheng, J; Wang, YH; Chen, A; Hoogstraten-Miller, S; Miller, GF; Kwon, O; Levine, M; Guttentag, SH; Nussbaum, RL				Sotiriou, S; Gispert, S; Cheng, J; Wang, YH; Chen, A; Hoogstraten-Miller, S; Miller, GF; Kwon, O; Levine, M; Guttentag, SH; Nussbaum, RL			Ascorbic-acid transporter Slc23a1 is essential for vitamin C transport into the brain and for perinatal survival	NATURE MEDICINE			English	Article							DEHYDROASCORBIC ACID; PREMATURE-INFANT; CLONING; PLASMA; CELLS	The only proven requirement for ascorbic acid (vitamin C) is in preventing scurvy(1,2), presumably because it is a cofactor for hydroxylases required for post-translational modifications that stabilize collagen(3). We have created mice deficient in the mouse ortholog (solute carrier family 23 member 1 or Slc23a1) of a rat ascorbic-acid transporter, Svct2 (ref. 4). Cultured embryonic fibroblasts from homozygous Slc23a1(-/-) mice had less than 5% of normal ascorbic-acid uptake. Ascorbic-acid levels were undetectable or markedly reduced in the blood and tissues of Slc23a1(-/-) mice. Prenatal supplementation of pregnant females did not elevate blood ascorbic acid in Slc23a1(-/-) fetuses, suggesting Slc23a1 is important in placental ascorbic-acid transport. Slc23a1(-/-) mice died within a few minutes of birth with respiratory failure and intraparenchymal brain hemorrhage. Lungs showed no postnatal expansion but had normal surfactant protein B levels. Brain hemorrhage was unlikely to be simply a form of scurvy since Slc23a1(-/-) mice showed no hemorrhage in any other tissues and their skin had normal skin 4-hydroxyproline levels despite low ascorbic-acid content. We conclude that Slc23a1 is required for transport of ascorbic acid into many tissues and across the placenta. Deficiency of the transporter is lethal in newborn mice, thereby revealing a previously unrecognized requirement for ascorbic acid in the perinatal period.	NHGRI, Genet Dis Res Branch, Bethesda, MD 20892 USA; NIDDKD, Mol & Clin Nutr Sect, Digest Dis Branch, Bethesda, MD 20892 USA; NIH, Vet Resources Program, Off Director, Bethesda, MD 20892 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Neonatol, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Nussbaum, RL (corresponding author), NHGRI, Genet Dis Res Branch, Bethesda, MD 20892 USA.		Guttentag, Susan H/D-8705-2013; Guttentag, Susan/ABE-7405-2020	Guttentag, Susan H/0000-0003-4420-5879; Guttentag, Susan/0000-0003-4420-5879	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK054506, Z01DK054506] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agus DB, 1997, J CLIN INVEST, V100, P2842, DOI 10.1172/JCI119832; Bass WT, 1998, AM J PERINAT, V15, P133, DOI 10.1055/s-2007-993913; BYERS PH, 2001, METABOLIC MOL BASES, V4, P5241; CHOI JL, 1989, AM J PHYSIOL, V257, pC110, DOI 10.1152/ajpcell.1989.257.1.C110; Daruwala R, 1999, FEBS LETT, V460, P480, DOI 10.1016/S0014-5793(99)01393-9; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; Gispert S, 2000, DNA RES, V7, P339, DOI 10.1093/dnares/7.6.339; GOLDENBERG H, 1994, J BIOENERG BIOMEMBR, V26, P359, DOI 10.1007/BF00762776; HODGES RE, 1971, AM J CLIN NUTR, V24, P432; Hogan B, 1994, MANIPULATING MOUSE E; JENNESS R, 1984, COMP BIOCHEM PHYS B, V78, P167, DOI 10.1016/0305-0491(84)90162-7; KRATZING CC, 1986, INT J VITAM NUTR RES, V56, P101; Levine M, 1999, JAMA-J AM MED ASSOC, V281, P1415, DOI 10.1001/jama.281.15.1415; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NORKUS EP, 1979, J NUTR, V109, P2205, DOI 10.1093/jn/109.12.2205; Rajan DP, 1999, BIOCHEM BIOPH RES CO, V262, P762, DOI 10.1006/bbrc.1999.1272; ROSSO P, 1976, J NUTR, V106, P767, DOI 10.1093/jn/106.6.767; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Rumsey SC, 1998, J NUTR BIOCHEM, V9, P116, DOI 10.1016/S0955-2863(98)00002-3; SILVERS KM, 1994, ARCH DIS CHILD-FETAL, V71, pF40, DOI 10.1136/fn.71.1.F40; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; VOLPE JJ, 1989, CLIN PERINATOL, V16, P361, DOI 10.1016/S0095-5108(18)30637-7; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; WELCH RW, 1993, BIOCHEM J, V294, P505, DOI 10.1042/bj2940505	25	266	276	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					514	517		10.1038/nm0502-514	http://dx.doi.org/10.1038/nm0502-514			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984597	Green Published			2022-12-27	WOS:000175336800038
J	Karpuj, MV; Becher, MW; Springer, JE; Chabas, D; Youssef, S; Pedotti, R; Mitchell, D; Steinman, L				Karpuj, MV; Becher, MW; Springer, JE; Chabas, D; Youssef, S; Pedotti, R; Mitchell, D; Steinman, L			Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine	NATURE MEDICINE			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; MOUSE MODEL; NEURODEGENERATIVE DISEASES; TISSUE TRANSGLUTAMINASE; EXPANDED POLYGLUTAMINE; NEUROLOGICAL PHENOTYPE; AGGREGATE FORMATION; APOPTOSIS; SUPPRESSION; PROTEIN	An expanded polyglutamine domain in huntingtin underlies the pathogenic events in Huntington disease (HD), characterized by chorea, dementia and severe weight loss, culminating in death. Transglutaminase (TGase) may be critical in the pathogenesis, via cross-linking huntingtin. Administration of the TGase competitive inhibitor, cystamine, to transgenic mice expressing exon 1 of huntingtin containing an expanded polyglutamine repeat, altered the course of their HD-like disease. Cystamine given intraperitoneally entered brain where it inhibited TGase activity. When treatment began after the appearance of abnormal movements, cystamine extended survival, reduced associated tremor and abnormal movements and ameliorated weight loss. Treatment did not influence the appearance or frequency of neuronal nuclear inclusions. Unexpectedly, cystamine treatment increased transcription of one of the two genes shown to be neuroprotective for polyglutamine toxicity in Drosophila, dnaj (also known as HDJI and Hsp40 in humans and mice, respectively). Inhibition of TGase provides a new treatment strategy for HD and other polyglutamine diseases.	Stanford Univ, Dept Neurol Sci, Stanford, CA 94305 USA; Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA; Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Stanford University; University of New Mexico; University of New Mexico's Health Sciences Center; University of Kentucky	Steinman, L (corresponding author), Stanford Univ, Dept Neurol Sci, Stanford, CA 94305 USA.	steinman@stanford.edu		Steinman, Lawrence/0000-0002-2437-2250	PHS HHS [R0118235] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bates GP, 1998, BRAIN PATHOL, V8, P699, DOI 10.1111/j.1750-3639.1998.tb00196.x; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Clarke G, 2000, NATURE, V406, P195, DOI 10.1038/35018098; Cooper AJL, 1997, J NEUROCHEM, V69, P431; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Curtis C G, 1976, Methods Enzymol, V45, P177; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Ferrante RJ, 2000, J NEUROSCI, V20, P4389, DOI 10.1523/JNEUROSCI.20-12-04389.2000; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FOLK JE, 1966, BIOCHIM BIOPHYS ACTA, V122, P244, DOI 10.1016/0926-6593(66)90066-X; GREEN H, 1993, CELL, V74, P955, DOI 10.1016/0092-8674(93)90718-6; Huang CC, 1998, SOMAT CELL MOLEC GEN, V24, P217, DOI 10.1023/B:SCAM.0000007124.19463.e5; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; Jeitner TM, 2001, J NEUROCHEM, V79, P1109, DOI 10.1046/j.1471-4159.2001.00673.x; Kahlem P, 1998, MOL CELL, V1, P595, DOI 10.1016/S1097-2765(00)80059-3; Karpuj MV, 1999, P NATL ACAD SCI USA, V96, P7388, DOI 10.1073/pnas.96.13.7388; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; Lesort M, 1999, J NEUROCHEM, V73, P2018; Lorand L, 1996, P NATL ACAD SCI USA, V93, P14310, DOI 10.1073/pnas.93.25.14310; LORAND L, 1979, BIOCHEMISTRY-US, V18, P1756, DOI 10.1021/bi00576a019; Lorand L, 1998, NAT GENET, V20, P231, DOI 10.1038/3033; LORAND L, 1984, MOL CELL BIOCHEM, V58, P25; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Newcomb R, 1997, J BIOL CHEM, V272, P11276; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Ordway JM, 1997, CELL, V91, P753, DOI 10.1016/S0092-8674(00)80464-X; Orr HT, 2000, CELL, V101, P1, DOI 10.1016/S0092-8674(00)80617-0; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Rittling SR, 1998, BIOCHEM BIOPH RES CO, V250, P287, DOI 10.1006/bbrc.1998.9306; Sathasivam K, 1999, HUM MOL GENET, V8, P813, DOI 10.1093/hmg/8.5.813; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Yu SP, 1999, SCIENCE, V284, P336, DOI 10.1126/science.284.5412.336; ZAINELLI G, 2000, SOC NEUR ABSTR, V26, P1297	46	316	343	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2002	8	2					143	149		10.1038/nm0202-143	http://dx.doi.org/10.1038/nm0202-143			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821898				2022-12-27	WOS:000173600600023
J	Asakura, M; Kitakaze, M; Takashima, S; Liao, Y; Ishikura, F; Yoshinaka, T; Ohmoto, H; Node, K; Yoshino, K; Ishiguro, H; Asanuma, H; Sanada, S; Matsumura, Y; Takeda, H; Beppu, S; Tada, M; Hori, M; Higashiyama, S				Asakura, M; Kitakaze, M; Takashima, S; Liao, Y; Ishikura, F; Yoshinaka, T; Ohmoto, H; Node, K; Yoshino, K; Ishiguro, H; Asanuma, H; Sanada, S; Matsumura, Y; Takeda, H; Beppu, S; Tada, M; Hori, M; Higashiyama, S			Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy	NATURE MEDICINE			English	Article							FACTOR RECEPTOR TRANSACTIVATION; PROTEIN-COUPLED RECEPTORS; CONGESTIVE-HEART-FAILURE; GROWTH-FACTOR; EXPRESSION; GENES; DISINTEGRIN; REGRESSION; MYOCYTES	G-protein-coupled receptor (GPCR) agonists,are well-known inducers of cardiac hypertrophy. We found that the shedding of heparin-binding epidermal growth factor (HB-EGF) resulting from metalloproteinase activation and subsequent transactivation of the epidermal growth factor receptor occurred when cardiomyocytes were stimulated by GPCR agonists, leading to cardiac hypertrophy. A new inhibitor of HB-EGF shedding, KB-R7785, blocked this signaling. We cloned a disintegrin and metalloprotease 12 (ADAM12) as a specific enzyme to shed HB-EGF in the heart and found that dominant-negative expression of ADAM12 abrogated this signaling. KB-R7785 bound directly to ADAM12, suggesting that inhibition of ADAM 12 blocked the shedding of HB-EGF. In mice with cardiac hypertrophy; KB-R7785 inhibited the shedding of HB-EGF and attenuated hypertrophic changes. These data suggest that shedding of HB-EGF by ADAM12 plays an important role in cardiac hypertrophy, and that inhibition of HB-EGF shedding could be a potent therapeutic strategy for cardiac hypertrophy.	Osaka Univ, Fac Med, Dept Biochem, Sch Allied Hlth Sci, Osaka 530, Japan; Osaka Univ, Fac Med, Dept Echocardiog, Sch Allied Hlth Sci, Osaka 530, Japan; Osaka Univ, Dept Internal Med & Therapeut, Grad Sch Med, Osaka, Japan; Osaka Univ, Dept Pathol & Pathophysiol, Grad Sch Med, Osaka, Japan; Osaka Univ, Dept Med Informat, Grad Sch Med, Osaka, Japan; Fujita Hlth Univ, Sch Med, Inst Comprehens Med Sci, Toyoake, Aichi 47011, Japan; Nippon Organon KK, Osaka, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Osaka University; Fujita Health University	Higashiyama, S (corresponding author), Osaka Univ, Fac Med, Dept Biochem, Sch Allied Hlth Sci, Osaka 530, Japan.		Liao, Yulin/AAP-6315-2021					CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Friddle CJ, 2000, P NATL ACAD SCI USA, V97, P6745, DOI 10.1073/pnas.100127897; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; KATZ AM, 1990, NEW ENGL J MED, V322, P100; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Saadane N, 1999, BRIT J PHARMACOL, V127, P1165, DOI 10.1038/sj.bjp.0702676; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Schmieder RE, 1996, JAMA-J AM MED ASSOC, V275, P1507, DOI 10.1001/jama.275.19.1507; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; Spinale FG, 1999, CIRC RES, V85, P364, DOI 10.1161/01.RES.85.4.364; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	22	609	635	2	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2002	8	1					35	40		10.1038/nm0102-35	http://dx.doi.org/10.1038/nm0102-35			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	507XQ	11786904				2022-12-27	WOS:000173056900028
J	Bremer, C; Tung, CH; Weissleder, R				Bremer, C; Tung, CH; Weissleder, R			In vivo molecular target assessment of matrix metalloproteinase inhibition	NATURE MEDICINE			English	Article							IV COLLAGENASE; TISSUE INHIBITORS; CATHEPSIN-B; CANCER; EXPRESSION; METASTASIS; GELATINASE; BLOOD; CELLS; SPECIFICITY	A number of different matrix metalloproteinase (MMP) inhibitors have been developed as cytostatic and anti-angiogenic agents and are currently in clinical testing. One major hurdle in assessing the efficacy of such drugs has been the inability to sense or image anti-proteinase activity directly and non-invasively in vivo. We show here that novel, biocompatible near-infrared fluorogenic MMP substrates can be used as activatable reporter probes to sense MMP activity in intact tumors in nude mice. Moreover, we show for the first time that the effect of MMP inhibition can be directly imaged using this approach within hours after initiation of treatment using the potent MMP inhibitor, prinomastat (AC3340). The developed probes, together with novel near-infrared fluorescence imaging technology will enable the detailed analysis of a number of proteinases critical for advancing the therapeutic use of clinical proteinase inhibitors.	Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA USA	Harvard University; Massachusetts General Hospital; Harvard University	Tung, CH (corresponding author), Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA.		Tung, Ching-Hsuan/AIE-6009-2022; Tung, Ching-Hsuan/AHC-5070-2022	Tung, Ching-Hsuan/0000-0001-6648-6195; Tung, Ching-Hsuan/0000-0001-6648-6195; /0000-0003-0828-4143	NATIONAL CANCER INSTITUTE [R33CA088365, R21CA088365] Funding Source: NIH RePORTER; NCI NIH HHS [CA088365] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BROWN PD, 1990, CANCER RES, V50, P6184; Brown PD, 1999, APMIS, V107, P174, DOI 10.1111/j.1699-0463.1999.tb01541.x; Callahan RJ, 1998, AM J ROENTGENOL, V171, P137, DOI 10.2214/ajr.171.1.9648777; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chance B, 1998, ANN NY ACAD SCI, V838, P29, DOI 10.1111/j.1749-6632.1998.tb08185.x; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DAVIES B, 1993, CANCER RES, V53, P5365; Drummond AH, 1999, ANN NY ACAD SCI, V878, P228, DOI 10.1111/j.1749-6632.1999.tb07688.x; Erlichman C, 2001, ANN ONCOL, V12, P389, DOI 10.1023/A:1011183905848; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; Frosch BA, 1999, APMIS, V107, P28, DOI 10.1111/j.1699-0463.1999.tb01523.x; Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945-053X(98)90019-1; Giraudon P, 1997, MOL PSYCHIATR, V2, P107, DOI 10.1038/sj.mp.4000218; Haq M, 2000, CANCER RES, V60, P3207; HOISKIN BP, 1995, ANAL BIOCHEM, V227, P148; Ishiguro N, 1999, J RHEUMATOL, V26, P34; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Lozonschi L, 1999, CANCER RES, V59, P1252; Maekawa R, 1999, CANCER RES, V59, P1231; Mahmood U, 1999, RADIOLOGY, V213, P866, DOI 10.1148/radiology.213.3.r99dc14866; Marecos E, 1998, BIOCONJUGATE CHEM, V9, P184, DOI 10.1021/bc970146w; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Moses MA, 1998, CANCER RES, V58, P1395; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; NIEDZWIECKI L, 1992, BIOCHEMISTRY-US, V31, P12618, DOI 10.1021/bi00165a011; Ntziachristos V, 2000, P NATL ACAD SCI USA, V97, P2767, DOI 10.1073/pnas.040570597; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SELTZER JL, 1990, J BIOL CHEM, V265, P20409; Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x; STEARNS ME, 1993, CANCER RES, V53, P878; Tsukifuji R, 1999, BRIT J CANCER, V80, P1087, DOI 10.1038/sj.bjc.6690468; Tung CH, 2000, CANCER RES, V60, P4953; Tung CH, 1999, BIOCONJUGATE CHEM, V10, P892, DOI 10.1021/bc990052h; Van Noorden CJF, 1998, CLIN EXP METASTAS, V16, P159; VanNoorden CJF, 1997, ANAL BIOCHEM, V252, P71, DOI 10.1006/abio.1997.2312; Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933; Whittaker M, 1999, CHEM REV, V99, P2735, DOI 10.1021/cr9804543; Wojtowicz-Praga S, 1998, J CLIN ONCOL, V16, P2150, DOI 10.1200/JCO.1998.16.6.2150; Zucker S, 1999, ANN NY ACAD SCI, V878, P212, DOI 10.1111/j.1749-6632.1999.tb07687.x; Zucker S, 1999, ANN NY ACAD SCI, V878, P208, DOI 10.1111/j.1749-6632.1999.tb07686.x	43	587	632	1	116	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2001	7	6					743	748		10.1038/89126	http://dx.doi.org/10.1038/89126			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385514				2022-12-27	WOS:000169081500045
J	Stewart, GR; Snewin, VA; Walzl, G; Hussell, T; Tormay, P; O'Gaora, P; Goyal, M; Betts, J; Brown, IN; Young, DB				Stewart, GR; Snewin, VA; Walzl, G; Hussell, T; Tormay, P; O'Gaora, P; Goyal, M; Betts, J; Brown, IN; Young, DB			Overexpression of heat-shock proteins reduces survival of Mycobacterium tuberculosis in the chronic phase of infection	NATURE MEDICINE			English	Article							STREPTOMYCES-ALBUS-G; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; MOLECULAR CHAPERONES; STRESS PROTEINS; FUSION PROTEINS; GENE; DNAK; MICE; INDUCTION	Elevated expression of heat-shock proteins (HSPs) can benefit a microbial pathogen struggling to penetrate host defenses during infection, but at the same time might provide a crucial signal alerting the host immune system to its presence. To determine which of these effects predominate, we constructed a mutant strain of Mycobacterium tuberculosis that constitutively overexpresses Hsp70 proteins. Although the mutant was fully virulent in the initial stage of infection, it was significantly impaired in its ability to persist during the subsequent chronic phase. Induction of microbial genes encoding HSPs might provide a novel strategy to boost the immune response of individuals with latent tuberculosis infection.	Univ London Sch Pharm, Dept Microbiol & Infect Dis, London, England; Univ London Sch Pharm, Dept Biochem, Ctr Mol Microbiol & Infect, London, England; Univ Hertfordshire, Dept Biosci, Hatfield AL10 9AB, Herts, England; GlaxoSmithKline, Stevenage, Herts, England	University of London; University College London; University of London School of Pharmacy; University of London; University College London; University of London School of Pharmacy; University of Hertfordshire; GlaxoSmithKline	Stewart, GR (corresponding author), Univ London Sch Pharm, Dept Microbiol & Infect Dis, London, England.		Hussell, Tracy/O-4630-2014; O'Gaora, Peadar/F-9400-2011; Walzl, Gerhard/N-6371-2016	Hussell, Tracy/0000-0001-7186-6141; O'Gaora, Peadar/0000-0002-6417-7054; Stewart, Graham/0000-0002-6867-6248; Walzl, Gerhard/0000-0003-2487-125X; Goyal, Madhu/0000-0001-7921-4586				Arnold-Schild D, 1999, J IMMUNOL, V162, P3757; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Baldwin SL, 1998, INFECT IMMUN, V66, P2951, DOI 10.1128/IAI.66.6.2951-2959.1998; BLUM P, 1992, J BACTERIOL, V174, P7436, DOI 10.1128/jb.174.22.7436-7444.1992; Bucca G, 2000, MOL MICROBIOL, V38, P1093, DOI 10.1046/j.1365-2958.2000.02194.x; BUCCA G, 1997, J BACTERIOL, V179, pS999; BUCHMEIER NA, 1990, SCIENCE, V248, P730, DOI 10.1126/science.1970672; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Cho BK, 2000, IMMUNITY, V12, P263, DOI 10.1016/S1074-7613(00)80179-X; COHEN IR, 1991, IMMUNOL TODAY, V12, P105, DOI 10.1016/0167-5699(91)90093-9; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; De Smet KAL, 1999, MICROBIOL-UK, V145, P3177, DOI 10.1099/00221287-145-11-3177; Dussurget O, 2001, INFECT IMMUN, V69, P529, DOI 10.1128/IAI.69.1.529-533.2001; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; Grandvalet C, 1997, MOL MICROBIOL, V23, P77, DOI 10.1046/j.1365-2958.1997.1811563.x; Grandvalet C, 1999, MOL MICROBIOL, V31, P521, DOI 10.1046/j.1365-2958.1999.01193.x; GROSSMAN AD, 1984, CELL, V38, P383, DOI 10.1016/0092-8674(84)90493-8; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hecker M, 1996, MOL MICROBIOL, V19, P417, DOI 10.1046/j.1365-2958.1996.396932.x; Huang Q, 2000, J EXP MED, V191, P403, DOI 10.1084/jem.191.2.403; LEE BY, 1995, J CLIN INVEST, V96, P245, DOI 10.1172/JCI118028; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Lowrie DB, 1999, NATURE, V400, P269, DOI 10.1038/22326; Manabe YC, 1999, P NATL ACAD SCI USA, V96, P12844, DOI 10.1073/pnas.96.22.12844; Mangan JA, 1997, NUCLEIC ACIDS RES, V25, P675, DOI 10.1093/nar/25.3.675; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; MEHLERT A, 1989, MOL MICROBIOL, V3, P125, DOI 10.1111/j.1365-2958.1989.tb01801.x; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Parish T, 1997, MICROBIOL-UK, V143, P2267, DOI 10.1099/00221287-143-7-2267; Parrish NM, 1998, TRENDS MICROBIOL, V6, P107, DOI 10.1016/S0966-842X(98)01216-5; Pelicic V, 1996, J BACTERIOL, V178, P1197, DOI 10.1128/jb.178.4.1197-1199.1996; Qoronfleh MW, 1998, INFECT IMMUN, V66, P3024, DOI 10.1128/IAI.66.6.3024-3027.1998; Rhoades ER, 1997, TUBERCLE LUNG DIS, V78, P57, DOI 10.1016/S0962-8479(97)90016-2; Simmons CP, 2001, J IMMUNOL, V166, P1106, DOI 10.4049/jimmunol.166.2.1106; Spohn G, 1999, MOL MICROBIOL, V34, P663, DOI 10.1046/j.1365-2958.1999.01625.x; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; VANBOGELEN RA, 1987, GENE DEV, V1, P525, DOI 10.1101/gad.1.6.525; Wu SC, 1998, J BACTERIOL, V180, P2830, DOI 10.1128/JB.180.11.2830-2835.1998; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P4267, DOI 10.1073/pnas.85.12.4267; YOUNG DB, 1991, INFECT IMMUN, V59, P3086, DOI 10.1128/IAI.59.9.3086-3093.1991	45	118	121	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2001	7	6					732	737		10.1038/89113	http://dx.doi.org/10.1038/89113			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385512				2022-12-27	WOS:000169081500043
J	Morgan, D; Whitworth, JAG				Morgan, D; Whitworth, JAG			The natural history of HIV-1 infection in Africa	NATURE MEDICINE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS-INFECTION; TRIMETHOPRIM-SULFAMETHOXAZOLE; RAPID PROGRESSION; UGANDAN ADULTS; COTE-DIVOIRE; SEX WORKERS; SURVIVAL; AIDS; COHORT; SEROCONVERSION		Uganda Virus Res Inst, MRC, Programme AIDS, Entebbe, Uganda	Uganda Virus Research Institute	Morgan, D (corresponding author), Uganda Virus Res Inst, MRC, Programme AIDS, POB 49, Entebbe, Uganda.	mrc@starcom.co.ug						*AIDS INC HIV SURV, 2000, LANCET, V355, P1131; Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; [Anonymous], 1986, Weekly Epidemiological Record, V61, P69; Anzala AO, 2000, J INFECT DIS, V182, P459, DOI 10.1086/315733; ANZALA OA, 1995, J INFECT DIS, V171, P686, DOI 10.1093/infdis/171.3.686; BWAYO JJ, 1995, J ACQ IMMUN DEF SYND, V10, P457, DOI 10.1097/00042560-199512000-00009; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; COLEBUNDERS R, 1991, J INFECT DIS, V164, P450, DOI 10.1093/infdis/164.3.450; French N, 1999, J ACQ IMMUN DEF SYND, V22, P509; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; GHIRARDINI A, 1995, AIDS, V9, P1351, DOI 10.1097/00002030-199512000-00008; Hendriks JCM, 1998, AIDS, V12, P1537, DOI 10.1097/00002030-199812000-00017; Koblin BA, 1999, AM J EPIDEMIOL, V150, P1026, DOI 10.1093/oxfordjournals.aje.a009926; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LEROY V, 1995, J ACQ IMMUN DEF SYND, V9, P415; MANN JM, 1986, LANCET, V2, P707; MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; Moore RD, 1999, AIDS, V13, P1933, DOI 10.1097/00002030-199910010-00017; Morgan D, 2000, SEX TRANSM INFECT, V76, P193, DOI 10.1136/sti.76.3.193; MORGAN D, 2000, 13 INT AIDS C DURB 9; Mouton Y, 1997, AIDS, V11, pF101, DOI 10.1097/00002030-199712000-00003; NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704; Rogers P A, 1997, Commun Dis Rep CDR Rev, V7, pR93; Touloumi G, 1998, J ACQ IMMUN DEF SYND, V19, P89, DOI 10.1097/00042560-199809010-00014; *UNAIDS, 2000, REP GLOB HIV AIDS EP; van Benthem BHB, 1998, AIDS, V12, P1039, DOI 10.1097/00002030-199809000-00011; Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201; WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011; *WHO, 1990, WKLY EPIDEMIOL REC, V65, P221; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0	31	67	68	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2001	7	2					143	145		10.1038/84564	http://dx.doi.org/10.1038/84564			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175832				2022-12-27	WOS:000166756300016
J	Napolitano, LA; Grant, RM; Deeks, SG; Schmidt, D; De Rosa, SC; Herzenberg, LA; Herndier, BG; Andersson, J; McCune, JM				Napolitano, LA; Grant, RM; Deeks, SG; Schmidt, D; De Rosa, SC; Herzenberg, LA; Herndier, BG; Andersson, J; McCune, JM			Increased production of IL-7 accompanies HIV-l-mediated T-cell depletion: implications for T-cell homeostasis	NATURE MEDICINE			English	Article							BONE-MARROW TRANSPLANT; THYMIC FUNCTION; GROWTH-HORMONE; INTERLEUKIN-7; LYMPHOCYTES; VIRUS; MICE; PROLIFERATION; LYMPHOPOIESIS; REPLICATION	We hypothesized that HIV-1-mediated T-cell loss might induce the production of factors that are capable of stimulating lymphocyte development and expansion. Here we perform cross-sectional (n = 168) and longitudinal (n = 11) analyses showing that increased circulating levels of interleukin (IL)-7 are strongly associated with CD4+ T lymphopenia in HIV-1 disease. Using immunohistochemistry with quantitative image analysis, we demonstrate that IL-7 is produced by dendritic-like cells within peripheral lymphoid tissues and that IL-7 production by these cells is greatly increased in lymphocyte-depleted tissues. We propose that IL-7 production increases as part of a homeostatic response to T-cell depletion.	San Francisco Gen Hosp, Gladstone Inst Virol & Immunol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94110 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA; Huddinge Univ Hosp, Karolinska Inst, Dept Infect Dis, Stockholm, Sweden	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Karolinska Institutet	McCune, JM (corresponding author), San Francisco Gen Hosp, Gladstone Inst Virol & Immunol, San Francisco, CA 94110 USA.	nunccune@gladstone.ucsf.edu		Grant, Robert/0000-0002-0851-7085	NATIONAL CANCER INSTITUTE [U01CA066529, R01CA042059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041536] Funding Source: NIH RePORTER; NCI NIH HHS [CA42059, CA66529] Funding Source: Medline; NIAID NIH HHS [AI01597, AI41536] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Andersson J, 1998, AIDS, V12, pF123, DOI 10.1097/00002030-199811000-00004; BARDAYAN Y, 1994, THYMUS, V23, P95; Berzins SP, 1998, J EXP MED, V187, P1839, DOI 10.1084/jem.187.11.1839; BESCHORNER WE, 1991, TRANSPLANTATION, V52, P879, DOI 10.1097/00007890-199111000-00024; Bjork L, 1996, J LEUKOCYTE BIOL, V59, P287; Bolotin E, 1996, BLOOD, V88, P1887; Bolotin E, 1999, BONE MARROW TRANSPL, V23, P783, DOI 10.1038/sj.bmt.1701655; CHAZEN GD, 1989, P NATL ACAD SCI USA, V86, P5923, DOI 10.1073/pnas.86.15.5923; Chene L, 1999, J VIROL, V73, P7533; Di Santo JP, 1999, J EXP MED, V189, P563, DOI 10.1084/jem.189.3.563; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Elbeik T, 2000, J CLIN MICROBIOL, V38, P1113, DOI 10.1128/JCM.38.3.1113-1120.2000; Gabor MJ, 1997, EUR J IMMUNOL, V27, P2986, DOI 10.1002/eji.1830271135; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; GRZEGORZEWSKI KJ, 1995, J EXP MED, V181, P369, DOI 10.1084/jem.181.1.369; Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625; Haynes BF, 1999, J CLIN INVEST, V103, P453, DOI 10.1172/JCI5201; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; HICKMAN CJ, 1990, J IMMUNOL, V145, P2415; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kato T, 1998, STEM CELLS, V16, P322, DOI 10.1002/stem.160322; KELLEY KW, 1986, P NATL ACAD SCI USA, V83, P5663, DOI 10.1073/pnas.83.15.5663; Komschlies KL, 1995, J LEUKOCYTE BIOL, V58, P623, DOI 10.1002/jlb.58.6.623; Kroncke R, 1996, EUR J IMMUNOL, V26, P2541, DOI 10.1002/eji.1830261040; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; Litton MJ, 1997, AM J PATHOL, V150, P1607; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; Mackall C L, 1997, Semin Immunol, V9, P339, DOI 10.1006/smim.1997.0091; McCune J M, 1997, Semin Immunol, V9, P397, DOI 10.1006/smim.1997.0098; McCune JM, 1998, J CLIN INVEST, V101, P2301, DOI 10.1172/JCI2834; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MORRISSEY PJ, 1991, J IMMUNOL, V146, P1547; Pallard C, 1999, IMMUNITY, V10, P525, DOI 10.1016/S1074-7613(00)80052-7; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Poulin JF, 1999, J EXP MED, V190, P479, DOI 10.1084/jem.190.4.479; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; RYAN DH, 1995, LEUKEMIA LYMPHOMA, V17, P375, DOI 10.3109/10428199509056848; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Smithgall MD, 1996, J IMMUNOL, V156, P2324; Tanchot C, 1997, Semin Immunol, V9, P331, DOI 10.1006/smim.1997.0090; Tang JH, 1997, J IMMUNOL, V159, P117; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WATANABE M, 1995, J CLIN INVEST, V95, P2945, DOI 10.1172/JCI118002; Zhang LQ, 1999, J EXP MED, V190, P725, DOI 10.1084/jem.190.5.725	46	434	441	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					73	79		10.1038/83381	http://dx.doi.org/10.1038/83381			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135619				2022-12-27	WOS:000166243100038
J	Fox, JG; Wang, TC				Fox, JG; Wang, TC			The 'African enigma' - another explanation - Reply	NATURE MEDICINE			English	Letter							HELICOBACTER-PYLORI; GASTRITIS; ULCER; MICE		MIT, Div Comparat Med, Cambridge, MA 02139 USA; Univ Massachusetts, Med Ctr, Div Gastroenterol, Worcester, MA 01605 USA	Massachusetts Institute of Technology (MIT); University of Massachusetts System; University of Massachusetts Worcester	Fox, JG (corresponding author), MIT, Div Comparat Med, 77 Massachusetts Ave,Bldg 16-825C, Cambridge, MA 02139 USA.							Blaser MJ, 2000, NAT MED, V6, P376, DOI 10.1038/74627; Blaser MJ, 1999, J INFECT DIS, V179, P1523, DOI 10.1086/314785; BYERS T, 1995, AM J CLIN NUTR, V62, P13855; Correa P, 1992, J Natl Cancer Inst Monogr, P75; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; *FLOR AGR R DRUG A, 1986, B NORC, V38, P27; Fox JG, 2000, NAT MED, V6, P536, DOI 10.1038/75015; Fox JG, 1999, CANCER RES, V59, P4823; Fox JG, 2000, INFEC DIS S, P371; GENTA RM, 1994, GASTROINTEST ENDOSC, V40, P342, DOI 10.1016/S0016-5107(94)70067-2; Graham DY, 1997, GASTROENTEROLOGY, V113, P1983, DOI 10.1016/S0016-5085(97)70019-2; Graham DY, 1996, J CLIN PATHOL, V49, P829, DOI 10.1136/jcp.49.10.829; HOLCOMBE C, 1992, GUT, V33, P429, DOI 10.1136/gut.33.4.429; Kidd M, 1999, J GASTROEN HEPATOL, V14, P851, DOI 10.1046/j.1440-1746.1999.01975.x; LIST PH, 1993, HAGERS HDB PHARMAZEU, V94; Mitchell HM, 2000, GUT, V47, pA38; RECAVARRENARCE S, 1992, J CLIN GASTROENTEROL, V15, P296, DOI 10.1097/00004836-199212000-00006; Sutton P, 1999, GUT, V45, P335, DOI 10.1136/gut.45.3.335; Wang TC, 1998, GASTROENTEROLOGY, V114, P675, DOI 10.1016/S0016-5085(98)70581-5	19	3	3	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1297	1298		10.1038/82066	http://dx.doi.org/10.1038/82066			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100086				2022-12-27	WOS:000165704100003
J	Daubersies, P; Thomas, AW; Millet, P; Brahimi, K; Langermans, JAM; Ollomo, B; Ben Mohamed, L; Slierendregt, B; Eling, W; Van Belkum, A; Dubreuil, G; Meis, JFGM; Guerin-Marchand, C; Cayphas, S; Cohen, J; Gras-Masse, H; Druilhe, P				Daubersies, P; Thomas, AW; Millet, P; Brahimi, K; Langermans, JAM; Ollomo, B; Ben Mohamed, L; Slierendregt, B; Eling, W; Van Belkum, A; Dubreuil, G; Meis, JFGM; Guerin-Marchand, C; Cayphas, S; Cohen, J; Gras-Masse, H; Druilhe, P			Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved preerythrocytic liver-stage antigen 3	NATURE MEDICINE			English	Article							IRRADIATED SPOROZOITES; IMMUNE-RESPONSES; T-HELPER; VACCINE; INDUCTION; PROTEIN; HUMANS; INFECTION; PARASITES; POTENT	In humans, sterile immunity against malaria can be consistently induced through exposure to the bites of thousands of irradiated infected mosquitoes. The same level of protection has yet to be achieved using subunit vaccines. Recent studies have indicated an essential function for intrahepatic parasites, the stage after the mosquito bite, and thus for antigens expressed during this stage. We report here the identification of liver-stage antigen 3, which is expressed both in the mosquito and liver-stage parasites. This Plasmodium falciparum 200-kilodalton protein is highly conserved, and showed promising antigenic and immunogenic properties. In chimpanzees (Pan troglodytes), the primates most closely related to humans and that share a similar susceptibility to P. falciparum liver-stage infection, immunization with LSA-3 induced protection against successive heterologous challenges with large numbers of P. falciparum sporozoites.	Inst Pasteur, Unite Parasitol Biomed, F-75015 Paris, France; Biomed Primate Res Ctr, Dept Parasitol, NL-2280 GH Rijswijk, Netherlands; Ctr Int Rech Med Franceville, Franceville, Gabon; Univ Nijmegen, Dept Med Microbiol, Nijmegen, Netherlands; Univ Nijmegen, Dept Med Parasitol, Nijmegen, Netherlands; SmithKline Beecham Biol SA, B-1330 Rixensart, Belgium; Inst Pasteur, Lab Chim Biomol, CNRS, URA 1309, F-59019 Lille, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Radboud University Nijmegen; Radboud University Nijmegen; GlaxoSmithKline; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Druilhe, P (corresponding author), Inst Pasteur, Unite Parasitol Biomed, 28 Rue Dr Roux, F-75015 Paris, France.	druilhe@pasteur.fr	Slierendregt, Bas/AAB-4535-2021; Meis, Jacques F/A-9241-2010	Meis, Jacques F/0000-0003-3253-6080				Aidoo M, 2000, INFECT IMMUN, V68, P227, DOI 10.1128/IAI.68.1.227-232.2000; Anders RF, 2000, PARASITOL TODAY, V16, P444, DOI 10.1016/S0169-4758(00)01784-1; [Anonymous], 1997, NEW ENGL J MED, DOI DOI 10.1056/NEJM199701093360202; BARNES DA, 1995, EXP PARASITOL, V81, P79, DOI 10.1006/expr.1995.1095; Benmohamed L, 2000, VACCINE, V18, P2843, DOI 10.1016/S0264-410X(00)00068-2; BenMohamed L, 1997, EUR J IMMUNOL, V27, P1242, DOI 10.1002/eji.1830270528; Bottius E, 1996, J IMMUNOL, V156, P2874; BOURGAULT I, 1994, J IMMUNOL, V152, P2530; DRUILHE P, 1984, AM J TROP MED HYG, V33, P336, DOI 10.4269/ajtmh.1984.33.336; Druilhe P., 1998, MALARIA PARASITE BIO; EGAN JE, 1993, AM J TROP MED HYG, V49, P166, DOI 10.4269/ajtmh.1993.49.166; Facer CA, 1997, ADV PARASIT, V39, P1, DOI 10.1016/S0065-308X(08)60044-5; FIDOCK DA, 1994, J IMMUNOL, V153, P190; Gahery-Segard H, 2000, J VIROL, V74, P1694, DOI 10.1128/JVI.74.4.1694-1703.2000; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; GUERINMARCHAND C, 1987, NATURE, V329, P164, DOI 10.1038/329164a0; HERRINGTON D, 1991, AM J TROP MED HYG, V45, P539, DOI 10.4269/ajtmh.1991.45.539; KEMP DJ, 1990, ADV PARASIT, V29, P75; Kwiatkowski D, 1997, LANCET, V350, P1696, DOI 10.1016/S0140-6736(97)03256-X; LONDONO JA, 1990, J IMMUNOL, V145, P1557; MARCHAND C, 1990, B WORLD HEALTH ORGAN, V68, P158; MEIS JFGM, 1990, EXP PARASITOL, V70, P1, DOI 10.1016/0014-4894(90)90080-V; MELLOUK S, 1990, LANCET, V335, P721, DOI 10.1016/0140-6736(90)90832-P; MIYAMOTO MM, 1988, P NATL ACAD SCI USA, V85, P7627, DOI 10.1073/pnas.85.20.7627; MOELANS IIMD, 1992, PARASITOL TODAY, V8, P118, DOI 10.1016/0169-4758(92)90278-A; MURPHY JR, 1989, J CLIN MICROBIOL, V27, P1434, DOI 10.1128/JCM.27.7.1434-1437.1989; NUSSLER AK, 1993, EUR J IMMUNOL, V23, P882, DOI 10.1002/eji.1830230417; PONNUDURAI T, 1989, T ROY SOC TROP MED H, V83, P67, DOI 10.1016/0035-9203(89)90708-6; Roggero MA, 1995, MOL IMMUNOL, V32, P1301, DOI 10.1016/0161-5890(95)00136-0; SCHELLER LF, 1995, P NATL ACAD SCI USA, V92, P4066, DOI 10.1073/pnas.92.9.4066; Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657; VITIELLO A, 1995, J CLIN INVEST, V95, P341, DOI 10.1172/JCI117662	32	136	151	0	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2000	6	11					1258	1263		10.1038/81366	http://dx.doi.org/10.1038/81366			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062538	Bronze			2022-12-27	WOS:000165114800034
J	Frey, N; McKinsey, TA; Olson, EN				Frey, N; McKinsey, TA; Olson, EN			Decoding calcium signals involved in cardiac growth and function	NATURE MEDICINE			English	Review							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; LIGHT-CHAIN PHOSPHORYLATION; ATRIAL-NATRIURETIC-FACTOR; STAGE HEART-FAILURE; GENE-EXPRESSION; DILATED CARDIOMYOPATHY; TRANSCRIPTION FACTORS; RECEPTOR EXPRESSION; TRANSGENIC MICE	Calcium is central in the regulation of cardiac contractility, growth and gene expression. Variations in the amplitude, frequency and compartmentalization of calcium signals are decoded by calcium/calmodulin-dependent enzymes, ion channels and transcription factors. Understanding the circuitry for calcium signaling creates opportunities for pharmacological modification of cardiac function.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.		Frey, Norbert/M-7749-2019; Frey, Norbert/A-9695-2010	Frey, Norbert/0000-0001-7611-378X; 				Aoki H, 2000, NAT MED, V6, P183, DOI 10.1038/72287; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Blaeser F, 2000, J BIOL CHEM, V275, P197, DOI 10.1074/jbc.275.1.197; Bottinelli R, 1998, CIRC RES, V82, P106; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Cheng H, 1996, CELL CALCIUM, V20, P129, DOI 10.1016/S0143-4160(96)90102-5; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Colomer JM, 2000, MOL ENDOCRINOL, V14, P1125, DOI 10.1210/me.14.8.1125; Ding B, 1999, CIRC RES, V84, P729, DOI 10.1161/01.RES.84.6.729; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P6400, DOI 10.1073/pnas.96.11.6400; Dzhura I, 2000, NAT CELL BIOL, V2, P173, DOI 10.1038/35004052; Elliott K, 2000, J BIOL CHEM, V275, P22069, DOI 10.1074/jbc.M002502200; Gao WD, 1997, CIRC RES, V80, P393, DOI 10.1161/01.res.0000435855.49359.47; Gao WD, 1999, J CLIN INVEST, V103, P661, DOI 10.1172/JCI5220; Genazzani AA, 1999, P NATL ACAD SCI USA, V96, P5797, DOI 10.1073/pnas.96.10.5797; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hasenfuss G, 1999, CIRCULATION, V99, P641, DOI 10.1161/01.CIR.99.5.641; Hill JA, 2000, CIRCULATION, V101, P2863, DOI 10.1161/01.CIR.101.24.2863; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; IRONS CE, 1992, J BIOL CHEM, V267, P5211; Janssen PML, 2000, CARDIOVASC RES, V47, P99, DOI 10.1016/S0008-6363(00)00052-3; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; Kirchhefer U, 1999, CARDIOVASC RES, V42, P254, DOI 10.1016/S0008-6363(98)00296-X; Kolodziejczyk SM, 1999, CURR BIOL, V9, P1203, DOI 10.1016/S0960-9822(00)80027-5; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lim HW, 1999, NAT MED, V5, P246, DOI 10.1038/6430; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; McKinsey TA, 1999, CURR OPIN GENET DEV, V9, P267, DOI 10.1016/S0959-437X(99)80040-9; MCKINSEY TA, IN PRESS NATURE; MERCADIER JJ, 1990, J CLIN INVEST, V85, P305, DOI 10.1172/JCI114429; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORANO I, 1985, FEBS LETT, V189, P221, DOI 10.1016/0014-5793(85)81027-9; MOSCHELLA MC, 1993, J CELL BIOL, V120, P1137, DOI 10.1083/jcb.120.5.1137; Mukherjea P, 1999, BIOCHEMISTRY-US, V38, P13296, DOI 10.1021/bi9906120; Murphy AM, 2000, SCIENCE, V287, P488, DOI 10.1126/science.287.5452.488; Netticadan T, 2000, CIRC RES, V86, P596, DOI 10.1161/01.RES.86.5.596; NOLAND TA, 1993, BIOCHEM BIOPH RES CO, V193, P254, DOI 10.1006/bbrc.1993.1617; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Post SR, 1999, ANNU REV PHARMACOL, V39, P343, DOI 10.1146/annurev.pharmtox.39.1.343; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reddy LG, 1996, J BIOL CHEM, V271, P14964, DOI 10.1074/jbc.271.25.14964; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Sanbe A, 1999, J BIOL CHEM, V274, P21085, DOI 10.1074/jbc.274.30.21085; Sato Y, 1998, J BIOL CHEM, V273, P28470, DOI 10.1074/jbc.273.43.28470; Shimoyama M, 1999, CIRCULATION, V100, P2449, DOI 10.1161/01.CIR.100.24.2449; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Tsao LN, 2000, NAT MED, V6, P2, DOI 10.1038/71478; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Xu AD, 2000, J BIOL CHEM, V275, P4407, DOI 10.1074/jbc.275.6.4407; Yanaga F, 1999, J BIOL CHEM, V274, P8806, DOI 10.1074/jbc.274.13.8806; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Zhang WG, 1999, CIRC RES, V84, P722, DOI 10.1161/01.RES.84.6.722; Zhu WD, 2000, J BIOL CHEM, V275, P15239, DOI 10.1074/jbc.275.20.15239	79	281	297	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1221	1227		10.1038/81321	http://dx.doi.org/10.1038/81321			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062532				2022-12-27	WOS:000165114800028
J	Binder, CJ; Chang, MK; Shaw, PX; Miller, YI; Hartvigsen, K; Dewan, A; Witztum, JL				Binder, CJ; Chang, MK; Shaw, PX; Miller, YI; Hartvigsen, K; Dewan, A; Witztum, JL			Innate and acquired immunity in atherogenesis	NATURE MEDICINE			English	Review							LOW-DENSITY-LIPOPROTEIN; C-REACTIVE PROTEIN; HUMAN ATHEROSCLEROTIC LESIONS; VASCULAR ENDOTHELIAL-CELLS; SCAVENGER RECEPTOR CD36; MACROPHAGE FOAM CELL; SMOOTH-MUSCLE-CELLS; TOLL-LIKE RECEPTORS; E-DEFICIENT MICE; OXIDIZED PHOSPHOLIPIDS	Traditional risk factors like hypercholesterolemia are important for atherogenesis, but it is now apparent that the immune system also plays an important role. Uncovering the mechanisms by which specific components of the immune system impact atherogenesis will not only provide new insights into the pathogenesis of lesion formation, but could also lead to novel therapeutic approaches that involve immune modulation.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Witztum, JL (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	jwitztum@ucsd.edu		Binder, Christoph J./0000-0001-8313-7050				Afek A, 2000, J AUTOIMMUN, V14, P115, DOI 10.1006/jaut.1999.0351; Ameli S, 1996, ARTERIOSCL THROM VAS, V16, P1074, DOI 10.1161/01.ATV.16.8.1074; Beck JD, 1999, AM HEART J, V138, pS528, DOI 10.1016/S0002-8703(99)70293-0; Berliner JA, 2001, TRENDS CARDIOVAS MED, V11, P142, DOI 10.1016/S1050-1738(01)00098-6; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Boullier A, 2000, J BIOL CHEM, V275, P9163, DOI 10.1074/jbc.275.13.9163; BRILES DE, 1982, J EXP MED, V156, P1177, DOI 10.1084/jem.156.4.1177; Buono C, 2002, CIRCULATION, V105, P3025, DOI 10.1161/01.CIR.0000019584.04929.83; Caligiuri G, 2002, J CLIN INVEST, V109, P745, DOI 10.1172/JCI200207272; Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699; Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353; Colles SM, 2001, TRENDS CARDIOVAS MED, V11, P131, DOI 10.1016/S1050-1738(01)00106-2; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; Cyrus T, 2001, CIRCULATION, V103, P2277; Dansky HM, 1997, P NATL ACAD SCI USA, V94, P4642, DOI 10.1073/pnas.94.9.4642; Daugherty A, 1997, J CLIN INVEST, V100, P1575, DOI 10.1172/JCI119681; Edfeldt K, 2002, CIRCULATION, V105, P1158, DOI 10.1161/circ.105.10.1158; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Freigang S, 1998, ARTERIOSCL THROM VAS, V18, P1972, DOI 10.1161/01.ATV.18.12.1972; Friedman P, 2002, J BIOL CHEM, V277, P7010, DOI 10.1074/jbc.M108860200; Gaut JP, 2001, TRENDS CARDIOVAS MED, V11, P103, DOI 10.1016/S1050-1738(01)00101-3; George J, 2000, CIRCULATION, V102, P1822; George J, 1998, ATHEROSCLEROSIS, V138, P147, DOI 10.1016/S0021-9150(98)00015-X; Gerdes N, 2002, J EXP MED, V195, P245, DOI 10.1084/jem.20011022; Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353; Gillotte KL, 2000, J LIPID RES, V41, P824; Gillotte-Taylor K, 2001, J LIPID RES, V42, P1474; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220; Horkko S, 2000, FREE RADICAL BIO MED, V28, P1771, DOI 10.1016/S0891-5849(00)00333-6; Horkko S, 1999, J CLIN INVEST, V103, P117, DOI 10.1172/JCI4533; Hubacek JA, 1999, CIRCULATION, V99, P3218, DOI 10.1161/01.CIR.99.25.3218; Huber SA, 2001, CIRCULATION, V103, P2610; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; King VL, 2002, ARTERIOSCL THROM VAS, V22, P456, DOI 10.1161/hq0302.104905; Landmesser U, 2001, CIRCULATION, V104, P2638, DOI 10.1161/circ.104.22.2638; Laurat E, 2001, CIRCULATION, V104, P197, DOI 10.1161/01.CIR.104.2.197; Lee TS, 1999, ARTERIOSCL THROM VAS, V19, P734, DOI 10.1161/01.ATV.19.3.734; LEITERSDORF E, 1990, J CLIN INVEST, V85, P1014, DOI 10.1172/JCI114531; Li AC, 2002, NAT MED, V8, P1235, DOI 10.1038/nm1102-1235; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Libby P, 1997, CIRCULATION, V96, P4095; Lutgens E, 2000, P NATL ACAD SCI USA, V97, P7464, DOI 10.1073/pnas.97.13.7464; Lutgens E, 2002, ARTERIOSCL THROM VAS, V22, P975, DOI 10.1161/01.ATV.0000019729.39500.2F; Lutgens E, 1999, NAT MED, V5, P1313, DOI 10.1038/15271; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; Mallat Z, 2001, CIRC RES, V89, P930, DOI 10.1161/hh2201.099415; Marathe GK, 2001, TRENDS CARDIOVAS MED, V11, P139, DOI 10.1016/S1050-1738(01)00100-1; Maron R, 2002, CIRCULATION, V106, P1708, DOI 10.1161/01.CIR.0000029750.99462.30; Mayr M, 2000, CIRCULATION, V102, P833; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Millonig G, 2001, CURR OPIN LIPIDOL, V12, P547, DOI 10.1097/00041433-200110000-00011; Nicoletti A, 1998, J CLIN INVEST, V102, P910, DOI 10.1172/JCI119892; Ochsenbein AF, 2000, J IMMUNOL, V164, P6296, DOI 10.4049/jimmunol.164.12.6296; Palinski W, 2000, J INTERN MED, V247, P371, DOI 10.1046/j.1365-2796.2000.00656.x; PALINSKI W, 1995, P NATL ACAD SCI USA, V92, P821, DOI 10.1073/pnas.92.3.821; Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853; Paulsson G, 2000, ARTERIOSCL THROM VAS, V20, P10, DOI 10.1161/01.ATV.20.1.10; Pinderski LJ, 2002, CIRC RES, V90, P1064, DOI 10.1161/01.RES.0000018941.10726.FA; Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Pratico D, 2001, TRENDS CARDIOVAS MED, V11, P112, DOI 10.1016/S1050-1738(01)00099-8; Reardon CA, 2001, ARTERIOSCL THROM VAS, V21, P1011, DOI 10.1161/01.ATV.21.6.1011; ROBINETTE CD, 1977, LANCET, V2, P127; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schiller NK, 2002, ARTERIOSCL THROM VAS, V22, P1341, DOI 10.1161/01.ATV.0000024082.46387.38; Schonbeck U, 2000, P NATL ACAD SCI USA, V97, P7458, DOI 10.1073/pnas.97.13.7458; Shaw PX, 2000, J CLIN INVEST, V105, P1731, DOI 10.1172/JCI8472; Skalen K, 2002, NATURE, V417, P750, DOI 10.1038/nature00804; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; SOHMA Y, 1995, P NATL ACAD SCI USA, V92, P4937, DOI 10.1073/pnas.92.11.4937; Song L, 2001, J CLIN INVEST, V108, P251, DOI 10.1172/JCI11380; STEMME S, 1995, P NATL ACAD SCI USA, V92, P3893, DOI 10.1073/pnas.92.9.3893; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Tsimikas S, 2001, ARTERIOSCL THROM VAS, V21, P95, DOI 10.1161/01.ATV.21.1.95; Tuzcu EM, 2001, CIRCULATION, V103, P2705; Uyemura K, 1996, J CLIN INVEST, V97, P2130, DOI 10.1172/JCI118650; VLAICU R, 1985, ATHEROSCLEROSIS, V57, P163, DOI 10.1016/0021-9150(85)90030-9; Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6; Vos Q, 2000, IMMUNOL REV, V176, P154; Whitman SC, 2000, AM J PATHOL, V157, P1819, DOI 10.1016/S0002-9440(10)64820-1; Whitman SC, 2002, CIRC RES, V90, pE34, DOI 10.1161/hh0202.105292; Wick G, 2001, TRENDS IMMUNOL, V22, P665, DOI 10.1016/S1471-4906(01)02089-0; Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012; Witztum JL, 2002, J CLIN INVEST, V109, P721, DOI 10.1172/JCI200215310; Witztum JL, 1998, CURR OPIN LIPIDOL, V9, P441, DOI 10.1097/00041433-199810000-00008; Witztum JL, 2001, TRENDS CARDIOVAS MED, V11, P93, DOI 10.1016/S1050-1738(01)00111-6; Wright SD, 2000, J EXP MED, V191, P1437, DOI 10.1084/jem.191.8.1437; Yasojima K, 2001, AM J PATHOL, V158, P1039, DOI 10.1016/S0002-9440(10)64051-5; YLAHERTTUALA S, 1994, ARTERIOSCLER THROMB, V14, P32, DOI 10.1161/01.ATV.14.1.32; Zhou X, 1999, SCAND J IMMUNOL, V50, P25; Zhou XH, 2000, CIRCULATION, V102, P2919; Zhou XH, 2001, ARTERIOSCL THROM VAS, V21, P108, DOI 10.1161/01.ATV.21.1.108	98	535	566	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2002	8	11					1218	1226		10.1038/nm1102-1218	http://dx.doi.org/10.1038/nm1102-1218			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12411948				2022-12-27	WOS:000179221200026
J	Dzau, VJ; Braun-Dullaeus, RC; Sedding, DG				Dzau, VJ; Braun-Dullaeus, RC; Sedding, DG			Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies	NATURE MEDICINE			English	Review							SMOOTH-MUSCLE CELLS; DEPENDENT KINASE INHIBITOR; OXIDE SYNTHASE GENE; PORCINE CORONARY-ARTERIES; RAT CAROTID-ARTERY; NITRIC-OXIDE; IN-VIVO; GROWTH-FACTOR; INTIMAL HYPERPLASIA; NEOINTIMAL HYPERPLASIA	In atherosclerosis, the vascular smooth muscle cell (VSMC) contributes to vessel wall inflammation and lipoprotein retention as well as to the formation of the fibrous cap that provides stability to the plaque. The VSMC can undergo a proliferative response that underlies the development of in stent restenosis, bypass graft occlusion and transplant vasculopathy Although the benefit/risk of therapeutic inhibition of VSMC proliferation in atherosclerosis is unclear, experimental and human evidence strongly suggests the therapeutic potential of antiproliferative therapy for in-stent restenosis, bypass graft failure and other vascular proliferative disorders.	Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Giessen, Dept Med, Giessen, Germany	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Justus Liebig University Giessen	Dzau, VJ (corresponding author), Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.		Braun-Dullaeus, Ruediger C/G-1844-2013	Braun-Dullaeus, Ruediger C/0000-0003-3888-6532				Axel DI, 1997, CIRCULATION, V96, P636; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; Braun-Dullaeus RC, 1999, J CLIN INVEST, V104, P815, DOI 10.1172/JCI5339; Braun-Dullaeus RC, 1998, CIRCULATION, V98, P82, DOI 10.1161/01.CIR.98.1.82; Braun-Dullaeus RC, 2001, ARTERIOSCL THROM VAS, V21, P1152, DOI 10.1161/hq0701.092104; Brooks EE, 1997, J BIOL CHEM, V272, P29207, DOI 10.1074/jbc.272.46.29207; Campbell JH, 2001, ANN NY ACAD SCI, V947, P18; CHANCELIER JP, 1995, MATH MOD METH APPL S, V5, P267, DOI 10.1142/S0218202595000176; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; DeRuiter MC, 1997, CIRC RES, V80, P444, DOI 10.1161/01.RES.80.4.444; DZAU VJ, 1991, HYPERTENSION, V18, P11100; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Frimerman A, 1999, CIRCULATION, V99, P697, DOI 10.1161/01.CIR.99.5.697; Fukui R, 1997, ATHEROSCLEROSIS, V132, P53, DOI 10.1016/S0021-9150(97)00086-5; FUSTER V, 1994, CIRCULATION, V90, P2126, DOI 10.1161/01.CIR.90.4.2126; Gallo R, 1999, CIRCULATION, V99, P2164, DOI 10.1161/01.CIR.99.16.2164; Gershlick AH, 2002, ATHEROSCLEROSIS, V160, P259, DOI 10.1016/S0021-9150(01)00618-9; GIASSON E, 1995, J BIOL CHEM, V270, P5225, DOI 10.1074/jbc.270.10.5225; Gilroy DW, 2001, FASEB J, V15, P288; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; GRANT MB, 1994, CIRCULATION, V89, P1511, DOI 10.1161/01.CIR.89.4.1511; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Gray N, 1999, CURR MED CHEM, V6, P859; GREGORY CR, 1993, TRANSPLANTATION, V55, P1409, DOI 10.1097/00007890-199306000-00037; Grise MA, 2002, CIRCULATION, V105, P2737, DOI 10.1161/01.CIR.0000018126.87045.E0; Guo K, 1998, CIRCULATION, V97, P2066, DOI 10.1161/01.CIR.97.20.2066; Hillebrands JL, 2001, J CLIN INVEST, V107, P1411, DOI 10.1172/JCI10233; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Ishida A, 1997, J BIOL CHEM, V272, P10050; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; KATSUDA S, 1992, AM J PATHOL, V140, P907; KINSELLA MG, 1986, J CELL BIOL, V102, P678; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Kutryk MJB, 2002, J AM COLL CARDIOL, V39, P281, DOI 10.1016/S0735-1097(01)01741-7; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Liistro F, 2002, CIRCULATION, V105, P1883, DOI 10.1161/01.CIR.0000016042.69606.61; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; Mangi AA, 2001, ANN MED, V33, P153, DOI 10.3109/07853890109002071; Mann MJ, 1999, LANCET, V354, P1493, DOI 10.1016/S0140-6736(99)09405-2; Mann MJ, 1997, J CLIN INVEST, V99, P1295, DOI 10.1172/JCI119288; Mano T, 1999, CIRC RES, V84, P647, DOI 10.1161/01.RES.84.6.647; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; Narita N, 1996, GENOMICS, V36, P345, DOI 10.1006/geno.1996.0472; OBRIEN ER, 1993, CIRC RES, V73, P223, DOI 10.1161/01.RES.73.2.223; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Perlman H, 1998, J BIOL CHEM, V273, P13713, DOI 10.1074/jbc.273.22.13713; Poon M, 1996, J CLIN INVEST, V98, P2277, DOI 10.1172/JCI119038; Qian HS, 1999, CIRCULATION, V99, P2979, DOI 10.1161/01.CIR.99.23.2979; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Ruef J, 1999, CIRCULATION, V100, P659, DOI 10.1161/01.CIR.100.6.659; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; Schwartz S M, 2000, Curr Atheroscler Rep, V2, P422, DOI 10.1007/s11883-000-0081-5; Schwartz SM, 1998, ANNU REV MED, V49, P437; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; Scott NA, 1996, CIRCULATION, V93, P2178, DOI 10.1161/01.CIR.93.12.2178; Scott S, 2002, CIRC RES, V90, P398, DOI 10.1161/hh0402.105900; SEHGAL SN, 1975, J ANTIBIOT, V28, P727, DOI 10.7164/antibiotics.28.727; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHI Y, 1994, CIRCULATION, V90, P944, DOI 10.1161/01.CIR.90.2.944; Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121; SIMONS M, 1994, J CLIN INVEST, V93, P2351, DOI 10.1172/JCI117240; Simper D, 2002, CIRCULATION, V106, P1199, DOI 10.1161/01.CIR.0000031525.61826.A8; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; VELICAN C, 1976, ATHEROSCLEROSIS, V23, P345, DOI 10.1016/0021-9150(76)90108-8; von der Leyen HE, 2001, CIRCULATION, V103, P2760; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; Waksman R, 2000, CIRCULATION, V101, P2165, DOI 10.1161/01.CIR.101.18.2165; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; Yonemitsu Y, 1997, ANN NY ACAD SCI, V811, P395, DOI 10.1111/j.1749-6632.1997.tb52019.x; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	83	676	711	3	94	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2002	8	11					1249	1256		10.1038/nm1102-1249	http://dx.doi.org/10.1038/nm1102-1249			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12411952				2022-12-27	WOS:000179221200030
J	Nagy, ZA; Hubner, B; Lohning, C; Rauchenberger, R; Reiffert, S; Thomassen-Wolf, E; Zahn, S; Leyer, S; Schier, EM; Zahradnik, A; Brunner, C; Lobenwein, K; Rattel, B; Stanglmaier, M; Hallek, M; Wing, M; Anderson, S; Dunn, M; Kretzschmar, T; Tesar, M				Nagy, ZA; Hubner, B; Lohning, C; Rauchenberger, R; Reiffert, S; Thomassen-Wolf, E; Zahn, S; Leyer, S; Schier, EM; Zahradnik, A; Brunner, C; Lobenwein, K; Rattel, B; Stanglmaier, M; Hallek, M; Wing, M; Anderson, S; Dunn, M; Kretzschmar, T; Tesar, M			Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells	NATURE MEDICINE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-II MOLECULES; HUMAN B-LYMPHOCYTES; SINGLE-CHAIN FV; C-KIT LIGAND; DOWN-REGULATION; ANTIGEN; APOPTOSIS; INHIBITION; HEMATOPOIESIS	The Human Combinatorial Antibody Library (HuCAL) was screened for antibodies specific to human leukocyte antigen-DR (HLA-DR) that induce programmed death of lymphoma/leukemia cells expressing the target antigen. The active Fab fragments were affinity-matured, and engineered to IgG(4) antibodies of sub-nanomolar affinity. The antibodies exhibited potent in vitro tumoricidal activity on several lymphoma and leukemia cell lines and on chronic lymphocytic leukemia patient samples. They were also active in vivo in xenograft models of non-Hodgkin lymphoma. Cell death occurred rapidly, without the need for exogenous immunological effector mechanisms, and was selective to activated/tumor-transformed cells. Although the expression of HLA-DR on normal hematopoietic cells is a potential safety concern, the antibodies caused no long-lasting hematological toxicity in primates, in vivo. Such monoclonal antibodies offer the potential for a novel therapeutic approach to lymphoid malignancies.	GPC Biotech AG, Martinsried, Germany; MorphoSys AG, Martinsried, Germany; Clin Grosshadern, Med Clin 3, Munich, Germany; Huntingdon Life Sci, Huntingdon, England; GPC Biotech Inc, Waltham, MA USA	GPC Biotech; MorphoSys; University of Munich	Nagy, ZA (corresponding author), GPC Biotech AG, Martinsried, Germany.		Hallek, Michael/Y-3191-2019	Hallek, Michael/0000-0002-7425-4455				ALTOMONTE M, 1993, J IMMUNOL, V151, P5115; BILLING R, 1983, TRANSPLANT P, V15, P649; BRIDGES SH, 1987, J IMMUNOL, V139, P4242; Buhmann R, 1999, BLOOD, V93, P1992, DOI 10.1182/blood.V93.6.1992.406k23_1992_2002; Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192; DeNardo S J, 1988, Int J Cancer Suppl, V3, P96; Drenou B, 1999, J IMMUNOL, V163, P4115; DYER MJS, 1989, BLOOD, V73, P1431; EPSTEIN AL, 1987, CANCER RES, V47, P830; FERREIRA MU, 1995, J IMMUNOL METHODS, V187, P297, DOI 10.1016/0022-1759(95)00186-4; GINGRICH RD, 1990, BLOOD, V75, P2375; GORGA JC, 1984, METHOD ENZYMOL, V108, P607; HONG DS, 1995, BLOOD, V86, P3341, DOI 10.1182/blood.V86.9.3341.bloodjournal8693341; Ito K, 1996, J EXP MED, V183, P2635, DOI 10.1084/jem.183.6.2635; JONKER M, 1988, TRANSPLANTATION, V45, P677, DOI 10.1097/00007890-198804000-00002; KABELITZ D, 1989, CELL IMMUNOL, V120, P21, DOI 10.1016/0008-8749(89)90171-8; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; Knappik A, 2000, J MOL BIOL, V296, P57, DOI 10.1006/jmbi.1999.3444; Krebs B, 2001, J IMMUNOL METHODS, V254, P67, DOI 10.1016/S0022-1759(01)00398-2; Lee JW, 1997, J IMMUNOL, V159, P3211; Link BK, 1998, INT J CANCER, V77, P251, DOI 10.1002/(SICI)1097-0215(19980717)77:2<251::AID-IJC14>3.3.CO;2-O; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; Marget M, 2000, TISSUE ANTIGENS, V56, P1, DOI 10.1034/j.1399-0039.2000.560101.x; NEWELL MK, 1993, P NATL ACAD SCI USA, V90, P10459, DOI 10.1073/pnas.90.22.10459; PEIPER SC, 1988, BLOOD, V72, P314; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; Schier R, 1996, J MOL BIOL, V255, P28, DOI 10.1006/jmbi.1996.0004; TEDDER TF, 1988, P NATL ACAD SCI USA, V85, P208, DOI 10.1073/pnas.85.1.208; TRUMAN JP, 1994, INT IMMUNOL, V6, P887, DOI 10.1093/intimm/6.6.887; VAICKUS L, 1989, CELL IMMUNOL, V119, P445, DOI 10.1016/0008-8749(89)90257-8; Vidovic D, 1995, EUR J IMMUNOL, V25, P3349, DOI 10.1002/eji.1830251222; Vidovic D, 1998, CANCER LETT, V128, P127, DOI 10.1016/S0304-3835(98)00034-2; VIRNEKAS B, 1994, NUCLEIC ACIDS RES, V22, P5600, DOI 10.1093/nar/22.25.5600; Vose JM, 2001, J CLIN ONCOL, V19, P389, DOI 10.1200/JCO.2001.19.2.389; YOSHINO T, 1995, EUR J IMMUNOL, V25, P2190, DOI 10.1002/eji.1830250811	35	121	163	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2002	8	8					801	807		10.1038/nm736	http://dx.doi.org/10.1038/nm736			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12101408				2022-12-27	WOS:000177200900025
J	Grimm, C; Wenzel, A; Groszer, M; Mayser, H; Seeliger, M; Samardzija, M; Bauer, C; Gassmann, M; Reme, CE				Grimm, C; Wenzel, A; Groszer, M; Mayser, H; Seeliger, M; Samardzija, M; Bauer, C; Gassmann, M; Reme, CE			HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration	NATURE MEDICINE			English	Article							INDUCED APOPTOSIS; GROWTH-FACTOR; CELL-DEATH; PHOTORECEPTORS; RHODOPSIN; DAMAGE; EXPRESSION; MICE; ACTIVATION; MEDIATOR	Erythropoietin (Epo) is upregulated by hypoxia and provides protection against apoptosis of erythroid progenitors in bone marrow and brain neurons. Here we show in the adult mouse retina that acute hypoxia dose-dependently stimulates expression of Epo, fibroblast growth factor 2 and vascular endothelial growth factor via hypoxia-inducible factor-1alpha (HIF-1alpha) stabilization. Hypoxic preconditioning protects retinal morphology and function against light-induced apoptosis by interfering with caspase-1 activation, a downstream event in the intracellular death cascade. In contrast, induction of activator protein-1, an early event in the light-stressed retina, is not affected by hypoxia. The Epo receptor required for Epo signaling localizes to photoreceptor cells. The protective effect of hypoxic preconditioning is mimicked by systemically applied Epo that crosses the blood-retina barrier and prevents apoptosis even when given therapeutically after light insult. Application of Epo may, through the inhibition of apoptosis, be beneficial for the treatment of different forms of retinal disease.	Univ Hosp, Dept Ophthalmol, Retinal Cell Biol, Zurich, Switzerland; Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90024 USA; Univ Tubingen, Dept Ophthalmol, Retinal Electrodiagnost Res Grp, Tubingen, Germany; Univ Zurich, Inst Physiol, Zurich, Switzerland; Univ Zurich, Inst Vet Physiol, Zurich, Switzerland	University of Zurich; University Zurich Hospital; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Zurich; University of Zurich	Grimm, C (corresponding author), Univ Hosp, Dept Ophthalmol, Retinal Cell Biol, Zurich, Switzerland.	cgrimm@opht.unizh.ch	Samardzija, Marijana/B-9245-2008	Samardzija, Marijana/0000-0003-0991-4653; Groszer, Matthias/0000-0002-6209-305X; Grimm, Christian/0000-0001-9318-4352; Gassmann, Max/0000-0003-2750-8878				Adler R, 1999, MOL VIS, V5; BARBE MF, 1988, SCIENCE, V241, P1817, DOI 10.1126/science.3175623; Bowers F, 2001, INVEST OPHTH VIS SCI, V42, P804; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Chattopadhyay A, 2000, BIOCHEM PHARMACOL, V59, P419, DOI 10.1016/S0006-2952(99)00277-4; Chilov D, 2001, FASEB J, V15, P2613, DOI 10.1096/fj.01-0092com; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246; FAKTOROVICH EG, 1992, J NEUROSCI, V12, P3554; FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0; FANDREY J, 1993, BLOOD, V81, P617; Fry J.C., 1993, BIOL DATA ANAL PRACT; Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614; Grimm C, 2000, MOL VIS, V6, P252; HOFER T, 2002, PFLUGERS ARCH, V443, P5403; Honig LS, 2000, AM J MED, V108, P317, DOI 10.1016/S0002-9343(00)00291-6; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; Keller C, 2001, INVEST OPHTH VIS SCI, V42, P476; Kueng-Hitz N, 2000, INVEST OPHTH VIS SCI, V41, P909; LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592; Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1; MIURA Y, 1994, J BIOL CHEM, V269, P29962; Nickells RW, 1999, SURV OPHTHALMOL, V43, pS151, DOI 10.1016/S0039-6257(99)00029-6; OSTROY SE, 1993, INVEST OPHTH VIS SCI, V34, P447; Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182; Pierce EA, 1999, NAT GENET, V22, P248, DOI 10.1038/10305; Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3; Robinson GS, 2001, FASEB J, V15, P1215, DOI 10.1096/fj.00-0598fje; Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3; Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Siren AL, 2001, EUR ARCH PSY CLIN N, V251, P179, DOI 10.1007/s004060170038; Spencer B, 2001, MOL THER, V3, P746, DOI 10.1006/mthe.2001.0307; STEINBERG RH, 1987, INVEST OPHTH VIS SCI, V28, P1888; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; TOUTENBERG H, 1995, EXPT DESIGN MODEL CH; Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0; Wenzel A, 2000, J NEUROSCI, V20, P81, DOI 10.1523/JNEUROSCI.20-01-00081.2000; Wenzel A, 2001, INVEST OPHTH VIS SCI, V42, P1653; Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001; Yamada H, 2001, AM J PATHOL, V159, P1113, DOI 10.1016/S0002-9440(10)61787-7; Zaman K, 1999, J NEUROSCI, V19, P9821	44	421	464	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2002	8	7					718	724		10.1038/nm723	http://dx.doi.org/10.1038/nm723			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12068288				2022-12-27	WOS:000176495200033
J	Xu, J; Kao, SY; Lee, FJS; Song, WH; Jin, LW; Yankner, BA				Xu, J; Kao, SY; Lee, FJS; Song, WH; Jin, LW; Yankner, BA			Dopamine-dependent neurotoxicity of alpha-synuclein: A mechanism for selective neurodegeneration in Parkinson disease	NATURE MEDICINE			English	Article							LEWY BODIES; PATHOGENESIS; DEATH; AGGREGATION; APOPTOSIS; DEMENTIA; MUTATION; SYSTEM; CELLS	The mechanism by which dopaminergic neurons are selectively lost in Parkinson disease (PD) is unknown. Here we show that accumulation of alpha-synuclein in cultured human dopaminergic neurons results in apoptosis that requires endogenous dopamine production and is mediated by reactive oxygen species. In contrast, alpha-synuclein is not toxic in non-dopaminergic human cortical neurons, but rather exhibits neuroprotective activity. Dopamine-dependent neurotoxicity is mediated by 54-83-kD soluble protein complexes that contain alpha-synuclein and 14-3-3 protein, which are elevated selectively in the substantia nigra in PD. Thus, accumulation of soluble alpha-synuclein protein complexes can render endogenous dopamine toxic, suggesting a potential mechanism for the selectivity of neuronal loss in PD.	Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; University of Washington; University of Washington Seattle	Yankner, BA (corresponding author), Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.		Song, Weihong/O-7623-2017; Lee, Frank J.S./D-5899-2017	Song, Weihong/0000-0001-9928-889X; Lee, Frank J.S./0000-0002-5768-3776; Xu, Jin/0000-0001-6617-5311	NATIONAL INSTITUTE ON AGING [R01AG017573] Funding Source: NIH RePORTER; NIA NIH HHS [AG17573] Funding Source: Medline; NINDS NIH HHS [NS03352] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baba M, 1998, AM J PATHOL, V152, P879; BREAKEFIELD XO, P NATL ACAD SCI US, V71, P2530; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; Campbell BCV, 2001, J NEUROCHEM, V76, P87, DOI 10.1046/j.1471-4159.2001.00021.x; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; Drukarch B, 1996, J NEUROSCI, V16, P6038; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; Iwata A, 2001, J BIOL CHEM, V276, P45320, DOI 10.1074/jbc.M103736200; Junn E, 2002, NEUROSCI LETT, V320, P146, DOI 10.1016/S0304-3940(02)00016-2; Kawamoto Y, 2002, J NEUROPATH EXP NEUR, V61, P245, DOI 10.1093/jnen/61.3.245; Kirik D, 2002, J NEUROSCI, V22, P2780, DOI 10.1523/JNEUROSCI.22-07-02780.2002; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tabrizi SJ, 2000, HUM MOL GENET, V9, P2683, DOI 10.1093/hmg/9.18.2683; Tompkins MM, 1997, BRAIN RES, V775, P24, DOI 10.1016/S0006-8993(97)00874-3; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhou WB, 2000, BRAIN RES, V866, P33, DOI 10.1016/S0006-8993(00)02215-0; Zhou WB, 2002, BRAIN RES, V926, P42, DOI 10.1016/S0006-8993(01)03292-9	30	605	631	1	63	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2002	8	6					600	606		10.1038/nm0602-600	http://dx.doi.org/10.1038/nm0602-600			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042811				2022-12-27	WOS:000175907300031
J	Andrews, NC				Andrews, NC			The other physician-scientist problem: Where have all the young girls gone?	NATURE MEDICINE			English	Editorial Material									Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Andrews, NC (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.			Andrews, Nancy/0000-0003-0243-4462				Bradford WD, 1996, ACAD MED, V71, P484, DOI 10.1097/00001888-199605000-00019; Chait R., 2002, HARVARD MAG, V104, P33; MIT, 2002, REP COMM STAT WOM FA; Varki A, 2002, NAT MED, V8, P437, DOI 10.1038/nm0502-437; Wasserman E., 2002, DOOR DREAM CONVERSAT; *WELLC TRUST, 2001, WOM SCI; 1999, MIT FACULTY NEWSLETT, V11	7	68	69	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					439	441		10.1038/nm0502-439	http://dx.doi.org/10.1038/nm0502-439			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984578				2022-12-27	WOS:000175336800016
J	LeBlanc, H; Lawrence, D; Varfolomeev, E; Totpal, K; Morlan, J; Schow, P; Fong, S; Schwall, R; Sinicropi, D; Ashkenazi, A				LeBlanc, H; Lawrence, D; Varfolomeev, E; Totpal, K; Morlan, J; Schow, P; Fong, S; Schwall, R; Sinicropi, D; Ashkenazi, A			Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax	NATURE MEDICINE			English	Article							MICROSATELLITE MUTATOR PHENOTYPE; FLICE-INHIBITORY PROTEIN; CYTOCHROME-C RELEASE; SIGNALING COMPLEX; TRAIL RECEPTOR-2; IN-VIVO; LIGAND; CASPASE-8; CANCER; FADD	The importance of Bax for induction of tumor apoptosis through death receptors remains unclear. Here we show that Bax can be essential for death receptor-mediated apoptosis in cancer cells. Bax-deficient human colon carcinoma cells were resistant to death-receptor ligands, whereas Bax-expressing sister clones were sensitive. Bax was dispensable for apical death-receptor signaling events including caspase-8 activation, but crucial for mitochondrial changes and downstream caspase activation. Treatment of colon tumor cells deficient in DNA mismatch repair with the death-receptor ligand apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selected in vitro or in vivo for refractory subclones with Bax frameshift mutations including deletions at a novel site. Chemotherapeutic agents upregulated expression of the Apo2L/TRAIL receptor DR5 and the Bax homolog Bak in Bax(-/-) cells, and restored Apo2L/TRAIL sensitivity in vitro and in vivo. Thus, Bax mutation in mismatch repair-deficient tumors can cause resistance to death receptor-targeted therapy, but pre-exposure to chemotherapy rescues tumor sensitivity.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Analyt Assay Technol, San Francisco, CA 94080 USA; Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Ashkenazi, A (corresponding author), Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA.		Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Perucho M, 1996, BIOL CHEM, V377, P675; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Pollack IF, 2001, CLIN CANCER RES, V7, P1362; Qin JZ, 2001, NAT MED, V7, P385, DOI 10.1038/86401; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Roy S, 2000, J EXP MED, V192, pF21, DOI 10.1084/jem.192.8.F21; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	41	460	470	1	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2002	8	3					274	281		10.1038/nm0302-274	http://dx.doi.org/10.1038/nm0302-274			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875499				2022-12-27	WOS:000174139500033
J	Air, EL; Strowski, MZ; Benoit, SC; Conarello, SL; Salituro, GM; Guan, XM; Liu, K; Woods, SC; Zhang, BB				Air, EL; Strowski, MZ; Benoit, SC; Conarello, SL; Salituro, GM; Guan, XM; Liu, K; Woods, SC; Zhang, BB			Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity	NATURE MEDICINE			English	Article							ANTIDIABETIC ACTIVITY; SODIUM APPETITE; SENSITIVITY; DISCOVERY; INFUSION; RECEPTOR; BRAIN; PICA; MICE	Obesity and insulin resistance are major risk factors for a number of metabolic disorders, such as type 2 diabetes mellitus(1,2). Insulin has been suggested to function as one of the adiposity signals to the brain for modulation of energy balance. Administration of insulin into the brain reduces food intake and body weight(3-5), and mice with a genetic deletion of neuronal insulin receptors are hyperphagic and obese(6). However, insulin is also an anabolic factor; when administered systemically, pharmacological levels of insulin are associated with body weight gain in patients(7). In this study, we investigated the efficacy and feasibility of small molecule insulin mimetic compounds(8,9) to regulate key parameters of energy homeostasis. Central intracerebroventricular (i.c.v.) administration of an insulin mimetic resulted in a dose-dependent reduction of food intake and body weight in rats, and altered the expression of hypothalamic genes known to regulate food intake and body weight. Oral administration of a mimetic in a mouse model of high-fat diet-induced obesity reduced body weight gain, adiposity and insulin resistance. Thus, insulin mimetics have a unique advantage over insulin in the control of body weight and hold potential as a novel anti-obesity treatment.	Merck Res Labs, Dept Mol Endocrinol & Metab Disorders, Rahway, NJ 07065 USA; Univ Cincinnati, Coll Med, Dept Biomed Sci & Cell Biol, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Dept Neurobiol & Anat, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH USA; Merck Res Labs, Dept Med Chem, Rahway, NJ USA	Merck & Company; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Merck & Company	Zhang, BB (corresponding author), Merck Res Labs, Dept Mol Endocrinol & Metab Disorders, Rahway, NJ 07065 USA.	bei_zhang@merck.com						BAURA GD, 1993, J CLIN INVEST, V92, P1824, DOI 10.1172/JCI116773; BERNSTEIN IL, 1983, BEHAV NEURAL BIOL, V37, P134, DOI 10.1016/S0163-1047(83)91145-7; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; DeFronzo RA, 1999, ANN INTERN MED, V131, P281, DOI 10.7326/0003-4819-131-4-199908170-00008; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Liu K, 2000, J MED CHEM, V43, P3487, DOI 10.1021/jm000285q; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Madden LJ, 1999, BEHAV NEUROSCI, V113, P826, DOI 10.1037/0735-7044.113.4.826; MITCHELL D, 1976, PHYSIOL BEHAV, V17, P691, DOI 10.1016/0031-9384(76)90171-2; Qureshi SA, 2000, J BIOL CHEM, V275, P36590, DOI 10.1074/jbc.M006287200; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; SIPOLS AJ, 1995, DIABETES, V44, P147, DOI 10.2337/diabetes.44.2.147; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STRICKER EM, 1987, BEHAV NEUROSCI, V101, P560, DOI 10.1037/0735-7044.101.4.560; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; WOODS SC, 1979, NATURE, V282, P503, DOI 10.1038/282503a0; Woods SC, 2000, ANNU REV PSYCHOL, V51, P255, DOI 10.1146/annurev.psych.51.1.255; Zhang B, 1999, SCIENCE, V284, P974, DOI 10.1126/science.284.5416.974	22	127	135	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2002	8	2					179	183		10.1038/nm0202-179	http://dx.doi.org/10.1038/nm0202-179			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821903				2022-12-27	WOS:000173600600028
J	Coggins, KG; Latour, A; Nguyen, MS; Audoly, L; Coffman, TM; Koller, BH				Coggins, KG; Latour, A; Nguyen, MS; Audoly, L; Coffman, TM; Koller, BH			Metabolism of PGE(2) by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus	NATURE MEDICINE			English	Letter							FETAL; CLOSURE; BIRTH											CHALLIS JRG, 1976, PROSTAGLANDINS, V11, P1041, DOI 10.1016/0090-6980(76)90011-3; ENSOR CM, 1995, J LIPID MEDIAT CELL, V12, P313, DOI 10.1016/0929-7855(95)00040-W; FRIEDMAN WF, 1976, NEW ENGL J MED, V295, P526, DOI 10.1056/NEJM197609022951003; GITTENBERGERDEGROOT AC, 1985, J AM COLL CARDIOL, V6, P394, DOI 10.1016/S0735-1097(85)80178-9; HEYMANN MA, 1976, NEW ENGL J MED, V295, P530, DOI 10.1056/NEJM197609022951004; Loftin CD, 2001, P NATL ACAD SCI USA, V98, P1059, DOI 10.1073/pnas.031573498; MITCHELL MD, 1980, J REPROD FERTIL, V58, P283, DOI 10.1530/jrf.0.0580283; Nguyen MT, 1997, NATURE, V390, P78, DOI 10.1038/36342; Reese J, 2000, P NATL ACAD SCI USA, V97, P9759, DOI 10.1073/pnas.97.17.9759; Smith GCS, 1998, PHARMACOL REV, V50, P35; SUN FF, 1974, PROSTAGLANDINS, V7, P327, DOI 10.1016/S0090-6980(74)80088-2	11	98	100	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2002	8	2					91	92		10.1038/nm0202-91	http://dx.doi.org/10.1038/nm0202-91			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821873				2022-12-27	WOS:000173600600002
J	Daigle, I; Yousefi, S; Colonna, M; Green, DR; Simon, HU				Daigle, I; Yousefi, S; Colonna, M; Green, DR; Simon, HU			Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils	NATURE MEDICINE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; FAS-MEDIATED APOPTOSIS; COLONY-STIMULATING FACTOR; KINASE C-DELTA; CELL-DEATH; INHIBITORY RECEPTORS; HUMAN EOSINOPHILS; T-LYMPHOCYTES; ACTIVATION; EXPRESSION	Death domain-containing receptors of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family can induce apoptosis upon activation in many cellular systems. We show here that a conserved phosphotyrosine-containing motif within the death domain of these receptors can mediate inhibitory functions. The Src homology domain 2 (SH2)-containing tyrosine phosphatase-1 (SHP-1), SHP-2 and SH2-containing inositol phosphatase (SHIP) bound to this motif in a caspase-independent but cell-dependent manner. We also found that stimulation of death receptors disrupted anti-apoptosis pathways initiated (apt least under certain conditions) by survival factors in neutrophils. In these cells, activation of the tyrosine kinase Lyn, an important anti-apoptotic event, was prevented as a consequence of deaths-receptor stimulation, most likely through association of the receptor with activated SHP-1. Thus, we provide molecular and functional evidence for negative signaling by death receptors.	Univ Bern, Dept Pharmacol, Bern, Switzerland; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Basel Inst Immunol, Basel, Switzerland; La Jolla Inst Allergy & Immunol, San Diego, CA USA	University of Bern; Swiss Institute of Allergy & Asthma Research; La Jolla Institute for Immunology	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, Bern, Switzerland.		Yousefi, Shida/L-9689-2016; Simon, Hans-Uwe/AAU-7410-2020; Green, Douglas R/N-8083-2018; Yousefi, Shida/AAU-7986-2020; Simon, Hans-Uwe/AAU-5079-2020	Yousefi, Shida/0000-0002-9855-4305; Simon, Hans-Uwe/0000-0002-9404-7736; Green, Douglas R/0000-0002-7332-1417; Yousefi, Shida/0000-0002-9855-4305; Colonna, Marco/0000-0001-5222-4987				Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; Cambier JC, 1997, P NATL ACAD SCI USA, V94, P5993, DOI 10.1073/pnas.94.12.5993; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Colonna M, 1997, J EXP MED, V186, P1809, DOI 10.1084/jem.186.11.1809; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Fleming TJ, 1997, J EXP MED, V186, P1307, DOI 10.1084/jem.186.8.1307; Gradl G., 1996, APOPTOSIS, V1, P131, DOI DOI 10.1007/BF01321019; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Guo DQ, 2000, J BIOL CHEM, V275, P11216, DOI 10.1074/jbc.275.15.11216; GUTHMANN MD, 1995, P NATL ACAD SCI USA, V92, P9397, DOI 10.1073/pnas.92.20.9397; HOLLER P, 1989, MAR GEOTECHNOL, V8, P1, DOI 10.1080/10641198909379855; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; Khwaja A, 1999, BLOOD, V94, P291, DOI 10.1182/blood.V94.1.291.413k10_291_301; Landowski TH, 1997, BLOOD, V89, P1854, DOI 10.1182/blood.V89.6.1854; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; Pazdrak K, 1998, J EXP MED, V188, P421, DOI 10.1084/jem.188.3.421; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; Rebel VI, 1999, J EXP MED, V190, P1493, DOI 10.1084/jem.190.10.1493; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Simon HU, 1997, EUR J IMMUNOL, V27, P3536, DOI 10.1002/eji.1830271256; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; Song KM, 2000, J EXP MED, V191, P1095, DOI 10.1084/jem.191.7.1095; SU X, 1995, IMMUNITY, V2, P353, DOI 10.1016/1074-7613(95)90143-4; Thangaraju M, 1999, J BIOL CHEM, V274, P29549, DOI 10.1074/jbc.274.41.29549; THOMBERRY NA, 1992, NATURE, V356, P768; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Wei S, 1996, J IMMUNOL, V157, P5155; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868	43	151	160	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2002	8	1					61	67		10.1038/nm0102-61	http://dx.doi.org/10.1038/nm0102-61			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	507XQ	11786908				2022-12-27	WOS:000173056900032
J	Novak, K				Novak, K			Nano-nukers	NATURE MEDICINE			English	News Item														Novak, Kristine/0000-0001-9314-1803					0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2001	7	12					1290	1290		10.1038/nm1201-1290	http://dx.doi.org/10.1038/nm1201-1290			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726967	Bronze			2022-12-27	WOS:000172610300031
J	Wolf, D; Witte, V; Laffert, B; Blume, K; Stromer, E; Trapp, S; D'Aloja, P; Schurmann, A; Baur, AS				Wolf, D; Witte, V; Laffert, B; Blume, K; Stromer, E; Trapp, S; D'Aloja, P; Schurmann, A; Baur, AS			HIV-1 Nef associated PAK and PI3-kinases stimulate Akt-independent Bad-phosphorylation to induce anti-apoptotic signals	NATURE MEDICINE			English	Article							PROTEIN-KINASE B; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; IMMUNODEFICIENCY VIRUS NEF; MIDDLE-T-ANTIGEN; RHESUS MACAQUES; TYPE-1 NEF; CELLS; COMPLEX; DEATH; GENE	A highly conserved signaling property of Nef proteins encoded by human or simian immunodeficiency virus is the binding and activation of a PAK kinase whose function is unclear. Here we show that Nef-mediated p2l-activated kinase (PAK) activation involves phosphatidylinositol 3-kinase, which acts upstream of PAK and is bound and activated by Nef similar to the manner of Polyoma virus middle T antigen. The Nef-associated phosphatidylinositol-3-PAK complex phosphorylated the pro-apoptotic Bad protein without involving the protein kinase B-Akt kinase, which is generally believed to inactivate Bad by serine phosphorylation. Consequently, Nef, but not a Nef mutant incapable of activating PAK, blocked apoptosis in T cells induced by serum starvation or HIV replication. Nef anti-apoptotic effects are likely a crucial mechanism for viral replication in the host and thus in AIDS pathogenesis.	Univ Erlangen Nurnberg, Dept Dermatol Erlangen, Erlangen, Germany; Rhein Westfal TH Aachen, Inst Pharmakol & Toxikol, D-5100 Aachen, Germany	University of Erlangen Nuremberg; RWTH Aachen University	Baur, AS (corresponding author), Univ Erlangen Nurnberg, Dept Dermatol Erlangen, Erlangen, Germany.	andreas.baur@derma.med.uni-erlangen.de		Schurmann, Annette/0000-0002-4113-4377; d'aloja, paola/0000-0001-5780-0277				Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Arold ST, 2001, TRENDS BIOCHEM SCI, V26, P356, DOI 10.1016/S0968-0004(01)01846-1; Arora VK, 2000, J VIROL, V74, P11081, DOI 10.1128/JVI.74.23.11081-11087.2000; Baur AS, 1997, IMMUNITY, V6, P283, DOI 10.1016/S1074-7613(00)80331-3; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; Boulanger E, 1998, ANN BIOL CLIN-PARIS, V56, P643; BRADLY AD, 2000, BLOOD, V96, P2951; Brown A, 1999, J VIROL, V73, P9899, DOI 10.1128/JVI.73.12.9899-9907.1999; CHOWERS MY, 1994, J VIROL, V68, P2906, DOI 10.1128/JVI.68.5.2906-2914.1994; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Dahl J, 1998, J VIROL, V72, P3221, DOI 10.1128/JVI.72.4.3221-3226.1998; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Fackler OT, 2000, MOL CELL BIOL, V20, P2619, DOI 10.1128/MCB.20.7.2619-2627.2000; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Geffin R, 2000, AIDS RES HUM RETROV, V16, P1855, DOI 10.1089/08892220050195810; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Graziani A, 1996, J BIOL CHEM, V271, P6590, DOI 10.1074/jbc.271.12.6590; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Hinton HJ, 1999, J IMMUNOL, V162, P7002; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Khan IH, 1998, J VIROL, V72, P5820, DOI 10.1128/JVI.72.7.5820-5830.1998; Kim YH, 1999, VIROLOGY, V257, P208, DOI 10.1006/viro.1999.9642; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; Lang SM, 1997, NAT MED, V3, P860, DOI 10.1038/nm0897-860; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; Lu XB, 1996, CURR BIOL, V6, P1677, DOI 10.1016/S0960-9822(02)70792-6; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; Meinl E, 1998, IMMUNOL TODAY, V19, P474, DOI 10.1016/S0167-5699(98)01309-7; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Renkema GH, 2000, FRONT BIOSCI-LANDMRK, V5, pD268, DOI 10.2741/Renkema; Renkema GH, 1999, CURR BIOL, V9, P1407, DOI 10.1016/S0960-9822(00)80086-X; Rudel T, 1998, J IMMUNOL, V160, P7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520; Xu XN, 1999, J EXP MED, V189, P1489, DOI 10.1084/jem.189.9.1489; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5	47	235	245	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2001	7	11					1217	1224		10.1038/nm1101-1217	http://dx.doi.org/10.1038/nm1101-1217			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689886				2022-12-27	WOS:000172054100029
J	Kaushal, S; Amiel, GE; Guleserian, KJ; Shapira, OM; Perry, T; Sutherland, FW; Rabkin, E; Moran, AM; Schoen, FJ; Atala, A; Soker, S; Bischoff, J; Mayer, JE				Kaushal, S; Amiel, GE; Guleserian, KJ; Shapira, OM; Perry, T; Sutherland, FW; Rabkin, E; Moran, AM; Schoen, FJ; Atala, A; Soker, S; Bischoff, J; Mayer, JE			Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo	NATURE MEDICINE			English	Article							NITRIC-OXIDE; STRESS; DIFFERENTIATION; INHIBITION; RELAXATION; EXPRESSION; RETENTION; ADHESION; ARTERIES; GRAFTS	Arterial conduits are increasingly preferred for surgical bypass because of inherent functional properties conferred by arterial endothelial cells, especially nitric oxide production in response to physiologic stimuli. Here we tested whether endothelial progenitor cells (EPCs) can replace arterial endothelial cells and promote patency in tissue-engineered small-diameter blood vessels (4 mm). We isolated EPCs from peripheral blood of sheep, expanded them ex vivo and then seeded them on decellularized porcine iliac vessels. EPC-seeded grafts remained patent for 130 days as a carotid interposition graft in sheep, whereas non-seeded grafts occluded within 15 days. The EPC-explanted grafts exhibited contractile activity and nitric-oxide-mediated vascular relaxation that were similar to native carotid arteries. These results indicate that EPCs can function similarly to arterial endothelial cells and thereby confer longer vascular-graft survival. Due to their unique properties, EPCs might have other general applications for tissue-engineered structures and in treating vascular diseases.	Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Childrens Hosp, Dept Cardiac Surg, Boston, MA 02115 USA; Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA; Childrens Hosp, Dept Urol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Boston Univ, Sch Med, Dept Cardiothorac Surg, Boston, MA 02118 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Boston University	Bischoff, J (corresponding author), Childrens Hosp, Dept Surg, Boston, MA 02115 USA.	joyce.bischoff@tch.harvard.edu	BISCHOFF, JOYCE/K-3354-2019	BISCHOFF, JOYCE/0000-0002-6367-1974; Atala, Anthony/0000-0001-8186-2160; Aikawa, Elena/0000-0001-7835-2135	NHLBI NIH HHS [R01 HL60463, R01 HL60490, R01 HL060490-04, R01 HL060490] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060490, R01HL060463] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; AZUMA H, 1986, BRIT J PHARMACOL, V88, P411, DOI 10.1111/j.1476-5381.1986.tb10218.x; Bhattacharya V, 2000, BLOOD, V95, P581, DOI 10.1182/blood.V95.2.581; Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728; Dardik A, 1999, J VASC SURG, V29, P157, DOI 10.1016/S0741-5214(99)70357-5; DAVIDS L, 1999, TISSUE ENG PROSTHETI, P3; DEUTSCH M, 1999, TISSUE ENG PROSTHETI, P180; Gehling UM, 2000, BLOOD, V95, P3106; Huynh T, 1999, NAT BIOTECHNOL, V17, P1083, DOI 10.1038/15062; Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198; Kalka C, 2000, ANN THORAC SURG, V70, P829, DOI 10.1016/S0003-4975(00)01633-7; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; KEANEY JF, 1995, PROG CARDIOVASC DIS, V38, P129, DOI 10.1016/S0033-0620(05)80003-9; Kraling BM, 1998, IN VITRO CELL DEV-AN, V34, P308; KUBES P, 1994, AM J PHYSIOL, V267, pH931, DOI 10.1152/ajpheart.1994.267.3.H931; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; LUSCHER TF, 1988, NEW ENGL J MED, V319, P462, DOI 10.1056/NEJM198808253190802; Marks DS, 1995, J CLIN INVEST, V96, P2630, DOI 10.1172/JCI118328; MIYATA T, 1991, J SURG RES, V50, P485, DOI 10.1016/0022-4804(91)90029-L; Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; ORTENWALL P, 1988, SURGERY, V103, P199; PEARSON PJ, 1992, ANN THORAC SURG, V54, P1078, DOI 10.1016/0003-4975(92)90073-D; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; QUYYUMI AA, 1995, J CLIN INVEST, V95, P1747, DOI 10.1172/JCI117852; RADOMSKI MW, 1987, BIOCHEM BIOPH RES CO, V148, P1482, DOI 10.1016/S0006-291X(87)80299-1; ROSENMAN JE, 1985, J VASC SURG, V2, P778, DOI 10.1067/mva.1985.avs0020778; Schmidt CE, 2000, BIOMATERIALS, V21, P2215, DOI 10.1016/S0142-9612(00)00148-4; Shapira OM, 1999, CIRCULATION, V100, P322; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Shen BQ, 1997, AM J PHYSIOL-LUNG C, V272, pL1115, DOI 10.1152/ajplung.1997.272.6.L1115; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121; Sullivan S. J., 2000, PRINCIPLES TISSUE EN, P447; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Tu JV, 1997, NEW ENGL J MED, V336, P1500, DOI 10.1056/NEJM199705223362106; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012	41	669	742	4	92	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2001	7	9					1035	1040		10.1038/nm0901-1035	http://dx.doi.org/10.1038/nm0901-1035			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533707	Green Accepted			2022-12-27	WOS:000170853300029
J	Nestle, FO; Banchereau, J; Hart, D				Nestle, FO; Banchereau, J; Hart, D			Dendritic cells: On the move from bench to bedside	NATURE MEDICINE			English	Editorial Material							CANCER-IMMUNOTHERAPY; PROSTATE-CANCER; METASTATIC MALIGNANCIES; PEPTIDE VACCINATION; MELANOMA PATIENTS; ANTIGEN; IMMUNITY; MATURE; INJECTION; VACCINES		Mater Med Res Inst, S Brisbane, Qld, Australia; Univ Zurich, Dept Dermatol, Sch Med, Zurich, Switzerland; Baylor Inst Immunol Res, Dallas, TX USA	Mater Research; University of Zurich; Baylor Scott & White Health	Hart, D (corresponding author), Mater Med Res Inst, S Brisbane, Qld, Australia.							Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BANCHEREAU J, 2000, J EXP MED, V192; Barratt-Boyes SM, 2000, J IMMUNOL, V164, P2487, DOI 10.4049/jimmunol.164.5.2487; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Boczkowski D, 2000, CANCER RES, V60, P1028; CLARK GJ, 1998, DENDRITIC CELLS BIOL, P555; Dhodapkar MV, 2000, J CLIN INVEST, V105, pR9, DOI 10.1172/JCI9051; Dhodapkar MV, 1999, J CLIN INVEST, V104, P173, DOI 10.1172/JCI6909; Dhodapkar MV, 2001, J EXP MED, V193, P233, DOI 10.1084/jem.193.2.233; Eggert AAO, 1999, CANCER RES, V59, P3340; Feuerstein B, 2000, J IMMUNOL METHODS, V245, P15, DOI 10.1016/S0022-1759(00)00269-6; Fong L, 2000, ANNU REV IMMUNOL, V18, P245, DOI 10.1146/annurev.immunol.18.1.245; Fong L, 2001, J IMMUNOL, V166, P4254, DOI 10.4049/jimmunol.166.6.4254; Gilboa E, 1998, CANCER IMMUNOL IMMUN, V46, P82, DOI 10.1007/s002620050465; HART DN, 2000, LEUCOCYTE TYPING, V7; Hart DNJ, 1999, IMMUNOL CELL BIOL, V77, P451, DOI 10.1046/j.1440-1711.1999.00859.x; Heiser A, 2001, CANCER RES, V61, P3388; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Kammula US, 2000, J NATL CANCER I, V92, P1336, DOI 10.1093/jnci/92.16.1336; Kugler A, 2000, NAT MED, V6, P332, DOI 10.1038/73193; Lodge PA, 2000, CANCER RES, V60, P829; Lotze MT, 1997, ADV EXP MED BIOL, V417, P551; Ludewig B, 2000, J EXP MED, V191, P795, DOI 10.1084/jem.191.5.795; Mackensen A, 2000, CANCER IMMUNOL IMMUN, V49, P152, DOI 10.1007/s002620050614; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; MCGUCKIN MA, 2000, LEUCOCYTE TYPING, V7; Morse MA, 1999, CLIN CANCER RES, V5, P1331; Morse MA, 1999, CANCER RES, V59, P56; Murphy GP, 1999, PROSTATE, V38, P73; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Panelli MC, 2000, J IMMUNOL, V164, P495, DOI 10.4049/jimmunol.164.1.495; Randolph GJ, 1999, IMMUNITY, V11, P753, DOI 10.1016/S1074-7613(00)80149-1; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Romero P, 1998, MOL MED TODAY, V4, P305, DOI 10.1016/S1357-4310(98)01280-5; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; Serody JS, 2000, J IMMUNOL, V164, P4961, DOI 10.4049/jimmunol.164.9.4961; Small EJ, 2000, J CLIN ONCOL, V18, P3894, DOI 10.1200/JCO.2000.18.23.3894; Thomas R, 1999, MELANOMA RES, V9, P474, DOI 10.1097/00008390-199910000-00007; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Timmerman JM, 1999, ANNU REV MED, V50, P507; Toes REM, 1998, J IMMUNOL, V160, P4449; Vonderheide RH, 1999, IMMUNITY, V10, P673, DOI 10.1016/S1074-7613(00)80066-7; Young JW, 1996, J EXP MED, V183, P7, DOI 10.1084/jem.183.1.7	44	242	269	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					761	765		10.1038/89863	http://dx.doi.org/10.1038/89863			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433329				2022-12-27	WOS:000169808600014
J	Feuerer, M; Beckhove, P; Bai, LH; Solomayer, EF; Bastert, G; Diel, IJ; Pedain, C; Oberniedermayr, M; Schirrmacher, V; Umansky, V				Feuerer, M; Beckhove, P; Bai, LH; Solomayer, EF; Bastert, G; Diel, IJ; Pedain, C; Oberniedermayr, M; Schirrmacher, V; Umansky, V			Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow	NATURE MEDICINE			English	Article							LYMPHOCYTES; BREAST; PEPTIDE; ANTIGEN; IDENTIFICATION; VACCINATION; ACTIVATION; MATURATION; IMMUNITY; PROTEIN	In an analysis of 84 primary-operated breast cancer patients and 11 healthy donors, we found that the bone marrow of most patients contained memory T cells with specificity for tumor-associated antigens. Patients' bone marrow and peripheral blood contained CD8(+) T cells that specifically bound HLA/peptide tetramers. In short-term culture with autologous dendritic cells pre-pulsed with tumor lysates, patients' memory T cells from bone marrow (but not peripheral blood) could be specifically reactivated to interferon-gamma -producing and cytotoxic effector cells. A single transfer of restimulated bone-marrow T cells into NOD/SCID mice caused regression of autologous tumor xenotransplants associated with infiltration by human T cells and tumor-cell apoptosis and necrosis. T cells from peripheral blood showed much lower anti-tumor reactivity. Our findings reveal an innate, specific recognition of breast cancer antigens and point to a possible novel cancer therapy using patients' bone-marrow-derived memory T cells.	German Canc Res Ctr, Tumor Immunol Program, Div Cellular Immunol, D-6900 Heidelberg, Germany; Univ Hosp, Dept Obstet & Gynecol, Heidelberg, Germany; Univ Hosp, Dept Obstet & Gynecol, Giessen, Germany; St Josephs Hosp, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Umansky, V (corresponding author), German Canc Res Ctr, Tumor Immunol Program, Div Cellular Immunol, D-6900 Heidelberg, Germany.	v.umansky@dkfz-heidelberg.de						BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Briskin M, 1997, AM J PATHOL, V151, P97; Brossart P, 1996, J EXP MED, V183, P2449, DOI 10.1084/jem.183.6.2449; Brossart P, 1999, BLOOD, V93, P4309, DOI 10.1182/blood.V93.12.4309.412k19_4309_4317; Diel IJ, 1996, JNCI-J NATL CANCER I, V88, P1652, DOI 10.1093/jnci/88.22.1652; Disis ML, 1999, CLIN CANCER RES, V5, P1289; ERLE DJ, 1994, J IMMUNOL, V153, P517; Feuerer M, 2001, INT J CANCER, V92, P96, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1152>3.0.CO;2-Q; FINN OJ, 1995, IMMUNOL REV, V145, P61, DOI 10.1111/j.1600-065X.1995.tb00077.x; FISK B, 1995, J EXP MED, V181, P2109, DOI 10.1084/jem.181.6.2109; Garcia S, 1999, IMMUNITY, V11, P163, DOI 10.1016/S1074-7613(00)80091-6; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; KHAZAIE K, 1994, P NATL ACAD SCI USA, V91, P7430, DOI 10.1073/pnas.91.16.7430; Kugler A, 2000, NAT MED, V6, P332, DOI 10.1038/73193; Kuroda MJ, 2000, BLOOD, V96, P1474, DOI 10.1182/blood.V96.4.1474.h8001474_1474_1479; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; Lanzavecchia A, 2000, CURR OPIN IMMUNOL, V12, P92, DOI 10.1016/S0952-7915(99)00056-4; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Muerkoster S, 1998, CLIN CANCER RES, V4, P3095; Muller M, 1998, CANCER RES, V58, P5439; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Pantel K, 1999, JNCI-J NATL CANCER I, V91, P1113, DOI 10.1093/jnci/91.13.1113; PAPAYANNOPOULOU T, 1997, P NATL ACAD SCI USA, V92, P9647; Paramithiotis E, 1997, P NATL ACAD SCI USA, V94, P208, DOI 10.1073/pnas.94.1.208; Price PW, 1999, EUR J IMMUNOL, V29, P1051, DOI 10.1002/(SICI)1521-4141(199903)29:03<1051::AID-IMMU1051>3.0.CO;2-Y; ROSENBERG SA, 1993, JNCI-J NATL CANCER I, V85, P622, DOI 10.1093/jnci/85.8.622; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; SCHIRRMACHER V, 1993, IMMUNOL CELL BIOL, V71, P311, DOI 10.1038/icb.1993.36; Schuler G, 1999, DENDRITIC CELLS BIOL, P515; Shimizu K, 1999, P NATL ACAD SCI USA, V96, P2268, DOI 10.1073/pnas.96.5.2268; SHULTZ LD, 1995, J IMMUNOL, V154, P180; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; Slavin RG, 1996, PEDIATR PULM, V21, P1, DOI 10.1002/1099-0496(199601)21:1<1::AID-PPUL1950210102>3.0.CO;2-K; Slifka MK, 1997, BLOOD, V90, P2103, DOI 10.1182/blood.V90.5.2103; Sprent J, 1997, IMMUNOL REV, V156, P79, DOI 10.1111/j.1600-065X.1997.tb00960.x; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; TSOMIDES TJ, 1994, J EXP MED, V180, P1283, DOI 10.1084/jem.180.4.1283; Valmori D, 2000, CANCER RES, V60, P4499; Veiga-Fernandes H, 2000, NAT IMMUNOL, V1, P47, DOI 10.1038/76907; Visonneau S, 1998, AM J PATHOL, V152, P1299; Zinkernagel RM, 1996, ANNU REV IMMUNOL, V14, P333, DOI 10.1146/annurev.immunol.14.1.333	45	242	250	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2001	7	4					452	458		10.1038/86523	http://dx.doi.org/10.1038/86523			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283672				2022-12-27	WOS:000167960500040
J	Kim, MS; Kwon, HJ; Lee, YM; Baek, JH; Jang, JE; Lee, SW; Moon, EJ; Kim, HS; Lee, SK; Chung, HY; Kim, CW; Kim, KW				Kim, MS; Kwon, HJ; Lee, YM; Baek, JH; Jang, JE; Lee, SW; Moon, EJ; Kim, HS; Lee, SK; Chung, HY; Kim, CW; Kim, KW			Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CELL-PROLIFERATION; DNA METHYLATION; HYPOXIA MARKER; MESSENGER-RNA; UP-REGULATION; APOPTOSIS; P53; HIF-1-ALPHA; EXPRESSION	Low oxygen tension influences tumor progression by enhancing angiogenesis; and histone deacetylases (HDAC) are implicated in alteration of chromatin assembly and tumorigenesis. Here we show induction of HDAC under hypoxia and elucidate a role for HDAC in the regulation of hypoxia-induced angiogenesis. Overexpressed wild-type HDAC1 downregulated expression of p53 and von Hippel-Lindau tumor suppressor genes and stimulated angiogenesis of human endothelial cells. A specific HDAC inhibitor, trichostatin A (TSA), upregulated p53 and von Hippel-Lindau expression and downregulated hypoxia-inducible factor-1 alpha and vascular endothelial growth factor. TSA also blocked angiogenesis in vitro and in vivo. TSA specifically inhibited hypoxia-induced angiogenesis in the Lewis lung carcinoma model. These results indicate that hypoxia enhances HDAC function and that HDAC is closely involved in angiogenesis through suppression of hypoxia-responsive tumor suppressor genes.	Seoul Natl Univ, Coll Pharm, Angiogenesis Res Lab, Seoul, South Korea; Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea; Pusan Natl Univ, Dept Pharm, Pusan 609735, South Korea; Sejong Univ, Dept Biosci & Biotechnol, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 151, South Korea	Seoul National University (SNU); Pusan National University; Pusan National University; Sejong University; Seoul National University (SNU)	Kim, KW (corresponding author), Seoul Natl Univ, Coll Pharm, Angiogenesis Res Lab, Seoul, South Korea.	qwonkim@plaza.snu.ac.kr	권, 호정/AAS-3642-2021; Kim, Kyu Won/AAJ-7213-2020; Kim, Chul-Woo/F-7008-2011					Baek JH, 2000, ONCOGENE, V19, P4621, DOI 10.1038/sj.onc.1203814; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Conrad KP, 1997, AM J REPROD IMMUNOL, V37, P240; Dangond F, 1998, BIOCHEM BIOPH RES CO, V247, P833, DOI 10.1006/bbrc.1998.8891; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Kim KW, 1998, CANCER RES, V58, P348; Kim MS, 2000, INT J CANCER, V87, P269, DOI 10.1002/1097-0215(20000715)87:2&lt;269::AID-IJC19&gt;3.0.CO;2-W; Kosugi H, 1999, LEUKEMIA, V13, P1316, DOI 10.1038/sj.leu.2401508; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Krieg M, 1998, BLOOD, V92, P3388, DOI 10.1182/blood.V92.9.3388.421a09_3388_3393; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lee YM, 2001, DEV DYNAM, V220, P175, DOI 10.1002/1097-0177(20010201)220:2<175::AID-DVDY1101>3.0.CO;2-F; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; MEININGER CJ, 1988, AM J PHYSIOL, V255, pH554, DOI 10.1152/ajpheart.1988.255.3.H554; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; PASSANITI A, 1992, LAB INVEST, V67, P519; Prowse AH, 1997, AM J HUM GENET, V60, P765; Ravi R, 2000, GENE DEV, V14, P34; Royds JA, 1998, J CLIN PATHOL-MOL PA, V51, P55; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Schroeder M, 1997, BIOCHEM BIOPH RES CO, V235, P403, DOI 10.1006/bbrc.1997.6796; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; Stratmann R, 1997, J NEUROPATH EXP NEUR, V56, P1242, DOI 10.1097/00005072-199711000-00009; Varia MA, 1998, GYNECOL ONCOL, V71, P270, DOI 10.1006/gyno.1998.5163; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; Wood SM, 1997, INT J BIOCHEM CELL B, V29, P1419, DOI 10.1016/S1357-2725(97)00129-5; Yamamoto H, 1996, CANCER RES, V56, P3605; Zhong H, 1999, CANCER RES, V59, P5830	45	554	598	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2001	7	4					437	443		10.1038/86507	http://dx.doi.org/10.1038/86507			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283670				2022-12-27	WOS:000167960500038
J	Pabst, T; Mueller, BU; Harakawa, N; Schoch, C; Haferlach, T; Behre, G; Hiddemann, W; Zhang, DE; Tenen, DG				Pabst, T; Mueller, BU; Harakawa, N; Schoch, C; Haferlach, T; Behre, G; Hiddemann, W; Zhang, DE; Tenen, DG			AML1-ETO downregulates the granulocytic differentiation factor C/EBP alpha in t(8;21) myeloid leukemia	NATURE MEDICINE			English	Article							ENHANCER-BINDING-PROTEIN; STIMULATING FACTOR-RECEPTOR; ACUTE MYELOGENOUS LEUKEMIA; FUSION PROTEIN; GENE PROMOTER; TRANSCRIPTION FACTORS; MESSENGER-RNA; EXPRESSION; CELLS; AML1/ETO	The transcription factor CCAAT/enhancer binding protein alpha, or C/EBP alpha, encoded by the CEBPA gene, is crucial for the differentiation of granulocytes. Conditional expression of C/EBP alpha triggers neutrophilic differentiation, and Cebpa knockout mice exhibit an early block in maturation. Dominant-negative mutations of CEBPA have been found in some patients with acute myeloid leukemia (AML), but not in AML with the t(8;21) translocation which gives rise to the fusion gene RUNX1-CBF2T1 (also known as AML1-ETO) encoding the AML1-ETO fusion protein. RUNX1-CBF2T1 positive-AML blasts had eight-fold fewer CEBPA RNA levels and undetectable C/EBP alpha protein levels compared with other subgroups of AML patients. Conditional expression of RUNX7-CBF2T7 in U937 cells downregulated CEBPA mRNA, protein and DNA binding activity. AML1-ETO appears to suppress C/EBP alpha expression indirectly by inhibiting positive autoregulation of the CEBPA promoter. Conditional expression of C/EBP alpha in AML1-ETO-positive Kasumi-1 cells results in neutrophilic differentiation. We suggest that restoring C/EBP alpha expression will have therapeutic implications in RUNX1-CBF2T1-positive leukemias.	Harvard Univ, Sch Med, Harvard Inst Med, Div Hematol Oncol, Boston, MA 02115 USA; Natl Res Ctr Environm & Hlth, Dept Med 3, Grosshadern, Munich, Germany; Natl Res Ctr Environm & Hlth, Clin Cooperat Grp Acute Myeloid Leukemia, Munich, Germany; Scripps Res Inst, La Jolla, CA USA	Harvard University; Harvard Medical School; University of Munich; University of Munich; Scripps Research Institute	Tenen, DG (corresponding author), Harvard Univ, Sch Med, Harvard Inst Med, Div Hematol Oncol, Boston, MA 02115 USA.			Tenen, Daniel/0000-0002-6423-3888	NATIONAL CANCER INSTITUTE [P01CA072009] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056745] Funding Source: NIH RePORTER; NCI NIH HHS [CA72009] Funding Source: Medline; NHLBI NIH HHS [HL56745] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASOU H, 1991, BLOOD, V77, P2031; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; ERICKSON P, 1992, BLOOD, V80, P1825; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Frank R, 1995, ONCOGENE, V11, P2667; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HUETTNER C, 1995, AM J PATHOL, V146, P317; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3467, DOI 10.1073/pnas.95.7.3467; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, BLOOD, V81, P883; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Rhoades KL, 2000, BLOOD, V96, P2108; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; Schwaller J, 1997, BRIT J HAEMATOL, V99, P896, DOI 10.1046/j.1365-2141.1997.4863289.x; SCOTT LM, 1992, BLOOD, V80, P1725; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Swart GWM, 1997, BIOL CHEM, V378, P373, DOI 10.1515/bchm.1997.378.5.373; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	45	367	383	1	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2001	7	4					444	451		10.1038/86515	http://dx.doi.org/10.1038/86515			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283671				2022-12-27	WOS:000167960500039
J	Nicole, O; Docagne, F; Ali, C; Margaill, I; Carmeliet, P; MacKenzie, ET; Vivien, D; Buisson, A				Nicole, O; Docagne, F; Ali, C; Margaill, I; Carmeliet, P; MacKenzie, ET; Vivien, D; Buisson, A			The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling	NATURE MEDICINE			English	Article							GROWTH; INJURY	Tissue-plasminogen activator (t-PA) is now available for the treatment of thrombo-embolic stroke but adverse effects have been reported in some patients, particularly hemorrhaging. In contrast, the results of animal studies have indicated that t-PA could increase neuronal damage after focal cerebral ischemia. Here we report for the first time that t-PA potentiates signaling mediated by glutamatergic receptors by modifying the properties of the N-methyl-D-aspartate (NMDA) receptor. When depolarized, cortical neurons release bio-active t-PA that interacts with and cleaves the NR1 subunit of the NMDA receptor. Moreover, the treatment with recombinant t-PA leads to a 37% increase in NMDA-stimulated fura-2 fluorescence, which may reflect an increased NMDA-receptor function. These results were confirmed in vivo by the intrastriatal injection of recombinant-PA, which potentiated the excitotoxic lesions induced by NMDA. These data provide insight into the regulation of NMDA-receptor-mediated signaling and could initiate therapeutic strategies to improve the efficacy of t-PA treatment in man.	Univ Caen, CNRS, UMR 6551, F-14074 Caen, France; CEA Univ LRA10V, UPRES EA 2609, F-14074 Caen, France; Univ Paris 05, Fac Sci Pharmaceut & Biol, Lab Pharmacol, F-75006 Paris, France; Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium	Centre National de la Recherche Scientifique (CNRS); Universite de Caen Normandie; CEA; UDICE-French Research Universities; Universite Paris Cite	Buisson, A (corresponding author), Univ Caen, CNRS, UMR 6551, Bd H Becquerel,Cyeron BP 5229, F-14074 Caen, France.	d.vivien@neuro.unicaen.fr; a.buisson@neuro.unicaen.fr	buisson, alain/AAI-8218-2020; Nicole, Olivier/AAZ-2865-2020; Margaill, Isabelle/ABA-4362-2020; Mackenzie, Eric Thomson/L-1938-2015; Docagne, Fabian/S-8308-2018; Carmeliet, Peter/AAQ-5140-2020	buisson, alain/0000-0002-4281-7911; Nicole, Olivier/0000-0001-9981-1820; Margaill, Isabelle/0000-0002-7941-6644; Carmeliet, Peter/0000-0001-7961-1821; Ali, Carine/0000-0001-8007-7910; MacKenzie, Eric T/0000-0003-1057-7033; Docagne, Fabian/0000-0003-1745-0625; VIVIEN, DENIS/0000-0002-7636-2185				Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; Buisson A, 1998, FASEB J, V12, P1683, DOI 10.1096/fasebj.12.15.1683; CAMRELIET P, 1997, AM J PHYSIOL, V273, pH2091; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; FRIEDMAN GC, 1994, DEV BRAIN RES, V81, P41, DOI 10.1016/0165-3806(94)90066-3; Gils A, 1997, J BIOL CHEM, V272, P12662, DOI 10.1074/jbc.272.19.12662; Gualandris A, 1996, J NEUROSCI, V16, P2220; Hirai H, 1996, P NATL ACAD SCI USA, V93, P6031, DOI 10.1073/pnas.93.12.6031; Kim YH, 1999, SCIENCE, V284, P647, DOI 10.1126/science.284.5414.647; Kirkegaard T, 1999, EUR J BIOCHEM, V263, P577, DOI 10.1046/j.1432-1327.1999.00545.x; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LIJNEN HR, 1980, J BIOL CHEM, V255, P214; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MORI H, 1995, NEUROPHARMACOLOGY, V34, P1219, DOI 10.1016/0028-3908(95)00109-J; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Parmer RJ, 1997, J BIOL CHEM, V272, P1976, DOI 10.1074/jbc.272.3.1976; Paxinos G., 2004, J CHEM INF MODEL, V5th; Rogove AD, 1998, CURR BIOL, V8, P19, DOI 10.1016/S0960-9822(98)70016-8; Rose K, 1993, IN VITRO BIOL METHOD, P46; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; Sattler R, 1998, J NEUROCHEM, V71, P2349; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Verderio C, 1999, J NEUROSCI, V19, P6723, DOI 10.1523/JNEUROSCI.19-16-06723.1999; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228	27	577	608	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					59	64		10.1038/83358	http://dx.doi.org/10.1038/83358			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135617				2022-12-27	WOS:000166243100036
J	Young, DB				Young, DB			A post-genomic perspective	NATURE MEDICINE			English	Editorial Material							MYCOBACTERIUM-TUBERCULOSIS; MICROARRAY	The complete genome sequence of Mycobacterium tuberculosis, along with novel genetic tools, provides the foundation for a new era of post-genomic research. The challenge is now to translate these opportunities into an improved understanding of the complex biology of tuberculosis infection.	Univ London Imperial Coll Sci Technol & Med, London W2 1PG, England	Imperial College London	Young, DB (corresponding author), Univ London Imperial Coll Sci Technol & Med, London W2 1PG, England.							Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Brosch R, 2000, RES MICROBIOL, V151, P135, DOI 10.1016/S0923-2508(00)00117-0; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Dillon DC, 1999, INFECT IMMUN, V67, P2941, DOI 10.1128/IAI.67.6.2941-2950.1999; Duncan K, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P297; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x; Hatfull GF, 2000, MOL GENETICS MYCOBAC; Ho TBL, 2000, YEAST, V17, P272, DOI 10.1002/1097-0061(200012)17:4&lt;272::AID-YEA48&gt;3.0.CO;2-2; Jungblut PR, 1999, MOL MICROBIOL, V33, P1103, DOI 10.1046/j.1365-2958.1999.01549.x; MCCUNE RM, 1966, J EXP MED, V123, P445, DOI 10.1084/jem.123.3.445; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; Musser JM, 2000, GENETICS, V155, P7; Opie EL, 1927, ARCH PATHOL LAB MED, V4, P1; Ramakrishnan L, 2000, SCIENCE, V288, P1436, DOI 10.1126/science.288.5470.1436; REES RJ, 1961, BRIT J EXP PATHOL, V42, P83; Rich A., 1951, PATHOGENESIS TUBERCU, V2nd; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; WALLACE JG, 1961, AM REV RESPIR DIS, V83, P866; WAYNE LG, 1982, INFECT IMMUN, V37, P1042, DOI 10.1128/IAI.37.3.1042-1049.1982; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833	21	15	16	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					11	13		10.1038/83250	http://dx.doi.org/10.1038/83250			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135599				2022-12-27	WOS:000166243100016
J	Lin, HZ; Yang, SQ; Chuckaree, C; Kuhajda, F; Ronnet, G; Diehl, AM				Lin, HZ; Yang, SQ; Chuckaree, C; Kuhajda, F; Ronnet, G; Diehl, AM			Metformin reverses fatty liver disease in obese, leptin-deficient mice	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; UNCOUPLING PROTEIN-2 EXPRESSION; DEPENDENT DIABETES-MELLITUS; INDUCED INSULIN-RESISTANCE; CULTURED RAT HEPATOCYTES; ADIPOSE-TISSUE; CELLULAR MECHANISMS; NUCLEAR SREBP-1C; ZUCKER RATS; GLUCOSE	There is no known treatment for fatty liver, a ubiquitous cause of chronic liver disease. However, because it is associated with hyperinsulinemia and insulin-resistance, insulin-sensitizing agents might be beneficial. To evaluate this possibility, insulin-resistant ob/ob mice with fatty livers were treated with metformin, an agent that improves hepatic insulin-resistance. Metformin improved fatty liver disease, reversing hepatomegaly, steatosis and aminotransferase abnormalities. The therapeutic mechanism likely involves inhibited hepatic expression of tumor necrosis factor (TNF) alpha and TNF-inducible factors that promote hepatic lipid accumulation and ATP depletion. These findings suggest a mechanism of action for metformin and identify novel therapeutic targets in insulin-resistant states.	Dept Med, Baltimore, MD 21224 USA; Dept Pathol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Dept Neurosci & Neurol, Baltimore, MD 21205 USA	Johns Hopkins University	Diehl, AM (corresponding author), Dept Med, Bldg AA,Room 154-A,4940 Eastern Ave, Baltimore, MD 21224 USA.							Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; Campfield LA, 1996, HORM METAB RES, V28, P619, DOI 10.1055/s-2007-979867; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cortez-Pinto H, 1999, GASTROENTEROLOGY, V116, P1184, DOI 10.1016/S0016-5085(99)70022-3; Cortez-Pinto H, 1998, BIOCHEM BIOPH RES CO, V251, P313, DOI 10.1006/bbrc.1998.9473; Cusi K, 1996, J CLIN ENDOCR METAB, V81, P4059, DOI 10.1210/jc.81.11.4059; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DEFRONZO RA, 1991, J CLIN ENDOCR METAB, V73, P1294, DOI 10.1210/jcem-73-6-1294; ELHASSAN AY, 1992, BRIT J RADIOL, V65, P774, DOI 10.1259/0007-1285-65-777-774; GIEHL AM, 1994, AM J PHYSIOL, V267, pG552; HOLLENBECK CB, 1991, DIABETES METAB, V17, P483; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HUUPPONEN R, 1993, RES COMMUN CHEM PATH, V79, P219; Kushi A, 1998, P NATL ACAD SCI USA, V95, P15659, DOI 10.1073/pnas.95.26.15659; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; Lawler JF, 1998, J BIOL CHEM, V273, P5053, DOI 10.1074/jbc.273.9.5053; Marceau P, 1999, J CLIN ENDOCR METAB, V84, P1513, DOI 10.1210/jc.84.5.1513; Marchesini G, 1999, AM J MED, V107, P450, DOI 10.1016/S0002-9343(99)00271-5; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; MCCLAIN C, 1993, SEMIN LIVER DIS, V13, P170, DOI 10.1055/s-2007-1007347; MEGLASSON MD, 1993, J PHARMACOL EXP THER, V266, P1454; MELIN B, 1990, METABOLISM, V39, P1089, DOI 10.1016/0026-0495(90)90171-8; NI N, 1994, HEPATOLOGY, V19, P182; Paolisso G, 1998, EUR J CLIN INVEST, V28, P441, DOI 10.1046/j.1365-2362.1998.00304.x; PERRIELLO G, 1994, DIABETES, V43, P920, DOI 10.2337/diabetes.43.7.920; Pizer ES, 2000, CANCER RES, V60, P213; PURRELLO F, 1988, DIABETOLOGIA, V31, P385, DOI 10.1007/BF02341508; Ricquier D, 1998, BIOCHEM SOC T, V26, P120, DOI 10.1042/bst0260120; ROURU J, 1992, LIFE SCI, V50, P1813, DOI 10.1016/0024-3205(92)90066-X; Sheth SG, 1997, ANN INTERN MED, V126, P137, DOI 10.7326/0003-4819-126-2-199701150-00008; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shulman GI, 1999, AM J CARDIOL, V84, p3J; Solomon SS, 1997, HORM METAB RES, V29, P379, DOI 10.1055/s-2007-979059; STUMVOLL M, 1995, NEW ENGL J MED, V333, P550, DOI 10.1056/NEJM199508313330903; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Wiernsperger NF, 1999, DRUGS, V58, P31, DOI 10.2165/00003495-199958001-00009; Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557; Yin M, 1999, GASTROENTEROLOGY, V117, P942, DOI 10.1016/S0016-5085(99)70354-9; ZAIBI MS, 1995, BIOCHEM PHARMACOL, V50, P775, DOI 10.1016/0006-2952(95)00199-A	43	525	556	3	40	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					998	1003		10.1038/79697	http://dx.doi.org/10.1038/79697			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973319				2022-12-27	WOS:000089190500031
J	Novak, K; MacFarlane, J; Gavin, K				Novak, K; MacFarlane, J; Gavin, K			Research news	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					979	979		10.1038/79673	http://dx.doi.org/10.1038/79673			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973315				2022-12-27	WOS:000089190500027
J	Akbari, O; Freeman, GJ; Meyer, EH; Greenfield, EA; Chang, TT; Sharpe, AH; Berry, G; DeKruyff, RH; Umetsu, DT				Akbari, O; Freeman, GJ; Meyer, EH; Greenfield, EA; Chang, TT; Sharpe, AH; Berry, G; DeKruyff, RH; Umetsu, DT			Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; HEAT-KILLED LISTERIA; MOUSE BONE-MARROW; DENDRITIC CELLS; IN-VIVO; IMMUNE-RESPONSES; CO-STIMULATION; MOLECULE ICOS; INFLAMMATION; EXPRESSION	Asthma is caused by T-helper cell 2 (Th2)-driven immune responses, but the immunological mechanisms that protect against asthma development are poorly understood. T-cell tolerance, induced by respiratory exposure to allergen, can inhibit the development of airway hyperreactivity (AHR), a cardinal feature of asthma, and we show here that regulatory T (T-R) cells can mediate this protective effect. Mature pulmonary dendritic cells in the bronchial lymph nodes of mice exposed to respiratory allergen induced the development of TR cells, in a process that required T-cell costimulation via the inducible costimulator (ICOS)-ICOS-ligand pathway. The TR cells produced IL-10, and had potent inhibitory activity; when adoptively transferred into sensitized mice, TR cells blocked the development of AHR. Both the development and the inhibitory function of regulatory cells were dependent on the presence of IL-10 and on ICOS-ICOS-ligand interactions. These studies demonstrate that TR cells and the ICOS-ICOS-ligand signaling pathway are critically involved in respiratory tolerance and in downregulating pulmonary inflammation in asthma.	Stanford Univ, Dept Pediat, Sch Med, Div Immunol & Allergy, Stanford, CA 94305 USA; Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Div Immunol Res, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Stanford University; Stanford University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Umetsu, DT (corresponding author), Stanford Univ, Dept Pediat, Sch Med, Div Immunol & Allergy, Stanford, CA 94305 USA.	umetsu@stanford.edu	Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616; Berry, Gerald/0000-0002-6176-2629	NATIONAL CANCER INSTITUTE [R01CA084500] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007290, R01AI038310, P01AI039671, R21AI024571, R01AI026322, R37AI038310, R01AI024571] Funding Source: NIH RePORTER; NCI NIH HHS [CA84500] Funding Source: Medline; NHLBI NIH HHS [R01HL62348] Funding Source: Medline; NIAID NIH HHS [AI24571, AI26322, AI38310, AI39671, T32 AI007290] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P1022; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; COFFMAN RL, 1991, RES IMMUNOL, V142, P7, DOI 10.1016/0923-2494(91)90002-Z; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; DING L, 1993, J IMMUNOL, V151, P1224; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gonzalo JA, 2001, NAT IMMUNOL, V2, P597, DOI 10.1038/89739; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Hansen G, 2000, J IMMUNOL, V164, P223, DOI 10.4049/jimmunol.164.1.223; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Huang FP, 2000, J EXP MED, V191, P435, DOI 10.1084/jem.191.3.435; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Kim TS, 1997, J IMMUNOL, V158, P4137; Levings MK, 2000, J ALLERGY CLIN IMMUN, V106, pS109, DOI 10.1067/mai.2000.106635; Ling V, 2000, J IMMUNOL, V164, P1653, DOI 10.4049/jimmunol.164.4.1653; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Mages HW, 2000, EUR J IMMUNOL, V30, P1040, DOI 10.1002/(SICI)1521-4141(200004)30:4<1040::AID-IMMU1040>3.0.CO;2-6; Makela MJ, 2000, P NATL ACAD SCI USA, V97, P6007, DOI 10.1073/pnas.100118997; MALONEY DG, 1985, HYBRIDOMA, V4, P191, DOI 10.1089/hyb.1985.4.191; MARRACK P, 1983, J EXP MED, V158, P1635, DOI 10.1084/jem.158.5.1635; McAdam AJ, 2000, J IMMUNOL, V165, P5035, DOI 10.4049/jimmunol.165.9.5035; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nakajima A, 1997, INT IMMUNOL, V9, P637, DOI 10.1093/intimm/9.5.637; Oro AS, 1996, J ALLERGY CLIN IMMUN, V97, P1402, DOI 10.1016/S0091-6749(96)70210-5; Randolph DA, 1999, J IMMUNOL, V162, P2375; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Roncarolo MG, 2001, J EXP MED, V193, pF5, DOI 10.1084/jem.193.2.F5; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; SANDER B, 1991, IMMUNOL REV, V119, P65, DOI 10.1111/j.1600-065X.1991.tb00578.x; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; SCHEICHER C, 1992, J IMMUNOL METHODS, V154, P253, DOI 10.1016/0022-1759(92)90199-4; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; STOCKINGER B, 1994, INT IMMUNOL, V6, P247, DOI 10.1093/intimm/6.2.247; Swallow MM, 1999, IMMUNITY, V11, P423, DOI 10.1016/S1074-7613(00)80117-X; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Umetsu DT, 1997, J ALLERGY CLIN IMMUN, V100, P1, DOI 10.1016/S0091-6749(97)70186-6; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Yeung VP, 1998, J IMMUNOL, V161, P4146; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582	59	614	658	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2002	8	9					1024	1032		10.1038/nm745	http://dx.doi.org/10.1038/nm745			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12145647				2022-12-27	WOS:000177757900039
J	Levy, BD; DeSanctis, GT; Devchand, PR; Kim, E; Ackerman, K; Schmidt, BA; Szczeklik, W; Drazen, JM; Serhan, CN				Levy, BD; DeSanctis, GT; Devchand, PR; Kim, E; Ackerman, K; Schmidt, BA; Szczeklik, W; Drazen, JM; Serhan, CN			Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4)	NATURE MEDICINE			English	Article							ASPIRIN-TRIGGERED 15-EPI-LXA(4); BRONCHIAL HYPERRESPONSIVENESS; LEUKOTRIENE B-4; CUTTING EDGE; EOSINOPHILS; RESPONSES; RECEPTOR; ASTHMA; GENERATE; PROTEIN	The prevalence of asthma continues to increase and its optimal treatment remains a challenge. Here, we investigated the actions of lipoxin A(4) (LXA(4)) and its leukocyte receptor in pulmonary inflammation using a murine model of asthma. Allergen challenge initiated airway biosynthesis of LXA(4) and increased expression of its receptor. Administration of a stable analog of LXA(4) blocked both airway hyper-responsiveness and pulmonary inflammation, as shown by decreased leukocytes and mediators, including interleukin-5, interleukin-13, eotaxin, prostanoids and cysteinyl leukotrienes. Moreover, transgenic expression of human LXA(4) receptors in murine leukocytes led to significant inhibition of pulmonary inflammation and eicosanoid-initiated eosinophil tissue infiltration. Inhibition of airway hyper-responsiveness and allergic airway inflammation with a stable LXA(4) analog highlights a unique counter-regulatory profile for the LXA(4) system and its leukocyte receptor in airway responses. Moreover, our findings suggest that lipoxin and related pathways offer novel multi-pronged therapeutic approaches for human asthma.	Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pulm & Crit Care Med, Dept Internal Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Serhan, CN (corresponding author), Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu	Drazen, Jeffrey M/E-5841-2012; Szczeklik, Wojciech/N-8096-2014	Szczeklik, Wojciech/0000-0002-1349-1123; Drazen, Jeffrey/0000-0003-2715-9890	NHLBI NIH HHS [P50-HL56383, HL-36110, K08-HL03788] Funding Source: Medline; NIDCR NIH HHS [P01-DE13499] Funding Source: Medline; NIDDK NIH HHS [DK-50305] Funding Source: Medline; NIGMS NIH HHS [GM-38765] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056383, K08HL003788, P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038765, R37GM038765, R01GM038765] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aliberti J, 2002, NAT IMMUNOL, V3, P76, DOI 10.1038/ni745; BADR KF, 1989, P NATL ACAD SCI USA, V86, P3438, DOI 10.1073/pnas.86.9.3438; Bandeira-Melo C, 2000, J IMMUNOL, V164, P1029, DOI 10.4049/jimmunol.164.2.1029; Bandeira-Melo C, 2000, J IMMUNOL, V164, P2267, DOI 10.4049/jimmunol.164.5.2267; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Chiang N, 1999, J CLIN INVEST, V104, P309, DOI 10.1172/JCI7016; CHRISTIE PE, 1992, AM REV RESPIR DIS, V145, P1281, DOI 10.1164/ajrccm/145.6.1281; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Cowburn AS, 1999, J IMMUNOL, V163, P456; Dahlen S E, 1988, Adv Exp Med Biol, V229, P107; de Sanctis GT, 1999, J CLIN INVEST, V103, P507, DOI 10.1172/JCI4017; De Sanctis GT, 1999, J EXP MED, V189, P1621, DOI 10.1084/jem.189.10.1621; Drazen JM, 1998, AM J RESP CRIT CARE, V158, pS193, DOI 10.1164/ajrccm.158.supplement_2.13tac180; Drazen JM, 2000, BRIT MED BULL, V56, P1054, DOI 10.1258/0007142001903535; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; Gronert K, 2001, AM J PATHOL, V158, P3, DOI 10.1016/S0002-9440(10)63937-5; Hisada T, 1999, AM J RESP CRIT CARE, V160, P571, DOI 10.1164/ajrccm.160.2.9810101; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Laporte JC, 2001, AM J RESP CRIT CARE, V164, P141, DOI 10.1164/ajrccm.164.1.2008060; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; LEE TH, 1990, AM REV RESPIR DIS, V141, P1453, DOI 10.1164/ajrccm/141.6.1453; Leff AR, 2000, AM J RESP CRIT CARE, V161, pS125, DOI 10.1164/ajrccm.161.supplement_1.ltta-25; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; McMahon B, 2001, TRENDS PHARMACOL SCI, V22, P391, DOI 10.1016/S0165-6147(00)01771-5; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Samuelsson B, 1982, PRIX NOBEL NOBEL PRI, P153; Sanak M, 2000, EUR RESPIR J, V16, P44, DOI 10.1034/j.1399-3003.2000.16a08.x; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SOYOMBO O, 1994, ALLERGY, V49, P230, DOI 10.1111/j.1398-9995.1994.tb02654.x; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Venkayya R, 2002, AM J RESP CELL MOL, V26, P202, DOI 10.1165/ajrcmb.26.2.4600; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702	36	293	320	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2002	8	9					1018	1023		10.1038/nm748	http://dx.doi.org/10.1038/nm748			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12172542				2022-12-27	WOS:000177757900038
J	Seo, SH; Hoffmann, E; Webster, RG				Seo, SH; Hoffmann, E; Webster, RG			Lethal H5N1 influenza viruses escape host anti-viral cytokine responses	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; A-VIRUS; NS1 PROTEIN; HONG-KONG; INTERFERON-PRODUCTION; WILD-TYPE; INFECTION; HUMANS; GENES; PATHOGENESIS	The H5N1 influenza viruses transmitted to humans in 1997 were highly virulent, but the mechanism of their virulence in humans is largely unknown. Here we show that lethal H5N1 influenza viruses, unlike other human, avian and swine influenza viruses, are resistant to the antiviral effects of interferons and tumor necrosis factor. The nonstructural (NS) gene of H5N1 viruses is associated with this resistance. Pigs infected with recombinant human H1N1 influenza virus that carried the H5N1 NS gene experienced significantly greater and more prolonged viremia, fever and weight loss than did pigs infected with wild-type human H1N1 influenza virus. These effects required the presence of glutamic acid at position 92 of the NS1 molecule. These findings may explain the mechanism of the high virulence of H5N1 influenza viruses in humans.	St Jude Childrens Res Hosp, Dept Infect Dis, Div Virol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Webster, RG (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, Div Virol, 332 N Lauderdale St, Memphis, TN 38105 USA.	robert.webster@stjude.org			NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095357] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21765] Funding Source: Medline; NIAID NIH HHS [AI-29860, AI-95357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Basler CF, 2001, P NATL ACAD SCI USA, V98, P2746, DOI 10.1073/pnas.031575198; BOSCH FX, 1979, VIROLOGY, V95, P197, DOI 10.1016/0042-6822(79)90414-8; Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0; deJong JC, 1997, NATURE, V389, P554, DOI 10.1038/39218; ENNIS FA, 1981, LANCET, V2, P891; Fritz RS, 1999, J INFECT DIS, V180, P586, DOI 10.1086/314938; Gao P, 1999, J VIROL, V73, P3184, DOI 10.1128/JVI.73.4.3184-3189.1999; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; GREEN JA, 1982, J INFECT DIS, V145, P837, DOI 10.1093/infdis/145.6.837; Guan Y, 1999, P NATL ACAD SCI USA, V96, P9363, DOI 10.1073/pnas.96.16.9363; Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882; HILL DA, 1972, J AMER MED ASSOC, V219, P1179, DOI 10.1001/jama.219.9.1179; Hoffmann E, 2000, J VIROL, V74, P6309, DOI 10.1128/JVI.74.14.6309-6315.2000; Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697; Isaacs A., 1957, P R SOC LOND B, V147, P258; Jameson J, 1999, J IMMUNOL, V162, P7578; Lin YP, 2000, P NATL ACAD SCI USA, V97, P9654, DOI 10.1073/pnas.160270697; Lu XH, 1999, J VIROL, V73, P5903, DOI 10.1128/JVI.73.7.5903-5911.1999; LU Y, 1995, VIROLOGY, V214, P222, DOI 10.1006/viro.1995.9937; MURPHY BR, 1973, J INFECT DIS, V128, P488, DOI 10.1093/infdis/128.4.488; Naniche D, 2000, J VIROL, V74, P7478, DOI 10.1128/JVI.74.16.7478-7484.2000; OGAWA T, 1981, VIROLOGY, V113, P304, DOI 10.1016/0042-6822(81)90157-4; Qian XY, 1995, RNA, V1, P948; RICHMAN DD, 1976, J CLIN MICROBIOL, V3, P223; Rimmelzwaan GF, 2001, J VIROL, V75, P6687, DOI 10.1128/JVI.75.14.6687-6691.2001; Seo SH, 2002, J VIROL, V76, P1071, DOI 10.1128/JVI.76.3.1071-1076.2002; Seo SH, 2001, J VIROL, V75, P9517, DOI 10.1128/JVI.75.19.9517-9525.2001; Shortridge KF, 1998, VIROLOGY, V252, P331, DOI 10.1006/viro.1998.9488; STAEHELI P, 1988, MOL CELL BIOL, V8, P4518, DOI 10.1128/MCB.8.10.4518; Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393; Talon J, 2000, J VIROL, V74, P7989, DOI 10.1128/JVI.74.17.7989-7996.2000; Taubenberger JK, 1997, SCIENCE, V275, P1793, DOI 10.1126/science.275.5307.1793; To KF, 2001, J MED VIROL, V63, P242, DOI 10.1002/1096-9071(200103)63:3&lt;242::AID-JMV1007&gt;3.0.CO;2-N; Van Reeth K, 1998, J INFECT DIS, V177, P1076, DOI 10.1086/517398; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; Zitzow LA, 2002, J VIROL, V76, P4420, DOI 10.1128/JVI.76.9.4420-4429.2002	36	546	626	3	49	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2002	8	9					950	954		10.1038/nm757	http://dx.doi.org/10.1038/nm757			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12195436				2022-12-27	WOS:000177757900029
J	McMahon, TJ; Moon, RE; Luschinger, BP; Carraway, MS; Stone, AE; Stolp, BW; Gow, AJ; Pawloski, JR; Watke, P; Singel, DJ; Piantadosi, CA; Stamler, JS				McMahon, TJ; Moon, RE; Luschinger, BP; Carraway, MS; Stone, AE; Stolp, BW; Gow, AJ; Pawloski, JR; Watke, P; Singel, DJ; Piantadosi, CA; Stamler, JS			Nitric oxide in the human respiratory cycle	NATURE MEDICINE			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; S-NITROSOHEMOGLOBIN; BLOOD-FLOW; HEMOGLOBIN; OXYGEN; NITROSYLATION; HYPERTENSION; ERYTHROCYTES; CIRCULATION; HEMATOCRIT	Interactions of nitric oxide (NO) with hemoglobin (Hb) could regulate the uptake and delivery of oxygen (O-2) by subserving the classical physiological responses of hypoxic vasodilation and hyperoxic vasconstriction in the human respiratory cycle. Here we show that in in vitro and ex vivo systems as well as healthy adults alternately exposed to hypoxia or hyperoxia (to dilate or constrict pulmonary and systemic arteries in vivo), binding of NO to hemes (FeNO) and thiols (SNO) of Hb varies as a function of HbO(2) saturation (FeO2). Moreover, we show that red blood cell (RBC)/SNO-mediated vasodilator activity is inversely proportional to FeO2 over a wide range, whereas RBC-induced vasoconstriction correlates directly with FeO2. Thus, native RBCs respond to changes in oxygen tension (pO(2)) with graded vasodilator and vasoconstrictor activity, which emulates the human physiological response subserving O-2 uptake and delivery. The ability to monitor and manipulate blood levels of NO, in conjunction with O-2 and carbon dioxide, may therefore prove useful in the diagnosis and treatment of many human conditions and in the development of new therapies. Our results also help elucidate the link between RBC dyscrasias and cardiovascular morbidity.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Montana State Univ, Dept Chem, Bozeman, MT 59717 USA	Duke University; Duke University; Duke University; Howard Hughes Medical Institute; Montana State University System; Montana State University Bozeman	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.	staml001@mc.duke.edu	Gow, Andrew/AAR-2309-2020; McMahon, Tim/K-3986-2012; Gow, Andrew/N-8566-2013; Moon, Richard/AAF-2170-2019	Gow, Andrew/0000-0003-0876-5158; McMahon, Tim/0000-0002-3404-3223; Gow, Andrew/0000-0003-0876-5158; Moon, Richard/0000-0003-4432-0332; Stamler, Jonathan/0000-0002-6866-1572	NHLBI NIH HHS [HL04424-09, K08 HL04014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004014, K08HL004424] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrews D A, 1999, Curr Opin Hematol, V6, P76, DOI 10.1097/00062752-199903000-00004; ANTONINI E, 1971, FRONTIERS BIOL, V13; Balagopalakrishna C, 1998, BIOCHEMISTRY-US, V37, P13194, DOI 10.1021/bi980941c; BAUR TS, 1990, CARDIOVASC RES, V24, P733, DOI 10.1093/cvr/24.9.733; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Blitzer ML, 1996, J AM COLL CARDIOL, V28, P591, DOI 10.1016/0735-1097(96)00218-5; CIRILLO M, 1992, HYPERTENSION, V20, P319, DOI 10.1161/01.HYP.20.3.319; COBURN RF, 1973, AM J PHYSIOL, V224, P870, DOI 10.1152/ajplegacy.1973.224.4.870; DAUT J, 1990, SCIENCE, V247, P1341, DOI 10.1126/science.2107575; DEBELDER AJ, 1994, CARDIOVASC RES, V28, P691; Deem S, 1998, AM J RESP CRIT CARE, V157, P1181, DOI 10.1164/ajrccm.157.4.9707165; Embury SH, 1999, J CLIN INVEST, V103, P915, DOI 10.1172/JCI5977; FREEMAN G, 1978, ARCH ENVIRON HEALTH, V33, P19, DOI 10.1080/00039896.1978.10667303; French JA, 1997, BLOOD, V89, P4591, DOI 10.1182/blood.V89.12.4591; Funai EF, 1997, BIOCHEM BIOPH RES CO, V239, P875, DOI 10.1006/bbrc.1997.7565; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P9943, DOI 10.1073/pnas.180155397; GORCZYNSKI RJ, 1978, AM J PHYSIOL, V235, pH505, DOI 10.1152/ajpheart.1978.235.5.H505; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; HART RG, 1990, STROKE, V21, P1111, DOI 10.1161/01.STR.21.8.1111; Hebert PC, 1999, NEW ENGL J MED, V340, P1056; Heyman SN, 1999, MICROCIRCULATION, V6, P199; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Ketcham EM, 1999, ANN EMERG MED, V33, P326, DOI 10.1016/S0196-0644(99)70370-7; KOHNO M, 1995, FREE RADICAL BIO MED, V18, P451, DOI 10.1016/0891-5849(94)00165-G; KOSAKA H, 1994, BIOCHEM BIOPH RES CO, V204, P1055, DOI 10.1006/bbrc.1994.2569; Lipton AJ, 2001, NATURE, V413, P171, DOI 10.1038/35093117; McMahon TJ, 2000, J BIOL CHEM, V275, P16738, DOI 10.1074/jbc.M000532200; McMahon TJ, 1999, METHOD ENZYMOL, V301, P99; Padron J, 2000, BIOCHEM BIOPH RES CO, V271, P217, DOI 10.1006/bbrc.2000.2617; PARK KH, 1992, CIRC RES, V71, P992, DOI 10.1161/01.RES.71.4.992; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; Perutz MF, 1998, ANNU REV BIOPH BIOM, V27, P1, DOI 10.1146/annurev.biophys.27.1.1; Pezacki JP, 2001, J AM CHEM SOC, V123, P4615, DOI 10.1021/ja015716o; PINARD E, 1989, BRAIN RES, V481, P124, DOI 10.1016/0006-8993(89)90492-7; Reddy PL, 1997, CLIN CHEM, V43, P1442; Roccatello D, 1997, NEPHROL DIAL TRANSPL, V12, P292, DOI 10.1093/ndt/12.2.292; Ruschitzka FT, 2000, P NATL ACAD SCI USA, V97, P11609, DOI 10.1073/pnas.97.21.11609; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Stephansson O, 2000, JAMA-J AM MED ASSOC, V284, P2611, DOI 10.1001/jama.284.20.2611; Takahashi Y, 1998, AM J PHYSIOL-HEART C, V274, pH349, DOI 10.1152/ajpheart.1998.274.1.H349; Tsuda K, 2000, BIOCHEM BIOPH RES CO, V275, P946, DOI 10.1006/bbrc.2000.3408; Weinberg JB, 1998, FREE RADICAL BIO MED, V24, P191, DOI 10.1016/S0891-5849(97)00217-7; Wu WC, 2001, NEW ENGL J MED, V345, P1230, DOI 10.1056/NEJMoa010615	45	382	400	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2002	8	7					711	717		10.1038/nm718	http://dx.doi.org/10.1038/nm718			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12042776				2022-12-27	WOS:000176495200032
J	Yussman, MG; Toyokawa, T; Odley, A; Lynch, RA; Wu, GY; Colbert, MC; Aronow, BJ; Lorenz, JN; Dorn, GW				Yussman, MG; Toyokawa, T; Odley, A; Lynch, RA; Wu, GY; Colbert, MC; Aronow, BJ; Lorenz, JN; Dorn, GW			Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy	NATURE MEDICINE			English	Article							HEAVY-CHAIN GENE; HEART-FAILURE; PRESSURE-OVERLOAD; MYOCARDIAL HYPERTROPHY; CARDIOVASCULAR BIOLOGY; TRANSGENIC MICE; CELL-DEATH; IN-VIVO; EXPRESSION; MYOCYTES	Loss of cardiomyocytes through programmed cell death is a key event in the development of heart failure, but the inciting molecular mechanisms are largely unknown. We used microarray analysis to identify a genetic program for myocardial apoptosis in Gq-mediated and pressure-overload cardiac hypertrophy. A critical component of this apoptotic program was Nix/Bnip3L. Nix localized to mitochondria and caused release of cytochrome c, activation of caspase-3 and apoptotic cell death, when expressed in HEK293 fibroblasts. A previously undescribed truncated Nix isoform, termed sNix, was not targeted to mitochondria but heterodimerized with Nix and protected against Nix-mediated apoptosis. Forced in vivo myocardial expression of Nix resulted in apoptotic cardiomyopathy and rapid death. Conversely, sNix protected against apoptotic peripartum cardiomyopathy in Galphaq-overexpressors. Thus, Nix/Bnip3L is upregulated in myocardial hypertrophy, and is both necessary and sufficient for Gq-mediated apoptosis of cardiomyocytes and resulting hypertrophy decompensation.	Univ Cincinnati, Med Ctr, Dept Internal Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Dept Pediat, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Ctr Cardiovasc, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Dorn, GW (corresponding author), Univ Cincinnati, Med Ctr, Dept Internal Med, Cincinnati, OH 45267 USA.	dorngw@ucmail.uc.edu	Aronow, Bruce J/F-8438-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059888, R01HL058010] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58010, HL59888] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JW, 2000, CIRC RES, V87, P1180, DOI 10.1161/01.RES.87.12.1180; Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Aronow BJ, 2001, PHYSIOL GENOMICS, V6, P19, DOI 10.1152/physiolgenomics.2001.6.1.19; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIEN KR, 1993, SCIENCE, V260, P916, DOI 10.1126/science.8493528; Cook SA, 1999, CIRC RES, V85, P940; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; Fatkin D, 1999, J CLIN INVEST, V103, P147, DOI 10.1172/JCI4631; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; KATZ AM, 1990, NEW ENGL J MED, V322, P100; Leri A, 1998, J CLIN INVEST, V101, P1326, DOI 10.1172/JCI316; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; MacLellan WR, 1997, CIRC RES, V81, P137, DOI 10.1161/01.RES.81.2.137; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; Mallat Z, 1996, NEW ENGL J MED, V335, P1190, DOI 10.1056/NEJM199610173351604; MIRSKY I, 1969, BIOPHYS J, V9, P189, DOI 10.1016/S0006-3495(69)86379-4; Misao J, 1996, CIRCULATION, V94, P1506, DOI 10.1161/01.CIR.94.7.1506; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Sakata Y, 1998, CIRCULATION, V97, P1488; Schneider MD, 2000, CIRCULATION, V102, P3026; Shi YG, 2001, NAT STRUCT BIOL, V8, P394, DOI 10.1038/87548; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Williams RS, 1999, NEW ENGL J MED, V341, P759, DOI 10.1056/NEJM199909023411012; Yasuda M, 1999, CANCER RES, V59, P533; Zhang D, 2000, NAT MED, V6, P556, DOI 10.1038/75037	36	246	257	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2002	8	7					725	730		10.1038/nm719	http://dx.doi.org/10.1038/nm719			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12053174				2022-12-27	WOS:000176495200034
J	Miki, T; Suzuki, M; Shibasaki, T; Uemura, H; Sato, T; Yamaguchi, K; Koseki, H; Iwanaga, T; Nakaya, H; Seino, S				Miki, T; Suzuki, M; Shibasaki, T; Uemura, H; Sato, T; Yamaguchi, K; Koseki, H; Iwanaga, T; Nakaya, H; Seino, S			Mouse model of Prinzmetal angina by disruption of the inward rectifier Kir6.1	NATURE MEDICINE			English	Article							SENSITIVE K+ CHANNELS; CORONARY-ARTERY; POTASSIUM CHANNELS; ATP; SUBUNIT; MUSCLE; DEATH; JAPANESE; SPASM; MICE	The inwardly rectifying K+ channel Kir6.1 forms K+ channels by coupling with a sulfonylurea receptor in reconstituted systems, but the physiological roles of Kir6.1-containing K+ channels have not been determined. We report here that mice lacking the gene encoding Kir6.1 (known as Kcnj8) have a high rate of sudden death associated with spontaneous ST elevation followed by atrioventricular block as seen on an electrocardiogram. The K+ channel opener pinacidil did not induce K+ currents in vascular smooth-muscle cells of Kir6.1-null mice, and there was no vasodilation response to pinacidil. The administration of methylergometrine, a vasoconstrictive agent, elicited ST elevation followed by cardiac death in Kir6.1-null mice but not in wild-type mice, indicating a phenotype characterized by hypercontractility of coronary arteries and resembling Prinzmetal (or variant) angina in humans. The Kir6.1-containing K+ channel is critical in the regulation of vascular tonus, especially in the coronary arteries, and its disruption may cause Prinzmetal angina.	Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba, Japan; Chiba Univ, Grad Sch Med, Dept Pharmacol & Mol Embryol, Chiba, Japan; Chiba Univ, Ctr Gene Res, Chiba, Japan; Hokkaido Univ, Grad Sch Vet Med, Lab Anat, Sapporo, Hokkaido, Japan	Chiba University; Chiba University; Chiba University; Hokkaido University	Seino, S (corresponding author), Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba, Japan.	seino@med.m.chiba-u.ac.jp	MIKI, Takashi/ABD-3995-2020; Koseki, Haruhiko/I-3825-2014	MIKI, Takashi/0000-0001-5741-1626; Koseki, Haruhiko/0000-0001-8424-5854				Abraham MR, 1999, FASEB J, V13, P1901; Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Ammala C, 1996, J PHYSIOL-LONDON, V494, P709, DOI 10.1113/jphysiol.1996.sp021526; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; Barry DM, 1998, CIRC RES, V83, P560, DOI 10.1161/01.RES.83.5.560; BEECH DJ, 1993, BRIT J PHARMACOL, V110, P573, DOI 10.1111/j.1476-5381.1993.tb13849.x; Beltrame JF, 1999, J AM COLL CARDIOL, V33, P1442, DOI 10.1016/S0735-1097(99)00073-X; Drici MD, 1998, CIRC RES, V83, P95, DOI 10.1161/01.RES.83.1.95; EGASHIRA K, 1992, CIRC RES, V71, P435, DOI 10.1161/01.RES.71.2.435; Gutstein DE, 2001, CIRC RES, V88, P333, DOI 10.1161/01.RES.88.3.333; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Jan LY, 1997, J PHYSIOL-LONDON, V505, P267, DOI 10.1111/j.1469-7793.1997.267bb.x; KAJIOKA S, 1991, J PHYSIOL-LONDON, V444, P397, DOI 10.1113/jphysiol.1991.sp018885; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Kono Y, 2000, PFLUG ARCH EUR J PHY, V440, P692, DOI 10.1007/s004240000315; Kupershmidt S, 1999, CIRC RES, V84, P146, DOI 10.1161/01.RES.84.2.146; Li RA, 2000, CIRC RES, V87, P837, DOI 10.1161/01.RES.87.10.837; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; MACALPIN RN, 1993, AM HEART J, V125, P1011, DOI 10.1016/0002-8703(93)90108-L; MASERI A, 1987, J AM COLL CARDIOL, V9, P249, DOI 10.1016/S0735-1097(87)80372-8; Miki T, 2001, NAT NEUROSCI, V4, P507, DOI 10.1038/87455; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Myerburg RJ, 1997, AM J CARDIOL, V80, pF10, DOI 10.1016/S0002-9149(97)00477-3; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Okumura K, 1996, J AM COLL CARDIOL, V27, P45, DOI 10.1016/0735-1097(95)00432-7; PRINZMETAL M, 1959, AM J MED, V27, P375, DOI 10.1016/0002-9343(59)90003-8; Pristipino C, 2000, CIRCULATION, V101, P1102, DOI 10.1161/01.CIR.101.10.1102; Robbins J, 2000, NAT MED, V6, P968, DOI 10.1038/79652; Seharaseyon J, 2000, J BIOL CHEM, V275, P17561, DOI 10.1074/jbc.275.23.17561; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869; Suzuki M, 2002, J CLIN INVEST, V109, P509, DOI 10.1172/JC1200214270; Suzuki M, 2001, CIRC RES, V88, P570, DOI 10.1161/01.RES.88.6.570; Suzuki M, 1997, BIOCHEM BIOPH RES CO, V241, P693, DOI 10.1006/bbrc.1997.7891; Tanaka J, 1996, ARCH HISTOL CYTOL, V59, P485, DOI 10.1679/aohc.59.485; Thomzig A, 2001, MOL CELL NEUROSCI, V18, P671, DOI 10.1006/mcne.2001.1048; Yamada M, 1997, J PHYSIOL-LONDON, V499, P715, DOI 10.1113/jphysiol.1997.sp021963	40	269	276	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2002	8	5					466	472		10.1038/nm0502-466	http://dx.doi.org/10.1038/nm0502-466			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984590				2022-12-27	WOS:000175336800031
J	Dickinson, AM; Wang, XN; Sviland, L; Vyth-Dreese, FA; Jackson, GH; Schumacher, TNM; Haanen, JBAG; Mutis, T; Goulmy, E				Dickinson, AM; Wang, XN; Sviland, L; Vyth-Dreese, FA; Jackson, GH; Schumacher, TNM; Haanen, JBAG; Mutis, T; Goulmy, E			In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens	NATURE MEDICINE			English	Article							CHRONIC MYELOID-LEUKEMIA; RELAPSED LEUKEMIA; DISEASE; MARROW; LYMPHOCYTES; HA-1; IMMUNOTHERAPY; RECIPIENTS; REMISSION; MODEL	Minor histocompatibility antigens (mHags) are immunogenic peptides from polymorphic cellular proteins that induce strong T-cell responses after human leukocyte antigen (HLA)-matched, mHag-mismatched stem-cell transplantation(1,2). mHags with broad or limited tissue expression are target antigens for graft-versus-host (GvH) and graft-versus-leukemia (GvL) reactivities(1). Separation of these activities is crucial for adoptive immunotherapy of leukemia without GvH disease. Therefore, using a skin-explant assay we investigated the in situ activities of cytotoxic T lymphocytes (CTLs) specific for the ubiquitously expressed mHag H-Y and for the hematopoietic-restricted mHags HA-1 and HA-2. H-Y-specific CTLs, visualized by tetrameric HLA mHag peptide complexes(3), infiltrated male skin sections within 24 hours, induced severe GvH reactions of grade III-IV and produced high levels of IFN-gamma. In contrast, CTLs specific for the hematopoietic system specific mHags HA-1 and HA-2 induced no or low GvH reactions above background and produced little or no interferon-gamma, unless the skin sections were preincubated with HA-1/HA-2 synthetic peptides. These results provide the first in situ dissection of GvH effects by mHag-specific CTLs and show that ubiquitously expressed mHags are the prime targets of GvH disease.	Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands; Newcastle Univ, Royal Victoria Infirm, Dept Haematol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Haukeland Hosp, Dept Pathol, Bergen, Norway; Netherlands Canc Inst, Dept Immunol, Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Newcastle University - UK; University of Bergen; Haukeland University Hospital; Netherlands Cancer Institute	Goulmy, E (corresponding author), Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands.	e.a.j.m.goulmy@lumc.nl	Schumacher, Ton/Y-2432-2019; Haanen, John/AAD-8578-2022; Jackson, Graham/GMW-7638-2022; Haanen, John/AAD-8534-2022	Schumacher, Ton/0000-0003-0517-8804; Jackson, Graham/0000-0003-0756-969X; Haanen, John/0000-0001-5884-7704				den Haan JMM, 1998, SCIENCE, V279, P1054, DOI 10.1126/science.279.5353.1054; DICKINSON AM, 1994, BONE MARROW TRANSPL, V13, P65; DICKINSON AM, 1988, BONE MARROW TRANSPL, V3, P323; Dickinson AM, 1998, TRANSPLANTATION, V66, P857, DOI 10.1097/00007890-199810150-00008; Falkenburg JHF, 1999, BLOOD, V94, P1201, DOI 10.1182/blood.V94.4.1201.416k08_1201_1208; Fontaine P, 2001, NAT MED, V7, P789, DOI 10.1038/89907; Goulmy E, 1996, NEW ENGL J MED, V334, P281, DOI 10.1056/NEJM199602013340501; Goulmy E, 1997, IMMUNOL REV, V157, P125, DOI 10.1111/j.1600-065X.1997.tb00978.x; Haanen JBAG, 1999, J EXP MED, V190, P1319, DOI 10.1084/jem.190.9.1319; Haanen JBAG, 2000, NAT MED, V6, P1056, DOI 10.1038/79573; Koh MBC, 1999, BONE MARROW TRANSPL, V23, P1071, DOI 10.1038/sj.bmt.1701749; Krenger W, 1997, TRANSPLANTATION, V64, P553, DOI 10.1097/00007890-199708270-00001; LERNER KG, 1974, TRANSPLANT P, V6, P367; Marijt WAF, 2000, BLOOD, V96, p478A; Molldrem JJ, 1997, BLOOD, V90, P2529, DOI 10.1182/blood.V90.7.2529.2529_2529_2534; Mutis T, 1999, BLOOD, V93, P2336, DOI 10.1182/blood.V93.7.2336.407k26_2336_2341; Mutis T, 1999, NAT MED, V5, P839, DOI 10.1038/10563; Mutis T, 2001, BONE MARROW TRANSPL, V27, pS1; Ruggeri L, 1999, BLOOD, V94, P333, DOI 10.1182/blood.V94.1.333.413a31_333_339; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; Stauss HJ, 1999, IMMUNOL TODAY, V20, P180, DOI 10.1016/S0167-5699(99)01443-7; Sviland L, 1999, J CLIN PATHOL, V52, P910, DOI 10.1136/jcp.52.12.910; Tseng LH, 1999, BLOOD, V94, P2911, DOI 10.1182/blood.V94.8.2911.420k21_2911_2914; VANELS CACM, 1992, IMMUNOGENETICS, V35, P161, DOI 10.1007/BF00185109; VOGELSANG GB, 1985, NEW ENGL J MED, V313, P645, DOI 10.1056/NEJM198509123131101	25	202	208	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2002	8	4					410	414		10.1038/nm0402-410	http://dx.doi.org/10.1038/nm0402-410			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927949				2022-12-27	WOS:000174704800035
J	Bennett, JJ; Tjuvajev, J; Johnson, P; Doubrovin, M; Akhurst, T; Malholtra, S; Hackman, T; Balatoni, J; Finn, R; Larson, SM; Federoff, H; Blasberg, R; Fong, YM				Bennett, JJ; Tjuvajev, J; Johnson, P; Doubrovin, M; Akhurst, T; Malholtra, S; Hackman, T; Balatoni, J; Finn, R; Larson, SM; Federoff, H; Blasberg, R; Fong, YM			Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer	NATURE MEDICINE			English	Article							KINASE GENE-TRANSFER; REPLICATION-COMPETENT; CHEMOTHERAPEUTIC-AGENTS; LIVER METASTASES; MALIGNANT GLIOMA; COLON-CARCINOMA; PHASE-I; THERAPY; EXPRESSION; TYPE-1	Molecular therapy using viruses would benefit greatly from a non-invasive modality for assessing dissemination of viruses. Here we investigated whether positron emission tomography (PET) scanning using [I-124]-5-iodo-2'-fluoro-1-beta -D-arabinofuranosyl-uracil (FIAU) could image cells infected with herpes simplex viruses (HSV). Using replication-competent HSV-1 oncolytic viruses with thymidine kinase (TK) under control of different promoters, we demonstrate that viral infection, proliferation and promoter characteristics all interact to influence FIAU accumulation and imaging. In vivo, as few as 1 x 10(7) viral particles injected into a 0.5-cm human colorectal tumor can be detected by [I-124]FIAU PET imaging. PET signal intensity is significantly greater at 48 hours compared with that at 8 hours after viral injection, demonstrating that PET scanning can detect changes in TK activity resulting from local viral proliferation. We also show the ability of FIAU-PET scanning to detect differences in viral infectivity at 0.5 log increments. Non-invasive imaging might be useful in assessing biologically relevant distribution of virus in therapies using replication-competent HSV.	Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiol & Med Phys, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Radiochem Cyclotron Core Facil, New York, NY 10021 USA; Neurovir, Vancouver, BC, Canada; Univ Rochester, Ctr Aging & Dev Biol, Rochester, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Rochester	Fong, YM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA.	fongy@mskcc.org	Doubrovin, Mikhail/C-5859-2017	Doubrovin, Mikhail/0000-0001-6607-2646	NCI NIH HHS [R24 CA83084, R01 CA72632, P50 CA86438, R01 CA61524, R01 CA69769, R01 CA75416] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061524, R01CA072632, R24CA083084, P50CA086438, R01CA075416, R01CA069769] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Advani SJ, 1999, CANCER RES, V59, P2055; Alauddin MM, 1996, NUCL MED BIOL, V23, P787, DOI 10.1016/0969-8051(96)00075-3; Balatoni J. A., 1997, Journal of Labelled Compounds and Radiopharmaceuticals, V40, P103; Bennett JJ, 2000, J MOL MED-JMM, V78, P166, DOI 10.1007/s001090000092; Carew JF, 1999, HUM GENE THER, V10, P1599, DOI 10.1089/10430349950017608; CARUSO M, 1993, P NATL ACAD SCI USA, V90, P7024, DOI 10.1073/pnas.90.15.7024; DELUCA NA, 1988, J VIROL, V62, P732, DOI 10.1128/JVI.62.3.732-743.1988; Gambhir SS, 1999, P NATL ACAD SCI USA, V96, P2333, DOI 10.1073/pnas.96.5.2333; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; JOLLY D, 1994, CANCER GENE THER, V1, P51; Karpoff HM, 1997, J CLIN INVEST, V99, P799, DOI 10.1172/JCI119226; KOOBY DA, 1999, FASEB J, V6, P499; LORENCE RM, 1994, CANCER RES, V54, P6017; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; MCGEOCH DJ, 1985, J MOL BIOL, V181, P1, DOI 10.1016/0022-2836(85)90320-1; MEIGNIER B, 1988, J INFECT DIS, V158, P602, DOI 10.1093/infdis/158.3.602; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; ORKIN SH, 1997, REPORT RECOMMENDATIO, P135; Rampling R, 2000, GENE THER, V7, P859, DOI 10.1038/sj.gt.3301184; TJUVAJEV JG, 1995, CANCER RES, V55, P6126; Tjuvajev JG, 1998, CANCER RES, V58, P4333; Tjuvajev JG, 1999, CANCER RES, V59, P5186; Tjuvajev JG, 1996, CANCER RES, V56, P4087; Tjuvajev Juri G., 1999, Neoplasia (New York), V1, P315, DOI 10.1038/sj.neo.7900053; Topf N, 1998, GENE THER, V5, P507, DOI 10.1038/sj.gt.3300611; Toyoizumi T, 1999, HUM GENE THER, V10, P3013, DOI 10.1089/10430349950016410; YAZAKI T, 1995, CANCER RES, V55, P4752; Yoon SS, 2000, FASEB J, V14, P301, DOI 10.1096/fasebj.14.2.301; Zuckerman JB, 1999, HUM GENE THER, V10, P2973, DOI 10.1089/10430349950016384	29	87	99	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2001	7	7					859	863		10.1038/89991	http://dx.doi.org/10.1038/89991			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433353				2022-12-27	WOS:000169808600040
J	Ciurea, A; Hunziker, L; Martinic, MMA; Oxenius, A; Hengartner, H; Zinkernagel, RM				Ciurea, A; Hunziker, L; Martinic, MMA; Oxenius, A; Hengartner, H; Zinkernagel, RM			CD4(+) T-cell-epitope escape mutant virus selected in vivo	NATURE MEDICINE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; RECEPTOR ANTAGONISTS; DEFICIENT MICE; IMMUNE-RESPONSES; VIRAL-INFECTION; IN-VIVO; VARIANTS; PERSISTENCE; HIV-1; CLEARANCE	Mutations in viral genomes that affect T-cell-receptor recognition by CD8(+) cytotoxic T lymphocytes have been shown to allow viral evasion from immune surveillance during persistent viral infections. Although CD4(+) T-helper cells are crucially involved in the maintenance of effective cytotoxic T-lymphocyte and neutralizing-antibody responses, their role in viral clearance and therefore in imposing similar selective pressures on the virus is unclear. We show here that transgenic virus-specific CD4(+) T cells, transferred into mice persistently infected with lymphocytic choriomeningitis virus, select for T-helper epitope mutant viruses that are not recognized. Together with the observed antigenic variation of the same T-helper epitope during polyclonal CD4(+) T-cell responses in infected pore-forming protein-deficient C57BL/6 mice, this finding indicates that viral escape from CD4(+) T lymphocytes is a possible mechanism of virus persistence.	Univ Hosp, Inst Expt Immunol, Zurich, Switzerland	University of Zurich; University Zurich Hospital	Ciurea, A (corresponding author), Univ Hosp, Inst Expt Immunol, Zurich, Switzerland.		Oxenius, Annette/G-7794-2015	Martinic, Marianne/0000-0003-4407-3423; Hunziker, Lukas/0000-0003-0081-8518; Ciurea, Adrian/0000-0002-7870-7132				BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; Borrow P, 1998, IMMUNOL REV, V164, P37, DOI 10.1111/j.1600-065X.1998.tb01206.x; Borrow Persephone, 1997, P593; Ciurea A, 2001, J EXP MED, V193, P297, DOI 10.1084/jem.193.3.297; Ciurea A, 2000, P NATL ACAD SCI USA, V97, P2749, DOI 10.1073/pnas.040558797; DECAMPOSLIMA PO, 1993, SCIENCE, V260, P98, DOI 10.1126/science.7682013; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Guidotti LG, 1999, J EXP MED, V189, P1555, DOI 10.1084/jem.189.10.1555; Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65; Guidotti LG, 1999, SCIENCE, V284, P825, DOI 10.1126/science.284.5415.825; Harcourt GC, 1998, J EXP MED, V188, P1785, DOI 10.1084/jem.188.10.1785; HOTCHIN JE, 1958, CAN J MICROBIOL, V4, P149, DOI 10.1139/m58-016; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; Kamperschroer C, 1999, CELL IMMUNOL, V193, P134, DOI 10.1006/cimm.1999.1458; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; LEHMANNGRUBE F, 1993, J VIROL, V67, P332, DOI 10.1128/JVI.67.1.332-339.1993; McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; MOSKOPHIDIS D, 1995, J GEN VIROL, V76, P381, DOI 10.1099/0022-1317-76-2-381; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MULLER D, 1992, SCIENCE, V255, P1576, DOI 10.1126/science.1347959; Ossendorp F, 1996, IMMUNITY, V5, P115, DOI 10.1016/S1074-7613(00)80488-4; Oxenius A, 1998, EUR J IMMUNOL, V28, P390, DOI 10.1002/(SICI)1521-4141(199801)28:01<390::AID-IMMU390>3.0.CO;2-O; Oxenius A, 1996, J EXP MED, V183, P2209, DOI 10.1084/jem.183.5.2209; Oxenius A, 1998, IMMUNITY, V9, P449, DOI 10.1016/S1074-7613(00)80628-7; Parren PWHI, 1999, AIDS, V13, pS137; Perarnau B, 1999, EUR J IMMUNOL, V29, P1243, DOI 10.1002/(SICI)1521-4141(199904)29:04<1243::AID-IMMU1243>3.0.CO;2-A; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; RAULET DH, 1994, ADV IMMUNOL, V55, P381; Reid SW, 1996, J EXP MED, V184, P2279, DOI 10.1084/jem.184.6.2279; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Varga SM, 1998, J IMMUNOL, V161, P3215; Wang H, 1999, J IMMUNOL, V162, P4177; Zajac AJ, 1996, P NATL ACAD SCI USA, V93, P14730, DOI 10.1073/pnas.93.25.14730; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205; ZINKERNAGEL RM, 1985, J EXP MED, V162, P2125, DOI 10.1084/jem.162.6.2125	45	61	61	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					795	800		10.1038/89915	http://dx.doi.org/10.1038/89915			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433343				2022-12-27	WOS:000169808600030
J	Cumming, RC; Lightfoot, J; Beard, K; Youssoufian, H; O'Brien, PJ; Buchwald, M				Cumming, RC; Lightfoot, J; Beard, K; Youssoufian, H; O'Brien, PJ; Buchwald, M			Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1	NATURE MEDICINE			English	Article							DISULFIDE-BOND FORMATION; GLUTATHIONE TRANSFERASES; INTERLEUKIN-3 WITHDRAWAL; STRESS; GENE; FAC; OVEREXPRESSION; IDENTIFICATION; INACTIVATION; LOCALIZATION	The Fanconi anemia group C protein (FANCC) plays an important role in hematopoiesis by ensuring the survival of hematopoietic progenitor cells through an unknown mechanism. We investigated the function of FANCC by identifying FANCC-binding proteins in hematopoietic cells. Here we show that glutathione S-transferase P1-1 (GSTP1) interacts with FANCC, and that overexpression of both proteins in a myeloid progenitor cell line prevents apoptosis following factor deprivation. FANCC increases GSTP1 activity after the induction of apoptosis. GSTP1 is an enzyme that catalyzes the detoxification of xenobiotics and by-products of oxidative stress, and it is frequently upregulated in neoplastic cells. Although FANCC lacks homology with conventional disulfide reductases, it functions by preventing the formation of inactivating disulfide bonds within GSTP1 during apoptosis. The prevention of protein oxidation by FANCC reveals a novel mechanism of enzyme regulation during apoptosis and has implications for the treatment of degenerative diseases with thiol reducing agents.	Hosp Sick Children, Res Inst, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Grad Dept Mol & Med Genet, Toronto, ON, Canada; Univ Toronto, Fac Pharm, Toronto, ON, Canada; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; Baylor College of Medicine	Buchwald, M (corresponding author), Hosp Sick Children, Res Inst, Program Genet & Genom Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	buchwald@sickkids.on.ca	Cumming, Robert/G-2185-2010					Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; Bojes HK, 1997, BIOCHEM J, V325, P315, DOI 10.1042/bj3250315; Bojes HK, 1999, CELL DEATH DIFFER, V6, P61, DOI 10.1038/sj.cdd.4400452; Cumming RC, 1996, BLOOD, V88, P4558, DOI 10.1182/blood.V88.12.4558.bloodjournal88124558; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Garcia-Higuera I, 1999, Curr Opin Hematol, V6, P83, DOI 10.1097/00062752-199903000-00005; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Haneline LS, 1998, BLOOD, V91, P4092; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Herzenberg LA, 1997, P NATL ACAD SCI USA, V94, P1967, DOI 10.1073/pnas.94.5.1967; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hoshino T, 1998, BLOOD, V91, P4379, DOI 10.1182/blood.V91.11.4379.411k14_4379_4386; Joenje H, 2000, AM J HUM GENET, V67, P759, DOI 10.1086/303067; JOENJE H, 1981, NATURE, V290, P142, DOI 10.1038/290142a0; JOENJE H, 1989, FANCONI ANEMIA CLIN, P174; Kampranis SC, 2000, J BIOL CHEM, V275, P29207, DOI 10.1074/jbc.M002359200; Kodym R, 1999, J BIOL CHEM, V274, P5131, DOI 10.1074/jbc.274.8.5131; Kruyt FAE, 1998, BLOOD, V92, P3050, DOI 10.1182/blood.V92.9.3050.421k56_3050_3056; Lay AJ, 2000, NATURE, V408, P869, DOI 10.1038/35048596; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; Otsuki T, 1999, J CELL PHYSIOL, V179, P79, DOI 10.1002/(SICI)1097-4652(199904)179:1<79::AID-JCP10>3.0.CO;2-O; Rathbun RK, 1997, BLOOD, V90, P974, DOI 10.1182/blood.V90.3.974.974_974_985; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Ruppitsch W, 1998, FEBS LETT, V422, P99, DOI 10.1016/S0014-5793(97)01608-6; SATO K, 1989, ADV CANCER RES, V52, P205; SHEA TC, 1988, CANCER RES, V48, P527; SHEN H, 1993, ARCH BIOCHEM BIOPHYS, V300, P137, DOI 10.1006/abbi.1993.1019; SHEN H, 1991, ARCH BIOCHEM BIOPHYS, V286, P178, DOI 10.1016/0003-9861(91)90025-E; TERADA T, 1993, ARCH BIOCHEM BIOPHYS, V300, P495, DOI 10.1006/abbi.1993.1067; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wang JX, 1998, CANCER RES, V58, P3538; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Wong JCY, 1997, MAMM GENOME, V8, P522, DOI 10.1007/s003359900490; Yin ZM, 2000, CANCER RES, V60, P4053; Youssoufian H, 1996, J CLIN INVEST, V97, P2003, DOI 10.1172/JCI118635; YOUSSOUFIAN H, 1994, P NATL ACAD SCI USA, V91, P7975, DOI 10.1073/pnas.91.17.7975	45	184	185	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2001	7	7					814	820		10.1038/89937	http://dx.doi.org/10.1038/89937			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433346				2022-12-27	WOS:000169808600033
J	Delgado, M; Abad, C; Martinez, C; Laceta, J; Gomariz, RP				Delgado, M; Abad, C; Martinez, C; Laceta, J; Gomariz, RP			Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease	NATURE MEDICINE			English	Article							COLLAGEN-INDUCED ARTHRITIS; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; RHEUMATOID-ARTHRITIS; T-CELLS; MACROPHAGES; ANTIBODIES; ACTIVATION; INDUCTION; CYTOKINE	Rheumatoid arthritis (RA) is a chronic and debilitating autoimmune disease of unknown etiology, characterized by chronic inflammation in the joints and subsequent destruction of the cartilage and bone. We describe here a new strategy for the treatment of arthritis: administration of the neuropeptide vasoactive intestinal peptide (VIP). Treatment with VIP significantly reduced incidence and severity of arthritis in an experimental model, completely abrogating joint swelling and destruction of cartilage and bone. The therapeutic effect of VIP was associated with downregulation of both inflammatory and autoimmune components of the disease. Our data indicate VIP as a viable candidate for the development of treatments for RA.	Univ Complutense, Fac Biol, Dept Cell Biol, E-28040 Madrid, Spain	Complutense University of Madrid	Delgado, M (corresponding author), Univ Complutense, Fac Biol, Dept Cell Biol, E-28040 Madrid, Spain.		Leceta, Javier/H-6940-2017; Martínez, Carmen/AAC-2077-2020; Delgado, Mario/P-1524-2016; Gomariz, Rosa P./H-2470-2017; Martinez/G-9713-2017	Leceta, Javier/0000-0003-4845-0046; Delgado, Mario/0000-0003-1893-5982; Abad, Catalina/0000-0001-9144-9310; Gomariz, Rosa P./0000-0003-2839-1923; Martinez/0000-0003-3541-0571				BRENNAN FM, 1989, LANCET, V2, P244; Butler DM, 1999, EUR J IMMUNOL, V29, P2205, DOI 10.1002/(SICI)1521-4141(199907)29:07<2205::AID-IMMU2205>3.0.CO;2-Z; Butler DM, 1997, J IMMUNOL, V159, P2867; Delgado M, 1999, ANN NY ACAD SCI, V897, P401, DOI 10.1111/j.1749-6632.1999.tb07909.x; Delgado M, 1998, J BIOL CHEM, V273, P31427, DOI 10.1074/jbc.273.47.31427; Delgado M, 1999, J IMMUNOL, V162, P4685; Delgado M, 1999, J NEUROIMMUNOL, V96, P167, DOI 10.1016/S0165-5728(99)00023-5; Delgado M, 1999, J IMMUNOL, V163, P3629; Dinant HJ, 1999, PHARM WORLD SCI, V21, P49, DOI 10.1023/A:1008661630718; Doncarli A, 1997, EUR J IMMUNOL, V27, P1451, DOI 10.1002/eji.1830270623; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Horsfall AC, 1997, J IMMUNOL, V159, P5687; Joosten LAB, 1997, ARTHRITIS RHEUM, V40, P249, DOI 10.1002/art.1780400209; Kusaba M, 1998, J RHEUMATOL, V25, P1466; Malfait AM, 1998, CLIN EXP IMMUNOL, V111, P377; Mauri C, 1996, EUR J IMMUNOL, V26, P1511, DOI 10.1002/eji.1830260716; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; MORO O, 1996, J BIOL CHEM, V271, P966; Myers LK, 1997, LIFE SCI, V61, P1861, DOI 10.1016/S0024-3205(97)00480-3; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Pozo D, 2000, IMMUNOL TODAY, V21, P7, DOI 10.1016/S0167-5699(99)01525-X; Robbins JR, 1999, DEV BIOL, V212, P255, DOI 10.1006/dbio.1999.9373; Seetharaman R, 1999, J IMMUNOL, V163, P1577; SEKI N, 1988, J IMMUNOL, V140, P1477; Takeba Y, 1999, ARTHRITIS RHEUM-US, V42, P2418, DOI 10.1002/1529-0131(199911)42:11<2418::AID-ANR21>3.0.CO;2-7; TAYLOR PC, 1995, EUR J IMMUNOL, V25, P763, DOI 10.1002/eji.1830250321; Walmsley M, 1996, ARTHRITIS RHEUM-US, V39, P495, DOI 10.1002/art.1780390318; Watt I., 1996, Arthritis and Rheumatism, V39, pS123; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629	33	326	349	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					563	568		10.1038/87887	http://dx.doi.org/10.1038/87887			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329057				2022-12-27	WOS:000169961100035
J	Stoeckli, M; Chaurand, P; Hallahan, DE; Caprioli, RM				Stoeckli, M; Chaurand, P; Hallahan, DE; Caprioli, RM			Imaging mass spectrometry: A new technology for the analysis of protein expression in mammalian tissues	NATURE MEDICINE			English	Article							INTRAOPERATIVE DIAGNOSIS; LASER-DESORPTION; NEURONS; MICROSCOPY; CARCINOMA; PEPTIDES; SECTIONS; PATTERN; TUMORS; BRAIN		Vanderbilt Univ, Sch Med, Mass Spectrometry Res Ctr, Nashville, TN 37212 USA	Vanderbilt University	Caprioli, RM (corresponding author), Vanderbilt Univ, Sch Med, Mass Spectrometry Res Ctr, Nashville, TN 37212 USA.				NATIONAL CANCER INSTITUTE [R01CA070937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058008] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58506, CA 70937] Funding Source: Medline; NIGMS NIH HHS [GM 58008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Caprioli RM, 1997, ANAL CHEM, V69, P4751, DOI 10.1021/ac970888i; Chaurand P, 1999, ANAL CHEM, V71, P5263, DOI 10.1021/ac990781q; Cheng L, 1999, J CLIN ONCOL, V17, P3182, DOI 10.1200/JCO.1999.17.10.3182; Firlik KS, 1999, J NEUROSURG, V91, P454, DOI 10.3171/jns.1999.91.3.0454; Gibbs JF, 1999, ANN SURG ONCOL, V6, P699; HALL AK, 1991, INT J CANCER, V48, P672, DOI 10.1002/ijc.2910480507; Iguchi K, 1999, BIOCHEM PHARMACOL, V57, P1105, DOI 10.1016/S0006-2952(99)00030-1; Jimenez CR, 1998, BIOCHEMISTRY-US, V37, P2070, DOI 10.1021/bi971848b; KARAS M, 1987, INT J MASS SPECTROM, V78, P53, DOI 10.1016/0168-1176(87)87041-6; LEVISETTI R, 1993, SCANNING MICROSCOPY, V7, P1161; LI KW, 1994, J BIOL CHEM, V269, P30288; Longacre TA, 1999, AM J SURG PATHOL, V23, P69, DOI 10.1097/00000478-199901000-00007; Moroz LL, 1999, J EXP BIOL, V202, P333; NELSON DF, 1993, CLIN ONCOLOGY, P617; Pacholski ML, 1999, CHEM REV, V99, P2977, DOI 10.1021/cr980137w; Paciucci R, 1996, FEBS LETT, V385, P72, DOI 10.1016/0014-5793(96)00352-3; Richter T, 1999, J CLIN PATHOL, V52, P461, DOI 10.1136/jcp.52.6.461; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Shah AB, 1998, ACTA CYTOL, V42, P1149, DOI 10.1159/000332104; Silbergeld DL, 1997, J NEUROSURG, V86, P525, DOI 10.3171/jns.1997.86.3.0525; Stoeckli M, 1999, J AM SOC MASS SPECTR, V10, P67, DOI 10.1016/S1044-0305(98)00126-3; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; Todd PJ, 1997, ANAL CHEM, V69, pA529, DOI 10.1021/ac971763g; Turner RR, 1999, AM J CLIN PATHOL, V112, P627; VALASKOVIC GA, 1992, SCANNING MICROSCOPY, V6, P305; Wang HW, 1999, IEEE T BIO-MED ENG, V46, P1246, DOI 10.1109/10.790502	26	898	948	8	263	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2001	7	4					493	496		10.1038/86573	http://dx.doi.org/10.1038/86573			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283679				2022-12-27	WOS:000167960500047
J	Backskai, BJ; Kajdasz, ST; Christie, RH; Carter, C; Games, D; Seubert, P; Schenk, D; Hyman, BT				Backskai, BJ; Kajdasz, ST; Christie, RH; Carter, C; Games, D; Seubert, P; Schenk, D; Hyman, BT			Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; PEPTIDE; MOUSE; ANTIBODIES; PATHOLOGY; NEURONS		Massachusetts Gen Hosp, Alzheimers Dis Res Lab, Charlestown, MA 02129 USA; Elan Pharmaceut, S San Francisco, CA USA	Harvard University; Massachusetts General Hospital	Hyman, BT (corresponding author), Massachusetts Gen Hosp, Alzheimers Dis Res Lab, Charlestown, MA 02129 USA.				NIA NIH HHS [AG08487, P01AG15453] Funding Source: Medline; NIGMS NIH HHS [T32 GM007753, T32GM07753] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG008487, P01AG015453, R01AG008487] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Davis DG, 1999, J NEUROPATH EXP NEUR, V58, P376, DOI 10.1097/00005072-199904000-00008; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GomezIsla T, 1996, J NEUROSCI, V16, P4491; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; Irizarry MC, 1997, J NEUROSCI, V17, P7053; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Solomon B, 1996, P NATL ACAD SCI USA, V93, P452, DOI 10.1073/pnas.93.1.452; Svoboda K, 1997, NATURE, V385, P161, DOI 10.1038/385161a0; VIGOPELFREY C, 1995, NEUROLOGY, V45, P788, DOI 10.1212/WNL.45.4.788; Yang XJ, 1998, P NATL ACAD SCI USA, V95, P7715, DOI 10.1073/pnas.95.13.7715	14	393	442	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					369	372		10.1038/85525	http://dx.doi.org/10.1038/85525			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231639				2022-12-27	WOS:000167380400046
J	Cornelis, GR; Denecker, G				Cornelis, GR; Denecker, G			Yersinia lead SUMO attack	NATURE MEDICINE			English	Editorial Material							NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; DOWN-REGULATION; SUPPRESSION; INHIBITION; PROTEIN; YOPJ; MACROPHAGES; ACTIVATION; INFECTION	Little is known about the mechanism by which Yops, proteins that Yersinia inject into the cytosol of macrophage, cause downregulation of the inflammatory response and diseases such as the plague. Now it appears that Yops are the first bacterial member of a new family of ubiquitin-like proteases.	Univ Louvain, Christian de Duve Inst Cellular Pathol, Microbial Pathogenesis Unit, B-1200 Brussels, Belgium; Univ Louvain, Fac Med, B-1200 Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain	Cornelis, GR (corresponding author), Univ Louvain, Christian de Duve Inst Cellular Pathol, Microbial Pathogenesis Unit, 74 Av Hippocrate, B-1200 Brussels, Belgium.		Denecker, Geertrui/E-8134-2010	Denecker, Geertrui/0000-0002-2515-2911				Boland A, 1998, INFECT IMMUN, V66, P1878, DOI 10.1128/IAI.66.5.1878-1884.1998; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Meijer LK, 2000, CELL MICROBIOL, V2, P231, DOI 10.1046/j.1462-5822.2000.00049.x; Mills SD, 1997, P NATL ACAD SCI USA, V94, P12638, DOI 10.1073/pnas.94.23.12638; Monack DM, 1998, J EXP MED, V188, P2127, DOI 10.1084/jem.188.11.2127; NAKAJIMA R, 1993, INFECT IMMUN, V61, P23, DOI 10.1128/IAI.61.1.23-31.1993; Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Palmer LE, 1998, MOL MICROBIOL, V27, P953, DOI 10.1046/j.1365-2958.1998.00740.x; Palmer LE, 1999, INFECT IMMUN, V67, P708, DOI 10.1128/IAI.67.2.708-716.1999; Ruckdeschel K, 1998, J EXP MED, V187, P1069, DOI 10.1084/jem.187.7.1069; Schesser K, 1998, MOL MICROBIOL, V28, P1067, DOI 10.1046/j.1365-2958.1998.00851.x; VandenAckerveken G, 1996, CELL, V87, P1307, DOI 10.1016/S0092-8674(00)81825-5; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	14	13	14	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					21	23		10.1038/83298	http://dx.doi.org/10.1038/83298			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135606				2022-12-27	WOS:000166243100021
J	Ashcroft, GS; Lei, KJ; Jin, WW; Longenecker, G; Kulkarni, AB; Greenwell-Wild, T; Hale-Donze, H; McGrady, G; Song, XY; Wahl, SM				Ashcroft, GS; Lei, KJ; Jin, WW; Longenecker, G; Kulkarni, AB; Greenwell-Wild, T; Hale-Donze, H; McGrady, G; Song, XY; Wahl, SM			Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; AMINO-ACID SEQUENCE; LATENT TGF-BETA; INFLAMMATORY RESPONSE; NEUTROPHIL ELASTASE; POTENT INHIBITOR; AGED HUMANS; ANTILEUKOPROTEASE; MATRIX; DEGRADATION	Secretory leukocyte protease inhibitor (SLPI) is a serine protease inhibitor with anti-microbial properties found in mucosal fluids. It is expressed during cutaneous wound healing. Impaired healing states are characterized by excessive proteolysis and often bacterial infection, leading to the hypothesis that SLPI may have a role in this process. We have generated mice null for the gene encoding SLPI (Slpi), which show impaired cutaneous wound healing with increased inflammation and elastase activity. The altered inflammatory profile involves enhanced activation of local TGF-beta in Slpi-null mice. We propose that SLPI is a pivotal endogenous factor necessary for optimal wound healing.	Natl Inst Dent & Craniofacial Res, Oral Infect & Immun Branch, NIH, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Gene Targeting Facil, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Wahl, SM (corresponding author), Natl Inst Dent & Craniofacial Res, Oral Infect & Immun Branch, NIH, Bldg,30 Convent Dr,MSC 4352, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000046, Z01DE000691] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ashcroft GS, 1999, MICROBES INFECT, V1, P1275, DOI 10.1016/S1286-4579(99)00257-9; Ashcroft GS, 1999, AM J PATHOL, V155, P1137, DOI 10.1016/S0002-9440(10)65217-0; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Ashcroft GS, 1997, NAT MED, V3, P1209, DOI 10.1038/nm1197-1209; BARCELLOSHOFF MH, 1994, J CLIN INVEST, V93, P892, DOI 10.1172/JCI117045; BARCELLOSHOFF MH, 1995, AM J PATHOL, V147, P1228; CERGNEUX M, 1982, J PERIODONTAL RES, V17, P169, DOI 10.1111/j.1600-0765.1982.tb01142.x; Chen WJ, 1998, J IMMUNOL, V161, P6297; EISENBERG SP, 1990, J BIOL CHEM, V265, P7976; Ferry G, 1997, FEBS LETT, V402, P111, DOI 10.1016/S0014-5793(96)01508-6; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Franzke CW, 1996, J BIOL CHEM, V271, P21886, DOI 10.1074/jbc.271.36.21886; GRINNELL F, 1994, J INVEST DERMATOL, V103, P155, DOI 10.1111/1523-1747.ep12392625; GROSSO LE, 1993, ARCH BIOCHEM BIOPHYS, V305, P401, DOI 10.1006/abbi.1993.1438; HEINE U I, 1990, Archiv fuer Geschwulstforschung, V60, P289; Herrick S, 1997, LAB INVEST, V77, P281; Hiemstra PS, 1998, EUR RESPIR J, V12, P1200, DOI 10.1183/09031936.98.12051200; JAMES J, 1986, HISTOCHEMISTRY, V85, P129, DOI 10.1007/BF00491759; Jin FY, 1997, CELL, V88, P417, DOI 10.1016/S0092-8674(00)81880-2; Kafienah W, 1998, BIOCHEM J, V330, P897, DOI 10.1042/bj3300897; Karonen T, 1997, BRIT J DERMATOL, V137, P51, DOI 10.1046/j.1365-2133.1997.17671859.x; Lentsch AB, 1999, AM J PATHOL, V154, P239, DOI 10.1016/S0002-9440(10)65270-4; MCDONALD JA, 1980, J BIOL CHEM, V255, P8848; MCNEELY TB, 1995, J CLIN INVEST, V96, P456, DOI 10.1172/JCI118056; McNeely TB, 1997, BLOOD, V90, P1141, DOI 10.1182/blood.V90.3.1141.1141_1141_1149; NUNES I, 1995, J IMMUNOL, V155, P1450; ODEKON LE, 1994, J CELL PHYSIOL, V158, P398, DOI 10.1002/jcp.1041580303; Pemberton AD, 1998, BBA-GEN SUBJECTS, V1379, P29, DOI 10.1016/S0304-4165(97)00078-0; Raghunath M, 1998, J INVEST DERMATOL, V111, P559, DOI 10.1046/j.1523-1747.1998.00339.x; SANKAR G, 1998, ANNU REV IMMUNOL, V161, P6297; Schiessler H, 1976, Methods Enzymol, V45, P847; SCUDERI P, 1991, CELL IMMUNOL, V135, P299, DOI 10.1016/0008-8749(91)90275-G; SEEMULLER U, 1986, FEBS LETT, V199, P43, DOI 10.1016/0014-5793(86)81220-0; SHAH M, 1995, J CELL SCI, V108, P985; Song XY, 1999, J EXP MED, V190, P535, DOI 10.1084/jem.190.4.535; STETLER G, 1986, NUCLEIC ACIDS RES, V14, P7883, DOI 10.1093/nar/14.20.7883; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; Tomee JFC, 1997, J INFECT DIS, V176, P740, DOI 10.1086/514098; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; WEISS SJ, 1986, J IMMUNOL, V136, P636; Wiedow O, 1998, BIOCHEM BIOPH RES CO, V248, P904, DOI 10.1006/bbrc.1998.9069; Wingens M, 1998, J INVEST DERMATOL, V111, P996, DOI 10.1046/j.1523-1747.1998.00425.x; Zhang YH, 1997, J CLIN INVEST, V99, P894, DOI 10.1172/JCI119254	45	328	348	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1147	1153		10.1038/80489	http://dx.doi.org/10.1038/80489			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017147				2022-12-27	WOS:000089674700040
J	Beer, DG; Kardia, SLR; Huang, CC; Giordano, TJ; Levin, AM; Misek, DE; Lin, L; Chen, GA; Gharib, TG; Thomas, DG; Lizyness, ML; Kuick, R; Hayasaka, S; Taylor, JMG; Iannettoni, MD; Orringer, MB; Hanash, S				Beer, DG; Kardia, SLR; Huang, CC; Giordano, TJ; Levin, AM; Misek, DE; Lin, L; Chen, GA; Gharib, TG; Thomas, DG; Lizyness, ML; Kuick, R; Hayasaka, S; Taylor, JMG; Iannettoni, MD; Orringer, MB; Hanash, S			Gene-expression profiles predict survival of patients with lung adenocarcinoma	NATURE MEDICINE			English	Article							K-RAS ONCOGENE; ENDOTHELIAL GROWTH-FACTOR; BREAST-CANCER; MOLECULAR CLASSIFICATION; PROGNOSTIC FACTORS; STAGING SYSTEM; UP-REGULATION; ACTIVATION; MUTATIONS; CARCINOMA	Histopathology is insufficient to predict disease progression and clinical outcome in lung adenocarcinoma. Here we show that gene-expression profiles based on microarray analysis can be used to predict patient survival in early-stage lung adenocarcinomas. Genes most related to survival were identified with univariate Cox analysis. Using either two equivalent but independent training and testing sets, or 'leave-one-out' cross-validation analysis with all tumors, a risk index based on the top 50 genes identified low-risk and high-risk stage I lung adenocarcinomas, which differed significantly with respect to survival. This risk index was then validated using an independent sample of lung adenocarcinomas that predicted high-and low-risk groups. This index included genes not previously associated with survival. The identification of a set of genes that predict survival in early-stage lung adenocarcinoma allows delineation of a high-risk group that may benefit from adjuvant therapy.	Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Beer, DG (corresponding author), Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA.		Chen, Guoan/J-9140-2018	Chen, Guoan/0000-0001-5608-6761; Giordano, Thomas/0000-0003-0641-8873	NCI NIH HHS [CA-46952, U19 CA-85953] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085953] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; COX DR, 1972, J R STAT SOC B, V34, P187; EBINA M, 1994, CANCER RES, V54, P2496; Fry WA, 1999, CANCER, V86, P1867, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1867::AID-CNCR31>3.0.CO;2-9; GAIL MH, 1984, CANCER, V54, P1802, DOI 10.1002/1097-0142(19841101)54:9<1802::AID-CNCR2820540908>3.0.CO;2-4; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Giordano TJ, 2001, AM J PATHOL, V159, P1231, DOI 10.1016/S0002-9440(10)62509-6; Girardin SE, 2001, EMBO J, V20, P3437, DOI 10.1093/emboj/20.13.3437; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Golub TR, 2001, NEW ENGL J MED, V344, P601, DOI 10.1056/NEJM200102223440809; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANSON LA, 1991, EXP LUNG RES, V17, P371, DOI 10.3109/01902149109064425; HARPOLE DH, 1995, CANCER RES, V55, P51; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Herbst RS, 2000, CLIN CANCER RES, V6, P790; HORIO Y, 1993, CANCER RES, V53, P1; ICHINOSE Y, 1993, J THORAC CARDIOV SUR, V106, P90, DOI 10.1016/S0022-5223(19)33744-4; Johnson RA, 1988, APPL MULTIVARIATE ST, P543; Kaisermann MC, 2001, ONCOL REP, V8, P189; Kansra S, 2000, INT J CANCER, V87, P373, DOI 10.1002/1097-0215(20000801)87:3<373::AID-IJC10>3.0.CO;2-X; KERN JA, 1994, J CLIN INVEST, V93, P516, DOI 10.1172/JCI117001; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kos J, 2000, INT J BIOL MARKER, V15, P84, DOI 10.1177/172460080001500116; Krepela E, 1998, NEOPLASMA, V45, P318; Lin L, 2000, CANCER RES, V60, P1341; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; Liu EB, 2000, CANCER RES, V60, P2361; Mehdi S A, 1999, Clin Lung Cancer, V1, P59, DOI 10.3816/CLC.1999.n.004; MILLS NE, 1995, CANCER RES, V55, P1444; NARUKE T, 1988, J THORAC CARDIOV SUR, V96, P440; Ohta Y, 1997, BRIT J CANCER, V76, P1041, DOI 10.1038/bjc.1997.505; PAIROLERO PC, 1984, ANN THORAC SURG, V38, P331, DOI 10.1016/S0003-4975(10)62281-3; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; ROGGLI VL, 1985, HUM PATHOL, V16, P569, DOI 10.1016/S0046-8177(85)80106-4; ROTENBERG Z, 1988, CLIN CHEM, V34, P668; Schneider PM, 2000, BRIT J CANCER, V83, P473, DOI 10.1054/bjoc.2000.1287; Shibusa T, 1998, CLIN CANCER RES, V4, P1483; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; STONE M, 1977, BIOMETRIKA, V64, P29; TAKISE A, 1988, CANCER, V61, P2083, DOI 10.1002/1097-0142(19880515)61:10<2083::AID-CNCR2820611025>3.0.CO;2-U; Vadgama JV, 1999, ONCOLOGY-BASEL, V57, P330, DOI 10.1159/000012052; Volm M, 1995, ANTICANCER RES, V15, P2607; WILLIAMS DE, 1981, J THORAC CARDIOV SUR, V82, P70	45	1512	1620	2	65	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2002	8	8					816	824		10.1038/nm733	http://dx.doi.org/10.1038/nm733			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12118244				2022-12-27	WOS:000177200900027
J	Kleymann, G; Fischer, R; Betz, UAK; Hendrix, M; Bender, W; Schneider, U; Handke, G; Eckenberg, P; Hewlett, G; Pevzner, V; Baumeister, J; Weber, O; Henninger, K; Keldenich, J; Jensen, A; Kolb, J; Bach, U; Popp, A; Maben, J; Frappa, I; Haebich, D; Lockhoff, O; Rubsamen-Waigmann, H				Kleymann, G; Fischer, R; Betz, UAK; Hendrix, M; Bender, W; Schneider, U; Handke, G; Eckenberg, P; Hewlett, G; Pevzner, V; Baumeister, J; Weber, O; Henninger, K; Keldenich, J; Jensen, A; Kolb, J; Bach, U; Popp, A; Maben, J; Frappa, I; Haebich, D; Lockhoff, O; Rubsamen-Waigmann, H			New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease	NATURE MEDICINE			English	Article							VIRUS; INFECTIONS; EFFICACY; MODEL; MICE	The vast majority of the world population is infected with at least one member of the human herpesvirus family. Herpes simplex virus (HSV) infections are the cause of cold sores and genital herpes as well as life-threatening or sight-impairing disease mainly in immunocompromized patients, pregnant women and newborns. Since the milestone development in the late 1970s of acyclovir ( Zovirax), a nucleosidic inhibitor of the herpes DNA polymerase, no new non-nucleosidic anti-herpes drugs have been introduced. Here we report new inhibitors of the HSV helicase-primase with potent in vitro anti-herpes activity, a novel mechanism of action, a low resistance rate and superior efficacy against HSV in animal models. BAY 57-1293 (N- [5- (aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide), a well-tolerated member of this class of compounds, significantly reduces time to healing, prevents rebound of disease after cessation of treatment and, most importantly, reduces frequency and severity of recurrent disease. Thus, this class of drugs has significant potential for the treatment of HSV disease in humans, including those resistant to current medications.	Bayer AG, Pharma Res, Wuppertal, Germany	Bayer AG	Kleymann, G (corresponding author), Bayer AG, Pharma Res, Wuppertal, Germany.	gerald.kleymann@freenet.de						Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; BROWN SM, 1998, HERPES SIMPLEX VIRUS; Collins P., 1991, REV MED VIROL, V1, P19; CRUMPACKER CS, 1979, ANTIMICROB AGENTS CH, V15, P642, DOI 10.1128/AAC.15.5.642; DECLERCQ E, 1976, J INFECT DIS, V133, pA226, DOI 10.1093/infdis/133.Supplement_2.A226; FIELD HJ, 1984, J GEN VIROL, V65, P707, DOI 10.1099/0022-1317-65-4-707; FISCHER R, 2000, Patent No. 1161423; FISCHER R, 2000, Patent No. 01498; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Keating MR, 1999, MAYO CLIN PROC, V74, P1266, DOI 10.4065/74.12.1266; KERN ER, 1984, HERPESVIRUS, P617; OBRIEN JJ, 1989, DRUGS, V37, P233, DOI 10.2165/00003495-198937030-00002; Roizman B, 2001, FIELDS VIROLOGY, P2399; SCHAEFFER HJ, 1978, NATURE, V272, P583, DOI 10.1038/272583a0; SIMMONS A, 1984, J VIROL, V52, P816, DOI 10.1128/JVI.52.3.816-821.1984; Spector FC, 1998, J VIROL, V72, P6979, DOI 10.1128/JVI.72.9.6979-6987.1998; 2000, Patent No. 0053591	17	240	263	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2002	8	4					392	398		10.1038/nm0402-392	http://dx.doi.org/10.1038/nm0402-392			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927946				2022-12-27	WOS:000174704800032
J	Tamashiro, KLK; Wakayama, T; Akutsu, H; Yamazaki, Y; Lachey, JL; Wortman, MD; Seeley, RJ; D'Alessio, DA; Woods, SC; Yanagimachi, R; Sakai, RR				Tamashiro, KLK; Wakayama, T; Akutsu, H; Yamazaki, Y; Lachey, JL; Wortman, MD; Seeley, RJ; D'Alessio, DA; Woods, SC; Yanagimachi, R; Sakai, RR			Cloned mice have an obese phenotype not transmitted to their offspring	NATURE MEDICINE			English	Article							NUCLEAR TRANSFER; FETAL OVERGROWTH; TELOMERE LENGTHS; CLONING; EMBRYO; CELLS; CATTLE	Mammalian cloning using somatic cells has been accomplished successfully in several species, and its potential basic, clinical and therapeutic applications are being pursued on many fronts. Determining the long-term effects of cloning on offspring is crucial for consideration of future application of the technique. Although full-term development of animals cloned from adult somatic cells has been reported, problems in the resulting progeny indicate that the cloning procedure may not produce animals that are phenotypically identical to their cell donor. We used a mouse model to take advantage of its short generation time and lifespan. Here we report that the increased body weight of cloned B6C3F1 female mice reflects an increase of body fat in addition to a larger body size, and that these mice share many characteristics consistent with obesity. We also show that the obese phenotype is not transmitted to offspring generated by mating male and female cloned mice.	Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45221 USA; Univ Cincinnati, Coll Med, Div Endocrinol, Cincinnati, OH USA; Univ Hawaii, John A Burns Sch Med, Inst Biogenesis Res, Dept Anat & Reprod Biol, Honolulu, HI 96822 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Hawaii System	Sakai, RR (corresponding author), Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45221 USA.	randall.sakai@uc.edu	Wortman, Matt/A-6536-2010	Wortman, Matt/0000-0002-5081-9554; Wortman, Matthew/0000-0002-1263-4145; Seeley, Randy/0000-0002-3721-5625; Tamashiro, Kellie/0000-0002-9398-8796	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK048061, R37DK017844, R01DK017844, R01DK048061] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-48061, DK-17844] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baguisi A, 1999, NAT BIOTECHNOL, V17, P456, DOI 10.1038/8632; COLEMAN A, 1999, CLONING, V1, P185; DULIOUST E, 1995, P NATL ACAD SCI USA, V92, P589, DOI 10.1073/pnas.92.2.589; Eggan K, 2000, SCIENCE, V290, P1578, DOI 10.1126/science.290.5496.1578; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; ENSINCK JW, 1991, DIABETES, V40, P1163, DOI 10.2337/diabetes.40.9.1163; Evans MJ, 1999, NAT GENET, V23, P90, DOI 10.1038/12696; Galli C, 1999, Cloning, V1, P161, DOI 10.1089/15204559950019924; Humpherys D, 2001, SCIENCE, V293, P95, DOI 10.1126/science.1061402; Inoue K, 2002, SCIENCE, V295, P297, DOI 10.1126/science.295.5553.297; *JACKS LAB, 1997, 468 JAX JACKS LAB MA, P442; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; Kikyo N, 2000, J CELL SCI, V113, P11; Kubota C, 2000, P NATL ACAD SCI USA, V97, P990, DOI 10.1073/pnas.97.3.990; Lanza RP, 2000, SCIENCE, V288, P665, DOI 10.1126/science.288.5466.665; LANZA RP, 2001, NATURE, V294, P1893; Ogura A, 2000, BIOL REPROD, V62, P1579, DOI 10.1095/biolreprod62.6.1579; Ohgane J, 2001, GENESIS, V30, P45, DOI 10.1002/gene.1031; Polejaeva IA, 2000, NATURE, V407, P86, DOI 10.1038/35024082; Prather R S, 2000, Cloning, V2, P117, DOI 10.1089/152045500750039815; Renard JP, 1999, LANCET, V353, P1489, DOI 10.1016/S0140-6736(98)12173-6; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Seeley RJ, 1997, NATURE, V390, P349, DOI 10.1038/37016; Shiels PG, 1999, NATURE, V399, P316, DOI 10.1038/20580; Solter D, 2000, NAT REV GENET, V1, P199, DOI 10.1038/35042066; Steinborn R, 2000, NAT GENET, V25, P255, DOI 10.1038/77000; Tamashiro KLK, 2000, BIOL REPROD, V63, P328, DOI 10.1095/biolreprod63.1.328; Tian XC, 2000, NAT GENET, V26, P272, DOI 10.1038/81559; Tsunoda Y, 2000, ZOOL SCI, V17, P1177, DOI 10.2108/zsj.17.1177; Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492; Wakayama T, 2000, NATURE, V407, P318, DOI 10.1038/35030301; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wakayama T, 2001, MOL REPROD DEV, V58, P376, DOI 10.1002/1098-2795(20010401)58:4<376::AID-MRD4>3.0.CO;2-L; Wakayama T, 1999, NAT GENET, V22, P127, DOI 10.1038/9632; Walker SK, 1996, THERIOGENOLOGY, V45, P111, DOI 10.1016/0093-691X(95)00360-K; Wells DN, 1999, BIOL REPROD, V60, P996, DOI 10.1095/biolreprod60.4.996; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; Yamazaki Y, 2001, P NATL ACAD SCI USA, V98, P14022, DOI 10.1073/pnas.231489398; YANAGIMACHI R, IN PRESS MOL CELL EN; Young LE, 2000, THERIOGENOLOGY, V53, P627, DOI 10.1016/S0093-691X(99)00263-0; Young LE, 1998, REV REPROD, V3, P155, DOI 10.1530/revreprod/3.3.155; Young LE, 2001, NAT GENET, V27, P153, DOI 10.1038/84769	43	266	286	0	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2002	8	3					262	267		10.1038/nm0302-262	http://dx.doi.org/10.1038/nm0302-262			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875497				2022-12-27	WOS:000174139500031
J	Capecchi, MR				Capecchi, MR			Generating mice with targeted mutations	NATURE MEDICINE			English	Editorial Material							CULTURED MAMMALIAN-CELLS; EMBRYONIC STEM-CELLS; BETA-GLOBIN GENE; THYMIDINE KINASE GENE; HOMOLOGOUS RECOMBINATION; CARCINOMA-CELLS; MOUSE EMBRYOS; GERM-LINE; TERATOCARCINOMA CELLS; DNA-SEQUENCES		Univ Utah, Sch Med, Dept Human Genet, Howard Hughes Med Inst, Salt Lake City, UT 84132 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Capecchi, MR (corresponding author), Univ Utah, Sch Med, Dept Human Genet, Howard Hughes Med Inst, Salt Lake City, UT 84132 USA.							BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; CAPECCHI MR, 1980, CELL, V22, P479, DOI 10.1016/0092-8674(80)90358-X; CAPECCHI MR, 1994, SCI AM, V270, P52, DOI 10.1038/scientificamerican0394-52; COSTANTINI F, 1981, NATURE, V294, P92, DOI 10.1038/294092a0; DENG CX, 1993, MOL CELL BIOL, V13, P2134, DOI 10.1128/MCB.13.4.2134; DENG CX, 1992, MOL CELL BIOL, V12, P3365, DOI 10.1128/MCB.12.8.3365; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; EVANS M, 1981, J REPROD FERTIL, V62, P625; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; EVANS MJ, 1972, J EMBRYOL EXP MORPH, V28, P163; EVANS MJ, 1975, ROCH S TER DIFF; EVANS MJ, 1983, GENETIC MANIPULATION; FOLGER K, 1984, COLD SPRING HARB SYM, V49, P123, DOI 10.1101/SQB.1984.049.01.016; FOLGER KR, 1985, MOL CELL BIOL, V5, P59, DOI 10.1128/MCB.5.1.59; FOLGER KR, 1982, MOL CELL BIOL, V2, P1372, DOI 10.1128/MCB.2.11.1372; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KLEINSMITH LJ, 1964, CANCER RES, V24, P1544; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8927, DOI 10.1073/pnas.86.22.8927; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LEVINSON B, 1982, NATURE, V295, P568, DOI 10.1038/295568a0; LOVELLBADGE RH, 1980, J EMBRYOL EXP MORPH, V59, P187; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; PAPAIOANNOU VE, 1975, NATURE, V258, P70, DOI 10.1038/258070a0; Pierce G B, 1967, Curr Top Dev Biol, V2, P223; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; SLIGHTOM JL, 1980, CELL, V21, P627, DOI 10.1016/0092-8674(80)90426-2; SMITHIES O, 1955, NATURE, V176, P1265, DOI 10.1038/1761265a0; SMITHIES O, 1962, NATURE, V196, P232, DOI 10.1038/196232a0; SMITHIES O, 1967, SCIENCE, V157, P267, DOI 10.1126/science.157.3786.267; SMITHIES O, 1955, BIOCHEM J, V61, P629, DOI 10.1042/bj0610629; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; SMITHIES O, 1995, P NATL ACAD SCI USA, V92, P5266, DOI 10.1073/pnas.92.12.5266; SMITHIES O, 1953, BIOCHEM J, V55, P57, DOI 10.1042/bj0550057; Stevens L C, 1967, Adv Morphog, V6, P1; STINNAKRE MG, 1981, J EMBRYOL EXP MORPH, V61, P117; Sturtevant AH, 1925, GENETICS, V10, P117; THOMAS KR, 1986, CELL, V44, P419, DOI 10.1016/0092-8674(86)90463-0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMAS KR, 1992, MOL CELL BIOL, V12, P2919, DOI 10.1128/MCB.12.7.2919; WAGNER EF, 1981, P NATL ACAD SCI-BIOL, V78, P5016, DOI 10.1073/pnas.78.8.5016; WAGNER TE, 1981, P NATL ACAD SCI-BIOL, V78, P6376, DOI 10.1073/pnas.78.10.6376; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WONG EA, 1987, MOL CELL BIOL, V7, P2294, DOI 10.1128/MCB.7.6.2294	51	75	90	1	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2001	7	10					1086	1090		10.1038/nm1001-1086	http://dx.doi.org/10.1038/nm1001-1086			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590420				2022-12-27	WOS:000171524500015
J	Gorelik, L; Flavell, RA				Gorelik, L; Flavell, RA			Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells	NATURE MEDICINE			English	Article							TGF-BETA; CTLA-4 BLOCKADE; ANTIGEN; LYMPHOCYTES; EXPRESSION; INDUCTION; SECRETION; RESPONSES; TOLERANCE; ANTIBODY	Despite the existence of tumor-specific antigens and demonstrated presence of tumor-specific immune cells, the majority of tumors manage to avoid immune-mediated destruction. Various mechanisms have been suggested for tumor evasion from immune response. One such mechanism is thought to be mediated by transforming growth factor-beta (TGF-beta), an immunosuppressive cytokine found at the site of most tumors. We demonstrate here that T-cell-specific blockade of TGF-beta signaling allows the generation of an immune response capable of eradicating tumors in mice challenged with live tumor cells. In addition, we provide mechanisms through which abrogation of TGF-beta signaling leads to the enhancement of anti-tumor immunity. Our data indicate that T-cell-specific blockade of TGF-beta signaling has strong therapeutic potential to shift the balance of the immune response in favor of anti-tumor immunity.	Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Howard Hughes Med Inst, New Haven, CT 06510 USA	Yale University; Howard Hughes Medical Institute	Flavell, RA (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA.							Agarwal RK, 1999, J IMMUNOL, V162, P2648; AWWAD M, 1988, J EXP MED, V168, P2193, DOI 10.1084/jem.168.6.2193; Chakravarthy D, 1999, INT J ONCOL, V15, P187; Chen WJ, 1998, J EXP MED, V188, P1849, DOI 10.1084/jem.188.10.1849; DALPORTO J, 1993, P NATL ACAD SCI USA, V90, P6671, DOI 10.1073/pnas.90.14.6671; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Gorelik L, 1996, J IMMUNOL, V156, P4298; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lefrancois L, 2000, J IMMUNOL, V164, P725, DOI 10.4049/jimmunol.164.2.725; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Lu ZB, 2000, J EXP MED, V191, P541, DOI 10.1084/jem.191.3.541; Maeda H, 1996, J IMMUNOL, V156, P73; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; NELSON RC, 1994, SPORT SCI REV, V3, P1; Pasche B, 2001, J CELL PHYSIOL, V186, P153, DOI 10.1002/1097-4652(200002)186:2<153::AID-JCP1016>3.0.CO;2-J; Seo N, 1999, J IMMUNOL, V163, P242; Shrikant P, 1999, IMMUNITY, V11, P483, DOI 10.1016/S1074-7613(00)80123-5; Sotomayor EM, 1999, P NATL ACAD SCI USA, V96, P11476, DOI 10.1073/pnas.96.20.11476; Sullivan TJ, 2001, P NATL ACAD SCI USA, V98, P2587, DOI 10.1073/pnas.051632398; Tamada K, 1997, J IMMUNOL, V158, P4846; van Elsas A, 1999, J EXP MED, V190, P355, DOI 10.1084/jem.190.3.355; VANROOZENDAAL CEP, 1995, MOL CELL ENDOCRINOL, V111, P1, DOI 10.1016/0303-7207(95)03539-J	25	607	663	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1118	1122		10.1038/nm1001-1118	http://dx.doi.org/10.1038/nm1001-1118			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590434				2022-12-27	WOS:000171524500032
J	Birmingham, K				Birmingham, K			Alfred Gilman	NATURE MEDICINE			English	Biographical-Item								At the age of 10, Alfred Gilman wanted to go to the moon; on a visit to New York's Hayden Planetarium with his parents, he signed up to be an astronaut. Fifty years later, Gilman Is preparing to take on a different, yet equally astronomical task. Instead of traveling to outer space, he is heading up a research program to detail the workings of cellular space.										2000, NAT MED, V6, P1072	1	0	0	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2001	7	8					879	879		10.1038/90898	http://dx.doi.org/10.1038/90898			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479609	Bronze			2022-12-27	WOS:000171740400012
J	Shimizu, K; Sugiyama, S; Aikawa, M; Fukumoto, Y; Rabkin, E; Libby, P; Mitchell, RN				Shimizu, K; Sugiyama, S; Aikawa, M; Fukumoto, Y; Rabkin, E; Libby, P; Mitchell, RN			Host bone-marrow cells are a source of donor intimal smooth-muscle-like cells in murine aortic transplant arteriopathy	NATURE MEDICINE			English	Article							CHRONIC REJECTION; EXPRESSION; ORIGIN; GRAFT	Long-term solid-organ allografts typically develop diffuse arterial intimal lesions (graft arterial disease; GAD), consisting of smooth-muscle cells (SMC), extracellular matrix and admired mononuclear leukocytes. GAD eventually culminates in vascular stenosis and ischemic graft failure. Although the exact mechanisms are unknown, chronic low-level alloresponses likely induce inflammatory cells and/or dysfunctional vascular wall cells to secrete growth factors that promote SMC intimal recruitment, proliferation and matrix synthesis(1-3). Although prior work demonstrated that the endothelium and medial SMCs lining GAD lesions in cardiac allografts are donor-derived, the intimal SMC origin could not be determined(4). They are generally presumed to originate from the donor media(5), leading to interventions that target donor medial SMC proliferation, with limited efficacy(6,7). However, other reports indicate that allograft vessels may contain host-derived endothelium and SMCs (refs. 8,9). Moreover, subpopulations of bone-marrow and circulating cells can differentiate into endothelium(10,11), and implanted synthetic vascular grafts are seeded by host SMCs and endothelium(12,13). Here we used murine aortic transplants to formally identify the source of SMCs in GAD lesions. Allografts in beta -galactosidase transgenic recipients showed that intimal SMCs derived almost exclusively from host cells. Bone-marrow transplantation of beta -galactosidase-expressing cells into aortic allograft recipients demonstrated that intimal cells included those of marrow origin. Thus, smooth-muscle-like cells in GAD lesions can originate from circulating bone-marrow-derived precursors.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med,Leducq Ctr Cardiovasc Res, Dept Med,Cardiovasc Div, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Mitchell, RN (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.	rmitchell@rics.bwh.harvard.edu	Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X; Aikawa, Masanori/0000-0002-9275-2079; Aikawa, Elena/0000-0001-7835-2135	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043364] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-43364] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACLAND R, 1972, SURGERY, V72, P744; AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Campbell JH, 1999, CIRC RES, V85, P1173; DILLEY RJ, 1992, CELL TISSUE RES, V269, P281, DOI 10.1007/BF00319619; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; Hasegawa S, 1998, AM J PATHOL, V153, P69, DOI 10.1016/S0002-9440(10)65547-2; Hayry P, 1998, TRANSPL P, V30, P3993, DOI 10.1016/S0041-1345(98)01316-5; Kennedy DW, 1997, BLOOD, V90, P986, DOI 10.1182/blood.V90.3.986.986_986_993; KENNEDY LJ, 1971, NEW ENGL J MED, V285, P884, DOI 10.1056/NEJM197110142851603; LIBBY P, 1989, TRANSPLANT P, V21, P3677; LIBBY P, 1994, CLIN TRANSPLANT, V8, P313; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; MANN MJ, 1995, P NATL ACAD SCI USA, V92, P4502, DOI 10.1073/pnas.92.10.4502; Miyamoto T, 1997, ATHEROSCLEROSIS, V129, P207, DOI 10.1016/S0021-9150(96)06043-1; OWENS GK, 1995, PHYSIOL REV, V75, P487; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; PLISSONNIER D, 1995, TRANSPLANTATION, V60, P414, DOI 10.1097/00007890-199509000-00003; Saiura A, 2001, NAT MED, V7, P382, DOI 10.1038/86394; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; Shears LL, 1997, J CLIN INVEST, V100, P2035, DOI 10.1172/JCI119736; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; WU MHD, 1995, J VASC SURG, V21, P862, DOI 10.1016/S0741-5214(05)80019-9; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789	25	398	414	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2001	7	6					738	741		10.1038/89121	http://dx.doi.org/10.1038/89121			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385513				2022-12-27	WOS:000169081500044
J	Buseyne, F; Le Gall, S; Boccaccio, C; Abastado, JP; Lifson, JD; Arthur, LO; Riviere, Y; Heard, JM; Schwartz, O				Buseyne, F; Le Gall, S; Boccaccio, C; Abastado, JP; Lifson, JD; Arthur, LO; Riviere, Y; Heard, JM; Schwartz, O			MHC-I-restricted presentation of HIV-1 virion antigens without viral replication	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXIC T-LYMPHOCYTES; DENDRITIC CELLS; EXOGENOUS ANTIGENS; CHEMOKINE-CORECEPTORS; NEF PROTEIN; MOLECULES; INFECTION; RESPONSES; TYPE-1	Dendritic cells and macrophages can process extracellular antigens for presentation by MHC-I molecules. This exogenous pathway may have a crucial role in the activation of CD8(+) cytotoxic T lymphocytes during human viral infections. We show here that HIV-1 epitopes derived from incoming virions are presented through the exogenous MHC-I pathway in primary human dendritic cells, and to a lower extent in macrophages, leading to cytotoxic T-lymphocyte activation in the absence of viral protein synthesis. Exogenous antigen presentation required adequate virus-receptor interactions and fusion of viral and cellular membranes. These results provide new insights into how anti-HIV cytotoxic T lymphocytes can be activated and have implications for anti-HIV vaccine design.	Inst Pasteur, Unite Retrovirus & Transfert Genet, Paris, France; Inst Pasteur, Lab Immunopathol Virale, Paris, France; Inst Cordeliers, ImmunoDesigned Mol Res Labs, Paris, France; NCI, Retroviral Pathogenesis Lab, AIDS Vaccine Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21701 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Schwartz, O (corresponding author), Inst Pasteur, Unite Retrovirus & Transfert Genet, Paris, France.		Schwartz, Olivier/AAZ-3765-2021	Schwartz, Olivier/0000-0002-0729-1475; Le Gall, Sylvie/0000-0003-0385-926X	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aiken C, 1997, J VIROL, V71, P5871, DOI 10.1128/JVI.71.8.5871-5877.1997; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Arthur LO, 1998, AIDS RES HUM RETROV, V14, pS311; Ayehunie S, 1997, BLOOD, V90, P1379, DOI 10.1182/blood.V90.4.1379.1379_1379_1386; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BERGERON L, 1992, J VIROL, V66, P2389, DOI 10.1128/JVI.66.4.2389-2397.1992; Brander C, 1999, CURR OPIN IMMUNOL, V11, P451, DOI 10.1016/S0952-7915(99)80076-4; Buseyne F, 1996, VIROLOGY, V225, P248, DOI 10.1006/viro.1996.0597; Buseyne F, 1998, VIROLOGY, V250, P316, DOI 10.1006/viro.1998.9373; Cameron P, 1996, J LEUKOCYTE BIOL, V59, P158, DOI 10.1002/jlb.59.2.158; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; CZERKINSKY C, 1988, J IMMUNOL METHODS, V110, P29, DOI 10.1016/0022-1759(88)90079-8; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Goxe B, 1998, RES IMMUNOL, V149, P643, DOI 10.1016/S0923-2494(99)80031-5; Granelli-Piperno A, 1999, CURR BIOL, V9, P21, DOI 10.1016/S0960-9822(99)80043-8; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; Gromme M, 1999, P NATL ACAD SCI USA, V96, P10326, DOI 10.1073/pnas.96.18.10326; Jondal M, 1996, IMMUNITY, V5, P295, DOI 10.1016/S1074-7613(00)80255-1; Klagge IM, 1999, J GEN VIROL, V80, P823, DOI 10.1099/0022-1317-80-4-823; Knight SC, 1997, ANNU REV IMMUNOL, V15, P593, DOI 10.1146/annurev.immunol.15.1.593; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Lanzavecchia A, 1996, CURR OPIN IMMUNOL, V8, P348, DOI 10.1016/S0952-7915(96)80124-5; Lapham CK, 1999, NAT MED, V5, P303, DOI 10.1038/6523; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PINTO LA, 1995, J CLIN INVEST, V96, P867, DOI 10.1172/JCI118133; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Reimann J, 1999, IMMUNOL REV, V172, P131, DOI 10.1111/j.1600-065X.1999.tb01362.x; ROCK KL, 1996, IMMUNOL TODAY, V17, P129; Rodriguez A, 1999, NAT CELL BIOL, V1, P362, DOI 10.1038/14058; Rossiter J C, 1992, Contemp Nurse, V1, P75; Rowland-Jones S, 1997, ADV IMMUNOL, V65, P277, DOI 10.1016/S0065-2776(08)60745-2; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; Schwartz O, 1998, J VIROL, V72, P3845, DOI 10.1128/JVI.72.5.3845-3850.1998; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Sigal LJ, 1999, NATURE, V398, P77, DOI 10.1038/18038; Singh-Jasuja H, 2000, J EXP MED, V191, P1965, DOI 10.1084/jem.191.11.1965; TSOMIDES TJ, 1994, J EXP MED, V180, P1283, DOI 10.1084/jem.180.4.1283; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; WHITT MA, 1990, J VIROL, V64, P4907, DOI 10.1128/JVI.64.10.4907-4913.1990; Yang OO, 1996, J VIROL, V70, P5799, DOI 10.1128/JVI.70.9.5799-5806.1996; Yewdell JW, 1999, ADV IMMUNOL, V73, P1, DOI 10.1016/S0065-2776(08)60785-3; YEWDELL JW, 1988, SCIENCE, V239, P637, DOI 10.1126/science.3257585	45	132	134	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					344	349		10.1038/85493	http://dx.doi.org/10.1038/85493			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231634				2022-12-27	WOS:000167380400041
J	Hoch, W; McConville, J; Helms, S; Newsom-Davis, J; Melms, A; Vincent, A				Hoch, W; McConville, J; Helms, S; Newsom-Davis, J; Melms, A; Vincent, A			Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies	NATURE MEDICINE			English	Article							MUSCLE-SPECIFIC KINASE; NEUROMUSCULAR-JUNCTION; PHOSPHORYLATION; AGGREGATION; COMPLEX; CELLS	Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction. In approximately 80% of patients, auto-antibodies to the muscle nicotinic acetylcholine receptor (AChR) are present(1). These antibodies cause loss of AChR numbers and function, and lead to failure of neuromuscular transmission with muscle weakness(2). The pathogenic mechanisms acting in the 20% of patients with generalized MC who are seronegative for AChR-antibodies (AChR-Ab)(3) have not been elucidated, but there is evidence that they also have an antibody-mediated disorder(4,5), with the antibodies directed towards another, previously unidentified muscle-surface-membrane target(6-8). Here we show that 70% of AChR-Ab-seronegative MC patients, but not AChR-Ab-seropositive MG patients, have serum auto-antibodies against the muscle-specific receptor tyrosine kinase, MUSK. MuSK mediates the agrin-induced clustering of AChRs during synapse formation, and is also expressed at the mature neuromuscular junction(9-12). The MUSK antibodies were specific for the extracellular domains of MUSK expressed in transfected COS7 cells and strongly inhibited MUSK function in cultured myotubes. Our results indicate the involvement of MUSK antibodies in the pathogenesis of AChR-Ab-seronegative MC, thus defining two immunologically distinct forms of the disease. Measurement of MUSK antibodies will substantially aid diagnosis and clinical management.	Max Planck Inst Dev Biol, Tubingen, Germany; John Radcliffe Hosp, Inst Mol Med, Neurosci Grp, Oxford OX3 9DU, England; Univ Tubingen, Dept Neurol, D-7400 Tubingen, Germany	Max Planck Society; University of Oxford; Eberhard Karls University of Tubingen	Vincent, A (corresponding author), Max Planck Inst Dev Biol, Tubingen, Germany.	angela.vincent@imm.ox.ac.uk	Barrett-Jolley, Richard/G-7704-2011; Vincent, Angela/AAE-7310-2019	Barrett-Jolley, Richard/0000-0003-0449-9972; 				Aarli JA, 1998, ANN NY ACAD SCI, V841, P505, DOI 10.1111/j.1749-6632.1998.tb10971.x; Blaes F, 2000, ANN NEUROL, V47, P504, DOI 10.1002/1531-8249(200004)47:4<504::AID-ANA14>3.3.CO;2-H; BROOKS EB, 1990, J NEUROIMMUNOL, V28, P83, DOI 10.1016/0165-5728(90)90043-M; DRACHMAN DB, 1994, NEW ENGL J MED, V330, P1797, DOI 10.1056/NEJM199406233302507; DRACHMAN DB, 1987, ANN NY ACAD SCI, V505, P90; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Hopf C, 1998, EUR J BIOCHEM, V253, P382, DOI 10.1046/j.1432-1327.1998.2530382.x; Hopf C, 1998, J BIOL CHEM, V273, P6467, DOI 10.1074/jbc.273.11.6467; Hopf C, 1997, EUR J NEUROSCI, V9, P1170, DOI 10.1111/j.1460-9568.1997.tb01471.x; LINDSTROM JM, 1976, NEUROLOGY, V26, P1054, DOI 10.1212/WNL.26.11.1054; MIER AK, 1985, POSTGRAD MED J, V61, P725, DOI 10.1136/pgmj.61.718.725; MOSSMAN S, 1986, LANCET, V1, P116; NAKANO S, 1993, NEUROLOGY, V43, P1167, DOI 10.1212/WNL.43.6.1167; NewsomDavis J, 1997, NEUROSCIENTIST, V3, P337, DOI 10.1177/107385849700300515; Robertson NP, 1998, J NEUROL NEUROSUR PS, V65, P492, DOI 10.1136/jnnp.65.4.492; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; Sanders Donald B., 1997, Neurology, V48, pS40; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; TAYLOR SI, 1989, ENDOCRIN METAB CLIN, V18, P123, DOI 10.1016/S0889-8529(18)30392-X; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; VINCENT A, 1993, ANN NY ACAD SCI, V681, P529, DOI 10.1111/j.1749-6632.1993.tb22936.x; VINCENT A, 1985, J NEUROL NEUROSUR PS, V48, P1246, DOI 10.1136/jnnp.48.12.1246; WILLCOX N, 1991, J NEUROL, V238, P256; YAMAMOTO T, 1991, ANN NEUROL, V30, P550, DOI 10.1002/ana.410300407; Zhou H, 1999, J CELL BIOL, V146, P1133, DOI 10.1083/jcb.146.5.1133	25	791	832	3	73	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2001	7	3					365	368		10.1038/85520	http://dx.doi.org/10.1038/85520			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231638				2022-12-27	WOS:000167380400045
J	Miele, G; Manson, J; Clinton, M				Miele, G; Manson, J; Clinton, M			A novel erythroid-specific marker of transmissible spongiform encephalopathies	NATURE MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; DIFFERENTIAL DISPLAY; BONE-MARROW; GENE-EXPRESSION; PRION PROTEIN; MESSENGER-RNA; SCRAPIE; PRP; MOUSE; INFECTIVITY	Transmissible spongiform encephalopathies (TSE) are a group of invariably fatal neurodegenerative diseases and include scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle, chronic wasting disease in deer and elk, and Kuru disease, Creutzfeldt-Jakob disease (CJD) and variant CID in humans(1,2). The pathological effects of disease occur predominantly in the CNS (central nervous system), where common hallmarks include vacuolation, gliosis, accumulation of a protease-resistant, abnormally folded isoform of the prion protein (PrPSc) and neuronal cell death(1,2). Lack of understanding of the molecular mechanisms underlying disease pathogenesis, particularly in non-CNS tissues, means that there are currently no effective strategies for early diagnosis or therapeutic intervention of TSEs. Here we report the first identification of a molecular marker that is easily detectable in readily accessible tissues. We demonstrate that a dramatic: decrease in expression of a transcript specific to erythroid lineage cells is a common feature of TSEs. Our findings indicate a previously unrecognized role for involvement of the erythroid lineage in the etiology of TSE pathogenesis and should provide a new focus for research into diagnostic and therapeutic strategies.	Roslin Inst, Div Gene Express & Dev, Roslin EH25 9PS, Midlothian, Scotland; BBSRC, Inst Anim Hlth, Neuropathogenesis Unit, Edinburgh, Midlothian, Scotland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Roslin Institute; University of Edinburgh	Clinton, M (corresponding author), Roslin Inst, Div Gene Express & Dev, Roslin EH25 9PS, Midlothian, Scotland.							BERNARD J, 1991, BLOOD CELLS, V17, P5; Bessis M, 1983, HEMATOLOGY, P257; Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; BRADY G, 1995, CURR BIOL, V5, P909, DOI 10.1016/S0960-9822(95)00181-3; Brown KL, 1999, NAT MED, V5, P1308, DOI 10.1038/15264; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CARP RI, 1981, INTERVIROLOGY, V16, P8, DOI 10.1159/000149241; Dandoy-Dron F, 1998, J BIOL CHEM, V273, P7691, DOI 10.1074/jbc.273.13.7691; DUGUID J, 1993, P NATL ACAD SCI USA, V90, P114, DOI 10.1073/pnas.90.1.114; DUGUID JR, 1990, NUCLEIC ACIDS RES, V18, P2789, DOI 10.1093/nar/18.9.2789; FRASER H, 1970, NATURE, V226, P462, DOI 10.1038/226462a0; FRASER H, 1968, J COMP PATHOL, V78, P301, DOI 10.1016/0021-9975(68)90006-6; Fraser H, 1996, J GEN VIROL, V77, P1935, DOI 10.1099/0022-1317-77-8-1935; Houston F, 2000, LANCET, V356, P999, DOI 10.1016/S0140-6736(00)02719-7; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; Klein MA, 1998, NAT MED, V4, P1429, DOI 10.1038/4022; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Manson JC, 1999, EMBO J, V18, P6855, DOI 10.1093/emboj/18.23.6855; MANSON JC, 1994, NEURODEGENERATION, V3, P331; Miele G, 1998, BIOTECHNIQUES, V25, P138, DOI 10.2144/98251rr02; Miele G, 1999, PREP BIOCHEM BIOTECH, V29, P245, DOI 10.1080/10826069908544927; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Schmerr MJ, 1999, J CHROMATOGR A, V853, P207, DOI 10.1016/S0021-9673(99)00514-2; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Voura EB, 1997, EXP HEMATOL, V25, P1172; Wada R, 2000, P NATL ACAD SCI USA, V97, P10954, DOI 10.1073/pnas.97.20.10954; Wells GAH, 1999, VET REC, V144, P292, DOI 10.1136/vr.144.11.292	29	117	129	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2001	7	3					361	364		10.1038/85515	http://dx.doi.org/10.1038/85515			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231637				2022-12-27	WOS:000167380400044
J	Ohdo, S; Koyanagi, S; Suyama, H; Higuchi, S; Aramaki, H				Ohdo, S; Koyanagi, S; Suyama, H; Higuchi, S; Aramaki, H			Changing the dosing schedule minimizes the disruptive effects of interferon on clock function	NATURE MEDICINE			English	Article							CIRCADIAN-RHYTHM; SUPRACHIASMATIC NUCLEUS; PERIPHERAL-TISSUES; EXPRESSION; ALPHA; LIGHT; INDUCTION; PACEMAKER; LOCOMOTOR; RECEPTOR	The effectiveness and toxicity of many drugs vary depending on the relationship between the dosing schedule and the 24-hour rhythms of biochemical, physiological and behavioral processes. In addition, several drugs can cause alterations to the 24-hour rhythms leading to illness and altered homeostatic regulation. However, the mechanisms of this drug-based disruption of circadian 'clock' genes remain unclear. Here, we show the disruptive effect of interferon-alpha on the rhythm of locomotor activity, body temperature and clock-gene mRNA expression in the periphery and suprachiasmatic nuclei, a primary circadian pacemaker. The rhythmicity of clock genes and the photic induction of the Per gene in suprachiasmatic nuclei were disturbed by the repetitive administration of interferon-alpha. Moreover, alteration of clock function, a new concept of adverse effects, can be overcome by optimizing the dosing schedule to minimize adverse drug effects.	Kyushu Univ, Grad Sch, Dept Clin Pharmacokinet, Div Pharmaceut Sci,Higashi Ku, Fukuoka 812, Japan; Fukuoka Univ, Fac Pharmaceut Sci, Dept Biochem, Jonan Ku, Fukuoka 81401, Japan; Daiichi Coll Pharmaceut Sci, Dept Mol Biol, Minami Ku, Fukuoka 815, Japan	Kyushu University; Fukuoka University	Ohdo, S (corresponding author), Kyushu Univ, Grad Sch, Dept Clin Pharmacokinet, Div Pharmaceut Sci,Higashi Ku, Fukuoka 812, Japan.	ohdo@phar.kyushu-u.ac.jp	Koyanagi, Satoru/AAE-6843-2020	Koyanagi, Satoru/0000-0003-4849-2377				Akiyama M, 1999, J NEUROSCI, V19, P1115; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; BOCCI V, 1985, CANC DRUG DEL, V2, P313, DOI 10.1089/cdd.1985.2.313; BOULOS Z, 1980, NEUROSCI BIOBEHAV R, V4, P119, DOI 10.1016/0149-7634(80)90010-X; BRANCA AA, 1981, NATURE, V294, P768, DOI 10.1038/294768a0; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Duncan WC, 1996, PHARMACOL THERAPEUT, V71, P253, DOI 10.1016/S0163-7258(96)00092-7; Fattovich G, 1996, J HEPATOL, V24, P38, DOI 10.1016/S0168-8278(96)80184-X; HALBERG F, 1969, ANNU REV PHYSIOL, V31, P675, DOI 10.1146/annurev.ph.31.030169.003331; Horikawa K, 2000, J NEUROSCI, V20, P5867, DOI 10.1523/JNEUROSCI.20-15-05867.2000; Hunter CA, 1997, IMMUNOL LETT, V59, P1, DOI 10.1016/S0165-2478(97)00091-6; IACOBELLI S, 1995, AM J CLIN ONCOL-CANC, V18, P27; JANSSENS W, 1994, AIDS, V8, P21, DOI 10.1097/00002030-199401000-00004; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Jones CR, 1999, NAT MED, V5, P1062, DOI 10.1038/12502; Kalsbeek A, 1996, J NEUROSCI, V16, P5555, DOI 10.1523/jneurosci.16-17-05555.1996; KOREN S, 1993, J NATL CANCER I, V85, P1927, DOI 10.1093/jnci/85.23.1927; Koyanagi S, 1997, J PHARMACOL EXP THER, V283, P259; KUMAR R, 1995, EXP CELL RES, V216, P143, DOI 10.1006/excr.1995.1018; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; LABRECQUE G, 1991, PHARMACOL THERAPEUT, V52, P95, DOI 10.1016/0163-7258(91)90088-4; LEMMER B, 1991, ANN NY ACAD SCI, V618, P166, DOI 10.1111/j.1749-6632.1991.tb27245.x; Lohmann CP, 1999, LANCET, V353, P1326, DOI 10.1016/S0140-6736(99)00403-1; Lu JQ, 1997, CELL MOL LIFE SCI, V53, P224, DOI 10.1007/PL00000594; Lundkvist GB, 1998, NEUROREPORT, V9, P1059, DOI 10.1097/00001756-199804200-00018; MOORE RY, 1972, BRAIN RES, V42, P201, DOI 10.1016/0006-8993(72)90054-6; NAGAYAMA H, 1987, EXPERIENTIA, V43, P625, DOI 10.1007/BF02126357; Ohdo S, 1996, J PHARMACOL EXP THER, V278, P74; Ohdo S, 2000, J PHARMACOL EXP THER, V294, P488; PURVIN VA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1041, DOI 10.1001/archopht.1995.01100080093034; REINBERG A, 1971, ANNU REV PHARMACOLOG, V11, P455, DOI 10.1146/annurev.pa.11.040171.002323; Ripperger JA, 2000, GENE DEV, V14, P679; ROOSTH J, 1986, J NEUROIMMUNOL, V12, P311, DOI 10.1016/0165-5728(86)90037-8; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Takane H, 2000, J PHARMACOL EXP THER, V294, P746; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Ueyama T, 1999, NAT NEUROSCI, V2, P1051, DOI 10.1038/15973; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	40	161	172	0	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2001	7	3					356	360		10.1038/85507	http://dx.doi.org/10.1038/85507			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	409JK	11231636				2022-12-27	WOS:000167380400043
J	Ault, A				Ault, A			Female Japanese scientist wins harassment case	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1305	1305		10.1038/82095	http://dx.doi.org/10.1038/82095			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100100	Bronze			2022-12-27	WOS:000165704100016
J	Liu, Y; Jones, M; Hingtgen, CM; Bu, GJ; Laribee, N; Tanzi, RE; Moir, RD; Nath, A; He, JJ				Liu, Y; Jones, M; Hingtgen, CM; Bu, GJ; Laribee, N; Tanzi, RE; Moir, RD; Nath, A; He, JJ			Uptake of HIV-1 Tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; BETA-AMYLOID PRECURSOR; LONG TERMINAL REPEAT; ALZHEIMER-DISEASE; INFECTION; EXPRESSION; APOPTOSIS; CELLS; ASTROCYTES; ACTIVATION	Neurological disorders develop in most people infected with human immunodeficiency virus type 1 (HIV-1). However, the underlying mechanisms remain largely unknown. Here we report that binding of HIV-1 transactivator (Tat) protein to low-density lipoprotein receptor-related protein (LRP) promoted efficient uptake of Tat into neurons. LRP-mediated uptake of Tat was followed by translocation to the neuronal nucleus. Furthermore, the binding of Tat to LRP resulted in substantial inhibition of neuronal binding, uptake and degradation of physiological ligands for LRP, including alpha (2)-macroglobulin, apolipoprotein E4, amyloid precursor protein and amyloid beta -protein. In a model of macaques infected with a chimeric strain of simian-human immunodeficiency virus, increased staining of amyloid precursor protein was associated with Tat expression in the brains of simian-human immunodeficiency virus-infected macaques with encephalitis. These results indicate that HIV-1 Tat may mediate HIV-1-induced neuropathology through a pathway involving disruption of the metabolic balance of LRP ligands and direct activation of neuronal genes.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol, Lexington, KY 40536 USA; Univ Kentucky, Dept Immunol, Lexington, KY 40536 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02129 USA; Walther Canc Inst, Indianapolis, IN 46206 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of Kentucky; University of Kentucky; University of Kentucky; Washington University (WUSTL); Washington University (WUSTL); Harvard University; Massachusetts General Hospital; Walther Cancer Institute	He, JJ (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.		Moir, Robert D./M-7612-2017; Tanzi, Rudolph/AAE-9622-2019	Moir, Robert D./0000-0001-5431-3553; Tanzi, Rudolph/0000-0002-7032-1454; Laribee, R. Nicholas/0000-0003-4519-4470	NINDS NIH HHS [NS39253] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039253] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		An SF, 1997, J NEUROPATH EXP NEUR, V56, P1262, DOI 10.1097/00005072-199711000-00011; BANATI RB, 1993, GLIA, V9, P199, DOI 10.1002/glia.440090305; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BU GJ, 1994, J BIOL CHEM, V269, P18521; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; CHANAKYA HN, 1997, BIOENERGY NEWS, V1, P11; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FITZGERALD DJ, 1995, J CELL BIOL, V130, P1015; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; GENDELMAN HE, 1994, J LEUKOCYTE BIOL, V56, P389, DOI 10.1002/jlb.56.3.389; Giometto B, 1997, ANN NEUROL, V42, P34, DOI 10.1002/ana.410420108; He JL, 1997, P NATL ACAD SCI USA, V94, P3954, DOI 10.1073/pnas.94.8.3954; HIGGINS LS, 1995, P NATL ACAD SCI USA, V92, P4402, DOI 10.1073/pnas.92.10.4402; HIGUCHI M, 1994, GENE, V141, P155, DOI 10.1016/0378-1119(94)90565-7; Howard GC, 1996, J CLIN INVEST, V97, P1193, DOI 10.1172/JCI118533; Hudson L, 2000, J NEUROVIROL, V6, P145, DOI 10.3109/13550280009013158; Jones M, 1998, J NEUROPATH EXP NEUR, V57, P563, DOI 10.1097/00005072-199806000-00004; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOLSON DL, 1993, AIDS RES HUM RETROV, V9, P677, DOI 10.1089/aid.1993.9.677; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kruman II, 1999, AM J PATHOL, V155, P39, DOI 10.1016/S0002-9440(10)65096-1; Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958; LEE SHC, 1993, AM J PATHOL, V143, P1032; Liu S, 1999, J POROUS MEDIA, V2, P295, DOI 10.1615/JPorMedia.v2.i3.60; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MARCUZZI A, 1992, J VIROL, V66, P4228, DOI 10.1128/JVI.66.7.4228-4232.1992; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MILANI D, 1993, J GEN VIROL, V74, P2587, DOI 10.1099/0022-1317-74-12-2587; Mouchel Y, 1995, NEUROREPORT, V7, P205; Narita M, 1997, J NEUROCHEM, V69, P1904; New DR, 1998, J BIOL CHEM, V273, P17852, DOI 10.1074/jbc.273.28.17852; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; Raghavan R, 1997, BRAIN PATHOL, V7, P851, DOI 10.1111/j.1750-3639.1997.tb00888.x; Raja F, 1997, ACTA NEUROPATHOL, V93, P184, DOI 10.1007/s004010050601; Rappaport J, 1999, J LEUKOCYTE BIOL, V65, P458, DOI 10.1002/jlb.65.4.458; RHIM H, 1994, J ACQ IMMUN DEF SYND, V7, P1116; Rusnati M, 1997, J BIOL CHEM, V272, P11313, DOI 10.1074/jbc.272.17.11313; SABATIER JM, 1991, J VIROL, V65, P961, DOI 10.1128/JVI.65.2.961-967.1991; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0	46	309	316	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1380	1387		10.1038/82199	http://dx.doi.org/10.1038/82199			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100124				2022-12-27	WOS:000165704100043
J	Peyron, C; Faraco, J; Rogers, W; Ripley, B; Overeem, S; Charnay, Y; Nevsimalova, S; Aldrich, M; Reynolds, D; Albin, R; Li, R; Hungs, M; Pedrazzoli, M; Padigaru, M; Kucherlapati, M; Fan, J; Maki, R; Lammers, GJ; Bouras, C; Kucherlapati, R; Nishino, S; Mignot, E				Peyron, C; Faraco, J; Rogers, W; Ripley, B; Overeem, S; Charnay, Y; Nevsimalova, S; Aldrich, M; Reynolds, D; Albin, R; Li, R; Hungs, M; Pedrazzoli, M; Padigaru, M; Kucherlapati, M; Fan, J; Maki, R; Lammers, GJ; Bouras, C; Kucherlapati, R; Nishino, S; Mignot, E			A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains	NATURE MEDICINE			English	Article							NEUROHYPOPHYSEAL DIABETES-INSIPIDUS; ENDOPLASMIC-RETICULUM; CANINE NARCOLEPSY; OREXIN-A; HYPOTHALAMUS; EXPRESSION; PROTEIN; SYSTEMS; GENE; RAT	We explored the role of hypocretins in human narcolepsy through histopathology of six narcolepsy brains and mutation screening of Hcrt, Hcrtr1 and Hcrtr2 in 74 patients of various human leukocyte antigen and family history status. One Hcrt mutation, impairing peptide trafficking and processing, was found in a single case with early onset narcolepsy. In situ hybridization of the perifornical area and peptide radioimmunoassays indicated global loss of hypocretins, without gliosis or signs of inflammation in all human cases examined. Although hypocretin loci do not contribute significantly to genetic predisposition, most cases of human narcolepsy are associated with a deficient hypocretin system.	Stanford Univ, Ctr Narcolepsy, Sch Med, Stanford, CA 94305 USA; Leiden Univ, Med Ctr, NL-2300 RC Leiden, Netherlands; HUG, Belle Idee, Div Neuropsychiat, CH-1225 Chene Bourg, Geneva, Switzerland; Charles Univ Prague, Fac Med 1, Dept Neurol, Prague 12821, Czech Republic; Univ Michigan, Dept Neurol, Ann Arbor, MI 48104 USA; VAMC, Ctr Geriatr Res Educ & Clin, Ann Arbor, MI 48104 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Neurocrine Biosci Inc, San Diego, CA 92121 USA	Stanford University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Geneva; Charles University Prague; University of Michigan System; University of Michigan; Geriatric Research Education & Clinical Center; Yeshiva University; Albert Einstein College of Medicine; Neurocrine Biosciences	Mignot, E (corresponding author), Stanford Univ, Ctr Narcolepsy, Sch Med, 1201 Welch Rd, Stanford, CA 94305 USA.	mignot@leland.stanford.edu	Kucherlapati, Raju/ABC-8807-2021; Pedrazzoli, Mario/B-3757-2013; Peyron, Christelle/H-6223-2017; Nevšímalová, Soňa/H-3533-2017; Maki, Robert G/J-9145-2019; Overeem, Sebastiaan/D-2139-2010	Pedrazzoli, Mario/0000-0002-5257-591X; Peyron, Christelle/0000-0002-9317-3546; Nevšímalová, Soňa/0000-0003-0083-3742; Maki, Robert G/0000-0002-9853-2528; Lammers, Gert Jan/0000-0003-4755-7060; Overeem, Sebastiaan/0000-0002-6445-9836; ripley, beth/0000-0001-7723-169X	NHLBI NIH HHS [HL59601] Funding Source: Medline; NINDS NIH HHS [NS33797, NS 23724] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059601] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023724, R01NS033797, R37NS033797, P01NS023724] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDRICH MS, 1990, NEW ENGL J MED, V323, P389; BOIVIN DB, 1989, CLIN NEUROPHARMACOL, V12, P339, DOI 10.1097/00002826-198908000-00012; Broberger C, 1998, J COMP NEUROL, V402, P460; Carlander B., 1993, Neurophysiologie Clinique, V23, P15, DOI 10.1016/S0987-7053(05)80279-5; Charnay Y, 1999, J CHEM NEUROANAT, V17, P123, DOI 10.1016/S0891-0618(99)00028-9; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Elias CF, 1998, J COMP NEUROL, V402, P442, DOI 10.1002/(SICI)1096-9861(19981228)402:4<442::AID-CNE2>3.0.CO;2-R; Gagliardi PC, 1997, J CLIN ENDOCR METAB, V82, P3643, DOI 10.1210/jc.82.11.3643; Guilleminault C, 1998, ANN NEUROL, V43, P135, DOI 10.1002/ana.410430125; Hagan JJ, 1999, P NATL ACAD SCI USA, V96, P10911, DOI 10.1073/pnas.96.19.10911; HONDA Y, 1983, SLEEP WAKE DISORDERS; Hong SC, 2000, SLEEP MED, V1, P33, DOI 10.1016/S1389-9457(99)00007-6; Ito M, 1997, J CLIN INVEST, V99, P1897, DOI 10.1172/JCI119357; JUJI T, 1984, TISSUE ANTIGENS, V24, P316, DOI 10.1111/j.1399-0039.1984.tb02144.x; KARAPLIS AC, 1995, J BIOL CHEM, V270, P1629, DOI 10.1074/jbc.270.4.1629; Kilduff TS, 2000, TRENDS NEUROSCI, V23, P359, DOI 10.1016/S0166-2236(00)01594-0; Kollias G, 1999, ANN RHEUM DIS, V58, P32, DOI 10.1136/ard.58.2008.i32; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; Mai J.K., 1997, ATLAS HUMAN BRAIN; MIGNOT E, 1995, ADV NEUROIMMUNOL, V5, P23, DOI 10.1016/0960-5428(94)00043-N; MIGNOT E, 1993, J NEUROSCI, V13, P1057; Mignot E, 1997, SLEEP, V20, P1012; MIGNOT E, 1994, SLEEP, V17, pS60, DOI 10.1093/sleep/17.suppl_8.S60; Mignot E, 1998, NEUROLOGY, V50, pS16, DOI 10.1212/WNL.50.2_Suppl_1.S16; Mignot E, 2000, SLEEP MED, V1, P87, DOI 10.1016/S1389-9457(00)00013-7; Mondal MS, 1999, NEUROSCI LETT, V273, P45, DOI 10.1016/S0304-3940(99)00624-2; Nijenhuis M, 1999, J BIOL CHEM, V274, P21200, DOI 10.1074/jbc.274.30.21200; Nishino S, 1997, PROG NEUROBIOL, V52, P27, DOI 10.1016/S0301-0082(96)00070-6; Nishino S, 2000, LANCET, V355, P39, DOI 10.1016/S0140-6736(99)05582-8; Peyron C, 1998, J NEUROSCI, V18, P9996; Sakurai T, 1999, J BIOL CHEM, V274, P17771, DOI 10.1074/jbc.274.25.17771; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Schmitt AB, 1998, NEUROPATH APPL NEURO, V24, P167; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; Tafti M, 1996, J NEUROSCI, V16, P4588; Taheri S, 1999, FEBS LETT, V457, P157, DOI 10.1016/S0014-5793(99)01030-3; YOSS R E, 1960, Pediatrics, V25, P1025	38	1504	1572	1	77	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2000	6	9					991	997		10.1038/79690	http://dx.doi.org/10.1038/79690			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973318				2022-12-27	WOS:000089190500030
J	Bosch, X				Bosch, X			Spain releases xenotransplantations guidelines	NATURE MEDICINE			English	News Item																		Bach FH, 1998, NAT MED, V4, P141, DOI 10.1038/nm0298-141; 1998, NAT MED, V4, P131	2	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1998	4	8					876	876		10.1038/nm0898-876b	http://dx.doi.org/10.1038/nm0898-876b			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	106AK	11645084	Bronze			2022-12-27	WOS:000075107400016
J	McLaurin, J; Cecal, R; Kierstead, ME; Tian, X; Phinney, AL; Manea, M; French, JE; Lambermon, MHL; Darabie, AA; Brown, ME; Janus, C; Chishti, MA; Horne, P; Westaway, D; Fraser, PE; Mount, HTJ; Przybylski, M; St George-Hyslop, P				McLaurin, J; Cecal, R; Kierstead, ME; Tian, X; Phinney, AL; Manea, M; French, JE; Lambermon, MHL; Darabie, AA; Brown, ME; Janus, C; Chishti, MA; Horne, P; Westaway, D; Fraser, PE; Mount, HTJ; Przybylski, M; St George-Hyslop, P			Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; MASS-SPECTROMETRY; MOUSE MODEL; PROTEIN; EPITOPE; MICE; IDENTIFICATION; NEUROTOXICITY; IMMUNIZATION; DEPOSITION	Immunization of transgenic mouse models of Alzheimer disease using amyloid-beta pepticle (Abeta) reduces both the Alzheimer disease-like neuropathology and the spatial memory impairments of these mice. However, a therapeutic trial of immunization with Abeta(42) in humans was discontinued because a few patients developed significant meningo-encephalitic cellular inflammatory reactions. Here we show that beneficial effects in mice arise from antibodies selectively directed against residues 4-10 of Abeta(42), and that these antibodies inhibit both Abeta fibrillogenesis and cytotoxicity without eliciting an inflammatory response. These findings provide the basis for improved immunization antigens as well as attempts to design small-molecule mimics as alternative therapies.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON, Canada; Univ Toronto, Dept Lab Med, Toronto, ON, Canada; Univ Toronto, Dept Pathobiol, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Konstanz, Dept Chem, Analyt Chem Lab, D-7750 Constance, Germany; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Hlth Network, Toronto Western Hosp, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Konstanz; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	McLaurin, J (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON, Canada.	j.mclaurin@utoronto.ca; Michael.Przybylski@uni-konstanz.de	Mount, Howard/B-4097-2013					ALTIN JG, 1995, ANAL BIOCHEM, V224, P382, DOI 10.1006/abio.1995.1054; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bauer SHJ, 2001, ANAL BIOCHEM, V298, P25, DOI 10.1006/abio.2001.5330; Check E, 2002, NATURE, V415, P462, DOI 10.1038/415462a; Chishti MA, 2001, J BIOL CHEM, V276, P21562, DOI 10.1074/jbc.M100710200; Craig DB, 1996, ANAL CHEM, V68, P697, DOI 10.1021/ac950650z; Delgado M, 2001, Arch Physiol Biochem, V109, P372, DOI 10.1076/apab.109.4.372.4240; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Fligge TA, 2000, BIOCHEMISTRY-US, V39, P8491, DOI 10.1021/bi9922751; Frenkel D, 2000, J NEUROIMMUNOL, V106, P23, DOI 10.1016/S0165-5728(99)00232-5; FRIDMAN WH, 1997, MOL BIOL INTELLIGENC; GOWING E, 1994, J BIOL CHEM, V269, P10987; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hochleitner EO, 2000, PROTEIN SCI, V9, P487, DOI 10.1110/ps.9.3.487; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; JUCKER M, 1994, NEUROSCIENCE, V60, P875, DOI 10.1016/0306-4522(94)90269-0; Kalback W, 2002, BIOCHEMISTRY-US, V41, P922, DOI 10.1021/bi015685+; KOHLMANN M, IN PRESS J PEPT SCI; Kuo YM, 2001, J BIOL CHEM, V276, P12991, DOI 10.1074/jbc.M007859200; Macht M, 1996, BIOCHEMISTRY-US, V35, P15633, DOI 10.1021/bi961727w; Marshall AG, 1998, MASS SPECTROM REV, V17, P1, DOI 10.1002/(SICI)1098-2787(1998)17:1<1::AID-MAS1>3.0.CO;2-K; Mayer-Fligge P, 1998, J PEPT SCI, V4, P355, DOI 10.1002/(SICI)1099-1387(199808)4:5<355::AID-PSC153>3.0.CO;2-3; McLaurin J, 2000, J BIOL CHEM, V275, P18495, DOI 10.1074/jbc.M906994199; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Papanastassiou M., 1994, J ECON BUS, V2, P199; Przybylski M, 1998, NATO ADV SCI I C-MAT, V510, P17; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Small DH, 2001, NAT REV NEUROSCI, V2, P595, DOI 10.1038/35086072; Solomon B, 1996, P NATL ACAD SCI USA, V93, P452, DOI 10.1073/pnas.93.1.452; Solomon B, 1997, P NATL ACAD SCI USA, V94, P4109, DOI 10.1073/pnas.94.8.4109; SUCKAU D, 1990, P NATL ACAD SCI USA, V87, P9848, DOI 10.1073/pnas.87.24.9848; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Yang DS, 2001, AMYLOID, V8, P10; YOUHNOVSKI N, IN PRESS ANGEW CHEM	36	367	433	1	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2002	8	11					1263	1269		10.1038/nm790	http://dx.doi.org/10.1038/nm790			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12379850				2022-12-27	WOS:000179221200032
J	Yamauchi, T; Kamon, J; Minokoshi, Y; Ito, Y; Waki, H; Uchida, S; Yamashita, S; Noda, M; Kita, S; Ueki, K; Eto, K; Akanuma, Y; Froguel, P; Foufelle, F; Ferre, P; Carling, D; Kimura, S; Nagai, R; Kahn, BB; Kadowaki, T				Yamauchi, T; Kamon, J; Minokoshi, Y; Ito, Y; Waki, H; Uchida, S; Yamashita, S; Noda, M; Kita, S; Ueki, K; Eto, K; Akanuma, Y; Froguel, P; Foufelle, F; Ferre, P; Carling, D; Kimura, S; Nagai, R; Kahn, BB; Kadowaki, T			Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase	NATURE MEDICINE			English	Article							INSULIN-RESISTANCE; OBESITY; MICE; EXPRESSION; MECHANISM	Adiponectin (Ad) is a hormone secreted by adipocytes that regulates energy homeostasis and glucose and lipid metabolism. However, the signaling pathways that mediate the metabolic effects of Ad remain poorly identified. Here we show that phosphorylation and activation of the 5'-AMP-activated protein kinase (AMPK) are stimulated with globular and full-length Ad in skeletal muscle and only with full-length Ad in the liver. In parallel with its activation of AMPK, Ad stimulates phosphorylation of acetyl coenzyme A carboxylase (ACC), fatty-acid oxidation, glucose uptake and lactate production in myocytes, phosphorylation of ACC and reduction of molecules involved in gluconeogenesis in the liver, and reduction of glucose levels in vivo. Blocking AMPK activation by dominant-negative mutant inhibits each of these effects, indicating that stimulation of glucose utilization and fatty-acid oxidation by Ad occurs through activation of AMPK. Our data may provide a novel paradigm that an adipocyte-derived antidiabetic hormone, Ad, activates AMPK, thereby directly regulating glucose metabolism and insulin sensitivity in vitro and in vivo.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo, Japan; Japan Sci & Technol Corp, CREST, Saitama, Japan; Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Asahi Life Fdn, Inst Diabet Care & Res, Tokyo, Japan; Inst Pasteur, CNRS, Inst Biol, F-59019 Lille, France; Ctr Rech Biomed Cordeliers, INSERM, U465, Paris, France; Hammersmith Hosp, Imperial Coll Sch Med, MRC, Clin Sci Ctr,Cellular Stress Grp, London, England	University of Tokyo; Japan Science & Technology Agency (JST); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Asahi Life Foundation; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Imperial College London	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo, Japan.		Carling, David/F-1943-2014; Robles-Sardin, Alma E/M-7714-2015; Ferré, Pascal/K-1250-2013; FROGUEL, Philippe/O-6799-2017; sheng, jian/E-9474-2012; Noda, Mitsuhiko/W-3905-2019; Waki, Hironori/AAE-3942-2020	Carling, David/0000-0002-2316-1830; Robles-Sardin, Alma E/0000-0003-2044-7793; Ferré, Pascal/0000-0003-0115-7045; FROGUEL, Philippe/0000-0003-2972-0784; Noda, Mitsuhiko/0000-0003-0413-4631; Waki, Hironori/0000-0002-5302-9793; Minokoshi, Yasuhiko/0000-0002-7119-4805; FOUFELLE, Fabienne/0000-0002-0752-622X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK056116, R01DK043051] Funding Source: NIH RePORTER; Medical Research Council [G0000477] Funding Source: Medline; NIDDK NIH HHS [R01 DK 43051, P01 DK 56116] Funding Source: Medline; MRC [G0000477] Funding Source: UKRI	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Lochhead PA, 2000, DIABETES, V49, P896, DOI 10.2337/diabetes.49.6.896; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tsao TS, 2002, J BIOL CHEM, V277, P29359, DOI 10.1074/jbc.C200312200; Tsubamoto Y, 2001, J BIOL CHEM, V276, P2979, DOI 10.1074/jbc.M005816200; Ueki K, 2000, J CLIN INVEST, V105, P1437, DOI 10.1172/JCI7656; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	25	3192	3416	8	387	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2002	8	11					1288	1295		10.1038/nm788	http://dx.doi.org/10.1038/nm788			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12368907				2022-12-27	WOS:000179221200036
J	Ishiuchi, S; Tsuzuki, K; Yoshida, Y; Yamada, N; Hagimura, N; Okado, H; Miwa, A; Kurihara, H; Nakazato, Y; Tamura, M; Sasaki, T; Ozawa, S				Ishiuchi, S; Tsuzuki, K; Yoshida, Y; Yamada, N; Hagimura, N; Okado, H; Miwa, A; Kurihara, H; Nakazato, Y; Tamura, M; Sasaki, T; Ozawa, S			Blockage of Ca2+-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells	NATURE MEDICINE			English	Article							GLUTAMATE RECEPTORS; CENTRAL NEUROCYTOMA; EXPRESSION; ACTIVATION; CHANNELS; PROTEIN; GROWTH; RELEASE; DIFFERENTIATION; DEPOLARIZATION	Glioblastoma multiforme is the most undifferentiated type of brain tumor, and its prognosis is extremely poor. Glioblastoma cells exhibit highly migratory and invasive behavior, which makes surgical intervention unsuccessful. Here, we showed that glioblastoma cells express Ca2+ permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)-type glutamate receptors assembled from the GluR1 and/or GluR4 subunits, and that their conversion to Ca2+-impermeable receptors by adenovirus-mediated transfer of the GluR2 cDNA inhibited cell locomotion and induced apoptosis. In contrast, overexpression of Ca2+-permeable AMPA receptors facilitated migration and proliferation of the tumor cells. These findings indicate that Ca2+-permeable AMPA receptors have crucial roles in growth of glioblastoma. Blockage of these Ca2+-permeable receptors may be a useful therapeutic strategy for the prevention of glioblastoma invasion.	Gunma Univ, Sch Med, Dept Neurosurg, Gunma, Japan; Gunma Univ, Sch Med, Dept Physiol, Gunma, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama, Japan; Tokyo Metropolitan Inst Neurosci, Dept Neurobiol, Fuchu, Tokyo 183, Japan; Gunma Univ, Sch Med, Dept Pathol, Gunma, Japan; Kyushu Univ, Sch Med, Dept Neurosurg, Fukuoka 812, Japan	Gunma University; Gunma University; Japan Science & Technology Agency (JST); Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Gunma University; Kyushu University	Ishiuchi, S (corresponding author), Gunma Univ, Sch Med, Dept Neurosurg, Gunma, Japan.	ishogo@showa.gunma-u.ac.jp		Ozawa, Seiji/0000-0003-4893-3443				Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; BLAKEMORE WF, 1996, GLIAL CELL DEV BASIC, P209; Chew LJ, 1997, J NEUROSCI, V17, P227, DOI 10.1523/JNEUROSCI.17-01-00227.1997; Cotrina ML, 1998, J NEUROSCI, V18, P8794; Gallo V, 2000, TRENDS PHARMACOL SCI, V21, P252, DOI 10.1016/S0165-6147(00)01494-2; GALLO V, 1987, J NEUROSCI, V7, P2203; GALLO V, 1994, GLIA, V10, P149, DOI 10.1002/glia.440100209; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Ishiuchi S, 1998, J NEUROSCI RES, V51, P526, DOI 10.1002/(SICI)1097-4547(19980215)51:4<526::AID-JNR12>3.0.CO;2-1; Ishiuchi S, 1997, ACTA NEUROPATHOL, V94, P425, DOI 10.1007/s004010050729; Ishiuchi S, 2001, NEUROREPORT, V12, P745, DOI 10.1097/00001756-200103260-00026; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KHINE MM, 1994, LAB INVEST, V70, P125; Kleihues P., 2000, PATHOLOGY GENETICS T, P29; Kohara A, 1998, J PHARM PHARMACOL, V50, P795, DOI 10.1111/j.2042-7158.1998.tb07142.x; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; Kondo M, 1997, J NEUROSCI, V17, P1570; Labrakakis C, 1998, EUR J NEUROSCI, V10, P2153, DOI 10.1046/j.1460-9568.1998.00226.x; Lino M, 2001, SCIENCE, V292, P926, DOI 10.1126/science.1058827; Meucci O, 1996, J NEUROSCI, V16, P519; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; NAKAZATO Y, 1985, VIRCHOWS ARCH A, V405, P299, DOI 10.1007/BF00710066; NOBLE M, 1995, GLIA, V15, P222, DOI 10.1002/glia.440150304; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; Rzeski W, 2001, P NATL ACAD SCI USA, V98, P6372, DOI 10.1073/pnas.091113598; SAKURAI T, 1992, BRAIN RES, V573, P197, DOI 10.1016/0006-8993(92)90763-Y; Sasaki A, 1998, J NEUROPATH EXP NEUR, V57, P653, DOI 10.1097/00005072-199807000-00002; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sudo M, 1999, MOL BRAIN RES, V65, P176, DOI 10.1016/S0169-328X(98)00348-9; Takano T, 2001, NAT MED, V7, P1010, DOI 10.1038/nm0901-1010; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Yoshioka A, 1996, J NEUROSCI RES, V46, P164	34	231	245	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2002	8	9					971	978		10.1038/nm746	http://dx.doi.org/10.1038/nm746			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12172541				2022-12-27	WOS:000177757900032
J	Shindo, T; Manabe, I; Fukushima, Y; Tobe, K; Aizawa, K; Miyamoto, S; Kowase, KK; Moriyama, N; Imai, Y; Kawakami, H; Nishimatsu, H; Ishikawa, T; Suzuki, T; Morita, H; Maemura, K; Sata, M; Hirata, Y; Komukai, M; Kagechika, H; Kadowaki, T; Kurabayashi, M; Nagai, R				Shindo, T; Manabe, I; Fukushima, Y; Tobe, K; Aizawa, K; Miyamoto, S; Kowase, KK; Moriyama, N; Imai, Y; Kawakami, H; Nishimatsu, H; Ishikawa, T; Suzuki, T; Morita, H; Maemura, K; Sata, M; Hirata, Y; Komukai, M; Kagechika, H; Kadowaki, T; Kurabayashi, M; Nagai, R			Kruppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE-CELLS; RETINOBENZOIC ACIDS; GENE-TRANSCRIPTION; EXPRESSION; GROWTH; BTEB2; DEFICIENT; PATHWAYS; MYOCYTES; FAMILY	We recently isolated a Kruppel-like zinc-finger transcription factor 5 (KLF5; also known as BTEB2 and IKLF), which is markedly induced in activated vascular smooth-muscle cells and fibroblasts. Here we describe our analysis of the in vivo function of KLF5 using heterozygous KLF5-knockout mice ( Klf5(+/-)). In response to external stress, Klf5(+/-) mice showed diminished levels of arterial- wall thickening, angiogenesis, cardiac hypertrophy and interstitial fibrosis. Also, angiotensin II induced expression of KLF5, which in turn activated platelet-derived growth factor-A (PDGF-A) and transforming growth factor-beta (TGF-beta) expression. In addition, we determined that KLF5 interacted with the retinoic-acid receptor (RAR), that synthetic RAR ligands modulated KLF5 transcriptional activity, and that in vivo administration of RAR ligands affected stress responses in the cardiovascular system in a KLF5-dependent manner. KLF5 thus seems to be a key element linking external stress and cardiovascular remodeling.	Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan; Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan; Univ Tokyo, Grad Sch Med, Dept Metab Dis, Tokyo, Japan; Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo, Japan; Gunma Univ, Sch Med, Dept Internal Med 2, Gunma, Japan; Kyorin Univ, Dept Anat, Tokyo, Japan; Inst Med Mol Design Inc, Tokyo, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Gunma University; Kyorin University	Nagai, R (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan.	nagai-tky@umin.ac.jp	Manabe, Ichiro/E-1529-2014; Manabe, Ichiro/AAE-5105-2021	Kagechika, Hiroyuki/0000-0002-6747-1013; Suzuki, Toru/0000-0002-8371-664X				AIKAWA M, 1995, ANN NY ACAD SCI, V748, P578; Akishita M, 1997, ATHEROSCLEROSIS, V130, P1, DOI 10.1016/S0021-9150(96)06023-6; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Carmeliet P, 2000, J PATHOL, V190, P387; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; EYROLLES L, 1994, J MED CHEM, V37, P1508, DOI 10.1021/jm00036a017; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Glass CK, 2000, GENE DEV, V14, P121; Hoshino Y, 2000, CIRCULATION, V102, P2528, DOI 10.1161/01.CIR.102.20.2528; Karlsson L, 2000, DEVELOPMENT, V127, P3457; Kawai-Kowase K, 1999, CIRC RES, V85, P787, DOI 10.1161/01.RES.85.9.787; Kihm AJ, 1998, P NATL ACAD SCI USA, V95, P14816, DOI 10.1073/pnas.95.25.14816; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KUROO M, 1989, J BIOL CHEM, V264, P18272; Libby P, 2000, J INTERN MED, V247, P349, DOI 10.1046/j.1365-2796.2000.00654.x; Manabe I, 1997, BIOCHEM BIOPH RES CO, V239, P598, DOI 10.1006/bbrc.1997.7512; Manabe I, 2001, CIRC RES, V88, P1127, DOI 10.1161/hh1101.091339; Matsusaka T, 1999, J CLIN INVEST, V103, P1451, DOI 10.1172/JCI5056; Moroi M, 1998, J CLIN INVEST, V101, P1225, DOI 10.1172/JCI1293; Oh-hashi Y, 2001, CIRC RES, V89, P983, DOI 10.1161/hh2301.100812; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Shindo T, 2001, CIRCULATION, V104, P1964, DOI 10.1161/hc4101.097111; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Umemiya H, 1997, J MED CHEM, V40, P4222, DOI 10.1021/jm9704309; Valen G, 2001, J AM COLL CARDIOL, V38, P307, DOI 10.1016/S0735-1097(01)01377-8; Wang HD, 2001, CIRC RES, V88, P947, DOI 10.1161/hh0901.089987; Watanabe N, 1999, CIRC RES, V85, P182, DOI 10.1161/01.RES.85.2.182; Weir MR, 1999, AM J HYPERTENS, V12, p205S; Yamauchi-Takihara K, 2000, TRENDS CARDIOVAS MED, V10, P298, DOI 10.1016/S1050-1738(01)00066-4; Zdunek M, 2001, KIDNEY INT, V60, P2097, DOI 10.1046/j.1523-1755.2001.00041.x	33	317	343	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2002	8	8					856	863		10.1038/nm738	http://dx.doi.org/10.1038/nm738			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12101409				2022-12-27	WOS:000177200900032
J	Ferguson, NM; Anderson, RM				Ferguson, NM; Anderson, RM			Predicting evolutionary change in the influenza A virus	NATURE MEDICINE			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, London, England	Imperial College London	Ferguson, NM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, London, England.		Ferguson, Neil/B-8578-2008	Ferguson, Neil/0000-0002-1154-8093; Anderson, Roy/0000-0002-9528-3175				Bush RM, 2000, P NATL ACAD SCI USA, V97, P6974, DOI 10.1073/pnas.97.13.6974; Bush RM, 1999, SCIENCE, V286, P1921, DOI 10.1126/science.286.5446.1921; Everitt B. S., 2001, CLUSTER ANAL; FITCH WM, 1991, P NATL ACAD SCI USA, V88, P4270, DOI 10.1073/pnas.88.10.4270; Glezen WP, 1996, EPIDEMIOL REV, V18, P64, DOI 10.1093/oxfordjournals.epirev.a017917; Gordon AD, 1999, CLASSIFICATION; Plotkin JB, 2002, P NATL ACAD SCI USA, V99, P6263, DOI 10.1073/pnas.082110799	7	19	19	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2002	8	6					562	563		10.1038/nm0602-562	http://dx.doi.org/10.1038/nm0602-562			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042802				2022-12-27	WOS:000175907300023
J	Dumont, EA; Reutelingsperger, CPM; Smits, JFM; Daemen, MJAP; Doevendans, PAF; Wellens, HJJ; Hofstra, L				Dumont, EA; Reutelingsperger, CPM; Smits, JFM; Daemen, MJAP; Doevendans, PAF; Wellens, HJJ; Hofstra, L			Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart	NATURE MEDICINE			English	Article							DEATH	We report a novel real-time imaging model to visualize apoptotic membrane changes of single cardiomyocytes in the injured heart of the living mouse, using fluorescent labeled annexin-V. Annexin-V binds to externalized phosphatidylserine (PS) of cells undergoing programmed cell death. With high-magnification (x100-160) real-time imaging, we visualized the binding of annexin-V to single cardiomyocytes. Kinetic studies at the single-cell level revealed that cardiomyocytes started to bind annexin-V within minutes after reperfusion, following an ischemic period of 30 minutes. The amount of bound annexin-V increased rapidly and reached a maximum within 20-25 minutes. Caspase inhibitors decreased the number of annexin-V-positive cardiomyocytes and slowed down the rate of PS exposure of cardiomyocytes that still bound annexin-V. This technology to study cell biology in the natural environment will enhance knowledge of intracellular signaling pathways relevant for cell-death regulation and strategies to manipulate these pathways for therapeutic effect.	Cardiovasc Res Inst Maastricht, Maastricht, Netherlands	Maastricht University	Dumont, EA (corresponding author), Cardiovasc Res Inst Maastricht, Univ Singel 50, Maastricht, Netherlands.							Bell JI, 1999, NAT MED, V5, P477, DOI 10.1038/8353; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; Dumont EAWJ, 2000, CIRCULATION, V102, P1564, DOI 10.1161/01.CIR.102.13.1564; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; KOOPMAN G, 1994, BLOOD, V84, P5; MARTIN SJ, 1995, J EXP MED, V182, P552; Plymale DR, 1999, NAT MED, V5, P351, DOI 10.1038/6574; Sweeney TJ, 1999, P NATL ACAD SCI USA, V96, P12044, DOI 10.1073/pnas.96.21.12044; Tempany CMC, 2001, JAMA-J AM MED ASSOC, V285, P562, DOI 10.1001/jama.285.5.562; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang M, 2001, P NATL ACAD SCI USA, V98, P2616, DOI 10.1073/pnas.051626698	11	171	178	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2001	7	12					1352	1355		10.1038/nm1201-1352	http://dx.doi.org/10.1038/nm1201-1352			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726977				2022-12-27	WOS:000172610300042
J	Lyden, D; Hattori, K; Dias, S; Costa, C; Blaikie, P; Butros, L; Chadburn, A; Heissig, B; Marks, W; Witte, L; Wu, Y; Hicklin, D; Zhu, ZP; Hackett, NR; Crystal, RG; Moore, MAS; Hajjar, KA; Manova, K; Benezra, R; Rafii, S				Lyden, D; Hattori, K; Dias, S; Costa, C; Blaikie, P; Butros, L; Chadburn, A; Heissig, B; Marks, W; Witte, L; Wu, Y; Hicklin, D; Zhu, ZP; Hackett, NR; Crystal, RG; Moore, MAS; Hajjar, KA; Manova, K; Benezra, R; Rafii, S			Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth	NATURE MEDICINE			English	Article							PROGENITOR CELLS; MOBILIZATION; CONTRIBUTES; LETHALITY; KINASE	The role of bone marrow (BM)-derived precursor cells in tumor angiogenesis is not known, We demonstrate here that tumor angiogenesis is associated with recruitment of hematopoietic and circulating endothelial precursor cells (CEPs). We used the angiogenic defective, tumor resistant ld-mutant mice to show that transplantation of wild-type BM or vascular endothelial growth factor (VEGF)-mobilized stem cells restore tumor angiogenesis and growth. We detected donor-derived CEPs throughout the neovessels of tumors and Matrigel-plugs in an Id1(+/-)Id3(-/-) host, which were associated with VEGF-receptor-1-positive (VEGFR1(+))myeloid cells. The angiogenic defect in ld-mutant mice was due to impaired VEGF-driven mobilization of VEGFR2(+) CEPs and impaired proliferation and incorporation of VEGFR1(+) cells. Although targeting of either VEGFR1 or VEGFR2 alone partially blocks the growth of tumors, inhibition of both VEGFR1 and VEGFR2 was necessary to completely ablate tumor growth. These data demonstrate that recruitment of VEGF-responsive BM-derived precursors is necessary and sufficient for tumor angiogenesis and suggest new clinical strategies to block tumor growth.	Mem Sloan Kettering Canc Ctr, Dept Cell Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Cellular Biochem & Biophys, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Hematol Oncol, New York, NY USA; Cornell Univ, Coll Med, Dept Pulm Med, New York, NY USA; Cornell Univ, Coll Med, Dept Pathol, New York, NY USA; Cornell Univ, Coll Med, Dept Pediat, New York, NY USA; ImClone Syst Inc, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University; Cornell University; Cornell University; Eli Lilly	Benezra, R (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Cell Biol, 1275 York Ave, New York, NY 10021 USA.	r-benezra@ski.mskcc.org; srafii@med.cornell.edu	Dias, Sergio/L-1250-2014; Heissig, Beate/AAF-6771-2021	Dias, Sergio/0000-0002-7603-4616; Heissig, Beate/0000-0002-0348-5934; Costa, Carla/0000-0001-5977-6207	NCI NIH HHS [CA 08748] Funding Source: Medline; NHLBI NIH HHS [HL66592, R01 HL61849, HL67839] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061849, P01HL067839] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Donovan MJ, 2000, DEVELOPMENT, V127, P4531; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; Gill M, 2001, CIRC RES, V88, P167; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Prewett M, 1999, CANCER RES, V59, P5209; Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; TAM PP, 1999, DEVELOPMENT, V124, P1631; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	29	1518	1628	4	101	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2001	7	11					1194	1201		10.1038/nm1101-1194	http://dx.doi.org/10.1038/nm1101-1194			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689883				2022-12-27	WOS:000172054100026
J	Tuttle, RL; Gill, NS; Pugh, W; Lee, JP; Koeberlein, B; Furth, EE; Polonsky, KS; Naji, A; Birnbaum, MJ				Tuttle, RL; Gill, NS; Pugh, W; Lee, JP; Koeberlein, B; Furth, EE; Polonsky, KS; Naji, A; Birnbaum, MJ			Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKB alpha	NATURE MEDICINE			English	Article							INSULIN-RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; S6 KINASE; DROSOPHILA; SIZE; MICE; ACTIVATION; APOPTOSIS; MODEL; MASS	The physiological performance of an organ depends on an interplay between changes in cellular function and organ size, determined by cell growth, proliferation and death. Nowhere is this more evident than in the endocrine pancreas, where disturbances in function or mass result in severe disease. Recently, the insulin signal-transduction pathway has been implicated in both the regulation of hormone secretion from beta cells in mammals as well as the determination of cell and organ size in Drosophila melanogaster. A prominent mediator of the actions of insulin and insulin-like growth factor 1 (IGF-1) is the 3'-phosphoinositide-dependent protein kinase Akt, also known as protein kinase B (PKB). Here we report that overexpression of active Akt1 in the mouse beta cell substantially affects compartment size and function. There was a significant increase in both beta -cell size and total islet mass, accompanied by improved glucose tolerance and complete resistance to experimental diabetes.	Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Internal Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Washington University (WUSTL)	Birnbaum, MJ (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Internal Med, Philadelphia, PA 19104 USA.			Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [DK19525, R01 DK56886, P30DK50306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, R01DK056886, P30DK050306] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; Coffer PJ, 1998, BIOCHEM J, V335, P1; Edgar BA, 1999, NAT CELL BIOL, V1, pE191, DOI 10.1038/70217; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HEYNER S, 1994, BIOESSAYS, V16, P55, DOI 10.1002/bies.950160109; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; LeRoith D, 1997, NEW ENGL J MED, V336, P633, DOI 10.1056/NEJM199702273360907; LIKE AA, 1976, SCIENCE, V193, P415, DOI 10.1126/science.180605; Mauricio D, 1998, DIABETES, V47, P1537, DOI 10.2337/diabetes.47.10.1537; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MONTANA E, 1993, J CLIN INVEST, V91, P780, DOI 10.1172/JCI116297; OBrien BA, 1996, J PATHOL, V178, P176; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116	30	424	446	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1133	1137		10.1038/nm1001-1133	http://dx.doi.org/10.1038/nm1001-1133			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590437				2022-12-27	WOS:000171524500035
J	Sonoshita, M; Takaku, K; Sasaki, N; Sugimoto, Y; Ushikubi, F; Narumiya, S; Oshima, M; Taketo, MM				Sonoshita, M; Takaku, K; Sasaki, N; Sugimoto, Y; Ushikubi, F; Narumiya, S; Oshima, M; Taketo, MM			Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice	NATURE MEDICINE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; MESSENGER-RNA; COLON CARCINOGENESIS; EXPRESSION; GENE; SYNTHASE; GROWTH; CELLS; E-2; ANGIOGENESIS	Arachidonic acid is metabolized to prostaglandin H-2 (PGH(2)) by cyclooxygenase (COX). COX-2, the inducible COX isozyme, has a key role in intestinal polyposis(1,2). Among the metabolites of PGH,, PGE, is implicated in tumorigenesis because its level is markedly elevated in tissues of intestinal adenoma and colon cancer(3). Here we show that homozygous deletion of the gene encoding a cell-surface receptor of PGE(2), EP2, causes decreases in number and size of intestinal polyps in Apc(Delta 716) mice (a mouse model for human familial adenomatous polyposis). This effect is similar to that of COX-2 gene disruption. We also show that COX-2 expression is boosted by PGE(2) through the EP2 receptor via a positive feedback loop. Homozygous gene knockout for other PGE(2) receptors, EP1 or EP3, did not affect intestinal polyp formation in Apc(Delta 716) mice. We conclude that EP2 is the major receptor mediating the PGE(2) signal generated by COX-2 upregulation in intestinal polyposis, and that increased cellular CAMP stimulates expression of more COX-2 and vascular endothelial growth factor in the polyp stroma.	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Biomed Genet, Tokyo, Japan; Kyoto Univ, Grad Sch Med, Dept Pharmacol, Kyoto, Japan; Kyoto Univ, Grad Sch Pharmacuet Sci, Dept Physiol Sci, Kyoto, Japan; Asahikawa Med Coll, Dept Pharmacol, Asahikawa, Hokkaido 078, Japan	University of Tokyo; Kyoto University; Kyoto University; Asahikawa Medical College	Taketo, MM (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Biomed Genet, Tokyo, Japan.		SONOSHITA, MASAHIRO/Q-1571-2019; Sasaki, Nobuya/F-6579-2012; Sugimoto, Yukihiko/AAV-6470-2021; Sonoshita, Masahiro/AAE-5516-2019; Oshima, Masanobu/F-9958-2014	SONOSHITA, MASAHIRO/0000-0003-2890-336X; Sugimoto, Yukihiko/0000-0001-6973-932X; Oshima, Masanobu/0000-0002-3304-0004				Cheng T, 1998, INVEST OPHTH VIS SCI, V39, P581; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; Daniel TO, 1999, CANCER RES, V59, P4574; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; Gupta RA, 1998, GASTROENTEROLOGY, V114, P1095, DOI 10.1016/S0016-5085(98)70330-0; Hewitt RE, 1997, BRIT J CANCER, V75, P221, DOI 10.1038/bjc.1997.37; Hinz B, 2000, BIOCHEM BIOPH RES CO, V278, P790, DOI 10.1006/bbrc.2000.3885; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; KARGMAN SL, 1995, CANCER RES, V55, P2556; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Morimoto K, 1997, AM J PHYSIOL-GASTR L, V272, pG681, DOI 10.1152/ajpgi.1997.272.3.G681; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Taketo MM, 1998, J NATL CANCER I, V90, P1529, DOI 10.1093/jnci/90.20.1529; Tjandrawinata RR, 1997, BRIT J CANCER, V75, P1111, DOI 10.1038/bjc.1997.192; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; Watanabe K, 1999, CANCER RES, V59, P5093; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Yamada Y, 2000, CANCER RES, V60, P3323; Yang VW, 1998, CANCER RES, V58, P1750	26	501	517	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2001	7	9					1048	1051		10.1038/nm0901-1048	http://dx.doi.org/10.1038/nm0901-1048			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533709	Green Submitted			2022-12-27	WOS:000170853300031
J	Khan, J; Wei, JS; Ringner, M; Saal, LH; Ladanyi, M; Westermann, F; Berthold, F; Schwab, M; Antonescu, CR; Peterson, C; Meltzer, PS				Khan, J; Wei, JS; Ringner, M; Saal, LH; Ladanyi, M; Westermann, F; Berthold, F; Schwab, M; Antonescu, CR; Peterson, C; Meltzer, PS			Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks	NATURE MEDICINE			English	Article							MOLECULAR CLASSIFICATION; DIFFERENTIAL-DIAGNOSIS; NEUROECTODERMAL TUMOR; CDNA MICROARRAYS; EWINGS-SARCOMA; HUMAN BREAST; CELL TUMORS; ROUND-CELL; GROWTH; PATTERNS	The purpose of this study was to develop a method of classifying cancers to specific diagnostic categories based on their gene expression signatures using artificial neural networks (ANNs). We trained the ANNs using the small, round blue-cell tumors (SRBCTs) as a model. These cancers belong to four distinct diagnostic categories and often present diagnostic dilemmas in clinical practice. The ANNs correctly classified all samples and identified the genes most relevant to the classification. Expression of several of these genes has been reported in SRBCTs, but most have not been associated with these cancers. To test the ability of the trained ANN models to recognize SRSCTs, we analyzed additional blinded samples that were not previously used for the training procedure, and correctly classified them in all cases. This study demonstrates the potential applications of these methods for tumor diagnosis and the Identification of candidate targets for therapy.	NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; NCI, Pediat Oncol Branch, Ctr Adv Technol, Gaithersburg, MD USA; Univ Lund, Dept Theoret Phys, Complex Syst Div, S-22362 Lund, Sweden; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; German Canc Res Ctr, Dept Cytogenet, D-6900 Heidelberg, Germany; Univ Cologne, Klin Kinderheilkunde, Dept Pediat, Cologne, Germany	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Lund University; Memorial Sloan Kettering Cancer Center; Helmholtz Association; German Cancer Research Center (DKFZ); University of Cologne	Khan, J (corresponding author), NHGRI, Canc Genet Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.		Westermann, Frank/F-7509-2013; Ringnér, Markus/G-3641-2011; Ladanyi, Marc/AAG-8585-2019; Saal, Lao H/A-2919-2011; Khan, Javed/P-9157-2014	Ringnér, Markus/0000-0001-5469-8940; Saal, Lao H/0000-0002-0815-1896; 	NATIONAL CANCER INSTITUTE [Z01SC010366] Funding Source: NIH RePORTER; NCI NIH HHS [Z01 SC010366-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdolmaleki P, 1997, Radiat Med, V15, P283; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Ashizawa K, 1999, ACAD RADIOL, V6, P2, DOI 10.1016/S1076-6332(99)80055-5; Bishop C.M., 1995, NEURAL NETWORKS PATT; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Brown MPS, 2000, P NATL ACAD SCI USA, V97, P262, DOI 10.1073/pnas.97.1.262; CAVAZZANA AO, 1987, AM J PATHOL, V127, P507; Chen Y., 1997, BIOMED OPTICS, V2, P364; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DeRisi J, 1996, NAT GENET, V14, P457; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; Furey TS, 2000, BIOINFORMATICS, V16, P906, DOI 10.1093/bioinformatics/16.10.906; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GREEN BN, 1994, ENDOCRINOLOGY, V134, P954, DOI 10.1210/en.134.2.954; Heden B, 1997, CIRCULATION, V96, P1798, DOI 10.1161/01.CIR.96.6.1798; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; HOLTRICH U, 1991, P NATL ACAD SCI USA, V88, P10411, DOI 10.1073/pnas.88.23.10411; Hughes SE, 1997, J HISTOCHEM CYTOCHEM, V45, P1005, DOI 10.1177/002215549704500710; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; Jollife I. T., 1986, PRINCIPAL COMPONENT; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Khan J, 1998, CANCER RES, V58, P5009; KOVAR H, 1990, ONCOGENE, V5, P1067; Kumar S, 2000, MODERN PATHOL, V13, P988, DOI 10.1038/modpathol.3880179; LEE MGS, 1984, NUCLEIC ACIDS RES, V12, P5823, DOI 10.1093/nar/12.14.5823; McKarney LA, 1997, INT J DEV BIOL, V41, P485; McManus AP, 1996, J PATHOL, V178, P116, DOI 10.1002/(SICI)1096-9896(199602)178:2<116::AID-PATH494>3.0.CO;2-H; Mu J, 1998, J BIOL CHEM, V273, P34850, DOI 10.1074/jbc.273.52.34850; Nagano T, 1998, MOL BRAIN RES, V53, P13, DOI 10.1016/S0169-328X(97)00271-4; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PIZZO P, 1997, PRINCIPLES PRACTICE; Savchenko VL, 2000, NEUROSCIENCE, V96, P195, DOI 10.1016/S0306-4522(99)00538-2; SHAOUL E, 1995, ONCOGENE, V10, P1553; SILIPO R, 1995, COMPUT BIOMED RES, V28, P305, DOI 10.1006/cbmr.1995.1021; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; STROHMAN RC, 1983, SCIENCE, V221, P955, DOI 10.1126/science.6879193; TAKAHASHI Y, 1993, J BIOL CHEM, V268, P8893; TAYLOR C, 1993, BRIT J CANCER, V67, P128, DOI 10.1038/bjc.1993.22; TRICHE TJ, 1983, HUM PATHOL, V14, P569	40	1841	2014	3	263	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2001	7	6					673	679		10.1038/89044	http://dx.doi.org/10.1038/89044			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385503	Green Accepted			2022-12-27	WOS:000169081500034
J	Basu, S; Nagy, JA; Pal, S; Vasile, E; Eckelhoefer, IA; Bliss, VS; Manseau, EJ; Dasgupta, PS; Dvorak, HF; Mukhopadhyay, D				Basu, S; Nagy, JA; Pal, S; Vasile, E; Eckelhoefer, IA; Bliss, VS; Manseau, EJ; Dasgupta, PS; Dvorak, HF; Mukhopadhyay, D			The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor	NATURE MEDICINE			English	Article							ASCITES TUMOR-GROWTH; RHEUMATOID-ARTHRITIS; PITUITARY-ADENOMAS; B-16 MELANOMA; PATHOGENESIS; ACCUMULATION; EXPRESSION; HYPERPERMEABILITY; SCHIZOPHRENIA; INNERVATION	Angiogenesis has an essential role in many important pathological and physiological settings. It has been shown that vascular permeability factor/vascular endothelial growth factor (VPF/VEGF), a potent cytokine expressed by most malignant tumors, has critical roles in vasculogenesis and both physiological and pathological angiogenesis. We report here that at non-toxic levels, the neurotransmitter dopamine strongly and selectively inhibited the vascular permeabilizing and angiogenic activities of VPF/VEGF. Dopamine acted through D2 dopamine receptors to induce endocytosis of VEGF receptor 2, which is critical for promoting angiogenesis, thereby preventing VPF/VEGF binding, receptor phosphorylation and subsequent signaling steps. The action of dopamine was specific for VPF/VEGF and did not affect other mediators of microvascular permeability or endothelial-cell proliferation or migration. These results reveal a new link between the nervous system and angiogenesis and indicate that dopamine and other D2 receptors, already in clinical use for other purposes, might have value in anti-angiogenesis therapy.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Mukhopadhyay, D (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA.							Ashraf S, 1997, CLIN EXP METASTAS, V15, P484, DOI 10.1023/A:1018466608614; BACIC F, 1991, J NEUROCHEM, V57, P1774, DOI 10.1111/j.1471-4159.1991.tb06380.x; Basu S, 2000, J NEUROIMMUNOL, V102, P113, DOI 10.1016/S0165-5728(99)00176-9; Basu S, 1999, DIGEST DIS SCI, V44, P916, DOI 10.1023/A:1026644110737; Basu S, 2000, ENDOCRINE, V12, P237, DOI 10.1385/ENDO:12:3:237; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; Braunwald E, 1998, LANCET, V352, P1771, DOI 10.1016/S0140-6736(98)03212-7; Brown LF, 1997, REGULATION ANGIOGENE; Chamary VL, 2000, EUR J SURG ONCOL, V26, P588, DOI 10.1053/ejso.2000.0952; DASGUPTA PS, 1987, J CANCER RES CLIN, V113, P363, DOI 10.1007/BF00397720; DASILVA JAP, 1990, J RHEUMATOL, V17, P1592; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; DVORAK HF, 1979, J IMMUNOL, V122, P166; Egan MF, 1997, CURR OPIN NEUROBIOL, V7, P701, DOI 10.1016/S0959-4388(97)80092-X; EWING AG, 1983, SCIENCE, V221, P169, DOI 10.1126/science.6857277; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; GOLDSTEIN M, 1992, FASEB J, V6, P2413, DOI 10.1096/fasebj.6.7.1348713; GRAYBIEL AM, 1990, ADV NEUROL, V53, P17; Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275; HEEG K, 1985, J IMMUNOL METHODS, V77, P237, DOI 10.1016/0022-1759(85)90036-5; KATZUNG BG, 1998, BASIC CLIN PHARM; Miller LE, 2000, FASEB J, V14, P2097, DOI 10.1096/fj.99-1082com; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Nagai Y, 2000, HORM METAB RES, V32, P326, DOI 10.1055/s-2007-978645; NAGY JA, 1995, CANCER RES, V55, P360; NAGY JA, 1995, CANCER RES, V55, P376; NAGY JA, 1995, CANCER RES, V55, P369; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Otsuka F, 1999, REGUL PEPTIDES, V83, P31, DOI 10.1016/S0167-0115(99)00048-8; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; RICCI A, 1994, J AUTON PHARMACOL, V14, P61, DOI 10.1111/j.1474-8673.1994.tb00590.x; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Takechi Akihiko, 1994, Neurologia Medico-Chirurgica, V34, P729, DOI 10.2176/nmc.34.729; Turner HE, 2000, J ENDOCRINOL, V165, P475, DOI 10.1677/joe.0.1650475; WICK MM, 1978, J INVEST DERMATOL, V71, P163, DOI 10.1111/1523-1747.ep12546959.1; WICK MM, 1979, J NATL CANCER I, V63, P1465; WICK MM, 1979, CANCER TREAT REP, V63, P991; WICK MM, 1981, CANCER TREAT REP, V65, P861; WICK MM, 1981, J NATL CANCER I, V66, P351; WICK MM, 1980, CANCER RES, V40, P1414; ZAROSLINSKI JF, 1977, P ROY SOC MED, V70, P2, DOI 10.1177/00359157770700S202	41	289	312	1	28	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					569	574		10.1038/87895	http://dx.doi.org/10.1038/87895			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329058				2022-12-27	WOS:000169961100036
J	Paul, R; Zhang, ZG; Eliceiri, BP; Jiang, Q; Boccia, AD; Zhang, RL; Chopp, M; Cheresh, DA				Paul, R; Zhang, ZG; Eliceiri, BP; Jiang, Q; Boccia, AD; Zhang, RL; Chopp, M; Cheresh, DA			Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke	NATURE MEDICINE			English	Article							TYROSINE KINASE; FAMILY KINASES; MUTANT MICE; BRAIN; CELLS; ISCHEMIA; INJURY; WATER; EDEMA; RAT	Vascular endothelial growth factor (VEGF), an angiogenic factor produced in response to ischemic injury, promotes vascular permeability (VP). Evidence is provided that Src kinase regulates VEGF-mediated VP in the brain following stroke and that suppression of Src activity decreases VP thereby minimizing brain injury. Mice lacking pp60(c-sr)c are resistant to VEGF-induced VP and show decreased infarct volumes after stroke whereas mice deficient in pp59(c-fyn), another Src family member, have normal VEGF-mediated VP and infarct size. Systemic application of a Src-inhibitor given up to six hours following stroke suppressed VP protecting wild-type mice from ischemia-induced brain damage without influencing VEGF expression. This was associated with reduced edema, improved cerebral perfusion and decreased infarct volume 24 hours after injury as measured by magnetic resonance imaging and histological analysis. Thus, Src represents a key intermediate and novel therapeutic target in the pathophysiology of cerebral ischemia where it appears to regulate neuronal damage by influencing VEGF-mediated VP.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA	Scripps Research Institute; Scripps Research Institute; Henry Ford Health System; Henry Ford Hospital	Cheresh, DA (corresponding author), Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA.	cheresh@scripps.edu		Eliceiri, Brian/0000-0003-1811-1916	NATIONAL CANCER INSTITUTE [R03CA050287, R01CA045726] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009435] Funding Source: NIH RePORTER; NCI NIH HHS [CA50287, CA45726] Funding Source: Medline; NHLBI NIH HHS [1F32HL09435] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES A, 1968, AM J PATHOL, V52, P437; Cheung HH, 2000, J CEREBR BLOOD F MET, V20, P505, DOI 10.1097/00004647-200003000-00009; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Go K G, 1997, Adv Tech Stand Neurosurg, V23, P47; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; JIANG Q, 1993, J NEUROL SCI, V120, P123, DOI 10.1016/0022-510X(93)90262-W; Jiang Q, 1998, J CEREBR BLOOD F MET, V18, P758, DOI 10.1097/00004647-199807000-00007; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; Patel SC, 1999, PROG CARDIOVASC DIS, V42, P217, DOI 10.1016/S0033-0620(99)70004-6; Pfister HW, 1997, CURR OPIN NEUROL, V10, P254, DOI 10.1097/00019052-199706000-00015; Risau W, 1998, PATHOL BIOL, V46, P171; Rosenberg GA, 1999, PROG CARDIOVASC DIS, V42, P209, DOI 10.1016/S0033-0620(99)70003-4; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Takagi N, 1999, J CEREBR BLOOD F MET, V19, P880, DOI 10.1097/00004647-199908000-00007; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; ZHANG WG, 1995, MAGNET RESON MED, V33, P370, DOI 10.1002/mrm.1910330310; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zhang ZG, 1997, J CEREBR BLOOD F MET, V17, P1081, DOI 10.1097/00004647-199710000-00010	31	294	329	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2001	7	2					222	227		10.1038/84675	http://dx.doi.org/10.1038/84675			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175854				2022-12-27	WOS:000166756300040
J	Suzuki, A; Obata, S; Hayashida, M; Kawano, H; Nakano, T; Shiraki, K				Suzuki, A; Obata, S; Hayashida, M; Kawano, H; Nakano, T; Shiraki, K			RETRACTED: SADS: A new component of Fas-DISC is the accelerator for cell death signaling and is downregulated in patients with colon carcinoma (Retracted Article. See vol 7, pg 749, 2001)	NATURE MEDICINE			English	Article; Retracted Publication							MEDIATED APOPTOSIS; PROTEIN; RECEPTOR; ANTIGEN; FADD; INVOLVEMENT; CASPASE-8; ACTIVATION; PROTEASES; PATHWAYS	Fas is the death receptor, transducing cell death signaling upon stimulation by Fas ligand. During Fas-initiated cell death signaling, the formation of Fas-death inducing signaling complex (Fas-DISC) is the first step. Here we have identified a new component of Fas-DISC which we call 'small-accelerator for death signaling' (SADS). SADS cDNA encodes a 150 amino acid polypeptide (Mr = 16,700). During Fas-mediated cell death, SADS enhances the interaction of Fas-death domain-interactive factors (FADD) and procaspase-8, and deletion mutant analysis has identified FADD- and caspase-8-interactive domains in SADS. Inhibition or removal of SADS delays Fas-mediated cell death. In addition, we demonstrate the deletion or mutation of SADS in patients with colon carcinoma and that exogenous SADS expression in human colon carcinoma SW480 cells that lack SADS leads to re-acquisition of Fas-mediated cell death. Here, we propose that SADS is one of the cell death-associated factors and enhances Fas-DISC formation, especially FADD and procaspase-8 recruitment.	Daiichi Pharmaceut Co Ltd, Basic Technol Res Lab, Project Cell Death Res, Tokyo R&D Ctr,Edogawa Ku, Tokyo 1348630, Japan; Kishida Chem Co Ltd, Sanda Factory, Res & Dev Grp, Biochem Lab, Sanda, Hyogo 6691339, Japan; Mie Univ, Sch Med, Dept Internal Med 1, Tsu, Mie 5148507, Japan	Daiichi Sankyo Company Limited; Mie University	Suzuki, A (corresponding author), Daiichi Pharmaceut Co Ltd, Basic Technol Res Lab, Project Cell Death Res, Tokyo R&D Ctr,Edogawa Ku, Kitakasai 1-16-13, Tokyo 1348630, Japan.	LEB00373@nifty.ne.jp						Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Hasegawa J, 1996, CANCER RES, V56, P1713; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Suzuki A, 1999, P SOC EXP BIOL MED, V221, P72, DOI 10.1046/j.1525-1373.1999.d01-56.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	26	14	14	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					88	93		10.1038/83401	http://dx.doi.org/10.1038/83401			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135621				2022-12-27	WOS:000166243100040
J	Lagasse, E; Connors, H; Al-Dhalimy, M; Reitsma, M; Dohse, M; Osborne, L; Wang, X; Finegold, M; Weissman, IL; Grompe, M				Lagasse, E; Connors, H; Al-Dhalimy, M; Reitsma, M; Dohse, M; Osborne, L; Wang, X; Finegold, M; Weissman, IL; Grompe, M			Purified hematopoietic stem cells can differentiate into hepatocytes in vivo	NATURE MEDICINE			English	Article							TYROSINEMIA TYPE-I; BONE-MARROW; MONOCLONAL-ANTIBODIES; HEPATIC-DYSFUNCTION; BETA-GALACTOSIDASE; MURINE MODEL; TRANSPLANTATION; PROGENITORS; EXPRESSION; GENE	The characterization of hepatic progenitor cells is of great scientific and clinical interest. Here we report that intravenous injection of adult bone marrow cells in the FAH(-/-) mouse, an animal model of tyrosinemia type I, rescued the mouse and restored the biochemical function of its liver. Moreover, within bone marrow, only rigorously purified hematopoietic stem cells gave rise to donor-derived hematopoietic and hepatic regeneration. This result seems to contradict the conventional assumptions of the germ layer origins of tissues such as the liver, and raises the question of whether the cells of the hematopoietic stem cell phenotype are pluripotent hematopoietic cells that retain the ability to transdifferentiate, or whether they are more primitive multipotent cells.	StemCells, Sunnyvale, CA 94085 USA; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Texas Childrens Hosp, Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Stanford Univ, Sch Med, Dept Pathol & Dev Biol, Stanford, CA 94305 USA	Oregon Health & Science University; Baylor College of Medicine; Stanford University	Lagasse, E (corresponding author), StemCells, 525 Del Rey Ave,Suite C, Sunnyvale, CA 94085 USA.			Grompe, Markus/0000-0002-6616-4345				Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Braun KM, 2000, NAT MED, V6, P320; Carella AM, 2000, BONE MARROW TRANSPL, V25, P345, DOI 10.1038/sj.bmt.1702204; Ferrari G, 1998, SCIENCE, V281, P923; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; GROMPE M, 1993, GENE DEV, V7, P2298, DOI 10.1101/gad.7.12a.2298; GROMPE M, 1995, NAT GENET, V10, P453, DOI 10.1038/ng0895-453; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hale DA, 2000, TRANSPLANTATION, V69, P1242, DOI 10.1097/00007890-200004150-00008; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Murata M, 1997, INT J HEMATOL, V66, P239; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; Overturf K, 1996, NAT GENET, V12, P458, DOI 10.1038/ng0496-458a; Overturf K, 1999, AM J PATHOL, V155, P2135, DOI 10.1016/S0002-9440(10)65531-9; Overturf K, 1997, AM J PATHOL, V151, P1273; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; RITT AW, 1988, JAMA-J AM MED ASSOC, V259, P3099; SELL S, 1997, LIVER STEM CELLS, P29; Shizuru J A, 1996, Biol Blood Marrow Transplant, V2, P3; SHIZURU JA, 1996, BIOL BLOOD MARROW TR, V3, P50; SMITH LG, 1991, P NATL ACAD SCI USA, V88, P2788, DOI 10.1073/pnas.88.7.2788; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Strom SC, 1999, SEMIN LIVER DIS, V19, P39, DOI 10.1055/s-2007-1007096; TALBOT NC, 1994, IN VITRO CELL DEV-AN, V30A, P851; Taniguchi H, 1996, NAT MED, V2, P198, DOI 10.1038/nm0296-198; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135; TILL J, 1961, RAD RES, V14; Uchida N, 1997, BLOOD, V90, P4354; UCHIDA N, 1992, J EXP MED, V175, P175, DOI 10.1084/jem.175.1.175; UCHIDA N, 1992, THESIS STANFORD U ST, P152; VANEWIJK W, 1981, J IMMUNOL, V127, P2594; WEISSMAN IL, 1994, IMMUNITY, V1, P529, DOI 10.1016/1074-7613(94)90042-6; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; WU AM, 1968, J EXP MED, V127, P455, DOI 10.1084/jem.127.3.455; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789	48	1880	2152	4	130	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1229	1234		10.1038/81326	http://dx.doi.org/10.1038/81326			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062533				2022-12-27	WOS:000165114800029
J	Liechty, KW; MacKenzie, TC; Shaaban, AF; Radu, A; Moseley, AB; Deans, R; Marshak, DR; Flake, AW				Liechty, KW; MacKenzie, TC; Shaaban, AF; Radu, A; Moseley, AB; Deans, R; Marshak, DR; Flake, AW			Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep	NATURE MEDICINE			English	Article							MARROW STROMAL CELLS; BONE-MARROW; NONHEMATOPOIETIC TISSUES; OSTEOGENESIS IMPERFECTA; EXPRESSION; DYSTROPHIN; MICE	Mesenchymal stem cells are multipotent cells that can be isolated from adult bone marrow and can be induced in vitro and in vivo to differentiate into a variety of mesenchymal tissues, including bone, cartilage, tendon, fat, bone marrow stroma, and muscle(1,2). Despite their potential clinical utility for cellular and gene therapy, the fate of mesenchymal stem cells after systemic administration is mostly unknown. To address this, we transplanted a well-characterized human mesenchymal stem cell population(3) into fetal sheep early in gestation, before and after the expected development of immunologic competence. In this xenogeneic system, human mesenchymal stem cells engrafted and:persisted in multiple tissues for as long as 13 months after transplantation. Transplanted human cells underwent site-specific differentiation into chondrocytes, adipocytes, myocytes and cardiomyocytes, bone marrow stromal cells and thymic stroma. Unexpectedly, there was long-term engraftment even when cells were transplanted after the expected development of immunocompetence. Thus, mesenchymal stem cells maintain their multipotential capacity after transplantation, and seem to have unique immunologic characteristics that allow persistence in-a xenogeneic environment. Our data support the possibility of the transplantability of mesenchymal stem cells and their potential utility in tissue engineering, and cellular and gene therapy applications.	Childrens Hosp Philadelphia, Childrens Inst Surg Sci, Philadelphia, PA 19104 USA; Osiris Therapeut, Baltimore, MD 21231 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Osiris Therapeutics	Flake, AW (corresponding author), Childrens Hosp Philadelphia, Childrens Inst Surg Sci, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.			Shaaban, Aimen/0000-0002-9459-107X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009856] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL009856] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANKLESARIA P, 1987, P NATL ACAD SCI USA, V84, P7681, DOI 10.1073/pnas.84.21.7681; CAPLAN AI, 1994, CLIN PLAST SURG, V21, P429; Culling CFA, 1974, HDB HISTOPATHOLOGICA, V3rd; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; FLAKE AW, 1986, SCIENCE, V233, P776, DOI 10.1126/science.2874611; Fourcade C, 1992, Eur Cytokine Netw, V3, P539; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Hou Z, 1999, P NATL ACAD SCI USA, V96, P7294, DOI 10.1073/pnas.96.13.7294; KEATING A, 1982, NATURE, V298, P280, DOI 10.1038/298280a0; NICHOLSON LVB, 1992, ACTA NEUROL SCAND, V86, P8, DOI 10.1111/j.1600-0404.1992.tb08046.x; Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; SHARP AH, 1993, J NEUROSCI, V13, P3051; SILVERSTEIN AM, 1964, J EXP MED, V119, P955, DOI 10.1084/jem.119.6.955; VANDERLOOS CM, 1993, HISTOCHEM J, V25, P1; Zanjani ED, 1996, INT J HEMATOL, V63, P179; Zanjani ED, 1998, EXP HEMATOL, V26, P353; ZANJANI ED, 1993, BLOOD, V81, P399; Zanjani ED, 1997, STEM CELLS, V15, P79, DOI 10.1002/stem.5530150812; ZANJANI ED, 1994, J CLIN INVEST, V93, P1051, DOI 10.1172/JCI117054; [No title captured]	25	963	1137	2	73	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1282	1286		10.1038/81395	http://dx.doi.org/10.1038/81395			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062543				2022-12-27	WOS:000165114800039
J	Kikuchi, T; Worgall, S; Singh, R; Moore, MAS; Crystal, RG				Kikuchi, T; Worgall, S; Singh, R; Moore, MAS; Crystal, RG			Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4(+) T cells	NATURE MEDICINE			English	Article							IN-VIVO; ADENOVIRUS VECTOR; PSEUDOMONAS-AERUGINOSA; ANTITUMOR IMMUNITY; CYSTIC-FIBROSIS; B-LYMPHOCYTES; GENE-TRANSFER; RESPONSES; INFECTION; MICE	We have investigated whether dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can trigger B cells to produce antigen-specific antibodies without CD4(+) T-cell help. Dendritic cells modified with a recombinant adenovirus vector to express CD40 ligand and pulsed with heat-killed Pseudomonas induced naive B cells to produce antibodies against Pseudomonas in the absence of CD4(+) T cells in vitro, initiated Pseudomonas-specific humoral immune responses in vivo in wild-type and CD4(-/-) mice, and protected immunized wild-type and CD4(-/-), but not B-cell(-/-) mice, from lethal intrapulmonary challenge with Pseudomonas. Thus, genetic modification of dendritic cells with CD40 ligand enables them to present a complex mixture of microbial antigens and establish CD4(+) T cell-independent, B cell-mediated protective immunity against a specific microbe.	Cornell Univ, Weill Med Coll, Dept Med, Div Pulm & Crit Care Med, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pediat, New York, NY USA; Cornell Univ, Weill Med Coll, Belfer Gene Therapy Core Facil, New York, NY USA; Cornell Univ, Weill Med Coll, Inst Med Genet, New York, NY USA; Mem Sloan Kettering Canc Ctr, James Ewing Lab Dev Hematopoiesis, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University; Cornell University; Memorial Sloan Kettering Cancer Center	Crystal, RG (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Pulm & Crit Care Med, New York, NY 10021 USA.		Singh, Ravi/B-1221-2010; Singh, Ravi N/A-5740-2011	Singh, Ravi N/0000-0003-0750-1804	NHLBI NIH HHS [P01 HL51746-06A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL051746] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson WF, 1998, NATURE, V392, P25; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barr TA, 1999, INFECT IMMUN, V67, P3637, DOI 10.1128/IAI.67.7.3637-3640.1999; Beland JL, 1998, BLOOD, V92, P4472, DOI 10.1182/blood.V92.11.4472.423k47_4472_4478; Brown MP, 1998, NAT MED, V4, P1253, DOI 10.1038/3233; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; Dubois B, 1998, J IMMUNOL, V161, P2223; Dubois B, 1997, J EXP MED, V185, P941, DOI 10.1084/jem.185.5.941; Dullforce P, 1998, NAT MED, V4, P88, DOI 10.1038/nm0198-088; Fayette J, 1997, J EXP MED, V185, P1909, DOI 10.1084/jem.185.11.1909; Ferlin WG, 1998, EUR J IMMUNOL, V28, P525, DOI 10.1002/(SICI)1521-4141(199802)28:02&lt;525::AID-IMMU525&gt;3.0.CO;2-M; GOLD MR, 1994, ADV IMMUNOL, V55, P221; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Gurunathan S, 1998, J IMMUNOL, V161, P4563; HERSH J, 1995, GENE THER, V2, P124; Kikuchi T, 1999, HUM GENE THER, V10, P1375, DOI 10.1089/10430349950018049; Kikuchi T, 2000, BLOOD, V96, P91, DOI 10.1182/blood.V96.1.91.013k19_91_99; Kovacs JA, 2000, NEW ENGL J MED, V342, P1416, DOI 10.1056/NEJM200005113421907; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; REIS, 1999, CURR OPIN IMMUNOL, V11, P392; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; Song W, 1997, J EXP MED, V186, P1247, DOI 10.1084/jem.186.8.1247; STARKE JR, 1987, PEDIATR RES, V22, P698, DOI 10.1203/00006450-198712000-00017; STEVENSON MM, 1995, CLIN EXP IMMUNOL, V99, P98, DOI 10.1111/j.1365-2249.1995.tb03478.x; Svensson M, 1997, J IMMUNOL, V158, P4229; Timmerman JM, 1999, ANNU REV MED, V50, P507; VanKooten C, 1996, ADV IMMUNOL, V61, P1; Wiley JA, 1997, J IMMUNOL, V158, P2932; Wilson JM, 1996, NEW ENGL J MED, V334, P1185, DOI 10.1056/NEJM199605023341809; WORGALL S, 1999, PEDIAT PULMONOL, V19, P311	34	68	94	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1154	1159		10.1038/80498	http://dx.doi.org/10.1038/80498			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017148				2022-12-27	WOS:000089674700041
J	Zhu, DC; Kepley, CL; Zhang, M; Zhang, K; Saxon, A				Zhu, DC; Kepley, CL; Zhang, M; Zhang, K; Saxon, A			A novel human immunoglobulin Fc gamma-Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation	NATURE MEDICINE			English	Article							MAST-CELL ACTIVATION; AFFINITY IGE RECEPTOR; NEGATIVE REGULATION; PHOSPHATASE SHIP; BINDING-SITE; BASOPHILS; MICE	Human mast cells and basophils that express the high-affinity immunoglobulin E (IgE) receptor, Fcepsilon receptor 1 (FcepsilonRI), have key roles in allergic diseases. FcepsilonRI cross-linking stimulates the release of allergic mediators(1). Mast cells and basophils co-express FcgammaRIIb, a low affinity receptor containing an immunoreceptor tyrosine-based inhibitory motif and whose co-aggregation with FcepsilonRI can block FcepsilonRI-mediated reactivity(2-4). Here we designed, expressed and tested the human basophil and mast-cell inhibitory function of a novel chimeric fusion protein, whose structure is gammaHinge-CHgamma2-CHgamma3-15aa linker-CHepsilon2-CHepsilon3-CHepsilon4. This Fcgamma-Fcepsilon fusion protein was expressed as the predicted 140-kD dimer that reacted with anti-human epsilon- and gamma-chain specific antibodies. Fcgamma-Fcepsilon bound to both human FcepsilonRI and FcgammaRII. It also showed dose- and time-dependent inhibition of antigen-driven IgE-mediated histamine release from fresh human basophils sensitized with IgE directed against NIP (4-hydroxy-3-iodo-5-nitrophenylacetyl). This was associated with altered Syk signaling. The fusion protein also showed increased inhibition of human anti-NP (4-hydroxy-3-nitrophenylacetyl) and anti-dansyl IgE-mediated passive cutaneous anaphylaxis in transgenic mice expressing human FcepsilonRIalpha. Our results show that this chimeric protein is able to form complexes with both FcepsilonRI and FcgammaRII, and inhibit mast-cell and basophil function. This approach, using a Fcgamma-Fcepsilon fusion protein to co-aggregate FcepsilonRI with a receptor containing an immunoreceptor tyrosine-based inhibition motif, has therapeutic potential in IgE- and FcepsilonRI-mediated diseases.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol,Hart & Louise Lyon Lab, Los Angeles, CA 90024 USA; Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of New Mexico; University of New Mexico's Health Sciences Center	Saxon, A (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol,Hart & Louise Lyon Lab, Los Angeles, CA 90024 USA.				NIAID NIH HHS [R01 AI015251, R21 AI015251, AI-15251] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI015251, R01AI015251] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Daeron M, 1997, INT ARCH ALLERGY IMM, V113, P138, DOI 10.1159/000237528; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; Daeron M, 1996, IMMUNOL LETT, V54, P73, DOI 10.1016/S0165-2478(96)02652-1; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Dombrowicz D, 1996, J IMMUNOL, V157, P1645; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; FungLeung WP, 1996, J EXP MED, V183, P49, DOI 10.1084/jem.183.1.49; HELM B, 1988, NATURE, V331, P180, DOI 10.1038/331180a0; HENDERSHOT LM, 1988, MOL IMMUNOL, V25, P585, DOI 10.1016/0161-5890(88)90081-8; HULETT MD, 1994, J BIOL CHEM, V269, P15287; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Malbec O, 1998, J IMMUNOL, V160, P1647; Oliver JM, 2000, IMMUNOPHARMACOLOGY, V48, P269, DOI 10.1016/S0162-3109(00)00224-1; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ott VL, 2000, J ALLERGY CLIN IMMUN, V106, P429, DOI 10.1067/mai.2000.109428; Ravetch JV, 1997, CURR OPIN IMMUNOL, V9, P121, DOI 10.1016/S0952-7915(97)80168-9; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Wedi B, 1996, ARCH DERMATOL RES, V289, P21, DOI 10.1007/s004030050147	21	171	220	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					518	521		10.1038/nm0502-518	http://dx.doi.org/10.1038/nm0502-518			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984598	Green Accepted			2022-12-27	WOS:000175336800039
J	Novak, K				Novak, K			Antibiotic sweat	NATURE MEDICINE			English	News Item														Novak, Kristine/0000-0001-9314-1803					0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2001	7	12					1290	1290		10.1038/nm1201-1290	http://dx.doi.org/10.1038/nm1201-1290			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726967	Bronze			2022-12-27	WOS:000172610300030
J	Wettschureck, N; Rutten, H; Zywietz, A; Gehring, D; Wilkie, TM; Chen, J; Chien, KR; Offermanns, S				Wettschureck, N; Rutten, H; Zywietz, A; Gehring, D; Wilkie, TM; Chen, J; Chien, KR; Offermanns, S			Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of G alpha(q)/G alpha(11) in cardiomyocytes	NATURE MEDICINE			English	Article							CARDIAC-HYPERTROPHY; MICE; RECEPTOR; EXPRESSION; FAILURE; OVEREXPRESSION; CARDIOMYOPATHY; MYOCYTES; PATHWAYS; GROWTH	Myocardial hypertrophy is an adaptational response of the heart to increased work load, but it is also associated with a high risk of cardiac mortality(1-3) due to its established role in the development of cardiac failure, one of the leading causes of death in developed countries. Multiple growth factors(2,3) and various downstream signaling pathways involving, for example, ras', gp-130 (ref. 4), JNK/p38 (refs. 5,6) and calcineurin/NFAT/CaM-kinase(7) have been implicated in the hypertrophic response. However, there is evidence that the initial phase in the development of myocardial hypertrophy involves the formation of cardiac para- and/or autocrine factors like endothelin-1, norepinephrine or angiotensin II (refs. 7,8), the receptors of which are coupled to G-proteins of the G(q/11)-, G(12/13)- and G(i/o)-families(5,6,8). Cardiomyocyte-specific transgenic overexpression of alpha (1)-adrenergic or angiotensin (AT(1))-receptors as well as of the G(q) alpha -subunit, G alpha (q), results in myocardial hypertrophy(9-12). These data demonstrate that chronic activation of the G(q)/G(11)-family is sufficient to induce myocardial hypertrophy. In order to test whether G(q)/G(11) mediate the physiological hypertrophy response to pressure overload, we generated a mouse line lacking both G alpha (q) and G alpha (11) in cardiomyocytes. These mice showed no detectable ventricular hypertrophy in response to pressure-overload induced by aortic constriction. The complete lack of a hypertrophic response proves that the G(q)/G(11)-mediated pathway is essential for cardiac hypertrophy induced by pressure overload and makes this signaling process an interesting target for interventions to prevent myocardial hypertrophy.	Heidelberg Univ, Inst Pharmacol, D-6900 Heidelberg, Germany; Aventis Pharma, DG Cardiovasc, Frankfurt, Germany; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA	Ruprecht Karls University Heidelberg; Sanofi-Aventis; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Diego	Offermanns, S (corresponding author), Heidelberg Univ, Inst Pharmacol, D-6900 Heidelberg, Germany.	stefan.offermanns@urz.uni-heidelberg.de	Chen, Ju/E-5579-2011; Wettschureck, Nina/L-3651-2017; Offermanns, Stefan/L-3313-2017	Wettschureck, Nina/0000-0001-6858-1460; Offermanns, Stefan/0000-0001-8676-6805				Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Clerk A, 2000, CIRC RES, V86, P1019, DOI 10.1161/01.RES.86.10.1019; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Georgakopoulos D, 1999, NAT MED, V5, P327, DOI 10.1038/6549; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Griendling KK, 1996, ANNU REV PHARMACOL, V36, P281, DOI 10.1146/annurev.pharmtox.36.1.281; Hamawaki M, 1998, AM J PHYSIOL-HEART C, V274, pH868, DOI 10.1152/ajpheart.1998.274.3.H868; Harada K, 1998, CIRCULATION, V97, P1952, DOI 10.1161/01.CIR.97.19.1952; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; Hilal-Dandan R, 2000, J MOL CELL CARDIOL, V32, P1211, DOI 10.1006/jmcc.2000.1156; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; ITO H, 1994, CIRCULATION, V89, P2198, DOI 10.1161/01.CIR.89.5.2198; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Yamazaki T, 1999, ANN NY ACAD SCI, V874, P38, DOI 10.1111/j.1749-6632.1999.tb09223.x	25	295	305	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2001	7	11					1236	1240		10.1038/nm1101-1236	http://dx.doi.org/10.1038/nm1101-1236			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689889				2022-12-27	WOS:000172054100032
J	Perreault, M; Marette, A				Perreault, M; Marette, A			Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; SKELETAL-MUSCLE; ADIPOSE-TISSUE; HEART-DISEASE; MICE LACKING; L-ARGININE; EXPRESSION; RECEPTOR; RATS; HYPERINSULINEMIA	Inducible nitric oxide synthase (iNOS) is induced by inflammatory cytokines in skeletal muscle and fat. It has been proposed that chronic iNOS induction may cause muscle insulin resistance. Here we show that iNOS expression is increased in muscle and fat of genetic and dietary models of obesity. Moreover, mice in which the gene encoding iNOS was disrupted (Nos2(-/-) mice) are protected from high-fat-induced insulin resistance. Whereas both wild-type and Nos2(-/-) mice developed obesity on the high-fat diet, obese Nos2(-/-) mice exhibited improved glucose tolerance, normal insulin sensitivity in vivo and normal insulin-stimulated glucose uptake in muscles. iNOS induction in obese wild-type mice was associated with impairments in phosphatidylinositol 3-kinase and Akt activation by insulin in muscle. These defects were fully prevented in obese Nos2(-/-) mice. These findings provide genetic evidence that iNOS is involved in the development of muscle insulin resistance in diet-induced obesity.	Univ Laval, Hosp Res Ctr, Dept Anat & Physiol, Lipid Res Unit, St Foy, PQ G1K 7P4, Canada; Univ Laval, Hosp Res Ctr, Res Ctr Energy Metab, St Foy, PQ G1K 7P4, Canada	Laval University; Laval University	Marette, A (corresponding author), Univ Laval, Hosp Res Ctr, Dept Anat & Physiol, Lipid Res Unit, St Foy, PQ G1K 7P4, Canada.		Marette, Andre/E-9342-2013					Anai M, 1999, DIABETES, V48, P158, DOI 10.2337/diabetes.48.1.158; Bedard S, 1997, BIOCHEM J, V325, P487, DOI 10.1042/bj3250487; Behr-Roussel D, 2000, CIRCULATION, V102, P1033, DOI 10.1161/01.CIR.102.9.1033; Cromheeke KM, 1999, CARDIOVASC RES, V43, P744, DOI 10.1016/S0008-6363(99)00148-0; Dawson V L, 1995, Adv Pharmacol, V34, P323; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Grundy SM, 1999, AM J CARDIOL, V83, p25F; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Kapur S, 1997, DIABETES, V46, P1691, DOI 10.2337/diabetes.46.11.1691; Kapur S, 1999, AM J PHYSIOL-ENDOC M, V276, pE635, DOI 10.1152/ajpendo.1999.276.4.E635; Kwon G, 1999, J BIOL CHEM, V274, P18702, DOI 10.1074/jbc.274.26.18702; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; Liu DB, 2000, DIABETES, V49, P1116, DOI 10.2337/diabetes.49.7.1116; MACMICKING JD, 1995, CELL, V81, P1170; Maggi LB, 2000, DIABETES, V49, P346, DOI 10.2337/diabetes.49.3.346; McMillan K, 2000, P NATL ACAD SCI USA, V97, P1506, DOI 10.1073/pnas.97.4.1506; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Parkinson JF, 1997, J MOL MED, V75, P174, DOI 10.1007/s001090050102; Perreault M, 2000, DIABETOLOGIA, V43, P427, DOI 10.1007/s001250051325; Pickup JC, 1998, DIABETOLOGIA, V41, P1241, DOI 10.1007/s001250051058; Pilon G, 2000, HORM METAB RES, V32, P480, DOI 10.1055/s-2007-978674; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimabukuro M, 1997, J CLIN INVEST, V100, P290, DOI 10.1172/JCI119534; Shulman GI, 1999, AM J CARDIOL, V84, p3J; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Stichtenoth DO, 1998, BRIT J RHEUMATOL, V37, P246; Tesauro M, 2000, P NATL ACAD SCI USA, V97, P2832, DOI 10.1073/pnas.97.6.2832; Tremblay F, 2001, DIABETES, V50, P1901, DOI 10.2337/diabetes.50.8.1901; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Weyer C, 2000, DIABETES, V49, P2094, DOI 10.2337/diabetes.49.12.2094; Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784; Zierath JB, 1997, DIABETES, V46, P215, DOI 10.2337/diabetes.46.2.215	42	395	423	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1138	1143		10.1038/nm1001-1138	http://dx.doi.org/10.1038/nm1001-1138			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590438				2022-12-27	WOS:000171524500036
J	Marrack, P; Kappler, J; Kotzin, BL				Marrack, P; Kappler, J; Kotzin, BL			Autoimmune disease: why and where it occurs	NATURE MEDICINE			English	Review							T-CELL-CLONES; MOLECULAR MIMICRY; LUPUS NEPHRITIS; CELIAC-DISEASE; GENETIC SUSCEPTIBILITY; RHEUMATOID-ARTHRITIS; MULTIPLE-SCLEROSIS; CROSS-REACTIVITY; EPITOPE MIMICRY; DENDRITIC CELLS	Autoimmune disease is controlled by genetic and environmental factors. Both of these affect susceptibility to autoimmunity at three levels: the overall reactivity of the immune system, the specific antigen and its presentation, and the target issue.	Howard Hughes Med Inst, Denver, CO USA; Natl Jewish Med & Res Ctr, Integrated Dept Immunol, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Biol, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA	Howard Hughes Medical Institute; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Marrack, P (corresponding author), Howard Hughes Med Inst, Denver, CO USA.	marrackp@njc.org	Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017134, R37AI018785, P01AI022295, R37AI017134, R56AI017134, R01AI018785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037070] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-17134, AI-18785, AI-22295] Funding Source: Medline; NIAMS NIH HHS [AR-37070] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBANI S, 1992, RHEUM DIS CLIN N AM, V18, P729; ALBANI S, 1992, J CLIN INVEST, V89, P327, DOI 10.1172/JCI115580; Anderson AC, 2000, J EXP MED, V191, P761, DOI 10.1084/jem.191.5.761; Bachmaier K, 1999, SCIENCE, V283, P1335, DOI 10.1126/science.283.5406.1335; Becker KG, 1998, P NATL ACAD SCI USA, V95, P9979, DOI 10.1073/pnas.95.17.9979; Bell JI, 1996, NAT GENET, V13, P377, DOI 10.1038/ng0896-377; BELLGRAU D, 1990, P NATL ACAD SCI USA, V87, P313, DOI 10.1073/pnas.87.1.313; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; Bergsteinsdottir K, 2000, J IMMUNOL, V164, P1564, DOI 10.4049/jimmunol.164.3.1564; BERNARD NF, 1992, DIABETES, V41, P40, DOI 10.2337/diabetes.41.1.40; BOILLOT D, 1986, DIABETES, V35, P198, DOI 10.2337/diabetes.35.2.198; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; BRACKERTZ D, 1977, ARTHRITIS RHEUM, V20, P841, DOI 10.1002/art.1780200314; CarrascoMarin E, 1996, J IMMUNOL, V156, P450; CHILLER JM, 1973, P NATL ACAD SCI USA, V70, P2129, DOI 10.1073/pnas.70.7.2129; Clynes R, 1998, SCIENCE, V279, P1052, DOI 10.1126/science.279.5353.1052; Cook HB, 2000, J GASTROEN HEPATOL, V15, P1032, DOI 10.1046/j.1440-1746.2000.02290.x; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; CUMBERBATCH M, 1995, IMMUNOLOGY, V84, P31; Davies JM, 1997, IMMUNOL CELL BIOL, V75, P113, DOI 10.1038/icb.1997.16; DELL A, 1991, EUR HEART J, V12, P158, DOI 10.1093/eurheartj/12.suppl_D.158; Donner H, 1997, J CLIN ENDOCR METAB, V82, P4130, DOI 10.1210/jc.82.12.4130; Edelson RL, 2000, NEW ENGL J MED, V343, P60, DOI 10.1056/NEJM200007063430111; Encinas JA, 2000, CURR OPIN IMMUNOL, V12, P691, DOI 10.1016/S0952-7915(00)00164-3; Encinas JA, 1999, NAT GENET, V21, P158, DOI 10.1038/5941; ESQUIVEL PS, 1977, J EXP MED, V145, P1250, DOI 10.1084/jem.145.5.1250; GOODWIN JS, 1982, CLIN EXP IMMUNOL, V48, P403; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Griffiths MM, 1999, CURR OPIN IMMUNOL, V11, P689, DOI 10.1016/S0952-7915(99)00038-2; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; Harley JB, 1998, CURR OPIN IMMUNOL, V10, P690, DOI 10.1016/S0952-7915(98)80090-3; HASKINS K, 1990, SCIENCE, V249, P1433, DOI 10.1126/science.2205920; Hiemstra HS, 2001, P NATL ACAD SCI USA, V98, P3988, DOI 10.1073/pnas.071050898; Hogaboam CM, 1997, GASTROENTEROLOGY, V112, P1986, DOI 10.1053/gast.1997.v112.pm9178691; Holopainen P, 1999, TISSUE ANTIGENS, V53, P470, DOI 10.1034/j.1399-0039.1999.530503.x; Horak I, 1995, IMMUNOL REV, V148, P35, DOI 10.1111/j.1600-065X.1995.tb00092.x; HUTCHINGS P, 1992, EUR J IMMUNOL, V22, P1913, DOI 10.1002/eji.1830220735; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; JAKOBIEC FA, 1984, OPHTHALMOLOGY, V91, P635; Jawaheer D, 2001, AM J HUM GENET, V68, P927, DOI 10.1086/319518; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Kennedy NP, 2000, BIOMED PHARMACOTHER, V54, P373, DOI 10.1016/S0753-3322(01)80004-4; Khare SD, 2000, P NATL ACAD SCI USA, V97, P3370, DOI 10.1073/pnas.050580697; Klein L, 2000, NAT MED, V6, P56, DOI 10.1038/71540; KONNO N, 1994, J CLIN ENDOCR METAB, V78, P393, DOI 10.1210/jc.78.2.393; Kotzin BL, 1996, CELL, V85, P303, DOI 10.1016/S0092-8674(00)81108-3; Kotzin BL, 2000, P NATL ACAD SCI USA, V97, P291, DOI 10.1073/pnas.97.1.291; Kuan AP, 1999, IMMUNOGENETICS, V49, P79, DOI 10.1007/s002510050466; Kukreja A, 2000, CELL MOL LIFE SCI, V57, P534, DOI 10.1007/PL00000715; Locksley RM, 1998, ADV EXP MED BIOL, V452, P45; Lucey DR, 1996, CLIN MICROBIOL REV, V9, P532, DOI 10.1128/CMR.9.4.532; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; Masuda MO, 1998, FASEB J, V12, P1551, DOI 10.1096/fasebj.12.14.1551; MATHEWS MB, 1983, NATURE, V304, P177, DOI 10.1038/304177a0; Matsumoto I, 1999, SCIENCE, V286, P1732, DOI 10.1126/science.286.5445.1732; Miller SD, 1997, NAT MED, V3, P1133, DOI 10.1038/nm1097-1133; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Nakamura RM, 2000, J CLIN LAB ANAL, V14, P305, DOI 10.1002/1098-2825(20001212)14:6<305::AID-JCLA10>3.0.CO;2-P; Nepom GT, 1998, ADV IMMUNOL, V68, P315, DOI 10.1016/S0065-2776(08)60563-5; Nepom GT, 1998, DIABETES, V47, P1177, DOI 10.2337/diabetes.47.8.1177; Poltorak A, 1998, BLOOD CELL MOL DIS, V24, P340, DOI 10.1006/bcmd.1998.0201; QUAYLE AJ, 1992, EUR J IMMUNOL, V22, P1315, DOI 10.1002/eji.1830220529; Rasooly L, 1996, CLIN IMMUNOL IMMUNOP, V81, P287, DOI 10.1006/clin.1996.0191; Ringrose JH, 1999, ANN RHEUM DIS, V58, P598, DOI 10.1136/ard.58.10.598; Romagnani S, 1999, INFLAMM BOWEL DIS, V5, P285, DOI 10.1097/00054725-199911000-00009; Salmon JE, 1996, J CLIN INVEST, V97, P1348, DOI 10.1172/JCI118552; Schloot NC, 2001, HUM IMMUNOL, V62, P299, DOI 10.1016/S0198-8859(01)00223-3; SCHWIMMBECK PL, 1989, J CLIN INVEST, V84, P1174, DOI 10.1172/JCI114282; Segal BM, 1997, J IMMUNOL, V158, P5087; Seko Y, 1998, CIRC RES, V83, P463, DOI 10.1161/01.RES.83.4.463; Shamim E A, 2000, Curr Rheumatol Rep, V2, P201, DOI 10.1007/s11926-000-0080-0; Sher A, 1998, BRAZ J MED BIOL RES, V31, P85, DOI 10.1590/S0100-879X1998000100011; Shimoda S, 2000, HEPATOLOGY, V31, P1212, DOI 10.1053/jhep.2000.8090; Slingsby JH, 1996, ARTHRITIS RHEUM, V39, P663, DOI 10.1002/art.1780390419; Sobel ES, 1999, J IMMUNOL, V162, P2415; SOBEL ES, 1991, J EXP MED, V173, P1441, DOI 10.1084/jem.173.6.1441; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Stratmann T, 2000, J IMMUNOL, V165, P3214, DOI 10.4049/jimmunol.165.6.3214; STREILEIN JW, 1992, J NEUROIMMUNOL, V39, P185, DOI 10.1016/0165-5728(92)90253-H; Tanaka H, 2000, J EXP MED, V192, P405, DOI 10.1084/jem.192.3.405; Theofilopoulos AN, 1999, P ASSOC AM PHYSICIAN, V111, P228, DOI 10.1046/j.1525-1381.1999.99244.x; Theofilopoulos AN, 1999, ANN RHEUM DIS, V58, P49, DOI 10.1136/ard.58.2008.i49; Ufret-Vincenty RL, 1998, J EXP MED, V188, P1725, DOI 10.1084/jem.188.9.1725; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; Vella AT, 1997, J IMMUNOL, V158, P4714; VERGE C, 1992, WILLIAMS TXB ENDOCRI; Vyse TJ, 1997, J IMMUNOL, V158, P5566; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; Vyse TJ, 1998, ANNU REV IMMUNOL, V16, P261, DOI 10.1146/annurev.immunol.16.1.261; Vyse TJ, 1996, J CLIN INVEST, V98, P1762, DOI 10.1172/JCI118975; Wakeland EK, 1999, CURR OPIN IMMUNOL, V11, P701, DOI 10.1016/S0952-7915(99)00039-4; Wong FS, 1996, J EXP MED, V183, P67, DOI 10.1084/jem.183.1.67; Wu JM, 1997, J CLIN INVEST, V100, P1059, DOI 10.1172/JCI119616; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; YEAMAN SJ, 1988, LANCET, V1, P1067; Yu LP, 1996, J CLIN ENDOCR METAB, V81, P4264, DOI 10.1210/jc.81.12.4264; Yunis E J, 1975, Birth Defects Orig Artic Ser, V11, P185	99	394	407	4	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2001	7	8					899	905		10.1038/90935	http://dx.doi.org/10.1038/90935			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479621				2022-12-27	WOS:000171740400026
J	Mercer, DF; Schiller, DE; Elliott, JF; Douglas, DN; Hao, CH; Rinfret, A; Addison, WR; Fischer, KP; Churchill, TA; Lakey, JRT; Tyrrell, DLJ; Kneteman, NM				Mercer, DF; Schiller, DE; Elliott, JF; Douglas, DN; Hao, CH; Rinfret, A; Addison, WR; Fischer, KP; Churchill, TA; Lakey, JRT; Tyrrell, DLJ; Kneteman, NM			Hepatitis C virus replication in mice with chimeric human livers	NATURE MEDICINE			English	Article							BLOOD MONONUCLEAR-CELLS; ADULT HUMAN HEPATOCYTES; MOUSE-LIVER; TRANSPLANTATION; INFECTION; CULTURE; GENOME; PCR	Lack of a small animal model of the human hepatitis C virus (HCV) has impeded development of antiviral therapies against this epidemic infection. By transplanting normal human hepatocytes into SCID mice carrying a plasminogen activator transgene (Alb-uPA), we generated mice with chimeric human livers. Homozygosity of Alb-uPA was associated with significantly higher levels of human hepatocyte engraftment, and these mice developed prolonged HCV infections with high viral titers after inoculation with infected human serum. Initial increases in total viral load were up to 1950-fold, with replication confirmed by detection of negative-strand viral RNA in transplanted livers. HCV viral proteins were localized to human hepatocyte nodules, and infection was serially passaged through three generations of mice confirming both synthesis and release of infectious viral particles. These chimeric mice represent the first murine model suitable for studying the human hepatitis C virus in vivo.	Univ Alberta, Surg Med Res Inst, Dept Surg, Edmonton, AB, Canada; Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada; Univ Alberta, Dept Pathol, Edmonton, AB, Canada; Hop St Luc, CHUM, Ctr Rech, Montreal, PQ H2X 1P1, Canada	University of Alberta; University of Alberta; University of Alberta; Universite de Montreal	Kneteman, NM (corresponding author), Univ Alberta, Surg Med Res Inst, Dept Surg, Edmonton, AB, Canada.			schiller, dan/0000-0001-7190-5198				BALLET F, 1984, HEPATOLOGY, V4, P849, DOI 10.1002/hep.1840040509; Brody RI, 1998, AM J CLIN PATHOL, V110, P32; Brown JJ, 2000, HEPATOLOGY, V31, P173, DOI 10.1002/hep.510310126; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CLEMENT B, 1984, HEPATOLOGY, V4, P373, DOI 10.1002/hep.1840040305; DORKO K, 1994, CELL TRANSPLANT, V3, P387, DOI 10.1177/096368979400300505; HECKEL JL, 1990, CELL, V62, P447, DOI 10.1016/0092-8674(90)90010-C; LANFORD RE, 1995, J VIROL, V69, P8079, DOI 10.1128/JVI.69.12.8079-8083.1995; LANFORD RE, 1994, VIROLOGY, V202, P606, DOI 10.1006/viro.1994.1381; Mellor J, 1998, J GEN VIROL, V79, P705, DOI 10.1099/0022-1317-79-4-705; MURPHY D, 1994, J INFECT DIS, V169, P473, DOI 10.1093/infdis/169.2.473; Petersen J, 1998, P NATL ACAD SCI USA, V95, P310, DOI 10.1073/pnas.95.1.310; Petersen J, 1999, HEPATOLOGY, V30, p423A; RHIM JA, 1994, SCIENCE, V263, P1149, DOI 10.1126/science.8108734; RHIM JA, 1995, P NATL ACAD SCI USA, V92, P4942, DOI 10.1073/pnas.92.11.4942; RYAN CM, 1993, SURGERY, V113, P48; SANDGREN E, 1991, CELL, V68, P245; Sarbah SA, 2000, J CLIN GASTROENTEROL, V30, P125, DOI 10.1097/00004836-200003000-00005; Schmid CW, 1996, PROG NUCLEIC ACID RE, V53, P283, DOI 10.1016/S0079-6603(08)60148-8; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; ZIETKIEWICZ E, 1992, P NATL ACAD SCI USA, V89, P8448, DOI 10.1073/pnas.89.18.8448	22	688	771	0	38	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2001	7	8					927	933		10.1038/90968	http://dx.doi.org/10.1038/90968			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479625	Bronze			2022-12-27	WOS:000171740400030
J	Synold, TW; Dussault, I; Forman, BM				Synold, TW; Dussault, I; Forman, BM			The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux	NATURE MEDICINE			English	Article							PREGNANE-X-RECEPTOR; HUMAN CYTOCHROMES P450; P-GLYCOPROTEIN; MULTIDRUG TRANSPORTER; ACTIVATED RECEPTOR; ANTITUMOR-ACTIVITY; HORMONE RECEPTORS; HUMAN HEPATOCYTES; GENE SUBFAMILY; N-COR	Cytochrome P450 3A4 is an important mediator of drug catabolism that can be regulated by the steroid and xenobiotic receptor (SXR). We show here that SXR also regulates drug efflux by activating expression of the gene MDR1, which encodes the protein P-glycoprotein (ABCB1). Paclitaxel (Taxol), a commonly used chemotherapeutic agent, activated SXR and enhanced P-glycoprotein-mediated drug clearance. In contrast, docetaxel (Taxotere), a closely related antineoplastic agent, did not activate SXR and displayed superior pharmacokinetic properties. Docetaxel's silent properties reflect its inability to displace transcriptional corepressors from SXR. We also found that ET-743, a potent antineoplastic agent, suppressed MDR1 transcription by acting as an inhibitor of SXR. These findings demonstrate how the molecular activities of SXR can be manipulated to control drug clearance.	City Hope Natl Med Ctr, Dept Mol Med, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Gonda Diabet & Genet Res Ctr, Duarte, CA 91010 USA	City of Hope; City of Hope; City of Hope; Beckman Research Institute of City of Hope	Forman, BM (corresponding author), City Hope Natl Med Ctr, Dept Mol Med, 1500 E Duarte Rd, Duarte, CA 91010 USA.			Synold, Timothy/0000-0002-4075-2544	NATIONAL CANCER INSTITUTE [P30CA033572] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 33572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Clarke SJ, 1999, CLIN PHARMACOKINET, V36, P99, DOI 10.2165/00003088-199936020-00002; Crown J, 2000, LANCET, V355, P1176, DOI 10.1016/S0140-6736(00)02074-2; Dorr RT, 1997, PHARMACOTHERAPY, V17, pS96; Dotzlaw H, 1999, CLIN CANCER RES, V5, P2103; Eckardt JR, 1997, AM J HEALTH-SYST PH, V54, pS2, DOI 10.1093/ajhp/54.suppl_2.S2; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Glass CK, 2000, GENE DEV, V14, P121; GOLDSTEIN JA, 1994, PHARMACOGENETICS, V4, P285, DOI 10.1097/00008571-199412000-00001; Izbicka E, 1998, ANN ONCOL, V9, P981, DOI 10.1023/A:1008224322396; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Jin S, 2000, P NATL ACAD SCI USA, V97, P6775, DOI 10.1073/pnas.97.12.6775; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kearns CM, 1997, PHARMACOTHERAPY, V17, pS105; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kostrubsky VE, 1998, ARCH BIOCHEM BIOPHYS, V355, P131, DOI 10.1006/abbi.1998.0730; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Martinez EJ, 1999, P NATL ACAD SCI USA, V96, P3496, DOI 10.1073/pnas.96.7.3496; Masuyama H, 2001, MOL CELL ENDOCRINOL, V172, P47, DOI 10.1016/S0303-7207(00)00395-6; MCKINNON RA, 1995, GUT, V36, P259, DOI 10.1136/gut.36.2.259; Minuzzo M, 2000, P NATL ACAD SCI USA, V97, P6780, DOI 10.1073/pnas.97.12.6780; Monsarrat B, 1997, B CANCER, V84, P125; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Pallis M, 2000, BLOOD, V95, P2897, DOI 10.1182/blood.V95.9.2897.009k14_2897_2904; Pascussi JM, 2000, BIOCHEM BIOPH RES CO, V274, P707, DOI 10.1006/bbrc.2000.3219; Royer I, 1996, CANCER RES, V56, P58; Ruth AC, 2000, CANCER RES, V60, P2576; SAKUMA T, 1995, ARCH BIOCHEM BIOPHYS, V319, P267, DOI 10.1006/abbi.1995.1291; Savas U, 1999, MOL PHARMACOL, V56, P851, DOI 10.1124/mol.56.5.851; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Smith DA, 1998, XENOBIOTICA, V28, P1095, DOI 10.1080/004982598238859; Sparreboom A, 1998, ANTI-CANCER DRUG, V9, P1, DOI 10.1097/00001813-199801000-00001; Sparreboom A, 1997, P NATL ACAD SCI USA, V94, P2031, DOI 10.1073/pnas.94.5.2031; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wentworth JM, 2000, J ENDOCRINOL, V166, pR11, DOI 10.1677/joe.0.166R011; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116	43	690	722	0	39	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					584	590		10.1038/87912	http://dx.doi.org/10.1038/87912			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329060				2022-12-27	WOS:000169961100038
J	Brooks, DG; Kitchen, SG; Kitchen, CMR; Scripture-Adams, DD; Zack, JA				Brooks, DG; Kitchen, SG; Kitchen, CMR; Scripture-Adams, DD; Zack, JA			Generation of HIV latency during thymopoiesis	NATURE MEDICINE			English	Article							CD4(+) T-CELLS; VIRUS TYPE-1 INFECTION; REPLICATION; LYMPHOCYTES; RESERVOIR; COMBINATION; PERSISTENCE; EXPRESSION; DISRUPTION; THYMUS	The use of combination antiretroviral therapy results in a substantial reduction in viremia, a rebound of CD4(+) T cells and increased survival for HIV-infected individuals. However, this treatment does not result in the total eradication of HIV. Rather, the virus is thought to remain latent in a subset of cells, where it avoids elimination by the immune system. In this state the virus is capable of reactivation of productive infection following cessation of therapy. These latently infected cells are very few in number and it has thus been difficult to determine their origin and to study the molecular nature of the latent viral genome. HIV replication is linked to cellular gene transcription and requires target cell activation. Therefore, should an activated, infected cell become transcriptionally inactive prior to cytopathic effects, the viral genome might be maintained in a latent state. We used the SCID-hu (Thy/Liv) mouse model to establish that activation-inducible HIV can be generated at high frequency during thymopoiesis, a process where previously activated cells mature towards quiescence. Moreover, we showed that these cells can be exported into the periphery where the virus remains latent until T-cell receptor stimulation, indicating that the thymus might be a source of latent HIV in humans.	Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, AIDS Inst, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Zack, JA (corresponding author), Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90024 USA.	jzack@ucla.edu	Ramirez, Christina/AAT-5088-2021	Ramirez, Christina/0000-0002-8435-0416; Scripture-Adams, Deirdre/0000-0002-3676-1771; Brooks, David/0000-0001-7763-8764	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036554, R37AI036059, R01AI036059] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 36059, AI 36554] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDROVANDI GM, 1993, NATURE, V363, P732, DOI 10.1038/363732a0; ARRIGO SJ, 1989, J VIROL, V63, P4875, DOI 10.1128/JVI.63.11.4875-4881.1989; Berkowitz RD, 1998, J IMMUNOL, V161, P3702; BONYHADI ML, 1993, NATURE, V363, P728, DOI 10.1038/363728a0; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1998, J EXP MED, V188, P617; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1998, J EXP MED, V188, P83, DOI 10.1084/jem.188.1.83; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Jamieson BD, 1998, J VIROL, V72, P6520, DOI 10.1128/JVI.72.8.6520-6526.1998; JAMIESON BD, 1995, J VIROL, V69, P6259, DOI 10.1128/JVI.69.10.6259-6264.1995; Kitchen SG, 1997, J VIROL, V71, P6928, DOI 10.1128/JVI.71.9.6928-6934.1997; KOLLMANN TR, 1994, J EXP MED, V179, P513, DOI 10.1084/jem.179.2.513; Korin YD, 1999, J VIROL, V73, P6526, DOI 10.1128/JVI.73.8.6526-6532.1999; Livingstone WJ, 1996, LANCET, V348, P649, DOI 10.1016/S0140-6736(96)02091-0; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; PAPIERNIK M, 1992, PEDIATRICS, V89, P297; Pedroza-Martins L, 1998, J VIROL, V72, P9441, DOI 10.1128/JVI.72.12.9441-9452.1998; Persaud D, 2000, J CLIN INVEST, V105, P995, DOI 10.1172/JCI9006; Pierson T, 2000, J VIROL, V74, P7824, DOI 10.1128/JVI.74.17.7824-7833.2000; Schmid I, 2000, CYTOMETRY, V39, P108, DOI 10.1002/(SICI)1097-0320(20000201)39:2<108::AID-CYTO3>3.0.CO;2-4; Sharkey ME, 2000, NAT MED, V6, P76, DOI 10.1038/71569; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; Unutmaz D, 1999, J EXP MED, V189, P1735, DOI 10.1084/jem.189.11.1735; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353	36	159	164	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2001	7	4					459	464		10.1038/86531	http://dx.doi.org/10.1038/86531			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283673				2022-12-27	WOS:000167960500041
J	Winston, R				Winston, R			Embryonic stem cell research - The case for ...	NATURE MEDICINE			English	Editorial Material							PREIMPLANTATION EMBRYOS		Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, London, England	Imperial College London	Winston, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, London, England.							Blau HM, 1999, SEMIN CELL DEV BIOL, V10, P267, DOI 10.1006/scdb.1999.0311; Delhanty JDA, 1997, HUM GENET, V99, P755, DOI 10.1007/s004390050443; EDWARDS RG, 1992, FETAL TISSUE TRANSPL, pR11; EVANS MJ, 1981, NATURE, V292, P7634; Fallon J, 2000, P NATL ACAD SCI USA, V97, P14686, DOI 10.1073/pnas.97.26.14686; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Ourednik V, 2000, NOVART FDN SYMP, V231, P242, DOI 10.1002/0470870834.ch15; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Shinohara T, 2000, DEV BIOL, V220, P401, DOI 10.1006/dbio.2000.9655; Sinclair KD, 1999, J REPROD FERTIL, V116, P177, DOI 10.1530/jrf.0.1160177	13	16	20	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2001	7	4					396	397		10.1038/86442	http://dx.doi.org/10.1038/86442			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283652				2022-12-27	WOS:000167960500018
J	Chinetti, G; Lestavel, S; Bocher, V; Remaley, AT; Neve, B; Torra, IP; Teissier, E; Minnich, A; Jaye, M; Duverger, N; Brewer, HB; Fruchart, JC; Clavey, V; Staels, B				Chinetti, G; Lestavel, S; Bocher, V; Remaley, AT; Neve, B; Torra, IP; Teissier, E; Minnich, A; Jaye, M; Duverger, N; Brewer, HB; Fruchart, JC; Clavey, V; Staels, B			PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway	NATURE MEDICINE			English	Article							BINDING CASSETTE TRANSPORTER-1; RECEPTOR LXR-ALPHA; TANGIER-DISEASE; DENSITY-LIPOPROTEIN; ATHEROSCLEROSIS; METABOLISM; EXPRESSION; CORONARY; DIFFERENTIATION; PROGRESSION	Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate lipid and glucose metabolism and cellular differentiation. PPAR-alpha and PPAR-gamma are both expressed in human macrophages where they exert anti-inflammatory effects. The activation of PPAR-gamma may promote foam-cell formation by inducing expression of the macrophage scavenger receptor CD36. This prompted us to investigate the influence of different PPAR- activators on cholesterol metabolism and foam-cell formation of human primary and THP-1 macrophages. Here we show that PPAR-alpha and PPAR-gamma activators do not influence acetylated low density lipoprotein-induced foam-cell formation of human macrophages. In contrast, PPAR-alpha and PPAR-gamma activators induce the expression of the gene encoding ABCA1, a transporter that controls apoAI-mediated cholesterol efflux from macrophages. These effects are likely due to enhanced expression of liver-x-receptor alpha, an oxysterol-activated nuclear receptor which inducer ABCA1- promoter transcription. Moreover, PPAR-alpha and PPAR-gamma activators increase apoAI-induced cholesterol efflux from normal macrophages. In contrast, PPAR-alpha or PPAR-gamma activation does not influence cholesterol efflux from macrophages isolated from patients with Tangier disease, which is due to a genetic defect in ABCA1. Here we identify a regulatory role for PPAR-alpha and PPAR-gamma in the first steps of the reverse-cholesterol-transport pathway through the activation of ABCA1-mediated cholesterol efflux in human macrophages.	Inst Pasteur, F-59019 Lille, France; INSERM, U325, Lille, France; Univ Lille 2, Lille, France; NHLBI, NIH, Bethesda, MD 20892 USA; Aventis Pharma, Collegeville, PA 19426 USA; Aventis Pharma, Core Genom Dept, Vitry Sur Seine, France; Aventis Pharma, Cardiovasc Dept, Vitry Sur Seine, France	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Sanofi-Aventis; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France	Staels, B (corresponding author), Inst Pasteur, F-59019 Lille, France.		Lestavel, Sophie/B-4658-2017; chinetti, giulia/Q-6901-2016; Staels, Bart/N-9497-2016; Neve, Bernadette/J-6008-2014	Lestavel, Sophie/0000-0001-7839-4757; chinetti, giulia/0000-0001-8048-8138; Staels, Bart/0000-0002-3784-1503; Neve, Bernadette/0000-0003-1516-1379				Balfour JAB, 1999, DRUGS, V57, P921; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Costet P, 2000, J BIOL CHEM, V275, P28240; Delerive P, 2000, FEBS LETT, V471, P34, DOI 10.1016/S0014-5793(00)01364-8; Ericsson CG, 1996, LANCET, V347, P849, DOI 10.1016/S0140-6736(96)91343-4; FOLCH J, 1957, J BIOL CHEM, V226, P497; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; Forte Trudy M., 1994, Current Opinion in Lipidology, V5, P354, DOI 10.1097/00041433-199410000-00007; Frick MH, 1997, CIRCULATION, V96, P2137; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; Hobbs HH, 1999, J CLIN INVEST, V104, P1015, DOI 10.1172/JCI8509; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kritharides L, 1998, ARTERIOSCL THROM VAS, V18, P1589, DOI 10.1161/01.ATV.18.10.1589; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; Tobin KAR, 2000, MOL ENDOCRINOL, V14, P741, DOI 10.1210/me.14.5.741; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Torra IP, 1999, CURR OPIN LIPIDOL, V10, P151, DOI 10.1097/00041433-199904000-00009; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Wolffenbuttel BHR, 2000, DIABETIC MED, V17, P40, DOI 10.1046/j.1464-5491.2000.00224.x	38	925	984	4	79	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2001	7	1					53	58		10.1038/83348	http://dx.doi.org/10.1038/83348			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135616				2022-12-27	WOS:000166243100035
J	Chen, DX; Endres, RL; Erickson, CA; Weis, KF; McGregor, MW; Kawaoka, Y; Payne, LG				Chen, DX; Endres, RL; Erickson, CA; Weis, KF; McGregor, MW; Kawaoka, Y; Payne, LG			Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice	NATURE MEDICINE			English	Article							TRANSCUTANEOUS IMMUNIZATION; CHOLERA-TOXIN; MURINE MODEL; VIRUS; INFECTION; CELLS; CHALLENGE; EFFICACY; IMMUNITY; MUCOSAL		PowderJect Vaccines, Madison, WI 53719 USA; Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Chen, DX (corresponding author), PowderJect Vaccines, 585 Sci Dr, Madison, WI 53719 USA.							Becker Y, 1996, Adv Exp Med Biol, V397, P97; BERNARD KW, 1987, JAMA-J AM MED ASSOC, V257, P1059, DOI 10.1001/jama.257.8.1059; BOS JD, 1997, SKIN IMMUNE SYSTEM S, P9; BREMAN JG, 1980, NEW ENGL J MED, V303, P1263, DOI 10.1056/NEJM198011273032204; Chen DX, 1996, INFECT IMMUN, V64, P1900, DOI 10.1128/IAI.64.6.1900-1905.1996; Condon C, 1996, NAT MED, V2, P1122, DOI 10.1038/nm1096-1122; FADDA G, 1987, EUR J EPIDEMIOL, V3, P176; FENNER F, 1982, REV INFECT DIS, V4, P916; Flohe SB, 1998, EUR J IMMUNOL, V28, P3800, DOI 10.1002/(SICI)1521-4141(199811)28:11&lt;3800::AID-IMMU3800&gt;3.0.CO;2-0; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; Glenn GM, 1999, INFECT IMMUN, V67, P1100, DOI 10.1128/IAI.67.3.1100-1106.1999; Glenn GM, 1998, J IMMUNOL, V161, P3211; Glenn GM, 1998, NATURE, V391, P851, DOI 10.1038/36014; HOROWITZ MM, 1988, ANN INTERN MED, V108, P185, DOI 10.7326/0003-4819-108-2-185; NOVAK M, 1993, VACCINE, V11, P55, DOI 10.1016/0264-410X(93)90339-Y; Paul A, 1998, VACCINE, V16, P188, DOI 10.1016/S0264-410X(97)00185-0; Rimmelzwaan GF, 1999, VACCINE, V17, P2512, DOI 10.1016/S0264-410X(99)00063-8; Saelens X, 1999, EUR J BIOCHEM, V260, P166, DOI 10.1046/j.1432-1327.1999.00150.x; Sarphie DF, 1997, J CONTROL RELEASE, V47, P61, DOI 10.1016/S0168-3659(96)01616-1; SARPHIE DF, 1995, DIABETES, V44, P129; SHEERAR MG, 1989, J GEN VIROL, V70, P3297, DOI 10.1099/0022-1317-70-12-3297; Swain W E, 2000, Dev Biol (Basel), V104, P115; Teunissen M. B., 1997, SKIN IMMUNE SYSTEM S, P59; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WEBSTER RG, 1980, EUR J IMMUNOL, V10, P396, DOI 10.1002/eji.1830100515; WRAITH DC, 1987, J GEN VIROL, V68, P433, DOI 10.1099/0022-1317-68-2-433	26	95	104	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1187	1190		10.1038/80538	http://dx.doi.org/10.1038/80538			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017153				2022-12-27	WOS:000089674700046
J	Scribner, BH				Scribner, BH			Medical dilemmas: the old is new	NATURE MEDICINE			English	Editorial Material							DIALYSIS		Univ Washington, Dept Med, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle	Scribner, BH (corresponding author), Univ Washington, Dept Med, Seattle, WA 98104 USA.	Scrib@u.washington.edu						Blagg CR, 1998, NEPHROLOGY, V4, P295, DOI 10.1111/j.1440-1797.1998.tb00362.x; BRESCIA MJ, 1966, NEW ENGL J MED, V275, P1089, DOI 10.1056/NEJM196611172752002; Charra B, 1998, AM J KIDNEY DIS, V32, P720, DOI 10.1016/S0272-6386(98)70147-7; Charra Bernard, 1999, Home Hemodial Int, V3, P16, DOI 10.1111/hdi.1999.3.1.16; Fishbane SA, 2002, SEMIN DIALYSIS, V15, P144, DOI 10.1046/j.1525-139X.2002.00060.x; Jonsen A.R., 1998, BIRTH BIOETHICS; QUINTON W, 1960, T AM SOC ART INT ORG, V6, P104; Scribner B H, 1999, Nephrol News Issues, V13, P22; SCRIBNER BH, 1964, T AM SOC ART INT ORG, V10, P209; SCRIBNER BH, 1990, AM J KIDNEY DIS, V16, P511, DOI 10.1016/S0272-6386(12)81034-1; SCRIBNER BH, 1960, T AM SOC ART INT ORG, V6, P88; SCRIBNER BH, 1960, T AM SOC ART INT ORG, V6, P114; Scribner BH, 2002, DIALYSIS TRANSPLANT, V31, P13; Scribner BH, 1998, J AM SOC NEPHROL, V9, P899; SKEGGS LT, 1949, P SOC EXP BIOL MED, V72, P539	15	17	17	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1066	1067		10.1038/nm772	http://dx.doi.org/10.1038/nm772			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12357234				2022-12-27	WOS:000178311000020
J	Hynes, RO				Hynes, RO			A reevaluation of integrins as regulators of angiogenesis	NATURE MEDICINE			English	Editorial Material							ENDOTHELIAL GROWTH-FACTOR; ALPHA-V INTEGRINS; PROTEIN-KINASE-II; CELL-MIGRATION; CASPASE-3 ACTIVATION; VASCULAR DEVELOPMENT; INDUCE APOPTOSIS; BETA-1 INTEGRIN; MICE LACKING; TUMOR-GROWTH		MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Hynes, RO (corresponding author), MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA.							Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Adderley SR, 2000, J BIOL CHEM, V275, P5760, DOI 10.1074/jbc.275.8.5760; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bilato C, 1997, J CLIN INVEST, V100, P693, DOI 10.1172/JCI119582; Bloch W, 1997, J CELL BIOL, V139, P265, DOI 10.1083/jcb.139.1.265; Blystone SD, 1999, J CELL BIOL, V145, P889, DOI 10.1083/jcb.145.4.889; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Cheresh DA, 2002, NAT MED, V8, P193, DOI 10.1038/nm0302-193; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DU XP, 1993, J BIOL CHEM, V268, P23087; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; Horton MA, 2001, P NUTR SOC, V60, P275; Huang XZ, 1996, J CELL BIOL, V133, P921, DOI 10.1083/jcb.133.4.921; Huang XZ, 2000, MOL CELL BIOL, V20, P755, DOI 10.1128/MCB.20.3.755-759.2000; Hynes RO, 1999, BRAZ J MED BIOL RES, V32, P501, DOI 10.1590/S0100-879X1999000500002; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; Legler DF, 2001, J CELL SCI, V114, P1545; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; MCCARTY JH, 2002, IN PRESS MOL CELL BI; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Peter K, 2001, THROMB RES, V103, pS21, DOI 10.1016/S0049-3848(01)00300-0; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Simon KO, 1997, J BIOL CHEM, V272, P29380, DOI 10.1074/jbc.272.46.29380; STEPHENS LE, 1995, GENE DEV, V9, P1883, DOI 10.1101/gad.9.15.1883; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; YANG JT, 1993, DEVELOPMENT, V119, P1093; Zhu JW, 2002, DEVELOPMENT, V129, P2891	58	435	450	0	41	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2002	8	9					918	921		10.1038/nm0902-918	http://dx.doi.org/10.1038/nm0902-918			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12205444				2022-12-27	WOS:000177757900014
J	Garnett, GP; Bartley, L; Grassly, NC; Anderson, RM				Garnett, GP; Bartley, L; Grassly, NC; Anderson, RM			Antiretroviral therapy to treat and prevent HIV/AIDS in resource-poor settings	NATURE MEDICINE			English	Editorial Material							ANTITUBERCULOSIS DRUG-RESISTANCE; GAY MEN; HIV-1; TUBERCULOSIS; TRANSMISSION; BEHAVIOR		Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, London SW7 2AZ, England	Imperial College London	Garnett, GP (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, London SW7 2AZ, England.	g.garnett@ic.ac.uk	Grassly, Nicholas C/C-6381-2008; Garnett, Geoffrey P/A-9312-2008	Grassly, Nicholas C/0000-0001-6067-4507; Anderson, Roy/0000-0002-9528-3175				Adje C, 2001, J ACQ IMMUN DEF SYND, V26, P501, DOI 10.1097/00126334-200104150-00018; ANDERSON RM, 1991, NATURE, V350, P356, DOI 10.1038/350356a0; Berwick D, 2002, BRIT MED J, V324, P214, DOI 10.1136/bmj.324.7331.214; Boden D, 1999, JAMA-J AM MED ASSOC, V282, P1135, DOI 10.1001/jama.282.12.1135; Churchyard GJ, 2000, INT J TUBERC LUNG D, V4, P433; Dodds JP, 2000, BRIT MED J, V320, P1510, DOI 10.1136/bmj.320.7248.1510; Ekstrand ML, 1999, AIDS, V13, P1525, DOI 10.1097/00002030-199908200-00013; Farmer P, 1998, BRIT MED J, V317, P671, DOI 10.1136/bmj.317.7159.671; FRANCE T, 2002, GLOBAL FUND WHICH CO; Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2; Harries AD, 2001, LANCET, V358, P410, DOI 10.1016/S0140-6736(01)05551-9; Hogg RS, 2002, AIDS, V16, P1051, DOI 10.1097/00002030-200205030-00012; Katz MH, 2002, AM J PUBLIC HEALTH, V92, P388, DOI 10.2105/AJPH.92.3.388; Kenyon TA, 1999, INT J TUBERC LUNG D, V3, P4; Kuaban C, 2000, INT J TUBERC LUNG D, V4, P427; Ramsay S, 2002, LANCET, V359, P1581, DOI 10.1016/S0140-6736(02)08531-8; Schwartlander B, 2001, SCIENCE, V292, P2434, DOI 10.1126/science.1062876; Sweat M, 2000, LANCET, V356, P113, DOI 10.1016/S0140-6736(00)02447-8; *UNAIDS WHO, 2001, AIDS EP UPD DEC 2001; UNGASS, 2001, UN GEN ASS SPEC SESS; Van de Ven P, 2000, AIDS, V14, P2951, DOI 10.1097/00002030-200012220-00023; Vergne L, 2002, J ACQ IMMUN DEF SYND, V29, P165, DOI 10.1097/00042560-200202010-00009; Warndorff DK, 2000, INT J TUBERC LUNG D, V4, P752; World Bank, 1999, CONFR AIDS PUBL PRIO; World Health Organization (WHO), 2002, STRAT PLAN VIS 2020, P1; YARNEY G, 2002, BMJ-BRIT MED J, V324, P181; Yerly S, 1999, LANCET, V354, P729, DOI 10.1016/S0140-6736(98)12262-6; 1923, CDR WEEKLY	28	26	26	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2002	8	7					651	654		10.1038/nm0702-651	http://dx.doi.org/10.1038/nm0702-651			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12091892				2022-12-27	WOS:000176495200012
J	Mikszta, JA; Alarcon, JB; Brittingham, JM; Sutter, DE; Pettis, RJ; Harvey, NG				Mikszta, JA; Alarcon, JB; Brittingham, JM; Sutter, DE; Pettis, RJ; Harvey, NG			Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery	NATURE MEDICINE			English	Article							TOPICAL APPLICATION; HAIR FOLLICLE; DNA; VACCINATION	Skin is an attractive target for delivery of genetic therapies and vaccines. However, new approaches are needed to access this tissue more effectively. Here, we describe a new delivery technology based on arrays of structurally precise, micron-scale silicon projections, which we term microenhancer arrays (MEAs). In a human clinical study, these devices effectively breached the skin barrier, allowing direct access to the epidermis with minimal associated discomfort and skin irritation. In a mouse model, MEA-based delivery enabled topical gene transfer resulting in reporter gene activity up to 2,800-fold above topical controls. MEA-based delivery enabled topical immunization with naked plasmid DNA, inducing stronger and less variable immune responses than via needle-based injections, and reduced the number of immunizations required for full seroconversion. Together, the results provide the first in vivo use of microfabricated devices to breach the skin barrier and deliver vaccines topically, suggesting significant clinical and practical advantages over existing technologies.	BD Technol, Res Triangle Pk, NC USA		Mikszta, JA (corresponding author), BD Technol, Res Triangle Pk, NC USA.							ALEXANDER MY, 1995, HUM MOL GENET, V4, P2279, DOI 10.1093/hmg/4.12.2279; Babiuk S, 2000, J CONTROL RELEASE, V66, P199, DOI 10.1016/S0168-3659(99)00274-6; Domashenko A, 2000, NAT BIOTECHNOL, V18, P420, DOI 10.1038/74480; Fan HR, 1999, NAT BIOTECHNOL, V17, P870, DOI 10.1038/12856; Glenn GM, 2000, NAT MED, V6, P1403, DOI 10.1038/82225; GRACELY RH, 1978, PAIN, V5, P19, DOI 10.1016/0304-3959(78)90021-0; GROVE GL, 1998, SKIN RES TECHNOL, V4, P1; LI LN, 1995, NAT MED, V1, P705, DOI 10.1038/nm0795-705; Lu B, 1997, J INVEST DERMATOL, V108, P803, DOI 10.1111/1523-1747.ep12292254; McAllister DV, 2000, ANNU REV BIOMED ENG, V2, P289, DOI 10.1146/annurev.bioeng.2.1.289; McCluskie MJ, 1999, MOL MED, V5, P287, DOI 10.1007/BF03402065; Patrick Esther, 1994, P767; Paul A, 1998, VACCINE, V16, P188, DOI 10.1016/S0264-410X(97)00185-0; PISANO A, 1999, Patent No. 5928207; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; Roy MJ, 2000, VACCINE, V19, P764, DOI 10.1016/S0264-410X(00)00302-9; Schneck Jonathan P., 2000, Immunological Investigations, V29, P163, DOI 10.3109/08820130009062300; Tang DC, 1997, NATURE, V388, P729, DOI 10.1038/41917; Watabe S, 2001, VACCINE, V19, P4434, DOI 10.1016/S0264-410X(01)00194-3; Yu WH, 1999, J INVEST DERMATOL, V112, P370, DOI 10.1046/j.1523-1747.1999.00513.x	20	278	316	2	39	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2002	8	4					415	419		10.1038/nm0402-415	http://dx.doi.org/10.1038/nm0402-415			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927950				2022-12-27	WOS:000174704800036
J	Medley, GF; Lindop, NA; Edmunds, WJ; Nokes, DJ				Medley, GF; Lindop, NA; Edmunds, WJ; Nokes, DJ			Hepatitis-B virus endemicity: heterogeneity, catastrophic dynamics and control	NATURE MEDICINE			English	Article							TRANSMISSION DYNAMICS; MATHEMATICAL-MODEL; VACCINATION; BIFURCATION; INFECTION; IMMUNIZATION; PREVALENCE; COUNTRIES; DISEASE; HBV	Hepatitis-B virus infection is globally ubiquitous, but its distribution is very heterogeneous, with prevalence of serological markers in various nations ranging from less than 1% to more than 90%. We propose an explanation for this diversity using a mathematical model of hepatitis-B virus transmission dynamics that shows, for the first time,'catastrophic' behavior using realistic epidemiological processes and parameters. Our major conclusion is that the prevalence of infection is largely determined by a feedback mechanism that relates the rate of transmission, average age at infection and age-related probability of developing carriage following infection. Using the model we identify possible, highly non-linear, consequences of chemotherapy and immunization interventions, for which the starting prevalence of carriers is the most influential, predictive quantity. Taken together, our results demand a re-evaluation of public health policy towards hepatitis-B.	Univ Warwick, Dept Biol Sci, Ecol & Epidemiol Grp, Coventry CV4 7AL, W Midlands, England; Xilinx Scotland, Edinburgh, Midlothian, Scotland; CDSC, Immunisat Dis, London, England; Wellcome Trust Res Labs, Kenya Unit, Kilifi, Kenya	University of Warwick; Xilinx	Medley, GF (corresponding author), Univ Warwick, Dept Biol Sci, Ecol & Epidemiol Grp, Coventry CV4 7AL, W Midlands, England.	graham.medley@warwick.ac.uk	Medley, Graham/B-7289-2008	Medley, Graham/0000-0002-0030-7278				ANDERSON R E, 1992, P95; ANDERSON R M, 1991; Dushoff J, 1998, J MATH BIOL, V36, P227, DOI 10.1007/s002850050099; Dushoff J, 1996, J THEOR BIOL, V180, P181, DOI 10.1006/jtbi.1996.0094; Edmunds W J, 1998, Commun Dis Public Health, V1, P221; Edmunds WJ, 1999, STAT MED, V18, P3263, DOI 10.1002/(SICI)1097-0258(19991215)18:23&lt;3263::AID-SIM315&gt;3.0.CO;2-3; Edmunds WJ, 1996, EPIDEMIOL INFECT, V117, P313, DOI 10.1017/S0950268800001497; EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197, DOI 10.1098/rspb.1993.0102; Edmunds WJ, 1996, STAT MED, V15, P2215, DOI 10.1002/(SICI)1097-0258(19961030)15:20&lt;2215::AID-SIM369&gt;3.0.CO;2-2; Gay NJ, 1998, BRIT MED J, V316, P1457, DOI 10.1136/bmj.316.7142.1457; Greenhalgh D, 2000, MATH BIOSCI, V165, P1, DOI 10.1016/S0025-5564(00)00012-2; Hadeler KP, 1997, MATH BIOSCI, V146, P15, DOI 10.1016/S0025-5564(97)00027-8; HADELER KP, 1995, MATH BIOSCI, V128, P41, DOI 10.1016/0025-5564(94)00066-9; Hill AVS, 1998, ANNU REV IMMUNOL, V16, P593, DOI 10.1146/annurev.immunol.16.1.593; HUANG WZ, 1992, SIAM J APPL MATH, V52, P835, DOI 10.1137/0152047; HYAMS KC, 1995, CLIN INFECT DIS, V20, P992, DOI 10.1093/clinids/20.4.992; KUZNETSOV YA, 1994, J MATH BIOL, V32, P109, DOI 10.1007/BF00163027; MAYANS MV, 1990, LANCET, V336, P1107, DOI 10.1016/0140-6736(90)92580-B; MAYANS MV, 1994, LANCET, V343, P761, DOI 10.1016/S0140-6736(94)91838-4; Maynard JE, 1988, VIRAL HEPATITIS LIVE, P967; MCLEAN AR, 1994, P ROY SOC B-BIOL SCI, V256, P7, DOI 10.1098/rspb.1994.0042; MCMAHON BJ, 1985, J INFECT DIS, V151, P599, DOI 10.1093/infdis/151.4.599; Mortimer PP, 1997, BRIT MED J, V314, P1036, DOI 10.1136/bmj.314.7086.1036; O'Connell T, 2000, EPIDEMIOL INFECT, V125, P701, DOI 10.1017/S095026880000491X; OKOTH FA, 1991, E AFR MED J, V68, P515; Panagiotopoulos T, 1999, BRIT MED J, V319, P1462, DOI 10.1136/bmj.319.7223.1462; POSTON T, 1978, CASTROPHE THEORY ITS; SCHREEDER MT, 1983, AM J EPIDEMIOL, V118, P543, DOI 10.1093/oxfordjournals.aje.a113659; SIMON CP, 1992, SIAM J APPL MATH, V52, P541, DOI 10.1137/0152030; THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604; van den Driessche P, 2000, J MATH BIOL, V40, P525, DOI 10.1007/s002850000032; WHITTLE HC, 1983, LANCET, V1, P1203; Williams JR, 1996, EPIDEMIOL INFECT, V116, P71, DOI 10.1017/S0950268800058970; Wilson JN, 2000, EPIDEMIOL INFECT, V124, P295, DOI 10.1017/S0950268800003605; Wodarz D, 1999, P NATL ACAD SCI USA, V96, P14464, DOI 10.1073/pnas.96.25.14464; Zhao SJ, 2000, INT J EPIDEMIOL, V29, P744, DOI 10.1093/ije/29.4.744	36	121	126	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2001	7	5					619	624		10.1038/87953	http://dx.doi.org/10.1038/87953			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329065				2022-12-27	WOS:000169961100043
J	Klein, MA; Kaeser, PS; Schwarz, P; Weyd, H; Xenarios, I; Zinkernagel, RM; Carroll, MC; Verbeek, JS; Botto, M; Walport, MJ; Molina, H; Kalinke, U; Acha-Orbea, H; Aguzzi, A				Klein, MA; Kaeser, PS; Schwarz, P; Weyd, H; Xenarios, I; Zinkernagel, RM; Carroll, MC; Verbeek, JS; Botto, M; Walport, MJ; Molina, H; Kalinke, U; Acha-Orbea, H; Aguzzi, A			Complement facilitates early prion pathogenesis	NATURE MEDICINE			English	Article							CREUTZFELDT-JAKOB-DISEASE; FOLLICULAR DENDRITIC CELLS; T-DEPENDENT ANTIGEN; B-CELLS; TARGETED DISRUPTION; TONSIL BIOPSY; MICE; SCRAPIE; EXPRESSION; PRP	New-variant Creutzfeldt-Jakob disease and scrapie are typically initiated by extracerebral exposure to the causative agent, and exhibit early prion replication in lymphoid organs(1,2). In mouse scrapie, depletion of B-lymphocytes prevents neuropathogenesis after intraperitoneal inoculation(3,4), probably due to impaired lymphotoxin-dependent maturation of follicular dendritic cells(5) (FDCs), which are a major extracerebral prion reservoir(6). FDCs trap immune complexes with Fc-gamma receptors and C3d/C4b-opsonized antigens with CD21/CD35 complement receptors. We examined whether these mechanisms participate in peripheral prion pathogenesis. Depletion of circulating immunoglobulins or of individual Fc-gamma receptors had no effect on scrapie pathogenesis if B-cell maturation was unaffected. However, mice deficient in C3, C1q, Bf/C2, combinations thereof(7,8) or complement receptors(9) were partially or fully protected against spongiform encephalopathy upon intraperitoneal exposure to limiting amounts of prions. Splenic accumulation of prion infectivity and PrPSc was delayed, indicating that activation of specific complement components is involved in the initial trapping of prions in lymphoreticular organs early after infection.	Univ Zurich, Inst Neuropathol, Zurich, Switzerland; Univ Zurich, Inst Expt Immunol, CH-8091 Zurich, Switzerland; Ctr Blood Res, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Leiden Univ, Med Ctr, Dept Human & Clin Genet, Leiden, Netherlands; Imperial Coll Sch Med, Div Med, Rheumatol Sect, London, England; Washington Univ, Sch Med, Div Rheumatol, St Louis, MO USA; European Mol Biol Lab, Mouse Biol Programme, Monterotondo, Italy; Univ Lausanne, Lausanne Branch, Inst Biochem, CH-1066 Epalinges, Switzerland; Univ Lausanne, Lausanne Branch, Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland	University of Zurich; University of Zurich; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Imperial College London; Washington University (WUSTL); European Molecular Biology Laboratory (EMBL); University of Lausanne; Ludwig Institute for Cancer Research; University of Lausanne	Aguzzi, A (corresponding author), Univ Zurich, Inst Neuropathol, Schmelzbergstr, Zurich, Switzerland.		Aguzzi, Adriano/A-3351-2008; Xenarios, Ioannis/ABD-5045-2021	Xenarios, Ioannis/0000-0002-3413-6841; Kalinke, Ulrich/0000-0003-0503-9564; Walport, Mark/0000-0001-7220-5273; Aguzzi, Adriano/0000-0002-0344-6708				Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; Carroll MC, 1998, SEMIN IMMUNOL, V10, P279, DOI 10.1006/smim.1998.0120; Croix DA, 1996, J EXP MED, V183, P1857, DOI 10.1084/jem.183.4.1857; EBENBICHLER CF, 1991, J EXP MED, V174, P1417, DOI 10.1084/jem.174.6.1417; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Fischer MB, 1998, SCIENCE, V280, P582, DOI 10.1126/science.280.5363.582; FRASER H, 1970, NATURE, V226, P462, DOI 10.1038/226462a0; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Klein MA, 1998, NAT MED, V4, P1429, DOI 10.1038/4022; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; Klickstein LB, 1997, IMMUNITY, V7, P345, DOI 10.1016/S1074-7613(00)80356-8; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; Park SY, 1998, J CLIN INVEST, V102, P1229, DOI 10.1172/JCI3256; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; Seiler P, 1998, J VIROL, V72, P2253, DOI 10.1128/JVI.72.3.2253-2258.1998; SITIA R, 1987, EMBO J, V6, P3969, DOI 10.1002/j.1460-2075.1987.tb02739.x; SZAKAL AK, 1968, EXP MOL PATHOL, V8, P75, DOI 10.1016/0014-4800(68)90007-5; Takahashi K, 1996, COLLOID SURFACE B, V6, P379, DOI 10.1016/0927-7765(96)01276-3; Taylor PR, 1998, J BIOL CHEM, V273, P1699, DOI 10.1074/jbc.273.3.1699; Wu XB, 2000, J IMMUNOL, V165, P3119, DOI 10.4049/jimmunol.165.6.3119; YAMAKAWA M, 1992, IMMUNOLOGY, V76, P378	31	260	265	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2001	7	4					488	492		10.1038/86567	http://dx.doi.org/10.1038/86567			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283678				2022-12-27	WOS:000167960500046
J	Takahashi, H				Takahashi, H			RETRACTED: A SADS defect in tumor cells provides optimism (Retracted Article. See vol 7, pg 749, 2001)	NATURE MEDICINE			English	Editorial Material; Retracted Publication							APOPTOSIS	SADS, a new component of the Fas-mediated apoptotic pathway, is downregulated in patients with colon carcinoma. Could this downregulation be a widespread mechanism of tumor cell immune evasion?	Jikei Univ, Sch Med, Inst Clin Med & Res, Minato Ku, Tokyo 1058461, Japan	Jikei University	Takahashi, H (corresponding author), Jikei Univ, Sch Med, Inst Clin Med & Res, Minato Ku, 3-25-8 Nishi Shinbashi, Tokyo 1058461, Japan.	takahashi@jikei.ac.jp						BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; MARTIN PJ, 1975, BRIT MED J, V1, P17, DOI 10.1136/bmj.1.5948.17; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; Suzuki A, 2001, NAT MED, V7, P88, DOI 10.1038/83401; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464	9	4	4	2	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					26	27		10.1038/83306	http://dx.doi.org/10.1038/83306			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135609				2022-12-27	WOS:000166243100024
J	Takeda, K; Hayakawa, Y; Smyth, M; Kayagaki, N; Yamaguchi, N; Kakuta, S; Iwakura, Y; Yagita, H; Okumura, K				Takeda, K; Hayakawa, Y; Smyth, M; Kayagaki, N; Yamaguchi, N; Kakuta, S; Iwakura, Y; Yagita, H; Okumura, K			Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells	NATURE MEDICINE			English	Article							IFN-GAMMA PRODUCTION; HUMAN NK CELLS; FAS LIGAND; T-CELLS; MEDIATED CYTOTOXICITY; TUMORICIDAL ACTIVITY; INTERLEUKIN (IL)-12; INTERFERON-GAMMA; DENDRITIC CELLS; DEATH RECEPTOR	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in various tumor cells in vitro, but its physiological role in tumor surveillance remains unknown. Here, we report that TRAIL is constitutively expressed on murine natural killer (NK) cells in the liver and plays a substantial role in suppressing tumor metastasis. Freshly isolated NK cells, but not natural killer T cells or ordinary T cells, from the liver expressed cell surface TRAIL, which was responsible for spontaneous cytotoxicity against TRAIL-sensitive tumor cells in vitro along with perforin and Fas ligand (FasL). Administration of neutralizing monoclonal antibody against TRAIL significantly increased experimental liver metastases of several TRAIL-sensitive tumor cell lines. Such an anti-metastatic effect of TRAIL was not observed in NK cell-depleted mice or interferon-gamma -deficient mice, the latter of which lacked TRAIL on liver NK cells. These findings provide the first evidence for the physiological function of TRAIL as a tumor suppressor.	Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan; Japan Sci & Technol Corp, CREST, Chiyoda Ku, Tokyo 1010062, Japan; Toyama Med & Pharmaceut Univ, Res Inst Nat Med, Dept Pathogen Biochem, Toyama, Japan; Peter MacCallum Canc Inst, Melbourne, Vic 8006, Australia; Univ Tokyo, Inst Med Sci, Ctr Med Expt, Div Cell Biol,Minato Ku, Tokyo 1088639, Japan	Juntendo University; Japan Science & Technology Agency (JST); University of Toyama; Peter Maccallum Cancer Center; University of Tokyo	Takeda, K (corresponding author), Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan.	ktakeda@med.juntendo.ac.jp	Smyth, Mark J/H-8709-2014; Iwakura, Yoichiro/E-5457-2011; Kakuta, Shigeru/L-2241-2018	Smyth, Mark J/0000-0001-7098-7240; Iwakura, Yoichiro/0000-0002-9934-5775; Kakuta, Shigeru/0000-0002-5900-1425				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bonfoco E, 1998, IMMUNITY, V9, P711, DOI 10.1016/S1074-7613(00)80668-8; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Johnsen AC, 1999, CYTOKINE, V11, P664, DOI 10.1006/cyto.1999.0489; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kashii Y, 1999, J IMMUNOL, V163, P5358; Kayagaki N, 1997, P NATL ACAD SCI USA, V94, P3914, DOI 10.1073/pnas.94.8.3914; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Kayagaki N, 1999, J IMMUNOL, V163, P1906; Kitamura H, 1999, J EXP MED, V189, P1121, DOI 10.1084/jem.189.7.1121; Kodama T, 1999, EUR J IMMUNOL, V29, P1390, DOI 10.1002/(SICI)1521-4141(199904)29:04<1390::AID-IMMU1390>3.3.CO;2-3; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Munder M, 1998, J EXP MED, V187, P2103, DOI 10.1084/jem.187.12.2103; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NASTALA CL, 1994, J IMMUNOL, V153, P1697; Ogasawara K, 1998, J IMMUNOL, V160, P3522; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Puddu P, 1997, J IMMUNOL, V159, P3490; SAIKI I, 1991, JPN J CANCER RES, V82, P1120, DOI 10.1111/j.1349-7006.1991.tb01766.x; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Smyth MJ, 1999, J IMMUNOL, V162, P6658; Tagawa Y, 1997, J IMMUNOL, V159, P1418; Takeda K, 2000, INT IMMUNOL, V12, P909, DOI 10.1093/intimm/12.6.909; Takeda K, 1998, IMMUNITY, V8, P383, DOI 10.1016/S1074-7613(00)80543-9; TALMADGE JE, 1980, NATURE, V284, P622, DOI 10.1038/284622a0; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; Tsutsui H, 1997, J IMMUNOL, V159, P3961; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wigginton JM, 1996, JNCI-J NATL CANCER I, V88, P38, DOI 10.1093/jnci/88.1.38; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, CANCER RES, V59, P2770; Zamai L, 1998, J EXP MED, V188, P2375, DOI 10.1084/jem.188.12.2375	44	567	589	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2001	7	1					94	100		10.1038/83416	http://dx.doi.org/10.1038/83416			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	389MX	11135622				2022-12-27	WOS:000166243100041
J	Bucci, M; Gratton, JP; Rudic, RD; Acevedo, L; Roviezzo, F; Cirino, G; Sessa, WC				Bucci, M; Gratton, JP; Rudic, RD; Acevedo, L; Roviezzo, F; Cirino, G; Sessa, WC			In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation	NATURE MEDICINE			English	Article							ANTENNAPEDIA HOMEODOMAIN; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; 3RD HELIX; SYNTHASE; PROTEIN; ANGIOGENESIS; CHOLESTEROL; ACTIVATION; CELLS	Caveolin-1, the primary coat protein of caveolae, has been implicated as a regulator of signal transduction through binding of its "scaffolding domain" to key signaling molecules. However, the physiological importance of caveorin-1 in regulating signaling has been difficult to distinguish from its traditional functions in caveolae assembly, transcytosis, and cholesterol transport. To directly address the importance of the caveolin scaffolding domain in vivo, we generated a chimeric peptide with a cellular internalization sequence fused to the caveolin-1 scaffolding domain (amino acids 82-101). The chimeric peptide was efficiently taken up into blood vessels and endothelial cells, resulting in selective inhibition of acetyl-choline (Ach)-induced vasodilation and nitric oxide (NO) production, respectively, More importantly, systemic administration of the peptide to mice suppressed acute inflammation and vascular leak to the same extent as a glucocorticoid or an endothelial nitric oxide synthase (eNOS) inhibitor. These data imply that the caveolin-1 scaffolding domain can selectively regulate signal transduction to eNOS in endothelial cells and that small-molecule mimicry of this domain may provide a new therapeutic approach.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Dipartimento Farmacol Sperimental, I-80131 Naples, Italy	Yale University	Sessa, WC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.		Sessa, William C/B-6844-2011; Rudic, Dan/B-3432-2016	Sessa, William C/0000-0001-5759-1938; Cirino, Giuseppe/0000-0003-3954-4083; Roviezzo, Fiorentina/0000-0003-1582-7396; Rudic, Dan/0000-0001-9122-3127; Gratton, Jean-Philippe/0000-0001-9877-8520	NHLBI NIH HHS [HL64793, HL61371, HL57665] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057665, R37HL061371, R01HL061371, R01HL064793] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Ghosh S, 1998, J BIOL CHEM, V273, P22267, DOI 10.1074/jbc.273.35.22267; He P, 1997, AM J PHYSIOL-HEART C, V273, pH747, DOI 10.1152/ajpheart.1997.273.2.H747; Hobbs AJ, 1999, ANNU REV PHARMACOL, V39, P191, DOI 10.1146/annurev.pharmtox.39.1.191; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; IALENTI A, 1992, EUR J PHARMACOL, V211, P177, DOI 10.1016/0014-2999(92)90526-A; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lee PC, 1999, AM J PHYSIOL-HEART C, V277, pH1600, DOI 10.1152/ajpheart.1999.277.4.H1600; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; POLLOCK JS, 1993, AM J PHYSIOL, V265, pC1379, DOI 10.1152/ajpcell.1993.265.5.C1379; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829, DOI 10.1111/j.1476-5381.1996.tb15475.x; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; SMITH W, 1997, ADV EXP MED BIOL, P989; Sternberg PW, 1999, NAT CELL BIOL, V1, pE35, DOI 10.1038/10028	29	440	470	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2000	6	12					1362	1367		10.1038/82176	http://dx.doi.org/10.1038/82176			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100121				2022-12-27	WOS:000165704100040
J	Kwak, B; Mulhaupt, F; Myit, S; Mach, F				Kwak, B; Mulhaupt, F; Myit, S; Mach, F			Statins as a newly recognized type of immunomodulator	NATURE MEDICINE			English	Article							CLASS-II TRANSACTIVATOR; EXPRESSION; DEFICIENCY	Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, or statins, are effective lipid-lowering agents, extensively used in medical practice(1-3). Statins have never been shown to be involved in the immune response, although a report has indicated a better outcome of cardiac transplantation in patients under Pravastatin therapy(4). Major histocompatibility complex class II (MHC-II) molecules are directly involved in the activation of T lymphocytes and in the control of the immune response. Whereas only a limited number of specialized cell types express MHC-II constitutively, numerous other cells become MHC-II positive upon induction by interferon gamma (IFN-gamma)(5). This complex regulation is under the control of the transactivator CIITA (refs 6,7). Here we show that statins act as direct inhibitors of induction of MHC-II expression by IFN-gamma and thus as repressors of MHC-II-mediated T-cell activation. This effect of statins is due to inhibition of the inducible promoter IV of the transactivator CIITA and is observed in several cell types, including primary human endothelial cells (ECs) and monocyte-macrophages (M phi). It is of note that this inhibition is specific for inducible MHC-II expression and does not concern constitutive expression of CIITA and MHC-II. In repressing induction of MHC-II, and subsequent T-lymphocyte activation, statins therefore provide a new type of immunomodulation. This unexpected effect provides a scientific rationale for using statins as immunosuppressors, not only in organ transplantation but in numerous other pathologies as well.	Fdn Med Res, Geneva Med Sch, Univ Hosp, Dept Med,Cardiol Div, Geneva, Switzerland	University of Geneva	Mach, F (corresponding author), Fdn Med Res, Geneva Med Sch, Univ Hosp, Dept Med,Cardiol Div, Geneva, Switzerland.	machf@cmu.unige.ch		Kwak, Brenda/0000-0003-0015-0044				Arrighi JF, 1999, BLOOD, V93, P2244, DOI 10.1182/blood.V93.7.2244.407a29_2244_2252; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003; Kovalik JP, 2000, J IMMUNOL, V165, P1285, DOI 10.4049/jimmunol.165.3.1285; Lee YJ, 1996, J IMMUNOL, V157, P1559; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; Maron DJ, 2000, CIRCULATION, V101, P207, DOI 10.1161/01.CIR.101.2.207; Masternak K, 1998, NAT GENET, V20, P273, DOI 10.1038/3081; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Otten LA, 1998, EUR J IMMUNOL, V28, P473, DOI 10.1002/(SICI)1521-4141(199802)28:02<473::AID-IMMU473>3.0.CO;2-E; Pedersen TR, 1999, AM HEART J, V138, pS177, DOI 10.1016/S0002-8703(99)70340-6; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Vaughan CJ, 2000, J AM COLL CARDIOL, V35, P1, DOI 10.1016/S0735-1097(99)00525-2; Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2	17	1088	1153	1	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2000	6	12					1399	1402		10.1038/82219	http://dx.doi.org/10.1038/82219			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	380LV	11100127				2022-12-27	WOS:000165704100046
J	DeFeo-Jones, D; Garsky, VM; Wong, BK; Feng, DM; Bolyar, T; Haskell, K; Kiefer, DM; Leander, K; McAvoy, E; Lumma, P; Wai, J; Senderak, ET; Motzel, SL; Keenan, K; Van Zwieten, M; Lin, JH; Freidinger, R; Huff, J; Oliff, A; Jones, RE				DeFeo-Jones, D; Garsky, VM; Wong, BK; Feng, DM; Bolyar, T; Haskell, K; Kiefer, DM; Leander, K; McAvoy, E; Lumma, P; Wai, J; Senderak, ET; Motzel, SL; Keenan, K; Van Zwieten, M; Lin, JH; Freidinger, R; Huff, J; Oliff, A; Jones, RE			A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo	NATURE MEDICINE			English	Article							COMPLEX-FORMATION; PROTEIN; INHIBITORS	We covalently linked doxorubicin with a peptide that is hydrolyzable by prostate-specific antigen. In the presence of prostate tumor cells secreting prostate-specific antigen, the peptide moiety of this conjugate, L-377,202, was hydrolyzed, resulting in the release of leucine-doxorubicin and doxorubicin, which are both very cytotoxic to cancer cells. However, L-377,202 was much less cytotoxic than conventional doxorubicin to cells in culture that do not secrete prostate-specific antigen. L-377,202 was approximately 15 times more effective than was conventional doxorubicin at inhibiting the growth of human prostate cancer tumors in nude mice when both drugs were used at their maximally tolerated doses. Nude mice inoculated with human prostate tumor cells secreting prostate-specific antigen showed considerable reductions in tumor burden with minimal total body weight loss when treated with L-377,202. This improvement in therapeutic index correlated with the selective localization of leucine-doxorubicin and free doxorubicin in tissues secreting prostate-specific antigen after exposure to L-377,202.	Merck Res Labs, Canc Res, W Point, PA 19486 USA; Merck Res Labs, Med Chem, W Point, PA 19486 USA; Merck Res Labs, Lab Anim Resources, W Point, PA 19486 USA; Merck Res Labs, Drug Metab, W Point, PA 19486 USA; Merck Res Labs, Safety Assessment, W Point, PA 19486 USA; Merck Res Labs, Vaccine Biometr Res, W Point, PA 19486 USA; Dupont Pharmaceut, Expt Stn, Wilmington, DE 19880 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; DuPont	Jones, RE (corresponding author), Merck Res Labs, Canc Res, W Point, PA 19486 USA.							AKIYAMA K, 1987, FEBS LETT, V225, P168, DOI 10.1016/0014-5793(87)81151-1; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHRISTENSSON A, 1994, EUR J BIOCHEM, V220, P45, DOI 10.1111/j.1432-1033.1994.tb18597.x; CHRISTENSSON A, 1990, EUR J BIOCHEM, V194, P755, DOI 10.1111/j.1432-1033.1990.tb19466.x; Denmeade SR, 1998, CANCER RES, V58, P2537; DIAMANDIS EP, 1995, SCAND J CLIN LAB INV, V55, P105, DOI 10.3109/00365519509090573; DIAMANDIS EP, 1994, BREAST CANCER RES TR, V32, P301, DOI 10.1007/BF00666007; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; HUSAIN MH, 1996, SEMIN ONCOL, V23, P24; JOHANSEN PB, 1981, CANCER CHEMOTH PHARM, V5, P267, DOI 10.1007/BF00434396; Leinonen J, 1996, J UROLOGY, V155, P1099, DOI 10.1016/S0022-5347(01)66399-7; LEVESQUE M, 1995, J CLIN LAB ANAL, V9, P123, DOI 10.1002/jcla.1860090209; LILJA H, 1985, J CLIN INVEST, V76, P1899, DOI 10.1172/JCI112185; MACREZ C, 1967, PATHOL BIOL, V15, P949; Otto A, 1998, J UROLOGY, V159, P297, DOI 10.1016/S0022-5347(01)64085-0; *SAS I, 1990, SAS STAT US GUID VER, P897; SAS Institute, 1996, SAS STAT SOFTW CHANG; TAN C, 1967, CANCER-AM CANCER SOC, V20, P333, DOI 10.1002/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; WESTFALL PH, 1993, RESAMPLING BASED MUL, P112; YU H, 1994, J CLIN LAB ANAL, V8, P251, DOI 10.1002/jcla.1860080412; YU H, 1994, CLIN BIOCHEM, V27, P75, DOI 10.1016/0009-9120(94)90015-9	22	133	153	1	32	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1248	1252		10.1038/81351	http://dx.doi.org/10.1038/81351			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062536				2022-12-27	WOS:000165114800032
J	Morita, Y; Perez, GI; Paris, F; Miranda, SR; Ehleiter, D; Haimovitz-Friedman, A; Fuks, Z; Xie, ZH; Reed, JC; Schuchman, EH; Kolesnick, RN; Tilly, JL				Morita, Y; Perez, GI; Paris, F; Miranda, SR; Ehleiter, D; Haimovitz-Friedman, A; Fuks, Z; Xie, ZH; Reed, JC; Schuchman, EH; Kolesnick, RN; Tilly, JL			Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy	NATURE MEDICINE			English	Article							PROGRAMMED CELL-DEATH; SPHINGOSINE 1-PHOSPHATE; CHEMOTHERAPY; SURVIVAL; BAX; EXPRESSION; GROWTH; MOUSE; INVOLVEMENT; REQUIREMENT	The time at which ovarian failure (menopause) occurs in females is determined by the size of the oocyte reserve provided at birth, as well as by the rate at which this endowment is depleted throughout post-natal life. Here we show that disruption of the gene for acid sphingomyelinase in female mice suppressed the normal apoptotic deletion of fetal oocytes, leading to neonatal ovarian hyperplasia. Ex vivo, oocytes lacking the gene for acid sphingomyelinase or wild-type oocytes treated with sphingosine-1-phosphate resisted developmental apoptosis and apoptosis induced by anti-cancer therapy, confirming cell autonomy of the death defect. Moreover, radiation-induced oocyte loss in adult wild-type female mice, the event that drives premature ovarian failure and infertility in female cancer patients, was completely prevented by in vivo therapy with sphingosine-1-phosphate. Thus, the sphingomyelin pathway regulates developmental death of oocytes, and sphingosine-1-phosphate provides a new approach to preserve ovarian function in vivo.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol,Vincent Ctr Reprod Biol, Boston, MA 02114 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Burnham Inst, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Icahn School of Medicine at Mount Sinai; Sanford Burnham Prebys Medical Discovery Institute	Tilly, JL (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol,Vincent Ctr Reprod Biol, Boston, MA 02114 USA.		Perez, Gloria I/GMX-1286-2022; Paris, francois E/L-4915-2015	Paris, francois E/0000-0002-0176-7348	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012279] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG12279] Funding Source: Medline; NICHD NIH HHS [R01-HD34226] Funding Source: Medline; NIEHS NIH HHS [R01-ES08430] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAKER TG, 1963, PROC R SOC SER B-BIO, V158, P417, DOI 10.1098/rspb.1963.0055; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Blumenfeld Z, 1999, J SOC GYNECOL INVEST, V6, P229, DOI 10.1016/S1071-5576(99)00028-3; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Ding HF, 1998, CRIT REV ONCOGENESIS, V9, P83, DOI 10.1615/CritRevOncog.v9.i1.60; Dong LW, 1996, J MOL RECOGNIT, V9, P383, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<383::AID-JMR269>3.0.CO;2-Z; Edsall LC, 1997, J NEUROSCI, V17, P6952; FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3; Goetzl EJ, 1999, ADV EXP MED BIOL, V469, P259; Gosden R, 1996, NATURE, V383, P485, DOI 10.1038/383485a0; Gosden RG, 1998, REPROD FERT DEVELOP, V10, P73, DOI 10.1071/R98043; Gougeon A, 1996, ENDOCR REV, V17, P121, DOI 10.1210/er.17.2.121; Hammond CB, 1996, OBSTET GYNECOL, V87, pS2, DOI 10.1016/0029-7844(95)00429-7; Hardy K, 1999, REV REPROD, V4, P125; He XX, 1999, BBA-PROTEIN STRUCT M, V1432, P251, DOI 10.1016/S0167-4838(99)00069-2; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Jurisicova A, 1995, HUM REPROD UPDATE, V1, P558, DOI 10.1093/humupd/1.6.558; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; LANTZ ME, 1999, CANC OBSTET GYNECOLO, P87; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Morita Y, 1999, DEV BIOL, V213, P1, DOI 10.1006/dbio.1999.9344; Morita Y, 1999, MOL ENDOCRINOL, V13, P841, DOI 10.1210/me.13.6.841; Morita Y, 1999, ENDOCRINOLOGY, V140, P2696, DOI 10.1210/en.140.6.2696; Morita Y, 1999, ENDOCRINOLOGY, V140, P941, DOI 10.1210/en.140.2.941; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Perez GI, 1999, NAT GENET, V21, P200, DOI 10.1038/5985; Perez GI, 2000, NATURE, V403, P500, DOI 10.1038/35000651; Perez GI, 1999, MOL HUM REPROD, V5, P414, DOI 10.1093/molehr/5.5.414; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; RATTS VS, 1995, ENDOCRINOLOGY, V136, P3665, DOI 10.1210/en.136.8.3665; Reynolds T, 1999, J NATL CANCER I, V91, P664, DOI 10.1093/jnci/91.8.664; RIED HL, 1994, SEMIN ROENTGENOL, V29, P6, DOI 10.1016/S0037-198X(05)80068-9; Rudin CM, 1997, ANNU REV MED, V48, P267; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; WANG E, 1991, J BIOL CHEM, V266, P14486; WAXMAN J, 1983, J ROY SOC MED, V76, P144, DOI 10.1177/014107688307600212; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559	46	464	490	2	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1109	1114		10.1038/80442	http://dx.doi.org/10.1038/80442			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017141				2022-12-27	WOS:000089674700034
J	Steinberg, D				Steinberg, D			Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime	NATURE MEDICINE			English	Review							LOW-DENSITY-LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN-1; MOUSE PERITONEAL-MACROPHAGES; ENDOTHELIAL-CELL EXPRESSION; LEUKOCYTE ADHESION MOLECULE; SMOOTH-MUSCLE-CELLS; OXIDIZED-LDL; ATHEROSCLEROTIC LESIONS; ARTERIAL PROTEOGLYCANS; CORONARY EVENTS	A historical perspective on atherosclerosis allows us to reflect on the once controversial hypotheses in the field. Plaque formation was once thought to be dependent upon hypercholesterolemia alone, or solely in response to injury. More recently, inflammatory cascades were thought to be at the root of lesion development. A more realistic view may be that atherosclerosis is neither exclusively an inflammatory disease nor solely a lipid disorder: it is both.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Steinberg, D (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	dsteinberg@ucsd.edu						Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Bird DA, 1999, P NATL ACAD SCI USA, V96, P6347, DOI 10.1073/pnas.96.11.6347; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Boullier A, 2000, J BIOL CHEM, V275, P9163, DOI 10.1074/jbc.275.13.9163; Boullier A, 2001, ANN NY ACAD SCI, V947, P214; Bourdillon MC, 2000, ARTERIOSCL THROM VAS, V20, P2630, DOI 10.1161/01.ATV.20.12.2630; Brand K, 1997, ARTERIOSCL THROM VAS, V17, P1901, DOI 10.1161/01.ATV.17.10.1901; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BRUSCHKE AVG, 1989, AM HEART J, V117, P296, DOI 10.1016/0002-8703(89)90772-2; Camejo G, 1998, ATHEROSCLEROSIS, V139, P205, DOI 10.1016/S0021-9150(98)00107-5; Chatterjee S, 1996, GLYCOBIOLOGY, V6, P303, DOI 10.1093/glycob/6.3.303; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; DAVIES PF, 1976, ATHEROSCLEROSIS, V25, P125, DOI 10.1016/0021-9150(76)90054-X; Dong ZM, 1998, J CLIN INVEST, V102, P145, DOI 10.1172/JCI3001; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FEI HH, 1993, ARTERIOSCLER THROMB, V13, P1711, DOI 10.1161/01.ATV.13.11.1711; FRANK JS, 1989, J LIPID RES, V30, P967; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Gould AL, 1998, CIRCULATION, V97, P946; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Han KH, 1999, J LIPID RES, V40, P1053; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; Horkko S, 1999, J CLIN INVEST, V103, P117, DOI 10.1172/JCI4533; HURTCAMEJO E, 1992, ARTERIOSCLER THROMB, V12, P569, DOI 10.1161/01.ATV.12.5.569; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; JIMI S, 1995, ATHEROSCLEROSIS, V116, P15, DOI 10.1016/0021-9150(95)05515-X; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KHOO JC, 1992, ARTERIOSCLER THROMB, V12, P1258, DOI 10.1161/01.ATV.12.11.1258; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; LaRosa JC, 2001, AM J CARDIOL, V88, P291, DOI 10.1016/S0002-9149(01)01643-5; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; LI H, 1993, ARTERIOSCLER THROMB, V13, P197, DOI 10.1161/01.ATV.13.2.197; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Mackness MI, 1998, CURR OPIN LIPIDOL, V9, P319, DOI 10.1097/00041433-199808000-00006; Marathe GK, 2000, FREE RADICAL BIO MED, V28, P1762, DOI 10.1016/S0891-5849(00)00234-3; Marathe GK, 1999, J BIOL CHEM, V274, P28395, DOI 10.1074/jbc.274.40.28395; Marathe S, 2000, ARTERIOSCL THROM VAS, V20, P2607, DOI 10.1161/01.ATV.20.12.2607; MCMURRAY HF, 1993, J CLIN INVEST, V92, P1004, DOI 10.1172/JCI116605; MILLS GL, 1971, COMP BIOCHEM PHYSIOL, V40, P489, DOI 10.1016/0305-0491(71)90234-3; MUROHARA T, 1994, AM J PHYSIOL-HEART C, V267, pH2441, DOI 10.1152/ajpheart.1994.267.6.H2441; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PEDERSEN TR, 1994, LANCET, V344, P1383; PITAS RE, 1990, J BIOL CHEM, V265, P12722; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; PODREZ EA, 2002, J BIOL CHEM; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; Rajavashisth TB, 1999, J BIOL CHEM, V274, P11924, DOI 10.1074/jbc.274.17.11924; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; ROSS R, 1976, NEW ENGL J MED, V295, P420, DOI 10.1056/NEJM197608192950805; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; Sata M, 1998, J CLIN INVEST, V102, P1682, DOI 10.1172/JCI3531; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P908, DOI 10.1161/01.ATV.9.6.908; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Skalen K, 2002, NATURE, V417, P750, DOI 10.1038/nature00804; SMITH EB, 1990, EUR HEART J, V11, P72, DOI 10.1093/eurheartj/11.suppl_E.72; Sparrow CP, 2001, ARTERIOSCL THROM VAS, V21, P115, DOI 10.1161/01.ATV.21.1.115; Steinberg D, 2002, CIRCULATION, V105, P2107, DOI 10.1161/01.CIR.0000014762.06201.06; STEINBERG D, 1989, CIRCULATION, V80, P1070, DOI 10.1161/01.CIR.80.4.1070; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steinberg D., 1999, MOL BASIS CARDIOVASC, P458; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Sukhova GK, 2002, ARTERIOSCL THROM VAS, V22, P1452, DOI 10.1161/01.ATV.0000030360.72503.56; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; TERKELTAUB R, 1994, ARTERIOSCLER THROMB, V14, P47, DOI 10.1161/01.ATV.14.1.47; THORIN E, 1995, ATHEROSCLEROSIS, V114, P185, DOI 10.1016/0021-9150(94)05482-X; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; WEINSTEIN DB, 1976, BIOCHIM BIOPHYS ACTA, V424, P404, DOI 10.1016/0005-2760(76)90030-8; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Yokoya K, 1999, CIRCULATION, V100, P903, DOI 10.1161/01.CIR.100.9.903; YUI S, 1993, ARTERIOSCLER THROMB, V13, P331, DOI 10.1161/01.ATV.13.3.331	94	532	591	1	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2002	8	11					1211	1217		10.1038/nm1102-1211	http://dx.doi.org/10.1038/nm1102-1211			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12411947				2022-12-27	WOS:000179221200025
J	Linker, RA; Maurer, M; Gaupp, S; Martini, R; Holtmann, B; Giess, R; Rieckmann, P; Lassmann, H; Toyka, KV; Sendtner, M; Gold, R				Linker, RA; Maurer, M; Gaupp, S; Martini, R; Holtmann, B; Giess, R; Rieckmann, P; Lassmann, H; Toyka, KV; Sendtner, M; Gold, R			CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation	NATURE MEDICINE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MULTIPLE-SCLEROSIS; PROGENITOR CELLS; LESIONS; PATHOGENESIS; APOPTOSIS; NECROSIS; THERAPY; RAT	Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS)(1). So far, immunological mechanisms responsible for demyelination have been the focus of interest(2). However, mechanisms regulating axon maintenance as well as glial precursor-cell proliferation and oligodendrocyte survival might also influence disease outcome(3). The cytokine ciliary neurotrophic factor (CNTF), which was originally identified as a survival factor for isolated neurons, promotes differentiation, maturation and survival of oligodendrocytes(4-6). To investigate the role of endogenous CNTF in inflammatory demyelinating disease, we studied myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) in CNTF-deficient and wild-type C57BL/6 mice. Disease was more severe in CNTF-deficient mice and recovery was poor, with a 60% decrease in the number of proliferating oligodendrocyte precursor cells (OPCs) and a more than 50% increase in the rate of oligodendrocyte apoptosis. In addition, vacuolar dystrophy of myelin and axonal damage were more severe in CNTF-deficient mice. These specific pathological features could be prevented by treatment with an antiserum against tumor necrosis factor-alpha, suggesting that endogenous CNTF may counterbalance this effect of TNF-alpha (ref. 7). Here we identify a factor that modulates, in an inflammatory environment, glial cell survival and is an outcome determinant of EAE.	Univ Wurzburg, Dept Neurol, Clin Res Grp Multiple Sclerosis, D-8700 Wurzburg, Germany; Univ Wurzburg, Dept Neurol, Sect Dev Neurobiol, D-8700 Wurzburg, Germany; Univ Wurzburg, Dept Clin Neurobiol, Wurzburg, Germany; Brain Res Inst, Vienna, Austria	University of Wurzburg; University of Wurzburg; University of Wurzburg	Gold, R (corresponding author), Univ Wurzburg, Dept Neurol, Clin Res Grp Multiple Sclerosis, Josef Schneider Str 11, D-8700 Wurzburg, Germany.		Messier, Claude/A-2322-2008; Sendtner, Michael/M-8137-2014; Linker, Ralf/AAD-8884-2020; Sendtner, Michael/J-1542-2012; Lassmann, Hans/Z-2269-2019	Messier, Claude/0000-0002-4791-1763; Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974; Lassmann, Hans/0000-0001-8617-5052; Martini, Rudolf/0000-0002-5463-5592				Arnason BGW, 1999, NEUROLOGY, V53, P457, DOI 10.1212/wnl.53.3.457; Bachmann R, 1999, AM J PATHOL, V154, P1417, DOI 10.1016/S0002-9440(10)65395-3; Barres BA, 1996, MOL CELL NEUROSCI, V8, P146, DOI 10.1006/mcne.1996.0053; BARRES BA, 1993, DEVELOPMENT, V118, P283; BROSNAN CF, 1989, J NEUROIMMUNOL, V25, P227, DOI 10.1016/0165-5728(89)90141-0; Chang A, 2000, J NEUROSCI, V20, P6404, DOI 10.1523/JNEUROSCI.20-17-06404.2000; DITTRICH F, 1994, ANN NEUROL, V35, P151, DOI 10.1002/ana.410350206; Dupree JL, 1998, J NEUROSCI, V18, P1642; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; Giess R, 2002, ARCH NEUROL-CHICAGO, V59, P407, DOI 10.1001/archneur.59.3.407; GOLD R, 1994, LAB INVEST, V71, P219; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; HARTUNG HP, 1988, BRAIN, V111, P1039, DOI 10.1093/brain/111.5.1039; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Lassmann H, 2001, TRENDS MOL MED, V7, P115, DOI 10.1016/S1471-4914(00)01909-2; Lassmann H, 1997, GLIA, V19, P104, DOI 10.1002/(SICI)1098-1136(199702)19:2<104::AID-GLIA2>3.3.CO;2-R; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; Probert L, 2000, BRAIN, V123, P2005, DOI 10.1093/brain/123.10.2005; Raine CS, 1997, J NEUROIMMUNOL, V77, P135, DOI 10.1016/S0165-5728(97)00073-8; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1995, BAILLIERE CLIN NEUR, V4, P575; Storch MK, 1998, BRAIN PATHOL, V8, P681, DOI 10.1111/j.1750-3639.1998.tb00194.x; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Weishaupt A, 2000, J IMMUNOL, V165, P7157, DOI 10.4049/jimmunol.165.12.7157; YAO DL, 1995, P NATL ACAD SCI USA, V92, P6190, DOI 10.1073/pnas.92.13.6190	25	334	344	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2002	8	6					620	624		10.1038/nm0602-620	http://dx.doi.org/10.1038/nm0602-620			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042814				2022-12-27	WOS:000175907300034
J	Ye, ZM; Hellstrom, I; Hayden-Ledbetter, M; Dahlin, A; Ledbetter, JA; Hellstrom, KE				Ye, ZM; Hellstrom, I; Hayden-Ledbetter, M; Dahlin, A; Ledbetter, JA; Hellstrom, KE			Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB	NATURE MEDICINE			English	Article							ANTITUMOR IMMUNITY; CYTOPLASMIC TAIL; T-LYMPHOCYTES; CELL SURFACE; COSTIMULATION; CD28; VACCINATION; ANTIGEN; B7; AMPLIFICATION	Monoclonal antibodies against the T-cell activation molecule 4-1BB have been effective in the treatment of established mouse tumors. To create a vaccine that stimulates the immune system similarly to the efficacious monoclonal anti-4-1BB antibody, 1D8, we constructed a vector encoding cell-bound single-chain Fv fragments from 1D8. We transfected the vector into cells from the K1735 melanoma, selected because of its low immunogenicity and very low expression of major histocompatibility complex class I. The transfected cells induced a strong type 1 T-helper cell response, for which CD4(+) but not CD8(+) T lymphocytes were necessary and that involved natural killer cells. Vaccinated mice rejected established wild-type K1735 tumors growing as subcutaneous nodules or in the lung. An analogous approach may be effective against micrometastases in human patients, including tumors whose expression of major histocompatibility complex class I is very low.	Pacific NW Res Inst, Seattle, WA USA; Second Mil Med Univ, Int Canc Inst, Shanghai, Peoples R China	Naval Medical University	Hellstrom, KE (corresponding author), Pacific NW Res Inst, Seattle, WA USA.	khellstrom@pnri.org			NATIONAL CANCER INSTITUTE [R01CA085780, R01CA090143, R01CA079490, P50CA083636] Funding Source: NIH RePORTER; NCI NIH HHS [CA90143, CA79490, 1P50 CA83636, CA85780] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boon T, 1997, IMMUNOL TODAY, V18, P267, DOI 10.1016/S0167-5699(97)80020-5; CHEEVER MA, 1995, IMMUNOL REV, V145, P33, DOI 10.1111/j.1600-065X.1995.tb00076.x; CHEN LP, 1994, J EXP MED, V179, P523, DOI 10.1084/jem.179.2.523; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; Chen WJ, 1998, J EXP MED, V188, P1849, DOI 10.1084/jem.188.10.1849; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Doty RT, 1996, J IMMUNOL, V157, P3270; Doty RT, 1998, J IMMUNOL, V161, P2700; ESTIN CD, 1988, P NATL ACAD SCI USA, V85, P1052, DOI 10.1073/pnas.85.4.1052; FERRONE S, 1995, IMMUNOL TODAY, V16, P487, DOI 10.1016/0167-5699(95)80033-6; FIDLER IJ, 1981, CANCER RES, V41, P3266; Gilliland LK, 1996, TISSUE ANTIGENS, V47, P1, DOI 10.1111/j.1399-0039.1996.tb02509.x; Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118; GREENBERG PD, 1991, ADV IMMUNOL, V49, P281; Hayden MS, 1996, TISSUE ANTIGENS, V48, P242, DOI 10.1111/j.1399-0039.1996.tb02642.x; Hellstrom KE, 1999, HANDB EXP PHARMACOL, V133, P463; KAHN M, 1991, J IMMUNOL, V146, P3235; KARRE K, 1995, SCIENCE, V267, P978, DOI 10.1126/science.7863341; Kiessling R, 1999, CANCER IMMUNOL IMMUN, V48, P353, DOI 10.1007/s002620050586; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Li YW, 1996, J EXP MED, V183, P639, DOI 10.1084/jem.183.2.639; LI YW, 1994, J IMMUNOL, V153, P421; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Melero I, 1998, EUR J IMMUNOL, V28, P1116, DOI 10.1002/(SICI)1521-4141(199803)28:03<1116::AID-IMMU1116>3.0.CO;2-A; MELIEF CJM, 1995, IMMUNOL REV, V145, P167, DOI 10.1111/j.1600-065X.1995.tb00081.x; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Pardoll DM, 2000, CLIN IMMUNOL, V95, pS44, DOI 10.1006/clim.1999.4819; Pardoll DM, 1996, CURR OPIN IMMUNOL, V8, P619, DOI 10.1016/S0952-7915(96)80076-8; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; WARD PL, 1989, J EXP MED, V170, P217, DOI 10.1084/jem.170.1.217; Winberg G, 1996, IMMUNOL REV, V153, P209, DOI 10.1111/j.1600-065X.1996.tb00926.x; YANG G, 1997, EXPERT OPIN INV DRUG, V6, P1	34	130	158	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2002	8	4					343	348		10.1038/nm0402-343	http://dx.doi.org/10.1038/nm0402-343			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927939				2022-12-27	WOS:000174704800025
J	AbdAlla, S; Lother, H; el Massiery, A; Quitterer, U				AbdAlla, S; Lother, H; el Massiery, A; Quitterer, U			Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness	NATURE MEDICINE			English	Article							OXIDATIVE STRESS; B-2 RECEPTOR; PRESSOR-RESPONSE; MODULATION; EXPRESSION; ECLAMPSIA; CALCIUM	Several examples of functional G-protein-coupled receptor heterodimers have been identified. However, it is not known whether receptor heterodimerization is involved in the pathogenesis of human disorders. Here we show that in preeclamptic hypertensive women, a significant increase in heterodimerization occurs between the AT(1)-receptor for the vasopressor angiotensin II and the B-2-receptor for the vasodepressor bradykinin. AT(1)-B-2-receptor heterodimerization in preeclampsia correlated with a 4-5-fold increase in B-2-receptor protein levels. Expression of the AT(1)-B-2 heterodimer increased the responsiveness to angiotensin II and conferred resistance in AT(1)-receptors to inactivation by reactive oxygen species raised in normotensive and preeclamptic pregnancies. We suggest that AT(1)-B-2 heterodimers contribute to angiotensin II hypersensitivity in preeclampsia. Moreover, we identify preeclampsia as the first disorder associated with altered G-protein-coupled receptor heterodimerization.	Inst Pharmakol & Toxikol, Wurzburg, Germany; Ain Champs Univ Hosp, Med Res Ctr, Cairo, Egypt; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-2000 Hamburg, Germany	University of Wurzburg; Heinrich Pette Institute; University of Hamburg	Quitterer, U (corresponding author), Inst Pharmakol & Toxikol, Wurzburg, Germany.	toph029@rzbox.uni-wuerzburg.de						AALKJAER C, 1985, CLIN SCI, V69, P477, DOI 10.1042/cs0690477; AbdAlla S, 1996, EUR J BIOCHEM, V241, P498, DOI 10.1111/j.1432-1033.1996.00498.x; AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; ABDULKARIM R, 1961, AM J OBSTET GYNECOL, V82, P246, DOI 10.1016/0002-9378(61)90053-9; Akoev VR, 1998, BBA-BIOMEMBRANES, V1371, P284, DOI 10.1016/S0005-2736(98)00037-6; Belfort MA, 1996, AM J OBSTET GYNECOL, V174, P687, DOI 10.1016/S0002-9378(96)70451-9; BELLOMO G, 1987, J BIOL CHEM, V262, P1530; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; CUNNINGHAM FG, 1992, NEW ENGL J MED, V326, P927; DEJONG CLD, 1991, CLIN PERINATOL, V18, P683, DOI 10.1016/S0095-5108(18)30491-3; Devi LA, 2000, TRENDS PHARMACOL SCI, V21, P324, DOI 10.1016/S0165-6147(00)01519-4; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; GANT NF, 1973, J CLIN INVEST, V52, P2682, DOI 10.1172/JCI107462; Haddad EB, 2000, MOL PHARMACOL, V57, P1123; HALLER H, 1989, AM J HYPERTENS, V2, P238, DOI 10.1093/ajh/2.4.238; Hubel CA, 1999, P SOC EXP BIOL MED, V222, P222, DOI 10.1046/j.1525-1373.1999.d01-139.x; Masse J, 1998, CLIN BIOCHEM, V31, P251, DOI 10.1016/S0009-9120(98)00021-6; ONEY T, 1982, AM J OBSTET GYNECOL, V142, P17; Pesquero JB, 1996, IMMUNOPHARMACOLOGY, V33, P36, DOI 10.1016/0162-3109(96)00080-X; Pouliot L, 1998, OBSTET GYNECOL, V91, P591, DOI 10.1016/S0029-7844(97)00702-3; Quitterer U, 1999, J BIOL CHEM, V274, P14773, DOI 10.1074/jbc.274.21.14773; Quitterer U, 1996, BIOCHEMISTRY-US, V35, P13368, DOI 10.1021/bi961163w; Quitterer U, 1999, P NATL ACAD SCI USA, V96, P10626, DOI 10.1073/pnas.96.19.10626; Rath Hope Heidi, 2000, Protein Expression and Purification, V18, P269; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; TOUYZ RM, 1993, J HYPERTENS, V11, P551, DOI 10.1097/00004872-199305000-00011; Tschope C, 2000, J HYPERTENS, V18, P223, DOI 10.1097/00004872-200018020-00014; Vagnoni KE, 1998, AM J PHYSIOL-HEART C, V275, pH1845, DOI 10.1152/ajpheart.1998.275.5.H1845	29	373	390	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2001	7	9					1003	1009		10.1038/nm0901-1003	http://dx.doi.org/10.1038/nm0901-1003			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533702				2022-12-27	WOS:000170853300024
J	Nakada, K; Inoue, K; Ono, T; Isobe, K; Ogura, A; Goto, Y; Nonaka, I; Hayashi, JI				Nakada, K; Inoue, K; Ono, T; Isobe, K; Ogura, A; Goto, Y; Nonaka, I; Hayashi, JI			Inter-mitochondrial complementation: Mitochondria-specific system preventing mice from expression of disease phenotypes by mutant mtDNA	NATURE MEDICINE			English	Article							WILD-TYPE; MOUSE; DNA; DELETION; CELLS; EMBRYOGENESIS; DYSFUNCTION; ELIMINATION; MYOPATHY; GENOME	Here we investigated the pathogenesis of deletion mutant mitochondrial (mt)DNA by generating mice with mutant mtDNA carrying a 4696-basepair deletion (Delta mtDNA4696), and by using cytochrome c oxidase (COX) electron micrographs to identify COX activity at the individual mitochondrial level. All mitochondria in tissues with Delta mtDNA4696 showed normal COX activity until Delta mtDNA4696 accumulated predominantly; this prevented mice from expressing disease phenotypes. Moreover, we did not observe coexistence of COX-positive and -negative mitochondria within single cells. These results indicate the occurrence of inter-mitochondrial complementation through exchange of genetic contents between exogenously introduced mitochondria with Delta mtDNA4696 and host mitochondria with normal mtDNA. This complementation shows a mitochondria-specific mechanism for avoiding expression of deletion-mutant mtDNA, and opens the possibility of a gene therapy in which mitochondria possessing full-length DNA are introduced.	Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Ultrastruct Res, Tokyo, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Tokyo, Japan; Natl Inst Infect Dis, Dept Vet Sci, Tokyo, Japan	University of Tsukuba; University of Tsukuba; National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; National Institute of Infectious Diseases (NIID)	Hayashi, JI (corresponding author), Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki, Japan.		Ogura, Atsuo/J-3916-2014	Ogura, Atsuo/0000-0003-0447-1988				CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1994, J CELL BIOL, V125, P43, DOI 10.1083/jcb.125.1.43; Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826; Inoue K, 1997, J BIOL CHEM, V272, P15510, DOI 10.1074/jbc.272.24.15510; Ito S, 1999, P NATL ACAD SCI USA, V96, P2099, DOI 10.1073/pnas.96.5.2099; KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; LOMBES A, 1989, REV NEUROL-FRANCE, V145, P671; MIYABAYASHI S, 1984, BRAIN DEV-JPN, V6, P362, DOI 10.1016/S0387-7604(84)80112-6; MULLERHOCKER J, 1992, BRAIN PATHOL, V2, P149, DOI 10.1111/j.1750-3639.1992.tb00683.x; NONAKA I, 1989, J NEUROL SCI, V92, P193, DOI 10.1016/0022-510X(89)90136-6; Ono T, 2001, NAT GENET, V28, P272, DOI 10.1038/90116; SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; Shitara H, 2000, GENETICS, V156, P1277; SZABOLCS MJ, 1994, KIDNEY INT, V45, P1388, DOI 10.1038/ki.1994.181; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089; Yamaoka M, 2000, GENETICS, V155, P301; Yamaoka M, 2001, BIOCHEM BIOPH RES CO, V282, P707, DOI 10.1006/bbrc.2001.4646; YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699	22	324	336	0	21	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2001	7	8					934	940		10.1038/90976	http://dx.doi.org/10.1038/90976			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479626				2022-12-27	WOS:000171740400031
J	Drexler, W; Morgner, U; Ghanta, RK; Kartner, FX; Schuman, JS; Fujimoto, JG				Drexler, W; Morgner, U; Ghanta, RK; Kartner, FX; Schuman, JS; Fujimoto, JG			Ultrahigh-resolution ophthalmic optical coherence tomography	NATURE MEDICINE			English	Article							FIBER LAYER THICKNESS; GLAUCOMATOUS EYES; BIOPSY; MICROSCOPY; RETINA		MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA; MIT, Elect Res Lab, Cambridge, MA 02139 USA; Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Tufts University	Fujimoto, JG (corresponding author), MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.		Schuman, Joel S/M-2389-2019; Schuman, Joel S/K-7304-2012; Morgner, Uwe/U-9155-2017	Schuman, Joel S/0000-0002-8885-3766; Schuman, Joel S/0000-0002-8885-3766; Morgner, Uwe/0000-0001-5103-9632; Drexler, Wolfgang/0000-0002-3557-6398	NATIONAL EYE INSTITUTE [R01EY011289, R29EY011006] Funding Source: NIH RePORTER; NEI NIH HHS [EY11006-04, R01 EY011289, R29 EY011006-05, R01 EY011289-14, R01-EY11289-13] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1993, Z1361 ANSI; Bamber JC, 1988, PHYSICS MED IMAGING, P319; BILLE JF, 1990, NONINVASIVE DIAGNOST, P528; Boppart SA, 1998, NAT MED, V4, P861, DOI 10.1038/nm0798-861; Bowd C, 2000, ARCH OPHTHALMOL-CHIC, V118, P22; Chauhan DS, 1999, INVEST OPHTH VIS SCI, V40, P2332; Drexler W, 1999, OPT LETT, V24, P1221, DOI 10.1364/OL.24.001221; FERCHER AF, 1993, AM J OPHTHALMOL, V116, P113, DOI 10.1016/S0002-9394(14)71762-3; FUJIMOTO JG, 1995, NAT MED, V1, P970, DOI 10.1038/nm0995-970; Fujimoto JG, 2000, NEOPLASIA, V2, P9, DOI 10.1038/sj.neo.7900071; Gass JD, 1997, STEREOSCOPIC ATLAS M, V1, P1; Hee MR, 1998, OPHTHALMOLOGY, V105, P360, DOI 10.1016/S0161-6420(98)93601-6; Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5; HEE MR, 1995, OPHTHALMOLOGY, V102, P748, DOI 10.1016/S0161-6420(95)30959-1; HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025; HOGAN H, 1971, HISTOLOGY HUMAN EYE, P393; HOWLAND HC, 1977, J OPT SOC AM, V67, P1508, DOI 10.1364/JOSA.67.001508; HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; Huang YJ, 1998, INVEST OPHTH VIS SCI, V39, P2405; KNIGHTON RW, 2000, INVEST OPHTH VIS SCI, P41; KREBS W, 1991, PRIMATE RETINA CHORO, P4; MARSHALL J, 1988, RETINITIS PIGMENTOSA, P37; MASTERS BR, 1994, APPL OPTICS, V33, P695, DOI 10.1364/AO.33.000695; Morgner U, 2000, OPT LETT, V25, P111, DOI 10.1364/OL.25.000111; Morgner U, 1999, OPT LETT, V24, P411, DOI 10.1364/OL.24.000411; Oyster CW, 1999, HUMAN EYE STRUCTURE, V660; PAVLIN CJ, 1992, OPHTHALMOLOGY, V99, P1220; PULIAFITO CA, 1995, OPTICAL COHERENCE TO; RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857; Rohen JW, 1977, AUGENHEILKUNDE KLIN; SCHUMAN JS, 1995, ARCH OPHTHALMOL-CHIC, V113, P586, DOI 10.1001/archopht.1995.01100050054031; Schuman JS, 1996, OPHTHALMOLOGY, V103, P1889, DOI 10.1016/S0161-6420(96)30410-7; SPALTON DJ, 1994, ATLAS CLIN OPHTHALMO; SWANSON EA, 1993, OPT LETT, V18, P1864, DOI 10.1364/OL.18.001864; TAKADA K, 1987, APPL OPTICS, V26, P1603, DOI 10.1364/AO.26.001603; Tearney GJ, 1997, SCIENCE, V276, P2037, DOI 10.1126/science.276.5321.2037; Thrane L, 2000, J OPT SOC AM A, V17, P484, DOI 10.1364/JOSAA.17.000484; Toth CA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1425, DOI 10.1001/archopht.1997.01100160595012; WEBB RH, 1980, APPL OPTICS, V19, P2991, DOI 10.1364/AO.19.002991; YOUNGQUIST RC, 1987, OPT LETT, V12, P158, DOI 10.1364/OL.12.000158; Zeimer R, 1998, OPHTHALMOLOGY, V105, P224, DOI 10.1016/S0161-6420(98)92743-9	41	735	814	3	63	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2001	7	4					502	507		10.1038/86589	http://dx.doi.org/10.1038/86589			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283681	Green Accepted			2022-12-27	WOS:000167960500049
J	Stacker, SA; Caesar, C; Baldwin, ME; Thornton, GE; Williams, RA; Prevo, R; Jackson, DG; Nishikawa, S; Kubo, H; Achen, MG				Stacker, SA; Caesar, C; Baldwin, ME; Thornton, GE; Williams, RA; Prevo, R; Jackson, DG; Nishikawa, S; Kubo, H; Achen, MG			VEGF-D promotes the metastatic spread of tumor cells via the lymphatics	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; IN-VIVO; TYROSINE KINASES; BREAST-CANCER; FACTOR FAMILY; ANGIOGENESIS; RECEPTOR; EXPRESSION; INHIBITION; LIGAND	Metastasis to local lymph nodes via the lymphatic vessels is a common step in the spread of solid tumors. To investigate the molecular mechanisms underlying the spread of cancer by the lymphatics, we examined the ability of vascular endothelial growth factor (VEGF)-D, a ligand for the lymphatic growth factor receptor VEGFR-3/Flt-4, to induce formation of lymphatics in a mouse tumor model. Staining with markers specific for lymphatic endothelium demonstrated that VEGF-D induced the formation of lymphatics within tumors. Moreover, expression of VEGF-D in tumor cells led to spread of the tumor to lymph nodes, whereas expression of VEGF, an angiogenic growth factor which activates VEGFR-2 but not VEGFR-3, did not. VEGF-D also promoted tumor angiogenesis and growth. Lymphatic spread induced by VEGF-D could be blocked with an antibody specific for VEGF-D. This study demonstrates that lymphatics can be established in solid tumors and implicates VEGF family members in determining the route of metastatic spread.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic, Australia; Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Pathol, Parkville, Vic, Australia; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med,MRC, Human Immunol Unit,Inst Mol Med, Oxford OX3 9DU, England; Kyoto Univ, Grad Sch Med, Dept Mol Genet, Kyoto, Japan; Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, Helsinki, Finland	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; University of Melbourne; University of Oxford; Kyoto University; University of Helsinki	Stacker, SA (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic, Australia.			Achen, Marc/0000-0002-3791-803X; , david/0000-0002-4133-9364; Stacker, Steven/0000-0003-4096-9273				Achen MG, 2000, EUR J BIOCHEM, V267, P2505, DOI 10.1046/j.1432-1327.2000.01257.x; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; ACHEN MG, IN PRESS J PATHOL; Ansink AC, 1999, CANCER, V86, P652, DOI 10.1002/(SICI)1097-0142(19990815)86:4<652::AID-CNCR14>3.0.CO;2-R; Babu S, 1998, J IMMUNOL, V161, P1428; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; deWaal RMW, 1997, AM J PATHOL, V150, P1951; Drevs J, 2000, CANCER RES, V60, P4819; Dukes CE, 1932, J PATHOL BACTERIOL, V35, P323, DOI 10.1002/path.1700350303; FISHER B, 1983, CANCER-AM CANCER SOC, V52, P1551, DOI 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kubo H, 2000, BLOOD, V96, P546; Layton JE, 1997, GROWTH FACTORS, V14, P117, DOI 10.3109/08977199709021515; Leu AJ, 2000, CANCER RES, V60, P4324; LIOTTA LA, 1992, SCI AM, V266, P34; Lymboussaki A, 1998, AM J PATHOL, V153, P395, DOI 10.1016/S0002-9440(10)65583-6; Lymboussaki A, 2000, CURR TOP MICROBIOL, V251, P75; MANDRIOTA SJ, 2001, IN PRESS EMBOJ; Millauer B, 1996, CANCER RES, V56, P1615; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Niki T, 2000, CLIN CANCER RES, V6, P2431; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; PLATE KH, 1993, CANCER RES, V53, P5822; Prewett M, 1999, CANCER RES, V59, P5209; Saleh M, 1996, CANCER RES, V56, P393; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; Stacker SA, 1999, GROWTH FACTORS, V17, P1, DOI 10.3109/08977199909001058; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Taipale J, 1999, CURR TOP MICROBIOL, V237, P85; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Vujanovic Nikola L., 1996, Methods (Orlando), V9, P394, DOI 10.1006/meth.1996.0044; WHITESIDE TL, 1995, CURR OPIN IMMUNOL, V7, P704, DOI 10.1016/0952-7915(95)80080-8; Wood JM, 2000, CANCER RES, V60, P2178	41	987	1098	0	32	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2001	7	2					186	191		10.1038/84635	http://dx.doi.org/10.1038/84635			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175849				2022-12-27	WOS:000166756300035
J	Schmitt, CA; Rosenthal, CT; Lowe, SW				Schmitt, CA; Rosenthal, CT; Lowe, SW			Genetic analysis of chemoresistance in primary murine lymphomas	NATURE MEDICINE			English	Article							NON-HODGKINS-LYMPHOMAS; B-CELL; C-MYC; CLONOGENIC SURVIVAL; HEMATOLOGIC MALIGNANCIES; ANTICANCER AGENTS; INDUCED APOPTOSIS; TREATMENT FAILURE; TRANSGENIC MICE; DRUG-RESISTANCE	Understanding the basis of chemoresistance is a principal goal of molecular oncology. We have exploited a murine lymphoma model and retroviral gene transfer to rapidly generate a series of spontaneous tumors differing only in a gene of interest, and subsequently studied the impact of the test gene on the treatment sensitivity of tumors at their natural site. We demonstrate that the Bcl-2 oncoprotein produces multi-drug resistance when assessed in primary lymphomas in vivo. In contrast, this effect was dramatically reduced when the primary lymphomas were subjected to long-term culture, and completely missed in the standard clonogenic survival assay. This model highlights the importance of physiological test systems to address the complexity of clinical drug resistance and provides a novel strategy to evaluate compounds targeting specific genetic lesions.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Lowe, SW (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.		Schmitt, Clemens A/S-9479-2017	Schmitt, Clemens A/0000-0002-4731-2226				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Bearss DJ, 2000, ONCOGENE, V19, P1114, DOI 10.1038/sj.onc.1203275; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Brown JM, 1999, CANCER RES, V59, P1391; Chang BD, 1999, CANCER RES, V59, P3761; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELROUBY S, 1993, BLOOD, V82, P3452; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Gascoyne RD, 1997, BLOOD, V90, P244; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Hermine O, 1996, BLOOD, V87, P265, DOI 10.1182/blood.V87.1.265.bloodjournal871265; HSU B, 1995, ONCOGENE, V11, P175; Ichikawa A, 1997, NEW ENGL J MED, V337, P529, DOI 10.1056/NEJM199708213370804; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; Liu R, 1999, AM J PATHOL, V155, P1861, DOI 10.1016/S0002-9440(10)65505-8; Lock RB, 1996, CANCER RES, V56, P4006; Moller MB, 1999, CLIN CANCER RES, V5, P1085; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; Navaratnam S, 1998, LEUKEMIA LYMPHOMA, V29, P139, DOI 10.3109/10428199809058389; Omer CA, 2000, CANCER RES, V60, P2680; Pomp J, 1996, RADIOTHER ONCOL, V40, P121, DOI 10.1016/0167-8140(96)01767-7; PRINCE VE, 1991, J VIROL, V65, P1803, DOI 10.1128/JVI.65.4.1803-1811.1991; Reed J C, 1996, Behring Inst Mitt, P72; Reed JC, 1997, SEMIN HEMATOL, V34, P9; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 1999, J PATHOL, V187, P127; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Taylor ST, 2000, J NATL CANCER I, V92, P18, DOI 10.1093/jnci/92.1.18; Uckun FM, 1997, BLOOD, V89, P3769, DOI 10.1182/blood.V89.10.3769.3769_3769_3777; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Walker A, 1997, CANCER RES, V57, P1939; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; Wilson WH, 1997, BLOOD, V89, P601, DOI 10.1182/blood.V89.2.601; YIN DX, 1995, CANCER RES, V55, P4922	35	233	249	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					1029	1035		10.1038/79542	http://dx.doi.org/10.1038/79542			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973324				2022-12-27	WOS:000089190500036
J	Camp, RL; Chung, GG; Rimm, DL				Camp, RL; Chung, GG; Rimm, DL			Automated subcellular localization and quantification of protein expression in tissue microarrays	NATURE MEDICINE			English	Article							BETA-CATENIN EXPRESSION; COLORECTAL-CANCER; TECHNOLOGY; CARCINOMA	The recent development of tissue microarrays-composed of hundreds of tissue sections from different tumors arrayed on a single glass slide-facilitates rapid evaluation of large-scale outcome studies. Realization of this potential depends on the ability to rapidly and precisely quantify the protein expression within each tissue spot. We have developed a set of algorithms that allow the rapid, automated, continuous and quantitative analysis of tissue microarrays, including the separation of tumor from stromal elements and the sub-cellular localization of signals. Validation studies using estrogen receptor in breast carcinoma show that automated analysis matches or exceeds the results of conventional pathologist-based scoring. Automated analysis and sub-cellular localization of beta-catenin in colon cancer identifies two novel, prognostically significant tumor subsets, not detected by traditional pathologist-based scoring. Development of automated analysis technology empowers tissue microarrays for use in discovery-type experiments (more typical of cDNA microarrays), with the added advantage of inclusion of long-term demographic and patient outcome information.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Yale University	Rimm, DL (corresponding author), Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.			Rimm, David/0000-0001-5820-4397	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K08ES011571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057604] Funding Source: NIH RePORTER; NIEHS NIH HHS [K0-8 ES11571] Funding Source: Medline; NIGMS NIH HHS [R0-1 GM57604] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bacus S, 1997, ANAL QUANT CYTOL, V19, P316; Chung GG, 2001, CLIN CANCER RES, V7, P4013; Gunther K, 1998, DIS COLON RECTUM, V41, P1256, DOI 10.1007/BF02258226; Hugh TJ, 1999, INT J CANCER, V82, P504, DOI 10.1002/(SICI)1097-0215(19990812)82:4<504::AID-IJC6>3.0.CO;2-6; Kallioniemi OP, 2001, HUM MOL GENET, V10, P657, DOI 10.1093/hmg/10.7.657; Kobayashi M, 2000, BRIT J CANCER, V82, P1689; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Maruyama K, 2000, ONCOLOGY-BASEL, V59, P302, DOI 10.1159/000012187; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Osborne C K, 1981, Adv Exp Med Biol, V138, P377; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Rao JY, 2002, BIOTECHNIQUES, V32, P924, DOI 10.2144/02324pt04; Rimm DL, 2001, CANCER J, V7, P24; Robinson JP, 2001, METHOD CELL BIOL, V63, P89; Tarnok A, 2002, CYTOMETRY, V50, P133, DOI 10.1002/cyto.10099; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R	19	618	663	2	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2002	8	11					1323	1327		10.1038/nm791	http://dx.doi.org/10.1038/nm791			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	614ZK	12389040				2022-12-27	WOS:000179221200041
J	Borowsky, B; Durkin, MM; Ogozalek, K; Marzabadi, MR; DeLeon, J; Heurich, R; Lichtblau, H; Shaposhnik, Z; Daniewska, I; Blackburn, TP; Branchek, TA; Gerald, C; Vaysse, PJ; Forray, C				Borowsky, B; Durkin, MM; Ogozalek, K; Marzabadi, MR; DeLeon, J; Heurich, R; Lichtblau, H; Shaposhnik, Z; Daniewska, I; Blackburn, TP; Branchek, TA; Gerald, C; Vaysse, PJ; Forray, C			Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist	NATURE MEDICINE			English	Article							MCH; MICE; IDENTIFICATION; DISTRESS; CLONING; SYSTEM	Melanin concentrating hormone (MCH) is an orexigenic hypothalamic neuropeptide, which plays an important role in the complex regulation of energy balance and body weight. Here we show that SNAP-7941, a selective, high-affinity MCH1 receptor ( MCH1-R) antagonist, inhibited food intake stimulated by central administration of MCH, reduced consumption of palatable food, and, after chronic administration to rats with diet-induced obesity, resulted in a marked, sustained decrease in body weight. In addition, after mapping the binding sites for [H-3] SNAP-7941 in rat brain, we evaluated its effects in a series of behavioral models. SNAP-7941 produced effects similar to clinically used antidepressants and anxiolytics in three animal models of depression/ anxiety: the rat forced-swim test, rat social interaction and guinea pig maternal-separation vocalization tests. Given these observations, an MCH1-R antagonist may be useful not only in the management of obesity but also as a treatment for depression and/or anxiety.	Synapt Pharmaceut Corp, Paramus, NJ USA		Forray, C (corresponding author), Synapt Pharmaceut Corp, Paramus, NJ USA.	cforray@synapticcorp.com						BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; Bonini JA, 2000, J BIOL CHEM, V275, P39324, DOI 10.1074/jbc.M004385200; Bradley RL, 2000, DIABETES, V49, P1073, DOI 10.2337/diabetes.49.7.1073; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; FILE SE, 1978, BRIT J PHARMACOL, V62, P19, DOI 10.1111/j.1476-5381.1978.tb07001.x; GERALD C, 1995, J BIOL CHEM, V270, P26758, DOI 10.1074/jbc.270.45.26758; Gonzalez MI, 1996, PEPTIDES, V17, P171, DOI 10.1016/0196-9781(95)02092-6; Hervieu GJ, 2000, EUR J NEUROSCI, V12, P1194, DOI 10.1046/j.1460-9568.2000.00008.x; Hill J, 2001, J BIOL CHEM, V276, P20125, DOI 10.1074/jbc.M102068200; Kokkotou EG, 2001, ENDOCRINOLOGY, V142, P680, DOI 10.1210/en.142.2.680; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; LIGHTOWLER S, 1994, PHARMACOL BIOCHEM BE, V49, P281, DOI 10.1016/0091-3057(94)90422-7; Lucki I, 2001, PSYCHOPHARMACOLOGY, V155, P315, DOI 10.1007/s002130100694; Ludwig DS, 2001, J CLIN INVEST, V107, P379, DOI 10.1172/JCI10660; Monzon ME, 1999, PHYSIOL BEHAV, V67, P813, DOI 10.1016/S0031-9384(99)00117-1; NAHON JL, 1989, ENDOCRINOLOGY, V125, P2056, DOI 10.1210/endo-125-4-2056; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PETTIJOHN TF, 1979, PSYCHOL REP, V44, P918, DOI 10.2466/pr0.1979.44.3.918; PETTIJOHN TF, 1979, DEV PSYCHOBIOL, V12, P73, DOI 10.1002/dev.420120109; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Sailer AW, 2001, P NATL ACAD SCI USA, V98, P7564, DOI 10.1073/pnas.121170598; Saito Y, 1999, NATURE, V400, P265, DOI 10.1038/22321; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341	25	411	451	3	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2002	8	8					825	830		10.1038/nm741	http://dx.doi.org/10.1038/nm741			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12118247	Bronze			2022-12-27	WOS:000177200900028
J	Nieuwenhuis, EES; Matsumoto, T; Exley, M; Schleipman, RA; Glickman, J; Bailey, DT; Corazza, N; Colgan, SP; Onderdonk, AB; Blumberg, RS				Nieuwenhuis, EES; Matsumoto, T; Exley, M; Schleipman, RA; Glickman, J; Bailey, DT; Corazza, N; Colgan, SP; Onderdonk, AB; Blumberg, RS			CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung	NATURE MEDICINE			English	Article							KILLER T-CELLS; TUMOR-NECROSIS-FACTOR; ALPHA-GALACTOSYLCERAMIDE; HOST-DEFENSE; NKT CELLS; ALVEOLAR MACROPHAGES; TH1 RESPONSE; ACTIVATION; CD1D; EXPRESSION	CD1d-restricted T cells are implicated as key players in host defense against various microbial infections. However, the mechanisms involved and the role they play, if any, at the mucosal surfaces where pathogenic infections are initiated is unknown. In a murine pneumonia model established by intranasal application of Pseudomonas aeruginosa, CD1d(-/-) mice showed markedly reduced pulmonary eradication of P. aeruginosa compared with wild-type mice; this was associated with significantly lower amounts of macrophage inflammatory protein-2 and reduced numbers of neutrophils within the bronchoalveolar lavage fluid. Corollarily, treatment of mice with alpha-galactosylceramide-a lipid that activates CD1d-restricted T cells-increased the amount of interferon-gamma; this was associated with rapid pulmonary clearance through enhanced phagocytosis of P. aeruginosa by alveolar macrophages. These results reveal a crucial role played by CD1d-restricted T cells in regulating the antimicrobial immune functions of macrophages at the lung mucosal surface.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gastroenterol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Lab Mucosal Immunol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Channing Lab, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Canc Biol Program, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Blumberg, RS (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gastroenterol, Boston, MA 02115 USA.		Colgan, Sean P./B-4573-2009	Exley, Mark/0000-0002-5088-1032	NIDCR NIH HHS [P01 DE 13499] Funding Source: Medline; NIDDK NIH HHS [DK51362, DK53056, DK44319] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053056, R01DK051362, R37DK044319, R01DK044319] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen GH, 2000, J IMMUNOL, V165, P6496, DOI 10.4049/jimmunol.165.11.6496; Cheung DOY, 2000, INFECT IMMUN, V68, P4585, DOI 10.1128/IAI.68.8.4585-4592.2000; Contursi C, 2000, P NATL ACAD SCI USA, V97, P91, DOI 10.1073/pnas.97.1.91; Exley MA, 2001, J LEUKOCYTE BIOL, V69, P713; Faunce DE, 2001, J IMMUNOL, V166, P313, DOI 10.4049/jimmunol.166.1.313; Gonzalez-Aseguinolaza G, 2000, P NATL ACAD SCI USA, V97, P8461, DOI 10.1073/pnas.97.15.8461; Hashimoto S, 1996, AM J PHYSIOL-LUNG C, V270, pL819, DOI 10.1152/ajplung.1996.270.5.L819; Kawakami K, 2001, J IMMUNOL, V167, P6525, DOI 10.4049/jimmunol.167.11.6525; Kawakami K, 2001, INFECT IMMUN, V69, P213, DOI 10.1128/IAI.69.1.213-220.2001; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; Kooguchi K, 1998, INFECT IMMUN, V66, P3164, DOI 10.1128/IAI.66.7.3164-3169.1998; Kumar H, 2000, J IMMUNOL, V165, P4797, DOI 10.4049/jimmunol.165.9.4797; MUNOZFERNANDEZ MA, 1992, EUR J IMMUNOL, V22, P301, DOI 10.1002/eji.1830220203; Naidenko OV, 1999, J EXP MED, V190, P1069, DOI 10.1084/jem.190.8.1069; PAULNOCK DM, 1992, CURR OPIN IMMUNOL, V4, P344, DOI 10.1016/0952-7915(92)90087-U; Porcelli SA, 1999, ANNU REV IMMUNOL, V17, P297, DOI 10.1146/annurev.immunol.17.1.297; Roark JH, 1998, J IMMUNOL, V160, P3121; Saubermann LJ, 2000, GASTROENTEROLOGY, V119, P119, DOI 10.1053/gast.2000.9114; Schroeder TH, 2001, J IMMUNOL, V166, P7410, DOI 10.4049/jimmunol.166.12.7410; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Sonoda KH, 1999, J EXP MED, V190, P1215, DOI 10.1084/jem.190.9.1215; Spada FM, 2000, EUR J IMMUNOL, V30, P3468, DOI 10.1002/1521-4141(2000012)30:12<3468::AID-IMMU3468>3.0.CO;2-C; SPEERT DP, 1992, J CLIN INVEST, V90, P1085, DOI 10.1172/JCI115924; STOUT RD, 1989, J IMMUNOL, V142, P760; Tsai WC, 2000, INFECT IMMUN, V68, P4289, DOI 10.1128/IAI.68.7.4289-4296.2000; Vernacchio L, 2000, J INFECT DIS, V181, P1162, DOI 10.1086/315307; Wilson SB, 2001, CURR OPIN IMMUNOL, V13, P555, DOI 10.1016/S0952-7915(00)00258-2	27	249	278	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2002	8	6					588	593		10.1038/nm0602-588	http://dx.doi.org/10.1038/nm0602-588			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042809				2022-12-27	WOS:000175907300029
J	Lock, C; Hermans, G; Pedotti, R; Brendolan, A; Schadt, E; Garren, H; Langer-Gould, A; Strober, S; Cannella, B; Allard, J; Klonowski, P; Austin, A; Lad, N; Kaminski, N; Galli, SJ; Oksenberg, JR; Raine, CS; Heller, R; Steinman, L				Lock, C; Hermans, G; Pedotti, R; Brendolan, A; Schadt, E; Garren, H; Langer-Gould, A; Strober, S; Cannella, B; Allard, J; Klonowski, P; Austin, A; Lad, N; Kaminski, N; Galli, SJ; Oksenberg, JR; Raine, CS; Heller, R; Steinman, L			Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; MYELIN BASIC-PROTEIN; B-CELL; MOLECULAR-CLONING; EXPRESSION; FAMILY; CSF; AUTOANTIBODIES; IDENTIFICATION	Microarray analysis of multiple sclerosis (MS) lesions obtained at autopsy revealed increased transcripts of genes encoding inflammatory cytokines, particularly interleukin-6 and -17, interferon-gamma and associated downstream pathways. Comparison of two poles of MS pathologyacute lesions with inflammation versus 'silent' lesions without inflammation-revealed differentially transcribed genes. Some products of these genes were chosen as targets for therapy of experimental autoimmune encephalomyelitis (EAE) in mice. Granulocyte colony-stimulating factor is upregulated in acute, but not in chronic, MS lesions, and the effect on ameliorating EAE is more pronounced in the acute phase, in contrast to knocking out the immunoglobulin Fc receptor common gamma chain where the effect is greatest on chronic disease. These results in EAE corroborate the microarray studies on MS lesions. Large-scale analysis of transcripts in MS lesions elucidates new aspects of pathology and opens possibilities for therapy.	Roche Biosci, Palo Alto, CA 94304 USA; Albert Einstein Coll Med, Dept Pathol Neuropathol & Neurol, Bronx, NY 10467 USA; Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Lung Biol Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Stanford Univ, Dept Neurol & Neurosci, Beckman Ctr, Stanford, CA 94305 USA; Stanford Univ, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; Rosetta Inpharmat, Informat, Kirkland, WA USA	Roche Holding; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Stanford University; Stanford University; Merck & Company	Heller, R (corresponding author), Roche Biosci, Palo Alto, CA 94304 USA.	rheller@stanford.edu; steinman@stanford.edu		Steinman, Lawrence/0000-0002-2437-2250; Brendolan, Andrea/0000-0003-0109-6879; Kaminski, Naftali/0000-0001-5917-4601; Lock, Christopher/0000-0002-4087-5894; Hermans, Guy/0000-0001-7767-6912	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI035761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS011920, P01NS011920] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35761] Funding Source: Medline; NINDS NIH HHS [NS11920, NS08953] Funding Source: Medline; PHS HHS [18235, 41402, 28579, 30201] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACHIRON A, 1994, J CLIN INVEST, V93, P600, DOI 10.1172/JCI117012; Akassoglou K, 1997, J IMMUNOL, V158, P438; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; DABIRI GA, 1992, J BIOL CHEM, V267, P16545; Davoust N, 1999, J IMMUNOL, V163, P6551; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532; GIJBELS K, 1995, MOL MED, V1, P795, DOI 10.1007/BF03401894; Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469; HAUSER SL, 1990, NEUROLOGY, V40, P1735, DOI 10.1212/WNL.40.11.1735; HONG JX, 1993, J IMMUNOL, V150, P3895; JACOBS CA, 1991, J IMMUNOL, V146, P2983; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Matarese G, 2001, J IMMUNOL, V166, P5909, DOI 10.4049/jimmunol.166.10.5909; Matusevicius D, 1999, MULT SCLER J, V5, P101, DOI 10.1177/135245859900500206; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Pedotti R, 2001, NAT IMMUNOL, V2, P216, DOI 10.1038/85266; Penkowa M, 2001, J NEUROIMMUNOL, V119, P248, DOI 10.1016/S0165-5728(01)00357-5; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Poliak S, 1997, J IMMUNOL, V158, P5751; Raine CS, 1998, REV NEUROL-FRANCE, V154, P577; Raine CS, 1997, MULTIPLE SCLEROSIS C, P151; Rehli M, 1997, GENOMICS, V43, P221, DOI 10.1006/geno.1997.4778; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; Schadt EE, 2001, J CELL BIOCHEM, V84, P120, DOI 10.1002/jcb.10073; Schadt EE, 2000, J CELL BIOCHEM, V80, P192; Steinman L, 1999, NEURON, V24, P511, DOI 10.1016/S0896-6273(00)81107-1; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; WALSH LA, 1992, TISSUE ANTIGENS, V40, P213, DOI 10.1111/j.1399-0039.1992.tb02048.x; Waring JF, 2001, TOXICOL APPL PHARM, V175, P28, DOI 10.1006/taap.2001.9243; WARREN KG, 1995, P NATL ACAD SCI USA, V92, P11061, DOI 10.1073/pnas.92.24.11061; Whitney LW, 1999, ANN NEUROL, V46, P425; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; Wucherpfennig KW, 1997, J CLIN INVEST, V100, P1114, DOI 10.1172/JCI119622; YAN YM, 1993, NEURON, V11, P423, DOI 10.1016/0896-6273(93)90147-J; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; Zavala F, 2002, J IMMUNOL, V168, P2011, DOI 10.4049/jimmunol.168.4.2011	43	1302	1381	1	53	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2002	8	5					500	508		10.1038/nm0502-500	http://dx.doi.org/10.1038/nm0502-500			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984595				2022-12-27	WOS:000175336800036
J	Crute, JJ; Grygon, CA; Hargrave, KD; Simoneau, B; Faucher, AM; Bolger, G; Kibler, P; Liuzzi, M; Cordingley, MG				Crute, JJ; Grygon, CA; Hargrave, KD; Simoneau, B; Faucher, AM; Bolger, G; Kibler, P; Liuzzi, M; Cordingley, MG			Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease	NATURE MEDICINE			English	Article							RIBONUCLEOTIDE REDUCTASE INHIBITOR; ANTIVIRAL ACTIVITY; ORAL ACYCLOVIR; IN-VIVO; TYPE-1; INFECTIONS; REPLICATION; DNA; VALACICLOVIR; RESISTANCE	Herpes simplex virus infections are the cause of significant morbidity, and currently used therapeutics are largely based on modified nucleoside analogs that inhibit viral DNA polymerase function. To target this disease in a new way, we have identified and optimized selective thiazolylphenyl-containing inhibitors of the herpes simplex virus (HSV) helicase-primase enzyme. The most potent compounds inhibited the helicase, the primase and the DNA-dependent ATPase activities of the enzyme with IC50 (50% inhibitory concentration) values less than 100 nM. Inhibition of the enzymatic activities was through stabilization of the interaction between the helicase-primase and DNA substrates, preventing the progression through helicase or primase catalytic cycles. Helicase-primase inhibitors also prevented viral replication as demonstrated in viral growth assays. One compound, BILS 179 BS, displayed an EC50 (effective concentration inhibiting viral growth by 50%) of 27 nM against viral growth with a selectivity index greater than 2,000. Antiviral activity was also demonstrated for multiple strains of HSV, including strains resistant to nucleoside-based therapies. Most importantly, BILS 179 BS was orally active against HSV infections in murine models of HSV-1 and HSV-2 disease and more effective than acyclovir when the treatment frequency per day was reduced or when initiation of treatment was delayed up to 65 hours after infection. These studies validate the use of helicase-primase inhibitors for the treatment of acute herpesvirus infections and provide new lead compounds for optimization and design of superior anti-HSV agents.	Boehringer Ingelheim Pharmaceut Inc, Ctr Res & Dev, Ridgefield, CT 06877 USA; Boehringer Ingelheim Canada Ltd, Res & Dev, Laval, PQ, Canada	Boehringer Ingelheim; Boehringer Ingelheim	Crute, JJ (corresponding author), Boehringer Ingelheim Pharmaceut Inc, Ctr Res & Dev, 90 E Ridge POB 368, Ridgefield, CT 06877 USA.							Bolger GT, 1997, ANTIVIR RES, V35, P157, DOI 10.1016/S0166-3542(97)00024-7; Challberg M., 1996, DNA REPLICATION EUKA, P721; CHATIS PA, 1992, ANTIMICROB AGENTS CH, V36, P1589, DOI 10.1128/AAC.36.8.1589; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DRACHEVA S, 1995, J BIOL CHEM, V270, P14148, DOI 10.1074/jbc.270.23.14148; Duan JM, 1998, ANTIMICROB AGENTS CH, V42, P1629, DOI 10.1128/AAC.42.7.1629; ERLICH KS, 1989, NEW ENGL J MED, V320, P293, DOI 10.1056/NEJM198902023200506; KERN ER, 1982, AM J MED, V73, P100, DOI 10.1016/0002-9343(82)90073-0; KIMBERLIN DW, 1995, ANTIVIR RES, V26, P423, DOI 10.1016/0166-3542(95)00031-G; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P145; LANGELIER Y, 1978, J VIROL, V26, P547, DOI 10.1128/JVI.26.3.547-553.1978; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lawetz C, 1998, ANTIVIR RES, V39, P35, DOI 10.1016/S0166-3542(98)00028-X; Lehman IR, 1999, J BIOL CHEM, V274, P28059, DOI 10.1074/jbc.274.40.28059; LIUZZI M, 1994, NATURE, V372, P695, DOI 10.1038/372695a0; MATTHEWS JT, 1993, ANTIVIR RES, V20, P89, DOI 10.1016/0166-3542(93)90001-Y; MORAHAN PS, 1977, J IMMUNOL, V119, P2030; Perry CM, 1996, DRUGS, V52, P754, DOI 10.2165/00003495-199652050-00009; REARDON J E, 1991, P1; REICHMAN RC, 1984, JAMA-J AM MED ASSOC, V251, P2103, DOI 10.1001/jama.251.16.2103; Selway CN, 1996, BIOORGAN MED CHEM, V4, P645, DOI 10.1016/0968-0896(96)00058-2; Shin YK, 2001, J CLIN MICROBIOL, V39, P913, DOI 10.1128/JCM.39.3.913-917.2001; Spector FC, 1998, J VIROL, V72, P6979, DOI 10.1128/JVI.72.9.6979-6987.1998; SPRUANCE SL, 1990, J INFECT DIS, V161, P185, DOI 10.1093/infdis/161.2.185; TENNEY DJ, 1995, J BIOL CHEM, V270, P9129, DOI 10.1074/jbc.270.16.9129; Thackray AM, 1996, J INFECT DIS, V173, P291, DOI 10.1093/infdis/173.2.291; Vere Hodge R. A., 1993, Antiviral Chemistry and Chemotherapy, V4, P67; WHITLEY RJ, 1995, FIELDS VIROLOGY, P2297; ZHU LA, 1992, J VIROL, V66, P1458	31	180	200	2	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2002	8	4					386	391		10.1038/nm0402-386	http://dx.doi.org/10.1038/nm0402-386			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927945				2022-12-27	WOS:000174704800031
J	Pai, R; Soreghan, B; Szabo, IL; Pavelka, M; Baatar, D; Tarnawski, AS				Pai, R; Soreghan, B; Szabo, IL; Pavelka, M; Baatar, D; Tarnawski, AS			Prostaglandin E-2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy	NATURE MEDICINE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; PROTEIN-COUPLED RECEPTORS; RECTAL MUCOSA; FACTOR-ALPHA; EXPRESSION; CHEMOPREVENTION; CARCINOMA; NEOPLASIA; RAT	Prostaglandins (PGs), bioactive lipid molecules produced by cyclooxygenase enzymes (COX-1 and COX-2), have diverse biological activities, including growth-promoting actions on gastrointestinal mucosa(1-5). They are also implicated in the growth of colonic polyps and cancers(6). However, the precise mechanisms of these trophic actions of PGs remain unclear. As activation of the epidermal growth factor receptor (EGFR) triggers mitogenic signaling in gastrointestinal mucosa, and its expression is also upregulated in colonic cancers and most neoplasms(7-9), we investigated whether PGs transactivate EGFR. Here we provide evidence that prostaglandin E-2 (PGE(2)) rapidly phosphorylates EGFR and triggers the extracellular signal-regulated kinase 2 (ERK2)-mitogenic signaling pathway in normal gastric epithelial (RGM1) and colon cancer (Caco-2, LoVo and HT-29) cell lines. Inactivation of EGFR kinase with selective inhibitors significantly reduces PGE(2)-induced ERK2 activation, c-fos mRNA expression and cell proliferation. Inhibition of matrix metalloproteinases (MMPs), transforming growth factor-alpha (TGF-alpha) or c-Src blocked PGE(2)-mediated EGFR transactivation and downstream signaling indicating that PGE(2)-induced EGFR transactivation involves signaling transduced via TGF-alpha, an EGFR ligand, likely released by c-Src-activated MMP(s). Our findings that PGE(2) transactivates EGFR reveal a previously unknown mechanism by which PGE(2) mediates trophic actions resulting in gastric and intestinal hypertrophy as well as growth of colonic polyps and cancers.	Dept Vet Affairs Med Ctr, Med Serv, Long Beach, CA USA; Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine	Tarnawski, AS (corresponding author), Dept Vet Affairs Med Ctr, Med Serv, Long Beach, CA USA.							Barnes CJ, 1999, CANCER EPIDEM BIOMAR, V8, P311; Baselga J, 2000, ANN ONCOL, V11, P187, DOI 10.1023/A:1011144502974; Callejas NA, 2001, HEPATOLOGY, V33, P860, DOI 10.1053/jhep.2001.23002; DEMBINSKI A, 1985, AM J PHYSIOL, V248, pG170, DOI 10.1152/ajpgi.1985.248.2.G170; DuBois RN, 1996, J GASTROENTEROL, V31, P898, DOI 10.1007/BF02358623; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; JOHANSSON C, 1983, ADV PROSTAG THROMB L, V12, P403; JOHANSSON C, 1982, SCAND J GASTROENTERO, V17, P21; Kinoshita T, 1999, BBA-MOL CELL BIOL L, V1438, P120, DOI 10.1016/S1388-1981(99)00034-7; Kobayashi I, 1996, IN VITRO CELL DEV-AN, V32, P259; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; MaleckaPanas E, 1997, HEPATO-GASTROENTEROL, V44, P435; MOSKAL TL, 1995, CANCER EPIDEM BIOMAR, V4, P127; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; REINHART WH, 1983, GASTROENTEROLOGY, V85, P1003; RESNICK MB, 1995, CANCER-AM CANCER SOC, V76, P187, DOI 10.1002/1097-0142(19950715)76:2<187::AID-CNCR2820760205>3.0.CO;2-C; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Shimada N, 1998, J GASTROEN HEPATOL, V13, P794, DOI 10.1111/j.1440-1746.1998.tb00735.x; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; Yang VW, 2000, PROSTAG OTH LIPID M, V60, P83, DOI 10.1016/S0090-6980(99)00054-4; Younes M, 1996, ANTICANCER RES, V16, P1999	26	717	753	2	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2002	8	3					289	293		10.1038/nm0302-289	http://dx.doi.org/10.1038/nm0302-289			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875501				2022-12-27	WOS:000174139500035
J	Sgadari, C; Barillari, G; Toschi, E; Carlei, D; Bacigalupo, I; Baccarini, S; Palladino, C; Leone, P; Bugarini, R; Malavasi, L; Cafaro, A; Falchi, M; Valdembri, D; Rezza, G; Bussolino, F; Monini, P; Ensoli, B				Sgadari, C; Barillari, G; Toschi, E; Carlei, D; Bacigalupo, I; Baccarini, S; Palladino, C; Leone, P; Bugarini, R; Malavasi, L; Cafaro, A; Falchi, M; Valdembri, D; Rezza, G; Bussolino, F; Monini, P; Ensoli, B			HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma	NATURE MEDICINE			English	Article							FIBROBLAST-GROWTH-FACTOR; ACTIVE ANTIRETROVIRAL THERAPY; VIRUS-1 TAT PROTEIN; INFLAMMATORY CYTOKINES; VASCULAR-PERMEABILITY; CELL-GROWTH; IN-VIVO; ENDOTHELIAL-CELLS; T-CELLS; HUMAN-HERPESVIRUS-8	Treatment with HIV-1 protease inhibitors (PI) is associated with a reduced incidence or regression of Kaposi sarcoma (KS). Here we show that systemic administration of the PIs indinavir or saquinavir to nude mice blocks the development and induces regression of angioproliferative KS-like lesions promoted by primary human KS cells, basic fibroblast growth factor (bFGF), or bFGF and vascular endothelial growth factor (VEGF) combined. These PIs also block bFGF or VEGF-induced angiogenesis in the chorioallantoic membrane assay with a potency similar to paclitaxel (Taxol). These effects are mediated by the inhibition of endothelial- and KS-cell invasion and of matrix metalloproteinase-2 proteolytic activation by PIs at concentrations present in plasma of treated individuals. As PIs also inhibit the in vivo growth and invasion of an angiogenic tumor-cell line, these data indicate that PIs are potent anti-angiogenic and anti-tumor molecules that might be used in treating non-HIV KS and in other HIV-associated tumors.	Ist Super Sanita, Virol Lab, I-00161 Rome, Italy; Ist Super Sanita, Epidemiol & Biostat Lab, I-00161 Rome, Italy; Ist Super Sanita, Lab Ultrastruct, I-00161 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy; Univ Turin, Dept Oncol Sci, Inst Canc Res & Treatment, Turin, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); University of Rome Tor Vergata; University of Turin	Ensoli, B (corresponding author), Ist Super Sanita, Virol Lab, Viale Regina Elena 299, I-00161 Rome, Italy.	ensoli@iss.it	Sgadari, Cecilia/H-4302-2016; Palladino, Clelia/K-7555-2016; Ensoli, Barbara/J-9169-2016; Bussolino, Federico/AES-3951-2022; iMed.ULisboa, EEPHIV/B-4222-2014; Monini, Paolo/K-1429-2016; Cafaro, Aurelio/K-5314-2016; Toschi, Elena/M-7051-2017; rezza, giovanni/D-4393-2016; Bussolino, Federico/K-2500-2016	Sgadari, Cecilia/0000-0003-0364-4912; Palladino, Clelia/0000-0003-0740-5863; Ensoli, Barbara/0000-0002-0545-8737; Monini, Paolo/0000-0002-4941-6854; rezza, giovanni/0000-0003-0268-6790; Valdembri, Donatella/0000-0003-4590-417X; Toschi, Elena/0000-0002-9720-5971; Bacigalupo, ilaria/0000-0002-4249-1982; Carlei, Davide/0000-0002-7151-6077; Cafaro, Aurelio/0000-0001-9675-6344; Baccarini, Sara/0000-0001-8070-1656; Falchi, Mario/0000-0002-8290-5406; Bussolino, Federico/0000-0002-5348-1341; Leone, Patrizia/0000-0002-5281-4917				Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Andre P, 1998, P NATL ACAD SCI USA, V95, P13120, DOI 10.1073/pnas.95.22.13120; Appleby P, 2000, JNCI-J NATL CANCER I, V92, P1823, DOI 10.1093/jnci/92.22.1823; Ascherl G, 1999, BLOOD, V93, P4232; Ascherl G, 2001, AIDS RES HUM RETROV, V17, P1035, DOI 10.1089/088922201300343717; Barillari G, 1999, BLOOD, V94, P663; Barillari G, 1999, J IMMUNOL, V163, P1929; Belotti D, 1996, CLIN CANCER RES, V2, P1843; Bower M, 1999, AIDS, V13, P2105, DOI 10.1097/00002030-199910220-00014; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; Cassone A, 1999, J INFECT DIS, V180, P448, DOI 10.1086/314871; Cattelan AM, 1999, EUR J CANCER, V35, P1809, DOI 10.1016/S0959-8049(99)00161-6; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chavan S, 2001, BLOOD, V98, P383, DOI 10.1182/blood.V98.2.383; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; Cornali E, 1996, AM J PATHOL, V149, P1851; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1994, J CLIN INVEST, V94, P1736, DOI 10.1172/JCI117521; Ensoli B, 1998, CYTOKINE GROWTH F R, V9, P63, DOI 10.1016/S1359-6101(97)00037-3; Ensoli B, 2001, ADV CANCER RES, V81, P161, DOI 10.1016/S0065-230X(01)81005-8; Fiorelli V, 1998, BLOOD, V91, P956; Gruber A, 2001, J BIOL CHEM, V276, P47840, DOI 10.1074/jbc.M105582200; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; Kedes DH, 1997, J CLIN INVEST, V99, P2082, DOI 10.1172/JCI119380; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Lebbe C, 1998, AIDS, V12, pF45, DOI 10.1097/00002030-199807000-00002; Ledru E, 2000, BLOOD, V95, P3191, DOI 10.1182/blood.V95.10.3191.010k10_3191_3198; Liang JS, 2001, NAT MED, V7, P1327, DOI 10.1038/nm1201-1327; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; Monini P, 1999, BLOOD, V93, P4044; Nakamura S, 1997, J IMMUNOL, V158, P4992; Osman M, 1999, J VIROL, V73, P6136, DOI 10.1128/JVI.73.7.6136-6140.1999; Rabkin CS, 1997, NEW ENGL J MED, V336, P988, DOI 10.1056/NEJM199704033361403; REAL FX, 1985, NEW ENGL J MED, V313, P1659; Ribatti D, 1996, INT J DEV BIOL, V40, P1189; Samaniego F, 1997, J IMMUNOL, V158, P1887; Samaniego F, 1998, AM J PATHOL, V152, P1433; Sgadari C, 2000, J IMMUNOL, V165, P509, DOI 10.4049/jimmunol.165.1.509; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Sturzl M, 2001, ADV CANCER RES, V81, P125, DOI 10.1016/S0065-230X(01)81004-6; Torre-Cisneros J, 2000, AIDS, V14, P2215, DOI 10.1097/00002030-200009290-00026; Toschi E, 2001, MOL BIOL CELL, V12, P2934, DOI 10.1091/mbc.12.10.2934; Tovo PA, 2000, AIDS, V14, P743, DOI 10.1097/00002030-200004140-00014; Vaccher E, 1999, J ACQ IMMUN DEF SYND, V22, P407; Wang QJ, 2000, J INFECT DIS, V182, P928, DOI 10.1086/315777; Weichold FF, 1999, J HUMAN VIROL, V2, P261	50	253	268	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2002	8	3					225	232		10.1038/nm0302-225	http://dx.doi.org/10.1038/nm0302-225			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875492				2022-12-27	WOS:000174139500026
J	Ichikawa, K; Liu, WM; Zhao, LM; Wang, Z; Liu, D; Ohtsuka, T; Zhang, HG; Mountz, JD; Koopman, WJ; Kimberly, RP; Zhou, T				Ichikawa, K; Liu, WM; Zhao, LM; Wang, Z; Liu, D; Ohtsuka, T; Zhang, HG; Mountz, JD; Koopman, WJ; Kimberly, RP; Zhou, T			Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity	NATURE MEDICINE			English	Article							NF-KAPPA-B; APOPTOSIS-INDUCING LIGAND; TRAIL-INDUCED APOPTOSIS; FADD-DEPENDENT APOPTOSIS; DEATH DOMAIN; RECEPTOR; CASPASE-8; FAMILY; MEMBER; ACTIVATE	A novel anti-human DR5 monoclonal antibody, TRA-8, induces apoptosis of most tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-sensitive tumor cells both in vitro and in vivo. In contrast to both the membrane-bound form of human TRAIL, which induced severe hepatitis in mice, and the soluble form of human TRAIL, which induced apoptosis of normal human hepatocytes in vitro, TRA-8 did not induce significant cell death of normal human hepatocytes. However, both primary hepatocellular carcinoma cells and an established liver cancer cell line were highly susceptible to the killing mediated by TRA-8. We show here that elevated levels of cell-surface expression of DRS and increased susceptibility to DRS-mediated apoptosis are characteristics of malignant tumor cells. In contrast, DR5 alone is not sufficient to trigger apoptosis of normal hepatocytes. Therefore, selective, specific targeting of DR5 with an agonistic antibody might be a safe and effective strategy for cancer therapy.	Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; Sankyo Co Ltd, Biomed Res Labs, Tokyo 140, Japan	University of Alabama System; University of Alabama Birmingham; Daiichi Sankyo Company Limited	Zhou, T (corresponding author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.			Kimberly, Robert/0000-0002-5330-3086	NIAMS NIH HHS [R03-AR44982] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR044982] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Griffith TS, 1999, J IMMUNOL, V162, P2597; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; Jeremias I, 1998, EUR CYTOKINE NETW, V9, P687; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kagawa S, 2001, CANCER RES, V61, P3330; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641	26	471	576	0	25	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2001	7	8					954	960		10.1038/91000	http://dx.doi.org/10.1038/91000			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479629				2022-12-27	WOS:000171740400034
J	Brown, EB; Campbell, RB; Tsuzuki, Y; Xu, L; Carmeliet, P; Fukumura, D; Jain, RK				Brown, EB; Campbell, RB; Tsuzuki, Y; Xu, L; Carmeliet, P; Fukumura, D; Jain, RK			In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy	NATURE MEDICINE			English	Article							IN-VIVO; VASCULAR-PERMEABILITY; BLOOD-FLOW; GROWTH	Intravital microscopy coupled with chronic animal window models has provided stunning insight into tumor pathophysiology, including gene expression, angiogenesis, cell adhesion and migration, vascular, interstitial and lymphatic transport, metabolic microenvironment and drug delivery. However, the findings to date have been limited to the tumor surface (< 150 <mu>m). Here, we show that the multiphoton laser-scanning microscope can provide high three-dimensional resolution of gene expression and function in deeper regions of tumors. These insights could be critical to the development of novel therapeutics that target not only the tumor surface, but also internal regions.	Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Jain, RK (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA.		Xu, Lei/GRR-9174-2022; Jain, Rakesh K/I-1384-2017; Carmeliet, Peter/AAQ-5140-2020	Jain, Rakesh K/0000-0001-7571-3548; Carmeliet, Peter/0000-0001-7961-1821	NATIONAL CANCER INSTITUTE [R35CA056591, R24CA085140, P01CA080124, T32CA073479] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA73479, P01 CA080124, R24 CA85140, R35 CA56591, P01 CA80124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berk DA, 1997, P NATL ACAD SCI USA, V94, P1785, DOI 10.1073/pnas.94.5.1785; Brown EB, 1999, BIOPHYS J, V77, P2837, DOI 10.1016/S0006-3495(99)77115-8; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1998, NATURE, V395, P525, DOI 10.1038/26791; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; ENDRICH B, 1979, J NATL CANCER I, V62, P387; Fukumura D, 1997, AM J PATHOL, V150, P713; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Jain RK, 1996, CANCER METAST REV, V15, P195, DOI 10.1007/BF00437472; JAIN RK, 2001, TUMOR MODELS CANC; Kim KH, 1999, APPL OPTICS, V38, P6004, DOI 10.1364/AO.38.006004; Kleinfeld D, 1998, P NATL ACAD SCI USA, V95, P15741, DOI 10.1073/pnas.95.26.15741; LEUNIG M, 1992, CANCER RES, V52, P6553; Lichtenbeld Hera C., 1996, Microcirculation (Philadelphia), V3, P349, DOI 10.3109/10739689609148307; Naumov GN, 1999, J CELL SCI, V112, P1835; Squirrell JM, 1999, NAT BIOTECHNOL, V17, P763, DOI 10.1038/11698; Wong CW, 2001, CANCER RES, V61, P333; Yu JL, 2001, AM J PATHOL, V158, P1325, DOI 10.1016/S0002-9440(10)64083-7; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765	21	472	485	1	34	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					864	868		10.1038/89997	http://dx.doi.org/10.1038/89997			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433354				2022-12-27	WOS:000169808600041
J	Phillips, RE; Harcourt, GC; Price, DA				Phillips, RE; Harcourt, GC; Price, DA			CD4(+) T cells: The great escape	NATURE MEDICINE			English	Editorial Material							RESISTANT VIRUS VARIANTS; NEUTRALIZING ANTIBODY; IN-VIVO; SELECTION; RESPONSES; MICE	Mutation is one way in which RNA viruses evade the destructive actions of CD8(+) cytotoxic lymphocytes. New research shows that they employ the same method to escape attack by CD4(+) T cells.	John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England	University of Oxford	Phillips, RE (corresponding author), John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.		Price, David A/C-7876-2013	Price, David A/0000-0001-9416-2737				Ciurea A, 2001, NAT MED, V7, P795, DOI 10.1038/89915; Ciurea A, 2000, P NATL ACAD SCI USA, V97, P2749, DOI 10.1073/pnas.040558797; Harcourt GC, 1998, J EXP MED, V188, P1785, DOI 10.1084/jem.188.10.1785; HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255; Kelleher AD, 2001, J EXP MED, V193, P375, DOI 10.1084/jem.193.3.375; Lanzavecchia A, 1998, NATURE, V393, P413, DOI 10.1038/30845; Oxenius A, 1998, EUR J IMMUNOL, V28, P390, DOI 10.1002/(SICI)1521-4141(199801)28:01<390::AID-IMMU390>3.0.CO;2-O; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; Seiler P, 1999, J IMMUNOL, V162, P4536; Sewell AK, 2000, STEM CELLS, V18, P230, DOI 10.1634/stemcells.18-4-230	10	4	4	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					777	778		10.1038/89892	http://dx.doi.org/10.1038/89892			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433338				2022-12-27	WOS:000169808600021
J	Carmeliet, P; Moons, L; Luttun, A; Vincenti, V; Compernolle, V; De Mol, M; Wu, Y; Bon, F; Devy, L; Beck, H; Scholz, D; Acker, T; DiPalma, T; Dewerchin, M; Noel, A; Stalmans, I; Barra, A; Blacher, S; Vandendriessche, T; Ponten, A; Eriksson, U; Plate, KH; Foidart, JM; Schaper, W; Charnock-Jones, DS; Hicklin, DJ; Herbert, JM; Collen, D; Persico, MG				Carmeliet, P; Moons, L; Luttun, A; Vincenti, V; Compernolle, V; De Mol, M; Wu, Y; Bon, F; Devy, L; Beck, H; Scholz, D; Acker, T; DiPalma, T; Dewerchin, M; Noel, A; Stalmans, I; Barra, A; Blacher, S; Vandendriessche, T; Ponten, A; Eriksson, U; Plate, KH; Foidart, JM; Schaper, W; Charnock-Jones, DS; Hicklin, DJ; Herbert, JM; Collen, D; Persico, MG			Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions	NATURE MEDICINE			English	Article							MONOCYTE ACTIVATION; TYROSINE KINASE; FACTOR RECEPTOR; FACTOR VEGF; IN-VIVO; EXPRESSION; FLT-1; HYPOXIA; TUMORS; MICE	Vascular endothelial growth factor (VEGF) stimulates angiogenesis by activating VEGF receptor-2 (VEGFR-2). The role of its homolog, placental growth factor (PIGF), remains unknown. Both VEGF and PIGF bind to VEGF receptor-1 (VEGFR-1), but it is unknown whether VECFR-1, which exists as a soluble or a membrane-bound type, is an inert decoy or a signaling receptor for PIGF during angiogenesis. Here, we report that embryonic angiogenesis in mice was not affected by deficiency of PIGF (Pgf(-/-)). VEGF-B, another ligand of VEGFR-1, did not rescue development in Pgf(-/-) mice. However, loss of PIGF impaired angiogenesis, plasma extravasation and collateral growth during ischemia, inflammation, wound healing and cancer. Transplantation of wild-type bone marrow rescued the impaired angiogenesis and collateral growth in Pgf(-/-) mice, indicating that PIGF might have contributed to vessel growth in the adult by mobilizing bone-marrow-derived cells. The synergism between PIGF and VEGF was specific, as PIGF deficiency impaired the response to VEGF, but not to bFGF or histamine. VECFR-1 was activated by PIGF, given that anti-VEGFR-1 antibodies and a Src-kinase inhibitor blocked the endothelial response to PIGF or VEGF/PIGF. By upregulating PIGF and the signaling subtype of VEGFR-1, endothelial cells amplify their responsiveness to VEGF during the 'angiogenic switch' in many pathological disorders.	Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium; CNR, Ist Int Genet & Biofis, I-80125 Naples, Italy; ImClone Syst, New York, NY USA; Sanofi Synthelabo, Cardiovasc Thrombosis Res Dept, Toulouse, France; Univ Liege, Lab Tumor & Dev Biol, B-4000 Sart Tilman Par Liege, Belgium; FAU Erlangen Nurnberg, Dept Neuropathol, Erlangen, Germany; Max Planck Inst, Dept Expt Cardiol, Bad Nauheim, Germany; Univ Cambridge, Dept Obstet & Gynaecol, Reprod Mol Res Grp, Cambridge, England; Ludwig Inst Canc Res, S-10401 Stockholm, Sweden	Flanders Institute for Biotechnology (VIB); KU Leuven; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Eli Lilly; Sanofi-Aventis; Sanofi France; University of Liege; University of Erlangen Nuremberg; Max Planck Society; University of Cambridge; Ludwig Institute for Cancer Research	Carmeliet, P (corresponding author), Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	Luttun, Aernout/AAZ-6540-2020; Carmeliet, Peter/AAQ-5140-2020; Charnock-Jones, D. Stephen/AAE-3391-2020; Di+Palma, Tina/AAN-6853-2021; Charnock-Jones, D. Stephen/B-3743-2009	Luttun, Aernout/0000-0001-7902-9524; Carmeliet, Peter/0000-0001-7961-1821; Charnock-Jones, D. Stephen/0000-0002-2936-4890; Charnock-Jones, D. Stephen/0000-0002-2936-4890; Noel, Agnes/0000-0002-7670-6179; Moons, Lieve (Godelieve)/0000-0003-0186-1411; Vandendriessche, Thierry/0000-0003-4230-745X; Acker, Till/0000-0001-6357-7227				AASE K, IN PRESS CIRCULATION; Achen MG, 1997, GROWTH FACTORS, V15, P69, DOI 10.3109/08977199709002113; Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Cao YH, 1996, J CLIN INVEST, V98, P2507, DOI 10.1172/JCI119069; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Clark DE, 1998, BIOL REPROD, V59, P1540, DOI 10.1095/biolreprod59.6.1540; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; Dvorak HF, 2000, SEMIN PERINATOL, V24, P75, DOI 10.1016/S0146-0005(00)80061-0; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Hatva E, 1996, AM J PATHOL, V148, P763; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Heymans S, 1999, NAT MED, V5, P1135, DOI 10.1038/13459; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; Khaliq A, 1998, LAB INVEST, V78, P109; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; Monsky WL, 1999, CANCER RES, V59, P4129; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nicosia RF, 1999, INT REV CYTOL, V185, P1; Nomura M, 1998, J NEURO-ONCOL, V40, P123, DOI 10.1023/A:1006198422718; Olofsson B, 1999, CURR OPIN BIOTECH, V10, P528, DOI 10.1016/S0958-1669(99)00024-5; PARK JE, 1994, J BIOL CHEM, V269, P25646; PASSANITI A, 1992, LAB INVEST, V67, P519; Persico MG, 1999, CURR TOP MICROBIOL, V237, P31; Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774; Ryan HE, 2000, CANCER RES, V60, P4010; Shibuya M, 1999, CURR TOP MICROBIOL, V237, P59; Simpson DAC, 1999, BIOCHEM BIOPH RES CO, V262, P333, DOI 10.1006/bbrc.1999.1201; Takahashi A, 1999, BIOCHEM BIOPH RES CO, V257, P855, DOI 10.1006/bbrc.1999.0465; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; VICAUT E, 1990, MICROVASC RES, V39, P120, DOI 10.1016/0026-2862(90)90063-W; Viglietto G, 1996, ONCOGENE, V13, P577; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427	45	1266	1340	4	88	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					575	583		10.1038/87904	http://dx.doi.org/10.1038/87904			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329059	Green Submitted			2022-12-27	WOS:000169961100037
J	Sachs, JD				Sachs, JD			A new global commitment to disease control in Africa	NATURE MEDICINE			English	News Item								Despite the availability of effective therapies in developed nations, infectious diseases continue to take a grave toll on the population and economy of sub-Saharan Africa. Aside from a few succeses, the global donor community has not adequately helped African governments meet these health challenges. However, if annual donor contributions increased approximately 10-20-fold, millions of lives could be saved, helping Africa escape the cycle of disease and impoverishment.	Harvard Univ, Ctr Int Dev, Cambridge, MA 02138 USA; WHO, Commiss Macroecon & Hlth, CH-1211 Geneva, Switzerland	Harvard University; World Health Organization	Sachs, JD (corresponding author), Harvard Univ, Ctr Int Dev, Cambridge, MA 02138 USA.							Attaran A, 2001, LANCET, V357, P57, DOI 10.1016/S0140-6736(00)03576-5; *STAT FAIL TASK FO, 1999, ENV CHANG SEC PROJ R, P49; *UN DEV PROGR, 2001, HUM DEV REP 2000, P189; *WORLD BANK, 2001, WORLD DEV REP 2000 2, P274; World Health Organization, 2000, WORLD HLTH REP 2000	5	16	16	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					521	523		10.1038/87830	http://dx.doi.org/10.1038/87830			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329042				2022-12-27	WOS:000169961100018
J	Angelillo-Scherrer, A; de Frutos, PG; Aparicio, C; Melis, E; Savi, P; Lupu, F; Arnout, J; Dewerchin, M; Hoylaerts, MF; Herbert, M; Collen, D; Dahlback, B; Carmeliet, P				Angelillo-Scherrer, A; de Frutos, PG; Aparicio, C; Melis, E; Savi, P; Lupu, F; Arnout, J; Dewerchin, M; Hoylaerts, MF; Herbert, M; Collen, D; Dahlback, B; Carmeliet, P			Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis	NATURE MEDICINE			English	Article							RECEPTOR TYROSINE KINASE; ARREST-SPECIFIC GENE-6; PLASMINOGEN-ACTIVATOR INHIBITOR-1; VASCULAR SMOOTH-MUSCLE; K-DEPENDENT PROTEINS; GROWTH-ARREST; CELL-ADHESION; BLEEDING-TIME; AXL; LIGAND	The growth arrest-specific gene 6 product (Gas6) is a secreted protein related to the anticoagulant protein S but its role in hemostasis is unknown. Here we show that inactivation of the Gas6 gene prevented venous and arterial thrombosis in mice, and protected against fatal collagen/epinephrine-induced thrombo embolism. Gas6(-/-) mice did not, however, suffer spontaneous bleeding and had normal bleeding after tail clipping. In addition, we found that Gas6 antibodies inhibited platelet aggregation in vitro and protected mice against fatal thrombo embolism without causing bleeding in vivo. Gas6 amplified platelet aggregation and secretion in response to known agonists. Platelet dysfunction in Gas6(-/-) mice resembled that of patients with platelet signaling transduction defects. Thus, Gas6 is a platelet-response amplifier that plays a significant role in thrombosis. These findings warrant further evaluation of the possible therapeutic use of Gas6 inhibition for prevention of thrombosis.	Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol, Louvain, Belgium; Lund Univ, Univ Malta, Dept Clin Chem, Wallenberg Lab, Malmo, Sweden; Sanofi Synthelabo, Cardiovasc Thrombosis Res Dept, Toulouse, France; Thrombosis Res Inst, Vasc Biol Lab, London SW3 6LR, England	Lund University; University of Malta; Sanofi-Aventis; Sanofi France; Thrombosis Research Institute	Carmeliet, P (corresponding author), Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol, Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	Carmeliet, Peter/AAQ-5140-2020; de Frutos, Pablo García/B-8594-2011; Lupu, Florea/AAV-3257-2021; Lupu, Florea/C-3162-2009	Carmeliet, Peter/0000-0001-7961-1821; de Frutos, Pablo García/0000-0003-1547-1190; Lupu, Florea/0000-0003-1249-9278; Lupu, Florea/0000-0003-1249-9278; Hoylaerts, Marc/0000-0002-6474-3933; Angelillo-Scherrer, Anne/0000-0003-2872-4863; Dahlback, Bjorn/0000-0003-1546-0328				Avanzi GC, 1997, EXP HEMATOL, V25, P1219; BENNETT JS, 1991, ANN NY ACAD SCI, V614, P214, DOI 10.1111/j.1749-6632.1991.tb43704.x; Borgel D, 1997, THROMB HAEMOSTASIS, V78, P351; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; Crosier KE, 1997, PATHOLOGY, V29, P131, DOI 10.1080/00313029700169744; Dahlback B, 2000, LANCET, V355, P1627, DOI 10.1016/S0140-6736(00)02225-X; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DEJANA E, 1979, THROMB RES, V15, P191, DOI 10.1016/0049-3848(79)90064-1; DIMINNO G, 1983, J PHARMACOL EXP THER, V225, P57; Evenas P, 2000, THROMB HAEMOSTASIS, V84, P271, DOI 10.1055/s-0037-1614007; Fabre JE, 1999, NAT MED, V5, P1199, DOI 10.1038/13522; Fridell YWC, 1998, J BIOL CHEM, V273, P7123, DOI 10.1074/jbc.273.12.7123; Gabbeta J, 1996, BLOOD, V87, P1368, DOI 10.1182/blood.V87.4.1368.bloodjournal8741368; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GRINNELL BW, 1990, BLOOD, V76, P2546; HERBERT JM, 1992, BLOOD, V80, P2281; Ishimoto Y, 2000, FEBS LETT, V466, P197, DOI 10.1016/S0014-5793(99)01795-0; Kawasaki T, 1999, THROMB HAEMOSTASIS, V81, P306, DOI 10.1055/s-0037-1614471; Leon C, 1999, J CLIN INVEST, V104, P1731, DOI 10.1172/JCI8399; Li RH, 1996, J NEUROSCI, V16, P2012; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; LUPU F, 1993, ARTERIOSCLER THROMB, V13, P1090, DOI 10.1161/01.ATV.13.7.1090; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARCUS AJ, 1996, DISORDERS HEMOSTASIS, P79; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; MATSUNO H, 1992, BRIT J PHARMACOL, V106, P533, DOI 10.1111/j.1476-5381.1992.tb14370.x; McCloskey P, 1997, J BIOL CHEM, V272, P23285, DOI 10.1074/jbc.272.37.23285; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; Nakano T, 1997, J BIOL CHEM, V272, P29411, DOI 10.1074/jbc.272.47.29411; NEUBAUER A, 1994, BLOOD, V84, P1931; O'Donnell K, 1999, AM J PATHOL, V154, P1171, DOI 10.1016/S0002-9440(10)65369-2; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Rao AK, 2000, ARTERIOSCL THROM VAS, V20, P285, DOI 10.1161/01.ATV.20.2.285; ROTH J, 1989, METHOD CELL BIOL, V31, P513; Savi P, 1998, FEBS LETT, V422, P291, DOI 10.1016/S0014-5793(98)00025-8; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; STASSEN JM, 1990, FIBRINOLYSIS, V4, P15, DOI 10.1016/0268-9499(90)90349-O; Umemura K, 1996, THROMB HAEMOSTASIS, V76, P799; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; VOGEL GMT, 1989, THROMB RES, V54, P399, DOI 10.1016/0049-3848(89)90210-7; Yan SB, 1996, J MOL RECOGNIT, V9, P211	45	338	364	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2001	7	2					215	221		10.1038/84667	http://dx.doi.org/10.1038/84667			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	398KU	11175853	Green Published			2022-12-27	WOS:000166756300039
J	Varnum-Finney, B; Xu, LW; Brashem-Stein, C; Nourigat, C; Flowers, D; Bakkour, S; Pear, WS; Bernstein, ID				Varnum-Finney, B; Xu, LW; Brashem-Stein, C; Nourigat, C; Flowers, D; Bakkour, S; Pear, WS; Bernstein, ID			Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling	NATURE MEDICINE			English	Article							DROSOPHILA-NOTCH; HUMAN HOMOLOG; GENE; PROGENITORS; EXPRESSION; MARROW; DIFFERENTIATION; JAGGED-1; LIGAND; CHOICE	Hematopoietic stem cells give rise to progeny that either self-renew in an undifferentiated state or lose self-renewal capabilities and commit to lymphoid or myeloid lineages. Here we evaluated whether hematopoietic stem cell self-renewal is affected by the Notch pathway. Notch signaling controls cell fate choices in both invertebrates and vertebrates(1-7) by inhibiting certain differentiation pathways, thereby permitting cells to either differentiate along an alternative pathway or to self-renew(1). Notch receptors are present in hematopoietic precursors and Notch signaling enhances the in vitro generation of human and mouse hematopoietic precursors(8-15), determines T- or B-cell lineage specification from a common lymphoid precursor(16,17) and promotes expansion of CD8(+) cells(18-20). Here, we demonstrate that constitutive Notch1 signaling in hematopoietic cells established immortalized, cytokine-dependent cell lines that generated progeny with either lymphoid or myeloid characteristics both in vitro and in vivo. These data support a role for Notch signaling in regulating hematopoietic stem cell self-renewal. Furthermore, the establishment of clonal, pluripotent cell lines provides the opportunity to assess mechanisms regulating stem cell commitment and demonstrates a general method for immortalizing stem cell populations for further analysis.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; Univ Penn, Inst Med & Engn, Philadelphia, PA 19104 USA; Univ Washington, Dept Pediat, Seattle, WA 98105 USA	Fred Hutchinson Cancer Center; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Washington; University of Washington Seattle	Varnum-Finney, B (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D2-373, Seattle, WA 98109 USA.				NCI NIH HHS [R01-CA82308-01] Funding Source: Medline; NHLBI NIH HHS [P50 HL54881] Funding Source: Medline; NIAID NIH HHS [R01-AI47833-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082308] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047833] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Carlesso N, 1999, BLOOD, V93, P838, DOI 10.1182/blood.V93.3.838.403k29_838_848; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; Deftos ML, 2000, IMMUNITY, V13, P73, DOI 10.1016/S1074-7613(00)00009-1; DELAMO FF, 1992, DEVELOPMENT, V115, P737; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Han W, 2000, BLOOD, V95, P1616, DOI 10.1182/blood.V95.5.1616.005k31_1616_1625; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Jones P, 1998, BLOOD, V92, P1505, DOI 10.1182/blood.V92.5.1505.417k42_1505_1511; Kiem HP, 1998, BLOOD, V92, P1878, DOI 10.1182/blood.V92.6.1878.418k39_1878_1886; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; MILNER LA, 1994, BLOOD, V83, P2057; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Ohishi K, 2000, BLOOD, V95, P2847, DOI 10.1182/blood.V95.9.2847.009k19_2847_2854; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; Simpson P, 1998, SEMIN CELL DEV BIOL, V9, P581, DOI 10.1006/scdb.1998.0265; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Walker L, 1999, STEM CELLS, V17, P162, DOI 10.1002/stem.170162; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; Yasutomo K, 2000, NATURE, V404, P506, DOI 10.1038/35006664	27	466	524	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1278	1281		10.1038/81390	http://dx.doi.org/10.1038/81390			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062542				2022-12-27	WOS:000165114800038
J	Alter, HJ; Houghton, M				Alter, HJ; Houghton, M			Hepatitis C virus and eliminating post-transfusion hepatitis	NATURE MEDICINE			English	Editorial Material							NON-B-HEPATITIS; NON-A-HEPATITIS; VIRAL-HEPATITIS; ANTIBODY; BLOOD; CHIMPANZEES; INFECTION; ANTIGEN; AGENTS; TRANSMISSION		NIH, Warren G Magnuson Clin Ctr, Dept Transfus Med, Immunol Sect, Bethesda, MD 20892 USA; Chiron Corp, Emeryville, CA 94608 USA	National Institutes of Health (NIH) - USA; Novartis	Alter, HJ (corresponding author), NIH, Warren G Magnuson Clin Ctr, Dept Transfus Med, Immunol Sect, NIH Bldg 10,Room 1C711,9000 Rockville Pike, Bethesda, MD 20892 USA.			Houghton, Michael/0000-0003-3762-6771				Alter Harvey, 1999, American Journal of Medicine, V107, p16S; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1981, JAMA-J AM MED ASSOC, V246, P630, DOI 10.1001/jama.246.6.630; ALTER HJ, 1966, BLOOD-J HEMATOL, V27, P297, DOI 10.1182/blood.V27.3.297.297; ALTER HJ, 1984, SCIENCE, V226, P549, DOI 10.1126/science.6093251; ALTER HJ, 1978, LANCET, V1, P459; ALTER HJ, 1972, ANN INTERN MED, V77, P691, DOI 10.7326/0003-4819-77-5-691; BLUMBERG BS, 1965, J AMER MED ASSOC, V191, P541, DOI 10.1001/jama.1965.03080070025007; BRADLEY DW, 1985, J VIROL METHODS, V10, P307, DOI 10.1016/0166-0934(85)90047-3; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; ConryCantilena C, 1996, NEW ENGL J MED, V334, P1691, DOI 10.1056/NEJM199606273342602; Davis GL, 2000, GASTROENTEROLOGY, V118, pS104, DOI 10.1016/S0016-5085(00)70009-6; De Francesco R, 2000, SEMIN LIVER DIS, V20, P69, DOI 10.1055/s-2000-9504; EZZELL C, 1988, NATURE, V333, P195; Farci P, 2000, SCIENCE, V288, P339, DOI 10.1126/science.288.5464.339; FARCI P, 1994, P NATL ACAD SCI USA, V91, P7792, DOI 10.1073/pnas.91.16.7792; FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; FEINSTONE SM, 1973, SCIENCE, V182, P1026, DOI 10.1126/science.182.4116.1026; FEINSTONE SM, 1975, NEW ENGL J MED, V292, P767, DOI 10.1056/NEJM197504102921502; FEINSTONE SM, 1983, INFECT IMMUN, V41, P816, DOI 10.1128/IAI.41.2.816-821.1983; HE LF, 1987, J INFECT DIS, V156, P636, DOI 10.1093/infdis/156.4.636; HOLLINGER FB, 1978, INTERVIROLOGY, V10, P60, DOI 10.1159/000148969; Houghton M, 2000, CURR TOP MICROBIOL, V242, P327; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Nelson DR, 1998, HEPATOLOGY, V28, P225, DOI 10.1002/hep.510280129; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SHIH JWK, 1986, PROG LIVER DIS, V8, P433; SHIMIZU YK, 1979, SCIENCE, V205, P197, DOI 10.1126/science.451589; Simmonds P, 1999, J HEPATOL, V31, P54, DOI 10.1016/S0168-8278(99)80375-4; STEVENS CE, 1984, ANN INTERN MED, V104, P488; TABOR E, 1978, LANCET, V1, P463, DOI 10.1016/s0140-6736(78)90132-0; Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	39	67	68	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2000	6	10					1082	1086		10.1038/80394	http://dx.doi.org/10.1038/80394			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017126				2022-12-27	WOS:000089674700017
J	Ries, SJ; Brandts, CH; Chung, AS; Biederer, CH; Hann, BC; Lipner, EM; McCormick, F; Korn, WM				Ries, SJ; Brandts, CH; Chung, AS; Biederer, CH; Hann, BC; Lipner, EM; McCormick, F; Korn, WM			Loss of p14(ARF) in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015)	NATURE MEDICINE			English	Article							P53 STATUS; G(1) ARREST; DNA-DAMAGE; MDM2; SUPPRESSOR; INFECTION; PROTEINS; P19(ARF); ACCUMULATION; EXPRESSION	The adenovirus mutant dl1520 (ONYX-015) does not express the E1B-55K protein that binds and inactivates p53. This virus replicates in tumor cells with mutant p53, but not in normal cells with functional p53. Although intra-tumoral injection of dl1520 shows promising responses in patients with solid tumors, previous in vitro studies have not established a close correlation between p53 status and dl1520 replication. Here we identify loss of p14(ARF) as a mechanism that allows dl1520 replication in tumor cells retaining wild-type p53. We demonstrate that the re-introduction of p14(ARF) into tumor cells with wild-type p53 suppresses replication of dl1520 in a p53-dependent manner. Our study supports the therapeutic use of dl1520 in tumors with lesions within the p53 pathway other than mutation of p53.	Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, Canc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Korn, WM (corresponding author), Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA 94143 USA.			Brandts, Christian H./0000-0003-1732-2535				BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; Billon N, 1996, ONCOGENE, V13, P2047; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHANG FJ, 1995, J CLIN ONCOL, V13, P1009, DOI 10.1200/JCO.1995.13.4.1009; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; Ganly I, 2000, CLIN CANCER RES, V6, P798; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Roth E, 1998, CLIN NUTR, V17, P1, DOI 10.1016/S0261-5614(98)80034-4; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Steegenga WT, 1999, ONCOGENE, V18, P5032, DOI 10.1038/sj.onc.1202886; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Turnell AS, 1999, J VIROL, V73, P2074, DOI 10.1128/JVI.73.3.2074-2083.1999; WALDMAN T, 1995, CANCER RES, V55, P5187; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	34	165	179	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1128	1133		10.1038/80466	http://dx.doi.org/10.1038/80466			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017144				2022-12-27	WOS:000089674700037
J	Zimhony, O; Cox, JS; Welch, JT; Vilcheze, C; Jacobs, WR				Zimhony, O; Cox, JS; Welch, JT; Vilcheze, C; Jacobs, WR			Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis	NATURE MEDICINE			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; VITRO ANTIMYCOBACTERIAL ACTIVITY; SHORT-COURSE CHEMOTHERAPY; VAR BOVIS BCG; PYRAZINOIC ACID; MYCOLIC ACIDS; GENE; SYNTHASE; RESISTANCE; MUTATIONS	Tuberculosis treatment is shortened to six months by the indispensable addition of pyrazinamide (PZA) to the drug regimen that includes isoniazid and rifampin(1,2). PZA is a pro-drug of pyrazinoic acid (POA) (ref. 3), whose target of action has never been identified. Although PZA is active only against Mycobacterium tuberculosis, the PZA analog 5-chloro-pyrazinamide (5-CI-PZA) displays a broader range of anti-mycobacterial activity(4). We have found that the eukaryotic-like fas1 gene(5) (encoding fatty acid synthetase I, FASI) from M. avium, M. bovis BCG or M. tuberculosis confers resistance to 5-CI-PZA when present on multi-copy vectors in M, smegmatis. 5-CI-PZA and PZA markedly inhibited the activity of M, tuberculosis FASI, the biosynthesis of C-16 to C-24/C26 fatty acids from acetyl-CoA (ref.6). Importantly, PZA inhibited FASI in M. tuberculosis in correlation with PZA susceptibility. These results indicate that FASI is a primary target of action for PZA in M. tuberculosis. Further characterization of FASI as a drug target for PZA may allow the development of new drugs to shorten the therapy against M. tuberculosis and may provide more options for treatment against M. bovis, M. avium and drug resistant M. tuberculosis.	Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Montefiore Med Ctr, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Div Infect Dis, Bronx, NY 10461 USA; SUNY Albany, Dept Chem, Albany, NY 12222 USA	Howard Hughes Medical Institute; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Jacobs, WR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Montefiore Med Ctr, Dept Microbiol & Immunol, Bronx, NY 10461 USA.	jacobs@aecom.yu.edu		Jacobs, William/0000-0003-3321-3080				Anderson RJ, 1929, J BIOL CHEM, V85, P327; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Bloch K, 1975, Methods Enzymol, V35, P84, DOI 10.1016/0076-6879(75)35141-0; BRINDLEY DN, 1969, NATURE, V224, P666, DOI 10.1038/224666a0; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cynamon MH, 1998, ANTIMICROB AGENTS CH, V42, P462; CYNAMON MH, 1995, J MED CHEM, V38, P3902, DOI 10.1021/jm00020a003; Fernandes ND, 1996, GENE, V170, P95, DOI 10.1016/0378-1119(95)00842-X; FOLCH J, 1957, J BIOL CHEM, V226, P497; Good R. C., 1985, Clinical Microbiology Newsletter, V7, P133, DOI 10.1016/S0196-4399(85)80012-X; GROSSET J, 1978, TUBERCLE, V59, P287, DOI 10.1016/0041-3879(78)90007-7; HAGEN SR, 1995, J CHROMATOGR A, V692, P167, DOI 10.1016/0021-9673(94)00743-S; KIKUCHI S, 1992, ARCH BIOCHEM BIOPHYS, V295, P318, DOI 10.1016/0003-9861(92)90524-Z; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; KONNO K, 1967, AM REV RESPIR DIS, V95, P461; KUSHNER S, 1952, J AM CHEM SOC, V74, P3617, DOI 10.1021/ja01134a045; MCCUNE RM, 1956, J EXP MED, V104, P763, DOI 10.1084/jem.104.5.763; MCDERMOTT W, 1954, AM REV TUBERC PULM, V70, P748; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; Mehta A, 1998, J CHROMATOGR B, V719, P9, DOI 10.1016/S0378-4347(98)00403-4; MITCHISON DA, 1985, TUBERCLE, V66, P219, DOI 10.1016/0041-3879(85)90040-6; Omura S, 1981, Methods Enzymol, V72, P520; SALFINGER M, 1990, J INFECT DIS, V162, P201, DOI 10.1093/infdis/162.1.201; Scorpio A, 1996, NAT MED, V2, P662, DOI 10.1038/nm0696-662; Scorpio A, 1997, ANTIMICROB AGENTS CH, V41, P540, DOI 10.1128/AAC.41.3.540; Slayden RA, 1996, ANTIMICROB AGENTS CH, V40, P2813, DOI 10.1128/AAC.40.12.2813; STEELE MA, 1988, CHEST, V94, P845, DOI 10.1378/chest.94.4.845; TAKAYAMA K, 1975, J LIPID RES, V16, P308; Telenti A, 1997, NAT MED, V3, P567, DOI 10.1038/nm0597-567; Zhang Y, 1999, J BACTERIOL, V181, P2044, DOI 10.1128/JB.181.7.2044-2049.1999	32	193	200	0	20	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2000	6	9					1043	1047		10.1038/79558	http://dx.doi.org/10.1038/79558			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973326				2022-12-27	WOS:000089190500038
J	Novak, K				Novak, K			Hypertrophy prevention	NATURE MEDICINE			English	News Item														Novak, Kristine/0000-0001-9314-1803					0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2001	7	12					1290	1290		10.1038/nm1201-1290	http://dx.doi.org/10.1038/nm1201-1290			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726967	Bronze			2022-12-27	WOS:000172610300032
J	Novak, K				Novak, K			Immunoregulation of diabetes	NATURE MEDICINE			English	News Item														Novak, Kristine/0000-0001-9314-1803					0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2001	7	12					1290	1290		10.1038/nm1201-1290	http://dx.doi.org/10.1038/nm1201-1290			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726967	Bronze			2022-12-27	WOS:000172610300028
J	Birmingham, K				Birmingham, K			UK approves human stem cell research	NATURE MEDICINE			English	News Item																		DONALDSON L, 1999, NAT MED, V5, P855	1	0	0	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					950	950		10.1038/79622	http://dx.doi.org/10.1038/79622			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973298				2022-12-27	WOS:000089190500014
J	DeFrancesco, L; Cimons, M				DeFrancesco, L; Cimons, M			Stem cell losses and gains in the US	NATURE MEDICINE			English	News Item																			0	18	18	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1076	1076		10.1038/nm1001-1076a	http://dx.doi.org/10.1038/nm1001-1076a			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590410	Bronze			2022-12-27	WOS:000171524500005
J	DeFrancesco, L				DeFrancesco, L			Prostate cancer prevention trial launched	NATURE MEDICINE			English	News Item																			0	18	18	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1076	1076		10.1038/nm1001-1076a	http://dx.doi.org/10.1038/nm1001-1076a			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590410	Bronze			2022-12-27	WOS:000171524500006
J	Birmingham, K				Birmingham, K			NIH funds gender biology research	NATURE MEDICINE			English	News Item																			0	0	0	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					950	950		10.1038/79622	http://dx.doi.org/10.1038/79622			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973298				2022-12-27	WOS:000089190500013
